<SEC-DOCUMENT>0001193125-13-373552.txt : 20131107
<SEC-HEADER>0001193125-13-373552.hdr.sgml : 20131107

<ACCEPTANCE-DATETIME>20130920173015

<PRIVATE-TO-PUBLIC>

ACCESSION NUMBER:		0001193125-13-373552

CONFORMED SUBMISSION TYPE:	S-1/A

PUBLIC DOCUMENT COUNT:		23

FILED AS OF DATE:		20130920

DATE AS OF CHANGE:		20131009


FILER:


	COMPANY DATA:	

		COMPANY CONFORMED NAME:			MACROGENICS INC

		CENTRAL INDEX KEY:			0001125345

		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]

		IRS NUMBER:				000000000

		STATE OF INCORPORATION:			DE

		FISCAL YEAR END:			1231



	FILING VALUES:

		FORM TYPE:		S-1/A

		SEC ACT:		1933 Act

		SEC FILE NUMBER:	333-190994

		FILM NUMBER:		131108719



	BUSINESS ADDRESS:	

		STREET 1:		9640 MEDICAL CENTER DRIVE

		CITY:			Rockville

		STATE:			MD

		ZIP:			20850

		BUSINESS PHONE:		301-251-5172



	MAIL ADDRESS:	

		STREET 1:		9640 MEDICAL CENTER DRIVE

		CITY:			ROCKVILLE

		STATE:			MD

		ZIP:			20850



</SEC-HEADER>

<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>d575431ds1a.htm
<DESCRIPTION>AMENDMENT NO.1 TO FORM S-1
<TEXT>
<HTML><HEAD>
<TITLE>Amendment No.1 to Form S-1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As filed with the Securities and Exchange Commission on September&nbsp;20, 2013
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Registration Statement No.&nbsp;333-190994 </B></FONT></P>
<P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>  <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>AMENDMENT
NO. 1 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>TO </B></FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="5"><B>FORM S-1 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>REGISTRATION STATEMENT </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B><I>UNDER </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B><I>THE SECURITIES ACT OF 1933 </I></B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>MACROGENICS,
INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact Name of Registrant as Specified in Its Charter) </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware<BR></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2834</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>06-1591613</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or other jurisdiction of</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>incorporation or organization)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Primary Standard Industrial</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Classification Code Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(I.R.S. Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>9640 Medical Center Drive </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Rockville, MD 20850 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(301) 251-5172 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address, including zip code and telephone number, including area code, of registrant&#146;s principal executive offices)
</B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Scott Koenig, M.D., Ph.D. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>President and Chief Executive Officer </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>9640 Medical Center Drive
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Rockville, MD 20850 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(301) 251-5172 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Name, address, including zip code, and telephone number,
including area code, of agent for service) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Copies to:
</I></B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Richard E. Baltz</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Arnold &amp; Porter LLP</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>555 12<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> Street NW</FONT></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Washington, DC 20004-1206</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(202) 942-5000</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Steven D. Singer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Lisa Firenze</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Wilmer Cutler Pickering Hale and Dorr LLP</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>7 World Trade Center<BR>New York, NY 10007</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(212) 230-8000</B></FONT></P></TD></TR>
</TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Approximate date of commencement of proposed sale to the public: </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">As soon as practicable after this Registration Statement becomes effective. </FONT></P>
<P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:4px;margin-bottom:0px; text-indent:3%"><FONT STYLE="font-family:Times New Roman" SIZE="1">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the
Securities Act of 1933, check the following box.&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P> <P STYLE="margin-top:4px;margin-bottom:0px; text-indent:3%"><FONT STYLE="font-family:Times New Roman" SIZE="1">If this Form is
filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for
the same offering.&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P> <P STYLE="margin-top:4px;margin-bottom:0px; text-indent:3%"><FONT STYLE="font-family:Times New Roman" SIZE="1">If this Form is a post-effective amendment
filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P> <P STYLE="margin-top:4px;margin-bottom:0px; text-indent:3%"><FONT STYLE="font-family:Times New Roman" SIZE="1">If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the
Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P>
<P STYLE="margin-top:4px;margin-bottom:0px; text-indent:3%"><FONT STYLE="font-family:Times New Roman" SIZE="1">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller
reporting company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule 12b-2 of the Exchange Act. </FONT></P>
<P STYLE="margin-top:4px;margin-bottom:0px; text-indent:3%"><FONT STYLE="font-family:Times New Roman" SIZE="1">(Check one): </FONT></P> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">Large&nbsp;accelerated&nbsp;filer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">Accelerated filer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD></TR>
<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">Non-accelerated&nbsp;filer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;(Do not check if a smaller reporting company)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">Smaller&nbsp;reporting&nbsp;company</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD></TR>
</TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>   <center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:4px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant
shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective
on such date as the Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></FONT></P> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2" COLOR="#c21128">The information in this prospectus is not complete and may be changed. We cannot sell these
securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and we are not soliciting an offer to buy these securities in any state where the
offer or sale is not permitted. </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2" COLOR="#c21128">Subject to completion </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2" COLOR="#c21128">Preliminary Prospectus dated September 20, 2013 </FONT></P>  <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>PROSPECTUS
</U></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shares </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g575431g97j81.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>Common Stock </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:19%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This is MacroGenics, Inc.&#146;s initial public offering. We are selling
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We expect the public
offering price to be between $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. Currently, no public market exists for the shares. After pricing of the offering, we expect that the
shares will trade on the NASDAQ Global Market under the symbol &#147;MGNX&#148;. </FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are an &#147;emerging growth
company&#148; as that term is used in the Jumpstart Our Business Startups Act of 2012 and, as such, have elected to comply with certain reduced public company reporting requirements for this prospectus and future filings. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:19%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Investing in our common stock involves risks that are described in the &#147;<A HREF="#cov575431_1">Risk Factors</A>&#148; section
beginning on page 11 of this prospectus. </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:19%">&nbsp;</P></center> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="86%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:32pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Per&nbsp;share</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:18pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Initial public offering price</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Underwriting discounts and commissions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proceeds before expenses, to us</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The underwriters may also exercise their option to purchase up to an additional
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares from us, at the public offering price, less the underwriting discount, for 30 days after the date of this prospectus. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities, or
determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The shares
will be ready for delivery on or about &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2013. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:19%">&nbsp;</P></center>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="53%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>BofA&nbsp;Merrill&nbsp;Lynch</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>Leerink&nbsp;Swann</B></FONT></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="98%"></TD></TR>
<TR>
<TD HEIGHT="16"></TD></TR>

<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>Stifel</B></FONT></TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="44%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="54%"></TD></TR>


<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>Lazard&nbsp;Capital&nbsp;Markets</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>Wedbush&nbsp;PacGrow&nbsp;Life&nbsp;Sciences</B></FONT></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:19%">&nbsp;</P></center> <P STYLE="margin-top:60px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">The date of
this prospectus is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2013. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom575431_1">Prospectus Summary</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom575431_2">Risk Factors</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom575431_3">Special Note Regarding Forward-Looking Statements</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">44</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom575431_4">Use of Proceeds</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">46</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom575431_5">Dividend Policy</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">47</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom575431_6">Capitalization</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">48</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom575431_7">Dilution</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom575431_8">Selected Consolidated Financial Data</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">52</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom575431_9">Management&#146;s Discussion and Analysis of Financial Condition and Results of
Operations</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom575431_10">Business</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">77</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom575431_11">Management</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">123</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom575431_12">Certain Relationships and Related Party Transactions</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">140</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom575431_13">Principal Stockholders</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">141</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom575431_14">Description of Capital Stock</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">145</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom575431_15">Shares Eligible for Future Sale</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">150</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom575431_16">Material U.S. Federal Tax Consequences for Non-U.S. Holders</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">152</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom575431_17">Underwriting</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">156</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom575431_18">Legal Matters</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">163</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom575431_19">Experts</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">163</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom575431_20">Where You Can Find More Information</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">163</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom575431_21">Index to Consolidated Financial Statements </A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have not authorized anyone to provide you with information other than that contained in this
prospectus or in any free writing prospectus prepared by or on behalf of us or to which we have referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give to you. We
are offering to sell shares of our common stock, and seeking offers to buy shares of our common stock, only in jurisdictions where offers and sales are permitted. The information contained in this prospectus is accurate only as of the date of this
prospectus, regardless of the time of delivery of this prospectus or any sale of our common stock. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Neither we nor any of the
underwriters have taken any action to permit a public offering of the shares of our common stock or the possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than the United States. You
are required to inform yourselves about and to observe any restrictions relating to this offering and the distribution of this prospectus. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom575431_1"></A>PROSPECTUS SUMMARY </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>This summary highlights information contained elsewhere in this prospectus and is qualified in its entirety by the more detailed
information and consolidated financial statements included elsewhere in this prospectus. This summary does not contain all of the information that may be important to you. You should read and carefully consider the following summary together with
the entire prospectus, including our consolidated financial statements and the notes thereto appearing elsewhere in this prospectus and the matters discussed in the sections in this prospectus entitled &#147;Risk Factors,&#148; &#147;Selected
Consolidated Financial Data&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; before deciding to invest in our common stock. Some of the statements in this prospectus constitute
forward-looking statements that involve risks and uncertainties. See &#147;Special Note Regarding Forward-Looking Statements.&#148; Our actual results could differ materially from those anticipated in such forward-looking statements as a result of
certain factors, including those discussed in the &#147;Risk Factors&#148; and other sections of this prospectus. </I></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Except as otherwise indicated herein or as the context otherwise requires, references in this prospectus to &#147;MacroGenics&#148;
&#147;the company,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; refer to MacroGenics, Inc. and its consolidated subsidiaries. </I></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Overview </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are a
clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. We generate our pipeline of product candidates from our proprietary
suite of next-generation antibody technology platforms, which we believe improve the performance of monoclonal antibodies and antibody-derived molecules. These product candidates, which we have identified through our understanding of disease biology
and immune-mediated mechanisms, may address disease-specific challenges which are not currently being met by existing therapies. We create both differentiated molecules that are directed to novel cancer targets, as well as &#147;bio-betters,&#148;
which are drugs designed to improve upon marketed medicines. The combination of our technology platforms and antibody engineering expertise has allowed us to generate promising product candidates and enter into several strategic collaborations with
global pharmaceutical and biotechnology companies. These collaborations provide us with funding and allow us to leverage the additional expertise of our collaborators to advance the development of our product candidates. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have three versatile, proprietary technology platforms that can be applied in combination with one another to custom design an
antibody or antibody-derived molecule that is optimized to treat a specific disease. These technologies are described below. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our <I>Dual Affinity Re-Targeting, or DART, platform</I> enables the targeting of multiple antigens or cells by using a single molecule with an antibody-like structure,
and also includes the ability to recruit any T cell in a patient&#146;s body to destroy targeted cancer cells. We have created over 100 DART-based molecules, or DARTs, which we believe improve upon the human immune system and have more potent immune
properties than the parent antibody molecules from which they are derived. </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our<I> Fc Optimization platform</I> enhances the body&#146;s immune system to mediate the killing of cancer cells through a mechanism called antibody-dependent cellular
cytotoxicity, or ADCC, in which antibodies and immune cells cooperate to destroy targets such as tumor cells. To date, we have successfully incorporated our Fc Optimization technology into our two lead oncology product candidates and have
pre-clinical data demonstrating that these antibodies have substantially greater ability to kill cancer cells than similar antibodies that have not been Fc-optimized. </FONT></TD></TR></TABLE>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our<I> Cancer Stem-like Cell, or CSLC, platform</I> provides a unique discovery tool to identify cancer targets shared both by tumor-initiating cells and the
differentiated cancer cells derived from them. Using this platform, we can create antibodies or antibody-derived molecules that specifically target and destroy CSLCs, potentially enabling us to address the large, unmet medical needs of many cancers
that are difficult to treat. </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We utilize one or more of our technology platforms for engineering and optimizing
our antibody and antibody-derived product candidates. Many of our cancer product candidates are derived from our library of over 1,900 purified antibodies. We believe our approach allows us to take advantage of the enhanced properties of an
engineered antibody or antibody-derived molecule to kill cancer cells and to interfere with autoimmune disorders more effectively than a wild type, or non-engineered, monoclonal antibody. Our methods for improving the effectiveness of antibodies
include the following: enhancing the body&#146;s immune system; targeting multiple antigens on the surface of the same target cell; increasing the strength of the binding of an antibody to its antigen targets; and reducing the likelihood of an
unwanted immune response to the antibody or antibody-derived molecule. We believe our differentiated product candidates have the potential to provide new approaches to treat cancer, autoimmune disorders and other complex diseases and to improve
clinical outcomes. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have entered into strategic collaborations with Les Laboratoires Servier and Institut de Recherches
Servier, or collectively, Servier, Gilead Sciences, Inc., or Gilead, Boehringer Ingelheim International GmbH, or Boehringer, and Pfizer, Inc., or Pfizer, among others. Under our current strategic collaborations, we have received approximately $106
million in non-equity funding during the three year period ended June 30, 2013. Under these agreements we are entitled to receive substantial milestone and other payments, including over $100&nbsp;million of potential payments that we believe are
likely to be received by the end of 2015, assuming all of our collaboration programs advance as currently contemplated. As of June 30, 2013, we had $33.8&nbsp;million in cash and cash equivalents. Subsequently, we received a $10 million milestone
payment in August 2013. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Our Product Candidates </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We currently have two oncology product candidates in clinical development. Additionally, we have several proprietary product candidates in pre-clinical development and we expect to commence Phase 1
clinical trials on two of these product candidates in 2014. We believe the profile of our compounds provides us with the flexibility to pursue either monotherapy or combination therapy, depending on disease characteristics, current standards of
care, and overall safety, tolerability and efficacy of specific regimens. </FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The table below depicts the current status of our product candidates: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g575431g95y29.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Margetuximab</I>, also known as MGAH22, is a monoclonal antibody that targets HER2-expressing tumors, including breast, gastroesophageal, bladder
and other cancers. HER2, or human epidermal growth factor receptor 2, is critical for the growth of many types of tumors. Using our Fc Optimization platform, we have engineered the constant region, or Fc region, of margetuximab to enhance the
antibody&#146;s ability to kill tumor cells expressing lower levels of HER2 than that of currently approved anti-HER2 agents (such as Herceptin) and also to increase margetuximab&#146;s ability to kill tumor cells through ADCC. We designed
margetuximab to benefit a large sub-group of patients, which represents 80% or more of the overall population whose Fc receptors, or Fc<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>Rs, expressed on immune cells bind less effectively to currently
available antibodies that have not been optimized by our technology. Margetuximab represents a new class of bio-betters that may potentially help larger HER2 positive, or HER2+, patient populations than those treated with current HER2 therapies, as
well as improve the outcomes for patients who would be eligible for other HER2 targeted drugs and drug candidates. Phase 1 data from our open-label, dose escalation trial of margetuximab presented at the June 2013 Annual Meeting of the American
Society of Clinical Oncology, or ASCO, demonstrated that anti-tumor activity had been observed at a range of doses tested, including the lowest dose level, even in patients who were heavily pre-treated (frequently including with other anti-HER2
agents). We currently are enrolling a Phase 2a clinical trial in metastatic breast cancer and anticipate commencing a Phase 3 potential registration clinical trial in advanced gastroesophageal cancer in the second half of 2014.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>MGA271</I> is an Fc-optimized monoclonal antibody that targets B7-H3, a member of the B7 family of molecules which are involved in immune
regulation, and is over-expressed on a wide variety of solid tumor types. MGA271 represents one of the few novel molecules that may provide relief from immune checkpoint inhibition by releasing a restraint, or brake, on the anti-tumor immune
response. Inhibition of immune checkpoints has been shown to have powerful anti-tumor effects in several solid tumor types. For example, in presentations by others at ASCO and in publications in the <I>New England Journal of Medicine,</I> complete
or partial tumor regression was observed in patients with certain cancers who participated in clinical trials of antibodies targeting CTLA4, PD-1 and PD-L1, which are also members of the B7 family or their associated checkpoint receptors on
</FONT></P></TD></TR></TABLE>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="11%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P><FONT STYLE="font-family:Times New Roman" SIZE="2">
T&nbsp;cells. We have engineered MGA271 to utilize the same Fc Optimization enhancements that we incorporated in margetuximab, and to target the over-expression of B7-H3 on differentiated tumor
cells and CSLCs, as well as on the supporting tumor vasculature and underlying tissues. MGA271 is designed to destroy all of these components of the cancer in addition to reducing its inhibitory properties on T cells. We have initiated a Phase 1
clinical trial that we expect to complete by the end of 2014. We plan to initiate a Phase 2 clinical trial no later than early 2015. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>MGD006 </I>is a humanized DART molecule that recognizes both CD123 and CD3. CD123, the Interleukin-3 receptor, or IL3R, alpha chain is expressed on
leukemia and leukemic stem cells, but not on normal hematopoietic stem cells. T cells, which express CD3, can destroy tumor cells. In pre-clinical studies, we have demonstrated the ability of MGD006 at extremely low doses to recruit, activate, and
expand T cell populations to eliminate leukemia cells. We expect to commence a Phase 1 clinical trial in the first half of 2014. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>MGD007</I> is a humanized DART molecule that recognizes both the glycoprotein gpA33 and CD3. gpA33 is expressed on gastrointestinal tumors,
including more than 95% of human colon cancers. We have demonstrated that this molecule is able to mediate T&nbsp;cell killing of gpA33-expressing cancer cells and CSLCs in pre-clinical experiments. We expect to commence a Phase 1 clinical trial in
the second half of 2014. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Our Collaborations </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have entered into several strategic collaborations for our product candidates and technology platforms, including: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Servier</I>. In November 2011, we entered into a collaboration agreement with Servier under which we granted Servier an option to obtain an
exclusive license to develop and commercialize MGA271 in all countries other than the United States, Canada, Mexico, Japan, South Korea and India. We have received a $20 million option grant fee and a $10 million milestone payment, and may be
eligible to receive up to approximately $415&nbsp;million in license grant fees, and clinical, development, regulatory and sales milestone payments if Servier exercises the option, obtains regulatory approval for, and successfully commercializes
MGA271. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:11%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In September 2012, we entered into a second agreement with Servier and granted it options to
obtain three separate exclusive licenses to develop and commercialize DART-based molecules, consisting of those designated by us as MGD006 and MGD007, as well as a third DART-based molecule, in all countries other than the United States, Canada,
Mexico, Japan, South Korea and India. We received a $20 million option grant fee and may be eligible to receive up to approximately $1 billion in additional license grant fees, and clinical, development, regulatory and sales milestone payments if
Servier exercises all three of its options and successfully develops, obtains regulatory approval for and commercializes a product under each license. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:11%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Additionally, under both agreements, Servier would be obligated to pay us low double digit to mid-teen royalties on product sales in its territories. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Gilead.</I> In January 2013, we entered into an agreement with Gilead to grant it an exclusive worldwide license to research, develop and
commercialize up to four DART-based molecules. Gilead has exclusive worldwide rights for three of the programs. For one program, we retain development and commercialization rights outside of North America, the European Union, Norway, Iceland,
Turkey, Australia and New Zealand. We received an initial $7.5 million license grant fee </FONT></P></TD></TR></TABLE>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="11%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P><FONT STYLE="font-family:Times New Roman" SIZE="2">
for the first DART-based molecule, and are eligible to receive up to an additional $22.5 million in grant fees on the remaining three DART-based molecules. We are further eligible to receive up
to an additional $85 million in pre-clinical milestones across the four DART programs and additional clinical, regulatory and sales milestones and royalty payments. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Boehringer</I>. In October 2010, we entered into an agreement with Boehringer to discover, develop and commercialize up to ten DART-based molecules
which may span multiple therapeutic areas. We granted Boehringer an exclusive worldwide, royalty-bearing, license and received an upfront payment of $15 million. We subsequently received two annual maintenance payments and anticipate receiving a
third annual maintenance payment in the fourth quarter of 2013. We have the potential to earn development, regulatory and sales milestones and royalty payments for each of the DART programs under this agreement. Boehringer provides funding for our
internal and external research costs under the agreement. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Pfizer.</I> In October 2010, we entered into a three year agreement with Pfizer to discover, develop and commercialize up to two DART-based
molecules. We granted Pfizer a non-exclusive worldwide, royalty-bearing license and received upfront and milestone payments and funding for our internal and external research costs under the agreement. We are eligible to receive technical,
development and sales milestones and royalty payments for each DART program under this agreement. Under this collaboration, one DART program is currently being pursued and we will complete our research obligations under this program in January 2014.
</FONT></P></TD></TR></TABLE>  <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Our Strategy </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our goal is to be a leader in the discovery, development and commercialization of antibody-based therapeutics for the treatment of patients with cancer, autoimmune disorders and other complex diseases.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Key elements of our strategy to achieve this goal are to: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Rapidly and concurrently advance our clinical oncology product candidates in multiple tumor types. </I>We intend to pursue the fastest feasible
pathways to approval and to address large, underserved markets. We are developing product candidates that we believe could address disease specific challenges which are not currently being met by existing therapies. We are currently enrolling a
Phase 2a clinical trial of margetuximab in metastatic breast cancer for which we expect to have results in 2014. We anticipate commencing a Phase 3 potential registration clinical trial of margetuximab in advanced gastroesophageal cancer in the
second half of 2014. We are currently enrolling the dose-expansion portion of a Phase 1 clinical trial of MGA271 as a single-agent in the treatment of 45&nbsp;patients with solid tumors. In addition, we are currently optimizing multiple DART
therapeutics as candidates for clinical development. We anticipate that we will begin Phase 1 clinical trials of MGD006, our first DART candidate, in the first half of 2014, and MGD007, our second DART candidate, in the second half of 2014.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Leverage collaborative relationships. </I>We have multiple programs in development under our collaborations and are working closely with our
collaborators to advance these programs. We believe that these collaborations help to validate and rapidly advance our discovery efforts, technology platforms, and product candidates while providing significant funding to advance our pipeline and
access to the development and commercial expertise of our collaborators. To facilitate the capital-efficient development and commercialization of our proprietary programs, we intend to enter into additional collaboration agreements with
biopharmaceutical companies. We anticipate that we would structure these collaborations in ways that would allow us to retain development and commercialization rights in key markets. </FONT></P></TD></TR></TABLE>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Create new product candidates that combine the potency and target selectivity of our DART and Fc Optimization technologies with small molecule and
toxin conjugation technologies</I>. We are working with several companies to combine their proprietary linkers and drug conjugates with our monoclonal antibodies and our DART molecules. Our goal is to identify and further develop new clinical
product candidates, either antibody-drug conjugates, or ADCs, or DART-drug conjugates, through these research efforts. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Establish commercialization and marketing capabilities in the United States</I>. We have retained commercialization rights in the United States for
our clinical stage programs as well as the three DART programs that we are developing in collaboration with Servier. We intend to build a targeted specialty sales force and marketing capabilities in the United States to commercialize our product
candidates that receive regulatory approval. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Strengthen our leadership position in fully integrated antibody engineering and development capabilities. </I>We have built a powerful and fully
integrated set of capabilities that are critical to our ability to discover, optimize and develop antibody-based therapeutic product candidates in a rapid and efficient manner. We currently manufacture the drug substance for all of our product
candidates at our manufacturing facility. We intend to build on our technology platforms, methods and know-how that together comprise our capabilities in order to expand our product pipeline. Our goal is to file one or more new investigational new
drug applications, or INDs, annually for the next several years. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom575431_2"></A><A NAME="cov575431_1"></A>Risk Factors </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Investing in our common stock involves substantial risk. You should carefully consider all of the information in this prospectus prior to investing in our common stock. There are numerous risk factors
related to our business that are described under &#147;Risk Factors&#148; and elsewhere in this prospectus. Among these important risks are the following: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our clinical trials may not be successful, and clinical results may not reflect results seen in previously conducted pre-clinical studies;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we do not have adequate funding to complete development in some areas, and may be unable to access additional capital on reasonable terms or at all to
complete development and begin commercialization of our product candidates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our current or future collaborators may not adequately support development in designated areas, or they may elect to change their strategic or business
priorities, and these changes may have an adverse impact on us, our development plans, or our business; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may encounter unexpected regulatory changes that delay or impede our development and commercialization efforts; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may not be able to obtain adequate protection for the intellectual property covering our product candidates or develop and commercialize our product
candidates without infringing on the intellectual property rights of third parties; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">product reimbursement may be challenging for us due to recent and proposed changes in healthcare law; </FONT></P></TD></TR></TABLE>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may encounter manufacturing and distribution challenges; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may be unable to recruit or retain well qualified personnel who are necessary for us to conduct our business. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Our Corporate Information </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We were incorporated under the laws of the state of Delaware in 2000 under the name MacroGenics, Inc. Our principal executive offices are located at 9640 Medical Center Drive, Rockville, Maryland 20850
and our telephone number is (301)&nbsp;251-5172. Our website address is www.macrogenics.com. The information contained on, or that can be accessed through, our website is not a part of this prospectus. We have included our website address in this
prospectus solely as an inactive textual reference. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">DART<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>, the phrase &#147;Breakthrough Biologics, Life-Changing Medicines&#148; and the MacroGenics logo are our registered trademarks. The other trademarks, trade names and
service marks appearing in this prospectus are the property of their respective owners. </FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">7 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>THE OFFERING</B> </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="52%"></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common stock offered by us</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Over-allotment option</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common stock to be outstanding after this offering</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Use of proceeds</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">We intend to use the net proceeds of this offering, combined with our current cash and cash equivalents and anticipated collaboration payments, to fund approximately $70 million
of clinical development expenses for margetuximab and MGA271; approximately $30 million to fund research and development expenses to advance our remaining product candidates, including MGD006, MGD007 and MGD010; and the remainder for working capital
and general corporate purposes, which may include other research and development programs, in-licensing or acquiring other products or technologies. See &#147;Use of Proceeds.&#148;</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Risk factors</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">See &#147;Risk Factors&#148; and the other information included in this prospectus for a discussion of factors you should consider carefully before investing in shares of our
common stock.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proposed NASDAQ Global Market symbol</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;MGNX&#148;</FONT></TD></TR>
</TABLE>   <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The number of shares of our common stock to be outstanding after this offering is based on
38,163,345 shares of our common stock outstanding as of August 31, 2013 and excludes: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">54,420,900 shares of common stock issuable upon the exercise of outstanding options to issue common stock, as of August 31, 2013, at a weighted average
exercise price of $0.07 per share; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,473,394 shares of common stock reserved for future grant or issuance under our stock option plans, as of August 31, 2013.
</FONT></P></TD></TR></TABLE>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unless otherwise indicated, all information in this prospectus reflects and assumes: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the automatic conversion of all outstanding shares of our convertible preferred stock into 318,327,547 shares of common stock upon the closing of this
offering; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the exercise of outstanding warrants, as of August 31, 2013 to purchase &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
of our Series <FONT STYLE="white-space:nowrap">D-2</FONT> preferred stock, at a weighted average exercise price of $0.6521 per share and the subsequent conversion of these shares of our Series D-2 preferred stock into
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock; </FONT></P></TD></TR></TABLE>  <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">no exercise by the underwriters of their option to purchase up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional
shares of common stock; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a &nbsp;&nbsp;&nbsp;&nbsp;for &nbsp;&nbsp;&nbsp;&nbsp;reverse split of our common stock effected on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2013; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the filing of our amended and restated certificate of incorporation immediately after the completion of this offering. </FONT></P></TD></TR></TABLE>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SUMMARY CONSOLIDATED FINANCIAL DATA </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following tables summarize our consolidated financial data for the periods presented and should be read together with
&#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and our consolidated financial statements and related notes appearing elsewhere in this prospectus. The consolidated statements of operations and
comprehensive income (loss) data for the years ended December&nbsp;31, 2011 and 2012 included in this prospectus have been derived from our audited consolidated financial statements and footnotes included elsewhere in this prospectus. The following
summary consolidated statements of operations and comprehensive income (loss) data for the six months ended June 30, 2012 and 2013 and the balance sheet data as of June&nbsp;30, 2013 have been derived from our unaudited consolidated financial
statements and footnotes included elsewhere in this prospectus. We have prepared the unaudited consolidated financial statements on the same basis as the audited consolidated financial statements and have included all adjustments, consisting only of
normal recurring adjustments, which in our opinion are necessary to state fairly the financial information set forth in those statements. Our historical results are not necessarily indicative of the results we expect in the future, and our interim
results should not necessarily be considered indicative of results we expect for the full year. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:89pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year Ended December&nbsp;31,</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:93pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Six Months Ended June 30,</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands, except share and per share data)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Consolidated Statements of Operations and Comprehensive Income (loss):</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total revenues</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">57,207</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">63,826</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37,946</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22,896</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Costs and expenses:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">41,089</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">45,433</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24,957</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,146</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">General and administrative</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,868</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,188</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,126</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,336</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total costs and expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">51,957</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">55,621</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30,083</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">26,482</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Income (loss) from operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,205</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,863</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,586</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other income (expense):</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest income (expense)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other income (expense)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,459</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">151</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(72</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total other income (expense)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,467</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">157</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(74</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net comprehensive income (loss)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,717</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,362</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,866</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,660</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Basic net income (loss) per common share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Diluted net income (loss) per common share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Basic weighted average number of common shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19,254,567</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,337,513</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,106,584</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22,237,823</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Diluted weighted average number of common shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19,254,567</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,337,513</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">401,152,574</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22,237,823</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pro forma basic net income (loss) per common share (1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.02</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.01</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pro forma diluted net income (loss) per common share (1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.02</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.01</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pro forma basic weighted average number of common shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">338,665,060</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">340,565,370</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pro forma diluted weighted average number of common shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">403,144,899</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">340,565,370</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">9 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:111pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Six&nbsp;Months&nbsp;Ended&nbsp;June 30,&nbsp;2013</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:22pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Actual</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Pro</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:32pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Forma(2)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:48pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Pro&nbsp;Forma&nbsp;As<BR>Adjusted(3)</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(unaudited) </B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in&nbsp;thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Consolidated Balance Sheet Data:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">33,781</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42,183</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37,308</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Convertible preferred stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,947</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total stockholders&#146; equity (deficit)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(10,930</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The pro forma basic and diluted net income (loss) per share reflects the issuance of common stock upon the automatic conversion of all outstanding shares of our
preferred stock upon the closing of this offering, assuming all such shares of preferred stock had been converted to common stock for all periods in which such shares of preferred stock were outstanding. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pro forma consolidated balance sheet data give effect to the automatic conversion of all outstanding shares of preferred stock into an aggregate of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock upon the closing of this offering. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pro forma as adjusted consolidated balance sheet data give additional effect to the issuance of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares of common stock at an initial offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the estimated price range set forth on the cover page of this prospectus, after deducting the
estimated underwriting discounts and commissions and estimated offering expenses payable by us. A $1.00 increase or decrease in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
per share, the midpoint of the estimated price range set forth on the cover page of this prospectus, would increase or decrease total stockholders&#146; equity (deficit) and total capitalization on a pro forma as adjusted basis by approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, assuming that the number of shares offered, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts
and commissions and estimated offering expenses payable by us. </FONT></TD></TR></TABLE>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom575431_2"></A>RISK FACTORS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Investing in our common stock involves a high degree of risk. You should consider carefully the following risk factors, as well as the
other information in this prospectus, before you decide to purchase our common stock. If any of the following risks actually occur, our business, financial condition or results of operations could be materially adversely affected, the value of our
common stock could decline and you may lose all or part of your investment.</I> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to Our Business and the Development and
Commercialization of Our Product Candidates. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>All of our product candidates are in pre-clinical or clinical development. Clinical
drug development is expensive, time consuming and uncertain and we may ultimately not be able to obtain regulatory approvals for the commercialization of some or all of our product candidates. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The research, testing, manufacturing, labeling, approval, selling, marketing and distribution of drug products are subject to extensive
regulation by the U.S. Food and Drug Administration, or FDA, and non-U.S. regulatory authorities, which regulations differ from country to country. We are not permitted to market our product candidates in the United States or in other countries
until we receive approval of a Biologics License Application, or BLA, from the FDA or marketing approval from applicable regulatory authorities outside the United States. Our product candidates are in various stages of development and are subject to
the risks of failure inherent in drug development. We have not submitted an application for or received marketing approval for any of our product candidates. We have limited experience in conducting and managing the clinical trials necessary to
obtain regulatory approvals, including approval by the FDA. Obtaining approval of a BLA can be a lengthy, expensive and uncertain process. In addition, failure to comply with FDA and non-U.S. regulatory requirements may, either before or after
product approval, if any, subject our company to administrative or judicially imposed sanctions, including: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">restrictions on the products, manufacturers or manufacturing process; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">warning letters; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">civil and criminal penalties; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">injunctions; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">suspension or withdrawal of regulatory approvals; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">product seizures, detentions or import bans; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">voluntary or mandatory product recalls and publicity requirements; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">total or partial suspension of production; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">imposition of restrictions on operations, including costly new manufacturing requirements; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">refusal to approve pending BLAs or supplements to approved BLAs. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The FDA and foreign regulatory authorities also have substantial discretion in the drug approval process. The number of pre-clinical
studies and clinical trials that will be required for regulatory approval varies </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
depending on the product candidate, the disease or condition that the product candidate is designed to address, and the regulations applicable to any particular drug candidate. Regulatory
agencies can delay, limit or deny approval of a product candidate for many reasons, including: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a product candidate may not be deemed safe or effective; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the results may not confirm the positive results from earlier pre-clinical studies or clinical trials; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">regulatory agencies may not find the data from pre-clinical studies and clinical trials sufficient; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">regulatory agencies might not approve or might require changes to our manufacturing processes or facilities; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">regulatory agencies may change their approval policies or adopt new regulations. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any delay in obtaining or failure to obtain required approvals could materially adversely affect our ability to generate revenue from the
particular product candidate, which likely would result in significant harm to our financial position and adversely impact our stock price. Furthermore, any regulatory approval to market a product may be subject to limitations on the indicated uses
for which we may market the product. These limitations may limit the size of the market for the product. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If clinical trials for our
product candidates are prolonged, delayed or stopped, we may be unable to obtain regulatory approval and commercialize our product candidates on a timely basis, which would require us to incur additional costs and delay our receipt of any product
revenue. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are currently enrolling a Phase 2a clinical trial of margetuximab in patients with metastatic breast
cancer and anticipate commencing a Phase 3 potential registration clinical trial of margetuximab in advanced gastroesophageal cancer in the second half of 2014. We have initiated a Phase 1 clinical trial of MGA271 that we expect to complete by the
end of 2014. We expect to commence a Phase 1 clinical trial of MGD006 in the first half of 2014 and expect to commence a Phase 1 clinical trial of MGD007 in the second half of 2014. The commencement of these planned clinical trials could be
substantially delayed or prevented by several factors, including: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">further discussions with the FDA or other regulatory agencies regarding the scope or design of our clinical trials; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the limited number of, and competition for, suitable sites to conduct our clinical trials, many of which may already be engaged in other clinical trial
programs, including some that may be for the same indication as our product candidates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any delay or failure to obtain regulatory approval or agreement to commence a clinical trial in any of the countries where enrollment is planned;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">inability to obtain sufficient funds required for a clinical trial; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">clinical holds on, or other regulatory objections to, a new or ongoing clinical trial; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">delay or failure to manufacture sufficient supplies of the product candidate for our clinical trials; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">delay or failure to reach agreement on acceptable clinical trial agreement terms or clinical trial protocols with prospective sites or clinical
research organizations, or CROs, the terms of which can be subject to extensive negotiation and may vary significantly among different sites or CROs; and </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">delay or failure to obtain institutional review board, or IRB, approval to conduct a clinical trial at a prospective site.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The completion of our clinical trials could also be substantially delayed or prevented by several factors,
including: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">slower than expected rates of patient recruitment and enrollment; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">failure of patients to complete the clinical trial; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">unforeseen safety issues, including severe or unexpected drug-related adverse effects experienced by patients, including possible deaths;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">lack of efficacy during clinical trials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">termination of our clinical trials by one or more clinical trial sites; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">inability or unwillingness of patients or clinical investigators to follow our clinical trial protocols; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">inability to monitor patients adequately during or after treatment by us and/or our CROs; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the need to repeat or terminate clinical trials as a result of inconclusive or negative results or unforeseen complications in testing.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Changes in regulatory requirements and guidance may also occur and we may need to significantly amend
clinical trial protocols to reflect these changes with appropriate regulatory authorities. Amendments may require us to renegotiate terms with CROs or resubmit clinical trial protocols to IRBs for re-examination, which may impact the costs, timing
or successful completion of a clinical trial. Our clinical trials may be suspended or terminated at any time by the FDA, other regulatory authorities, the IRB overseeing the clinical trial at issue, any of our clinical trial sites with respect to
that site, or us, due to a number of factors, including: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">unforeseen safety issues or any determination that a clinical trial presents unacceptable health risks; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">lack of adequate funding to continue the clinical trial due to unforeseen costs or other business decisions; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">upon a breach or pursuant to the terms of any agreement with, or for any other reason by, current or future collaborators that have responsibility for
the clinical development of any of our product candidates. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any failure or significant delay in completing
clinical trials for our product candidates would adversely affect our ability to obtain regulatory approval and our commercial prospects and ability to generate product revenue will be diminished. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>The results of previous clinical trials may not be predictive of future results, and the results of our current and planned clinical trials may not
satisfy the requirements of the FDA or non-U.S. regulatory authorities. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We currently have no products approved for
sale and we cannot guarantee that we will ever have marketable products. Clinical failure can occur at any stage of clinical development. Clinical trials may produce </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">13 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
negative or inconclusive results, and we or any of our current and future collaborators may decide, or regulators may require us, to conduct additional clinical or pre-clinical testing. We will
be required to demonstrate with substantial evidence through well-controlled clinical trials that our product candidates are safe and effective for use in a diverse population before we can seek regulatory approvals for their commercial sale.
Success in early clinical trials does not mean that future larger registration clinical trials will be successful because product candidates in later-stage clinical trials may fail to demonstrate sufficient safety and efficacy to the satisfaction of
the FDA and non-U.S. regulatory authorities despite having progressed through initial clinical trials. Product candidates that have shown promising results in early clinical trials may still suffer significant setbacks in subsequent registration
clinical trials. Similarly, the outcome of pre-clinical testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. A number of
companies in the pharmaceutical industry, including those with greater resources and experience than us, have suffered significant setbacks in advanced clinical trials, even after obtaining promising results in earlier clinical trials. For example,
although early stage trials of our product candidate teplizumab were promising, it did not meet its primary efficacy endpoint in a Phase 3 clinical trial and our collaboration with Eli Lilly &amp; Co., or Eli Lilly, was subsequently terminated.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, the design of a clinical trial can determine whether its results will support approval of a product and flaws in
the design of a clinical trial may not become apparent until the clinical trial is well advanced. We may be unable to design and execute a clinical trial to support regulatory approval. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In some instances, there can be significant variability in safety and/or efficacy results between different trials of the same product
candidate due to numerous factors, including changes in trial protocols, differences in size and type of the patient populations, adherence to the dosing regimen and other trial protocols and the rate of dropout among clinical trial participants. We
do not know whether any Phase&nbsp;2, Phase&nbsp;3 or other clinical trials we or any of our collaborators may conduct will demonstrate consistent or adequate efficacy and safety to obtain regulatory approval to market our product candidates.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Further, our product candidates may not be approved even if they achieve their primary endpoints in Phase 3 clinical trials
or registration trials. The FDA or other non-U.S. regulatory authorities may disagree with our trial design and our interpretation of data from pre-clinical studies and clinical trials. In addition, any of these regulatory authorities may change
requirements for the approval of a product candidate even after reviewing and providing comments or advice on a protocol for a pivotal Phase 3 clinical trial that has the potential to result in FDA or other agencies&#146; approval. In addition, any
of these regulatory authorities may also approve a product candidate for fewer or more limited indications than we request or may grant approval contingent on the performance of costly post-marketing clinical trials. The FDA or other non-U.S.
regulatory authorities may not approve the labeling claims that we believe would be necessary or desirable for the successful commercialization of our product candidates. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>We use new technologies in the development of our product candidates and the FDA and other regulatory authorities have not approved products that utilize these technologies. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our products in development are based on new technologies, such as Fc Optimization, bi-specific DARTs and CSLCs. Given the complexity of
our technologies, we intend to work closely with FDA and other regulatory authorities to perform the requisite scientific analyses and evaluation of our methods to obtain regulatory approval for our product candidates. It is possible that the
validation process may take time and resources, require independent third-party analyses or not be accepted by the FDA and other regulatory authorities. For some of our product candidates that are based on these technology platforms, the regulatory
approval path and requirements may not be clear, which could add significant delay and expense. Delays or failure to obtain regulatory approval of any of the products that we develop would adversely affect our business. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">14 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may not be successful in our efforts to use and expand our technology platforms to build a pipeline
of product candidates. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A key element of our strategy is to use and expand our technology platforms to build a
pipeline of product candidates and progress these product candidates through clinical development for the treatment of a variety of different types of diseases. Although our research and development efforts to date have resulted in a pipeline of
product candidates directed at&nbsp;various cancers and autoimmune disorders, we may not be able to develop product candidates that are safe and effective. Even if we are successful in continuing to build our pipeline, the potential product
candidates that we identify may not be suitable for clinical development, including as a result of being shown to have harmful side effects or other characteristics that indicate that they are unlikely to be products that will receive marketing
approval and achieve market acceptance. If we do not continue to successfully develop and begin to commercialize product candidates, we will face difficulty in obtaining product revenues in future periods, which could result in significant harm to
our financial position and adversely affect our stock price. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may expend our limited resources to pursue a particular product
candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Because we have limited financial and managerial resources, we focus on research programs and product candidates that we identify for specific indications. As a result, we may forego or delay pursuit of
opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market
opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target
market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole
development and commercialization rights. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Even if we obtain FDA approval of any of our product candidates, we may never obtain approval
or commercialize our products outside of the United States, which would limit our ability to realize their full market potential. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In order to market any products outside of the United States, we must establish and comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy. Clinical
trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. Approval procedures vary among
countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approvals could result in significant delays, difficulties and costs for us and may require additional
pre-clinical studies or clinical trials which would be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. Satisfying these and
other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. In addition, our failure to obtain regulatory approval in any country may delay or have negative effects on the process for regulatory approval
in other countries. We do not have any product candidates approved for sale in any jurisdiction, including international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with
regulatory requirements in international markets or to obtain and maintain required approvals, our target market will be reduced and our ability to realize the full market potential of our products will be harmed. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">15 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We are seeking fast-track designation of margetuximab and may seek fast track designation for some of
our other product candidates. There is no assurance that the FDA will grant such designation and, even if it does grant fast track designation to margetuximab or one of our other product candidates, that designation may not actually lead to a faster
development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval in the United States. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are seeking fast-track designation of margetuximab and may seek fast track designation and review for some of our other product
candidates. If a drug is intended for the treatment of a serious or life-threatening condition or disease, the drug sponsor may apply for FDA fast track designation. The FDA has broad discretion whether or not to grant this designation, so even if
we believe a particular product candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it. Moreover, even if we do receive fast track designation, we may not experience a faster development process,
review or approval compared to conventional FDA procedures. In addition, the FDA may withdraw fast track designation if it believes that the designation is no longer supported by data from our clinical development program. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may seek breakthrough therapy designation by the FDA for any of our product candidates but that is not assured and may not, in any event, lead
to a faster development or regulatory review or approval process, and it does not increase the likelihood that our product candidates will receive marketing approval in the United States. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may apply for breakthrough therapy designation for some of our product candidates. The FDA is authorized to designate a product
candidate as a breakthrough therapy if it finds that the product is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the
product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For products designated as breakthrough therapies,
interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Products designated as
breakthrough therapies by the FDA are also eligible for accelerated approval. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Designation as a breakthrough therapy is within
the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt
of a breakthrough therapy designation for a product candidate may not result in a faster development process, review or approval compared to product candidates considered for approval under conventional FDA procedures and, in any event, does not
assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that the product candidates no longer meet the conditions for qualification or decide that
the time period for FDA review or approval will not be shortened. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may be unable to obtain orphan product designation or exclusivity
for some or all of our product candidates. If our competitors are able to obtain orphan product exclusivity for their products that are the same as our product candidates, we may not be able to have competing products approved by the applicable
regulatory authority for a significant period of time. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Regulatory authorities in some jurisdictions, including the
United States and Europe, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, FDA may designate a product candidate as an orphan drug if it is a drug intended to treat a rare disease or condition,
which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Generally, if a product candidate with an orphan drug designation subsequently receives the first marketing approval for the indication
for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the EMA or the FDA from approving another marketing application for </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">16 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
the same drug for that time period. The applicable period is seven years in the United States and ten years in Europe. The European exclusivity period can be reduced to six years if a product no
longer meets the criteria for orphan drug designation or if the product is sufficiently profitable so that market exclusivity is no longer justified. Orphan drug exclusivity may be lost if the FDA or EMA determines that the request for designation
was materially defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of patients with the rare disease or condition. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs can be approved for the same condition. In the
United States, even after an orphan drug is approved, the FDA can subsequently approve the same drug for the same condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a
major contribution to patient care. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our product candidates may have undesirable side effects which may delay or prevent marketing
approval, or, if approval is received, require them to be taken off the market, require them to include safety warnings or otherwise limit their sales. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Although all of our product candidates have undergone or will undergo safety testing, not all adverse effects of drugs can be predicted or anticipated. Unforeseen side effects from any of our product
candidates could arise either during clinical development or, if approved by regulatory authorities, after the approved product has been marketed. All of our product candidates are still in clinical or pre-clinical development. While our clinical
trials for our initial product candidates to date have demonstrated a favorable safety profile, the results from future trials may not support this conclusion. The results of future clinical trials may show that our product candidates cause
undesirable or unacceptable side effects, which could interrupt, delay or halt clinical trials, and result in delay of, or failure to obtain, marketing approval from the FDA and other regulatory authorities, or result in marketing approval from the
FDA and other regulatory authorities with restrictive label warnings or potential product liability claims. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If any of our
product candidates receives marketing approval and we or others later identify undesirable or unacceptable side effects caused by such products: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">regulatory authorities may require us to take our approved product off the market; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">regulatory authorities may require the addition of labeling statements, specific warnings, a contraindication or field alerts to physicians and
pharmacies; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may be required to change the way the product is administered, conduct additional clinical trials or change the labeling of the product;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may be subject to limitations on how we may promote the product; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">sales of the product may decrease significantly; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may be subject to litigation or product liability claims; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our reputation may suffer. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Any of these events could prevent us, our collaborators or our potential future partners from achieving or maintaining market acceptance of the affected product or could substantially increase
commercialization costs and expenses, which in turn could delay or prevent us from generating significant revenue from the sale of our products. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">17 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Even if approved, if any of our product candidates do not achieve broad market acceptance among
physicians, patients, the medical community, and third-party payors our revenue generated from their sales will be limited. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The commercial success of our product candidates will depend upon their acceptance among physicians, patients and the medical community. The degree of market acceptance of our product candidates will
depend on a number of factors, including: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">limitations or warnings contained in the approved labeling for a product candidate; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">changes in the standard of care for the targeted indications for any of our product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">limitations in the approved clinical indications for our product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">demonstrated clinical safety and efficacy compared to other products; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">lack of significant adverse side effects; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">sales, marketing and distribution support; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">availability and extent of reimbursement from managed care plans and other third-party payors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">timing of market introduction and perceived effectiveness of competitive products; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the degree of cost-effectiveness of our product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">availability of alternative therapies at similar or lower cost, including generic and over-the-counter products; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the extent to which the product candidate is approved for inclusion on formularies of hospitals and managed care organizations;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">whether the product is designated under physician treatment guidelines as a first-line therapy or as a second- or third-line therapy for particular
diseases; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">adverse publicity about our product candidates or favorable publicity about competitive products; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">convenience and ease of administration of our products; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">potential product liability claims. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If any of our product candidates are approved, but do not achieve an adequate level of acceptance by physicians, patients and the medical community, we may not generate sufficient revenue from these
products, and we may not become or remain profitable. In addition, efforts to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources and may never be successful. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">18 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We are subject to a multitude of manufacturing risks, any of which could substantially increase our
costs and limit supply of our products. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The process of manufacturing our products is complex, highly regulated and
subject to several risks, including: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The process of manufacturing biologics, such as margetuximab, MGA271, and our other product candidates, is extremely susceptible to product loss due to
contamination, equipment failure or improper installation or operation of equipment, vendor or operator error, contamination and inconsistency in yields, variability in product characteristics, and difficulties in scaling the production process.
Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our product candidates or in the
manufacturing facilities in which our product candidates are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The manufacturing facilities in which our product candidates are made could be adversely affected by equipment failures, labor shortages, natural
disasters, power failures and numerous other factors. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We must comply with the FDA&#146;s current Good Manufacturing Practice, or cGMP, regulations and guidelines. We may encounter difficulties in achieving
quality control and quality assurance and may experience shortages in qualified personnel. We are subject to inspections by the FDA and comparable agencies in other jurisdictions to confirm compliance with applicable regulatory requirements. Any
failure to follow cGMP or other regulatory requirements or delay, interruption or other issues that arise in the manufacture, fill-finish, packaging, or storage of our product candidates as a result of a failure of our facilities or the facilities
or operations of third parties to comply with regulatory requirements or pass any regulatory authority inspection could significantly impair our ability to develop and commercialize our product candidates, including leading to significant delays in
the availability of drug product for our clinical trials or the termination or hold on a clinical trial, or the delay or prevention of a filing or approval of marketing applications for our product candidates. Significant noncompliance could also
result in the imposition of sanctions, including fines, injunctions, civil penalties, failure of regulatory authorities to grant marketing approvals for our product candidates, delays, suspension or withdrawal of approvals, license revocation,
seizures or recalls of products, operating restrictions and criminal prosecutions, any of which could damage our reputation. If we are not able to maintain regulatory compliance, we may not be permitted to market our product candidates and/or may be
subject to product recalls, seizures, injunctions, or criminal prosecution. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any adverse developments affecting manufacturing operations for our product candidates, if any are approved, may result in shipment delays, inventory
shortages, lot failures, product withdrawals or recalls, or other interruptions in the supply of our products. We may also have to take inventory write-offs and incur other charges and expenses for products that fail to meet specifications,
undertake costly remediation efforts or seek more costly manufacturing alternatives. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We currently have no marketing,
sales or distribution infrastructure. If we are unable to develop sales, marketing and distribution capabilities on our own or through collaborations, we will not be successful in commercializing our product candidates. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We currently have no marketing, sales and distribution capabilities and we have no sales or marketing experience within our organization.
If any of our product candidates are approved, we intend either to establish a sales and marketing organization with technical expertise and supporting distribution capabilities to commercialize our product candidates, or to outsource this function
to a third party. Either of these options would </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">19 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
be expensive and time consuming. These costs may be incurred in advance of any approval of our product candidates. In addition, we may not be able to hire a sales force in the United States that
is sufficient in size or has adequate expertise in the medical markets that we intend to target. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of
our products. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">With respect to certain of our existing and future product candidates, we have entered into collaboration or
other licensing arrangements with third party collaborators that have direct sales forces and established distribution systems. To the extent that we enter into additional collaboration agreements, our product revenue may be lower than if we
directly marketed or sold any approved products. In addition, any revenue we receive will depend in whole or in part upon the efforts of these third party collaborators, which may not be successful and are generally not within our control. If we are
unable to enter into these arrangements on acceptable terms or at all, we may not be able to successfully commercialize any approved products. If we are not successful in commercializing any approved products, either on our own or through
collaborations with one or more third parties, our future product revenue will suffer and we may incur significant additional losses. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We face significant competition and if our competitors develop and market products that are more effective, safer or less expensive than our
product candidates, our commercial opportunities will be negatively impacted. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The life sciences industry is highly
competitive and subject to rapid and significant technological change. We are currently developing therapeutics that will compete with other drugs and therapies that currently exist or are being developed. Products we may develop in the future are
also likely to face competition from other drugs and therapies, some of which we may not currently be aware. We have competitors both in the United States and internationally, including major multinational pharmaceutical companies, established
biotechnology companies, specialty pharmaceutical companies, universities and other research institutions. Many of our competitors have significantly greater financial, manufacturing, marketing, drug development, technical and human resources than
we do. Large pharmaceutical companies, in particular, have extensive experience in clinical testing, obtaining regulatory approvals, recruiting patients and in manufacturing pharmaceutical products. These companies also have significantly greater
research and marketing capabilities than we do and may also have products that have been approved or are in late stages of development, and collaborative arrangements in our target markets with leading companies and research institutions.
Established pharmaceutical companies may also invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make the product candidates that we develop obsolete. As a result of all of these
factors, our competitors may succeed in obtaining patent protection and/or FDA approval or discovering, developing and commercializing products in our field before we do. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Specifically, there are a large number of companies developing or marketing treatments for cancer and autoimmune disorders, including many major pharmaceutical and biotechnology companies. These
treatments consist both of small molecule drug products, as well as biologic therapeutics that work by using next-generation antibody technology platforms to address specific cancer targets. In addition, several companies are developing therapeutics
that work by targeting multiple specificities using a single recombinant molecule. Amgen, Inc., or Amgen, is in late-stage clinical development of cancer product candidates which work by targeting antigens both on immune effector cell populations
and those expressed on certain cancer cells. In addition, other companies are developing new treatments for cancer and autoimmune diseases that enhance the Fc regions of antibodies to create more potent antibodies, including F. Hoffmann-La Roche
Ltd., or Roche, and Xencor, Inc. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our commercial opportunity could be reduced or eliminated if our competitors develop and
commercialize products that are safer, more effective, have fewer or less severe effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their
products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by
insurers or other third party payors seeking to encourage the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">20 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
use of biosimilar products. Biosimilar products are expected to become available over the coming years. For example, certain HER2 biosimilar products may be approved prior to margetuximab. Even
if our product candidates achieve marketing approval, they may be priced at a significant premium over competitive biosimilar products if any have been approved by then. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Patient Protection and Affordable Care Act, as amended by the Healthcare and Education Affordability Reconciliation Act, or collectively, ACA created a new regulatory scheme authorizing the FDA to
approve biosimilars. Under the ACA, a manufacturer may submit an application for licensure of a biologic product that is &#147;biosimilar to&#148; or &#147;interchangeable with&#148; a previously approved biological product or &#147;reference
product.&#148; Under this new statutory scheme, an application for a biosimilar product may not be submitted to the FDA until four years following approval of the reference product. The FDA may not approve a biosimilar product until 12 years from
the date on which the reference product was approved. Even if a product is considered to be a reference product eligible for exclusivity, another company could market a competing version of that product if the FDA approves a full BLA for such
product containing the sponsor&#146;s own pre-clinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. Furthermore, recent legislation has proposed that the 12 year
exclusivity period for each a reference product may be reduced to seven years. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Smaller and other early stage companies may
also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel,
establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. In addition, the biopharmaceutical industry is characterized by rapid
technological change. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Technological advances or products developed by our competitors may render our technologies or product candidates obsolete,
less competitive or not economical. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Reimbursement decisions by third-party payors may have an adverse effect on pricing and market
acceptance. If there is not sufficient reimbursement for our products, it is less likely that our products will be widely used. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Even if our product candidates are approved for sale by the appropriate regulatory authorities, market acceptance and sales of these products will depend on reimbursement policies and may be affected by
future healthcare reform measures. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which drugs they will reimburse and establish payment levels. We cannot be certain that
reimbursement will be available for any products that we develop. Also, we cannot be certain that reimbursement policies will not reduce the demand for, or the price paid for, our products. If reimbursement is not available or is available on a
limited basis, we may not be able to successfully commercialize any of our approved products. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the United States, the
Medicare Prescription Drug, Improvement, and Modernization Act of 2003, also called the Medicare Modernization Act, or MMA, changed the way Medicare covers and pays for pharmaceutical products. The legislation established Medicare Part D, which
expanded Medicare coverage for outpatient prescription drug purchases by the elderly but provided authority for limiting the number of drugs that will be covered in any therapeutic class. The MMA also introduced a new reimbursement methodology based
on average sales prices for physician-administered drugs. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The United States and several foreign jurisdictions are
considering, or have already enacted, a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell any of our future approved products profitably. Among policy makers and payors in
the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access to healthcare. In the United States, the
pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">21 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
legislative initiatives. We expect to experience pricing pressures in connection with the sale of any products that we develop, due to the trend toward managed healthcare, the increasing
influence of health maintenance organizations and additional legislative proposals. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In March 2010, the ACA became law in the
United States. The goal of ACA is to reduce the cost of health care and substantially change the way health care is financed by both governmental and private insurers. While we cannot predict what impact on federal reimbursement policies this
legislation will have in general or on our business specifically, the ACA may result in downward pressure on pharmaceutical reimbursement, which could negatively affect market acceptance of, and the price we may charge for, any products we develop
that receive regulatory approval. We also cannot predict the impact of ACA on our business or financial condition as many of the ACA reforms require the promulgation of detailed regulations implementing the statutory provisions, which has not yet
occurred. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If any product liability lawsuits are successfully brought against us or any of our collaborators, we may incur substantial
liabilities and may be required to limit commercialization of our product candidates. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We face an inherent risk of
product liability lawsuits related to the testing of our product candidates in seriously ill patients, and will face an even greater risk if product candidates are approved by regulatory authorities and introduced commercially. Product liability
claims may be brought against us or our collaborators by participants enrolled in our clinical trials, patients, health care providers or others using, administering or selling any of our future approved products. If we cannot successfully defend
ourselves against any such claims, we may incur substantial liabilities. Regardless of their merit or eventual outcome, liability claims may result in: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">decreased demand for our future approved products; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">injury to our reputation; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">withdrawal of clinical trial participants; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">termination of clinical trial sites or entire trial programs; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">increased regulatory scrutiny; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">significant litigation costs; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">substantial monetary awards to or costly settlement with patients or other claimants; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">product recalls or a change in the indications for which they may be used; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">loss of revenue; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">diversion of management and scientific resources from our business operations; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the inability to commercialize our product candidates. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If any of our product candidates are approved for commercial sale, we will be highly dependent upon consumer perceptions of us and the safety and quality of our products. We could be adversely affected if
we are subject to negative publicity. We could also be adversely affected if any of our products or any similar products distributed by other companies prove to be, or are asserted to be, harmful to patients. Because of our dependence upon consumer
perceptions, any adverse publicity associated with illness or other adverse effects resulting from patients&#146; use or misuse of our products or any similar products distributed by other companies could have a material adverse impact on our
financial condition or results of operations. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">22 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We currently hold $15 million in product liability insurance coverage in the aggregate, with
a per incident limit of $15 million, which may not be adequate to cover all liabilities that we may incur. We may need to increase our insurance coverage when we begin the commercialization of our product candidates. Insurance coverage is becoming
increasingly expensive. As a result, we may be unable to maintain or obtain sufficient insurance at a reasonable cost to protect us against losses that could have a material adverse effect on our business. A successful product liability claim or
series of claims brought against us, particularly if judgments exceed any insurance coverage we may have, could decrease our cash resources and adversely affect our business, financial condition and results of operation. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our business may become subject to economic, political, regulatory and other risks associated with international operations. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our business is subject to risks associated with conducting business internationally. Some of our suppliers and collaborative and
clinical trial relationships are located outside the United States. Accordingly, our future results could be harmed by a variety of factors, including: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">economic weakness, including inflation, or political instability in particular foreign economies and markets; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">differing regulatory requirements for drug approvals in foreign countries; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">potentially reduced protection for intellectual property rights; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">difficulties in compliance with non-U.S. laws and regulations; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">changes in non-U.S. regulations and customs, tariffs and trade barriers; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">changes in non-U.S. currency exchange rates and currency controls; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">changes in a specific country&#146;s or region&#146;s political or economic environment; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">trade protection measures, import or export licensing requirements or other restrictive actions by U.S. or non-U.S. governments;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">negative consequences from changes in tax laws; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">workforce uncertainty in countries where labor unrest is more common than in the United States; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">difficulties associated with staffing and managing foreign operations, including differing labor relations; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">business interruptions resulting from geo-political actions, including war and terrorism, or natural disasters including earthquakes, typhoons, floods
and fires. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">23 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to Our Financial Position and Need for Additional Capital </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We have incurred significant losses since inception and anticipate that we will continue to incur losses for the foreseeable future. We have no
products approved for commercial sale, and to date we have not generated any revenue or profit from product sales. We may never achieve or sustain profitability. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We are a clinical-stage biopharmaceutical company. We have incurred significant losses since our inception. As of June&nbsp;30, 2013, our accumulated deficit was approximately $179.1&nbsp;million. We
expect to continue to incur losses for the foreseeable future, and we expect these losses to increase as we continue our research and development of, and seek regulatory approvals for, our product candidates, prepare for and begin to commercialize
any approved products, and add infrastructure and personnel to support our product development efforts and operations as a public company. The net losses and negative cash flows incurred to date, together with expected future losses, have had, and
likely will continue to have, an adverse effect on our stockholders&#146; deficit and working capital. The amount of future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to
accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. For example, our expenses could increase if we are required by the FDA, to perform trials in addition to those that we currently
expect to perform, or if there are any delays in completing our currently planned clinical trials or in the development of any of our product candidates. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">To become and remain profitable, we must succeed in developing and commercializing products with significant market potential. This will require us to be successful in a range of challenging activities
for which we are only in the preliminary stages, including developing product candidates, obtaining regulatory approval for them, and manufacturing, marketing and selling those products for which we may obtain regulatory approval. We may never
succeed in these activities and may never generate revenue from product sales that is significant enough to achieve profitability. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Our
failure to become or remain profitable would depress our market value and could impair our ability to raise capital, expand our business, develop other product candidates, or continue our operations. A decline in the value of our company could also
cause you to lose all or part of your investment. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We will require substantial additional funding, which may not be available to us on
acceptable terms, or at all, and, if not available, may require us to delay, scale back, or cease our product development programs or operations. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We are advancing our product candidates through clinical development. Developing pharmaceutical products, including conducting pre-clinical studies and clinical trials, is expensive. In order to obtain
such regulatory approval, we will be required to conduct clinical trials for each indication for each of our product candidates. We will continue to require additional funding beyond this contemplated offering to complete the development and
commercialization of our product candidates and to continue to advance the development of our other product candidates, and such funding may not be available on acceptable terms or at all. Although it is difficult to predict our liquidity
requirements, based upon our current operating plan, we anticipate that the net proceeds from this offering, together with our existing cash and cash equivalents, will enable us to fund our operating expenses and capital expenditure requirements for
at least the next 18 months. Because successful development of our product candidates is uncertain, we are unable to estimate the actual funds we will require to complete research and development and to commercialize our product candidates.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our future funding requirements will depend on many factors, including but not limited to: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the number and characteristics of other product candidates that we pursue; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">24 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the scope, progress, timing, cost and results of research, pre-clinical development, and clinical trials; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the costs, timing and outcome of seeking and obtaining FDA and non-U.S. regulatory approvals; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the costs associated with manufacturing our product candidates and establishing sales, marketing, and distribution capabilities;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to maintain, expand, and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be
required to make in connection with the licensing, filing, defense and enforcement of any patents or other intellectual property rights; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our need and ability to hire additional management, scientific, and medical personnel; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the effect of competing products that may limit market penetration of our product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our need to implement additional internal systems and infrastructure, including financial and reporting systems; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the economic and other terms, timing of and success of our existing collaborations, and any collaboration, licensing, or other arrangements into which
we may enter in the future, including the timing of receipt of any milestone or royalty payments under these agreements. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Until we can generate a sufficient amount of product revenue to finance our cash requirements, which we may never do, we expect to finance future cash needs primarily through a combination of public or
private equity offerings, debt financings, strategic collaborations, and grant funding. If sufficient funds on acceptable terms are not available when needed, or at all, we could be forced to significantly reduce operating expenses and delay, scale
back or eliminate one or more of our development programs or our business operations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Raising additional capital may cause dilution to
our stockholders, including purchasers of common stock in this offering, restrict our operations or require us to relinquish substantial rights. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these new securities may include
liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing, if available at all, may involve agreements that include covenants limiting or restricting our ability to take specific actions such as
incurring additional debt, making capital expenditures, or declaring dividends. If we raise additional funds through collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our
technologies, product candidates, or future revenue streams, or grant licenses on terms that are not favorable to us. We cannot assure you that we will be able to obtain additional funding if and when necessary. If we are unable to obtain adequate
financing on a timely basis, we could be required to delay, scale back or eliminate one or more of our development programs or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">25 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to Our Dependence on Third Parties </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our existing therapeutic collaborations are important to our business, and future collaborations may also be important to us. If we are unable to
maintain any of these collaborations, or if these collaborations are not successful, our business could be adversely affected. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have limited capabilities for drug development and do not yet have any capability for sales, marketing or distribution. Accordingly, we have entered into collaborations with other companies that we
believe can provide such capabilities, including our collaboration and license agreements with Servier, Gilead, Boehringer, Pfizer and Green Cross Corp., or Green Cross. These collaborations also have provided us with important funding for our
development programs and technology platforms and we expect to receive additional funding under these collaborations in the future. Our existing therapeutic collaborations, and any future collaborations we enter into, may pose a number of risks,
including the following: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">collaborators may not perform their obligations as expected; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">collaborators may not pursue development and commercialization of any product candidates that achieve regulatory approval or may elect not to continue
or renew development or commercialization programs based on clinical trial results, changes in the collaborators&#146; strategic focus or available funding, or external factors, such as an acquisition, that divert resources or create competing
priorities; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product
candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product
candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or products,
which may cause collaborators to cease to devote resources to the commercialization of our product candidates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit
sufficient resources to the marketing and distribution of such product or products; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development,
might cause delays or termination of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of
which would be time-consuming and expensive; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite
litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; and
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">26 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">collaborations may be terminated for the convenience of the collaborator and, if terminated, we could be required to raise additional capital to pursue
further development or commercialization of the applicable product candidates. For example, each of our collaboration and license agreements with Servier, Gilead, and Boehringer may be terminated for convenience upon the completion of a specified
notice period. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If our therapeutic collaborations do not result in the successful development and
commercialization of products or if one of our collaborators terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under the collaboration. If we do not receive the funding we expect under
these agreements, our development of our technology platforms and product candidates could be delayed and we may need additional resources to develop product candidates and our technology platforms. All of the risks relating to product development,
regulatory approval and commercialization described in this prospectus also apply to the activities of our program collaborators. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Additionally, subject to its contractual obligations to us, if one of our collaborators is involved in a business combination, the collaborator might deemphasize or terminate the development or
commercialization of any product candidate licensed to it by us. If one of our collaborators terminates its agreement with us, we may find it more difficult to attract new collaborators. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For some of our product candidates, we may in the future determine to collaborate with additional pharmaceutical and biotechnology
companies for development and potential commercialization of therapeutic products. We face significant competition in seeking appropriate collaborators. Our ability to reach a definitive agreement for a collaboration will depend, among other things,
upon our assessment of the collaborator&#146;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#146;s evaluation of a number of factors. These factors may include the design or results of
clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product
candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and
industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive
than the one with us for our product candidate. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Collaborations are complex and time-consuming to negotiate and document. In
addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. If we are unable to reach agreements with suitable
collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail the development of a product candidate, reduce or delay one or more of our other development programs, delay its potential commercialization or reduce the scope
of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to
obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and
commercialization activities, we may not be able to further develop our product candidates or bring them to market or continue to develop our technology platforms and our business may be materially and adversely affected. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may also be restricted under existing collaboration agreements from entering into future agreements on certain terms with potential
collaborators. Aside from our agreement with Green Cross, subject to certain specified exceptions, each of our existing therapeutic collaborations contains a restriction on our engaging in activities that are the subject of the collaboration with
third parties for specified periods of time. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">27 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Independent clinical investigators and CROs that we engage to conduct our clinical trials may not
devote sufficient time or attention to our clinical trials or be able to repeat their past success. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We expect to
continue to depend on independent clinical investigators and CROs to conduct our clinical trials. CROs may also assist us in the collection and analysis of data. There is a limited number of third-party service providers that specialize or have the
expertise required to achieve our business objectives. Identifying, qualifying and managing performance of third-party service providers can be difficult, time consuming and cause delays in our development programs. These investigators and CROs will
not be our employees and we will not be able to control, other than by contract, the amount of resources, including time, which they devote to our product candidates and clinical trials. If independent investigators or CROs fail to devote sufficient
resources to the development of our product candidates, or if their performance is substandard, it may delay or compromise the prospects for approval and commercialization of any product candidates that we develop. In addition, the use of
third-party service providers requires us to disclose our proprietary information to these parties, which could increase the risk that this information will be misappropriated. Further, the FDA requires that we comply with standards, commonly
referred to as current Good Clinical Practice, or cGCP, for conducting, recording and reporting clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial subjects
are protected. Failure of clinical investigators or CROs to meet their obligations to us or comply with cGCP procedures could adversely affect the clinical development of our product candidates and harm our business. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Failure of our third party contractors to successfully develop and commercialize companion diagnostics for use with our product candidates could
harm our ability to commercialize our product candidates. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We plan to develop companion diagnostics for our product
candidates. Companion diagnostics are used to identify patients who could potentially benefit from our therapeutic product candidates. We expect that, at least in some cases, the FDA and similar regulatory authorities outside the United States may
require the development and regulatory approval of a companion diagnostic as a condition to approving our product candidates. We do not have experience or capabilities in developing or commercializing diagnostics and plan to rely in large part on
third parties to perform these functions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We plan to outsource the development, production and commercialization of companion
diagnostics to third parties. By outsourcing these companion diagnostics to third parties, we become dependent on the efforts of our third party contractors to successfully develop and commercialize these companion diagnostics. Our contractors:
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">may not perform their obligations as expected; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">may encounter production difficulties that could constrain the supply of the companion diagnostic; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">may have difficulties gaining acceptance of the use of the companion diagnostic in the clinical community; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">may not commit sufficient resources to the marketing and distribution of such product; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">may terminate their relationship with us. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If any companion diagnostic for use with one of our product candidates fails to gain market acceptance, our ability to derive revenues from sales of such product candidate could be harmed. If our third
party contractors fail to commercialize such companion diagnostic, we may not be able to enter into arrangements with another diagnostic company to obtain supplies of an alternative diagnostic test for use in connection with such product candidate
or do so on commercially reasonable terms, which could adversely affect and delay the development or commercialization of such product candidate. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">28 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We expect to contract with third parties for the manufacture of our product candidates for clinical
testing in the future and expect to continue to do so for commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable
cost, which could delay, prevent or impair our development or commercialization efforts. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We currently have a
manufacturing facility located in Rockville, Maryland. We manufacture drug substance at this facility that we use for research and development purposes and for clinical trials of our product candidates. We currently have capacity to produce Phase 2
material for our antibody product candidates and all clinical and commercial material for our DART therapeutics, but our current facility will be insufficient to support our needs for our Phase 3 clinical trials for our antibody product candidates
and for commercial quantities of such candidates. We do not have experience in manufacturing products at commercial scale. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We
anticipate engagement of contract manufacturing organizations in 2014 to supplement our clinical supply and internal capacity as we advance pre-clinical product candidates into clinical development. We expect to use third parties for the manufacture
of certain of our product candidates for clinical testing, as well as for commercial manufacture of some of our product candidates that receive marketing approval and that are not manufactured by one of our third party collaborators. We plan
eventually to enter into long term supply agreements with several manufacturers for commercial supplies. We may be unable to reach agreement with any of these contract manufacturers, or to identify and reach arrangements on satisfactory terms with
other contract manufacturers, to manufacture any of our product candidates. Additionally, the facilities used by any contract manufacturer to manufacture any of our product candidates must be the subject of a satisfactory inspection before the FDA
and other regulatory authorities approve a BLA or marketing authorization for the product candidate manufactured at that facility. We will depend on these third-party manufacturing partners for compliance with the FDA&#146;s requirements for the
manufacture of our finished products. If our manufacturers cannot successfully manufacture material that conforms to our specifications and the FDA and other regulatory authorities&#146; cGMP requirements, our product candidates will not be approved
or, if already approved, may be subject to recalls. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reliance on third-party manufacturers entails risks to which we would not
be subject if we manufactured the product candidates ourselves, including: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the possibility of a breach of the manufacturing agreements by the third parties because of factors beyond our control; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the possibility of termination or nonrenewal of the agreements by the third parties before we are able to arrange for a qualified replacement
third-party manufacturer; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the possibility that we may not be able to secure a manufacturer or manufacturing capacity in a timely manner and on satisfactory terms in order to
meet our manufacturing needs. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any of these factors could cause the delay of approval or commercialization
of our product candidates, cause us to incur higher costs or prevent us from commercializing our product candidates successfully. Furthermore, if any of our product candidates are approved and contract manufacturers fail to deliver the required
commercial quantities of finished product on a timely basis and at commercially reasonable prices, and we are unable to find one or more replacement manufacturers capable of production at a substantially equivalent cost, in substantially equivalent
volumes and quality and on a timely basis, we would likely be unable to meet demand for our products and could lose potential revenue. It may take several years to establish an alternative source of supply for our product candidates and to have any
such new source approved by the FDA or any other relevant regulatory authorities. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">29 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to Our Intellectual Property </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>If we are unable to obtain and enforce patent protection for our product candidates and related technology, our business could be materially harmed. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Issued patents may be challenged, narrowed, invalidated or circumvented. In addition, court decisions may introduce uncertainty in the
enforceability or scope of patents owned by biotechnology companies. The legal systems of certain countries do not favor the aggressive enforcement of patents, and the laws of foreign countries may not allow us to protect our inventions with patents
to the same extent as the laws of the United States. Because patent applications in the United States and many foreign jurisdictions are typically not published until 18 months after filing, or in some cases not at all, and because publications of
discoveries in scientific literature lag behind actual discoveries, we cannot be certain that we were the first to make the inventions claimed in our issued patents or pending patent applications, or that we were the first to file for protection of
the inventions set forth in our patents or patent applications. As a result, we may not be able to obtain or maintain protection for certain inventions. Therefore, the enforceability and scope of our patents in the United States and in foreign
countries cannot be predicted with certainty and, as a result, any patents that we own or license may not provide sufficient protection against competitors. We may not be able to obtain or maintain patent protection from our pending patent
applications, from those we may file in the future, or from those we may license from third parties. Moreover, even if we are able to obtain patent protection, such patent protection may be of insufficient scope to achieve our business objectives.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our strategy depends on our ability to identify and seek patent protection for our discoveries. This process is expensive and
time consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner or in all jurisdictions where protection may be commercially advantageous. Despite our efforts to
protect our proprietary rights, unauthorized parties may be able to obtain and use information that we regard as proprietary. The issuance of a patent does not ensure that it is valid or enforceable, so even if we obtain patents, they may not be
valid or enforceable against third parties. In addition, the issuance of a patent does not give us the right to practice the patented invention. Third parties may have blocking patents that could prevent us from marketing our own patented product
and practicing our own patented technology. Third parties may also seek to market biosimilar versions of any approved products. Alternatively, third parties may seek approval to market their own products similar to or otherwise competitive with our
products. In these circumstances, we may need to defend and/or assert our patents, including by filing lawsuits alleging patent infringement. In any of these types of proceedings, a court or agency with jurisdiction may find our patents invalid
and/or unenforceable. Even if we have valid and enforceable patents, these patents still may not provide protection against competing products or processes sufficient to achieve our business objectives. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The patent position of pharmaceutical or biotechnology companies, including ours, is generally uncertain and involves complex legal and
factual considerations. The standards which the United States Patent and Trademark Office and its foreign counterparts use to grant patents are not always applied predictably or uniformly and can change. There is also no uniform, worldwide policy
regarding the subject matter and scope of claims granted or allowable in pharmaceutical or biotechnology patents. The laws of some foreign countries do not protect proprietary information to the same extent as the laws of the United States, and many
companies have encountered significant problems and costs in protecting their proprietary information in these foreign countries. Outside the United States, patent protection must be sought in individual jurisdictions, further adding to the cost and
uncertainty of obtaining adequate patent protection outside of the United States. Accordingly, we cannot predict whether additional patents protecting our technology will issue in the United States or in foreign jurisdictions, or whether any patents
that do issue will have claims of adequate scope to provide competitive advantage. Moreover, we cannot predict whether third parties will be able to successfully obtain claims or the breadth of such claims. The allowance of broader claims may
increase the incidence and cost of patent interference proceedings, opposition proceedings, and/or reexamination proceedings, the risk of infringement litigation, and the vulnerability of the claims to challenge. On the other hand, the allowance of
narrower claims </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">30 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
does not eliminate the potential for adversarial proceedings, and may fail to provide a competitive advantage. Our issued patents may not contain claims sufficiently broad to protect us against
third parties with similar technologies or products, or provide us with any competitive advantage. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may become involved in lawsuits
to protect or enforce our patents, which could be expensive, time consuming and unsuccessful. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Even after they have
issued, our patents and any patents which we license may be challenged, narrowed, invalidated or circumvented. If our patents are invalidated or otherwise limited or will expire prior to the commercialization of our product candidates, other
companies may be better able to develop products that compete with ours, which could adversely affect our competitive business position, business prospects and financial condition. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following are examples of litigation and other adversarial proceedings or disputes that we could become a party to involving our
patents or patents licensed to us: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we or our collaborators may initiate litigation or other proceedings against third parties to enforce our patent rights; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">third parties may initiate litigation or other proceedings seeking to invalidate patents owned by or licensed to us or to obtain a declaratory judgment
that their product or technology does not infringe our patents or patents licensed to us; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">third parties may initiate opposition or reexamination proceedings challenging the validity or scope of our patent rights, requiring us or our
collaborators and/or licensors to participate in such proceedings to defend the validity and scope of our patents; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">there may be a challenge or dispute regarding inventorship or ownership of patents currently identified as being owned by or licensed to us;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the U.S. Patent&nbsp;and Trademark Office may initiate an interference between patents or patent applications owned by or licensed to us and those of
our competitors, requiring us or our collaborators and/or licensors to participate in an interference proceeding to determine the priority of invention, which could jeopardize our patent rights; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">third parties may seek approval to market biosimilar versions of our future approved products prior to expiration of relevant patents owned by or
licensed to us, requiring us to defend our patents, including by filing lawsuits alleging patent infringement. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">These lawsuits and proceedings would be costly and could affect our results of operations and divert the attention of our managerial and scientific personnel. There is a risk that a court or
administrative body would decide that our patents are invalid or not infringed by a third party&#146;s activities, or that the scope of certain issued claims must be further limited. An adverse outcome in a litigation or proceeding involving our own
patents could limit our ability to assert our patents against these or other competitors, affect our ability to receive royalties or other licensing consideration from our licensees, and may curtail or preclude our ability to exclude third parties
from making, using and selling similar or competitive products. Any of these occurrences could adversely affect our competitive business position, business prospects and financial condition. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">31 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The degree of future protection for our proprietary rights is uncertain because legal means
afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">others may be able to develop a platform that is similar to, or better than, ours in a way that is not covered by the claims of our patents;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">others may be able to make compounds that are similar to our product candidates but that are not covered by the claims of our patents;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we might not have been the first to make the inventions covered by patents or pending patent applications; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we might not have been the first to file patent applications for these inventions; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any patents that we obtain may not provide us with any competitive advantages or may ultimately be found invalid or unenforceable; or
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may not develop additional proprietary technologies that are patentable. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of third parties. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our success will depend in part on our ability to operate without infringing the proprietary rights of third parties. Other entities may
have or obtain patents or proprietary rights that could limit our ability to make, use, sell, offer for sale or import our future approved products or impair our competitive position. For example, certain patents held by third parties cover Fc
engineering methods and mutations in Fc regions to enhance the binding of Fc regions to Fc receptors on immune cells. Although we believe that these patents are invalid, if they cover margetuximab or MGA271 and we are unable to invalidate their
patents, or if licenses for them are not available on commercially reasonable terms, our business could be harmed, perhaps materially. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Patents that we may ultimately be found to infringe could be issued to third parties. Third parties may have or obtain valid and enforceable patents or proprietary rights that could block us from
developing product candidates using our technology. Our failure to obtain a license to any technology that we require may materially harm our business, financial condition and results of operations. Moreover, our failure to maintain a license to any
technology that we require may also materially harm our business, financial condition, and results of operations. Furthermore, we would be exposed to a threat of litigation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In the pharmaceutical industry, significant litigation and other proceedings regarding patents, patent applications, trademarks and other intellectual property rights have become commonplace. The types of
situations in which we may become a party to such litigation or proceedings include: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we or our collaborators may initiate litigation or other proceedings against third parties seeking to invalidate the patents held by those third
parties or to obtain a judgment that our products or processes do not infringe those third parties&#146; patents; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">if our competitors file patent applications that claim technology also claimed by us or our licensors, we or our licensors may be required to
participate in interference or opposition proceedings to determine the priority of invention, which could jeopardize our patent rights and potentially provide a third party with a dominant patent position; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">32 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">if third parties initiate litigation claiming that our processes or products infringe their patent or other intellectual property rights, we and our
collaborators will need to defend against such proceedings; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">if a license to necessary technology is terminated, the licensor may initiate litigation claiming that our processes or products infringe or
misappropriate their patent or other intellectual property rights and/or that we breached our obligations under the license agreement, and we and our collaborators would need to defend against such proceedings. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">These lawsuits would be costly and could affect our results of operations and divert the attention of our management and scientific
personnel. There is a risk that a court would decide that we or our collaborators are infringing the third party&#146;s patents and would order us or our collaborators to stop the activities covered by the patents. In that event, we or our
collaborators may not have a viable alternative to the technology protected by the patent and may need to halt work on the affected product candidate or cease commercialization of an approved product. In addition, there is a risk that a court will
order us or our collaborators to pay the other party damages. An adverse outcome in any litigation or other proceeding could subject us to significant liabilities to third parties and require us to cease using the technology that is at issue or to
license the technology from third parties. We may not be able to obtain any required licenses on commercially acceptable terms or at all. Any of these outcomes could have a material adverse effect on our business. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The pharmaceutical and biotechnology industries have produced a significant number of patents, and it may not always be clear to industry
participants, including us, which patents cover various types of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform or predictable. If we are sued for patent
infringement, we would need to demonstrate that our products or methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid, and we may not be able to do this. Proving invalidity is difficult. For
example, in the United States, proving invalidity requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if we are successful in these proceedings, we may incur substantial costs
and divert management&#146;s time and attention in pursuing these proceedings, which could have a material adverse effect on us. If we are unable to avoid infringing the patent rights of others, we may be required to seek a license, defend an
infringement action or challenge the validity of the patents in court. Patent litigation is costly and time consuming. We may not have sufficient resources to bring these actions to a successful conclusion. In addition, if we do not obtain a
license, develop or obtain non-infringing technology, fail to defend an infringement action successfully or have infringed patents declared invalid, we may incur substantial monetary damages, encounter significant delays in bringing our product
candidates to market and be precluded from manufacturing or selling our product candidates. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The cost of any patent litigation
or other proceeding, even if resolved in our favor, could be substantial. Some of our competitors may be able to sustain the cost of such litigation and proceedings more effectively than we can because of their substantially greater resources.
Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. Patent litigation and other proceedings may also absorb
significant management time. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If we fail to comply with our obligations under our intellectual property licenses with third parties, we
could lose license rights that are important to our business. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are currently party to various intellectual property
license agreements. These license agreements impose, and we expect that future license agreements may impose, various diligence, milestone payment, royalty, insurance and other obligations on us. For example, we have entered into patent and know-how
license agreements which grant us the right to use a certain technology related to biological manufacturing to manufacture margetuximab and MGA271. These licenses typically include an obligation to pay an upfront
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">33 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
payment, yearly maintenance payments and royalties on sales. If we fail to comply with our obligations under the licenses, the licensors may have the right to terminate their respective license
agreements, in which event we might not be able to market any product that is covered by the agreements. Termination of the license agreements or reduction or elimination of our licensed rights may result in our having to negotiate new or reinstated
licenses with less favorable terms, which could adversely affect our competitive business position and harm our business. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If we are
unable to protect the confidentiality of our proprietary information, the value of our technology and products could be adversely affected. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In addition to patent protection, we also rely on other proprietary rights, including protection of trade secrets, and other proprietary information. To maintain the confidentiality of trade secrets and
proprietary information, we enter into confidentiality agreements with our employees, consultants, collaborators and others upon the commencement of their relationships with us. These agreements require that all confidential information developed by
the individual or made known to the individual by us during the course of the individual&#146;s relationship with us be kept confidential and not disclosed to third parties. Our agreements with employees and our personnel policies also provide that
any inventions conceived by the individual in the course of rendering services to us shall be our exclusive property. However, we may not obtain these agreements in all circumstances, and individuals with whom we have these agreements may not comply
with their terms. Thus, despite such agreement, such inventions may become assigned to third parties. In the event of unauthorized use or disclosure of our trade secrets or proprietary information, these agreements, even if obtained, may not provide
meaningful protection, particularly for our trade secrets or other confidential information. To the extent that our employees, consultants or contractors use technology or know-how owned by third parties in their work for us, disputes may arise
between us and those third parties as to the rights in related inventions. To the extent that an individual who is not obligated to assign rights in intellectual property to us is rightfully an inventor of intellectual property, we may need to
obtain an assignment or a license to that intellectual property from that individual, or a third party or from that individual&#146;s assignee. Such assignment or license may not be available on commercially reasonable terms or at all. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Adequate remedies may not exist in the event of unauthorized use or disclosure of our proprietary information. The disclosure of our
trade secrets would impair our competitive position and may materially harm our business, financial condition and results of operations. Costly and time consuming litigation could be necessary to enforce and determine the scope of our proprietary
rights, and failure to maintain trade secret protection could adversely affect our competitive business position. In addition, others may independently discover or develop our trade secrets and proprietary information, and the existence of our own
trade secrets affords no protection against such independent discovery. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As is common in the biotechnology and pharmaceutical
industries, we employ individuals who were previously or concurrently employed at research institutions and/or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. We may be subject to claims that
these employees, or we, have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers, or that patents and applications we have filed to protect inventions of these employees, even those
related to one or more of our product candidates, are rightfully owned by their former or concurrent employer. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could
result in substantial costs and be a distraction to management. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Obtaining and maintaining our patent protection depends on compliance
with various procedural, documentary, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to
the USPTO and various foreign patent offices at various points over the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">34 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
lifetime of our patents and/or applications. We have systems in place to remind us to pay these fees, and we rely on our outside counsel to pay these fees when due. Additionally, the USPTO and
various foreign patent offices require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and
in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with rules applicable to the particular jurisdiction. However, there are situations in which noncompliance can result in abandonment or lapse
of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If such an event were to occur, it could have a material adverse effect on our business. In addition, we are responsible for
the payment of patent fees for patent rights that we have licensed from other parties. If any licensor of these patents does not itself elect to make these payments, and we fail to do so, we may be liable to the licensor for any costs and
consequences of any resulting loss of patent rights. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If we do not obtain protection under the Hatch-Waxman Amendments and similar
foreign legislation for extending the term of patents covering each of our product candidates, our business may be materially harmed. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Depending upon the timing, duration and conditions of FDA marketing approval of our product candidates, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug
Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent term extension of up to five years for a patent covering an approved product as compensation for
effective patent term lost during product development and the FDA regulatory review process. However, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise
fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can
enforce our patent rights for that product will be shortened and our competitors may obtain approval to market competing products sooner. As a result, our revenue from applicable products could be reduced, possibly materially. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to Legal Compliance Matters </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our research and development involves, and may in the future involve, the use of potentially hazardous materials and chemicals. Our
operations may produce hazardous waste products. Although we believe that our safety procedures for handling and disposing of these materials comply with the standards mandated by local, state and federal laws and regulations, the risk of accidental
contamination or injury from these materials cannot be eliminated. If an accident occurs, we could be held liable for resulting damages, which could be substantial. We are also subject to numerous environmental, health and workplace safety laws and
regulations and fire and building codes, including those governing laboratory procedures, exposure to blood-borne pathogens, use and storage of flammable agents and the handling of biohazardous materials. Although we maintain workers&#146;
compensation insurance as prescribed by the States of Maryland and California to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of these materials, this insurance may not provide adequate
coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us. Additional federal, state and local laws and regulations affecting our operations may be adopted
in the future. We may incur substantial costs to comply with, and substantial fines or penalties if we violate, any of these laws or regulations. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">35 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If we market products in a manner that violates healthcare fraud and abuse laws, or if we violate
government price reporting laws, we may be subject to civil or criminal penalties. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to FDA restrictions on
marketing of pharmaceutical products, several other types of state and federal healthcare laws commonly referred to as &#147;fraud and abuse&#148; laws have been applied in recent years to restrict certain marketing practices in the pharmaceutical
industry. These laws include false claims and anti-kickback statutes. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Federal false claims laws prohibit any person from
knowingly presenting, or causing to be presented, a false claim for payment to the federal government or knowingly making, or causing to be made, a false statement to get a false claim paid. The federal healthcare program anti-kickback statute
prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce, or in return for, purchasing, leasing, ordering or arranging for the purchase, lease or order of any healthcare item or service
reimbursable under Medicare, Medicaid or other federally financed healthcare programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers
on the other. Although there are several statutory exemptions and regulatory safe harbors protecting certain common activities from prosecution, the exemptions and safe harbors are drawn narrowly, and practices that involve remuneration intended to
induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exemption or safe harbor. Most states also have statutes or regulations similar to the federal anti-kickback law and federal false claims laws,
which may apply to items such as pharmaceutical products and services reimbursed by private insurers. Administrative, civil and criminal sanctions may be imposed under these federal and state laws. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Over the past few years, a number of pharmaceutical and other healthcare companies have been prosecuted under these laws for a variety of
promotional and marketing activities, such as: providing free trips, free goods, sham consulting fees and grants and other monetary benefits to prescribers; reporting to pricing services inflated average wholesale prices that were then used by
federal programs to set reimbursement rates; engaging in off-label promotion; and submitting inflated best price information to the Medicaid Rebate Program to reduce liability for Medicaid rebates. At such time, if ever, as we market any of our
future approved products and these products are paid for by governmental programs, it is possible that some of our business activities could also be subject to challenge under one or more of these &#147;fraud and abuse&#148; laws. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider
trading. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include
intentional failures to comply with FDA regulations, to provide accurate information to the FDA, to comply with federal and state health care fraud and abuse laws and regulations, to report financial information or data accurately or to disclose
unauthorized activities to us. In particular, sales, marketing and business arrangements in the health care industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive
practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee misconduct could also involve the
improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. We intend to adopt a code of conduct prior to the completion of this offering, but it is not always
possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or
other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a
significant impact on our business, including the imposition of significant fines or other sanctions. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">36 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Relating to Employee Matters and Managing Growth </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are highly dependent on the research and development, clinical and business development expertise of Scott Koenig, M.D., Ph.D., our
President and Chief Executive Officer, as well as the other members of our senior management, scientific and clinical team. Although we have entered into employment letter agreements with our executive officers, each of them may terminate their
employment with us at any time. We currently maintain $1 million in &#147;key person&#148; insurance coverage for Dr.&nbsp;Koenig. The loss of the services of our executive officers or other key employees could impede the achievement of our
research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Recruiting and retaining qualified scientific, clinical, manufacturing and sales and marketing personnel will also be critical to our success. In addition, we will need to expand and effectively manage
our managerial, operational, financial, development and other resources in order to successfully pursue our research, development and commercialization efforts for our existing and future product candidates. Furthermore, replacing executive officers
and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and
commercialize products. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology
companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical
advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other
entities that may limit their availability to us. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>We will need to grow our organization, and we may experience difficulties in managing this growth, which could disrupt our operations. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of August 31, 2013, we had 159 full-time employees. As our development and commercialization plans and strategies develop, we expect
to expand our employee base for managerial, operational, sales, marketing, financial and other resources. Future growth would impose significant added responsibilities on members of management, including the need to identify, recruit, maintain,
motivate and integrate additional employees. Also, our management may need to divert a disproportionate amount of their attention away from our day-to-day activities and devote a substantial amount of time to managing these growth activities. We may
not be able to effectively manage the expansion of our operations which may result in weaknesses in our infrastructure, give rise to operational errors, loss of business opportunities, loss of employees and reduced productivity among remaining
employees. Our expected growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of existing and additional product candidates. If our management is unable to effectively
manage our expected growth, our expenses may increase more than expected, our ability to generate and/or grow revenue could be reduced and we may not be able to implement our business strategy. Our future financial performance and our ability to
commercialize our product candidates and compete effectively with others in our industry will depend, in part, on our ability to effectively manage any future growth. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">37 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Relating to Our Common Stock and this Offering </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our stock price is likely to be volatile and the market price of our common stock after this offering may drop below the price you pay.
</I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">You should consider an investment in our common stock as risky and invest only if you can withstand a significant
loss and wide fluctuations in the market value of your investment. Prior to this offering, there was not a public market for our common stock. We will negotiate and determine the initial public offering price with the representatives of the
underwriters based on several factors. This price may vary from the market price of our common stock after this offering. You may be unable to sell your shares of common stock at or above the initial offering price due to fluctuations in the market
price of our common stock arising from changes in our operating performance or prospects. In addition, the stock market has recently experienced significant volatility, particularly with respect to pharmaceutical, biotechnology, and other life
sciences company stocks. The volatility of pharmaceutical, biotechnology, and other life sciences company stocks often does not relate to the operating performance of the companies represented by the stock. Some of the factors that may cause the
market price of our common stock to fluctuate or decrease below the price paid in this offering include: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">results and timing of our clinical trials and clinical trials of our competitors&#146; products; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">failure or discontinuation of any of our development programs; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">issues in manufacturing our product candidates or future approved products; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">regulatory developments or enforcement in the United States and foreign countries with respect to our product candidates or our competitors&#146;
products; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">competition from existing products or new products that may emerge; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">developments or disputes concerning patents or other proprietary rights; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">introduction of technological innovations or new commercial products by us or our competitors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">announcements by us, our collaborators or our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations or
capital commitments; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">changes in estimates or recommendations by securities analysts, if any cover our common stock; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">fluctuations in the valuation of companies perceived by investors to be comparable to us; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">public concern over our product candidates or any future approved products; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">litigation; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">future sales of our common stock; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">share price and volume fluctuations attributable to inconsistent trading volume levels of our shares; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">additions or departures of key personnel; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">changes in the structure of health care payment systems in the United States or overseas; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">failure of any of our product candidates, if approved, to achieve commercial success; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">38 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">economic and other external factors or other disasters or crises; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">period-to-period fluctuations in our financial condition and results of operations, including the timing of receipt of any milestone or other payments
under commercialization or licensing agreements; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">general market conditions and market conditions for biopharmaceutical stocks; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">overall fluctuations in U.S. equity markets. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In addition, in the past, when the market price of a stock has been volatile, holders of that stock have instituted securities class action litigation against the company that issued the stock. If any of
our stockholders brought a lawsuit against us, we could incur substantial costs defending the lawsuit and divert the time and attention of our management, which could seriously harm our business. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>There may not be an active, liquid trading market for our common stock. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prior to this offering, there has been no established trading market for our common stock. There is no guarantee that an active trading
market for our common stock will develop or, if developed, be maintained after this offering on the NASDAQ Global Market or any other exchange. If a trading market does not develop or is not maintained, you may experience difficulty in reselling, or
an inability to sell, your shares quickly or at the latest market price. The lack of an active market may also reduce the fair market value of your shares. An inactive market may also impair our ability to raise capital to continue to fund
operations by selling shares and may impair our ability to acquire other companies or technologies by suing our shares as consideration. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Insiders will continue to have substantial control over us which could delay or prevent a change in corporate control or result in the entrenchment
of management and/or the board of directors. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">After this offering, our directors, executive officers and principal
stockholders, together with their affiliates and related persons, will beneficially own, in the aggregate, approximately &nbsp;&nbsp;&nbsp;&nbsp;% of our outstanding common stock. As a result, these stockholders, if acting together, may have the
ability to determine the outcome of matters submitted to our stockholders for approval, including the election and removal of directors and any merger, consolidation, or sale of all or substantially all of our assets. In addition, these persons,
acting together, may have the ability to control the management and affairs of our company. Accordingly, this concentration of ownership may harm the market price of our common stock by: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">delaying, deferring, or preventing a change in control; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">entrenching our management and/or the board of directors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">impeding a merger, consolidation, takeover, or other business combination involving us; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control of us. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We have broad discretion in the use of the net proceeds from this offering and may not use them effectively. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Management will retain broad discretion over the use of the net proceeds from this offering. Stockholders may not agree with such uses,
and our use of the proceeds may not yield a significant return or any return at all for our stockholders. We intend to use the proceeds from this offering to fund research and development of our current and future product candidates. We may also
spend a portion of the net proceeds on working capital and general corporate purposes, which may include in-licensing or acquiring other products or technologies. Because of the number and variability of factors that will determine our use of the
proceeds from </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">39 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
this offering, their ultimate use may vary substantially from their currently intended use. Any failure by our management to apply the proceeds effectively could affect our ability to continue to
develop and eventually manufacture and sell our products. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We are an &#147;emerging growth company&#148; and as a result of the reduced
disclosure requirements applicable to emerging growth companies, our common stock may be less attractive to investors. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are an &#147;emerging growth company,&#148; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and we
intend to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not &#147;emerging growth companies&#148; including, but not limited to, not being required to comply with the
auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a
nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition
period for complying with new or revised accounting standards. This provision allows an emerging growth company to delay the adoption of some accounting standards until those standards would otherwise apply to private companies. We have irrevocably
elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. We cannot
predict whether investors will find our common stock less attractive because we will rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and
our stock price may be more volatile. We may take advantage of these reporting exemptions until we are no longer an &#147;emerging growth company.&#148; We could remain an &#147;emerging growth company&#148; until the earliest to occur of the
following: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the last day of the fiscal year in which we have total annual gross revenue of $1 billion or more; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the last day of our fiscal year following the fifth anniversary of the date of the first sale of common equity securities pursuant to this prospectus;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the date on which we have issued more than $1 billion in non-convertible debt during the previous three years; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the date on which we are deemed to be a &#147;large accelerated filer&#148; under SEC rules and regulations. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We will incur significant increased costs as a result of operating as a public company, and our management will be required to devote substantial
time to corporate governance standards. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As a public company, we will incur significant legal, accounting and other
expenses that we did not incur as a private company. In addition, our administrative staff will be required to perform additional tasks. For example, in anticipation of becoming a public company, we will need to adopt additional internal controls
and disclosure controls and procedures, retain a transfer agent and adopt an insider trading policy. Once we are a public company, we will bear all of the internal and external costs of preparing and distributing periodic public reports in
compliance with our obligations under the securities laws. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, regulations and standards relating to corporate
governance and public disclosure, including the Sarbanes-Oxley Act and related regulations implemented by the Securities and Exchange Commission and the NASDAQ Global Market, have increased legal and financial compliance costs and will make some
compliance activities more time consuming. We are currently evaluating these rules, and cannot predict or estimate the amount of additional costs we may incur or the timing of such costs. We intend to invest resources to comply with evolving laws,
regulations and standards, and this investment will result in increased general and administrative expenses and may divert management&#146;s time and attention from our other business activities. If our efforts to comply with new laws, regulations
and standards differ from the activities intended by regulatory </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">40 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
or governing bodies due to ambiguities related to practice, regulatory authorities may initiate legal proceedings against us and our business may be harmed. In connection with this offering, we
are increasing our directors&#146; and officers&#146; insurance coverage which will increase our insurance cost. In the future, it may be more expensive or more difficult for us to obtain director and officer liability insurance, and we may be
required to accept reduced coverage or incur substantially higher costs to obtain coverage. These factors could also make it more difficult for us to attract and retain qualified members of our board of directors, particularly to serve on our audit
committee and compensation committee, and qualified executive officers. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the corporate governance standards of the
NASDAQ Global Market, a majority of our board of directors and each member of our audit committee must be an independent director no later than the first anniversary of the completion of this offering. We may encounter difficulty in attracting
qualified persons to serve on our board of directors and the audit committee, and our board of directors and management may be required to divert significant time and attention and resources away from our business to identify qualified directors. If
we fail to attract and retain the required number of independent directors, we may be subject to the delisting of our common stock from the NASDAQ Global Market. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Provisions of our charter, bylaws, and Delaware law may make an acquisition of us or a change in our management more difficult. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certain provisions of our restated certificate of incorporation and restated bylaws that will be in effect upon the completion of this
offering could discourage, delay, or prevent a merger, acquisition, or other change in control that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions also
could limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. Stockholders who wish to participate in these transactions may not have the
opportunity to do so. Furthermore, since our board of directors is responsible for appointing the members of our management team, these provisions could prevent or frustrate attempts by our stockholders to replace or remove our management by making
it more difficult for stockholders to replace members of our board of directors. These provisions: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">allow the authorized number of directors to be changed only by resolution of our board of directors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">establish a classified board of directors, providing that not all members of the board of directors be elected at one time;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">authorize our board of directors to issue without stockholder approval blank check preferred stock that, if issued, could operate as a &#147;poison
pill&#148; to dilute the stock ownership of a potential hostile acquirer to prevent an acquisition that is not approved by our board of directors; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit stockholder action by written consent;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">establish advance notice requirements for stockholder nominations to our board of directors or for stockholder proposals that can be acted on at
stockholder meetings; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">limit who may call stockholder meetings; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">require the approval of the holders of 75% of the outstanding shares of our capital stock entitled to vote in order to amend certain provisions of our
restated certificate of incorporation and restated bylaws. </FONT></P></TD></TR></TABLE>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, because we are incorporated in
Delaware, we are governed by the provisions of Section&nbsp;203 of the Delaware General Corporation Law, which may, unless certain criteria are met, prohibit large stockholders, in particular those owning 15% or more of our outstanding voting stock,
from merging or combining with us for a prescribed period of time. This provision could have the effect of delaying or preventing a change of control, whether or not it is desired by or beneficial to our stockholders. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">41 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We do not anticipate paying cash dividends, and accordingly, stockholders must rely on stock
appreciation for any return on their investment. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We currently intend to retain our future earnings, if any, to fund
the development and growth of our businesses. As a result, capital appreciation, if any, of our common stock will be your sole source of gain on your investment for the foreseeable future. Investors seeking cash dividends should not invest in our
common stock. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Investors in this offering will pay a much higher price than the book value of our common stock and therefore you will
incur immediate and substantial dilution of your investment. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The initial public offering price will be substantially
higher than the net tangible book value per share of shares of our common stock based on the total value of our tangible assets less our total liabilities immediately following this offering. Therefore, if you purchase common stock in this offering,
you will experience immediate and substantial dilution of approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, representing the difference between our pro forma as adjusted net tangible book value per share after giving
effect to this offering at an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. In the past, we issued options and warrants to acquire common stock at prices below the assumed initial public
offering price. To the extent these outstanding options are ultimately exercised, you will experience further dilution. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>A significant
portion of our total outstanding shares of common stock is restricted from immediate resale but may be sold into the market in the near future. This could cause the market price of our common stock to drop significantly, even if our business is
doing well. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sales of a substantial number of shares of our common stock in the public market could occur in the
future. These sales, or the perception in the market that the holders of a large number of shares of common stock intend to sell shares, could reduce the market price of our common stock. After this offering, we will have
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; outstanding shares of common stock based on the number of shares outstanding as of June&nbsp;30, 2013. Of these shares,
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares sold in this offering may be resold in the public market immediately and the remaining shares are currently restricted under securities laws or
as a result of lock-up agreements but will be able to be resold after the offering as described in the &#147;Shares Eligible for Future Sale&#148; section of this prospectus. Moreover, after this offering, holders of an aggregate of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock, which includes &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common
stock issuable upon the conversion of all our outstanding shares of our preferred stock will have rights, subject to certain conditions, to require us to file registration statements covering their shares or to include their shares in registration
statements that we may file for ourselves or other stockholders. We also intend to register all &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock that we may issue under our equity
compensation plans. Once we register these shares, they can be freely sold in the public market upon issuance and once vested, subject to the lock-up agreements described in the &#147;Underwriting&#148; section of this prospectus. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Future issuances of our common stock or rights to purchase common stock pursuant to our equity incentive plans or outstanding warrants could result
in additional dilution of the percentage ownership of our stockholders and could cause our share price to fall. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of August 31, 2013, we have options to purchase 54,420,900 shares outstanding under our equity compensation plans. We are also
authorized to grant equity awards, including stock options, to our employees, directors and consultants, covering up to 1,473,394 shares of our common stock, pursuant to our equity compensation plans. We plan to register the number of shares
available for issuance or subject to outstanding awards under our equity compensation plans after the completion of this offering. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our share price and
trading volume could decline. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The trading market for our common stock will depend on the research and reports that
securities or industry analysts publish about us or our business. We do not have any control over these analysts. We cannot </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">42 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
assure you that analysts will cover us or provide favorable coverage. If one or more of the analysts who cover us downgrade our stock or change their opinion of our stock, our share price would
likely decline. If one or more of these analysts cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which could cause our share price or trading volume to decline. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our ability to use our net operating loss carryforwards and other tax attributes may be limited. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our ability to utilize our federal net operating losses, or NOLs, and federal tax credits is currently limited, and may be limited
further, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Internal Revenue Code. The limitations apply if an ownership change, as defined by Section&nbsp;382, occurs. Generally, an ownership change occurs when
certain shareholders increase their aggregate ownership by more than 50 percentage points over their lowest ownership percentage in a testing period, which is typically three years or since the last ownership change. We are already subject to
Section&nbsp;382 limitations due to an acquisition we made in 2008. As of December&nbsp;31, 2012, we had federal NOL carryforwards of $100.9 million, state NOL carryforwards of $64.2 million and research and development tax credit carryforwards of
$21.8 million available. Future changes in stock ownership, including resulting from this offering, may also trigger an ownership change and, consequently, another Section&nbsp;382 limitation. Any limitation may result in expiration of a portion of
the net operating loss or tax credit carryforwards before utilization which would reduce our gross deferred income tax assets and corresponding valuation allowance. As a result, if we earn net taxable income, our ability to use our pre-change net
operating loss carryforwards and tax credit carryforwards to reduce United States federal income tax may be subject to limitations, which could potentially result in increased future cash tax liability to us. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">43 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom575431_3"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This prospectus includes forward-looking statements within the meaning of federal securities laws. Forward-looking
statements include statements that may relate to our plans, objectives, goals, strategies, future events, future revenues or performance, capital expenditures, financing needs and other information that is not historical information. Many of these
statements appear, in particular, under the headings &#147;Prospectus Summary&#148;, &#147;Risk Factors&#148;, &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and &#147;Business&#148;.
Forward-looking statements can often be identified by the use of terminology such as &#147;subject to&#148;, &#147;believe&#148;, &#147;anticipate&#148;, &#147;plan&#148;, &#147;expect&#148;, &#147;intend&#148;, &#147;estimate&#148;,
&#147;project&#148;, &#147;may&#148;, &#147;will&#148;, &#147;should&#148;, &#147;would&#148;, &#147;could&#148;, &#147;can&#148;, the negatives thereof, variations thereon and similar expressions, or by discussions of strategy. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">All forward-looking statements, including, without limitation, our examination of historical operating trends, are based upon our current
expectations and various assumptions. We believe there is a reasonable basis for our expectations and beliefs, but they are inherently uncertain. We may not realize our expectations, and our beliefs may not prove correct. Actual results could differ
materially from those described or implied by such forward-looking statements. The following uncertainties and factors, among others (including those set forth under &#147;Risk Factors&#148;), could affect future performance and cause actual results
to differ materially from those matters expressed in or implied by forward-looking statements: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our plans to develop and commercialize our product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ongoing and planned clinical trials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the timing of and our ability to obtain and maintain regulatory approvals for our product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to identify additional products or product candidates with significant commercial potential that are consistent with our commercial
objectives; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the rate and degree of market acceptance and clinical utility of our products; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our commercialization, marketing and manufacturing capabilities and strategy; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">significant competition in our industry; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">costs of litigation and the failure to successfully defend lawsuits and other claims against us; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">economic, political and other risks associated with our international operations; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to receive research funding and achieve anticipated milestones under our collaborations; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our intellectual property position; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">costs of compliance and our failure to comply with new and existing governmental regulations including, but not limited to, tax regulations;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">loss or retirement of key members of management; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">costs of compliance and our failure to comply with new and existing governmental regulations including, but not limited to, tax regulations;
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">44 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">failure to successfully execute our growth strategy, including any delays in our planned future growth; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our failure to maintain effective internal controls. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Consequently, forward-looking statements should be regarded solely as our current plans, estimates and beliefs. You should not place undue reliance on forward-looking statements. We cannot guarantee
future results, events, levels of activity, performance or achievements. We do not undertake and specifically decline any obligation to update, republish or revise forward-looking statements to reflect future events or circumstances or to reflect
the occurrences of unanticipated events. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">45 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom575431_4"></A>USE OF PROCEEDS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We estimate that the net proceeds from the sale of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of
common stock in this offering will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million at an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the price range
set forth on the cover of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. If the underwriters exercise their option to purchase additional shares in full, we estimate
that the net proceeds will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Each $1.00 increase or decrease in
the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share would increase or decrease our net proceeds by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, assuming the number of shares offered
by us, as set forth on the cover of this prospectus, remains the same and after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are undertaking this offering in order to access the public capital markets and to increase our liquidity. We intend to use the net
proceeds of this offering together with our cash and cash equivalents and anticipated collaboration payments, as follows: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Approximately $50 million and $20 million to fund clinical development expenses for margetuximab and MGA271, respectively;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Approximately $5 million, $15 million and $10 million to fund research and development expenses to advance our remaining product candidates, including
MGD006, MGD007 and MGD010, respectively; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The remainder for working capital and general corporate purposes, which may include other research and development programs, in-licensing or acquiring
other products or technologies. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our expected use of net proceeds from this offering represents our current
intentions based upon our present plans and business condition. As of the date of this prospectus, we cannot predict with certainty all of the particular uses for the net proceeds to be received upon the completion of this offering or the amounts
that we will actually spend on the uses set forth above. Due to the many variables inherent to the development of oncology and autoimmune therapeutics at this time, such as the timing of patient enrollment and evolving regulatory requirements, we
cannot currently predict the stage of development that our product candidates will reach using the net proceeds of this offering. Based upon our current operating plan, we anticipate that the net proceeds from this offering, together with our
existing cash and cash equivalents, will enable us to fund our operating expenses and capital expenditure requirements for at least the next 18 months. Further, we anticipate that the net proceeds from this offering together with our existing cash
and cash equivalents and approximately $100 million in collaboration payments we anticipate receiving through 2015, will enable us to fund the above product candidates, assuming all of our collaboration programs advance as currently contemplated.
</FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The amount and timing of our actual expenditures will depend upon numerous factors, including the results of our
research and development efforts, the timing and success of pre-clinical studies, our ongoing clinical trials or clinical trials we may commence in the future and the timing of regulatory submissions. As a result, our management will have broad
discretion over the use of the net proceeds from this offering. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pending our use of the net proceeds from this offering, we
intend to invest the net proceeds in a variety of capital preservation investments, including short-term, interest-bearing, investment-grade securities, certificates of deposit or government securities. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">46 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom575431_5"></A>DIVIDEND POLICY </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have never paid any dividends on our common stock. We currently intend to retain any future earnings to finance the growth and
development of our business, and we do not anticipate that we will declare or pay any cash dividends on our common stock in the foreseeable future. Any future determination to pay cash dividends will be at the discretion of our board of directors
and will be dependent upon our financial condition, results of operations, capital requirements, restrictions under any future indebtedness and other factors the board of directors deems relevant. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">47 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom575431_6"></A>CAPITALIZATION </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table indicates our capitalization at June&nbsp;30, 2013: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">on an actual basis; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">on a pro forma basis to reflect the conversion of all of our outstanding preferred stock into an aggregate of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock immediately prior to the completion of this offering; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">on a pro forma as adjusted basis to give further effect to our issuance and sale of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock in this offering at an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the price
range set forth on the cover page of this prospectus, after deducting underwriting discounts and commissions and estimated offering expenses payable by us. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">This table should be read in conjunction with our consolidated financial statements and the related notes included elsewhere in this prospectus. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="8" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:66pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As of June&nbsp;30, 2013</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:22pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Actual</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:37pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Pro&nbsp;Forma</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Pro&nbsp;Forma</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:42pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As&nbsp;Adjusted</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="8" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(unaudited)</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands, except share data)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">33,781</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stockholders&#146; equity (deficit):</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Preferred stock, $0.01 par value per share:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Series A-1: 26,874,792 shares authorized, issued and outstanding, actual;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized, issued and outstanding, pro forma and pro forma as adjusted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">269</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Series A-2: 7,364,582 shares authorized, issued and outstanding, actual;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized, issued and outstanding, pro forma, and pro forma as adjusted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">74</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Series B: 71,401,237 shares authorized, issued and outstanding, actual;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized, issued and outstanding, pro forma, and pro forma as adjusted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">714</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Series C: 110,952,217 shares authorized, issued and outstanding, actual;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized, issued and outstanding, pro forma, and pro forma as adjusted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,110</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Series D: 30,000,000 shares authorized, 14,446,227 shares issued and outstanding, actual;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized, issued and outstanding, pro forma, and pro forma as adjusted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">144</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Series D-2: 75,000,000 shares authorized; 63,681,176 shares issued and outstanding, actual,
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized, issued and outstanding, pro forma, and pro forma as adjusted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">637</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common stock, $0.01 par value; 425,000,000 shares authorized, 36,836,099 shares issued and outstanding, actual;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares authorized, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares issued and outstanding, pro forma;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares authorized, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares issued and outstanding, pro forma as adjusted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">368</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Treasury stock, at cost, 270,000 shares actual; and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares pro forma and pro forma as adjusted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(58</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additional paid-in capital</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">164,944</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accumulated deficit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(179,132</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total stockholders&#146; equity (deficit)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(10,930</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total capitalization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(10,930</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">48 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The shares of our common stock to be outstanding after this offering are based on 36,836,099
shares of our common stock outstanding as of June&nbsp;30, 2013 and exclude: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">51,879,146 shares of common stock issuable upon the exercise of outstanding options, as of June&nbsp;30, 2013, at a weighted average exercise price of
$0.05 per share; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,342,394 shares of common stock reserved for future grant or issuance under our stock option plans as of June&nbsp;30, 2013. For additional
information regarding our capital structure, see &#147;Management&#151;Employee Benefit Plans,&#148; &#147;Description of Capital Stock&#148; and Note 5 of the Notes to our Consolidated Financial Statements. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">49 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom575431_7"></A>DILUTION </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our historical net tangible book value as of June 30, 2013 was $(13.9) million, or $(0.38) per share of our common stock. Historical net
tangible book value per share represents our total tangible assets less total liabilities divided by the number of shares of our common stock outstanding. Our pro forma net tangible book value (deficit) as of June 30, 2013 was approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share of common stock. Pro forma tangible book value per share represents our total
tangible assets less total liabilities divided by the number of shares of common stock outstanding as of June 30, 2013 after giving effect to the conversion of all of our outstanding preferred stock into common stock immediately prior to the closing
of this offering. After giving effect to (a)&nbsp;the conversion of all of our outstanding preferred stock into common stock immediately prior to the closing of this offering; and (b)&nbsp;our sale of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock offered by this prospectus and the receipt and application of those net proceeds, our pro forma net tangible book value as of June 30, 2013 would have
been $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share of common stock. This represents an immediate increase in pro forma net tangible book value of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share to existing stockholders and an immediate dilution in pro forma net tangible book value of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share to investors purchasing common stock
in this offering. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table illustrates this per share dilution: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Assumed initial public offering price per share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Historical net tangible book value per share as of June 30, 2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.38</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Decrease attributable to the conversion of outstanding preferred stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pro forma net tangible book value per share as of June 30, 2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Increase in net tangible book value per share attributable to new investors</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pro forma net tangible book value per share after this offering</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dilution per share to new investors</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A $1.00 increase or decrease in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share would increase or decrease our pro forma net tangible book value by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, our pro forma net tangible book value per share after
this offering by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and dilution per share to new investors by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming that the number of shares offered by us, as set
forth on the cover page of this prospectus, remains the same. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table summarizes on a pro forma basis as of June
30, 2013, the difference between the number of shares of common stock purchased from us, the total consideration paid and the average price per share paid by existing stockholders and by new investors, assuming an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the price range set forth on the cover page of this prospectus, and before deducting estimated underwriting discounts and commissions and estimated offering expenses
payable by us: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:61pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Shares Purchased</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:48pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total<BR>Consideration</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:48pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Average&nbsp;Price<BR>per Share</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:26pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Percent</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Amount</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:26pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Percent</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Existing stockholders</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">New investors</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The table above is based on shares outstanding as of June 30, 2013 and includes
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional shares of our common stock issuable upon the automatic conversion of all outstanding shares of our preferred stock into shares of common stock upon the closing of
this offering. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The table above excludes: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">51,879,146 shares of our common stock issuable upon the exercise of stock options outstanding as of June 30, 2013 at a weighted average exercise price
of $0.05 per share; and </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">50 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,342,394 shares of our common stock reserved for future grant or issuance under our stock option plans as of June 30, 2013. For additional information
regarding our capital structure, see &#147;Management&#151;Employee Benefit Plans&#148; and Note 5 of the Notes to our Consolidated Financial Statements. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The foregoing discussion and tables assume no exercise of any stock options outstanding as of June 30, 2013. To the extent that these options are exercised, new investors will experience further dilution.
As of June&nbsp;30, 2013, options to purchase 51,879,146 shares of common stock were outstanding at a weighted average exercise price of $0.05 per share. Assuming all of our outstanding options are exercised, new investors will own approximately
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of our outstanding shares while contributing approximately &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the total amount paid to fund our company. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the underwriters exercise their option to purchase additional shares in full, the following will occur: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the percentage of shares of our common stock held by existing stockholders will decrease to approximately
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the total number of shares of our common stock outstanding after this offering; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the number of shares of our common stock held by new investors will increase to approximately
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the total number of shares of our common stock outstanding after this offering. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">51 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom575431_8"></A>SELECTED CONSOLIDATED FINANCIAL DATA </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The consolidated statements of operations and comprehensive income (loss) data for the years ended December&nbsp;31, 2012 and 2011 and
the consolidated balance sheet data as of December&nbsp;31, 2012 included in this prospectus have been derived from our audited consolidated financial statements and footnotes included elsewhere in this prospectus. The following selected
consolidated statements of operations and comprehensive income (loss) data for the six months ended June 30, 2012 and 2013 and the balance sheet data as of June 30, 2013 have been derived from our unaudited consolidated financial statements and
footnotes included elsewhere in this prospectus. The unaudited consolidated financial statements have been prepared on a basis consistent with our audited consolidated financial statements and, in the opinion of management, include all adjustments,
consisting only of normal recurring adjustments, which management considers necessary for the fair presentation of the information for the unaudited periods. Historical results are not necessarily indicative of future results, and our interim period
results are not necessarily indicative of results to be expected for a full year or any other interim period. The following data should be read in conjunction with &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of
Operations&#148; and the consolidated financial statements and related notes included elsewhere in this prospectus. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:89pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year Ended December&nbsp;31,</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:93pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Six Months Ended June 30,</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="6" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands, except share and per share data)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Consolidated Statements of Operations and Comprehensive Income (loss):</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total revenues</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">57,207</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">63,826</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37,946</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22,896</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Costs and expenses:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">41,089</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">45,433</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24,957</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,146</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">General and administrative</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,868</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,188</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,126</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,336</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total costs and expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">51,957</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">55,621</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30,083</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">26,482</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Income (loss) from operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,205</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,863</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,586</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other income (expense):</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest income (expense)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other income (expense)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,459</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">151</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(72</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total other income (expense)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,467</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">157</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(74</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net comprehensive income (loss)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,717</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,362</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,866</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,660</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Basic net income (loss) per common share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Diluted net income (loss) per common share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Basic weighted average number of common shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19,254,567</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,337,513</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,106,584</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22,237,823</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Diluted weighted average number of common shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19,254,567</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,337,513</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">401,152,574</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22,237,823</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pro forma basic net income (loss) per common share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.02</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.01</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pro forma diluted net income (loss) per common share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.02</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.01</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pro forma basic weighted average number of common shares </FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">338,665,060</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">340,565,370</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pro forma diluted weighted average number of common shares </FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">403,144,899</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">340,565,370</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">52 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:89pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:63pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Six&nbsp;Months&nbsp;Ended<BR>June&nbsp;30,
2013</B></FONT></P></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Consolidated Balance Sheet Data:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">55,218</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">47,743</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">33,781</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">62,681</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">53,747</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42,183</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54,890</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">44,080</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37,308</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Convertible preferred stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,947</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,947</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,947</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total stockholders&#146; equity (deficit)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(17,484</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8,237</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(10,930</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">53 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom575431_9"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>FINANCIAL CONDITION AND RESULTS OF OPERATIONS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>The following discussion of our financial condition and results of operations should be read together with our selected consolidated financial data and the consolidated financial statements and related
notes included elsewhere in this prospectus. This discussion contains forward-looking statements that involve risks and uncertainties. As a result of many factors, such as those set forth under the section entitled &#147;Risk Factors&#148; and
elsewhere in this prospectus, our actual results may differ materially from those anticipated in these forward-looking statements. </I></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Overview </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are a
clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. We generate our pipeline of product candidates from our proprietary
suite of next-generation antibody technology platforms which we believe improve the performance of monoclonal antibodies and antibody-derived molecules. These product candidates, which we have identified through our understanding of disease biology
and immune-mediated mechanisms, may address disease-specific challenges which are not currently being met by existing therapies. The combination of our technology platforms and antibody engineering expertise has allowed us to generate promising
product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. These collaborations provide us with funding and allow us to leverage the additional expertise of our collaborators to advance
the development of our product candidates. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We currently have two oncology product candidates in clinical development.
Additionally, we have several proprietary product candidates in pre-clinical development and we expect to commence Phase 1 clinical trials on two of these product candidates in 2014. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Margetuximab</I>, also known as MGAH22, is a monoclonal antibody that targets HER2-expressing tumors, including breast, gastroesophageal, bladder
and other cancers. HER2, or human epidermal growth factor receptor 2, is critical for the growth of many types of tumors. We currently are enrolling a Phase 2a clinical trial in metastatic breast cancer and anticipate commencing a Phase&nbsp;3
potential registration clinical trial in advanced gastroesophageal cancer in the second half of 2014. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>MGA271</I> is an Fc-optimized monoclonal antibody that targets B7-H3, a member of the B7 family of molecules and is over-expressed on a wide variety
of solid tumor types. We have initiated a Phase 1 clinical trial that we expect to complete by the end of 2014. We plan to initiate a Phase 2 clinical trial no later than early 2015. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>MGD006 </I>is a humanized DART molecule that recognizes CD123, the Interleukin-3 receptor, or IL3R, alpha chain which is expressed on leukemia and
leukemic stem cells, but not on normal hematopoietic stem cells, and CD3, which is expressed on T cells. We expect to commence a Phase 1 clinical trial in the first half of 2014. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>MGD007</I> is a humanized DART molecule that recognizes both the glycoprotein gpA33, expressed on gastrointestinal tumors, including more than 95%
of human colon cancers, and CD3, which is expressed on T cells. We expect to commence a Phase 1 clinical trial in the second half of 2014. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We commenced active operations in 2000, and have since devoted substantially all of our resources to staffing our company, business planning, raising capital, developing our technology platforms,
identifying potential product candidates, undertaking pre-clinical studies and conducting clinical trials. We have not generated any revenues from the sale of any products to date. We have financed our operations primarily through the private
placements of our convertible preferred stock, collaborations and government grants and contracts. From inception through June 30, 2013, we have received $151.3 million from the sale of convertible preferred
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">54 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
stock and warrants. We have received an additional $180.0 million of upfront, milestone and annual maintenance payments from our collaborators and have been reimbursed $216.1 million through our
collaborations and government grants and contracts. Although it is difficult to predict our liquidity requirements, based upon our current operating plan, we anticipate that the net proceeds from this offering, together with our existing cash and
cash equivalents, will enable us to fund our operating expenses and capital expenditure requirements for at least the next 18 months. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Through June 30, 2013, we had an accumulated deficit of $179.1 million. Due primarily to upfront fees paid by our collaborators, we realized a profit of $6.7 million and $8.4 million for the years ended
December&nbsp;31, 2011 and 2012, respectively. We have recognized a loss of $3.7 million for the six months ended June 30, 2013. We expect that over the next several years we will increase our expenditures in research and development in connection
with our ongoing activities with several clinical trials. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Strategic Collaborations and Licenses </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have entered into several strategic collaborations which provide us with significant additional funding in order to continue development of our
pipeline and to extend our technology platforms and on-going programs. Our collaborations have allowed us to speed up the progress of our on-going pre-clinical and clinical stage programs. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Servier</I>. In November 2011, we entered into a collaboration agreement with Servier under which we granted Servier an option to obtain an
exclusive license to develop and commercialize MGA271 in all countries other than the United States, Canada, Mexico, Japan, South Korea and India. We have received a $20 million option grant fee and a $10 million milestone payment, and may be
eligible to receive up to approximately $415&nbsp;million in license grant fees, and clinical, development, regulatory and sales milestone payments. In the event Servier exercises its option, Servier must pay a license grant fee, which we estimate
to be $30 million, based on the number of different indications represented within the planned Phase 1 patient population. We and Servier will share Phase 2 and Phase 3 development costs. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:11%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In September 2012, we entered into a second agreement with Servier and granted it options to obtain three separate exclusive licenses to
develop and commercialize DART-based molecules, consisting of those designated by us as MGD006 and MGD007, as well as a third DART molecule, in all countries other than the United States, Canada, Mexico, Japan, South Korea and India. We received a
$20 million option grant fee. In addition, we will be eligible to receive up to approximately $1 billion in additional license grant fees, and clinical, development, regulatory and sales milestone payments if Servier exercises all three of its
options and successfully develops, obtains regulatory approval for, and commercializes a product under each license, including $5&nbsp;million upon IND acceptance for each of MGD006, MGD007 and a third DART molecule. In addition to these milestone
payments, we and Servier will share Phase 2 and Phase 3 development costs. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:11%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additionally, under both agreements, Servier
would be obligated to pay us low double digit to mid-teen royalties on product sales in its territories. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Gilead.</I> In January 2013, we entered into an agreement with Gilead to grant it an exclusive worldwide license to research, develop and
commercialize up to four DART-based molecules. Gilead has exclusive worldwide rights for three of the programs. For one program, we retain development and commercialization rights outside of North America, the European Union, Norway, Iceland,
Turkey, Australia and New Zealand. We received an initial $7.5 million license grant fee for the first DART-based molecule, and are eligible to receive up to an additional $22.5 million in grant fees on the remaining three DART-based molecules. We
are further eligible to receive up to an additional $85 million in pre-clinical milestones across the four DART programs and up to </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">55 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="11%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P><FONT STYLE="font-family:Times New Roman" SIZE="2">
approximately $1 billion in additional clinical, regulatory and sales milestone payments if Gilead exercises all four of the options and achieves all of the requisite milestones under each option
and license. Gilead also provides funding for our internal and external research costs under the agreement. We are also eligible to receive tiered royalties on the net sales at percentages ranging from the high-single digits to the low double
digits, but less than teens, subject to reductions in specified circumstances. </FONT></P></TD></TR></TABLE>  <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Boehringer</I>. In October 2010, we entered into an agreement with Boehringer to discover, develop and commercialize up to ten DART-based molecules
which may span multiple therapeutic areas. We granted Boehringer an exclusive worldwide, royalty-bearing, license and received an upfront payment of $15 million. We subsequently received two annual maintenance payments and anticipate receiving a
third annual maintenance payment in the fourth quarter of 2013. We have the potential to earn development, regulatory and sales milestone payments that can reach up to approximately $210 million for each of the DART programs under this agreement.
Boehringer provides funding for our internal and external research costs and is required to pay us mid-single digit royalties on product sales. From the commencement of the collaboration through June 30, 2013, we have received $37.9&nbsp;million
under this agreement, including upfront, annual maintenance and milestone payments as well as research funding. In addition, Boehringer purchased $10 million of our Series D-2 Preferred Stock in January 2011. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Pfizer.</I> In October 2010, we entered into a three year agreement with Pfizer to discover, develop and commercialize up to two DART-based
molecules. We granted Pfizer a non-exclusive worldwide, royalty-bearing license and received an upfront payment of $5 million and have received milestone payments and funding for our internal and external research costs under the agreement. We are
eligible to receive technical, development and sales milestone payments that can reach up to approximately $210 million for each DART program under this agreement. Pfizer is responsible for all pre-clinical and clinical development costs for the
program. In addition, Pfizer is required to pay us mid-single digit to low-teen royalties on product sales. Under this collaboration, one DART program is currently being pursued and we will complete our research obligations under this program in
January 2014. </FONT></P></TD></TR></TABLE>  <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Green Cross.</I> In June 2010, we entered into a collaboration agreement with Green Cross for the development of margetuximab. We granted Green
Cross an exclusive license for all indications for all pharmaceutical forms of margetuximab in South Korea. Under the terms of this agreement, we received an upfront, nonrefundable payment of $1.0 million and are eligible to receive clinical,
development and commercial milestone payments up to $4.5 million as well as royalties ranging from the low-single digits to the low-twenties on net sales of margetuximab in South Korea. In addition, Green Cross purchased $2.0 million of our Series
D-2 Preferred Stock in January 2011. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Financial Operations Overview </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Revenues </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our
revenue consists of collaboration revenue, including amounts recognized relating to upfront nonrefundable payments for licenses or options to obtain future licenses, research and development funding and milestone payments earned under our
collaboration and license agreement with our strategic collaborators, including Servier, Gilead, Boehringer, Pfizer and Green Cross. In addition, we have earned revenues through several grants and/or contracts with the U.S. government and other
educational institutions on behalf of the U.S. government, primarily with respect to research and development activities related to infectious disease product candidates. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Research and Development Expense </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development expenses
consist of expenses incurred in performing research and development activities. These expenses include conducting pre-clinical experiments and studies, clinical trials, </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">56 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
manufacturing efforts and regulatory filings for all product candidates, and other indirect expenses in support of our research and development activities. We capture research and development
expense on a program-by-program basis for our product candidates that are in clinical development and recognize these expenses as they are incurred. The following are items we include in research and development expenses: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Employee-related expenses such as salaries and benefits; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Employee-related overhead expenses such as facilities and other allocated items; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock-based compensation expense to employees and consultants engaged in research and development activities; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Depreciation of laboratory equipment, computers and leasehold improvements; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fees paid to consultants, subcontractors, clinical research organizations, or CROs, and other third party vendors for work performed under our
pre-clinical and clinical trials including but not limited to investigator grants, laboratory work and analysis, database management, statistical analysis, and other items; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amounts paid to vendors and suppliers for laboratory supplies; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Costs related to manufacturing clinical trial materials, including vialing, packaging and testing; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">License fees and other third party vendor payments related to in-licensed product candidates and technology; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Costs related to compliance with regulatory requirements. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The following table shows a summary of our research and development expenses for the years ended December&nbsp;31, 2011 and 2012, the six months ended June&nbsp;30, 2012 and 2013, and from our inception
in 2000 to June&nbsp;30, 2013. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:89pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:93pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center">
<P STYLE="border-bottom:1px solid #000000;width:41pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>From<BR>Inception&nbsp;to<BR>June&nbsp;30,<BR>2013</B></FONT></P></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(dollars in millions)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Research and development expense</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Margetuximab</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">28.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">MGA271</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">DART-based product candidates</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">36.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Teplizumab</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">195.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other discovery and pre-clinical programs, collectively</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">115.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total research and development expense</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">41.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">45.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">399.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">It is difficult to determine with certainty the duration and completion costs of our current or future
pre-clinical programs and clinical trials of our product candidates, or if, when or to what extent we will generate revenues from the commercialization and sale of any of our product candidates that obtain regulatory approval. We may never succeed
in achieving regulatory approval for any of our product candidates. The duration, costs and timing of clinical trials and development of our product candidates will depend on a variety of factors, including the uncertainties of future clinical
trials and pre-clinical studies, uncertainties in clinical trial enrollment rate and significant and changing government regulation. In addition, the probability of success for each product candidate will depend on numerous factors, including
competition, manufacturing capability and </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">57 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
commercial viability. We will determine which programs to pursue and how much to fund each program in response to the scientific and clinical success of each product candidate, as well as an
assessment of each product candidate&#146;s commercial potential. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>General and Administrative Expense </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">General and administrative expenses consist of salaries and related benefit costs for employees in our executive, finance, legal and
intellectual property, business development, human resources and other support functions, travel expenses and other legal and professional fees. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Other Income (Expense) </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other income (expense) consists of interest
income earned on our cash equivalents, offset by interest expense and other expense, including changes in the fair market value of the preferred stock warrant liability. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Critical Accounting Policies and Significant Judgments and Estimates </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our
management&#146;s discussion and analysis of financial conditions and results of operations is based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States
of America. The preparation of these consolidated financial statements requires us to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the
date of the balance sheets and the reported amount of the revenue and expenses recorded during the reporting period. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable. We review and
evaluate these estimates on an on-going basis. These assumptions and estimates form the basis for making judgments about the carrying values of assets and liabilities and amounts that have been recorded as revenues and expenses. Actual results and
experiences may differ from these estimates. The results of any material revisions would be reflected in the consolidated financial statements prospectively from the date of the change in estimate. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">While a summary of significant accounting policies is described fully in Note 2 in our consolidated financial statements, we believe that
the following accounting policies are the most critical to assist you in fully understanding and evaluating our financial results and any affect the estimates and judgments we used in preparing our consolidated financial statements. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Revenue Recognition </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We enter into collaboration and license agreements with collaborators for the development of monoclonal antibody-based therapeutics to treat cancer and other complex diseases. The terms of these
agreements contain multiple deliverables which may include (i)&nbsp;licenses, or options to obtain licenses, to our technological platforms, such as our Fc engineering and DART technologies, (ii)&nbsp;rights to future technological improvements,
(iii)&nbsp;research and development activities to be performed on behalf of the collaborative partner or as part of the collaboration, and (iv)&nbsp;the manufacture of pre-clinical or clinical materials for the collaborative partner. Payments to us
under these agreements may include nonrefundable license fees, option fees, exercise fees, payments for research and development activities, payments for the manufacture of pre-clinical or clinical materials, license maintenance payments, payments
based upon the achievement of certain milestones and royalties on product sales. Other benefits to us from these agreements include the right to sell products resulting from the collaborative efforts of the parties in specific geographic
territories. We follow the provisions of the Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic 605-25, <I>Revenue Recognition&#150;Multiple-Element Arrangements</I>, and ASC Topic 605-28, <I>Revenue
Recognition&#150;Milestone Method</I>, in accounting for these agreements. In order to account for these agreements, we must identify the deliverables included within the agreement and evaluate which deliverables represent separate units of
accounting based on the achievement of certain criteria, including whether the delivered element has stand-alone value to the collaborator. The consideration received is allocated among the separate units of accounting, and the applicable revenue
recognition criteria are applied to each of the separate units. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">58 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of December&nbsp;31, 2012, we had the following two types of agreements: 1) exclusive
development and commercialization licenses to use our technology and/or certain other intellectual property to develop compounds against specified targets, which we refer to as exclusive licenses; and 2) option/research agreements to secure on
established terms development and commercialization licenses to anticancer and other therapeutic product candidates to collaborator selected targets developed by us during an option period, which we refer to as right-to-develop agreements.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Exclusive Licenses </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The deliverables under an exclusive license agreement generally include the exclusive license to our technology with respect to a specified antigen target, and may also include deliverables related to
rights to future technological improvements, research and pre-clinical development activities to be performed on behalf of the collaborator. In some cases we may have an option to participate in the co-development of product candidates that result
from such agreements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Generally, exclusive license agreements contain nonrefundable terms for payments and, depending on the
terms of the agreement, provide that we will (i)&nbsp;at the collaborator&#146;s request, provide research and pre-clinical development services at negotiated prices which are generally consistent with what other third parties would charge,
(ii)&nbsp;earn payments upon the achievement of certain milestones, (iii)&nbsp;earn royalty payments, and (iv)&nbsp;in some cases grant us an option to participate in the development and commercialization of products that result from such
agreements. Royalty rates may vary over the royalty term depending on our intellectual property rights and whether we exercise any co-development and co-commercialization rights. We may provide technical assistance and share any technology
improvements with our collaborators during the term of the collaboration agreements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We do not directly control when any
collaborator will achieve milestones or become liable for royalty payments. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In determining the units of accounting,
management evaluates whether the exclusive license has stand-alone value from the undelivered elements to the collaborator based on the consideration of the relevant facts and circumstances for each arrangement. Factors considered in this
determination include the research capabilities of the collaborator and the availability of technology platform and product research expertise in the general marketplace. If we conclude that the license has stand-alone value and therefore will be
accounted for as a separate unit of accounting, we then determine the estimated selling prices of the license and all other units of accounting based on market conditions, similar arrangements entered into by third parties, and entity-specific
factors such as the terms of our previous collaboration agreements, recent pre-clinical and clinical testing results of therapeutic product candidates that use our technology platforms, our pricing practices and pricing objectives, the likelihood
that technological improvements will be made, the likelihood that technological improvements made will be used by our collaborators and the nature of the research services to be performed on behalf of our collaborators and market rates for similar
services. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upfront payments on exclusive licenses are deferred if facts and circumstances dictate that the license does not
have stand-alone value. Prior to the adoption of Accounting Standards Update, or ASU, No.&nbsp;2009-13, <I>Revenue Arrangements with Multiple Deliverables</I>, on January&nbsp;1, 2011, we determined that our licenses lacked stand-alone value and
were combined with other elements of the arrangement and any amounts associated with the license were deferred and amortized over a certain period, which we refer to as our period of substantial involvement. The determination of the length of the
period over which to defer revenue is subject to judgment and estimation and can have an impact on the amount of revenue recognized in a given period. Historically, our involvement with the development of a collaborator&#146;s product candidate has
been significant at the early stages of development, and lessens as it progresses into clinical trials. Accordingly, we generally estimate this period of substantial involvement to begin at the inception of the collaboration agreement and conclude
at the end of our substantial involvement. We reassess our periods of substantial involvement over which we amortize our upfront </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">59 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
license fees and make adjustments as appropriate. In the event a collaborator elects to discontinue development of a specific product candidate under a single target license, but retains its
right to use our technology to develop an alternative product candidate to the same target or a target substitute, we would cease amortization of any remaining portion of the upfront fee until there is substantial pre-clinical activity on another
product candidate and its remaining period of substantial involvement can be estimated. In the event that a single target license were to be terminated, we would recognize as revenue any portion of the upfront fee that had not previously been
recorded as revenue, but was classified as deferred revenue, at the date of such termination or through the remaining substantial involvement in the wind down of the agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upfront payments on exclusive licenses may be recognized upon delivery of the license if facts and circumstances dictate that the license
has stand-alone value from the undelivered elements, which generally include rights to future technological improvements, research services and the manufacture of pre-clinical and clinical materials. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We recognize revenue related to research and pre-clinical development services that represent separate units of accounting as they are
performed, as long as there is persuasive evidence of an arrangement, the fee is fixed or determinable, and collection of the related receivable is probable. We recognize revenue related to the rights to future technological improvements over the
estimated term of the applicable license. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We typically perform research activities and pre-clinical development services,
including generating and engineering product candidates, on behalf of our licensees during the early evaluation and pre-clinical testing stages of drug development under our exclusive licenses. We record amounts received for research materials
produced or services performed as revenue from collaborative research. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our license agreements have milestone payments which
for reporting purposes are aggregated into three categories: (i)&nbsp;development milestones, (ii)&nbsp;regulatory milestones, and (iii)&nbsp;sales milestones. Development milestones are typically payable when a product candidate initiates or
advances into different clinical trial phases. Regulatory milestones are typically payable upon submission for marketing approval with the FDA or other countries&#146; regulatory authorities or on receipt of actual marketing approvals for the
compound or for additional indications. Sales milestones are typically payable when annual sales reach certain levels. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">At the
inception of each agreement that includes milestone payments, we evaluate whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of whether
(a)&nbsp;the consideration is commensurate with either (1)&nbsp;our performance to achieve the milestone, or (2)&nbsp;the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from our performance to achieve
the milestone, (b)&nbsp;the consideration relates solely to past performance and (c)&nbsp;the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. We evaluate factors such as the scientific,
regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether the milestone consideration is reasonable relative to all
deliverables and payment terms in the arrangement in making this assessment. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-refundable development and regulatory
milestones that are expected to be achieved as a result of our efforts during the period of substantial involvement are considered substantive and are recognized as revenue upon the achievement of the milestone, assuming all other revenue
recognition criteria are met. Milestones that are not considered substantive because we did not contribute effort to the achievement of such milestones are generally achieved after the period of substantial involvement and are recognized as revenue
upon achievement of the milestone, as there are no undelivered elements remaining and no continuing performance obligations, assuming all other revenue recognition criteria are met. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Right-to-Develop Agreements </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our right-to-develop agreements
provide collaborators with an exclusive option to obtain licenses to develop and commercialize in specified geographic territories product candidates developed by us under agreed </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">60 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
upon research and pre-clinical development programs. The product candidates resulting from each program are all directed to a specific target selected by the collaborator. Under these agreements,
fees may be due to us (i)&nbsp;at the inception of the arrangement (referred to as &#147;upfront&#148; fees or payments), (ii)&nbsp;the selection of a target for a program, (iii)&nbsp;upon the exercise of an option to acquire a development and
commercialization license, referred to as exercise fee, for a program, or (iv)&nbsp;some combination of all of these fees. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The accounting for right-to-develop agreements is dependent on the nature of the options granted to the collaborative partner. Options
are considered substantive if, at the inception of a right-to-develop agreement, we are at risk as to whether the collaborative partner will choose to exercise the options to secure development and commercialization licenses. Factors that are
considered in evaluating whether options are substantive include the overall objective of the arrangement, the benefit the collaborator might obtain from the agreement without exercising the options, the cost to exercise the options relative to the
total upfront consideration, and the additional financial commitments imposed on the collaborator as a result of exercising the options. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">For right-to-develop agreements where the options to secure a development and commercialization licenses to a product program are considered substantive, we do not consider the development and
commercialization licenses to be a deliverable at the inception of the agreement. For those right-to-develop agreements entered into prior to the adoption of ASU No.&nbsp;2009-13 where the options to secure development and commercialization licenses
are considered substantive, we have deferred the upfront payments received and recognize this revenue over the period during which the collaborator could elect to exercise options for development and commercialization licenses. These periods are
specific to each collaboration agreement. If a collaborator selects a target for a product program, any substantive option fee is deferred and recognized over the life of the option, generally 12 months. If a collaborator exercises an option and
acquires a development and commercialization license to a product program, we attribute the exercise fee to the development and commercialization license. Upon exercise of an option to acquire a development and commercialization license, we would
also attribute any remaining deferred option fee to the development and commercialization license and apply the multiple-element revenue recognition criteria to the development and commercialization license and any other deliverables to determine
the appropriate revenue recognition, which will be consistent with our accounting policy for upfront payments on exclusive licenses. In the event a right-to-develop agreement were to be terminated, we would recognize as revenue any portion of the
upfront fee that had not previously been recorded as revenue, but was classified as deferred revenue, at the date of such termination. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">For right-to-develop agreements where the options to secure development and commercialization licenses to product programs are not considered substantive, we consider the development and commercialization
licenses to be a deliverable at the inception of the agreement and apply the multiple-element revenue recognition criteria to determine the appropriate revenue recognition. All of our right-to-develop agreements have been determined to contain
substantive options. We do not directly control when any collaborator will exercise its options for development and commercialization licenses. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Research and Development Expense and related Accrued Expenses </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As part of the process of preparing our consolidated financial statements, we may be required to estimate accrued expenses. In order to obtain reasonable estimates, we review open contracts and purchase
orders. In addition, we communicate with applicable personnel in order to identify services that have been performed, but for which we have not yet been invoiced. In most cases, our vendors provide us with monthly invoices in arrears for services
performed. We confirm our estimates with these vendors and make adjustments as needed. The following are examples of our accrued expenses: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fees paid to CROs for services performed on clinical trials; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fees paid to investigative sites for services performed on clinical trials; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fees paid for professional services. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">61 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expenses related to clinical trials performed by our CROs are dependent on the successful
enrollment of patients. These expenses can vary from site to site and contract to contract. We base our estimated accruals on the time period over which the services are to be performed and the level of effort to be expended in each period based on
the estimated enrollment of patients in each trial. We will adjust accordingly should the estimates vary from the actual expenses. However, we do not anticipate that our payment of actual expenses will differ materially from our estimates.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Income Taxes </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that
are expected to be in effect when the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized as income in the period that such tax rate changes are enacted. The measurement of a
deferred tax asset is reduced, if necessary, by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized. Financial statement recognition of a tax position taken or expected to be
taken in a tax return is determined based on a more-likely-than-not threshold of that position being sustained. If the tax position meets this threshold, the benefit to be recognized is measured as the largest amount that is more than 50% likely to
be realized upon ultimate settlement. Our policy is to record interest and penalties related to uncertain tax positions as a component of income tax expense. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We recorded deferred tax assets of $78.1&nbsp;million as of December&nbsp;31, 2012, which have been fully offset by a valuation allowance due to uncertainties surrounding our ability to realize these tax
benefits. The deferred tax assets are primarily comprised of federal and state tax net operating loss, or NOL, carryforwards and research and development tax credit carryforwards. As of December&nbsp;31, 2012, we had federal NOL carryforwards of
$100.9 million, state NOL carryforwards of $64.2 million and research and development tax credit carryforwards of $21.8 million available. These federal NOL carryforwards will begin to expire at various dates starting in 2023. We are already subject
to Section&nbsp;382 limitations due to an acquisition we made in 2008. Future changes in stock ownership, including resulting from this offering, may also trigger an ownership change and, consequently, another Section&nbsp;382 limitation. Any
limitation may result in expiration of a portion of the net operating loss or tax credit carryforwards before utilization which would reduce our gross deferred income tax assets and corresponding valuation allowance. As a result, if we earn net
taxable income, our ability to use our pre-change net operating loss carryforwards and tax credit carryforwards to reduce United States federal income tax may be subject to limitations, which could potentially result in increased future cash tax
liability to us. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Stock-Based Compensation </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We recognize stock-based compensation expense in accordance with the provisions of ASC Topic 718, <I>Compensation&#151;Stock Compensation.</I> The fair value of stock-based payments is estimated, on the
date of grant, using a Black-Scholes model. The resulting fair value is recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the option. The use of a Black-Scholes model requires us to apply
judgment and make assumptions and estimates that include the following: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Fair Value of Common Stock&#151;</I>Given that there is no public market for our common stock, our board of directors has historically determined
the fair value of our common stock. Since 2007, the board has relied on contemporaneous valuations to determine the fair value of our common stock. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Expected Volatility</I>&#151;Volatility is a measure of the amount by which a financial variable such as a share price has fluctuated (historical
volatility) or is expected to fluctuate (expected volatility) during a given period. As we are not a publicly traded company, we have historically identified several public companies of similar size, complexity and stage of development and
calculated the historical volatility using the volatility of these companies. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Expected Dividend Yield&#151;</I>We have never declared or paid dividends. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">62 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Risk-Free Interest Rate&#151;</I>We have historically used the United States Treasury rate for the week of each option grant during the year, having
a term that most closely resembles the expected life of our options. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Expected Term&#151;</I>This is the period of time that the options granted are expected to remain unexercised. Options granted have a maximum term
of ten year and we have estimated the expected life of the option term to be seven years. We use a simplified method to calculate the average expected term. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Expected Forfeiture Rate&#151;</I>The forfeiture rate is the estimated percentage of options granted that is expected to be forfeited or canceled on
an annual basis before becoming fully vested. We estimate the forfeiture rate based on historical turnover data with further consideration given to the class of the employees to whom the options were granted. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The assumptions used in the Black-Scholes option pricing model for the years ended December&nbsp;31, 2011 and 2012 and for the six months
ended June&nbsp;30, 2013 are set forth in our consolidated financial statements included within this prospectus. The stock-based compensation expense includes stock options granted to employees and non-employees and has been reported in our
consolidated financial statements as follows: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="86%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="53%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:89pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:93pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011(1)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,019</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">472</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">236</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">173</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">General and administrative expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,328</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">366</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">183</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">85</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,347</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">838</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">419</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">258</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">In March 2011, we exchanged outstanding options to purchase 36,081,455 shares of our common stock with exercise prices ranging from $0.10 to $0.25 per share, for new
options to purchase the same number of shares of our common stock with an exercise price of $0.05 per share, which we deemed to represent the fair market value of the shares of our common stock as of December&nbsp;31, 2010. The exchange was
implemented because one of our product candidates, teplizumab, did not meet the primary efficacy endpoint in a Phase 3 clinical trial and our collaboration with Eli Lilly&nbsp;was subsequently terminated. We recognized compensation expense of $2.1
million related to this modification as of the exchange date. </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our board of directors has historically estimated
the fair value of our common stock relying on contemporaneous valuations. The contemporaneous valuations were performed in accordance with applicable methodologies, approaches and assumptions of the technical practice-aid issued by the American
Institute of Certified Public Accountants Practice Aid entitled <I>Valuation of Privately-Held Company Equity Securities Issued as Compensation</I>, or the AICPA Practice Aid, and considered many objective and subjective factors to determine the
common stock fair market value each valuation date. The following factors, among others, were considered: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our financial condition and operating results, including our projected results; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our stage of development and business strategy; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The financial condition and operating results of publicly-owned companies with similar lines of business and their historical volatility;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">External market conditions that could affect companies in the life sciences and biotechnology sectors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The prices of our preferred stock sold to outside investors and the rights, preferences and privileges of our preferred stock as compared to those of
our common stock, including the liquidation preference of our preferred stock; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">63 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The likelihood of a liquidity event such as an initial public offering, a merger or the sale of our company; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any recent valuations prepared in accordance with the AICPA Practice Aid. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The dates of our valuations have historically coincided with our year end and would therefore not always fall on the same dates as when
options have been granted. However, we have historically granted the majority of our equity awards on an annual basis coinciding with the beginning of each calendar year. Therefore, our board of directors has historically used the valuation closest
to the grant date of options granted in determining the exercise prices. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We considered several types of approaches in the
preparation of our valuations as follows: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Market Approach&#151;</I>The market approach values a business by reference to guideline companies, for which enterprise values are known. This
approach has two principal methodologies. The guideline public company methodology derives valuation multiples from the operating data and share prices of similar publicly traded companies. The guideline acquisition methodology focuses on
comparisons between the subject company and guideline acquired public or private companies. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Income Approach&#151;</I>The income approach values a business based upon the future benefits that will accrue to it, with the value of the future
economic benefits discounted back to a present value at an appropriate discount rate. This approach uses two methods to value an investment. The discounted cash flow analysis forecasts future revenues and free cash flow, or net operating profit
after tax from continuing operations, associated with those revenues. The capitalization of earnings analysis uses a single year&#146;s estimated free cash flow and converts it into a value in one step by dividing free cash flow from operation by a
capitalization rate. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Asset Approach&#151;</I>The asset approach considers the underlying value of a company&#146;s individual assets net of its liabilities. This
approach uses the most recent balance sheet as a basis for determining value. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, we also
considered several types of allocation methods as follows: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Current Value Method&#151;</I>This method allocates the enterprise value of a company to its conversion value. The method assumes that each
preferred shareholder will, at the valuation date, exercise its conversion rights in the manner that is most beneficial. If the conversion of a class of preferred stock into common stock would result in a value less than the total liquidation
preference of that class, that class is considered to be &#147;out of the money&#148; and would not convert. On the other hand, if the value of the common stock would be greater than the liquidation preference of that class, the preferred stock is
considered to be &#147;in the money&#148; and would convert. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Option-Pricing Method&#151;</I>Under this method, each class of stock is modeled as a call option with a distinct claim on the enterprise value of
the company. The option&#146;s exercise prices would be based on a comparison with the enterprise value. The method assumes that a formula, such as the Black-Scholes model, would calculate the fair value when provided with certain values, including
share price, expiration date, volatility and the risk free interest rate. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Probability Weighted Expected Return Method&#151;</I>Using the probability weighted expected return, or PWERM method, the value of a company&#146;s
common stock is estimated based upon the analysis of future values for the company assuming various possible future liquidity events like an initial public offering, or IPO, sale or merger. Share value is based upon the probability-weighted present
value of expected future net cash flows, considering each of the possible future events, as well as the rights and preferences of each share class. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">64 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table illustrates our stock option grant information from January&nbsp;1, 2011
through August&nbsp;31, 2013, including the estimated fair value of our common stock on the date of grant. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="86%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="17%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="17%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="17%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:38pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Grant Date</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number&nbsp;of&nbsp;Options&nbsp;Granted</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option&nbsp;Exercise&nbsp;Price</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Estimated&nbsp;Fair&nbsp;Value&nbsp;of<BR>Common Stock</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">January&nbsp;9, 2011</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,456,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">March&nbsp;16, 2011</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">29,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">June&nbsp;15, 2011</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">211,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">September&nbsp;7,&nbsp;2011</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">263,600</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">November&nbsp;10,&nbsp;2011</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">January&nbsp;8, 2012</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,119,225</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">March&nbsp;14, 2012</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,878,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">June&nbsp;13, 2012</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">81,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">September&nbsp;19,&nbsp;2012</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">150,400</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">November&nbsp;8,&nbsp;2012</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">295,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">January&nbsp;6, 2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,332,100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.08</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.08</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">March&nbsp;8, 2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">263,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.08</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.08</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">June 19, 2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,117,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">July 19, 2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,869,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.25</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.25</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">September&nbsp;18,&nbsp;2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,352,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>   <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The intrinsic value of all outstanding vested and unvested options as of August 31, 2013 was
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million based on an assumed public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range set forth on the cover page of this
prospectus, and based on 54,420,900 shares of common stock issuable upon the exercise of options outstanding as of August 31, 2013 with a weighted average exercise price of $0.07 per share. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:3%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>December&nbsp;31, 2010 Valuation </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We determined that the income approach was best suited to use for the December&nbsp;31, 2010 valuation. We focused on determining the market value of our total capitalization. The market value of
non-operating assets was added to determine the market value of the total common equity. We used the option pricing method as the allocation method. We utilized a long-term forecast that represented our best estimate of expected performance. We
determined that a 14.71% cost of capital would be appropriate. We developed a long-term model that projected our product candidates&#146; performance and potential commercialization over the next twenty years. We assumed that we would continue
development of additional product candidates in our pipeline and generate revenue through commercialization of our product candidates or through collaborations. This normalized cash flow was then discounted back to a present value at the above
mentioned cost of capital. The cost of capital utilized was 14.71%. The Company&#146;s capital structure did not contain any debt; therefore the weighted average cost of capital did not contain a cost of debt. We noted that the capital structure of
100% equity and 0% debt was comparable to the median capital structure of the guideline public companies of 99.6% equity and 0.4% debt. We determined the cost of capital utilizing the following inputs: (i) yield on a 20-year Treasury bond of 4.13%
derived from the U.S. Federal Reserve website; (ii) market risk premium of 5.18% based upon Morningstar&#146;s publication &#147;Stocks, Bonds, Bills, and Inflation: Valuation Edition 2010 Yearbook&#148;; (iii) an unlevered beta of 1.00 based upon
an analysis of betas of publicly-traded guideline companies, debt-to-equity ratios and tax rates; and (iv) a small stock premium of 5.4% based upon stocks in the 10th decile, including companies with market capitalizations ranging from $1.0 million
to $214.1 million from Morningstar&#146;s publication &#147;Stocks, Bonds, Bills and Inflation: Valuation Edition 2010 Yearbook.&#148; The total market value of our capital stock, based upon a discounted cash flow analysis, on a minority interest
basis was approximately $74.0 million. We added free cash in the amount of $43.5 million and determined that the market value of total equity, on a marketable minority interest basis was approximately $117.5 million. Using the option pricing method
approach, this value was then allocated among the preferred and common stock and we applied a discount rate of 30% to account for the lack of marketability of our common stock. We concluded that the fair value of our common stock was $0.05 per share
at December&nbsp;31, 2010. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">65 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:3%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Stock Option Grants from January 2011 to November 2011 </I></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our board of directors granted options to purchase common stock on January&nbsp;9, 2011,&nbsp;March&nbsp;16, 2011,&nbsp;June&nbsp;15,
2011,&nbsp;September&nbsp;7, 2011 and November&nbsp;10, 2011, with each option having an exercise price of $0.05 per share. In establishing this exercise price, our board of directors considered input from management, including the valuation we
conducted of our common stock as of December&nbsp;31, 2010, as well as the objective and subjective factors outlined above. At each grant date, our board of directors considered the events and circumstances most likely to affect the value of our
common stock that occurred between December 2010 and the grant date, and whether those events and circumstances were part of the assumptions used in the December 2010 valuation. Our board of directors determined that there were no other events and
circumstances that occurred between December 2010 and November 2011 that were indicative of a significant change in the fair value of our common stock. Based on these factors, our board of directors determined that the fair value of our common stock
at January&nbsp;9, 2011,&nbsp;March&nbsp;16, 2011,&nbsp;June&nbsp;15, 2011,&nbsp;September&nbsp;7, 2011 and November&nbsp;10, 2011 was $0.05 per share. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:3%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>December&nbsp;31, 2011 Valuation </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We determined that the income approach
was best suited to us for the December&nbsp;31, 2011 valuation. We focused on determining the market value of total capitalization. The market value of non-operating assets was added to determine the market value of the total common equity. We used
the option pricing method as the allocation method. We utilized a long-term forecast that represented our best estimates of expected performance. We determined that a 15.46% cost of capital would be appropriate. We developed a long-term model that
projected our product candidates&#146; performance and potential commercialization over the next twenty years. We assumed that we would continue development of additional product candidates in our pipeline and generate revenue through
commercialization of our product candidates or though collaborations. This normalized cash flow was then discounted back to a present value at the above mentioned cost of capital. The total market value of our capital stock, based upon a discounted
cash flow analysis, on a minority interest basis was approximately $61.6 million. We added free cash in the amount of $48.2 million and determined that the market value of total equity, on a marketable minority interest basis was approximately
$109.8 million. Using the option pricing method approach, this value was then allocated among the preferred and common stock and applying a discount rate of 30% to account for the lack of marketability of our common stock. We concluded that the fair
value of our common stock was&nbsp;$0.05&nbsp;per share as December&nbsp;31, 2011. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:3%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Stock Option Grants from January 2012
to November 2012 </I></FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our board of directors granted options to purchase common stock on January&nbsp;8,
2012,&nbsp;March&nbsp;14, 2012,&nbsp;June&nbsp;13, 2012,&nbsp;September&nbsp;19, 2012 and November&nbsp;8, 2012, with each option having an exercise price of $0.05 per share. In establishing this exercise price, our board of directors considered
input from management, including the valuation we conducted of our common stock as of December&nbsp;31, 2011, as well as the objective and subjective factors outlined above. At each grant date, our board of directors considered the events and
circumstances most likely to affect the value of our common stock that occurred between December 2011 and the grant date and whether those events and circumstances were part of the assumptions used in the December 2011 valuation. Our board of
directors determined that there were no other events and circumstances that occurred between December 2011 and November 2012 that were indicative of a significant change in the fair value of our common stock. For example, although we entered into a
collaboration agreement with Servier, the cash received offset cash used in operations between January 2012 and November 2012, and thus the value of the Company had not been altered significantly from December 2011. Based on these factors, our board
of directors determined that the fair value of our common stock at January&nbsp;8, 2012,&nbsp;March&nbsp;14, 2012,&nbsp;June&nbsp;13, 2012,&nbsp;September&nbsp;19, 2012 and November&nbsp;08, 2012 was $0.05 per share. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">66 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:3%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>December&nbsp;31, 2012 Valuation </I></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We used the PWERM method to allocate the equity value to our common stock in the December&nbsp;31, 2012 valuation. For the various
scenarios, we utilized a combination of the market approach (e.g., consideration of pre-money IPO value indications from companies in the pharmaceutical and biotechnology industries with similar product candidates and at similar stages of clinical
development) and the income approach (e.g., projected future cash flows) to determine the value of our business and ultimately the fair value of our common stock. We utilized the following probability-weighted scenarios to determine the equity value
of our company: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="86%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:29pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Scenario</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Probability</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">An IPO by second quarter 2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">An IPO by fourth quarter 2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">An IPO by first quarter 2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">A merger or acquisition by fourth quarter 2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Remain private through the middle of 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">55</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In this valuation, we incorporated IPO scenarios as this strategy was considered a possibility based on
our stage of development and current market conditions. We believed that a second quarter 2013 IPO was unlikely given the tremendous effort required to file a registration statement and our lack of need for additional cash and therefore applied a 5%
probability to this scenario. We determined that an IPO either in the fourth quarter of 2013 or first quarter of 2014 was somewhat more likely due to the progression of our lead product candidates and therefore applied a probability of 15% to each
of those scenarios. We determined that the likelihood of a merger or acquisition was low based on the timing of availability of key clinical data and assigned a probability of 10% to that scenario. We determined that given our relatively low need to
raise capital as a result of our collaboration agreements and anticipated milestone payments, the scenario most likely to occur would be to remain a private company and therefore assigned a probability of 55% to that scenario. We concluded that
after applying a discount rate of 25.0% for lack of marketability, the value of our common stock as December&nbsp;31, 2012 was $0.08 per share. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:3%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Stock Option Grants from January 2013 to March 2013 </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our board of
directors granted options to purchase common stock on January&nbsp;6, 2013 and March&nbsp;8, 2013, with each option having an exercise price of $0.08 per share. In establishing this exercise price, our board of directors considered input from
management, including the valuation we conducted of our common stock as of December&nbsp;31, 2012, as well as the objective and subjective factors outlined above. At each grant date, our board of directors considered the events and circumstances
most likely to affect the value of our common stock that occurred between December 2012 and the grant date and whether those events and circumstances were part of the assumptions used in the December 2012 valuation. Our board of directors determined
that there were no other events and circumstances that occurred between December 2012 and March 2013 that were indicative of a significant change in the fair value of our common stock. Based on these factors, our board of directors determined that
the fair value of our common stock at January&nbsp;6, 2013 and March&nbsp;8, 2013 was $0.08 per share. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:3%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>March&nbsp;31, 2013
Valuation </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Due to the market conditions for IPOs of biotechnology companies, we determined that obtaining a valuation of
our common stock on a quarterly rather than annual basis was warranted in 2013. In the first of our quarterly valuations, we used the PWERM method to allocate the equity value to our common stock in the March&nbsp;31, 2013 valuation. For the various
scenarios, we utilized a combination of the market approach (e.g., consideration of pre-money IPO value indications from companies in the pharmaceutical and biotechnology industries with similar product candidates and at similar stages of clinical
development) and the income approach </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">67 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
(e.g., projected future cash flows) to determine the value of our business and ultimately the fair value of our common stock. We utilized the following probability-weighted scenarios to determine
the equity value of our company: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="86%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:29pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Scenario</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Probability</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">An IPO by fourth quarter 2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">An IPO by first quarter 2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">A merger or acquisition by third quarter 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Remain private through the end of 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
</TABLE>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In this valuation, we believed that the possibility of a fourth quarter 2013 IPO or a first quarter
2014 IPO were equal, given that only two biotechnology companies had successfully completed IPOs from December 2012 to our board meeting in March 2013. Therefore we applied a 20% probability to each of those scenarios. Additionally, the value
assigned to the FPO scenarios was increased as a result of the higher market values that were reflected by IPOs completed in March 2013 trading at premiums to the offering price. We determined that the likelihood of a merger or acquisition was low
based on the timing of availability of key clinical data and assigned a probability of 15% to that scenario. We determined that given our relatively low need to raise capital as a result of our collaboration agreements and anticipated milestone
payments, the scenario most likely to occur would be to remain a private company and therefore assigned a probability of 45% to that scenario. We concluded that after applying a discount rate of 20.0% for lack of marketability, the value of our
common stock at March&nbsp;31, 2013 was $0.14 per share. </FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:3%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Stock Option Grants from April 2013 to June 2013
</I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our board of directors granted options to purchase common stock on June 19, 2013, with each option having an exercise
price of $0.14 per share. In establishing this exercise price, our board of directors considered input from management, including the valuation we conducted of our common stock as of March 31, 2013, as well as the objective and subjective factors
outlined above. At the grant date, our board of directors considered the events and circumstances most likely to affect the value of our common stock that occurred between March 31, 2013 and the grant date and whether those events and circumstances
were part of the assumptions used in the March 31, 2013 valuation. Our board of directors determined that there were no other events and circumstances that occurred between March 31, 2013 and June 19, 2013 that were indicative of a significant
change in the fair value of our common stock. Based on these factors, our board of directors determined that the fair value of our common stock at June 19, 2013 was $0.14 per share. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:3%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>June 30, 2013 Valuation </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In this quarterly valuation, we again used the PWERM method to allocate value to our common stock as of June 30, 2013. For the various scenarios, we utilized a combination of the market approach (e.g.,
consideration of pre-money IPO value indications from companies in the pharmaceutical and biotechnology industries with similar product candidates and at similar stages of clinical development) and the income approach (e.g., projected future cash
flows) to determine the value of our business and ultimately the fair value of our common stock. We utilized the following probability-weighted scenarios to determine the equity value of our company: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="86%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:29pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Scenario</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Probability</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">An IPO by fourth quarter 2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">An IPO by first quarter 2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">A merger or acquisition by third quarter 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Remain private through the end of 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In this valuation, we believed that the possibility of a fourth quarter 2013 IPO was more probable than
in previous valuations. This is due primarily to the recent market for biotechnology IPOs. We assigned a 32.5% </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">68 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
probability to that scenario. While we determined that this was the most likely scenario, we assigned a 22.5% probability to an IPO in the first quarter of 2014. We determined that the likelihood
of a merger or acquisition by the third quarter of 2015 was relatively low based on the timing of availability of key clinical data and assigned a probability of 15.0% to that scenario. We determined that given our relatively low need to raise
capital as a result of our collaboration agreements and anticipated milestone payments, the scenario where we would remain a private company was more likely and therefore assigned a probability of 30.0% to that scenario. We concluded that after
applying a discount rate of 15.0% for lack of marketability, the value of our common stock at June 30, 2013 was $0.25 per share. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Stock Option Grants in July 2013 </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our board of directors granted options
to purchase common stock on July 19, 2013, with each option having an exercise price of $0.25 per share. In establishing this exercise price, our board of directors considered input from management, including the valuation we conducted of our common
stock as of June 30, 2013, as well as the objective and subjective factors outlined above. At the grant date, our board of directors considered the events and circumstances most likely to affect the value of our common stock that occurred between
June 30, 2013 and the grant date and whether those events and circumstances were part of the assumptions used in the June 2013 valuation. Our board of directors determined that there were no other events and circumstances that occurred between June
30, 2013 and July 19, 2013 that were indicative of a significant change in the fair value of our common stock. Based on these factors, our board of directors determined that the fair value of our common stock at July 19, 2013 was $0.25 per share.
</FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>August&nbsp;31, 2013 Valuation</I> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In this valuation, we again used the PWERM method to allocate value to our common stock as of August&nbsp;31, 2013. For the various scenarios, we utilized a combination of the market approach (e.g. ,
consideration of pre-money IPO value indications from companies in the pharmaceutical and biotechnology industries with similar product candidates and at similar stages of clinical development) and the income approach (e.g., projected future cash
flows) to determine the value of our business and ultimately the fair value of our common stock. We utilized the following probability-weighted scenarios to determine the equity value of our company: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="70%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:29pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Scenario</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Probability</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">An IPO by fourth quarter 2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">60.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">An IPO by first quarter 2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">A merger or acquisition by third quarter 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Remain private through end of 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
</TABLE>   <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In this valuation, we believed that given where we were in the IPO process and the recent
activity of IPOs in our industry, the possibility of a fourth quarter 2013 IPO was much more probable than in previous valuations and therefore assigned a 60.0% probability to that scenario. While we determined that a fourth quarter 2013 IPO was the
most likely scenario, we assigned a 15.0% probability to the scenario where an IPO is completed by the first quarter of 2014. We again determined that the likelihood of a merger or acquisition by the third quarter of 2015 was relatively low based on
the timing of availability of key clinical data and assigned a 15.0% probability to that scenario. We determined that given our progress in the IPO process, the scenario to remain a private company through the end of 2015 was relatively low and
assigned a 10.0% probability to that scenario. We concluded that after applying a discount rate of 12.5% for lack of marketability, the value of our common stock at August&nbsp;31, 2013 was $0.40 per share. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">69 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock Option Grants in September 2013 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our board of directors granted options to purchase common stock on September&nbsp;18, 2013, with each option having an exercise price of
$0.40 per share. In establishing this exercise price, our board of directors considered input from management, including the valuation we conducted of our common stock as of August&nbsp;31, 2013, as well as the objective and subjective factors
outlined above. At the grant date, our board of directors considered the events and circumstances most likely to affect the value of our common stock that occurred between August&nbsp;31, 2013 and the grant date and whether those events and
circumstances were part of the assumptions used in the August 2013 valuation. Our board of directors determined that there were no other events and circumstances that occurred between August&nbsp;31, 2013 and September&nbsp;18, 2013 that were
indicative of a significant change in the fair value of our common stock. Based on these factors, our board of directors determined that the fair value of our common stock at September&nbsp;18, 2013 was $0.40 per share. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Determination of Estimated Offering Price </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In June 2013, we selected underwriters for this offering. The midpoint of the preliminary range for this offering as determined by us and the underwriters was $&nbsp;&nbsp;&nbsp;&nbsp; per share. In
comparison, our estimate of the fair value of our common stock was $0.25 per share as of the June 30, 2013 valuation. We note that, as typical in IPOs, the preliminary range was not derived using a formal determination of fair value, but was
determined based upon discussions between us and the underwriters. Among the factors that were considered in setting this range were our prospects and the recent market prices of, and the demand for, publicly traded common stock of comparable
companies. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We believe that the difference between the fair value of our common stock as of June 30, 2013 and the midpoint of
the estimated price range for this offering is the result of these factors as well as the fact that the estimated IPO price range necessarily assumes that the IPO has occurred, a public market for our common stock has been created and our preferred
stock has converted into common stock in connection with the IPO. The estimated IPO price range therefore excludes any discount for lack of marketability of our common stock and any consideration of the preferences of our convertible preferred
stock, which we factored into the June 30, 2013 contemporaneous valuation. In addition, since the time of the June 30, 2013 valuation, our product candidates have continued to progress through clinical and pre-clinical development, including
achievement of additional partial responses in our margetuximab Phase 1 clinical trial, and we have had further discussion with the FDA regarding our development plans for a potential Phase 3 clinical trial of margetuximab in gastroesophageal
cancer; we received a $10 million milestone payment for dosing a first patient in the dose expansion portion of our MGA271 Phase 1 clinical trial; we have generated additional supportive pre-clinical data for multiple proprietary as well as
partnered DART-based programs; and finally, other clinical-stage oncology companies, including those with differentiated technology platforms, have gone public during this time. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>JOBS Act </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In April 2012, the Jumpstart Our Business Startups Act of
2012, or the JOBS Act, was enacted. Section 107 of the JOBS Act provides that an &#147;emerging growth company&#148; can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, or
the Securities Act, for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably
elected not to avail ourselves of this extended transition period and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are in the process of evaluating the benefits of relying on other exemptions and reduced reporting requirements under the JOBS Act.
Subject to certain conditions, as an emerging growth company, we may rely on certain of these exemptions, including without limitation, (i) providing an auditor&#146;s attestation report on our
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">70 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
system of internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act and (ii)&nbsp;complying with any requirement that may be adopted by the Public Company
Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#146;s report providing additional information about the audit and the financial statements, known as the auditor discussion and analysis. We will
remain an emerging growth company until the earlier of (i) the last day of the fiscal year in which we have total annual gross revenues of $1 billion or more; (ii) the last day of the fiscal year following the fifth anniversary of the date of the
completion of this offering; (iii) the date on which we have issued more than $1 billion in nonconvertible debt during the previous three years; or (iv) the date on which we are deemed to be a large accelerated filer under the rules of the
Securities and Exchange Commission. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Results of Operations for the Six Months Ended June&nbsp;30, 2012 and 2013 </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Research and Development Revenue </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The following represents a comparison of our research and development revenue for the six months ended June&nbsp;30, 2012 and 2013: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="86%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="54%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:93pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Six Months&nbsp;Ended&nbsp;June&nbsp;30,</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="6" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:67pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Increase/(Decrease)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(dollars&nbsp;in&nbsp;millions)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Revenues:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenue from collaborative research</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">34.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(12.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(37</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Grant revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(69</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total revenues</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">38.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(15.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(39</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)%&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The decrease in collaboration revenue of $15.0 million from the six months ended June&nbsp;30, 2012 to
the same period in 2013 is primarily due to the conclusion of the teplizumab clinical trial related reimbursement from our former collaborator, Eli Lilly. Aside from reimbursing us for the continued monitoring expense of one on-going trial, Eli
Lilly&#146;s participation in the teplizumab development concluded in the first quarter of 2013. In addition, we have experienced a reduction in the amount of revenue from our government grants in the first half of 2013 as compared to the same
period in 2012. This is due primarily to the completion of grants to study H5N1 influenza virus, small pox and West Nile virus. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Research and Development Expense </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The following represents a comparison of our research and development expense for the six months ended June&nbsp;30, 2012 and 2013: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="86%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="57%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:93pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Six Months&nbsp;Ended&nbsp;June&nbsp;30,</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="6" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:50pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Increase/(Decrease)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(dollars&nbsp;in&nbsp;millions)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Research and development expense</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Margetuximab</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">MGA271</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">DART-based product candidates</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">108</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Teplizumab</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(87</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other discovery and pre-clinical programs, collectively</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(49</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total research and development expense</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)%&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">71 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">During the six months ended June&nbsp;30, 2013, as compared to the same period in 2012, our
research and development expense decreased overall by $3.9 million. This was due primarily to the reduction in spending on teplizumab related clinical development as we ended trial enrollment and began closing down the trials during this period. In
addition, we significantly reduced our CSLC related activities. These decreases were partially offset by an increase in spending on MGA271 and our various DART-based product candidates. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>General and Administrative Expense </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following represents a
comparison of our general and administrative expense for the six months ended June&nbsp;30, 2012 and 2013: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="86%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="55%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:93pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Six Months&nbsp;Ended&nbsp;June&nbsp;30,</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="6" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:66pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Increase/(Decrease)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(dollars&nbsp;in&nbsp;millions)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>General and administrative expense</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">General and administrative expense for the six months ended June&nbsp;30, 2013 was $0.2 million higher
than the same period in 2012 primarily due to an increase in patent filing and related legal expenses. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Results of Operations for the Years
Ended December&nbsp;31, 2011 and 2012 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Research and Development Revenue </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following represents a comparison of our research and development revenue for the years ended December&nbsp;31, 2011 and 2012:
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="86%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="53%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:89pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:67pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Increase/(Decrease)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(dollars&nbsp;in&nbsp;millions)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Revenues:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenue from collaborative research</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">47.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">59.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">27</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Grant revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(59</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total revenues</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">57.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">63.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Collaboration revenue was $12.6 million higher for the year ended December&nbsp;31, 2012 compared to the
year ended December&nbsp;31, 2011 primarily due to two Servier collaborations signed in late 2011 and late 2012. Grant revenue decreased as our contract with the U.S. government to develop a monoclonal antibody for the treatment of West Nile Virus
ended in September 2011. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">72 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Research and Development Expense </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following represents a comparison of our research and development expense for the years ended December&nbsp;31, 2011 and 2012:
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="86%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="54%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:89pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="6" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:67pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Increase/(Decrease)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(dollars&nbsp;in&nbsp;millions)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Research and development expense</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Margetuximab</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">MGA271</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">31</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">DART-based product candidates</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">64</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Teplizumab</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">66</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other discovery and pre-clinical programs, collectively</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(56</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total research and development expense</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">41.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">45.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expenditures in research and development increased by $4.3 million overall from the year ended
December&nbsp;31, 2011 to the year ended December&nbsp;31, 2012. This was due to the following: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Increased spending in support of the MGA271 Phase 1 clinical trial; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Increased spending on toxicology related studies and increased efforts on our DART-based product candidates as a result of additional collaborations;
and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Despite ceasing enrollment on teplizumab-related clinical trials, we continued to follow the patients for an additional 18 months and closed down the
trials in late 2012. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">These increases were partially offset by: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Completion of our contract with the U.S. government to study West Nile Virus that resulted in a reduction in spending; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reduced spending on our CSLC efforts. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>General and Administrative Expense </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following represents a
comparison of our general and administrative expense for the years ended December&nbsp;31, 2011 and 2012: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="86%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="53%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:89pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="6" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:67pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Increase/(Decrease)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(dollars&nbsp;in&nbsp;millions)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>General and administrative expense</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)%&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The decrease in general and administrative expense of $0.7 million is due primarily to reduced patent
filing and related legal expense, which was partially offset by an increase in the amount of bonuses paid in the year ended December&nbsp;31, 2012. Additionally, we realized a savings from a consolidation of personnel from three to two facilities in
Rockville, Maryland. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">73 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cash Flows </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The following table represents a summary of our cash flows for the years ended December&nbsp;31, 2011 and 2012 and the six months ended June&nbsp;30, 2013: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="86%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:89pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:93pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:24pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;2011&nbsp;&nbsp;</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:24pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;2012&nbsp;&nbsp;</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:32pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;2012&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:32pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(dollars in millions)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Net cash provided by (used in):</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(18.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(13.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Investing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Financing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Net increase (decrease) in cash and cash equivalents</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(18.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(14.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Operating Activities </I></B></FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Net cash used in operating activities reflects, among other things, the amounts used to run our clinical trials and perform toxicology studies. The differences between the year ended December&nbsp;31,
2011 and 2012 were primarily due to the upfront fees received from our collaborators. The primary difference between the six months ended June&nbsp;30, 2012 and 2013 was due to the recognition of upfront fees and accounts receivable due from our
collaborators. The decrease in accounts payable from the year ended December 31, 2011 to the year ended December 31, 2012 and from the six months ended June 30, 2012 to the six months ended June 30, 2013, is due to the fluctuation in payments due to
clinical research organizations. Specifically, we ceased enrollment of the teplizumab trial in late 2011. While we did continue to incur costs under this trial, we were no longer enrolling new patients and the costs significantly decreased from the
prior year. </FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Investing Activities </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Net cash used in investing activities in all periods was primarily due to the acquisition of additional lab equipment needed to further our research and development activities. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Financing Activities </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Other than stock option exercises, we had no financing activity in the six months ended June&nbsp;30, 2013 or 2012 and in the year ended December&nbsp;31, 2012. However, during the year ended
December&nbsp;31, 2011 we sold 18.4&nbsp;million shares of Series D-2 preferred stock to our collaborators for net proceeds of $12.0 million. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Liquidity and Capital Resources </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Since our inception through June&nbsp;30, 2013, we have raised an aggregate of $547.4 million to fund our operations. Of this total amount, we have received $151.3 million from the sale of preferred
stock, $341.8 million from our collaborators, including payments in the form of upfront, milestone and annual maintenance payments and reimbursement for research and development services performed, and $54.3 million from government grants and
contracts. As of June&nbsp;30, 2013, we had $33.8 million in cash and cash equivalents. Subsequently, we received a $10&nbsp;million milestone payment in August 2013. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In addition to our existing cash and cash equivalents, we expect to continue to receive additional reimbursement from our collaborators for research and development services rendered, additional milestone
payments, annual license maintenance payments and grant revenue. However, our ability to receive these milestone payments is dependent upon our ability to achieve certain levels of research and development activities and is therefore uncertain at
this time. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">74 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Funding Requirements </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have not generated any revenue from product sales to date and do not expect to do so until such time as we obtain regulatory approval of and commercialize one or more of our product candidates. As we
are currently in the clinical trial stage of development, it will be some time before we expect to achieve this and it is uncertain that we ever will. We expect that we will continue to increase our operating expenses in connection with ongoing as
well as additional clinical trials and pre-clinical development of product candidates in our pipeline. We expect to continue our collaboration arrangements and will look for additional collaboration opportunities. We also expect to continue our
efforts to pursue additional grants and contracts from the U.S. government in order to further our research and development. Based upon our current operating plan, we anticipate that the net proceeds from this offering, together with our existing
cash and cash equivalents, will enable us to fund our operating expenses and capital expenditure requirements for at least the next 18 months. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Contractual Obligations and Contingent Liabilities </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The following table represents future minimum operating lease payments under noncancelable operating leases as of June&nbsp;30, 2013: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="86%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:55pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Less&nbsp;than&nbsp;1&nbsp;year</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:38pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>1&nbsp;to&nbsp;3&nbsp;years</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:38pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>3&nbsp;to&nbsp;5&nbsp;years</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:62pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>More&nbsp;than&nbsp;5&nbsp;years</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in millions)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Operating Leases</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our current obligations and contingent liabilities are limited to the operating leases at our three
facilities, including two in Rockville, Maryland and one in South San Francisco, California. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with an Asset
Purchase Agreement with Tolerance Therapeutics, Inc., or Tolerance, entered into in June 2005, we may be required to give Tolerance additional consideration as follows: (i)&nbsp;a maximum of $10.9&nbsp;million if certain milestones are met,
including the initiation of Phase&nbsp;3 trials and the filing of various regulatory product license applications; (ii) 678,398 shares of our common stock; and (iii) royalty payments between 1.75% and 4.0% of net sales of products acquired from or
patented by Tolerance or other product fees earned by us. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In July 2008, we acquired Raven Biotechnologies, or Raven. The
Raven purchase agreement provides for certain contingent payments that are based on the achievement of development and commercialization activities for product candidates derived from the acquired Raven technology. We are required to make a onetime
payment of $5.0 million to the former Raven stockholders upon the initiation of patient dosing in the first Phase&nbsp;2 clinical trial of any product derived from the Raven cancer stem cell program. No payment shall be made if the Phase&nbsp;2
trial start date has not occurred on or before July 15, 2018. Other consideration includes a percentage of revenue (excluding consideration for research and development, equity and certain cost reimbursements) we may receive for each license of a
product candidate derived from the Raven cancer stem cell program. The revenue percentage in each case is based upon the execution date of the subject license. No consideration is owed for licenses executed after July 16, 2018. There is additional
contingent consideration of one time payments of $8 million and $12 million, which depend upon the achievement of a specified level of sales of a product derived from the Raven cancer stem cell program. At our sole discretion, each payment can be
made in cash, common stock or a combination thereof. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The contractual obligations table does not include any potential future
payments we may be required to make under our Asset Purchase Agreement with Tolerance or the purchase agreement with Raven. Due to the uncertainty of the achievement and timing of the events requiring payment under that agreement, the amounts to be
paid by us are not fixed or determinable at this time. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">75 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Off-Balance Sheet Arrangements </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have never entered into any off-balance sheet arrangements, as defined under the rules and regulations of the Securities and Exchange
Commission. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Tax Loss Carryforwards </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We are already subject to Section&nbsp;382 limitations due to an acquisition we made in 2008. As of December&nbsp;31, 2012, we had federal NOL carryforwards of $100.9 million, state NOL carryforwards of
$64.2&nbsp;million and research and development tax credit carryforwards of $21.8 million available. Future changes in stock ownership, including resulting from this offering, may also trigger an ownership change and, consequently, another
Section&nbsp;382 limitation. Any limitation may result in expiration of a portion of the net operating loss or tax credit carryforwards before utilization which would reduce our gross deferred income tax assets and corresponding valuation allowance.
As a result, if we earn net taxable income, our ability to use our pre-change net operating loss carryforwards and tax credit carryforwards to reduce United States federal income tax may be subject to limitations, which could potentially result in
increased future cash tax liability to us. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Recent Accounting Pronouncements </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In May&nbsp;2011, FASB issued ASU No.&nbsp;2011-04, which amended ASC Topic 820 to achieve common fair value measurements and disclosure
requirements in U.S. GAAP and International Financial Reporting Standards, or IFRS. The amendments in ASU No.&nbsp;2011-05 result in common fair value measurement and disclosure requirements in U.S. GAAP and IFRS. Consequently, the amendments change
the wording used to describe many of the requirements in U.S. GAAP for measuring fair value and for disclosing information about fair value measurements. This amendment is effective for fiscal years, beginning after December&nbsp;15, 2011. The
adoption of this amendment did not have a material impact on our consolidated financial statements for the year ended December&nbsp;31, 2012. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In June&nbsp;2011, the FASB issued ASU No.&nbsp;2011-05, which amended ASC Topic 220 regarding presentation of comprehensive income. The amendments in ASU No.&nbsp;2011-05 require that all nonowner
changes in stockholders&#146; equity be presented either in a single continuous statement of comprehensive income or in two separate but consecutive statements. In the two-statement approach, the first statement should present total net income and
its components followed consecutively by a second statement that should present total other comprehensive income, the components of other comprehensive income, and the total of comprehensive income. This amendment is effective for fiscal years
beginning after December&nbsp;15, 2011. The adoption of this amendment did not have a material impact on our consolidated financial statements for the year ended December&nbsp;31, 2012. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We evaluated all ASUs through the date the consolidated financial statements were issued and believe that the adoption of these will not
have a material impact on our consolidated financial statements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Quantitative and Qualitative Disclosures about Market Risk
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our primary objective when considering our investment activities is to preserve capital in order to fund our operations.
As of June 30, 2013, we had cash and cash equivalents of $33.8 million, of which $29.0 million was invested in money market funds. Our primary exposure to market risk is related to changes in interest rates and our current investment policy is to
invest principally in deposits and securities issued by the U.S. government and its agencies and money market instruments. We do not believe that our cash and cash equivalents have significant risk. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">76 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom575431_10"></A>BUSINESS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Overview </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are a
clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. We generate our pipeline of product candidates from our proprietary
suite of next-generation antibody technology platforms, which we believe improve the performance of monoclonal antibodies and antibody-derived molecules. These product candidates, which we have identified through our understanding of disease biology
and immune-mediated mechanisms, may address disease-specific challenges which are not currently being met by existing therapies. We create both differentiated molecules that are directed to novel cancer targets, as well as &#147;bio-betters,&#148;
which are drugs designed to improve upon marketed medicines. The combination of our technology platforms and antibody engineering expertise has allowed us to generate promising product candidates and enter into several strategic collaborations with
global pharmaceutical and biotechnology companies. These collaborations provide us with funding and allow us to leverage the additional expertise of these collaborators to advance the development of our product candidates. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have three versatile, proprietary technology platforms consisting of: (1)&nbsp;our Dual Affinity Re-Targeting, or DART, platform,
which enables the targeting of multiple antigens or cells by using a single molecule with an antibody-like structure, and also includes the ability to recruit any T cell in a patient&#146;s body to destroy targeted cancer cells; (2)&nbsp;our Fc
Optimization platform, which enhances the body&#146;s immune system to mediate the killing of cancer cells through a mechanism called antibody-dependent cellular cytotoxicity, or ADCC, in which antibodies and immune cells cooperate to destroy
targets such as tumor cells; and (3)&nbsp;our Cancer Stem-like Cell, or CSLC, platform, which provides a unique discovery tool to identify cancer targets shared both by tumor-initiating cells and the differentiated cancer cells derived from them.
These versatile technology platforms can be applied in combination with one another to custom-design an antibody or antibody-derived molecule that is optimized to treat a specific disease. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Antibodies, which are proteins produced by specialized cells of the body&#146;s immune system usually in response to foreign substances,
such as bacteria and viruses, or to cancer cells, serve as the primary resource for our product candidates. Many of our cancer product candidates are derived from our library of over 1,900 purified antibodies. Our antibodies are targeted to more
than 70 different antigens, or components of the foreign substance that induce the production of antibodies, expressed on the surface of cancer cells. In addition, we continue to generate new antibodies for our library using our proprietary CSLC
lines and soluble protein antigens. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We initially select a specific antibody based on its functional properties related to a
disease target as well as its distribution on tissues in the body. We then utilize one or more of our technology platforms for engineering and optimizing our product candidate. We believe our approach allows us to take advantage of the enhanced
properties of an engineered antibody or antibody-derived molecule to kill cancer cells and to interfere with autoimmune diseases more effectively than a wild type, or non-engineered, monoclonal antibody. Our methods for improving the effectiveness
of antibodies include the following: enhancing the body&#146;s immune system, targeting multiple antigens on the surface of the same target cell, increasing the strength of the binding of an antibody to its antigen targets, and reducing the
likelihood of an unwanted immune response to the antibody or antibody-derived molecule. We believe our differentiated product candidates have the potential to provide new approaches to treat cancer, autoimmune disorders and other complex diseases.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We currently have two oncology product candidates in clinical development. Additionally, we have several proprietary product
candidates in pre-clinical development and we expect to commence Phase 1 clinical trials on two of these product candidates in 2014. We believe the profile of our compounds provides us with the flexibility to pursue either monotherapy or combination
therapy, depending on disease characteristics, current standards of care, and overall safety, tolerability, and efficacy of specific regimens. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">77 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The table below depicts the current status of our product candidates: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g575431g95y29.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Margetuximab</I>, also known as MGAH22, is a monoclonal antibody that targets HER2-expressing tumors, including breast, gastroesophageal, bladder
and other cancers. HER2, or human epidermal growth factor receptor 2, is critical for the growth of many types of tumors. Using our Fc Optimization platform, we have engineered the constant region, or Fc region, of margetuximab to enhance the
antibody&#146;s ability to kill tumor cells expressing lower levels of HER2 than that of currently approved anti-HER2 agents (such as Herceptin) and also to increase margetuximab&#146;s ability to kill tumor cells through ADCC. We designed
margetuximab to benefit a large sub-group of patients, which represents 80% or more of the overall population whose Fc receptors, or Fc<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>Rs, expressed on immune cells bind less effectively to currently
available antibodies that have not been optimized by our technology. Margetuximab represents a new class of bio-betters that may potentially help larger HER2+ patient populations than those treated with current HER2 therapies, as well as improve the
outcomes for patients who would be eligible for other HER2 targeted drugs and drug candidates. Phase 1 data from our open-label, dose escalation trial of margetuximab presented at the June 2013 Annual Meeting of the American Society of Clinical
Oncology, or ASCO, demonstrated anti-tumor activity had been observed at a range of doses tested, including the lowest dose level of margetuximab, even in patients who were heavily pre-treated (frequently including with other anti-HER2 agents). We
currently are enrolling a Phase 2a clinical trial in metastatic breast cancer and anticipate commencing a Phase 3 potential registration clinical trial in advanced gastroesophageal cancer in the second half of 2014. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>MGA271</I> is an Fc-optimized monoclonal antibody that targets B7-H3, a member of the B7 family of molecules which are involved in immune
regulation, and is over-expressed on a wide variety of solid tumor types. MGA271 represents one of the few novel molecules that may provide relief from immune checkpoint inhibition by releasing a restraint, or brake, on the anti-tumor immune
response. Inhibition of immune checkpoints has been shown to have powerful anti-tumor effects in several solid tumor types. For example, in presentations by others at ASCO and in publications in the <I>New England Journal of Medicine,</I> complete
or partial tumor regression was observed in patients with certain cancers who participated in clinical trials of antibodies targeting CTLA4, PD-1 and PD-L1, which are also members of the B7 family or their associated checkpoint receptors on
T&nbsp;cells. We have engineered MGA271 to utilize the same Fc Optimization enhancements that we </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">78 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="11%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P><FONT STYLE="font-family:Times New Roman" SIZE="2">
incorporated in margetuximab, and to target the over-expression of B7-H3 on differentiated tumors and CSLCs, as well as on the supporting tumor vasculature and underlying tissues. MGA271 is
designed to destroy all of these components of the cancer in addition to reducing its inhibitory properties on T cells. We have initiated a Phase 1 clinical trial that we expect to complete by the end of 2014. We plan to initiate a Phase 2 clinical
trial no later than early 2015. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>MGD006 </I>is a humanized DART molecule that recognizes both CD123 and CD3. CD123, the Interleukin-3 receptor, or IL3R, alpha chain is expressed on
leukemia and leukemic stem cells, but not on normal hematopoietic stem cells. T cells, which express CD3, can destroy tumor cells. In pre-clinical studies, we have demonstrated the ability of MGD006 at extremely low doses to recruit, activate, and
expand T cell populations to eliminate leukemia cells. We expect to commence a Phase 1 clinical trial of MGD006 in the first half of 2014. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>MGD007</I> is a humanized DART molecule that recognizes both the glycoprotein gpA33 and CD3. gpA33 is expressed on gastrointestinal tumors,
including more than 95% of human colon cancers. We have demonstrated that this molecule is able to mediate T&nbsp;cell killing of gpA33-expressing cancer cells and CSLCs in pre-clinical experiments. We expect to commence a Phase 1 clinical trial of
MGD007 in the second half of 2014. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We pursue a balanced approach between product candidates that we develop
ourselves and those that we develop with our collaborators. Under our current strategic collaborations we have received approximately $106 million in non-equity funding over the three year period ended June 30, 2013. Under these agreements we are
entitled to receive substantial milestone and other payments, including over $100 million of potential payments that we believe are likely to be received by the end of 2015, assuming all of our collaboration programs advance as currently
contemplated. Our collaborators include: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Servier</I>. In November 2011, we entered into a collaboration agreement with Servier under which we granted Servier an option to obtain an
exclusive license to develop and commercialize MGA271 in all countries other than the United States, Canada, Mexico, Japan, South Korea and India. We have received a $20 million option grant fee and a $10 million milestone payment upon dosing the
first patient in the expansion cohort of our Phase I clinical trial of MGA271, and may be eligible to receive up to approximately $415&nbsp;million in license grant fees, and clinical, development, regulatory and sales milestone payments if Servier
exercises the option, obtains regulatory approval for, and successfully commercializes an MGA271 licensed product. In the event Servier exercises its option, Servier must pay a license grant fee, which we estimate to be $30 million, based on the
number of different indications represented within the planned Phase 1 patient population. We and Servier will share Phase 2 and Phase 3 development costs. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">In September 2012, we entered into a second agreement with Servier and granted it options to obtain three separate exclusive licenses to develop and commercialize
DART-based molecules, consisting of those designated by us as MGD006 and MGD007, as well as a third DART-based molecule, in all countries other than the United States, Canada, Mexico, Japan, South Korea and India. We received a $20 million option
grant fee. In addition, we will be eligible to receive up to approximately $1 billion in additional license grant fees, and clinical, development, regulatory and sales milestone payments if Servier exercises all three of its options and successfully
develops, obtains regulatory approval for, and commercializes a product under each license, including $5&nbsp;million upon IND acceptance for each of MGD006, MGD007 and a third DART molecule. In addition to these milestones, we and Servier will
share Phase 2 and Phase 3 development costs. </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additionally, under both agreements, Servier would be obligated to pay us low doublt digit to mid-teen royalties on product sales in its territories.
</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">79 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Gilead.</I> In January 2013, we entered into an agreement with Gilead to grant it an exclusive worldwide license to research, develop and
commercialize up to four DART-based molecules. Gilead has exclusive worldwide rights for three of the programs. For one program, we retain development and commercialization rights outside of North America, the European Union, Norway, Iceland,
Turkey, Australia and New Zealand. We received an initial $7.5 million license grant fee for the first DART-based molecule, and are eligible to receive up to an additional $22.5 million in grant fees on the remaining three DART-based molecules. We
are further eligible to receive up to an additional $85 million in pre-clinical milestones across the four DART programs and up to approximately $1 billion in additional clinical, regulatory and sales milestone payments if Gilead exercises all four
of the options and achieves all of the requisite milestones under each option and license. Gilead also provides funding for our internal and external research costs under the agreement. We are also eligible to receive tiered royalties on the net
sales at percentages ranging from the high-single digits to the low double digits, but less than teens, subject to reductions in specified circumstances. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Boehringer</I>. In October 2010, we entered into an agreement with Boehringer to discover, develop and commercialize up to ten DART-based molecules
which may span multiple therapeutic areas. We granted Boehringer an exclusive worldwide, royalty-bearing, license and received an upfront payment of $15 million. We subsequently received two annual maintenance payments and anticipate receiving a
third annual maintenance payment in the fourth quarter of 2013. We have the potential to earn development, regulatory and sales milestone payments that can reach up to approximately $210 million for each of the DART programs under this agreement.
Boehringer provides funding for our internal and external research costs and is required to pay us mid-single digit royalties on product sales. Boehringer purchased $10 million of our Series D-2 Preferred Stock in January 2011.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Pfizer.</I> In October 2010, we entered into a three year agreement with Pfizer to discover, develop and commercialize up to two DART-based
molecules. We granted Pfizer a non-exclusive worldwide, royalty-bearing license and received upfront and milestone payments and funding for our internal and external research costs under the agreement. We are eligible to receive technical,
development and sales milestone payments that can reach up to approximately $210 million for each DART program under this agreement. Pfizer is responsible for all pre-clinical and clinical development costs for the program. In addition, Pfizer is
required to pay us mid-single digit to low-teen royalties on product sales. Under this collaboration, one DART program is currently being pursued and we will complete our research obligations under this program in January 2014.
</FONT></P></TD></TR></TABLE>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We currently manufacture all of the drug substance for research and development efforts for all of our
product candidates in-house. Drug substance for all of our clinical trials is manufactured using current good manufacturing practices, or cGMP, at our manufacturing facility, located in Rockville, Maryland. We contract with vendors to provide fill
finish manufacture of drug product. We currently have capacity to produce Phase 2 material for our antibody product candidates and all clinical and commercial material for our DART therapeutics. We intend to enter into agreements with contract
manufacturing organizations to supplement our clinical supply and internal capacity as we advance additional pre-clinical candidates into clinical development. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Our Strategy </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our goal is to be a leader in the discovery, development and
commercialization of antibody-based therapeutics for the treatment of patients with cancer, autoimmune disorders and other complex diseases. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Key elements of our strategy to achieve this goal are to: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Rapidly and concurrently advance our clinical oncology product candidates in multiple tumor types. </I>We intend to pursue the fastest feasible
pathways to approval and to address large, underserved markets. We are developing product candidates that we believe could address disease </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">80 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="11%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P><FONT STYLE="font-family:Times New Roman" SIZE="2">
specific challenges which are not currently being met by existing therapies. We are currently enrolling a Phase 2a clinical trial of margetuximab in metastatic breast cancer for which we expect
to have results in 2014. We anticipate commencing a Phase 3 potential registration clinical trial of margetuximab in advanced gastroesophageal cancer in the second half of 2014. We are currently enrolling the dose-expansion portion of a Phase 1
clinical trial of MGA271 as a single-agent in the treatment of 45 patients with solid tumors, including: 15 patients with melanoma; 15 patients with prostate cancer and an additional group of 15 patients with other solid tumor types. Servier has
indicated that it intends to evaluate MGA271 in up to 90 additional cancer patients representing additional types of cancers beginning in the fourth quarter of 2013. We intend to assess and prioritize future indications for MGA271 clinical trials
based on data from these cohorts and determine the best path forward to potential commercialization. In addition, we are currently optimizing multiple DART therapeutics as candidates for clinical development. We anticipate that we will begin Phase 1
clinical trials of MGD006, our first DART candidate, in the first half of 2014, and MGD007, our second DART candidate, in the second half of 2014. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Leverage collaborative relationships. </I>We have multiple programs in development under our collaborations and are working closely with our
collaborators to advance these programs. We believe that these collaborations help to validate and rapidly advance our discovery efforts, technology platforms, and product candidates while providing significant funding to advance our pipeline and
access the development and commercial expertise of our collaborators. To facilitate the capital-efficient development and commercialization of our proprietary programs, we intend to enter into additional collaboration agreements with
biopharmaceutical companies. We anticipate that we would structure these collaborations in ways that would allow us to retain development and commercialization rights in key markets. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Create new product candidates that combine the potency and target selectivity of our DART and Fc Optimization technologies with small molecule and
toxin conjugation technologies</I>. We are working with several companies to combine their proprietary linkers and drug conjugates with our monoclonal antibodies. We believe that such linkers and drug conjugates can be combined with the selective
targeting properties of our DART technology and the enhanced immune activities of our Fc Optimization technology. Our goal is to identify and further develop new clinical candidates, either antibody-drug conjugates, or ADCs, or DART-drug conjugates,
through these research efforts. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Establish commercialization and marketing capabilities in the United States</I>. We have retained commercialization rights in the United States for
our clinical stage programs as well as the three DART programs that we are developing in collaboration with Servier. We intend to build a targeted specialty sales force and marketing capabilities in the United States to commercialize our product
candidates that receive regulatory approval. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Strengthen our leadership position in fully integrated antibody engineering and development capabilities. </I>We have built a powerful and fully
integrated set of capabilities that are critical to our ability to discover, optimize and develop antibody-based therapeutic product candidates in a rapid and efficient manner. We intend to build on our technology platforms, methods and know-how
that comprise our capabilities in order to expand our product pipeline. Our goal is to file one or more new investigational new drug applications, or INDs, annually for the next several years. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">81 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Background </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Immune System and Antibodies </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The immune system, composed of both
innate and adaptive elements, defends against invading pathogens such as viruses, parasites, and bacteria, and provides surveillance against cancers. The adaptive immune system includes: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">B cells, which mature into plasma cells and produce antibodies; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Helper T cells, including those that enable, or help, the B cells to produce antibodies; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cytotoxic T cells, which can destroy tumor cells or cells infected with viruses. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">T cells and B cells (and the antibodies derived from the mature B cell) of this adaptive immune system respond to small structural
differences found, for example, on a cancer cell. This normally imparts exquisite specificity on these individual immune components. As a result, billions of different structural variants can be recognized by the adaptive immune system, but each
individual T cell or B cell or antibody can only bind and respond to a single structure or molecule. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As shown in the
following illustration, the antibody is a Y-shaped molecule that has two identical variable regions at the tip of the arms of the antibody (Fab region), which bind to antigens, and a constant region (Fc), as its opposite end that binds to
F<I>c</I><I>y</I>Rs. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Monoclonal Antibody Structure </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g575431g79f34.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">An antibody&#146;s structure is amenable to engineering either the variable regions to improve its
strength of target recognition or affinity, or the constant regions to modify its engagement and collaboration with other components of the immune system, or both. The two variable region arms naturally target the same antigen; however, they can be
artificially engineered to target two different antigens, allowing the creation of a bi-specific antibody. The Fc region can bind, recruit and activate immune cells to amplify the immune response to targets bound by the variable region of the
antibody molecule. The Fc region can be modified to enhance the engagement with other immune cells and increase the potency of the immune response. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Therapeutic monoclonal antibodies are typically derived from natural antibodies and are obtained from immune cells of mammals that have been immunized with a desired antigen and are all clones of the
unique </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">82 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
parent cell. The antibody&#146;s ability to bind specifically to a target or antigen is also referred to as its specificity. Using this mechanism, antibodies can tag foreign substances for attack
by other immune system cells or neutralize the targets directly. In treating diseases such as cancer, researchers find antigens specific to cancer cells and create antibodies that bind those antigens to use the body&#146;s immune system to destroy
these cancer cells. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Monoclonal antibodies are typically produced in mice and although they are relatively easy to generate,
they can have drawbacks as targeted therapeutics. The major drawback is that a mouse monoclonal antibody is recognized by the human immune system as a foreign target and therefore, the immune system attacks the antibody, rendering it useless against
its intended target. Many advances have been made to genetically engineer and humanize monoclonal antibodies. In addition, fully human antibodies can be created, which also significantly reduce newly generated immune responses in patients treated
with monoclonal antibodies. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Cancer </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Cancer is a broad group of diseases in which cells divide and grow in an uncontrolled fashion, forming malignancies that can invade other parts of the body. In normal tissues, the rates of new cell growth
and cell death are tightly regulated and kept in balance. In cancerous tissues, this balance is disrupted as a result of mutations, causing unregulated cell growth that leads to tumor formation and growth. While tumors can grow slowly or rapidly,
the dividing cells will nevertheless accumulate and the normal organization of the tissue will become disrupted. Cancers subsequently can spread throughout the body by processes known as invasion and metastasis. Once cancer spreads to sites beyond
the primary tumor, it may be incurable. Cancer cells that arise in the lymphatic system and bone marrow are referred to as hematological malignancies. Cancer cells that arise in other tissues or organs are referred to as solid tumors. Cancer can
arise in virtually any part of the body, with the most common types arising in the prostate gland, breast, lung, colon and skin. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Cancer is the second leading cause of death in the United States, exceeded only by heart disease, and accounts for almost one of every four deaths. The American Cancer Society estimates that in 2013 there
will be approximately 1.6&nbsp;million new cases of cancer and approximately 580,000 deaths from cancer. The National Institutes of Health estimates that the direct medical cost of cancer of all types, including solid tumors, in the United States in
2010 was approximately $125 billion and according to IMS Health the amount spent in the United States on drugs to treat cancer exceeded $23 billion in 2011. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">83 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:3%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Solid Tumors&#151;Incidence and Therapies </I></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table sets forth information about selected solid tumor types for which we are developing, or may develop, therapeutic
product candidates. The estimated U.S. annual incidence and five-year relative survival rates are based on information from the American Cancer Society in 2013. Relative survival compares survival among cancer patients to that of people not
diagnosed with cancer who are of the same age, race and sex. It represents the percentage of cancer patients who are alive after a designated time period relative to persons without cancer. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Solid Tumors </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="21%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="61%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:43pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Tumor Type</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:32pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>U.S.<BR>Annual<BR>Incidence</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE="border-bottom:1px solid #000000;width:32pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B><FONT STYLE="white-space:nowrap">Five-year</FONT><BR>Relative<BR>Survival<BR>Rate</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:99pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Selected Marketed Therapies</B></FONT></P></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prostate</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">238,590</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">~100</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">sipuleucel-T (Provenge); radium 223 dichloride (Xofigo); docetaxel (Taxotere); abiraterome (Zytiga)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Breast</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">232,240</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">90</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">ado-trastuzumab emtansine (Kadcyla); trastuzumab (Herceptin); lapatinib (Tykerb); docetaxel (Taxotere); paclitaxel (Taxol, Abraxane); capecitabine (Xeloda); anastrazole
(Arimidex); letrozole (Femara); exemestane (Aromasin)</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lung</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">228,190</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">bevacizumab (Avastin); erlotinib (Tarceva); crizotinib (Xalkori); pemetrexed (Alimta)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Colorectal</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">142,820</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">65</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">bevacizumab (Avastin); ziv-aflibercept (Zaltrap); cetuximab (Erbitux); panitumumab (Vectibix)</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Melanoma</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">76,690</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">91</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">vemurafenib (Zelboraf); ipilimumab (Yervoy)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Bladder</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">72,570</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">80</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">doxorubicin hydrochloride (Adriamycin); cisplatin</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Kidney</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">65,150</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">72</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">bevacizumab (Avastin); axitinib (Inlyta); everolimus (Afinitor); temsirolimus (Torisel)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pancreatic</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">45,220</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">gemcitabine (Gemzar); erlotinib (Tarceva); protein-bound paclitaxel (Abraxane)</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ovarian</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22,240</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">44</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">paclitaxel (Taxol); topotecan (Hycamtin); etoposide (Etopophos); docetaxel (Taxotere); gemcitabine (Gemzar)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gastroesophageal</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,600</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">28</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">capecitabine (Xeloda); trastuzumab (Herceptin)</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to the marketed therapies listed above, there are many generic chemotherapies and regimens
commonly used to treat these cancers. Although the various marketed therapies and regimens provide benefits to some patients when given as monotherapies or in combination with other therapies, each has efficacy and adverse event limitations and none
of them are successful in treating all patients. The level of morbidity and mortality from these cancers remains high. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">84 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:3%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Hematological Malignancies&#151;Incidence and Therapies </I></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table sets forth information about the hematological malignancies for which we are developing, or may develop, therapeutic
product candidates. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Hematological Malignancies </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="36%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="43%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:43pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Tumor Type</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:32pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>U.S.<BR>Annual<BR>Incidence</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:46pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Five Year<BR>Relative<BR>Survival&nbsp;Rate</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:99pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Selected Marketed Therapies</B></FONT></P></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Acute myeloid leukemia</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,590</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">daunorubicin (DaunoXome); doxorubicin hydrochloride (Adriamycin); cyclophosphamide; cytarabine; vincristine sulfate</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Myelodysplastic syndromes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,673</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;<BR>&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Highly<BR>variable</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;<BR>&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">decitabine (Dacogen)</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Acute lymphocytic leukemia</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,070</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">68</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">dasatinib (Sprycel)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Hairy cell leukemia</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,199</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">93</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">cladribine; pentostatin; rituximab (Rituxan)</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Currently Available Cancer Treatments </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The most common methods of treating patients with cancer are surgery, radiation and drug therapy. A cancer patient often receives
treatment with a combination of these methods. For patients with localized disease, surgery and radiation therapy are particularly effective. Systemic drug therapies are generally used by physicians in patients who have cancer that has spread beyond
the primary site or cannot otherwise be treated through surgery. The goal of these therapies is to damage and kill cancer cells or to interfere with the molecular and cellular processes that control the development, growth and survival of cancer
cells. In many cases, drug therapy entails the administration of several different drugs in combination. Over the past several decades, drug therapy has evolved from non-specific drugs that kill both healthy and cancerous cells, to drugs that target
specific molecular pathways involved in cancer. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:3%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Cytotoxic Chemotherapies </I></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The earliest approach to pharmacological cancer treatment was to develop drugs, referred to as cytotoxic drugs, which kill rapidly
proliferating cancer cells through non-specific mechanisms, such as disrupting cell metabolism or causing damage to cellular components required for tumor survival and rapid growth. While these drugs have been effective in the treatment of some
cancers, cytotoxic drug therapies act in an indiscriminate manner, killing healthy cells along with cancerous cells. Due to their mechanism of action, many cytotoxic drugs have a narrow dose range above which the toxicity causes unacceptable or even
fatal levels of damage and below which the drugs are not effective in eradicating cancer cells. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:3%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Targeted Therapeutics
</I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The next approach to pharmacological cancer treatment was to develop drugs, referred to as targeted therapeutics,
including monoclonal antibodies, that target specific biological molecules in the human body that play a role in rapid cell growth and the spread of cancer. Included in this category are small molecule drugs as well as large molecule drugs, also
known as biologics. With heightened vigilance and new diagnostic tests, targeted therapies (including monoclonal antibodies such as Herceptin, Rituxan and Avastin as well as small molecules such as Nexavar and Tarceva), have resulted in improvements
in overall survival for many cancer patients. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">85 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Next Generation Antibody-based Therapeutics for Cancer </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">While targeted antibody therapeutics have been highly successful in treating various cancers, the therapeutic effects of many such
therapies are often relatively transient. Acquired resistance to cancer therapies remains a significant clinical problem with patients frequently relapsing and the tumors metastasizing to distant organs. The significant need for improvement in the
treatment of cancer through antibody-based therapies is driving the growing focus on next-generation antibody-based therapies. Opportunities to create next-generation antibody based therapeutics lie in several technology advances including:
antibodies that target multiple antigens, Fc-optimization, and ADCs. Multi-specific antibodies and ADCs have the potential to increase efficacy for cancer treatments and reduce systemic toxicity. Fc Optimization may enable modification of the
antibody to enhance the immune system&#146;s response and augment the therapeutic potential of the antibody, and may increase its half-life, which can potentially lead to less frequent dosing (a competitive advantage for injectables) and a lower
cost of goods. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Growth of the Biologics Market </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Over the last 20 years, recombinant biologic therapeutic drugs, including monoclonal antibodies, the largest subclass of recombinant biologics, have had a dramatic impact on cancer therapy. The
improvement of engineering technologies, efficacy and safety of biologic drugs have driven significant market growth, with worldwide sales in 2011 of $157 billion according to data from the IMS Institute for Healthcare Informatics. Data from La
Merie, a business intelligence firm, indicates that therapeutic antibody products represent approximately 52% of total biologic drug sales, with 2012 global sales of approximately $65 billion, an increase from approximately $22 billion in 2006.
Approximately 40 antibody product candidates have been approved by the FDA and international regulatory authorities since the first approval in 1986, and the three largest selling cancer drugs are monoclonal antibodies, Rituxan, Herceptin and
Avastin, which had 2012 worldwide sales of approximately $7.1 billion, $6.3 billion and $6.1 billion, respectively. Today, more than 300 monoclonal antibodies are in various stages of clinical development. According to a 2010 statistical analysis by
Tufts University, antibody product candidates have shown a 2.5 times higher probability of successful clinical development as compared to small-molecule drugs. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Our Platforms for Creating Next-Generation Antibody-based Therapies </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We
apply our understanding of disease biology, immune-mediated mechanisms and next generation antibody technologies to design highly targeted antibody-based product candidates. Our antibody-based platforms consist of: DART, Fc Optimization, and CSLCs.
Through these platforms, we have designed antibody-based product candidates that have the potential to improve on standard treatments by having: (1)&nbsp;multi-specificities; (2)&nbsp;increased abilities to interact with the body&#146;s immune
system to fight tumors; (3)&nbsp;capacity to bind more avidly to antigen targets: (4)&nbsp;increased potency; (5)&nbsp;reduced immunogenicity; or (6)&nbsp;the ability to target cancer cells which are resistant to standard treatments. Moreover, these
technology platforms are complementary and can be combined. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">86 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>DART Platform: Our Proprietary Approach to Engineer Multi-Specific Antibodies </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We use our DART platform to create derivatives of antibodies with the ability to bind to multiple targets instead of a single target
found in traditional monoclonal antibodies. Our current DART product candidates are bi-specific. An example of a bi-specific molecule is illustrated below: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g575431g77g14.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Because cancer cells have derived ways to escape the immune system, we have created DART molecules
which improve upon the human immune system, by creating alternative antibody-like structures with more potent immune properties than the parent antibody molecules from which they are derived. The two variable regions of an antibody are mono-specific
and are able to target only a single type structural component of an antigen. For many years, researchers have sought to create recombinant molecules that are multi-specific and capable of targeting multiple antigens or epitopes (i.e., specific part
of antigen bound to the antibody) within the same molecule. The challenges in creating such molecules have been the instability of the resulting bi-specifics and their inherent short half-lives, as well as the inefficiencies in manufacturing these
compounds. We believe our DART platform has overcome these engineering challenges by incorporating proprietary covalent di-sulfide linkages and particular amino acid sequences that efficiently pair the chains of the DART molecule. This results in a
structure with enhanced manufacturability, long-term structural stability, and the ability to tailor the half-lives of the DARTs to their clinical needs. This engineered antibody-like protein has a very compact and stable structure and enables the
targeting of multiple different antigens within a single recombinant molecule. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The DART platform has been specifically
engineered to accommodate virtually any variable region sequence with predictable expression, folding, and antigen recognition. To date, we have produced over 100 different DART molecules and have completed numerous <I>in vitro</I> and <I>in
vivo</I> proof of concept studies on most of these molecules. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">87 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We believe our DART platform may provide a significant advantage over current biological
interventions in cancer and autoimmune disorders by enabling a range of modalities, including those described below. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.40em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&nbsp;&nbsp;&nbsp;&nbsp;<I>Redirected T Cell Activation and Killing.</I> In this version of the DART molecule, we are
enabling the cancer-fighting properties of the adaptive immune system to: (1)&nbsp;recognize and bind to structures expressed on a cancer cell (e.g., CD123, the first specificity in the example on the right), (2)&nbsp;enable the recruitment of all
types of cytotoxic, or cell killing, T cells, irrespective of their ability to recognize cancer cells (e.g., CD3, a common component of the T cell antigen receptor, is the second specificity in the example on the right), and (3)&nbsp;trigger T cell
activation, expansion, and cell killing mechanisms to destroy a cancer cell. The outcome is that any of the body&#146;s T cells, in theory, could be recruited to destroy a cancer cell and thus, are not limited to the small numbers of specific T
cells that are normally generated to kill a cancer cell. Furthermore, since any T cell could be recruited for this killing process, only small amounts of a DART molecule are required to trigger this potent immune response. Additionally, the compact
structure of the DART protein makes it well suited for maintaining cell-to-cell contact, apparently contributing to the high level of target cell killing.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px">


<IMG SRC="g575431g18q24.jpg" ALT="LOGO">
</P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ROWSPAN="2"> <P STYLE="margin-left:5.40em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&nbsp;&nbsp;&nbsp;&nbsp;<I>Modulation of receptor signaling. </I>In another configuration of the DART molecule,
we have taken advantage of the two (or more) different specificities engineered in a DART structure to bind not only to particular cells involved in autoimmune processes, such as autoimmune B cells, but also to usurp the immune checkpoint signaling
pathways programmed within the cells to impede the pathogenic autoimmune responses. Our MGD010 product candidate targets both CD32B, a checkpoint inhibitory molecule, and CD79B, part of the B cell antigen receptor complex, two proteins expressed on
the immune system&#146;s B cells. Using a single DART molecule, we not only target two receptors with a single molecule, but also promote the interaction of these two receptors to interrupt the autoimmune response. This is critical because
interruption of the autoimmune B cell response cannot be achieved merely by using two separate antibodies. In this particular example, the activity of an immune checkpoint molecule, CD32B on B cells, is captured to curb a destructive immune
response.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px">


<IMG SRC="g575431g73g29.jpg" ALT="LOGO">
</P></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="middle"> <P STYLE="margin-left:5.40em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&nbsp;&nbsp;&nbsp;&nbsp;<I>Simultaneous targeting of multiple pathologic factors, such as cytokines and growth factors
and their receptors.</I> Targeting multiple soluble proteins or receptors that are important to the perpetuation of an autoimmune disease or generation of a cancer may create therapeutic synergies within a single DART molecule. Examples of this DART
include the targeting of different inflammatory cytokines, such as TNF-a, IL-1, and IL-6, involved in the pathogenesis of autoimmune diseases or those receptors contributing to the growth of cancers such as members of the EGFR family including
EGFR1, HER2 and HER3.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px">


<IMG SRC="g575431g85w60.jpg" ALT="LOGO">
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">88 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.40em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&nbsp;&nbsp;&nbsp;&nbsp;<I>Targeting multiple epitopes on a pathogen for enhanced neutralization and/or clearance.
</I>Infectious agents with slightly different genetic sequences or structures may perpetuate disease. Sometimes multiple variants may infect one individual and may evade the patient&#146;s normal immune responses. Creating DARTs that eliminate
multiple infectious variants of a virus or multiple toxins produced by a bacterium could be an advantage for prevention or treatment. Examples of this include targeting the major genetic and serological forms of dengue virus, the cause of a major
viral disease transmitted by mosquitoes, quasi-species of HIV, or different bacterial toxins derived from pathogenic clostridium species.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px">


<IMG SRC="g575431g37d02.jpg" ALT="LOGO">
</P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, we have the ability to tailor a DART molecule&#146;s valency (number of binding sites), the
strength by which the binding sites attach to its targets, and its half-life in the blood circulation after delivery to a patient. Furthermore, when an Fc domain is incorporated in a DART, changes can be included that can modulate the DART&#146;s
engagement with different immune cells. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have developed proof-of-concept data and are developing specific product
candidates using this technology, including MGD006, MGD007 and MGD010. We have been able to produce DART molecules in both bacterial and mammalian expression systems. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Fc Optimization Platform: Our Proprietary Approach to Enhance Immune-Mediated Cancer Cell Killing </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">To enhance the body&#146;s immune ability, we developed our Fc Optimization platform which introduces certain mutations into the Fc region of an antibody and is able to modulate antibody interaction with
immune effector cells. Such interaction enhances the body&#146;s immune ability to mediate the killing of cancer cells through ADCC. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>ADCC </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g575431g04y47.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Fc region mediates the function of certain antibodies by binding to different activating Fc<FONT
STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>Rs and inhibitory Fc<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>Rs on immune effector cells found within the innate immune system. By engineering Fc regions to bind with an increased affinity to the
activating Fc<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>Rs and with a reduced affinity to the inhibitory Fc<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>Rs, we </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">89 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
have been able to impart a more effective immune response, and improve effector functions, such as ADCC. This is another example in which small changes in antibody structure can confer
improvements on normal immune processes. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have established a proprietary platform to engineer, screen, identify and test
antibodies&#146; Fc regions with customizable activity. In particular, we have licenses to use transgenic mice that express human Fc<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>Rs. These mice can be used for <I>in vivo </I>testing of antibodies
that incorporate Fc domain variants, including those antibodies intended for cancer therapy. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To date, we have successfully
incorporated our Fc variants in our lead product candidates, margetuximab and MGA271. We have pre-clinical data demonstrating that these Fc variants have substantially improved the antibody&#146;s therapeutic effects. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Cancer Stem-like Cell Platform: Our Proprietary Approach to Discover Cancer Targets </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our CSLC platform provides new approaches to discover and identify cancer targets that are unresponsive to current cancer therapies.
Cancer stem cells represent important potential targets in oncology drug development because they are theorized to be the basis for tumor re-growth and metastasis and are refractory to much standard chemotherapy. Therefore, the ability to
specifically target and destroy CSLCs could potentially address an unmet medical need in many hard-to-treat cancers today. Using our CSLC platform, we can create antibodies that target and kill CSLCs. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Building on our expertise in growing stem cells from normal tissues using proprietary media and culture conditions, we have produced
CSLCs from primary human tumor tissues. These CSLCs have been generated <I>in</I> <I>vitro</I> from a range of solid tumors and many have demonstrated tumor growth and differentiation <I>in vivo</I>. We believe that this technology holds great
promise in creating the next generation of oncology therapeutics that target both differentiated tumor cells and their precursor cells which traditionally have been resistant to conventional chemotherapy and radiation therapy. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our strategy has been to generate CSLCs from a range of primary tumors, including those derived from the colon, lung and ovary. We
analyze and characterize the CSLCs for the following: (a)&nbsp;ability for self-renewal, (b)&nbsp;ability to form tumors <I>in vivo</I> that differentiate with the expected histological characteristics, and (c)&nbsp;genetic and protein stem cell
marker expression profiles. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To date, we have created novel antibodies that target antigens on both CSLCs and bulk
differentiated tumor cells, which are derived from the CSLCs. In addition to their value for identifying potential immune-based therapeutics, other opportunities include their use in small molecule compound screening and diagnostic applications.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have generated over 1,900 monoclonal antibodies that we have screened by immunohistochemistry, or IHC, for lower-binding
to normal, non-malignant tissues. Many of these antibodies have been characterized for binding to primary tumors and cancer cell lines and we are developing the most promising of these antibodies into product candidates. This collection of
antibodies is selective for both validated and novel cancer targets. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have utilized our CSLC technology to generate or
characterize the antibodies we use in our MGA271 and MGD007 product candidates. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Product Candidate Pipeline </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We currently have two oncology product candidates in clinical development. Additionally, we have several proprietary product candidates
in pre-clinical development and we expect to commence Phase 1 clinical trials on two of these product candidates in 2014. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">90 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Margetuximab: Fc-Optimized Antibody for HER2-expressing Solid Tumors </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Overview </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Margetuximab, or MGAH22, is an Fc-optimized, monoclonal antibody that targets and binds to the HER2 protein on cancer cells and is
intravenously administered in order to kill tumor cells or inhibit tumor cell growth. We are developing margetuximab as an improved, more potent, anti-HER2 treatment for a variety of HER2-expressing tumors such as breast, gastroesophageal and
bladder cancer. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">An important mechanism of anti-HER2 monoclonal antibody action is the mediation of ADCC. In ADCC, the
anti-HER2 antibody binds to tumor cells and then recruits immune cells, such as macrophages, through their Fc<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>Rs. Fc<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>R-mediated mechanisms play a critical part
in the effectiveness of targeted tumor antibodies including anti-HER2 antibodies. Therefore, we have optimized the important Fc region of MGAH22 and thereby improved the cell-killing properties of margetuximab, compared to current anti-HER2
therapies (including trastuzumab). Specifically, we increased binding to activating receptors and decreased binding to the inhibitory receptor on immune effector cells. As a result, we believe margetuximab has the potential to be effective in a much
broader population than the approximately 25% of breast cancer patients treated with trastuzumab today and may overcome resistance in populations who no longer respond to trastuzumab. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The HER2 gene and receptor have an important role in normal cell growth and differentiation. When the HER2 gene has multiple copies,
which is referred to as gene amplification, it results in increased HER2 protein production. This causes cells to multiply in number and grow more rapidly than normal cells, contributing to the formation of cancer. HER2 gene amplification and
protein over-expression occurs in approximately 25% of women with breast cancer. The level of HER2 protein on tumors can be detected by IHC and is scored as 0, 1+, 2+ or 3+, where 3+ indicates the highest expression of HER2 positivity. Fluorescence
in situ hybridization, or FISH, testing is a method used to determine the number of HER2 gene copies that are in a tumor cell. Breast cancer patients with HER2 gene amplification and protein over-expression have a more aggressive disease, greater
likelihood of recurrence, poorer prognosis, and decreased survival compared to patients with HER2-negative breast cancer. Currently, anti-HER2 therapies are only approved for treating approximately 25% of all breast cancer patients whose tumors
overexpress HER2 at the 3+ level, or if 2+, when accompanied by HER2 gene amplification. As illustrated in the figure below, this population of 25% of breast cancer patients represents 60.5% of the 42% of all patients who are HER2+. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g575431g74d12.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We plan to study several patient populations in which we believe margetuximab, because of its
optimized structure, has the potential for particular benefit. The first populations being tested include breast and gastroesophageal cancer, but there is also potential to explore other HER2-expressing cancers such as bladder, ovarian and colon.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">91 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We presented data from our Phase 1 clinical trial of margetuximab at ASCO in June 2013. We
expect to complete this clinical trial by early 2014. We recently initiated enrollment in an exploratory Phase 2a clinical trial in patients with metastatic breast cancer whose tumors exhibit expression of the HER2 protein at the 2+ level by IHC and
lack evidence of HER2 gene amplification by FISH. We plan to initiate a Phase 3 clinical trial in patients with HER2+ gastroesophageal cancers that have progressed after standard first and second-line therapy. We expect to begin enrollment in this
clinical trial in the second half of 2014 and anticipate that such a trial should be concluded in approximately three years. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Current
Treatments for HER2-expressing Solid Tumors </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The management of breast cancer is largely based on the stage, grade,
hormone receptor status and type, and includes surgery, radiation and drug therapy. Cytotoxic chemotherapies are a mainstay of metastatic breast cancer treatment, irrespective of hormone and HER2 status. Patients who have no detectable cancer after
surgery are often given additional drug treatment to prevent recurrence. This is known as adjuvant therapy. Some patients receive treatment before surgery to shrink the tumor. This is known as neoadjuvant therapy. While anti-HER2 therapies have
initially been tested in patients with metastatic cancer, often as single agents, benefit has been shown in the much larger population of patients treated earlier in adjuvant and neoadjuvant settings. We expect that this paradigm will also be true
for margetuximab, but in a larger population. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The management of gastroesophageal cancer is based on radical surgical
resection of the tumor, which when carried out at an early stage of disease may be curative. When surgical resection of the tumor is not possible, or the tumor recurs or metastasizes, chemotherapeutic agents are utilized. The incidence of
gastroesophageal cancer has been declining steadily since the 1930s, yet it remains a major cause of cancer death in the United States and a greater problem in the rest of the world. Gastroesophageal cancer is the fourth most common cancer in the
world (989,000 new cases diagnosed in 2008) and the second most common cause of cancer-related death in the world. Advanced and metastatic cancers are treated with chemotherapy and radiation therapy. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Several drugs directed at HER2 have been approved for the treatment of early and advanced stage breast cancer and advanced
gastroesophageal cancer. Most patients treated with existing HER2 therapies, such as trastuzumab (Herceptin), pertuzumab (Perjeta), lapatinib (Tykerb), and ado-trastuzumab emtansine (Kadcyla, also referred to as T-DM1), will either fail to respond
or become resistant to continued treatment. In addition, existing HER2 therapies are not effective in the treatment of patients who do not highly over-express HER2. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Potential Advantages of Margetuximab </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Margetuximab is an
Fc-optimized, monoclonal antibody believed to mediate its therapeutic activity against HER2+ tumors by a combination of mechanisms including: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Modulation of the receptor signaling resulting in growth retardation or the induction of apoptosis, or cell death; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">ADCC and improved binding to immune cells to enhance destruction of HER2+ tumor cells; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Presentation of antigens by cells such as macrophages that engulf the tumor cells, digest them, and display the tumor antigens to other cells of the
immune system including T cells. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fc<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>R mediated mechanisms play
a critical part in the activity of several antibodies including anti-HER2 antibodies. Fc<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>R sequences will differ among people and a single amino acid difference in an
Fc<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>R can significantly alter an antibody&#146;s Fc binding properties. Clinical data shows improved outcomes in metastatic breast cancer patients who have a higher binding form of an activating Fc<FONT
STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>R, CD16A, in response to treatment with chemotherapy plus trastuzumab. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">92 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The table below shows the difference in progression-free survival between patients treated
with trastuzumab who have the higher-binding form of CD16A and those who have the lower-binding form of CD16A. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g575431g63f08.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Knowing that approximately 80% of subjects express the lower-binding
Fc<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>R, we specifically optimized the Fc domain of margetuximab to enhance binding to the lower-binding form of CD16A. We believe margetuximab will have greater activity than trastuzumab and may overcome
resistance in populations of patients whose tumors do not respond, or no longer respond, to trastuzumab. In addition, the optimized Fc domain of margetuximab imparts reduced binding to the inhibitory
Fc<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>R, CD32B, a feature expected to further enhance the activating properties of margetuximab. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have conducted <I>in vitro</I> and <I>in vivo</I> pre-clinical studies that support the superiority of margetuximab compared to trastuzumab. In these pre-clinical models, margetuximab exhibits enhanced
anti-tumor activity against HER2-expressing tumor cell lines in <I>in vitro</I> ADCC assays and in human tumor xenograft models in human CD16A+ transgenic mice. We have also demonstrated superior effects of margetuximab over trastuzumab in <I>ex
vivo </I>studies using patient samples from the Phase 1 clinical trial. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Clinical Development of Margetuximab </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Based on the pre-clinical laboratory studies conducted with margetuximab, we assumed that margetuximab would have clinical benefit in
patients with tumors not currently thought to be targets for trastuzumab therapy, including those whose tumors express the HER2 protein at less than 3+ levels by IHC and lack evidence of HER2 gene amplification by FISH. We also assumed that
margetuximab benefits would extend to patients bearing the lower-binding form of CD16A. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:3%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Phase 2a Metastatic Breast Cancer
Study </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We submitted an IND in January 2010 for margetuximab for the treatment of HER2-positive carcinomas, including
breast cancer. We are currently enrolling a Phase 2a clinical trial to determine if margetuximab has sufficient activity in patients with metastatic breast cancer who are not currently considered candidates for trastuzumab therapy to further
evaluate margetuximab in this patient population. We are enrolling patients with metastatic breast cancer whose tumors exhibit expression of the HER2 protein at the 2+ level by IHC and lack evidence of HER2 gene amplification by FISH. This group of
patients represents an unmet medical </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">93 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
need which may be addressed by margetuximab. Margetuximab will be administered as a 6 mg/kg intravenous, or IV, solution weekly on Days 1, 8, and 15 of each 28-day cycle. If fewer than two
partial or complete responses are observed in the first 21 patients evaluable for response at the first tumor re-evaluation on day 22 of cycle 2 of treatment, no additional patients will be enrolled and the trial will end. If two or more responses
are observed at the first tumor re-evaluation on day 22 of cycle 2 of treatment, we will expand the clinical trial to include a total of 41 patients evaluable for response. If five or more partial or complete responses are observed in these 41
patients, then we will consider margetuximab to have adequate activity in this patient population to justify additional clinical development. We are conducting this clinical trial at six sites in the United States. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:3%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Anticipated Margetuximab Clinical Trials </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We plan to file a separate IND for margetuximab for the treatment of HER2-positive gastroesophageal cancer by the first quarter of 2014. We intend to commence a randomized Phase 3 clinical trial to
evaluate the addition of margetuximab to standard cytotoxic chemotherapy (irinotecan or paclitaxel) in the third line treatment of patients with advanced gastroesophageal cancers which have progressed after standard frontline and second-line
treatment of advanced disease in the second half of 2014. The primary analysis will compare the overall survival of patients randomized to chemotherapy plus placebo to the overall survival of patients randomized to chemotherapy plus margetuximab.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:3%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Other Anticipated Phase 2 Development </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We anticipate conducting exploratory clinical trials in patients with other HER2 expressing malignancies. The design of these clinical trials will be informed by the results of the ongoing Phase 2a
clinical trial in metastatic breast cancer. If the results of that clinical trial are positive, then we will pursue a population of patients with HER2 2+ or 3+ tumors. Such a population would represent approximately one-third to one-half of patients
with metastatic bladder cancer, and smaller proportions of patients with ovarian cancer, endometrial cancer, and colon cancer. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:3%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Phase 1 Clinical Study Results </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Phase 1 clinical trial is an open-label, multi-dose, single-arm, dose-escalation study conducted to define the safety profile and pharmacokinetics, or PK, of margetuximab and to begin to explore the
antitumor activity of margetuximab in patients with refractory HER2+ tumors. We enrolled a total of 34 patients in the dose escalation (0.1 to 6.0 mg/kg) and expansion (6.0 mg/kg) phases of the trial. This patient population was heavily pre-treated
with prior therapies, including 19 patients with other prior anti-HER2 therapies. In the absence of dose limiting toxicity, an additional cohort of patients was treated at the top dose. We expect to complete this clinical trial in 2014. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">During the dose escalation and expansion segments of the Phase 1 clinical trial of margetuximab, a dose of 6.0 mg/kg has been
well-tolerated in patients with refractory HER2+ tumors who were treated weekly for four weeks. Approximately one-third of patients received additional cycles of margetuximab treatment. Using margetuximab as a single agent, tumor response was
observed even in patients who had failed prior therapies including other anti-HER2 treatment. Responses to date include: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">unconfirmed partial response in one patient with mucoepidermoid carcinoma of the salivary gland treated at 1.0 mg/kg; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">confirmed partial response in one patient with breast cancer treated at 3.0 mg/kg; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">confirmed partial response in one patient with breast cancer treated at 6.0 mg/kg; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">confirmed partial response in one patient with a gastroesophageal junction tumor treated at 6.0 mg/kg; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">94 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">unconfirmed partial response in one patient with colorectal cancer at 6.0 mg/kg; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">four patients with times to progression exceeding five months. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, we are exploring intermittent administration of margetuximab as a more convenient dosing regimen. In this portion of the
Phase 1 clinical trial, a patient with breast cancer experienced a confirmed partial response at 10.0 mg/kg (administered every three weeks) with a time to progression currently exceeding five months. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Evidence of activity was seen at doses as low as 0.1 mg/kg weekly, to which a patient with metastatic breast cancer whose tumor had
progressed after two prior anti-HER2 therapies (trastuzumab and ado-trastuzumab emtansine) experienced stability of disease and time to progression that exceeded nine months. The maximum percent reduction (below baseline) or increase (above
baseline) in the size of target tumors at any time from patients treated with different doses of margetuximab is shown below: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g575431g19e20.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The most frequent adverse events observed in patients participating in the dose escalation portion of
this trial were infusion reactions, which we observed in approximately 27% of patients on the day of infusion. Most of these events were mild or moderate in severity. Institution of pre-medications has reduced the incidence and severity of
infusion-associated adverse events. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">We assessed the <I>ex vivo</I> ADCC response of peripheral blood
mononuclear cells, or PBMCs, obtained from subjects in the dose escalation portion of this Phase 1 trial. Each patient sample was divided and exposed separately to margetuximab and trastuzumab. Margetuximab outperformed trastuzumab in <I>in
vitro</I> ADCC assays, reducing the dose required to achieve equivalent cell killing and increasing total cell killing. The concentration of drug required to achieve a half maximal effect (EC</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUB
STYLE="vertical-align:baseline; position:relative; top:.4ex">50</SUB></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2">) on ADCC was much lower for margetuximab (mean 3.5 <U>+</U> 1.0 ng/ml) than trastuzumab (mean 40.7 <U>+</U> 17.1 ng/ml).
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">95 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MGA271: Fc-Optimized Antibody for B7-H3-Expressing Solid Tumors </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Overview </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">MGA271
is a humanized, Fc enhanced, monoclonal antibody that targets B7-H3 expressing tumors and is intravenously administered in order to kill tumor cells or inhibit their growth. We are developing MGA271 to treat multiple solid tumors such as melanoma,
glioblastoma, prostate cancer, and breast cancer. We believe that targeting B7-H3 using MGA271 has significant potential to treat a variety of solid tumors because it incorporates multiple complementary mechanisms of action in one molecule. These
potentially include: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Enhanced ADCC through Fc Optimization; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Targeting of both CSLCs and tumor cells; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Opportunity to differentially target tumor vasculature and underlying supporting tissues; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Potential for enhanced anti-tumor immunity by blockade of T cell inhibition (inhibiting the inhibitor). </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">MGA271 has been engineered to have enhanced binding to CD16A. MGA271 also exhibits reduced binding to CD32B. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We initiated a Phase 1 clinical trial of MGA271 in patients with B7-H3 tumors in August 2011. We have completed the dose escalation
portion of this trial without exceeding a maximally tolerated dose, or MTD. We commenced an expansion phase in the third quarter of 2013, in which we are enrolling patients and treating them at the highest dose tested during the dose escalation
portion of the trial. We also plan to initiate a Phase 2 clinical trial no later than early 2015. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Role of B7 Family of Immune
Regulators, Including B7-H3, in Cancer </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The B7 family of cell surface molecules consists of structurally related
protein ligands that bind to receptors on lymphocytes and regulate immune responses. B7 homolog 3 (B7-H3) is a novel member of the B7 family of immune regulatory molecules. This family of molecules is an area of interest across the pharmaceutical
industry, and is being explored by companies including Amplimmune, Inc., or Amplimmune, AstraZeneca PLC, or AstraZeneca, Bristol-Myers Squibb Co., or Bristol-Myers, GlaxoSmithKline plc, or GSK, and Merck&nbsp;&amp; Co., or Merck. The chart below
describes our understanding of various B7 immune regulator targets and current marketed products and clinical stage product candidates addressing such targets. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">96 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>B7 Immune Regulator Family </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="39%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:81pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B><FONT STYLE="white-space:nowrap">Antigen-Presenting&nbsp;Cell</FONT></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:21pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>T Cell</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:30pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Function</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:107pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Product or Product Candidates</B></FONT></P></TD></TR>


<TR>
<TD VALIGN="top" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">CD80 (B7-1) or CD86 (B7-2)</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">CTLA4</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Inhibitory</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ipilimumab (marketed by Bristol-Myers)</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Anti-CTLA4 (AstraZeneca, Phase 2)</FONT></P></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">CD80 (B7-1) or CD86 (B7-2)</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">CD28</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Activating</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">PD-L1 (B7-H1) or PD-L2 (B7-DC)</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">PD1</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Inhibitory</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Anti-PD1 (Merck, Phase 2)</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Anti-PD1 (Bristol-Myers, Phase 3)</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Anti-PD-L1 (Bristol-Myers, Phase 2)</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Anti-PD-L1/Fc fusion (GSK/Amplimmune, Phase 1)</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Anti-PD-L1 (Roche, Phase 2)</FONT></P></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">B7RP1 (B7-H2)</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">ICOS</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Activating</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">AMG 557 (Amgen/AstraZeneca, Phase&nbsp;1)</FONT></P></TD></TR>
<TR BGCOLOR="#cccccc">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">B7-H3</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unknown</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Inhibitory</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">MGA271 (MacroGenics, Phase 1)</FONT></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">B7-H4</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unknown</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Inhibitory</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">B7-H5 (VISTA)</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unknown</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Inhibitory</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">B7-H6</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">NKp30</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Activating</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In our own analysis of fixed tumor microarrays representing more than 700 samples across various tumor
types including glioblastoma, thyroid, gastroesophageal, breast, pancreas, prostate, melanoma and ovarian cancers, we saw B7-H3 expression in approximately 70 &#150; 99% of tumor samples, with high expression (2+ or greater by IHC) in most of these
tumor types. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">B7-H3 inhibits T cell activation and cytokine production. Other examples of inhibitors of T cell activation
include the immune check-point regulators PD1 and CTLA4. Anti-PD1 and anti-CTLA4 (e.g., ipilimumab) antibodies have shown therapeutic effects in patients with melanoma, renal cell carcinoma, and non-small-cell lung cancer and are being tested in
individuals with several other types of cancers. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Pre-Clinical Development of MGA271 </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have evaluated the ability of MGA271 to mediate ADCC activity across multiple cancer types expressing varying levels of B7-H3 as
determined by flow cytometry. The cancer types tested included melanoma, lung cancer, prostate cancer, breast cancer, bladder cancer, and renal cancer cell lines. MGA271 mediated ADCC activity against all tumor lines that express B7-H3 at detectable
levels. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">97 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">MGA271 exhibited anti-tumor activity in mouse models when administered
approximately one week after tumor cell implantation (as shown below), or after tumors were allowed to become fully established (approximately three weeks after implantation when tumors were approximately 300 mm</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">3</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> in volume). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Anti-Tumor Efficacy of MGA271 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>in a Pre-clinical Model of Renal Cell Carcinoma </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g575431g30v39.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Cells from a renal cell carcinoma tumor line were implanted subcutaneously in immunodeficient mice that expressed
the lower-binding form of human CD16A. MGA271 was administered intravenously weekly at the indicated dose levels as shown by arrows above. All dosages of MGA271, including 0.1 mg/kg, inhibited tumor growth when compared to both control groups,
vehicle or lgG. </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A repeat dose Good Laboratory Practice, or GLP, toxicology study was conducted in cynomolgus monkeys to
determine the potential toxicity of MGA271. MGA271 was well tolerated when administered by IV infusion at four weekly doses of up to150 mg/kg. The no observed adverse effect level was considered to be 150&nbsp;mg/kg. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Clinical Development of MGA271 </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have initiated a Phase 1 clinical trial that we expect to complete in 2014. We plan to initiate a Phase 2 clinical trial no later than early 2015. We submitted an IND in March 2011 for MGA271 for the
treatment of patients with refractory B7-H3-expressing tumors. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:3%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Phase 1 Clinical Trial </I></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Phase 1 trial is an open-label, multi-dose, single-arm, multi-center, dose-escalation clinical trial. This trial includes patients
with B7-H3-expressing tumors, such as prostate cancer, pancreatic cancer, melanoma and ovarian cancer, and tumors whose vasculature exhibits B7-H3 expression, such as glioblastoma, renal cell carcinoma and ovarian cancer. The clinical trial began
with a dose escalation segment in which patients were </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">98 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
treated with increasing weekly doses of MGA271 from 0.01 mg/kg up to 15 mg/kg. We have not seen any dose limiting toxicity, and we initiated an expansion phase in the third quarter of 2013 at a
dose of 15 mg/kg. During the expansion phase, we are recruiting an additional 15 patients to each of three cohorts that represent a distinct patient population determined by histology: 1) patients with melanoma, 2) patients with prostate cancer and
3) patients with any B7-H3 positive tumor other than melanoma or prostate cancer with the limitation of a maximum of five patients with any single histologic type such as colorectal adenocarcinoma or histologic subgroup such as sarcoma. In addition,
Servier has indicated that it intends to evaluate MGA271 in up to 90 additional cancer patients representing additional types of cancers beginning in the fourth quarter of 2013. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have enrolled a total of 26 patients in the trial through the dose escalation portion, with 15 different types of tumors. Ten patients
received additional cycles of MGA271 treatment and all have had stable disease at the first tumor re-assessment. The most frequent adverse events in the trial were mild or moderate infusion reactions. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Because anti-cancer monoclonal antibodies are target specific, the presence of the target on tumor cells is usually required for the
desired biological effect of the antibody. An immunohistochemistry based companion diagnostic for MGA271 would detect the presence of B7-H3 on the cellular membrane of tumor cells. A positive result detecting B7-H3 on the cellular surface is
currently required for trial eligibility and we expect it will be required for identification of appropriate candidates for MGA271 treatment should the product candidate be approved. We are working with two third party vendors for the development of
the companion diagnostic, and we plan to contract with a vendor for future commercialization based on the results. We plan to have a companion diagnostic ready for incorporation into potential Phase 3 trials and are working with a collaborator to
develop it. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MGD006: DART-Based Molecule for Acute Myeloid Leukemia </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Overview </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">MGD006 is a humanized DART molecule that recognizes both
CD123 and CD3. We are developing MGD006 for the treatment of hematologic cancers. The primary mechanism of action of MGD006 is its ability to redirect T cells which express CD3 to kill CD123 expressing cells, such as leukemic cells. We plan to
submit the IND for MGD006 in early 2014. In addition, we plan to initiate a Phase 1 clinical trial of MGD006 in patients with relapsed or refractory acute myeloid leukemia, or AML, or in patients with untreated AML who are not candidates for
standard induction chemotherapy in the first half of 2014. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Role of CD123 in Acute Myeloid Leukemia </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">CD123 has been reported to be overexpressed on malignant cells in a wide range of hematologic malignancies including AML and
myelodysplastic syndrome, or MDS. Overexpression of CD123 is associated with a poorer prognosis in AML. AML and MDS are thought to arise in and be perpetuated by a small population of leukemic stem cells, or LSCs, which generally resist conventional
chemotherapeutic agents. LSCs are characterized by high levels of CD123 expression, which is not present in the corresponding normal hematopoietic stem cell population in normal human bone marrow. CD123 is also expressed by plasmacytoid dendritic
cells, or pDCs, basophils, endothelial cells and, to a lesser extent, monocytes and eosinophils. The anti-CD123 component of MGD006 is based on a humanized version of 7G3, a mouse monoclonal antibody directed against CD123. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Potential Advantages of MGD006 </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As a targeted therapy for CD123 expressing cells, we believe that MGD006 will have fewer side effects than conventional chemotherapeutic agents which broadly target rapidly dividing cells including cancer
cells, normal hematopoietic stem cells and certain immune cells such as activated lymphocytes. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">99 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Moreover, because CD123 is expressed on the LSCs that perpetuate this disease, MGD006 will
be targeting the source of the disease, and potentially deliver more durable remissions. This would represent an advance in AML therapy, because the LSCs that sustain this disease are generally resistant to the chemotherapy which is the standard
approach to disease treatment. The resistance of LSCs to chemotherapy may be due to the fact that they are a rare, relatively dormant, cell type within the leukemic cell population and, therefore, are less susceptible to the primary mechanism of
action of chemotherapeutic agents. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Pre-clinical Development of MGD006 </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have demonstrated in<I> in vitro</I> experiments that MGD006 is able to mediate T&nbsp;cell killing of CD123-expressing cells. In an
<I>in vitro</I> model of T cell-mediated killing of AML cells, addition of MGD006 led to destruction of AML cells derived from leukemia patients. Three leukemia cell lines expressing CD123 were exposed to MGD006 or a control DART protein in the
presence of T cells. Dose-dependent increases in cell killing were observed following treatment with MGD006. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the chart
below, primary AML PBMC samples were incubated with a phosphate buffered saline, or PBS control, a DART protein control or MGD006. Treatment with MGD006 resulted in a dose-dependent decrease in leukemic blast cell number counts. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AML Blasts </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g575431g37v45.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We performed pilot toxicology studies in cynomolgus monkeys. Complete depletion of CD123-expressing
pDCs, an indication of activity in healthy animals, occurred at doses as low as 10 ng/kg/day. Importantly, this effect was reversible as pDCs were observed in peripheral blood a few weeks following cessation of dosing. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">No significant infusion reactions were observed at the lowest starting doses studied, including the pharmacologically active dose levels
(10-30 ng/kg/day). Administration of MGD006 at higher doses was associated with acute infusion reactions, which typically decreased or disappeared with subsequent dosing. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">100
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MGD007: DART-Based Molecule for Gastrointestinal Cancers </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Overview </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">MGD007
is a DART protein in which the first specificity is for the glycoprotein gpA33 and the second specificity is for CD3. MGD007 also contains an Fc domain which provides for an extended serum half-life compared to basic DARTs. gpA33 was identified
through immunizations using our proprietary CSLC lines. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are developing MGD007 as a potential therapeutic agent for the
treatment of colorectal cancer. Other tumors of the gastrointestinal tract, such as pancreatic and gastroesophageal cancers, may also be potential indications for development. In a survey of normal tissues examined, the gpA33 antigen was expressed
almost exclusively in the intestinal epithelium. It was present in more than&nbsp;95% of human colon cancers, and in approximately 50% of gastroesophageal and pancreatic cancers. Studies by others with a radiolabeled monoclonal antibody against
gpA33 demonstrated preferential binding to tumors over normal colonic mucosa. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have conducted pre-clinical <I>in vitro</I>
and <I>in&nbsp;vivo</I> proof-of-concept studies with MGD007 or a basic DART form of MGD007 without the Fc domain. In addition, we are currently conducting several small, non-GLP toxicology studies in cynomolgus monkeys. These non-GLP toxicology
studies will inform the design of the IND-enabling GLP toxicology study, which we plan to initiate by the end of 2013. We are planning to submit an IND in 2014 and commence a Phase 1 clinical trial for MGD007 in the second half of 2014. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Pre-clinical Development of MGD007 </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The results of <I>in vivo</I> experiments shown below demonstrate that a gpA33 x CD3 DART is able to mediate T&nbsp;cell killing of gpA33-expressing cancer cells: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g575431g54r32.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Cells from a colorectal cancer line and activated human T cells were implanted subcutaneously in immunodeficient
mice. A gpA33 x CD3 DART was administered intravenously daily for four days at the time of tumor implantation. Inhibition of tumor growth was observed at all dose levels tested when compared to animals treated with a control. </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">101
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MGD010: DART-Based Molecule for Autoimmune Diseases </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Autoimmune diseases including rheumatoid arthritis, or RA, Crohn&#146;s disease, systemic lupus erythematosis, or SLE, and multiple
sclerosis, or MS, collectively affect more than 20&nbsp;million people in the United States. Autoimmune disease involves self-tissue destruction by T cells and antibodies due to lack of self-tolerance. Anti-inflammatory therapies, such as TNF (tumor
necrosis factor) inhibitors, have been able to improve diseases like RA; however, it has become increasingly known that, in addition to T cells, B cells play an important role in many common autoimmune and allergic disorders by initiating and
amplifying the pathological disease processes. Current B cell targeted therapies either cause depletion of B cells, thus limiting their applicability due to the potential for infections (e.g., rituximab, or <I>Rituxan</I>), or exhibit a delayed
onset of action and limited efficacy across patient populations (e.g., belimumab, or <I>Benlysta</I>). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To address limitations
of existing B cell targeted therapies, MacroGenics has developed a novel CD32B x CD79B DART, called MGD010. In pre-clinical studies, this DART modulates the function of human B cells without B cell depletion. In normal conditions, B cells utilize
CD32B as one of the key negative regulators to ensure that tolerance to self is maintained and autoimmune disease does not occur. MGD010 exploits this mechanism and triggers this inhibitory &#147;immune checkpoint&#148; loop. We believe this
molecule preferentially blocks those B cells that are activated to produce the pathogenic antibodies that promote the autoimmune process. Studies in SLE patient B cells and humanized mouse models have demonstrated that MGD010 can block B cell
activation in the absence of B cell depletion. To advance this program to the clinic, we recently performed studies in non-human primates with MGD010 demonstrating a favorable safety profile and pharmacological effects on targeted B cells.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the chart below, treatment with MGD010 prolongs survival compared to a PBS control or a single dose of rituximab in a
mouse model of graft versus host disease. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MGD010 in a Chronic Graft versus Host Disease </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(Transplantation) Mouse Model </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g575431g35e13.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Immunodeficient mice administered human PBMCs by injection were treated intravenously either with MGD010 at 5.0 or
10.0 mg/kg or PBS control every four days (9 total doses) or with rituximab at 5.0 mg/kg for one dose. </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">102
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Teplizumab: Fc-Modified Antibody for Type 1 Diabetes </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Overview </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Teplizumab is a humanized, anti-CD3 monoclonal antibody being developed for the treatment of Type 1 Diabetes, or T1D. Teplizumab has been
engineered to alter the function of the T cells that mediate the destruction of the insulin-producing beta cells of the islets of the pancreas. Teplizumab potentially represents an advance in the treatment of T1D by addressing the underlying
disorder, rather than merely using insulin replacement therapy. In 2007, we entered into a collaboration with Eli Lilly. During the clinical development of teplizumab, Eli Lilly provided financial, manufacturing, and commercial support to us while
we conducted our Phase 3 clinical trials. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In June 2011, we published the results of Prot&eacute;g&eacute;, a Phase 3 clinical
study of teplizumab in T1D, in <I>The Lancet</I> and follow-up data in <I>Diabetes</I> in 2013. The primary clinical endpoint of this trial, a composite of glycated hemoglobin, or HbA1c, and insulin usage, was not met. HbA1c is a form of hemoglobin
that reflects average plasma glucose concentration over prolonged periods of time. When T1D is poorly controlled, the glucose and consequently, HbA1c levels rise. Insulin use was measured as units used per day. Subjects were required to have a low
HbA1c level (&lt;6.5%) and low daily insulin usage (&lt;0.5 units per day). Similar numbers of patients in the 14 day teplizumab regimen and placebo (insulin only) achieved this endpoint. Although this trial did not meet its primary clinical
endpoint, an exploratory, post-hoc analysis suggests that teplizumab, when used in a full dose regimen, may preserve insulin production by beta cells in the pancreas, as measured by C-peptide, and increase the percentage of patients requiring very
low doses of insulin compared to those on placebo. Preservation of insulin production as measured by C-peptide, relative to standard of care, is now recognized as an acceptable primary endpoint by the FDA. The findings suggest that future studies of
immunotherapeutic intervention with teplizumab might have increased success in prevention of a decline in beta cell function (measured by C-peptide) and preservation of glycemic control at reduced doses of insulin, particularly in children, if
intervention occurs soon after diagnosis. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Teplizumab is currently being evaluated in a Phase 2 clinical trial, called At
Risk, for the prevention or delay of onset of T1D in patients determined to be at very high risk for developing the disease. This clinical trial is being sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases, or NIDDK. In
2011, Eli Lilly terminated its collaboration with us to develop teplizumab and pursuant to the terms of the agreement, we reacquired the commercial rights to teplizumab. We are actively seeking a collaborator for further development of teplizumab.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Collaborations </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have entered into several strategic collaborations for our therapeutic programs. These therapeutic collaborations have provided us with approximately $106 million in non-equity funding during the three
year period ended June 30, 2013. Under these agreements we are entitled to receive substantial payments including over $100 million of potential additional option exercise fees and milestone payments that we believe are likely to be received by the
end of 2015, assuming all of our collaboration programs advance as currently contemplated. Key terms of these collaborations are summarized below. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Servier MGA271 Agreement </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Overview</I>. In November 2011, we
entered into a collaboration agreement with Servier under which we granted Servier an option to obtain an exclusive license to develop and commercialize the Fc engineered antibody we designated as MGA271 and certain other Fc engineered antibodies
that also bind the B7-H3 receptor, collectively referred to as the MGA271 licensed products, in all countries other than the United States, Canada, Mexico, Japan, South Korea and India. We have received a $20 million option grant fee and a $10
million milestone payment upon dosing the first patient in the expansion cohort of our Phase I clinical trial of </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">103
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
MGA271, and may be eligible to receive up to approximately $415 million in license grant fees, and clinical, development, regulatory and sales milestone payments if Servier exercises the option,
obtains regulatory approval for and successfully commercializes an MGA271 licensed product. In addition to these milestones, we and Servier will share Phase 2 and Phase 3 development costs. Under the agreement we are also eligible to receive
royalties on the net sales of MGA271 licensed products at percentages ranging from the low double digits to the mid-teens, subject to reductions in specified circumstances. Under specific circumstances, Servier may defer payment of certain milestone
payments. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Research Plan</I>. Under the agreement, we are responsible for conducting research according to an agreed upon
research plan during a specified research term. The activities under the research plan include the generation of data by us that the parties have agreed will be included in a data package, or MGA271 data package. We will continue conducting the
current Phase 1 trial of MGA271 under the research plan. Under the agreement, Servier may conduct separate development and clinical activities under the research plan, subject to our approval. The term of the research plan begins on the effective
date of the agreement and ends on the earlier of November&nbsp;24, 2015 or the expiration of Servier&#146;s option under the agreement. In general, during the research term, each party is responsible for the internal and external costs it incurs to
conduct its activities under the research plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Manufacturing</I>. Under the agreement we are obligated to supply cGMP
produced MGA271 licensed products to supply Servier&#146;s clinical development needs for its Phase 1 and first two Phase 2 clinical trials according to a clinical supply agreement negotiated between the parties. Servier is obligated to pay for such
supply of MGA271 licensed product under the clinical supply agreement at our fully burdened manufacturing cost. Prior to exercising its option, we can supply clinical material for Servier&#146;s additional needs at our discretion. If Servier
exercises its option, upon its request, we are obligated to enter into negotiations to execute a commercial supply agreement for MGA271 licensed product. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Option</I>. Generally, Servier may exercise its option at any time after the effective date of the agreement until ninety days after Servier&#146;s receipt of the MGA271 data package which shall
include results from completed expansion cohorts from the Phase 1 clinical trial. In the event Servier exercises the option, Servier must pay a license grant fee, which we estimate to be $30 million, based on the number of different indications
represented within the patient population in a planned expansion cohort in our Phase 1 clinical trial of MGA271. If Servier elects not to exercise the option, it will lose all rights to develop and commercialize MGA271 licensed products and we will
be entitled to develop and commercialize MGA271 licensed products throughout the world exclusively or with a third party or parties. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>License/Exclusivity</I>. If Servier exercises the option it will receive an exclusive license to develop and commercialize MGA271 licensed products in all countries of the world other than the United
States, Canada, Mexico, Japan, South Korea and India. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to Servier&#146;s exclusive right to develop and
commercialize MGA271 licensed products under the agreement, there are additional obligations regarding exclusivity and noncompetition. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In addition to these provisions, in the event that we seek to grant rights to a third party to develop and/or commercialize certain DARTs that bind the B7-H3 receptor outside the United States, Servier
has a right of first negotiation to obtain such rights. If Servier declines to enter negotiations or the parties fail to execute an agreement granting Servier such rights within a specified time period, subject to specified exceptions, we will have
the right to enter negotiations with a third party for the same rights. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Term and Termination</I>.&nbsp;If Servier does not
exercise its&#146; option, the agreement terminates upon the expiration of the option. If Servier exercises the option, the agreement will terminate in its entirety upon the later of the expiration of the last-expiring patent related to an MGA271
licensed product, the regulatory based exclusivity period or 12 years after the first commercial sale of any MGA271 licensed product. The agreement contains customary termination rights. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">104
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Servier DART Agreement </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Overview</I>. In September 2012, we entered into a second agreement with Servier and granted it options to obtain three separate
exclusive licenses to develop and commercialize DART-based molecules, consisting of those designated by us as MGD006 and MGD007, as well as a third DART molecule, collectively referred to as the DART-licensed products, in all countries other than
the United States, Canada, Mexico, Japan, South Korea and India. Under the terms of the agreement, we received a $20 million option grant fee. In addition, we will be eligible to receive up to approximately $1 billion in additional license grant
fees, and clinical, development, regulatory and sales milestone payments if Servier exercises all of the options and successfully develops, obtains regulatory approval for and commercializes a product under each license, including $5 million upon
IND acceptance for each of MGD006, MGD007 and a third DART molecule. In addition to these milestones, we and Servier will share Phase 2 and Phase 3 development costs. Under the agreement we are also eligible to receive royalties on the net sales of
DART licensed products at percentages ranging from the low double digits to the mid-teens, subject to reductions in specified circumstances. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Research Programs</I>. Under the agreement, we are responsible for conducting research according to an agreed upon research plan for each option target during the specified research term. Each research
plan and its activities are considered a research program. The activities under each research plan include the generation of data by us that the parties have agreed that will be included in a data package, or the Servier DART data package. With our
consent, Servier may conduct separate development and clinical activities under a research plan. The research term for each research program begins on the effective date of the agreement and ends on the earlier of September&nbsp;19, 2016 or the
expiration of the applicable option. In general, during each research term, each party is responsible for the internal and external costs it incurs to conduct its activities under that research plan. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Manufacturing</I>. Under the agreement we are obligated to negotiate a clinical supply agreement with Servier regarding the supply of
cGMP produced material to supply Servier&#146;s clinical development needs for its Phase 1 and first two Phase 2 clinical trials for each DART licensed product. Servier pays for such supply of each DART licensed product under each clinical supply
agreement at our fully burdened manufacturing cost. Prior to exercising one of its options, we can supply clinical material for Servier&#146;s additional needs at our discretion. If Servier exercises an option, then upon Servier&#146;s request, we
are obligated to enter negotiations to execute a commercial supply agreement for DART licensed products subject to that option. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Option</I>. Under the terms of the agreement, each option may be exercised by Servier within ninety days after Servier&#146;s receipt
of the applicable Servier DART data package. In the event Servier exercises an option, Servier must pay a specified license grant fee for exercising that option. The respective license grant fees are $15 million for the MGD006 option, which becomes
exercisable upon completion of our GLP toxicology study, and additional amounts related to MGD007, and a remaining DART molecule, which become exercisable after a significant portion of the Phase 1 trials for each of these programs is completed. If
Servier elects not to exercise an option, it will lose all rights to develop and commercialize DARTs that bind such option target and we will be entitled to develop and commercialize DARTs that bind the former option target throughout the world
exclusively or with a third party or parties, subject to Servier&#146;s right of first negotiation, as described below. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Licenses/Exclusivity. </I>If Servier exercises an option it will receive an exclusive license to develop and commercialize DARTs that
bind to the option target for that option, and pharmaceutical products that comprise or contain such DARTs, in all countries of the world other than the United States, Canada, Mexico, Japan, South Korea and India. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to Servier&#146;s exclusive right to develop and commercialize DARTs under each license, under the agreement there are
additional obligations regarding exclusivity and noncompetition. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to these provisions, in the event that we seek
to enter into a transaction under which we would grant rights to a third party to develop and/or commercialize certain product candidates in Servier&#146;s </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">105
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
territory that bind an option target in exchange for certain consideration, Servier has a right of first negotiation to obtain such rights. If Servier declines to enter negotiations or the
parties fail to execute an agreement granting Servier such rights within a specified time period, we will have the right, subject to specified exceptions, to enter negotiations with a third party for the same rights. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Term and Termination.</I> If Servier does not exercise any option, the agreement terminates upon the expiration of the last to expire
option. If Servier exercises an option, the agreement will terminate in its entirety with respect to such DART licensed product upon the later of the expiration of the last-expiring patent related to a DART licensed product, the regulatory based
exclusivity period or 12 years after the first commercial sale of a DART licensed product. The agreement contains customary termination rights. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Gilead </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Overview</I><B>.</B> In January 2013, we entered into an agreement with Gilead to grant Gilead (i)&nbsp;an exclusive worldwide license
to research, develop, manufacture and commercialize DARTs that bind to a first pair of specified targets; (ii)&nbsp;an exclusive option for an exclusive license to research, develop, manufacture and commercialize DARTs that bind to a second pair of
specified targets in North America, the European Union, Norway, Iceland, Turkey, Australia and New Zealand; and (iii)&nbsp;separate exclusive options for worldwide exclusive licenses to research, develop, manufacture and commercialize DARTs that
bind to third and fourth pairs of targets to be subsequently identified by Gilead and accepted by us within a specified time period after the effective date of the agreement, which we collectively refer to as the Gilead licensed products. We
received an initial $7.5 million license grant fee for granting Gilead a license to the first target pair, and are eligible to receive up to an additional $22.5 million in grant fees on the remaining three pairs of targets. We are further eligible
to receive up to an additional $85 million in pre-clinical milestones across the four DART programs and up to approximately $1 billion in additional clinical, regulatory and sales milestones payments if Gilead exercises all four of the options and
achieves all of the requisite milestones under each option and license. Under the agreement, we are also eligible to receive tiered royalties on the net sales of Gilead licensed products at percentages ranging from the high-single digits to the low
double digit, but less than teen royalties subject to reductions in specified circumstances. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Research Programs.</I> During
specified research terms, we are responsible for conducting research according to an agreed upon research plan for each pair of targets for which Gilead exercises its option. Each research plan and its activities are considered a research program.
Upon approval by the joint research committee, Gilead may conduct separate development and clinical activities under a research plan. The term of the research plan for the first target pair has already begun. The research terms of the research plans
for the second, third and fourth target pairs can begin only after Gilead&#146;s exercise of the options for such target pairs. Gilead has fixed time periods to exercise its options for the second, third and fourth target pairs and we may decline to
accept Gilead&#146;s selections of the third and fourth target pairs under specified circumstances. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">During each research
term, Gilead will reimburse us for all internal and external costs we incur to conduct our assigned activities under that research plan, subject to specified limitations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Licenses.</I> Under the agreement, we granted Gilead an exclusive worldwide license to research, develop, manufacture and commercialize DARTs that bind to the first pair of specified targets. Upon
initiation of the research term for the second target pair, we will grant Gilead an exclusive license to research, develop, manufacture and commercialize DARTs that bind to that pair of specified targets in North America, the European Union, Norway,
Iceland, Turkey, Australia and New Zealand. Upon initiation of each of the research terms for the third and fourth target pairs we will grant Gilead a worldwide exclusive license to research, develop, manufacture and commercialize DARTs that bind to
the corresponding target pair. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the event that we seek to license our rights to develop DARTs that bind to the second
target pair in countries not included in the license for the second target pair, Gilead has a right of first negotiation to obtain such rights. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">106
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Pre-clinical Milestone</I>. Notice by Gilead to pay the pre-clinical milestone for each
target pair category must be provided to us within specified time periods. Upon providing notice to pay a pre-clinical milestone for a target pair category, Gilead will become responsible for all research, development and commercialization
activities with respect to licensed products within such target pair category in Gilead&#146;s territory for such target pair license. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Exclusivity</I>. Subject to specified exceptions, during the term of the agreement, other than with respect to the research and development activities pursuant to the agreement, we may not, directly or
indirectly, research, develop, manufacture or commercialize a product that binds to both targets from any target pair category covered by the agreement in a country where Gilead has been granted a license for such target pair. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Term and Termination.</I> The agreement will terminate in its entirety upon the later of the expiration of the last-expiring patent
related to a Gilead licensed product, the regulatory based exclusivity period or 12 years after the first commercial sale of a Gilead licensed product. Gilead has the right to terminate the agreement at any time with respect to one or more selected
target pairs or in its entirety, upon prior written notice to us. The agreement contains customary termination rights. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Boehringer
</I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Overview.</I> In October 2010 we entered into a collaboration and license agreement with Boehringer to discover,
develop and commercialize up to ten DART-based molecules which span multiple therapeutic areas. Under the terms of the agreement, we granted Boehringer an exclusive, worldwide, royalty-bearing, license under our intellectual property to research,
develop, and market DARTs generated under the agreement, or the Boehringer licensed products, throughout the world. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the
agreement, we received an upfront payment of $15 million. We subsequently received two annual maintenance payments and anticipate receiving a third annual maintenance payment in the fourth quarter of 2013. We have the potential to earn development,
regulatory and sales milestone payments that can reach up to approximately $210 million for each of the DART programs under this agreement in the case of full commercial success of multiple DART products. Boehringer also provides funding for our
internal and external research costs and is required to pay us mid-single digit royalties, on a licensed product-by-licensed product basis, on worldwide net sales, subject to reductions in specified circumstances. We have the option to co-promote
certain DART products in the United States and may elect to co-fund Phase 3 clinical development in exchange for an increased royalty rate on net sales. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Research.</I> Under the agreement, Boehringer is entitled to select up to ten pairs of targets for which we would generate DARTs that bind to such targets. Several of the targets were identified in the
agreement. Subsequent target pairs are selected according to a process which permits us to decline to accept such target pairs under specified circumstances. During the research term of the agreement, we are responsible for generating pre-clinical
DART candidates that bind the accepted target pairs and generating data according to specified criteria which will be presented to Boehringer as a data package. If Boehringer accepts a pre-clinical DART candidate it will be responsible for
subsequent development and commercialization of such pre-clinical DART candidate. We have the right to co-fund a portion of the Phase 3 clinical development in exchange for an increased royalty rate. We also have the right to co-promote up to two
DART products that are developed under the agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Equity Purchase.</I> Boehringer purchased $10 million of our Series
D-2 preferred stock in January 2011. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Exclusivity</I>. Subject to specified exceptions, during the term of the agreement,
other than with respect to Boehringer licensed products, we agreed not to research, develop or commercialize any product using our DART platform that is directed to a target covered under the agreement. Subject to specified exceptions, we further
agreed not to grant any third party rights to research, develop or commercialize any product using our DART platform that is directed to a specified number of specific targets identified in the agreement, until a specified time period or the date on
which neither of the identified targets has been selected as a target subject to development and commercialization under the agreement. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">107
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Term and Termination.</I> The agreement will terminate in its entirety upon the later of
the expiration of the last-expiring patent related to a Boehringer licensed product, or 12 years after the first commercial sale of a Boehringer licensed product. Boehringer has the right to terminate the agreement at any time with respect to one or
more selected target pairs or in its entirety, upon prior written notice to us. However, it must maintain research efforts during a specified time period of the agreement. The agreement may also be terminated by either Boehringer or us in the event
of an uncured material breach by the other party. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Pfizer </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Overview.</I> In October 2010, we entered into a research collaboration and license agreement with Pfizer. Under the agreement, we
granted Pfizer a non-exclusive worldwide, royalty-bearing license and received upfront and milestone payments and funding for our internal and external research costs under the agreement. Under the terms of the agreement, we received a
non-refundable, non-creditable $5 million upfront fee. In addition, we are eligible to receive up to approximately $210 million per Pfizer DART molecule, as defined in the agreement, in technical, development and sales milestone payments if
specified net sales thresholds are reached. We are also entitled to receive royalties from Pfizer at percentages ranging from the mid-single digits to the low-teens on net sales of any Pfizer DART. Under this collaboration, one DART program is
currently being pursued and we will complete our research obligations under this program in January 2014. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Research.</I> Under the agreement, we are obligated to construct Pfizer DARTs that bind to a first and second target identified in the
agreement that are each expressed on cancer cells. During the research term of the agreement, which expires on October&nbsp;13, 2013, we conduct pre-clinical development of the Pfizer DARTs in collaboration with Pfizer according to an agreed upon
research plan. Under certain circumstances, Pfizer has the right to substitute the second target during specified periods. Pfizer has exercised those rights at various times during the specified periods which have now expired. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Product Development.</I> Upon expiration of the research term in October 2013, Pfizer will use commercially reasonable efforts to
develop and obtain regulatory approval for each Pfizer DART in both the United States and other specified countries. In addition, Pfizer will use commercially reasonable efforts to commercialize a Pfizer DART in each country where Pfizer has
received regulatory approval. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Commercialization.</I> Under the Agreement, Pfizer has sole responsibility and authority for
commercialization of Pfizer DARTs at its sole expense. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Manufacturing.</I> Pfizer has the exclusive right to manufacture
Pfizer DARTs. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>License.</I> Under the Agreement we granted Pfizer an exclusive, worldwide license to use, develop,
manufacture, and commercialize Pfizer DARTs. The license includes the right to sublicense. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Exclusivity</I>. Subject to
specified exceptions, until October&nbsp;3, 2015, we agreed not to research, develop, commercialize, manufacture, or grant any third party rights to research, develop, commercialize, or manufacture, (i)&nbsp;a Pfizer DART that binds to a cancer
target for which a Pfizer DART is under development in the agreement; or (ii)&nbsp;product candidates based on an antibody that we have supplied to serve as the basis for generating a Pfizer DART that is in development under the agreement.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Term and Termination.</I> The agreement will terminate in its entirety upon the later of the expiration of the
last-expiring patent related to a Pfizer DART licensed product, or 12 years after the first commercial sale of a Pfizer DART licensed product. We or Pfizer may terminate the agreement in the event of an uncured material breach by the other party.
After a specified period, Pfizer may terminate the agreement for convenience upon prior written notice to us. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">108
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Green Cross </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Overview.</I> In June 2010, we entered into a Collaboration Agreement with Green Cross Corp., or Green Cross, to grant Green Cross an exclusive license to conduct specified Phase 1 and Phase 2 trials
and commercialize margetuximab in South Korea. Under the terms of the agreement, we received a non-refundable $1.0 million upfront fee and are eligible to receive clinical, development and commercial milestone payments up to $4.5 million if Green
Cross commercializes margetuximab. We are also entitled to receive royalties ranging from the low-single digits to the low-twenties on net sales of margetuximab by Green Cross in South Korea. In addition, Green Cross purchased $2.0 million of our
Series D-2 Preferred Stock in January 2011. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Clinical Development.</I> Initial development of margetuximab under the
agreement is being conducted according to a Phase 1 development plan that has been agreed upon by the parties. We hold the clinical trial application for the ongoing Phase 1 clinical trial conducted in South Korea. Based upon an amendment to the
agreement, Green Cross is responsible for all of its costs to conduct the Phase 1 development plan up to a specified amount and, we are responsible for all of our own costs to conduct the Phase 1 development plan. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Development of margetuximab under the agreement after completion of the Phase 1 clinical trial will be conducted according to a Phase 2
development plan. In that regard, Green Cross is obligated to use best efforts to initiate a Phase 2 clinical trial with margetuximab in South Korea within a specified period of time after the completion of the Phase 1 trial. The costs of conducting
the Phase 2 trial will be the responsibility of Green Cross. After completion of the Phase 1 trial, Green Cross has the responsibility for submitting clinical trial applications to the Korea Food and Drug Administration, or KFDA. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Green Cross shall have the option to participate in any additional studies to the extent such studies are required by the KFDA to obtain
approval of margetuximab in South Korea. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Commercialization.</I> Under the Agreement Green Cross has sole responsibility
and authority for commercialization of margetuximab in South Korea at its sole expense. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Manufacturing.</I> We are
responsible for supply of margetuximab that is used for clinical development by Green Cross in South Korea. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>License.</I>
Under the Agreement we granted Green Cross an exclusive license to conduct specified Phase&nbsp;1 and Phase 2 trials and commercialize margetuximab in South Korea. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Consideration.</I> Under the Agreement, we received a non-refundable $1.0 million upfront fee and are eligible to receive clinical, development and commercial milestone payments up to $4.5 million if
Green Cross commercializes margetuximab. In addition, we are entitled to receive royalties which are determined by a formula that allocates the cost of commercial supply and third party royalties against net sales. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Term and Termination</I>. The agreement will terminate in its entirety upon the later of the expiration of the last-expiring patent
related to margetuximab, or 12 years after the first commercial sale of margetuximab in South Korea. The agreement may also be terminated by either Green Cross or us in the event of an uncured material breach by the other party. The agreement may be
terminated by us immediately in the event Green Cross participates or actively assists in a legal challenge to one of the patents exclusively licensed to Green Cross under the agreement. Either party may terminate the agreement in the event of a
change in control of the other party upon 30 days prior written notice to the other party. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">109
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Intellectual Property </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We strive to protect the proprietary technologies that we believe are important to our business, including seeking and maintaining patent protection intended to protect, for example, the composition of
matter of our product candidates, their methods of use, the technology platforms used to generate them, related technologies and/or other aspects of the inventions that are important to our business. We also rely on trade secrets and careful
monitoring of our proprietary information to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We plan to continue to expand our intellectual property estate by filing patent applications directed to dosage forms, methods of treatment and additional compositions created or identified from our
technology platforms and ongoing development of our product candidates. Specifically, we seek patent protection in the United States and internationally for novel compositions of matter directed to aspects of the molecules, basic structures and
processes for manufacturing these molecules and the use of these molecules in a variety of therapies. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our success will depend
significantly on our ability to obtain and maintain patent and other proprietary protection for commercially important technology, inventions and know-how related to our business, defend and enforce our patents, maintain our licenses to use
intellectual property owned by third parties, preserve the confidentiality of our trade secrets and operate without infringing the valid and enforceable patents and other proprietary rights of third parties. We also rely on know-how, continuing
technological innovation and in-licensing opportunities to develop, strengthen, and maintain our proprietary positions. We currently use multiple industry-standard patent monitoring systems to monitor new United States Patent and Trademark Office,
or USPTO, filings for any applications by third parties that may infringe on our patents. To date, we have not identified any potential infringement of our patents by third parties. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A third party may hold intellectual property, including patent rights that are important or necessary to the development of our product
candidates or use of our technology platforms. It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our product candidates, in which case we would be required to obtain a license from these third
parties on commercially reasonable terms, or our business could be harmed, possibly materially. For example, certain patents held by third parties cover Fc engineering methods and mutations in Fc regions to enhance the binding of Fc regions to Fc
receptors on immune cells. Although believe that these patents are invalid, if they cover margetuximab or MGA271 and we are unable to invalidate them, or if licenses for them are not available on commercially reasonable terms, our business could be
harmed, perhaps materially. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The patent positions of biopharmaceutical companies like us are generally uncertain and involve
complex legal, scientific and factual questions. In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted by the courts after issuance. Consequently, we do
not know whether any of our product candidates will be protectable or remain protected by enforceable patents. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or
whether the claims of any issued patents will provide sufficient proprietary protection from competitors. Any patents that we hold may be challenged, narrowed, circumvented or invalidated by third parties. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Because patent applications in the United States and certain other jurisdictions are maintained in secrecy for 18 months or potentially
even longer, and since publication of discoveries in the scientific or patent literature often lags behind actual discoveries, we cannot be certain of the priority of inventions covered by pending patent applications. Moreover, we may have to
participate in interference proceedings declared by the USPTO to determine priority of invention. We are participating in post-grant challenge proceedings, such as oppositions, that challenge the patentability of third party patents and may have to
participate in such proceedings again in the future. Such proceedings could result in substantial cost, even if the eventual outcome is favorable to us. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">110
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The patent portfolios for our most advanced programs are summarized below. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Margetuximab</I>. We own our margetuximab patent portfolio, which includes one issued patent and one pending U.S. patent application.
Our issued patent relates to the composition of or methods of making or using margetuximab and covers Fc engineered HER2 binding antibodies. This patent will expire in 2025. Related Patent Cooperation Treaty, or PCT, and national patent applications
filed in a number of other countries are pending. Any patents resulting from these patent applications, if issued, will expire in 2025. Our current pending U.S. application relates to the composition of margetuximab. If issued, this patent will
expire in 2029. We filed related PCT and national patent applications in a number of other countries. Any patents resulting from these patent applications, if issued, also will expire 2029. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certain issued patents and pending U.S. patent applications for our Fc Optimization platform portfolio provide additional intellectual
property protection for margetuximab. We own three issued patents in this portfolio, two that relate to compositions of matter and one that covers methods of use. In addition, we have four current pending U.S. patent applications relating to
compositions of matter, methods of using, and methods of making. The issued patents and any patents resulting from the pending patent applications, if issued, will expire between 2024 and 2030. PCT and national patent applications filed in a number
of other countries are pending. Any patents resulting from these applications, if issued, will expire on the same dates as our corresponding U.S. patents. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>MGA271. </I>We own our MGA271 patent portfolio. This portfolio includes two pending U.S. patent applications. One of these pending patent applications claims MGA271 variable domains that bind to the
B7-H3 receptor. Both pending patent applications cover the composition of or methods of making or using MGA271. In addition, related PCT and related national patent applications are pending in several other countries. The U.S. pending patent
applications and national patent applications, if issued, will expire in 2031. MGA271 is also covered by the same patents and patent applications from our Fc Optimization platform portfolio that cover margetuximab. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>MGD006.</I> We own our MGD006 patent portfolio. This portfolio includes one U.S. pending provisional patent application that claims
general composition of or methods of making or using MGD006. Any patents resulting from this application, if issued, will expire in 2034. We expect to file PCT and national patent applications in other countries in the future. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Three pending U.S. patent applications for our DART platform portfolio claiming compositions of matter, methods of using, methods of
making also cover MGD006. These patents, if issued, will expire between 2026 and 2031. In addition, related PCT and national patent applications filed in a number of other countries are pending. Any patents resulting from these patent applications,
if issued, will expire on the same dates as our corresponding U.S. patents. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>MGD010</I>. We own our MGD010 patent
portfolio. This portfolio includes four pending U.S. patent applications. Each patent application claims compositions of matter, methods of using, and methods of making. If issued, any patents resulting from these applications will expire between
2022 and 2034. In addition, related PCT and national patent applications in a number of other countries are pending. Any patents resulting from these patent applications, if issued, will expire on the same dates as our corresponding U.S. patents.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Three pending U.S. patent applications for our DART platform portfolio claiming compositions of matter, methods of using,
methods of making also cover MGD010. Any patents resulting from these U.S. patent applications will expire between 2026 and 2031. In addition, related PCT and national patent applications in a number of other countries are pending. Any patents
resulting from these patent applications, if issued, will expire on the same dates as our corresponding U.S. patents. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">111
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>DART Platform.</I> We own our DART platform patent portfolio. This portfolio includes
seven pending U.S. patent applications, each of which claims compositions of matter, methods of using, and methods of making. Patents resulting from six of these U.S. patent applications, if issued, will expire between 2026 and 2031. The remaining
application, which relates to certain mutations incorporated into our DARTs, if issued, will expire in 2032. In addition, related PCT and national patent applications in a number of other countries are pending. Any patents resulting from these
patent applications, if issued, will expire on the same dates as our corresponding U.S. patents. A PCT application in our DART Platform patent portfolio also relates to a particular binding component of our DARTs. Related national applications will
be filed in the future. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Fc Optimization Platform.</I> We own our Fc Optimization platform patent portfolio. This portfolio
includes three issued U.S. patents that cover the compositions of antibody Fc regions with certain mutations that affect their binding to Fc receptors. These patents expire in 2024. Related national patents have issued in a number of other countries
or are pending. The issued patents and any patents resulting from the pending patent applications, if issued, will expire in 2024. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Cancer Stem-like Cell Platform. </I>We own our cancer stem-like cell platform patent portfolio. This portfolio consists of one issued U.S. patent that will expire in 2028. Related national patents have
issued in a number of other countries and will expire on the same date. In addition to patent protection, we will also rely on the use of trade secrets to protect our cancer stem-like cell platform. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries
in which we file, the patent term is 20 years from the earliest date of filing a non-provisional patent application. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">However,
the term of the U.S. patents may be extended due to delays encountered during prosecution which are caused by the USPTO or by delays incurred due to compliance with FDA regulations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>FDA Regulatory Review Process </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Hatch-Waxman Act permits a
patent term extension for FDA-approved drugs of up to five years beyond the expiration of the patent. The length of the patent term extension is related to the length of time the drug is under regulatory review. Patent extension cannot extend the
remaining term of a patent beyond a total of 14 years from the date of product approval and only one patent applicable to an approved drug may be extended. Similar provisions are available in Europe and other jurisdictions to extend the term of a
patent that covers an approved drug. In the future, if and when our pharmaceutical product candidates receive FDA approval, we expect to apply for patent term extensions on patents covering those products. We intend to seek patent term extensions to
any of our issued patents in any jurisdiction where these are available, however there is no guarantee that the applicable authorities, including the FDA in the United States, will agree with our assessment of whether such extensions should be
granted, and even if granted, the length of such extensions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Trade Secrets </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We also rely on trade secret protection for our confidential and proprietary information. Although we take steps to protect our
proprietary information and trade secrets, including through contractual means with our employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to
our trade secrets or disclose our technology. Thus, we may not be able to meaningfully protect our trade secrets. It is our policy to require our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to
execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements provide that all confidential information concerning our business or financial affairs developed or made known to the
individual during the course of the individual&#146;s relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances. In the case of employees, the agreements provide that all inventions
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">112
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
conceived by the individual, and which are related to our current or planned business or research and development or made during normal working hours, on our premises or using our equipment or
proprietary information, are our exclusive property. In many cases our confidentiality and other agreements with consultants, outside scientific collaborators, sponsored researchers and other advisors require them to assign or grant us licenses to
inventions they invent as a result the work or services they render under such agreements or grant us an option to negotiate a license to use such inventions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Also included in our trade secrets are hybridomas which express antibodies that bind to proteins which are or may be expressed on cancerous cells, including cancer stem cells. The antibodies produced by
each hybridoma are unique and may have properties that are absent in antibodies expressed by other hybridomas. These properties could confer advantages and capabilities to product candidates developed with antibodies that exhibit such properties. We
closely control and monitor access to the hybridomas and the antibodies they produce. Before receiving such materials, our collaborators, prospective collaborators and all other parties are required to execute material transfer agreement or other
agreement which contractually limit their permitted uses and dissemination of such materials. In many cases our agreements with other parties granting access to and use of our biological materials require them to assign or grant us licenses to
inventions they invent as a result or their use of the materials or grant us an option to negotiate a license to use such inventions </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>In-Licensed Intellectual Property </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have entered into patent and know-how license agreements which grant us the right to use a certain technology related to biological manufacturing to manufacture margetuximab and MGA271. We anticipate
using this technology for future product candidates. This licensor has a business dedicated to licensing this technology and we anticipate that licenses to use the technology for our future products will be available. The licenses typically include
an obligation to pay an upfront payment, yearly maintenance payment and sales royalties. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have entered into a research
evaluation agreement for a technology related to biological manufacturing that we anticipate using to manufacture certain DART products. This licensor has a business dedicated to licensing this technology and we anticipate that licenses will be
available to use it to manufacture quantities of the DART products for clinical and commercial uses. The licenses may include an obligation to pay an upfront payment, yearly maintenance payments, milestones and sales royalties. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In establishing our Fc Optimization platform, we entered into patent license agreements which grant us the right to use technologies to
generate mutant Fc regions. The licenses include obligations to pay a yearly maintenance payment, development milestones and sales royalties on products we develop and commercialize that include mutant Fc regions generated using the patented
technologies. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Manufacturing </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We currently have a manufacturing facility located in Rockville, Maryland. This facility has been used to manufacture all of the current clinical supply for margetuximab and MGA271 to date. We currently
have capacity to produce Phase 2 material for our antibody product candidates and all clinical and commercial material for our DART therapeutics. For our Phase 3 clinical trials for our antibody product candidates and for commercial sale quantities
of such candidates, we anticipate that we will need to obtain additional manufacturing capacity through contract manufacturers to be able to supply the quantities required. We intend to screen multiple manufacturers to provide the drug substance for
commercial purposes for some of our product candidates prior to the filing of a BLA. We currently rely on and will continue to rely on contract fill-finish service providers to fulfill our fill-finish needs for our current and future product
candidates. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">All of our product candidates are biologics and are manufactured in disposable bioreactors in CHO cells in
accordance with current Good Manufacturing Practices, or cGMP. We expect to continue to develop product candidates that can be produced at our manufacturing facility and at contract manufacturing facilities. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">113
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We generate cell lines internally that serve as the source for our biologic drug substance.
These cell lines are then sent to a vendor where they are expanded and banked, and are available upon our request to use in developing drug substance. All other manufacturing materials used in the production of drug substance are readily available
in the ordinary course of business from a number of standard biotechnology vendors. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We generally expect to rely on third
parties for the development and manufacturing of our companion diagnostics. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Commercialization </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have not yet established a sales, marketing or product distribution infrastructure because our lead product candidates are still in
clinical development. We generally seek to retain commercial rights in the United States for our clinical product candidates for which we hope to receive marketing approvals and have done so to date in our collaborations other than our Boehringer,
Gilead and Pfizer collaborations. We believe that it will be possible for us to access the United States oncology market through a targeted specialty sales force. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Subject to receiving marketing approvals, we expect to commence commercialization activities by building a focused sales and marketing organization in the United States to sell our products. We believe
that such an organization will be able to address the community of oncologists who are the key specialists in treating the patient populations for which our oncology product candidates are being developed. Outside the United States, we expect to
enter into distribution and other marketing arrangements with third parties for any of our product candidates that obtain marketing approval. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We also plan to build a marketing and sales management organization to create and implement marketing strategies for any products that we market through our own sales organization and to oversee and
support our sales force. The responsibilities of the marketing organization would include developing educational initiatives with respect to approved products and establishing relationships with thought leaders in relevant fields of medicine.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We expect that our collaborators for any companion diagnostics we may develop in the future for use with our product
candidates will hold the commercial rights to these diagnostic products. We expect to coordinate closely with our diagnostic collaborators in connection with the marketing and sale of our related product candidates. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Competition </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
biopharmaceutical industry is characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. While we believe that our technology, knowledge, experience and scientific resources provide us with
competitive advantages, we face potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions and governmental agencies and public and private research
institutions. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There are a large number of companies developing or marketing treatments for cancer and autoimmune disorders, including many major
pharmaceutical and biotechnology companies. These treatments consist both of small molecule drug products, as well as biologic therapeutics that work by using next-generation antibody technology platforms to address specific cancer targets. In
addition, several companies are developing therapeutics that work by targeting multiple specificities using a single recombinant molecule. Amgen is now in late-stage clinical development of cancer product candidates which work by targeting antigens
both on immune effector cell populations and those expressed on certain cancer cells. In addition, other companies are developing new treatments for cancer and autoimmune diseases that enhance the Fc regions of antibodies to create more potent
antibodies, including Roche and Xencor, Inc. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">114
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Many of our competitors have significantly greater financial, manufacturing, marketing, drug
development, technical and human resources than we do. Mergers and acquisitions in the pharmaceutical, biotechnology and diagnostic industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or
early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining top qualified scientific and
management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The key competitive factors affecting the success of all of our therapeutic product candidates, if approved, are likely to be their
efficacy, safety, dosing convenience, price, the effectiveness of companion diagnostics in guiding the use of related therapeutics, the level of generic competition and the availability of reimbursement from government and other third party payors.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are
safer, more effective, have fewer or less severe effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may
obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other third party payors
seeking to encourage the use of biosimilar products. Biosimilar products are expected to become available over the coming years. For example, certain HER2 biosimilar products may be approved prior to margetuximab. Even if our product candidates
achieve marketing approval, they may be priced at a significant premium over competitive biosimilar products if any have been approved by then. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The most common methods of treating patients with cancer are surgery, radiation and drug therapy. There are a variety of available drug therapies marketed for cancer. In many cases, these drugs are
administered in combination to enhance efficacy. While our product candidates may compete with many existing drug and other therapies, to the extent they are ultimately used in combination with or as an adjunct to these therapies, our product
candidates will not be competitive with them. Some of the currently approved drug therapies are branded and subject to patent protection, and others are available on a generic basis. Many of these approved drugs are well established therapies and
are widely accepted by physicians, patients and third party payors. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to currently marketed therapies, there are
also a number of products in late stage clinical development to treat cancer. These product candidates in development may provide efficacy, safety, dosing convenience and other benefits that are not provided by currently marketed therapies. As a
result, they may provide significant competition for any of our product candidates for which we obtain marketing approval. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If
our lead product candidates are approved for the indications for which we are currently undertaking clinical trials, they will compete with the therapies and currently marketed drugs discussed below. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Margetuximab</I>. Irrespective of HER2 status, metastatic breast cancers are often treated with cytotoxic chemotherapies such as
anthracyclines and taxanes, as well as capecitabine. Advanced and metastatic cancers are treated with chemotherapy and radiation therapy. In addition, there are several approved therapies specifically indicated for the treatment of early and
advanced stage breast cancer and advanced gastroesophageal cancer that are HER2+, including Herceptin, Kadcyla, Tykerb and Perjeta, and each of those drugs targets HER2+ tumors. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>MGA271</I>. The most common treatments for solid tumors are various chemotherapeutic agents, radiation therapy and certain targeted
therapies including monoclonal antibodies such as Herceptin, Avastin, Erbitux and Vectibix, as well as small molecule agents, including, Tarceva, Sunitinib and Sorafenib. No therapies are approved specifically for the treatment of tumors associated
with the expression of B7-H3. Yervoy, which targets CTLA4, an inhibitory molecule on T cells, is currently indicated for the treatment of melanoma and marketed by </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">115
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Bristol-Myers. In addition, there are several antibodies in development that target other members of the B7&nbsp;family or their associated checkpoint receptors. These include anti-PD1 molecules
by Merck and Bristol-Myers, and anti-PD-L1 molecules by Bristol-Myers and Roche and a PD-L1 Fc fusion protein by GSK and Amplimmune. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>MGD006</I>. The most common treatments for AML are various chemotherapeutic agents, radiation and stem cell transplants. No therapies are approved specifically for the treatment of AML associated with
the expression of CD123. We are aware of a monoclonal antibody currently being developed by CSL Limited which targets CD123. In addition, StemLine Therapeutics, Inc. has treated patients in a clinical trial with a recombinant protein composed of
IL-3 linked to a truncated diphtheria toxin payload. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>MGD007</I>. The most common treatments for gastroesophageal tumors
are various chemotherapeutic agents, radiation therapy, monoclonal antibodies including Herceptin, Avastin, Erbitux, Vectibix, as well as small molecule agents. No therapies are approved specifically for the treatment of tumors associated with the
expression of gpA33. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>MGD010</I>. Current B cell targeted therapies for autoimmune diseases include Rituxan and Arzerra for
the treatment of rheumatoid arthritis and Benlysta for the treatment of SLE. In addition, several other therapies are available to reduce inflammation, including nonsteroidal anti-inflammatory drugs such as Advil and Aleve; corticosteroids such as
prednisone; disease-modifying antirheumatic drugs such as methotrexate and hydroxychloroquine; immunosuppressants such as cyclosporine; and other drugs which target a variety of processes involved with inflammation such as Actemra, Kineret, Enbrel,
Remicade, Humira, Simponi, Cimzia, Orencia and Xeljanz. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Government Regulation and Product Approval </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Government authorities in the United States, at the federal, state and local level, and in other countries extensively regulate, among
other things, the research, development, testing, manufacture, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, import and export of pharmaceutical products such as those we are developing. The processes
for obtaining regulatory approvals in the United States and in foreign countries, along with subsequent compliance with applicable statutes and regulations, require the expenditure of substantial time and financial resources. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>FDA Approval Process </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">All of our current product candidates are subject to regulation in the United States by the FDA as biological products, or biologics. The Food and Drug Administration (FDA) subjects biologics to extensive
pre- and post-market regulation. The Public Health Service Act (PHSA), the Federal Food, Drug, and Cosmetic Act (FDC Act) and other federal and state statutes and regulations, govern, among other things, the research, development, testing,
manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of biologics. Failure to comply with applicable U.S. requirements may subject a
company to a variety of administrative or judicial sanctions, such as FDA refusal to approve pending BLAs, withdrawal of approvals, clinical holds, warning letters, product recalls, product seizures, total or partial suspension of production or
distribution, injunctions, fines, civil penalties, or criminal penalties. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The PHSA emphasizes the importance of manufacturing
control for products whose attributes cannot be precisely defined. The PHSA also provides authority to the FDA to immediately suspend licenses in situations where there exists a danger to public health, to prepare or procure products in the event of
shortages and critical public health needs, and to authorize the creation and enforcement of regulations to prevent the introduction, or spread, of communicable diseases in the United States and between states. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">116
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The process required by the FDA before a new biologic may be marketed in the United States
is long, expensive, and inherently uncertain. Biologics development in the United States typically involves pre-clinical laboratory and animal tests, the submission to the FDA of an IND, which must become effective before clinical testing may
commence, and adequate and well-controlled clinical trials to establish the safety and effectiveness of the biologic for each indication for which FDA approval is sought. Developing the data to satisfy FDA pre-market approval requirements typically
takes many years and the actual time required may vary substantially based upon the type, complexity, and novelty of the product or disease. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pre-clinical tests include laboratory evaluation of product chemistry, formulation, and toxicity, as well as animal trials to assess the characteristics and potential safety and efficacy of the product.
The conduct of the pre-clinical tests must comply with federal regulations and requirements, including good laboratory practices. The results of pre-clinical testing are submitted to the FDA as part of an IND along with other information, including
information about product chemistry, manufacturing and controls, and a proposed clinical trial protocol. Long term pre-clinical tests, such as animal tests of reproductive toxicity and carcinogenicity, may continue after the IND is submitted.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">An IND must become effective before United States clinical trials may begin. A 30-day waiting period after the submission of
each IND is required prior to the commencement of clinical testing in humans. If the FDA has neither commented on nor questioned the IND within this 30-day period, the clinical trial proposed in the IND may begin. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Clinical trials involve the administration of the investigational new drug or biologic to healthy volunteers or patients with the
condition under investigation, all under the supervision of a qualified investigator. Clinical trials must be conducted: (i)&nbsp;in compliance with federal regulations; (ii)&nbsp;in compliance with good clinical practice, or GCP, an international
standard meant to protect the rights and health of patients and to define the roles of clinical trial sponsors, administrators, and monitors; as well as (iii)&nbsp;under protocols detailing the objectives of the trial, the parameters to be used in
monitoring safety, and the effectiveness criteria to be evaluated. Each protocol involving testing on U.S. patients and subsequent protocol amendments must be submitted to the FDA as part of the IND. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The FDA may order the temporary, or permanent, discontinuation of a clinical trial at any time, or impose other sanctions, if it believes
that the clinical trial either is not being conducted in accordance with FDA requirements or presents an unacceptable risk to the clinical trial patients. The study protocol and informed consent information for patients in clinical trials must also
be submitted to an institutional review board (IRB) for approval. An IRB may also require the clinical trial at the site to be halted, either temporarily or permanently, for failure to comply with the IRB&#146;s requirements, or may impose other
conditions. The study sponsor may also suspend a clinical trial at any time on various grounds, including a determination that the subjects or patients are being exposed to an unacceptable health risk. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Clinical trials to support BLAs for marketing approval are typically conducted in three sequential phases, but the phases may overlap or
be combined. In Phase 1, the biologics initially introduced into healthy human subjects or patients, and the biologic is tested to assess pharmacokinetics, pharmacological actions, side effects associated with increasing doses, and, if possible,
early evidence on effectiveness. In the case of some products for severe or life-threatening diseases, such as cancer treatments, initial human testing may be conducted in the intended patient population. Phase 2 usually involves trials in a limited
patient population to determine the effectiveness of the biologic for a particular indication, dosage tolerance, and optimum dosage, and to identify common adverse effects and safety risks. If a compound demonstrates evidence of effectiveness and an
acceptable safety profile in Phase 2 evaluations, Phase 3 trials are undertaken to obtain the additional information about clinical efficacy and safety in a larger number of patients, typically at geographically dispersed clinical trial sites.,
These Phase 3 clinical trials are intended to establish data sufficient to demonstrate substantial evidence of the efficacy and safety of the product to permit FDA to evaluate the overall benefit-risk relationship of the biologic and to provide
adequate information for the labeling of the biologic. Trials conducted outside of </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">117
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
the US under similar, GCP-compliant conditions in accordance with local applicable laws may also be acceptable to FDA in support of product licensing. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sponsors of clinical trials for investigational drugs must publicly disclose certain clinical trial information, including detailed trial
design and trial results in FDA public databases. These requirements are subject to specific timelines and apply to most controlled clinical trials of FDA-regulated products. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">After completion of the required clinical testing, a BLA is prepared and submitted to the FDA. FDA review and approval of the BLA is required before marketing of the product may begin in the United
States. The BLA must include the results of all pre-clinical, clinical, and other testing and a compilation of data relating to the product&#146;s pharmacology, chemistry, manufacture, and controls and must demonstrate the safety and efficacy of the
product based on these results. The BLA must also contain extensive manufacturing information. The cost of preparing and submitting a BLA is substantial. Under federal law, the submission of most BLAs is additionally subject to a substantial
application user fee, as well as annual product and establishment user fees, which may total several million dollars and are typically increased annually. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The FDA has 60 days from its receipt of a BLA to determine whether the application will be accepted for filing based on the agency&#146;s threshold determination that it is sufficiently complete to permit
substantive review. Once the submission is accepted for filing, the FDA begins an in-depth review. The FDA has agreed to certain performance goals in the review of BLAs. Most such applications for standard review biologics are reviewed within ten
months from the date the application is accepted for filing. Although FDA often meets its user fee performance goals, the FDA can extend these timelines if necessary, and FDA review may not occur on a timely basis at all. The FDA usually refers
applications for novel biologics, or biologics which present difficult questions of safety or efficacy, to an advisory committee&#151;typically a panel that includes clinicians and other experts&#151;for review, evaluation, and a recommendation as
to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations. Before approving a BLA, the FDA will typically inspect one, or more, clinical sites to
assure compliance with GCP. Additionally, the FDA will inspect the facility or the facilities at which the biologic is manufactured. The FDA will not approve the product unless it verifies that compliance with current good manufacturing practice, or
GMP&#151;a quality system regulating manufacturing&#151;is satisfactory and the BLA contains data that provide substantial evidence that the biologic is safe and effective in the indication studied. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">After the FDA evaluates the BLA and the manufacturing facilities, it issues either an approval letter or a complete response letter. A
complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing, or information, in order for the FDA to reconsider the application. If, or when, those deficiencies have been addressed to
the FDA&#146;s satisfaction in a resubmission of the BLA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of information included. The FDA approval is never
guaranteed, and the FDA may refuse to approve a BLA if applicable regulatory criteria are not satisfied. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the PHSA, the
FDA may approve a BLA if it determines that the product is safe, pure and potent and the facility where the product will be manufactured meets standards designed to ensure that it continues to be safe, pure, and potent. An approval letter authorizes
commercial marketing of the biologic with specific prescribing information for specific indications. The approval for a biologic may be significantly more limited than requested in the application, including limitations on the specific diseases and
dosages or the indications for use, which could restrict the commercial value of the product. The FDA may also require that certain contraindications, warnings, or precautions be included in the product labeling. In addition, as a condition of BLA
approval, the FDA may require a risk evaluation and mitigation strategy (REMS) to help ensure that the benefits of the biologic outweigh the potential risks. REMS can include medication guides, communication plans for healthcare professionals, and
elements to assure safe use (ETASU). ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring, and the use of patient registries. The
requirement for a REMS or use of a companion </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">118
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
diagnostic with a biologic can materially affect the potential market and profitability of the biologic. Moreover, product approval may require, as a condition of approval, substantial
post-approval testing and surveillance to monitor the biologic&#146;s safety or efficacy. Once granted, product approvals may be withdrawn if compliance with regulatory standards is not maintained or problems are identified following initial
marketing. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">After a BLA is approved, the product may also be subject to official lot release. As part of the manufacturing
process, the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. If the product is subject to official lot release by the FDA, the manufacturer submits samples of each lot of product
to the FDA together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#146;s tests performed on the lot. The FDA may also perform certain confirmatory tests on lots of some
products, such as viral vaccines, before releasing the lots for distribution by the manufacturer. In addition, the FDA conducts laboratory research related to the regulatory standards on the safety, purity, potency, and effectiveness of biological
products. After approval of biologics, manufacturers must address any safety issues that arise, are subject to recalls or a halt in manufacturing, and are subject to periodic inspection after approval. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Because biologically sourced raw materials are subject to unique contamination risks, their use may be restricted in some countries.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Fast Track </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Fast Track program, a provision of the FDA Modernization Act of 1997, is designed to facilitate interactions between a sponsoring company and the FDA before and during submission of a BLA for an
investigational agent that, alone or in combination with one or more other drugs, is intended to treat a serious or life-threatening disease or condition, and which demonstrates the potential to address an unmet medical need for that disease or
condition. Under the Fast Track program, the FDA may consider reviewing portions of a marketing application before the sponsor submits the complete application if FDA determines, after a preliminary evaluation of the clinical data, that a fast track
product may be effective. A Fast Track designation provides the opportunity for more frequent interactions with the FDA, and a fast track product could be eligible for priority review if supported by clinical data at the time of submission of the
BLA. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Biosimilars </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Patient Protection and Affordable Care Act (Affordable Care Act) signed into law on March&nbsp;23, 2010, included a subtitle called the Biologics Price Competition and Innovation Act of 2009. That Act
created an approval pathway authorizing the FDA to approve biosimilars and interchangeable biosimilars. Biosimilars are biological products which are &#147;highly similar&#148; to a previously approved biologic product or &#147;reference
product&#148; and for which there are no clinically meaningful differences between the biosimilar product and the reference product in terms of the safety, purity, and potency. For FDA to approve a biosimilar product as interchangeable with a
reference product, the agency must find that the biosimilar product can be expected to produce the same clinical results as the reference product and, for products administered multiple times, the biosimilar and the reference biologic may be
switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. However, complexities associated with the larger, and often more complex,
structures of biological products, as well as the process by which such products are manufactured, pose significant hurdles to implementation, which are still being worked out by the FDA. To date, no biosimilar or interchangeable biologic has been
licensed under the BPCIA framework, although such approvals have occurred in Europe, and it is anticipated that FDA will approve a biosimilar in the relatively near future. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">119
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A reference biologic is granted 12 years of exclusivity from the time of first licensure of
the reference product. A biosimilar application may be filed four (4)&nbsp;years after the approval of the reference biologic. Although the patents for the reference biologic may be challenged by the biosimilar applicant during that time period
pursuant to the BPCIA statutory patent challenge framework, no biosimilar or interchangeable product will be licensed by FDA until the end of the exclusivity period. The first biologic product submitted under the abbreviated approval pathway that is
determined to be interchangeable with the reference product has exclusivity against other biologics submitting under the abbreviated approval pathway for the lesser of (i)&nbsp;one year after first commercial marketing, (ii)&nbsp;18 months after the
initial application if there is no legal challenge, (iii)&nbsp;18 months after the resolution in the applicant&#146;s favor of a lawsuit challenging the biologics&#146; patents if an application has been submitted, or (iv)&nbsp;42 months after the
application has been approved if a lawsuit is ongoing within the 42-month period. At this juncture, it is unclear whether products deemed &#147;interchangeable&#148; by FDA, in fact, will be readily substituted by pharmacies, which are governed by
state pharmacy law. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Advertising and Promotion </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Once a BLA is approved, a product will be subject to continuing post-approval regulatory requirements. For instance, FDA closely regulates the post-approval marketing and promotion of biologics, including
standards and regulations for direct-to-consumer advertising, off-label promotion, industry-sponsored scientific and educational activities and promotional activities involving the internet. Failure to comply with these regulations can result in
significant penalties, including the issuance of warning letters directing a company to correct deviations from FDA standards, a requirement that future advertising and promotional materials be precleared by the FDA, and federal and state civil and
criminal investigations and prosecutions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Biologics may be marketed only for the approved indications and in accordance with
the provisions of the approved labeling. Changes to some of the conditions established in an approved application, including changes in indications, labeling, or manufacturing processes or facilities, require submission and FDA approval of a new BLA
or BLA supplement before the change can be implemented. A BLA supplement for a new indication typically requires clinical data similar to that in the original application, and the FDA uses the same procedures and actions in reviewing BLA supplements
as it does in reviewing BLAs. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Adverse Event Reporting and GMP Compliance </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Adverse event reporting and submission of periodic reports are required following FDA approval of a BLA. The FDA also may require
post-marketing testing, known as Phase 4 testing, REMS, and surveillance to monitor the effects of an approved product, or the FDA may place conditions on an approval that could restrict the distribution or use of the product. In addition,
manufacture, packaging, labeling, storage and distribution procedures must continue to conform to current cGMPs after approval. Biologics manufacturers and certain of their subcontractors are required to register their establishments with the FDA
and certain state agencies. Registration with the FDA subjects entities to periodic unannounced inspections by the FDA, during which the agency inspects manufacturing facilities to assess compliance with cGMPs. Accordingly, manufacturers must
continue to expend time, money, and effort in the areas of production and quality control to maintain compliance with cGMPs. Regulatory authorities may withdraw product approvals, request product recalls, or impose marketing restrictions through
labeling changes or product removals if a company fails to comply with regulatory standards, if it encounters problems following initial marketing, or if previously unrecognized problems are subsequently discovered. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Companion Diagnostics </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The FDA regulates the sale or distribution, in interstate commerce, of medical devices, including IVDs. IVDs are a type of medical device that are intended to detect diseases, conditions, or infections,
or the presence of certain genetic or other biomarkers. If safe and effective use of a therapeutic depends on an IVD, the FDA generally will require approval of the companion diagnostic, at the same time that the FDA approves the
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">120
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
therapeutic. The FDA previously has required <I>in vitro</I> companion diagnostics intended to identify the patients most likely to respond to a treatment to obtain approval of a premarket
approval application (PMA) simultaneously with approval of the biologic. A required companion diagnostic has the potential to delay approval of the biologic and create barriers to patient access. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Orphan Drug </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the Orphan Drug Act, the FDA may grant orphan drug designation to biologics intended to treat a rare disease or
condition&#151;generally a disease or condition that affects fewer than 200,000 individuals in the United States. Orphan drug designation must be requested before submitting a BLA. After the FDA grants orphan drug designation, the generic identity
of the biologic and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not necessarily convey any advantage in, or shorten the duration of, the regulatory review and approval process. The first BLA applicant to
receive FDA approval for a particular product to treat a particular disease with FDA orphan drug designation is entitled to a seven-year exclusive marketing period in the United States for that product, for that indication. During the seven-year
exclusivity period, the FDA may not approve any other applications to market the same drug for the same disease, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity. Orphan drug
exclusivity does not prevent the FDA from approving a different biologic for the same disease or condition, or the same biologic for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain
research and a waiver of the BLA application user fee. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We anticipate seeking orphan drug designation for margetuximab,
MGA271, MGD006 and MGD007. Such designation would be sought in those populations that are being, or will be, studied to treat a disease or condition that affects fewer than 200,000 individuals in the United States. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Other Healthcare Laws and Compliance Requirements </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In the United States, our activities are potentially subject to regulation by federal, state, and local authorities in addition to the FDA, including the Centers for Medicare and Medicaid Services, other
divisions of the U.S. Department of Health and Human Services (e.g., the Office of Inspector General), the U.S. Department of Justice and individual U.S. Attorney offices within the Department of Justice, and state and local governments. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>International Regulation </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In addition to regulations in the United States, a variety of foreign regulations govern clinical trials, commercial sales, and distribution of product candidates. The approval process varies from country
to country and the time to approval may be longer or shorter than that required for FDA approval. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Pharmaceutical Coverage, Pricing, and
Reimbursement </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the United States and other countries, sales of any products for which we receive regulatory
approval for commercial sale will depend in part on the availability of reimbursement from third-party payors, including government health administrative authorities, managed care providers, private health insurers, and other organizations.
Third-party payors are increasingly examining the medical necessity and cost effectiveness of medical products and services in addition to safety and efficacy and, accordingly, significant uncertainty exists as to the reimbursement status of newly
approved therapeutics. Third-party reimbursement adequate to enable us to realize an appropriate return on our investment in research and product development may not be available for our products. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">121
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Facilities </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our headquarters are located in Rockville, Maryland, where we occupy office and laboratory space under a lease that expires on March&nbsp;31, 2018. Our manufacturing facility is also located in Rockville
under a lease with the same landlord that expires on December&nbsp;31, 2014. We have an option under each lease to continue the respective lease for five years under the same terms. We also sublease office and laboratory space in South San Francisco
under a lease that expires on December&nbsp;31, 2018. We are seeking to sublease a substantial portion of this space. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Employees
</B></FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of August 31, 2013, we had 159 full-time employees, 125 of whom were primarily engaged in research and development
activities and 34 of whom had an M.D. or Ph.D. degree. </FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Legal Proceedings </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are not currently a party to any material legal proceedings. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">122
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom575431_11"></A>MANAGEMENT </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Executive Officers and Directors </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The following table provides information with respect to our directors and executive officers as of August 31, 2013. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="43%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="51%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:13pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Age</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:35pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Position(s)</B></FONT></P></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Executive Officers</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Scott Koenig, M.D., Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">60</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">President and CEO and Director</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">James Karrels</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">46</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President, Chief Financial Officer and Secretary</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ezio Bonvini, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">59</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Vice President, Research</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Kathryn Stein, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">68</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Vice President, Product Development and Regulatory Affairs</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Jon Wigginton, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">51</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Vice President, Clinical Development</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stanford Stewart, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">62</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President, Clinical Oncology Research</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eric Risser</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">41</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President, Business Development</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lynn Cilinski</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">55</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President, Controller and Treasurer</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Directors</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Paulo Costa (2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">63</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chairman of the Board</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Kenneth Galbraith (1)(3)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">50</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Edward Hurwitz (1)(2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">49</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eran Nadav, Ph.D (2)(3)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">43</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Arnold Oronsky, Ph.D (1)(3)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">73</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">David Stump, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">63</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD></TR>
</TABLE>  <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Member of the Audit Committee </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Member of the Compensation Committee </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Member of the Nominating and Corporate Governance Committee </FONT></TD></TR></TABLE>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Koenig has been our President and Chief Executive Officer and a director since September 2001 and was one of our co-founders. Prior to joining us, Dr.&nbsp;Koenig served as Senior Vice President
of Research at MedImmune Inc., where he participated in the selection and maturation of their product pipeline. From 1984 to 1990, he worked in the Laboratory of Immunoregulation at the National Institute of Allergy and Infectious Diseases at the
National Institutes of Health, where he investigated the immune response to retroviruses and studied the pathogenesis of AIDS. Dr.&nbsp;Koenig currently serves as Chairman of the Board of Directors of Applied Genetic Technologies Corporation and of
the Children&#146;s Research Institute of Children&#146;s National Medical Center, and serves as a Board member of the Biotechnology Industry Organization (BIO) and Children&#146;s National Medical Center. Dr.&nbsp;Koenig received his A.B. and Ph.D.
from Cornell University and his M.D. from the University of Texas Health Science Center in Houston. We believe that Dr.&nbsp;Koenig&#146;s detailed knowledge of our company and his over 29 years in research and the biotechnology industry provide a
valuable contribution to our board of directors. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Karrels joined us as Vice President and Chief Financial Officer in
May 2008 and has over 20 years of experience in finance, including approximately 15 years working for, or on behalf of, life sciences companies. Prior to joining us, he was at Jazz Pharmaceuticals, Inc., most recently serving as Executive Director
of Finance, where he was responsible for the company&#146;s financial planning and analysis and investor relations activities. Prior to joining Jazz Pharmaceuticals, Mr.&nbsp;Karrels spent 11 years in the Investment Banking Group at Merrill Lynch,
most recently serving as a Director in the Global Healthcare Group. Mr.&nbsp;Karrels holds an M.B.A. from Stanford University and a B.B.A. from the University of Notre Dame. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Bonvini, Senior Vice President, Research, joined us in June 2003. From 1985 to 2003, Dr.&nbsp;Bonvini was with the FDA in the Center for Biologics Evaluation and Research, or CBER, which is
responsible for </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">123
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
regulating therapeutic monoclonal antibodies and other proteins, ultimately serving as Acting Deputy Director, Division of Monoclonal Antibodies and Chief, Laboratory of Immunobiology. From 1982
to 1984, Dr.&nbsp;Bonvini was a Visiting Fellow at the National Cancer Institute at the National Institutes of Health. Dr.&nbsp;Bonvini received a Diploma in Science from the Scientific Lyceum in Genoa, Italy, and his M.D. and Specialty
Certification in Clinical Hematology from the University of Genoa, School of Medicine. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Stein joined us as Vice
President, Product Development and Regulatory Affairs in May 2002 and has served as a Senior Vice President since 2006. From 1980 to 2002, Dr.&nbsp;Stein was at the FDA, including serving as Director, Division of Monoclonal Antibodies in the Office
of Therapeutics Research and Review at CBER from 1992 to 2002. While at the FDA, Dr.&nbsp;Stein worked on all regulatory aspects of therapeutic proteins and monoclonal antibodies and was a leader in policy development at FDA for these products. Many
currently marketed monoclonal antibodies were approved under her leadership. Dr.&nbsp;Stein received her Ph.D. in Microbiology and Immunology from the Albert Einstein College of Medicine of Yeshiva University and her B.A.&nbsp;in Chemistry from Bard
College. Dr.&nbsp;Stein commits half of her time to us. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr. Wigginton joined us as Senior Vice President, Clinical Research
in August 2013. Dr. Wigginton was previously the Therapeutic Area Head, Immuno-Oncology, Early Clinical Research and Executive Director, Discovery Medicine-Clinical Oncology at Bristol-Myers from October&nbsp;2008 to August&nbsp;2013. While there,
he led the early clinical development of the Bristol-Myers&#146; Immuno-Oncology portfolio including anti-PD-1 and anti-PD-L1. Prior to joining Bristol-Myers, Dr. Wigginton was the Director of Clinical Oncology at Merck Research Laboratories from
May 2006 to October 2008, where he led early- and late-stage clinical development teams for small molecules and biologics. During his academic career, Dr. Wigginton held several positions at the National Cancer Institute Center for Cancer Research
(NCI-CCR), including Head of Investigational Biologics Section, Pediatric Oncology Branch. Dr. Wigginton received his M.D. and B.S. in Biology from the University of Michigan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Stewart joined us as Vice President, Clinical Oncology Research in July 2008. From 2005 to 2008, Dr.&nbsp;Stewart served as Vice President, Clinical Research at Raven Biotechnologies, Inc., which
we acquired in July 2008. From 2001 to 2005, Dr.&nbsp;Stewart was with Corixa Corporation, most recently as Vice President, Clinical Research. Dr.&nbsp;Stewart was with ALZA Corporation in 2001 and from 1998 to 2001, he was with Genentech, where he
was Clinical Scientist on the Herceptin project and guided post-marketing clinical development, including the adjuvant breast cancer program. Dr.&nbsp;Stewart trained in Medical Oncology at Stanford University, and served as a member of the faculty
of the School of Medicine at Vanderbilt University for more than twelve years. Dr.&nbsp;Stewart received his M.D. from Baylor College of Medicine and his B.A. degree from Rice University. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Risser joined us as Vice President, Business Development in May 2009. Prior to joining us, Mr.&nbsp;Risser held the position of
Senior Director, Business Development in the pharmaceutical group at Johnson&nbsp;&amp; Johnson, where he worked from 2003 to 2009. Before Johnson&nbsp;&amp; Johnson, Mr.&nbsp;Risser started and built a consulting practice that provided counsel to
emerging life science companies in the United States and Europe. Earlier in his career, Mr.&nbsp;Risser held venture capital and investment banking positions with BA Venture Partners and Lehman Brothers Holdings Inc., respectively. Mr.&nbsp;Risser
holds an M.B.A. from Stanford University and a B.A. from Yale University. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ms. Cilinski, Vice President, Controller and
Treasurer, joined us in October 2003. Prior to joining us, Ms. Cilinski spent a year as a consultant to various companies providing services to the government. Prior to that, she spent more than 20 years with Covanta Energy Inc. (formerly Ogden
Corporation) where she held the position of Corporate Controller for four subsidiary companies that provided services to the federal government. Ms.&nbsp;Cilinski holds a B.S. from Strayer University. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Costa has served as a director since June 2009 and became chairman of the board in September 2013. Mr.&nbsp;Costa served as
President and Chief Executive Officer of Novartis U.S. Corporation, a pharmaceutical </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">124
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
and consumer health company, from October 2005 to August 2008. From August 2009 to August 2012, Mr.&nbsp;Costa served as chairman of the board of directors of Amylin Pharmaceuticals Inc., a
publicly held company, and currently serves as a director of two privately-held companies. Based on Mr.&nbsp;Costa&#146;s diverse experience in the pharmaceutical industry, ranging from successful product development, launch and commercialization
and his extensive senior management experience within the industry, the board of directors believes Mr.&nbsp;Costa has the appropriate set of skills to serve as a member of the board of directors. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Galbraith has served as a director since July 2008. Mr.&nbsp;Galbraith joined Ventures West in 2007 and leads the firm&#146;s
biotech practice. Mr.&nbsp;Galbraith has over 25 years of experience acting as an executive, director, investor and advisor to companies in the biotechnology, medical device, pharmaceutical and healthcare sectors. Mr.&nbsp;Galbraith has served as a
director of Celator Pharmaceuticals, Inc., a publicly held company, since July 2007, and has also served as a director of Tekmira Pharmaceuticals Corp., a publicly held company, since January 2010. In addition, Mr.&nbsp;Galbraith serves as a
director of several privately-held companies. Based on Mr.&nbsp;Galbraith&#146;s depth of experience in the biotechnology industry, ranging from executive officer to director roles, the board of directors believes Mr.&nbsp;Galbraith has the
appropriate set of skills to serve as a member of the board of directors. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Hurwitz has served as a director since
October 2004. Mr.&nbsp;Hurwitz has served as a Director of Alta Partners, a venture capital firm, since June 2002. Mr.&nbsp;Hurwitz also serves as a director of Sunesis Pharmaceuticals, Inc., a publicly held company, as well as several
privately-held companies. The board of directors has concluded that Mr.&nbsp;Hurwitz should serve on the board of directors due to his financial and scientific expertise, as well as his deep understanding of the biotechnology industry, which the
board of directors believes makes him an important resource for the board of directors as it assesses both financial and strategic decisions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Nadav has served as a director since June 2013. Dr.&nbsp;Nadav is a Managing Director at TPG Biotech, the life science venture investment arm of TPG, a global private investment firm.
Dr.&nbsp;Nadav joined TPG Biotech in 2007 with a focus on global pharmaceuticals and biotechnology investments. Prior to TPG, Dr.&nbsp;Nadav served as Business Development Director at Eisai Pharmaceuticals in New Jersey for four years, where he
evaluated and negotiated notable licensing and acquisition deals. Prior to this, Dr.&nbsp;Nadav worked for Johnson&nbsp;&amp; Johnson Development Corporation, the venture capital subsidiary of Johnson&nbsp;&amp; Johnson, and for Neurim
Pharmaceuticals. Based on Dr.&nbsp;Nadav&#146;s business experience and scientific expertise, the board of directors believes that Dr.&nbsp;Nadav has the appropriate set of skills to serve as a member of our board of directors. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Oronsky has served as a director since 2000. Dr.&nbsp;Oronsky has been a general partner with InterWest&nbsp;Partners, a venture
capital firm, since 1994, focusing primarily on life science companies. Dr.&nbsp;Oronsky serves as a director of Tesaro, Inc., a publicly held company, as well as several privately held life science companies. The board of directors believes that
Dr.&nbsp;Oronsky&#146;s experience in the life sciences industry as a venture capitalist and his service on the boards of directors of other public and private life sciences companies provides him with the qualifications and skills to serve as a
director. </FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr. Stump joined our board of directors in September 2013. Dr. Stump was most recently Executive Vice
President, Research and Development at Human Genome Sciences, Inc. from November 1999 until his retirement in December 2012. Dr. Stump also serves as a director of Sunesis Pharmaceuticals, Inc., a publicly held company, and as a director of Dendreon
Corporation, also a publicly held company. The board of directors believes that Dr. Stump&#146;s medical training and 23 years of experience in research and development and operations in the biotechnology industry qualify him to serve as a member of
our board of directors. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">125
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Board Composition and Election of Directors </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Board Composition </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our board of directors currently consists of
seven members, all of whom were elected as directors pursuant to a stockholders agreement that we have entered into with the holders of our preferred stock. The stockholders agreement will terminate upon the closing of this offering and there will
be no further contractual obligations regarding the election of our directors. Our directors hold office until their successors have been elected and qualified or until the earlier of their resignation or removal. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our certificate of incorporation and bylaws that will become effective upon the closing of this offering provide that the authorized
number of directors may be changed only by resolution of our board of directors. Our certificate of incorporation and bylaws also provide that our directors may be removed only for cause by the affirmative vote of the holders of at least 75% of the
votes that all our stockholders would be entitled to cast in an annual election of directors, and that any vacancy on our board of directors, including a vacancy resulting from an enlargement of our board of directors, may be filled only by vote of
a majority of our directors then in office. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In accordance with the terms of our certificate of incorporation and bylaws that
will become effective upon the closing of this offering, our board of directors will be divided into three classes, class I, class II and class III, with members of each class serving staggered three-year terms. Upon the closing of this offering,
the members of the classes will be divided as follows: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Class I, whose term will expire at the annual meeting of stockholders to be held in 2014; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Class II, whose term will expire at the annual meeting of stockholders to be held in 2015; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Class III, whose term will expire at the annual meeting of stockholders to be held in 2016. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Class I shall consist of Messrs. Koenig, Nadav and Oronsky, Class II shall consist of Messrs. Galbraith and Stump, and Class III shall
consist of Messrs. Costa and Hurwitz. At each annual meeting of stockholders after the initial classification, the successors to directors whose terms will then expire serve from the time of election and qualification until the third annual meeting
following election and until their successors are duly elected and qualified. A resolution of the board of directors or affirmative vote of at least 66 2/3% of our outstanding voting stock may change the authorized number of directors. Any
additional directorships resulting from an increase in the number of directors will be distributed among the three classes so that, as nearly as possible, each class will consist of one third of the directors. This classification of the board of
directors may have the effect of delaying or preventing changes in control or management of our company. </FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have no
formal policy regarding board diversity. Our priority in selection of board members is identification of members who will further the interests of our stockholders through his or her established record of professional accomplishment, the ability to
contribute positively to the collaborative culture among board members, knowledge of our business and understanding of the competitive landscape. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Independence of the Members of the Board of Directors </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Director Independence
</I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Applicable NASDAQ rules require a majority of a listed company&#146;s board of directors to be comprised of
independent directors within one year of listing. Under applicable NASDAQ rules, a director will only qualify as an &#147;independent director&#148; if, in the opinion of the listed company&#146;s board of directors, that person does not have a
relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">126
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consistent with these considerations, the board of directors has affirmatively determined
that all of the members of our board of directors, except for Dr.&nbsp;Koenig, are independent directors within the meaning of the applicable NASDAQ listing requirements. In making its determination of independence, the board of directors considered
the relationships of our directors, other than Mr.&nbsp;Costa, with certain of our principal stockholders. Our board of directors does not believe that these stockholder relationships interfere with these directors&#146; exercise of independent
judgment in carrying out their responsibilities as directors. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Board Committees </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our board of directors has an audit committee, a compensation committee and a nominating and corporate governance committee. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Compensation Committee </I></B></FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our compensation committee currently consists of Messrs. Hurwitz, Costa and Nadav. All members of the compensation committee are independent directors, as defined in the NASDAQ Global Market qualification
standards. The functions of this committee include: </FONT></P>  <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reviewing and, as it deems appropriate, recommending to our board of directors, policies, practices and procedures relating to the compensation of our
directors, officers and other managerial employees and the establishment and administration of our employee benefit plans; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">exercising authority under our employee benefit plans; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reviewing and approving executive officer and director indemnification and insurance matters; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">advising and consulting with our officers regarding managerial personnel and development. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Audit Committee </I></B></FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our audit committee consists of Messrs. Hurwitz, Galbraith and Oronsky. All members of the audit committee are independent directors, as defined in the NASDAQ Global Market qualification standards. Each
of Mr. Galbraith and Mr. Hurwitz qualifies as an &#147;audit committee financial expert&#148; as that term is defined in the rules and regulations established by the SEC. The functions of this committee include: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">meeting with our management periodically to consider the adequacy of our internal controls and the objectivity of our financial reporting;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">meeting with our independent auditors and with internal financial personnel regarding these matters; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">pre-approving audit and non-audit services to be rendered by our independent auditors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">recommending to our board of directors the engagement of our independent auditors and oversight of the work of our independent auditors;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reviewing our financial statements and periodic reports and discussing the statements and reports with our management, including any significant
adjustments, management judgments and estimates, new accounting policies and disagreements with management; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">establishing procedures for the receipt, retention and treatment of complaints received by us regarding accounting, internal accounting controls and
auditing matters; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">127
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reviewing our financing plans and reporting recommendations to our full board of directors for approval and to authorize action; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">administering and discussing with management and our independent auditors our Code of Ethics. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Both our independent auditors and internal financial personnel regularly meet privately with the audit committee and have unrestricted
access to this committee. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Nominating and Corporate Governance Committee </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our nominating and corporate governance committee is comprised of Messrs. Galbraith, Nadav and Oronsky. All members of the nominating and
corporate governance committee are independent directors, as defined in the NASDAQ Global Market qualification standards. The functions of this committee include: </FONT></P>  <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">identifying qualified candidates to become members of our board of directors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">selecting nominees for election of directors at the next annual meeting of stockholders (or special meeting of stockholders at which directors are to
be elected); </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">selecting candidates to fill vacancies of our board of directors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">developing and recommending to our board of directors our corporate governance guidelines; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">overseeing the evaluation of our board of directors. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Code of Conduct and Ethics </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our board of directors has adopted a code of
conduct and ethics that establishes the standards of ethical conduct applicable to all directors, officers and employees of our company. The code addresses, among other things, conflicts of interest, compliance with disclosure controls and
procedures and internal control over financial reporting, corporate opportunities and confidentiality requirements. The audit committee is responsible for applying and interpreting our code of conduct and ethics in situations where questions are
presented to it. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Compensation Committee Interlocks and Insider Participation </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">None of the members of our compensation committee at any time has been one of our officers or employees. None of our executive officers
currently serves, or in the past year has served, as a member of the board of directors or compensation committee of any entity that has one or more executive officers on our board of directors or compensation committee. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Executive Compensation </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our named executive officers for the year ended December&nbsp;31, 2012 include our principal executive officer and two other officers:
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Scott Koenig, M.D., Ph.D., President and Chief Executive Officer; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Anastasia Daifotis, M.D., our former Senior Vice President, Clinical Development; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ezio Bonvini, M.D., Senior Vice President, Research. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">128
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2012 Summary Compensation Table </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table presents the compensation awarded to, earned by or paid to each of our named executive officers for the year ended
December&nbsp;31, 2012. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:64pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name and Position</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Salary&nbsp;$</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:42pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option<BR>Awards&nbsp;$(1)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:58pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Nonequity<BR>Incentive Plan<BR>Compensation(2)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:64pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>All Other<BR>Compensation&nbsp;$(3)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:24pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total&nbsp;$</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Scott Koenig, M.D., Ph.D</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;President and Chief Executive Officer</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2012</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">441,648</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">200,000</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">220,000</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,675</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">865,323</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Anastasia Daifotis, M.D.</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;Senior Vice President, Clinical Development(4)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2012</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">357,690</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24,000</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">94,000</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">43,038</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">518,728</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ezio Bonvini, M.D.</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;Senior Vice President, Research</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2012</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">298,143</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">40,000</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">100,000</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,675</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">441,818</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The amounts reflect the grant date fair value for awards granted during 2012. The grant date fair value was computed in accordance with Financial Accounting Standards
Board Accounting Standards Codification Topic 718,<I>&nbsp;Compensation &#150; Stock Compensation</I>. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The amounts reflect the performance bonuses paid in 2013 for performance during 2012, as discussed further below under &#147;Narrative to Summary Compensation
Table&#151;Nonequity Incentive Plan Compensation.&#148; </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The amounts reflect $3,675 in 401(k) matching for each of Dr.&nbsp;Koenig, Dr.&nbsp;Daifotis and Dr.&nbsp;Bonvini, and $39,363 in reimbursement for travel-related
expenses and lodging in connection with Dr.&nbsp;Daifotis&#146; commuting from her personal residence in New Jersey to our headquarters in Maryland. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr. Daifotis left the Company in September 2013. She now serves as a consultant to us. </FONT></TD></TR></TABLE>  <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Narrative to Summary Compensation Table </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Annual Salary </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We review compensation annually for all employees, including our executives. In setting executive base salaries and bonuses and granting
equity incentive awards, we consider compensation for comparable positions in the market, the historical compensation levels of our executives, individual performance as compared to our expectations and objectives, our desire to motivate our
employees to achieve short- and long-term results that are in the best interests of our stockholders, and a long-term commitment to our company. We do not target a specific competitive position or a specific mix of compensation among base salary,
bonus or long-term incentives. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our board of directors has historically determined our executives&#146; compensation. Our
compensation committee typically reviews and discusses management&#146;s proposed compensation with the chief executive officer for all executives other than the chief executive officer. Based on those discussions and its discretion, the
compensation committee then recommends the compensation for each executive officer. Our board of directors, without members of management present, discusses the compensation committee&#146;s recommendations and ultimately approves the compensation
of our executive officers. To date, our compensation committee has not engaged a compensation consultant or adopted a peer group of companies for purposes of determining executive compensation. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">129
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Nonequity Incentive Plan Compensation </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our bonus plan motivates and rewards our executives for achievements relative to our goals and expectations for each fiscal year. Each
named executive officer has a target bonus opportunity, defined as a percentage of his or her annual salary. Following the end of each year, our board of directors determines bonuses. Material considerations in determining bonuses include
achievement of an executive&#146;s corporate objectives for the year; the executive&#146;s handling of unplanned events and opportunities; and the chief executive officer&#146;s input with respect to the performance of the company, our executives
and our financial performance relative to our plan. Based on these factors and in the sole discretion of our board of directors, we approved the bonuses in the table above for our named executive officers in 2013. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Specific achievements and performance considered by our board of directors in determining bonuses for 2012 included: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Advancing development of margetuximab, including additional enrollment of patients in the Phase&nbsp;1 clinical trial and the initiation of activities
related to the Phase 2a metastatic breast cancer clinical trial; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Advancing development of MGA271, including completing enrollment of the 5.0 mg/kg dosing cohort in the dose escalation portion of a Phase 1 clinical
trial and submitting a paper for publication; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Advancing our existing DART collaborations with Boehringer and Pfizer; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Finalizing candidate nomination and initiating IND-enabling activities for MGD006; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Initiating a safety study for MGD010; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Achieving cash proceeds from new business development activities of at least $10 million; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Maintaining a cash balance greater than $30 million throughout the year and ending the year with more than $35 million in cash and cash equivalents.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Long-Term Incentives </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our 2000 Stock Option and Incentive Plan, or 2000 Plan, and our 2003 Equity Incentive Plan, or 2003 Plan, authorized us to make grants to eligible recipients of non-qualified stock options, incentive
stock options, stock awards, and other forms of award, such as stock appreciation rights. Although the 2000 Plan and 2003 Plan provide for a range of types of awards, our equity grants to our executive officers have been only in the form of stock
options. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We typically grant equity incentive awards at the start of employment to each executive and our other employees.
Through 2012, we have not maintained a practice of granting additional equity on an annual basis, but we have retained discretion to provide additional targeted grants in certain circumstances. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We award our equity grants on the date our board of directors approves the grant. We set the option exercise price and grant date fair
value based on our per-share valuation on the date of grant. For grants in connection with initial employment, vesting begins on the initial date of employment. Time vested stock option grants to our executives typically vest 12.5% six months after
the date of grant with the remainder vesting in 14&nbsp;equal quarterly installments. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">130
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of August 31, 2013, options to purchase 54,420,900 shares of common stock at a
weighted average exercise price per share of $0.07 were outstanding. As of August 31, 2013, 1,473,394 shares of common stock remained available for future issuance under the 2003 Plan. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Please see &#147;&#151;Employee Benefit Plans&#148; for information relating to additional current and future benefit plans. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Other Compensation </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We paid $39,363 for commercial airfare and other travel-related expenses and lodging in connection with Dr.&nbsp;Daifotis&#146; commuting from her personal residence in New Jersey to our headquarters in
Maryland on a regular basis. Other amounts shown in the &#147;All Other Compensation&#148; column in the Summary Compensation Table relate to 401(k) matching contributions made to Dr.&nbsp;Koenig&#146;s, Dr.&nbsp;Daifotis&#146; and
Dr.&nbsp;Bonvini&#146;s 401(k) accounts, consistent with the matching contributions offered to all of our employees. </FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Consulting
Agreement with Dr. Daifotis </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In September 2013, we entered into a clinical consulting agreement with Dr. Daifotis. Dr.
Daifotis will provide up to eight hours per week or a total of 110 hours of services to us until January 10, 2014. In consideration for her services, Dr. Daifotis&#146; stock options will continue to vest in accordance with their original terms
until the expiration date of the consulting agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Employment Arrangements </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Please see &#147;&#151;Amended and Restated Employment, Severance and Change in Control Agreements.&#148; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">131
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Outstanding Equity Awards at 2012 Fiscal Year End </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table lists all outstanding equity awards held by our named executive officers as of December&nbsp;31, 2012. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="30%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:48pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Grant&nbsp;Date(1)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number&nbsp;of&nbsp;Securities<BR>Underlying<BR>Unexercised&nbsp;Options</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:72pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B># Exercisable</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number&nbsp;of&nbsp;Securities<BR>Underlying<BR>Unexercised&nbsp;Options</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:72pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B># Unexercisable</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option<BR>Exercise<BR>Price&nbsp;$</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:80pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option&nbsp;Expiration&nbsp;Date</B></FONT></P></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Scott Koenig, M.D., Ph.D</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">11/13/2001</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">408,222</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">.01</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">11/12/2013</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">5/21/2002</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,499,670</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">5/20/2015</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/14/2004</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">340,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/13/2015</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">3/24/2005</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,497,922</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">.0375</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">3/24/2015</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">12/15/2005</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">260,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">.0375</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">12/15/2015</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/7/2007</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,200,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/6/2017</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">11/16/2007</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">11/15/2017</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/11/2009</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,875,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">125,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/10/2019</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/10/2010</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">103,125</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">46,875</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/9/2020</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">3/14/2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">468,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,031,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">3/13/2022</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/6/2013</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">.08</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/5/2023</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Anastasia Daifotis, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">11/5/2009</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,137,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">712,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">11/4/2019</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/9/2011</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">87,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">112,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/8/2021</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">3/14/2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">56,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">243,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">3/13/2022</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/6/2013</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">300,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">.08</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/5/2023</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ezio Bonvini, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">4/17/2003</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">250,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">4/16/2014</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/14/2004</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/13/2015</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">3/24/2005</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,510,969</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">.0375</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">3/23/2016</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">12/15/2005</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">.0375</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">12/14/2015</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/7/2007</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">580,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/6/2017</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/6/2008</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">225,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/5/2018</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/11/2009</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">234,374</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,626</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/10/2019</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/11/2010</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">85,937</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">39,063</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/10/2020</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/9/2011</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">87,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">112,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/8/2021</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">3/14/2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">93,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">406,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">3/13/2022</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/6/2013</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">500,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">.08</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/5/2023</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Options vest and become exercisable with respect to (i)12.5 percent of the underlying shares six months after the grant date and (ii)&nbsp;the remainder of the
underlying shares in 14 equal quarterly installments. </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Director Compensation </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Except as discussed below, during and prior to 2012, we did not pay cash compensation to any non-employee director for his or her service
as a director. We reimburse our non-employee directors for reasonable travel and other expenses incurred in connection with attending board of director and committee meetings or otherwise in direct service of our company. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with his service as a director, Mr.&nbsp;Costa receives $25,000 per year. In addition, with his election as a director in
June 2009, we granted Mr.&nbsp;Costa an option to purchase 928,093 shares of our common stock. In 2013, Mr.&nbsp;Costa exercised the option in its entirety. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">132
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In September 2013, our board of directors approved a director compensation program to be
effective at the time of this offering. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under this director compensation program, we will pay our non-employee directors a
cash retainer for service on the board of directors and for service on each committee on which the director is a member. The chairman of each committee will receive higher retainers for such service. The fees paid to non-employee directors for
service on the board of directors and for service on each committee of the board of directors on which the director is a member are as follows: </FONT></P>  <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="86%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Member</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Annual&nbsp;
Retainer</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Chairman<BR>Additional<BR>Annual&nbsp;Retainer</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Board of Directors</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">35,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Audit Committee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Compensation Committee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Nominating and Corporate Governance Committee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>   <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We will also continue to reimburse our non-employee directors for reasonable travel and
out-of-pocket expenses incurred in connection with attending our board of director and committee meetings. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, under
our director compensation program, each non-employee director serving on our board of directors upon the closing of this offering and each non-employee director elected to our board of directors after the closing of this offering will receive an
option to purchase &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock. With respect to each non-employee director serving on our board of directors upon the closing of this offering, each of these options will vest as to
33.33% of the shares of our common stock underlying such option annually, beginning on the first anniversary of the grant date, subject to the director&#146;s continued service as a director. Further, on the date of the first board meeting held
after each annual meeting of stockholders, each non-employee director will receive an option to purchase an additional &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock. Each of these options will vest in full on the one
year anniversary of the grant date, subject to the non-employee director&#146;s continued service as a director. The exercise price of these options will equal the fair market value of our common stock on the date of grant. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This program is intended to provide a total compensation package that enables us to attract and retain qualified and experienced
individuals to serve as directors and to align our directors&#146; interests with those of our stockholders. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Amended and Restated
Employment, Severance and Change in Control Agreements </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In September 2013, we entered into an employment agreement with
Dr. Koenig. Dr. Koenig is employed &#147;at-will,&#148; which means that he has no definitive term of employment. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.
Koenig&#146;s employment agreement includes non-competition and non-solicitation provisions that will prohibit him from competing with us, soliciting our customers or employees, or hiring our employees for a period of two years following the end of
his employment with us for any reason. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr. Koenig is eligible to receive severance benefits in specified circumstances, as
set forth in the employment agreement. Under the terms of the agreement, upon execution and delivery of an irrevocable release of claims against the Company and subject to his continued compliance with the non-competition and son-solicitation
provisions, Dr. Koenig will be entitled to severance benefits if we terminate his employment without cause or if he terminates employment with us for good reason within 12 months following a change in control. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">133
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additionally, Dr. Koenig is entitled to specified accelerated vesting of options related
to a change of control. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following definitions are used in the employment agreement: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;Cause&#148; means: (a) a failure to substantially perform the duties with us (if the failure to substantially perform is not cured, if curable,
within thirty (30) days after receipt of written notice from the board of directors that specifies the conduct constituting Cause under this clause (a); (b) willful misconduct, or gross negligence in the performance of duties to us; (c)&nbsp;the
conviction or entry of a guilty plea or plea of no contest with respect to, any crime that constitutes a felony or involves fraud, dishonesty or moral turpitude; (d) commission of an act of fraud, embezzlement or misappropriation against us; (e) a
material breach of the fiduciary duty owed to us; (f) engaging in any improper conduct that has or is likely to have an adverse economic or reputational impact on us; or (g) a material breach of the employment agreement.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;Good reason&#148; means the occurrence of any of the following events (without Dr. Koenig&#146;s consent): (i) material adverse change in
functions, duties, or responsibilities that would cause executive&#146;s position to become one of materially lesser responsibility, importance, or scope or (ii) a material breach of the agreement by us. No resignation will be treated as &#147;good
reason&#148; unless (a) Dr. Koenig has given written notice of such event to the us within ninety (90) days after the initial occurrence, (b) we have failed to cure the condition constituting &#147;good reason&#148; within 30 days following the
delivery of the notice, and (c) Dr. Koenig terminates employment within thirty (30) days after expiration of such cure period. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;Change of Control&#148; means: (a) any person (excluding our employee benefit plans) is or becomes the &#147;beneficial owner&#148; (as defined
in Rules 13d-3 and 13d-5 under the Securities Exchange Act of 1934, as amended) directly or indirectly, of securities representing more than fifty percent (50%) of the combined voting power of our then outstanding securities; (b) we consummate a
merger, consolidation, share exchange, division or other reorganization or transaction with any other corporation unless our outstanding securities continue to represent at least 50% of the combined voting power immediately after the transaction; or
(c) liquidation or winding-up of our company or the consummation of the sale or disposition of all or substantially all of our assets; or (d) during any period of 24 consecutive months, individuals who at the beginning of such period constituted our
board (including for this purpose any new director whose election or nomination for election by the stockholders was approved by a vote of at least two-thirds of the directors then still in office who were directors at the beginning of such period
or whose appointment, election or nomination was previously so approved or recommended) cease for any reason to constitute at least a majority of the board of directors. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table summarizes the schedule of severance benefits Dr. Koenig would receive in the event of a qualifying termination.
</FONT></P>  <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:35pt"><FONT STYLE="font-family:Times New Roman" SIZE="2">Scenario</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:80pt"><FONT STYLE="font-family:Times New Roman" SIZE="2">Salary Continuation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Continuation of</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:62pt"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Health Benefits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Acceleration of</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:67pt"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Unvested Equity</FONT></P></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Absent a Change in Control</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">24 months of base salary and target bonus (55% of base&nbsp;salary)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">12 months</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">50% of the shares with respect to which the stock option&nbsp;is&nbsp;not vested</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Termination occurs within Two Years Following a Change in Control</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">24 months of base salary and target bonus (55% of base salary)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">12 months</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">100% of the shares with respect to which the stock option is not vested</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">134
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, upon the occurrence of a change of control (irrespective of whether Dr.
Koenig&#146;s employment terminates), each outstanding stock option held by Dr. Koenig that was granted by us to him prior to the date of this offering will become fully vested. </FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Employee Benefit Plans </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our employees, including our executive officers,
are entitled to various employee benefits. These benefits include the following: medical and dental care plans; flexible spending accounts for healthcare; life, accidental death and dismemberment and disability insurance; employee assistance
programs (confidential counseling); benefit advocacy counseling; a 401(k) plan; and paid time off. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Pension Benefits </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We do not have any qualified or non-qualified defined benefit plans. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Non-qualified Deferred Compensation </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We do not have any
non-qualified defined contribution plans or other deferred compensation plans. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>401(k) Plan </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our employees are eligible to participate in our 401(k) plan. Our 401(k) plan is intended to qualify as a tax-qualified plan under
Section&nbsp;401 of the Internal Revenue Code of 1986, as amended. Our 401(k) plan provides that each participant may contribute a portion of his or her pre-tax compensation, up to a statutory limit, which for most employees is $17,500 in 2013.
Participants that are 50 years or older can also make &#147;catch-up&#148; contributions, which in 2013 may be up to an additional $5,500 above the statutory limit. Employee contributions are held and invested by the plan&#146;s trustee. Our 401(k)
plan also permits us to make discretionary contributions and matching contributions. We match participant contributions up to 1.5% of a participant&#146;s annual compensation, subject to statutory limits. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>2000 Stock Option and Incentive Plan </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our 2000 Plan is administered by our compensation committee and provided for the grant of incentive stock options within the meaning of Section&nbsp;422 of the Internal Revenue Code, non-statutory stock
options, restricted stock, and other stock-based awards. Our employees, officers, directors, consultants and advisors were eligible to receive awards under our 2000 Plan. Upon an acquisition of us, the exercisability of options or the vesting of
restricted stock awards issued under the 2000 Plan will be accelerated. In addition, the Board will make appropriate provisions for the continuation of awards by us or substitution of awards by the surviving or acquiring entity. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of August&nbsp;31, 2013, under our 2000 Plan, there were options to purchase an aggregate of 726,817&nbsp;shares of common stock
outstanding at a weighted average exercise price of $0.046 per share. The 2000 Plan has expired, and no further awards may be issued under the plan. Any shares of common stock subject to awards under our 2000 Plan that expire, terminate, or are
otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised, or resulting in any common stock being issued, will become available for issuance under our 2013 Stock Incentive Plan, or the 2013 Plan, up to a specified
number of shares. </FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>2003 Equity Incentive Plan </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We implemented our 2003 Plan in February 2003, and it was amended and approved by our stockholders in 2005. Our board of directors has delegated the administration of the 2003 Plan to our compensation
committee. The 2003 Plan provides for the for the grant of incentive stock options, non-statutory </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">135
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
stock options, stock appreciation rights, restricted stock, and other stock-based awards. The 2003 Plan also permits the payment of cash awards. Our employees, officers, directors and consultants
are eligible to receive awards under our 2003 Plan. As of June&nbsp;30, 2013, we have only granted stock options under the 2003 Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In the event of changes in our capital structure, our compensation committee will make appropriate adjustments to&nbsp;the number of shares reserved for issuance under the 2003 Plan,&nbsp;the number of
shares underlying by each outstanding option or stock purchase agreement, the exercise price or purchase price under each outstanding option or stock purchase agreement, the repurchase prices, the number of options that may be granted to any
individual and/or the class of shares issuable and the terms of any stock appreciation right. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we merge with another entity
and are not the surviving entity or if, as a result of any other transaction or event, other securities are substituted for the shares of common stock or shares may no longer be issued then our board of directors will accelerate the vesting of any
outstanding incentive stock options by a period of 24&nbsp;months. In addition, if an employee&#146;s employment is terminated following such a transaction without cause or he or she terminates his or her employment for good reason (as defined in
the 2003 Plan), then the incentive stock option will be exercisable in full without regard to its vesting schedule. Our board, in its discretion, may also: (a)&nbsp;arrange for the substitution, in exchange for awards, of options to purchase equity
securities other than shares of our common stock; (b)&nbsp;accelerate the vesting and termination of outstanding awards, in whole or in part, so that awards can be exercised before or otherwise in connection with the closing or completion of a
transaction or event but then terminate; (c)&nbsp;cancel or arrange for the cancellation of awards in exchange for cash payments to awardees; and (d)&nbsp;either arrange for any of our repurchase rights with respect to shares of common stock to
apply to the securities issued in substitution for shares or terminate repurchase rights on such shares. Our board does not need to adopt the same rules for each award or awardee. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our board may also, in its discretion, specify that other transactions or events constitute a &#147;change of control,&#148; either
before or after the transaction. In connection with a change of control, our board may take any one or more of the actions described above and extend the date for the exercise of awards, but not beyond the original expiration date. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of August&nbsp;31, 2013, under our 2003 Plan, there were options to purchase an aggregate of 53,694,083&nbsp;shares of common stock
outstanding at a weighted average exercise price of $0.07 per share. There were 1,473,394&nbsp;shares remaining and available for issuance under the 2003 Plan as of that date. Upon the closing of this offering, we will grant no further stock options
or other awards under our 2003 Plan. Any shares of common stock subject to awards under our 2003 Plan that expire, terminate, or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised, or resulting in any
common stock being issued, will become available for issuance under our 2013 Plan, up to a specified number of shares. </FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>2013 Equity
Incentive Plan </I></B></FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our board of directors adopted the 2013 Plan in September 2013 and our stockholders approved the
2013 Plan in September 2013. The 2013 Plan will become effective immediately upon the signing of the underwriting agreement for this offering. The 2013 Plan will terminate in September 2023, unless terminated earlier by our board of directors.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Awards</I>. The 2013 Plan provides for the grant of incentive stock options, nonqualified stock options, restricted stock
awards, restricted stock unit awards, stock appreciation rights, performance awards, and other stock-based awards (collectively, &#147;stock awards&#148;), which may be granted to employees, officers, directors, and consultants. Currently, we only
intend to award stock options under the 2013 Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Share Reserve</I>. Following this offering, the aggregate number of
shares of common stock that may be issued initially pursuant to stock awards under the 2013 Plan is 36.8 million shares. The number of shares of common stock reserved for issuance will automatically increase on January&nbsp;1st, from January&nbsp;1,
2014 through </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">136
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
and including January&nbsp;1, 2023, by the lesser of (a) 36.8 million shares, (b)&nbsp;4.0% of the total number of shares of common stock outstanding on December&nbsp;31st of the preceding
calendar year, or (c)&nbsp;the number of shares of common stock determined by our board of directors. The maximum number of shares that may be issued pursuant to the exercise of incentive stock options over the term of the 2013 Plan is 36.8 million
shares. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If a stock award granted under the 2013 Plan expires or otherwise terminates without being exercised in full, the
shares of common stock not acquired pursuant to the stock award again become available for subsequent issuance under the 2013 Plan. In addition, shares that are forfeited to or repurchased by us prior to becoming fully vested under the 2013 Plan
will become available for the grant of new stock awards under the 2013 Plan. Shares issued under the 2013 Plan may be previously unissued shares or reacquired shares, including shares bought on the open market. As of the date hereof, no shares of
common stock have been issued under the 2013 Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Administration</I>. Our board of directors has delegated its authority
to administer the 2013 Plan to our compensation committee. Subject to the terms of the 2013 Plan, our board of directors or an authorized committee, referred to as the plan administrator, determines recipients, dates of grant, the numbers and types
of stock awards to be granted, and the terms and conditions of the stock awards, including the period of their exercisability and vesting. Subject to the limitations set forth below, the plan administrator will also determine the exercise price of
options granted, the consideration to be paid for restricted stock awards, and the base price of stock appreciation rights. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Stock Options</I>. Incentive and nonqualified stock options are granted pursuant to incentive and nonqualified stock option agreements
adopted by the plan administrator. The plan administrator determines the exercise price for a stock option provided that the exercise price of an incentive stock option and nonqualified stock option cannot be less than 100% of the fair market value
of our common stock on the date of grant. Options granted under the 2013 Plan vest at the rate specified by the plan administrator. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Generally, the plan administrator determines the term of stock options granted under the 2013 Plan, up to a maximum of ten years (except in the case of certain incentive stock options, as described
below). In no event, however, may an option be exercised beyond the expiration of its term. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Acceptable consideration for the
purchase of common stock issued upon the exercise of a stock option will be determined by the plan administrator and may include (a)&nbsp;cash or check, (b)&nbsp;a broker-assisted delivery of cash, (c)&nbsp;the tender of common stock previously
owned by the optionee, or (d)&nbsp;a net exercise of the option. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Tax Limitations on Incentive Stock Options</I>. Incentive
stock options may be granted only to our employees. No incentive stock option may be granted to any person who, at the time of the grant, owns or is deemed to own stock possessing more than 10% of our total combined voting power or that of any of
our affiliates unless (a)&nbsp;the option exercise price is at least 110% of the fair market value of the stock subject to the option on the date of grant and (b)&nbsp;the term of the incentive stock option does not exceed five years from the date
of grant. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Restricted Stock Awards</I>. Restricted stock awards may be granted pursuant to restricted stock award
agreements adopted by the plan administrator. Shares of common stock acquired under a restricted stock award may, but need not, be subject to forfeiture to us in accordance with a vesting schedule to be determined by the plan administrator. Rights
to acquire shares under a restricted stock award may be transferred only upon such terms and conditions as set by the plan administrator, which may include the achievement of performance goals. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Restricted Stock Unit Awards</I>. Restricted stock unit awards may be granted pursuant to restricted stock unit award agreements
adopted by the plan administrator. A restricted stock unit award may be settled by cash, delivery of stock, a combination of cash and stock as deemed appropriate by the plan administrator, or in any other form of consideration set forth in the
restricted stock unit award agreement. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">137
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Stock Appreciation Rights</I>. Stock appreciation rights may be granted pursuant to
stock appreciation rights agreements adopted by the plan administrator. The plan administrator determines the base price for a stock appreciation right which cannot be less than 100% of the fair market value of the common stock on the date of grant.
Upon the exercise of a stock appreciation right, we will pay the participant an amount equal to the product of (a)&nbsp;the excess of the per share fair market value of our common stock on the date of exercise over the base price, multiplied by
(b)&nbsp;the number of shares of common stock with respect to which the stock appreciation right is exercised. A stock appreciation right granted under the 2013 Plan vests at the rate specified in the stock appreciation right agreement and such
vesting may be contingent upon the achievement of performance goals. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The plan administrator determines the term of stock
appreciation rights granted under the 2013 Plan up to a maximum of ten years. In no event, however, may a stock appreciation right be exercised beyond the expiration of its term. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Performance Awards</I>. The 2013 Plan permits the grant of performance awards denominated in shares of common stock or unit equivalent
of shares of common stock and/or units of value, including dollar value of shares of common stock that may qualify as performance-based compensation that is not subject to the $1 million limitation on the income tax deductibility of compensation
paid to certain executive officers imposed by Section&nbsp;162(m) of the Internal Revenue Code. To assure that the compensation attributable to one or more performance stock awards will so qualify, our compensation committee can structure one or
more such awards so that stock will be issued or paid pursuant to such award only upon the achievement of certain pre-established performance goals during a designated performance period. The maximum cash amount payable to an employee during a
calendar year pursuant to all performance awards is $3 million. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Other Stock-Based Awards</I>. The plan administrator may
grant other awards based in whole or in part by reference to our common stock. The plan administrator will set the number of shares under the award and all other terms and conditions of such awards. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Changes to Capital Structure</I>. In the event that there is a specified type of change in our capital structure, such as a stock
split, appropriate adjustments will be made to (a)&nbsp;the number of shares reserved under the 2013 Plan, (b)&nbsp;the maximum number of shares for which awards may thereafter be granted under the 2013 Plan, (c)&nbsp;the maximum number of shares
with respect to which any person may be granted awards per calendar year and (d)&nbsp;the number of shares and exercise price or base price, if applicable, of all outstanding stock awards. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Corporate Transactions</I>. In the event of certain significant corporate transactions as set forth in the 2013 Plan outstanding stock
awards under the 2013 Plan may be (a) vested in whole or in part, (b) assumed or continued by any successor or acquirer and/or (c) canceled in whole or in part in consideration of a payment equal to the fair value of the canceled award or portion of
award. The cancellation payment will be in such form as the plan administrator may specify. The fair value of a canceled award or portion of award will be determined by the plan administrator in its discretion, provided the fair value of an option
or stock appreciation right will be deemed to be equal to (a) the number of unexercised shares covered by the award, multiplied by (b) the excess, if any, of the per share fair market value on the date of cancellation over the exercise price or base
price. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Employee Stock Purchase Plan </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our board of directors adopted and our stockholders approved our 2013 Employee Stock Purchase Plan, or 2013 purchase plan, in September, 2013. The 2013 purchase plan will become effective immediately upon
the signing of the underwriting agreement for this offering. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Share Reserve</I>. Following this offering, the 2013 purchase
plan authorizes the issuance of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock pursuant to purchase rights granted to our employees or to employees of any of our designated affiliates. The 2013 purchase plan is intended to
qualify as an &#147;employee stock purchase plan&#148; within the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">138
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
meaning of Section 423 of the Internal Revenue Code. As of the date hereof, no shares of common stock have been purchased under the 2013 purchase plan. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Administration</I>. Our board of directors will administer the 2013 purchase plan or delegate administration to a committee. The 2013
purchase plan is implemented through a series of offerings of purchase rights to eligible employees. Under the 2013 purchase plan, we may specify offerings with a duration of not more than 27 months, and may specify shorter purchase periods within
each offering. Each offering will have one or more purchase dates on which shares of common stock will be purchased for employees participating in the offering. We have not yet determined when we will commence offerings under the 2013 purchase plan.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Payroll Deductions</I>. Generally, all regular employees, including executive officers, employed by us or by any of our
affiliates may participate in the 2013 purchase plan and may contribute, normally through payroll deductions, a percentage of their earnings, not to exceed 15%, for the purchase of common stock under the 2013 purchase plan. Unless otherwise
determined by our board of directors, common stock will be purchased for accounts of employees participating in the 2013 purchase plan at a price per share equal to the lower of (a) 85% of the fair market value of a share of our common stock on the
first date of an offering or (b) 85% of the fair market value of a share of our common stock on the date of purchase. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Limitations</I>. Employees may have to satisfy one or more of the following service requirements before participating in the 2013
purchase plan, as determined by our board of directors: (a) customarily employed for more than 20 hours per week, (b) customarily employed for more than five months per calendar year or (c) continuous employment with us or one of our affiliates for
a period of time not to exceed two years. No employee may receive rights to purchase shares under the 2013 purchase plan or any other stock purchase plans we may offer that accrue at a rate in excess of $25,000 worth of our common stock valued based
on the fair market value per share of our common stock at the beginning of an offering for each year such a purchase right is outstanding. Finally, no employee will be eligible for the grant of any purchase rights under the 2013 purchase plan if
immediately after such rights are granted, such employee has voting power over 5% or more of our outstanding capital stock measured by vote or value. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Changes to Capital Structure</I>. In the event that there is a specified type of change in our capital structure, such as a stock split, appropriate adjustments will be made to (a) the number of shares
reserved under the 2013 purchase plan, (b) the maximum number of shares that may be issued pursuant to the exercise of purchase rights over the term of the 2013 purchase plan and (c) the number of shares and purchase price of all outstanding
purchase rights. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Corporate Transactions</I>. In the event of certain significant corporate transactions as set forth in
the 2013 purchase plan, any then-outstanding rights to purchase our stock under the 2013 purchase plan will be assumed, continued or substituted for by any surviving or acquiring entity (or its parent company). If the surviving or acquiring entity
(or its parent company) elects not to assume, continue or substitute for such purchase rights, then the participants&#146; accumulated contributions will be used to purchase shares of our common stock within ten business days prior to such corporate
transaction, and such purchase rights will terminate immediately thereafter. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">139
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom575431_12"></A>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Transactions with Management and Others </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Since January&nbsp;1, 2010, there has not been, nor is there any proposed transaction where we were or will be a party in which the amount involved exceeded or will exceed $120,000 and in which any
director, executive officer, holder of more than 5% of any class of our voting securities, or any member of the immediate family of any of the foregoing persons had or will have a direct or indirect material interest, other than the compensation
agreements and other agreements and transactions which are described in &#147;Management&#148;. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Policies and Procedures for Related Party
Transactions </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the written charter of our audit committee adopted March&nbsp;24, 2005, our audit committee of
the board of directors is responsible for reviewing and approving, prior to our entry into any such transaction, all related party transactions and potential conflict of interest situations involving a principal stockholder, a member of the board of
directors or senior management. In addition, our company policies require that our officers and employees avoid using their positions for purposes that are, or give the appearance of being, motivated by a desire for personal gain, and our policies
further require that all officers and employees who have authority to initiate related party transactions provide a written report, on an annual basis, of all activities which could result in a conflict of interest or impair their professional
judgment. All such written reports concerning related party transactions or conflicts of interest are submitted to, and reviewed by, our Chief Financial Officer and our audit committee. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">140
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom575431_13"></A>PRINCIPAL STOCKHOLDERS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table indicates information as of August&nbsp;31, 2013 regarding the ownership of our common stock, after giving effect to
the sale of common stock offered in this offering, for: </FONT></P>  <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">each person who is known by us to own more than 5% of our shares of common stock; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">each named executive officer; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">each of our directors; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">all of our directors and executive officers as a group. </FONT></P></TD></TR></TABLE>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The number of shares beneficially owned and the percentage of shares beneficially owned are based on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock outstanding as of
August&nbsp;31, 2013, which includes &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock resulting from the conversion of all outstanding shares of our preferred stock immediately upon the closing of this
offering, as if this conversion had occurred as of August&nbsp;31, 2013. Percentage ownership of our common stock after this offering (assuming no exercise of the underwriters&#146; over-allotment option to purchase additional shares) assumes our
sale of shares in this offering. Unless otherwise indicated in the footnotes to the table, and subject to community property laws where applicable, the following persons have sole voting and investment control with respect to the shares beneficially
owned by them. In accordance with SEC rules, if a person has a right to acquire beneficial ownership of any shares of common stock, on or within 60&nbsp;days of August&nbsp;31, 2013, upon exercise of outstanding options or otherwise, the shares are
deemed beneficially owned by that person and are deemed to be outstanding solely for the purpose of determining the percentage of our shares that person beneficially owns. These shares are not included in the computations of percentage ownership for
any other person. Except as otherwise indicated, the address of each of the persons in this table is 9640 Medical Center Drive, Rockville, Maryland 20850. </FONT></P>  <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="21%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="21%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:134pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name and Address of Beneficial Owner</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:91pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Shares&nbsp;Beneficially&nbsp;Owned<BR>Prior to the Offering</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:91pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Shares&nbsp;Beneficially&nbsp;Owned<BR>After the Offering</B></FONT></P></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5% Stockholders:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Entities affiliated with TPG (1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Entities affiliated with Alta BioPharma Partners (2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Entities affiliated with InterWest Partners (3)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Entities affiliated with MPM BioVentures (4)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Caisse de d&eacute;p&ocirc;t et placement du Qu&eacute;bec (5)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ventures West 8 Limited Partnership (6)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Directors and Named Executive Officers:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eran Nadav, Ph.D. (8)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Edward Hurwitz (9)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Arnold Oronsky, Ph.D. (10)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">David Stump, M.D. (11)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Kenneth Galbraith (7)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Paulo Costa (12)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Scott Koenig, M.D., Ph.D. (13)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Anastasia Daifotis, M.D. (14)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ezio Bonvini, M.D. (15)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">All executive officers and directors as a group (15&nbsp;persons)&nbsp;(16)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicates ownership of less than 1%. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of (i)&nbsp;21,352,187 shares of common stock issuable upon conversion of Series B Preferred Stock, (ii)&nbsp;19,724,839 shares of common
stock issuable upon conversion of Series C Preferred Stock, (iii)&nbsp;383,376 </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">141
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">
shares of common stock issuable upon conversion of Series D-2 Preferred Stock and (iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock
issuable upon conversion of Series D-2 Preferred Stock underlying warrants to purchase our Series D-2 Preferred Stock exercisable within 60 days after June&nbsp;30, 2013 held of record by entities affiliated with TPG. TPG Biotechnology Partners,
L.P., a Delaware limited partnership, whose general partners is TPG Biotechnology GenPar, L.P., a Delaware limited partnership, whose general partner is TPG Biotechnology GenPar Advisors, LLC, a Delaware limited liability company
(&#147;Biotechnology GenPar Advisors&#148;), and (ii)&nbsp;TPG Ventures, L.P., a Delaware limited partnership, whose general partner is TPG Ventures GenPar Advisors LLC, a Delaware limited liability company (&#147;Ventures GenPar Advisors&#148;) are
collectively referred to as the entities affiliated with TPG. The sole member of each of Biotechnology GenPar Advisors and Ventures GenPar Advisors is TPG Holdings I, L.P., a Delaware limited partnership, whose general partner is TPG Holdings I-A,
LLC, a Delaware limited liability company, whose sole member is TPG Group Holdings (SBS), L.P., a Delaware limited partnership, whose general partner is TPG Group Holdings (SBS) Advisors, Inc., a Delaware corporation. David Bonderman and James G.
Coulter are officers and sole shareholders of TPG Group Holdings (SBS) Advisors, Inc. and may therefore be deemed to be the beneficial owners of the securities held by TPG Biotechnology Partners, L.P. and TPG Ventures, L.P. Messrs. Bonderman and
Coulter disclaim beneficial ownership of the securities held by TPG Biotechnology Partners, L.P. and TPG Ventures, L.P. except to the extent of their pecuniary interest therein. The address of each of TPG Group Holdings (SBS) Advisors, Inc. and
Messrs. Bonderman and Coulter is c/o TPG Global, LLC, 301 Commerce Street, Suite 3300, Fort Worth, TX 76102. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of (i)&nbsp;21,352,186 shares of common stock issuable upon conversion of Series B Preferred Stock, (ii)&nbsp;12,328,024 shares of common stock issuable upon
conversion of Series C Preferred Stock, (iii)&nbsp;3,833,767 shares of common stock issuable upon conversion of Series D-2 Preferred Stock and (iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock
issuable upon conversion of Series D-2 Preferred Stock underlying warrants to purchase our Series D-2 Preferred Stock exercisable within 60 days after June&nbsp;30, 2013 held of record by entities affiliated with Alta BioPharma Partners. Alta
BioPharma Partners, L.P., Alta BioPharma Partners III GmbH&nbsp;&amp; Co. Beteiligings KG and Alta Embarcadero BioPharma Partners III, LLC are collectively referred to as the entities affiliated with Alta BioPharma Partners. The directors of Alta
BioPharma Management Partners III, LLC, which is the general partner of Alta Biopharma Partners III, L.P., the managing limited partner of Alta Biopharma Partners III GmbH&nbsp;&amp; Co. Beteiligungs KG, and the manager of Alta Embarcadero Biopharma
Partners III, LLC, exercise sole dispositive and voting power over the shares owned by the entities affiliated with Alta BioPharma Partners. Edward Hurwitz, one of our directors, Farah Champsi and Edward Penhoet are directors of Alta BioPharma
Management Partners III, LLC and managers of Alta Embarcadero Biopharma Partners III, LLC. These individuals may be deemed to share dispositive and voting power over the shares held by the entities affiliated with Alta BioPharma Partners. Each of
these individuals disclaims beneficial ownership of such shares except to the extent of his or her pecuniary interest therein. The principal address for the entities affiliated with Alta BioPharma Partners is One Embarcadero Center, Suite 3700, San
Francisco, CA 94111. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of (i)&nbsp;18,075,905 shares of common stock issuable upon conversion of Series A-1 Preferred Stock, (ii)&nbsp;11,551,327 shares of common
stock issuable upon conversion of Series B Preferred Stock (iii)&nbsp;5,547,611&nbsp;shares of common stock issuable upon conversion of Series C Preferred Stock (iv)&nbsp;613,402&nbsp;shares of common stock issuable upon conversion of Series D-2
Preferred Stock and (v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock issuable upon conversion of Series D-2 Preferred Stock underlying warrants to purchase our Series D-2 Preferred Stock
exercisable within 60 days after June&nbsp;30, 2013 held of record by entities affiliated with InterWest Partners. InterWest Partners VIII, L.P. (&#147;IW8&#148;), InterWest Investors Q VIII, L.P., and InterWest Investors VIII, L.P. are collectively
referred to as the entities affiliated with InterWest Partners. InterWest Management Partners VIII, LLC (&#147;IMP8&#148;) is the general partner of the entities affiliated with InterWest Partners and has sole voting and investment control over the
shares held by the entities affiliated with InterWest Partners. Harvey B. Cash, Philip T. Gianos, W.&nbsp;Scott Hedrick, W. Stephen Holmes, Gilbert H. Kliman and Arnold L. Oronsky, a member of our board of directors, are the managing directors of
IMP8. Each of the managing directors share voting and investment control with respect to the shares held by the entities affiliated with InterWest Partners. Dr.&nbsp;Oronsky disclaims beneficial ownership of all shares held by
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">142
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">
the entities affiliated with InterWest Partners except to the extent of his pecuniary interest therein. The address for these entities is c/o InterWest Partners, 2710 Sand Hill Road, Suite 200,
Menlo Park, California 94025. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of (i) 15,061,999 shares of common stock issuable upon conversion of Series A-1 Preferred Stock, (ii) 9,743,982 shares of common stock issuable upon conversion
of Series B Preferred Stock and (iii) 8,629,617 shares of common stock issuable upon conversion of Series C Preferred Stock held of record by entities affiliated with MPM. MPM BioVentures II, L.P., MPM BioVentures II-QP, L.P., MPM BioVentures GmbH
&amp; Co. Parallel-Beteiligungs KG, MPM Asset Management Investors 2000B LLC and MPM BioVentures IV Strategic Fund, L.P. are collectively referred to as the entities affiliated with MPM. MPM Asset Management II L.P. is the general partner of MPM
BioVentures II, L.P. and MPM BioVentures II-QP, L.P. and the special limited partner of MPM BioVentures GmbH &amp; Co. Parallel-Beteiligungs KG. MPM BioVentures II LLC is the general partner of MPM Asset Management II L.P. Ansbert Gadicke, Luke
Evnin, Nicholas Galakatos, Michael Steinmetz and Kurt Wheeler are the investment managers of MPM BioVentures II LLC and MPM Asset Management Investors 2000B LLC and share voting and dispositive power over the shares held by MPM BioVentures II, L.P.,
MPM BioVentures II-QP, L.P., MPM BioVentures GmbH &amp; Co. Parallel-Beteiligungs KG and MPM Asset Management Investors 2000B LLC. MPM BioVentures IV GP LLC is the general partner of MPM BioVentures IV Strategic Fund, L.P. MPM BioVentures IV LLC is
the Managing Member of MPM BioVentures IV GP LLC. Ansbert Gadicke, Luke Evnin, Todd Foley, Vaughn Kailian, Jim Scopa and John Vander Vort are members of MPM BioVentures IV LLC and share voting and dispositive power over the shares held by MPM
BioVentures IV Strategic Fund, L.P. Each individual identified in this footnote disclaims beneficial ownership of the shares except to the extent of his respective proportionate pecuniary interest in such shares. The address for the entities
affiliated with MPM is 200 Clarendon Street, 54th Floor, Boston, MA 02116. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of (i) 24,656,048 shares of common stock issuable upon conversion of Series C Preferred Stock held of record by Caisse de d&eacute;p&ocirc;t et placement du
Qu&eacute;bec, or CDP. An investment committee has voting and dispositive power over the shares held by Caisse de d&eacute;p&ocirc;t et placement du Qu&eacute;bec.&nbsp;The members of the investment committee are Pierre Pharand, Claude Lafond,
Anne-Marie Laberge, Manon Hamel, Fran&ccedil;ois Libotte, Michel Paquette, J&eacute;r&ocirc;me Marquis, Martin Garand and Mohamed Kortas. Each committee member disclaims beneficial ownership of such shares, except to the extent of any pecuniary
interest therein. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of (i)&nbsp;19,724,839 shares of common stock issuable upon conversion of Series C Preferred Stock, (ii)&nbsp;3,833,767 shares of common stock issuable upon
conversion of Series D-2 Preferred Stock and (iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock issuable upon conversion of Series D-2 Preferred Stock underlying warrants to purchase our Series
D-2 Preferred Stock exercisable within 60 days after June&nbsp;30, 2013 held of record by Ventures West 8 Limited Partnership. Kenneth Galbraith is General Partner and Senior Vice President of Ventures West 8 Management Ltd., the general partner of
the stockholder. Mr.&nbsp;Galbraith, one of our directors, along with the other partners of Ventures West 8 Management, Inc., have sole voting and investment control over the interest owned by Ventures West 8 Limited Partnership and disclaims
beneficial ownership of such shares except to the extent of any pecuniary interest therein. The address for Ventures West 8 Limited Partnership is Suite 400-999 West Hastings Street, Vancouver, BC, V6C 2W2. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of the shares described in footnote (6)&nbsp;above. Mr.&nbsp;Galbraith is a General Partner of Ventures West Capital Ltd., and as such Mr.&nbsp;Galbraith may
be deemed to share voting and dispositive power with respect to all shares held by these entities. Mr.&nbsp;Galbraith disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Mr.&nbsp;Galbraith&#146;s
business address is c/o Ventures West 8 Limited Partnership, Suite 400-999 West Hastings Street, Vancouver, BC, V6C 2W2. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr. Nadav, a member of our board of directors, is Managing Director of TPG Biotech. Dr. Nadav has no voting or investment power over and disclaims beneficial ownership
of the securities held by TPG Biotechnology Partners, L.P. and TPG Ventures, L.P. Dr. Nadav&#146;s business address is c/o TPG Global, LLC, 301 Commerce Street, Suite 3300, Fort Worth, TX 76102. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of the shares described in footnote (2)&nbsp;above. Mr.&nbsp;Hurwitz is a director of Alta BioPharma Management Partners III, LLC and , and as such
Mr.&nbsp;Hurwitz may be deemed to share voting and dispositive power with respect to all shares held by these entities. Mr.&nbsp;Hurwitz disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.
Mr.&nbsp;Hurwitz&#146;s business address is c/o Alta BioPharma Partners, One Embarcadero Center, Suite 3700, San Francisco, CA 94111. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">143
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(10)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of the shares described in footnote (3)&nbsp;above. Dr.&nbsp;Oronsky is Managing Director of the general partner of the entities affiliated with InterWest
Partners, and as such Dr.&nbsp;Oronsky may be deemed to share voting and dispositive power with respect to all shares held by these entities. Dr.&nbsp;Oronsky disclaims beneficial ownership of such shares except to the extent of any pecuniary
interest therein. Dr.&nbsp;Oronsky&#146;s business address is c/o InterWest Partners, 2710 Sand Hill Road, Suite 200, Menlo Park, California 94025. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(11)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr. Stump was appointed to our board of directors in September 2013. Dr. Stump&#146;s business address is c/o&nbsp;MacroGenics, Inc., 9640 Medical Center Drive,
Rockville, Maryland 20850. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(12)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of 928,093 shares of common stock. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(13)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of (i)&nbsp;1,000,000 shares of common stock, (ii) 12,037,983 shares of common stock owned jointly by Dr. Koenig and his spouse, of which Dr. Koenig has shared
voting and dispositive power, (iii) 1,000,000 shares of common stock held by the Scott Koenig Family Trust, an irrevocable trust, of which Dr. Koenig&#146;s spouse and brother-in-law are co-trustees, and of which Dr. Koenig may be deemed to have
shared voting and dispositive power, and (iv) 7,205,331 shares of common stock issuable upon the exercise of options exercisable within 60 days after June&nbsp;30, 2013. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(14)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of 2,750,000 shares of common stock issuable upon the exercise of options exercisable within 60&nbsp;days after June&nbsp;30, 2013. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(15)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of 3,380,344 shares of common stock issuable upon the exercise of options exercisable within 60&nbsp;days after June&nbsp;30, 2013. </FONT></TD></TR></TABLE>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(16)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of (i)&nbsp;18,075,905 shares of common stock issuable upon conversion of Series A-1 Preferred Stock, (ii)&nbsp;54,255,700 shares of common stock issuable upon
conversion of Series B Preferred Stock, (iii)&nbsp;81,981,361 shares of common stock issuable upon conversion of Series C Preferred Stock, (iv)&nbsp;8,664,312 shares of common stock issuable upon conversion of Series D-2 Preferred Stock,
(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock issuable upon conversion of Series D-2 Preferred Stock underlying warrants to purchase our Series D-2 Preferred Stock exercisable within 60 days
after June&nbsp;30, 2013, (vi)&nbsp;16,472,326&nbsp;shares of common stock and (vii)&nbsp;16,166,890 shares of common stock issuable upon the exercise of options exercisable within 60 days after June&nbsp;30, 2013. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">144
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom575431_14"></A>DESCRIPTION OF CAPITAL STOCK </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following description of our securities and provisions of our amended and restated certificate of incorporation and bylaws that we
expect to become effective upon the closing of this offering is only a summary. You should also refer to the copies of our certificate and bylaws which have been filed with the Securities and Exchange Commission as exhibits to our registration
statement, of which this prospectus forms a part. The description of common stock and preferred stock reflect changes to our capital structure that will occur upon the closing of this offering in accordance with the terms of the amended and restated
certificate of incorporation that will be adopted by us immediately prior to the closing of this offering. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upon the closing
of this offering, our authorized capital stock will consist of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock, par value $0.01 per share, and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of preferred stock, par
value $0.01 per share. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Common Stock </B></FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Currently, we are authorized to issue 425,000,000 shares of common stock. At August&nbsp;31, 2013, 38,163,345 shares of common stock were deemed outstanding and held of record by 147 holders. Under the
amended and restated certificate of incorporation and bylaws, holders of common stock do not have cumulative voting rights. Holders of shares representing a majority of the voting power of common stock can elect all of the directors. The holders of
the remaining shares will not be able to elect any directors. The shares of common stock offered by this prospectus, when issued, will be fully paid and non-assessable and will not be subject to any redemption or sinking fund provisions. Holders of
common stock do not have any preemptive, subscription or conversion rights. </FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Holders of common stock are entitled to
receive dividends declared by the board of directors out of legally available funds, subject to the rights of preferred stockholders, if any, and the terms of any future agreements between us and our lenders, if any. We presently intend to retain
future earnings, if any, for use in the operation and expansion of our business. We do not anticipate paying cash dividends on our common stock in the foreseeable future. See &#147;Dividend Policy.&#148; In the event of our liquidation, dissolution
or winding up, common stockholders are entitled to share ratably in all assets legally available for distribution after payment of all debts and other liabilities, and subject to the prior rights of any holders of outstanding shares of preferred
stock, if any. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Preferred Stock </B></FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Currently, we are authorized to issue 321,592,828 shares of preferred stock. As of August&nbsp;31, 2013, there were 294,720,231 shares of preferred stock held by 77 stockholders of record. Upon completion
of this offering, all shares of our preferred stock will convert into &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock. See Note 4 of Notes to Consolidated Financial Statements. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upon the closing of this offering, the board of directors will be authorized to issue from time to time up to an aggregate of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of preferred stock in one or more series and to fix or alter the designations, preferences, rights and any qualifications, limitations or restrictions of the shares of each of these series,
including the dividend rights, dividend rates, conversion rights, voting rights, term of redemption, including sinking fund provisions, redemption price or prices, liquidation preferences and the number of shares constituting any series or
designations of a series without further vote or action by the stockholders. The issuance of preferred stock may have the effect of delaying, deferring or preventing a change in control of us without further action by the stockholders and may
adversely affect the voting and other rights of the holders of common stock. The issuance of preferred stock with voting and conversion rights may adversely affect the voting power of the holders of common stock, including the loss of voting control
to others. We currently have no plans to issue any shares of preferred stock. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We believe that the ability to issue preferred
stock without the expense and delay of a special stockholders&#146; meeting will provide us with increased flexibility in structuring possible future financings and </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">145
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
acquisitions, and in meeting other corporate needs that might arise. This also permits the board of directors to issue preferred stock containing terms which could impede the completion of a
takeover attempt, subject to limitations imposed by the securities laws. The board of directors will make any determination to issue these shares based on its judgment as to the best interests of our company and our stockholders at the time of
issuance. This could discourage an acquisition attempt or other transaction which stockholders might believe to be in their best interests or in which they might receive a premium for their stock over the then market price of the stock. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Anti-Takeover Provisions </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are subject to the provisions of Section&nbsp;203 of the Delaware General Corporation Law. Subject to exceptions, Section&nbsp;203
prohibits a publicly-held Delaware corporation from engaging in a &#147;business combination&#148; with an &#147;interested stockholder&#148; for a period of three years from the date of the transaction in which the person became an interested
stockholder, unless the interested stockholder attained this status with the approval of the board of directors or unless the business combination is approved in a prescribed manner. A &#147;business combination&#148; includes mergers, asset sales
and other transactions resulting in a financial benefit to the interested stockholder. Subject to exceptions, an &#147;interested stockholder&#148; is a person who, together with affiliates and associates, owns, or within three years did own, 15% or
more of the corporation&#146;s voting stock. This statute could prohibit or delay the accomplishment of mergers or other takeover or change in control attempts with respect to us and, accordingly, may discourage attempts to acquire us. Our amended
and restated certificate of incorporation and bylaws, upon completion of this offering, will include a number of provisions that may make it more difficult to acquire control of us. These provisions could deprive stockholders of the opportunity to
realize a premium on the shares of common stock owned by them. In addition, these provisions may adversely affect the prevailing market price of the stock and are intended to: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">enhance the likelihood of continuity and stability in the composition of the board and in the policies formulated by the board;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">discourage transactions which may involve an actual or threatened change in control of us; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">discourage tactics that may be used in proxy fights; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">encourage persons seeking to acquire control of us to consult first with the board of directors to negotiate the terms of any proposed business
combination or offer; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reduce our vulnerability to an unsolicited proposal for a takeover that does not contemplate the acquisition of all of our outstanding shares or that
is otherwise unfair to our stockholders. </FONT></P></TD></TR></TABLE>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Classified Board of Directors; Removal; Filling Vacancies
and Amendment</I>. Our amended and restated certificate of incorporation and bylaws will provide for the board to be divided into three classes of directors serving staggered, three-year terms. The classification of the board has the effect of
requiring at least two annual stockholder meetings, instead of one, to replace a majority of members of the board. Subject to the rights of the holders of any outstanding series of preferred stock, the amended and restated certificate of
incorporation will authorize only the board to fill vacancies, including newly created directorships. Accordingly, this provision could prevent a stockholder from obtaining majority representation on the board by enlarging the board of directors and
filling the new directorships with its own nominees. Our amended and restated certificate of incorporation will also provide that directors may be removed by stockholders only for cause and only by the affirmative vote of holders of 75% of the
outstanding shares of voting stock. </FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Voting Rights. </I>Cumulative voting for the election of directors will not be
provided for in our amended and restated certificate of incorporation, which means that the holders of a majority of the shares voted can elect all of the directors then standing for election. A director may be removed only for cause and only by the
affirmative vote of the holders of at least 75% of the votes that all of our stockholders would be entitled to cast in </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">146
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
an annual election of directors. Any vacancy on our board of directors, including a vacancy resulting from an enlargement of our board of directors, may be filled only by vote of a majority of
our directors then in office. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Delaware General Corporation Law provides generally that, unless otherwise specified in a
corporation&#146;s certificate of incorporation or bylaws, the affirmative vote of a majority of the shares entitled to vote on any matter is required to approve such matter. Effective upon the completion of this offering, our bylaws may be amended
or repealed by a majority vote of our board of directors or by the affirmative vote of the holders of at least 75% of the votes that all of our stockholders would be entitled to cast in any annual election of directors. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Special Stockholder Meetings</I>. Our amended and restated certificate of incorporation will provide that special meetings of the
stockholders for any purpose or purposes, unless required by law, shall only be called by the Chairman of the board of directors, a majority of the entire board of directors or the Chief Executive Officer. A special meeting of the stockholders may
not be held absent a written request of this nature. The request shall state the purpose or purposes of the proposed meeting. This limitation on the right of stockholders to call a special meeting could make it more difficult for stockholders to
initiate actions that are opposed by the board of directors. These actions could include the removal of an incumbent director or the election of a stockholder nominee as a director. They could also include the implementation of a rule requiring
stockholder ratification of specific defensive strategies that have been adopted by the board of directors with respect to unsolicited takeover bids. In addition, the limited ability of the stockholders to call a special meeting of stockholders may
make it more difficult to change the existing board and management. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Advance Notice Requirements.</I>&nbsp;Our bylaws will
require advance notice by a stockholder of proposals relating to the nomination of candidates for election as directors or new business to be brought before meetings of our stockholders. These procedures provide that notice of stockholder proposals
must be timely given in writing to our corporate secretary prior to the meeting at which the action is to be taken. Generally, to be timely, notice must be received at our principal executive offices not less than 90&nbsp;days nor more than
120&nbsp;days prior to the first anniversary of the preceding year&#146;s annual meeting date. The notice must contain certain information specified in the bylaws. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Written Consent</I>. Our amended and restated certificate of incorporation will prohibit the taking of stockholder action by written consent without a meeting. These provisions will make it more
difficult for stockholders to take action opposed by the board of directors. </FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Amendment of Provisions in the Amended
and Restated Certificate of Incorporation</I>. Our amended and restated certificate of incorporation will generally require the affirmative vote of the holders of at least 75% of the outstanding voting stock in order to amend any provisions of the
amended and restated certificate of incorporation concerning: </FONT></P>  <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the removal or appointment of directors; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the authority of stockholders to act by written consent; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the required vote to amend the amended and restated certificate of incorporation; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">calling a special meeting of stockholders; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">procedure and content of stockholder proposals concerning business to be conducted at a meeting of stockholders; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">director nominations by stockholders. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">147
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">These voting requirements will make it more difficult for minority stockholders to make
changes in the amended and restated certificate of incorporation that could be designed to facilitate the exercise of control over us. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Undesignated Preferred Stock.</I> Our amended and restated certificate of incorporation provides for
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; authorized shares of preferred stock. The existence of authorized but unissued shares of preferred stock may enable our board of
directors to render more difficult or to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise. For example, if in the due exercise of its fiduciary obligations, our board of directors were to
determine that a takeover proposal is not in the best interests of us or our stockholders, our board of directors could cause shares of preferred stock to be issued without stockholder approval in one or more private offerings or other transactions
that might dilute the voting or other rights of the proposed acquirer or insurgent stockholder or stockholder group. In this regard, our amended and restated certificate of incorporation grants our board of directors broad power to establish the
rights and preferences of authorized and unissued shares of preferred stock. The issuance of shares of preferred stock could decrease the amount of earnings and assets available for distribution to holders of shares of common stock. The issuance may
also adversely affect the rights and powers, including voting rights, of these holders and may have the effect of delaying, deterring or preventing a change in control of us. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Options and Warrants </B></FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of August 31, 2013, options to purchase a
total of 54,420,900 shares of our common stock were outstanding, and up to 1,473,394 additional shares of our common stock were reserved for future issuance under our stock plans, excluding the 2013 Plan, which will become effective upon the signing
of the underwriting agreement in connection with this offering. For a more complete discussion of our stock option plans, please see &#147;&#151;Employee Benefit Plans.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As of August 31, 2013, warrants to purchase up to an aggregate of 3,394,035 shares of our Series D-2 preferred stock were outstanding at a weighted average exercise price of $0.65 per share. Each warrant
expires and terminates upon the completion of this offering. The exercise price and the shares issuable upon exercise are subject to adjustment in the event of stock dividends, stock splits, reorganizations and reclassifications and the warrants are
permitted to be exercised on a cashless basis. </FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Registration Rights </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have entered into a fourth amended and restated registration rights agreement, dated September&nbsp;19, 2008, which we refer to as the
registration rights agreement, with holders of our preferred stock. Upon completion of this offering, the holders of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock, or their transferees, will be
entitled to certain rights with respect to the registration of such shares, or registrable securities, under the Securities Act of 1933, as amended, or the Securities Act, as follows: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Demand Registration Rights.</I> The holders of shares representing at least 40% of the registrable securities issued or issuable upon
conversion of our Series A-1, Series A-2, Series B, and Series C preferred stock collectively then outstanding may request that we register all or a portion of their shares of registrable securities, provided that the reasonably anticipated
aggregate price to the public of such public offering would exceed $5,000,000. In addition, the holders of shares representing at least 40% of the registrable securities issued or issuable upon conversion of our Series D and Series D-2 preferred
stock collectively then outstanding may request that we register all or a portion of their shares of registrable securities, provided that the reasonably anticipated aggregate price to the public of such public offering would exceed $25,000,000.
Upon their request, we must, subject to some restrictions and limitations, use our best efforts to cause a registration statement covering the number of shares of registrable securities that are subject to the request to become effective. The
holders of registrable securities may only require us to file a maximum of one registration statement in response to their demand registration rights, provided, however, that such obligation will be deemed satisfied only when a
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">148
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
registration statement covering all shares of registrable securities that are requested to be registered has become effective. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Piggyback Registration Rights. </I>In the event that we propose to register any of our securities under the Securities Act, the
holders of registrable securities are entitled to notice of such registration and are entitled to include their registrable securities in such registration, subject to certain marketing and other limitations. These registration opportunities are
unlimited, but the number of shares that may be registered may be cut back in limited situations by the underwriters. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Form
S-3 Registration Rights.</I> The holders of shares of the registrable securities issued or issuable upon conversion of our Series A-1, Series A-2, Series B, Series C and Series D-2 preferred stock then outstanding may request that we register all or
a portion of their shares if we are eligible to file a registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> and if the reasonably anticipated aggregate price to the public of the public offering would exceed $1,000,000. In
addition, the holders of shares of the registrable securities issued or issuable upon conversion of our Series D preferred stock then outstanding may request that we register all or a portion of their shares if we are eligible to file a registration
statement on Form S-3 and if the reasonably anticipated aggregate price to the public of the public offering would exceed $5,000,000. The holders of registrable securities may only require us to file one registration statement on Form S-3 in any
twelve month period, provided, however, that such obligation will be deemed satisfied only when a registration statement covering all shares of registrable securities that are requested to be registered has become effective. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are generally obligated to bear the expenses, other than underwriting discounts and sales commissions, of these registrations.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NASDAQ Global Market Listing </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have applied to have our common stock listed on the NASDAQ Global Market under the symbol &#147;MGNX&#148;. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Transfer Agent and Registrar </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The transfer agent and registrar for our
common stock is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">149
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom575431_15"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prior to this offering, there has been no public market for our common stock, and we cannot predict the effect, if any, that market sales
of shares of our common stock or the availability of shares of our common stock for sale will have on the market price of our common stock prevailing from time to time. Nevertheless, sales of substantial amounts of our common stock, including shares
issued upon exercise of outstanding options, or the perception that these sales could occur in the public market after this offering could adversely affect market prices prevailing from time to time and could impair our ability to raise capital
through the sale of our equity securities. </FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Immediately after the closing of this offering, based on the number of shares
outstanding as of August&nbsp;31, 2013, we will have &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock outstanding, assuming no exercise of the underwriters&#146; option to purchase additional shares, and no exercise of
outstanding options prior to the closing of this offering. All of the&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares sold in this offering will be freely tradable, except that any shares held or purchased in this offering by our affiliates,
as that term is defined in Rule&nbsp;144 under the Securities Act, may only be sold in compliance with the limitations described below. </FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The remaining outstanding shares of our common stock will be deemed restricted securities as defined under Rule&nbsp;144. Restricted securities may be sold in the public market only if registered or if
they qualify for an exemption from registration under Rule&nbsp;144 or Rule&nbsp;701 promulgated under the Securities Act, which rules are summarized below. In addition, certain of our stockholders have entered into market standoff agreements with
us or lock-up agreements with the underwriters under which they agreed, subject to specified exceptions, not to sell any of their stock for at least 180 days following the date of this prospectus. Subject to the provisions of Rule&nbsp;144 or
Rule&nbsp;701, based on an assumed offering date of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2013,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;restricted shares will be available for sale in the public market as follows: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Beginning 180 days after the date of this prospectus,
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional shares will become eligible for sale in the public market, of which &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares will be freely tradable under Rule&nbsp;144 and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares will be held by affiliates and subject to the volume and other restrictions of Rule&nbsp;144 as described below.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In general, under Rule 144 as currently in effect, any person who is or has been an affiliate of ours
during the 90 days immediately preceding the sale and who has beneficially owned shares for at least six months is entitled to sell, within any three-month period commencing 90 days after the date of this prospectus, a number of shares that does not
exceed the greater of: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1% of the then outstanding shares of common stock, which will equal &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares immediately after this
offering; or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the average weekly trading volume during the four calendar weeks preceding the sale, subject to the filing of a Form 144 with respect to the sale.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sales under Rule 144 by our affiliates are also subject to certain manner of sale provisions and notice
requirements and to the availability of current public information about us. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A person who is not deemed to have been an
affiliate of ours at any time during the 90 days immediately preceding the sale and who has beneficially owned his or her shares for at least six months is entitled to sell his or her shares under Rule 144 without regard to the limitations described
above, subject only to the availability of current public information about us during the six months after the initial six-month holding period is met. After a nonaffiliate has beneficially owned his or her shares for one year or more, he or she may
freely sell his or her shares under Rule 144 without complying with any Rule 144 requirements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">150
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are unable to estimate the number of shares that will be sold under Rule 144, since this
will depend on the market price for our common stock, the personal circumstances of the sellers and other factors. Prior to the offering, there has been no public market for the common stock, and there can be no assurance that a significant public
market for the common stock will develop or be sustained after the offering. Any future sale of substantial amounts of the common stock in the open market may adversely affect the market price of the common stock offered by this prospectus.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Lock-up Agreements </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We, our directors and executive officers, and certain of our other stockholders have agreed that, subject to certain exceptions, they will not sell any common stock without the prior written consent of
the underwriters for a period of 180 days from the date of this prospectus. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Employee Benefit Plans </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any employee or consultant who purchased his or her shares under a written compensatory plan or contract is entitled to rely on the
resale provisions of Rule 701, which permits non-affiliates to sell their Rule 701 shares without having to comply with the public information, holding period, volume limitation or notice provisions of Rule 144 and permits affiliates to sell their
Rule 701 shares without having to comply with the Rule&nbsp;144 holding period restrictions, in each case commencing 90 days after the date of this prospectus. As of August 31, 2013, the holders of options to purchase approximately 54,420,900 shares
of common stock will be eligible to sell their shares upon the expiration of the 180-day lockup period, subject to the vesting of those options. </FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We intend to file a registration statement on Form S-8 under the Securities Act as soon as practicable after the completion of the offering to register &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares of common stock subject to outstanding stock options or reserved for issuance under our stock plans. This registration will permit the resale of these shares by non-affiliates in the public market without restriction under the Securities Act,
upon completion of the lock-up period described above. Shares registered under the Form S-8 registration statement held by affiliates will be subject to Rule 144 volume limitations. See &#147;Management&#151;Executive Compensation&#148; and
&#147;&#151;Employee Benefit Plans.&#148; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">151
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom575431_16"></A>MATERIAL U.S. FEDERAL TAX CONSEQUENCES FOR NON-U.S. HOLDERS
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following is a general discussion of the material U.S. federal income and estate tax consequences of the ownership
and disposition of our common stock by a beneficial owner that is a &#147;non-U.S. holder.&#148; For purposes of this discussion, a &#147;non-U.S. holder&#148; means a beneficial owner of our common stock that is not, for U.S. federal income tax
purposes: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an individual who is a resident of the United States; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a corporation, or other entity treated as a corporation for U.S. federal income tax purposes, created or organized under the laws of the United States
or any state or political subdivision thereof; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an estate, the income of which is subject to United States federal income taxation regardless of its source; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a trust, if a U.S. court is able to exercise primary supervision over the administration of the trust and one or more U.S. persons have the authority
to control all substantial decisions of the trust or if the trust has a valid election to be treated as a U.S. person under applicable regulations issued by the U.S. Department of the Treasury (&#147;Treasury Regulations&#148;).
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This discussion is based on the Internal Revenue Code of 1986, as amended (the &#147;Code&#148;), and
administrative pronouncements, judicial decisions and final, temporary and proposed Treasury Regulations, changes to any of which subsequent to the date of this prospectus may affect the tax consequences described herein, possibly with a retroactive
effect. In addition, the Internal Revenue Service (the &#147;IRS&#148;) could challenge one or more of the tax consequences described in this prospectus. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The discussion below is limited to non-U.S. holders that hold our shares of common stock as capital assets (generally, property held for investment) within the meaning of the Code. This discussion does
not address all aspects of U.S. federal income and estate taxation, including the Medicare contribution tax, that may be relevant to a particular non-U.S. holder in light of that non-U.S. holder&#146;s individual circumstances nor does it address
any aspects of U.S. state, local or non-U.S. taxes. This discussion also does not consider any specific facts or circumstances that may apply to a non-U.S. holder and does not address the special tax rules under the Code applicable to particular
non-U.S. holders, such as: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">financial institutions; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">brokers or dealers in securities; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">tax-exempt organizations; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">pension plans; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">owners that hold our common stock as part of a straddle, hedge, conversion transaction, synthetic security or other integrated investment;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">insurance companies; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">controlled foreign corporations; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">passive foreign investment companies; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">certain U.S. expatriates. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">152
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If a partnership, or any entity treated as a partnership for U.S. federal income tax
purposes, is a holder of our common stock, the tax treatment of a partner in the partnership will generally depend upon the status of the partner and the activities of the partnership. A holder that is a partnership, and the partners in such
partnership, should consult their own tax advisers regarding the tax consequences of the acquisition, holding and disposition of our common stock, as applicable. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Prospective holders are urged to consult their tax advisers with respect to the particular tax consequences to them of acquiring, holding and disposing of our common stock, including the consequences
under the laws of any state, local or foreign jurisdiction. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As discussed in the section entitled &#147;Dividend
Policy,&#148; we do not anticipate paying any dividends on our common stock in the foreseeable future. In the event that we do make distributions of cash or other property on our common stock (other than certain pro rata distributions of our common
stock or rights to acquire our common stock), those distributions generally will be treated as dividends to the extent paid from our accumulated earnings and profits, as determined under U.S. federal income tax principles. If a distribution exceeds
our current and accumulated earnings and profits, the excess will be treated as a tax-free return of the non-U.S. holder&#146;s investment, up to such holder&#146;s tax basis in the common stock. Any remaining excess will be treated as capital gain,
subject to the tax treatment described below under the heading &#147;Gain on Dispositions of Common Stock.&#148; Any such distribution would also be subject to the discussion below under the section titled &#147;Withholding and Information Reporting
Requirements&#150;FATCA.&#148; Dividends paid to a non-U.S. holder of our common stock generally will be subject to withholding tax at a 30% rate, or a reduced rate specified by an applicable income tax treaty. In order to obtain a reduced rate of
withholding under an applicable income tax treaty, a non-U.S. holder must provide an IRS Form&nbsp;W-8BEN (or successor form) certifying its entitlement to benefits under the treaty. Non-U.S. holders are urged to consult their own tax advisors
regarding their entitlement to benefits under a relevant income tax treaty. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The withholding tax does not apply to dividends
paid to a non-U.S. holder that provides an IRS Form&nbsp;W-8ECI (or successor form), certifying that the dividends are effectively connected with the non-U.S. holder&#146;s conduct of a trade or business within the United States (&#147;effectively
connected dividends&#148;). Instead, effectively connected dividends will be subject to regular U.S. income tax as if the non-U.S. holder were a U.S. resident, subject to any applicable income tax treaty providing otherwise. A non-U.S. corporation
receiving effectively connected dividends may also be subject to an additional &#147;branch profits tax,&#148; currently at the rate of 30% (or a lower rate prescribed under an applicable income tax treaty). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A non-U.S. holder that is eligible for a reduced rate of U.S. withholding tax under an income tax treaty may obtain a refund or credit
against any excess amounts withheld by timely filing an appropriate claim with the IRS. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Gain on Disposition of Common Stock
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A non-U.S. holder generally will not be subject to U.S. federal income tax on gain realized on a sale or other
disposition of common stock unless: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the gain is effectively connected with a trade or business of the non-U.S. holder in the United&nbsp;States, and if an applicable tax treaty so
provides, the gain is attributable to a permanent establishment or fixed base maintained by the non-U.S. holder in the United States; in these cases, the non-U.S. holder will be taxed on a net income basis at the regular graduated rates and in the
manner applicable to U.S. persons, subject to an applicable income tax treaty providing otherwise and if the non-U.S. holder is a corporation, an additional branch profits tax at a rate of 30%, or a lower rate as may be specified by an applicable
income tax treaty, may also apply; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the non-U.S. holder is a nonresident alien present in the United States for 183 days or more in the taxable year of the disposition and certain other
requirements are met, in which case the non-U.S. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">153
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="11%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P><FONT STYLE="font-family:Times New Roman" SIZE="2">
holder will be subject to a 30% tax (or such lower rate as may be specified by an applicable income tax treaty) on the net gain derived from the disposition, which may be offset by U.S.-source
capital losses of the non-U.S. holder, if any; or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we are or have been a &#147;U.S. real property holding corporation,&#148; as defined below, at any time within the five-year period preceding the
disposition or during the non-U.S. holder&#146;s holding period, whichever period is shorter. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are not,
and do not anticipate becoming, a U.S. real property holding corporation. Generally, a corporation is a &#147;U.S. real property holding corporation&#148; if the fair market value of its U.S. real property interests (as defined in the Code and the
applicable Treasury Regulations) equals or exceeds 50% of the aggregate fair market value of its worldwide real property interests and its other assets used or held for use in a trade or business. Even if we were to become a U.S. real property
holding corporation, gain on the sale or other disposition of common stock by a non-U.S. holder generally would not be subject to U.S. federal income tax, provided that the common stock is regularly traded on an established securities market and the
non-U.S. holder does not actually or constructively own more than 5% of the common stock during the shorter of (1)&nbsp;the five-year period ending on the date of the disposition or (2)&nbsp;the period of time during which the holder held such
shares. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Information Reporting Requirements and Backup Withholding </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We must report annually to the IRS and to each non-U.S. holder the gross amount of the distributions on our common stock paid to such
holder and the tax withheld, if any, with respect to such distributions. Unless a non-U.S. holder complies with certification procedures to establish that it is not a U.S. person (as defined in the Code), information returns may be filed with the
IRS in respect of the proceeds from a sale or other disposition of common stock and the non-U.S. holder may be subject to U.S. backup withholding (currently at 28%) on payments of dividends or on the proceeds from a sale or other disposition of
common stock. The certification procedures required to claim a reduced rate of withholding under a treaty will satisfy the certification requirements necessary to avoid the backup withholding tax as well. Generally, information reporting and backup
withholding will not apply to a payment of disposition proceeds to a non-U.S. holder where the transaction is effected outside the United States through a non-U.S. office or broker. However, for information reporting purposes, dispositions effected
through a non-U.S. office of a broker with substantial U.S. ownership or operations generally will be treated in a manner similar to dispositions effected through a U.S. office of a broker. Non-U.S. holders should consult their own tax advisors
regarding the application of the information reporting and backup withholding rules to them. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Copies of information returns
may be made available to the tax authorities of the country in which the non-U.S. holder resides or is incorporated under the provisions of a specific treaty or agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The amount of any backup withholding from a payment to a non-U.S. holder will be allowed as a credit against such holder&#146;s U.S. federal income tax liability and may entitle such holder to a refund or
credit against the non-U.S. holder&#146;s U.S. federal income tax liability, provided that the required information is furnished to the IRS. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Federal Estate Tax </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Individual Non-U.S. holders and entities the property of which is potentially includible in such an individual&#146;s gross estate for
U.S. federal estate tax purposes (for example, a trust funded by a non-U.S. holder individual and with respect to which the individual has retained certain interests or powers), should note that, absent an applicable treaty benefit, the common stock
will be treated as U.S. situs property subject to U.S. federal estate tax. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">154
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Withholding and Information Reporting Requirements&#150;FATCA </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Foreign Account Tax Compliance Act, which is commonly referred to as &#147;FATCA,&#148; will impose a U.S. federal withholding tax of
30% on payments of dividends on and gross proceeds from the sale or disposition of, our common stock if paid to a foreign entity unless (i)&nbsp;if the foreign entity is a &#147;foreign financial institution,&#148; the foreign entity undertakes
certain due diligence, reporting, withholding, and certification obligations, (ii)&nbsp;if the foreign entity is not a &#147;foreign financial institution,&#148; the foreign entity identifies certain of its U.S. investors, if any, or (iii)&nbsp;the
foreign entity is otherwise exempt under FATCA. Although this legislation is effective with regards to amounts paid after December&nbsp;31, 2012, under final Treasury Regulations issued on January&nbsp;17, 2013 and IRS Notice 2013-43 released on
July&nbsp;12, 2013, withholding under FATCA will only apply (1)&nbsp;to payments of dividends on our common stock made after June&nbsp;30, 2014 and (2)&nbsp;to payments of gross proceeds from a sale or other disposition of our common stock made
after December&nbsp;31, 2016. Under certain circumstances, a non-U.S. holder may be eligible for refunds or credits for such taxes. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Prospective investors should consult their own tax advisors regarding the possible implication of the FATCA rules on their investment in our common stock, and the entities through which they holder our
common stock, including, without limitation, the process and deadlines for meeting the applicable requirements to prevent the imposition of this 30% withholding tax under FATCA. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">155
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom575431_17"></A>UNDERWRITING </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith Incorporated, and Leerink Swann LLC are acting as representatives of each of the
underwriters named below. Subject to the terms and conditions set forth in an underwriting agreement among us and the underwriters, we have agreed to sell to the underwriters, and each of the underwriters has agreed, severally and not jointly, to
purchase from us, the number of shares of common stock set forth opposite its name below. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="86%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Underwriter</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number&nbsp;of<BR>Shares</B></FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Merrill Lynch, Pierce, Fenner &amp; Smith</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Incorporated</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Leerink Swann LLC</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stifel, Nicolaus &amp; Company, Incorporated</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lazard Capital Markets LLC</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Wedbush Securities Inc.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.15em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subject to the terms and conditions set forth in the underwriting agreement, the underwriters have
agreed, severally and not jointly, to purchase all of the shares sold under the underwriting agreement if any of these shares are purchased. If an underwriter defaults, the underwriting agreement provides that the purchase commitments of the
nondefaulting underwriters may be increased or the underwriting agreement may be terminated. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have agreed to indemnify the
underwriters against certain liabilities, including liabilities under the Securities Act, or to contribute to payments the underwriters may be required to make in respect of those liabilities. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The underwriters are offering the shares, subject to prior sale, when, as and if issued to and accepted by them, subject to approval of
legal matters by their counsel, including the validity of the shares, and other conditions contained in the underwriting agreement, such as the receipt by the underwriters of officer&#146;s certificates and legal opinions. The underwriters reserve
the right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Commissions and Discounts
</B></FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The representatives have advised us that the underwriters propose initially to offer the shares to the public at the
public offering price set forth on the cover page of this prospectus and to dealers at that price less a concession not in excess of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. After the initial offering, the public offering price,
concession or any other term of the offering may be changed. </FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table shows the public offering price,
underwriting discount and proceeds before expenses to us. The information assumes either no exercise or full exercise by the underwriters of their option to purchase additional shares. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="86%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:34pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Per&nbsp;Share</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:54pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Without&nbsp;Option</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:43pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>With&nbsp;Option</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Public offering price</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Underwriting discount</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proceeds, before expenses, to MacroGenics</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">156
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The expenses of the offering, not including the underwriting discount, are estimated at
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and are payable by us. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lazard Fr&egrave;res&nbsp;&amp; Co. LLC referred
this transaction to Lazard Capital Markets LLC and will receive a referral fee from Lazard Capital Markets LLC in connection therewith. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Option to Purchase Additional Shares </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have granted an option to the underwriters, exercisable for 30 days after the date of this prospectus, to purchase up to additional shares at the public offering price, less the underwriting discount.
If the underwriters exercise this option, each will be obligated, subject to conditions contained in the underwriting agreement, to purchase a number of additional shares proportionate to that underwriter&#146;s initial amount reflected in the above
table. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>No Sales of Similar Securities </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We, our executive officers and directors and certain of our other existing security holders have agreed not to sell or transfer any common stock or securities convertible into, exchangeable for,
exercisable for, or repayable with common stock, for 180 days after the date of this prospectus without first obtaining the written consent of Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith Incorporated. Specifically, we and these other persons have
agreed, with certain limited exceptions, not to directly or indirectly: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">offer, pledge, sell or contract to sell any common stock; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">sell any option or contract to purchase any common stock; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">purchase any option or contract to sell any common stock; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">grant any option, right or warrant for the sale of any common stock; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">lend or otherwise dispose of or transfer any common stock; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">request or demand that we file a registration statement related to the common stock; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">enter into any swap or other agreement that transfers, in whole or in part, the economic consequence of ownership of any common stock whether any such
swap or transaction is to be settled by delivery of shares or other securities, in cash or otherwise. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This
lock-up provision applies to common stock and to securities convertible into or exchangeable or exercisable for or repayable with common stock. It also applies to common stock owned now or acquired later by the person executing the agreement or for
which the person executing the agreement later acquires the power of disposition. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Nasdaq Global Market Listing </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We expect the shares to be approved for listing on the Nasdaq Global Market, subject to notice of issuance, under the symbol
&#147;MGNX&#148;. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Before this offering, there has been no public market for our common stock. The initial public offering
price will be determined through negotiations between us and the representatives. In addition to prevailing market conditions, the factors to be considered in determining the initial public offering price are </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the valuation multiples of publicly traded companies that the representatives believe to be comparable to us, </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">157
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our financial information, </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the history of, and the prospects for, our company and the industry in which we compete, </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an assessment of our management, its past and present operations, and the prospects for, and timing of, our future revenues,
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the present state of our development, and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the above factors in relation to market values and various valuation measures of other companies engaged in activities similar to ours.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">An active trading market for the shares may not develop. It is also possible that after the offering the
shares will not trade in the public market at or above the initial public offering price. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The underwriters do not expect to
sell more than 5% of the shares in the aggregate to accounts over which they exercise discretionary authority. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Price Stabilization, Short
Positions and Penalty Bids </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Until the distribution of the shares is completed, SEC rules may limit underwriters and
selling group members from bidding for and purchasing our common stock. However, the representatives may engage in transactions that stabilize the price of the common stock, such as bids or purchases to peg, fix or maintain that price. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with the offering, the underwriters may purchase and sell our common stock in the open market. These transactions may
include short sales, purchases on the open market to cover positions created by short sales and stabilizing transactions. Short sales involve the sale by the underwriters of a greater number of shares than they are required to purchase in the
offering. &#147;Covered&#148; short sales are sales made in an amount not greater than the underwriters&#146; option to purchase additional shares described above. The underwriters may close out any covered short position by either exercising their
option to purchase additional shares or purchasing shares in the open market. In determining the source of shares to close out the covered short position, the underwriters will consider, among other things, the price of shares available for purchase
in the open market as compared to the price at which they may purchase shares through the option granted to them. &#147;Naked&#148; short sales are sales in excess of such option. The underwriters must close out any naked short position by
purchasing shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of our common stock in the open market after pricing that could adversely
affect investors who purchase in the offering. Stabilizing transactions consist of various bids for or purchases of shares of common stock made by the underwriters in the open market prior to the completion of the offering. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The underwriters may also impose a penalty bid. This occurs when a particular underwriter repays to the underwriters a portion of the
underwriting discount received by it because the representatives have repurchased shares sold by or for the account of such underwriter in stabilizing or short covering transactions. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Similar to other purchase transactions, the underwriters&#146; purchases to cover the syndicate short sales may have the effect of
raising or maintaining the market price of our common stock or preventing or retarding a decline in the market price of our common stock. As a result, the price of our common stock may be higher than the price that might otherwise exist in the open
market. The underwriters may conduct these transactions on the Nasdaq Global Market, in the over-the-counter market or otherwise. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Neither we nor any of the underwriters make any representation or prediction as to the direction or magnitude of any effect that the transactions described above may have on the price of our common stock.
In addition, neither we nor any of the underwriters make any representation that the representatives will engage in these transactions or that these transactions, once commenced, will not be discontinued without notice. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">158
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Reserved Share Program </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">At our request, the underwriters have reserved for sale, at the initial public offering price, up to 5% of the shares offered by this prospectus for sale to some of our directors, officers, employees,
business associates and related persons. If these persons purchase reserved shares it will reduce the number of shares available for sale to the general public. Any reserved shares that are not so purchased will be offered by the underwriters to the
general public on the same terms as the other shares offered by this prospectus. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Electronic Distribution </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with the offering, certain of the underwriters or securities dealers may distribute prospectuses by electronic means, such
as e-mail. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Other Relationships </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Affiliates of Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith Incorporated have passive limited partnership interests in certain holders of our common stock, which, in the aggregate, account for less than
one percent of our common stock. Some of the underwriters and their affiliates have engaged in, and may in the future engage in, investment banking and other commercial dealings in the ordinary course of business with us or our affiliates. They have
received, or may in the future receive, customary fees and commissions for these transactions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, in the ordinary
course of their business activities, the underwriters and their affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank
loans) for their own account and for the accounts of their customers. Such investments and securities activities may involve securities and/or instruments of ours or our affiliates. The underwriters and their affiliates may also make investment
recommendations and/or publish or express independent research views in respect of such securities or financial instruments and may hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to Prospective Investors in the European Economic Area </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In relation to each Member State of the European Economic Area (each, a &#147;Relevant Member State&#148;), no offer of shares may be
made to the public in that Relevant Member State other than: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">A.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">to any legal entity which is a qualified investor as defined in the Prospectus Directive; </FONT></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">B.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">to fewer than 100 or, if the Relevant Member State has implemented the relevant provision of the 2010 PD Amending Directive, 150, natural or legal persons (other than
qualified investors as defined in the Prospectus Directive), as permitted under the Prospectus Directive, subject to obtaining the prior consent of the representatives; or </FONT></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">C.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">in any other circumstances falling within Article 3(2) of the Prospectus Directive, provided that no such offer of shares shall require the Company or the
representatives to publish a prospectus pursuant to Article 3 of the Prospectus Directive or supplement a prospectus pursuant to Article 16 of the Prospectus Directive. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each person in a Relevant Member State who initially acquires any shares or to whom any offer is made will be deemed to have represented,
acknowledged and agreed that it is a &#147;qualified investor&#148; within the meaning of the law in that Relevant Member State implementing Article 2(1)(e) of the Prospectus Directive. In the case of any shares being offered to a financial
intermediary as that term is used in Article 3(2) of the Prospectus Directive, each such financial intermediary will be deemed to have represented, acknowledged and agreed that the shares acquired by it in the offer have not been acquired on a
non-discretionary basis on behalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances which may give rise to an </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">159
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
offer of any shares to the public other than their offer or resale in a Relevant Member State to qualified investors as so defined or in circumstances in which the prior consent of the
representatives has been obtained to each such proposed offer or resale. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company, the representatives and their
affiliates will rely upon the truth and accuracy of the foregoing representations, acknowledgements and agreements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This
prospectus has been prepared on the basis that any offer of shares in any Relevant Member State will be made pursuant to an exemption under the Prospectus Directive from the requirement to publish a prospectus for offers of shares. Accordingly any
person making or intending to make an offer in that Relevant Member State of shares which are the subject of the offering contemplated in this prospectus may only do so in circumstances in which no obligation arises for the Company or any of the
underwriters to publish a prospectus pursuant to Article 3 of the Prospectus Directive in relation to such offer. Neither the Company nor the underwriters have authorized, nor do they authorize, the making of any offer of shares in circumstances in
which an obligation arises for the Company or the underwriters to publish a prospectus for such offer. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For the purpose of the
above provisions, the expression &#147;an offer to the public&#148; in relation to any shares in any Relevant Member State means the communication in any form and by any means of sufficient information on the terms of the offer and the shares to be
offered so as to enable an investor to decide to purchase or subscribe the shares, as the same may be varied in the Relevant Member State by any measure implementing the Prospectus Directive in the Relevant Member State and the expression
&#147;Prospectus Directive&#148; means Directive 2003/71/EC (including the 2010 PD Amending Directive, to the extent implemented in the Relevant Member States) and includes any relevant implementing measure in the Relevant Member State and the
expression &#147;2010&nbsp;PD Amending Directive&#148; means Directive 2010/73/EU. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to Prospective Investors in the United Kingdom
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, in the United Kingdom, this document is being distributed only to, and is directed only at, and any offer
subsequently made may only be directed at persons who are &#147;qualified investors&#148; (as defined in the Prospectus Directive) (i)&nbsp;who have professional experience in matters relating to investments falling within Article 19 (5)&nbsp;of the
Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the &#147;Order&#148;) and/or (ii)&nbsp;who are high net worth companies (or persons to whom it may otherwise be lawfully communicated) falling within Article
49(2)(a) to (d)&nbsp;of the Order (all such persons together being referred to as &#147;relevant persons&#148;). This document must not be acted on or relied on in the United Kingdom by persons who are not relevant persons. In the United Kingdom,
any investment or investment activity to which this document relates is only available to, and will be engaged in with, relevant persons. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to Prospective Investors in Switzerland </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The shares may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange (&#147;SIX&#148;) or on any other stock exchange or regulated trading facility in Switzerland. This
document has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing
Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this document nor any other offering or marketing material relating to the shares or the offering may be publicly distributed or otherwise
made publicly available in Switzerland. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Neither this document nor any other offering or marketing material relating to the
offering, the Company, the shares have been or will be filed with or approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of shares will not be supervised by, the Swiss Financial Market
Supervisory Authority FINMA (FINMA), and the offer of shares has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes (&#147;CISA&#148;). The investor protection afforded to acquirers of interests in
collective investment schemes under the CISA does not extend to acquirers of shares. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">160
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to Prospective Investors in the Dubai International Financial Centre </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This prospectus relates to an Exempt Offer in accordance with the Offered Securities Rules of the Dubai Financial Services Authority
(&#147;DFSA&#148;). This prospectus is intended for distribution only to persons of a type specified in the Offered Securities Rules of the DFSA. It must not be delivered to, or relied on by, any other person. The DFSA has no responsibility for
reviewing or verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus nor taken steps to verify the information set forth herein and has no responsibility for the prospectus. The shares to which this
prospectus relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the shares offered should conduct their own due diligence on the shares. If you do not understand the contents of this prospectus you should
consult an authorized financial advisor. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to Prospective Investors in Australia </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">No placement document, prospectus, product disclosure statement or other disclosure document has been lodged with the Australian
Securities and Investments Commission (&#147;ASIC&#148;), in relation to the offering. This prospectus does not constitute a prospectus, product disclosure statement or other disclosure document under the Corporations Act 2001 (the
&#147;Corporations Act&#148;), and does not purport to include the information required for a prospectus, product disclosure statement or other disclosure document under the Corporations Act. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any offer in Australia of the shares may only be made to persons (the &#147;Exempt Investors&#148;) who are &#147;sophisticated
investors&#148; (within the meaning of section 708(8) of the Corporations Act), &#147;professional investors&#148; (within the meaning of section 708(11) of the Corporations Act) or otherwise pursuant to one or more exemptions contained in section
708 of the Corporations Act so that it is lawful to offer the shares without disclosure to investors under Chapter 6D of the Corporations Act. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The shares applied for by Exempt Investors in Australia must not be offered for sale in Australia in the period of 12 months after the date of allotment under the offering, except in circumstances where
disclosure to investors under Chapter 6D of the Corporations Act would not be required pursuant to an exemption under section 708 of the Corporations Act or otherwise or where the offer is pursuant to a disclosure document which complies with
Chapter 6D of the Corporations Act. Any person acquiring shares must observe such Australian on-sale restrictions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This
prospectus contains general information only and does not take account of the investment objectives, financial situation or particular needs of any particular person. It does not contain any securities recommendations or financial product advice.
Before making an investment decision, investors need to consider whether the information in this prospectus is appropriate to their needs, objectives and circumstances, and, if necessary, seek expert advice on those matters. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to Prospective Investors in Hong Kong </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The shares have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than (a)&nbsp;to &#147;professional investors&#148; as defined in the Securities and
Futures Ordinance (Cap.&nbsp;571) of Hong Kong and any rules made under that Ordinance; or (b)&nbsp;in other circumstances which do not result in the document being a &#147;prospectus&#148; as defined in the Companies Ordinance (Cap. 32) of Hong
Kong or which do not constitute an offer to the public within the meaning of that Ordinance. No advertisement, invitation or document relating to the shares has been or may be issued or has been or may be in the possession of any person for the
purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with
respect to shares which are or are intended to be disposed of only to persons outside Hong Kong or only to &#147;professional investors&#148; as defined in the Securities and Futures Ordinance and any rules made under that Ordinance. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">161
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to Prospective Investors in Japan </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The shares have not been and will not be registered under the Financial Instruments and Exchange Law of Japan (Law No.&nbsp;25 of 1948,
as amended) and, accordingly, will not be offered or sold, directly or indirectly, in Japan, or for the benefit of any Japanese Person or to others for re-offering or resale, directly or indirectly, in Japan or to any Japanese Person, except in
compliance with all applicable laws, regulations and ministerial guidelines promulgated by relevant Japanese governmental or regulatory authorities in effect at the relevant time. For the purposes of this paragraph, &#147;Japanese Person&#148; shall
mean any person resident in Japan, including any corporation or other entity organized under the laws of Japan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to Prospective
Investors in Singapore </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore.
Accordingly, this prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of shares may not be circulated or distributed, nor may the shares be offered or sold, or be made the
subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i)&nbsp;to an institutional investor under Section&nbsp;274 of the Securities and Futures Act, Chapter 289 of Singapore (the
&#147;SFA&#148;), (ii)&nbsp;to a relevant person pursuant to Section&nbsp;275(1), or any person pursuant to Section&nbsp;275(1A), and in accordance with the conditions specified in Section&nbsp;275, of the SFA, or (iii)&nbsp;otherwise pursuant to,
and in accordance with the conditions of, any other applicable provision of the SFA. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Where the shares are subscribed or
purchased under Section&nbsp;275 of the SFA by a relevant person which is: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which is to hold investments and the entire share
capital of which is owned by one or more individuals, each of whom is an accredited investor; or </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an
accredited investor, </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">securities (as defined in Section&nbsp;239(1) of the SFA) of that corporation or the beneficiaries&#146;
rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the shares pursuant to an offer made under Section&nbsp;275 of the SFA except: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">to an institutional investor or to a relevant person defined in Section&nbsp;275(2) of the SFA, or to any person arising from an offer referred to in
Section&nbsp;275(1A) or Section&nbsp;276(4)(i)(B) of the SFA; </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">where no consideration is or will be given for the transfer; </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">where the transfer is by operation of law; </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">as specified in Section&nbsp;276(7) of the SFA; or as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures)
Regulations 2005 of Singapore. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">162
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom575431_18"></A>LEGAL MATTERS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The validity of the issuance of the shares of common stock offered by this prospectus will be passed upon for us by Arnold&nbsp;&amp;
Porter LLP, Washington, District of Columbia. Legal matters relating to the sale of common stock in this offering will be passed upon for the underwriters by Wilmer Cutler Pickering Hale and Dorr LLP, New York, New York. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom575431_19"></A>EXPERTS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Ernst&nbsp;&amp; Young LLP, independent registered accounting firm, has audited our consolidated financial statements at December 31, 2011 and 2012, and for the years then ended, as set forth in their
report. We&#146;ve included our financial statements in this Prospectus and elsewhere in the Registration Statement in reliance on Ernst&nbsp;&amp; Young LLP&#146;s report, given on their authority as experts in accounting and auditing. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom575431_20"></A>WHERE YOU CAN FIND MORE INFORMATION </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have filed a registration statement on Form S-1 with the Securities and Exchange Commission under the Securities Act with respect to
the common stock offered by this prospectus. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration statement or the exhibits and schedules filed therewith. For
further information with respect to us and our common stock, please see the registration statement and the exhibits and schedules filed with the registration statement. Statements contained in this prospectus regarding the contents of any contract
or any other document that is filed as an exhibit to the registration statement are not necessarily complete, and each such statement is qualified in all respects by reference to the full text of such contract or other document filed as an exhibit
to the registration statement. The registration statement, including its exhibits and schedules, may be inspected without charge at the public reference room maintained by the SEC, located at 100 F Street, N.E., Room 1580, Washington, D.C. 20549,
and copies of all or any part of the registration statement may be obtained from such offices upon the payment of the fees prescribed by the SEC. Please call the SEC at 1-800-SEC-0330 for further information about the public reference room. The SEC
also maintains an Internet website that contains reports, proxy and information statements and other information regarding registrants that file electronically with the SEC. The address of the site is <I>www.sec.gov</I>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upon completion of this offering, we will become subject to the information and periodic reporting requirements of the Exchange Act and,
in accordance therewith, will file periodic reports, proxy statements and other information with the SEC. Such periodic reports, proxy statements and other information will be available for inspection and copying at the public reference room and on
the SEC website referred to above. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">163
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom575431_21"></A>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MacroGenics, Inc.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin575431_1">Report of Independent Registered Public Accounting Firm</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin575431_2">Consolidated Balance Sheets as of December&nbsp;31, 2011 and 2012 and June&nbsp;
30, 2013 (unaudited) and June&nbsp;30, 2013 pro&nbsp;forma</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin575431_3">Consolidated Statements of Operations and Comprehensive Income for the years ended December&nbsp;
31, 2011 and 2012 and the six months ended June&nbsp;30, 2013 (unaudited) and 2012 (unaudited)</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin575431_4">Consolidated Statements of Stockholders&#146; Equity (Deficit) for the years ended December&nbsp;
31, 2011 and 2012 and the six months ended June&nbsp;30, 2013 (unaudited)</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin575431_5">Consolidated Statements of Cash Flows for the years ended December&nbsp;
31, 2011 and 2012 and the six months ended June&nbsp;30, 2013 (unaudited) and 2012 (unaudited)</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin575431_6">Notes to Consolidated Financial Statements</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-1
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="fin575431_1"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Board of Directors and Shareholders of </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">MacroGenics, Inc. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have audited the accompanying consolidated balance sheets
of MacroGenics, Inc. as of December&nbsp;31, 2011 and 2012, and the related consolidated statements of operations and comprehensive income (loss), stockholders&#146; equity (deficit) and cash flows for the years then ended. These financial
statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on these financial statements based on our audits. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable
assurance about whether the financial statements are free of material misstatement. We were not engaged to perform an audit of the Company&#146;s internal control over financial reporting. Our audits included consideration of internal control over
financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company&#146;s internal control over financial reporting.
Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by
management, and evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of MacroGenics, Inc. at December&nbsp;31, 2011 and 2012, and the
consolidated results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:54%; text-indent:-2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">/s/ Ernst&nbsp;&amp; Young LLP </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">McLean, Virginia </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">March&nbsp;8, 2013 </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-2
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="fin575431_2"></A>MACROGENICS, INC. </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CONSOLIDATED BALANCE SHEETS </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="57%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:46pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June&nbsp;30,</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></P></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June&nbsp;30,</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:37pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Pro&nbsp;Forma</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Assets</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Current assets:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">55,218,361</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">47,743,155</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">33,780,963</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounts receivable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,397,869</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,046,219</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,153,061</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prepaid expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">46,474</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">137,634</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">70,709</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total current assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">58,662,704</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">49,927,008</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">38,004,733</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Restricted cash</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">582,171</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">404,850</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">404,850</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Property and equipment, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,287,683</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,267,796</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,626,322</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">148,026</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">147,246</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">147,246</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">62,680,584</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">53,746,900</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42,183,151</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Liabilities and stockholders&#146; equity (deficit)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Current liabilities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounts payable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,051,456</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,739,125</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,118,796</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accrued expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,051,825</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,237,025</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">941,030</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lease exit liability &#150; current</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">533,560</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">628,768</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,024,762</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred revenue &#150; current</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">31,652,533</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24,123,176</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23,990,542</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total current liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">44,289,374</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">29,728,094</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">28,075,130</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lease exit liability</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,073,939</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,445,171</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,741,774</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred rent expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,360,838</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,801,653</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,854,574</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Preferred stock warrant liability</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">203,642</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">52,947</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">124,900</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred revenue, net of current portion</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23,237,075</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19,956,343</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,317,049</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">80,164,868</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">61,984,208</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">53,113,428</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stockholders&#146; equity (deficit):</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Series A-1 convertible preferred stock, $0.01 par value&nbsp;&#150; 26,874,792 shares authorized, 26,874,792&nbsp;shares issued
and outstanding at December&nbsp;31, 2011 and 2012 and June&nbsp;30, 2013; aggregate liquidation preference of $27,000,000 at December&nbsp;31, 2012 and June&nbsp;30, 2013 (unaudited), and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares outstanding at June&nbsp;30, 2013 (Pro Forma)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">268,748</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">268,748</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">268,748</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Series A-2 convertible preferred stock, $0.01 par value&nbsp;&#150; 7,364,582 shares authorized, 7,364,582&nbsp;shares issued and
outstanding at December&nbsp;31, 2011 and 2012 and June&nbsp;30, 2013; aggregate liquidation preference of $7,000,000 at December&nbsp;31, 2012 and June&nbsp;30, 2013 (unaudited), and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares outstanding at June&nbsp;30, 2013 (Pro Forma)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">73,646</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">73,646</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">73,646</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Series B convertible preferred stock, $0.01 par value &#150; 71,401,237 shares authorized, 71,401,237 shares issued and
outstanding at December&nbsp;31, 2011 and 2012 and June&nbsp;30, 2013; aggregate liquidation preference of $31,000,000 at December&nbsp;31, 2012 and June&nbsp;30, 2013 (unaudited), and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares outstanding at June&nbsp;30, 2013 (Pro Forma)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">714,012</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">714,012</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">714,012</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-3
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MACROGENICS, INC. </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CONSOLIDATED BALANCE SHEETS&#151;(Continued) </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="53%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:46pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June&nbsp;30,</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></P></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June&nbsp;30,</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:37pt" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Pro&nbsp;Forma</B></FONT></P></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Series C convertible preferred stock, $0.01 par value &#150; 110,952,217 shares authorized, 110,952,217 shares issued and
outstanding at December&nbsp;31, 2011 and 2012 and June&nbsp;30, 2013; aggregate liquidation preference of $45,000,000 at December&nbsp;31, 2012 and June&nbsp;30, 2013 (unaudited), and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares outstanding at June&nbsp;30, 2013 (Pro Forma)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,109,522</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,109,522</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,109,522</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Series D convertible preferred stock, $0.01 par value &#150; 30,000,000 shares authorized, 14,446,227 shares issued and
outstanding at December&nbsp;31, 2011 and 2012 and June&nbsp;30, 2013; aggregate liquidation preference of $9,400,000 at December&nbsp;31, 2012 and June&nbsp;30, 2013 (unaudited), and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares outstanding at June&nbsp;30, 2013 (Pro Forma)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">144,462</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">144,462</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">144,462</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Series D-2 convertible preferred stock, $0.01 par value &#150; 75,000,000 shares authorized, 63,681,176 shares issued and
outstanding at December&nbsp;31, 2011 and 2012 and June&nbsp;30, 2013; aggregate liquidation preference of $41,500,000 at December&nbsp;31, 2012 and June&nbsp;30, 2013 (unaudited), and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares outstanding at June&nbsp;30, 2013 (Pro Forma)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">636,812</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">636,812</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">636,812</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common stock, $0.01 par value &#150; 425,000,000 shares authorized, 19,694,392 issued and outstanding at December&nbsp;31, 2011,
20,630,906 issued and outstanding at December&nbsp;31, 2012, 36,836,099 issued and outstanding at June&nbsp;30, 2013 and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;at June&nbsp;30, 2013 (Pro Forma)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">196,944</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">206,309</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">368,361</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Treasury stock, at cost; 270,000 shares at December&nbsp;31, 2011 and 2012, June&nbsp;30, 2013 and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; June&nbsp;30, 2013 (Pro Forma) </FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(57,742</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(57,742</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(57,742</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additional paid-in capital</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">163,263,470</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">164,139,326</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">164,944,140</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accumulated deficit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(183,834,158</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(175,472,403</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(179,132,237</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total stockholders&#146; equity (deficit)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(17,484,284</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8,237,308</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(10,930,276</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total liabilities and stockholders&#146; equity (deficit)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">62,680,584</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">53,746,900</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42,183,151</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-4
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="fin575431_3"></A>MACROGENICS, INC. </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:89pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year Ended December&nbsp;31,</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:93pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Six Months Ended June&nbsp;30,</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenues:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenue from collaborative research</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">47,054,397</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">59,645,819</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">34,750,830</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,904,821</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Grant revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,152,969</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,180,279</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,195,183</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">991,343</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total revenues</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">57,207,366</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">63,826,098</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37,946,013</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22,896,164</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Costs and expenses:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">41,088,899</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">45,432,894</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24,956,734</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,145,909</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">General and administrative</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,868,791</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,187,894</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,126,406</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,336,419</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total costs and expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">51,957,690</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">55,620,788</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30,083,140</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">26,482,328</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Income (loss) from operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,249,676</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,205,310</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,862,873</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,586,164</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other income (expense):</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest income (expense)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,009</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,195</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,720</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other income (expense)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,459,435</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">150,695</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(71,950</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total other income (expense)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,467,444</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">156,445</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,195</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(73,670</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net comprehensive income (loss)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,717,120</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,361,755</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,866,068</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,659,834</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Basic net income (loss) per common share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Diluted net income (loss) per common share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Basic weighted average number of common shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19,254,567</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,337,513</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,106,584</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22,237,823</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Diluted weighted average number of common shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19,254,567</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,337,513</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">401,152,574</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22,237,823</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pro forma basic net income (loss) per common share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.02</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.01</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pro forma diluted net income (loss) per common share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.02</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.01</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pro forma basic weighted average number of common shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">338,665,060</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">340,565,370</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pro forma diluted weighted average number of common shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">403,144,899</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">340,565,370</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-5
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="fin575431_4"></A>MACROGENICS, INC. </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#146; EQUITY </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:40pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Series A-1 <BR>Convertible<BR>Preferred Stock</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:40pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Series A-2 <BR>Convertible<BR>Preferred Stock</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:40pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Series B <BR>Convertible<BR>Preferred Stock</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Series C</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Convertible</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:40pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Preferred
Stock</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:40pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Series D <BR>Convertible<BR>Preferred Stock</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:40pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Series D-2 <BR>Convertible<BR>Preferred Stock</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:39pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Common Stock</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:39pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Treasury Stock</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:27pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Additional<BR>Paid-In<BR>Capital</B></FONT></P></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:34pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Accumulated<BR>Deficit</B></FONT></P></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:35pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total
<BR>Stockholders&#146;<BR>Equity<BR>(Deficit)</B></FONT></P></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:17pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Shares</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:21pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Amount</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:17pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Shares</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:21pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Amount</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:17pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Shares</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:21pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Amount</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:17pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Shares</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:21pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Amount</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:17pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Shares</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:21pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Amount</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:17pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Shares</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:21pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Amount</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:17pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Shares</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:21pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Amount</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:17pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Shares</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:21pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Amount</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Balance, December&nbsp;31, 2010</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">26,874,792</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">268,748</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">7,364,582</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">73,646</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">71,401,237</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">714,012</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">110,952,217</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1,109,522</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">14,446,227</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">144,462</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">45,253,788</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">452,538</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">18,786,686</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">187,867</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">270,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(57,742</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">149,024,167</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(190,551,278</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(38,634,058</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Share-based compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,347,439</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,347,439</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Issuance of convertible Series D-2 stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">18,427,388</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">184,274</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">11,830,541</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">12,014,815</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Stock option exercises</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">907,706</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">9,077</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">61,323</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">70,400</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Net income (loss)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">6,717,120</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">6,717,120</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Balance, December&nbsp;31, 2011</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">26,874,792</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">268,748</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">7,364,582</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">73,646</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">71,401,237</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">714,012</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">110,952,217</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1,109,522</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">14,446,227</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">144,462</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">63,681,176</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">636,812</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">19,694,392</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">196,944</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">270,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(57,742</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">163,263,470</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(183,834,158</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(17,484,284</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Share-based compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">838,395</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">838,395</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Stock option exercises</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">936,514</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">9,365</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">37,461</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">46,826</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Net income (loss)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">8,361,755</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">8,361,755</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Balance, December&nbsp;31, 2012</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">26,874,792</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">268,748</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">7,364,582</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">73,646</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">71,401,237</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">714,012</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">110,952,217</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1,109,522</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">14,446,227</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">144,462</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">63,681,176</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">636,812</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">20,630,906</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">206,309</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">270,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(57,742</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">164,139,326</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(175,472,403</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(8,237,308</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Share-based compensation (unaudited)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">257,625</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">257,625</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Stock option exercises (unaudited)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">16,205,193</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">162,052</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">547,189</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">709,241</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Net income (loss) (unaudited)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(3,659,834</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(3,659,834</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Balance, June 30, 2013 (unaudited)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">26,874,792</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">268,748</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">7,364,582</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">73,646</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">71,401,237</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">714,012</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">110,952,217</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1,109,522</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">14,446,227</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">144,462</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">63,681,176</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">636,812</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">36,836,099</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">368,361</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">270,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(57,742</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">164,944,140</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(179,132,237</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(10,930,276</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-6
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="fin575431_5"></A>MACROGENICS, INC. </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CONSOLIDATED STATEMENTS OF CASH FLOWS </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:89pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year Ended December&nbsp;31,</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:93pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Six Months Ended June&nbsp;30,</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="6" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Operating activities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net income (loss)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,717,120</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,361,755</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,866,068</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,659,834</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Depreciation expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,147,300</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">959,930</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">486,952</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">517,764</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Share-based compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,347,439</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">838,395</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">419,198</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">257,625</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fair value adjustment of warrant liability</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,459,435</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(150,695</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">71,953</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Changes in operating assets and liabilities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounts receivable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,551,066</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,351,650</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,405,069</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,106,842</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prepaid expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">76,876</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(91,160</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(59,180</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">66,925</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Restricted cash</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(513</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">177,321</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">177,321</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(133,782</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">780</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounts payable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(10,271,048</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7,312,331</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6,090,373</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,620,329</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lease exit liability</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(447,019</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(533,560</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(260,855</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(307,403</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accrued expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">272,988</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">185,200</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">174,738</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(295,995</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4,275,976</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(10,810,089</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(18,623,512</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6,771,928</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred rent</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">232,324</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">440,815</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">355,831</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">52,921</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash provided by (used in) operating activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,757,340</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6,581,989</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(17,958,881</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(13,795,143</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cash flows from investing activities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Purchases of property and equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(500,213</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(940,043</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(245,063</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(876,290</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash used in investing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(500,213</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(940,043</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(245,063</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(876,290</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cash flows from financing activities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proceeds from issuance of preferred stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,014,816</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proceeds from issuance of common stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">70,400</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">46,826</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">34,747</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">709,241</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash provided by financing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,085,216</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">46,826</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">34,747</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">709,241</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net change in cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,342,343</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7,475,206</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(18,169,197</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(13,962,192</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents at beginning of year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">36,876,018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">55,218,361</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">55,218,361</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">47,743,155</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents at end of year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">55,218,361</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">47,743,155</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37,049,164</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">33,780,963</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>See accompanying notes. </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-7
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="fin575431_6"></A>MACROGENICS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1. Organization and Nature of Operations </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">MacroGenics, Inc. (the &#147;Company&#148;) was incorporated in Delaware on August&nbsp;14, 2000. The Company is a clinical-stage biopharmaceutical company focused on discovering and developing innovative
monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. The Company generates its pipeline of product candidates from its proprietary suite of next-generation antibody technology platforms which it believes
improve the performance of monoclonal antibodies and antibody-derived molecules. These product candidates, which the Company has identified through its understanding of disease biology and immune-mediated mechanisms may address disease-specific
challenges which are not currently being met by existing therapies. The Company creates both differentiated molecules that are directed to novel cancer targets, as well as &#147;bio-betters&#148; which are drugs designed to improve upon marketed
medicines. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2. Summary of Significant Accounting Policies </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Basis of Presentation </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The consolidated financial statements
include the accounts of MacroGenics, Inc. and its wholly owned subsidiary, MacroGenics West, Inc. All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in one operating segment. Operating
segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company
views its operations and manages its business in one segment, which is developing monoclonal antibody-based therapeutics for cancer, autoimmune and infectious diseases. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Principals of consolidation </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The accompanying consolidated
financial statements include the accounts of the Company and its wholly-owned subsidiary, MacroGenics West, Inc. All intercompany balances and transactions have been eliminated in consolidation. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Use of Estimates </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The preparation of the financial statements in accordance with U.S. generally accepted accounting principles (GAAP) requires the Company
to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In preparing these consolidated financial
statements, management has made its best estimates and judgments of certain amounts included in the financial statements, giving due consideration to materiality. On an ongoing basis, the Company evaluates its estimates, including those related to
revenue recognition, fair values of assets, convertible preferred stock and common stock, preferred stock warrant liability, income taxes, pre-clinical study and clinical trial accruals and other contingencies. Management bases its estimates on
historical experience or on various other assumptions that it believes to be reasonable under the circumstances. Actual results could differ from these estimates. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In addition, the Company utilizes estimates and assumptions in determining the fair value of its common stock. The Company granted stock options at exercise prices not less than the fair value of its
common stock as determined by the board of directors, with input from management. Management uses contemporaneous valuations in estimating the fair value of its common stock. The board of directors has determined the estimated fair value of the
common stock based on a number of objective and subjective factors, including external market </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-8
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MACROGENICS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
considerations affecting the biotechnology industry and the historic prices at which the Company sold shares of its preferred stock. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Unaudited Interim Financial Information </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The accompanying unaudited
interim consolidated balance sheet as of June&nbsp;30, 2013, the consolidated statements of operations and comprehensive income and cash flows for the six months ended June&nbsp;30, 2013 and 2012, the consolidated statement of changes in
stockholders&#146; equity (deficit) for the six months ended June&nbsp;30, 2013, and the related interim information contained within the notes to the consolidated financial statements have been prepared in accordance with the rules and regulations
of the Securities and Exchange Commission (SEC) for interim financial information. In the opinion of management, the unaudited interim consolidated financial statements reflect all adjustments, consisting of normal and recurring adjustments,
necessary for the fair presentation of the Company&#146;s financial position at June 30, 2013 and results of its operations and its cash flows for the six months ended June 30, 2013 and 2012. The results for the six months ended June 30, 2013 are
not necessarily indicative of future results. All references to June 30, 2013 or to the six months ended June 30, 2013 and 2012 in the notes to the consolidated financial statements are unaudited. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Unaudited Pro Forma Balance Sheet Presentation </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The unaudited pro forma balance sheet as of June 30, 2013, reflects the expected automatic conversion of the outstanding shares of Series&nbsp;A-1, Series A-2, Series B, Series C, Series D, and Series D-2
convertible preferred stock into shares of common stock as though the completion of the Company&#146;s initial public offering (IPO) had occurred on June 30, 2013. The shares of common stock issued in the IPO and any related estimated net proceeds
are excluded from such pro forma information. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Cash and Cash Equivalents </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company considers all investments in highly liquid financial instruments with an original maturity of three months or less at the
date of purchase to be cash equivalents. Cash and cash equivalents consist of certificates of deposit and investment in money market funds with commercial banks and financial institutions. Cash equivalents are stated at amortized cost, plus accrued
interest, which approximates fair value. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Accounts Receivable </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounts receivable that management has the intent and ability to collect are reported in the consolidated balance sheets at outstanding
amounts, less an allowance for doubtful accounts. The Company writes off uncollectible receivables when the likelihood of collection is remote. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Company evaluates the collectability of accounts receivable on a regular basis. The allowance, if any, is based upon various factors including the financial condition and payment history of customers,
an overall review of collections experience on other accounts and economic factors or events expected to affect future collections experience. No allowance was recorded as of December&nbsp;31, 2011, December&nbsp;31, 2012, and June 30, 2013, as the
Company has a history of collecting on all outstanding accounts. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Restricted Cash </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company is required to maintain certificates of deposit that serve as collateral for various operating leases and corporate credit
card accounts. Amounts classified as restricted cash on the consolidated balance sheets are $582,171 at December 31, 2011 and $404,850 at December 31, 2012 and June 30, 2013. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-9
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MACROGENICS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Fair Value of Financial Instruments </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The fair market values of the financial instruments included in the financial statements, which include cash equivalents and money market
accounts, approximate their carrying values at December&nbsp;31, 2012 and 2011, due to their short-term maturities. The Company accounts for recurring and non-recurring fair value measurements in accordance with Accounting Standards Codification
820, <I>Fair Value Measurements and Disclosures</I> (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC
820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value, and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Level 1&nbsp;&#150; Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and
liabilities. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Level 2&nbsp;&#150; Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can
include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest
rates and yield curves that can be corroborated by observable market data. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Level 3&nbsp;&#150; Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves
significant and subjective judgments to be made by a reporting entity&nbsp;&#150; e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the
appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820
hierarchy. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Financial assets and liabilities subject to fair value measurements as of December 31, 2011, December&nbsp;31,
2012 and June 30, 2013, were as follows: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:164pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Fair Value Measurements at December&nbsp;31, 2011</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:18pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></P></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:64pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Quoted&nbsp;Prices&nbsp;in<BR>Active&nbsp;Markets&nbsp;for<BR>Identical
Assets</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:63pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Significant&nbsp;Other<BR>Observable&nbsp;Inputs</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:47pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Significant<BR>Unobservable<BR>Inputs</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:24pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Level 1</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:24pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Level 2</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:24pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Level 3</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Assets:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">31,049,050</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">31,049,050</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Money market funds</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24,169,311</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24,169,311</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Restricted cash</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">582,171</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">582,171</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">55,800,532</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">31,631,221</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24,169,311</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Liabilities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Preferred stock warrant liability</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(203,642</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(203,642</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-10
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MACROGENICS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:164pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Fair Value Measurements at December&nbsp;31, 2012</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:18pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></P></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:64pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Quoted&nbsp;Prices&nbsp;in<BR>Active&nbsp;Markets&nbsp;for<BR>Identical
Assets</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:63pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Significant&nbsp;Other<BR>Observable&nbsp;Inputs</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:47pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Significant<BR>Unobservable<BR>Inputs</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:24pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Level 1</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:24pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Level 2</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:24pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Level 3</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Assets:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,695,197</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,695,197</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Money market funds</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">29,047,958</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">29,047,958</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Restricted cash</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">404,850</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">404,850</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">48,148,005</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">48,148,005</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Liabilities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Preferred stock warrant liability</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(52,947</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(52,947</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:145pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Fair Value Measurements at June 30, 2013</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:18pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></P></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:64pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Quoted&nbsp;Prices&nbsp;in<BR>Active&nbsp;Markets&nbsp;for<BR>Identical
Assets</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:63pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Significant&nbsp;Other<BR>Observable&nbsp;Inputs</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:47pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Significant<BR>Unobservable<BR>Inputs</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:24pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Level 1</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:24pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Level 2</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:24pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Level 3</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Assets:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,733,549</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,733,549</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Money market funds</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">29,047,414</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">29,047,414</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Restricted cash</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">404,850</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">404,850</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">34,185,813</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">34,185,813</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Liabilities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Preferred stock warrant liability</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(124,900</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(124,900</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of December&nbsp;31, 2012, the Company transferred its money market funds from Level 2 to Level 1
because the inputs are now based upon a quoted market price. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s Level 1 securities primarily consist of
restricted cash, cash equivalents and money market funds. The Company determines the estimated fair value for its Level 1 securities using quoted (unadjusted) prices for identical assets or liabilities in active markets. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company determines the estimated fair value for its Level 2 securities using the following methods: quoted prices for similar
assets/liabilities in active markets, inputs other than quoted prices that are observable for the asset/liability (e.g., interest rates, yield curves volatilities, default rates, etc.) and inputs that are derived principally from or corroborated by
other observable market data. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-11
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MACROGENICS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table presents information about the Company&#146;s preferred stock
warrant liability, which was the only financial instrument measured at fair value on a recurring basis using significant unobservable inputs (Level 3) as defined in ASC 820 as of December&nbsp;31, 2011,&nbsp;December&nbsp;31, 2012, and June 30,
2013: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="70%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:46pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December 31,</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:46pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June&nbsp;30,&nbsp;2013</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance beginning of year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,663,077</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(203,642</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(52,947</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total unrealized gains (losses) included in earnings</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,459,435</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">150,695</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(71,953</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance end of year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(203,642</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(52,947</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(124,900</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In order to estimate the fair value of the preferred stock purchase warrants, the business enterprise
value was established based on a discounted cash flow model (income approach). The Company utilized an option pricing method to value the shares using a contingent claims analysis, which applies a series of call options whose inputs reflect the
liquidation preferences and conversion behavior of the different classes of equity. After the equity value of the business enterprise was determined, the total equity value is allocated to the various equity instruments such as preferred stock,
stock options and preferred stock purchase warrants. Key management estimates relate to the time period to liquidation and conversion behavior of a particular class of stockholders. The business enterprise value includes assumptions related to
product approval, market penetration and costs to develop the product. Significant changes to these assumptions would result in increases/decreases to the fair value of the outstanding warrants. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The total unrealized gains (losses) on the preferred stock warrants included in earnings is included as a component of other income
(expense) in the consolidated statement of operations and comprehensive income. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Concentration of Credit Risk </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Substantially all of the Company&#146;s cash and cash equivalents are maintained with major financial institutions in the United States.
Deposits held with banks may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and, therefore, bear minimal risk. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents, and accounts receivable. The counterparties are various
corporations, financial institutions and government agencies of high credit standing. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For the years ended December&nbsp;31,
2011 and 2012, and the quarter ended June 30, 2013, all of the Company&#146;s grant revenue was related to contracts and research grants received from U.S. government agencies. Collaborations with Eli Lilly&nbsp;&amp; Co. (Eli Lilly), Boehringer
Ingelheim GmbH (Boehringer), Pfizer, Inc. (Pfizer), and Les Laboratoires Servier and Institut de Recherches Servier (collectively, Servier) account for all other revenue. All outstanding receivables are due from Eli Lilly, Boehringer, Pfizer, and
U.S. government agencies. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-12
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MACROGENICS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
The following table represents the percentage of all significant revenue earned in the years ended December&nbsp;31, 2011 and 2012 as well as in the six month period ended June 30, 2013:
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="70%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:46pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June 30,<BR>2013 </B></FONT></P></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eli Lilly</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">48.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Boehringer</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pfizer</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Servier</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">47.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gilead Sciences, Inc.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Government Agencies</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table represents the percentage of all significant accounts receivable balances as of
December&nbsp;31, 2011, December&nbsp;31, 2012 and June 30, 2013: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="70%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:46pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June&nbsp;30,<BR>2013</B></FONT></P></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eli Lilly</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">28.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Boehringer</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">40.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pfizer</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">28.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">45.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gilead Sciences, Inc.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Servier</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">52.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Government Agencies</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Property and Equipment </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Property and equipment are stated at cost. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is
credited or charged to operations. Repairs and maintenance costs are expensed as incurred. Depreciation and amortization are computed using the straight-line method over the following estimated useful lives: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Computer equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 years</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Software</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 years</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Furniture</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">10 years</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Laboratory and office equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">5 years</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Leasehold improvements</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Shorter of lease term or useful life</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Impairment of Long-Lived Assets </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Company assesses the recoverability of its long-lived assets in accordance with the provisions of ASC 360, <I>Property, Plant and Equipment</I>. ASC 360 requires that long-lived assets be reviewed for
impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future
undiscounted net cash flows expected to be generated by the asset or asset group. If carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of the underlying asset group. Any impairment to be recognized
is measured by the amount by which the carrying amount of the asset </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-13
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MACROGENICS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
group exceeds the estimated fair value of the asset group. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell. As of December&nbsp;31,
2011 and 2012, and June&nbsp;30, 2013, the Company determined that there were no impaired assets and had no assets held-for-sale. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Income Taxes </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and
liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized as income in
the period that such tax rate changes are enacted. The measurement of a deferred tax asset is reduced, if necessary, by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized.
Financial statement recognition of a tax position taken or expected to be taken in a tax return is determined based on a more-likely-than-not threshold of that position being sustained. If the tax position meets this threshold, the benefit to be
recognized is measured as the largest amount that is more than 50% likely to be realized upon ultimate settlement. The Company&#146;s policy is to record interest and penalties related to uncertain tax positions as a component of income tax expense.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Revenues </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:3%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Revenue Recognition </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company enters into collaboration and license
agreements with collaborators for the development of monoclonal antibody-based therapeutics to treat cancer and other complex diseases. The terms of these agreements contain multiple deliverables which may include (i)&nbsp;licenses, or options to
obtain licenses, to the Company&#146;s technological platforms, such as its Fc Optimization and Dual-Affinity Re-Targeting, or DART, technologies, (ii)&nbsp;rights to future technological improvements, (iii)&nbsp;research and development activities
to be performed on behalf of the collaborator or as part of the collaboration, and (iv)&nbsp;the manufacture of pre-clinical or clinical materials for the collaborator. Payments to the Company under these agreements may include nonrefundable license
fees, option fees, exercise fees, payments for research and development activities, payments for the manufacture of pre-clinical or clinical materials, license maintenance payments, payments based upon the achievement of certain milestones and
royalties on product sales. Other benefits to the Company of these agreements include the right to sell products resulting from the collaborative efforts of the parties in specific geographic territories. The Company follows the provisions of the
Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 605-25, <I>Revenue Recognition&nbsp;&#150;&nbsp;Multiple-Element Arrangements</I>, and ASC Topic 605-28, <I>Revenue Recognition&#150;Milestone Method</I>, in
accounting for these agreements. In order to account for these agreements, the Company must identify the deliverables included within the agreement and evaluate which deliverables represent separate units of accounting based on the achievement of
certain criteria, including whether the delivered element has stand-alone value to the collaborator. The consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each
of the separate units. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For the periods presented, the Company had the following two types of agreements with the parties
identified below: 1) exclusive development and commercialization licenses to use the Company&#146;s technology and/or certain other intellectual property to develop compounds against specified targets (referred to herein as exclusive licenses); and
2) Option/research agreements to secure on established terms, development and commercialization licenses to anticancer and other therapeutic product candidates to collaborator selected targets developed by the Company during an option period
(referred to herein as right-to-develop agreements). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There are no performance, cancellation, termination or refund provisions
in any of the arrangements that contain material financial consequences to the Company. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-14
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MACROGENICS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:3%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Exclusive Licenses </I></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The deliverables under an exclusive license agreement generally include the exclusive license to the Company&#146;s DART technology with
respect to a specified antigen target, and may also include deliverables related to rights to future technological improvements, research and pre-clinical development activities to be performed on behalf of the collaborator. In some cases the
Company may have an option to participate in the co-development of product candidates that result from such agreements. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Generally, exclusive license agreements contain nonrefundable terms for payments and, depending on the terms of the agreement, provide
that the Company will (i)&nbsp;at the collaborator&#146;s request, provide research and pre-clinical development services at negotiated prices which are generally consistent with what other third parties would charge, (ii)&nbsp;earn payments upon
the achievement of certain milestones, (iii)&nbsp;earn royalty payments, and (iv)&nbsp;in some cases grant the Company an option to participate in the development and commercialization of products that result from such agreements. Royalty rates may
vary over the royalty term depending on the Company&#146;s intellectual property rights and whether the Company exercises any co-development and co-commercialization rights. The Company may provide technical assistance and share any technology
improvements with its collaborators during the term of the collaboration agreements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company does not directly control
when any collaborator will achieve milestones or become liable for royalty payments. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In determining the units of accounting,
management evaluates whether the exclusive license has stand-alone value from the undelivered elements to the collaborator based on the consideration of the relevant facts and circumstances for each arrangement. Factors considered in this
determination include the research and development capabilities of the partner and the availability of technology platform and product research expertise in the general marketplace. If the Company concludes that the license has stand-alone value and
therefore will be accounted for as a separate unit of accounting, the Company then determines the estimated selling prices of the license and all other units of accounting based on market conditions, similar arrangements entered into by third
parties, and entity-specific factors such as the terms of the Company&#146;s previous collaboration agreements, recent pre-clinical and clinical testing results of therapeutic product candidates that use the Company&#146;s technology platforms, the
Company&#146;s pricing practices and pricing objectives, the likelihood that technological improvements will be made, the likelihood that technological improvements made will be used by the Company&#146;s collaborators and the nature of the research
services to be performed on behalf of its collaborators and market rates for similar services. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upfront payments on exclusive
licenses are deferred if facts and circumstances dictate that the license does not have stand-alone value. Prior to the adoption of Accounting Standards Update (ASU) No.&nbsp;2009-13, <I>Revenue Arrangements with Multiple Deliverables</I>, on
January&nbsp;1, 2011, the Company determined that its licenses lacked stand-alone value because it did not have vendor-specific objective evidence of selling price (&#147;VSOE&#148;), and were combined with other elements of the arrangement and any
amounts associated with the license were deferred and amortized over a certain period, which the Company refers to as the Company&#146;s period of substantial involvement. In making the determination of the length of the period over which to defer
revenue for contracts entered in to prior to the adoption of ASU No. 2009-13, significant judgment and estimation is used by the Company and can have an impact on the amount of revenue recognized in a given period. Historically, the Company&#146;s
involvement with the development of a collaborator&#146;s product candidate has been significant at the early stages of development, and lessens as it progresses into clinical trials. Accordingly, the Company generally estimates this period of
substantial involvement to begin at the inception of the collaboration agreement and conclude at the end of the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-15
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MACROGENICS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Company&#146;s substantial involvement. ASU No. 2009-13 amends the criteria for separating and allocating consideration in a multiple element arrangement by modifying the fair value requirements
for revenue recognition and eliminating the use of the residual value method. The selling prices of deliverables under an arrangement may be derived using third-party evidence (&#147;TPE&#148;), or a best estimate of selling price
(&#147;BESP&#148;), if VSOE is not available. The objective of BESP is to determine the price at which the Company would transact a sale if the element within the license agreement was sold on a standalone basis. Establishing BESP involves
management&#146;s judgment and considers multiple factors, including market conditions and company-specific factors, including those factors contemplated in negotiating the agreements, as well as internally developed models that include assumptions
related to market opportunity, discounted cash flows, estimated development costs, probability of success and the time needed to commercialize a product candidate pursuant to the license. In validating the BESP, management considers whether changes
in key assumptions used to determine the BESP will have a significant effect on the allocation of the arrangement consideration between the multiple deliverables. Deliverables under the arrangement are separate units of accounting if (i) the
delivered item has value to the customer on a standalone basis and (ii) if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item is considered probable and substantially
within the Company&#146;s control. The arrangement consideration that is fixed or determinable at the inception of the arrangement is allocated to the separate units of accounting based on their relative selling prices. The appropriate revenue
recognition model is applied to each element and revenue is accordingly recognized as each element is delivered. Management exercises significant judgment in determining whether a deliverable is a separate unit of accounting. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In determining the separate units of accounting, the Company evaluated whether the exclusive license had standalone value to the
collaborator based on consideration of the relevant facts and circumstances for each arrangement. Factors considered in this determination included the research and development capabilities of the collaborator and the availability of relevant
research expertise in the marketplace. In addition, the Company considered whether or not (i) the collaborator could use the license for its intended purpose without the receipt of the remaining deliverables, (ii) the value of the license was
dependent on the undelivered items and (iii) the collaborator or other vendors could provide the undelivered items. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
Company reassesses its periods of substantial involvement over which the Company amortizes its upfront license fees and makes adjustments as appropriate. In the event a collaborator elects to discontinue development of a specific product candidate
under a single target license, but retains its right to use the Company&#146;s technology to develop an alternative product candidate to the same target or a target substitute, the Company would cease amortization of any remaining portion of the
upfront fee until there is substantial pre-clinical activity on another product candidate and its remaining period of substantial involvement can be estimated. In the event that a single target license were to be terminated, the Company would
recognize as revenue any portion of the upfront fee that had not previously been recorded as revenue, but was classified as deferred revenue, at the date of such termination or through the remaining substantial involvement in the wind down of the
agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upfront payments on exclusive licenses may be recognized upon delivery of the license if facts and circumstances
dictate that the license has stand-alone value from the undelivered elements, which generally include rights to future technological improvements, research services and the manufacture of pre-clinical and clinical materials. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company recognizes revenue related to research and pre-clinical development services that represent separate units of accounting as
they are performed, as long as there is persuasive evidence of an arrangement, the fee is fixed or determinable, and collection of the related receivable is probable. The Company recognizes revenue related to the rights to future technological
improvements over the estimated term of the applicable license. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-16
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MACROGENICS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company typically performs research activities and pre-clinical development
services, including generating and engineering product candidates, on behalf of its licensees during the early evaluation and pre-clinical testing stages of drug development under its exclusive licenses. The Company records amounts received for
research materials produced or services performed as revenue from collaborative research. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s license
agreements have milestone payments which for reporting purposes are aggregated into three categories: (i)&nbsp;development milestones, (ii)&nbsp;regulatory milestones, and (iii)&nbsp;sales milestones. Development milestones are typically payable
when a product candidate initiates or advances into different clinical trial phases. Regulatory milestones are typically payable upon submission for marketing approval with the FDA or other countries&#146; regulatory authorities or on receipt of
actual marketing approvals for the compound or for additional indications. Sales milestones are typically payable when annual sales reach certain levels. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">At the inception of each agreement that includes milestone payments, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the
milestone. This evaluation includes an assessment of whether (a)&nbsp;the consideration is commensurate with either (1)&nbsp;the entity&#146;s performance to achieve the milestone, or (2)&nbsp;the enhancement of the value of the delivered item(s) as
a result of a specific outcome resulting from the entity&#146;s performance to achieve the milestone, (b)&nbsp;the consideration relates solely to past performance and (c)&nbsp;the consideration is reasonable relative to all of the deliverables and
payment terms within the arrangement. The Company evaluates factors such as the scientific, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the
respective milestone and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the arrangement in making this assessment. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Non-refundable development and regulatory milestones that are expected to be achieved as a result of the Company&#146;s efforts during the period of substantial involvement are considered substantive and
are recognized as revenue upon the achievement of the milestone, assuming all other revenue recognition criteria are met. Milestones that are not considered substantive because the Company does not contribute effort to the achievement of such
milestones are generally achieved after the period of substantial involvement and are recognized as revenue upon achievement of the milestone, as there are no undelivered elements remaining and no continuing performance obligations, assuming all
other revenue recognition criteria are met. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:3%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Right-to-Develop Agreements </I></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s right-to-develop agreements provide collaborators with an exclusive option to obtain licenses to develop and
commercialize in specified geographic territories product candidates developed by the Company under agreed upon research and pre-clinical development product programs. The product candidates resulting from each program are all directed to a specific
target selected by the collaborator. Under these agreements, fees may be due to the Company (i)&nbsp;at the inception of the arrangement (referred to as &#147;upfront&#148; fees or payments), (ii)&nbsp;the selection of a target for a program,
(iii)&nbsp;upon the exercise of an option to acquire a development and commercialization license (referred to as exercise fees or payments earned) for a program, or (iv)&nbsp;some combination of all of these fees. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The accounting for right-to-develop agreements is dependent on the nature of the options granted to the collaborator. Options are
considered substantive if, at the inception of a right-to-develop agreement, the Company is at risk as to whether the collaborator will choose to exercise the options to secure development and commercialization licenses. Factors that are considered
in evaluating whether options are substantive include the overall objective of the arrangement, the benefit the collaborator might obtain from the agreement without exercising the options, the cost to exercise the options relative to the total
upfront consideration, and the additional financial commitments imposed on the collaborator as a result of exercising the options. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-17
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MACROGENICS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For right-to-develop agreements where the options to secure development and
commercialization licenses to a product program are considered substantive, the Company does not consider the development and commercialization licenses to be a deliverable at the inception of the agreement. For those right-to-develop agreements
entered into prior to the adoption of ASU No.&nbsp;2009-13 where the options to secure development and commercialization licenses are considered substantive, the Company has deferred the upfront payments received and recognizes this revenue over the
period during which the collaborator could elect to exercise options for development and commercialization licenses. These periods are specific to each collaboration agreement. If a collaborator selects a target for a product program, any
substantive option fee is deferred and recognized over the life of the option, generally 12 months. Subsequent to the adoption of ASU No. 2009-13, the Company&#146;s evaluation of whether the option is substantive is consistent with pre-adoption of
ASU No. 2009-13. How the Company determines the selling price of the option is the only difference between pre and post adoption of ASU No. 2009-13. Post adoption of ASU No. 2009-13, the selling prices of deliverables under an arrangement may be
derived using TPE or a BESP, if VSOE is not available. The objective of BESP is to determine the price at which the Company would transact a sale if the element within the right-to-develop agreement was sold on a standalone basis. Establishing BESP
involves management&#146;s judgment and considers multiple factors, including market conditions and company-specific factors, including those factors contemplated in negotiating the agreements, as well as internally developed models that include
assumptions related to market opportunity, discounted cash flows, estimated development costs, probability of success and the time needed to commercialize a product candidate pursuant to the right-to-develop agreement. In validating the BESP,
management considers whether changes in key assumptions used to determine the BESP will have a significant effect on the allocation of the arrangement consideration between the multiple deliverables. Deliverables under the arrangement are separate
units of accounting if (i) the delivered item has value to the customer on a standalone basis and (ii) if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item is
considered probable and substantially within the Company&#146;s control. The arrangement consideration that is fixed or determinable at the inception of the arrangement is allocated to the separate units of accounting based on their relative selling
prices. The appropriate revenue recognition model is applied to each element and revenue is accordingly recognized as each element is delivered. Management exercises significant judgment in determining whether a deliverable is a separate unit of
accounting. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If a collaborator exercises an option and acquires a development and commercialization license to a product
program, the Company attributes the exercise fee to the development and commercialization license. The Company determines the selling price of the option license, upon exercise, through management&#146;s best estimate. Management&#146;s
determination of selling price includes such factors as stage of development, market potential and cash flow models used during the negotiation with the collaborator. There have been no option license exercises to date for any period presented. Upon
exercise of an option to acquire a development and commercialization license, the Company would also attribute any remaining deferred option fee to the development and commercialization license and apply the multiple-element revenue recognition
criteria to the development and commercialization license and any other deliverables to determine the appropriate revenue recognition, which will be consistent with the Company&#146;s accounting policy for upfront payments on exclusive licenses
event a right-to-develop agreement were to be terminated, the Company would recognize as revenue any portion of the upfront fee that had not previously been recorded as revenue, but was classified as deferred revenue, at the date of such
termination. None of the Company&#146;s right-to-develop agreements have been determined to contain substantive options. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For right-to-develop agreements where the options to secure development and commercialization licenses to product programs are not
considered substantive, the Company considers the development and commercialization licenses to be a deliverable at the inception of the agreement and applies the multiple-element revenue recognition criteria to determine the appropriate revenue
recognition. The Company does not directly control when any collaborator will exercise its options for development and commercialization licenses. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-18
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MACROGENICS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Research and Development Costs </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development expenditures are expensed as incurred. Research and development costs primarily consist of employee related
expenses, including salaries and benefits, expenses incurred under agreements with contract research organizations, investigative sites and consultants that conduct the Company&#146;s clinical trials, the cost of acquiring and manufacturing clinical
trial materials and other allocated expenses, license fees for and milestone payments related to in-licensed products and technologies, stock-based compensation expense, and costs associated with non-clinical activities and regulatory approvals.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Comprehensive Income (Loss) </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Effective January&nbsp;1, 2012, the Company adopted FASB&#146;s Accounting Standards Update 2011-05, <I>Presentation of Comprehensive Income</I>. ASC 220, <I>Comprehensive Income</I>, requires the
presentation of the comprehensive income (loss) and its components, as part of the consolidated financial statements. Comprehensive income (loss) is comprised of the net income (loss) and other changes in equity that are excluded from net income
(loss). Comprehensive income (loss) equals net income (loss) for the years ended December&nbsp;31, 2011 and 2012, and for the quarter ended June&nbsp;30, 2013. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Stock-based Compensation </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock-based payments are accounted for in
accordance with the provisions of ASC&nbsp;718, <I>Compensation&nbsp;&#150; Stock Compensation</I>. The fair value of stock-based payments is estimated, on the date of grant, using the Black-Scholes model. The resulting fair value is recognized
ratably over the requisite service period, which is generally the vesting period of the option. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For all time-vesting awards
granted, expense is amortized using the straight-line attribution method. For awards that contain a performance condition, expense is amortized using the accelerated attribution method. Recognition of stock-based compensation expense is based on the
value of the portion of stock-based awards that is ultimately expected to vest during the period. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company utilizes the
Black-Scholes model for estimating fair value of its stock options granted. Option valuation models, including the Black-Scholes model, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the
grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Net Income (Loss) Per Share </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Income (loss) per share is calculated
under the two-class method under which all earnings (distributed and undistributed) are allocated to each class of common stock and participating securities based on their respective rights to receive dividends. In the event that the Board of
Directors shall declare a dividend payable in cash or other property on the then-outstanding shares of common stock, the holders of the Series&nbsp;A-1, A-2, B, C, D, and D-2 convertible preferred stock shall be entitled to receive the amount of
dividends per share of Preferred Stock that would be payable on the largest number of whole shares of Common Stock into which each share of Preferred Stock could then be converted. Therefore, the Series A-1, A-2, B, C, D and D-2 are participating
securities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Basic net income (loss) per common share is determined by dividing the net income (loss) allocable to common
stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net income (loss) per share is computed by dividing the net income (loss) allocable to common
stockholders by the weighted-average number of common stock equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company&#146;s </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-19
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MACROGENICS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
stock option grants and the if-converted method is used to determine the dilutive effect of the Company&#146;s Series&nbsp;A-1, A-2, B, C, D, and D-2 convertible preferred stock. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="52%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:89pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year Ended December&nbsp;31,</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:93pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Unaudited)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Basic Income (Loss) per Share</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="5" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net income (loss)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,717,120</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,361,755</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,866,068</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,659,837</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Less: Undistributed earnings allocated to participating securities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6,717,120</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8,361,755</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7,829,583</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net income (loss) allocable to common shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"> 36,485</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,659,837</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Basic weighted average common shares outstanding</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19,254,567</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,337,513</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,106,584</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22,237,823</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Basic earnings per common share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Diluted earnings per common share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net income (loss)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,717,120</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,361,755</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,866,068</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,659,837</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Less: Undistributed earnings allocated to participating securities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6,717,120</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8,361,755</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7,829,583</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net income (loss) allocable to common shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">36,485</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,659,837</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Basic weighted average common shares outstanding</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19,254,567</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,337,513</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,106,584</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22,237,823</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Effect of dilutive securities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">381,045,990</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Diluted weighted average common shares outstanding</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19,254,567</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,337,513</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">401,152,574</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22,237,823</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Diluted income per common share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following common stock equivalents were excluded in the calculation of diluted net income (loss) per
share because their effect would be anti-dilutive: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="86%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:46pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June&nbsp;30,</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Series A-1 Preferred Stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">40,478,808</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">40,478,808</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">40,478,808</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Series A-2 Preferred Stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,364,582</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,364,582</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,364,582</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Series B Preferred Stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">81,404,537</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">81,404,537</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">81,404,537</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Series C Preferred Stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">110,952,217</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">110,952,217</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">110,952,217</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Series D Preferred Stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,446,227</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,446,227</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,446,227</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Series D-2 Preferred Stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">63,681,176</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">63,681,176</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">63,681,176</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Warrants to Purchase Series D-2 Preferred Stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,394,035</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,394,035</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,394,035</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock options</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54,170,532</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">61,009,584</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">51,879,146</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The pro forma net income (loss) per share is computed using the weighted-average number of common shares
outstanding and assumes the conversion of all outstanding shares of the Company&#146;s Series&nbsp;A-1, A-2, B, C, D, and D-2 convertible preferred stock into shares of common stock upon completion of the Company&#146;s planned IPO, as if they had
converted at the beginning of the period. The Company believes the unaudited pro forma net income (loss) per share provides material information to investors, as the conversion of the Company&#146;s
<FONT STYLE="white-space:nowrap">Series&nbsp;A-1,</FONT> A-2, B, C, D, and D-2 convertible preferred stock to common stock is expected to occur upon the closing of an IPO, and the disclosure of pro forma net income (loss) per share thus provides an
indication of net income (loss) per share that is comparable to what will be reported by the Company as a public company. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-20
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MACROGENICS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year Ended</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:46pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,<BR>2012</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Six&nbsp;Months&nbsp;Ended</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:63pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June&nbsp;30,<BR>2013</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pro forma net income (loss) per common share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Numerator:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net income (loss) used to compute pro forma net income (loss) per common share:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Basic</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,361,755</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,659,837</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,512,450</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,587,884</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Denominator:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Weighted-average number of common shares, used to calculate net income (loss) per common share:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Basic</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,337,513</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22,237,823</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">84,817,352</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22,237,823</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Add: Pro forma adjustments to reflect assumed weighted-average effect of conversion of Series&nbsp;A convertible preferred
stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">318,327,547</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">318,327,547</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Weighted-average number of common shares used in calculating pro forma net income (loss) per common share:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Basic</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">338,665,060</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">340,565,370</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">403,144,899</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">340,565,370</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pro forma net income (loss) per common share:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Basic</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.02</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.01</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.02</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.01</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Recently Issued Accounting Standards Adopted </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In May&nbsp;2011, the Financial Accounting Standards Board (FASB) issued ASU No.&nbsp;2011-04, which amended ASC Topic 820 to achieve
common fair value measurements and disclosure requirements in U.S. GAAP and International Financial Reporting Standards (IFRS). The amendments in ASU No.&nbsp;2011-05 result in common fair value measurement and disclosure requirements in U.S. GAAP
and IFRSs. Consequently, the amendments change the wording used to describe many of the requirements in U.S. GAAP for measuring fair value and for disclosing information about fair value measurements. This amendment is effective for fiscal years,
beginning after December&nbsp;15, 2011. The adoption of this amendment did not have a material impact on the Company&#146;s consolidated financial statements for the year ended December&nbsp;31, 2012. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In June&nbsp;2011, the FASB issued ASU No.&nbsp;2011-05, which amended ASC Topic 220 regarding presentation of comprehensive income. The
amendments in ASU No.&nbsp;2011-05 require that all nonowner changes in stockholders&#146; equity be presented either in a single continuous statement of comprehensive income or in two separate but consecutive statements. In the two-statement
approach, the first statement should present total net income and its components followed consecutively by a second statement that should present total other comprehensive income, the components of other comprehensive income, and the total of
comprehensive income. This amendment is effective for fiscal years, beginning after December&nbsp;15, 2011. The adoption of this amendment did not have a material impact on the Company&#146;s consolidated financial statements for the year ended
December&nbsp;31, 2012. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company has evaluated all ASUs through the date the consolidated financials were issued and
believes that the adoption of these will not have a material impact on the Company&#146;s consolidated financial statements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-21
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MACROGENICS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3. Property and Equipment </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Property and equipment consists of the following: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:46pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June&nbsp;30,</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013 </B></FONT></P></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Computer equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,951,246</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,003,706</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,129,966</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Software</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,323,081</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,323,081</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,323,081</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Furniture</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">599,650</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">599,650</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">599,650</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lab equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,910,207</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,747,790</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,485,756</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Office equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">51,360</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">51,360</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">51,360</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Leasehold improvements</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,831,706</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,881,706</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,893,770</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Property and equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,667,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17,607,293</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,483,583</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Less accumulated depreciation and amortization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(13,379,567</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(14,339,497</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(14,857,261</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Property and equipment, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,287,683</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,267,796</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,626,322</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Depreciation and amortization expense for the years ended December&nbsp;31, 2011 and 2012, was $1,147,300
and $959,930, respectively, and $486,952 and $517,764 for the six months ended June&nbsp;30, 2012 and 2013, respectively. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4.
Stockholders&#146; Equity (Deficit) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">During 2002 and 2003, the Company issued a total of 34,239,374 shares of Series A-1
and Series A-2 convertible preferred stock (Series A preferred stock) for $1.00 per share resulting in net proceeds of approximately $34,000,000. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On October&nbsp;12, 2004, the Company entered into a series of transactions raising $30,261,672, net of related offering costs of approximately $238,000, from the sale of 71,401,237 shares of its Series B
convertible preferred stock (Series B preferred stock). In connection with the Series B preferred stock offering, 13,604,016 shares of common stock were allocated to holders of Series&nbsp;A-1 preferred stock as an anti-dilution measure but remained
unissued at December&nbsp;31, 2012. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On May&nbsp;16, 2006, the Company raised $44,898,754, net of related offering costs of
$101,246, from the sale of 110,952,217 shares of its Series C convertible preferred stock (Series C preferred stock). In connection with the Series C preferred stock offering, 10,003,300 shares of common stock were allocated to holders of Series B
preferred stock as an anti-dilution measure but remained unissued at December 31, 2012. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On July&nbsp;16, 2008, the Company
issued 12,466,039 shares of its Series D convertible preferred stock (Series D preferred stock) in exchange for all of the outstanding capital stock and convertible notes payable of Raven Biotechnologies, Inc. (Raven). Subsequently, in March 2011 a
settlement was reached with the former Raven stockholders bringing the total Series D preferred stock issued in connection with the Raven acquisition to 14,446,227 shares. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On September&nbsp;19, 2008, the Company raised $24,843,211, net of related offering costs of $156,788, from the sale of 38,337,678 shares of its Series D-2 convertible preferred stock (Series D-2
preferred stock). The Company also issued preferred stock warrants for the purchase of 2,875,327 shares of Series D-2 preferred stock. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-22
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MACROGENICS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
The preferred stock warrants are exercisable at any time prior to September&nbsp;2018, but expire upon an IPO, and have a stated exercise price of $0.65 per warrant. On May&nbsp;16, 2010, the
Company exercised a put notice to Lilly in accordance with the Series D-2 preferred stock purchase agreement, resulting in the issuance of 6,916,110 shares of Series D-2 preferred stock and a warrant to purchase 518,708 additional shares of Series
D-2 preferred stock. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On January&nbsp;11, 2011, the Company raised gross proceeds for $12,016,500 from the sale of
18,427,388&nbsp;shares of its Series D-2 preferred stock. Issuance costs associated with the sale were not material. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Due to
certain provisions in the Series D-2 convertible preferred stock warrant agreement, these warrants are required to be classified as a liability. Management believes that the circumstances requiring cash settlement of the award are remote. The Series
D-2 preferred stock warrant liability is recorded at fair value, which is adjusted at the end of each reporting period using the Option-Pricing Method, with changes in value recorded as &#147;Changes in fair value of preferred stock purchase warrant
liability&#148; in the accompanying consolidated statements of operations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Holders of the Series A-1, Series A-2, Series B,
Series C, Series D and Series D-2 preferred stock are entitled to vote, together with the common stockholders as one class, on all matters as to which common stockholders are entitled to vote. In any such vote, each share of Series A, Series B,
Series C and Series D preferred stock shall entitle the holder to the number of votes per share that equals the number of shares of common stock into which each such share of preferred stock is then convertible. For so long as at least
four&nbsp;million shares of each of the Series A, Series B and Series C preferred stock remain outstanding, the holders of each of the Series A, Series B and Series C preferred stock, each voting as a separate class, shall each be entitled to elect
two members of the Board of Directors of the Company. The holders of a majority of the common stock, voting as a separate class, shall have the right to elect one member of the Board of Directors of the Company. The holders of a majority of the
common stock and the holders of at least 66 2/3% of the preferred stock, each voting separately as a single class (and on an as-if-converted basis to common stock with respect to the preferred stock), shall be entitled to elect all remaining members
of the Board of Directors. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dividends are noncumulative and accrue on the Series A-1, Series A-2, Series B, Series C, Series D
and Series&nbsp;D-2 preferred stock at a rate of $0.08, $0.0341, $0.0324 and $0.0522 per annum, respectively, and are payable when and as declared by the Board of Directors. Dividends must be declared so that the Series A, Series&nbsp;B, Series C
and Series D preferred stock are paid in like-kind and participate equally to those of the Series&nbsp;D-2 preferred and common stock. No dividends have been declared and none are accrued at December&nbsp;31, 2012 and 2011. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s Series A-1, Series A-2, Series B, Series C, Series D and Series D-2 preferred stock are initially convertible into
1.506, 1.00, 1.14, 1.00, 1.00 and 1.00 shares, respectively, of common stock at the option of the holder. The conversion ratio of certain series of preferred stock is subject to change in the event specified dilutive transactions occur. These
dilutive events are considered to be the sale of common stock at a per share price less than the applicable preferred stock conversion price. There are no anti-dilution protections for the Series A-2 preferred stock and no adjustment to the Series
A-1 preferred stock conversion price is made if a common stock issuance is at a price per share greater than the conversion price of the Series C preferred stock. The conversion price shall be $0.66, $1.00, $0.37, $0.41, $0.65 and $0.65 for each
share of Series A-1, A-2, Series B, Series C, Series D and Series D-2 convertible preferred stock, respectively. The Company has reserved 321,592,828 shares of common stock for the potential conversion of the Series A-1, Series A-2, Series B,
Series&nbsp;C, Series D and Series D-2 preferred stock. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each share of Series A-1, Series A-2, Series B, Series C, Series D
and Series D-2 preferred stock automatically converts into shares of the Company&#146;s common stock upon closing of a firm commitment </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-23
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MACROGENICS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
underwritten public offering of common stock registered under the Securities Act of 1933 at a price of at least $1.96 per share (adjusted to reflect stock splits, stock dividends, stock
combinations, recapitalizations and like occurrences), and which generates net proceeds to the Company of at least $40&nbsp;million. The holders of two-thirds of the Series&nbsp;A-1, Series A-2, Series B, Series C, Series D and Series D-2 preferred
stock, voting together as a single class, but separately from the common stockholders, shall have the right to elect to convert all outstanding shares of Series A-1, Series A-2, Series B, Series C, Series D and Series D-2 preferred stock into shares
of common stock. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In liquidation, the holders of Series D-2 preferred stock are entitled to receive $0.65 per share prior to
any distribution to the holders of any Series C and Series D preferred stock. The holders of Series C and Series D preferred stock are entitled to receive $0.41 and $0.65 per share, respectively, on a <I>pari passu </I>basis, prior to any
distribution to the holders of any Series B preferred stock. The holders of Series B preferred stock are entitled to receive $0.37 per share prior to any distribution to the holders of any shares of Series A preferred stock. The holders of Series A
preferred stock are entitled to receive $0.66 per share prior to the holders of common stock. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5. Shared-Based Payments </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Stock Option Plan </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s 2000 Stock Option and Incentive Plan (the 2000 Plan) allowed for the grant of awards in respect of an aggregate of
2,454,222 shares, which was increased to 2,821,664 shares of the Company&#146;s common stock in the form of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock and restricted stock units and other
performance awards. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Effective February&nbsp;2003, the Company implemented the 2003 Equity Incentive Plan (the 2003 Plan), and
it was amended and approved by the Company&#146;s stockholders in 2005. The 2003 Plan originally allowed for the grant of awards in respect of an aggregate of 38,517,360 shares of the Company&#146;s common stock. During the year ended
December&nbsp;31, 2006, the maximum number of shares of common stock authorized to be issued by the Company under the 2003 Plan was increased by 8,650,000 shares to 47,167,360. During the year ended December&nbsp;31, 2008, the maximum number of
shares of common stock authorized to be issued by the Company under the 2003 Plan was increased by 14,000,000 shares to 61,167,360. During the year ended December&nbsp;31, 2010, the maximum number of shares of common stock authorized to be issued by
the Company under the 2003 Plan was increased by 10,000,000 shares to 71,167,360. During the year ended December&nbsp;31, 2012, the maximum number of shares of common stock authorized to be issued by the Company under the 2003 Plan was increased by
10,250,000 shares to 81,417,360. As of December&nbsp;31, 2012, a total of 12,417,150 shares were available for issuance under the 2003 Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Stock options granted under the 2003 Plan may be either incentive stock options as defined by the Internal Revenue Code (IRC), or non-qualified stock options. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Stock Option Exchange </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On March&nbsp;16, 2011 (Exchange Date), the Company modified certain outstanding options with exercise prices of $0.10 and $0.25 (Original Options). These Original Options were canceled and replaced with
options having an exercise price of $0.05 (Replacement Options), reflecting the current fair market value of the Company&#146;s common stock on the Exchange Date. Original Options submitted for exchange were replaced on a one-for-one basis with
Replacement Options. Additionally, the Replacement Options retain all terms and conditions of the Original Options except for the reduction to the exercise price as described above. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total compensation associated with the Replacement Options consisted of the grant-date fair value of the Original Options for which the
requisite service period is expected to be rendered (or has already been </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-24
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MACROGENICS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
rendered) at the Exchange Date, plus the incremental cost associated with the modification of terms. The incremental compensation expense was measured as the excess of the fair value of the
Replacement Options over the fair value of the Original Options re-measured as of the Exchange Date. A total of 36,081,455 Original Options were exchanged for Replacement Options. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following stock-based compensation amounts were recognized for the years ended December&nbsp;31, 2011 and 2012 and the six month
periods ended June 30, 2012 and 2013: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="86%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:46pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June&nbsp;30,</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(unaudited)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,018,935</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">471,809</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">235,904</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">172,393</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">General and administrative</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,328,504</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">366,586</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">183,294</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">85,232</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total stock-based compensation expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,347,439</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">838,395</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">419,198</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">257,625</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:3%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Employee Stock Options </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="70%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="55%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:46pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June 30,</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013 </B></FONT></P></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expected dividend yield</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expected volatility</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">62%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">51%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">58%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Risk-free interest rate</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.35%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.18%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.76%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expected average life of options</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7&nbsp;years</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7&nbsp;years</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7&nbsp;years</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fair market value of common stock at:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.08</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expected Forfeiture Rate</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.58%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.57%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.06%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Fair Value of Common Stock&nbsp;&#150;&nbsp;</B>Given the lack of an active public market for the
Company&#146;s common stock, the Company&#146;s Board of Directors determined the fair value of the common stock. The Board of Directors made determinations of fair value based, in part, upon contemporaneous valuations to determine fair value. In
the absence of a public market, and as a clinical-stage company with no significant revenues, the Company believes that it is appropriate to consider a range of factors to determine the fair market value of the common stock at each grant date. The
factors include: (1)&nbsp;the achievement of clinical and operational milestones by the Company; (2)&nbsp;the status of strategic relationships with collaborators; (3)&nbsp;the significant risks associated with the Company&#146;s stage of
development; (4)&nbsp;capital market conditions for life science companies, particularly similarly situated, privately held, early-stage life science companies; (5)&nbsp;the Company&#146;s available cash, financial condition and results of
operations; (6)&nbsp;the most recent sales of the Company&#146;s preferred stock and (7)&nbsp;the preferential rights of the outstanding preferred stock. The contemporaneous valuations were performed in accordance with applicable methodologies,
approaches and assumptions of the technical practice-aid issued by the American Institute of Certified Public Accountants Practice Aid entitled <I>Valuation of Privately-Held Company Equity Securities Issued as Compensation</I>. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-25
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MACROGENICS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Expected Volatility</B>&nbsp;&#150; Volatility is a measure of the amount by which a
financial variable such as a share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. The Company does not maintain an internal market for its shares and its shares are not traded
publicly. The Company has been able to identify several public entities of similar size, complexity and stage of development; accordingly, historical volatility has been calculated using the volatility of these companies. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Expected Dividend Yield</B>&nbsp;&#150; The Company has never declared or paid dividends and has no plans to do so in the foreseeable
future. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risk-Free Interest Rate</B>&nbsp;&#150; This is the U.S. Treasury rate for the week of each option grant during
the year, having a term that most closely resembles the expected life of the option. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Expected Term</B>&nbsp;&#150; This is
the period of time that the options granted are expected to remain unexercised. Options granted have a maximum term of ten years. The Company estimates the expected life of the option term to be seven years. The Company uses a simplified method to
calculate the average expected term. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Expected Forfeiture Rate</B>&nbsp;&#150; The forfeiture rate is the estimated
percentage of options granted that is expected to be forfeited or canceled on an annual basis before becoming fully vested. The Company estimates the forfeiture rate based on turnover data with further consideration given to the class of the
employees to whom the options were granted. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Equity instruments issued to non-employees are accounted for under the provisions
of <FONT STYLE="white-space:nowrap">ASC&nbsp;505-50,</FONT><I> Equity Based Payments to Non-Employees</I>. Accordingly, the estimated fair value of the equity instrument is recorded on the earlier of the performance commitment date or the date the
services required are completed. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Information with respect to stock options granted to employees and non-employees from
January&nbsp;1, 2012 through June 30, 2013 was as follows: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="86%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="43%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Grant Date</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:57pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number of<BR>Options&nbsp;Granted</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exercise<BR>Price</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:60pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Estimated&nbsp;Option<BR>Fair Value</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:29pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Intrinsic<BR>Value</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">01/08/2012</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,119,225</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.03</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">03/14/2012</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,878,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.03</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">06/13/2012</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">81,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.03</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">09/19/2012</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">150,400</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.03</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">11/08/2012</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">295,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.03</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">01/06/2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,332,100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.08</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">03/08/2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">263,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.08</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">06/19/2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,117,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-26
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MACROGENICS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table summarizes stock option activity under the Plan during the period
then ended: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="86%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:37pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number&nbsp;of<BR>Options</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:59pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Weighted-<BR>Average&nbsp;Exercise<BR>Price</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:62pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Weighted-<BR>Average<BR>Contractual&nbsp;Term<BR>(in
Years)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Outstanding, December&nbsp;31, 2011</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54,170,532</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Granted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,523,625</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exercised</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(936,514</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Forfeited or expired</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(748,059</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Outstanding, December&nbsp;31, 2012</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">61,009,584</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Granted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,712,100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.09</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exercised</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(16,205,194</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.04</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Forfeited or expired</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(637,344</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.06</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Outstanding, June 30, 2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">51,879,146</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">December&nbsp;31, 2012:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exercisable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">49,189,504</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vested and expected to vest</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">51,345,666</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">June 30, 2013:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exercisable (unaudited)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">35,947,528</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vested and Expected to Vest (unaudited)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50,406,715</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The aggregate intrinsic value of options outstanding and exercisable as of June 30, 2013 is approximately
$4,452,108 and $3,311,864, respectively. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The weighted-average grant-date fair value of options granted for the years ended
December&nbsp;31, 2012 and 2011 was $0.05. Total cash received for the options exercised was $46,826 and $53,225 for the years ended December&nbsp;31, 2012 and 2011, respectively. The total fair value of shares vested in the years ended
December&nbsp;31, 2012 and 2011, was $374,684 and $400,236, respectively. As of December&nbsp;31, 2012, there was $636,308 of total unrecognized compensation cost related to non-vested stock-based compensation arrangements granted under the 2000
Plan and 2003 Plan. That cost is expected to be recognized over a weighted-average period of approximately four years. As of June 30, 2013, the total unrecognized compensation expense, net of related forfeiture estimates, was $755,108, which the
Company expects to recognize over a weighted-average period of approximately four years. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>6. Income Taxes </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For the years ended December&nbsp;31, 2011 and 2012, there was no current provision for federal or state income taxes due to the taxable
losses which resulted or use of legacy net operating loss carryforwards. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-27
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MACROGENICS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The significant components of the Company&#146;s deferred tax assets (liabilities) were
as follows: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:46pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred income tax assets:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Federal U.S. net operating loss carryforward</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37,825,639</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">35,330,167</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">State net operating loss carryforward</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,493,151</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,521,722</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development credit, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,777,899</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,777,899</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Orphan drug credit, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,507,811</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19,039,613</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred rent</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,194,408</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,218,002</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,924,462</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,379,064</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Depreciation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,515,510</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,247,772</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,551,356</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,575,782</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gross deferred income tax assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">77,790,236</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">78,090,021</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Valuation allowance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(77,302,928</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(78,090,021</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net deferred income tax assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">487,308</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred tax liabilities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(487,308</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gross deferred income tax liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(487,308</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net deferred income tax asset/(liability)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company recognizes valuation allowances to reduce deferred tax assets to the amount that is more
likely than not to be realized. In assessing the likelihood of realization, management considers (i)&nbsp;future reversals of existing taxable temporary differences; (ii)&nbsp;future taxable income exclusive of reversing temporary difference and
carryforwards; (iii)&nbsp;taxable income in prior carryback years if carryback is permitted under applicable tax law; and (iv)&nbsp;tax planning strategies. The Company&#146;s net deferred income tax asset is not more likely than not to be utilized
due to the lack of sufficient sources of future taxable income and cumulative book losses which have resulted over the years. The net increase in the valuation allowance in 2012 is due to the fact the Company generated book and taxable income in the
current year; therefore, the net deferred tax asset amount decreased, although, the Company generated significant orphan drug credits which increased the net deferred tax asset. The increase in the orphan drug credits offset by the current year
income amount resulted in a net current year increase to the valuation allowance. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company has reported book losses from
inception through December&nbsp;31, 2010. The net operating loss carryforwards of approximately $100.9&nbsp;million for U.S.&nbsp;federal and approximately $64.2 million for state will expire in various years beginning in 2023 through 2030. In
addition, the Company has U.S. federal tax credits of $21.8 million which will expire in various years beginning in 2020 through 2032. During the six months ended June 30, 2013, the Company corrected an immaterial error of approximately $1.2 million
related to state net operating loss carryforwards. The correction of the immaterial error resulted in a reduction to the state net operating loss carryforward deferred tax asset and corresponding valuation allowance. The immaterial error and the
related correction of the error had no effect on the balance sheet, statements of operations and comprehensive income (loss) or statements of cash flows. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The use of the Company&#146;s net operating loss and tax credit carryforwards in future years are restricted due to changes in the Company&#146;s ownership and tax attributes acquired by the Company in a
purchase. As of December&nbsp;31, 2012, $10.6 million of the Company&#146;s net operating losses are limited for use over the years 2013&nbsp;&#150; 2027 in which a range of such amounts could be utilized on an annual basis of $0.2 million to
$2.1&nbsp;million. The remaining $90.3 million of net operating losses is not limited and can be offset against future taxable income. Additionally, despite the net operating loss and credit carryforwards, the Company may have a future tax liability
due to an alternative minimum tax or state tax requirements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-28
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MACROGENICS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The reconciliation of the reported estimated income tax benefit to the amount that would
result by applying the U.S. federal statutory tax rate to the net income is as follows: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="70%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:89pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year Ended December&nbsp;31,</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">United States federal tax at statutory rate</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,350,992</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,926,615</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">State taxes (net of federal benefit)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,480,185</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,460,289</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred income tax adjustments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(512,375</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Orphan drug credit, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7,056,607</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4,895,671</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Equity based compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">725,811</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">279,165</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fair value adjustment of preferred stock warrant liability</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(496,208</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(52,743</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other permanent items</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,696</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,627</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Change in valuation allowance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,991,131</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">787,093</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Income tax expense/(benefit)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The change in unrecognized tax benefits, for the years ended December&nbsp;31, 2011 and 2012, were as
follows: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="70%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Beginning balance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,246,025</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,533,986</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Increases/(decreases) for current year tax positions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">287,961</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">58,371</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Increases/(decreases) for prior year tax positions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Decreases as a result of expiration of statute of limitations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,533,986</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,592,357</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of December&nbsp;31, 2011 and 2012, of the total gross unrecognized tax benefits, approximately
$1,105,256 and $1,140,067 would favorably impact the Company&#146;s effective income tax rate, respectively. Although, due to the Company&#146;s determination that the deferred income tax asset would not more likely than not be realized, a valuation
allowance would be recorded, therefore, zero net impact would result within the Company&#146;s effective income tax rate. The Company&#146;s uncertain income tax position liability has been recorded to deferred income taxes to offset the tax
attribute carryforward amounts. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For the years ended December&nbsp;31, 2012 and 2011, the Company has not recognized any
interest or penalties related to the uncertain income tax positions due to the fact such position is related to tax attribute carryforwards which have not yet been utilized. The Company does not expect its unrecognized income tax position to
significantly decrease within the next twelve months. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s U.S. Federal and state income tax returns from 2001
to 2011 remain subject to examination by the tax authorities. The Company&#146;s 2001 through 2007 years remain open for examination, even though the statute of limitations has expired, due to the net operating losses and credits carried forward for
use in prospective years. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-29
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MACROGENICS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>7. Lease Exit Liability </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On July&nbsp;16, 2008, the Company acquired Raven Biotechnologies, Inc. (Raven), a private South San Francisco-based company focused on the development of monoclonal antibody therapeutics for treating
cancer. Raven was considered a development-stage enterprise as defined in ASC&nbsp;915, <I>Development Stage Entities</I>. In connection with the acquisition, the Company issued 12,466,039 shares of its Series D convertible preferred stock in
exchange for all of the outstanding capital stock and convertible notes payable of Raven. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company undertook restructuring
activities related to the acquisition of Raven. These restructuring activities included reductions in staffing levels and the intended exit of leased facilities. All severance-related payments were completed in the year ended December&nbsp;31, 2009.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with these restructuring activities, as part of the cost of acquisitions, the Company established a
restructuring liability attributed to an existing operating lease. The terms of the operating lease extend through 2018. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Changes in the lease exit liability for the years ended December&nbsp;31, 2012 and 2011 and the six months ended June 30, 2013 are as
follows: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="70%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:45pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exit Liability</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accrual balance at December&nbsp;31, 2010</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,054,518</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Principal payments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(447,019</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accrual balance at December&nbsp;31, 2011</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,607,499</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Principal payments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(533,560</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accrual balance at December&nbsp;31, 2012</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,073,939</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Principal payments (unaudited)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(307,403</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accrual balance at June&nbsp;30, 2013 (unaudited)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,766,536</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Future principal payments to be made under the lease agreement for the next five years and thereafter as
of December&nbsp;31, 2012 are as follows: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="38%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"> 628,768</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,438,742</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,641,905</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,866,031</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2017</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,113,118</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Thereafter</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,385,375</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,073,939</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The purchase agreement provides for a specified total of certain contingent milestones that are based on
the achievement of certain product sales derived from the acquired Raven technology. Also, a onetime payment of $5.0&nbsp;million will be made to the Raven stockholders upon the initiation of patient dosing in the first Phase 2 clinical trial of any
product derived from the Raven &#147;Cancer Stem Cell Program.&#148; No payment shall be made if the Phase 2 trial start date has not occurred on or before July&nbsp;15, 2018. Other consideration includes a percentage of revenue (excluding
consideration for research and development and equity) received by MacroGenics for license of a product derived from the Raven &#147;Cancer Stem Cell Program&#148; and a onetime payment ranging from
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-30
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MACROGENICS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
$8.0&nbsp;million to $12.0&nbsp;million dependent upon a specified level of sales of products derived from the Raven &#147;Cancer Stem Cell Program.&#148; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The contingent consideration will be accounted for as additional purchase price and recorded as incremental in-process research and
development expense when it is deemed probable that the contingencies will be attained. For the years ended December&nbsp;31, 2012 and 2011, no additional amounts have been recorded. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>8. Collaboration and License Agreements </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Les Laboratoires Servier
</I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In November 2011, the Company entered into a right-to-develop collaboration agreement with Servier for the
development and commercialization of MGA271 in all countries other than the United States, Canada, Mexico, Japan, South Korea and India. </FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Upon execution of the agreement, Servier made a nonrefundable payment of $20 million to the Company. The Company is eligible to receive up to $30 million in license grant fees, $47 million in clinical
milestone payments, including $10 million received in the third quarter of 2013, $140 million in regulatory milestone payments and $208 million in sales milestone payments if Servier exercises the option, obtains regulatory approval for and
successfully commercializes MGA271. The Company concluded that the license grant fees are not deliverables at the inception of the arrangement. The Company has determined that each potential future clinical, development and regulatory milestone is
substantive. Although sales milestones are not considered substantive, they are still recognized upon achievement of the milestone (assuming all other revenue recognition criteria have been met) because there are no undelivered elements that would
preclude revenue recognition at that time. In the event Servier exercises its option to continue development of MGA271, Servier must pay a license grant fee. Under this agreement, Servier would be obligated to pay the Company from low double digit
to mid-teen royalties on product sales in its territories. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company has evaluated the research collaboration agreement
with Servier and has determined that it is a revenue arrangement with multiple deliverables, or performance obligations. The Company concluded that the option is substantive and that the license fees for this option is not a deliverable at the
inception of the arrangement as there is considerable uncertainty that the option would be exercised and the additional fee to be paid upon exercise of the option represents its estimated selling price (i.e. no substantial discount was given). The
Company&#146;s substantive performance obligations under this research collaboration include an exclusive license to its technology, technical, scientific and intellectual property support to the research plan during the first year of the agreement
and participation on an executive committee and a research and development committee. The Company determined that these performance obligations represent a single unit of accounting, since the license does not have stand-alone value to Servier
without the Company&#146;s technical expertise and committee participation. As such, the initial upfront payment was deferred and is being recognized ratably over the initial 27-month period, which represents the expected period of development and
the Company&#146;s participation on the research and development committee. The Company further concluded that each potential future clinical, development and regulatory milestone is substantive. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">During the years ended December 31, 2011 and 2012 and the six months ended June&nbsp;30, 2013, the Company recognized revenue of $0.9
million, $9.1&nbsp;million and $6.6 million, respectively, under this agreement. No additional milestones have been recognized under this agreement through June&nbsp;30, 2013. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">At December 31, 2012, $10.0 million of revenue was deferred under this agreement, $9.1 million of which was included in current liabilities and $0.9 million was included in long-term liabilities. At
June&nbsp;30, 2013, $5.4 million of revenue was deferred under this agreement, all of which was included in current liabilities during the quarter ended June&nbsp;30, 2013. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-31
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


   <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MACROGENICS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In September 2012, the Company entered into a second right-to-develop collaboration
agreement with Servier and granted it options to obtain three separate exclusive licenses to develop and commercialize DART-based molecules, consisting of those designated by the Company as MGD006 and MGD007, as well as a third DART molecule, in all
countries other than the United States, Canada, Mexico, Japan, South Korea and India. </FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upon execution of the agreement,
Servier made a nonrefundable payment of $20 million to the Company. In addition, the Company will be eligible to receive up to $65 million in license grant fees, $98 million in clinical milestone payments, including $5 million upon IND acceptance
for each of MGD006, MGD007 and a third DART molecule, $300 million in regulatory milestone payments and $630 million in sales milestone payments if Servier exercises all of the options and successfully develops, obtains regulatory approval for, and
commercializes a product under each license. In addition to these milestones, the Company and Servier will share Phase 2 and Phase 3 development costs. The Company has determined that each potential future clinical, development and regulatory
milestone is substantive. Although sales milestones are not considered substantive, they are still recognized upon achievement of the milestone (assuming all other revenue recognition criteria have been met) because there are no undelivered elements
that would preclude revenue recognition at that time. Under this agreement, Servier would be obligated to pay the Company between high-single digit and <FONT STYLE="white-space:nowrap">mid-teen</FONT> royalties on net product sales in its
territories. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company has evaluated the research collaboration agreement with Servier and has determined that it is a
revenue arrangement with multiple deliverables, or performance obligations. The Company concluded that each option is substantive and that the license fees for each option are not deliverables at the inception of the arrangement and were not issued
with a substantial discount. The Company&#146;s substantive performance obligations under this research collaboration include an exclusive license to its technology, technical, scientific and intellectual property support to the research plan during
the first year of the agreement and participation on an executive committee and a research and development committee. The Company determined that the performance obligations with respect to the pre-clinical development represent a single unit of
accounting, since the license does not have stand-alone value to Servier without the Company&#146;s technical expertise and committee participation. As such, the initial up front license payment was deferred and is being recognized ratably over the
initial 29-month period, which represents the expected development period. The Company further concluded that each potential future clinical, development and regulatory milestone is substantive. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">During the year ended December&nbsp;31, 2012 and the six months ended June&nbsp;30, 2013, the Company recognized revenue of
$2.0&nbsp;million and $4.3 million, respectively, under this agreement. No additional milestones have been recognized under this agreement through June&nbsp;30, 2013. </FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">At December 31, 2012, $18.0 million of revenue was deferred under this agreement, $8.6 million of which was included in current liabilities and $9.4 million of which was included in long-term liabilities.
At June&nbsp;30, 2013, $13.7 million of revenue was deferred under this agreement, $8.6 million of which was included in current liabilities and $5.1 million of which was included in long-term liabilities. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Gilead Sciences, Inc. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In January 2013, the Company entered into an agreement with Gilead to grant it an exclusive worldwide license to research, develop and commercialize up to four DART-based molecules. Gilead has exclusive
worldwide rights for three of the programs. For one program, the Company retains development and commercialization rights outside of North America, the European Union, Norway, Iceland, Turkey, Australia and New Zealand. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company received an initial $7.5 million license grant fee for the first DART-based molecule. The Company may be eligible to receive
additional license grant fees of $22.5 million, $200 million related to pre-clinical and clinical milestones, $355 million related to regulatory milestones and $500 million related to sales </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-32
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MACROGENICS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
milestones if Gilead exercises all four of the options and successfully develops, obtains regulatory approval for, and commercializes a product under each option and license. The Company has
determined that the other licenses are conditional deliverables, which are substantive options that were not granted with a substantial discount. The Company has determined that each potential future clinical, development and regulatory milestone is
substantive. Although sales milestones are not considered substantive, they are still recognized upon achievement of the milestone (assuming all other revenue recognition criteria have been met) because there are no undelivered elements that would
preclude revenue recognition at that time. Gilead also provides funding for the Company&#146;s internal and external research costs under the agreement. Additionally, Gilead would be obligated to pay the Company high single digit to low double
digit, but less than teen royalties on product sales in its territories. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company has evaluated the research collaboration
agreement with Gilead and has determined that it is a revenue arrangement with multiple deliverables, or performance obligations. The Company&#146;s substantive performance obligations under this research collaboration include a license to its
technology and research and development services. The Company concluded that the deliverables do not have stand alone value and therefore, represent a combined single unit of accounting. Due to the lack of standalone value for the license and
research and development services, the combined unit of accounting (the upfront payment and the expected research and development reimbursements) is being recognized ratably over a period of 21 months, which represents the expected development
period. </FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company and Gilead have also agreed to establish a joint research committee to facilitate the governance and
oversight of the parties&#146; activities under the agreements. Management considered whether participation on the joint committee may be a deliverable and determined that it was not a deliverable. Had management considered participation on the
joint committee as a deliverable, it would not have had a material impact on the accounting for the arrangement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Receivables
of $1,015,466 as of June&nbsp;30, 2013 relate amounts due to the Company from Gilead for reimbursement work performed under the collaboration. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Company recognized revenues of approximately $3.7 million under this agreement for the six months ended June&nbsp;30, 2013. No additional milestones have been reached under this agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">At June&nbsp;30, 2013, $5.4 million of revenue was deferred under this agreement of which $4.3 million was included in current
liabilities and $1.1 million was included in non-current liabilities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Boehringer Ingelheim International GmbH </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In October 2010 the Company entered into a collaboration and license agreement with Boehringer to discover, develop and commercialize up
to ten DART-based molecules which span multiple therapeutic areas. Under the terms of the agreement, the Company granted Boehringer an exclusive, worldwide, royalty-bearing, license under its intellectual property to research, develop, and market
DARTs generated under the agreement, or the Boehringer licensed products, throughout the world. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upon execution of the
agreement, the Company received an upfront payment of $15 million. The Company subsequently received two annual maintenance payments and anticipates receiving a third annual maintenance payment in the fourth quarter of 2013. The first two
maintenance payments were solely attributed to the passage time. Because Boehringer has the option to cancel the program after the second anniversary of the agreement, the third maintenance payment will be recognized over the remaining obligation
period once received. The Company has the potential to earn milestone payments of approximately $41 million related to pre-clinical and clinical development, $89 million related to regulatory milestones and $83 million related to sales milestones
for each of the DART programs under this agreement in the case of full commercial success of </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-33
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MACROGENICS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
multiple DART products. The Company has determined that each potential future clinical, development and regulatory milestone is substantive. Although sales milestones are not considered
substantive, they are still recognized upon achievement of the milestone (assuming all other revenue recognition criteria have been met) because there are no undelivered elements that would preclude revenue recognition at that time. Boehringer also
provides funding for the Company&#146;s internal and external research costs and is required to pay the Company mid-single digit royalties on product sales. From the commencement of the collaboration through June 30, 2013, the Company has received
$37.9 million under this agreement, including upfront, annual maintenance and milestone payments as well as research funding. In addition, Boehringer purchased $10 million of the Company&#146;s Series D-2 Preferred Stock in January 2011. </FONT></P>
 <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company determined that the deliverables under the Boehringer agreement include the license, the research and development
services to be performed by the Company, and the co-promotion/manufacturing services. The Company concluded that the co-promotional activities were optional and were subject to further negotiation upon reaching regulatory approval. As such, the
co-promotional period is not included in the expected obligation period to perform services. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company concluded that the
undelivered element of research and development services had fair value. The Company concluded that the license does not have value on a standalone basis (e.g. absent the provision of the research and development services) and therefore does not
represent a separate unit of accounting. The Company concluded that because the drug candidate has not yet been developed, the license is of no value to Boehringer without the ensuing research and development activities using the DART technology,
which is proprietary to the Company. Likewise, Boehringer could not sell the license to another party (without the Company agreeing to provide the research and development activities for the other party). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Therefore, the upfront license fee and research and development services were treated as a combined unit of account and recognized over
the expected obligation period associated with the research and development services through September 2015, which represents the estimated period of development. </FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Company and Boehringer have also agreed to establish a joint research committee to facilitate the governance and oversight of the parties&#146; activities under the agreements. Management considered
whether participation on the joint committee may be a deliverable and determined that it was not a deliverable. However, had management considered participation on the joint committee as a deliverable, it would not have had a material impact on the
accounting for the arrangement as the period of participation in this committee matched the organization period for the research and development services. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">There have been no material modifications to this agreement since the adoption of ASU 2009-13 on January 1, 2011. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Receivables of $112,293, $355,568&nbsp;and $146,150 as of June 30, 2013, December 31, 2012, and December 31, 2011, respectively, relate to amounts due to the Company from Boehringer for reimbursement work
performed under the collaboration. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company recognized revenues of approximately $4.5 million, $11.7&nbsp;million, and
$8.9 million under this agreement during the six months ended June 30, 2013 and the years ended December 31, 2012 and 2011, respectively. One milestone payment of $2.0 million was recognized under this agreement through December 2012. No additional
milestones have been recognized under this agreement through June 30, 2013. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">At December 31, 2012, $14.0 million of revenue
was deferred under this agreement, $5.0 million of which was included in current liabilities and $9.0 million was included in long-term liabilities. At June 30, 2013, $11.5 million of revenue was deferred under this agreement, $5.0 million of which
was included in current liabilities and $6.5 million of which was included in long-term liabilities. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-34
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MACROGENICS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Pfizer, Inc. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In October 2010, the Company entered into a three year agreement with Pfizer to discover, develop and commercialize up to two DART-based molecules. The Company granted Pfizer a non-exclusive worldwide,
royalty-bearing license and received an upfront payment of $5 million and has received milestone payments and funding for the Company&#146;s internal and external research costs under the agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company is eligible to receive milestone payments of approximately $17 million related to pre-clinical and clinical development and
$195 million related to commercialization and sales milestones for each DART program under this agreement. The Company has determined that each potential future technical and development milestone is substantive. Although sales milestones are not
considered substantive, they are still recognized upon achievement of the milestone (assuming all other revenue recognition criteria have been met) because there are no undelivered elements that would preclude revenue recognition at that time.
Pfizer is responsible for all pre-clinical and clinical development costs for the program. In addition, Pfizer is required to pay the Company mid-single digit to low-teen royalties on product sales. Under this collaboration, one DART program is
currently being pursued and the Company will complete its research obligations under this program in October 2013. </FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
Company has evaluated the research collaboration agreement with Pfizer and has determined that it is a revenue arrangement with multiple deliverables, or performance obligations. The Company&#146;s substantive performance obligations under this
research collaboration include an exclusive license to its technology, research and development services and manufacturing services. The Company concluded that the manufacturing services were optional and were subject to further negotiation upon
reaching regulatory approval. As such, the manufacturing services are not included in the expected obligation period to perform services. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Company determined that it had fair value of the undelivered element of the research and development services. However, the Company concluded that the license does not have value on a standalone basis
(e.g. absent the provision of the research and development services) and therefore does not represent a separate unit of accounting. Facts that were considered included the development of the candidate noting that because the drug candidate has not
yet been developed, the license is of no value to Pfizer without the ensuing research and development activities using the DART technology, which is proprietary to the Company. Likewise, Pfizer could not sell the license to another party (without
the Company agreeing to provide the research and development activities for the other party). </FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Therefore, the upfront
license fee and research and development services were treated as a combined unit of accounting and recognized over the expected obligation period associated with the research and development services through October 2013, which represents the
estimated period of development. </FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The $5 million upfront payment received by the Company is non-refundable; therefore,
there is no right of return for the license. The Company is recognizing revenue associated with this non-refundable up-front license fee through October 2013. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Company and Pfizer have also agreed to establish a joint research committee to facilitate the governance and oversight of the parties&#146; activities under the agreements. Management considered
whether participation on the joint committee may be a deliverable and determined that it was not a deliverable because it is a participating right and not an obligation of the Company. However, had management considered participation on the joint
committee as a deliverable, it would not have had a material impact on the accounting for the arrangement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There have been no
material modifications to this agreement since the adoption of ASU 2009-13 on January 1, 2011. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-35
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MACROGENICS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Receivables of $564,032, $896,285,&nbsp;and $936,010 as of June 30, 2013, December 31,
2012, and December 31, 2011, respectively, relate to amounts due to the Company from Pfizer for reimbursement work performed under the collaboration. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Company recognized revenues of approximately $2.2 million, $5.5 million, and $5.2 million under this agreement during the six month period ended June 30, 2013 and the years ended December 31, 2012 and
2011, respectively. Included in the 2012 revenues are milestone payments totaling $500,000. No additional milestones have been recognized under this agreement through June 30, 2013. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">At June 30, 2013 and December 31, 2012, $0.5 million and $1.3 million of revenue was deferred under this agreement all of which was
included in current liabilities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Green Cross Corporation </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In June&nbsp;2010, the Company entered into a collaboration agreement with Green Cross for the development of the Company&#146;s
anti-HER2 antibody known as MGAH22, or margetuximab. This arrangement grants Green Cross an exclusive license to conduct specified Phase 1 and Phase 2 clinical trials and commercialize margetuximab in South Korea. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upon execution of the agreement, Green Cross made a nonrefundable payment of $1.0&nbsp;million to the Company. The Company is eligible to
receive clinical development and commercial milestone payments of up to $4.5 million. The Company has determined that each potential clinical development and commercial milestone is substantive. The Company is also entitled to receive royalties on
net sales of margetuximab in South Korea. The Company and Green Cross have formed a joint steering committee to coordinate and oversee activities on which the two companies collaborate under the agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company has evaluated the collaboration agreement with Green Cross and has determined that it is a revenue arrangement with multiple
deliverables or performance obligations. The Company&#146;s substantive performance obligations under this agreement include an exclusive license to its technologies and participation in a joint steering committee. The Company concluded that the
license does not have value on a standalone basis and therefore does not represent a separate unit of accounting. Likewise, Green Cross could not sell the license to another party. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The $1 million upfront payment received by the Company is non-refundable; as such, there is no right of return for the license.
Therefore, the upfront license fee and participation on the joint steering committee were treated as a combined unit of accounting and will be recognized over the term of the agreement through June 2020. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There have been no material modifications to this agreement since the adoption of ASU 2009-13 on January 1, 2011. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company recognized revenues of approximately $100,000 under this agreement during each of the years ended December&nbsp;31, 2012 and
2011, and $50,000 during the six months ended June 30, 2013. No additional milestones have been recognized under this agreement through June 30, 2013. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">At December 31, 2012, $750,000 of revenue was deferred under this agreement, $100,000 of which was included in current liabilities and $650,000 was included in long-term liabilities. At June 30, 2013,
$700,000 of revenue was deferred under this agreement, $100,000 of which was included in current liabilities and $600,000 was included in long-term liabilities. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-36
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MACROGENICS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Eli Lilly &amp; Co. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In October&nbsp;2007, the Company entered into an exclusive license and collaboration agreement (together, the Agreements) with Eli Lilly
to jointly develop and commercialize teplizumab, a humanized anti-CD3 monoclonal antibody. As part of the Agreements, Eli Lilly acquired the exclusive rights to the molecule. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Upon execution of the Agreements, Eli Lilly made a nonrefundable payment of $41.0&nbsp;million to the Company. In May&nbsp;2008, Eli Lilly paid the Company a milestone payment of $50.0&nbsp;million and in
May&nbsp;2010, Eli&nbsp;Lilly paid an additional milestone of $5.0&nbsp;million. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On October&nbsp;28, 2010, Lilly notified the
Company of its decision to terminate the agreement after review of one year of clinical data from the PROT&Eacute;G&Eacute; trial in Type 1 diabetes patients treated with teplizumab. Such data failed to support the primary efficacy end point in the
study. During the year ended December 31, 2012, Eli&nbsp;Lilly satisfied its obligation related to the cost of monitoring patients under the PROT&Eacute;G&Eacute; and ENCORE trials. The Company&#146;s obligations continued through September 2012,
which represented the follow up period for enrolled patients and the Company&#146;s final reporting of the trial&#146;s results. There is no additional clinical trial activity under the Eli Lilly Agreements as it relates to such trials. In February
2011, the Company reacquired the commercial rights to the molecule from Eli Lilly. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Receivables of $122,592, $558,516 and
$351,357 as of June 30, 2013, December 31, 2012, and, and December 31 2011, respectively, relate to amounts due to the Company from Eli Lilly for reimbursement work performed under the above mentioned clinical trials. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">During the six months ended June 30, 2013 and the years ended December 31, 2012 and 2011, the Company recognized revenue of $0.5 million,
$31.2&nbsp;million and $30.9 million, respectively, under this agreement. No additional milestones were recognized under this agreement through June 30, 2013. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>9. Commitments and Contingencies </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Operating Leases </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company leases office and laboratory space over periods extending through January&nbsp;30, 2018. Several of the leases contain rent
escalation clauses. Rent expense for the years ended December&nbsp;31, 2012 and 2011, was $3,133,850 and $3,190,413, respectively. The Company incurred $1,582,132 and $1,566,923 of rent expense for the six-month periods ending June 30, 2013 and
2012, respectively. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Future minimum lease payments under noncancelable operating leases at December&nbsp;31, 2012, are as
follows: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="54%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:35pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Operating<BR>Leases</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Year ending December&nbsp;31:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,797,540</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,557,749</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,214,401</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,310,833</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2017</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,410,159</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Thereafter</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,754,106</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19,044,788</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-37
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MACROGENICS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>10. Product Milestone Payments and Royalty Agreements </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with an Asset Purchase Agreement with Tolerance Therapeutics, Inc. (Tolerance) entered into during June 2005, the Company
may be required to issue Tolerance additional consideration as follows: (i)&nbsp;$10,950,000 if certain milestones are met, including the initiation of Phase 3 trials and filing of various regulatory product license applications; (ii)&nbsp;678,398
shares of common stock; and (iii)&nbsp;royalty payments between 1.75% and 4.0% of net sales of products acquired from or patented by Tolerance or other product fees earned by the Company. Any additional consideration required to be paid under the
Asset Purchase Agreement will be recorded as research and development expense when incurred. No payments related to the additional considerations have occurred during the years ended December&nbsp;31, 2012 and 2011 or during and the quarter ended
March&nbsp;31, 2013. Additionally, certain agreements require the Company to pay royalties. Currently, the Company is not obligated to pay royalties, as no other revenue from product sales is being generated by the Company. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>11. Employee Benefit Plan </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On September&nbsp;25, 2002, the Company established the MacroGenics 401(k) Plan (the 401(k) Plan) for its employees under Section&nbsp;401(k) of the IRC. Under this 401(k) Plan, all employees at least 21
years of age are eligible to participate in the 401(k) Plan, starting on the first day of each month. Employees may contribute up to 100% of their salary, subject to government maximums. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Employees are 100% vested in their contributions to the Plan. The Company&#146;s contribution to the Plan, as determined by the Board of
Directors, is discretionary. The Company&#146;s contributions to the Plan totaled $225,195, $217,097 and $139,187 for the years ended December&nbsp;31, 2012 and 2011 and the six months ended June 30, 2013, respectively. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>12. Subsequent Events </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subsequent to June 30, 2013, the Company issued approximately 3.9 million options to purchase shares of its common stock to employees.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On August 30, 2013, the Company received a $10 million milestone payment from Servier related to dosing the first patient in
the expansion cohort of the Company&#146;s Phase 1 clinical trial of MGA271. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-38
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Through and including
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2013 (the 25th day after the date of this prospectus), all dealers effecting transactions in these securities, whether or not
participating in this offering, may be required to deliver a prospectus. This is in addition to the dealers&#146; obligation to deliver a prospectus when acting as an underwriter and with respect to an unsold allotment or subscription. </FONT></P>
<P STYLE="margin-top:60px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shares </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g575431g97j81.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>Common Stock </B></FONT></P>
<P STYLE="font-size:60px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:30%">&nbsp;</P></center>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>P R O S P E C T U S </B></FONT></P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:30%">&nbsp;</P></center> <P STYLE="margin-top:60px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>BofA
Merrill Lynch </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>Leerink Swann </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="5"><B>Stifel </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>Lazard Capital Markets </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>Wedbush PacGrow Life Sciences </B></FONT></P> <P STYLE="margin-top:60px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2013 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PART II </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;13.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Other Expenses of Issuance and Distribution </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The following table sets forth the costs and expenses, other than underwriting discounts and commissions, payable in connection with the sale and distribution of the securities being registered. All
amounts are estimated except the SEC and FINRA registration fees. All of the expenses below will be paid by us. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:14pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B></B>Item<B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">SEC Registration fee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,184</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">FINRA filing fee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">NASDAQ Global Market listing fee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Printing and mailing expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Legal fees and expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounting fees and expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Transfer agent and registrar fees and expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Miscellaneous</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To be filed by amendment </FONT></TD></TR></TABLE> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;14.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Indemnification of Directors and Officers </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Under Section&nbsp;145 of the Delaware General Corporation Law, we can indemnify our directors and officers against liabilities they may incur in such capacities, including liabilities under the
Securities Act of 1933, as amended, or the Securities Act. Our bylaws that we expect to be effective upon the closing of this offering (Exhibit 3.4 to this registration statement) provide that we will indemnify our directors and officers to the
fullest extent permitted by law and require us to advance litigation expenses upon our receipt of an undertaking by the director or officer to repay such advances if it is ultimately determined that the director or officer is not entitled to
indemnification. Our bylaws further provide that rights conferred under such bylaws do not exclude any other right such persons may have or acquire under any bylaw, agreement, vote of stockholders or disinterested directors or otherwise. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our amended and restated certificate of incorporation that we expect to be effective upon the closing of this offering (Exhibit 3.2 to
this registration statement) provides that, pursuant to Delaware law, our directors shall not be liable for monetary damages for breach of the directors&#146; fiduciary duty of care to us and our stockholders. This provision in the amended and
restated certificate of incorporation does not eliminate the duty of care, and in appropriate circumstances equitable remedies such as injunctive or other forms of non-monetary relief will remain available under Delaware law. In addition, each
director will continue to be subject to liability for breach of the director&#146;s duty of loyalty to us or our stockholders, for acts or omissions not in good faith or involving intentional misconduct or knowing violations of law, for actions
leading to improper personal benefit to the director, and for payment of dividends or approval of stock repurchases or redemptions that are unlawful under Delaware law. The provision also does not affect a director&#146;s responsibilities under any
other law, such as the federal securities laws or state or federal environmental laws. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, our amended and restated
certificate of incorporation provides that we shall indemnify our directors and officers if such persons acted (i)&nbsp;in good faith, (ii)&nbsp;in a manner reasonably believed to be in or not opposed to our best interests, and (iii)&nbsp;with
respect to any criminal action or proceeding, with reasonable cause to believe such conduct was lawful. The amended and restated certificate of incorporation also provides that, pursuant to Delaware law, our directors shall not be liable for
monetary damages for breach of the directors&#146; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">II-1
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
fiduciary duty of care to us and our stockholders. This provision in the amended and restated certificate of incorporation does not eliminate the duty of care, and in appropriate circumstances
equitable remedies such as injunctive or other forms of non- monetary relief will remain available under Delaware law. In addition, each director will continue to be subject to liability for breach of the director&#146;s duty of loyalty to us for
acts or omissions not in good faith or involving intentional misconduct, for knowing violations of law, for actions leading to improper personal benefit to the fiduciary duty of care to us and our stockholders. This provision in the amended and
restated certificate of incorporation does not eliminate the duty of care, and in appropriate circumstances equitable remedies such as injunctive or other forms of non- monetary relief will remain available under Delaware law. In addition, each
director will continue to be subject to liability for breach of the director&#146;s duty of loyalty to us for acts or omissions not in good faith or involving intentional misconduct, for knowing violations of law, for actions leading to improper
personal benefit to the director, and for payment of dividends or approval of stock repurchases or redemptions that are unlawful under Delaware law. The provision also does not affect a director&#146;s responsibilities under any other law, such as
the federal securities laws or state or federal environmental laws. The amended and restated certificate of incorporation further provides that we are authorized to indemnify our directors and officers to the fullest extent permitted by law through
the bylaws, agreement, vote of stockholders or disinterested directors, or otherwise. We intend to obtain directors&#146; and officers&#146; liability insurance in connection with this offering. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, concurrently with this offering, we will enter into agreements to indemnify our directors and certain of our officers in
addition to the indemnification provided for in the amended and restated certificate of incorporation and bylaws. These agreements will, among other things, indemnify our directors and some of our officers for certain expenses (including attorneys
fees), judgments, fines and settlement amounts incurred by such person in any action or proceeding, including any action by or in our right, on account of services by that person as a director or officer of our company or as a director or officer of
any of our subsidiaries, or as a director or officer of any other company or enterprise that the person provides services to at our request. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The underwriting agreement (Exhibit 1.1 to this registration statement) provides for indemnification by the underwriters of us and our officers and directors, and by us of the underwriters, for certain
liabilities arising under the Securities Act or otherwise in connection with this offering. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;15.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Recent Sales of Unregistered Securities </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>(a) Sale of Stock Pursuant to Collaboration Agreement with Green Cross</I></B> </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In June 2010 we entered into a License Agreement with Green Cross. See &#147;Business &#151; Collaborations.&#148; Pursuant to that agreement, we issued and sold an aggregate of $1.0 million of our common
stock to Green Cross. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In January 2011, we issued and sold 18,427,388 shares of our Series D-2 preferred stock to three
investors at a for an aggregate purchase price of $12,016,500. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">No underwriters were involved in the foregoing sales of
securities. The securities described in this section (a)&nbsp;of Item&nbsp;15 were issued to investors in reliance upon the exemption from the registration requirements of the Securities Act, as set forth in Section&nbsp;4(2) under the Securities
Act relative to transactions by an issuer not involving any public offering, to the extent an exemption from such registration was required. All purchasers of shares of our common stock described above represented to the Company in connection with
their purchase that they were accredited investors and were acquiring the shares for their own account for investment purposes only and not with a view to, or for sale in connection with, any distribution thereof and that they could bear the risks
of the investment and could hold the securities for an indefinite period of time. The purchasers received written disclosures that the securities had not been registered under the Securities Act and that any resale must be made pursuant to a
registration statement or an available exemption from such registration. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">II-2
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>(b) Stock Option Grants</I></B> </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Between June&nbsp;30, 2010 and June&nbsp;30, 2013, we granted options to purchase an aggregate of 21,325,075 shares of common stock, with
exercise prices ranging from $0.05 to $0.08 per share, to our employees and directors pursuant to our 2003 Stock Plan. As of June&nbsp;30, 2013, 27,017,484 options to purchase shares of our common stock had been exercised for aggregate consideration
of $1,182,638, options to purchase 23,210,446 shares had been forfeited and options to purchase 51,879,146 shares of our common stock remained outstanding at a weighted-average exercise price of $0.05 per share. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The stock options and the common stock issuable upon the exercise of such options as described in this section (b)&nbsp;of Item&nbsp;15
were issued pursuant to written compensatory plans or arrangements with the Company&#146;s employees and directors in reliance on the exemption provided by Rule 701 promulgated under the Securities Act. All recipients either received adequate
information about the Company or had access, through employment or other relationships, to such information. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">All of the
foregoing securities described in sections (a)&nbsp;and (b)&nbsp;of Item&nbsp;15 are deemed restricted securities for purposes of the Securities Act. All certificates representing the issued shares of capital stock described in this Item&nbsp;15
included appropriate legends setting forth that the securities had not been registered and the applicable restrictions on transfer </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;16.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibits and Financial Statement Schedules </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The exhibits to the registration statement are listed in the Exhibit Index attached hereto and incorporated by reference herein. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;17.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Undertakings </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreement certificates in such denominations and registered in such names as required by the underwriters to permit prompt delivery to each
purchaser. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors,
officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as
expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling
person of the registrant in the successful defense of any action, suit, or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its
counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final
adjudication of such issue. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The undersigned registrant hereby undertakes that: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1) For purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus as
filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of this
registration statement as of the time it was declared effective. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2) For the purpose of determining any liability under the
Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and this offering of such securities at that time shall be deemed
to be the initial bona fide offering thereof. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">II-3
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this amendment to the registration statement
to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Rockville, State of Maryland, on September 20, 2013. </FONT></P>  <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MACROGENICS, INC.</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Scott Koenig</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Scott Koenig, M.D., Ph.D.</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">President and Chief Executive Officer</FONT></P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>POWER OF ATTORNEY </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">KNOW ALL MEN BY THESE PRESENTS, the undersigned hereby constitute and appoint Scott Koenig, M.D., Ph.D. and James Karrels and each of them, his true and lawful attorney-in-fact and agent, each with full
power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, or any related registration statement
filed pursuant to Rule 462(b) under the Securities Act of 1933, and to file the same, with exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents,
and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and
confirming all that each of said attorneys-in-fact and agents, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Act of 1933, this Registration Statement on Form S-1 has been signed by the following persons in the capacities and on the dates indicated: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="44%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:33pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Signature</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:15pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Title</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Date</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Scott Koenig</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Scott Koenig, M.D., Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">President and CEO and Director<BR>(Principal Executive Officer)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">September 20, 2013</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ James Karrels</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">James Karrels</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President, Chief Financial Officer and Secretary (Principal Financial Officer)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">September 20, 2013</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Lynn Cilinski</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Lynn Cilinski</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President, Controller and Treasurer (Principal&nbsp;Accounting Officer)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">September 20, 2013</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Paulo Costa</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">September 20, 2013</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Kenneth Galbraith</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">September 20, 2013</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Edward Hurwitz</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">September 20, 2013</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Eran Nadav, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">September 20, 2013</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Arnold Oronsky</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Arnold Oronsky, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">September 20, 2013</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ David Stump</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">David Stump, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">September 20, 2013</FONT></TD></TR>
</TABLE>  <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">*By:</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Scott Koenig</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Scott Koenig, M.D., Ph.D., Attorney-in-Fact</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">II-4
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT INDEX </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:39pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;1.1*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Underwriting Agreement</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;3.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amended and Restated Certificate of Incorporation of Company</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;3.2*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proposed Amended and Restated Certificate of Incorporation of Company</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;3.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Bylaws of Company</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;3.4*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proposed Bylaws of Company</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;4.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fourth Amended and Restated Registration Rights Agreement by and among the Company, the Founders, and the Investors, dated September 19, 2008</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;5.1*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Opinion of Arnold &amp; Porter LLP</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1+</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Company 2000 Stock Option and Incentive Plan</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.2+</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Incentive Stock Option Agreement under 2000 Stock Option and Incentive Plan</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.3+</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Company 2003 Equity Incentive Plan</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.4+</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Incentive Stock Option Agreement under 2003 Equity Incentive Plan</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.5+*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Company 2013 Equity Incentive Plan</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.6+*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Incentive Stock Option Agreement under 2013 Equity Incentive Plan</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.7+*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Restricted Stock Agreement under 2013 Equity Incentive Plan</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.8</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lease Agreement by and between Red Gate III LLC and the Company, dated May 31, 2011</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.9</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment to Lease Agreement by and between Red Gate III LLC and the Company, dated March&nbsp;26, 2013</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.10</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lease Agreement by and between W. M. Rickman Construction Co. LLC and the Company, dated December&nbsp;2, 2004</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.11</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment to Lease Agreement by and between W. M. Rickman Construction Co. LLC and the Company, dated January&nbsp;31, 2006</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.12</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Second Amendment to Lease Agreement by and between W. M. Rickman Construction Co. LLC and the Company, dated June 1, 2011</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.13</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sublease Agreement by and between Amgen SF, LLC and Raven biotechnologies, Inc., dated November 21, 2006</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.14*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Indemnification Agreement</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.15&#134;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Collaboration and License Agreement by and between Boehringer Ingelheim International GmbH and the Company, dated October 18, 2010</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.16&#134;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">License Agreement by and between the Company and Gilead Sciences, Inc., dated January 3, 2013</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.17&#134;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Collaboration Agreement by and between the Company and Green Cross Corp., dated June 30, 2010</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.18&#134;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">First Amendment to Collaboration Agreement by and between the Company and Green Cross Corp., dated January 19, 2011</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.19&#134;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Second Amendment to Collaboration Agreement by and between the Company and Green Cross Corp., dated December 13, 2012</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.20&#134;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Option for a License Agreement by and between the Company and Les Laboratoires Servier and Institut de Recherches Servier, dated September 19,
2012</FONT></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="90%"></TD></TR>

<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:39pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.21&#134;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Option for a License Agreement by and between the Company and Les Laboratoires Servier and Institut de Recherches Servier, dated November 24, 2011</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.22&#134;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research Collaboration and License Agreement by and between Pfizer Inc. and the Company, dated October 13, 2010</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.23&#134;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment No. 1 to Research Collaboration and License Agreement by and between Pfizer Inc. and the Company, dated August 9, 2012</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.24&#134;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment No. 2 to Research Collaboration and License Agreement by and between Pfizer Inc. and the Company, effective October 13, 2013</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.25+*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Employment Agreement, dated as of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2013, between the Company and Scott Koenig, M.D., Ph.D.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.26+</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consulting Agreement, dated as of September 6, 2013, between the Company and Anastasia Daifotis, M.D.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">21.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subsidiaries of Company</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">23.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consent of Ernst &amp; Young, LLP, Independent Registered Public Accounting Firm</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">23.2*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consent of Arnold &amp; Porter LLP (included in Exhibit 5.1)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">24.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Power of Attorney (included on signature pages hereto)</FONT></TD></TR>
</TABLE>  <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To be filed by amendment. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#134;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Confidential treatment is requested for certain confidential portions of this exhibit pursuant to Rule 406 under the Securities Act. In accordance with Rule 406, these
confidential portions have been omitted from this exhibit and filed separately with the Commission. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">+</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicates management contract or compensatory plan. </FONT></TD></TR></TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.24
<SEQUENCE>2
<FILENAME>d575431dex1024.htm
<DESCRIPTION>EXHIBIT 10.24
<TEXT>
<HTML><HEAD>
<TITLE>Exhibit 10.24</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 10.24 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Confidential Materials omitted and filed separately with the Securities and Exchange Commission. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Triple asterisks denote omissions. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Amendment No.&nbsp;2 to
Agreement </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(&#147;Amendment No.&nbsp;2&#148;) </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Amendment No.&nbsp;2 Effective Date: October&nbsp;13, 2013 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-bottom:1px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Name of Agreement: </B> </FONT></P></TD>
<TD><FONT STYLE="font-family:Times New Roman" SIZE="2">Research Collaboration and License Agreement dated October&nbsp;13, 2010 and subsequent Amendment No.&nbsp;1 dated August&nbsp;9, 2012 (together the &#147;Agreement&#148;)
</FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-bottom:1px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Effective Date of Agreement:</B> </FONT></P></TD>
<TD><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>October&nbsp;13, 2010 (&#147;Amendment Effective Date&#148;) </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-bottom:1px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Parties</B>: </FONT></P></TD>
<TD><FONT STYLE="font-family:Times New Roman" SIZE="2">Pfizer Inc. (&#147;Pfizer&#148;) and MacroGenics, Inc. (&#147;MacroGenics&#148;) </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, the Parties hereto desire to amend the Agreement in order to extend the Research Term an additional 3 months for completion of activities contemplated under the Research Plan and more fully
outlined in the attached Exhibit. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">NOW, THEREFORE, in order to accommodate the changes, the Parties have agreed as follows: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;1.117 shall be replaced with the following: </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#147;<B>Research Term</B>&#148; means the period commencing on the Effective Date and continuing until January&nbsp;13, 2014, or until such later date as may be mutually agreed to by the Parties.
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Except as expressly amended hereby, the Agreement shall remain unmodified and in full force and effect. The execution, delivery and effectiveness of this Amendment
No.&nbsp;2 shall not, except as expressly provided herein, operate as a waiver of any right, power or remedy of the parties to the Agreement, nor constitute a waiver of any provision of the Agreement. </FONT></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">This Amendment No.&nbsp;2 may be executed in any number of counterparts, each of which shall be an original instrument and all of which, when taken together, shall
constitute one and the same agreement. </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">SIGNATURES IMMEDIATELY FOLLOWING ON NEXT PAGE </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Page 1 of 3
</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:3%" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment.&nbsp;An
unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Confidential Materials omitted and filed separately with the Securities and Exchange
Commission. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Triple asterisks denote omissions. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">IN WITNESS WHEREOF, the duly authorized representatives of Pfizer and MacroGenics have executed this Amendment No.&nbsp;2 as of the date first above written. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MacroGenics,&nbsp;Inc.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Pfizer&nbsp;Inc.</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Scott Koenig</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Steven W. Adams</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">Print&nbsp;Name:</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Scott Koenig</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">Print&nbsp;Name:</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Steven W. Adams</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">CEO</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sr. Director, Operations, ORU</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">(Duly authorized)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">(Duly&nbsp;authorized)</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Page 2 of 3
</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:3%" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment.&nbsp;An
unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Confidential Materials omitted and filed separately with the Securities and Exchange
Commission. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Triple asterisks denote omissions. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>*** project: </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>MacroGenics will Perform the Following Preclinical Activities: </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Preclinical Studies </B></FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>a.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Perform assays to support a *** study, including: </B></FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>i.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>*** studies </B></FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ii.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>*** studies. </B></FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>iii.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>*** studies. </B></FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Preclinical Assays </B></FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>a.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Protocols to support a *** study, including: </B></FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>i.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>*** studies </B></FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ii.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>*** studies. </B></FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>iii.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>*** studies. </B></FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>b.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Reagents developed to support *** and *** preclinical assays: </B></FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>i.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Antibodies to detect ***. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Expected
FTE usage: *** FTEs for 3 months </B></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Page 3 of 3
</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:3%" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment.&nbsp;An
unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.26
<SEQUENCE>3
<FILENAME>d575431dex1026.htm
<DESCRIPTION>EXHIBIT 10.26
<TEXT>
<HTML><HEAD>
<TITLE>Exhibit 10.26</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 10.26 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>CONSULTING AGREEMENT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This Agreement, effective as of the EFFECTIVE DATE,
as defined below, by and between MacroGenics, Inc., a corporation having a principal place of business at 9640 Medical Center Drive, Rockville, MD 20850 (hereinafter &#147;MacroGenics&#148;) and Anastasia Daifotis, M.D. an individual residing at
Westfield, NJ 07090 (hereinafter &#147;Individual&#148;). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, MacroGenics is in the business of researching, developing,
manufacturing and selling pharmaceuticals and biologics; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, Individual has expertise in the design and conduct of
clinical trials and will be terminating her employment with MacroGenics; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, upon termination of her employment
(&#147;Termination Date&#148;), MacroGenics seeks to have Individual render services as a consultant to MacroGenics to support clinical trials to be conducted and being conducted by MacroGenics (hereinafter &#147;Services&#148;) and Individual will
have access to certain information, files, records, documents and data owned or controlled by MacroGenics (hereinafter &#147;MacroGenics Information&#148;); and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, Individual agrees to perform the Services for MacroGenics; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">NOW
THEREFORE, in consideration of the mutual promises and other good and valuable consideration, the parties hereto agree as follows: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Individual shall be available to render the Services up to eight (8)&nbsp;hours per week and up to a total of one hundred ten (110)&nbsp;hours during the Term upon
MacroGenics&#146; reasonable request in person, by phone or other means during the Term. </FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The term
(&#147;Term&#148;) of this agreement shall begin on the first business day after Individual&#146;s Termination Date (&#147;Effective Date) and shall automatically expire on January&nbsp;10, 2014. </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Individual shall receive the following compensation from MacroGenics for rendering the Services: </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Individual shall retain the stock options set forth on Schedule A hereto and such options shall i) continue to vest and become exercisable during the Term; ii) to the
extent they have vested prior to the expiration of the Term, shall be exercisable during the period of three (3)&nbsp;months after the expiration of the Term. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reimbursement made in accordance with policy and practice of MACROGENICS for reasonable, authorized, out-of-pocket expenses for each visit to
MACROGENICS or such other place as authorized by </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">
MACROGENICS, upon presentation of appropriate expense receipts. Invoices and receipts should be addressed and sent to Lynn Cilinski at the address indicated below. The fees and expenses shall be
payable in full within thirty (30)&nbsp;days of receipt of such invoices and receipts. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">MacroGenics, Inc. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Attention: Lynn Cilinski, Vice President&nbsp;&amp; Controller </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">9640 Medical Center Drive </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rockville, MD 20850 </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(301) 354-2637 </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">cilinskil@macrogenics.com </FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)
The consideration and reimbursement described in this Section&nbsp;2 shall be the only compensation due to Individual for rendering the Services under this Agreement. Individual specifically agrees that she will not receive and is not entitled to
receive compensation in the form of health care, retirement, hourly compensation, and worker&#146;s compensation benefits under this Agreement or pursuant to providing the Services. Individual shall be responsible for and liable for all taxes,
excises, assessments, insurance and any benefits including, but not limited to health, accident and compensation benefits and shall pay all taxes and contributions, which consultant is required to pay as a result for compensation received for
providing the Services. </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Individual will promptly disclose, grant and assign to MacroGenics, for its sole use and benefit, any and all inventions, improvements, technical information,
protocols, documents and suggestions relating in any way to the business of MacroGenics which Individual may develop or acquire in the course of performance of this Agreement (whether or not during the usual working hours), together with all patent
applications, letters patent, copyrights and reissues thereof that may at any time be granted for or upon any such invention, improvement or technical information (hereinafter &#147;Developed Technology&#148;). In connection therewith:
</FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Individual shall, without charge, but at the expense of MacroGenics, promptly at all times hereafter execute and deliver such applications, assignments,
descriptions and other instruments as may be necessary or proper in the reasonable opinion of MacroGenics to vest title to any such inventions, improvements, technical information and text, protocols, documents, patent applications, patents,
copyrights or reissues thereof in MacroGenics and to enable it to obtain and maintain the entire right and title thereto throughout the world; and </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Individual shall render to MacroGenics, at MacroGenics&#146; expense, all such reasonable assistance as may be required in the prosecution of applications for said
patents, copyrights or reissues thereof, in the prosecution or defense of interferences which may be declared involving any said applications, patents or copyrights and in any litigation in which MacroGenics may be involved relating to such
applications, patents or copyrights. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Individual hereby agrees that all MacroGenics Information received by Individual, whether provided by the management, employees, and/or consultants of MacroGenics or
third parties, whether before or after the Effective Date, shall be and was received in strict confidence and shall be used only for purposes of this Agreement. Upon request by MacroGenics, Individual will promptly return to MacroGenics all
MacroGenics Information received from MacroGenics and/or any and all materials and physical documents, including notes of the Individual produced for the Services, whether prepared by MacroGenics or by Individual, when such materials or documents
are, include or incorporate MacroGenics Information which is in tangible form, except that Individual shall have the right to retain one copy of such MacroGenics Information for the purpose of determining its legal obligations hereunder. The term
&#147;document&#148; is used in its broadest sense and includes electronic information in the form of discs, tapes, etc. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Individual&#146;s obligation of confidentiality shall not apply to that part of the MacroGenics Information which Individual is able to demonstrate by documentary
evidence: </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">was fully in Individual&#146;s possession prior to receipt from MacroGenics and not previously received under confidentiality from MacroGenics or any third party in
connection with the provision of any services to MacroGenics; </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">was in the public domain at the time of receipt from MacroGenics; </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">becomes part of the public domain through no fault of Individual; or </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">is lawfully received by Individual from a third party having a right of further disclosure and not under an obligation of confidentiality to MacroGenics.
</FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">If Individual is required by law or administrative or judicial order to disclose MacroGenics Information, Individual shall give MacroGenics prompt notice of such fact
so that MacroGenics may obtain a protective order or other appropriate remedy concerning any such disclosure and/or waive compliance with the non-disclosure provisions of this Agreement. Individual shall fully cooperate with MacroGenics in
connection with MacroGenics&#146; efforts to obtain any such order or other remedy. If any such order or other remedy does not fully preclude disclosure or MacroGenics waives such compliance, Individual will make such disclosure only to the extent
that such disclosure is legally required. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The fact the general information may be in or become part of the public domain, in and of itself, does not exclude any specific information or specific material from
the obligations of this Agreement. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Individual is engaged in an independent business and will perform the Services as an independent contractor and nothing in this Agreement is to be construed as creating
a joint venture, partnership or any relationship between MacroGenics and Individual other than that of independent contractor. Individual shall not act or attempt to act or represent itself, directly or by implication, as an agent of MacroGenics or
in any manner assume or create any obligation on behalf of or in the name of MacroGenics. No rights or licenses in or to MacroGenics Information are granted to Individual by virtue of this Agreement. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Neither party will use the name of the other party for promotional purposes without prior written approval from the other party, nor publicly disclose the fact of this
Agreement or its terms. Notwithstanding the foregoing, MacroGenics shall have the right to use Individual&#146;s name where appropriate on legal documents. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">At the request of MacroGenics, Individual shall return to MacroGenics any and all materials and physical documents, including notes and technical text of the Individual
produced for the Services, whether prepared by MacroGenics or by Individual, when such materials or documents are, include or incorporate MacroGenics Information. The term document is used in its broadest sense and includes electronic information in
the form of discs, tapes, etc. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Individual will provide professional advice and Services to MacroGenics in accordance with generally accepted professional standards as applied to similar services
performed under similar conditions prevailing in the industry at the time such advice and Services are rendered. Individual warrants that all services shall be performed in a manner of due diligence that is customary for the profession. Individual
is engaged to provide independent and objective opinions and recommendations. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Individual represents and warrants that to the best of her knowledge she is permitted to enter into this Agreement and perform the obligations contemplated thereby and
that this Agreement and the terms and obligations thereof are not inconsistent with or in violation of his/her present employment or with any other obligation he/she may have. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">This Agreement constitutes the entire and exclusive Agreement between Individual and MacroGenics with respect to the subject matter thereof and supersedes any prior or
contemporaneous agreements, representations and understandings of the parties with respect thereto. No supplement, modification or amendment of this Agreement shall be binding upon MacroGenics or Individual unless set forth in a written agreement
executed by MacroGenics and Individual. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">It is the desire and intent of the parties hereto that the provisions of this Agreement shall be enforced to the fullest extent permissible under the laws and public
policies applied in each jurisdiction in which enforcement is sought. Accordingly, to the extent that a restriction contained in the Agreement is more restrictive than permitted by the laws of any jurisdiction where this Agreement may be subject to
review and interpretation the terms of such restriction, for the purpose only of the operation of such restriction in such jurisdiction, shall be the maximum restriction allowed by the laws of such jurisdiction and such restriction shall be deemed
to have been revised accordingly herein. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Individual further consents to personal jurisdiction in the State of Maryland for the
purposes of enforcing this Agreement and further agrees that the State of Maryland is and shall be a convenient forum and the law of the State of Maryland shall govern this Agreement without regard to choice of law principles. </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">15.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Individual represents, warrants and agrees that it can and will perform the services required by this Agreement without disclosing or using any confidential information
and/or proprietary information of a third party. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upon any termination of this Agreement, Individual shall return any and all fully or partially completed work done pursuant to providing the Services or ad hoc request
to MacroGenics. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Neither MacroGenics not Individual shall be liable in any way for failure to perform any provision of this Agreement, if such failure is caused by any law, legislative
action, court order, or any cause beyond the control of the party in default (such as fire, failure of energy supply, strike, riot, or acts of God). </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">18.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The obligations of Sections 2.(b), 3-10, 13, 14, 16, 17 and 18 of this Agreement shall survive any termination of this Agreement. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>THE REMAINDER OF THIS PAGE HAS BEEN INTENTIONALLY LEFT BLANK </B></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">IN WITNESS THEREOF, the parties have signed this Agreement as of the date indicated below.
</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR>
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MacroGenics, Inc.</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Anastasia Daifotis, M. D.</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Scott Koenig</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Anastasia Daifotis</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Scott Koenig</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">CEO</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date:</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">6 September 2013</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date:</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">September 2, 2013</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SCHEDULE A </B></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">7 </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>d575431dex231.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML><HEAD>
<TITLE>Exhibit 23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit&nbsp;23.1 </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Consent of Independent Registered Public Accounting Firm </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We consent to the reference to our firm under the caption &#147;Experts&#148; and to the use of our report dated March&nbsp;8, 2013, in Amendment No. 1 to the Registration Statement (Form S-1 No.
333-190994) and related Prospectus of MacroGenics, Inc. for the registration of shares of its common stock. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/
Ernst&nbsp;&amp; Young LLP </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">McLean, Virginia </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">September 20, 2013 </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g575431g04y47.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g575431g04y47.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`)D%D
M;V)E`&3``````0,`%00#!@H-```8=0``77$``'UN``"A;__;`(0``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("
M`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"`@(!`@(#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\(`$0@`ZP$@`P$1
M``(1`0,1`?_$`2X``0`"`@,!`0$````````````&!P4(`P0)`@$*`0$``04!
M`0$``````````````0($!08'`P@)$``!!`$#`@0$!0,$`P`````%`@,$!@$`
M$`<@$3!`$A-0%!4U,306-C<S%PA@<"$R(B,D$0`"`@$"!`(&!@8#"@H+```"
M`P$$!1$&`"$2$S$405$B,A4'$"!A<4(C,(&1,R060*%2\+%B<I)#-"5VML'1
M\8*BLW1UM7?ALE-S1)2D-287"!(``0,!!0(("P8""`<``````1$"`P`A,4$2
M!%%A$"!Q@2(R$P5`D:&QP=%"4F)R%#!0\",S<^$5@/&"HK(T="62PD-3D[,&
M$P$!``("`0,#!`,!`0$!```!$0`A,4%1$"!A,'&!0/"1H;'!T5#A\7#_V@`,
M`P$``A$#$0```:#YQ^M^/IN0!\31B_;`9?PV(``#O56_5CVXXJ`'//GP1Z<%
M5KB/?7,];;:.>?/B5R*O%QOSRH%MW>E?T%[U^:$B],6(SYY7P+T?](Z1LN@0
M3)<FF^/ZG\*,)<:K(K7<Q#K_`)K)K3>NWYY".W6F=/TQOH7=Z)G_`$QL:\LM
M./?7LC5:ZNXWKU@^^LSCVU_K3YX3TQ&:\=AUSQ_4=@[_`)GS318WOJWF?KOU
M@![7[C\"[LYC@('RGP5TC]'=8\;UH``#XGS^X]`!(_3%SGWU[F>=I76H5':;
MK#/+/6)[ZOU8]HSYY:5^N&XHKJ2UW6W[O2.M'KAJ+ZOK?9AM]EN(^RNV_"<U
M]L"`,?3<_P`V7/?U6@4T][SRW)3Z@<<^27U%?7JL^U1?!*+7>A2FSWV"9+DT
MWQ_5.2GU`C]UI_9HO<OX;'CO7#=BF[[-%\`,[Z8[^DKH/Y5R'TQ@`Z--QXYZ
MG]S4!YY:B,7VCL47@&%N-8_4]NC(X;WUJ3V>]`86XUC-6^S@<=7C#+[F4WQ_
M4Q\S3]15A[C6^WYY'N^>3`MBZTSVXW'\_P"^+[G0``%26NZZ%X/Z-\S==^LN
M"/0``````?$T?<5B"Y'E$XQ_5?J*@+)N=5VLR?&_4[9?CW.UXZ4>N(```$;\
M\I1%GT#R5U;[6U\Q_3@`,!=:AG[7;P`(A?<YEMET3ZBH#KUV?8HO`![4[A\$
M;OYGY^`````QQ_/5'I[Y>69\_<']*>-^+[3/L9UX#`W.I9ZVVT<57AA+C5I!
M:[AT/7$]_P`LL!\S3"[_`)A-L?U$3;WP&T&1Y%Z8[%\F[`W_`#4````1@\T(
MK].)HSQYP:_]3>8FN?6\?\\GT:;@`=>NSY(]\'<:I(+7<``(=?\`-9=8]&^X
M]+6NM-]VMU_.SIW6FP@K!-IH^2T$62``?)1":=3NVI$"\-CD?IBO"72OT4H*
MQZ3DZK2*^68$1ON=2ZQZ*``!.+K3(A,82B\L&]YW[D;I^>G(0\ZYK]%4^1DY
M;&(G2)>`:TIU)BKT@FB6``P7GD==[#IWB/J?W/F;KY5C?.>NQ_<N_P#Y*-Y7
MB4EQ/;<I9<DZ.(T^ZNBX&A\/WO>;-?/.XN6X9V)\]L+[F\MGRUB32L33*=^I
MITDBJS9CJPO:8V50!YFJMYE-F```&G.*SNI^%B+?&O=8I]:YN!W7T#[/[=\&
M_P`[VD?HIO1\J?(%&?3>H;U[5H.ZF?O;4NM/```````IU,$-G4```"EO*O53
MC>[Z8Y[RL[Y;ZKZ/?<_#[QN,+XW?+O<ZVR>`W0VO!SCI6K;KYJP```````&A
M*K8A%W(````TXQ5[6G+=LU4UC-V?C[BY>L:;K=\Q=9L?Z9Y-/LG:>BN[X"ET
M66GOE((OU-/EI&,.0SI718H`!Y6Q7ZBS1W0````>=NGYRE_:BHOC;NFP._:W
M4/9]%ORFGT.ZAJ4J/,!$1EFS"&KJ*X-A$Y(ZIQ%-(_HTBH`#R`BOU_F@````
M#\*+3Y3?`_T?>F_:W>_?.<;L[]K7:!61ECN&O2,Z7.F!EF&,.P?)*0`#SUBK
MT*FD`````4>GRB^!_H^\]^UN]^^<XWCW[6@/,:8T_*^1F"9)SY7AL2>Q<2``
M!7QI>J]$5(`````H]/@Q\\T;+;#.WG0Y]!=B`<!USX.([!Q'R5D7&```#2I5
MMBID@````!2*?!SD7SYLKE]@VXV_H?H)E\^````````!YYJIF;LJ0```,$8I
M$>AY'VEAD)JV5N+NZJJMC9F3@```````&O"==HGT0FD``#@*-B-;T8Z`Z)$)
M3*&+E)#:69FB1$4X@GJ-8E5U(_2($L.^74@`"/'DA%?J1-%D``'2-,XIU93-
M$3&`$.EEBBTV&B7&0)HG8N9ZR8@5LF;Q%;IL:8PZ;)1L(@``4`GS^BKU[FCE
M`.J::Q37,(E+.G?A^@J29EB)=#]`/LW/F;(F0`````!TROC0R*O2&:<^"E8C
M4^(BLL]#N&GLSMTB)2[!(H1V4GAS0%-S,E1O4F[YD``````#3].N45;XS3DX
MIU"1$RI$V0B5PC\H%6PJ!]GP=HEU,R6'Z<IE8;L3-@S(``````%2)E2-88IT
M^BK3R9W,1C3NHK2J>M,0V)@Z>R6_-,/3)D2V$FIG)%>)WK1N_(```````5E$
M:<1&M:K]E#TBI*G9.B25'-*,Q/Z2.8C$39\T]>)R-,_AMFI]$IG,@``````&
MF44Z/IV`1DX:P35G)BFZIO!10"OF.4ZI^$1B9"C*RQT+ZB(_#81&VB=AYD``
M````#5F(U31-(<AK3-50U,<67,<IC#B*RB<P6),1XC*9^B_J%D1`W/F;+F0`
M`````*EB-/X@`0:I`:H`````G5,SVD-S9FS9D```#__:``@!`0`!!0*4Y*>D
M]&<X3B).B3D]:(LEU*DJ0KHRTZE&G'$,H@$HA)&WM.^WC&<YD!B\-.]&K'ZP
MLPD5!!C=B(807;Y#36F;7HTP8>TC"L)<;0Z@>+AC$[&BN1,=AWWF=%437((1
MN>V/XKLQ]B$(K4.SPVJK5%1<4FE$C%6%T1NWBV01CD:WV*Y%K.3I%;^2-T:H
M38<&A4==WB52BF#[C5>GW"\';7(N=IJ]("8Y&^U;\24^CM"]\XQG')W'\JE&
MNO.,*QT#BQ$3J)>[;!@`[A,'FK-R8X3B3+Q:9\PH8(F24[D2ZDHDZ^VTEAZR
MG)#<SD&YS\OWVV29RE*6J9R#<IXPC>K67BS[58";>W%Y:D?-!:Z$KK71+=CL
M13I))<S*EQX3*5)6G=2DH2E25ISG&,-/-2$;Q#$"=(T9C%Y&DXSA.Y2&Y/@P
M8RXD74J5'A,LO-2&^@7`<*DQ(]`D9T28S$R-<^$+`.+W/B"P`P#33;#>Y"$@
MA%@0TCXDF.W+8%BV!3&\<?$BO;J5Z4B#/U56W?&TZ#&(,1X[45G>FVJ14C(J
MO4`^QUWL"NRU$%P1$%P7,X6YXV,8QN4#9(R<?\8WJ]3-W"?3N%;#FS_I"J?+
M"@HH&QX!<7%-C;)0J^S2+CQL=I,/IC$X4Q_I(FH0QS&>^-T.M.9Z.!!4&)2_
M#E_-?+$O[B\E<HFZ\%L<3G&EUD16!+)IN3O&&0H;^RUI;1`)PR2=/1H\C.^?
M^<#`<<9(VKM?)6@L0X$O4-GC&L2JG3_",&15?'#O\@7K[R0@6-;5K_(UY_`<
M6`.'-28LF$_T9=:PXI*5I@#(@Q'2LW#:))4E6-47V_UH,H]6#&;U:W:>$>Y;
MID,9(YO&.'F.6Z5)U+Y=HT)@7;`QDMTYSC&&+V"*%*9PJ*I]KVL5:#VJ#`'0
M!46SB35OOT"!,*3#8EX$5V?#1'R/75JXBS6,O75AR28#_II<AV+<!'(:B4^\
MAZR3*L\.`F!4SB)A\J`X?F#*S.`<<P@8^=QX"/N<B4MJ<#.0+#`WY3>EMURL
MP9%U:!-%F`W0@=$CQ.-^,Q]'AV*<HB9K!.IFZ58*^6J3^T=%E9EZ?$FOJ]G'
MS:3)H8,7=:4Y@@W*$<7W^H7&\<.2+QFA\)@ZQ$%@`03&KS%E?JCC:CVVC1Z`
MP28NT]TK:`1/ABPX&%*#:;/IJL7IY_C".^@;OR&TKD%JIB"(<1U\AS9`8C-`
M.C8S*4V@5Q=QW#-$`5#(R[]=J=!MU;+)="N"FG1L6Q4PM;7..XYCB\V4I-6,
MD/'OMLQ2:L+J_%EJ,>!>Z>S<P@U^-R#7;%/E@BDQ4F6BG$:W<V%K2VF>L9R!
M>BMD#RCP&$NOP^-P,XX1\AS"2L295"AR&@W@\DUDA%EEXR+F&@3X0N6(.*XV
MM'+MDDF9Q5Q_*J*"AF7(,'^ZEDU:>1*127AA*`9'R9,:%'KW*?'=L)Z.7VHU
M\)&D,S(Q8K`!"QA*$9&ZLEJ"5-CILLI1^TQF$18_A6")_:JPNM!+A.L[KC_%
M)57KY10-Q)J$JQ-7UP(%&UP1KDF-8)?.TXZM?*'-LKD8IQ=>3]'M]F"7<PX[
M+AQZX,LI"VEY"S-NKS\ZPX+%@=IO9VZ%3GZ@1TUTLUGD#Q.24(;XTMO\7DOY
M/X,^WM,LL8VM!ZKU&`TQ7[$T9-AJ_#G7/CFBD>/*%5ZL*<`@WI!4U5!-C4,&
MKR[7P,A2P@9PA]#"YD]($7<Y5@\3DW^-[=_&!+^3^#/M^_,TJ99+Z-/V-OCS
MD2#(12;"Y#BN@[$7#S*_8I,0M25`+!?.)#5QL=XZ[.S9'A-:OEU8L?B<F_QN
M?,6]VDWHE8X/*W^.KTN17=_;;PY\K&RMR'$>0F!!0EJ+&CKCPH</+,"#'S6J
M0*JY;P)W%Y9\@*,"3L3P^3,9SQP?SC-(O'\K?X[?MWR?,(.1$)\'`Y`FN^#.
M)0AK;-A"OZ-V(-'CS*96JNN1-`\CEJX4@UT1#NY1C0DK'+Q?(\F0A<^O\?V"
M4)/];CC;*"MVCLZE2Y$U[:3&9EL!ZX/"+=88?Q],B8T+E%`T@=8"4W7U:<UK
M]2ADZN%TAU>JL<B!66PULKU@<JG-PH\AWDJF,Q'^2Z5&=F<PTJ.WGDVD8=%<
MA50Y-Z2T)PB-R,G5]^L6#Z_!Z9$AF*R?//&9%ILL@$L$5^LCMS)R$$8'D(Q.
M)=9QZ&\"49F"OE']9:=7JM11>"]CHH0]7W:4EJS<7T-5(@IX(`M!(_%WR"3/
M##30M7%KCBE<-PW6)=`CR[3U74<W$"5-BQA'T8RE.[SS<=JP6!XR]HF#&E\Q
M8L>$QO8ZM@\\#$I"C_QZ$JRA0"Q,&&_&D1V)<=P<FL`*=8W:'*&%!QJ#M=I_
MRX_1,T.$8COLRF='0-C6:]7MM*--Z:+L+RX^TTVV8CJRA:'$[6NQR0>JF=EE
M8=?MK<WR%IXO61J[*;Z7NE+N$*["+!8F0J9DR3/?^H0OG+359)J2$'+%"]$)
M2XK<B>_)3MZE9QIIYUA2#2M1Y\>3F8/A$$1(46`U^&JV6^JCO'N(8L7!U\",
MK`6W2/?.2K:Y`M4:T#DV"1R#6HT(?R94RDF5?PC$<GR0!7,FV\+`EW"Y.`V2
M]Q-0AP.]+?F_K`(F"3O\6`Y,NP&#)A6H2FR';,8_42[6L)',7:2HGPH5E%0/
MD+&?0(86M;JS=0)$30NGD81:N<?F`^F./S#8F=3K+\W,IA.0-F4B6LM<:<^=
M;?`&R&IU&(2XKE-(.CR@BT$VIE1L*VPP%\6>)"#+-D+TVR%B4NF/,/<?YFTP
M5`GQB4;Q[>GTGC5SGC#,*4B=$T0M.1=A!7I)S4.YJGGM2[M)8F8NCOT^-<GB
M2EW=[&579]"G[86FE97(+3(B1=?0:'7)NRN\<S99>MVFNG2)<2U*8&T)A?H\
M>\PEMS2%=$$Y"$);3JSU27)?!5:<PR*J)F`6'@LP"&:V,RMRHBEN8IH=&#M5
M;P\[2/>BP:J)'N9H8+Y;-1,-GXU::%-5&`T)KFU10A('Q[IV^B=!K\/#"_CM
M4/L/@__:``@!`@`!!0+/?OTK;6WX';/@8QG.7&EM9Z,I5CH9;]UQ*<(3LI*5
M:?\`;]S3"F,;8SG&7'EN[L,^\I6/2K3.6\.2,MY<C.+[);PYCVVNWLLJ4VEG
MW4^A4AUQU3BF6^RFF]+PEZ1AME2__#+KRW,NN-LHU(_Z[Q6F?3T2&,LK\1*E
M)UAYW&$.Y2MR1ZL9><SE2E*5E]Y6,O.JU[B\ZR^[G67W<YUE]W*5/.*QEQ:M
MXRF>Z$(1TY[=EJ]2D(4YG\.C\=?AME.4YW6PXVG3"F4]+*\-N.*PM>D(4XK.
M,IST)QZE)QZ4]&<=\.PUI5[;\76<Y5G=MS+:W%^XM*LH4\\IY6ZG%K3T/,>S
MTMN*:4I65JW:<RTI*&%^`\CW&D0L)QY)E_VD]#;2W<M0U^Y[3?9*$H\%2<+2
MMA/M.QULXZ5M+0GI:CN.XZ,XSCIA)QAKQ5H2YB8TVEM[+&4[J=<6G;&.^G&E
MM;84I/2[(4ZG9"%.*S">QJ.WEIKQI_\`U2A:]9QG'3VSV_#3CJW<].(Z\M;,
M_P!5++:5>06VES&$X3AQ*W7\8RK*T^A6R7UI:ZV\9<5E3J,^KOIA*5.^3].,
M8CQ\,X[9==G?+#(`4]$.8V?9;;;U-DL#(H,LQ8&OD<^GT8QE,;V77F$NZ99]
MK'EI3J8C,:6P59*P)E3-"'XIF&AE67WFL.M^C/JL1=^QE!8EFNBQT_YS2F6U
M9\RM"7$R&71DLH.C68572[]9*I]M>UZ/);U1Z_B(S.E+(2(,1,-GS<R*B6S$
MD.#I5W`8FQZ)8?6FS'4`Q]4!.'B!>=H1`]E/G2L#YE(II]N,)0ENX\D*_P#J
MK3?HK`\8ZI[X`%_=W)'YVK_M_P"`A?W=R1^=J_[?^`P0`=DQ9A`TD^)CLQ1W
MP&-]Q-_U8'Y/X#AAG#CK+3V,8[8_V-[?">W^U>/$SXO_V@`(`0,``04"92RA
MKH4I*$CBP\LWUJ=:3G&<*QT>M.5:>>:C-"#@TXUMZT^K\--3H3^=["7^AB9L
MR00E;19TV$JL9*K#:L\2RR=-X6EMYEJ0T'`#`2-K/8%5Z'$?S*C:L#95T35F
M3#`>XB1KC\TJ^)?68,X=R?/Q()B78E!):R,&K!!8*$)B6`K[\4T6]0YV77:L
M\9L4$:E1..$KXX,T"#E[!/S5_P`YO=#E@7,W_#52LK)^!UJ2E:>B3"BS-/5T
M+(D$`;$F`)J:8CS%>#QV(D&+!BQZN`BO1ZX%BZ0*'M*8K(*-INN!FH^,83AB
MM`HTN+7@T)Z.'&Q%;6Z%8/9GE)Y1?0RAQQX=%S"@D",,7&0M#J-UK0VAMQ#J
M,YPG$>3'F-;C;*(*S=6>#8YFF\*2C<\->+"A,)T</U/(0Q<:-)CS&>B7)3#B
M3)*ILOH:=<8=`\@C),+ZO6+HY'CLQ6-S`MLP/#C&PXZ=#8(1``")7HF\,,-@
M2MW%^VW7+-]?7MWQC8J)@F8D.''@1=SH=LU!F$[*-<ZZZ12)-$>17I<A./2G
MQL)2G<]65&IN,=L;ES,`'&.7X9@3];,^[,GS"#G@0ICP^4.L\])T#;!MB=Z8
M)T82E])JT"P+^,X5C=N0P\KHY'F2'CWBCR<X4]0#QB:5KT:T,SMX(,6-E;.N
MMLMB#HTXWJ3!AS,[YQWP#JD(%,V)DX@B%&Y'KKZ[:69-'/#[;\6H;S.F$AX_
M33K3[?0J0PEYQM#J`X(<#;Z7;2,8-H6AQ.K%ZOH,NP&)T#;MX??<65G!Y$F5
M(F/")L`)6Y$AB(P/FH(P]I58'RS768D1A,6/%"DF<PE-9M$Z5""^35*><>M5
MLDV!]#T<$">Y`-D"0FS343MJU8"Y<IHU9VXK<.X/05KY(8^=23<>9FV]%A!U
M^T3`FK&?P9>4M:NKOY!$B9*PZTY$7#DLF(,F]$AS1"QQ6:V`.2`A6:8A0AD"
M,F"PP>9<<(87G,,^8@QO,I5E.6UHDM19KHV03A-E8:ILS$/0)N:]%/DO>6PT
MF.W(>R\OS;#V65O-IDM`".6'+$,[:$CLD))@@D=&AL:F2/5GSL21[>9:VU.S
M,Y4$JV/_`$E5=RTF4E*/@$[[-5ORYC[E\!G?9JM^7,?<O@.+T[,SFV.5W7SV
M2?P*#]ZL_P#6%_;O*9\5,6.EY^-'DXQC&,?#.V_;X#WV[[=_]=]M=M=MNVNV
ML:[:[:[:[:[>:[Z[Z[Z[Z[ZQMWUWV[]'?S';;MKMKMKMKMKMKMKMKMYKOOWU
MWV[[=_BG_]H`"`$"`@8_`K;^,CPG@""^D?Q;0>(&5E;=P](+1$75X#VPJRE%
M]=/A14I.`=KU:_*ZM.:M@8:63KD*JV^*HPAS/IK+G*<5LIJ(O+0"(Q:,7LK=
M5R'.!>M'LU#FN`6NS*V8TT#&^V@!8Q:,-S+N:B!UP=M]2?,/-Q!*SK<7X#]K
M9B*R@V4USK0VAE7,"JF^E)M%9G=:D)JTT;;Z"FZLRVC@RDV4CC14W\.24#EK
MH!.+;=1=65M](>*AX$=?Q`]UQX#VH7BAY"BBX!!P96WTCK^*&[:#=G%0W5^7
M:VNUI3?Q,XHO-9A>*S'B!KC8.*+05XN9E]9G7\1<*$C0/L"W&L\Q\#+4!7BY
M65^:.A290E(VP?8Y3=1CC`%*Y.,'.%AXQ+;AQ;>+FQ/VR/M%!S0EM-[(=+B!
MKC8.%!?73X.B;^*&G#AR-OJQ#0:;_MVC!:Z()I#?Q5PI12OXW:B[A;RUG:$=
MX#E?=2-NIV0+;2"^LIO'"8A=]@(ELK(ZK6C\<E-0.O\`!$%*?U*Z-Y-2:W4Y
MG-C:MGF'/3VQ,,6J9;D+LRMV@H+L0G"US3:>!VMUJB%N&+B;FC>?(*>[31NC
MEC<`YI*V.5""@V%;*/OX4CC;33:12V9Z*HO)X.[495(I^FU#1:$+<"#39-.3
MD!S1.VMV'_"X>NAK]/U77M]QWM#FPW(:[([:R5E-B7[MJTW2Z($Z9KLD3?>/
MO<_D'/36EWYO6D(O<_8-PN&ZW;3FY<I&]:S$=+PHL?:TUF9=>T_CRT8[I[VG
MW'CT''=;3M/K`6Z<NRRM]TCVO[/E;S4)F(5%^[@/<^C_`%'#\TC9@SGO=N08
MFOYUK0D[V]!?99[W*[_#RT&1?IJC1Z:R>V;SX9V;NM@=AHLDZMSAZ:_G6B"S
M,;TT]IGO<K?\/)7\DU9Z0_2.[%G->W<HP%&1J?6261C?[W(WU#&CK=:KM&QR
MO)]M]^7TNW68U]'#U1UO5ZZ^IE_5-VX?Q\.[:+]<>45DU`L6P'93(V!&-U;@
M!N5U:5FR-WE(]50#3`"0Q$_VBMM=KJFD,;MQ/W#'_JG><UIOVCYZTO[7W%'_
M`*IWG-:;]H^>M+^U]Q-U<1U/U(E)M<S*MOP*G/4;]<9\S6D#(6C'',UU1:?3
MYNQ:U!FOYT3S?<0^<TSDJ/Y?N+M@T=IMI)6@I2"[^CW_`/_:``@!`P(&/P)K
M-.&B$"S+<FY.*7O(#`+33I.[Y6R,8[*4V^HX&XX?8(YS0>6E;=Q<H(S<#IYW
M!D+`I)N`ITW=[\P:4(N(V*-^']?#D49]E*;J8(9HGF1I+4<TY@+RU#:!B1Q)
M>\<N=S4`&]Q0+NVT_6ZHYM1(Y2?QY.'/HY9(G?"XCS5%-WR_/K'C-<`0T]4%
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M>DG25IN3`BI&.E,NG=W?)/&YT`BM;<6A2K"OM5ICWJZ+4:+6Z*63L^S3+V;,
MR+;FS8J$ML%.[YTSH2R=N=L09U'OD:T'-F+G-8"B.N*!:UNHG#\L4;'1R21-
M8<Q<`]N5I<TC8:EU&HD;-W@(7O&5N4+E5K0+50V+>:A[_<P2]XACI3)F.=TE
MN9JK;BW+Y%J*>=KG:#412%_Y;6LCZ)+.S<'%S@>J<U=S_P"AG_\`8>)+W-WC
MD9I0Y0UC;'B]KE*N\J+8EG$6@)"!WE&$D;M^,;CY#9L7CY7@%O%C^I9F[*42
M-W/;<[F6G:N:!IG<X.-KNL+G(J9OB1<#6KTND2&?5]9UZG>"=EEE2OU?8?2R
MP=F88VN$9M7.[.YQ+\!L&^I--'#^3*W*X%SG*W`=)Q0#!$2FZ'2MRZ5H0"TW
MVGK*3?C1U$&F8)"'#$A'!'(TG*%%A0"RRB8(`"8W,O<>@Z]MKC9L&&"5`]D0
M#M,PLCOZ+2$(WV;5J00Z9@;*W*X6D9250`E&A0"C4M`-2:1L/Y$H`<"YY4-*
M@*7$@`X!*RBZOKH-,QNI5<4!VAJY0>05V^EA#'VXN09K\K5RM7X0*B?IX@UT
M+"QE_1:XJ1?B>'^8=PZB4.8.G$,1[S-^UN.%M[9.\)72O:$!.SBMCA7MG.`"
M;3=46D<XO='&`2;5*6GG-?5ZYX9`"`N\^?U4)(R'1N"@BXCB&20@1M"DFX`8
MT)8R'1N"@BXBLSK`*$^E>V2$XM*CR<270:*3-/'XG;2PX@?Q"BW@@/<4XB:U
MXS"XW]9?::,68_%8`&O.9X%IN4[4XDN@@E,4KQ?_`,KL<KKBGEN,>CFF?/(P
M==UY_@,%4ICP'6:YX9`W'T`7D[A3=3I7M?`ZXBT<675OZD4;GGD:%J35N#6N
MD>7(VP!3AQ6SPDME8X$'81:#7^\O$&M8+;"C_B;E!MVM\5EQ[D1[T&<%,O53
MJGK+;LN6FZ;3M#(&!`!@.(_N^5SV,?BT_A1M!O\`+4?=T;G/;&+W>/F&P85)
MHM2O82-0H4/C'XVV4=+IB7%SLSG&\[/$/7Q)M9I(FLU$YZ1]6Q3:4O-O$,B$
MH%06D\@VU.SZ>6'L7);=R'8_:W#;PVX\!T>O;FCPVM.UIP/X-E,T>E;E@C"`
M?C';Q#IB2S4"V-XO:[U'VAB-Z5-W3K-1/BQ[7.+@A%O66QP-A&!4?8:?7/*1
M,?TOE=T7>0TW0?\`ST2/D>&B22]24&5GI<3\M!I*G;M^WZ(`4\.GU;=3+"(3
M:&^-6>Z_#-;9R6IQ!JN\'98RY`EI)Y*>[N2=>\2@;T7#+M=TFH4'EHS_`%>H
M$KKR)'CS&A-K9'2R@(KK2G+]BS6:=.WC*A0MNU-U]0=Z=ZS2RLC?;;@06G*V
MQHL."5)!HFRMDC:O3#0HNL1SKN:_C3:+1R!\\%^_>WW@#83MYN-%I]:7]I)[
MH7*WWCN7`*=U9A<>(YL+VN<QR.0KE.P[#Q?I)/\`+PQC*/F"N/HYOMCJ.[Y#
M%,6Y20EQ0I;R"I='JI7S1NB+^F2[(6D"S<<R$!,*U3N_)6OTA=T`-NUF+6`6
M93CSD\,NMT<09/-UO4WW03:0,>;A,TI#8FA23<`*=)W>]<CD(-AW%-CKP?2H
MX&.U4;'NC=F:HN(Q'$2I]9`][W2W9O9;>1\5OM&U+-I/`[7ZTD0,2ZTVE`@K
M)+VT(VN;9_<+CY*EU>F_RX1C3[P;[7/AN3'[?52D_FB)H'(76^9M#ZZ:*+-=
MF<&KXZ$T#FOB-Q!4'G'%;IG/:-0\$AJVD"]!NHQ2`.C<$(-Q%/B[O8F=RDFT
M[@NQMS?222>*>Y)SDD#%SFQBWY5Y+5NPOK/&06[N#6%A1PTTA7D:30[NUDSI
M-*'!W2M*@$=;K&_$^`G5=WNR3EA:J+8>7F/**.HU;W23NO+BIK1?7RMB!@9?
M>2X*@%YOP%.U.I<&0,"DG"H]=$"(I`H6],/&+>&/OR4R?4QI9F*$CJG<FP(#
MCBO'E[Z,+7S1L`)09BS,%"\ZI=3>\-(R/+(%#V=!W_$W*Y1LP-!L&JF8MP);
M(O\`Y`Y_B=6JCGFTKR^%S4MC?T^C8,S\QMV-YO!&SSN<][4O.#;AR;-E=E&K
M.ZVGHLV_$_?NN;RVF-^K.6#3Z=@/,T!.4FRF1]VAD$%V4@/7>XHMV#4YZ9H^
M^3&Z&:QDC6Y4?@UP4CI>R=MAOLX-9I=7#&S30.2QUK2J9,0^XE0B<X'`V'NL
MLE[PD<X#W69'%KW.Q0."#WC=3H^_S&8NS<YCV#*26IT,JFTKT4Y]HTSPPC0.
M8[M6V%S3F1I";$NQ#KNK0GTVGD,!;F#W.C:TMO7KEW]RM9`SLH)&QGH$ESGM
MVLL8/.1LHZ?-(=`ZW*TM!S;07,>F]$7;4;M.)F0QMN?*Z3IF\A2@P`0"@'$D
M#P8:22:0P+U2XEMFY4H2Q$V&^DDZUSAL.T><5!H)F9M1$>F__NM'4Y,W_4Y#
MM-.[]TQ5CH^A\YL`/([K<AINO!)83^8/?:;^?$;Z_FSG9M-D!:GMYNJ&[W4_
M5:I/J'J]YV8I^,:U/::5L\DL>2/.>C&U5)R^\;"H<""`E"1V6Y+&AJ)N'GO-
MY)-/T>FG>-(]A:6WA'6%%ZO*U/"LPOJWGIE@[-MA2]P)6W:1AXJ$D-L@"M.W
M=S^>OY6YQ^D$N?+L>F5>!GU;WNT43B8F$V`F]WJWDD5]#!U`>EO.SF\_)2NO
MQI?9\,S84K;\*^@GZA/1W'9S^?EKZ^$6>WZ_764_H-M=ZN>NP@LG<$'PC;ZO
MX5VS[\*[)O5\.R/ZE+'?1<[K&$>BI3\0I_:VM#O)66(VG[A=^T/14GS#S5+\
MWW$[]H>BI/F'FJ7YON+^5&)H:[H+R<]=BR,/[2WT;17UY&4RVI]Q-_=/IJ+Y
M3YZA^3[B^H:QO;G'&@W4,#@-M(+&C^CW_]H`"`$!`08_`GNNF]MMK".PRR1E
M8-Q3J9.)OYA,*?'7G]62*8$1B9F9G2(B.<S,SX1'!G5<+A6<K/IUY%'V3I/2
M7HGPG]!UKKO8,^!`IA#R\>8C,<2)B0%'*1*)$H^^)YQ]46$LX6?(62!0!?XI
M::3X?036D(+`9(S*=!$8\9F>"949U]$])C,2)AKKT]0SST/3E],-[9]J9TAG
M07;F?5!Z=.O+B(B)F9G2(CG,S/A$1Z9GBT=O%9*J%%RZUTK%&RD:=AP]Q*+4
ML4,5W-#F(EI)1]3'8&;/E%69<Q[X'K,:]9)V'0D?=[Q@O0=>43.OV<4\3C4]
MBC00**Z]9*8$><D93S-C"F2*?&2G7Z95E<90R*Y&1Z;M1%GE/]F6@4C/W>$\
M9*KM2KY;%4S\K/2]UA3[BI*+CD2\V$%?O>P,1,C,#K'*=/HK?"[`J@6QW1UZ
M"\>1D4ZP:0CQ#T_;P,&744#$$6G3U%IS+I]&L\&I@P:S&1,"C42&?&)CA@U%
MR/=+J,B+K.><](=4_@7KR_X_I!T5CL=;('^RL(Y:]P]"Z9+\/V\*;*S5W`$^
MVS2&!U1KTE$3.D_0\<><!9D?9G\4C^(5EX`PH\)_Y>%#D2ZG?AB>;05I'0#B
M_$R/[N?&\<<K*6@HX?Y?[HRN,K04=NED%,JN7:1'3[+!:\R]6I3Q%O=5(HSN
M<P>3S5?,V=RR68O330XJMRO@4U.P&/[=:`_.+4A&9CT<?+K'GCLB>4WH&.*W
MD$WF=%)0Y7M7&)I]ML-;:K%(S,Z`F`@])]KC;FW55J>/R-[*9IN0^%;G+.M'
M"8BL^Q4'6.]639RT!SC]X$!U:>(QM$Z*<;:O6[>6IVL32S%K+4*O14-]#)R=
M^BIK2[8,6:B]GJF"C332<96#'1B\';W!0KEC6VYO#`0Y*FH.RU:)-=ZP,\NF
M.@6=,>&O&>VF^;CL8S.*QB]OI37%:JJ,LE6)52DD$%,V_E"#AT[G7SU$M.*+
M5XY.-O5M\8C;64I4MQMSOY%TB&RB\Z:U==;(I)4Q/9Y1S\)Y1N:CB*%O'7-N
M;JQ&`9>NY#SR,DK,7RHLEM0U`NJFJ1>SH1$0C'5.LSP&P,1A<EB%8_+6@R&6
M9E#LORR*>-N7&K\NVM"ZUBR=6.U(:QV>J>GEQM*C3;3AF2OY2IE\5BLS>R:`
MK*HNLT+:[=JO5M*;UATL'G$S'+3C&TJ-)^*P9Y7'8ZR-J[-MY)\Z%:W=:^14
M*B>KVY"/9"?">,OLH+1X[`NM5<*C$C51\-J8B65@JV@3V>E(],BWNC(E&NFL
M1RXR=.G9K5LWA,IB$XY8Y>U=R.7$K:*^1C*474TU:3E@??#L%TS'+[_FG_ME
MMC_P>O\`4QN[,$-JWD6H-;+5^UW+%"R0=J]2\N@:]4.B2F(F5R4A,3$Z3]28
MGG$QI/W3PTD*,]OY!AMQ=F((A3$SU%C[!?A?6UT'6?S`T+QZHCZ^A1!1/HF-
M8_9/U;WP^T5;XGCK.)O=(K+S&.N='F:I=8%TBWMQK,:%R\>$8VKF7*IUD.JI
M7V:AF%2P)BVIYAE<K)5)[DZ*DY`9TF(B8CC;&1R<'E:>UR&*-&3&MVJ\$;(6
MMJUZZ@XNN.KJUF-)Y<8Q.,/,_$L;F&9A.XLQ:HLS%?J0=<<;4+'TJBUX_0^L
MHG7K/T:<N*&0L94O-XRP5NDVO5HTNS:9T0U\A3K(6YK87'7)P75'CXSP_,9&
MS+\C9-;&V16JO,FI8*5(A66E2N@%#$=(QX<+I7-PW6H4RJZ.2%.-E)P6*AOM
M)2NU9*O87!CW#+0XU\>%C<S#&BJ]5R8`-:BD(R-+7L79!%98E9U+VCGFS\?5
MQEU.R+37GK:;^7'I3'G+==I/2XIA<2L@:<S['3'&/*UG[AGB["[5-HPA+ALJ
M6:5V'.0E;;;A2T@ZG2<])3'A,\4,DS+3%W&->^DY-+'5H4^RJ$V'RJO44ESG
M+C0B,2*>",IU(RDBF?213K,_KGB</<S]Q]"5BHP.$=]J@D9%3KL)B\Y<2/ND
MR8XBGD<N=I.M>3(ZU(;+YJF+*_FKH5AN6^T81,=TSYQQD4W\DVPO+VZ]_(B2
MT#YJW55":[CZ%#(RI4:1`Z1](X/>F#QCEVF_P&<>$C-=K)_T;(%!B/EC+W&S
M^[GD7L<P<C"8Y&-389#7*K]<`;1'HADB1%'5T\M?3]6P^W(152AKK),B)6*%
M!)M(XGE(P$3KQD\H"%U5WKUBRJLI8*772QA2E(@OV([2M(XE]ED*7$B.L^F2
MG2(B(YS/_!P)@4$)1!"0SJ)#/.)B8Y3$Q]0C.8$1B2(BG2!&(UF9F>41$<"8
M%!`400D,ZP0SSB8GTQ,<:SRB.<S/A$<0U#0<N?`UE!C.GCS'6.7U'5:[>IB?
MLT%L1R(DE^,1G^[3Z*WPRU"8!HRT?<+QY,D^<,6$>(>G[>!@BZBB(@BTZ>J=
M.9:1RC6?J/JJ=*#9'(X\)T_S;-/:[9^$Z?\`HX378]EDUCI+F>]/V>F>D?1K
MK.GT%8LLA2A],ZSK,^`B,:D13ZHX%J6"U9QJ)A.HS_R?5QV+3,"[)7JE!13$
MS`LN/77"9@?:F()G%#&*:]Z\?414!UEA->T4+%<&TRYR1=/W1Z.7U;%.TH'U
M;:&UK*&1JMR'@2G*./2#%E,3Q_\`BE0\QB;IF5<(<E=C'3S+RML[+E`2ACW&
MZ\_Q:3XKR>XZU.*AW4UNS7M]^Y6<P'&#3E*Y0"Y[4CK#)YE$>G@$J"%K6,"`
M#X",?4;5,V+%D>\LM)B8YQK'@8Z^,3X\)J`9LA43[9SSF9F2GE^$=9Y1Z.&U
MG:]MPR!])2,Z?9,<2E,D<F<F;#]XI\!Y1RB!'ZEBPA(K;9G5I1_>&/`(*><Z
M>,_4(M"+I&2Z1CJ*=(UT&/24\61\HZOY<^G4^8SSTZ2G2.A\>D?1],?;RC[9
MTUY?JCZ)KV@Z@GF,QR-9>@UE^$HX770/0I0](C_PSZYF?'ZB;XI"[19(JRF-
M<(&B]3F?:"19!`-A>NJCT]DO\&2B<5N;%8+"E!%6R./O4Z**;EOK-ABY9-45
M%YBK87H0'KTD/3/A^@SN&2`LM6J1%2`I$.J]6(;5,>X<B"^NPD1UF8B->+.:
MWSD>XFC4?>=B\49"L4UDD]GFL@8"PM%C.HJ$=)CDR>&&"X6)$10L.J16)%R"
M)*2+I'73G.OZ?E$1K.LZ1IK,^,_?/TU'Q<?7\N7,`GT1,EUIYQVW^CJY\ONX
MT_O^/U#QV#KB]ZJYV7$U@I0E0R(ZL:7LQ)F40,>,S^OBDO=V'E6!4+K%HPO5
M6KM=L)A-6#HVR>ONO*-?=GHB>%4YVU@3JI'H4AF)H-6,:Q/@Q!<Y*-9GQF>?
M!U<11KXZLQLO*O5#M([Q``$P51[`$0KC72(UT_0V\3>[LT[RNQ9%+22;$R42
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ME<3CJ.'N5LBN@`TJRD!>"VE[9"S"X`G-3Y;J$IF9@>J/3RNSDG@Q$G^2,:3$
ME.D]2?Q*5`\NF?3^V?I?8KI%;;$^W,>$>L5QX+$BYS$>GZ2890``,D1%.@B,
M<YF9]$1'!E59U=LY$Q*.DXYSTGTSSZ&1&L3_`,/T+EZ5ME)PQ4F.L@<>!#]3
M3U^J9B?VQSCBS84QC)?R&&3^Z7[TAKK^9,GZ9YZ?KF?HK87$K!EVUW9#NG"E
M`"5&YK&LG6``0#]<\HYSP+:WPG*ETZFBE>E;@+TC_K!%%1_J+C'XR^4^>83K
M]Q6HR-5UN8/R@R'*>P$1!3J6K.K2=-/T=G+9O(5<7C:@]=BY<:*4KUF!$>HO
M>8PY@1&-2,ITB)GC;FR]BTI3A+&1)F5SF11$VKV.QU=U^XJI29J%"M:55E?<
M;JZ8.-!6?%$UT:BBQBVIQW:0M?D5/`5N55@!B$+8`1$P.D<OHVU7$"\LW)7'
M-9RZ!>BJ`5P+T]1KLMT_Q9X=\'Q&1RGEQZG>1IOL]N/1U=H"T*?1'C/#*MRN
M^I93/2VO94Q#U%I$Z,4T18$Z3Z8^J*98$-9!$"Y*.LQ#WI$?&8'7@@,8("B1
M(2C6"&>4Q,>F)CA@50Z>Z<F9%/4<\YZ0ZO'H7$Z#_P`?UIQK9E9PN"[Q^RKK
MGVH7,SX>Q.NOAZ..H9@HGPD9UB?UQ]&U!:L7+;N#$H-9Q!`8V+R43!B42)#^
M9SCT\-SV*Q%?'Y%U9M1DU>M5:5.8IIR%,2\JEDDJ.8",Z<1D:F*9GLI;R%+%
MXC"*L^39DKUQFLJBU->W"8124YY3VR]E4_?QA,G>MW5*SFWJ^YDC6Q64R?EL
M2SLC8M7F8ZG9"FC'L=`N-O0(3X\1MZAC[:K(;]PNSRMY3'9M6.MHR)5A?8J7
M*^,973?(K'\,IY`+0CN]7;F)XLRFUE"%%?&V4%_+^<B,HK-72QV&^#1-#KRI
M9>X!#7A,%W>DICV1*818L7\B(NK7K;`#`9QSZ",5D2Q.7/*UTX\W8J,5?"0L
M>8A<!I]L:Y/#XT[EJQB")5ZT&-R$8I=@`J-.H&7*M&-=;%5Y9=L624C,S&O0
M?3]69F8B(C69GE$1'C,SZN+VT^[8PNY)7<71QVYL3;I#DP7!@-[&A8FO7SE"
M=.J00[N=O7J@.,?NY5R;F4_EW(T,VTU"D<AGLCD*]QN:K5UQV:*R43T0@-`6
MGMC'@4S]`8W-UO-4UVT787#&*GO5^KI_,5(L@369`6DQ/24\*HXVG7HTTQHJ
MM54"5#ZYZ`B(ZBGG,^,SX\;N^"X^SD95FLD+&)#\A**;F5Q8^R4Q70N5U_9Z
MBC7T<^*^/Q]=MN[;:*:]=(]3&L+T1Z(B(YS,\ACG/+B[A[+%LLX]OE[))GJ5
M%@0'OK`OQ0ILR.OIT^E.2.6]Y6GLPR8`B#]V7K'I]4:1/[=?KT<2!JJVLD-B
MLNX:X+I)=6Q80MD^]V3>N(G[^+>.R>/\ED:;238$8[+H*/"8>B1EBS&>H2B9
M@AG6.7!E7L78!403/"TL(F>D9:;UM:(S,Z>_'&W&.NX*/+96K='XI>/!UNJ@
M?G1A]SHR4KZR1IK"2UF=.GA6//:6Z([K(7\8H8\LCMJ-2@8.,Q,4S(.>LSV(
MB!Y\;*/<IW7].8N8_#8BMU=B]E\ECFE%NUV>BR$8K'4K!P<&`C!EU:\HXR.%
M5D\N./N;>W#MBNJ3JG.-Q.X,Q.9)%5AUY,_(.GH3W.O1?*=>&Y)6XLF%<MT[
M7WDO$'7H34C.;7K5JB&3:&N.0[%U%,!8,'H/.8YZ:9?&;WMXVI@*N/PN3?;J
MAB,Q;^+[7=8NLR!]W:5$+FW?*R4>2R(Y)I=QFIZE,DZG=W+%&I?^66:@VT,/
MCL17_E/,9FG<LYU&.P^%JT$-5:O)6(BJ"*"U,2/J+B-^GN?(]>6HWL%5K?RX
M^CYE>-7C[EQEU&.V]5RV6/&5E+[;[?<A*S+0I]&$QYY^KYC<8T2PA`NTVI?^
M)Z_#@7D5(/'K=?Z?R0-HFST1Q\0QQ'*8MWZ#0:';?7NXRZ_'W:SU:SVVIM5B
MC[8Y^$_4Z$GM=]*T^:>6P6Z<A\&3N2A82T&8G&YKS*1QN59[R3D2CK&/=C7B
MQLRVS(9/!8TI8INX&QC?F?\`*;-J2YN))C3YYNFQBOX&Z@Y(AY')!$\8M&>L
M5KF:31KJR=NF)!6MW%K@'65`8+((><=6FD:3/U7TZ5=%)5CS!'%=(+&76NJ7
M6#$.CN-89:E,\RGQG@;+X5<W%95I<R&FH5Q/22I4.KF"!F/:/2#;/.=(T&-P
M945NL>9R&6RDC745ADJ.Q8ML,03$ZB"N<S'LP,:\HX<NOB;=G?>1W)6P5-M]
MUQ&&Q*+5:[=5D1;3D$W>BI09UH.>[+=-(Z.<T_B%M.3QN0+L*R::A4O+7_$:
MEI'?LA`V!_='!<YB8F(^EJ\UA+.+K,6%BDVRAR(<IRU.3-=C![=Y;$.$^L.4
M04>N/HH[>KU.WE\A6K7QBU!=FIBK5=5H<G9Z/:['8>.D>,G/3[W+BNK,W:MZ
MI>K6GTKM9!56DZG*(L56U"<^.K^)#H*#Y^GC-Y)`9:-P)R()Q5>GA\SEE%Y2
MOW;-2XS$T+M>I%WS0=!NE?281^"9X.E.*NA;6^:QHL=I!C8$^T235+"L@T6<
MM)#77C:5MPX<$.R"8C)H"[G*5"R8,@49!`E@G1/5,1$]8K.9T@]>7"K][=;*
M^:2`(%U/"X^MCV5HF2)+$:OR1%!3JLBMET<XTG7ED%YWM;DLWK'.;17&49H`
M$0NNW'6;+:K9)A&1P0D/.(]',QPN%Q.(AO[R,7CJ="&>'OQ52KK]V/'U?1\M
M,HH736JYO.XQ[5*)WD+.>VOE*6-R#!`)(5KMA"9/41'O\^,E;;C`NYQM'"XV
MP'QG%U\7G7*R9SDLXQM/#*ONR`5;+6]Z]W++N2IG\4;ES2=J'D]S]G?/PQM@
M#Q4*AV[R=71NK*W,3YI=VY3(`H%+'E%-1+Z8'G&_L0.'9CYA6:V[A+%MTC&:
M[N&%7Q`5G73-2I\2LF@9U9!PKKB=)CAU;&OM6WV_E"_:;QS.Y<ADU(W$S*;;
MN>5Q\9!]D:&+[6,;I">A4:#&G&U(:66VO.*C>R;-W^;V[@R]7XWA:]3&V$Y2
MPF'.45N)@T_A"/'GQ\M,9D-J8B-K;+JX*V['8[/*K#_-.,'RJ<G)-18LOQN&
M7J]%>"@W-+5ISIIQN;(-6U5?.[]W?F,<MP$L_ASLH=5#NT7M`%PJ9/'E&HMU
M].L_3.8QYXI%/;.Z,A\OK.,W(W6KN*;F>P%&\A#J-3)7-MWKF6QWDEME7<.J
MXBZE"?5PI.9N*R&8<RU9OV*XF-1)6KEFVK%XV'?G!A\.%GR]42TT4'A&NGZ#
M;&'VE6PF$W%O&YDZA;F=B:=E^-QF-I?$<CY=)`(V[UG0(6#>I7*9*.6L)^7>
MXKU!>&W#D2R6R=YX[!X[;[=N_,$#:^HC*T\,FKC&!DH80)9`!)CU)](R.7VU
MN>E%7,8]AXC<F,\"JW@CK3=IR6L^6M#`V*K8UB8TTF=.-T;<W#D8'/XFJH<6
MN5_Z;B+K.S_,JA.9&P:%:KD(U[-B8DIUZ.*^S,@DEMKY"1R<QK$1CZW\0^PL
MIT_+LU(U47XNL?7Q9PA*2IRU=>(?T1_`7$C_``\KTC4$E$=LXCQ7,_9Q;KWD
M-7;IV#ILI],S8FZ#)1Y0%QK).)T=,1'&2W9NIZUY:]778R3"*21AL713T8_!
MT_'2KC*P]/L\VMU*>J9CC`7+;1#<6\^]_+VTK=0C';VQU2)ENC.."Q$T6VCB
M#Z.B389`L"U$AC:OR_9D:6<VWN?XV-%@XQ6)R6*R^.QSLR]A]AS@OT+E>N8^
MW^:!]'M3'C4RM_#5&9.E:KW$WEC->R3JK`8GS+$2N;BXE<>RWK'3^@9+<GDC
MR$T/+]-,/-?G=VPI1];:E.\RNM:B(Y.5R,=//A'S!PE3"9C*0\+`YC%WF,05
MU4?EV+E.I:B@S)HU]]Z9>LO5,?H?(Q8+'9:C87E-O9A7[[$9JIU34MC_`&TE
MU2#@\#44QZN,QMG=5'R><QQ_!]U8F)Z78[)A'<K9&@?.8K6>D;5)\:Q,>$ST
MSPFUE&9"[\QL*=/#W:M>M9M#\QMBQ7<=;.4DUTLA.7PB*1'9(YT@P/4O;$>,
M+O39]E19S$1\2PKNJ8K96D\(FYA+L:A,U,HB.B8G0E,TGV9CBEO_`!56%Y&Y
MC9Q%ON\KU"46(9<P]X/PV:5P-)Y<XTGW>G@F,(0`!DS,Y@1`1C4B(IY"(QQ9
MWO6H5U8/%$5#;K@3VSW!<KD2;.Z+7AW0C3M4Y*->V/7RG3BM&<IY6YLS"6WQ
MVZ./LV:N]-]8\4/Q>R1LJ`TB(FZ&F)Z@TPZ9C2->,WOG>]JN&XLNOXEN"WU:
MU,)CJP25+;V.][IH8E/L^SU$]VI:E,CP7S-W)7;6M7:S*FR\+8CVMO[:?TEY
MUZ_=7F]P#$,=XRM/2O7QB/Z!BT;>LY]U;'+&UG:6R<A7C<5`[65Q44<CE,6M
MD9.WABP];)0H%Z`VSTP?+F+<ED,)4P.4SV4RN5M4DT*5&VNH_(VO@:<MY$1"
MQE*V"BN#B+4^N)B9U_15_F+M2L5C/X6OY?.XA'CNO;`EW+%&!CWLOC>;J9^]
M,Q*_:ZACC![RV5>2&>Q?^N=J92?W3I(9"WA<E&L%Y')!$U[*YTE9QKXCIQ7R
M6/KGCMI;JR5FF[$MCI/8/S`">K+[4M#H,(HY%W4ZG.@QZ(&(GB<[K,;/W-8K
M5=W(B)[>)R)%%>ANE8Q[@3)PJ[I[P=)^T4<#\L\,YB5V*R;V^,BF2`JF"L27
M8P2&CIT7<_T3U\_9J]7*>OBCL[;C$8V];I,8[(3$!1VEM?'A$9/<%R>I8(31
MK1TH@B&#=I&O+C%9Q%1M39>V4LI_+C$68F&VH9K&0WWEA(1)V5SK.HJ_5$=I
M)=41J4%P2SCK^7.T,C'G)GFC>6Z*9"8T1CW;&`P#8@G3/L/LZ#H0CK'%2ONO
M<F-P;[RF.J*NL(3>I10!L$0`YZ(,M.?%++8NTJ[CLC65<I6T3U)LUGA#%.7/
M*>DPGA]RY834J55,L6;5EH(KUT)&3:][FD*U*4`S)$4Q$1Q.&V[O#"9;*0+"
M&C6MQWW"D>MI519`><%:_:GM=>@Q,^$?1GMPW\Y3/&;8L#2SS,<?Q5V+O'8K
MU1HW*N-\U91<[]M<2LA@@ZM2T'GQ7MUS[E>TE5A#.DAZTO`6*/I.!,>H"\)B
M)XR.:RMB*F,Q-*SD<A:E;6Q7ITTG8LN[2`:]G;4$ST@)%/HB9XQ^7QKO,X[*
MT:F2H6.AJO,4KR%V:KNT\%N7W4-B>DQ$HUYQ$_1CK.<M'53ELUCMOTB"O8L]
MS*95A*II(:ZV$L#()U.=!'T_6W74V]9^8F*Q&X[<;-WA:J_+ZIN/;N2L8\6[
M=NSC,M-L;F&FNGKKML,4:(+V])Y<(JJZNU62I"^LI,NA(0L.HIYD72/C^CM9
MH`9'RYW3;*QE82EC5;,W*V/;R';0!FG`YZ1_,Y="+7/V1/2?FED\(KXCM)OR
MUOQG<@H6AB<AO3$L\WM^U2=(@%K)8BA79U.3,P.H1,\6GN,FN=M>BUK#GJ-C
M&5ZIF9E/.2,IUGCYF%X=I^T:OW]&UJ5KK_7YW33_``>-^YEM6W<1_P#MC#XO
M>#*D.?<9L#$4<%:=0%:>JQ\.K6<A+'`F(DE]4ERCBGLGY<9);1R"H^/[CQ8S
M-/:>W!&!=V70$)#-WP_(J)CVUSJ<]$#U<8_!X>J%/&8RLNI4KAX`M?XB+WF.
M:<R1G/M&<R4\Y^CY?)VT6W1RG\D;G(9W10NY+%=F+:N]UUJ%RC8EVGN3UZ1Q
MN#"_,7YCW=A)VKMS8S=KT=N9MFU\+N.]>J=_<%^KC'-L,S%=685-55-OF#['
M+QCJXW\G-[5IXK%TK6$>LL%G&YF]EL`C/I/*R]"ZN/.B"Z"@:SF4=OKUTB)G
MCY#X[Y;7\)E\QB]\8?)@.W#JM+![(H5R9G*MT*8%.)KG7A<>7;VI]C3I]6U[
M]?YG[DR.]H^=<[5/9#<\=FD[9]G,W9L>=P'[ZXJ`L:#<;)=E?2L)'MAT?/SX
M7\RM_8O=^U-V7+6-QJ-[9&F_,8WS^)QYYO+I5*GYBW,V9%ECJ@O<UX^:MI>_
M=Z8<-E?+78NZ\74PV;?2KNS%C;(6GG<T@FG6L,2<M4!`#C;U'U2(Z9K7?&[<
MO.Z__P":-P_,%_Q/*D08?=8U#L+O;<55765@TU^J84M$#T>.LS`Z?(O'L^:F
MX=L9:UL;9.Y-\6KN^SPN"9BUXNK9BM-)]RJO*[JW5?L3!R1,/LQUD!#X6[3-
MWX_"9K'_`#;+#V<+F?F58QZ)P"\HO&AM6G\M&8CR-^;]4_R+H/E[73K!04<M
MNY//[^S%G>[?GU1I9'Y>6,R+,;A,;CL^=>IY7;DCK1"B`!`VQ@(;+B`I,O#Z
MM%N.Q&Z=O8W/Y^OENM?S1>VCE/C.8W$A%O([/N8RQKY]VUK`M2IO6B)`"((+
M4?TF_P`%@*P'8^ZX$`&!$8^`W^4#&D1QD/\`9NK_`-36X^:/_>6U?]R\)Q\P
M/_,G*_[N[6XD4J6D2*3D5`*XDITB2F!B(DIB/I/=.Z+-+&4\?T5OBMFN36H\
M\Y:!0F4I=;T>THU$(^V>4<8C/A4QF6`Z]?)83*-IHL,"O;2-BM:HO>J7(AR6
MP42/3.D\>?SN3HXFB3TU?-9&PJM7E]D^VA'<<0A+''.D1Z>-UU!QRL3=V]@$
M[IW`>*V^*(9CK5@*ZS\S60H+MDW3'L]4S^R=$6L0OXBR_9R.=J9C)5*7Q9*M
MR-^(-JILKK*<BKH[W-?OXMW&X;$MMWTA7O6F8ZF=B[762S6BV\DRRPD"4,P)
MS,1(QZN-O[5OU$QE]_)R]>@L<:MJ<@C;&.&[<1D'0'3V:])VBQ9K$ZZ1QJ>/
MI'/DRQVI54%/P\_?H<P_T,O2KW)]7"C?A,0XT*4E)MQM-A)2B-$J41IF5J3'
MNC'(?1P.79B,8S*@,"&3.A5+(`,::"-V539$8Z8_%Z.'W9P^+\Y:-#+-OX?4
M\S8.L4'6-[^UW7'7,8D)*9Z9CE];8X9K9"*F2VMD,\S/[V:O:DX_)8^\C+SV
M\"FDN<I5G(Y*ZEX](5S5`E#>N3.?TOS!_P!B-U_^`W^,A_LY5_ZJMQ\T?^\M
MJ_[EX3CY@?\`F3E?]W=K?4V'L/';7L;TKX95[Y@[GV_6O8K&RZLD'8+;W<N9
MBW3HB(9*XUAKDI,H$>F/3&P?EX_(YS:NX-L?/O;_`,M<S-#(+1F5;>S5;.^4
MUMTC?2;TT[?;28=:NNJ#`UT$N/F9AKF=W-DL3L#YM8*MBF9/,WL@^GC,HBO%
MH;EEDDQZ4M*)3U_NVGK'M%S^<F*V[NG<&XMH.^3='-8LLON#)9M)NMYK%B=I
M,WVSI/O#$],3$3/&X4_*_=>Y=VC5^1;\QF:^1O7LV&$WO7L*4GL5;J>UC<M6
MK=?31`(]SHE?LZ#MUGRMWKN'?%[(?*C=^9WM2R>>R&XDU-Q4\#YO;UQR+AVU
MXS,7-RGV"1H&B_1[7M?('R6^=R[FS>7V[O\`/>L7L]D;SL!GLML>U%J:+&SK
MAKS70X.E1Q/132S2)]H]O;+S>1RO7\EL?NJKNRUYFV*=R9:SDFX+;0Y"9<<W
M0#"KFR$F1B9#)<_1]<XVG:QU7-KM8]Z/BPG..M5T7D-O4+3$U[3ZZ[U(35W%
MK)@=6HZ3SC&[5WCNWY55\J60=7O89+,C9W(^&W;'DZR'U;%+#5K3Z?;E`&J7
M$!!UA#)G]+\P?]B-U_\`@-_BW6M'MOX=.'0LX12R87>Q"T]/2UF28B':1'/H
MT^SCYCCA"P@J.YM@G_%:MZPSN1L["0/:FI>JB(=/KB>-Z.O^6FXSYAY0K$TP
M:NMW/Y>VO^Y!S'-$-/64_4EO;#ND,`3.F.Y(1.L#)Z=4C$SX<2R:Z.Y+`=)]
MI?7+5Q(K;)=.O<`9TB?&(X>IU6NU5J-+2V(6868TZ='@0R+HZ8T]K7CMA2J"
M'9&OT#73`^7#3H1TP&G9#3D/A'#V(KH2RTSO634I:SL-T@>Z\@&):SIC34M9
MTX=-2I6JS8;+K$UT*1+W3XM=VQ'NMG^U.L\=2*=5!2YEB9374N9>Z.EK]0"/
MSFC.A%XSQN[-U+&1NY/>F8#+Y:SDFUVDOL)\O1QM+R]2KV\9C43(I$^XR(GF
M9?H<DA>YZ-39^6W=6WIDL?&"'X^=ZO>J94J@;@F^()J3D*0F+.QWE+_+B=./
M/X7)X_+TI8Q,7,9<KWJLM272U</K,8J3`O&-?TGS`B(F9G9.ZXB(YS,S@K^D
M1'KXM:3[V'KZ?;U`B!T]?5,\?,?_`+7M>?U?R?A8U_;'&]/_`#$RO]6`VQ$_
MLF/Z)4WH.=QN'QXU,=BKKLOF=QU*M5U7)MMB2L#A8<C=!YK'6K%!M5@07;/4
M9\9&U9=:MM5=G$UJZ;6UW;3U#"X>GBXR(X^Q9?8LGD5I'6R8I)\*&9`9_10R
M[8%(E.@Q.I&7^(L()A:>G2.7'L9*M&O_`+4^Q_U\+X=5;VLGYA)J92#MN0U3
M@D379*>M4*8!:3'M3,3X<!FNC+9/&8^\BSCMIWLHQF"2X;$,J*9,)^(6*E(A
M@A6YQA/3H6NO%G+[A3E]NYY=-*2R6S;/85E*27=*T9>KD:>92+*BV]*K,:%'
M5ISB!'A&WMJO12I(8QY]-H;N3N6[)]RQ<R5MTDUURPR=2GI"/PP,#$1Q$6@1
M='TS(]AO^6J.W_T)XBRCV9]UR9F)-+/[):>,3Z)],?T*M7OY:<'>^.XAFV<J
MNFS(6ZFYTV.YB_(40:D;=Y_2:EK.>V4GI,3X3V-P6,]45NJ$JQS_`)C;E1_-
MV:R*S+RL8?8N.3-/;F(Z&.@]>T9%V^KPY_7)C3!2PC4C84``QZY(M(C@TXL/
M,-YQYED2*`GU@'(W:?\`-C[^"L6G&YI>)'/]0QX",>J.7TMK65PU#AZ&`7@4
M?JYQ,3X3XQ/#F5.\371TRQS.J15U=4+&!$!TB8CGIKQTO2IP^IJP9'[#B>/R
MA;6].E6Q8JAK_P"Z0T%3^N./,4,H_G'0Q%M->S78'J.`"L\ICT3W-8X@:[<#
MD&S_`)AQW]OOB?\`!5(Y\6_\T^/XK;V3"-?:=4;CKZ/O$5W5WS_^7X_B;1XW
MEK_K>G=PX_J/*5Z@%S]4Z:\7]SU@1FUTW8I`UZ^00E;3RV7HXA,E=Z;"D+!E
MWKDIB>0SQB4YQBZ&:RJ76`Q6'F[NQ::P9!V/39;D<%CG5U5[#5=(FV%#W>I<
M3)!/"E8?)+O&_"8S<2X6JR.N'S)VEXZT4M2L5D\Z38E1:.7T^V(\N"LY;'+P
M-#^6AW1%Y>65F@34+)HQ*Z.1KU*BK=+,6K=D8KUX6PK'.`UF-)JW&92P(W+U
M['*J?!,\66&YC.F<DFS@QQDYFE\/%@RXG(`5"8R4Q!#KE5/S,K^#(RMB\Z<9
ME_)]O!&"\T-&]%":65?BF,@;"JK',5/(ACBJVO9R62%^?K[?<%'!9QMJG9M4
MSOIL.HSCANLJOK#!)-:S\P,ZJZX@M,DJ<WI\*J9N]9<6-RXTW5MMQ)9XL7>F
MAY+.,Q,#/>728]@:>'%3'XJ]=NV;B(M*[>!W!"`K&VZE%BY<9BPJ8]%P\<[R
MYO-8V8#575$Q,_5NTDW;F.=9KM4J_C_+Q>IL,9@7U"M*?7%X?ADAG3@''4RV
MV+F9M'71BL&\=X?.K>5E`KLL^.[M.;-':M%M8E.8*#@5K*=2\.&D]**.8QMB
M,?N#$(NCD8PV7\K6NLQQ7UI2BVQ5:XN2-<2'5,CKJ,_698L,%25#U&9>$1_?
MF9GPCQF>.74NDHOX='K]'>;IREI?]&.7KUJJK(2T[`&R2?U](P!",1`@03,E
MS]/"KO:[)D3%L7K)#!K+3V2F(U$ATG[/#Z@MM21&R9A*%Q$M;,:=6FLP(@.O
M.9X7<J%));KIU#TF)#,B0$/H(2CA,U6-K8Z1'1U:9@BL:\QL'$=2_P#!'W2^
MWT5'7+0I883_`/":V)`3(1-IL=(2;`B)]R/'CVLG=^X1H!'ZI&EW(_RN/S<A
MEV_?ELB&OWBFPH/ZN*X7ZB;J;/\`"S&0UO#!'^Y+2Y+HF>]I_E3Q=V\JM5P]
M:_:PUFR>.H5%2WX+F*672IBQ6"V@PZ?;GJ\!.=.*FX\)E6X&`QE/#9#%4L?C
M3H9#&T<O9S"DB#J\S08Q]^P#&+]J0=.G2<0?&;&S[=W)9S(2H^]#@3MZG>N#
MMJA7T$>S6K4'RSMSK(M>SGPG"5\K=K(G;E3`9,T5:8_%VXG.5MP87+W42$H9
M?QUVO(:E!=VNTESRTTPC\1GYP>5PK,]TWL3@<-6K64;C3CU9`&XMB7U9L06)
MKF#2ZY@E^U!#[/&^?@3JUJ]N+&;I#&HO8['+MU;VY6,M/5\?A<7/)0]I0(S&
ML!,01%IQ;R#MV91VXK6XL%N'XZ>/Q4$);<Q[<7CJA8Y5=5$US4L,[I=(R9GK
MR\.+5!^XLF[%AC=\8[`TBK41G"?S\-@<PXK(+%^3)'FSBO#-.@2Y]7*8VYN;
MXBRJS;M959:Z=*I7N7E*K6Z_D[V6"(N/Q#/-=PJI:AW!B8TY_7SU["X7-/SN
M:;BP<S:%E&'S]^W6)57'G8R[/834JJB`8QL,%5?J]F8XN[;V]NNQN#?NX'WV
MY9>,L#D=H_+Y6;OQ=R6X=Q7^T"L_NU8ATIEG01E^6*X7[XB1290,1)S`Q)S$
M<RF!@1B2^R-/J,>XNA20)C"G\(!&I3RYSRXZ1ZE45%^2GTG/AWG:<I9,>$>`
MQ^N9X45]$M)'5"YAKEZ0>DE'Y9C$Q/3PNK55"4*C1:QUTC69*>93)3,E/IXT
M]/TU[`W/*L2J4EJGO"P.OK'_`#RNB0DB]>NO`48=YCI-C";T=KJ)A:_N^MG3
MH.D>/'/^[3G'[)^H)#.A#,$,QXQ,3K$Q]T\=L]$W@'\Q/H9$?YU/]H?7'B/]
M?Z=]6TE=BM92RO80X(8IZ'!*VI:!:B:V+*8F)\8XL(V7M[%`RJ,.J82F%;$5
M;<B:^^H"4"T+MNKB4`9Z#+>GKF(UGB*VX;6;9DLE\4R^\Z6:SBK=;:6&'-9(
ML/NG,..YE*^/S&8HVJM6,=39I8F(*(UB.JOD\3<KY"A:&21:JLAJ6=)$LX@H
M\#6P9$AGF)1,3S^E=()_,O'[7KA"9$R^[J9TQ]L:_0N;S^W+?W8"),841,=1
M=`1,](Z^/"[%=D-2X8-;!\"&?OTF/H?:4MUF&NEE:P@O94N9]A?,^I/:&=/M
MT]/'4XH]@(EA>$:Q'M3$?;/'L(,O\8H#^]!\1!@2M?Q>\,??II/]7'=,XZ/1
M,<^KU=/KUXT,37]OO1I]NG/^KCJ64&/K&=?IJKJ)6;;,-*6/$Y6(ATQH'08=
M3-2]?+]?'Q`^BO:KW"2)5NL(B5K2T3'J,RB?S?7P%/(R*;<Z"M_NIL3Z(+T*
M=/\`DE_5_0,AA,)F#19RD6_C5[+T*^:R&X.[,LH.O71LX:XS*;>,5_#'%8@$
M]H0."#PQ>!LH#;]"MA<MOR[M+#Y;X3F,Q>3974PUC=VY,/\`E)N[DSG4QBJW
M6E2U3K+"CV6Y2G5MTBJ9&[A\A4MPHIKY/&F*KJD6ZK'TLC5!D^P]!DL_LF)&
M(4(]ZZT.M2IU@`#61AK9_L]0SI$<YT]'!V;32:T_3/@,>@`'P`(]4<?#_,I\
M[T=SR_5'<Z?N_M:<]/'3GX<)N4WH!@)%!K?+!&8%AE!B0"S28[GAIQ5H,8+C
M1#>I@Q,#,M>UVD1//0>YI]`2OIZB/3VHUY1$Z^F/3Q`'TP.NN@1,:_?SGP^F
M(F9F!\(UY1KXZ1Z-?HZE'(3]GA/WQX3Q^8F)]<@73_T9B?[_`!`C,BR?P%'/
ME&LZ3&HSP(7:RK(A.H0P=>F9\9&?$=>.Q30%=75)]"_#K+2)+T\YTXUCE,<`
M1EK:KZ)M>N2B/8=]SAC7_&U_H&3J;;MTL/G<G71BYSCE%YBGBV68\]-=J5DZ
M;*JCG37C6!%Y1.H^/&-V_AT>6QN*JKJ55>)=`<R8TM([CWLF38?B9E,^GBU'
MX4"JN/\`S5P1_L8<\9K%W`0.'PVT/YE<]:G'>ZE66C8C]]VC4-=>L#`=75Z>
M!M3:ONZ;(Y-+@Q]X[&5IC9U:['KBO,VM`$NK3\O02Y],<86_-BTY.X*]M^)&
MK1LV+%J:4H!]<:ZPEWF898@>G3T3Z(UXQM6I9N$65;Y6NX\=<76"]/5ICWV#
M5"UW?9]SGRF)\)X79"7,6></;\SVC&1R(63J]/3I,]N6+GVO5Q-%QV%'4OEC
MK#!J665JUDC%0>:LP':4#61,!/ITGT<.J/99_A&5DWK:J=AU#'NMS$5UW;@!
M*D$R2C[M>>G`!CAJS:G(5J;'Y$3F@D'=7<8?8>EOY6G/U<^,:,7\-:MY7,15
M#);:IV<O2KT5K&7B*V66#8RG=+V5]7,/MY\9RUEK5A.-QYA1J4?@C5-?8DZR
MEEW-6/\`B5AA%_"<YB"U\!XN7G-LUXH65TK52Q3L*R"[;M/+UXIR'>,[$%J'
M3K$QSUY3QAX#&95HY&TZO8!N/NU[=7LCS$:IU^MUB9F)Z/[//AU=S+<C5-*K
MUQ5"TVACVV-.TJ];!<J0R>KG$^$^/"\%!O*^IH"Z`K,-"`=4"T#GV(CM*22W
MC$$4QJ?+C'[4VLG%NR5C',S-Z]E9L,H4,:M_EAGLTF*<][G^S$=8Q$]/HG6*
M-7<ZA=N&PNX\Z.V*E_)@5.F9=60!$K*Q7K=KIU[D^_RCJXQY8*XEN(O[*W#G
MDGY<2EEJBDCJ,_-"&AVC'0@G3GK$QQ2NW3@[>2P>,O63$(6)NZ?;*`"(`=2?
MX1_0>TF1.^X?R@\84/AWV1_ZL>F>"8PB-AE)F93J1$4ZR13/C,SQNC(H?1%.
M;V):VQ5%K'BU>0<5B1:^`K&(TXAL:D,D?^#QLJ\U](D[;VA&`NBMCY8VY%>L
MGN58*N(E6U3/,I`O\'CY;^9LXT_Y._G#XEV&VB[_`/,'>\GY'KJ+[G:[OYG7
MV]/1U<8&B5G&]W%_,96\+!0VUVRQR[-MTH3/E((KLB^/9F!#77V^+&/&QA9Q
M"=Z'N5+B.Y%\UE>*P54A%!(`EP9>OJ+3G$<;GJ`^C#<UN9>9JR3+';"J#ZK)
M"Q,5I(7]*9Y#!#X<^,PX:>(RF/S-P;G^L,CEZC:9D(>8`ZU*)1<7)#JOF,^B
M9X4>,957:"_6MM5=)@570GJZO:2EYB1Z\_9F)XP)648"A.(W%7RAIQK;<H93
M6DA/I[E%/\7+"\-('3\7&:'S%'OVMW#N;'"3;<(,%AVXJWC2M;TR8D6LJZM.
M6D\==>IA\5E49K$YJL`7\ID:]EN*$Q!>2LVE]W21<6D`$Q$:<8.^?P0<OB,L
M5X:@MNQ0FL:.SVBL]DWD\)YS,!`^KPY[AQ%1V(^$[FR992S<?-F;U([,USNI
M57[1*>,DC\J9,>F/5QN3)$:2J99>!52`385A88G'E3;YGJ4`1)G/L])%K'CI
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MU/V]?1]%JNC;[K:*F;3@#LCD*RI.[;!?DX4A@1J+&L@3DB&`B8G4N<0ZP6.I
MU;M3+V\-;J7\Y7J5PM5`6V>Q=\LP[?=6T=(!/KUTB->,4K$X8[EB_B!S=A3K
MR:D4Z162J1`,)3!LO)X%`C^7&D:S,<7Y#!M-5;.GMJFSSZ!^(9J+T5%H$)5K
M7KFN>Y+2]WW=)\>(IG@SG+QFHPC*"\@DDP]M(KU9X7C0L3KL7'/4!(.?*?"=
MM_#L<[S7F-VXW)8+XBI5=E[%+I#HR\2NTQ5?N20ET>GPXQ^851K$F[1*\=>S
MEZ]2[$*:27JIU>PYETEFN>?Y03RYZ\N`Q%?&@^2O8^AJS(K1<Z[],;WF5X[R
M[6,HUZY>VWJB.J-/#GQ.,KH*JK+5,H%"]6R'7<1Y<27#;B%(66,8P9ZTS#&3
MR]$\8C*/8?YU(!=K.OF+*=:[6SK_`&S5U3]L\,M54^:K2I(IGOUE=F!'VD]+
M7++]YJ6NGXN*2;Q]=I:`%Q:P7M1^&2CWY`>4SZ=->,A:F2[9&I`CK/1)A$L.
M9CPDA@Q_;_0*]Z/W5A,)F?[+4Z\I_P`991I]T\!:MUNMP:01"PU]T1]T70$Q
MUQ'[?U<"`1`@`P`#'*!$8T&(CU1'T;FN5!39I[BPF-HY&A,'-IEK&VS[+Z_2
M/3_H-@H\>L2"-/LZ,BW-+I^9K6T#;NVENFS29UA`CJ$Q7F"_,B8_-Y:ZZ<BL
M%DA729<RUFY%6]D-<@O(E8-:?AI@-+'%7-T%W%F1S(\!9&Y9.I5Q"<33JM>Y
MW*+!67VK),*8;8*8`!G\(1/KX>?2[JL9JKGV?FS_`/<*<IE)1RY*CL#J/IX)
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MTTY"/WA6#/[3BRU>O^2N/Z`6O:_TE&G<ZNK7VOW'3R[NGKY='5]6OX^+?N_S
M?]?Z1_O?@]71Z?U]7TU/'W[/C_VEOA]GZ+__V@`(`0$#`3\A=&7[4]*&K<^T
M[('AVC`!5<=G`06(48!>)X?H%*R%TJ`81,?(=6/@0GM8KU49:*'VX>O0[*D@
M%0X#(^5WLJ:0FKAGD0]$$G10V3F&S5ZP$SAE!`-HX,^:`&[.6'_03V<N=.-2
M"E'YPH41S<:"H;4>T6WU=[)@/$/)10@)LPX=J&<&PG20YC*%'2"J3:6-7V:@
M!@RY``@H=TZP.>D`,0Y$RL`4P!.8A)_+4KZ)*$4492&38)O[(HZ;AP"$!NR_
M?TV5J&O(LTU^'PZ2WO<Y$-Y5["#:RY>-NXB1IMH3>!+3-;UR6JPM@I)OLSI?
M.GXKC=B-\#5OT@N#<9PY6Z*4XJM]B;;!1Z!*[N0D*>^8_P"O[R6(K$?5=\B8
M**NA`P;Y-E'3MFY,^!//C_M5NGAJC'K5>+6W;R(T40BT7$H&1Y'"!<ML+AI:
MA\."%!PD-;K46H!8@>T-7E[E-O0@2=JOJ"=('A")^3+)L^+GB,L2(/T!><TC
M)N[H._;Y3;H#\2O)P&\J-MVDQ*I25F/&LW[&']L793(TI(VOWQY>"<#9S_`)
M_:76+*:*=7.4\L*?+(SGG6LR).8>V-CKBPS?T2+Q2"/LV$FS;1'U2`8:-#>W
M4O6[_$]U8*`Y'5&%N\=ESFF%?*9#L[>1&-M>[3;FHE",*7SX4'K!<],DD'!8
MU[%]5PL-%4;SM"M2C#6J)@P')B$0%X/:`KT27HIZNLT*97`USP?*6MN;T]26
M(<]Z`L+UA@/F$=O(*)[``_(<HX&JO!AL-D"0=I"CB!`"@`"JKH`R]";]*`:B
MY\>S>;[6E;`VXNKR7;T<=.#1D6HZS^QP-7*91@^2:''L`#\HWJP:?E3R5=S%
M6ML<%H$`Y](DY&QP`]$!<@>HTOW.UI.1T^T(8:NIY$E#;UB_4[.U2/3/``![
M?%C1%:/%=CF^-2(/`(M=9-%SJO>26Z>;QH="-61"(!V_=VOL!NK><_#%TAX8
MAP?MJ;-)Q#H>><"AE%.\L2)]GA$IDWJ?5:'1,-<M>_8/>P/,V^`6CE?9W;*=
M=%W)`[<Y`;'%H_/1QV^J"%!4%!HCR:/V/2JF4HHD1VOD32)K`HD&Z#E.5JG:
MM]F@)193/E;C4W!'*RLT\+8X6/#Z!8T(V[U"A`JRY\@9J7%`U$`Q<'?+A:T0
M%EVK]>ON21R23E.7U':$MS8(I.R.#X(A2P"JJ$J]K[`&B53ODWT7@1OSJK%)
MV.NERCA`(P8TR^*BCI7>;G97@(^]J*=[^B.D,AMDEV@2`G.%=/"X-"Q4`\,W
M^\XN-=T)'!J^TBE!X3JG-=-'P1?:[ZA0MZ)=#["8!'`!1&)2@$]D1G?R!$U`
M>'?M8!=N\P4'!Y&X?J`S<\8_*!F5>#G)YS)ZR!KE&,IK:*[&YQ\K6F:Z26^A
M5_Y.`.=%85X<-/EY^5]@0\3Q#GX$@#]A/0-5'"*NT!O.M]E,'\DA&F!#!&'P
M;U#LV?9GL`BL".@)-()\FS$T74*B*\W2@!SZ@>:1)X,A^E@"`EHV;XV"2G#5
M;KBIN:@OXW#N*$U?2')<>5V!*G$.`P<ZN7KSIE%%8C,4'&C,MD#K1Z.TEXK3
M++B22G6.#BCEI#+3_##A2RKT!>6;`8^T773<BZ]XAK#8;($J[2$3&A]@&C(X
M*=&VI7VM)7Z<R%B2#W>5P'MT(;R(CZ/0]?XU!>P0:S3WV-"R0MTIPX)L&+2N
M2HZ-JQ<HA]LHP9"FR&(:8<!RZ0/R.)OQQD'Q4-B;>+5$2:W$]<IJIB@G&25A
MH.^4>X(F<@`*AH!G;0ZE+@!9#D$"->W@S@(@%]0?_9M0.1HR#"+<W-M#?9+M
MYUU2MR=/$.4^<1QYLF=%]1@`T`5@J@%PO7+`:AX]SGA8>@I8S-38&6]=?)]`
M?;'F$5C%XJ"06&",Y\BXQD'H10XBN8)/@.$Y7O'H6K80T4X4$%9BC'D%4G3P
M@6QP<HBBJAS%QN+DK,?Q\IC7>AI$+2(3WGD.%AI8Z2`>!TY#2F5(^R[@I#W5
MK95\#8/7'H1'=ARRSWTBX0*TTU,Y!=7=]:3+P&@OKL9@#NZ[(HJ$$G%0"+=(
MV5%S$O>7U>Z.N9H$#VZY$:U`PH>YE,G;8EJ\`&D`8-,LWJ.(]$@42*G*7-@Z
MM;X/79F-N3Y+HWO@>#U($""(6V+[#@_18HOA8?HT.G'PX`<D%F)B-=6Z104Q
MRGB$GNB*B4QCL/L(PV7@Q"K@JS``((*P4G(9)%HF+LJ\T^<3:*YT`0&SA-/5
MU-:54['#QZ;4#SINE).2MF,^I)ARBIENOQ;63A#4ZN2IB59(AM0NBPDS[!-;
M*EX+H8L!)..%G>7#;@7P3(L'BRS3/6:3R-C'SH)!0*DE]@@'SXVC4].X7'8;
MN]2?1,$W1]]/`&`?=OXM7&%)CEOZHJ+W)C<1^B$#24'*J#@S+T!J[AU1.%,A
M6Z$_K_:OZ3-#I)]&[P"JQNC1`9DR!&`.]\8"HS)5.SZ*>S`#TV$)BI0$EE9*
M/,ACI9KOAB02.XY&.>(3]`GAZ(*F(CFO87'82W2]*L`3D4^@[&?5*`&[BWE:
M@Z*$[.U;F&)3@&[J4W`R\G'`"S$/;55G:2:EQZC^);C!^\)`KPEET)1M"*JL
M#)Z+RB?A;>-Q&3IEPY,=E5+D3^XMT%&ZB1HMB(+Q!,I6HL\/7]#H9^_#9C3N
M]&9%=`O\7)19/`5^C#;!(XUEWB0@!E9HB3[#?A7-ZH'.BN6V6[J@[EZEJ+:<
M1SC0`R@31=!EC+F/1@L1]U/$(W$%L&ICG;;<>JT%S'/^H@]FA`3$MZ8%9*U^
MN$J!;+'%),M1B1"4H/G#(1+^LGI!U4,L*)@[-LE8(-B9'5^O;5#&X2L/&&'G
M*?\`8B[!Q[P<,P<,L+B`81\(R`N#\##4#T5\RTE&<01&W%]L_.$\&`Z2426?
MA\%AL^*MKOZ>S-V^/0##N:B9$CMEW2N2:7"XNN;^QS#:/*XS@0!S-8]*^%M=
MPW.7@MNA)Q;'ABAKX#]CR(*$'&V?1;5M!JN5EQP0LHN--.)7D<90>2NRN("3
MNN.FD845F+#B6TZ4T3,=+*+>7&EM(D+.I!^3XUILBWV]MG(RULF-+NH(D#5Q
M4YUF+/*U^F!>[2,?Y18EZ=B(T"!*Q8%'-&7&FQI5`_JG![FOUBS%0KVIPOJ"
M"(@B1'8CR)V.<?Z\7%1_8PP#0"!UZA60).!-P)01>=>O1'SCA/):$(T1[M8*
MPZ1!@Z:J97<P`'<;8M&]KO3\S<E!@[M-L^',[M<>F9ID)-[,`HR8&4E6MA[1
M#,ZDIW.4=F?R6)U^-]..,D#@8'BSG9*PR""/&+L5$C_>P&!&$]T+E88+G.$)
M$7Z-XN*R'W?3&!6X`ACOZW37AV-T3JMP3_D8U'LC-HX,VD;8^4(0`L7%:W[=
M)F`FMX<!81,.X7_&<%CP(=XM39%4EB&4T$^PU*BKE4GT"6]J\*XKTHT&5'87
M(^DPG(,OK/%`IBY`W(!.[BO\4)Y$2`R]XD:4%H'3D-/^?8&8A4U6W#$3!<5!
M)%DJ%7:Z$'-7C1N=%@:-"9UT/MHF)CIU$,ZH:3KH/:H)<UR])CO>'FIYQ"N`
MO52*AP-BN6"@-[YRP_WC3Z"[#/QWR"*S2:C.&7`-&B"C\GU`?/`@(#:G$($&
MQ$8!'(`>;G#\D^XWV*GW,W4V,'ITI^4/R?I7`[D)<CH"T&1)EVX_$P)0^E+9
MC'Z6(;V3RR'Q2#/90C1_WK!8>>$J97+.11QNG-";O3B:2(!=3RG1!4`WA`B_
MRU>,Z/F*`HPE/9)X(/Y3%]B^3&^X4P\30_0MX:^".$G6-5<B9M@H?8\1A*1]
M!\]<#8(+[N%?8)!+JOEY:-8DI^4AT2=<`.CU3)&E3OE`@00`F\MEHU(EYW`F
MG/6?_GSNS[SY:1PZVP><*?&`0N0$[6O:EG#+D:;*LDHGQ9$'R<'&*("@.BB2
MNJGRS`PVMDL6Q5$J+07(Q;1Z!@T2_.*OA):*&\1RD@K9*H$PP2.:H[0EK>I8
M)/*L!;085W)X[S!82J-E2(4S%]`0&_+\30O4F[EE;S/&7?T!$0V)A0IG?]\7
MXY7NT0(EZQ6SNA+QR3,9J#6B)HT$)2^F3/UUB1%+[40`?@OY20*B&\8#34TZ
M:*1..1([8N7Y36@U-IDX<-V)-B;<]0;/*7V;$TGAR*)N`NJH,ED:F,JT!I1Y
M%$</<1?(2;J*0O*F-!VSH283R1L+@[5[%O8TG&/W:YYPS:,J;'EVN_#K!<*\
MIG*Z`+Q3G.Q1?0!L$#OV;=V^'W1)BZ167^4VA^Y`YL`874FCV<.N"4P*<6E$
MF0EHA"+_`/.<(*(W1H-T$2RV&8.(9"!+DB7#EQJ)06P&&W5MFX.1:[KW$@<'
MY^6!W:)CIFN;6Z%P*`,C95\T%M!4`70>PK-G2(R!@.`5ZS8,B[`78*#L5#?H
M`THGKFQZCD4FDQ6%F$.T"JJE5WE*454+M"6'++ZK4.B\10V8:TN)B"DM[HTT
MQ<FR]XAH!*,2[0F^PI\^Q(SXH.4Z0P/NL[U"KM?N'DB^L20UE+D%'(B./Y?Z
M%=:YB@5$]1DPY7LA_GR9$GL.!X#0]`3UUH\&^#%M7@@]`YM060`=S%#HKK*O
M*DZQ`(\B".GTFA3>$U4R,=41QK6P$J3D$.`YZPCJ/WQAX2TI'?("?.&0$5!L
M*)Y])B#;F2>,\-3H6&FS@@^VN$\>MW<K^F')%L&4</0\*GEG_?AB341A/7:G
M@TFB*+Z['L[Q();!&[G%<)[:$*4SSU$X3UMAZ[-_>*\AOP(,XJ!M*WRQ23;X
MS8$LZ`,_^I//P^5\;EFZ@EX9JP&-#FYN>B&H5>R/,L./0YESD+4!LTQ*PUH9
MQO8Z>K0VKIY53*<ST\XEK\#T_N80!WM:^<-<O$F5.``/-F/GK9#`'&!N.\:(
MKR239.@?XP5"*!$8B;$38CAD4>4YQ&OA`03C]`\(<2Q4;GY80@[OD;`;7_%+
MVLAC53[6^(^*%;N@`B0QK\.LT>`90KC7B%4KDX&E-,?+=ZT?!&TB6FN.5MR:
M#C-^(P"]I3KJ]S*0H4B^:B#HDBXWH"\:>M/:C-8\FF?VF+%T`:..@X?*EH./
M/@"(5:$W2$A--FB.;R%@!XJQ!4T(!#+H]V8S"B\V;0=^MX]`(NJ$0=AWBC#'
MP!)J.2)!1MG:34*MN/1TGA-H.$:70Q`*Z4-6S(781JPK@4LU*'0%T3]#?`UM
MWM5P;IQ^!QSZHFRI*E7-JQZT(\P!K'WLRQ0NU?FNSRG$7<J=;3H>.R1;;6>#
MEU^S0*K:A%*J\<H@V'#2P[*]6XZ;RJ/4`\>`OR$Z`")8]E*GO]B-RNGGFF.W
M*MNM:34.L"8!FZ[6QPNJ;%=)5C'O(%`%>36%\W\6K;&&<#F5%*;H9X&Y"U),
M3"AB1$'0EIK.6D6I`C=JUM8L(*=X;B>;C!01P*::O;6J=/W[00%+)QU`FDS0
MN`'@B0`&V=_9PFRH7Z[K<+IJ'W"OY84;^MOXGO0S1<0$,J_)J6/)1Y->BX^4
M/3H@DW2F(JKQX2,!'"-!@O!EE4/FI.FFX.)P+6>H8#`TP*!Z4I*:P5@7:L[`
M][<"-?!V'!!`,2A2;K00A<#A+F[&-FHJL&"Q!9)7!4-GK!3FA:VL7Y^&!B7#
M/PAOV,)'1(<+^T'.4`^6YSEE=W0XD]H*D)P><?SQ5:RTC70][<V\/X0@DD2U
MO8W#$7(X#;(PR@O/Z`B+M%MKP!\TRTOU%$@BZ;J27A@7U3BA;0*'H3V;)_&Z
MW&R%4Q"0.!!7J`>;:7CN#GAE^<Q2$6XW-IIHWYPQ"O`7/4KIF\AT.WG#OR.?
M8%@P=NXP%0:R:W5\2A5F'TF]0M:2GH4WO%A@;EB'2VH3QA/#9\Z"&U331-8T
M9)>-R-&G(O."H:2:(&@2)7$,H$Z$2E`%4VJ.3E!YH:*F&^'KU=H+=Y8=.@!\
M'Z#S#^]V:O\`-3V_NCAR_P`/S]2O!E>6S?ZYJ6]>O_YB_9?F_2__V@`(`0(#
M`3\A23?M`K#G$!"2_0$X'./;'GKT!'5AX)?6,O7I6@G.N/O[-L0<*:B>H\`?
M)DB(-?GOTYF*:_Y\/S_C&+T,!/!C8K@_?\^I.Q!^?P?YRI8QY./1`%_?GXQ*
M_P#"_'QA3*V?#YR5=OLIPZ<??#J(5O&]Z^?ZR"@E)Q./YPJV:B"0UIV?U@V@
M'5O[N)Z\/V74\=;R"D*0[//S]L@[GCFL_$PD=.-<@+Q(+\9'^I`)ZTUCB';`
M;;WMP*.TB:.C_NY<("FR[;I(>=>TX5!CE>/)X]NH?%_SZ`ILY]M6YH?LX+T9
M.N/'VSP@`Q0=H!^!`UA?<*:#?XQ4U67'G_.-\Y]\QZY.\0!T=?ES?G:G[[_.
M`5X6CO\`&<Y3=_?OG-NA^.O+RX<+"K]SUX1GC_K_`+@L`/M03T9HR"Y"MRBN
M!/8"H<N(KL,YR4D^7L*F?U??TY[DU_SX?G_&,6FCV11'[I\X*1NCT@&O'A(?
M:H'*#^<,BH)[0;8C-=U_K[_]R;@=>?YZQP]?L)`*><<@"X8Y[.!,-'L>(\?L
M"LR1ZC]_CY]M(3_+[XT:OV=Y]SR?OC#?)Q"?0</D:^_)B'2"P_V_\_G';]>K
MSZC]VC_?D^/;(E9DL^5LW_#GA5\&$1/@^BPY^+<"?NO.'E0O5_X>Z.;]V_=!
M/Y.WQG&O8,(0>/GVRKFW^/K1ELN#D1&M6X=,1O\`^^7Y]ETW%_\`?/JBY%CX
M#D_?\>E\0!'VEJ!X=O\`KU-\O#[^`_\`9GS$WXO7UV_,/\?_`+G21X,1BGM#
MHC/>"KL,/)P?O^?=R?KCO[XB,>?2=_$_YR'T)K_G'Z&7+5R6@^&7$V_UATZ\
M5?6(A7\?S]"\`G\68R1IT[/X:9.R/Y/]#^L="2O)K?@G]_I!`0'_`'G+1<O^
MC%<V?_G(^K/9Z.C:E='.`T>@?=YJ^)1%W/1,"?\`/S\>CW`D'%6W[CX%>,D,
M=!X&_!'2=W"/=$^#K?[_`/N,B[R`K_B?WC/4//`/SSG"8=M_TF2%D]`UD#C]
M,=`+K7*&WQYS<#ZMZ9_X^--P&2F<=T^4'A4;`.+!!G(]K_EU5X,$<YM]O_SC
M%G;KX<*(FJ=`.2Z#MR:[P[&+^>MXSAMY\CL$:9^TSLP7!I5M^2_+W_7B8'/#
M;]O\_G]4!0*)\845A^0>'_`_[EB!;70X>^KR1%#+UK3E$#.6GBV9=L*:1P;%
M;$>QY'TO<"=XY5\Z?<-`(M(3VC;O`<>/N@-2CY!>WW_H_.#1O=YG_AP?SW^L
M5ZN7[#7GXPL4O_@?;D\GWS5,D](T/(<^?LC(U]4>1O\`8.@!EDEF_#:/F%\K
MHVSN'/%NSNO^D2X7+.0?X_;_`(\Y!#3IY._O_0UV_KE$=/']7W.OX\8_<6[`
MN:>%NGYPN1L:`$!\!HRT')_A84`>2%39\KV_XRZ06<O^1R^>-[_\,RG_`%W^
M7_Q**?\`7?Y?_"B\%HHU0/)\OG#6)1T:\E]DRCC;0S7D`OV'_A%GW_VS^S_S
M_P"&#\=^&_V]N#A*U>L`CA-'_P##T])^O#)[T_5S#7I?2^ERX_K9D])[7]2'
MK?6Y?2^K^H/HSU?_`$3_V@`(`0,#`3\A%(\(`C@&@'4U[70*48`;570!M7$G
M)VM#X0>SB=IW]#X=R@?\X<87V;/:*,'DI3[GH]:JT!RKFPF2&NTFY*KACV`]
M*_R`7^.<4'`,&,1N*E19J@'3[(#SYP26<PMC:$)R4-EQMO0=`0'0!ZCPUM_F
MZ+^>>,[<!)6T8>801Y"7&"J[!ZDH`W5Y34Q,&$AH&_D.YUQC]DC5&D3&!.B'
M*[6Y,/Y2*]"?RUH]6!0:$W7P=)Z;D5B*">+?,=>BK%N=+RB&T^A\IE(E\7<Y
MO-&[V$1#D2@3V@V;0OL&/C,E4]6-/@)$<X-8"#6AT@@E5M#&P'D,K>0:><4@
MZZY!@)1%>,"QV)BE;-@9*S=:M+,(QTHP12G95NA0<"$IG&]F"<W6TVJ052/F
M!4Z(!1`,/QV3&@WDZ:.<JQ6VCI2$&ZDN[K%X$<2MI#47E2YQ&#$UIL5V*/-;
M8JGL6NR4AJVQYX]D]H@4`5Y?6"@1:J#U%4<F$--H#T![YV=_"OH'S'R)1_#[
M=2MZJ;DHE:::?&.14("HPDZ;`941190%UNJ%[`5I!IO!OF:M=EI"A/)RP%4\
M5EVMH8?@D,+BDETIHJA2T\YT.?$43%=W1=-8^DY5WEV&NC7SG'I1-TH&]$!R
M8$Q)5@$P1`#V`9]_G^5&@!`>)AD82'V,C1$$WEO93D7.E$PUQ+7(H\)<?O\`
MHO0*J\E:_/K8W.NRZ(LGV.^O.B`8:)LH&KO^?/MI*[!+0'S>,5X32BV%WR.+
MJD#M(`&UW`6%X'#O@0J-B)I$V)['6(0@%4N@#:O!@>P(5!1$Y$V./4!570!V
MYQU^(TYVDUWX]GV6AAFJ&YI=7T$@B=W7!N@U9_8\$;:D-`W#17<../9J1*/#
M&L/Y"CTN45QW^`.7H"``KTYS;*M7@%1T"]\#@D%JQ/R=G"<CIC[2CI!Y2^?@
MQQYX*F8#HOW>7?M/21N5P?(@F:$"'3J@@7@US6`S;;>=!LQ.Y([L#4'A@Z_Z
MNUV[]@:UZB)LIQ?PAX8$%\+;550XHZ=#6W:+25<D^-G^G@*18U_D7C0T$#7+
M>WL),!+_``.#HHY74]:$-X=`L[%P';K-DQ:W192$_GCMZK@0*A\L6'G0OV'T
MJA=HUU>H?D304F$B-%X\OE.T[55]E;+))UFD7BI]@(,'0=U-%#=04$W?H.>%
M&5A*0JQF`K-;R&Q,"A2%#:2@<AQD(P*E4YU"O.B?7N[@6$J\K\O;ZG]G5T+R
MC;LC@UQQ+M8<O/Y]BP0B%2NAO0*O!]TMKG$LIX"D,Y*.>,T)551_AZT'`:-9
M)%6VDJ#R8K+9P:^CS'3@"-4TJTNJ&*(\C:3E=AT`X=##+`[=LEO1+N>ULX!/
M'DGP$T?!3[7"-\Y0G7P3R*+LSP%.N?AV?GV2V>B7+$?P._;9D\+:OO5FG1.;
M]70:YQ),P$K)H>TIO7.7WO(R#3KB,6J)OBJP"*C_`)D&GD]A<U=1P=H<<``_
M`!Z([&M`*JO`'.;U&,CMVMR/A:80P_:W)>,G7^&%-'L)W8DTH_A(GW-F,BN!
M7=LW=WC`.7K=R@D40#L5?P5=#CG9=7K^"_/Y886K870J^==";C;ZFA7U$1/.
MURSX&WW,Y"N?PI1KR\'>'A.C&^$1_#[5[4($VJ5*W#6)[`!4$1'D328G`NY7
M;Y4F'15?<@K8Q<I(:DW`]WGP0"7PH1^R:]-O#\:1UJ;'6GK!7[-(@K(1:3<>
ML-Y'T1R/T)WC6O7A:AG!NJ-(%$AISDVPB?EZ.`X#1K*63@M68]UWI.76\=?5
M:`/W`-K`%<A2/Z56TZT1U97GUEXV@)/R<M=>P_0R+$ZE+3L**Y&_.,]3FL?,
M5**;08W%0:TXCJN:\+Y<U,PO1<T^2@'/RR89<N7QF\WQD?:9QOW0YI++HBM@
M"`T.#%R_.YG$N7UL&BU@F31-75@Y8!>W:;<35%[(K0!(\B[K296M/MV7$4ZG
M+T/&N<0/.[5BDH;I4/0,"]O-0)8E`=.PAF^^ZH*;)AI'XW"?_C4%$MRU<5.U
M)YG*&$<63>^&\X;8_2-OR35%8WAMFT=:=D#@7H\-U_8JJ53#`G%5Y`!#"%5A
MS#QO?H8HX\>G^V69K\X^PU]':RZ&(8CV!0UWE7H$["8G(HB_!X/+TZY'-\(:
MR/CW0+[@:((_1_B]YU#KX\G/[?D<_(YWJ?.*1+R90^^H3QRP%Q4@OR:P^"OW
M\M8-6E=D(E4(0!3E38"0H<`$/E5:J%52"UF##=;>1>_T`5S?'T0>D9!_:/GS
M_P`P6US!.6'_``?AC1GPF/[-\<N\[&Z^*%Y&M3S\WT97`8ZX!\;#P!!56MW>
M'_ZCMYP<]>KQ\?OO/"#@_0F/T@@^X\F#.A5_K]]Y<LWC^T8*.4X'GK\^/E'M
MPI0@GQT/G@>-O6'(04Z=?9X^>^V+\_\`9_Y_.;ITY^7_`(?HNOJ'2V_I_?[Y
MP@_R3SCZ*FOE2G(>>/\``_\`<K4BGX37VR%#XNC_`+_C]'U]4YS]^\?IACZ^
MJ<Y^_>/THQ_OD.K]4YROH=MZ7GX\80%^5NI\,)@XM77]OCS^DO\`/U3G"Q[_
M`-WH4UMX?Y?TAX^L2ETI.W+]WMY<1AE(X^SSOLX>\!&`@&@#@#P?I#']*;R9
M/1'(Y61R?K#67%OHOHOHNO>9_C_Q/OCO_P`2YJ8D_P##/6:RLK*R.5E8+@,?
M#*PQ61EP"5R7CC)K>=_HQ_SETX\OG/\`3(_,R*?;.&*93^L_TS^F"'VR.>\7
M4P21RG'H7=_2S1B3.%]AISZ/Z9$SE,X7--XD?T]Q<1ERN5E8/HKE929;SBUO
M_H__V@`,`P$``A$#$0``$&VWNVVV\6V\^F\6VR`*61NV`U%%"2ZQ@$VX`!&V
MVWVVV''&Y,8:V:``&(V^+FQF(VPVFVV<``F2V^3&VVV>W6.VWP```&VVVVVV
MV\WJVR=@```+`VVRVV]&V6VR`````(^:VTW4ZV[FX^````!5!;FVP(VVZFP"
M+2``(`!;GFXVVV_5X3=Y"`)J``NDW`\.\R!5@HB`#0```4K.#[P``````!*`
M``!T^)N&````````(````(EA]19&%!!``!@`````'[20I(V),P`!P`````))
M(!('QH````P`````(9``4[E@```*0`````)4P`)))(```!*`````(W``````
M````8````(65P`````````.```!S_P`LVP"$240``!D``2R_\W&T4$?$0```
M>`"'VO\`%?\`^P``````!?`/[_R@1?Y>```````*@Z0>A^^TJ>P``````!*=
MY?)FS:I)````````&^1:DBD5<80```````#CZ9Q)9G'\4```````(7Q'!;.+
M8O\`@``````#_P#Z_P#_`/\`_P"OV````/_:``@!`0,!/Q!R,>O:QA>45;[7
M31>UJ2J0`"N47!@:"J@$=EHSWJ9YA<,Q.$'23(CSL""FI'A!]JA,Z0E6?8([
M>'T2RX!4F``^ZZ-Y*P8(!,FTS%&O4"HKG`K)!T(JKPX?8F9PA6(`*K#.0V/'
MN^WGM,>SP&66NP&T\+<3%">RK276KRGJ&5[M,H46?80""&;0P0N;>F]!5GA&
M6O:VH7E3"'1L0^04H*@968[/W2D\1+&<O$Q<OM<V5?6*I:R5QN2<RS8\)16;
MCHK?8'`&ADH"M&[<N0%.)8S#A0WBI!%*<M(+'FMRO#;9&C$X'[NTAVJ4#CF)
M>:!:;!3V!+1#_JL3T^A!IO*HNP6RV!CW/R6ZNP],8]N!',5K9IX;G<;4O-*B
MHUEW_"=",6.P:Y4,88*$X4":T&WMI)3)'_VTT#BH-59`C`Y069>M0RP*/O.3
M?$3#BE5)\92%449.'MRO0SZV':YC63V;-KRGD/\`A$<'BG:W0M_1P?0N?Z`K
MP`)$!*<GM".[#CT6JUF01H`V:!&5Y)/@C[-:W<@\"A5-P%?8@D(XR[@`8/!U
M9!R=+;D$830R*=/<Q*E#9:F^&J"I+ZS1R))3`#IR-R@>`M#S5#*>0J)`#HXC
M?X5_%D`&W)7J.Y^ZQ75(?PRP6`+*_+FACMS8]\:%0HD$S"H4*52/"A&T#J/\
MW.1`B7UF'9/Z:^1I36#@TE7B@?((.DE[`TK*(PV]!$M,!TR/X;%"[VI$FT'3
M$RHLJ$1(D#@Z&"F!Q!$:>QV)]*3Y)H`"N)&'HS!I8!1'$7_`1+P.55@8UBRC
M@8H6"U:?50%6!M70!VX_0R@'HZ"1;#TZ4;U!UB62!"+5B[)GCF*8#5*AH]C0
M\E`#<(;04XR)5PP*D!41&8"YZ.H,NE1I&-`!9!08UK+*,=A%4$@(GM/#Q=*X
M#8I$%F1F]U)C\BBT@/8>B"+N'!<>EF7E+V_XP&FS8X6Q_P"K=FF,EUE8TXJ\
M1,JG:BA557V"7AF";@GN%.0P7+D4Q"17&,)54XGH;<:O@,:94I+_`":ZQA)`
M`1%!ZM0#P&CA848)L0GJ3X$!&AT^GM`.<"O@_B6`-8ZB;IZ(CV($LE$YA6CP
M/H/&12V)H&6+*E6Y3>NTH[8M++;[+K4+'&4)J+A3L'5\#D?'`71]X-1^TYK.
M&>+(5H"?/,<`=4.)C&HW5YZQ`H*_6)(QPI.CG.)M>?4L_;L`&&PA:3#\)/83
M1&E5[?9VL:`!E^.H(9E**4;;M]F4)/"$MH=YC.;Z!+@C_@1TPF0AK5]![0%U
M26P$TX(-;>??-,L9L:(!*:--IR.?:F_=FOLK17#E*Q<^XB^]?8JB1=E!5A;1
MKZF-1''8@G9[&>D!206DLQX]ODJ6#&P]$;^3Z9?^VB;*'5V`F.*B=8M>A2>+
M3`$2"[5G\MFEU*WP65^!]YCN"H=HD+2`89+5`'LM(.GHT8+H$PKH?4\.5T]6
M-BE@&,_JS"C([@IL#T&/0%R415`4M!1A/55"E`E).\=()L1P95Q*EA).FV!Z
M@,_NVLU<QI<R:7?2Y("9%,PG;-OI0XU8XZ*)I^FM7!!L)BCI4T67-.]\XY=;
MJ(^)M2CGZ.O`QL&2K:,EC1WA`H*#O;#LL:TNHP&FF3:L"U!,B>W7O#LA)B+0
M&WAP(P]&8-;$"(X=?5X2*9-)K1/<=$J(PCJ:@AG1$%+"6'`AOD?3=R^S@KQJ
MP5<XA8+R""TV\G5P'J(UD8:1TC!$8I+>4D)F"#*]A\5\2RK>5BY;?33@3^G8
MH7D+.-L&2\H>1UXP52&N:<4]Q^`/SC""E50`R^U-A7@]R$FX>#]0NPL(UJOU
ML'>N&_$)5MIA<W\C[MIE%3,2>7G\+%`EX92&4$@>=N_#@$?H]"9<-?)557KZ
M5M>C5J!HD2K7Z!/I@I&D\A#?33TJV-=ZJ7^1JDY-A$#HVPIAEC4U=!UHX!4K
M1F;KOB2A9$:;KF^S3KO<T(D2F82>"7UM%\"[9'7B2BK'\A"K+93[\5Z.$KY.
M1],9W0E9K\VL7YLM2+#CE$!KZ\4'$9<&$H_J'\_B@&^Q1O@Y4^]7V+(ESH3^
M9[<>R9LL*E<7(-7AB>V6D9EK6GU.H5Q,S#,!MZ`(7H"RUZ@RV[XQB``32MW(
M<*(FV=70=E;],U5TMQ4%"H*%E9HKQ<8VN+[`CD*8^BW2B=,\@$!:0:]%+*[9
M60(AA8.;_1=S>ZS76ZX,="F`G4,4C7":(4BL!QEY'YT6K0'0$&#@>BE83]9`
MQL,JKHF?C3:*A3P)B]9>U,-7`Q.+U5F5,4:JXA#%*@!$KJS>3K<&G9G<'0S4
MN&'4.B8#@%6@CP9`N:W"7'7>>RMIH-"YGILKA/-.I6B&7<+V&8_LY*>:.JH-
M7(_=TH=[2W^@]V+-?_[18\PM7LW\\P)U2"\'MPH:CPYCE^N3;B3P'.CK;.`F
M4-"I]0@`3@H1TJK(9`3DX"`8`K5,;RN7`/@+C8.:-PE40*03"`&F3Z;06EF3
MMDUO"66J."=X#>'"CE(Q<*"/Z`ES3U71_`U"!PSML,HLW1D6X^B2[+D!JL#I
M/@\<(4$`X!-'?],>D$$WZW_,:!8PI0)<.FH#K;YW3I\S.CE6!PK;W9I+PE4#
M"J6^:+$5.H`1BZB&4;NU$3:R3Y93\6_51S8);7@[/@#6N?T,][>Y(4;8<MOT
M^I3&>^;%\$U>@N?NZ(T`F"7(!J#!+:#/8!,<Z.C6%'C4,FHRH51^>M<IX]S?
M]F,VTABE.473AZ\BVIEF?0OX:\%%PGC+0>CU/Y#]$D'M9-&RZK>!&EJ2GQ_\
M!JPJ&P")@"KP1<QTZ5A<W;I/=.TOTZ/0BOMZ&9NIV*8S?AQ>CU.!EB$)87U#
M16_0*X#VMW3J,;"(P&)^#Q#H*%H:*CW)8YVNH0ZIJ&7RRQDS)V16I;?I[0UR
M!.?<+%'4GQ$XY.,`OZ"^=WERPJ$E4NW"8!?4AM030&!3*XVJV/YKG)8C-TL/
M+^&._A)(T@12AV?T$^[=UD7S?@=UM*IT#*O<@8!F,*/F9U^WW<`;O+'O01'4
M68L&5F-BQ@JE)*;06>'\E;&21LD[;<SJRI1SP,+XQ%>`N0$O33!5Q@WF3K0=
MW9Q=N(EV@FL1#8Y-Y?&0ETR*MK*3[KJYGU`D?"7ZL9$SA@!$*`8CSAK`.-0'
MBKH#```$````&@#U3-W_`/2RY>(D4`6!ZT(Q&-1Y6EF3/KV3^J@.13L!4PP.
MAS>S2`"74%!^7_>R<W6`7A7@_P`A)KV=4U3`_IU.E'Y%L)$203"ULV'!BF,F
M]JP!38PM`VX5=&U,9`&3(#"=&S=?0*>`!I&BL.'$+.*YD3VL.L7Q/TC(0.MS
MWFDS=PV6AR>*#/N\K/?2Z&?M04&%;Q9B$6WF<)XCJ]/Y3.1%,).#4]U]M\?U
MK!NFB4EQ0<0)C*$5[N_8L:,,]6Q$CDYVU`P!]#!`PCAP:+G1XTLTU`'PJP,6
M_5WODVN3-26=Z`(`%#Q8,*SG'N`UC^5T`#J4%3>$]AAF3SO0Y$,(5<>+IL/*
M*<QH"F>,_+7VB@!+@3(\\97K1H>I2(9\8W"PSP5$T`862W<(%P(D7.$5PTRY
MV(VL(S(/Q8S.+!@'97T0O2)[J1^.SC&DML"D\15-!D1^F.`+YU"J@`%5QBG*
M@91`!+8"TS5FD<Z4$#M(GA4Y'$(@6.T-AI?#S#L?TD[V0V]Y`'53@&I^3B)9
M'TL"I#6[`3).800:BEE7=D=K&@:B#\FL35HNQF@G&)2]10!JD8"?O#ER$CA[
MQ?"DBM7/A/F<\7LP74FB,=J.J=U-WFI."-E+IHR;8('Z),>[E+2!764Y!6"R
M-6',C0&?0*GH<GI&FO(&*1,'?8@40Q-8-I;AZ]%4U6PZZ`]8<=>I@C-B0``0
M9EG5$8:3M=EQI7B:@1$U%%UWE]W$..`-83J^BX7Z%2AW>,9T`00BX0`'*]KE
MQNX#@4]C@`#Q``))BHF#T%`-4GJ@@BOD-S!E-7PF`]+)8$U?J[%J!H=()T&#
MC%:J6]>5KA0$]&FS)VZ;A4<>%9FW+$>U$5B<3U@VY3"JLX?!L6Z-C<.5?8H"
M-D.$$VP^Z\4,[EH_0M9;L&1QT$M\:QM@.!%FMGPC(>55CW-%]P"@``*$A#4#
M3OS1@FEC8NW*XEV1?S\$P0&.28!Q#)=*^![%*:]2^JZ10T"`P#"4MO1-;>JD
M%%(XII0M360MR7%VW-,CM9A4-"%`E&$$TI+DW@"K28/1NR*UX:,J```Y'Y+U
M(@1%DM-KW%Y%%50%@*B#C#5%Y&=NS.4`AZ_],YKT`99MAP&>+]#P1>>2[XE!
M./)GQ=Q%6O+RZ3P5Z/XD!'@<"-^S7OVCO>-.WGF)&2'5`@XU\1^^,(K<'Z3C
M^$02'8N[&K)RP^$([J-NSYE(!`]0>4,T-9DQ"T%0SHNJ%0:%-B!U>@2GA5J)
MYJ]R!K&LS;BL$>N4KB;#%,&]483LXIZK@*EQ/81HTUYU`I]06ZB4"IZ,!P%#
M$`X@0!3D`FSV/5S\#*;$(])G%!_NR7X!WNC]=`S-:5:=:0\(IG)+%!N[SC6;
MZ65FSGQKF(_T)E^9--I=!@_^G7I.=$92]=#=$])OVF\OA]M/`KEA01.(HB#,
M@(GIL$\U@K8EF0BN,94G[S.*L[L"N25$[5G2<O\`?+OC2967!8;`NX;R?;ZE
MR)L_P3:@+@H>31B[,G%!&E>7MF2![2G:VHG9ZG79U/MWRT`Q";RJX$X,=B<)
M.1!NZ%#B11L&OZ';MO/10EV*.@]]RX%'0^MK+,JO*.QP'I;,*`90W0^TJ#`(
M9WXP`&%NZTQJRJMF6%];)OPVS>00&SZ-H012<#9*27,BLG![Q&,^FRGJ2[-[
MQUA<]A0W.UFQHNVH3TYBI;N4"18%>?0"<301.MV?#%WSA?>!5`;`M?$&!&5M
M[XH1;K4L,)8+)Z8&8B@+88O(:O3`Z'=],>R!Y<)@`HFQPLQLA3$%33T%7^@V
M*&B$Z;3H[N(@='AK.!>6S<SD2N+U)QHK?%[A&AQ@!Q":SYH-17VJEL`B#1F0
M!@HG/>;@R!G]KED4\X!5+<L`LO>RS[0F%`+V^I/!T`2A`.*_5$.3-1AL4`G3
M8F%D%IX])D3.,R)],IE9`NP!"4S8#.PE+13\"E+TT^,J0:<0)R':J2C@+HX&
MJ2>:,2QSBHNFE^!!Q*+ROJL+%F0@KP!)L5"S$ZU'?/,[Y/`U:(<C16$"H@RA
MMT`UW4_07<'.+DR(X.9-.=Y(S_#!:(55R/<KIOH\Q01`X;IK`0M0W:/,C'(<
M/YBQU-[3IA+3B#X,118,8*=0%S7R_P"*F(+?_11K/M:AG!B!42=E-F1!\"',
M>9'0WZTDVSJ(9$#V*0.V$$G(D":_5FC>8ZG&*;O53D6>(YO$%*;MO-DN`0E6
M\9?("(H\K@V#&="S6;19#B&7J2!N<&PVOP\O01VC.6,\-"A!8@G@*E3`6MP6
MLQY?`2I[^!)5`%0=B@?]`!H*5L4^WNJGD=8^>A3Y'(<Z2`X-ISXKFD:4'$4/
MIL"&^,JB5L07E'PJ=Z&\"_@P)\E^O9CHS=>@W.7D_GZ,F''(C^/)4BJ;=\4<
MSA5,-.X`]1C3.ZYF8\U,Z"-Y#D?`E;KAE]`89(>0+6TRHBG":OX&HKH".0Y=
M1/D1[(1DU@T2KEB?A5PV%E*<-@^T@NU$,!CLXC&KOS;#L!#[75XGJO)IDE(L
M((>T,*Z1X05^NU0@!59-J@\KP8[8B!/.,4AJ&QD"M8X6(&P-`>AX>IM"*A,J
M'!G;4)#0*&N"PV5AR%0Z5I[M7D$"!N$,H7:49;CI@6AF)L:"G`>6D(-XZ/Y+
M"$!R:/X?4E3`MR7"0U\1)T%0@)`MIGF@L&)FA<UB'W'`$)G#@H%1C@X?\Z51
M9"B57S1?%%5"\HBA`I63KQ*5:EK"[5/8M&M.W;UA\=*DBD\@HW=_0?[%$O;D
M)_ZY_<OZ?4<3XY]\/3?Y$]7[[/V#]*__V@`(`0(#`3\0;)-JMJ]V[OM!&J8!
MM5Z,/D`7L_'9V<CS]`2H/@<14=/M0*&N_1T"H!M5R@<*(T>+$[+LZ^R/KT#\
MNL!6'."HQA2*=A1I3@=OLLNT5[@*SY9#K!$T0?OMY7M]=*TZ'_)@O1]E$<BK
MJZ-S5-/I+*S7)QL!M.JUYY+:BJPMAT7N><=`JB:1.\+TZ@"'RSS%7\$`/4PK
M3RGK84.=M'WT086.Q'DLUZ,4%WX'I'8>0_LTC_.TY=D]?Y-2$P5(;Z!$'S5?
MSE5Y)<`P,:$VV%.L4E"D4&J(:C7B!CO!-IMY%?('^9+.@Z8*1$Z1="*U8DD3
MQ'K\@)4*+XT,ZRPM@D(`ATV=`<WL9D2$2=.0H`9\.>.HT!1-[:0V<16!6W`S
M;):V&A`MY%9CM29F"0`&D3CQ,3"W[$@1U*;AHZQ["`EN&B:ZA$XH:P(0,\`%
MP0X5,_:O#V%2I#0J2!!^2I&Q]B4CQCA*HK\?+Y.O)OFA[T:H.S7MV&HXMRIO
MS#C>.2$`E5S27EQ8.PH9:5_)(<P0Z=[OAUC-T0P-)J!V3M^,7;N!`I6`%9M;
M>\ND`K`V`&@`@'!@E,H]#54@%$$JQWS@@(@70\6@;\O?=QY2/AT-'C47J93/
M230T$%0%12UI3O-AD5`Q$6`%3E1<55>7-?MB,J>&*/A<I3IZIY$#0G:XZ8/2
M;"#HZ/&O798FPX7KX/73O6Q4PJAPOGVR3E+>(%;^,(T)H!`%T0\&L,O86?!V
MO!^>T.\>@JB.D3D3S[#)JP`;5>`/+CT$:(Z1.1P%0VN-@OD"/\/L_M0A=`Z4
MX_ACKT'#(UR<<#L>+UY%5I&JPMAT7N>?8$!NQY/Z(Y+_`$Q')C3@/_KRP"]>
M@Q_4^.U70'EQVB1$B?OKSU[=:93[H#_.*4!I:L)5]H1B`CPB1'[F;IMUL'XT
MFO%;[WS!+=L'L+I-->=,Q*R:KRK[&>+P*1YGA\)L^2B_1>#@A#[L-O;_`!DO
M=@H)_#_^G)'>$1``'!Y^=N]_!U[!%!`_[\H:%X-'LEV%0JP+VO1Y<[]M#D^0
MW7UI?'J"U.#T&=03D'@=G]G(CO*B#5_?`<!T>P20;3[/R:IRNGX45."A!"-+
M)L2(\)'Z`-W^"=CQ4"Y?`Y/J!7LXZ!]V(1"%X\?7>06$_'CU1[3I'XG\GAN^
M:+5>+[$<#36`?+\NC$Q1%A"#1:%9X8.:R4M"Q_9B=X;-"\6<=?1K)&,8IV7Y
MX?C)03C.41.1;#;<888+40N[R=2\/N7P'7D^!TIL'KY$/:3'R$[(^9VP^<12
MN3V`C&I$CR7D^3V][W7W('V#?W7ZQT8@#>02Z3I?YP\'8)`*CK:2BV;_``/`
M;72'CJCN.ON!ZL(+_P#I=@T+P?=OH'-0`&U7@,F7W";'R7SP3\E$7#&$`,H]
M/L&-.3\YRM)_`&=`Z-6O$#T,`:<L`"JO6C_6&:<X@_U']YSQZ'EM_`EYW8R?
M7.0:1>J0?R,?9RQK&Z,_C%)%R(B?<=GM4J8&&"\"\%ZPZB-1-(G"9<%J`('%
M9YBK^"`![0@#,C<&M#YU.>Y,BE!TZ?31`4:/R#_>+TA+@11?`ZY`_0GX$Q4V
M?)OA1^%PJ%\``_K^_.40"J<`DJ\!#5=XZ9L`Y7]_QRXFPI&<7L_#KU#"]VB@
M\/#?**=/$]Y99D*Q:,XK`7F98O8Z[^@>1")'`#%\H1_D/Y6&E1K6]R2+4Y_+
M])2HG`&^3KE>5[P-`GV/]'EY?M`'^E/&TU?`;^W&4(&&K:`NQ."-0')C=0;1
MOR@;28OJ5%\B0$%ACS`&K?A?0S#,/AQD*CJ!B@%J1F+HD9B+$0+0RT&P-@WS
M9=@G/#%8(H"(R<$W$(TZ@A="O[.A=#<?(-`")X2CX6S>MZ91SXF#0PKNK5Y_
MD0H!>?G],%4P`$I!&E(K>C0LQKH6\LSL9N'-!MKD[S*J:P:<!LE)_N9`#@EI
MJ&E0<&FG\2VI\/)W3$0`3><'$\'3\98M$\KU1`8J(`82QF@3B61`-94M@A_`
M#-(AGE9&U!D))71#38""233@"8SJ(#34)4D:XH_5)1&CA1$_^\G)O!D+1Q>/
M$*#Q*(Z!@O0<PQ=1HLRP&G"\,RH#:H1U;'23,:N0Y"@$!I$W)Z53L<<&1N.B
MC",`%-`,']A']+N\R0;0Y9$'OK9,L;9AQ"\/`\[T==P*_62'#A;`T_*X/:9$
M$\J.5H=="AJ:=!@049P`>D73>7;F+8=PXBE>R/)P:9<M)QLK7(AR.W0'^KE3
M4I<6OMH4,JD@-`IQ+00:=AK"Z!]N-DY>"Y[7@B9%]8GI/;S^B'&Q(A^1#G5=
MEV=4F+5D`C9$(W;HB8<:,0:,:``&@`SY\'>=%)J;6[O!-IJ<A0%.&3DX!TF,
MYDCY-*-5MCIS0SZ'&=:PE^<V6Y_B9XP,T_SGG(?U@?Q^D:L[7!_8_'Z%_;B_
MJS/['X^V^<9W?C!W\S/%\Y]_./SC8X^?/Z=VL2O8"W2@&)5N\YA97$(:X03D
M7>(,71,4-CB[!\?3OZ?4#&K[-_QW@:=?Z^%`?#_+^E/ITRY1@=`Y<MZ>AMK5
MKEU#(;7<=(,*6,*,P(!0```0`-`&@-!E_6WVWUN7]4N!<?9+Z$S7J?IU]+[1
MGO']*^D]1/2L7@*S+R3GU#'6#^C6>H^M'`'M0><^&*/8?HGGVE;ZR,4Q\,5P
M\LICB,5)WGW]3]"L]P,/&1C]\Y8ULR/]Y_MD_G$7[Y'CIP(K@O'Z1YR>RC\9
M=SU7+>/1_;*TSA<NYENL1/G!]#]`Y?4S;`<F0R&0Q-ZR9#(R-R3C!'U./T#Q
M[>WUQQ]+_]H`"`$#`P$_$#8$<FDH40"#CVA6`D?4P`*``*H&,D!(+4%F`2CP
M0CWJS.44NRB'9Q@$4H@AY$H_CVEE&BA:V#3DY.ST.^!(C4-`'Y715#)LK7LN
M,Q;F(4]="I8%=":VU!LW)LQZ@!56`&U5T`<N0JV378CRL,#KV:,VQ2-XAY;P
MB<'<R``P`&CA=&-!ZBG#L5/`02B!`J$4QI49"!&TAD4#Z01,F"`3!"4+V6<*
M`UD$!!0$@J!A9<!QQ(BI-(C^.2.*YP>`O<)YLOK'%@A%`U.BY<RQ8L6N]0@D
M"D[T.`",_.EL#<5(+I"V,U%33LRT<\Y;6XUHIJD:`0>ABNL%%>,?!!C972-@
M[4?C3((0C;,;*[R0D:Z"HJ8,R)=4YI#=`5P/N&!9&$:L:O5!^NOR84%>;L'5
M^^DP%MH!(8AQB,>W!WIW`;NUK\P'+'82C#PXQ5OL.X'!(J(/UBF:Y0`U9!),
M:P=8#CG2+/:%BKZXQ^-9IV"I]K^>OT!+40@$1#>P,K&$?";''9#A1#9B$B"S
MGT.B'&-,B4$8@E.0?;_B=G)Y`U;M0FAP:]*<J1,\%Q>RQVB9".)6#".:&)=7
M6U)[IB3AN^YJK!C&,*)2`,R2H659HMH6:QH>6H1<Z67);X1S%GR`8(!0-"`3
M#$A8CEB43HHBJO-'A8?]IT@+@)2P;0(MYX6B`8$@(#@"`?8)@IR3P`3;A$H0
M$`CB<!&>Q&7$0<+C6C`BA1`BAJH`UZGI\`@>U2;4PH!<VR-J;@4'8!H*B5?8
M6(5I"+)$3"&UP/,M:QO;0V00``#<]:"PGGF(0N5!AJF$1>4@@B(C/8'-/C`K
M`90`%4#`!%<(EQ$`"B(F()(@`*HP`!56!MQX=H_2@+!:%JT@^J@5T&;<+:T;
M;ELB@@IZ#N5-'0*0,)"+;BT>HG$&XC-4J-'L'_D:DR`8AH-A!R=[1.E7D`G6
M8`])'.`II%4]H`,4$"3?CPQ-(*H),$/8V(N$$*CH*H+H=NL.GI5`2@-`6\@I
M7V(2<^&5>EAT@YL:8CH%!!L][6ABF_WQ$H^@I)TA$L=F0F`Y7RA0HI7U+[':
M=\MI#A3D\NUF4#LT1N,8:ID*+@UP=@"(,:8Y(IE8R$:71L0`#`L/4&ADZ9%[
M1!@FU/8%:!1JHVY(]H#;@3"0^&..E8ZB;IZ26D5!!(/+0%:.!?0MK;4X2*HE
M+%EL>C<5`VH[:;2R5?82]199H6("@V&/H.[;:(H:"6HCZ`"S1)$+ANP`#&<J
MKV0X16`2<,EL(`!"P!!0`W`-?7*($$4K$%3:;7E]6<-(AL&`T$+?89\!&*50
ME7:\KV^QX562D-P:S`;8,$9DQEK3A=K=`.%[*H"B;8`2"(@:8%,>R$TUIU@Z
M(/HPK3*>C<(")#$0C<:5PL2(^#`Z7*4/<KK;=&<=I[@[-3$G5.<LL17W;6D8
MD6\DH)LH`@,6=2T%04H"1V`3A!]CK5'8`F2`BS'9I]IQD'")?+IO73IE?4*W
MH_.:\1]@I,LP`F#-22=@+Q8$$B0SI<#G#@I$LEB![)B[?2@;#T282GJD-?,F
MA>`!4L`Q[^J+P&;E"EH_2M7K[%A0VA!2T1-'JJX<F"2-:/"";$0<MZ$E(&'P
M8-A>ML/84CRB)/L`4,&U%(9^G\\(!'M!@D=`-BV*DK"8;](%8<XT\F5]#M4+
M9#DD=;1F(L'9O*X[Y(?P%%,VNE&@E(=$J%$Y/;M\A=H>)BT!5T,`$5QB'$04
M"(HYR\E'U9@G4U]PPTBM]D:`DL(;U\!<?1&\H4?(^@H?"HC*"C414>L'.MP1
M&`T38"(P5O1FY#IRI7Q?6D0K[Z#PQ!X7U'*V(4EI*SL$H"+4$L3M`JH&E!``
M#.-*)R<2/5Y%`.._@IY2O*K`%0P&&'6T\PPMA\(KT!(C;Y:!ER"16'T`[H4`
M--,W"BT*#],<&U$P!LQ@&-`T%D*P>4I&+`P4B$(E:'14((00P6F)!F7;W<XR
M=3&V\O\`OYRUQW_>-&F:+.,2<^SGW^,7[G].,NN/;?5L'2,8H5Q($RUQE`JE
M!"*W4,33;'E%D]``BE)`)7W:-'@<+`X4P6\=PGY>2`*`>@D2+&CS\8D)\0MV
MPG8R?H1^24P(=2SRSI7H!X1YT\3=$%8@\^O#^2T*-#PMJ?0%,4[*/ET!)UH5
M>V)K%<=/.*.4G<`?R$<(PURZEFTM')<0:,%6&A,94*H%*"%5Y7TX)\9]HR(+
MK7^.LT(X"[^6`KOCK+LW;_&<S['LZ'LN*+KCZ`7B"*`5JB0(($%P!@!:6IYW
MJG3L36Y"!U".^4A0W(;.)%B;G5)0K"T5-.&+/\6*O*7?1\:,3FT]<>FVQR\`
MY8AMQ5,82\M`AHLW(O<7%%YMJ,JS$!`&4;L8)[4;UCA?8GC<0!VUSP&@.[NB
MMQ<;HS2?H-!BDJSZ*0JQ$\F.B%3X'0>+RNG7(XO;"UGJT2M()*6\BZB]`!6L
M@`#1(T)6IC>$"02EJ>BD!)P'LLB*]`[%F13>\+Q)T9R^'AUHJ(`_@!N/@[G/
MD2-]C3XCR_+R_@X#]#/<OSG*#0^EN)>OY@^_8]/Q:C0_]`O`\/@7J8BOCR-V
M[P]GC[R4]Q`7"0B=.?R%<"&">N6QTX]@-^KT'H4!8#D!+P=@$&A=H?GE_+_M
MV$J;7N='7W/Y=]#Z4/6CZ7Z9H64V;^HBB>C_`'?9X?&GY`,2'00Z1[0FSX\8
MIY`-42/:JJ^<WCTGBNWY_P`/G#WR$5@"/`.CYFW(C!+P^+PN";%=,Q5:\^CS
MG>\;,8R8/\YY]/\`F>,W?SG^;[D[10\?[_/U>/[YH!QF?MWEG]E_@]]#`#ZB
MPQT];^KQ_<]!G[=Y9_9?X/8\S.I\X^A\>,^V')AX^@2^&,*(^KQ_<P3>J"1Y
M)5^<WQ@0A6-)Z':YX?OFZ(&D;2%3\E]_ISZ(9QPF(FGZG']S->LW)LE*?$WX
MP->LY0A'_,A_)O\`2/6F_P!_QBK^WZ=,L^^:-#%$B4X`H(`HK6\X#Z+98("#
M9H(88#\```@$```"!HRN#?T5CY)@IJ:\<?S]&^VWUN4]14RNN/XQ1SBCC;?6
M/\'I*.?<:<H_/]!^,2/Q[UN!<?8%]"9KTN#BJYPCO+,JWYS?DIAL7K/MU,\I
MO7]9R'GWK>^/G&.T@_E_^>Y;Z7VC,=^X;^@M=L'23KYQ)I]7TE]1/2Y?2^P+
MCK!_0$M?W^^\TKGJ_P#,HF+/49C]&^T_0('?&*K7G'G"PG*S-'6;$\8F*]9N
MGQ<J7XN"%,%;LF(72`=Z_9D0.3\_O^<V3SE;LU@Q=9]IRA:6:SN_DP-=A#$!
MAQ?T*ST$`\5B4/+<!TO#^L0J[W&=N^#`$WJ,#!40\&"MV3`K*V-X$3GID7=8
M3KO*1NC#2K!,!/8O]YR'+<"$4+>LB)NT<HAPOZ%YP/4H#E7^LU/G&-GC^_GT
M+*O5SE+I+QCLK0S.N]R_C/*\+@"KK6_OANK=\8<AZQC\/C+(<8)Z'Z!RSU)`
M['-M`N(.-Z_=QHDW;G^*9HFI)G)8W%Y\$_&$+KJ'C%J/#/ZS==<W.(G7]_?'
3Q/\`>4/+U./T#Q[7ZAZG'TO_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g575431g18q24.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g575431g18q24.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`)D%D
M;V)E`&3``````0,`%00#!@H-```-"P``,I4``$$_``!0BO_;`(0``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("
M`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"`@(!`@(#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\(`$0@`Q@",`P$1
M``(1`0,1`?_$`0X```("`@,!`0`````````````(!PD%!@(#!`$*`0$``04!
M`0$`````````````!@$#!`4'`@@)$``!!`(!`0<#!`,!```````%`@,$!@$'
M`#`0(!$6%S=($A,54"$4"&`Q&"(1``$$``0#`P<+`@4"!P````,!`@0%`!$2
M!B$3%#$B!Q`@03(C%3?P44*3L]/5%G:65V$D<8$S0S214J&B4T0E91<2``$"
M!`,$!0<+`P4```````$1`@`A$@,Q0011(A,%,&%Q,D(0@9&Q4B,&\*'!T>%B
M<I(S%!50<"2"LE-C)1,!`0`"`@$#`P,$`P$``````1$`(3%!43!A<1`@@?"1
MH4"QP=%08.'Q_]H`#`,!``(1`Q$```%HAFP`````````"M0LK&_```Q`E)&!
M'8VYO(QQR``*@1OQOP``*\#??&<H,8^TK/YO\0UGPW[!VR0_*4Z7-2\(`!4"
M-^-^```CNF^@*J[O<%[A'TW]W$0\^5K+&;G%;%=K\Z,GL.5@`5`C?C?@`$;8
M\I_.GJ_NS.QKH.*E/-=%\;K%Q+K_`)IIQQ[-3%[T)3\$^BML`J!&_&_`#$"O
M&5UO78!P>D>B[A:+BRFJ>[W#Y[L_IHVOY]R)D1@`"H$;\;\#02ODLM/S,:#]
M'H_U70N-["XYFIY8FT^V<VW.;_!MIEOB8`%0(WXWY$Y`@Y!ZQ$]+]#51VOH:
M"=/UGIW\$8W3%XW%+U]U\'[:@N=I5B3*%0(WXWA6X61'81YZ\HO)]5O6NV-/
M\$_2=G<>,7GROX%2K%Z^W&5R".3L)8/85`C?DSFC#(@:=6E:DJU&^[7$4[+L
MKYOM3`<ST+'0K?\`Z#.,3[=0`"H$;\@(L\`"IV=QRFOO/-YNAN_L:Y_)\]2M
M=.\UEN,"DC&1_9S2``5`C?FA#^``H.19J]Q/3X[;'9+7929:3.9_CTSAGI\6
M:^5ZF8@`"H$;\7HM$`!'^!3^%_SU^B-!ZS$F#^L>33_C75+CNP9;OO/]WE>I
MFL``J!&_/4-D<P-6HKWXC.6AU.;!FZP5EXU,MX^6^J?.V0>R?]"/GG?P`"H$
M;\S!NA.8$9V?:[<6F^HSC186;Z/>:TXV_3)VO6P9%N$"8200*@1OQIBOHL>`
M".1)ZM<IZ[*>OM?,FU\L/Y=U4B&>`J!&_&_$+)-&G`1A7Q5HL-N_Y5>]28?=
MES:TF>@`"H$;\;\!7"<1?C3S&>BU6K_M5Q1,WNPSBD_&3`"H$;\;\``KJ)\J
MBRM(8\7/"KO=:=M?$@T+H6U@!4"-^-^``*42J*76N"/AM:FQ4JOBC@#4`!4"
M-^-^```KAA3:ZLJ>H4BB0QYP`"H$;\;\```(`*^23C=1@1@0``*@1OQOP`#!
MG4>XUXY'$V$\IUG@-P`J!&_&_%#()&O%1-%)U/*80PIES5C028BR,"H$V09L
M``````````K4/__:``@!`0`!!0+3.F=7']7>@6F^>@6F^>@6F^>@6F^>@6F^
M>@6F^>@6F^>@6F^>@6F^>@6F^>@6F^>@6F^>@6F^>@6F^>@6F^>@6F^>G-'_
M`.A]!>S?=F3X0Z.?VY_/9`6N^'[)7ZQN-L1>B1H5)K%F&P26,XSW?EAH+V;[
MLKS'3+O6M95NBQA/]AC&;=6KI6+?'*[S$%Y4FB-"1FGQMB9C=SY8:"]F^[N+
M:6:5$M>U+M<!W&\J8RCZ_"N_V#(`ZE0MH5Z]QNY\L-!>S?<MUB\J`+F?*V6Q
MQ*%:9]9FTFXBA<T21AM\_P##"=5ZC,6QUIO#37;\L-!>S?:N?";G%]ILCK?L
MJ-K7,/6>Z`DY=6W>"/IMN[:,7K,^3_/GPYOX^?5+`-LX'N?+#07LWV'K!'!X
MJ`^T7XN[`A/NW&4V3M7BG.4(PC#F5XPI&%X3E//ZRETN0NY\L-!>S?+K;85*
MKU*B9V%66&&8K'(O]>J(W$V'0INOSN58PG[N/MD=7W$96HZ,/+'NRX%`<VRQ
M#9,[-BA<PI;<^%SY8:"]FU*2A++A_9-Y2E*$\M9SRW7_`.7<%J7:@5BA7("Y
M5[/J2B6/%U7E.$D-)5&>=*"1QN'C7E+PE-`J2.1X[$1CGRPT%[-W=HH_6=;5
M=L"/[+`%C6(*5+^4"BT)<3<M=S2(^1M':H?!4H6.YTK9+#6[P!-L'H/<^6&@
MO9N\/';7;NW^S5M-CL)880FKWP]5.5FY`;8R<KH:R1#]"AUPMJ745/K&:]]"
M[/W/EAH+V;@52UKV-V[EJM-L=;#ZQHN'ZCK+04A9RF:^8!#0EG,2`E=$5YB&
M/M8X]1G1/X/N?+#07LV"3#K>VNW;N%,D^2VF+!(J^NX8;DJ7%@QBVP"1!=`L
M%.SB#A"=@=SY8:"]F[3!9BVU*DK3V'%"&PV*%`L,L<-'B(=SV4)JC:R$PWF$
M4&$N+P0D&ZZ!2!B=SY8:"]F]N#(\JN:X+NF*AV7$7+,UG%\K"43I)XWF0#'.
MP42I#$=UT+8':R$J8MJP&XU=$2]FH'SZM8HMK`]GRPT%[-SQP\M$''G:!?NT
M^;P,:9#I:-JF3XQR09P^W6&!\&-DN@+F%$Q;H.*!3\2!@R`'A=GRPT%[-\VI
M0G9Q;5!<R8"=EK4=;O+JDH:A#HPQ$1HBF5B<\DD4$C"\.FR?JB]SY8:"]F^S
M96O'=@*KT:7""#[W8YUDV$/($9B&_!E""+<];C;6)\IV&Q(`Q"P^D&P3@^+-
MASVNWY8:"]F^X;!10>Q+;'<;)<C1BY:03JF9V(`;$58N47D2CM1&C-?:P#ZU
M*;*[?EAH+V;[FR00K"W'E38)>LRT'RI%#SJ\F15<@.RY4"FURT2^;<L<J4K7
MNK!VNYG;\L-!>S?=V:+MI2/&M8"3$=H?@_FEN?3!K:!TFX[5(&HVI@P:;,[G
MRPT%[-]XC0!<VPA[A<BLZM*OED$?1:]M:/`:VK8$OW?EAH+V;[CQ,;&>;+"G
MH>9L/$H?&K[TDT`K]ACM':\E&)L/,ILH->EK+"FF';"`8[?EAH+V;YMJ#L(E
M'VU9KB!'5XV2@O%:+8<LV?7IXV!*!RQW8^OJI9J^*\H;.,Z=,56?/-5^B6P?
ML$O3[@DE%U+L8="K6M"D9KL^6&F;??8.KO/6S.>>MF<\];,YYZV9SSULSGGK
M9G//6S.>>MF<\];,YYZV9SSULSGGK9G//6S.>>MF<\];,YYZV9SS#:O^A__:
M``@!`@`!!0+]+SG"<(FKR](CNQ'?Y_@I*OK3U)4G[6(\B`[!Q^W'9;LV24;&
MMR<OOQ4,R$/8Z3J_MHBM0)2<,N9;)P(<9F$01#A?2KPPHG99R8#J7NG(Q'\(
M\M&>)D\=F,J;22G/0!D%N2AM:7$=.%-AQGDQI;3)$C)*2!#`V1)@D)`N3,8F
M-J:&NQ('3Q!9\,J)*0Q#=?F)"/J+/CY,=9?\PWF"\IMG/2QCZL_PVOIPE^$\
M\Q,F26HLAJ5R2A<I[IX_;C,I+G9%?7"7&&#B&6A0YGEB@QDQNF`A,S)2&66T
MRPZ<\5A2%_ZRL_)C-3B<HAGIMD<BN(V@-FY44E3$XSE.9ECPRF1)?E+#N.N1
M>GL>/-D5[E?!F).6WY#<7&,JSY@KL.6*+"2;/4*,@Y#F<Y5F*/?E<L<"Z.XD
M0ID/.MV)J[%TW$_6C(^9AR&&0WSPQV*0AQ+;33*>OX\Q^J^'^:__V@`(`0,`
M`04"_2XT=Z9(GZU@-@F\*=85JW#T&=#<'S>I1ZA@\]FH3`EBSC"L1Q$,.,K#
M]BD#9-!%'2UCJ1.O.](*,_,$E?EJZP]8Q$<M4[B^:)E0WYT[E;65K16];A+'
M?QD6`M7UJZ55=M6'K71)\=)*C2XG`M!L$(MBK@QQFUF)$/A@;*$D>G)!&Y81
MTB)ES*]71U8'VR=8APXV`@6<:'GAY#6P#D8M8^F[LRQ*>"$:J21.+Q(0=RZ0
MFJH*OE<+/53-/>;MK<19[I9_;GWU>.'ON-`#(6*`M5I!S*QP+;Y`8/U%M93V
M/(P^AV7*C87,E.<%R'<N],D^XPSE:U99GYQS&<*3_O&!C3JX\1F-U%QL2\9J
M<ACF(;+.?#QXR,^O+;:&DS$I2[TZVXPV1X0G0V^9;;4[_KGX\B\U+B2XJ^I%
M7.;3X>''9"&N#9`5/&WF7L61;.!W33GP5B0SE+TU2N>/9C.4Y4I2\];PYX<S
M^J>/ASQYX_YI_]H`"`$"`@8_`OZ74<(G^F<HX.H%-U%2""-U8#A@>EI9^I%\
M:\O_`':>[3`GK[#MRPG"C&&W=>]SL`3G3U0G*WN?I:1B,#F)@>K.!:O6RVXD
ME"2RB7?V='6BQ?O<PNFU>#-P)WC\DV8K'%`W8LW=%<=<K9OKX72ZA\AC%_2W
M;#7\=NZX^')<#ACE.*PM.V&67O:;]"!=T(.S/S?,).9<E0XB75L^OI%O10Y&
MC*'"^$&,]D2:KMAC^)8`;!=5)N]MRRS^E(O:BY?;9-AJA?%C+$;$SQ$H#FX=
M)==JK`OL>"!U=<-YC0?V]<G))1\NS*/W.J3B(D@DH-OF=PVK-!0CVO0<E[8-
M_1.%2$3&([(%_6,+3>WP3FL6M4]S2V_,#9TDU6!RFV7OL.*M9CURANA[MYSZ
M=[(X3@\HKM\89K+!?3U0;;@"X.3=G%K2<V56,W!NX8>''#.<47&^[.+?I&P]
M?T1+#HD&,).J!J+?>;@8N:JYB7S<?L@<9I!!\@OWGN-P)C.0Z11".D[R5V0W
M!$/T?5A'$>]SK@'=[J>:9]#DC<M,\\_6L#56VAMVI)9KTAX\V,:J;8H8UH9L
M`BO1[I]G+S;/5V0;;PEP914).&<(X,>_:2GS9^9.R!QR*!D,.D.MK;;8P3+N
MZG7U1P]/K-*QWY?1Q)&*N.Y]L['2^:4*,8X5A'W]N7VQQ+[BYT>\R<@[.D_Q
M%-MET.N`>P`9]@<A/IR\@U5BX_2:3_D4@G\`!!=\S=KH&DXMU[!F]U3W=I^C
M#MQA!C'[?F%XDC&@%P'4YS<^IJ]9!E'_`)5UERVS(2([6E"/..EW-)IWW0>^
M;;?JGYY=4*<8J:$M[?JAUC2:8LY=_P!3@YS_`,6#T^Z&ANVK&*=7:N6G??:6
M^N&W[`/[5EM_$.2%NZ/STE.I<ND+-HCAT.7YO3A%>IWG[,OMA!AY*'@%IVQ1
M9:UK-@"?V[__V@`(`0,"!C\"_I;-+IQ5?N.#0.LR@MTA_P#88VKB%QI<G>"8
M`;)+(*<8_=6PXZ:HBI#2HR6+-W3:@V]8;32]KPK:DFA"$!?Q1=T-XM-VS<+#
M3@K2A3#U=*=;KP?XJV4V<1WLJ)H/$1V#JT>L^&+=K^/<Y-0;IJ=;8H7AK-7-
M5H(4KBC28I=W3%S1\CT]I@1[FVRM!N$>+&1*`[!A%7Q18MV.9BXX(P@AS)4N
MW7.3,(N2YQ=YGHM8TZ!]QQN"V0\BZJO`<I`VH5(P1,";@XF@7=NC#L=[)[9;
M">CM\NXK+/$/>=ZAM<<A)3)8Y;RGX9TS=9R_BEM^X7#=%6\9$(5+BN\E-**1
M`Y+?NANM+%GA/!JY.(F!L[1&MY7S-MBU?LW?<T.7BLWL"K@XM0$EIF'=T4F-
M)S'0<P-IW+KWO;3)ATPZAR/%*@4E09$[$C@$MXA'=S3LV1=U=FU<9H3>5U"O
M<7/D,3(#`*0/]1FVWH6B_J[]H&EXW6->%]ZW:A_3]*9EY12<I#T9=&=/\.FX
M&W"CBBVV_>-0+6IMQV1;U^C?<UFHN$"\O>-QQ[P^Z3)/#+)4T-SD+^+J7&BX
MYCN[>"NJJ'=:)CJH'B=#^+JG6=%3.Y9>0ZXOAV@YDN'8L-^)KMRZ-:RT+55R
MZK3*A75^))8IU+.-+RK3Z._JF\P<ZV76RG"&[O\`=<%WJ@M(W":I1=T6L7BM
M<=X@BL+)X7$.V])R[3<NUCM!J=.RV;E(6M&!6E"/%MD<Q%SX?-]G\@;)+K8=
MOACI+U&?:)'"/XWEE?`K+S4:B7%!U9`8`0W4?#6F9JM9QFAS7+^F54@!S9U4
MA5D"2F8;H.<L/#J:]&N0M>![0QQ(AVAY1=9<9HTM.`*EE(0`K/)%S(,U!A^D
MLL>VYHQPG$^*:RZ@2>W'I&OL\%EEOAIJJ_$3/\M,/^,KMNUI^9VFTWWDI3("
M>1!D&DA?#B(N<['O=%;LF[N(:F@+NS0J,)PSXM-C4'1N`W`!6%?0IFB+XE0A
M-L<&S=-MU`<.(*`=H"G$9C\JQJN<?"]'#NW3QG^\;O#>PN)2-]=T!DXOW=#J
M/W#'/J%R9QQ:OB`PE)$FN'1+'5#]/4X6[@1P4BKMVQHM-I-X#3M%#9D))RU'
MV@<2IQ&ZIC4V>6ZJT^^YK6AH*%"]H*#\*KU>2[R2W8LNT=QK\-QRW`A)(D[S
MA<E1$Z11AY*'DHJRZHI:T!NW'Y>B-YY]7JC@N)+$]'2#AR+CC%3B28IOS&W/
M[?7%39MA#A"@N#8]WCMZ3@4EQ."8KU15<LW7#T_[83A@.[)PD5/DR*;801N[
M.D]]WBPAO;+Z%]7DX3VMNW?9^O9Z^J.-2UKM@"`=D3CB:=GID?,#],?Y;7-<
M?G\^'2SO7`W94?D/-$H3Q0'W;BZC[P(`[,O.J]D+9<UPZBL%EQ.*7"GTS^9>
MD!BJH13:D/*HD85Y)/\`;O\`_]H`"`$!`08_`ME7%QLJEL+.PI12)LV0(JFD
M&4ID4A%0R)JR3'P]V_\`4G^_Q\/=O_4G^_Q\/=O_`%)_O\?#W;_U)_O\?#W;
M_P!2?[_'P]V_]2?[_'P]V_\`4G^_Q\/=O_4G^_Q\/=O_`%)_O\?#W;_U)_O\
M?#W;_P!2?[_'P]V_]2?[_'P]V_\`4G^_Q\/=O_4G^_Q\/=O_`%)_O\?#W;_U
M)_O\?DK\M5OY4YW4>X]!.BYWY!ZWF:>9KU=7W^WMQX>_I\/VY_.E2YTN/$C0
MHAY\P\@K!#C0HK%))EF<]40<<`VJKGKP1,5D?8I(@I-ANNMV?:6.Z*JYA$VM
M,O(G74$^7MN6*IL)L&^&G*BD4H!/*4>3G<6X@6%U5;QAZZB%35L';L,WY2K=
MYPKF\V_O0V[>8YJO@13,CRXRG)DL)OL4>?@K(5C:[V@V-Q;;`K[Z0(@O_CDA
M71IFZ]P55M+WYO%YBS(8^290PJ^"47+RC9*\>/#78%+N"53OW5-DU<W>$WI)
MUR.#MZH28048MA'+`-N3<#VM8TI1/[2/:-799%V+;;XB[FW1#EG$(AH@85@0
M+H_O"/76)((`4LB_C0$<1[`-"1T=O,4*=YR\%1<ER7+T+\W^/F_+^-L>'OZ?
M#]N?SM]SG^']GOF5O/IW;4W)7`@R1Q8?NV#`_).XB2I$=U!10K*,LGF)J`9I
MWD=[5%3%ON?<DGWW/=!Y]I-LA17@#%A69-SIS0B``5U8P[M[C"L);"SLT:C7
MM[%ZJX:T>T#$.+W;&B@?*@@<B=-*21DDB1($K$4B:]#D<[2WU<ED[>MXU@UK
MWC>+VD>6Q1]JDA2F!EL8J<4<K,E3%Q0[PV94[HVO[SEMA-<,)G+%#(*R(<T2
MP9)BGE('BCV*%6^CY\?_`*)LH4(+;"QD[TJY-Q%=6MV,*\K;8]ON"[BU=DL/
M>4>B@6)FU4)89),9Q^6T[H_=1TYPY=7M*2.5)AQ]P!:;>N\+>S-&ER]];HDZ
MU]U$F:',C0$34P+DYFG2-C?,^7\;8\/?T^'[<_G,J*0@UW-/&A6D<P9FU,-7
M*G5$$1KQ$D&5JH)CD5.USDRR1T>HM9P.@87FR61([(BS7-TJ+K.4NDK`JF;6
MHC6ZN*HJHW+"/`JB(Q=3',<K'-?Z%1S>\U<=],ES]'S8ATGN:-/M*P(:^!->
M9104KXP6BC=5&"B%+(`QB,[KAH].*KGGFQD<S8%VT><JEDD3J&JWUR0WKI2;
M&S^DWO-3UVM\WY?QMCP]_3X?MS^;/O?=LVV2"/F.B04;S,L\N:5SO]**+M*]
M&O5C..E<L3KRSB]-*L7A(L;(C&QXS8XA1&#0W?4?3,;D[Z7;Z<%W;#K"R:<4
MIT9S@YODN0:>VECC(G,+""3N.>W/)V?H:Y4]]6NW+.!6<P;.ID1GCT<W_24P
MW>V`QZ\$<]K4U*B=JIG7RYD27#CV`5E0"G`00IT='Z%+'>]&M*S4G:F?!4^=
M/(JY<,_\>W$2_G&F45"(C#QY@5='LY[AN1R+5N7B!C5_]QQ1%]5'+GD,2*]R
M#8P:.*1Y2N1C4:BD*17$(]<N+E555?,^7\;8\/?T^'[<_F1ZQ\N.RQEQI4R-
M"<5B2CQ(1(H9DD0%7F/#&+."U[D3)JD;\^*W;]?7MW)7SKB'MN;.I"S"GH+T
M\@HC`LB/KDV^1D9C-1@ML&S@((BJ!R(ND<_?@J\I(#'FA"ZAP+:7I1SNCC-B
MG!+E#*_Z"KRT7BN7;B=26L2NVM!@B/)H&A71"%50PJ0D`[U[9P0C4NM$1#=[
M@CD1';T9NID:-514+-JXL@02];2+RH2UI([\V2YY#:7:.]K4ZIZC,1>GVU'M
M[=A_[:FW#7#+!J7#9HZM[FZ@R!.8NEC!/1SD]?1V+)LB"BQB22N(X,*.&%"%
MK^A'B@:P(!M]")B#+Z0$Y(\H$A8LMG-B2$`5A%!)'_N`*B9.3TIBNN*I0I'D
M1PZHHBA(M>?E#<2O-R%TC-%U(BMX<,N'F_+^-L>'OZ?#]N?RP!*$TRRN99*^
MEK8Z>UL)XX,NQ<-2JG*BQQ0X)"$*_NL:WTN5K5C[S1![>,VUB6LMZU=K#9&L
M88!5R.B0;`Q>K/;;<8:KMA#D],X:0I(W-D#*!D,YHD<AJZ269`*\3%?#EGC2
MH9Y,=V68C&BSC#<Y.*M(Y/3C<<Z&9SHLJ_MI$4CE5ZOB$G'=%XJYRY(!6Y<>
MS&C/CEV>G+&28[B:ES_\,9._QQDU?5X?X8W31Z2ZXTR'9H[).5E+"L5Z:L\T
M)G#3T<4\WY?QMCP]_3X?MS^2=?S4:5D-H50"D>/-I94>*2250QYDEE?7-D<^
M4083.#&8]^AV62S5WE'BW]5*NUN::9U[C'B'52-D58I->V/%&;;$I"0FS*\W
M3S!ZE[JJ5F`QHPAQX\<0P1P!8T8@A"Q!B$(;41K!C8U$1$X(GD.&6MK,EG<K
MNN28D5T7-573"C!'TS1Y+V%:9?ZX=!EN21#D,=(J[)&Z6RXFO1D1.P<L"Y(1
MGHS1?5<F%=VIEGPQS,ER^;T_-B#NL]:I*R:!)3V1^82;71GC0HI%E%Y371PD
M&N>I-2,^GIX81D9CB$*1HVL&USGD(Y<FL8S+4YSE=P1.W&TYMAM^7MW=L(\.
M@H(=<""(\B7.,P`AR8LB7#CLJ;-C.=.!(()Z:'/9D9H78M'V&V+X1*J->N5H
MGTA.LF[8APYE[`$UER]`&C`EZVN<Y0O8(F1%5&(^VY]%:&94T,/<9#!E4O+6
MNEE:$?.U6;20I!RZFQQE:UTE1OT\&.5(DX*.0,V*"6)':-2#D":9B.Y;R#U:
M7_1<Y/F7R?+^-L>'OZ?#]N?"N<J-:U%<YSER:UJ<5557@B(F"RH-TVJH*\=W
M4P["@Y;CS=HV#(*2)E;N@3=S[:NB6]E7B[L9]59U*+FJO]56L8UK&,:C6,:B
M-:UK4R:UK4X(U$\EE<-!U1XPACA1%=RVR[*:<4"LBO)DJB')L)(V.=DJM:N>
M2]F.L+O:Y;:N7F:XH:T=.)<]72AHRPSQ70$ST>U4DK1_OZ^_A=N>*E1`BL/D
M`-\+G)MZ40CQHQR3G.ZW:D\I&IW#$Y*KDQLDKET8N*1\9T=D6<;H1ZE+KKBD
M4E>5A7*JF82(YO'//Y^.>-K6UC03ATJ%ERG331=<4;@5LLD;GYY\AZR]"-UY
M*C_ZX<I%:C$:JO5^2-1J)WE=GPTY8@;GHSOI2AL(=FZ+`9'-3R7Q9+)"J&,W
ME],IU'DO+)RT]#/G?7VL04V(\@#<HN?=-&,R1&.)[%:0,B.<;7L>Q4>QR9HN
M)[4V_#1+*(6#,R=(17PY'3=5%&[G:HP)O1!Y[1:$/RFZ]6E,2D;5O:DT00RD
M2RM<CLC@BQ1:_P"^XD;%A#%K]91-T*NE53`(L4(H\:,$<>/'`QH@@`%B#$$0
MV(C!B$-J(U$X(GD^7\;8\/?T^'[<^+"/4UB7)9*Q(TVJ0P(Y["DD3`"OXD(L
MJ3!BLL#TKSM`I#A8A53OIBWM25DNJM-UWEI>3X5@M0Z=$CFL9CJB'*?2A9$<
M8-:1CB(I)+V&(]JG(B(OEL:26\H0V$9X>HCN1LB*7@^-,C.5'-21#D,:4>:*
MW6U,T5.&(VW]Y3JB+.DJ@H%I&F@2NM7HU%[\8AEG4<M^:>QDIRE5VD1S+APR
M-:]CVJQ['HCFO:Y,G-<U>#FN3"#VO9=%TQ>JC4=@XIJ=AFA0")6N:[GTZ<EC
M6\MF<?)C41@_6P>AD7)]MR-:R)4.%4UL,QU>,8G21S9`K*2=A.4GMX\C)79]
M[/"K>V]M>=Y'97-G.M&-<WBU1BG'.(6E>S2B98J:S;C!28^X2S(<S;\F<6MJ
MYQ&5DR<*9S!0K%L.?%="1><T#E</4-V35U,66($B&<$F1`L:Z8@VS:RRAOY<
MJ%*03RA5S%R<Q['.$83F$&YS'M<OF?+^-L>'OZ?#]N?`*.3'NZZN%-L]OP+"
MM%O7;#E!;2(`EFON(VV+S;]L^OFU8I$?3:U>M6Z2(X:D&[R[=VM6RY5=7W$6
MRL+8\0KXY;%D0L.,"MYXE:5L-.H<^0Q%3FYC:O<U-<YK`B8U^>MK1L:UV?;J
M1$R=GG@<<3O>M,S)ONB8546,/_ZN:K2$BZ4[`NU@RX-0?K8>ZJE?W0$19E9)
M1`V4+/+_`%XVIVH6:Y(4:O"Y>QRXZ*Y@BEB3-P7KF.3$(J9<Z'*&K9$4V7TF
M.3-."\,1P6&\*^!02$<\EE-`*;>58$=ESY-%'FUI;>(SZ1HGM,\O8Y9O2-O"
MMO?SE-EPWMK+P?2I4@BR$T2"T\>*22UI9"(K'%>8Q$9FQJM17H[?98W_`!?>
M-*"0J(B-+=@H877$143VJMK"01*[T*+1VM7S?E_&V/#W]/A^W/BNMS[-V[04
M(I!Y)9U/*":P85(<IR"(6-*HVG@6$XSB$YE?(.D@SN]RUU-\H3[ML34A*R2O
MN6WA"?+L13IJ-8M?%K1!D'N$L>2W7$&QQ"<M'-TN8CVHFY]X;T"!R^R=`V(>
MM8].UO42F+O4<4:(G>4S0?Y+A&5"TN[)R(G-'8[C=>'X<?[BD?-Z(#^'%.E8
MN"#L*JBV]45B+*'80F1-N>Y'HU!];$LH?1K6O1O=54<C7M[CD<U5:LF-#M"@
MVNU[>AW795+8&Z;.,J+J;&HSA2$)[%3A/D1P,)VLA*W(BO#61>6\[D),F&(2
M58V!D3+G6%A)<27+(B<$UN5&-[K<FHB8WA3>&ON*#7F%MZ[MX\PAXKH-M;K>
M@M';<5E=9U4.UG0ZN(9[9`"!:1R%<-W.5<-A54:;`?5RY,*WKK4G.N8=TK^L
ML/?!^=(ZN?.)+ZI9"$>V4P[3,<YCVKYOR_C;'A[^GP_;GQ#HIDVL-9]8<81U
M]%)K&G6=0'FN;#]X^(]]8D;#CRAN,982B=J>C,N6]1^795A)S2I"Z]@*5W_'
MCWUFVI;2D*OJ@>:%'G1QD=DFL_*]8K47#Z:!11-T3P.1)`I0@NJ*ESD1[77%
MD:/*#!54R<@F,+*>G%HE3-4'*MIA[J:,K)$6&XLMFV:0[$<C7T.WC2Y,2'(:
MCO\`DOUR%^BYC5T(>9-D`B1(PW&D2I)6`C@$Q,WD*8BM&-C4[55<"%MFKLTI
M7$TS-P##7-MC`R7-VVJ>^EUL5^OZ$N8Y!)ZS0'8J+A:"H995MP7G64N)N(94
MNK@R(%DRS)9.))B79AIH8_D'*D<:,8C1B0:8W)T_JDVOM4MBB>IUOO#=`HA.
M"Y+*+"'I)]+E##GPT^;\OXVQX>_I\/VY\5]Q9[_J-N5J=';.K[&.R+9DC;>(
MB3HU?N(]Y#B0Z&:2>#K@/AG5^?KMU-T(YJHYKD1S7-7-KFKQ145."HJ>6T+N
M!L-]&&!*/;ML0LDP?=P0O++ZL!6$&8"!8JN:K5S3T8CSH]78;%V\-5(&EKKF
MXA6ML$@U:B6L.-8^Z-NQW(N?(C#=-3)N9P*CPX#7U<*-7PHZ*@8L0+`!9J57
M.5&,1$UO>JJY>USES7C@\>-'/N"['W$JJYS&LCF<-2";;61<H57K;Q1CU60Y
MJZF"<F:H&XWA&O"\HC3Q8SJ"S_*5*5$842B/"98TQK`+2(J29,E\CM4?*:JL
M1_NZQ@S^6JH_HI<>5H5%R5'\@C]*HN-LPMOOBIN=;J).JG2FE(")&AN5;N=-
M''<PZ5WN5YXY,G#YCI#1:VN(W!F$EFL[.PDNL+JWDM:R1:61!"`XZB'[*+'#
M'CC"`#.X``V,3/+-?,^7\;8\/?T^'[<^(]G(?4QQT-E&G29=G.CT;AP2ZHIA
M1-SEJ[8^VWDE&`]\@0VO<P2CUC1^MM2>3/\`>LR.)T&79HPW3V1H;U#U\&2<
M,9]G`E-:CA3.6-)3?::6*JL3R6]?`:,DXL9"PPF?RPR9,0PI@(9R+F@P3"1T
M$]W'2UZKDN-$JQ;!M$[I-N2QD9N=DCU71&;?:U]K,/KX-Y`BM+VC5S>."!D]
M9M:K[.A`0;=R3V.1%_OYX2$'M\#V.XAC:YW9F>,]'#P&N##@Q885U=,*!%0)
M">F2=K6,4TUV:YF<JO<JJKE=FN8AK++RXRJ9".>C%YB=L@CV(S,B-;ZR\<DP
M*5>T^W]R@RT<V7554PR(C>7S(\U8[C#.-.Q4?P_I@IML5577=7R^K?"BB#*+
MRT]F.61$ZA_*S72CE5$]';B5;RA2)`XZQA,C1$$Z5*E398($*(#GECQT+*FR
M6#12$8-%=FYR)FN#U\_;%U&?%?"B22K*H7A!9V4";80(A'-MO]&4*"Y$,W4U
MKGLUHWO:(%_#":/'G=2B!D.CO*,D29(@G:KXII`'(AXSLE1W%O:B+P3R?+^-
ML>'OZ?#]N?!8%I!AV4$^GGPI\8,R(;0]I&<V/(80)-)&HJ9IP5,6E9=DNK*+
M+#2P)V\+]H(\0.WJ6EFRJVQDSXT"%7\T5K:I`>>28LJTEE<UO+Z<8B^7D@5'
M32IW?2@6=G-<GS_]J8GWBS)ACV#-)1%)J"BYL74G#4JIHX9]F:X*0]C'-3/C
MJ@H8!)SPG;I3,C^4N?>:_P#W?3ZJ8D`=&1P3#>')2*URL(U6/U9)])J^CLP^
M##8\2J1\AZ$>XJOST,UZU1$3)$1,N&&S'SQ0,N"$*9@FOX9\O(BY%S1/5XYX
M),OHR/J[&&2(&A*Y71NE(J(>19"X-+/,0?<1<^F:B:<B*]<)+]QQEE('DMD/
M+*>5OL)$7J&/>=7-G]-+*SJ4_N-)7]_O.S%7UD44.&%QGL`)%RYLDY94HSW.
M5SRR)4HSRE(Y5>0CU<Y5<JKY?E_&V/#W]/A^W/Y*C?<>_E5+=NFYT^1T$S<<
MJI@R&QH$Z;MNM,<U95E;$]L:3TIB15#U`TU(1I2R959*@;<_L&[2-:333;B;
M`2$-DTDD\AQ)4^OZ]CG09Q^5)FQGH]X69(XGD<)L<"T)H(BO.CLRM,@-/>S5
M'(13,1-*(K="Y]O81SU5K$8Y7*F>:-RXY9<<\$#$<9XG&>]''<BD5.QN:,1K
M$70B=B8EOEG$2,]W]L)C>+$SX9]U,N[V\79KA(C8ID9RN;UB*J,1WS)W<OZ=
MN>>*U;@NE`N"YCN>V.A2E:Q%"Y7^MS\NQ,G?-B1"]$9['B3YAES16I_1KF?^
M;S?E_&V/#W]/A^W/Y=MB]X-@QJ>;/F'U-20QY20'-@.+6E"6';1F3F,0T<RB
M1P7.5A&D1JXK(4Z'4U\F%#%#="H>8E-''$3IX[*P9@1R1X?3C;H$K?8IW,W:
M=2BJ$V_`6&2S/7D,)F_VK&9%YCY!R6DWP[A[:4K8X'/:-TP3"KW!%(Y6:Y4:
M'8/KS*>(7J!J]%Y#0,]FG*>QR<?^N6&B*[GY#:,CWHF951NESG-3NYOQ9LFM
M$P#9+DA-'EF@=9-.?:[)1Z>WCC41[!MS1-3W(U,U[$S=DF:XYHHA9CE>UG*%
MVIJ^DN37NR_R[<0HUDTSNG5IT1I7#>PBM7N*K?0Q'9?Y8NI3+*&GNV1E:'(9
MH0PXXQ*YA3E+H&P&;2]_/1W5X\,<^#+C3`KV&BG%(%]8)SV^9\OXVQX>_I\/
MVY_-_.M="V@&EJK.L@;DF"K*[\SUUMN"3"<\FLVWUFRF3QWPW%>.T8C&&U,`
MI!N21U"M=RCB'I?]'6--#FY_.B(GDG%L8HZYHS\J(O%5D`179.<SF.74UN7>
MX([/@G##!$]L)CVO:YK^2[/U5U-553+)?^F$>1S7H/@-B-S;EEDBNU^E,6@[
M&`.''CG8RO(QRN62)>9J>YVMS7=U&KP1N6>7:F+ROK*WK9N\NB"6NAV5?6RK
M?GD0Y:^O-=2!0WG]V]0YH=2(3O(FE%S238;9HY.SMS[;L[ZSL=OV.VX5')Z.
M91UNWB5M8M7)DUCZVBER<SH-V?4R$=ED]JN\OR_C;'A[^GP_;G\VIW(+9:[A
MW$ES208EC`?`C659);-UTLTY+`)HCX`;16`*1S2/C@D/<UKDU)B-07T_;\;=
MDZ*6<RK@SE=FT!W+S(`IG)LID6,/(9#\EB*N:Z69Z4A39,N7%Z$>2PF.7D25
M1SG#*CD=H5CM?>X+J1$3A@VWX4Q8MU)AO+&)H?RQ=KN\5K7<M[AM7)4XIV]N
M6/5][7$8#6]WF%Y[^;IU]C#&Y0G9_P#<_3B,:0#IIIH['$CJCO9G<WU%;ZZ)
MJ]';B0W<CQL8TZN&805&O)_]-F8A-<JKV<%5K?6]"8KJ^KK]G[OVF&7T%;2S
MJIN[&;CM*^J/*L(X[>JD3"[<O.?)BP*\?*89\@I2O5([%7%N2NLIEC`G#$E;
M'M6ME3:5YI,J5=I&M2.=)6'<E6*YX$T#1\1'Y*]RN\SY?QMCP]_3X?MS^=4"
MVA`$^;UC4-;^^Y50>J%SHV>ML65`,>LE@YK93Q%?*8+N@%S"\\#=K;EO8TG<
M].T$*;/B-9+=,G,NH&V>KY%:PG1RI=E:0^IB.:WIGRT;FYK.;CJ@%A$E:.4L
MDL;DR.3GGR^:WGD5F?HSRPF4]FO+O(H%TY_T=S57+_+$>78SHR-;($P(\]#3
M22.T1AH\JL]HXRII:B*KEX8)"VO6H"GE5F\)@I^XXSFUF_JS:K2Q=R4NW[&G
MNFV6W9W(;(>*1,CL<Y!:V-T]LCQ#VY6)M6DNJ"#ML.TTK?=4X1]M6$Z&>9N4
M`I1HA+6.03@1]+&D''54(JN72SS/E_&V/#W]/A^W/Y]?;AC0(0&3Q7%TV/%R
MG7=E62&3:)AI.M&!KX=KG.*QK=1Y@@O<O!VJPMZ67>V;+BD\7/$.#1P)S$ER
M::+,J=E;`@5+)D.VA13O%7FG`3I9`RG)GRWYJU;\UWX@W^RZBLM97Y:MC1Z@
M,ZU1:2JED=/F;FV1MR3.I*2UZIO"MB/.BN8I7-"UZ[5.P$*'NJ^C;8M?><TA
M((Z>;`GQI[-TP@Q8YW%-JAMD`CMY;7H72KT;GAU_&CR&V+R3IC(B65F6@JK*
MYTOOIE#2R91854^V,BJ16-U9.5&Y(YR+YOR_C;'A[^GP_;G\UT>3808YV1B3
M'@-+`(S8@D<XLIPWO:](PT8NI_JIE@EB*SKRUXM7-G#FQGPQZ<M7,DM(H6:=
M29YKA("RXR3G"Y[8:G%U3@(NE3)'U<U1(OTLLL.MZH-064V*VE?8U[8A"MAQ
M#$DLJW28^:M!'D27/Y6>37/5<N.!Q]QTE->1(QDEB!=5L*RCQSL:YJ21CG!,
M,1F,>J:TR5$5<0QAN*9HY"<J`P5A!1AT&[D<N&UI<B(-Z:,F=B\,+`27&6<T
M7/=#0XNJ:!5TH98^KFH)5^EEE@L`-C!+.!GSH0Y8'RPZ<L^;&:13#RS]*8D2
M26=>.-$D.B2I#YL9H(TMCD8^+(*XB,#(:]R(K'*CD5<`0]Y4!64%DB-S;*$/
MJ`%5S1'!J,G-"1S51KFYHJIY?E_&V/#W]/A^W/Y*&'L<UA&B$F3?S%(IEKTM
MF!Z/16].L_=&SU9';+(I".%,YB.&S,1AJ\;J2'''N%BC!NN'&]W7-+%W!NF[
MJZVJ!M2V5L(XRDK9]A,,4\..QQW/0:/C\I7(VAV?:5-R>S%7''*N#28D\3X-
M+$A11[@M98Y17A?N2P<]L<3\Y)'#(YS41KLO&.M?L@5];[S_`#M.VSO9)>V_
M[<%QL@]+3T;GV=@"]KYD8B]"W0+I.29SE*UJN1=\/@^&!:]UYLNEVS6;<ZO9
M#),K=$!MTYN\K)@-PK011U;)K`!,V2><J+GRTT-RV[N"3X96,.NI(9;(=D,V
MPDGV5_:TAZDL3<TH6Z'6(ZRFKR<CEQV3623.1<^2%O,\4"2J&PA/ORMDT444
MK:U+N6:^/M@%7RF?E:<_:%&YLF*UD(PE$[_</WN.-T[6W,5;#>LJS8JR)-J#
MW;N.KASZ:6Z%"='>[W/!N*>&2"016C_N'E(Y-!-2DL0>":K5V&R;O;ON,I_#
MH`XUS-G5Q`6%JT&X21@@)&C*SG1.KD-&QO=S[J;!L9E8Z5'VQMDE1N#<LIVW
M&`LYJ[0J*?WG6GKY+-VVEC,G5J,,EL%P1`XB7/3B_D5&P%-=`\3UW]2;K+8;
M6CCDU4"+7D]QQ3MNO?S).X>B+`>(X8T9HI3G/(B8D;=-&KIL*_N?#3=%M<5L
MF`5D;<='N:K_`#?:RH%^_*=-LZH237MY)0%=%5F3G/1CO"\=OM>O63MG>F^9
M6Y9;O<A(\JNL*W>Z5MO$BB,YL>MM+6WCF%`"QO1$+_I,:S5Y?E_&V-E1*WPC
MNKR`"E$R-;1]V;*A!G#YILCCBV%R":!JKZ",:['P.W!^]_#W\?Q\#MP?O?P]
M_'\?`[<'[W\/?Q_'P.W!^]_#W\?Q\#MP?O?P]_'\?`[<'[W\/?Q_'P.W!^]_
M#W\?Q\#MP?O?P]_'\?`[<'[W\/?Q_'P.W!^]_#W\?Q\#MP?O?P]_'\?`[<'[
MW\/?Q_'P.W!^]_#W\?Q\#MP?O?P]_'\?`[<'[W\/?Q_'P.W!^]_#W\?Q[Y_(
M%E^8.=H_)_O_`&UUO+_(/)Y_O?WC[CT]/[;+G:LN[ZW#'__:``@!`0,!/R%+
MY`-:%(30<?U&'#APX<.'#APX<.'#AP^!6A\,Z7\[N:)8;;D74ER*^PHC#*M5
MK((7,Y1NG$\@^`<9/TG$2D[*/%=TU0H`Q620%Z9BMC33!4V!8,.5.!X]2PK0
MCCI357YT+B(0=+D?#B=,6Y.XY-`+OT>@Q#D^Y8JVQ.@0ZBY33#21_P"*VO;!
MVURZ&M%@$8YMZ$Q>*8G!+AZE6$=\1&"7^K,4&)1:ZZVA6._=@?3/7#T.7`'L
MV8UK7<A'HZ68BB91%WHP&(0XRE2Y`(CGT="A+Z5AHY.BWH^[^Z%(LX\I-K;`
M*A,Q-Y8G9/Z'STP+Q6`9V\.$(&A#A9,`8^E`FA1PCKC5\9JB-S*ET.7@P:(R
MBE`"\P&$8@O^0@&3UNF5?1L(PHNZHE<`!/#'$ZX_96YT^;R^P@'B-,VW+4T-
M^:5Y\`T@29EAXDBRF?':-&J&YX]YY'R,C0&#.9MP7%1:&'RURA\?FB)\EY5W
MD>+5*)TU]&4@3T;#LN,\'X*EQ_(:6?G;E,[C#G5]&<>0>O15RCP8NF8^N"@H
M`&+$.X/)FS\J[:U_^8+3@H_+C9WA<]4@>'Y_.*$CS@W34<CR6=I='4-C8.F?
M?8=&L`%-TS_ESR(J4KL8`N2`T/?=1Y)/G``/H&N2H>&#@BIK"I%_'4W=R9L5
M2\03RJ2ZZQ`;J<--^Z3+,"\S0;E00Y6A`N-['$'`-G65WW@$JH0US0T])2V4
M?6;BD0-3%-R6?A0?(-N!5MZM@KL>0W]EA`?\`BKP.JN@PRD4FQWGDN51Q/L3
M,X0AN`:#Z*/O$@-XEZJA"A*Y-*UPULI[KDESU.($G<GZU%5-RG6[(L:;30#P
M,29`888.$(Q/A()13K%VZF71OK]4-Q=A2X:@0EG:O<V8DN<.9V;]2@(`,H&!
M`HHJ=$5VP(!4=2>[("@0&OLL*;F$P><(D"QOV<+T+*T&([BL%,T/>U)]*0(&
M!1]JB&;1*ZB670E"U8HB1,[JI39X,`NM\XVQ]%*<\RGSP%46-_G8N@/TF2CZ
M[#4A13YPU]'WP!>S[UYHA807)>.?:]H)]A*ODQ"WF9,8,N+WKZ$/7]E;S<ZC
MT?B<8SA8MTXWP;9D*E#C`3ARQ"[M63U(J\@D3/\`.4!W[1`&$YP35B9;C,^:
MRU!X<OZ,I6TBM!??80;GUWL^H[**_93PR:#:#@"6<D;Q&W2IT#`.JQ@O=U'"
M1G=J26D(::>?>!)`OG$P$+V%@U*@"M;DUJB&P-QL8@)%0L4V`S\PKV!<B"'9
M])1)P2_=89?YL4\=Z6Z;[$Y^V_:1%-L@!^B]39FT"*/,@_BJP+;E58QIKAJ2
M=]4:V-0@Q^`NZH$'-/#'6^[<FN',TV0LVG4F$.(-"HPD;_NL*N)OP+)I=]Y`
M!_P"(O*ZB:3ZK)[#5D6=!"5Q@G,C1%<8.V#!=,5"UWE5K"*7-N.B4I482OAX
M-7SC(UD&-4F9`()"(PQ",1F\M`Z1F(D0`6GSLH7>RWB&&J_?6';T&B,ZT&A`
M9)[IK08<V2'ZI)&`2#R)+`!1")`32$4!\7*1;C?;2WS`VEY;$IQ!4V3UN[MO
MY,Q)(T.`@$X<3DR1HH2*.X:ZN."2^C9,#S:APO,II_CBBS&V4&#N0ZBT_K7%
M5>"117!3R;VP:7VUA(?X#P`>+5Q)L^W8K:3K)(&[<(B:6)WIEI$TI71&>>OV
M)Z5><_.QIF'*&\+V/(4`S9C-$)+[[8]SB.2ZF6X!;FA=M<KB:^@3@/T*CC%I
M88P0-YXE\AK6I`ZUK=.)&)MS.Z6L,PK83[;#:2&@QR>ZT>8X>8!0>3]Y_6MW
M&3`7IF[2PW=C&J.(P.N@.)NX\P36).=JA7.#""N>)69!V%.PG75/%'*;Y3X)
MO&A+O9]-N!1'D9<(>`A*]7_26$)9]9Q-00Y;DOZS=(5]I28S.I^2YT;V^F4(
MJ46Y>W&0I06^FXBZA'B1T"U0)O%RN<@T(4J[[+UG<>"^RE0X.\,;59E5U!DT
M]CCG)'HL1U]OP_@X&HL.'C*1=/(801T33!@M8^?2L+_3CB84P@#QG=()G>$\
M!E.8_265Z!M6AGM:%8Y6I?F.E(EVO3>#;SC`OJ9\'3NY4D0%AH!I!38I'\:/
M!4NE'I4C.L1,B:<H?5_I-6$&(IPMZ`KVL)H_#ZZ%U!,^&50T<\5C0'?!#E3P
MQHG(`\".G`UP'SE1T*M0@WDYK,DGYHOO%DT[QVD!-35_KGN"5P#(%IYGVDY*
MD-R@7KO=J+KTTK#$`9HC#?2Y-,9A/7F`P$?@!SP<W82%P!DM=6*-THL]II'N
M<3QXH`H?K*&,A+C.RT3V*)"Y-<QY-%_P]6D3;"V3/I-XWL;<?O>B#M7U7.N)
M:-9`C%7=,H1"MM]"'(5FST&0Q[A!A;*0-O4]L+(2)3A<M4FJD<6%(4'757$,
MIB&)E3%//8C?WD-#H#.')L1PK#J$*[XV*`4L7`CR.@P7UBF';6`8FU$0]]@M
M_>%DYE9LA"=C*8<:/2B%>H`$KB!$*H:E]N!@.ONL*O=J+18,B]`([DX8UV(K
MUQAEKG4<?QVCGKQRTT\VN0C,YO*JI8P1IV7+XAC;/C95')]2\@\R/82F^`>S
M!A>LF?7$Z0MD@$%**D2("\%5G-/`QI'MJ!&(CE?']4"!)3B80PVC6'FI9PRA
M%_E>6$UU`LCZP_A,[9$@3B'']#`@0($"!`@0($"!`@0('Z:L]_Q#67__V@`(
M`0(#`3\A_P"+<\(N'@[)'.^,XY#L%CPZ7#=.T3F?KXPJJ%_?U?-3^#S_`*R.
M8UZP/4G`M!Y,)1H&;.]J4AW&A05/+RY8M-6':;"\#?8W+D:4M5]T04\)ISKS
MM_IY].O2.C]<99R(ZT.N&FA*GD@YMRO]/QF[<`$?V`-0&IV4S2V6`5$"VIB.
MCG=`9H/E+\^<)$J)`:\-IVQ+[8';*!5JHV=4P$)Z?`=./+[><H@'\(=?/]\"
MO$0"5^SS>?>^,!0KP:/?_P"8HU^NHV'N>%ZZ,,)XN;>#=R%!4JN<X0_;V_'J
M6M`++7A1W/$3IPM3@2FUF^2D\F\M9UBIU`5]WE6JOXF54RF-)!71LD*`MT\C
M0-!4[<6#S3+]+`A:J37=FH)J)@K"2<\.?-)QPZ]0:*+N\?'_`+<E?:#9KT4F
MU!G>-(F\Q1X)2/.KA/-DM7-9I=/"C?&,04ZYC-3D>OYF55*HJ/RJN.SK@[7Y
MQ6<>+ZC6Q%(Q7TAQYC,-Q\G_`)D1;V(SKALUK&1!SH"\Z!XG!#1R@@B06^8]
M_/T-)XJ]@;V?OS7E?42CD,_\+7_7YSG$BE<%`6\$3>]J]G><E=-87\#>E.ES
MO=Y%_OD6#%0$UR'*2WF7\>FDGXA2POD/'F76E`M$0!^P3*LO+Y_+GX[\3EBI
MN>N3_9[E'S@HJJH&)\)LP)UY8?DP7Z'.0@<)0/GE5^5G7+ZB%85P#O;#\GW-
MY*BZWR?<_@E_.5/Y`?WXK-/+%8?M/_;XUB%Q\]?!P9M=1D?8?V=?QUZFG><P
M=B#E1)J7!OT3K.L?YZ]6AP#I[5^<C\>O``=U48-7T8^?)-[V'R">,`V3@M:>
M(*M["M[OJTU:;BG\/Y^Y<O&_I/P=>,_-#=_Y/\>4QP@HQ[WC0<]8H8]H^+?L
M3/E)0L%>%8.6_!>IMZ7+XI,W/5R'[O!\OSDJ?['\_H?.`'`/HPY3`$?D=9O1
M5B%\PAZTW<N_;^@-_C[>><?4Z^V:]>+]`>OW<]N\V'O]-]_T%_ZC_]H`"`$#
M`P$_(?\`BW.^1)8_EYZQ(R1"IMRWEO2U.?EA)R5#(I37N><W9[`TIE:M(O[8
MT1E2M%"*4[#Y#U>!LBJAP0%A0/#"KBND-E`V9BB<"0QZ%")Y'G&66`-(K<(@
M'I:#%N@,/%I+5VKJYH,U<)Q!=FT*7D&%3KH=_`;^/9[ST]M*!6?`>P=TH+A<
M8,!F=(33!OO`6GW5YCCM#+'8*<(FO%#HF*!H!A*N%DM8VF3J25JL:FDK@O;]
MDP98B#P'9#D/"5S\(-?0@3?<T?,3""`I@`K="`\`0-'IG5]%LA58/#75:,>)
M%;2`?F%E>Y2R>X$TC$/"=NFQX,7%VFDK`P3L@/?L>8L>!@R5:.-L<SO!*^8:
MUPZX*`G#R<+8`<A!3;=*H^I5Z2H02:.R@:."SD00%4=`0&3&AR0*N32BL!I`
M#5E59W!,F%$784N6#CR4<U`-0T-\B-@R(GEW3W4:AN`U!IGB.,5#D`EX0<SU
M"3$G$]SK?=?'-K;MMAJ@Y3$C88RDD7IVJ.86G=QJEE(T5"2+R!'`RBT0W4JO
M8TE\(N'*8T4.[I(B;)-C+CTH4=U<..4LR!@LWSZ2`K@SE$]F,("!(!H0D#LO
M#O$*><Q"4@,LY0D!:<$L`=%#2-;73]!BRT12$,-3CAK#U"4CQG>'TQ6SV<H0
M4X4%!E+^,MI77=^=%]FLZQ^W_AC]2;O>G^/;U#!Z3V$Z]W_>>_B55SFCP?[O
MT]SA9Q>$_7\.\00A?(['\9[$2"GX>OS?G"6&^5M_7P>H*:/3;P:=X1^E7/,_
M.2P+S_DWB!6S$W_C[?\`7YR.F/75I^?4V@"@^;I\L#_;Z%OGL"'S1/C%=885
MG'X2?Y=_!K%!=#-.P>+$//0]X]A-Y[D1=GP%4]G7J[I<X_[/\GO@!.&;(WQ/
M\^,1'Y][^QMGDO#IGQ@Z_L7'ZT7W04>VI?>=^I[$HYPR?S^W.?O`]_\`G]\K
MEY^E9H]FG/=D:U_GUKJ84?27GUM3W^VQUZI]#CZW=/7!B>\;S67U;K#SUFE]
MOHSK_L/_V@`,`P$``A$#$0``$````````!````!!```````L@``````/6/``
M````4!.50````$ECD````(&/?.```(`'++VH``(!^'K!(`!(!VL^P`````"'
M7(````!L/W8``!``V<G(``!``K*PX```(!%+I`(``(`-:BO```!`%O*P````
M)/%H^`````%78;`````,`,A``````A!``````!(!````````(`(``!)(!))`
M`````````!/_V@`(`0$#`3\0>^X"J_=Y%!K^AH4*%"A0H4*%"A0H4*%#]3"?
M>\-.<FOOH4GJA3;%0C4@R6J2/=:T3)1R0)R)9BR>R'T5:18V>SP#0>.=T!):
MA1HE3'T.T1/28HU+T;V/L%>^=TJV>H4.$5_[T>8/'R6`DFPQ?L2O-@2/Y(N<
M2Z@OBH'FN@X:CA-V1B+85_U=O/+7NFQW"33&3T>+60QF:QH(#L'J6E`;KL#A
M\&[60](L!2RP"@(AC*01'8Z3R8[?>_\`A;`1SHR_.A-`'2U5)>KW]$C(I-0F
M5Q3F'WG4@_:A5H+],4*.R-!GB:`@3((>?QV(CGBB@,O63"4XIQL,<D`&[YIO
MR;.-V(+`&[DJG4N`Q6K:%I*G"SF8B"Q$I0%@!HJ!\N^VX^R<]^>_'D\=UDRM
M;1`N%?0*"=P;GP@B0NC?!<'*M?A,!KB`-22?YZV)1#,\U0C`);F,P`29B7K8
MH;EBW,:!B0VCZJEK#&6-0]VQ=.'P*U0]WO=,D*QABQ@ZS[/T8??7G_HE!&[-
M20/X!TA]`R<0)P'YGL69+[NV_4B`?T%82S4N206"`H&*>QLP!%UPQOF;SOWU
ML`"K`-#@,E5O<[E('70YT-GA&/($1$T)8(PL7%@1BFW1+W'+;#5/4`SY-D0]
M`4)U0*C'P!:>A^DQ-$4_,JF(?0JFC.'W(LX`#Z*!D9]6Q`.%(,&AF!Q&&-O<
M/!ZLKTB/8Z*GOB4<E`:;FB#W8F)*#;AAV8I8PLJXD%?KH3Z,"LR60!.Z,+JN
MGV(JC"B0%A:9YZ8N^>?'BYD8YBMFU.4M&M$OJ4$'@MQK0!``JSZ:Q"^2I8SN
M]\U*DE0Q5/```'T%8O$O1XKP[<-,?)-,T*C\"<$VQK6!1C(#*929;T*H2X3#
MF!\#EW0`\5SW42A^VJ3!R;`&ZS6%B.AY=%:RYC`B)-R_.Y/,-307HY:3N[H.
M.!N2*2_5PRWN;=GD&^(K[0`^PH3VF7:;K:B+'V/BMK8+!3\(*\JRFN.*F8N`
MV.M-8_,V'TYIPK;W))+RD1'-`Q,^PJ:39TR6W;3313HCDLYHMB5:PB(4/CB>
MKR-:L"=\D>H+%4ZD"4ONNI0U..O)F$VV,Z3C9U!6#<(1B/,I/77`G`W9>7`E
MRS<@@?X=C%X+3?25P#5[`@-2&UA)#\L?RV/1I/;4?5I9W(>+UZ)N[6RR3$UN
M.:8RA/G`;[B@!#TZCP*?N_;4G`/E5[W>CF6+-+;(J03Y:S*AY!Y,6I8\)6&Z
MKQ987HX<S(!S/:B&A$-V7HM;EY)X?S=YNJ2;.6;`F$&C@Z.Y^\<=CIE"2@'D
M(T+"A]+O[#MC;;M^PV^:_P"O&XJ$M]X@J&*&Q(^L7%[IB,&XX14)NT$W+A,,
MIA,IKH9!Y?\`#B,`F(7SX:0P>1;J1<58!]XH7PL1\OOI@0;8`>"W&M`$%`C/
MJN<5DY<C%TH14F>E54>KQ."P6*7`)$T>L^@`.!UU76>&W\3F7F?&15QR1@A6
M.)W`RL@H[^DF#&L+U\7?U)*%)'IW,4P_>90#L7;IY(DYW(,F"#I(-`R3ZY(1
MH=?SAU^P"R"XI6NNE\(B3,KH(`JB'`AGN@&,BC,KMB/Y<[-@;WM4LLZ\U/KF
M\FX"/Q.)&%I\-^YYH02>NP`UFIG?9&@N?N$JT/2\`(`<:-N-4KXJ),"G[<4#
MI`SO(E7AAP(ENTK1%`0+'[/FT&]11=4AJU%Q4@QO8ZR*1`R\0]0J682!F6@B
M"U7FETA4`'+C4X3*L,N)=2)IIE*IMBQFYWPPT,CEG_D\UH468"`2`*9G9%6O
MY!VD@+[@JA8T7`4'Y8;7\]GB[NA4G"G7P*D5_P!7<7CR+0Q9WPT6$>8<7EWN
MAT3>-)HI/'))K%6D"FV[`#U+]78F%R@5R8PZY&!-;&(!$30Q0+1-O+E#@'@`
MKO)NB/[/0*!I3*0IN:^/C[Z<*W2[X:@\N"F`+'][*LS4S6UVFHX!5$QLX,44
MF1,]#Q6`$RG7(B`;2+9`&F?.6QO.1RE6C`'-=NM3"D\5,*-]I`1JSR0;!#OB
M.^);<C==Q:[R62F&*287$?2*`K=P\>IZ8SLL*%5KC>[.7P4U]&'G*-[$7+4\
MAFR0XT"CF(K5B3$^[?$88YX%0*N+Q]@S+!%91B(?U<8$GE.2R#HF6IS"FLL`
MO2$4#Q"Z!?D,\DN>20OC9?6:C<U@-RF61/T=*1R?O7=(1Y$PU#%$F6'1H;+K
M(>?#FR+F53D8M&M*XG(D3JWTTP*G#:Y*)%AY'J4((]A7-_WN_"(%!I1:="^=
MC'=]$\ZJT?#!#C735\SW%UXQV;"N':2C]5`Q&"I2PL!\[*)S6;'Y2L<)IL+[
M\R7DGG;J8:>QP11WU8H!6-BIWF^LF#QM](8*G&?IMPR6J*)JJS,[EBTI2>EL
M"R]6.1LAETT-&G392@<P@2>O;(IS(.1`T^&+@!6]*4?9+.P0QM`4:)AV'$R0
M%)VH;)N%'-;UE.$($N5#GSFR`II!A?9+.P01E$P*9C=F+]%@S>7:E,$>YQ'T
M)+E"`VX:_?@1&0:4'VE"+`%*S*5#,_5BF'F7VI9]O2B:E+J)8,Z'3D[85].K
MTNP.&#!>M@D'C2<&!DK(BZ0QR!Y%61W[RN0':<X&R(*29*`6^#37S^J1J\1E
M9%D#');UAB\>9`X3O*+V)`!?G$<.))89JH(3>M!<,2:BOV+@[8G;Z=53"UE%
M_H:%"A0H4*%"A0H4*%"A06)X7*__V@`(`0(#`3\0_P"+=2.3X`KEF$("."NE
M;+6;8<27NUM]\$Y$YTB=8ID0)D%E&BSPX.,!`Z8*6*7X7U6-"=NGW@T5Z.NW
M4$YT253$Z#9P#``KTH$3D38GN.:5H<\"!,BE>Q<!KT*XZ%(#D5%VN>15H.7`
M$@`HVTX((V._GP>YL[#T]-LWL^7P.V,-S!TN=#2+B-7H(Q.T!&N=<@Y0Z4X?
MAA&32\A1*/,DNX3^UN3/F"`T`\!A*$$@AR#6'8+<0!Y1N/%6F]FS$#FFN'VT
MFR#3T+8!"H$VU_*[7W?3028T6>TB(?'%VSG'"E6=`JKV`M]VA@OO4-0`"!5`
MY*S3(4+0;'MTG0(7N=K50;0T'H*E9+``%S#=T4XRHE@@&3,&A&H53AX3U`W;
M)IE'CT`Z`AA,VF<A1I92B"B'%62,HD`*C6V"6`7;]`%&$30:"2C/2,25`;HT
M.%!%2B);B$KGZ*E2DX6IV<%1"!NDJ?*=2OI_`7Q^`)/AB6]"@*HITG%*R-P*
M#R#?HLX@4$DN!6?&.!0:E$,(>3F@XV!:5#9-CV`M9OHT9KEN%0W7:Q**9*EC
M985J7<3E_P#;2F7;.J@"SF!\>EQ3(?*P_EPUZCOW[<)[.YWWB[416T51%)5$
M1@W-TH&-3>F#5YQ3*,K0!8$%"[8C>??Z!]QKW:-PY=12"A]->(PCX38X0:LW
M_>'^SR`7$!'8X<[96"L05-;"Z29'6.YR&S%1$-*-251X43Y%0^XGMD6GH(-(
M"()8!I/4'-""X+#[M>"ME8*7PAXD1`A%$21RH>8JG=Q*^(X`=QU%LYX'2B=/
MTEEMT%/\N$Z8[--%,&L&0MUS`NW1J(JR0*TYIA@-"X4C9Z<BW$HW='05"((`
M1;SV)?`P*/`WQ>6!.(S;X@'^##!7N&/[_P!\%@=(W\LU[+["B3%:MRM#P&CV
M`\M=XQY$&4+*[1$/C3U"E&?U"^0.8@"0,9_%CU(P61V_8/!(!V^J5<K2##AB
M$K)`%5\`;7#UXR#8;&-VDH)P&*B<;64V1`MT1Z:@5XQS=`JDNH&U[^]--UI!
M7H"`\``#0``#.'#:<(Z#'JZ+K$9B*W]'RX@Q!$BZ.H,R<E.G9,!9,,1>5D9[
M!%!Z:#U^3*OQ;C[C8:LO#BX-"4(=93XX@Y>?!9V,YD,<%@```@!H`X`.#`##
M,E!&Y@%%Z3-MB;#N8:,*RL]4+A&"C9PUJ:Q$ABASG?J#4P\;S77'T[Q`'JB+
M!K.HXB*?6$#BCQZAQ]**ZQ61:X*K>,@.O4&.2[,7ICY&"I7G!!Y>L,RELW]"
M_P#4/__:``@!`P,!/Q#_`(L0`^Y-&]$*M"KH<-+*H965'!:H2LU?P2.@0D*A
ML:08=0EVWT"0<NV:#*82)$FV3Q2J'J"#O1&PHBJ45PET5B\$*S;&!)X-XR@H
M"!.Q%$\8AY+%VE])Z)(Y"A81\C%P[>$/-3F('B(5U/J84>^TT'@E1TM492/2
MD%_O:%`/`36$5_6&_(&HU<\!DB0C#5OTYE)D.%F.^!4.RNHBHD8/T\J`6!B2
MN%02?9%KHM='!7X<6B,:,6875I!QM;4PLQ6KDOA"D$0458-```>G0\!!)-X4
MFIDU2WTS(CG&OX&YBO\`?B,"E-8Z@-'@`NXPQ'2.6SB:UX%D6-CC:W2%2#*S
M6P;S[L1K2A:T^R$0^H(2/FB+?:P\2AC+VF3&*,]&6TVPJ@P"P*&B666,U!X@
M>#@4Y(>V:802\H+15PV<#](LA73!T)$!X86^<2X]I-O&B7ID0M5@`.3T6,W:
M=X853?E>[Y\`@6@U?:1;@22&)HQ:S<\!":BCLMD@MPL-YGC&]492IM<&BUOR
M)"''1AQHQJ`']F3:&NNYQ>Y[>EPD"OP;QTSX'^>;^I@\&'%C"%A5"`P^Y0K6
MRJ:B&`W09N9OX5T%B.4BC3G-R`GW$8EHFG?4X";$1RGRWY/QW^/V,%&G.;C<
M](HT*',2!1501SLO`NM@5!V2<UI5TX^(`GS@(2-J2-BU%8\*B1M]-0"J'(4U
MUH!Z--Q#(JT"'R*J/O<F'PC@?'0/+KDNDSV0HI]ND3L`=F`"6``>%4?SP[-X
MTY29KS6H]C'X!6,<34.J`!=H%9;">F2!8)3P`O8T-%$13`K9N&@>P<'-'XS\
M#G3\E/[Y*(O3A!7[_P`:['[O%,.!7@V^Z\K\X3D1"<"4OM0%/SWZG$C3P-07
M095*L5)]!9,YGL==DCH44*A><Z,AU5WY93QH#U@2JZ#\X=["NHNH\(I=*&!`
MY*302V;(HD)H$]6&D0D@DWP4]@UHDR6@]GEVONKM>5VY_?\`4>ZZ?SX'`O6#
MX!2AQSADN-&KM'GR3'^'$C>"Y!T02F@?3TS=9YB,_.:")J*!]O-\#>KE&G&O
MG\>'Z)QE%14\]XM<(J"B(?"1,U^B52."I8>/6:PX,WA,;O`/A@+QCK7J39@%
M8<X<;Y^GMUE)ZI`U+EW3'0_58^S$3GU@(;P4Z.20UB`([Q3SZI$3!-\?`PP=
*<93UVY.O^I?_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g575431g19e20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g575431g19e20.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`)D%D
M;V)E`&3``````0,`%00#!@H-```8<P``=W0``)'%``"G5O_;`(0``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("
M`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"`@(!`@(#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\(`$0@!*`)+`P$1
M``(1`0,1`?_$`.\``0`!!`,!`0`````````````(!@<)"@,$!0(!`0$`````
M````````````````$``"`@$#`@,&!@(#```````%!@0'`P$""``W4#4V$"`4
M-!460&`1$D4X$QBP)!<1``$$`0($`P,'!@D*!`(+``,!`@0%!A$2`"$3%"(5
M!S$C%A`R)+1UM79004(S-+8@8%%A)2:&QHA`<5+20Y.S=#4V,%07"'*6D6-S
M1%65U5;6-Q@2`0```````````````````+`3`0$!`0`"`0,#`P0#`0$```$1
M`"$0,4%08%$@0&$P\)%Q@;'QH+"AP='_V@`,`P$``A$#$0```<_@`+!E('BD
MQ2`I-@J(`````````````````````````````````$.BWY2!+`P%&28RI@``
M``````````````QJDABQ!ZAZQYA6!31^%["1P````````````!9\T@S-\;#P
M````````````````+,%1E.'"?A4Y0A5)1Q=XJPX3J'>/L`````````%.%-`\
M<T@S-\;#P````````````````,8I)@A&=L^CS"X!9\X2K2A"Y!<D\4MX7()1
MDF0```````#'$18/3,BII>&<$V'@````````````````1Z+D%A3A+RGF':.$
MY"J2ISTP````````````6?-(,S?&P\````````````````"*Q<XL&4$?I)4L
MD4F562)+Q@````````````%GS2#,WQL/````````````````````````````
M``````&%DJ`G4:7AG!-AX``````````````````````````````````C\=X]
M,T@S-\;#P````````````````````````````````(@EZ"ZP!9\T@S-\;#P`
M```````````````````````````````,-1E!+J$!CSB51I!F;XV'@```````
M`````````````````````````0[+W%UB`QVRZ1I>&<$V'@``````````````
M``````````````````8IR<)?<`L^:09F^,KA>(O`````````````````````
M``````````"W95)CX)S%>%FRE"KS2#,WQ:DG,93SVBI0````````````````
M`````````````86C(J8^C(\7W,59Y),XTO#."88#*^9FRN3TBL#RCOES@```
M````````````````````````0$+O$<28!>L`L^:09F^,,!E?,<!/\GL7%.L=
MTR?@```````````````````````````Q;DP2"Y/DOL<!^%IS2#,WQA@,KYC@
M)_D0"_Y:`J`V>#QRORGB_P"`"&!U#T3H'$=,N*6D*L/%):E<````````````
M``````$)24A!$FT7*,3!9HR8&EX9IC#V91#'J3M(DE_"T![I-HI(R`EFC*:4
MT7C/D\$H4MP7&.L?9Z!USS3HE\#U#A!]G"?!V0<)V3X.$^P<)V3[.L<Q]G3.
M8'P<Q]G6.8'6/LYCX!S'"=`QZDO"-I.PKPI$[109I!F;XPP&5\QP$_R(!?\`
M+0%0%0%OR_Y$`V3B-YEO(=DS",A*\C22J(VDDBSY>`M>70+>%PP`````````
M````````8W211'XF`79`+/FD&9OC#`97S'`3_(@%_P`M`5`5`6_+_D0";YC@
M,TYBP-E4QMF5XQK&5(QQ&5@QZF3DAB3J(,D[3'&9'"`9/PAB3.+4%URVY7Y1
M!5Y3![YXAZYT#G/TZQW#QRH2E2MRA"XQ:@NN6H+KEJ"ZY:@NN8SR2!#(R8E>
M`Q0DPC3(,T9A\,I!CS)W$3"^Y:8]X]XH,ON1-)H&/,RCF)HS0F",S]&`4S\F
M`8V%S7H,_)@&,_1@%-D<Q;F94A(9,"&1D<+,$X"(Q)\CT7K+/EP2ARKCPSMG
MT=`]0\HJ`I0KXM427(,$Z""Y.@@N3I(+$Y2"1.8BV28+L@C(5V67+GEO#O'0
M.^?)]'`?AVSRCTCVC@*7/;/%*@*9+@EHR^Q&\EH1:)+$6"61%\E:0]+K%$%:
MEJR319(O066*U+`%WC5\)WF/@D^6@+@`M^7_`"(!-\@`9/S$`9OS`";#QKPF
MPZ:\1L?&N"9OC8^!BS+K$]@"SY>``````````````````````B$=\I4]0P1%
M;%C2WY?\B`3?(`&3\Q`&;\P`FP\:\)L.FO$;'QK@F;XV/@8TB;I=`B(4T2`+
MP```````````````````````$5SHFNP6_+_D0";Y``R?F(`S?F`$V'C7A-AT
MUXC8^-<$S?&Q\#$N9#2KB&Y3A?PD:=\```````````````````````&I$6_+
M_D0";Y``R?F(`S?F`$V'C7A-ATUXC8^-<$S?&Q\#&*36+R`%DRK3F!\'9/@X
M3F/@X3F.8ZQS'V=8',=8YCF.$',=8',<)]G,<(/LX3X.R#A.R?!PGV#A.R?9
MUCF/LQ/E,$"2(9-8@>9*C$\9GC!$9_3`$9_S``;$QKLF:PV4``"WY3)S%X``
M`````````````````"`92)0)?@B07].Z4^7_`"7Q1!T2))1A8(BJ>N8@#-^8
M`38>->$V'37B-CXUP3-\;'P`*2,4!P$]R1IWP``````````````````<1UCY
M.4XBG2J#B.<[``!;`HXH4I@QQ&`$V'C7A-ATUXC8^-<$S?&Q\```6?+P````
M````````````````````````&+@QNDQS!(9IC7:-CXUP3-\;'P``!9\O````
M`````````````````````````65/+.P6I(6&M$;'QK@F;XV/@`4D8@#M&08D
M:=\`````````````````````````````&-\PN&2DUG3-\;'P`!:0Y#K%X```
M```````````````````````````"B2-Y&8U8C-\;'P``!9\O````````````
M````````````````````8H#5B,WQL?``\TQE%0DQB\``````````````````
M`````````````!!$PT$W#-2`#Q"$Q41(HKD[X````````(O%.ES#Z*-+P%&'
MDE5%!%'%:@J8Z);PJTJ`J@M87&.4\LI4YSP2Y1>@````````MH6H/6)&````
M`````````$'RACTR&!,4^BE2M2@RN"Z)&<K4JPX"E3T"ERKCKE:'I$9"Y1;(
MIXG(2E``````````````````````````````````````````````!__:``@!
M`0`!!0+W'>P!Z-N<K0^R2N&XAN5FZMIT(+)41(W3!/Y$N!=<&J`PK]FL+I`J
MQPQGFV.;QD-_,FU!V3CE>+9;TWP)_LYL6;%L1K85NL@%N,.#H=?L,G'#W=H:
MTA6LS[Z3;WTK50:)?`_.5*7;,$"$Q^RN1?\`%MGS!;S7@[YKX$:24@H5RJ:W
MF"#$E('[]:X1MVD2MT2!DAJ"Q`$Y:JKO/"BHJA"S:U[6F+8,!"`V_K)DQXL>
M*7$S1=N[;OV_A")@2'T)N*H%*[7%4WL#9\P6\UX.^:^!6@"/?=,:(P3%`%#:
M%_&NS+BW24@%8XOK25>FX'ASVW%W3V"V1``H)MF=L=6NV@K"-/V8:7BDFXY+
M%+72^U`F37K`\"<MYQUV3DM'>ZU+':-B=^!Y#9`F.)9&_4G/&1I65D>)#/L)
M%/W?4^#OFO@3)8P]>(BVA>-1XURK63:)NU%+FLCVEX9)9^7AHC&\KV+)L=4$
MOILL-$R[A;"NL6Z)"AP,/XIL^8+>:\'?-?`F*O"A`V'5<8H8+J.7AQ:T1*SC
M,]`X,NC.D;CD!GJ-A;RG^OL?>-*4[-.LJ.I;4P3^+;/F"WFO!WS7\BVZSM$&
MQ(3*S[SSPRB(!(IKIN)\'?-?R*;JU#8C$>M4F*S-GS!;S7@[YK^0IEDM/[U5
MFSLF#VMGS!;S7@[YK^0G"3(<FY'C0H2?TQW#\#84>X#N5B;/F"WFO!WS7\A2
M4-VARU5>)`,'3G2TMI,PJ;E1F)X6`!`D4VZ;2?!WS7\A7SI#'N58#XXJOO:V
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MK#Z]C5K(/QC[56&@K2N^M<F/;O\`\N+_`"-GS!;S7@[YJV>J>$OKZV.Z?"KN
MG?O>3B'WDY(=[>+G?6S="^JU66&?BPO;'G5%A//'IICW'RPF,$VYKU7<4*3=
MRW&R:WJM:2Y-U#,O4[D&E08C,XG-D\->L.7H*O16.QO]@TW2,MG<#."\%E6,
MU079>*33(M[4J-6S:=@7HJKU:\9$8;*&_"9&YX+D(Q(IK^I/A3*SQ239ZIX9
MRL\1ZM3=KOL_AM)S1K1O/+DSVYQ,SY,%Q\A<^23<G&F1EBW9?-^6RGV;3O(6
MX&:R;AY'"D(Y6W*%3D&VQVDJJZJO#&3)[#$[=LPG)$C%_D^&(R%=<R]`*S"+
MY60KKV;/"4%:),VIBGGP&@`1HEYEM?G2]R2HZ"LR,G;=L>;G@X/JDW]?JT_]
M^(M/R;L96=OZ^KD/TU,$=-,A6=LZS%9V+74N0TU^J3?UT*SNL9<AOUQEI^_9
MN+3],>0P1V:;RL[;UN*3=O7U<A^N,K.WZXBDW)UC,$=^FTM/UQY"T_9LR%R&
MS74K.Z^J3?UT+D-=<)6=EUQE9V_K0P1UT^KD/TR%9VSK*6GX]WU:?^_ZI-_7
M0M/UU^N$^K`AFY+K5&"1%4[6DDQ5AJ\C)*7>I"^!F2-@<1C)-GS!;S7@[YJV
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M9,.;'(PGFD$L[8DN//B'60(M1QY"(4AG&$,M1!I*&7@FC@E=@B2\`Y!+EQ@$
M>&.#6"(5*C@8\"R!6:.0(0A4$`U`6?;GSX(N!?;`#3MZ5G=6=,72T[JS?NZ!
MNZLR3^AKNK%S?3IJ_#GZHLTJ6IM0BRF1O5XV:&N^R(_N60X\-*P.)$L.7*1X
M63(@HFTX<V1FX:28PMZM+9OD6;PXD8!EFWKI\7;O%#+C'6]R'_[MR\9]VV!=
MW*3?L(7-QX_Z5R\N\V$E:M-[=T6U>8\C`3LU"Q9<+US/E12C.K8<V-FYKS81
M7KX:3US3GP2HSX:3URBGP2%/?#2>K](0)G&_X:3U9D^#GXF?#2>B,^#KPL^&
MD]5ZWYE3B;_LS?\`U6%RF<M(9^7^:5/K&^(+JBFN1U%L1>O+I3+&&6BN!7TO
ML:EC)T^P8+`1%L*[''O6$6>)+)D&+7WK.O'9249!B%QZDKIW,C&`85<>YJV?
MCH)0,!!/4Y881B`3$@1[Y-6&$*GD5\;/>IJDRK2F2"PS;E/3&-92",405S-Z
MG'ZIX,NUOAS-RI'ZJ@,NU]*R-RIAVUX&74UHWMJIBQJH9=`V%]X*75BTHQ.#
M,H#2@@!:3RU)[4B3CI1/]D:IE2(T-GS"^S,WW17!<D97!+6Q['JKC#:7C_=;
M'#L6OC#:3+%F,V)L-',-I!C-,[,-L=5.M1%U:&!I'/@-C9RCX\&&V"QC&260
M?;'+L0G7<RLTQ_M$^U`8IEE9LCM:AQI!"F!G9][199=C#`&%M;<F2PB1X4LL
M;DY;EMPE3(*NSN+/JM-DTW!4"[8W8J_/S36!-WM+'HH!9<^6K#7!OWJTLPTX
MZB@M[/\`==;&&TK(#N[UD5D6:6GAUUH9]3==E")A0"N#=]5KLLQ$@L)N?I.$
M8RLQ-]M-99,]G<-PAH;9UU]W.(?>3DAWMXG][>6'>WC?WMYD]W*4[N<U>Z=3
M]T^;WJE3]4\Y_9SB\JZY6]E^N0W]9>OX[V7E-VKSAQ]7S813]K9\QX7IJ]P;
M&K:`X0Y$V<9B6.@_<6YFOJK+'/6YQKK*PEJW.6'>WC?WMYD]W*4[N<U>Z=3]
MT^;WJE3]4\Y_9SB\JZY6]E^N0W]9>OX[V7`:U7W9**:FU'I[LLPC$\%R_P"9
ME;/F/#V1?/R'Q55F."Z\L.]O&_O;S)[N4IW<YJ]TZG[I\WO5*GZIYS^SG%Y5
MURM[+]<AOZR]?QWLM9I4SS:APX8],-A(#".,U^\2':#43+A/O`#%-)1<&D6/
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MS5*0B`SKE(2ARZ>ZY!3XV7C?U\7@^`]TRU+J]+QV$EY69L^8\'>61[W/(*\C
M[1+B74R[=R'8Y-W80UZN(>)/OR6/(P;YSS)&^_344+75GRW\[U/6P10@*4EL
M'+LF,`SOJ\.3M]D\DJ6(V$\J7&LPHV=S>]4J?JGG/[.<7E77*WLOUR&_K+U_
M'>X;V'<@ZS%.U9#>."GLAYXW,^A*+\3K'\&TV;--VV-&QZ_"1>MN#!MZUB1=
MVD]?#%).N##NW?"QNMF+%CU]UD7-[#NQH$?[AMB2QQ(TW*8SO_.?V<XO*NN5
MO9?KD-_67K^.]]L^8\9Y+UA&L3"5XEX`Q3F,K,[.-_\`)[3ZY9XLN"G.N0W]
M9>OX[WVSYCQEW1`S[`EUX.G%+)&$C":Y!W%D*<VO0/7(;^LO7\=[ALKN"CG1
MR);G2`1);F)X8Q\$E%D8Y<?QSDU792Q$V5Q8;847D^+SA./G7\=[I5#3#AG"
MBI\9C;/F/'6(5F-A\]3Y9`[F3VCZ_CO?;/F/'^9/:/K^.]R7,B0,-AW*TKC]
M&MALRL#9\QX_R`48C^K0^+HJ=#^QA/T_W"`T<6BL]$CV$E$IN+&9"*<HF)46
M+&@Q_P`$:M(8"L@-=*L4+Z6?7NL'99U>Y,\ZZ*V@[/N]7_;+L1>TZRW!5^'7
M/8B-&*(-L+3UL9[ECJQTI<E;BX(BVTPWFWVA7F,3`M1&*-C);.X`6"VD&E;<
MEI5WB$;7A0WL+%9.H([I8"9];/OR6JRMEEH.0>RV0/C*0"S@)329;BYNEI+7
ME:HGX%B6MC'NPU0$PPO_`#F/_@_%V#4\US-[:6.AAJ53A1<84^MG9B%QJH98
M6`55+B+/JU"$U;$,IF;`'R*2<L^B?4S,#.[:F!37_+1;D4RG*>96>(LU1,%F
M:^JQB1#)]"8CC20IYC+Z%J:;R,()3Q,2[.*$99&??5,W=,>*PEMA2RJZ:!TM
M"6V4C.8:78P4-?`N4[%5HPC#P_E[_]H`"`$"``$%`O\`BLO_V@`(`0,``04"
M_P"*R__:``@!`@(&/P(K+__:``@!`P(&/P(K+__:``@!`0$&/P+^!0MG55W8
M)?7%?3"D5L)KX$`UE.C0`$L9T@H(X4<:2FT;5>9Z(JHS1%5((++$,B+CTFVJ
M:21E@7525L>QNU8D)@8+YZ7$\`W/T,48-@W)M3<[P\`IO(;<='+S"=Z?P\O>
M2O\`*Y&7U\8QSUB1>Z\Q0#R1B!$?I["&8J)RY_((1[N=C=$'%YMQ#+7GH*V3
MDU^"Q`$M$&XR6LM:T,F!5ZR`Q&L::<\FU%<C5;Q5RW];?*KH4A_<-&P^X\89
M'==@6#$TVKO$C6M:B^Q/XBX_6XO5TTQD#):/)9DFUOCU+FOQ^Q!.#`"`-):=
M9)Z-<U2J]O1T^8_7BCN;7%L8ML9QT5594N.KFTNO##RIT,3[*YLG?!\U;TU/
M*,4-?^SC1C.LK$>_1E;32`U#,.I/5^U]6(M\.R*^TEME#L2U^/NJ%AM0<@,V
MU>AC]7IJ)B;4UY+1DK\NO:D%K?0ZL\&'$Q0T80'5\\Q'@?:8S8S4,0L5JJKB
MO3FNB(GL+`6LPF>L(I8O>S*FW27*Z!'#Z\E(.00H:&)MU=T@C9K[&IQE4?):
M_'83*.+4FB+1Q+*,XCIQ9["I([^VLD<UJ16[=NW\_M_(9*N$43,:JX^`2K7K
MTJRX$>%DV16%/;S+:V`9LRK''CA8Z.Y@R-ZJ>--NO&8Y3'@AJ+NEBV1:\)S`
MM`N'&L5C09I.EL&K9\/:;I+XA;]J\TX2DM:8M[DI_42;AT*$08L4M(]<[&OB
M:ILKV%)65$`25&&1?</5KH^UR(I-1\7,X&+V0*V(`IJ>RG$EQ8-LYF2Q<:'$
M-)6H<*/8RSS&F!'BK8&*)'-:WJMZ?&,*'%Y$%F13+*K[RVL#0*L%U7W<BB2E
MC6#J@C)%G+D1^H()VPRO&Y-K5)J/B1ZCV5121+MTA(<`(#RRTWTO)(^-Q;*<
M,CF2HT6%(DJ^0/K.5PP*Y'MW[6,D9%*C9I,..UL1MC1?AZ6E;2PHTBRZ,.&V
M]67TG%U0CF``%KD0QF^%SECGQR?&I4G9+7)<][%,7NL9PP&=RD6K:QI486D-
MHB]1??>'FGB3%)TG!YQ+#-(<ZXH:J%9.LG&HX-5769)!S5E3-*&Q?YJ$*`Z+
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M(?*K=D?P1)+YI;)##$KE&I`V!WF$JHO1*Y7#VKQ8T,6CKATEL::>QJ5CM+72
MB67[<A(9MX.E)_2&B(S^;@=>?$JDT01#D8,PGE=]*`"+(&XSR*9\<L>*)JB5
MRCT$SEX6Z`D1<?KQ&C3YEH%R#5VR?84X\?FR=KW.:KY-*%L9VO)1IQ#H/(*(
M#FED6M=7M<@)H^F`5?)/7HPS)HH8HQ!A>T2H%K%:W331.)Y*N!'@OLY`I4]0
M-5O<R`0X]>$I.:IN'"B#&FGZ+$^1Y2O8(0F.(0A'(P8QL3<][WNT:UC6IJJK
M[.!S@RHY8)@,E!F",-\4L8K$**0.0URB>`@W(YKT7:J<^$<U4<UR(YKFKJUS
M5YHJ*G)45/\`)8SK:TKJMLV4&##=8S8T))<V0[9'AQEDD&AY1WKHP;=7.7V)
MQ7T=ODE'67%KM\NK)]G#BS9G4)T1=".8K"/ZYDV#Y>\?X6ZKRX=BC<DHW9,Q
MF]U"EG#\V1.EW"_0>KW&](_O%;IN0?B]G/C#_P`80ONJYXLOM"9]8)QZB?9^
M.?6+?\AY/=NQ1F8(?#:V)@#9F+IFE17W$4EP6ZI)U/UP^5%R(Q(>MBY.FP+-
MJNY;.,RKZY]W5Y)(IG0ZM+0<>'4U%V;#:\,1N+/CCWI10[%R*KGN*YLI#<]$
M1.)[<9].)%3V7ICT"G!BX*3*QY8MCC8;&L;F!&V_Q6.=TYD]Y0@(XBL;L=U=
MKN,?\V3-)48>8V4):YT`U2LG'3V=*Z%;SKPM>9_0K8#Y*K'GM`IQ:M:3N&HB
M8=1QY&;0!U]GZMR\C98)_14R=$OZ^TPF*6PDPRM?1W(B*KWQWMZW4D-:]/$B
M2'UZYBXKJ'$/BMUW7PA6<3*'WNF9_!`(\1KI%:.FW;>W85FW8L;4NJ<8*YDC
M),@(_OPR89JN701^F7()R0;'(;"1`52+5U*"8:-+9#?*CHA!.[ARZ,L)D_-X
M;7@]-HE^6V@5@+!F>6&91(>20L0"L4<633'K"N8W1KX;M1;%YDXA7X$S05O2
MXMZN_#-@L&.W(#Q?B2F/A-9D(703#\PLH,35P=C"F8/1WZ>MU<`%DE3C];09
M@27(/%#.I!+$].IMEC]F'JUD:LCM=E8V,:/JF-U6J,[]I&,X$ZDR/(YCAY=.
MC99V'F%]88V!V+09&/P@2@4()UE$DSC/E&?%B^!Q!")X&N5\&"6+DTBM+3>5
M7[D@[J6U;)]-B%/8`BBK!1JGKY8JM077/,&=JM<]H7B$GH,"UQRQNJ/&8.-?
M'>)CA=W-?V^$$KH;I=*_QV8J/('C(:+M([<Q';'*SEB4;#,:R;',)%<X^,]<
ME4R+3KC]@6>M\8M5'JQQ*9HI)$<YIC.FHK]Z(,>K4=US9E+ESL%PNQLW2H,)
M;6NMES.?"RR)0-)!CC;<#PX+"-`_>57.0G,BMXQUE7/S&+B368VZL-;TQ)19
MS%OIB9*#+1PZYJPR$JND,3YJQWBCJTB*LA"\0Y>8S;N5D-A(G'FQ[MH1%KV!
MFR(<.-&CBBQG!`Z#'&3Q[WO>]7;N?^18461"=(O8N9XS/BR04TVQEQ*.#>U\
MJ]>.5$AR.U`C!#<1FYKB[$T1VG'K)71HTZ3<^ID/T?E^EZMJK#JV<6*R$I21
M#K#1:]:B>PTB0A5&X#7;EY\N*/%6PYGQM6?^Y+(\TN'^7RQ[<.("W*6Y?9=N
MT'E=G!E11"\2=5=H].6G&+-KZBBDPVY5`6*>9D=A!DF/Y5:[AGB!Q:Q%&"FK
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M8)G$*4X@#:)RN>G%5!NY@,5O;A=D3&\AL*B/=]1\R1`C,4,*RGQ"]])C.;'<
M(Q&2%Y#5R\N+`+<FQ>>E*!;6T$^SKC)61X,A6NL)C"%5(HX4H7,CM.D[3FFJ
M<53!Y?CCGWCME0Q+>%OL']UV.R,SK;GN6=[E$_.;P?.Y<6,6HMJNX=7%=#M8
M\.2"6L,W5DQ7QIPV.?T2*6(5JL?S\"\)&@1(T*.U7.:"(`48*.<NKE006L8B
MN7V\O\KP_P#&$+[JN>++[0F?6"<>HGV?CGUBW_(>0W..Y0''US#'H6.9,"70
M^=]:/7>9#A6%07S>K2LM`QK8P]Q6RP*FU5%JG,^.]R,^-,I*K'ZFN[-`3(5;
M7U251AR[-AW.LGRAM16KTQ=+V<_;QC=?>96EQ3X30VU!B<>+1,JK"-'M*9V.
M-E75@MG8AMIL&B(X`U#'A#57;WL<O$2!.R^,4L+"L`PD$F/C+XR=E@&9-RB#
M+>$F12U63/AB9%+H]K4>BF3DO13-`MR`'0R@&9,@'DU=O*M:(^:G[BR5"NRT
M=),B,*Y=&,KHQB(C=YG*W5<6976K::XPVSA6U%9+7I/AMD1:Z35%CS:M)<)9
M%?,A3'L>QAQ/3EM>FG%+:7&>-<ZM/CTN1!C4=G&JWRJ#)#WJ/K*QF8=E#9/C
MD'&*LMEB=.W&]A6^)KBUI\I*K"8KE^.=8%,,).MDWJ"#/XT]R$L9#""K#QVQ
MG@5/I+-7;QZ[>(>4W>155A.?"JX%Y$3'[N%4S04MU)N*XE7"@9Q'=`E"=)VJ
MLQ]F+>U"(-JZZS*M)J6"S,AR._=(2)V>CK^YEVO;N'W$G>L1LE!=3=XT9KHW
MV)_E>'_C"%]U7/%E]H3/K!./43[/QSZQ;_Q&OW0,ER2+18ZST\67;TEC9Q:#
MTY\QM&OM?BV@C"[;*G7M81"#UZJ@8]NY&MY\468+D5^Z5;_^X2Z]-Y>-/LY+
ML>!B@!7,,,5M#JD(4VO;6,,LE!M,XCE<]=-.,7B232FGBY5`.9HZRTD,0;JJ
MUT5IH\(H2N]XGA:Y7?S<6+D]CITM4Y*G)3D5.2Z*G'J)]GXY]8M_XC%OKBA;
M+L978=^J6%M&A6OE:ZUWG-3$G@JKI86B=-903;41$3DB<$S`%$-E^27)L%DK
M,L7Q664P#8LNT!4$F.IXUI*CMV$DC`T[T]KN:\8?^,(7W5<\67VA,^L$X]1/
ML_'/K%O_`!#DOIO2+,I\"&8P26-O8XGB8R](KA(:)&O+P,XL4JMU:YXQJJ:<
MN:<3'2\7R;%94$[`&A9'#C`4RO'U$-7RX$R?`L(OYMXR<EY*B?P,/_&$+[JN
M>++[0F?6"<>HGV?CGUBW_B'?X50#GV,6NMYV06.*VDK%L@<^90R(T2RGU5)>
M'GNK8LY]UU8U?:A976*^]C%BO;[W&H-:2S-"@T\&#')<Q2P;960P-C*EC"."
M*2),:X2H\?38C'<D1$^29@\*RPRD;2+C[+.7ETV<,]G-OVLEBKZ<$!$'%:"`
M42NE27[.L=K$8NBKQ7F=44_P-;>IUCZ50I#)$UV1);P@36AN"L5B0%K9L^N*
MSI:(08]'*Y?9QA_XPA?=5SQ9?:$SZP3CU$^S\<^L6_\`$,Y*3UAMZ^/.D/Z8
M+W&<5R"4)Q'E,R)%LRQ:Z:8`4<Y!L,IE:QJ:+[=9GF^6WN73IQV'+,N&5D84
M?8/IH"MKZB#`AP8SOG.:B.57<]?DS`D;)8U=CGJ,W%4S6L-2+-LGKB73;$=1
M6B6<8,!TZ,`8B=6.;I[=[.:Z<1C%R0!L-KO4&R]3JS'VTZBM`Y+8ADM2,>Z\
MQ(`M/!DSC&$U(K"^/:YZHB+QB\R;5Q9$J5E4"/(,1';RA;56NT;M')X4Z;?_
M`*.+%K4T:V=+:B?R(AR(B<>HGV?CGUBW_B'A61)D>(Q;FL%&DUU/E0\D,L1E
M7?1+,UQ5_#==<&`ZP4:0Y"D`SJ#1$:5-')QB$"+8LMHX*.%T[$4<\0$I",ZR
MOC19+62(\5%)H)CT1S1HB+_`P_\`&$+[JN>++[0F?6"<>HGV?CGUBWXQJ!:9
M#;XEB$VIR.1,O*9&C.7(H9:5E+4GGN@6"0QF@RIIQCVM624"-\6BL=C$W)F%
M9>RJ>&:RZ\=L.0\[AIH>3#8P;8<J0/1Y!;6=-[E;M;IHGY>="MLGQZLFL:QS
MXEA=5L*4QI&[AN<"3)&5K7M75.7-.&3JJ?"LX1%>T<ROE`FQ7N&Y6$1DB,\@
MG*QZ:+HO)>(]Y01?5C'K.#%M,8-,QC`,?R4-K`!/!+8=[K<TH2P2'\41VQK]
M.I\W<[6E-8%M#S25L5\HUU71:FW(=PD4C[&LA-;#@3'.^>(:;&+R3Y,:I;RP
M=&LLMLA55'%'%E2G2)1I42$-3+&"5L2.LN<(?4*K6;G^WVZ?"3)%AWSK>7CH
M[!:J>E";(H$3OIM`*ZZ/8NM8T;FX>[VIMUW<N,/_`!A"^ZKGBR^T)GU@G'J)
M]GXY]8M^+BOCQ\3Z$&TL(8>I43'$Z4:64(][DMFHK]C.?+B\I\G%1LB5U`MD
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MA/#7L[WI@C;/HO22Q*>>@C1]I&H5[WHUW-R^WY(.54CJ"X8_._3F5`#)%.27
MCE-BIY$GWZ]Z`!*A+.:>5,:'Z07>U&?-1.*?$SX[8BAT7KQ<>J9<M*6"M)+Q
MXC;>7`$%S93IKK>7(MT$\/2]VK%<JZ>S%R0KV+#BORJ`V/&)2ME/CF\JM=QG
M2%L`]=KM'>':WV^WEQ8[EW.[Z7J[335>N35=.>FO'J)]GXY]8M^,E^W[G[QD
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M*<\*MW%<QJD=J[3G_`P_\80ONJYXLOM"9]8)QZB?9^.?6+?C)?M^Y^\9'&5_
MA!WWS5\>I?X_S+]XK'B__`%I^\6*\6N$97AN1W!<:MV[941T*/T+&,/W<^KF
MCM8=C".P<AS4(Q1OVN<GL5>('I[B&+WM$(,&?+B]\L)\48P.65)W$98S)9#R
M#'<Y7.W*YRJJKQ98+F,+*S3Z"PA2>YIP=L2#9BCBFPK"IM8ES`GQI4=DKD]F
MQ>;FKJU51:ST]PN+E8IEQ,O+`9;H*R.XGE'8Y'<3)]E*N)\PDB809GJJZ^-V
MG)/9^6+C&J[!J][\@L\;2J]1YF)XQ;UN.XF&I`F1FDR[`)9,G(TL0E%'CF16
MJ%6*Q6+IJD'(&E4U1;W=-72Y%,S'SV='5V4B'469:80HXH/=Q!(K48,;",T>
MC41W$P6-XUG4W*Q%^#Z&QJEQF+52[C#+6-FDZ9%DW99#$)C9(KV.%("@9_5<
M-$<K6O9A7D9Y\FI?C=26`:SZ?F#HYH@S-[MH?<#.S?HK!^[9IM9X43Y&#<1C
M2%W=,:N:CR;$17[&JNKMB+ST]G"AZ@^LC.HHM[>H@U71'JS7=LU_/QA_XPA?
M=5SQ9?:$SZP3CU$^S\<^L6_&2_;]S]XR.,K_``@[[YJ^/4O\?YE^\5CQ?_@"
MT_>+%>/4+\0&_P"`#B%]@7O_``!\9[]H5_W)5\8-_:;]S\@X'Y4RX('SW'UO
MQXZLU+XF,>;1?/65/ECF6?<+"UW=LJ25#OZ7CTXRE59D`<:+DKB8:#*O.4O!
M4_DU.V;U0Y"JWD6`3(6S'11RMIFB7YK6;$XG740`)$L<FHKXC)3GLACE7EU7
MT<:5.</0G80C6*&/MT=TF.T5%Y\99C>1NJ)=AC!J=4M:*#,K($V/=U[IH@OK
MIUG<FB3H?37>G<D1PWC?X=VU/X%;BV+U,:WF%IH]Q(B$K;J:>7WMX.JAPQ3:
MSZ'1#6/'F'?+F(H&-C_Y^"V'PYF)(8H]I9*9D&F1'X_33QUEADHVEOAO=4MF
MF:P2:=W)UU"$B([2P3R7*9$6)&G28<^+"JRQKQD#**S#7MIP^<I8$))R&T:"
M/U@`23TWN'N8B*Z[A>09>^3CM<>9<#!7U4SLI<7L.[I9'9W<CM[",^P:UQ2;
M(&X9420O2)M/#K:FT#:+"Q:3"?.^'ID*03+[2DJZ@<,=5E)95X'K7H>I)@]:
M"U=S>XWMV<#DK!R&00K(Z,AQ@4W<K..2Z1]3N/>`AMLH<>B(<K5*C$&4"(Y2
M&&-<6J\7941)%]07^4S3Y7&L&"J:>D!3K]/C1),0\$AI=V(;W/5>EH[PN5.*
M<ME26(&W43#0L$!E?'!6761TC+^6"?=W=U55SH[(%E"[<:(V697KTQE5=K"2
M*:HR>Q4EK%J:4`8=4Q^2%E0[2R614&D708(8T.JISRI/?%ADCA1JO8BD&CB3
M#5N1Q(Z4E)>1W314,,M@+(U@)41Z^))R`<R4Z1YD+?)0?EX/$A9#',>B5E_%
MB6$&/:1DDBB6@&1IX6JYS=L@0C2`ZKMU1S"/&]NCFN<U47\C9I01,&O\OKJ8
MM`D,U"^@C)!\PI(\Z0"8ZVMZXIBD.17-5K51&\N`S["BLL;E%>9KZFV)`+-`
M@BN&QY'ULN;$5IVMWMT(O)>>B\);9CDMCC5K<SK.ZC#9G&35GTN<NRTG08,"
MQ:D))*DVO<QK&N^;_-QCT?$R,+C(*B$*B*,QI#"5C`-2(]IY"N,5'"TYNYK\
ME#0PY%-3YK676-Y+E.9V-L.OD8]35J,+`I*PLV4Q26MX-6].+'3IM:JG*FKM
M5H+,?:KZG$_]R^2UMP]CF.R!,,#"N12H9M7.D_#L2E%&Z2<P-9HK.;E5<6`'
M%KVQ$'*H!!S8<C&&1I;UJK76.!MAD<&8TS=RZ]40Q^%?%[-;%5:K%6=+56NV
M[FZG)X5VJYNJ?S*J<>HK@ULVQ7RO'W[(;ZYCMS9T\:!_I"?`9U'L,XB<]FP+
MM51VQK\E^W[G[QD<94\%;-LW?!QUZ4%]<PB=.SKRL;K93Z\6IWM0;?%IO<F[
M:W5R>H[W#>)SL\R]SA$Z:D$JY#8*HWJ)Y1*]B\EVN<W^15XN5#7S+%28-:#>
MR&^`QP&>>XT3N"^83H+%#O&C/`KR;GIX=NYS<[,6*>"0MV][X<IT9TB,YT>.
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MRG&X)(0A7("@U`K5ZCD551?#IHJTF%8SZ5?#P;^YCQ42MLZX3.[G/&#NB`;6
M0V29#D:U-2$;JB(BN1$XG7Y<3NY/:MK&#A]WCH>I+MM@0!,=MU(Z`8EF8462
M1K2[7DWB:82*]+3'\APPM7>U(\;F2PU-U5VL,%9D[[44:5(D2C52H^O+2G20
M,"2'*U&N'O5VQK7DQ>]C:CCO>AI.,>YZTIP#,(H<C*S=""G7+HJM42^!7D]W
MQU@4%L=NU5]S+QHGC2Q[)1;V9"HNHD;Z7\[3M^6O7]SQ87(<)NGVDJ$.#(EC
M/B_<38=1-D>71&.-DPVM&3S(\@2.Z:;5=U-I-K%JQF]-9,MF+BF1:)7KC9&C
MC5QHIX0H_7R-'$CV,B.,L5LE$V$$CC(%R)Q=W#L;OKB7834D!:9F$P8\9*.S
M3+ZKL@54ZJ:]\O(B^Z?(YI)`BD0(_>$N7O\`3F>Y]Z9"VQPR*$"3C,"*Q[CP
M9,%XB&G1V">YK6.)):CGZC][Q&DQ?3`T$PGT?0.SX:&RO;"!'L8K(XP9$[M8
MM/.AA&00&;'RA,>QI6-0J"BD]-'QP$NF7Y-WP^UPKB\#(';6,@L7("&(^,%J
M"F(U2(5CV-$AF-79`G9#Z=6%E)!$%&8Z<;'"LCQ9\QKIL"6!F3+'E``L=AI`
M]IA$9MV=5R;$2SF>FLPTWNA77TI^-&UM&GKJ83B!^)21"2H==2Q)3-440P!'
MTU[EO21M+_Z8E)51),BQBP-<><%LL2^2L;&0N1ITFRJJ0]S!JK0)#W#?L(J!
M62)/2HYVM$D(3QNQM']K0E@K4MJRFR<1ZX,MT49`(U0.]QJ=!NVZCA1,3N11
M8(I46((1L::+MZN&!8+`(N0HK1V6O0C;MJM>->OT6;7N5/ARY5-2INZ^/:+T
MX'>-<FM[NT/(^BMY:]?F[:'WW&WX8O%36.G4Z^-;/?PUDD=SR'?I#,G;DY:J
M9=6;Q>]X$UV,7@$(2`QSRGQI6@;,$8D@Q>CD)GJ.J>-!GV(][GD;T4,W<YH=
MV-78>KV6_J'QQ>V[HQ!'ZW1ORZ^6,8A#=/?N8Y.CU7ZM1G]5KWQ!&14[C&-1
MO?-=%='?_6/3K!`G<NVZCZ*Z-<I=1(Y?A2_56C<]&I(Q;5[FSV0T"W7)$;U'
MQW+*3549T&JBJAM`J;;C5V;I=[LZ9\<3N>U,,0.CUK\6GF;'J0/4V;6-7K=)
M^C5>C,:NI.U\]J."?'$0B0QC?'(SN+\#MELYZMC[D1S7,7KH%-%5W]5KYVG=
M:*DC&-'="$DH6W7(T7Z:?Z,+730W,G3%[WA$^'+E$U$F[KX]HG4@=XYRZ7N[
M0$CZ*[EKU^;=P??<"_JU=)U'P6N13XY[A)<9YSD+I?JBLJRMZ)]F]SB.3HH4
M>KT"CL6O@]5\)KU)(QA4CI*<1IR&Z.1E565B,1QNGO<Y')T4*NJ()SL8O!*0
M<=[QD/C2O`XTQ\8@2]+(2,4D,+4D$V*]BA<B,5Y=1(KTQB\<Y!J]`M/C74<Y
M+#LNBBNR%H>HL?Z7S<C.WY:]?W/!5;BE^7II(5B#D8LBGZ,A@1M%U<E&B+,&
MY3#W[$0;5W['Z,4NW&KLO3?8M9L/CB==(73[8@NI?CT9<;U[??L<W8O70/AW
M$TQRY?L68C=I\>]]VT0<D+A[[UFB6)GJ`._:J%8JEZ0MI%_[6OO\_<8QI^Q=
MU_\`N/7]?]&_^VY_JO>\-W8U=BW/A-52'QQ48DJ$Z4<CNE?D796G;VQM-7*9
M=1(46I4%NQRY!U%@(Y2GQY>AWC3+(<7H7IE5*I1HA]F]7*1O1ZWBVB5V*7XN
MHD=7H21BRJ#K2'A(TO2R4B*L,;4,39O11N39O?JQ$>N,7C7*-'J%Q\:ZC7+8
M=ET55N0N#U$C_2^3E9V_+7K^YX*YN,7A5&.0]@QGQI'G<&8R,,(NKD(V(28%
MRR![U8Q`M5'JPN@E,C<6OC=)\UK%'(QA$D)%<-H"!ZV1B5&6:/5P>IL<U&KU
MD$NB*7^K5TO3?.:U$/CGOTB1F'`06M^B(RT*[H@W['-(U>L@AZ/54^'+E4U*
MF[KX]HO3@=XUR:WN[0\CZ*WEKU^;MH??<-_JM?-U[755D8QHWKPEE%W:9&J_
M0C_1BZ:ZFYCZ@O>\,1^-74;<^`U7&/CBH-)@R/D$?V]^=VRI<Q&R-J*YSGIT
M$,FJH'=C5V'J]EOZA\<7MNZ,01^MT;\NOEC&(0W3W[F.3H]5^K4:OPI?HKAM
M>K5D8MJQSI[X:A=IDBMZC([4E+HJLZ#D1%4VH4?_`%6O?"$A$3N,8U(]DUL5
ML=G]8].L8"]RW=H/HIHYR%T$IMN-79NEWNSIGQQ.Y[4PQ`Z/6OQ:>9L>I`]3
M9M8U>MTGZ-4K6XQ>'09)[&O$?&D:=L,021S"ZV0A>@[5Y%&#>C'M>-W60+=K
MG;?AB\1-9"=3KXUL]Q#22-W+(=^DPR]N/EJADU?L%[WA$^'+E$U$F[KX]HG4
M@=XYRZ7N[0$CZ*[EKU^;=P??<#3X8O&[UKT<JGQK07>1RFD.)ID*JJ5)!H&1
MMW*XCTZ'69N>W_L[)/V3N?VK$?UW_P"'_P#=7[7_`#_J/_K.+['I&>XMC>'9
M3:8Q9Y!,?F@Z;+*VDJ*8$69C%?5D(/MO/90.OW;5341G-?O;HWA0/M&V\`5[
MD(Z"1YX'(S"QUEM*;31)5R`\IDR1'AHB+[PCAIHQ5U;Q16D*ZR;&`OPVP@/N
M<2P(F:S9)%NHDA*VU0U5;0HT1K6=2-M'U4?U=7-:J;Z62:=/LRGK8I"6%I6-
MI;&8YPFJLB;4MC0VUTDOM<'I#V+RT3Y'3)=)42I;U8KY4BMAGD.4;6L&KC$"
MXCE8QB(G/DB<$N!U5:RW,+H&M608S;(H41J((DY!=R\6C$\*NTY<8?\`C"%]
MU7/%E]H3/K!./43[/QSZQ;\9+]OW/WC(XRO\(.^^:OCU+_'^9?O%8\7_`.`+
M3]XL5X]0OQ`;_@`XA?8%[_P!\9[]H5_W)5\8-_:;]S\@XR/[/QW[DA<8%]H6
M'W):<1_PA3?7;?CTY_%]']=%PN"YS0Y%=CO:`=@<-7"JY,$M=-EV$#HE),O*
MR0R2A:YZ^%OA\*H[7V1J/'<;]0PSLGMJV"6PN71KF7(E2"!KH*V%Q;YI;VY(
MD1"(C6[GH)FNQOYN+R%%9U9,RGLHL<>YC.H>1",(3-Y'-&W<1R)JJHB<78+R
MH=3)-7''`CR/A]DQ\JOQR#5VA'@Q6;-I.T63$3H&7;-D)JZ1XMO%O;I')+6K
MJY]BD07ZV4L**62D<?)WO#=/:G)>:\5%5=S\>N(^1X&F;QY%!728#:9_>U,7
MRPSS7%LV?%ELM=8QEZ+W]J7DOZ,N?(W)'@Q3RSJU-SD#&$XQ=K?TG;&>SC'8
M5YC]?4Q\SQ:9EN-&@71K4[8D!](LBON0EJ*X<6>D7(8Y$<%YA*O49KX6N?P$
M,.M6+7V%<:VIYDFYH_,+"L8=`1[)<>'.=<Q:ZQ35X"J-=6_K$&JZ?(2+51;N
M1%::;'%>^33F8_+/7&)'F,B6KA(`S!G$]C2_J2N:J#>[Y'8R*_K27S2F!Y:V
M0WK.E1@]S)AC7]46=&C>\(%KE*-FKG-1$7Y"XJV^JER0*:DI.]`EDWZ(*?IV
MBNZKG=B=IM$37I+N]G/\BY:OJIC@'U\U*%^&6Y_3]N0PIL0=.$=C%\VK**RL
M'7#+9#(\4I^QD=H>GMU=KW!JEU-"D7F1'H(9::'CTOX;-<2R4AIU1!C0H\22
M6$Y/]DQ[Q[7OU>Y7+4@^'B>H,,.*RR,PN#G+<0GU4U]HP:9603Y]:V9#.S2*
MA-[G@>SPL55Y8U6Y+*6;?0JB&"TD.D.F/=*8--S"3'^.:0*:,<9>95;N_/\`
MP,/_`!A"^ZKGBR^T)GU@G'J)]GXY]8M^,E^W[G[QD<97^$'??-7QZE_C_,OW
MBL>+_P#`%I^\6*\>H7X@-_P`<0OL"]_X`^,]^T*_[DJ^,&_M-^Y^0<9']GX[
M]R0N,"^T+#[DM.(_X0IOKMOQZ<_B^C^NBXH/P!5_O%E7&#_B_&OOF%QAP,;R
MK),?#)HYQ9(:2\LZH4@K)Z,:0XX$H#2D:WDBNU73C'P']1L[,$UW5",$N7Y`
M011$G@809!OL%:\;VKHJ+R5.,:25CI[_`.)/.=O1L1P.U\H\JW;^I#E];K^:
M?S:;/SZ\2UH/1N+1K/*AYRT\ZHK5FF3=H:6L*@#W)4WKXGZKSXIS9/7WE@&_
M).CQF4L2NE;>R''<?NFV%G6M1CVRDTTWZ\]>%E4>'^HT<R0O+(ZR>UM&U]6A
M6G\KJ!6V=314U7UAM=VT1`AU8WP^%-*7)\GF2JZKOEBL@*D"3,/U9<)U@,1A
M0&2>FY([%U756ZI[>(EQ797D[DJX-I64E9*J[@]915]S)A2YT.M;Y2V;VRE@
M#Z;#',P#4VC1K>7%=E%M=P*BAM0P30K&U,V`$J64;NX;%63L5AC1^>Q?%RXJ
MKD7K)BDF!00[JNI*Y\FJ%,CUUQ*?,2NG6XIFME"JC')VJ.`TC$>NY[UY\1;>
M)8PY%7."*1#L!R!K$D@.W<$H3[NF]A6^Q=>?%17R<BQ9V+4&>W^>P)(9)/B.
M9(NI60SQ5<UA'=B(<29D94?(:][CA&UO3'JJ\-($C"C=\T@W->QW/3PN:JHO
M/B3G/=5@Z)]^&\&WS>RDRW#;Z=QL,-"7&RT[:B).?+$I4L1S5.D;W.S1[D3A
M5FU&5V4@V<U8JR1&-FHL7@8,^%6;9<0M$1F)C/$EMEK8AM-#2'*B-WBZ>G&9
M.K[2FAAPFQQ.!'QB7`238Y>F01ZF28@9/?QY,=QG6CHL-`"=])CN5_41=C>*
M;&6U$29$L(^/R)4P\V;$*)M]E'PU[E[*N55!['=W"K,DQ6%1%&UV]6HO$&!?
M6K:^38B)(C-=%G&'VP9,2&65)D1HQH\&**5/"QQ#.&Q'$;S^2("XL4CR9[3O
MAPPQIEA.D!B]/NI#(-='ER^TB]9G4+LZ8]Z;E35.!'"]"!.-AA$;\UXR-1['
MI_,YJ\1%N9Z1GSRO#`BBCRY\^:\3.H;LZVN!*GR6QQ^(BL&K1HOBTXBSHA4-
M$FQPRXQFHY&ECR!M,$J(Y&N1'C>B\TUX!)NIS(;)<E(<,:"/*ESI;AD,D:#!
MABD39LCHA>]6"&]R,:KO8B\1[""7K1)3.H$BC*%5;JK51PCL&83VN:J*US4<
MU4T5.!S;N<.$`TD<.,BL,>1,F&W**'!A11FF3I;VL<Y!B8]^UJKIHB\`L:\J
MFB24<HB.">._W9'B(T@)(PR`D&4:M<U[6N:J<TX=974X,"&TH0(0NYSBR)#T
M%'BQ@":0\J7((NT8AM<1Z^Q.!V-:5YHI'%8CBQI4,S2!(X11FBS0QY0",(U4
M5KV-7B3;7$V/75T1K7'E27[!LZCVB$Q/:XACF>U@V-17D>Y&M155$X6;5F*4
M##/CDZ\.;7G$=C6/<,T2QCQ987;"M=XF)JCD7B5:VTP,"OAL0DF4=VT8T<]H
MV)RU<\A2O1C&-17/>Y&M155$X/*I)R3!Q)3X,QC@28DJ%,8,1G19L&:&--AG
MZ)V/VD&U58]KDY*G$NSLI0(-?!CEE3)<DB"!'CA:KRE*1W)K&-3B6ZDGI+=`
M*,,T!(\N#,B/,/J@[F#8`BS`LD"\0W.8C2-YM5>#2I1A1HT81#R)!R,"```L
M4A3&*16L$(3&JKG*J(B)Q(?137S&1FQWD<Z%80VN#+ZW:R8ZSHL9)D.3V[^F
M86\3]JZ.^207&K5MDR*.&<WT6=#(V/8-*^!*0-A&BE)$FMCDZ16HHW[':+R7
MY)3,>M6SR0A@/(&L6=#>D>424&/*$R?&BND1#&A&8TH]PU<-R:ZI\DZKI;5L
MR?7=SW,=8LZ,NV%/-53"1WS(T<<T,6RCO`1X5(QA$VJNOR3<<K[5IKFO=8,D
M0W19T?Q54@$2S;&D28P8LU8$B4-I>B\FSJ-U]J?)8@QVXPUC;BTQ;*HE9;9_
M)H+H]9C%<T%O7^3"KY+R4U@Z,13D:KA[457-7GP>=-LZ>UD6659C9O-0VY+V
MIC>89-9RVUT.T("-W0:UINBBM:C/!RY<0TR#TQEV_DM5>`@7^)^HL_#PR@2K
MP;H[QR0S@#BH>M&)"Q#,=(>0>_=L;IQ2Q9$*57'CUL418$VV=>RXA&"1'`D7
M+W/?9F&O)3*J[_;\M)E+LAD/I+OURM/2OX06#5-JX]$$5K%@6#)*0EM_.&2Z
MOKE?W*L?OV(U&ISQ:%89'109D3*H$B5$F6]?&DQ@.JK56G.`TAA0A=U6Z.<B
M)XD_EXL"#$0@WS9;V/8QSF/:XY%:YKFHJ.:J<>H#K.5&KD-`QY`K/..(A59(
MMMZ#60X>]6[DUT]FO&1/8(KV/O;=['L8YS7M=82%:YKD31S7)QE!;.0&N$3$
MU&PDXK(@WD\XK';&/.X;7/VIKIQZC'`QQP'SO+C!,%JD$41,@L'C*(C-6$&1
MBZHJ<E3B]/9&%7@=@EF%IIQ&1!.*[(,8>@FD.HV*16#5=/;HB\9[)B?28YKX
MKQ'C^^"5O1!XAE'N8]O^9>(<FP(R#'2BNV*>8YL8*.<$>UJE,K&;G?FY\9S*
MA_2XQ9\!12(WOP$1*6M:JC*+<-Z(Y-.2^WC"I4Y4AQ1?$?5DRE[<`]^)7PV;
MS&V#9O(]&IJO-5XR"5`>V;&?`H$9(B.22!RLI8;7HTH=XU5KDT7GR7C!I4SZ
M)&%/GJ61)]P`:+2V344A2[1L17+IS7V\1Y%<4<^/\)U`^O">V4'J-F6RN9U`
M*]F]J.3E_/QZ?2)+5CQPY92D,<Z*((AMF#5SR$?M8QC4]JKQ1'K3"L`-P2L"
MXT$C)8FE;D&3O43B`4C$(C"(NGMT5.,+*4;Q"%EF.$*4C',&,;+B&Y[WO<B-
M8QC4U55]G&%OK)(+%@J&>PCX)ARVC<M@BHU[H[B(QRI_+QCKWB*QC+VH>][V
M.:UC6V$=7.<Y4T:UJ<>FGE<N+9=#XRZ_8'%,Z/5^%.GU>W<3I]3INTU]NB\?
MLY_]T_\`U>/3]M9-B6*AGY"ID@2`RU$CX]3L4B1WDV([:NFOMTX_9S_[I_\`
MJ\>FD:!-B39()U,IX\20&2<*-Q>4-RE$%[WC1KUT75/;Q^SG_P!T_P#U>,#@
MQ)T.5-#\"]6'&DA/*%TL;DL+U(XWN*SI/71VJ<EX_9S_`.Z?_J\857`FQ#6`
MH.%(6`*0$DP:B#[U'Q6/4[%'^EJG+C]G/_NG_P"KP.J2;$6S["K3RY)`5GZM
M]1XAW)VF_N-4"F_YOS>?LX_9S_[I_P#J\1YE-<PZ[*JNJR<]>)SH!YP93LRN
M7"7RR:TZ%<X)-4:\3D5%UX_[Q/\`_*F)?_QWBXS?+K2%>Y74_$,D5?(=64TJ
M>.O1'PHB1*Z+'1O5]B.:!7+_`#\1K23Z.TDBSAIMAV)Y[BSXK>:Z1I9*%T@"
M:K^BY.+_`#'(($3&RT4^U#Y**T#)G3HE93P+3KQ!S6UKB'DNE/$-OS5>SYWM
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ML<D!E9`6&PU;?'J)9C0[2BN*^VI[2',HPN843EWLW,=R75**HFYM3WMA54U7
M7S[<US$))M)<*$"-)LI"EG23]:<<2D=O>]VKN;E7GQ2V-3GV(U]M0+=Q%CSL
M@8`$J#?5ZUEF#O:>WK[BFLP-:U\>7')U0O:J:>+5M126'J!1Y):U\)!S;1^0
MQY<F8_J.<XQ"2K&9-(C.HC-Y'N<NB:\44ZKSW$:ZYQJ=8%$*?>A9%E1K:HFT
M=G%(>LMH%K5S$BS5>"4`G5`1OL75=*NCLO4*BR.UB,E+)L29(*=(D=:;(E,8
MI["SFV,AD,)FA:\I'/<T:*NGLXI^PSO$JNZQJ_BY#7^86\(D,T@,"QK2PYXH
M]E$F##)@6Q=I!O0@2[")NV[5'46GJ)19#8K86\Q#/RI;4D>+.L9,R'6"FW-O
M86\V/4PRM`PAR*1S1ZKQ'A1LYQ6IMZJZI,BJRSK.NDQ/,:.>&QBAL826$4QH
M,KI;';",>W=O:NK4XG0KCU%Q^]G3[J=91F?%I;=*V)(%':*IB2[VXL;61&CJ
M!STW.Y=141.7"5@LWQ6IM(EK09!6&GV=>>,EACEW!O(+)L-+&*4\&2>O09-K
MVJC7*J<TXR2XN,YPN;>Y99094D%/;PA5T0-;51*B#$B,DV!Y<DRCC*\A7:;W
M/T1C4:G%ICA,UQNID3Q1R194BTK2H"3#F`G0S%B.GQG28W=PV]1B/9O9JFY/
M;QD&1W^=8+*O,D!0UJQ*.VBBKHT*@2S[)@N\L3RI4R3(N3N>[PIMV,1OAW.O
ML7L,QHJT60TUC4OD)=5;#!9/C$C*<3"RF(3I=373V.]B\9%99'ZG8E:+="HP
M1*R!D\A]5!D5B6;9MA7P+F_L15#KKO1;XL1&`'VS=-VO)O<9/CP-^NWK75:+
M=MTW;=\E-=->)C9_J)A4SN*7'*?H0,@841'X^EFGFACVUI),$TMMCL2-'044
M+1:M;N>[A.XR?'@;M=O6NJT>[3VZ;Y*:Z:\6,F=ZB85*274U]2T$'(&%0W86
M-O/9/D%M+20L4FELHVQXK11FZ*[17.UX:0V3X\)C_FO)=5K&NU35-KG241=4
MXM[Z7ZB84<$T62`'&B9`PCY*7V7R<H`>5W]H6+7OJQR7`0<,8QGZCB%W/1O"
M%)DV/#$[3:5]U7-&[<FK='NDHU=R<6V8F]1,*6+,FY?)%&CY`PLJ0+*;"NG-
MC2F3+1];`97K7(NZ()A)#E3J.5&HG'_=&._J>X_ZW6_L^NG7_:?U.OZ7LXN[
M>"7`"P;B=BT_^LU#:S[B.F-@"(E2*?!L8G3H[C81LH+41Q!&>FYJKKQ"KK<.
M,QYD;K,Z&(5DBGH!`ZSUCLA5\J3+*#02IO\`'HK]533C$^W2;%P\A(!+:17X
MK89(6T*2Y!&LJHDB`&8^G[.D5TD6@NI)?JUCO"J<8[8Y-%?#O9M8"38QBQNS
M,(I45[6GAZZQ)"A5JD$O,;]6Z)II\JY0QUNXB7L_*04A;(C\=BY/9QUC3\@C
MUFSE92!O>NKGN8UY'.:U'+KQA_XPA?=5SQ<1[UUSY=W600NW?C4A8-/(%EIZ
M_#%KIL"G&2;&O<5VS91"R)(PNVZN`B[%*>WE3)L^-D>75_=SJKR>1(KH>46P
M\?/V:0H`]A\<[1[7M'H]':JJOW<9-`OH%P.AC$='JB1*^3*KP-6;C=?5/*./
MBW>'DWA+@I4,.RE1Q"C'ZPHZ!5W$U^3K9/>E?CIBI9T[*A]=DDJ$=^58_!0=
M=6I-JZ28P;`FTD*Y7N13ET\-_`M8%PF*08Z>7E@5\F7%6*VGH9BVAP1\6E3)
MII-S82X@^WL]4[5=8>C7&6^'?K8NBACA>HI].RM#57*WN21I%152F5T'S2`*
MGB0B]17RU]XC^JK2MXC@<2YDXFVAMYMN")22;(5>>'$AR(I&-AXPR>[K^]V*
M&PGN*9>BD5JIO;?@NEL5@@2QW1YM.R!$J)@,HNH57"J)S*Z&MK'F8X`$@CW&
MF<U:]',:1&K"KW0;5^(MJ8\@I*V&60,A"0LKDV4V9T\8M"2QUSJJ(-L>//@R
M&FD#]W)ZS&<6,>:MKY+T,F>2)-H_+X-4D2VH!X6^NL'U<.1,+D-%+F2)+"2)
M+A$$C=`*BL7&ZV%`LC8W(CQ72R5H-ZR)4JP/'F=T1^-W(UBTT(0SO&V76E5A
M7*UYE1!H0:+;ICATEE#!F8\6OKX]$_'\:GTMNV?+J(L]MO.MILH)(QI"N8C7
ML6.QX7JE!$HUL61#I7.8*'3LL8=M*+E%+#M85O+6NFOJHL''#GD->TT1>3G[
MW-$YO"Q`R[0F/3L1BV<*)*QV96!BV#Y+'^\E3:N--9-/`)N<$Q&[$T3IM>CM
M<9?CI;%2GOJT$Z#`KTL.]K2W%.&PZ@WX_9,505YBZ)WU5HQ7EZKNEM2NC5WG
M+:`LJ&'LC8X>/6R:CRK)UN+>78S:<<V#-A7T"*`3%DB8]CF+TGH=CUI2XU!L
M9C"S)KK)*D2$LC)$K9$F#51'$QW*(P#W$MG28XT9@U?M8IP[T?Q70Z7SEE.A
MZ&*R/\.'2NMRID61U>=NL+";3K(ABQZL@1)$,HY$8,EQD5BR&/1.*H^,1)\A
MQK.2RR=6!ZU@D6/1V\^+%B*N-Y8*.>SM(@([2%@D&KB(+<-Q&D;3QZ-MW'@]
MUC\9T/X=*^%:')EH*[-0V<^54%=$!C^+N67&.&1&"<G-KSM39Q&D8T$[Y);>
M)'G'BB>61"K5#*,4XME#E'3<:2`4?>M?*:Q#:[4^>W&VT8,BKRK!!W\,F..D
MNF9*^7AITH+B46C?'!`;27$IYI418PNH(FT[>W*QII6.C>ZP6QI(KS#$\Q(5
M?,N8,6TGL&.JO':Q(!B.W]E*:']:\3V,<WB@-21LFK;I<;ES)L<F..L)<C+_
M`"&#/QG&[,C\9'"[.ZE%*V8>,"%T7LV*^(_P<7LNOE'A3P5LDD*3%@I921RD
M9[CH07`E,.5Y=&IN&1J*NJM5$TXH"41,@!:/I22K25#Q.5+.:]?C4N71U3HT
MNAEQNWM;R.HY'1&UPG(T?4"I&;K6=5!)YX&LZHV1(_?&`7W?=%B1-DCO3PQ*
M]XQ["]1S$;M?KM6T+`F9`N40I=T>FEOQDX)=U3^89+%QE\D"8/:U;YD^/6,)
MT!QH;R^ZU?';)&Y]U8TL,DC(PXS8S:F`2.U#&NAU9CP(9(J%*WJ$G(UBCWN3
M7EN7V\9%T;3(BVD>=-/B]S,QH]9,MJ438+!OGJS`;2KA&\RD&")JUC'G&)G)
M$>I^*F=9-F0[.5C\&7/:2OZ,^+/-7"-*:^J9WG2F`D.76.G5T>FSQ<6`YI,@
M;:IEPXX;D>.$F%'A@[C&HUK;UY_A"JK;(D./;D1BEJPD]V5>@9D8AG2;DTB?
M`RQF.&D@D,I&GLWV#=R5ROHG02,'/LO=H02QD:$A5U&U&[4:68Z\7'V])Y8;
M,6E%A+CI,+IYX\A'(BT;K-UP_-CR(*Q4.N@1JO;)MZO%RF1K9/$.OI#:6-.R
MJ2LR21-R,60X_7$975WF-7518E>X1E62KNNY>N35-N7&L:J[9E3035H`^3R9
M<$=HE;;V#JN($6*5+QK4#KO9)-.')>X0QRBD*C.));4\^:C+JW!56-I7,JK&
MRI@RW-@3)<$5?4B&][=6M<V,%"#:U^B[MRWL>_-="BD\YC`0N+270J&TBW.3
M>5A@2H-,+S""?%JL<DA3GD,<3IHA&+(&-]5,N#2Y%I]+#.-.K_*Y12!F'&-Y
M838<`8E?'1B^`36K^;C-P6]5;[HTVSB8T)M?()5[V75M6XY'5!8Q#.)UQ718
MTPLAUE.BM8?<YT5-!\7,B]E69VA+#\NLKBB2IG+U,:J)=LQ:T-93]>/6WQY(
M6*@$<O34:N>YBKQC""E7QS/L)<8CW8JP;+T@_4*)7/!=)Y`QM1%C8,?NV%%V
M2.\1-[^F]J-$'SE,;D2-T:#+QP]?7_"Q<-JK.+D#YTZGBV,:Y?F!I$%8I9#5
M03%UC(J=3CU&.#'[LP39WEY0F%53R"*(F06#QD&1@%:\;VKJBIR5.+T]C46<
M`+L$LQ---@2HHG%7(,8>@VD.)C5(K6*NGMT1>/4;\7WGUTO$+[`O?^`/C/?M
M"O\`N2KXQS[/R+[DF\9']GX[]R0N,"^T+#[DM.(_X0IOKMOQZ<_B^C^NBXH/
MP!5_O%E7'II^/\-_>*NXP?\`#]A]XIQC7V_3?>,?CTN_MM_='Y/3O[0R/ZO4
M?)Z7?\_2?NI+^3T^_L#^[$KY/\$']Z?EQ;)1Y/C=-8!K@C@AN<NNL:.-M;?1
M[:?]#J:RVCW<#((C.P>V8+H@=XT1RZ[9)[25"E1+DL"PKI-?>3KZ-;JM9''/
MR9DB?'C&B?$,AO5[?;H/3^?^!A_XPA?=5S^3+N>>LL+;%7L"*K9$F*-L>"M7
MCPDZ$4V50Z>1-6_?8/-UJY)#(S$<V2Y%&#BY?DWG#1DKZ0;DMK7S,<G)P3<C
M7([*E;YA/6!0S89JY(X42,-O3=H!B[M;3S#'+";BH*]3`+741YHE$.F6?)GO
M[;'9CK>RD6R+$9&%-[K78YH-G4<^^\UAS`QAMLD>V91!K(<*6S*+J/4Q\>G#
MK(*6<"1C`X[RO:64F[8KG-(YZ+FEO2X1DMI639L)\2?"JI4B+(8RHKQ/<(S!
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M(FXK-O*7'RY&.]KQ2DFW;F,"ZOQ_HGE6`(Y';"*XL=V]%VM<WQ<18/PR]N)3
M\\G^FT'+/.`O,?*J^/)>YJT387AJI$N&4(I"2G*Y6;E&B*G&'_C"%]U7/Y0Q
MC)::OC$#2AL'6!3RHL1;`)*.^B1JQDA@GV:*ME-`[I/U@_[9S5,(?%C?V8X\
M>/)!DR2CBL%E%NENK:@L,<`872&K6X96P)4)BO\`S2%Z7A<[C(_L_'?N2%Q@
M7VA8?<EIQ'_"%-]=M^/3G\7T?UT7%!^`*O\`>+*N/33\?X;^\5=Q@_X?L/O%
M.,:^WZ;[QC\>EW]MO[H_)Z=_:&1_5ZCY/2[_`)^D_=27\GI]_8']V)7R?X(/
M[T_*E!77OI0.1\-2(UMD&49Y.K.T/6Y)"E@I(WPY:QEK;VJLXC)3"'5LAGB:
M+EUT7&8<!U*2''IH(P%QR4:=1F8@6^^K)TDIY$R*9?$A2/>\FNYRJJ\%J[/O
M>T,X3W^7VMK2RM0D:5FRPIID"P$F]O-&E1')R75.*>VB$Q6UQ/$(E<#"Z+(K
M/(R&JY@(88\O(+%_:SR760MT<R-(D'(HA^/]<YS^($21/H?@:G]4[3U5KWA)
M8KDI;":*<Z)22(KXC*\4.%-LRN60DDCRL1J=-.:\8O*=9WT=9&50`J&'<S8L
M82-JK7WD>.(B#"9=G-R<^:_R\!C(0YD`-HT+*,^1()M33>8Y%5Y2+^=5YK^4
M<C^S\=^Y(7&!?:%A]R6G$?\`"%-]=M^/3G\7T?UT7%!^`*O]XLJX]-/Q_AO[
MQ5W&#_A^P^\4XQK[?IOO&/QZ7?VV_NC\GIW]H9']7J/D]+O^?I/W4E_)Z??V
M!_=B5\G^"#^]/RY;4Y_A%Y,NY&47TF@/4^G[;F/<4,R1NH6T4^NK7QR2AP7#
M:=)#T*DQ7[ET7EBK,DCMBWC:2"EC&0,>.X)NDF@S@B#%$#+:/3K-$UHT+NVH
MB:)_`P\I5<C/C.M9JT9"+N-7VP1^`37OT4CTYZ:)[5Y<-<AI6CQM*W^BK7YC
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MS?M147AK^M)VN&$J?T99Z[)$PD`2[>SW(JRA*BI[6M\2Z,5%X<Y32M&#<5W]
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M:Z_,=X7:/Y<"099"]98"#UKK%FJV;3.AZ[XC=F]`.W:Z=+]/;JFHMII7OV17
MC_HNT35LTSH\?=K"38KBL75':*Q.;M$Y\;VFE;>BP_\`TNT3W;[%:IJZ+"1=
MW>MTV_.1GC_5^+AZJ63[MAWO_HVR7PQIHZ\VFD1=RI**B(B<W-\::LU=P9'F
ME(L=\UA=*NT?HZN<-DO;LA.ZB-<5-JMU0GZ&[1>"(II.HUL$?_1EFO.KCBE3
M=-(>CM@#-5NGZU?"S<Y%3A6]61JBE3_IUC[0P/,R<^TTY0^?\[O`GC\/&SK2
M=VL=/^F6>FLN&L\'B[/;SBIJO^@[PNT?RX$P9I*N,2`(>M99LU?9A,>&BJ^&
MU&(\8';E71!+R?M54U#L+)7N.RZ6M;9,U\Q,2/$W;XC>GN*)=V[3IIS?M147
MAB]:5XPC.W^B[3]66:ZO8J_0O"Y9353:OB1OC7P>+ASE-*T8-Q7?T5:_,9/9
M6.5$2%JJ]X1$T3GM\?S/%P;>62G;][U=*VR?IY<8<>7MV1'=3:4J;=NO43FS
M<B*O#VE+)11OL&.VUMD3Q5@QEF:*.(Y'(QA4VJG(OZ&Y47AR*:5X>ZU_HNT7
M]CA)82/9"Y[8JZI_IN\#=7^'A&]61JJB3_IUC[30/,Q\^TTYP^?\SO`OC\/`
MO>R??/@L'_1MES=91GRXFOT3P(\`U5RKH@U\+]KN7`48:4JR'PF"UJ[1FKK%
MQ&1-V^$WIHYPEW*[1!_I[=4X$]AI.TPXY1ZUEFU59+F/@`56NAHYBK*&J*BZ
M*QOB=HSGPI5-)V-&I57RRS5=B6'E:KL2&KU7O>6FFNWQ_,\7!5>:5H%)"DTJ
MK5VB1)#(I]-L)5?H<B(FFN]/$W5O/@NXLGW#[%A-*VR=HZIZ7?;=L1=Z,ZS=
MBMU0O^SW:+P3<61[I9B/TKK%=%@1!SI6FV(N_;&*BMTUZCO"S5R*G&G6E?\`
MY7:?^2\P_P#)?^5Y_P#Q>#Y_AX:C"R?&^$QNM;9-\5A"=81?G1$T1T5BJY5Y
M#=X'Z/\`#P)!ED+UE@(/6NL6:K9M,Z'KOB-V;T`[=KITOT]NJ:PIMR[)_,LA
MA4[YLT4B?55T4!CNQZC``+L4LG+8V$J`]J,DDBL7;R?N<UBPI]*#,&&IBW*T
M]G.GNE!E3*Q:RFLAS*<>.1Y``]7(T:%R&<Y>D]Y&B9L5X"QU>YC<6K0*KPF"
MO4CV5T$J;#C&]6H1BZ.TVN]J:IQZ?RI"N:"/E=,4JL$4ST8R8-7*T0&$,1=/
MS-15XJ%C.(Y(V$UT0W4CR(^AQW^3/<C>X$+JLVE3QMU8O\OMX].CE54&'.\1
M*16L>1R,'D%>]RH,;7$>NU/8B*J\86L1Y7]/'#/=U(LJ-X9APRP:=R$.Y7`*
MBJB<V+X7:.14XQK[?IOO&/QZ7K$>5_N,ND^]B2XWN93L9:%?I0`^)5C/U;\Y
MOYT35->/3U(KRN5D[)5=U(DN/R:E=&7G)`)%]\!WL_-S]BHJ\>FD<#RJ4%K7
M`(CXLH34)#Q5>NC2&"P9&M[QFCFJK7ZKMUVNTXP:&QQ.XC/]/F&:L>0UB.?B
M)Y+=IG"0)4Z1$YM<J(O+V\ODVZOU_P#\4]I^I-^O^)NKIKT]-FS]/YG\^O\`
M"I8%W<0:V;D<]M91Q91=AK2>\@1-C1!\W$?U9(V_R(KVI^=.%PX>0P'Y&ABQ
MO+44NJRP1DF2(+)72[(EA'BKO>!"*9C?:WC#_P`80ONJY_)$JIP^38BK,8Q_
M&[J^?%CXJ6J$^SO+,D\=ZET)^02&_#%&;MQ5.A%.1G4>Q-%XAUV/XWC%A.MI
M%$RNZ67R#0(P;K'LFR22VZGQ<?.D6PQZ%2@9+"%AT4TI&,=JBZ`M;7R0L'7(
MBPV5EZ&+5-67GU=@F-Q,O/-HB/K8D9TU92R1G8YH0D<0:N5HD68584#'Z?%[
M^9.963?,ZJP*[,9V/T]T*>6%#ENBDCX99%`BC'J$Z.5%\/$JVR%"6;[<>-/J
M:*Z+04P*[XK#DF25UB&RJ*L?;T"XQ6,`-DTAYI9PWZ]-O/B762Z3&H$L#L1B
M(*9F@2!%8Y!(K06C;2UK*NPJ:N)0E=/&3J&[E5@[V@<,NK,:`N/5X'6;,=-9
M1RWAFV)(.13[4#;G&:_R=3W%+5U%2^SDF+VZ-C+M3Q(J\.L[/%J*N,0&$S8X
M39656B@Y?76EDY9($HTM)=A61XD52Q8$>85$GMTW=-^N3PA4((-/0&-%'8I<
M@DSG2X]G-K.C/J>@&5"[SR\I1+S1&,VN\?).(=K85<6585Z;8DDK-7B1K^J-
M%YHTG0,N\>Y%Z;_$W1W/A9U33PX,M88J_N`L7J)$$&%'0+5<YVWJ!K8R$5/$
M7MQ[U=L;IB$2XP?&+P5HR)'D6-EC5#<7,WK7L"J%71"VT4Q70*D5D^9+:+W@
MHVXR*C1O1\1E!@^``@#G,+5/K\(IHED*D^#JG(H&=1;0<,,L#"9+++6,5$0>
M\?+WK5XQ>YCY)24S)U1`Q&!%LH]V<\JT%975CKNJZR<"-&>.Q:U"&<-N_EKS
M;KA:6.9XP2;4Y+CMT^%'B9*Y#,@S'W20&V2TB5`+.9`II#P@*=A'M&JHFG/C
M!_P_8?>*<8U]OTWWC'X]+O[;?W1^3T[^T,C^KU'R>EW_`#])^ZDOY/3[^P/[
ML2OD_P`$']Z?X)6XW*J85LKA="1=P)EG7-8A&]="PX%E4R7N<+5&JAVZ.YKK
M[.,;R4^.5.5$B9IZ7"J9-/86D0=?%I)"V%WW%1Y+<EHZ:YR`KBRIQ)4CM8P8
MZ.:79JM)B#J.^9=4_P#[B;[U%L;@U//%3EQ$@[B2*T9D#PMK9/FC;$06A:9Q
MNHQ6N9X>,7\O!0OA_%4#M73)=@.2Z1Y5:[DD,#"*)@?G:*URK[.7`>]:!LOI
MM[AL5Y"1T-IXT"\K!D</7V*K47\CN>C&H]^W>]&HCG[==NYWM=MUY<-<R.!C
MF?-5HF-5O)6^%4;R\*Z<.3MH^CT5'^Y'XT<]2N1WA\2*1=W^?GP_:$3>HFTF
MT;$WMU>[1^B>)-Q'+S_TE_EXT=&CJF@DT4(U30&O03YOL#N7;_HZ\N*Z7/@!
MD'J;`EI!5RD:QD\E7/IG23!8]H9CTK;,XV]9I$;OU31R(J(]0B5Z#42.4;5<
M@G?.&BZ:]-VGL]G#?HX/`X;V^Y'X7A9TQ/;X>3A,Y-7\R</48QC4KU(16,:U
M2$7VO?M1-SU_E7^%2JEK*K4IKB+=-;&!#-W4F'^H89983*T3=SM=FBKNXC9%
M+N[:=(!+!8EC&'4CC3+*%#N:RNF'[6M`5G9U=TX2,$X;']$;W:NZBDI#8]32
MK=.ZG.L!5\'NK`_;5TB36U8Y"4=_Y:&TL&-&L@@A@&[;U2L&KM:\574V<>E#
M,JXK`NQ-04TH`)&5Q<LF6%G(I4>`D=T*"^"[N0L.U1O`A6$?N]+O[;?W1^3T
M[^T,C^KU'R>EW_/TG[J2_D]/O[`_NQ*^3_!!_>G_`,##_P`80ONJY_+6$EDY
M,F/K53+J!$CLHYM]+MI=R"NE(&+&@G$5BQ8U"4CE5%3;_)^>!43_`%-C#F6#
MH36=/#[4\:/YG8,J:M;"8"P)%KTM+8C8T?JN;U3+M;[%TP-F-8Y?9"^'.OW2
MV4=186SHK3`JT$Z0V!'.H6E4;MN[371>/_ZTS_\`^3<B_P#T[CTS`<9`F#9T
MXC!*QPRB*/%IC"#(-Z(YA&.3147FB_)Z??V!_=B5\G^"#^]/_@8?^,(7W5<_
MEJ+7W!)81Q#RS"+#;7O)I.JK"FEB5EG`LHNPT&R)XD&A1OVN8YKDUXC6DJVO
M2NCR*PKX;BUBQ)8*&]'DF.P9*^5=YVM#;CZ@%&89R:Z'(9.7%Q74T2QF6LD&
MRO'6V0ZHHY?M"<\DUE5C=$"_F]BO?N_T'<5,B!6SJ^-#:X$1774*.ZML2V.(
M6@\CE@A3U9('$A1K""HVK()NU1K5#(<_C%/Q>W[FM/D]/O[`_NQ*^3_!!_>G
M^"6P956UTHG";Y?21Q2K$O5(T>X03R(HW-%NW.\::-3C/<GO,?G6>+^GD7TS
M,*BE9C=8K;THLHB1)\B5!H:9KX%M?>8S5&59$EC6I#Z(W.U72@S!+2V7*++_
M`-Q]_@=E"=<3WPV8?'CW,9:9U'W*0F1ZN+!`9KNEN:1_4<J[DXQ:(:/>O+&R
MJ`<CH>+9/8QG,=56NB`FU]1)ARS>\348GO(G/ER70,H33M&<;2L;*BR8,A&O
M35$-#FBCRXQ/Y6$8UZ?G3\NU$.LLZ6J\IOQV,D]V2S8)XGPI<%@8S*JKMI1Y
M+C2F^%!^S7BIFR<Z]+QP[U@2U$GSS('`GQY"1W"EA*S%7,[)6RQ:F703>JW5
MR;DXQ.EE/"25466'U<E\=SW`>>!13XIG@<08B."X@EVJYK5T_,GR?X(/[T_P
MH>16^,T]C=P.CVMC+AB+(9VSU+%WJY-I^T*[>+>CND[FW1>"Y<#'*D62FZBD
MN&1!I,4AA-`8Z.^:V2<#=CRHB$>WDJZ<8?\`C"%]U7/Y>F589$>,Z8QHW$E1
MYDD/3WM<1CQ5]I2S/&U--621JG\Z<EHJDF3G)#I<6?A/O*J/W$G')P<:2Y%U
M120L#8S)6+`>(^QS8['/9TWZHY(_XOIOJ5O\G^"#^]/_`(&'_C"%]U7/\0(_
MXOIOJ5O\G^"#^]/\%TF=*C0HS%:CY$LXXX6J]=K4<4SF,17.71.?MX!C5,[&
MF@EAPX^+5T^'+EES\>1V?8VI(>11[6-5T`J87B9U1DZOSN;51.*RS<.B7"+C
MU:LO2>-6,@S?/Q%AAL!Q<A?:NL4BN278UI-\?M$Z8%;XE?JJ8?\`C"%]U7/\
M0*/#3W;J&3<957>7S%II]O'?*#&FL;&D+$488*%[GD0Q&-54T35>+NP%ZJ16
M0\?@MM;$TC#+F/\`T03S!(]M"&6:TME73'U4EH"`:1#.`Y&:\M?^XK+;_P"B
M/_H;I\&7?7^(/BC3=VV_K^8]7GV.F_M_I&_H^+^"^#:P(5G"(K'$AV$4$V*]
MPW(\:OCR6$$Y6/35-4Y+QD+X]^:FQ_+@8M&R"@BTU87Z/B#`AJH]!9/:TN/1
MT!'8BL&-Z(NJLVJO`;)V0S3XU#S6Q]1*[$5@PV1XF6V0#C)+\S;]*)`C&EF,
M"/M:@R$^<K4TX6=;XKCEK-=LW3+&CK)TIW29TQZR),8I5Z8_"G/DG`8<*.")
M$C#:&/%BB''C@$Q-&""$36C$-B>Q$1$3_(Z'TZF5TWJW]=%F!O&O#Y=&E6!;
MX5=72!Z]PAIK\>,UCD3;N<U/S\9Q"D[J:IPAT9#9)928S*NT0]O88^XD)6O<
M_9YY6$C"]JG?IM]J)Q6V/QA0I#MSR(M85T\3%FRHDN'`E1@!>J&=(C2K`+2,
MV[F=1%7ESXG1FYC0=:MC3ILQKK`+$%#K7N%/EM>]6C-%B&&YCR,5S$>U6ZZH
MO&.F?D]>6+DUM.I8,P)P]O'FUL=LB:ECUBA+#:#K!8NK=V^0+EH]%XCO\^JU
M;*DW$.,J2Q+UY>/BE&NXPM%\9JH4$SCM3F-!NU]G%.E//K+Y]O:8U"V0KJJ#
MV\/*5DK6VFLN4))(RAB$>,(MT@Z,7IM=IQ):3.\:18D=)1T\S`Y4"KVC5S-J
MKUG#<]-[6;G,1=7(B<5E*;*J5EG<L@OJXO?"<LQMHW=6=,C%<%%LF_LZ*Y%-
MJFS75.!1&3*ZNR5QK]I<9\S9,GA!1WL^HZ^[MXFYT@$1DE1[-XQF;[6Z/6_@
M2\7MI5'BLK%HF19'$F5BCKG9=TFU94JSR`SY@4.=K"=)'.;[=%XR.<N45L[X
M5AOG6L.OD!/,Z3)HZW2(QY!"F.=9&9'38]6]9[6*J*J<71H%S3FQ^AI8-O8Y
M$.]J"Q8KYAI(U@2X8I;Y\0P6@1=[V(,CG[&*KD5.(]X3,*(=7+?-%&E/FC;U
MCUSQ#G1F!70ZRHKCLWBV]1-R<N?$7#*^]AS+B?1Q+^O4$B,6)81)@I4H881F
M'5YYC:^*LIS$;RCN:_7GQEL$6/EM8^+&P6IW`G!CR9^19S-Z4:O8DEB1H\>'
M#/'*\CG_`.VTTTY\94+)HQL'LL*6`[)(5_*@*&+$MFJZJL8MG"DG@SH5AIL8
MK7(3JIL5B*K=8U\3,*-M3+FGK02^\:J.GQ&*67$<%$60(\0*;RM<U.FQ4<[1
M%3AN)LR.I?D;QH5E2V6-TIZ+&28C&HB[''6$O6Z>O4Z/CTV\^,JK6589L'$,
M+@9/:S26T*KTL+>SEQ*RGZUFZ/7QD-$KC&<8IFM;X4_.N@,:?DM./(CR'PTI
M5G@=.9.&/JOA$8QSD9*VZ[6*NI-%VZZ+P.%D>3TU-,*.*=D:?-$`_;S3R(T:
M4HW+N9$>>(1O570;58NJIQ+M!9;2'@0;$=1(D`F,.C;(S%*"&-@=Y9!I`D5X
MT&CNHQ%<W5$7B!D&'GK,ID9#>U>,XPD>7U:ZQM[*T2O(U\J)U%:&O"*08R_F
M9'=Q>):R:W'I%-D.;U*1YEJ%Q)5;@U@2%97Z]0418T)!L0A-4<P&[12.]O&.
M-Q^=6Y#"LLKJL5O21)NV9CY\AB6*T$F1"<+J=.?8P4"B/V:H_<W7B\65!976
M&/95?8M81AG62+K5,I.VDB*X8G*.?62`'1%:BMZFG^14ZDMK6L2EMHUR%M8E
M5ME2XG[.DOS.JLG=%FYW(2B5=RZK[-+&M2WR%8-G6#HI$=3U*(W'H@,@9540
MBCIV'2%3R<E/(`17.E*9&=4I6(K%Z/Q/DN[S+SWN-N,=?XD\R[_X@_[9Z7?=
M+Z+TMO8]M_L.I[S_`"RZO(=Q'JYI\3QBLQ^3T2/DT^1XMEEAE$&XW)X>BKI;
M1*B>+3=_+Q9Q,4R<59*D8=@V.1Y:]['E'EXQ<V-O=RI,^&]LR$[)'V)-3Q_?
M@>]SV\].*"_LK:!.?57/J)<E$CK>>;JYQ$QD`6"LKR7/LY):_P`D*UYSE<4S
M2:^U53B\Q.YHIM'W^//&"\LO/X;,9E5^;Q,HA8Y'#W@8,Z'<2@J0YZK:@FL3
M:]/`WBBLH/PU"R6JS]^7S$D7>;9%"MQ&Q@F-$=-M\CEV%XZR:$NK=-`[1L;[
M=7+4S&7.-$J<7RKU#R>B"Z'9^832YU77XQ@MW];M@LJIUNB+T6NZXD5?`Y-J
MU\`%_7RZ^-G&&9X=Y:_H3O,J2O-#O8$=T=C1MJ))%8Z`%>4-NYOBW;N,'AOM
M*TC\4QWU/II!&Q2HDH^?%`^-)#KS8V$UCD+KS=NY<8G7$RZ(6BQJL],@CAK)
MR**$$S!5KDLT#3P9P*6S;>+!ZK),X9S1E1&,:GZQ,/+:6V/2*+"+/.[NJ6NA
M3A7<Z;F[[%"Q;%YR.BI$@"M">-GB*K!HK4V:KDF;Y#$A7+K`^,R:.*?NW,JY
M-#7.AOD'B*;R^6=Q]I`N>-[A:<M%XORWV81;$]CB6=8K$F%D9#+<Y,FEPY-;
M-=6SIY:BB##%%0)(M<$;-&(]7$<OAOCVEQ30KBVQW`ZX3*Q;AM>*RP;(Y]V)
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MZS!3!H&<Y_B1FSF^[F2ZZ^J7Y47,AR)EQF$&?`NI-2D`Y8V,0;-,,*=";MD@
M@>J@"J-45&MX]5:*,Q\6!ZC>G6+"C7YXQBUL&UQRTN(9J\Q!::&)$M!F:SYS
MTU5/FKQ*E>90=9'K57^J7Z@N]*Z%40*[RE7?GEJ^*]R.^8B/XS2P#8PHWQ/Z
M7#]/XR'`4CX<IMO<V3IQ'-^=%<EDQ-K?%N'_`)N//,>0TI;'+,"F=2G@V,B7
MC\?$\*R#'WS'1ZG^E2MD29S$9VJ:L:NC_!N3CTS=?8H[%:+`L7MIT>N?+6:P
MV4V<Z725SW]Y)DV'7BXR,DQW7]X(UAL5RO8[3U4OJ&1'O9F=5?J,"QHDCJ64
M<.0VD^YQU*8TM7-BS:\M@1DD3=`R.3VM4K6ZTE5.Q:S8IO5["LGG93)%?L-9
M0,8JTGRI5C&R,I+&J%7+20ZZ/OVL.CO=IJBN7.[.RA2:YV3^I.3WD.+,"Z/(
M2L8VOHJ\[P$]X/OHU(ATU]K2(OL5/XO_`/_:``@!`0,!/R'].WOH$/>I\QYH
MXKX1DB<(/LK3`'[\W:T/H?%K8EU\A6(J<6\920_F8.R$`A]BG7^`+J%<9!](
M(=B8Y*`"38+&72<RACP+5B`/D#^""*;"`8U<)%@AM^P;DYG6N0+MX\@Q:>)]
M"1_%)*VAXE+KD<HFLQ@G^4.NX8(::,%<EZ/QOP4=ZPX\S(M7^9$GX0P(:.+$
M"FD75U,R^Q!T//E*RB&?.9RNZU!.^'`A$<,#JBN7F#[-"STRT2TV,8#_`&"#
M&!>N'H'IK4-OD?!*"D!*!)$GHZR'-PJ9>P?FZ3U!'>J^S(=>:;8,-Q3_`#2D
M$C:A701[TLX+E^38:X9.H(Y`^B3,B0S;?X7Q##GSNH\'RK%(HU*Q!N;PJ#ZB
MP'@(O`9!3$H@`*Y7VY?L\^!6!C@'_`(B\KJ)Q/VH5XH]@#(LM$=[([]<Z^E\
M18+C3Q/QY'WW^1$^C3`O78K@"Z+*N"BNLD2=\2@=RGAD-"@'S:K,=ZZ3K!]"
MD)CKN3AUIN!6`6;$Z7@8TN&U^]W=V(RRP"RC\^PE$>#^>\R%3(AY42=9!:39
MMS,IT;8T(%#,RV4229!7@VG%J\*])3-48H]!V::BOAZ`_DZ"9"&@!KJ?$@I9
MT/8GLR906%>"Q>30MY[7VE@DR(SC&)L%W;'@A^Q;N.JNS_X#H"\ZBF/BK,EA
MZ`.UY%/Q=>$$:2B7"C;]!_(NKJ2-W5_%5`B1/@]?1*Z8!1;/L<2A2N,UW>Y#
M5L66^#G[:.[_`)D!DDC`L9:FWPX1_P!0/,UB30!*M)+H2[FZ^^BXL8@'1-3I
MLQ#FKCI0>AL%\@.SD6HJQU\[2H`9R7@NE4NI5,L"@7HFMXZ.:\JU%+]@,"]<
MK$L7[I(-EE;Y%#Z\#TU5/$=P\H'N*73<@@8/33='/N&8K#-ZSWYM12"UE5H&
M##1M*7I].CZ"^N5/OR/PB5(K$\<Q\,JPV.:7&JKI4L$W,QA9%OT$G=]R3`O7
MFZQ><2^`<2P9V,T1>LMWJY`3<Q&>:D.:JWAE4UO4]8%$?2"?8]<3="*4LC<V
ME`@,$U.Y!J0RB]/L5@7KJ54:%#^JMADZ/,[NN1:MI3K\^R6!>N?G":$!(%(D
MSBX3YRL%L9)*!X>O87PBE0KFJ+'(&6!H<+S#]C6!>NFHD],9H!<.#WG`Z[>3
M24/J]0S31:>OB4-+LD6U:.IXW0ZC0BS5&AY($/\`$P9":]#A_`'V)7/*\)"@
M/HU;&]"4EIR_HOR"?K8%Z\9J/54N!`;1JJ\+.VA&?E]?P(ANGPA,S*PE,^.8
M8M1_FJ"/=1,$TO>:MM(`&U,&J41T"53P\<@)(^0,UI'PP:7I):!AS$!BC^BP
M+UU$7]8[L$-`%^#)L0TS!Z):;AOQF\1YIII7RUNF0W]+6"UV`V`?7`Q$\?*.
M^RR!)P^*R,IA;^(:,R#-*#,)<OZ,WX!>)P\J4$>5I&]8PMDTY<:H+R)O;]Y.
M\.3VK+N!I$PFQ%'Q:?Y`0(&43DW%=E9^BNI=.`X#AQ\7C>H!4<6IAU$Y&@Q$
MHQP=8E@Y:J!UJIZ@LX=TDWV!VOU2@^`L!)C+"V\0GHZ-/UB6W'23T639QZL2
MZ-W8^^Q,JJ!7D(@GX7J5'@_8J40F<!Y/Z8P+UU+J7/4(WVYNS^$U9D.N\!O=
MP@I9-QADZ3RD?58`"*WV3VAF04@?6<+F9RXV;'[L67!KY[`4*`3CA4X4*GF$
ME-]A6BUXW>['XW$/Y3+)B8863#W#%80T]0JKGB7^HP+UU+J7/PK:78<'-E[9
M'F9CZE3C=TW<(2L_0">41@M(UX0T`+%[!T8^'/PZ?I%DJN1\-WJA3F?)G+',
M"^K-9Z%)TKJN<S8/AJ[#2C_D<UA"T/6B%/(J\S>IL;$CP_\`T]7E?D!%6@(@
MLOJ[R"%G!5,J(%B\'(K*+0C58^J^>-(FEQ[L3OC[P$)C4`6JTB_1?E0"NAKV
MI'KA.@$*16*E#BAK@?I-@Y;=EI!!ED0*-%I6Z>$-[&IDL3P=$U`P8WWY6S5/
M,"IH(,\,C+TTMHR3DE4J^_'H>EPD]>^5FYH]15\12HN*;CQP_EA3STD+DAHL
M"E`X.[KO'EH/"CL?CHZZO'0INTH>EW)!&#W'$AK'BOX+I+R\=_1O$!YG)ERS
M:P,-1ZIJ%2AT8AC'1J;\<(R>Z,0FZ(2MP/!TG'CO"Q>7L*/TV&4BT^W08^4(
M<&=ET=6M!Z(@D1@XQ1+[";O'(M@"\@AL,]B'.Q#Y!AJW$DA=T#S7$<_ES$-3
M5.B$R"(#M&'>Y_MX6_-S5UFRB,<J:_38`,A[1A,#,]P0\8R7O4J1O4"%+![X
MY"IH_P`]7)5EVO(%@?Y!,#U??[&!+L4!`T*+<PEG^R*>%R1E0AA`(-3N!S9(
M?`N<D6#\:X#<`2#RU01FN`;J7\9;GIF_BFEATDNEW03`@43'A@3VGUR)SJU:
ML+^,MSTS?Q32PY4HJVQ#@52$=S`)R)Z9JMP1^AP6U&.$@BQ.:7-DD3UE*.Q(
MDD3%C1L+AY#D1I@J".XC^I[6PGP'C43T"KG/M$Y43K*/?I[$">Y_Q<*9]TOS
M+<?%9[)^(N2EJF?J<O[A_P`!J"0:$C,L`)+Y(2!`T(X(3MP"!XHG64>_3V($
M]Q'C41U*KO/I%Y01W$?U/:V$^&C87#R'(C3!0B.LI5V)$DB8LC*A#"`0:G<#
MFR,$G8GMFJ7!7['"I15MB/`J$([E_&6YZ9OXII8=3VGUR+SJU:L&2:W<!,01
M1$^&"_C+<],W\4TL.!(/+5!&:X#NHGR+G)%D_.N`S0MJ,<)!%B<TN;)@`4</
M-ENE#!^`T[U?J6,2%EHX0;F5$#:SP8LUWW:JK,*'*IX=>)Y1JN-B,0-Z4\,:
M0E;3LG>`'`PS'`-DT8-,'G#]@P+UU+J7/PK:78.D;-#PNV1;CN\KU^H(K$O>
MBSS[JK_4BI<3Q:)50WN-W)[ZRR0OIKBW=X/;5_VH.,4!F!%LTI*I<UUT';CA
MB#3Y./\`)#P%$2'0\8]<DA!\_$52"\?0T9FH+)P;#+K%X9$_>11VH`8&<YQ,
MX/34/'W]%=F5TQQ8RJ\#7HDU\@7*3"DK^:]*!&0"ZK5P8=5Y(F>ZA9]_:V!>
MNI=2Y^%;2[!TC9J>NY\'98+#L@X]9E'\A$SW&41YA2\DEB9$"<GO7X$"6,2:
M!1'V7O7(2CHH,._WX0.4H#6QSW'DG1J;1LQ)I/.8R%RO@C>A(*?V#4ME!RUP
M($B"J<<.1QZ*Y]L8RA&>JI0E2REP]8Z*T_2+&J[T.=2U+821F!./O':3@.:U
M:-6GC@G`&]\441+"'BN9].ILKV)>3Q`;K"Y40`*-GXA,!6Y/CE[I/?B5IB]%
M?4)PPJMTC1I7EC/3^'0K.C/:/`/DH)2C9H'E:X`AZ8E:+(`ZS(#@<(R[+#0W
M\]("3'!5JVX,<<ZY#[>\"BJ<E&`FC48J_0MT<QW%CNPJ-_H3^),/,%RO;H"I
M*$%.ZIT]68)D41WKK7&$<C:&`B/B8G=#&S>"Y3&)2^H'-7%S`;,L*/>@`.=3
M%X1>JDG*@;_6`J77?PS(G@4T3TGR?!>3I&$]F`JROQ&VP\.PCUA$9<#C"!UV
MW3`\"_\`=X1G>B>PY/9WL.0`W#7`2X(%0CXL[XASQJ`%#)W#\SKQOU5IG7?+
M5)9.V;(L]%OP`&`6]=!$'V<9JTS\JXE1%$S4V*=`2+!7"^\M]X-1:8B(Q-[Q
ME?M"0,%8+CK1L_0""LH$9@[[-.492+2I!S'$RUTBZR>T,6CL[>9:''3D+3VR
M[N4-*0)N0W)=_IP"$0=3*(YM,Q)8#@CD+3TR[N4,(5!C;YX<D22!J@/S@.;0
M5WPBH`,G?9IRC*385(F8?5)4M`$`!7=TG*GWPB"%,-]X-1:(JJP-_>4S#0<_
M6]/B,5)BK0D&T1TGKQ&"8M,-&(F*.>_$;\>ILQ\LI-HQ\1H?"YG$B/H/Y^(Q
M<FOE%CT9'H?Y/$860YO*1M\#A(^(L:%):PF@;R_/=@_SZZ5%82KO5O(A]J;J
M3??$C.L/QXP7BGH1YL0[A,399O2O!@SNO?):8.4G%?)7KJEF'5A3E,1U3L-'
MYQ*TRHN!45.ZL4P0W*13$P.$*G9FO0IU7Z2%[8-\P<'0IB*ZXK<!Y$,HJS&O
M?]XF%IP<+3V,'@]4L<801)`;#<.T,ZFM2A48Z:T"277$1<_:8W#B=%'E1&O-
MWA_C`E(HA^F(K,T4Y&4!`1!0PV>ZR&K_`(^W7P(H:L=BKMM".XRQJ]KN,(=]
M6NEY>AT6SQE0!7[F#K/^A,TA?9ZIGW1:((1;TG"@#83#!40Z<+/5W.MP2K32
MTBWPW#@:>$DQI'UKQ*&<+93ZT@/XQYRPH+2/3+FY]+H\]2(LX7G[>/\`_"OY
M_G,!Q`1I0`,%85F?T[DZ&8J0!FZC&,/E"_`"BWK2_=\4C`$(B'APS47Z8'1(
MA8S`9U/&\Q'*=;?$([E-DEY8NDAX[2:;%#6>ZA4^9C6*^IQ$@<"*S#(Y"(FA
M3`:*X[>AZ[H:-4H;;RL"S<;U38YU!>M+,F4,_14!)/*4#JN6USF$G^F3UD7)
M:7XB;!4F%))3)*8Y3EU5!J;ZSA])`A_/!//,^0^3+.BZV\[6Q3E36&6CR;!U
MK`B9N5,T>1KPA'4X(YX:8!F&I8K-8*.+@.!"AY[?YWQ8GVLUW"&[P!9%72"H
M[:S)U^T#1@P<`'^U+E"O,<H@FNX.O9.[A6$N?V*L"C<&J5%5\%,O'FYJ><G8
M(`B![N'PQH61^PO6PI)7@08T?AH.GQ8T$#6-52F+"N8&C!EK0:`4<1QT,:@I
MWO#OG.H03K-,+VEC)3C\Y7"RL(;@4`I,R2C=E[GD@SE33"[R6*-5V9TR5#8(
MI_EC=LH:%6KM-UF/MY\CSR.J-1[UO@[.?7[C3<`M69`\:GA!"'OD0/I&6CM0
MMC,Y<@[@*F\&*'Z8B9[K**<PH/\`.*Q[Q:5Z']P:6T@8.D;-3Y:52%>3.95'
MO]FHRN8;T:3.A1+)F0MP^H6$"L:SQP5V1:($B81?O>?<J^G1F1_.%MH`VLJ&
M?L9@"#_V$U<!8Y>58D>*8A9XM.',*\!^T!TC9J?+2J0KR9RB#\"6+3WLW@?=
M`6.CM$F)?/$6Z6O#+%B8HRI#240,>]Y8,^H,/610;<!F8=D47HK*S7%7M0/V
MA!TC9J?+2J0KR9SS(`#S;&YV3&/R)X+A]O'2%MM^.88G+VJ-$1G\RVFX!F1W
MZT**%A0`-7`2"$$7P"EB_D87?=&(13ZM3W]B`Z1LU/EI5(5Y,Y0:>G*M_P!>
M.H&%F44/F-!B^FGD8S7$P.$$\'H!3HYW"I(%:)!EEB^<I?$5.!,BQ,#'?Q6R
M,2&4CZ!<H2/!D>]$&Q2V<62M>I!P4$EL]]I96[)YS48G9\AP4+'HR/>B#((;
M.',S_"H@D^C%D?.4OJ:G0F0(&AX.=RHR!&"2[)*#\5].E,1X*1I`JA>_6"D-
M?*DME=`]6+FE"%.X(<24-X_J83/\@2,[L_Q\SD&R0%LS'`U"I`X2*"@BJ0C;
M7Q9$(<(IO^_1Z_-_QV_!R`W7K@Z]);5@('=/PFR@5:C_``F<V?X^9R#9)&61
MW0LK.0A'0HY7W1I(F14*H-=50O?K!2&OE`6R$:"GK<\2#U"W,,H(*KYLRF<>
MQ"-'6):)Z#K;"D0"8X&H5('"154$.>2\(K1!::'8@62M>I!P4$EL]]I.OI>O
MH<X-6S$1X3Q:@<[O$%!PYF?X5$$GT8LA+@/FZ=G2-AQ`C.#G<J,@1@DNR2@Y
MF?X5$$GV9DB=$#(,4X&Q%&`70/5BYI0A3N"!)&O$HZ(`6V>NT,B7#,5E+[$4
MQ!3'`U"I`X2*"@BLRO%ERKEXA(,?TK5^2(7-/U[`;KUP=>DMJP$<[OP<D?R]
M`6N3FS_'S.0;)(RS^8/[=XV"R3T1ERGED=`PE4+WZP4AKY0%LJ^Z=_!T?W]N
M*XP>&JRW17B<FI^F<`1`(.J#@2P468ACC?X'6CK`$_0$-8H)`#XM@&*+6.7`
M7&(.7A+#K.B4"&4F%PSX,>A_''$GC3;YUD510<I0'QPR"W$OYEPR!XEKH&"\
MO8QZHH4;_@H'_(@_)SX/U!)1R(8%`&#8C:NLVO'X(^_$H_26"UKN8E3T]SQH
M!TZB(</,E9F%QAFA<O=\;6"26344_D(AJ$VL2"%+6-\WI`3_`)RXN>1V@3;N
MKS^QEM]DAW-N,SYE!3)UZ;ZH*:K;"L*?&`C*9U`"T=[M['BW.":&87#6;+:]
MLCWF*<FKN.`U:3>@2E$0^F/@`.+RA=AP;PU;4!^3^+^PDJD*\F<NMB3$(3?4
M8`BH89!&D7(A5FW-Z(GINKYAT41$)S66\/Q#^1B;3/(,E_\`N4>P^CB^T`$0
M2(%=>KOG)!]LA-IQ\,T0B%N`(>$Z'VWVW^%=@VGUI14^6^:%-!<%%(?R<7&)
M0H63N2Y/X:$)&D%5B"^Z;NNZOHQ\HV3O,AC5@*0!:"':/ZC4_+FJ<F,?*'AO
M:[C[/C]T`HX<_*A$3A"$J^S"OZ2.=DC#RP8*\F<L/SQ29SB(&0D!M<W>K\S"
M(?Q3!"$1*]'(H.5CXEJI>D(F.XP"/?L:<L.+(1%;W``@/<2ZH.`;S<H%,CM=
M<F",4`<,]<W+6!4:^8YWO_Z+J<E(J5X`W5+0)?64ST';,WRN`3@0]*-'4Z47
MHBB+`A&,QZ!%'877Z+AI$>C>`_744TL13?N>K5YJCU^PI<X4+VQ;$*1^C02*
MRIS^@1-:.JG@176_SV:7IXJ9(S5"](_7F'04A3X"5A4Z]-=G9[^VPKM,G]I.
M;+`V1K@0\F5H#TH;VRP!\457=&B1NK,ZUE\D"!WV"&#0M/R@[6FG$3&*VK/5
MY5[&O'N_I4C0>IXYABU'^ZH"=S"H_4+5)8KUJ[.1<I.3L]P$?K^7*CG;.OQS
MF"SFD\;M8,/1^S`_MDV\NX2[G0:K7A)U!M/0JN^",:1$P_:M'GJ?>?G]S!5)
MBNQ],?\`M?\`!W6N0W=+'5N@(HK-F(T3B([^MJ6#GR3OP_@X9T&)]94P?M!!
M&#L*C=4D70<T+G1/,$*=[=]+*)`J;AK-VR?B#%D7[[/_`!.;,@P2,J;**OGL
MOR+)M7H<07S><06Y@GL[XB7I@'4K_'XM$V*)9-[]1V$J0@>P,OZF?06@DEI&
M\28T!#R8GMS7#\%LN(?5JN5Y&S)'UF?=GE-[,P2\IH>3M80?"8L&%Q/F$]X_
MX'<N>(!@>X,VBS[8P21CA'?S*CWE-<6`I7]BPW*E%5IF$@L3Q/I20#!S9O[?
M_9I\_P#\7G[SO!`I7_9>P3_BTZ`9Q!X`=ZD<,MO;Q?EQ_4@7=W7B`B>`@"WR
M'%Z?]9_Z4F;HEY6&N*YTI!FZ_BS+J3W?-Q&`$!-;_(??\GPW40%ZQ(,OU6U@
M4\]!C@6LE**Z&PJP$%OIG'P"W-GS3D,VX$]-A=8[OHE:YY$4/C.&,%))N3$M
MA"G-,.7WFGW.29'T.)4JW:HE6R.5WZN8+&$3Q30`V-;7]!=<\1D"4#R(2^5!
M:;-@LCS_`#J5\"./=Q3G_?,++P4,[PM;`-##&]PT)RFF?"B)K6D)>@N5<31"
MV&SGH2%KO8'NKJ<H=/>IS%90@`^W_P#_V@`(`0(#`3\A_P#59?_:``@!`P,!
M/R'_`-5E_]H`#`,!``(1`Q$``!``"2``````````````````````````````
M`````"`20`````````````````0``00`````````````````````````````
M``"`2""`````````````2```````````````````2`022`0"`````````"0`
M````````````````"`222````````````````````````````````"0`0"0`
M````````````````````````````````````````````````"```````````
M`````````````````````````2``````````````````````````````````
M"0```````````````````````````````````"``````````````````````
M``````````````"````````````````````````````````````"0``"0```
M```````````````````````````"``2``2``````````````````````````
M`````00``"0220````````````````````````````00``"22"0`````````
M``````````````````"20``"200"20``0""`2``````````````````"``00
M"200"2"2202222"02"`02"22"00""02""0```"200`"00`000000````````
M`````````"00``"200`"20`0"2``````0`0`0```""""""`2`"0"`"0```"0
M`"""`````&FR0""00""2"`"0`0"`02222222"""``"`"""22``2``22"``0`
M``````````````````````````222`22"``0``"00```````````````````
M`````2`22"``0``"0```````````````````````````22"``0```0``````
M````````````````````222"``0````"`````````````````````20"```2
M"``0````2```````````````````````````"2``0```````````````````
M```````````````2"0``````````````````````````````````220````2
M0``````````````````````````````"````2```````````````````````
M````````"0````````````````````````````````````0```0`````````
M```````````````````````"0```0`````````22022"2222"220````````
M"0`````````````0````0````2020```````````````````````````````
M```````````````#_]H`"`$!`P$_$/T*FGHL[,AA_;`BJJS5^"%5.(^!Z^0=
M:+`WWQ><VC-87NXC5829\<B2<U"P^Q$ML+TX@6F3NR)JF'86R9T1]@M5<F2(
M\U3[EM<@T_='#*LV+7S?SL<94KCEMBOM3-4&=41]#I0-([F$V$$O*[ED3Z71
MNX'&R"`/@;0%-<Q$@'VVM2Y*.T4H603PS#)2\#>^55R41+2+;;Q[=$3?W>-5
MR`Y6)!PO>*1*&?9.+^R(C'R95/Z*9I]@GO+2E#]M#&1JE!#DP<.J,*=,<:`P
M(#GV1Y2HY:^91-I<A8PU*.4%3CV94A26K9J\YQ/S$/G@5]@(%A[&(,38`-,G
ML%Y&P%*\=ZF35NM:&&`+I-#%,R^P!@DE%<Z`&:K#JF*0!<KQ7+\;Y)3,E`>"
MW&M`$%`C/VKV&%E=^H`T@#?Q>"0;!)OH7@/3#%96P!&@"_HQI2AM/>12\R\=
MBFX_H]$BHM-/,=2==P$XBJL]AD]R&A!S`:<+F]O7421*X%N1I*AA39EK?F\0
M;E>S;0O>9R60KEJ`#W+R3ENP@+8#7(-P:1;#48)B\C`<1*#K1#9?GAF],O)H
M"[UFD[5A>MJ^7E`3XZ*(S5QY>:F`F'[^&LUDFNY;+BZ7Y80PP6J?,5V,JL8C
M?LERQ!-,;,-(K)VI%Q:Y=06T5;\""&,Q5.D)C#@O=3`W2A%63J`T$P:O``-"
MLQ]$ATFM)'TSFO8,0"''<)F3`"0+OS7_`'N6;!CD:Q!.NMB$2LFI<P+2P'5E
M?X0"F8)WTNW?N,;-8Y%`"5QWCU>BV/.@@5TO8+:#=2%(#3Q2Z+OE[&V-%8JJ
M4`DI+5""JJ_8#2E#CL:82-0L?1.^G@-E)B17"_":H@T"S1EMC#@I>K#3?1R;
MTPRF,$UI$$R<;;)!/N'N^:APQF(>3=@ST97@`JUN$1Q\4'.3&;BH)Z]Y`@!7
M2ARM#4Q]R32E#/W3TJ6Q5BZY!<Z['4PIM1R[SP4_-R@5`!V6%$D6A5BJ!Q!^
MQX?3ZR+2R2[?,*5(B-E)@BJO]C!I2AM:@6\9NTAT4CQ,U$B\I7Y2+[(:4H95
M9;819-`/?TNIR,2;!<B3M#C[ZV/=@<EO=NT\K8&F+/\`V,:4H997#,&3N;Y-
M0<["Z+GPT!S/"0&8>\+9B]MX&45INZ(HL="DI!#PV4X`&=MP1"/<DK&#^#[%
MA@*7X;4+=[I`;Q5BT;Y4K-!^II2A@01A$",S?8"JTE9I5Z-%V?L6W2V+=@+B
M(B.%ZRBQ<A8#H"97`K;D"%D!:-DKEMED`@2$!XY,G#'F!D+5#XGY1XX5T38I
M'Z+2E#3KLS?A$-R4!@*/_#KLFO(^44.9#4,\9<E&^O#NS&!LL\!NL[52_<)J
M05\57K_D)[R"7N^<R4@#TY4U[[,)!8Y^Y8PL0OB8&WE!WP#WQLH<,`_!>!I<
MZR8Q&O*F(PP)5UL0PF^1)!HY#*^_U0S8NUTPQ!S/2+#)EI?'ISTO0VPJ03!`
M)H\!.!$#`Q<G7YT]E(2C=2EO<&[L1%[A[6#6^LF#5,'0>V@V!F4BK1QD,8,Y
M_KAJ'34TI%&,!3=E[%NG9XD?Z=I2AFQ:A8<^FNS50(?G'U<S+J38%IW=`%E_
M\0J&"%;VXG'E_P"D=+L'UH[Q00W]?)(LU6SA%*)BK#SXO0HPX7)V+YST'SN&
MG4%7B-QP.UR8V@`,":'<FMF*%2R^!O\`4:4H9L6H64+;99Q!+#2%USC4XC&6
M"'+[!\%;L-5FEW`*Y^D8&2%KP#?S'-_2AWCC88P"3P1I!:FL_;N85P^R)>^4
M+'MG-69AB35W52_0UH`_@UDJB9T8LO$D5Y,/CAY@P>M9-4=R3*3#91>9%.R^
M+F3T2(M^^$[S?HNPZ8<Z5!;DP?,UDKM,OHSL^J+M7X33B_5(B8<Z.#(C`AJ$
M"FI"Q%)YAWL`L=1+&QD[^QGHTFTVNIS`^9M8.9I,4RO4>YP&QZ["#36,,>K%
MQ`4"M85'`P10A$CB)53H#P2>;2ZU5H'BK`T>#LUYHO`*[&8KX)FJW-@R^Z-T
MI@-(KV5!>8DR!&C!00\EI'\%H2.,B[Y9,CM*2S(:%.:/P92:Z10XB,_5#B+,
MY&G>SJGIP`XU3>P1"8J:2%/&:`/3K#O:!1E[$-P##W5H]GV0<9N']@^-``A#
M8<U@R('$]M'Q/7%0C)Q-@WJ.I>%33-7\?*H]1XW7-"D!I7;^+;7;XU/64=N(
M@V#NA,5CSGO2\6$!*:FGF2FHQ2A&-A+`8TCB2/`$09T4>4DC=C#YH9*$24?Q
M):#5=>5J$IS^`&4#0J$24Z0Z0$3$HX6(V#.EV(?AF!Z^'B3_`#T%,9T5^5LT
M[TGRY:!$8=+9$W<MOD1K`8R=LRA)<717Y6S3O2?;EH@VGBB((849U^",!1PM
MOVK[JU&)*](<(&(J0C&1@PH42H;V9>D9NUE0+C'T'.J$$[XV;>8C)U*`'P9,
M92A63M2S&QE;<^&)!!:)[)CW=Y=MZLM\L`/]J$^F=X!0*`Q`RR/[L7_#UPHP
M>A6DU9.U+,;&1MSFLG4H`?!LPL*ESJA!.^-FWF)>D9NUE0+C7T1C`P84:)4-
M[,J$24Z0Z0$3$KX(P%'"6_*OFJ#:>*(@AA1G5T5^5LT[TGRY:,:P&<G;,H"7
M%(K#I;)F[EM\G17Y6S3O2?;EXGKX>)/\]!3&>,BMD3K=B3F8#48DKTAP@8BI
M`TZ:EN'G/AOBU:?@TSG0E8TY@),>0RX1S!NX3VI>MYM`)>,7LF(J^7$3,1Y&
M9@:XY;IPV?`!6`@@+7<%A(E_7:4H9L6H64+;99FV.2.4G8#=R@['4L<_G%PG
ME^4+=/\`MND\P6M/#%%ALJQM?4`JA$V)D@W"6/)(ST.U7PE$M%LD)/+9F&F)
M62,CYR/&R1;0AAH?!NM$O4K!`UJML8=Q`4^$4Y0!X(CELMW`J>"!!)%S%)!)
MXF*3!#Z(P]B%9BLP&V77CG]WGQ^&\/P9!#E;[AMYYZ&C((W(P0ZUU%_:-*4,
MV+4+*%MLLS;')"RVL=Q[TPQ>1(G&1_6#M,-LZ@I,+%VIP5`F8GT#5?V)]-*,
M@53V@)J2;'$#,8A%JON2A56F15+9B;AO:H#4`MK&Q(/0+]68[K)S%`$J%#"&
M"1V!98.XO?\`=^;I#=_JBC=#6LK<_P#042$V;KRI%(CN3&*`$]F>BME+!PQE
M#P8&'N-MF4C?H7H:FH<+P:"$P$]1GQ:>"8CU-\P:,X#A0K?1/ADQD\`XY6JD
M,;8P"G="(Y!ABQ$V_K"N);[PD2+%48$PA`:&"Y,JLE`"+84O[@V7=`*P&&@@
MJ/)5U#U[MB=$BL2+Y6`TU8+YWI'-;FM&>IN"B-00/1/$FXU"7(PE/P-E`:HT
MSI1Q8N)T0UYX>4&H8KA'A`T$4$`FT".TS<!&L@*@\?@K^;6H!DL$H$A*`")X
MC!!<*[<8=FC]@KPH=$OW<XGBR[ZJ]4?OS"EV$;=0()]1J0,7A@7<L;FMR%1S
MP@`O59W2L>&A-I'6(<G\E7H0`+<X0"5(JH#&N&$1"N0"KS37EZRER'/_`#><
MN&BIUN"RTY<74J;Q'X2_7`(HY83A-6EG-82(JGPV]J6"\H11R'(6P+\6?LY!
M<K>D(EG$?_!#F:^J0LPCTL2A+O+AQ$R0<(]YFCO-;HQ86D@.1PHA&)=6`DZ)
MO]P.]Z#B1!P%M2HG$_5*401,CA1",2ZL`)U#(8T>/=]9WA`%6U`<CO/@_50Q
M-?5(681ZV!2Y;0!6\UF*0!<,^Q]4-&]T`)A/AM[4L%X2J!O[V@R7[^:O+<A!
M.%5:6<4H*J;D)@,HDRY(2.(/'+_3GP`N60)KD\<O2,>"S,`(E\?'(61)PB7'
MKD0X'PY%Z+K*X<I&RSP5!SMV/!JD`N@&5<I`I[TNT)2KG&.W-*,HSA!+?BZ2
MJB=X,TU8NYGEZ_`GO)CBKM0KF#GA&F`"!L,96E'84LLR&#UWN"(#WE`LC=5,
M1K1;Z`6&P!H2"6!?PG)5T7*I3>30#_),?#[57].T_K1JHF:#L8Z>FK@Q@W=<
M=E9;(NMBWA(+$)CDHJLLES\8G$=NUN.F-@FM5]GK^>0PO/"RIML"?"S_`'M;
MPO=JA+162S]3Z8N:>7"`M".%&[5SM*W(A*2#J4U3VB-E=&]SN@=FI870SZE>
M%!JY5'G^[^:*_P"WM2F/W;J7Q5-%[5G-8.JRN!!7"^]&;#CTL+!CE5>R2]BS
M:!)13FOAT!4F`'Y79>\^FNNN(5)4IX:_@,^(1Y^$O^TPP\?\%=8P'),2ORVK
M<T\9&*9*YO+1HNF#*%\\E5D)5C,T.+$&'G]($.P'(QJL-J7B:,RB2F'K&A\]
M&,*>T-E1F!!JL6&9Z"RV*0;/A8`(D75D1P\:KQ^4R3HU@T3R"/A,(:#(:$'^
MTJN9?J34'\1,)T'HZ_Y.X-NCT!HT,R;L?+C0_@``NAL.Y:$#;ARB2J#1%FJ,
MIPM']T!W^A\L3#/$_82&8GG"!;*WK1J@3?XH,YU)@0ELO&3`8*D=K;3VR<43
M9=B,=;)4:=.A)9$\GL+32+VGYA;JL`.VQ(LJ!%!F"U@TT(\1&%]B8Z1\*:_F
M\EG\6>/B/^W`-[16V)E0V`IJ>D\90]T=`\\H30<EX`?^+P3LD#DIUG*'0BMC
M1S#\(X?PT.YP'6N<NB3'D'<V6_$D=:59W.DG5IUZ';>>R<4\9C:$F[YW=>+-
M*P;:BZ:HZ&:">!=9N/9XYCNE-.\P@0#E#`)G"BBIQG;`;5=;UPNDW,-0RMBL
M$Z?]QB=4Y0:*B96&QZJJP"JI.&O9..O:ZF#$S`(N#P?+85Y::\!OJ"W&6V=4
M4.8/\*_98^0`J/V\BVV9LVQR0L48S90W6EDCI:FK%#>P#'0"LZ5$)1]"OT]H
M]M3KUZXV?A"*E<<@OG69=KP?<:`"6H"-(`%ST-VW!X_&JK)HS0V@M0HZ.`7Q
MCTM1($1U_:,VQR0L48S90W6EJ4ZWM+I[$/&5<\J&W]F7&US(R+*7!B'LT0WM
MZ^6)Z,?GZC`-+2V,5_F"XA$-+`2155!3/8C?LV;8Y(6*,9LH;K2A])J&.-.S
M&<Y.,"B@6/.D8&PA!KEW_112>^"9#^^UT<0VK7/YWFVG6]1,6;)1@NE3;K[!
MM@YOIF:8*JOV*S;')"Q1C-E#=:410"*&90XSF7H,P^D>Y7R?Z!+V)!940-4W
M+YWA0#&",X"!\.2:$&53,"A)-/#$]1J,AJ@9`5<FTDTDUH`ZH3`#@89"74ZB
MF&8-%SHU#C0Y("KDVDFDFM`>\$$?.KO'.!`2:$&53,"A&\*"8P1G`2.<TH3'
M9`XH"+9G;(R!BU$):X5@)W("^0L[/X:($(9%U<]%"!%"/'UDQ9>Q!@@V9$P8
M-8<V-P"0(6;JQQ48I&0TA-.PAV2NFU'10L`UP:$85Y/S**K.3Q]9,67L08(-
MF$XV4(@20\(5R$YV6Q,A>[JAIVR,@8M1"6N%982+T3ADLR!`*!1!?VY%@`/$
M4<1-D)J(ND1!$P8-8<V-P"0#D$@FYT`5@=>=4)@!P,,A+J=0Q#&(D5(XJ0,P
M]2@%4FO,%7>O>""/G5VYP("!M@*G>HC(2)@;PH)C!&<!(YWO!!'SJ[<X$`13
M$VJABTUF@!.Y`7R%G9_#1#U0FH'"1R4.IU5L5E8760B$9/$3!@UAS8W`)`LS
MJ-"7%3C+<$X44``LQX!O3LE=-J.BA8!XN7(K@*@H&\?63%E[$&"#9_\`P;Q_
MMM=`AG(I+O[D#,(#MD9`Q:B$M<*Q:5#AG%+"H=]%RAAF-NX$+.(XT@97@B$8
ME+E!W8PV`IGBN9#`^D<W[`ZAL,L:8@JH@.A8"B`'3/Z`-?%"3-IR-D8('$$1
M=3X!$<D2HNBH'SX@XUM'^PAX8ILP)65/#S8B^,Y_MU?^U(#]3C]`4<H&(^'9
MXYDPBL.*"\Q</I+3`NM6\&!EWD@^E&&;)1M'P5G]*,++,'FFM/3L'.ZCE_YN
MB`]5;.Q<QYJ'H5:P&=SZVS>,C@ZN-V;FB`:6#*A#Z[2P5+MXNM<;UA^+^^$R
MRAS,Q>0@%$#E2F72XH6KRI2LQXOGB%OL/TM@4V`C!7[<#D`K//BFT;.+N78D
MS\C7]?&;*&ZTHQ"4Y='G$>E)U(3R'2PH\613DTAP7@*8)''7NCQ4>&GRHR6\
MRPW9C,E*JY]'+`1J,QD8-"@E=>6GSV*SNHK>BF`0`9E).Q*BRM=7LT?_`(D<
M#!55`$8`XDG%4HO8*6Y"2P;SJ-;NL2%56W9D)XJ,P("!0)`=,ICE^&#*1G42
M$12@5Y^IDRE&-*W`6JSM#`I.C/NKMQ32',?*?<P&[P\F`W=$1IE;OLL4-UI6
MC-`2BH;)9VND+G`5?$(4+E'D)BAK%9U7E34LH3.4WL,-LZ@!/L;2M+;E///8
MBX-2-^1@'V-)0F=)0(FD*F=%!0"%1RQ[1B,7^DZ@O2B`-CM96@L*,%8V[X_O
MX25#DKE(=_-,U+"6%#E6N6L6<BPL%`Y62(MBT8Y/KJ4CX.T/O-'XO7P:W6Y@
M!_)%3$0[OP-F*'$_KH\A6^I7;5BG^P'11-F26#%1L:2KDL*Z9PD12V2VM9KE
M\CTZ^TLIRM#E#P"#K<,P$E%#,")):GB-=+94PH7U862_L%)%$T$*DD3\Y#SA
M_"T3!K0#BN<%^JOI76"*]918N0L!T`=[>I"(SH)]I+72'J0!T5&ADK\>JG@G
MUZD28F&"YD:J<SZ@!^S2NBP(#J*'12PS!BE4>#Y''9/-/QVT(Q5CVX0@AC[)
MQ-SF"-OR?.ZQ9+J*@#B2W!$@`41(]3"6B(V>.,SMA]4-'Z#F;T+]M/R+B;=%
M#%"39L@S((<LV/GA,(6,)_P9)))D;\H=T8<"3Q)4S8MSHJR$J4:(KF93SMW`
M7.>LW;=,]/+-MW6+,*),FS04N:G@P8JZY43Z`+O5TYZ1!#NSK,LN8J4L.C3J
MZ\2K)36*KQ:Q(4VEA`<341PW0(F+)?0N$FS\EC3PVCLYR\%J;#!9`?Y1,)2"
M1,=)\QN+,##EE:@P8T6D19A<']E=Y0A(I@4BPT_?8LZ9?P$.SEN.4[6!.\B_
MJ%"#GW0,Y!YRMG<U[;\G9F!&O16S.F,:T2H?4YXQ"^5HL5R41@&IS7ZK.&1X
M965&9]$<G#8IM93T&#.29F+$'*AI1^KH80(=WQV"$F,SYM@.0.35,Y3BRF_1
M&3^>PA(%^ODF"5E#HG!C(Z?X?H<."WUP9,GBMW``J^3D"Y.!W92*=`Y0WJ&:
M]GS5VU0Q6IH(,59@AW>SA8P7CI]*+Q-Q3G@+A'2P?,!2;2;>`.TX%?'LN<EU
M3+#1\X#A;P)WY+^Z<D[Y7:CXHE&HG67!U`Y2:`<"S]DC@G2)B>Y0CM+UJ_B/
M0C(^WO_:``@!`@,!/Q#_`-5E_]H`"`$#`P$_$/\`QZ)_5CHZ.CHZ/_A<?__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g575431g30v39.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g575431g30v39.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@!7P'``P$1``(1`0,1`?_$`((``0`"`P$!`0$!````
M```````("08'"@4"!`L#`0$`````````````````````$```!@,!``$#`P(#
M!`@$!@,"`P0%!@<``0@)$Q$2%!46"B$7(B,8,==X&3(D)5>7F+@Y,U:V64$T
M)K<X6'G9.A$!`````````````````````/_:``P#`0`"$0,1`#\`[^,!@,".
MO6"I^:>?+.E+%T&=RT"!QEPL227F5"(=8@8+"($G-EDW<%46G:!SC:Q"*+M*
MH)YAI(S""MB,*^A@0X'+<M[_`/4Q#S<QRV;]/I:HL:$>6?3_`*W"42"@J23+
M;@C\<MQL:N<>;K&;G:+;:F1M4U,8@-E/[81L$F!(92D3$N)02B]'A+NF_0OL
M*P^L:RGSM9(6RG;,]/9YYS+>)E%<5BD50^%0[BIWO[^^0)SI.9;2F?-\[8P*
MW3[WY3'-QET3`3-FE!A*@P+5><NUK1M;I*9\OW?R3,.8[`C-)L-\M(W^VZJM
M1OD\)?YX]5ZFV2HK!U>$S2X$O3`IV,I0;]_V!UO6MZV$6PL+P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&!@MF5E7US0&559:T/8;`KF<M)S#,85*$!3K'9,R*1`$J:'IL4:$G<&U
M5\>M&DF:$6:#ZA%K8=[UL-67)Q_RKT.IKQ9>W.U-6ZHJ4X9U:#L.NXO*M0C1
MQ[,I4)8Z6[MJHIN;51\=;QG)`:TF.VB(^\L7Q`^@?H0\E<P-M^.'5"#G^HDG
M2+JA-;G&\2(%'"[.5ICV-#&#]FS`+?\`K.U1\8;2&P:C1NCQMQ6DHA[(_P`O
M`@#6TZ>)?[=7LTNE76)7I$$\\*WBS0^3?4&_1K0;M=+6*Z@G5=CA\XE[B.'F
MFN(D>OUM,R.H5B4X(T(2]%FF!<'@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#0G3$\OJM*>D4PYIY_:^GK>;E
MC"5'Z:>+C8J&121$O>T*%]6"LR21B7,S,9'V90>O"4<B'^9^/\`!`&,.\"N3
MRS])>M/1$IXG=A>?3'S)S^A46C%&RW$W8,3NUT=[5J>Q]UO(X%NM&VGZ]?V]
M'IS;'4P+P,\2006\.@!,TH+'H+EL!@,!@,!@,"GRMK`.FGMU>S0;`+$A@*_\
M\*WB1#Q-V-O:&:P"P=+6*Z[EE=J4;RZ*'N'[,<MI-*E)2(W:Q,<'1/V!"8,+
M@\!@:YLVX:DI1@3RNY;2KFI(NK<B&9+)+-F\9@3`I=U)"A2F:D[Q*G-J;CG)
M0F1FF`("9LT8"ABT'>@BWH,Z;G%O=V]"[-*Y&Z-;HC3.+:Y-RDE:WN+>M)`I
M1KD*Q,,U.K1JTYH3"C2Q"`8`6A!WO6];P,?>I[!HU)(9#9%-(FP2^QUCVWUY
M%7J1,[5))XX1IC5R:1H88QKEA#G*%C!&T![@M*0E'C2H23#S=!*`(>@_TB<W
MA<]0N+I!9?%YHV,\DDT-=G&)O[3(T+7+X6]KHS,8JXJV=6L3HI)$Y(V*6]S0
MFB"J0+DYI!X`&EB!H-<G=)T"EJ=YO=;<->MU,1V122)/UH.<F;&R$-$EA]DN
M5.R9F<)$O/3-R5<SVDT*6$T(QZ_[3*V3KZB^GU#.)O9$#K8J,'SV5LL3)FDV
MC-;Q0U[6`1@?YY,UNVZ*11M$9_10]/Z_7PI2=?XC3/Z:_K@9M@:;J?HKGV^U
M,S1T9>M-W0KKEX)CUA):GLZ$V*I@;^HVLT0QS,B'O;P;%W@_;<H^Q,NT0<+X
M#/H'?V"^@;DP/+:WQE>_U']%>&MW_2'16QNWZ6X)%_Z6](/C_/9W'\0XW\)T
M1?*#YDYOVFE_=K[@Z^NL#';$LB!U+$UT[LN5LL)AK8N8&UQDLA6`0-"%=*9"
MU1./)U2PW_+($ZR-\2(RMB^@=G*`:WO6M_7`S;`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8%('\>_\`]O!3_P`7_=?_`*M+:P+O\!@,
M!@,!@,"GRMK+9Y[[=7LR-<?L1F/K3SPK>%.ZV;UK.8$S2%Q!TM8KR-VKMYF#
M"S-UDP_13H$C3VR&+FH:PHX@!XC"3`A"X/`8''A[?_QT.L.\(S1JWGCMNSKC
M?JR?IP8^PCN*U25D:2HIN7%P!?ZV<:PIQ`C8W9$9'Q%KTJQ`:!4D$5^.<0(@
M1*H+2_/3R!L;CWGCF.M)GZ#]DO<HI1AC7[DA%>V=$T/.JMS;G<Q_<81'(C+*
ME<Y6?6)1B@3:$"E<G5*T0=F!`BV8$@@)4^F-#7+;%0U?:/+T6C\OZPY+O^LN
MC*!CDE?6^)LTQ6LZU7!;8K5ZEK@<E)8V.R*)G4F:S!C-`5I88E-%_B)+$$*K
MD/FWW)5E@<'QR*3^Z550U'2/.BBQ7.C[@8X:!EZ\3]0RR^^T;,G\(?[;JV+R
MZ`]%IYF!"LT%FGBM0TIW!`!"B&I+6*@P-H\R^_ZS@=S(Z@76-%Y!<]7>BRB3
M1]%U&]!AR>Y[&]28E>?)\@A$47V*=#:P=C^7765*5JV.I6H`5;BI*=!"<5._
MO#=`.)^Y).!:GF4(GR^Z67TUA71#IT'-.IQV#4]@T=%>HK5GM6.-8T2_SU[9
MJ<#2='/+`S*6=)&V0]9^&`@HMR"#[B0S[S[XC[>B/+?7U2]*V/>;5<U[<V0R
MJP2^S;E)MFO4]^:K6VX39-^5*X(+IM.P&DN=R"2,[J['+$T/,5:0(MI65&<2
MH^H8BT\V=GF<+\\T+'^)0<]/'/[]QE&+^A5&=-5[6<DZ^IRI&B:L-JPRL+4J
M^4Q.01..HY`8SR)(7*)#'EKTD6N;<?LK8SA.`:D_Y?7ILYP>NG)YGMTDV%5=
M,UDOJUO1=F3<88G935Z03NU$D-L9P)L9L9KO>JUX7E:.'N+O)2'EM?OPS2@#
M4'")%H,II[RUZ$A'2\R0'MMP1*B;`]8KSZWM*;0KKZQF!OLOGF9<W6TY4['A
ML4>N1OGR!1%^DE[$CE3<!,@,D*4PH*H;@UI?J0&I(9YY>F3[1MIU_9C;/U4K
M>J7YMBMHF63UXKNR+=.=1U[VO#;;GO2E7LLJFKRU4I#]5''%_P`;>-+%U*P+
MBD;]-!>FPC8@ZO<!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@4@?Q[__`&\%/_%_W7_ZM+:P+O\``8#`8#`8#`IZK2V()9/MS>S##G5<
MY.E4>>5=0"=$*XW*&$IJE1/3%C/1B!"LD+,U(I&ETW.Q`]+6PQ8AV(>R]';,
M`,(0N%P&!S;^K_O@/C&H54[Y-I.P;UE\!L93%;GC-R<H]S4S#XM$B`N;8IFS
M1<4JH>*U0M0M4M1)D(]">!%+RW$HY&8:$&_O#<G#/M]7]T<XU7/NKJSOFG[Y
ML$E6Z.U757P9Z+V7#XTUN3TK(A!"2Q6CF1^C,J5/D9TC<#E;>M.;P"6_$4:8
M$K9PPLKZ]Z)D7.;7STOCC"ROYEQ]=<\\[/`'L:X`&F.W',=1QY?FW\$].(;T
MU)?J-*$W8B-F?_$"+7],"M)3[E0NU8W+VOEKG^Q'NQ]VAS+25;26[)+2\:HY
MWGG6UL2ZIZO<92[51<-L6A&T;(9`7IY>8^XQQJE*1(C(1J4B%8X)@X&R"O3.
M703@3KGJ>8G4O>ED<P6@IJ+<:J2.W=0,74S][1TZGA,1L9EZ/8@3.N7`I\N5
MM4.JP@;RW?MX\A>F-&::8C(#:\I[7O'DZ+UY$^O:C;[XZ3MIXMIXKZN.`4"=
M2C<*FIJOH].K#F;S_JFLRI&MH40@;H:D/3%/RM8[_.W[;TABE4:B2AB\8]D^
M<9Q9E90"$55T?+(];"RAV>+7&U1"N"JL#).GN:P=2T%&7(QVMAML).Z617P3
MTA)A4>.0MCPGV4YJ$*8Y*K4!'J@O>JNK`H2J;BN3E#I*J5T^J'J[H63I8ZDK
M*PX=77/_`"#*&V-VE<C[)2;(8GU1$4JV0M[>400SC>5#T(Y*0A-)"G5*@V^O
M]5%DRE%'PR"TK8U+3UZ[)YHHRY:SZ688(;+$%1=+4M:5K0>?PUQI*YK)A(CI
M"DA(-)1FO"A4WJ4:Q(XMI)P?LT$IO17I6Y>2^=QW93L$K><F,=CU+'IR"R)1
M)&).QPNPK.B-<K'>,L\:87`^7R@M?+4X2$2EP94A16S%(U)NR`HU(1%8O3.V
MWKMDRK":ZK4?,&^_99YI!=@+Y,3>J2](GQ?_`*OSK1,+.4_LAPJU=M*IC.VP
MM.4Y)QEA<?RS=#"AV&86W[&5+55SSNCT7+O9-KR6$6E-Z/)?*KA-*.44FER5
MUSY'^JI;6\/62Z_88[G/S;S^^CD>CG%"VMQI"!2G`J$M_'3*`]"O/8WG"W>@
MN>N>:MKB\IP]=(1&K9O$)HW$4@TQ:.1RV^=5/4\<=IK&Y5>4?N5$RH:=3?DK
M'1NBCFSZ=#`M)"M0Y_<D"$/I=['32G'RK;JLEN;WOEKI;L_K&D*(C43A7ZC;
M4UKJB8(BJNEDE8G*9;&FEXF?2'5,3=5;4I?!IV_<??T!9@T))0UV@L%K/TYJ
M>U^TW;AN+U'=W]QHXEM$^63=4HH(VOH>?3;-4CC/$4K;&B^76Y&$29UO&--3
M:I41$"!^6+3#FM0L;DJI<2%DN`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&!X,IE,9@\9D$SF<@98G$(FRN<CE$HD;FC98_'8^RHSG%X?'QX<3DZ
M!K:6M`G,/4*#S`%$E`$(0M!UO>!0;_&PNZH;5X(F4>KBR8;-)#!^L>LW28L$
M??D#@^1AJLWHJT)O73L^,Y1VW%M:9Q%5>EK4J-+"0N*+.T2,8B#@EAT(8#`8
M#`B=VYUY`N&><)GT98C>J>FB-NT&BC-'D;LQQXV1S6S9S'JYA#*?)).M;HW%
MVE5)Y0F$XNK@>6C:VX!ZLW>P$[#L*TIY[:D0RMXI-H_S>SW>YH>:[H[/OE-S
MMU/35P5_5/*U'6`1`9-8$-MEA))C=SRQS4&GGHF%$2V!W^EN11ZT@:36S0W#
M"?7*&3[IJ-U0PTK*E'/4VZ6>>+X9U@&:Q(V.OO4C#0JCH=9!]UN7O<E10U5$
M6]6UI'X2H1BB1)#4FT`"0[5Z#7O-'5G-G6?KY9\QYEO"L[UBL7\X*XBDC?ZP
MEC5+6IDDI?3UEN@V)S6-*A04D=`-S@0?LD>]#T6:$7T^F]8%W^`P,-L.O(+;
M<$E]86=$V&=UY/XZ[1*:0V4-R9WCTFC3ZC-;W9F>&U6`Q.K0KD9X@#"+7^S?
MUU]-ZUO`RXDDI.4400460006`DDDD`2RB2BPZ`6446#00%EE@#K00ZUK6M:^
MFL#6=HTS6MT)H*DLN-_N5/6MH0:YH47^L/[/^BV56KK^M0J2?>P.C4-Q_17/
M_-_#5[/0*?\`HGD&@_PX%2_)GBE75$55/J$NJXY5TG0TPAM=1MNJ!9NSJ^AD
M<EU=3)ZFZ*]V%$*\)V.MKY7.RMNT%XK@5?MC<%E1C0MB<XHLPL)TQ7SXY*B=
M&7MS@"MGR95)TW()'*[]9[>MRZ;SDUJ265Q")0)Y?979=SV)/;/5N@HE`V9&
ME.`\EC;]-I!B39)H-&8&`O?ECQ?)H)&Z]D43NI];8A)I9*8U*W?L/LAQM]G5
M3NOVBJIHP);Y5WZ;=^J]E5=1]"T+XL*0BC*I&D*"8@%L`=Z#9#/P!R%'GMCD
M#!3+:Q.$9G5'V1'2F:43MK:&.7<W52II"DEK5'D,I(CZ%M@=6*QM!#:6E"V*
M2OM-5)SU``'!#&83YI<35ZC>6J.4K\C"^UGT12ZV*R>Q[:G<-3U#U?+(A.;_
M`*O989.9Y(XK&Z_G\J@K<KVT-R-*@:Q!4`;BDA:U:!0&!K/*;D=MJ:45Q7<=
MG$/D;M)&JPXU;TDN>][CM2'VM#*G?Z8JB<E3NV[5ELSDB.H8/(CTL>CKDYJ(
MTWAW]"T(?KO>!N"TN#^>;NYUK3EFV4]N2RH*L9Z^9V5N:^B+\K"12$%8-36V
MP];8<PINR*YDEB+&]0S)7+87A2K3B>4Y+AHK2PDDXL/QP_STY*@U[H.EF&NI
M(;<K:H(=DLDDMS7E-V?]Y%5.ST4HM53`9K9,@KM==[Q3[$GCSG.SVDR9.K9L
MXI8YG_DJ-FADBCA[EU5/%=FGUA\DX77A-NCU3W^];##\MSV+S:5R),9E^F@E
MH6@'ZQSP0&/?IP4^FI/]/SR$Q3GO:S`KD0^+*:N;Z=[6YFZILCF.&B@]:UY$
M8'6Y=DFO,8A%-\CM7*=85Z]2)SO0<%M.!QP$;:94,R5P]XF!SRV)P%R(@@HD
M)03->/,;C&9\\T%S)9U2);)K#F^H5U,5L@?7^4,ZA)&GRKRJDDSJN,ASW&P+
M)<_1@`C_`-6$':]O=Q:<D)J5P+*4@#2G.7EVOYP[#GO3L:Z;L93$)[-K:G+_
M`$T2HLHE!-5UF-$:9V5OMM<_77+*\L(-6`CPE+(\D0UGEJE>L4*'5Y<3#U.U
M`6T8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8'/C[:](UW<5$]+
M><$*<E"F2OM+E3'L2\DA4M<*JX%YYTYMDC46E>*BOD+K*'N829H9SS(]`VXH
M2][0%GK702%@+/6#"M[^*/R%Q]SM(.PI3S[WY%>VK!D3+5K!,$%751;=<P&L
MH>E<YBOCJI[<K(9VPJ12Z9N856DQ)82A-Z5L4?'\X5!HB0[+\!@,!@10[6Y,
MBW:U`/=%RB4/D&&=,*QLB(SB/(65X<HA85/6+&+1@CX*/29$Y1F3M9$FBB<M
M>V."<U,N0&G$[^,8@'%A5X\>#,"6,LM3Q_JFWX/*;V@G3M2];RV*06H$(KZJ
MGKBW4-O6O#66.&Q(^.T]^&XE+&UB5M!!YK<VN2D)P59QFSMA(F">2M<U]TFS
M6\R7%8)=)1+IF4=G0GE4++#2H''>G991&^>UT['-]-`[!=(Z@B+@YN")D,5A
M*)?7$Q2,XPK6TPP_'`K+KF>^VMT,<&G\)F;U6GG-6T*L=GB<J8I$Z5_,0]-6
M0]"B4V;V=>L5Q23:9G5*KV@7@(5?BJ2C?L^PP`MA;K@,#B"_DL3+W/CS5S@*
MBED_AD=46!=8$*GS,G78!D_=(V2FA6XWKH,B'QZ,(4WPH1_<W!`<J3Z6C7:*
MWH.ON$$M?!^3^YKWP9%UMD)JUECN*UK%*7/?HG8'7Y73VVTMU0Z`2L3OT+D:
MD453D;%^C_>L^,1?W?T!KZX%J?M$@OZ2<NU?7?--OV51-J6UUMSO5K39U5R)
M\B\CC1<QDZU"6L7N;`<0I-BI+L%(8ZI#M[1+D18TZD(R#!@$%([9VKZ<7_-G
MCL&J6^\X')[#\X/06'TIR2<GD;A"V_H;CZ#<:(WF?[IU>9N'R2T]]5VO9K%'
MCCTRQ6\,L<;R0A.+,&CP!G83HH;[7Y*X\FW<=[OW19G'T&BG1L&[>OGHN\AQ
MBQY#=$TZ/D33`.A(94T7XQZG@G/]!RI:L9(Y)2(TT+7UB$$:<XD"4(>I-NPI
MU9/-'G%6=H=5=$<E^@4/M0NF;SF,INB6TQ5L$:.0+R98KT5;O0D9:GI;7W0L
MXO6%11*BCL6<'!_1NJJ8;7D_$@2."\(6"H(.C6>@O?-D%=>]C4GR;SM3PX7;
M\ND'6ES2:MO]471\@06K,S*FAEP/EA4O6<9YOI\+6U(0,C&F+95TY&0A_&/:
M4^TH27\@.P8;;G$?`L`G=UN5D=13CDI)-YFFECG*)78;V[5*37,4NIZG$D=R
M5QP9%&9K9+.D<=.BP"XU6X!^T)GVF[`%:W"W7=E1'J57/>@;ROA3M&S^C9/H
M?7T\?+6FU.\Z3&->@\#J/SZ0P:O%A;S'J=<)=3[TN2-R.*)$R>2L10WE:4K$
MG/<20L0Y)O)J</67TBI4?4$XMUL#4_)\E@=;3.;)W>-UK-F29=9M%^0NJ8@S
M-+#%XPGA#>I@R1\T0E,=U&C&TUV6+5(P'["OVY_2+U,BRB^Y/`5_,P8A"&GV
M=G\%BTFYEME[D0(SY4]`-41@\->)0S]!L*)[>NC(-*R"=.)#6E"E&W;-2)C1
M'#,`&SJ\]@;6<>R.E$MM2VE*NY*YA@_4DRE\0?6B/L5JRM/1=8T_-F-JJMZ=
M+J5SZR9`G)E,J<92:.`L+6W)&AN*0F+@K1*M!%Q?9W7_``O:7G!(WD+H&3]%
M\YW];'=4RD**72VMN=I9V%WUQ#.[-LB10!`^MY,B_LD38YU?,1HE28J.LIVG
M([6VIN6I30L3\TO0CH;L7KSI.$V)*J4::EK9/=C3!*R:V!ABMNN[O6W5DZIQ
M+,6)".[YY84DJ^.5[%&8+Z\/D6B(A2V3?BD)"R4X`B"]K`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8&DSNEN<D[T;&S[_I,B1$.@V,Y@.M6"EO1+T6K
MV@,9S6H;\%<6Z%K@[)$GV7HW1NOLV'[OZ8&[,!@5.=+=96Y>5N3/@7ST=F]-
M>T?;VX'3/6+HS)Y/47#T9D:<PU.D,1B4`163U7)&K_-B\*UO\9`$>G5\-(1$
MA3+`TI;33#.,JQB_E_P?"&NW^R.LH_,G>5R&ZC%EF&HXG)@J6>[^[.[IHL2K
M'";HU:QP/(2HW099LS?S2&!K)+1E&%HPT;_%PYMKKGCS:?B8@A"HD\LZIZ:0
M3Z9*2"RW>8*:DMF24S%%"K01&[1(4<4@J812(!@B"%*A2:#_`!J#1"#I`P&`
MP&`P&`P*EH6YPAP]K[;(B3A%5SFV>;U<(9L3'%;0I7-\GUU!9IQB.4EMA@U"
M1^TWFD"V6KT%1\(@;WK[=AP+:<!@:WN"WJTH&KYU=-R3)GKZK:TC;C+9S,WX
MTTMJC[`U$[.6+5`4Q*A8I,W_`$`2G(*-4J3A@*)+,-&``@SQN<6]W;T+LTKD
M;HUNB-,XMKDW*25K>XMZTD"E&N0K$PS4ZM&K3FA,*-+$(!@!:$'>];UO`TCT
M?T_07(E;#N'I2SX[4-9$R*/10^9RG\_3,F?94O"VLB16:W(EYJ4E0IWO9J@P
M`4R4@`SCS"B2QF!#R'SL#F2,WHNYJD5TPECNQKIIVZ%=X2ZKSD(V6EV)=IO>
MK`?)`H3%Q5E96LT6C#]*EQ)Y2405(B])Q:-V&GXMZ;\,3*L;8N=COQIW5M)P
MU%8EA3=YAUD1AD1P-T,6$,\RC)TFAK.;8<9?5*$9+>MCH'5.X'B++3B-,.*"
M,,@L7T1XKJ5OHQXL/H*&QEEZ2:87(*:?5*:1*V&4QRQE+&B@DE7OC:R+6F&1
MF6+I(B(0N+Z<V(E!Y^B@F[,",(0QLWT\X616K85*OE]ML0L.JFFSGZ>-T]A-
MFU\PLC#3;ND8;*?"YU-H4P0-X98N[N"8@:M`YJDZ@:HC\<9NCBMC"0M0OM$W
MDUPWK*HM1>:);9JN-$0NXD#.<G=I+4BQ:MET=;T*YV0(GQ'&U;B]&KOQ1ED:
M,.&$9H-B++^P,0JOM#EZ[;?G]"59<4;F%MUB7(SY=#T*9\2GEI89*B8'-EL>
M=7-I0L,W;X-.E)3(^J&14XD,KP:!$M$0J&$K8?-6]G<W73=%D\^UC8*J4VM4
M1TI36$Q$P2QVQG8ED)DK=#Y6@*G3U$6V`O;DQ25U)2'IF]T5GA,V/>@;"4:(
M`2AP(9._GAQ)(IE+)](^:ZRDDEG#M+'^3&R-I/?V=>_SY8QKYX_D19X5K8JU
M/TY51I")Y6HT2=4Z_CZTJ&:$0]"#U:=[?YYO6PT]65])GA;,W(OI1?'DBV+/
MR-IE<<Y,NZ,<ZW5+HU)](CHRYQMCMZ7HVI&=I6$US^IIZ4LQ.2:8$/>I[C7F
M"@9L]V-3U,Q&"35_;9&R*GYI`XG'MS!,9J?8\MC<73N*]:AA<9D\^/V\.#:S
ME(4*QQ`6>:4,PHK8`DU@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,"#W>UY=8<
M]TV?9?*?.=<]%ND8)DDDLEHL:[ATLCBT!BT9<I`O>V=07!IH9*G8\Q!\($8?
MQ-@UO[ON']?H$-1^6'875W<E"-/1'0W,=:\[5_:$)K2QN?U4$O11;SI/(G.6
MMZ='8R7,BF`PTV!+H\02U[*!L]<);M>:'82/Q?N/"SW`8'+!*O,_SYD/\@ML
MJY]XSYR=JWE7D_9]^R2"+ZIB:F)OETF]LUU'3+.<V$QM$VJYD-A>E:/:T9>S
M=IE)A?U^T6]8'4_@4_WUTM<79-GV%P_Y[3(Z$_V\>D\1[,[L1(D[I&>=-*-)
MC7^C>?3U!:IIL#L%<RJ=_DCV`UFKPDT)[@,3J-*A"&3VE-J;\I^?JMYPY,IX
M-A7_`'/)G2(<S4`E=UQTVO\`NAS*)=)]<%UV,K(='HQE9"3126QI\^F&C*2@
M$(T\:D](08&\.'N-M\P1V;3RT)>3=/8/0SLVSGJOHE2V@;UE@S!`AVA88=$$
M`P_)$:1J5G,_1H='BOL(;FPK9I@1+52LXT(4_P`>_P#]O!3_`,7_`'7_`.K2
MVL"[_`8#`8#`8#`J6A<%A$/]K[;=(E#HK%G.<^;U<2F;.,<CS0R+IA)S.H+-
M;C)'*5;8C2J)`_&-Z$@@2Q6(Y1LDD`-C^T`=:"VG`8')[[@^(_7W7E;QZM.$
M+QN0]FL*>2&8]&,_4GH?UY*JL7LR):A?(1!(E2<JD%G5J-C+EQXG36Q-Z7;,
M8R-Y:+Z!&9H`2`\N/'2]JKY-@=<]\]&==E796#POB4?,YT]0NYVVJ'.I&0MM
M,K9*EA+/8M?1:%?MAJ-''PL[8V%MX&]I3&AW]QY@`!:/Z)\<J>X:FJRG3OVF
M?#6KI2F+%MAHERYV0)I+4$1=UW]QXPSC:&1\&HDC[&G(Y.B)4!3)##!_0U22
M'_%@4O1#P=Z9DD!5,W0O1U<R^UK$Y&[PY2MV[V;<S=WXUCM>N.-:!Y"7L,=>
MX^SE/3;$ZGY2->9PC/<&OZRR1N&T)BT*TY:6&X);YV^IW0,]TEMRZ:"I>C9/
M-N2Y=8-;0:]KRZIA*9ZYA?+<M9QD-64K=//]40&!1VT+=35:G4P<"TUC0L$9
M7B&K7''!3GA^-O\`-+T(B//'*O$JO_25T+R%S1=4PF[O$Y9T!<G/LOO&`UY=
M0K0XQA%A'QWDJ_61%#:D!^$H?HP@`64ZN,;9B@.VT!2XA<%E+7S=?S1UAUOV
M@\-E-V58+S6=:\_\6U>]67-X=$(A3$/4EV'.C[+G2:G)LKA4XM^ZW,:]R,:(
MU)BDC7%V`H!QQH#MEAKGS8KSL?EBJN2N'[EJ>I=0KGSD8,:L*]:RLR8S>*OD
M[B#[#834C##OWC5E2.QCE+8JVR9YD2$;8>5']$-A05ZG\T(A!%[FKSB[9YJL
M:%RED<.7)4U<K-??$=YH5/\`9%KER&Z&[O[MV$]*RMXZ!"CHX!53.%4UU%U#
M6WHV%5-"GM^5Z4FJ&Y,$PHT)0\\<<=$5;WI:%\@6QVGN990AZ#5N=.0KKWIW
MH-FO6T;;M^-SF,W@_P!%W+!(A3W*,N9&%L=ANC=`U;RF<G.0G@$HV0G`,T*S
M+G_C_2*U5%]R<UKYJ46';K3[.NZ:6.KW81*\RTNP^@&JZ/.B9/ZU%7AY^CN7
MSU#TL<#BP'CC#TYFGLA3J,\Y1H-`1.FNP*=[Z[`Z:0\/3Z[^CFJ.]H1KFNX"
MHCN,$,<EEE>4%#JLE,FG<TYZ3(;<BL\D4&V@C2M%;3JKAT?72$1\;;$;F>0B
M"<-X^+UKK5_G0GHN:50XP3A3GAIK2:UQ;S[-FV-=5RQ+T;R3<,E9[=TP0J9'
MJ(//=4O(I.M6F;6G!G9;(-2UN3:-Q*"&`^.7.]G5WWEU=;UR\ERZ&3ZPV7H]
M-_J,D$+-@6T,8=>X;!GL4JF0:?>?H8[6?,K&BLD;GLN2M5EV@V$QF+-#8I5(
MS4B0)X=.F`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P(_]9?\`\6.E_P#A_N7_
M`/;J1X$0/%+_`-H_SE_X0*/_`/HEKP+/\!@4@N7_`/TCPW__``@V7_Z\:FP,
MDM2^K?\`1>PI=RSPC8;Q5W/5;30^$=D][Q0SX',EP9QE[D_-/%SP8E6-LCN<
M\6_PI3-M:&T0).8("7:Q[&42E"3-FSWEKR:Y&C[5!JW)C4(C2IKK&@N?JK:A
M+9_=]SS(Y5^SJP@K<+:EVF=JVG)OE4+W5P-/4'&C6.[LJ^,M6J"&,\0<E6'%
M);-.TNPCF.4]U7XQD,TATT*"7:(<OTEIP*?XGR)3#B4`I,HA\+7Z"ID3Z466
MJF<FT:XJ1#)*0%)@LGP*0/X]_P#[>"G_`(O^Z_\`U:6U@7?X#`8#`8#`8%/E
M;5'6%:>W5[2&OH#$X6^6YYX5O8-GNL:9$#0MGLX'TM8K`9+94>B)*&\R`UF9
MDJ8:H[[CAE$`UL6_I@7!X#`YX^O?=*NX#T?!^=^8[9Y&6':@-S2JW9_T<[WT
MQQB(2JM)W5\'9ZT:$M75G*'=7)GT<R=5NSQE#0_CLYNOE+'\>CPR#BOWCYLM
M-NN2.]67;SE7MF5M?JRJXH?3JBXI!7MF0HRLJFFC//6%;-8$SR%"%1)9ZYLI
MQ*U.GV$YF$9K7QF!$()\^EO<KEY[\W%7XRTB\="O"JS(%7;=5\?EZ>%/;P9,
M5BL*I2SNJF-RHI8\(6YN/&B;]IB].*SXD^U";1FS@!#F=>Z-$PR]Y[#T=>O4
MUYQKKB:QNOWCI2(2A,Y&.SE6M;41=SM3L6K(<?)"ZO2VF>FH,\DNA\@2$`/?
MBDQR<L`#%00][?J[8L<K7H!UG]!\Z&]`U6LI.&0CDRD^_8!>%UN]W="SU#6E
M741>S(AJ&)+>>)XY2Q[1`5'!2RMH(2!7JBE:@E`8(8?ZV5ZW2F.<I<<=EUIR
MR7:%/]..E"Q26LBF\VZ$W!`[*O.R(Q5(:AK2L55:OJ^\;0@4O=W(+NW#4Q8H
M"9D5&@/W]AH20V*;WIU<A[7LWC\[B*"RPV)4=/N@H?):OZ[0R"6/<#2V:GK*
MD`6-"I]0M50VJ'Z[5WYZXM)^\7L;6CCSOLK;B-*0%8$Q.*^D`=A<E<Z=3%PX
M5>@O^H83:P(..0:E0XH"9,J9X"Q"D@66.:>Q-VE/Q[4Z0)-&[U]WQ`_V8&%\
M_=826Z.ENP^=Y-2#M4QO+#E5`&22/4\C$K66Q&K73V"I8YD3'XF2N00AI7)(
M%^8@2J75:Z&H7`G:],V+`'(BPC'(_;WSVB+I*&V1SJX6Q/#CIR:_R3_2[TDO
MA"2-U3:JJE+AL`J=-56KHBLK6GK-(*:)._E+1M;2O5ITYIWY!NBM!(R*>B/,
M$UZ'E?,K!(9L;8<*:;@>Y`\.566(PUDG;.?WR,Q6Z5J.T'V.-L)=4-;2V8-K
M0Z*4JPY*2YJ@)M&B,_PX$&:+]A")!-^7XW?D):Z^1]HTW*+RYV;(RU3=VL63
ML<RZ:)KSFF%$P+\)T>GB02?GI[;YK*',):%"RDD."DXE*W)33BPGISYW]SAU
M#;4XIFGG2P'>5P&'EV`YN$@J6R(1$'B%*+'FU2H)1$)7,8TQL\M8W>?UK(4"
M%4A,.)7;959I`C"2_DV$T\!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,"I;VY
M[O@7GMYUW;<$ZBK]-SI\VJZ"A$58%)#<:ZSBVHY(VEO-<WE4G6$,K*RM"1<X
M*3]DG"&%)HDL`C3@8%3?A![;<O2'S2YZI]SK7J\VUN:(?%^=WR(5#R3TSTL1
M+U<#C#`!++HY+:%J&<0YN3O;,MTJ,:79<WO"+:<_7P'$;2*E87#?\T#]5']D
M&\[_`%'G7R?_`)07^DG^U`%?S'_`@_Q=$V!3'Z?^H?\`3_Z[^+^&7_59^-@?
M6^WNVI!K:B">/O5)3:8$\U&MM_H7A"L5!Y9`])Q$J&2.]+VD_MZXQ7H6RPG)
M0D#3`V;H[ZB++&'%!T?<?LST1_(.25M-J=O"CRK+40OD*5U]3:/6TS5YV2RU
M(//+:01[I)AAJ%2&/OR!I4/+G/FU2A<&Y5HY.0<C+)V@`'?[+91RSYR<IKI`
MX)87SYS!SM"TY"-FCC04V,,=9RU92!FCD8CS42)6]2B5R)S*2(42<L]R>GI>
M`L.CU:G_`!A#_D"@;7Z`N%!Z0=L0]9#[5/8WADXZYA?C4JT'%5*RDD25S<)!
MIO6*F9TZ?N]F`0JE[IH(SV%"87'$AH2$ZO:D+9\#0G3$#OJRZ>D4/YIZ`:^8
M;><5C";'[E>*<8KY11M$@>T*Y]1BK.22>(LSR9(&9.>@":<M!^'^1\X`C&`.
ML"N3RS\VNM/.XIX@EA>@K'TWS^N46C*VRHTW'T3I)T:+5MBQ]V1(Y[NRVVX+
M"?W!'MS<W4L+.,@*0(7`.P"+TG+!L+EL#1W1'3%`<E5DZ7+TK;L%I6L6A4F;
MU,OGSZE96Y0[+2U)R!B:"C1"7/\`(G$E&<),W(2E*Y0$D>RRA:`+Z!5)K^1K
MY2%A2NRZW;F9Z_6JAIDMN/7(76#75A@0Z4!`M%+%E-%ED-IAZ89>U!A0"BMA
M$,W990!F!"X"G;FJ?H2M(I<E&V+#[8JJ<HU2^(S^!OJ"219_3H'):RN7Z>[-
MIQZ8Q0U/3:I1+"=[T<D6IC2#@@.*&`(?AO*]JBYIJZ275>T[9:TJR('1Y/))
MI(-J]-34HEDH985&R#](4RQ6,YYE<B0H"`EE#$-0I`'Z?U^N!&"6>HW`,&A%
M261+NG8$PPB\PRA363^N3R8"9\981)BX;,Y<Y$`8!K8A`8G*3BD+E(7HIO8T
M1YY.CE8/F*V,-E(>YN27/I([D-!>D+5]%$?.0*MR#',:D;NDBA,]611/(M-W
M[/5SQ#`SP/A\?*<!OA#*+2X:0*7_`#<"%=;5/7E;^W5[2&$1A&P/-L^>%;SZ
MQ%Z90O/.E$O'TM8K#M[6Z6JU)9*C]'9DJ?0"`E$Z`2'Z`^OUWL+@\!@0@Z8X
M5A_2=IUM=I5W='T!:M85_8=6,\UYTL"/PAU=Z^LZ1UY+93%Y&&2PF;HE[>;(
MZM9E96R2DYH#$_\`B&,.]:"&7<D<@PSC^.VLSQ:Q+AMA[NRX7&\[)L"\Y6SS
M&>2*>.->UQ5XCSW5BB\1;RVU)#ZJ9TY)(4>A!$4,6QB^_P"F@S^]>?(!T0W5
MJU6%MZVBJNZJSOB.$LRU(C"JFE4O6WV-)7H*QO<2U\=4+!;"L3!"4,\K?VZ-
M!_MP(&5EXJ\(597T:JAGA<N>ZUCM<]?U.HALHE@G)LDT"[6<*J,M-CD2I*VM
MSR,,9CM*QMABAR)4B/8V9M**",TX!:@`>$/Q/Y6E,YBLZO>P^D.ISXBGJIJ1
M1SHJPXK-(NZQ>CV.]FNIXC+$3)7D4<)@QPMXZ(?WT@;DJ5+U#\6C5JE)_P"-
MH`P_>U^-7/,,=JI75!<72](LU$V!>]D4I`Z\EE6JZYJ>0=$RI;+K!U`838E.
MSUCCA:98\.2-G4$%!<6AI=EZ!.I"E6'E#"7[7Q_"X[+NK+*BE@VQ%;8Z[<(*
MIG=J-+W%%$QA;56$2(AU>1*K@OD+>(U'8G$$(W!4E2+6YS^KD]N*HT9AJH6P
MAJCE#A!PY#<J9AD!Z+N23<U\_P#/C]2M<4S/75G<S%;I(I9$W)'*)D[QICB+
M,^EU?#H$E98H`;9M:F*>W@:I4?LXC18;&I_C2.TYTS?G4C?<]ZS.7=&(6IMG
M$)G3Y7JZMFQ#%75:MKY/%&F/UI&I*VAKAH=ES0T[4.RP0FU<;I9M6IT4I+"/
M<@\AN4I+!)97;BXVT%@F5(]N4"[C32]E*<`P7OSH]JZDO,Y&I%$S"B7Y)9;.
M26PJ!%C+;VO8B#BE1F]':""1GC'TB5:'=C]$NG*SK&)=RN'3[?9CY'*H;W^U
M)%`>C;8CSTV1TZ8NC4V3J&NE2T\8_LK:>DE+BW*'=<E6EH$"=*6D"%EMW>9?
M,UY6M2%U.Y$VA%B\U16$1.@WRMGUJCO]J44!L*.3YF51=(MCSRET<M2QX<<<
M$RH*EM7Q=S7(#DHOF":6$9_+GS3N7@2>V^[2:VJQD<#L]I7J7V-P>NVEND$]
MM1;;,]GI5NS&=KXTWV`0<VQB:FM!#$N>I.3\IZA8)=LT?T$%T.`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P-<VY;E9T+6<UN2Y)JPUU6%=,*R2S.9R59I$SL;
M.BT'0SCAZ"8>I5*3S`$)4I`#52Q4:6G3EF'&%EB"ETSEQ[]KV]LL[O.N)U6O
MG^2<N=^<^'':02>OI_<X%B)R;8]TMUDYPURCDRB#D>S.7YD,@+>X)C(]LS2]
MU4J5HRTJ(+1^1.+>7N#*A(HCDFH6&F:N*?G64GQ]G<)$_+7>3/04I3E())*Y
MD\R.82EZ/1H$R4*IR7JCBD:4A,6()!!)8`E#@,#%YM-H?6L.E-A6#)F.%P6$
M1]WE<PETF<DK-'HS&F%">YO3Z]NJXTE&W-;6WIC#CSC1A`66#>][^FL"H6@8
M7+/3*Y8'W7>T=?(SQ_4CX"6^=G/$H2+&A78+O\&RVSO2ZXV>:2<8^2)M4#_M
M?'W,C0HXQG_K)I('-Q+VE"Z+`8#`8#`HCZ^A7K5;W0UG,M2R&DJ]YBA$]CJB
MK'N5<K0:][$BK=%N7B+2*OR!KYM:R5NE$VEO10GBJ38^5'`.3*SK2WA,?]#-
MC&%@];]E4TA@]/1+IB]^<JIZ?DU<UH.T:4?+AK>/29AM:3QQI#*H:BA[K,53
MUL2:9*%2!,GT)2,P1>@!&;O_`!;"6<5B$3@C&GC,(B\=AL;2*G5<DC\59&V/
M,:9:^NRY_>UB=I:$R-`2J>7US4K51@2]#4*U!IQFQ&&#%L(O=Y4Q_J"YDF%4
M"J=XNDA[E%52`4&C5XNO.<J$NK>U899T=DT4MUD(&YQB20J5PU`[I/B.1[4F
M(OA_(*^_Z[#GWEGF9ZHOM=2\4R5P'H*?]*\%=G\"/2:X^A7%_=^4X+T/T$">
MTO)9%:;C72AYZ'<JLK%V&CD#@G1$.S@Z,3?I/^0246;@25IOS.ZLKSINO(<Z
M(H.Y\Y55Z7SKT:1],*[(5*;5F#7(..5_/K)11E:ZCYCJC>-363&[<5ZAX$UB
MC32G"`1I_P!J<0;WYHYDJCEWU\L^)U)_=#;/)/."N).["M2_;ZZ$>ANYG3UE
MMHQH9/T#9=GR9G;Q)4!>_P`)&L(1?+]YOP_*88,07?X#`Y&OY#O9OM=1?%<^
M>*;YM@_/E4#G!L<L7I[GWIB377<$4JPY4H3,K[J.&4-2Z^CD\L/"G)7/R-<_
MF-(E&DH%"0TTE:()H^;O5WN19G&O/LQOO@3GZ3SF0Q%`H<YY9W84AYPL>7Q\
M2@94?FTRHQDY$N)##)-((Z$A:J3!>4^U!QFS?P&S1ND9(2I]F)?TO&^7JWCW
M(]M/%*7I;75G/U.PZ>,I$?4G(W">218B;4#B3)VQU:#H^Y/I",MR*,+#I0A^
M4D0P@,%O`I12^L'=MX3*0]@40DF#17<H\X.\EU'\F/,,5.2)RZ6XPKOC=]L"
M;N41TV`ELA?(KT;T!,X*6C3N!FG)+"0Z+"$2C>QAZ#IZ-JH^RVMS)SMVGU'U
M+;E])^.XG6G0\,F](=4K"V>]I3;KQ<MSTS3O/M7)IC4]L0>A:-G,@-@RK\U.
MU&$,6_Q$@##%!H>]*?1"SK8Y@\X41?<$NYB]"E=E)*<N2MYG(J<J.G&MRY8N
M]H@?9-U]=1^X80@EI#:^1")*2&&)D/+6N6ODM0%)&X\12TU*$[VLRPG/T0[E
M!&/0?H*M>8><J6TDNN96=/JA>ZQJCI_I:2)["8(I5".=UO\`L",,O-M&HR#P
M!D!CP6E6S%I*5E*@)#BE`2G\E.Q(QT+PKP@IGW0$-L[I2U^6F*P)<D',8RYS
MZ4OL*;H4UV^]N#*T*-'%KHG*INVIG@O1!0D*I>468`&Q?301D\^^@9NZ>CO5
M5`6%?<FZ$=')#U!=,0=*\ZBJ^].<ZLJMK[#5Q*KJGD=716M8S,^=KQBU;REE
M:0-CD_/Y3K^AOIFAEF)=E@"*]@^S_>$4CMGV6TTYR4XUU":A]`>C6IL6N5PI
MYLJJOSD[62\DVA%G$92\;#^_K4)D"!W8EA0@M[1^,H`J(6;.*`4$CH+[%S!S
MZF[MCLYWSVP<R\&P_KB26JE0.PMWZA4\W2-B8HFC))<+5*->_P"Z32)W=S!$
MPU.E9?Q$C>-4H-<42H\(GM'4O7?#?1?G96%MRMX>I!U5SVBD73S]:LIG#Y17
M/]T]5=I1N8R:22*,D/1#SK]LND['4T`#K:!L;%+FT)EJM$W`&$P+#/+WTCN+
MOJY^B6]Y3<^-U.U,WF-[2U0)R/56ZQ6/JY[;@RV%30A5:<A6.#7&X!7C.[G/
M0XO'4[BME($A!11K8L+&%UV`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!I?H7H6
MGN5J>FU\WS-FNOZOK]K_`%.02!S^8T8QFG%I&MD9&M(6>Z2*42)T/)0M;6A)
M/7.*X\I.G*,-,"'85LT_S_</>UNP/L[M^(/E:TI7RQ#,^+N`I8$D*V"O0#1G
MLG2O7[2C5KF.2='G(]$J(Y%MF*VJM2C=_P")0_;/5)PN.P&`P/!E,IC,'C,@
MF<SD#+$XA$V5SD<HE$C<T;+'X['V5&<XO#X^/#B<G0-;2UH$YAZA0>8`HDH`
MA"%H.M[P.%^N*9>?3/\`D$$NA=F]2[\S;-IE;W[&J(O"?6"EK#I&&5;-H-5:
M1XBM)/\`(UR5!05A]$N"*1M3=(FM)IV84IYA*,A`K0:P.[P``%@"66$(``"$
M```#H(``#K00A"$.M:"$.M?36M?TUK`^L!@,!@,!@<''%?-MA2>R9]*(GY4^
M9UJPU!Z"=,!37GU[;L=;>W&-&V]53,]6?94;-3KW(J?046QZ92_QFXQ4VIV\
MT)!FC@K%8=X^`P&`P*?*VKE-!O;J]GDB86))A6-YX5O,5#9-YFZRIFAQP^EK
M%:!1ZNVYR$,J&P_Z-GY.FU-O\<*P\XT.M;,WK07!X#`C_P!(=*\W<O5_N;=0
M6W6]25^^.!<23+K)>VYM12AX=DZCXXHRM2S9BR5O#DC*-WIN1D*E!Q(![^/8
M`BWH,ZJ6WZLOJNXQ;=*6)#;6K&:(1.,5GL!D+9*8L^I"E)R)2)O>6A2J1FG(
M5Z4U,I*^[1J94282:$!I8P!#_.U;+I^IHRFF-WS^M:SAQ$BCS8CE5JRJ+PR,
MDRQY<BFZ*MZ9\ER]M:RY$ZNZ@LAO)`;I2>I&$!.A#WK6P_"&PJ,:K20TT"<5
M.W763"WFR&VJ@R:'H[2*KMT?](Y!/4,&TM+E@(6XRA/\2QT+2Z0G+P?:8;L[
M7TT&F(%U-P+*66T)_5_1G($BCM(_E2&Z9K`K>I=W9:B^-(\IUKY:$CCTA4(8
M#\:$IP`:I=CDGT*"H"(7VZ-U@>Y.;CXIBCE5@++M3EN-N]ZK$JND@3F<5,SN
M5QN$BVV'HE-6!?W1.JL)8^B<D8RAM'Y@U6SR=AV+[P?4/-9NN>$I?/+)H^/]
M.\DRBSHF=.%UOU`S733KW/(RHKT>V^R5EDP!%)5,@9CH.8T[(?#'1(6)L$F^
MQ5LO9?TT&=UK!>=).]QSI>H6^N9,JE-6IHA";5KQT;7Z+NM4/3\";;(@[A'E
MZR'[896^!3+EBUL#H3QM$AVH./`A1Z(#_8=Q\T0HRZ'`VU*+B1U0EH)#T0M'
M.(`PF5>4])5[NV/ET*1.B04*+=D1"I40I?!)M'E`-,`(0=#%@9)`7NE[?@S%
M8%7.]7VA6LS9W0Z-3:`N$4FT&E;`^.8U3T:Q22.FN;`^L[P\I1&*A)SC25"H
MO8C/N&'>]!$)S\J.#'R8RJ<R&D%TG>9C*K'FSNW2JX+TE$)1RFX;1B]SVN[Q
M6MI!9CE7<%.LBQX8W+WP#&UMQ3H448C4!,1*%"8T)8W+/*>J>(*+"N=;'V2*
M[>(/!#'AZ9#GP:Q[L:?QF#P**)4"!L=75S62BQ9$UHD:0DDW9BX\K>@ZWK[M
M!&#C?DWA>K52Z[>1F3]0VK:YY1"68"N.X+<:(XP0.[)N;8M60--9U@31FKV/
ML=YH7K3DV,)#<DVZ(_L&`04Q&BPGW@,!@,!@,!@,!@,!@,!@,!@,!@,#&9K,
M8U7<.EM@31U)88=!8R_3&6/B@I2>G9HU&&I4]OKJ>0B(4K#B6YK0FG"`468:
M((-Z"$0OIK857T_[S>2%^6C`J6J+M&#S.S[/E#3"X'$TD+MQN5R*4/JD")I9
MTRUZKUL:DZA<J,"6`1Z@HO[MZUL6L">W373]+<A5*\73>\L_:\.;7!IC[8E0
MMKC(I=-YI)%86V)5Y7<,8DRZ23JP)>Z#"F;6EM3GJU`_N%]H2BS3`!`B@.8K
MIZLMUA[9]#8NG8!Q!X)D7&7"Z]8VR6'<LIRBS`M5T7'^)M7';!['=DB@6PK"
MQ*VN`D&B2-!@U@U"[`MWP&`P-=VU;=9T/6TSN&Y)Q&ZVJ^O&-5(YI.):Y$-+
M!'V=)]H3%2U8H%K6S#CS`$IR2]#/5*32R20&&F``(*CXG5MJ>L$MC=S=00Z5
M4_YZ0F5));SWQ]+D*MAG'6RUIV!3%[X[&C:OXEK'52=:$*^)5<L+`-8+1;C)
M2Q_:F;@!YZE.G1_R/X,D2$$I4J7P[L=.F3)R@$)TZ<CNZI2B2""2@A+)))+#
MH(0AUH(0ZUK6OI@7B8#`8#`8#`8'"77]'L/0'3+];M;^:7B74$=CW8-B0]^9
M^D^D;/;.S&R457?CY%Y3+)#"6MR9FN.6%(UC)MY:6Y2B'HW\M,=K9Z904,8=
MVF`P&`P*?*V@CM#_`&ZO9U<;/L2P$\[\\*WE32Q3<V%F,U8(!=+6*U_LBN]1
M6%Q5T+AX5#>-=H+VJ>W+2Q6=_P!<^'XB2@N#P&!SE]X^6/3[I?'._5_/?1'7
MO0+U4<BO)/(*D>^EZFJNP(9'KR;HTG&_<O6++*.=X/#5T8'&=-Z]I>B=&/#$
MLVG)=D0B30K0][@#R`O.HZYG<BN3M/LNF;`N._[$OUWIJDNA:_D4*A)<U4,H
M$+!+98MY^:&^Q+$7(V$"N3O+6ULK4O=%9WXZ7>@[5J0G#ZK\:NG=]`UES^7'
M$LGA;KT]2#[<2!2Z-C4)/2K8[N22S'-$8Z*$X5CDWQUT,,3IR-C5&FZU\0=C
MUK`I+9O(CT9MYH?)QT#)H>U=37)PIZ`<@V);R.:IE3-&"72LN,:'Y+*,&Q+%
M$G.C]M%49-9X_"0@7#9G":+RSR@F&`1[#:\QY#]1.@7,^F`436]`<H3IPXX;
MI'5=S;Y%GU851$J!D=LW#:]409-RRQUA<EB\R3Z1P*LXD@89*]'OHT;N\FJ#
MDR(9Q(`\U5PMW)_I>XVX4NCDMMO>F^<;27-UIW%55A4*V61;7/\`S3>B6?<:
M5=#M759K/*:U@LH9&MA.E9OZRL?DR:.&M1(0[=#'%.%EJ[E272;K_L7K.X>9
M8O:T2C]00_G'DRA0'T\X#M2)N;RT7!T+:<E23!S2P9LE%IVLD8&Q&%_6I5*=
MM@A)YN@"6Z#H/Q^6"OH2@:(XPX)N;F280254KQHC!;%E'2^(R6!QJ0UV\0NM
MX)&VMWA:F1L$B<+A`*1.R(DMS)7M2"-&"7)2]K$NQ!!CH#ASJJPK/]'C*GX^
M1UU![DNC@N^8#HBP.?(Y&NB7OC3JIOM:WFM]:(U,E;DPRCI)M=%\C;W&1H$X
M%#D0(+Z<D4G_`%V$C4'%W5P?/:[ZPC[2Y5!<O0OHJEZC+KZL[=U!Y%45'V#Z
M'UK=-BPDFV(')F9"AEVN?FI[4O/[=<@IU#DX*T2$Y5LP!IX5W]"\C^@G'U'7
MW:T`L+I]P:!P3TBK9S2N765UW(K;JQDW9U'&>="R.L!]FR"71]TB?.1LG`N>
M&$]F>VEM&J+<W9M,/-6`#<?!T8EU_+^,*)<V'H]WKRFNI^MNZ.@K$N)OG7]N
M93-JLG2N)\L5C2LQE=I70JDM*1^=6FG>8@4?*75:815(52L0S#=FFA%BQ></
M1KBRANDS9E^\%D3M_J>$.%,.,.M^7H(72=8V1ZKW7;=I5=8L4IVRJ]=DL;N:
MMK&;).^3%.^Q]5MJ<U,=<WE%IK0(%@=$'D[K8?//F8HU1>J]8FBLE1NKSTDG
M<TMN29\16%,$C],'8AXFEBN(8K,GDD]UB^S'QT^Z*K&X05`P;#O`L1P&`P&`
MP&`P&`P&`P&`P&`P&`P&!S(5UVQSSRKZZ>ZLXL2;H7AW<X[Y6P6MZI@2EOE]
MQW5:Z6G[U9"*>IZNVY=^N3BRE4@<DR(Q`G#H+:(_YG`Q(E+./+"PSE_D^W[M
ML^*=X^BC.SBO]D_5%O,/+[8Z_N"J^%(=(R#"!)DQQ`PLUF=1R-F-++EDY-)&
M!&(.VQA"D;RC#5H6QX#`8&E^@NA:>Y:J:67=>TV:X%7,-1A4.;PX_,>K7KE`
M]$-,;C3*B+4/$JF$D<!`1M30WD*7%R6FED)R3#1A#L*T:EYZN'T'L.%]:]Z0
METKJAXBL8YQR'YXRSX3APY^0'FK6'HOL-O3&'-,PO\TD9:B/Q$P2EEKX@WZ&
MA4OOS*4P7+8'(=,O8WS4BWO\FMY^ZGB[?74*\S+/Y*E$E%#K0/*:NBBNTX#)
MQU>8WI8,>[J'C3%'5JC\@E.8W[T1L.E'W["$0=>.`P&`P&`P/)=7]B8MM@7Q
MZ:6;;V[)&!FTZN*-NV[OJ\!QB%E;-*SB=KW98!,8(I,5]YQFBQ;"'?V[^@<<
MM+^1W0M:71(9#8/C1Q-T,N<^M;+N%OZGM?L]X67F.(S6[GBPHV^2EI)K\]DD
M$N@;(Z%E)PIRV\E46B)`:3\^SU!X=C3(_L4F;P.\<>FF0-)BIQ0@<V1Q1NK>
M-:SN2MG=T8%J`X],)4U.Z`]*I+T+[R%))A0]!&`0=!ZV`P&!3U6D/F,8]N;V
M<)1;$JLENE_GE74BA[#(X_7S*AJB.#Z8L9""`197"8C&79_825R,Y:%7(%#N
M[[.5C`)7LD!1187"X#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8$&O0:8=L5WS^]6+PZIY:)G5>DR*<6`GZM8+9D,3<:TBD*DSZZM\.2U#*8D
M\$SI2\(404XUJG;?^-L_0]:'LL00C_Y$W_Z!=8<WPWIWM$/'2"%WW5M66E1#
M!R_&+KCLH86V7M;J[R1OMO5K3F<-1ZY.F4M84/Z,?LO1FE7RC%KX=X&^.O.[
MH7S.[1>GX/#9%T?V#:C:L6TMR?5RE`.?2A$G.VA-GT_=U@]LM-4<Q.0M`=YD
M_B(;4V@C*3!6K=`2##E,\:_XS_=O%'IO!>V.G[LI=QB57EV;)M:KF:S2P)S:
M<RL^!RF&'MTA/EM=PQ,C;T@YLJ<'-R.$:I4K$98$Y'_6-JTP=T&`P&!41[<=
M@6;Q9PE.+8Y_M^O*VZ4+?(VFH^'3N*!L!9>CZ!U3;DE40R!HR5LB?I0NB1RM
M>G-0)C0HC$(#5@TZ#\E04$3/(6H.AN^:@Y<]//3R;,]MVP>QK;!Y)I%@C35%
M*4H)B?E3BC8[K.AK4<K03'H";1S85"%\<#3Q1IF5$$("4BX2TX0=%6`P&`P&
M`P&`P&!H#ICE?GCL>JW&D^G:FB=R5BYN")X,B\L3*!`0/C:6J);9"P.S:I0/
ML9DC<0N/+3N+<J2K2"SS`@-"$P>MA32G\#_)0<S>HDY3>^9(W,!+"D?N>GWO
M>]5\28FU>-M3QYH>XH"T")FG:74>B2TJ=:OV6H^?0"];ULO00N_I"C:@YKJN
M'4?0E=16IZD@"%6WP^`PMK):(\QIW%T7/KH8F2$_79JYY?714O7*C1&*5JY4
M<H/,,.-,&(-K8#`8%/E;1ZPV3VZO99-[&1SEFD/GA6[O7;,FA"")G5S$!=+6
M*DU#5KJB=G$R;J`/"94LTYGE(SOL5!(V5O16C!A<'@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@08]+NA:>Y@X2Z@M>\ILWP.#)Z?F\2*=5I
M"]<>Y2N>L"^'0V-M#4U)5SHZO$@DCRG3%%$$C^,(Q'&[+3E'&EA1#Y,]\VGU
M#YR<8<@>9+,G<K4J;GBKJPZBZSMZ#R-%0?'S\PQDEK>&-LCST0P./1=[J"4?
MY3$P,PA1L)1Z=6[.I";>R#`O^Y!XBJ3CUEE2V-+)19EV6LX(Y%?_`$S;+IJ5
MWE>\N2)`(TSK-Y6:44%%'V1*#\9DCC64ACT?1:T0@1DZV8(P)CX#`8%=75_>
MH*JGR'EGF.OA=1=T2YE)>6"CF1XTSQ&IXLX!&!+<74=BEIES=352HQZT,D)X
M#7^1F:TE9D*LT8ADA'LW@L=9TWT_U=U/8(>H>[)1S#=;&[W0YL^V:"4U%'*N
MI(8JIOE.N#U*]%3M4HM&;)4'EC-D4F-^18\K5)QXBRPVUXI?^T?YR_\`"!1_
M_P!$M>!9_@,!@,!@,!@,!@,#^=W-*J5U-W#>_'XKV\P(FFZ0L.*0B[NJC>SH
M.9>3P\M?HBZ]<))M/:24FN5A%]9MJ8:"')V9>,3>A6MJ,_:P*;8=%A_1$P(+
M>CX^H%7)=@1;D.O9E8%N6$NC%=*_[<SBLJ_L:#5E,7U&T6Y8U</UO3*OX,&R
MHI71SB9&PJW9*$I^,2*!?(6086,.+R*L-U%\75Y"+UICLN`)8+Q9Z@L/GLP(
M#+:ETT%Z)&=[2M9S\YMRNGY#,5R6P(W%7]E88PODAB8PY`VOBIO&<UJ$BY4%
MH]&L]]'>EL"7SIKNO_7DC]+[!)NE\+;;@W4.O+Y'P<I+94ACT:,=,:JL^W%C
M"-G2DJABW/SE`P%B5_;@63<T-/4[1Z^6>1U=/^?["F!GG!7!D8=.>:AL6G(V
MDBO^IZRP%HWY@LB[KU='"0;=`J#-J4[DE3:3C++T1]X!&F!=_@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#\;BXM[0WKG9V7(VMK:T:EQ<G)Q
M4DHF]N;T1(U*Q<N6*1E)TB-(G*$8::8(("P!V(6]:UO>!SB]?5P\_P`AJ$2+
MFRJG%157FU$9@)SD/99S$%YEO2]S5XN7H&:/<I1I<Z-[4X41#7HXT;Y/7$L]
M%(UB?;>PEC)*4.>@F_Y`^1U/>05!2ZFZSG\PMB1V5./W]8]C3!$WL9CT[)6I
M,PLK8PQ5I.5HHY'V9J2[V`H:I<K-5*#S#%(BQ$DD!;/@,!@4[V#U]=_<$ODG
M/7F(^LK-!HP]+(GT'Z0/+.FEM1U6O1&C2OE:\LL2G>F3HWH%)O0@+%VCMPN'
M[V':Y0N7#`W:"<_*7'M(<;01RA=/LKL>[2UZ-F%KVM.GI3-+FO*Q5H/H\65<
MEC.@?UF:S)W-$(6QF?$B0E"TE0)D:,LE,6&"]T<K6UUS6**LZOZ]M#D=&K,D
M"&>NM8PFLYHJL6(R./K(^NB#T58S`]:;&_12T9@3D`TQ^Q"WH0M_0&P!KGS8
MX,L+SYJDZDW[L.UNH:RCT9KR&4S%;)@]9Q%'2<5@2%^;ALT8601C;GE^)D21
MR1`4#=U2T9.FHG9.P",/V8%D.`P&`P&`P&`P&`P.#3B5';#?8<Z:X!%_XX<!
MKIN]`.E4I4$[X<7^1>D,)0BZHF2E<P+9$R-#"AE$A3$J-FP-8K^<XYI-:PB4
M&%!+WH.\O`8#`8%/E;#MD?MU>P;(35V1'B_/"MPU,;"%TE5O*J`?ZEK%$`ZQ
M"'YO1(D$PT_;6`V4VF*46T821_)HP0P!"X/`8#`8#`UO<-FM-+U98%LOK-))
M$T5Y$WJ6KX_#D*-TEK\0RHC5FV:,-C@XM"%QD#H(O1",@U4G`<H,`#9@?K]<
M#6?(_2+=UGSG6G1;=`)O5;59+&>]IH;92-*U2UD*2+UC:I`[H"E!AR#[52`W
M[0*BTJK0`_4P@KZZU@85#/1#A2PH%.K2AG7'/S_6U9BBX)Y/$=H14$2C(YLW
MF.4/"X/ZEQ(;/NE!!!Q:#19@]JU2<],7]R@@XH`:IA/J%S[8_2$'YWA$4N1]
M26),'&KHQ>VHE'FJEE-T-'./^K)UIE8%]F37<3;/&JAO^V%@SX>!E1*?JV*'
M`IU")$$/T6!Z<T!6O1P^>I#&K4,0MM@`IR77ZW-,(441!+Q/YWF/5B6F90Z'
M6`ELO]Z&4/"E#Z<H;XNO86X"I(0N<4JE0$K0;8XF["9.X:927G%*:N2G(<\+
M$Q462W0?2HWR6-2ID:GHN0M:6E;FN=O;6\O]5TD.3.JIN=DRY.<4<C+^/Z["
M7^`P&`P&`P&`P&`P&`P&`P&`P&`P,/L"P8+5$*D]D6;,(W`*_A;.LD$MF<O>
M4$?C,<9$!?RJW-Y>7,],A0(R`_[1F##K>]ZUKZ[WK6PIM0QNU/8I<BDECM$X
MH_RH(4)G.'5"[$O4$NCT+*)&I`5*;N;MG-\DJ_D16846H9H@9I.\SQ(,"UYT
MF;3"&XT+KF-C98RRM$;C;0UQ^.Q]K;V-@8&-O2-+*R,K2D*0-;0T-:`I.A;6
MMM0IRR4Z<DL!1)0`@`'0=:UH/4P&!HFR.H.<:@@<KLZS;SJF%P&#LJR0RJ4/
M<ZCJ=M:&E"#[SCS=A7F''G&"V$L@@D!BA2>,!1(!FC``05?[8.B_6TPT<Y0V
M9R3YA.1>PI:],&\5OU9WE&U(0[_(L8\@Q!,.:>8).GU]-,!`T4WE[4<(+B8T
MH5(D9H7#5_7T%JB%1BMZRA\;@%?PMG1Q^)0R(,R"/QF.,B`OXDC8S,S80F0H
M$9`?]@"P!UO>][W]=[WO89A@,!@,!@,!@,!@,!@,!@<"71CMSA2-U$6/#NH?
M!6_Y@#L.M8^ZT%3/EWS7*.LAI9UT(P1!_%"7-!*'1^E]KP`+Z)P4GFFMZE2)
M`I4@4A5:*).#OMP&`P&!3Y6RRV57MU>Q=D1VNV*/(_/"MTU3*H1-)+*WF0P`
M/2UBC`\V(WOT"AB*'3`U^$L+VV-JE]1`1@),_/&8,9987!X#`8#`8'R,`#`"
M+,"$8!A$`8!AT(`P"UL(@B"+6]""+6_IO6_Z;U@:1Z/AEB3?F^]Z\I)PC<<M
M>84G9L+J9VDRYS9(E'Y_(8,],4'<WYPC[,_O#7'VB0+$QRDU$@5J2DY8ME$F
M#T$&PKNI[QDYX@%6M\*G]@W#;,^C8:,#6=Z"?V.I+4HXOFRIEM-TJGIAXHZ.
M5PWQ(F'1-\=_R-&I5@7\U[7`=P+4I_XH0R9I\JX]&[7L2WXOU'T(RR>022]+
M#JS_`+/I!S*H>W>EFR'LMT6Y#3'.HU)DJF;ZR1(3>U:DOZPW,#>Z+2$24`30
M;+#TEGEM#17S9E]-%_W*SN<OGUNW5`(4-EI61PNG>@+NI.*\^3FX8^DEE5/C
MG-'8=5QM0T(FN3JGAF0H7QR)*3:":1^,$B.+>,H!Q-7L]A4)D+],'2U[BF%[
MV5+G]D@,5-D-AS-MC;`M4-<.JR'P.O8@PM<9AS4W(D#6U)BP$(M&'".4FGGF
MA,'`8#`8#`8#`8#`8#`8#`8#`8#`TKT)T/3G+%3RF[;XG+3`*ZB*71J]V<A&
MG+')P4?<6TQF+LJ,M0\2R92-9H*5K9VXA2XN2PP!"<DPP6@["LVO^>;C]'IQ
M%^CN\X0[5CR]$GI!,.7//"2[*VH=ST9J%WB-^]T-:96K:I3:I)Y853)71FU+
M!"A:`-=^>\:,,3!<Y@,!@1:ZT[!ISC2NT<ZM56_.[U*7HB'5/45>LQLQN:\[
M&7EB&SUM3U?(C2W28RYR^W8Q!!LM(@3!&K6GIDA1IX`Y#/%SR+J55['>D%M=
M4<Y5_#)[SNHYYO&H.827]+:=<\^2OLP=F6\TDB>RD33')5-*79(.2W(=E(U+
M*W+G`\U`(P:%O6A#N8P&`P&`P&`P&`P&`P&`P&!'/J6'],3FIU;#R7<T#H:X
M#'QE5([!L>KA7!&4["F.,$^-1L,#)(KL]8YD;"$E1^7K\?8=[^T7UP.-BL^C
M95`.T&-J*ZDX^0%)^AD%32?K^%^%&X913];)]CDQB2P!%UVUS3\-NE3Q/"1M
M.WP6S&P+N8$[:LP`=F:#NSP&`P&!3U6DBL9\]N;V23JMT,$9X]YY5TSUT\))
MRAEYMCPT/3%C*BIFN;$C,U&P=4:ZJ%*3;6>8L-"%-H[YMZ-T$(7"X#`8#`KV
MLW@<ZSNM%75:SJ'HV+GIJ*G=(PZJX;-E+#7T&U9$941R53=G:TY@DBZ1&J2&
MQW3EK4YZ8I\9T2T8#34J3:8(Z1GR"`PP#D."+>WNP7LKFRWGZZ+`<C[.?4I_
M0<HE21"X/Z22Z*>1JXNR_O9K*7(2"5"W2)`L=$WU-6.JMT$&K9YV/V]//3"8
M<\<SIG1ZJ*D;GIVL9ZV*>=I<JIY:B=N7Y#?5TNUE]@;9G2#P1TBZN?UTVMD:
M;1BE1JYUV:%(L2_D@("('6<H]-IS$(4R=#5UV&<LD:/JTN2TWQ[!91&*Y)Z,
MA%,Q=KXRAD,NKEJ;S>X$]`67.+J7/KC.;&E3!'2WZO4VW9LC6B%#>>&_^UII
MT2LH3DFHEL'[GLR.5[_=ZM^I7ZD*UZ:CMEW[?]*\OG,=.M8);4J!KLAJHBZ>
MB)$%X%/]'((:L61TG2YU+;CS-J`CASO'^[V#I*HC^EW3N\RP^5'QN3W[9;'&
MNH)A1\KX^IKS18H.M*@C!%6J44WUA>G3?;]AK):H31Y%++`2KV#[!I2`MZ4D
MT+:O'@,]-XV$[VD/IL$]D_0?3\K=&WK6/WK';<C\9D5[3ATJ:.'INA&*/S98
MQL=+*(XG(4)R1-8CP'@(%]X#@`"TO`8#`8#`8#`8#`8#`8#`8&H;ZME11=13
M>V4M4V]=Y\*;4SB755"Q=MFMNS+:AS0MNV^$19XD$6;7AR3A7;4F%FN";04I
M!H]"WL.@B"N/A;V$@O?5J2:L:\XE]"ZH1P>6637,\M6^:/KR)5'!;4J8PE/-
M:IETJB5U3U<R6(VKCM)MMQJ'0@J/\LP1>]A^H37ZTZ_IWC6MR)_:JQ\=7:1/
M"2(U74L`:12ZY;QL5U,+(8ZUIZOTAY+I,Y@[*#@_4LO9:5"G^]4M/3)"CCRP
MA_SYR#<5ZVW%NW/1M*QJ[>BBPUWYCY#8'D,JH[BE(;M80AD@E@=Z:;?ZK<FA
M3K3Q.#B/QF<P9B*/%IDH-J%(6QX#`\MX?&6/(A.3^\-;&WA,+)$O>'!(V(@F
MF[WHHH2I:<01HPS>OH$/W?7?_P"&!`;JOT'A%*K8A4%#Q\GJ[L.X"5NJ6YLK
M24-&UK@B0F@3NUE6U-"MN+'3-(Q,9FQN4C=_L`<,L25O)6K=Z3X&#T!PI9,!
M=)_US>L\@/0GIA-Z]D;!%[0E#+)$_/G/:=R;%*J/45SW`0.6Y#!:&:9*:#]9
M<2C@3*7E[-4N:P1HR4Z8(3<F<:^T%0=ZWCUU;-C^8#M'.P'#F5FZ<CE=P_JP
MM[:H!S5'Y=$6(-$%264`0,,P>F":K!*SI`K>D1BP!(RRB"P#*-#H>P&`P&`P
M&`P&`P&`P&`P&!IGH2[F#G"G)Q=LJBEE3:-U^A0.CY':A@KQ95A*6Q6]-K0L
M7L4(8`&/3Z2Q$N.UZX*8`S26Y,>=H`_C^W8<IG-='5!W0>OY7YC]PX'-?.MU
MO1VNI^\^':@Z_BG73(4HZ#5=%R6E5,PL5;%KT:X6GMP9QNG99'#%R9+O;?\`
M0TL`3MAV,X#`8#`I\K:72^3>W5[-TGJF45RW1#SPK>/1"02!_@#T@M:.ZZ6L
M5P#/(LDADLD;PP,8G!:<@_$D"9I=M'HS!_B_CC).,"X/`8#`8#`8'BM$;CL>
M->SV!A96,^2O1TDD9S0UH6TV02)2B0-JA^>S$1!(W5Z/;FM*G&J/V8>(E,4#
M8MA+!K0>U@,!@,!@,!@,!@,!@,!@,!@,!@,#Y&,!8!&&""```B&,8Q:"```Z
MV(0A"%O6@A#K7UWO?]-:P.3SS9]&*9H^"^BL:J@:/JOI2\_:[T34<V\TT?+(
MQ(9O;*>56(QN,>L)P<TK@K::^Y\1MJDIR>I^Y["P-S3OYBAJU!B5(I"Y;D7B
M&9QJQ3^S.V)>QWEW5+F-0UIW1E(<@4KRE"WQ(D"Z4;R=%'Q2M/BL7WI.$I\D
MY_\`^I9B>`1Z\X!(@(R@LOP&!B,]G\%JN'2*Q+-F<5KR`Q%M.>)5-IO(&J*Q
M.-M)&PA.<GV0OBM"TM2$L0PZV:>:`&A"UKZ_7>L#G+](;6FGKWQ'T=1?*O/7
MZGR*Z5V[3*5]V=*MLKK>NW4NL?Q;%:G/C^J34+7:]Y2`+I'BQ-\I5@C<&WLD
MS1:]V)&(@P-P?QK>)*3Y2\MN;[&@D99S+8ZEK.,W=<EF#:$A$LE2J8A62&*1
M-6Z:T:MW%Z[87<MO;TFC=)M':4+-%@/6'[$'0%@,!@,!@,!@,!@,!@,!@,!@
M,#1O2;OT(Q4?8#IRI$:YG70:=M0`K*+VX^NL:K9Q>53VUI%ITO>6,(GA*TM;
M(>J6;`E^AYXR`E`WK8];T%"KGX>]&]P7+6_1OK)U34,IEU82Z*SR%T_Q'S?7
M571^,2.&NB%Y:$:KIVSXI+>DYM#35",LD]J/-;0B*3E""<$?]0ATN8$=^L'^
MS8MSS9TAIUY>(_8K0SH%C"[QRD73HZ3)"2WYIT_:B]*M$P@:R=RA3'!*RFTG
M;F60F7#*5'D+""#$:@.8J.>QG?%D\U))5$9[SO%[:YIX([1[KZ0/DE-2-0*T
MW3ECHM\JB*<UR"`*9ZQK>>K`?8)'S54T**5.JUKD2U$2AT4D-WO83/J/TVZJ
MLKJ"MYJ<.NVSEFT?1N7^;2/G(ZNW@%R1=7&>1'OH,F_EUJ#DA8UCAN=QE6A7
MLPX^2VIHV<F-T9^4,Q0`-W\T7=*;T]?+/D$KYKZ`YD5LWG!7#(EBO0R>G$TD
MD:0/3UEK=29A!3%QW.R;CYAJH2;6UBY&M_((,^J;1?V&#"[_``&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P(#>IT@KZ/><';HK0F#]!8A)>9K?KTZ0Q)(
M8Y3(+Y9L+=J]B+/"&8I4A,D$VDDLDR)N:&[1Q/Z@X*B4^S`!,V/0<_?\;7P&
MZ<\N[8LCJKJ&R:WW)[9H!OK&/4M6CC(I$;%TLLDL!L9]5V:^/T6BS>DG$2<(
M82T@1LXG9NWM0K,"O-#\.]AU^X'R,8"P",,$$``!$,8QBT$``!UL0A"$+>M!
M"'6OKO>_Z:U@533GTO,M282&DO->JO\`6Y;<>=#HW-[812+41XFH9[*$02M)
MMOI(I&[MLME#"):6<HA\#22>3;"`PM04@^W9H0^H#YH;LN8QR\/2*UQ=OW''
M')/)(36KG&P1#C&A7TO12A,93W-PU[TT2*3,"G[RTTQFJF128P(0&D&-_P#0
M@`;P]!V7L>3\[/\`7_$\"H&;S:PT,CKV9I+\G\QKMA8*]ED)DC$M?(JKAD.E
MIKE)F]U6)/C3*@ITWX^S-_<(6@AP([^/E/=]\U<S0/E_LR!\U1J*\\U+555T
MY*:+LV=3R23@F*-3DSR)UL!NE,&B;3'Q:3(FX:72$X_Y##C]""$(`"$%N.`P
M&`P&`P&`P&`P&`P&`P&`P&!R:\]>HO>]-]/R'@&?+>!>@K,-Z;L-NBQ\_P#1
MN&M?1C96LRLAQ=8M7$@A;57)S+(K3@$56"2)F5)MK7FIR$R4:$)P1J#PZRL#
M5]PTW7M\P9;7-GM+H\11>X,SL:0R2V8P1Y3N<?<TSPSN#7+("_QB6LRQ"XHR
MS`F(UQ`A:UL`M[`(0=A#IV\EO.M[AE:5\Y<MPDZ(U,EF3?$FDIYG"/:QIL:8
MM=A6"Q3YP12I.Z6U'9S.&9,ZO#=*SWI"Y+BM&J"C!;%O8;>:>$.2&/HU7UHT
MTE&T-_+'1RD`YN2X27\,B5O4);:V>INW0@;X*OFJP'FOFDAE62!*U$O2IL")
M.:J&488$00QK2QT\[]N;V9R8;8T5'7/GE74,/<9U#7**L\R-*Z8L9UW)*Z<5
M_P#DS&&F!<M$!<DW^2)42<5_TB]X%PN`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&!3Q.]F][^BL>J1*+\_E+S,DD4MJXE!8!&-%H][O;$3(:.JS:O18"'
M!KYBKU_+F[R44<:67)WV/E'%Z.0&:`%P^!7MTAZ/4W24_%SY6,<FW6O8*M*E
M4MW*?.:-NE=@,21Q$E+02:Z).N7MU=\[5[HQP3C.>YFZ-)0TYNAI"E@_M*$&
M@R^(NG>VA%R#TUM-"P5`M$6L0>>/+<LE+!2QB$>TZQ*V=07BG#&;*Z9<DXM:
M+7L:4$>@1AQ/T$W.1?T.&%K,%@<'J^'QVO:UAT7KZ!1!K3LD4A4*86N+Q2-,
MZ0.PI6MBC[*E1-32WI];W]A)!0"P_7?TU_7`RS`8#`8#`8#`8#`8#`8#`8#`
M8%770-@]64ATE(K>L.]^6J0\\FJL7%O,E5R6.R5LM9;1=XT%EAWZ]+YDQ[BS
M22LLY81LI((I1LU%]QWZF8/XX^:$&*3ZO[)Z3YY?:\YV[I\S[][8:>DEL\5,
M5)]#P.UFQJY!2V$H3*C5L.@[P[R8"4E4Z-J8@2A\2J/V^>2:H6ENNQ1XX.@J
M($R5/$XN1,U"%7,"(ZR$RM4V'_DMJF2EMJ8#ZH;U/Z1'_P`A"<Z!-$4/\!%]
MY>];_')^OQA#(L#^?I8ZRO(-9SGY7.5W^-9$-6=N'61OMM)-'5S[;BRIX["4
M7F*+.C/'(F]`0=2L#B(4-"88\`;TZ$)292<25\FPA_0+P&`P&!3Y6UI1&P_;
MJ]F"-:E@7*K//"MX++PR6N[#@R+]P!Z6L5]^Z*NTWBT=:;"CXVUW($!YCY[H
MSC-V,D*K9Q1I8`N#P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!"SOOJ=PY
M)YU>9O"XX7/+SL"21ND>8JN%L_0[0Z-M)4:QUE$S-IRS#26-&L">\OBC_#I%
M'FE>IV+6B=X$534%"^5'GNBJBW>DW:$6I9+;."7:[8S']S/H6_>S;N,<'R?V
MC4]4-;(_26UK1?[5E`W)J8R&MR*1H2TB10#3>FWL(4.^*D&]IO1]FZ(DO<7I
M-T%4M'59=4XY:F]2U]#ZEKKH"2V%5KC'%UBLI-G1Z%IY!1Z5F<#RFA<M9]B?
MC]B6)TBM#K6U)@=;W-W*O/7(D`U6?.54Q6K8H<N->'L+&E.42&9R12'05TPL
M.9NQ[C,+%FSG]-;5O+XN<'15O6OE/%]-?0)`X#`8#`8#`8#`8#`8#`8#`8#`
M8#`P>PZRK:WHNJA%L5[![/A:Y0C5KHA8<389K%UBIN4`5MZE4P25`YM*A0A5
M%A-)&,K8BC`Z$'>MZUO`HI_CI4C2\7XJ<;0C-15?';+5]+]O0A78C%`8HT3I
M3"VSJZQ$S;$%$M;VE._G1=O3,*$LAO$HVD*`B("$O6B2]!#H.P&!P:<2V%/H
MW8<YB44Z9\`^>X2D]`.E4R7G/KIQBTB[AAJ!QZHF2Q7&$\Q-,BRBPG)W_-&?
M"G7[W7Y6Y6WIPK1!("G3!WEX#`8#`I\K:UH+8WMU>S!#W98Y.M4^>%;P*=$*
M8])64EJE(.EK%?1MZ)<_,[8@D:<+8\)Q[5MAJQ%H8A%?+\I9@`A<'@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@4(_R#Z@E^N$;VZZK/JWL_G.SN8*8D[[#6
MCFKI6?4I7\P<US]'_A56A%(>J2`EZAJ!LP"0[1Z4\HLX8-C$'[=!"GKA\KJ/
MH+KIY7<..?0/7U0\MH5\1HCO#T8OF<7WSK!K]MJ)1R.=871`9`I-22V^7JO6
M6,)X5`85%CD[$E$OD3NY/R(MY3!.#H2C/*E6<"QFP^XK7:.CO0?L-JC1">7W
M6BKH5R=+OK0\.3<T+*[YFI2(E(X[4=<DJ7,:@49B*9"5^$$X]Q4+C"QJ-A`7
MPVZ*FZ"P^RZ6L;A_T-HQ=TMZ&]P=CU_8=\<@V5551-]7VW*T$MA;',+`DY"5
MMC]A+VU(,O;;]IQ(E6M%%*#!"#]0Z6\!@,!@,!@,!@,!@,"MI5S7W.=T+T_8
M;?VP)FJ2S::*AE`5U^Q6M]_LC8^WF4+D<Y,;G-&!F>A1;3D4>`P8S#GX"K]/
M<`:2-+>,P--).-_2HJF^+X7_`,PHQ'8--2!W<^C)A^UQ/AEM1U=$D+9'H>!V
M=&TMWF7[(5DJ4079Z`F5ONE>GI>7^J)RB\"XK`CIUM3DVZ"YQMFFJYM!TIB:
MS^-@9F&S64+@-TBR@#HW+U!Z,+<YM@MF."%&:CW^1I<W?:HW^<WNB/YVU4$2
MS.&N@1V%QW+A=D3@]GYT3DDV;'C4\J+(O@\J0O3VI<9:($[$)`X."%P(1_$P
MCCK1K90RE;>XQW\2*H0VUR5RW;G/MA=*R^R.C)->#-=,^9)7"([(2GTHJLFM
MLBC2QJ&5JVMD[FC.0FF(0D%#6$N+^-,C)&N>UXAA*2A.7`P.S+2K2EH0_P!F
M6_8$+JVNXJC$X26=6#)F:'Q)A1!WH/Y#M(']8@:T)8QBT$/R&A^\>]!#]1;U
MK`YR?4N^[P]8^"ND.6?,SCBY.C8M:K''F474,[=H9S-1#J3'Y_$Y6:&D%E[N
M\0EM\+%1L9.2_G(FYMB8`?<<6^'C"6F/""G\63R/]"?.*_>J)MV;S]_9N,61
M3\-BT+<_[K4C8?ZR_-4T-=EZ'\*JK)G+@W?`WBT9\JLH@D7_`$0CV+^F!VNX
M#`X2NC+CKFD;@(G,.[C\3;_D0.NZUBCKSK3/G/1,HZG&U3KH!@A3^GA*M!.'
M1XE]GP!.^B6J3#1MYRG\!2>!0%5HHDX.[7`8#`8%/5:6]5UF^W-[1^O9]%9F
M]U'YY5U7EGM4<>$;HN@4Z(Z8L9\.B<I3I3##&=^+9W=*I$F.T$S1*@`OI]!:
MP+A<!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@0D[#]`>=^*T+,VV0\O$OM^:M
M[DX5;SK5S<7,+RL\AI`:8ZN<?AY:M&2RPMA)3FG.\H?%+5&&5.28:N<"`@_J
M'%5Z>J/:KW;J(]7RY6BQQY7A\L$8]TS2TJBC54LE<$YB="UI0]'V#+8$7VK-
M(JZ"7?K9T,9RZPCYR0D+8XORW[UA(=6OA+ROTQQ;Y?\`.'.O6AK>FN"$IYNJ
M5Q-O=FN1:KJ-R>=R*3QF`+I*R*U[(_ND>;'<.E!J(\]&089M*0<>4G`>:%O>
M`P&`P&`P&`P&`P&`P&!79Z=\Q1OI'EV>*GZT.A*O74S"[*M>*N'/]WSJE%[A
M*(_7DB,:B9:K@[BW'2=C2G!^\*-3L181[V(/TWO?U"+O@?1":!>?7/\`?[C<
M'1MLV'UC05%6=9I][7O85Q,K3*@19R<%9]<LLW=W1)`4KPIE1WYY:'[-K0ID
M@3A#TE)^P+M<!@<ATR\<O-24^_R:H7[EB+N%=37S,L_K641H4QM`@IUZ*-[3
M@,8':!C@EG)#NG>-L4B6I_QR5!;?K1^Q:3_?H(@AT_=`]-\]<I04^R^D+EKN
MEH0488F3OE@R=MCX7AQ`2(\#'&4"H[3I*Y(J`'Z)VQL(5N"D>]!))&+>M;"O
MD/7'=78`!H>%>9A<_5.YDZ`1V-WY&9/"].#>I4!*!(*2XV:U3+=$^">T'A7-
MJN;KJ];CM[!]2U1>Q`V&>5OY74KJ;L%U]=3:PO0+H:/JDSLQ6-U(;'WJ!UV]
ME)]@&II#G"+L[!050$E*AB.3*43$H?B1_:(UT/,!HS`L]P&`P*L?:ZV;4HOS
M%Z?M:DI-((A:<01U0IA[[%WTR,OA*]QO6L&52@1OQ01B;"WQM<CT)YFPB!^.
MI'H81!WO6PA/6CQW<P6RPS=+_&PY`JR0NDL1*))<D5[CY/%.F`EX?$RJ0S`*
MUBYB:I*^.B,0AKQE`6EJ%AY6M?)HP6AZ#HFP-6W/8<BJVNGR:1*H;&OB2MYS
M.B9*JJDV")9K*7!\>F]D3EH7&SIK7<"9VUL$X?F.*YT>429&WISSON&(`2AA
M3JG]]N=WBDJ_NN'\[=2S5$YU->]_W=$6*/58FDO,]&\R6L.E+LLFQ3I!:S+'
MY:A8)^0>!N01!;('5W0(EBDI.#\4XH(27BOJW2\RZ@:>?&.L+F/@<DNUYY<B
MW4XVZ"ET5).GX]2@NA'FF6U+N=_W;`J3UD4<(M[/C)+"H=TJEO+5"-($+8:W
MIR[*:O'V)L*04I;=8W`P-'FE6S,ZO=6SV*V`T-COKJ.T%NVIP<HFZNR)$Y:1
M*BCO@,&$WXC`#^W[1:WL+C<!@,!@,!@,!@,!@,!@,!@,!@,!@,!@8W,)E$*\
MBS_.9_*HW!H5%6M6^2B83!\;(S%HVRH"MG+G=_D#TJ1-+.UHB0[&:H4'%E%A
MU]1"UK`YN^P/:R;V"9':PX)994R-UL"6M587TKJ==8EZ]$#3&JT;D?Y^<D/@
MF1=:$=;#B-_DVW81L<J-F"6:;\[SHO1(P]+C?Q$<Y:N?[@]#AJ'D^RG1))9E
MS$98RZW7NU5Z(;>L8W3OOIDU.SN_4[XS*VY.:F@+"DCM*QT]/]B!B7E[T?@=
M(S2TM3`U-C$Q-C>RLC*WHFEF9FE$F;FII:FY,6C;VQL;T99*1`WH$A("B22@
M`+*+!H(=:#K6L#T,!@,!@,!@,!@,#%9=.8=`6]$ZS63,L7;W-Z:HXVJGMP3H
M"W%_?%.DC2S(/G&$2QR7G?7XR2]"'L(1#^GV`$+0>'JWZJV^$1O5CPG;XI9=
MR),W:DS1L]0QA:=2`3F1O\OXS4H8_O3AL01;^B#?Y/\`\#_,P/:B$[AD_0N#
ME"90QRE"TOCU&750R.*9P"V2&..:IG?61Q"08,:%T:G-$:2<0;H!@!@_KKZ?
M3>PRS`8'*I_)V]7B>4..WFGN4.HX+&^L)'94;A-G5]&FV!VE+6.DIA#;`031
MNG3'((S-V>M@R`S:("0]>!K=C_IO:`S?VF[T$+?XR/H;Z06+P=(*]9>9'#LB
M&T#8C+253R45N\[<\1^IX%'*VA!K+6[L6ICZ2;RTML+6C6B>3D+VO-"JT4(T
MP1?VA#H\'TOZC#`("7RYK("D81`3C<_0R%I&T)XM;T2)P5-W/3RX)D(3-ZV:
M80C5G`+^NP$FBUH`@^3KU]=S"C2TWG+QPE4F%C`G5*_3:>*TJ8\8=A*/4I4_
MG>G4*4Y)F]"&6`PL8PZWH(@[WK>@_G^W?:GLX[^[$A?54VZ=J";+NI4W,6[!
MI;^ZMEU36-&RCH:/.KS`JYE<ZKV*M<SH9E?$Y3H2B=V9$UN`$@!*D80;$#`_
MHA<]^:?-E$SE+=TA)G'2_4($YI*OJGJ:6*;DNHG:@7W*"(0M>2$\.IEC%K_+
M`U0AGCC660$)?P;UK>]A8'@,!@,!@>6],;+)&U2RR%G:WYG6?#^8TO3>D=&U
M7^.H*5I_R4"XD]*?\"H@!@/N!O[3`!%KZ;UK>!ZF`P(K=L4=<?2G,=J491'1
M:[E&P[*928RFO5H@IEA/\-8%R]*&6`CC&1.:Y5H7Y^C6E3>F=$SLE6-(U7Y:
M86E!)0@A4I(O$>TGBL8O7D>ZYJ&K?GXJM'SFMK=6\8KV.*RWD"R)>QR@#)74
M6D'4\L<*TNED3EO:0R7N;M+4SJ-_.6+&@Q84$X8;SK?R%!6O1L8FK5?3:;RG
M`.P91WA`.8@TFA32IDZ-D_/)_/VCW&]-V*H0.M8QQ(\NK\ULI$,0N*9V7`T)
MU-3)22,#V*GC=/1#V?MF.U&P5K&`MOF]68)HQ5RUQ=ET@DZCIJR580RALC)"
M;25^/9E"4W6E8`J!)AE"_J#8-["XG`8#`8#`8#`8#`8#`8#`8#`8#`8#`KDZ
MW]*JAYKDRNEX(P/'2W5_[;,EA/.=7N["W+(7$``T(VR^AK3DRI%67,]/M^A@
M,4R"6KT>S2-[$WI7`P.RL"AV-PKLOV(FK?+7"5P.U:Q87PM8W6V]0R0JO+JB
MG!`MTE4`Y<Y]F@&&2^I/0$66I5&D]D6&4DJ9G6E;-:6Y2+8"A!T9<E\*47Q^
MFDCU"DTDG]SV)\!UP=*6^];G5^6ZL3?%^*7+ITK3IQ((NTA(++:XVSD-D:9B
M2PEH4!&M;^X)EX#`8&$V-9=<T]"G^RK;G\)JVN8FE*72F?V-*F*$0J-(CU:=
MO(6/\JDR]L8F9*<O6%$`,4GE@$<:`&M_<(.MA5!YI7_"GN?75`9)ZW\I=^SJ
MPY4.9U+7%0W334PF$`@K(D7#D!:>.0F3.#ZI0_8N2!4A)3;0(PH0GZV`:H[6
M@N5P&`P&!"!3Z)<K(;BOZC%TQE">><R5IJV;A3%UE8SDEC</)/=2W%0#]&C#
MBXK5B)(W%K""BTWT>D2PLYH$X@)6[2!K4KUGXK%6O,MK'369)HIUG)G.&5(;
MNLINN.6RUA;"%S_'%1[2SN+2XO2!<J+0)$[.J=37]5HT3)IS2I5:E.&ZNX^=
M.;>DJ!>V'JYJ>':G:Q=$5ZO0&9?*RC$1M4HG-_,<5;%$@+5DS1IF?\S_`+*,
M0.6S#1%GI"`N2="H("EZE>X/`._^WZ_?Z>N&TI5UG)82Q<Q1)N/JGT`81BC\
MMC!=?1UB?'Z956SH8VE71@D98%#JZHVO:O8WD[ZNH-.187@\G\>T3Q37SY6'
M/T<=(Q#Y#/)98KBW.4D>Y"'4@E[D8O6!0!=EBA.U-Z)/\*4HM,64)0$C\E8-
M4X'JUB@-+]#>E//='STZB88FG'4O5@TX3D?*W+["39]M-X3MZ`G<;*4$KV^!
MT9%_D&$1CM-GAA1:)WL98CMZ^S8:(_TZ^@_:W_7>PKG_`-$]#N/^/_2/Q=-U
MBJY)(U&_U_2;X[3_`$]I>V_YRMB*6M-9MS"7L`]@T_*P_P"+83QI+D'E_G&M
MR*BI&AZQKVO"UVG=7'F>*MI^GU^^TP!DHEKJZ%+WN9RY5HX?SN[LI6N2C8Q;
M,/'O>]X&\V2-QV,IS4D;8&6/I5!WY!Z9D:T+4G.4?8`KYS24!"<LP[XRPA^[
M>MB^W6M?7Z:P/:P&`P&`P&!H'IGHN(<K5$^W-.(G;4W8&%<RMQT;I*K9?<5A
M+U+ZYIVI)MKA,(;G)Y5)4YJC1BE1L`"$Y(1"&/7]-;"'G"OK;S+Z'2UZBE`P
MGIY`6R,,E?#IG:7.5C5U6JPR'RAMATFC;?8CNW&1(^9,S^YZ).:1*@+0[3J-
M?'O:<[0`M!P&`P&`P&`P*EH7!81#_:^VW2)0Z*Q9SG/F]7$IFSC'(\T,BZ82
M<SJ"S6XR1RE6V(TJB0/QC>A(($L5B.4;))`#8_M`'6@MIP&`P&`P&`P&`P&`
MP&`P&`P&`P*PO8#J3I#BSA>S^GN85_+2:;U`(J62-NZT72E#")1!&]H>S'6)
M07]J3:OE3C<,@>M-Q#`@/<RB7$S9J8`#%1J<&PYDN6O:?TZ]$*/:W*VYK17/
M<=N>3.T1IJJO..MY;.?2CHLZ(FKVV?,-6QVS+FM*!<XUZA/,+"[VG+R6I)&R
MR?E3"WLX"L@+C.3/&%.]1Q`?V7&H?#*<42@BRD7GG54LD,YK613\Y4)X%9G?
M'0<F-_N3W]>XW$PHU6)^.#"4*E-\29"X$!*48'0@V-C:R-K>S,S>A:&=H0I&
MQI:6Q(G0-K8VH$Y:1"WMZ%(64E1(424H!9118`EEEAT$.M:UK6!^[`8#`8%9
M7L9T'#.9O-CK6TI8NIK3HU5%*P5O&;V;(C)8'/K4+;3G"`0L^#S38F>>N3K(
M$!(D[3HHXU0,K[@@_P`&Q!#AE_C+>F+^Q=G]!MD^Y/:[+CTGA]^=+B5\@\7L
M,[O>NK`L2TZC0NX(]N`-V[!C?/#.ROR]K2QQE*4)$"AQ1DE)MEBWL(=PFO9S
MST:1A369:UB<^.`#!DKT'3O,W3W-WZ0<4>8F4`=':Z*>A4=3%I3B#=&G:6C3
ME?`=]QFO@.^P),5EWQPS=(2-U#V5RQ9QBGX]%IH'T!5,J7!--+`:%,>WLLK6
M+DJP(3`_<0:6`X&]_00=;_I@2Q`,!@`F%B",`PA&`8!:$`8!:T((@B#O>A!%
MK?UUO7]-ZP/K`KF[R767S[5TSZ!Y<XVHGHZS=M+B5;Z:RK!:J>^"F(NS3*>/
MR_3Z.OYP=+CM/VQ?]C_8ETJ4.`U(S!B+^T01O\K+"L3MSGBKK@O_`,_><>=J
M64US7]A\F&P>TFVX%SE%9]%E3>\(G>+K*SB2F"')(PA:RE`352S3F$T(#2_N
M2!&(+HU"A.C3GJU9Y*5*E)-4*5*@T!"=.G(`(TX\\XT02R222P[$(0MZ"$.M
M[WOZ8'\_WSR_D=UW8/K'V185?\6=%V/(/15KY)A55537[[7#K/6:0<N5);K,
MYD./Z^]Q6,JT<K528L_2H;@C3-2!.>H4C^PO>MAU%?Z=?0?M;_KO85S_`.B>
MAW'_`!_Z1^+INL57))&HW^OZ3?':?Z>TO;?\Y6Q%+6FLVYA+V`>P:?E8?\6P
ML'YYY@Y[Y.@1-9<X5#!Z?A8%`ERQKAS,2B5/[N9K?Y$@ES\=M1(9I*%NQ;VI
M='96M<5(M[$:</>_K@;WP&`P&`P&`P&`P&!2!_'O_P#;P4_\7_=?_JTMK`N_
MP&`P&`P&`P*>JTJ&KJR]N;VD%>P&*PQ[MSSRKJP[/=8XSHVM=/9T?TQ8S&=+
M)2H2EEF/#\8SM"5,)2=L1FR4X`_7Z!U@7"X#`8#`8#`8#`8#`8#`8#`8&+O<
MWA<:5%H9'+XO'UQJ<"LI&]O[2U*C4IAAI(%):=>K(.&G&<0,&AZUL.Q`%KZ_
M76\"OZ^_1>.L5@'<U\>00[M+KX]"A6+*SKR1H6^K*3:G@@9[5.>I[R"0[1*E
MXB<F!L]*W["XRQ\!K06IH5_?]X0Y6O9:@U?6K8+G>].VJ%G_`&*7.HJ?T%T7
M=MCJ^<O+[S-C>V*03%DY[J0"V3B:!]178ZM:)&GV^E3*Q7>((71<J3,C:,L)
M(3'_`(L?"K;P^Y]8M"7MKS6[#<+(9:Q=74/%-YI[UGM=#C3I,D2,B4/A;7'C
MVR"R5,[Z,++,0%[,<TV]!$+17W"#L'P&`P&!SP^\'MG9_C9_IR>(YS-"[YAU
M\_W$;3'1ZMQX@;U'9+`?VJJ-0:9$5?2=.L:U[7*2C"U7YFA_*686(D&@@&:&
MG?._VI[X]7Z(='OES@B*U5.U$ZD,8.O^Y9W*G3D2L(RU-+*,ES5K4D6A]B7A
M;0WE4K#J(18@MN2I?Q#G-^;A'[)"%I]+^851Q^9BO;J^4/7>753@TJ&A;=71
M+(Q.47A+4X$B+=(GSW0I!2JI^?H*J^8W0DS0D.>5I9P].;JXC$(S83AA-(4M
M6KJH?:YJ&KX`]JV\UI5/,)@$4BKJI:CU*18>V*'!B:4"LYO.5H"#1DB'LL1A
M)8MZ^X`=Z#:&!&JSN,./+L^7=S<G\TVWL\6AG[LZBJNGOS#T<4IT(W]U19U^
M06E!`#-;W]=_>`(O]NM;P(EF>+WFZA`9^P.?W*B5&PF?C+.9[LO_`)F.0&CT
MHV$]&30]I5\A"(HY6:;HL9(R!&'&[&`7RFZ&#?F9)8R9^73WI3Z:U<K3B+.;
MD[UT#"^D60DX@U0<06XM_7%27TX/"'9AA6CBS5H3#BR`@V;K0S_E"GGW*Y#]
MAS>`I1&J0[7N;KYQ<IU`VMPK"M.68Q75_/[$I4')7=R_N1SA)X(@#&4Z0)GZ
MRW[B1J-P)5;`+X`!!K013_CH<"^K!'/=TUST[TUWCPE7L?G4)9X75A\!@J:;
M/T1;XJ,OX:XG?1<`M1764*:1E@2B11=L;_\`-U]?GUK>P;#HN3^./$DA.(<>
MA&:Y>TGXI44K&Y]H]#7+T4QF#3J0K$I1-4S28F4:U)4BK6QEE((ND+U]^];U
ML/T#H(4<<?QB_.#AOI:JNK*7?.E55GT\[.SS$D\VL^*/L6,6/,9>XFLT[M*"
MM618L)TUOY^P!`J)V$W01;WO6MAV'1)@,!@04[_M?L^E*<.LKC>K.?[5<H8C
MELLM-KONQ9I7Z5N@<6BS@_FJX<.&Q.2F/<@.4(!%[(4C2%:#O7T$+8M[`&H?
M*+J?L[L_GMBZ2ZDISGVHH%<4!JZRN>D]+V--YO(GB,S1J?':0!LUKEL69$<5
M<FI.)HTC+0K'$)XU"K1FR]$E"."TG`8%"TB]O9BP]2.'(A/E-Z&OMOIHJ_V:
MVL;.ST"-1(:8CUB)*Q4V\S@6W8C3CAJB3N*4DHPX\D?W*0?=H.M[%H+Z<!@8
MK,IU"*Y8E$IL*8Q6"1E&((%<BF4A:(NQ)1B`88$*AW>UB%O($(LH8M:$9K>]
M!WO_`&:W@4A]_>]7&W/5`6J^\Q7[4'1M\QY1#XPQ-5;`EM[5S!76;3F/PE5-
M[3?Z1;Y(U)8_7:)Z/=U+/IT1.;V8A"V)!%JE90PAJ'Q7=[2YDL5/P+*9"]6/
M7]DT;=?><,>K'H%PYEZ&J&0R'JQ7#Y]![QJ4VRK.1MD>N"03H4GKU0,YM<!M
M"!S)4$&?`#9(=(F`P&`P&`P&!3U6E3P2MO;F]GZ'-2YM=+7\\JZG\Z/5R24/
MQ3K*CNF+&93%Z%'(7EU11Q+MN:2`:1-A:-#H0-F:)T8,8A!<+@,!@,!@,!@,
M!@<R/\C?VCZ7\@VKE15S;%^;)FZ7JX6RGD[%>L>M22O1*"`IH&8A=XFDKZ>5
MNV)&LA1*Q$N!BYP./&:<F"G3[!I08`(4>9?\J><]!4Q94CZXYUK\RS(U8`&N
M-*Z/M[EKFZJ"868PLR\PZ;+.XNY8?+$#PE6&+A[<$!"ME,)T22(PH\)WT";;
M[_)*K%":44@K#F!M$J+-4I]S;UB\^C0)DA`CRQ_K!U%69T&F1N"@:?>TZ9.8
ML$,LPL1FR=B$$(>+K^0!:DI,"FAU2<+,1GVGKMB>.O.Q+9<0-Y9I9)*5UCM!
M^7<V4,+D9^0`8SA*E3<$0!E!4&"V6(0?XC]@>YY*5HJ"QZBW9V,+/_!;J\\W
MO;N^-/0OM%O:YH<"N7J495[&V!)$9M4F5J0.!(M#*T2$/U&`SNSU8FGY&T:^
MX(X5HPAM;]5G_'V[":#7D9WQC.5)U747=41W''`HU1^.!2Z(0M(-E[-']Q6M
MC&'$;_(QNV_+8[<B+'T%.+FE4MK^D8NE,8KPYTKCF:3P13)'N1.XV-G@==63
M;2=9&75C+;'4M<M>A*#5BY2$*8@H(1&AT:>5/5_3UD>4M#<=>2?$W39143^^
M,]U]IM(.-*QD#7*9HC'+YN#E)UG5VUI#;2N!02]$LJ60R'87B#,:=O.<$+@Y
M[($`-#^^G6,3Y<\Z()YM1O@6:<A2*:6O$[96DW-:_&U\S>?-[08].$\L6PW&
MG.@;HN-/8]LOXBBW&8N@$*R0I/U-O_/&0:I3;")G\3V\.\8G8?5-?\8<\\UW
MBE7QNM)+8/\`>NT]4H[0Q,0=)V9&X1F5LD(G\S>V^3JRDH75$6@4H"#F]*;L
M)!RC9A@=?-R]!?R.&@G8J@\]//AZ-_'1F:"9UK,9CO9QAZHE41]LC8.?0?(2
M#11V_P#,^P)?UT$9I@OL+"-N^BO?Q0/9E^4_;U)EFDZ`:GY`X6X\O1N1@-V0
MATY)9)-/7FVI&,[1X3!E)Q1)08`9A:@\L*4!A.P:N.R'(6E'3_97\A"OV\H)
M`EI<'\NX=7<+:0G*MZ6$.4FYNX8O1]TE2J"B"-&`D1AQ@]B$F//3G;^@?(I_
MXU+A%;OWTP]&W5.28G`X-G3?6'I)RVRB5[,4(CE#W'4:7FMD:5#8ZG[-6"VF
M2A:C?L+-TG3_`&D[#ER_DCP[SFD*[FA7YR6U2]AQ1MK>Y9G9#C7_`$O%+V>B
MW=@>8`TMS?/'RR;]?[/B2@QN<0!9&P:4\3V::=IN3GG$JM:"^+^,7VQR'Q]Y
MMS>G.I>R^:*8D\)Z?N)1'HA;UY\_0*7J8F9&*\6K72/,2"V9&OF$;7R_]6_3
M7(CY0N>M?5)LY/LC>PLW[\][>,:KXWZ$LOCSL/G"SN@85!S'2K6M.DD5PPEX
MEA3DU?6/.VH"Y,J+\Q6U*3`Z^YW)$WC.*5'$GD@_'/"JS@3^1?9,X["@E9=0
M=@\<7)0[]3=B2::N_+7%G?+-+85:D751A,U0([=DP=B>32U`'X:K;FD87=%L
MA$>F5%MYYZ$\P.A;_G)>>'_?%/\`_P`K?6G^XS`?\Y+SP_[XI_\`^5OK3_<9
M@/\`G)>>'_?%/_\`RM]:?[C,!_SDO/#_`+XI_P#^5OK3_<9@5,^P_IWS%=G.
M]<5AS9U)UG65WS^]XE"H),*6,["Y.01I4]QF9J':76W+F&B%<UG=9PQ@:U3F
M;%(ZF4OCTY)T99(2R=*%!(:1\8._J?Y46=)TYV9W'UST9<L5#39PK*L)Z[>Z
M4J69Q>2,4J<FZ25E`K+HA/:M"R8MY3.+;(6YT+&A=0H4*MN4GE;-`G"YJT/:
MW@^-UK8,@BEW&H9:RPF4N<1/LWGOJZ*U\*6(F-<?&$LP?SJ52";F%<^@3D*!
M%#_)&`S["`C.$6`0444;_(][(>)/QC)KO:_/E93'2$XA359L>YRC?=%K]"TK
M%I6Q+Y(G+>H@PU[)XZ[SQW2-XD+6U1U3*5"ET,``90$X%*E.'07OUCI=VULZ
MO.9O26TV\03S4KS%?.'K^.L3@G3#T0H.;WFUZIK=N5")7_5.(D)GY/R@'O1>
MRRQF!#Z_YB-WOPOQ:[\FO1^3KC#/B(.EB'C:G&'9I17Y2LI2YVGV!&W%-\*3
M^I9OX`DJ@[>B2S=F_<$(?YE]4^FCX66*.>4+?'##BT^P%W+WI2,4TF-4[^OV
M.`Z@A'0.BRT!7]%0D^E6PF?X2`J`?YF!23[E]:]Z5C1W.Z3L2+<8<N\OVUTW
M&HI;<8K[L/J*R)U.X*FB<R<#8991U<<OTC-%E*$R!.V+9:5!URN1.*'1*0"7
M2,UP-*#`?#GJ#KBPUW9E4^;Z_@JZ^5:$L:IFJ%5S/+X[2KB&5R1,*_=]NKI0
M(K,I&]+JC%2R^31-2,IAD`1MR1X1N>V8[2/>A&A?QJ^?6QC^TA_\YN5)?^.8
M-,I=*Q]&Y%K]0,#\GQN+:PV1Q'!_Q6LS[=:V%0X_E`^[6_B%_BT$&NP/0QL^
MW;[Y$6>[:*,&2KU6O8_'4B&8+7R:+4M&K%L2H`K&\0@AV(2H2!0$`OKH@0M?
M;L..JP/=&9H>YI=Z)M8D<<Z,JU9,N-#>19O).+&JGBN.VCI9C%)X4Y6HAZX?
M+_>[\>7^,@?]2-C@ZYC2K?\`"D3KHV2:O4!V"A4>S]K[T(IN\].+V!Q^70=N
M:N]>XK-94PC-`*&<A;0\=UP2\``'8_M`N=DGTV'6Q;W]?M#_`$#YY]`6$>>K
MZ2]1^UYZ0?\`4&H;S\=4_&4#2IC0"T>F2+J/@1%YA_S!?<4>;.S517^SY1?0
M/VADT)\?O-F&/I4N7<HP&W9N2(PT$^Z9<)=U;.P*SAE&J'!/+^E)':C\A7*#
MRM#$8F/)WH6]_;]NM[U@;MZKG7,/,?+,X<[SK0MTYM3-;?!9=6$(HIZMUG=X
M_.'%)$OVZ?3\!B4E&[1M<-U"4L+$W"1`3B%\OT#]-;"NSR5ZF\AK%DU@5?YD
MT\\5PO?6M9-I^^(>5;DJR/R4BOG-N@VFMYM6;0=N:')9"UCP%"WL9SI]6\(E
M($B8O05&M!>?@,!@,#&9G-(?7,4D,\L"51V#PB)-*Q^E,OEKRW1V,QQD;B1*
M%[N^/CLH2-C4VHR`;&:<>:`L`=?7>]8&@)OW#QQ6D6I.;6-U'0T"B/2*5B7T
M'(IE:4.C+3;[=)FMI>F)TK]8\NR(J2M+@U/R`\*I-L:<(%R;[AAV>5H890GZ
MKYF57ZJY52W_`$ZHZ60L.I.LH8BQ(J;;*5CV@`[_`)Y\$`Z"D100LQ@%P@;3
MZ-"@,`IV'1`PF;"ONN:U9H'[=WJ^-3[83L?9?G=6DT=T$ULN>3YECSEOI.PV
M0ULKMGF<@?&^MHB:6U!4_HC&!"T@6GGGEIP#.'O87`X#`8#`8#`8&G;QZ$HS
MF:!K[/Z$MRO:9@#<+XCY58TJ:(JU'+!`$82UMQKJJ3C=WI9H&PIT*0)RQ2/Z
M`*+&+>M;#G8MK^1S"K71SLG@6',951P)X.B-D>B790)/37(=:R(Y/L:9G@<$
M"W:O+I:US-&%B105H0,KRM$:2(6P)1[4!#@C]@+8K_H"THO;"/IZ[^I[4>$<
MP-L"Y;\DT#8E$N(3.L23Q6.5)RI6*27:Y+K=G*='-2W,DHDP7M=HM88K:68T
M"4ER"5GA_P!FT;SU!YY`["O;HFKI^[6DBET6::OX3YB[,AA[0".-C:F=C3;4
M@LAMZ$S+]S)RRB0L:XIK.UHD1J<1^_E"'14[^[O.5*(QI(M[13(I8X!)7.,.
M=?&5$S3!.?\`.-*2>>)`11D6&A.1:"<5H6E9V@Z'_G[V()``_P`H%_(`Z\N!
M.5KE[JWG2Y7U,G`I;6'H3G'A_E4A^+*3(S0%2,4]]U8;8Q)@QKB`KS6J(E[`
M+9^TQ&A$#(`%E5!]+_R6KI-5N"&IO%DV,"^#2!S%:MR&'IBQJW!(:K=]TS=?
M2C=HLDYN&6(M.>9O0Q:T$8Q!-`4$SGPG^0NN8B"H\M\:X[(AI0_F*G%%VQ*6
MPI4,"CY0MY12F+':"4(902S3M&:WLL0Q$[T9HLL/YV_\DF0=YJ>X8;#/1&R>
M3K`OB"TE&TR=%R+'K&:H5#(=(WV0R)C9)"ZV;`(6^ODB7"6FKM;)4.J5,F4E
M@T:4;LXD(7:<6^X_?X^1.7/.#S!Y3H/H*]F+EB`11OM"F%-NR%%03T6B`Q'O
ME^PZ<<[4]3\6LA4K(4+UK@HDKS$?UI1^2Y.C@(P\I0'Y?0GP]]J+!Y*M>4/*
M/F*2M))T?Z'M&KX':L\N?LSHBTXY''QG>9K<UR3:B(:"R)M`XQ*G4+#%(F^,
M$*;TFC$+.R*31$`/#4?\??R,ZDZ3H!QZ<F?,OGM(*DD,=8ZYH!SZ[I>3+IF_
MMD,G]F2B1VI$U=)N,$E/ZL9*9@8S@E3XO4O2Y"RHD:4P#>U(=[#H.#X,WX[:
M^%):O$7/I9AQ3GMPYSJ;TPC#NA7EDED[0MXV/UMKMO2DJ"PZ"I7HR4"M7HK0
M1@^,TTK8?M0>!G:R!6B/9O=+M6MT"=<,T<8J9_Z?*B2)K-$?HUFCK'>W='08
M6PD[1NC1'JS7)5I5H1@#`%BV3@2TKSR>[(A24TA?[D>A\A,TG2HDIRMBYQ=?
MB1I2P@#^3NPJHL52K<#!!UL:OYBSS?Z_)L>][%@+#\K>Y98E*3QOW0[OC)B=
M.JV0:KKGF0__`+2-+$!*H4[@U8UFJ6-Y`OIL:4P[>Q_3?VF%[W]V@Y-/9[PU
MZG;+0K\5P=]]`]8'/=0W-/X-9TTXVZ4L]D0VNUV!2S9NDI$X\PH>AU4`%8T1
MDCU(&]V'&TJ,L^,?@J-&:6E*D0;\\BO'KN.&U!=)U&2A4\U]'.E7M%$G^;W5
MW/YHR:U$Z"IZA=C+`B->/O+4SD:=A2/Z\]E2.3NSHU*EQ:E@=#`0G),,"5?I
M/0GIE#N(;Y:)XQ=O(8Q*VF-UHZ*B?3BA^KJF(8K4LB(ULM99)#[:YMYTL^<I
M7]KF6T"31J\@TE>;\BE60G(TJ,"D?S"X5]'O++N>(O5K1GL?EV<7+`[OAS"H
MH7FRFNNIC.83#2H-+73\>-@>+:CSFC->P(A.I*$!*UO++).+<-EG?&:'4KOT
M4Z2KS9H7?T83QM:W%["?'N\?`SOFGS`E`3!'MS?+`K^=TW$D9>FY00M&$I&5
MH&OE4#T2DV$HH,TB7LI;CBM.1MG6O@C;#@E,T$R)O?;MP<=SU<=O1AH6AMBM
MHU;<BS]8.TC.("$[98`?(2H-V66/0!A,.!>D/7LU"4-@\^ZWNP!I9)I0N1O2
MCDVZ/S2#2Q*/RVO^Z6^<`*D9J$9:LD9NTXC$FC1B"`8"BSPV9KTTE+(45_<C
MS*]/X`?KZ`5?@4+65UI"C=)!*!F)CN<+SN)8K1B,).*+'M,6=L18?O*+^8C1
M@5S>IGL=Y9(>5'QHZQICLE^-')F]QKVKY?RMU_R78B"Z(<B<YC6K["[ML.`5
M$EK*7-SDS@.3/#&^G/+>F/$9^*<1L\D01V\4_97SRE]*3,RE.8NYUW5,I<(U
M,^KV2*5QU'WW9$MFZHAPB4=D\IZ36%6&_KX>0S1TLAGU+'%C(;231)DQ0Q%J
MSQ!<%+>_NH)'$Y$ZUMY/=+BB*)C<U+_+.M[;Y$Y=KE"SIT:P3TNDZ5TNZSK&
M0Q=O1%B-6GJ(OHO20!X_MV'17SAP/^0_2'9;EZ\Q.IV*4<AV+':GEEHIJ$YT
MO;NN0#X>IZ1.I3_'*_(XPDC7,[V+E$HCJ.6*&"%`C#+-5X&1W6A`0F"(YQ0A
M_0,_>OM#_P#UI\P/_/#U;_\`Z]L#QWVUO8&+MISS)J%\J(ZT)OI^0ZOO>?4#
M0VD?70A:^9<X>?J=*5]0AWO_`!"U_36\"#ED>Q-[5(L"U3VVO!%I?QJ"DA<3
M0^J=UR6:G*3U!J,@DB$Q;A-ZEB@P]80,D&@(Q?<<'9>OJ/\`PX'.'_(`[QZX
M[WY[I"H8C3<5>STEM2B;H9;R`H]#Y6WN[+#:4L*6S)F6K+NX<Y=K";-)<$:U
M\@--9GB1+6YNCZT\Q*0E^=0$,;_C4]1]W<-0[H>.1GS0ZN[!9+62\\V`G6Q"
M<ABNJYKQ6Q68*OW1KA$^)4M)S39"%6I6-JQ%IM_4$*,LP9JA.%%LL.NV(^M?
M02XHO]]^*_J;&5`B2]C#%H9SM-$I:D1FPFE[4.G04&/$E+*^@M&:(V,6_KKX
M]?[=AD-@^P1]=(5:MP\KO8R3'I0IA!;*^XN;9XN6;5&:``"0<9MMP;1"*#]1
M&_>H!HH(?\6];V'6P_G4VIZSNIWI5*.HP4XCB]K-R>YJJ!&9AQ;R<GET3?3^
MAY$Y5VQR:KE\!<Q.-F,57-;3''^1+E@YPC<U3BB3*S$)`25X?T.I_P"W%>5_
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M2Z)KZA.CY<CL@B6O%@0&20.R)"4VJF4A-MGDBIQ6.)AFCTA1JL.\C`8#`8$3
MNZH0HLGD._8&@H=5TN\RJ`KF>,TVB)J0U9(9@J5HPPU]3#O.:5[6*(ZO)5I'
M)`JUSPD4(MM'SH-'.):0@T.;&5\*=_OG+U(0,CAN7/TP=_"-^\@I/$YA<')2
M'5!WF%-4;('H9T>&Z]9.UR"B9+^AGN91L;5NDP!N+(@J(\2:H+T2$EZ5\_>P
M(/UA6\)D=2+E5<5CZF6%Z#.'<1L_I@:&?5;(N'5E`,M/D0=$_#NG5C.4R?26
MEW"LBZ)B+86`"A,Y[,,3IR@E3S1SZBYW]?+/C2*W>@+B`_\`G!7$A,>^AK;?
M[>DC68/IZRT&VEA>)`$)[1']:1Z.TC*UHH*@PP>M?4>\"[_`8#`8#`8'\@MB
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M%U6I#U+TSSC9$EL)7-)A'N2NM:"EM>3-GE$<8'"`3ET:(]";*7P.5"BVP,RQ
MJ<EA:K1C-L_XPZ.^P`7K._E.Q2M*-#/>\/2V=H]B)&2B>.IP,B!.(D0QZ'^F
MP.`P]N6G;&/ZZ-5E*#2_MUH`@:V+6PC),/XXGGK80#2I^[='3@L\G2<XN86T
MADP#D^E&U>B#0/4.6A,)TJW\OV[^H?D_Q?3Z_P!<#5[#_%(\:F)8)UU3MM+7
MS]24NA+X'H"SXXN0G*1??LEL3P=ZBC2V)2!"%\0$Z8OXPBV'6_LT$(0EG"_#
MCCVLD)J"K+3[]JTL:4Y*2.N_1;LN);1A-3)TFC$Q#3<1"'[BB49&@A,),*WH
M@L(@""'0<#^>G_(JXF34QZ126-UMT6=>K,X-M,PMT?.E>YJOM2_8G8TK:!&Z
MC-EFVG9+?:D/A+*V'HE87A_3$QYI;5I)BAQ*+%O[`Z\/"'R5XV?/-&@;!0RJ
MT(S?LA+EPKNL7C7TAZ+8F`^QFN:29I$D-4\R=*BI$<@1003<A6?IZ86]$"_J
M+8A[,$$H?1_Q\N:<<DV-`N"^E.TC>@YT)HBB)?T+ZG=X+JO9X.Z+0AL%2\QE
MQLV<,\S.=HN4>U%-B]"-$9^H[..^\)&R#@JA_C+><O3TZX10SZY^INH:RY\L
MD1LWY.;N:>QK*A9,51FRV<,-G,LKJ!0QFP:-G'39ET\(S$>UI#B<O6#6E?=O
M7R!T@F^;MFI0'?MGU8]/8X,XG81!.G_*<V3F*`:,_'4#U8_(DO6IPE[,^@RT
MBA(`T.M?=]1:"+0?Z:XU[Y0#%MJ]@K]<@'!#HX,YY.X1>1D#+V/[1-@X50-:
MZ("=HS_.TI"LV+8`?'LKZ#T8'R'G+U8;_CVU>G=$.@ME[+4AG?F^B>2OJ'[-
MEGH@PCKNM#4RC>]"^3Y1J2Q:WK[0`WKZ[#Y*BGM(T`)!_?;S&G(`$Z3C&LY:
MZEKA:(96B]`<E"I%UU8Z)4<IT$6S$Y2-(6`8OJ`?VZ^S84$_R#?4CTX\_>34
M%63]]XZA5G]7A?(#`9OR_,K[17!$(]%1L+A8MDLK9.(ZC:XRE.;W!.RE"`[J
M%R%2^@.2G'#1C-T$_?,CT6]2O2SCRL.E*AK/SD1MBXMTA,V6SB]>C#)R"RH(
MH)8Y03)JVB7.:6-0%1(1@+?DB9))7PHIK=$@="^HA;`&TNYI/Z:L/(?0;_T9
M1OEM;%,1^M7Q^F]8*2>J+H,L),R!*=&F&-=7GU_'R)=(I)(4B1(UD&+D8"G$
MT@X1Q>B]BT'*C_&;M'I1WZ0Z::*4X8X>8KV62JT;/C]D7E7=IT.7!4#D^QID
MM/ERKK0K2H;+U`FV*C/1G)(VK1C5H$6E@0EFE!.`$.U?5Z^M\>^U-(O._DR=
M"(,&4H>:G]%94G+7;,^0Y.H01ZT>)(08G1IR]A)/V>Y?-LT.QEE"`+Z!##9?
MT9UO)T(4MS>(]FV0TEI3=*D\9Z$X%MA.F)(,3J'`LIJM*Y:O5KB5`R0F(RTZ
M<PY4,G6C2DX_CT((=3Z/>?4X-/6W5_'!OA&N&H3_`);VH\^>-;%D&DIRL1Y2
MO];H"X;-D*I&8XKSA')B#35(1;,..("5OY1!JT$0\<(OH1BOCCUEY(,$(U*6
M\0"@O:&FVY"[:)`%,C0N7-8%<5<EQQ+<!66`G:Q&:-($P[ZF%?305%^RRCS2
MG//E/%-O8'I/T#5,'Z`)G=W45:UY6MN9(:F_L3?C$HGE/'>C\'TA<K4BU@R1
MF0)RRECJ[D(WM40G0C/_``MI0T+X=V=R'4!%WS.FO3&TO,*K[,J[F!J8X#-9
M#YH=`]!VW9,)?^D#K9(D$<3\Y3.P!Q6MGV;)]1MU>(E&)"\,KL(Q26H;4+<%
M"%T5[]BPIYHNZ(L@_D$O5E%/54V0RI8=(N*^>1/4XT[1)Z2%1)P=HK0</0!.
M?]J?P='(T*+8`FZ%K6AZV+8<P_.G75+W!8?-U'0N5R*M9G2MC<)NJ>T.5O*^
MD6OH'317S"$71LU=)9"*RN^\GV2\].X`)T!RAJ<"I8>$U8I;Q:%HD8=77W4Y
M/P@'(D'\F[KU`L,+4FDNC7U-RE%I"28`+K]3&N()^#8FI:S-$:&5\1!:?[E0
M0)M_4L`$X>LR\I4DX.)<@A7\:6R;-7)@BTBE7=]S<82YY$H*;M$Z`M%;_5'4
MDWT(9BD`-'B2G@V6G`9]WS)B2@A.6O47H[$"/T[GWRZ\U.46T!:@DM5(>MI"
M$W\<P:,C6@Q#G[APIO"8'16S?Q_UO12DHL`1'IQ_X=!4C_("CWJHZ\(.;K95
M$\B=#K2)8H20J)\N<Q=B7=;%)K7R#SE!*+V06JGLR/L58(Z[@0EQ6WMVB2YO
M4+'`DL1!&_M'@1R_C'T;W=-.-9D^U_93OPTX*W:$EDR2P_/<^5H>E*M-CB]?
M4MI1&ZI_.(2UV>E9BG!V;1%-9"I.VIBTAQAHM.!7U#I5%QWZ!+-@)</7NY4"
M3[MC-/B/(?$[8];^T`OC+)6RNH)TSE$B,WK9FA-Q@Q!U]`B!O?W:!K@3IYY&
M(V:>P?H*O.)"$M!N#P?SQK=.45O8Q'_J"5JX9<BG0X8]A^PP7V"+#K>O\6M_
MT#@,LGQ*[;=?<IXJ<RFWF?,TAD4C[#.*DEK<H-UN3[DE!T(TUQ+K=<7Y@AL8
MI-HN:2O<ETX$(=QP!R5<K!LQ,>608:,._7_EI2+_`.Y9Z?\`_C[5O^X/`?\`
M+2D7_P!RST__`/'VK?\`<'@8#+?&JG+&`9NT.K_06S%:@)0%JV8]1."O2P*=
M0-2E`-H;8JUQQ(2C,%]2BDR(@H&]?=H/W[$+85'^FW\7^C[-Y6L3_1LBGDHZ
MTT^0]VK@^Y;,CZR**C#I['%-@BD+RY1YM6(OU&%@<1;.*.,-/5A*`(`@C$((
M0Z_B1\+]G5+/Y5T9;;DPF\N,5<]94'5+.ADS:]N3/<;MT10#-<&@H/E)=FAA
M5KN7`B3!`6:B4&:,4:V0:>+\D.[+`8#`8#`8#`IZK2!N\-]N;V=7.T;&L-/.
M_/*NI6TL<Z,A`V>KV\SIBQFT,%KK42A$2<RX:2>@&L#I[4O;I^4J.^JW97QE
M%A<+@,!@,!@,#^0S1_F"^R_VW2\X/%`>C;'SDBZ,_6!SDKGV8-/0$.IV0SQ]
MCU0=%3QIDU2NC7$JS>YXV)E:YZ=&8"$II+5[V+YTYFM!_35I;RKX<I:6I+1_
MLZ&ZKR3!2#'T)U%*)1TU>(EJ/>MEN#78-U.TR<H8=L0=;^&/!:$9>M:"60`.
MM!T%B.!$3HG@/B;KB2,4QZ=Y7HR^)9&&/<9C\CM&NHY+WIGCVUZIT_1$#B[H
ME"HAK"Y+CSPD:%\833ABUK6QBWL/>YOXKY(X]!,0<L\XT[S_`*L(4?%.MU1!
M&&&#ENXIIZU&=2`QF1IAN@6#4C</Q-&[%I/M:?L&M?*/ZA)W`8#`8&GY3SU0
M4Y?ETIFU'4_,).Z?B_J<CE-:0N0/SC^$C3MR+\YW=F56X*_Q&](405\A@OC)
M*``/T"'6M!G41A4-@#*3&H'$HS"8ZG.4*$[!$6%JC;*0H5F;.5'DM3,E1(2C
ME)PMC,$$O0ABW]=[WO`C1V#PARYWI$XG!^IX`_6%%X/(E$KC+:QVS<E3#0OR
MEM/:#5REPINP*_<W</Z>I,+"2L.4$%['L00:'_BP-+\:>1?GYY^3AQL7D:D7
MZJ)4ZPUQK]:<;?/1EALHXDZO3/(E[43$K3MN;Q%&(YZ8$BC2DE"6J`(O>@&A
M"89H862X#`8#`JD]&_+UR]%T[G%)'V_U?1%,RFLTU:3^AJ97U<164_3DR%Z?
ME,DDB67UW)I`;('(MS3HS]EKRTWXK8F^PH!FC1FA(SBSDZ;\DPN1PV8]=]%]
M:E.S@SGQ]UZ&65ZL<($U,S2%J+C\4'!(/#A`:U@0!,."K$J^@RP?%\7U,V8&
MS.GZ!4],5&[5.DO;H3G!0ZNC&Z%VKS!/&JN+<:/T1Q*7C;FF3O<6F;82UO0"
M]IEQ)K>=\R<8M!V`?VC"%<W&GBW">(K;%:M<]]>EL[1.UG6%<T_J.V[^K20T
MW;=H6DA7)IK-[2B49HF&N$JD3RX+0N)JK:\DXQQ3$'#$/X_MV%SF`P&`P**_
M?3ACK7T9Y5B7+/-A$5_:4CG7[PN4Z07D;3!B\F%IDZRMHZ>5JBKJ*FD5.EZS
M;PO2:$RG$K6-O$6>9H8_C"-O\=GS#[=\K(U=--]`D5^?4ED%QRP4)\3OY99Q
M+;=#42GC<A71>#'4'5HH>QSF+:3[<!JGM\.T-B0%%_3ZG&C#H6NUQL1IIZSW
M*HX>98%HHH'*3Z^A!,V9ZV/E,P`S*_V^R)[`D,>EK#"U"]RV6`MS6M;BE1CW
MHTU,<`.RQ!PP^=GBOW7QMZ+L'7K9YQVC'F=)-H0=#5;MZP4%)G>MVF0-K_%^
MA7NWG1#SBK<^BVF?-\E$M):DC=&%B+28PG2I4H/+5I@[[L!@,""7<G"Q7<D=
MBD4<.MNS>88^P(9PU2%MY'M6'UDGM)IG:%E;5K3:`)765C:D;:S(FDTM`23^
M(`H+DL^71WR`^(-?^?7F='?.MJ-B4`Z][=O6M$D%C]?0RI>FK5KV?UQ5['&#
MPB9QUHR1*H*\51540BUM&((%)B4Q+O01$[$64,`66X'^*@@"I.>F-$<$M02:
M08).H4(U`0'`$6,1"M(:0J2G:"+_``F%#`8`7T$$6MZUO`HN/_CF>91TI%-@
ML/3Y,MTSJ(X1(R^U^JA/Z6,J7$MW,C*=^46N>]:C^W(@L_:42@10CBPF"T(S
M6A8%X+`R-\98F6.-`%1;3'VEN9&P"YQ<GA:!O:D9*!$!8[O"M>[NJH*8@.C%
M*H\Y2>/ZC-,&,0A;#UL!@1?ZUY!IOM:LF^I+PU8FHDU3!KG2$=96Q8].R$J0
M,[6^,R09TGK&2Q9[7->V^1*@F(%!QJ(TP19HBMG$DF%A$KC[QFX:X5LMLM7G
M9ANJ/R-G2RI.WM<DZ3O:<0@LZ:@4!DKDHK^53USAK@[.0EIY@E"E$<8%0:(\
M.]'Z"8$+5<!@,!@,!@,"GRMHO.8][=7LNEUGN%@-,H\\*W?(*QKHK%HZ76,7
M%TM8J+4'0N$=1(ULK1ENJ50M"O=-FK_JKV5L8@%@P+@\!@,!@,#PY/'T,LC<
MABKF<Z)FV3,;M'W!0QN[G'WHA"\H%#<K.:'YE5(7AD="B%(A)UB0XE2F-T$P
MH8!A"+04;(?X[_%R";K;)(O;T1#/G5E;(R]3,/=EY)Y:]Q9G7*')LBSM*4;T
MFD2V.H5RP\TE()5\1!IQ@R]`&+8L"^7`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8%/E;1^Q67VZO99.+%;
MYPSR'SPK=VKME0P=)$3*YAW^I:Q48(>N=$[X\'3A9IV2J5@G0XM$8+2K1.B`
M@*#O87!X#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8%/5:([;2^W-[&67(:Y>V!7YY5THJ5)!
M8=)HL\1^OM],6,`AHL5Q?YU,$4PF07L"LT3DV)6)$)*825I#HPL9QH7"X#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`Y6H;TK<+EZGH&7?2MJ*[\5>LUR\RROBE7;;R*N&?S@B
M?$;U8\2M[?.Z?\B+L"/<S(8I$DGGZ62Y.SF[B:QNHR0FD%!N%,H]7P^K\O4I
M(IY]&V1KSZ@B8S\B;])$5\*O@])668V'`6EUTH?BYT8_?D?.EV6)"!#HL0#A
MF;%K03!E%D^W4>G-81%#1/GA*&FP'"5(7R=,=D=+"B]8EQV++9$WKIQM;725
MU+1RM:CTUH!(DZO?YYH-&Z+`+[\#ZLJQO;N!LS$ZL=%>=UEGNUA5I"E[1"[+
MZ3VY1YEGT\C\,>+$<RGNO&HLV(ULWO@WQ[_&$>M`TH5!A!!PP:!L/8G4T]KX
M?")C+6NI/-Z<N<6BLAD;="8M8_4!DGF"YD:%CFDBT<+<:R0MYC](%"4*1&$\
M\DG:@X&AC`'ZBT'H1N3>U;['6![7UGYI1I<\,K6ZK8X\V7U%MXCZMP0D*U#(
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MW2CM:+5&GIKL;I\;'&1557:ZQG=5*!J*S)6DI7-`A_$2B3E';VK-`$?V!W]V
M!G5E63[=0-ICKBR43YX66H?+$KB$+&F%V1TL)?'6:<S1EBKW8CQ^M5TU)PP^
MMVMU->WG90S5FFU$=^.2>=]A0P_=9<]]M8%7,_G+'2_G-9;U#(3*I8SUQ"K)
MZ:%,;`=(ZQ+WAOA,2"]5NU,VY-*U:,"!!I6J3)?RCP?*:6#[AZ#*FY[]IUK>
MA6*(!YD-JA6C3*3VY79G4PE3><>2`TU$I$FJT],)0E&/98]EC&#8@[^T6]?3
M>!@]3V3[=617D8F\AHGSPJ9Y?T:A2OKN?61TL"7Q<XA>K1:1/>F&NGEG_(.+
M3!/!M.J.!LDT&_N^OUUH/J!6-[=S%58*9YHKSN@&H583M"FA1*K+Z3$GL!E;
MVAA=4=B1$QEKQTT.(O(WHQ*1^5^,M`I0J`&D%[#KZA\H[)]NE5LR*MS*)\\$
M<>8J[A<W2VRILCI8,`D+S*Y+/6%PKMF&"NA/QLPAR*&)G)ST8C`C`B?4'QG#
M,&8`L/I_L;V[9K"KR%(J*\[I`RS9#-E;W8C39?2>HC71L31LRIJ0R_\`-KQ*
M\[53<YT,(;-(DJL/R(SOGV4'[!"#`^@.E/7_`)Z0U*OD=7><4@+MZ_JDY\9P
M1VQNGS!L\BM^0ZCC-('G\ZLT82XZTJM_(L$5LP_1?_0+'O\`I@9Y;-C>W=;U
MC/[`CE%>=UMOL+B+])VNL(#9?2?[WGJQD;E#@5%8D"15XR,ATB>MD?`C+4*R
M"S3QA!]VMBU@;"_4?:'_`.3O,#_Q*ZM_W48&O:IL;V[L6NXI-Y%17G=4[S)&
MW]075W/++Z3_`'A%AB4GE%('\,>KQZ:"EQB<H!VP%*3=EA-T$?VF:$`(?-?V
M3[=30Z?E.]$^>%?@AEB/D(9SY;9'2P"[`9FAO9EB:Q(GIJKIR,W#WM0Z&IDN
MU>DRS9J([8B0@^,0P^F>QO;MSLV=P%517G<S,40BM>2-GLYQLOI/<)GJZ;+9
MZC>8M%MI*\4/H7ZNP0U(<[A6)$I/Q/R':<9WU.T4'R]63[=-5G0&`)J)\\'I
MBF47L.0.UG-MD=+;A$!7PA7!4S-%I8)371#V%\L0J7JSF?\`%2*"-EL*[\@P
MD7P:.!8MD^W4')AIK+1/GA8HY38D/A#B1#[(Z6$9#F:3.`D;G8DCV\5TV%@A
M\.3A_)<=I]G+/B^FB231[T'`P7JGI3U_Y/YMO'IB75=YQ2N+T36,OM*01N)6
M-T^=)GIHAS.I>5[>QEN=9M[<)R4)DHM%?.>45]W_`$AAU]=X&_OU'VA_^3O,
M#_Q*ZM_W48&O:FL;V[L>LH'/I'17G=4C[,8JRR-VK&?67TG^]H&N=D12Q1%I
M5J.UX]L07YG&;\*D*56H)":'>@C%]/K@?-=63[=3@F9&O5$^>%=#BUB3"$-Q
M$PLCI8)DQ9HRX!1MEB1S;/73F6.'S%.+\ENVHV2L^+ZZ.)*'K8<#Z8;&]NWB
MQ+"A"VBO.Z/LT*;8.X,EB.ME])BA]BCER9^-=$$1$AKQ6[@70=0R@)=`+DR3
M>A+4XB?E+']^@.]C>W;;9T%K])17G<\L4NB-B2=YL]OLOI,,(@2R#N->M[/%
M90-97B9['(K$U.%)[.6B2*BQ$,#@,\1.BR_D!/K&]NX:H@)+-17G=8`)E83-
M"G@^*67TGHJOV5T;7I>KL26;>:\;!?M%E.:2DRG\/2E;LY:3\9`P_?L(+6L;
MV[KJO91-8[17G=;#U'T)2M!7<#LOI/4NE!HUB9*-"Q_N&O&1F_*))/$>+1ZH
MD.RRA?3>Q?0.PRJ0RKV<CK`^2`^#>9"LAB9W-Y.2I+(ZK&J4E-B(]:8G3!'5
M0`"4'`(V$&M[UK8MZ^N]8&L><K\]A.D^>J(Z+B]:^;4=C5^TS5]U1V/R2R.H
M2Y$QL5IPACG+2SOP&^L5J`#TV('TLA5H@XXG1X!?8,8?H+89)7=C>W<W2RU2
M]45YW5UN.6%,X4UIYA9?2>E$P98H[FM3=8C"6S5XZ;+B,R`3M4V?E_CK1IMA
M&807H0?J'S'K)]NGNP[&A"RB?/"/,T&1PA2S6([V1TL&(6,=+$#LM=44-VDK
MI2\#40@QN*(<]K$J4'S+"M$"-UHS8`^EEC>W:6UH]71=%>=RN.O=>S&:J[83
MV7TGN!Q]ZBTD@K$W5V[Z'7@)$&73!#,%3DV_$B,1"1L2[Y3RS=$EFA\SNR?;
MJ'NU8-S51/GA.T]@6(5"'UVBMD=+"05@S&0N:2K=B3?]4KIO4!AY;I%4K(+:
M$"M9IR>T?^3\/S&E!]6G8WMW7D&=I='J*\[K5=6Q4P$$06"V7TG^Z'4AWD32
MRKUC?J05XS-8R8ZWN)KFJ")0$T:1&;HD)AVRRAAFCF^^TS>VN"\B`>93F<A0
MJUA+:ALGJG:UP-3)S#BT*/1U5E%;5*Q@T67]P@A^\6OKO6OZX&,UO._;:<UW
M`IL^TQYR5H^3&%Q:4O-<S*S.EQ2^`.L@8T+LXPF5"8:Y=V,4DBJM6-`NVB5J
MDFU1`_A.,+^T8@UKSKTIZ_\`2$5GLLC-7><4<10"_NAN?%Z:2V-T^6J<I%SG
M<LTI232!M_3ZS6E#CK^_PA0K;A#$`\2,TOY2RS/N`$,\C%C>W;_.+,B:^BO.
MZ,-,"715(PSE[LOI/]L6:5(8RD?W%="M(*\6.WXL47*1-B[:],C%^:4/X=&%
M?0S8?)ED^W1=LHZWU1/G@9'E==N<W';(+(Z6W`$CRWR5I82Z[4C_`+=?KP)@
MXHG,;D1K2/:,2)*;]3M&!T#8?4XL;V[B;S5[4T45YW3HBPK"%"GQWC-E])A;
M:O900.=3,RQ)R:\5XV&%Q$+A#D['K\(*I:8[/:$L!`@#,&6'S:MD^W5=09SE
MT?HGSPM9V0.$90IH+`[(Z6%*'0N02EECJM<BT_5TSM04<;1.ICHN$:H+V%`C
M.V#0QZ"`095))-[5L4=?WM!6?FE)5S.RNCJBCC-9?46GB0*V]">K3LC5M?6"
M-#IR=3B=$$?,<45\I@?O&$/U%H/PPB9>V$MA<0E3K4OFY!W231=@D#E"I/97
M3W[DAZ]Y:4CBLBTA_2JS<&S]<CZA2)(K_&4'D?D$C^,P8/H+8>'5MD^W5AQ'
M<E?Z)\\*L<@RRQ(T*(3JR.E@R#\*#6'*80TRH/Z%73NVCC]A-,=(D#,,)^S1
ML[HE$<`H[9A0`D)Q#T5T1<$QZZJ7IN%T_%++Y9NB#5B>OHYZG#Y`9:U3WGNH
M;Y;7IO66`SL+_P#D(4UJ!;E`=I@%Z4(C/MV+6ONV$_\``8#`8#`\L#&RENYT
M@+9VLM^4(]-Q[V!O2!=SV\(RC=(3G().EAB/1A`!:*$/8/N`'?T^NM8%5S5Z
MJ,+IURGH#5$RY/2SEU=+.$6;J$<TB)C$OZZA-)+[W?:[.K<K8I*BB.XZSKFA
M*_"5",/D:(U)M``D.U>@MEP&`P&`P&`P*X.Q^_Y3QW8M1Q=WX\O"TJ^N>T*@
MI*(7)`)WSBECRBWKFE"N,QZ!EP*8W+&KD<G!K+2"<5ZI)'3VY,V!-4B4:*3*
M1$A8_@,!@,!@,!@0(J#OZ!VCT+W-1#[7E@4RDX08ZMDT^LFWPL$7BTRBED@N
M<[<\BB8MW7.*"NV=)2C@I+=772']11'`5DDZ2;*/.#\OG9Z!P_T5K2W+.A=6
M634;;5-]/U(FL%JI6YLE3V6@KFKK7CTR,8T2E0KC2630JVVL_P#3'#1+FWG_
M`"D*B@&@WK`L!P&`P&`P&!75<O?ZVBNQN?.79WS);J6#]+SY94M6]'HI'4SI
M#'VR4-8++66-Y%=-4[<+?31%K9VQ4A7/BYF0ITKDE-U\8T?QK#`SCA_MMB[>
M9>A7IDJ2TJ9-Y[Z6E?-CY%[A0LS/-G!YBU=598PI(LCK,Z//[82NC7:B4!;>
ML/\`U%-LD6E12<[8TY03=P&`P&`P&!75V]W^MX?D52*)7S);MATS8=C5!5TF
MO.$R.I@,4%F%W6$96T+8$E?/,[0VS/WI*];3JG(EI9!D)VY:282>I.T>G(#6
MM(>L-<WGW%,>*F"H+`:G.+3#HVO@3M?(:]6JBY3RZN@S?8+C,JK9Y*OL>MZW
ME1\Z3;ATD=TA2*2E[*&4`K2M-\@6OX#`8#`8#`@EZ$=M&\$42YWVJI=^N&,1
MI+)'N8DL]G4Y60F&-Q&+NLM=S&XRV)K%UDYF3BULZC3/'&!*YNKJ:0:```;"
M#Y`U77'IS'[8[(WR%"^?;.$M;8K6DNE]A2NP.>()^S6^TJ507<Q)E]+R^X6G
MH:1+FMF<R&YUTPQ5V);'(0@J#"R2S#@A:#@,!@,!@,"/O4/0L?Y>I:46X]L+
MU-'!`JCT6@5;Q;:7<QM>U)[(6R%UA5<-)6&%)S9-/IP^(6U.(>_B3Z/$H.V$
M@DT00JOD'M"^,_%/)W?+?Q98$CY^Z$1TX=/'%IN*LM2NKW6Z;9;:?CT1A<$5
MA3S2\9@ED#H2J,2H6]I),;S@&`/V(M6!*%Z6`P&`P&`P*JH_Y7PUBZMUT!_>
MZQ5M6H>K9OW0P\RF,<)(A#7UC8%)GT4_6.HFI++J>.3"3''=U<TC&)2600_.
M9BD1IA.OQA!:K@,!@,!@,!@1`MKDM#<_5W+G1TSG"Q3%N3FNV7FOJ9+8P;8W
M.Z;08D$(27#(WPYX,*7.%?5V:\MC&ATVA$D4/ZI9I5]^BRPA+_`8#`8#`8#`
MJ,=_+ESL:_>ZK#O*_4=B4GWY6\!I^VZ.CE6O58/K=6U/_P!R$M5LC%<L;N12
M^IW!N:+0<$KZK`V$_KH0E["6B#\A8PW1P'YYP[@$73P(?;EQVLGZ3Z`6WDJW
M<%A3NPG6*;.@T/A25C$_3N82]VE<@$3%MFN$D5F@=78G:-*IV(AL1Z`%A>`P
M&`P&`P*MY3Y_W'(O21H[]_U:)54?BT-8:P@'/\NH)EES75E:J"&I1;;56$Z,
ML1J_:<UNJ0(3%#Q*M,BA["WZ3-031MR71!H9OPUQ?;'),OZDDDYZ+CMV(>I;
MV?ND9(T-=&?VJ/CEJ2>(5Y`7L]K=`VM/]*HJ;%JQ;`$MXTX#25>SSMJ1A,"4
M6%B.`P&`P&`P*M^Q?/\`N/I[JOFGI"+=:):UC/+J%:[0&B9903+<->;N!Y6N
MB5WO)4!=8D,+66$C@ZPIE8#ER5P#%_\`K2YMV0M6F&A#`:)\ETE*]R.G9X[\
M62IP5V!TY8&VP56,K%:LO_U,J6@T^OKIOE+*5KU;524TE9$B:#1TUH;DC"0W
M(-`V/:,`AA<-@,!@,!@,"`'HCQ.]]Y4R=1X+'KB"Q!Z:YJUR<JQN<(;T.("J
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ME+`-NBI(S3&@I&>H.-$%_F`P&`P&`P&`P&`P&`P&`P**.X^:;[L3TJX<L.)]
MH6A4RDK^^']E8%$(VWCJ*&_LBJV!]E7]Y(,H?2U/0/\`=5Y/5(G;Y'&.?@QS
M\5(T_I[D0<]*PO7P&`P&`P&`P*=O57EZQ^A%O-J])U?<U$P*+]#<_HXO%*&*
M8(E)@W"_6>6V)+;ET[?DTK!,6V$L:LG3%%#&I,RA<?R53K^K!,1IF\+7X,VR
MYGAL6:9[*&V;S5M86M#*IBSQG]EMDH?DJ,HAS?T<2_6Y(&.$NJH`C](PKU0"
M-C^P)FPZU@95@,!@,!@,"HGV]JF?VMYZW\GC-ZSBEH?#ZXF4WGJ*KR"V>?67
M^W6PM?$8:79!BXQ1"(/J0%:5/R=$W&KWU.46BTL1I1+"U@6*4)7\^JJJHK7=
MD6Z[7K(8@E-8T]I29@2,$TE4=0'F$1E3/]MSBM:Y#/B&,!!3P\I26TAX7`,5
MA0I-F[)"&XL!@,!@,!@:'Z3J.87O44DJ6'W)+*&W-_QF256)7S8UJ[&1P569
MLN7,U?/+UL]MA$LD;2(:(A_$C<%#26<8>E)"LTG4IPB#Y"51/*BX"YD9I1=\
MPNJ+2.AZ3GE>[LAO1JI]7+3-ZOC$F>JZ73Y$J(W/H?'Y"YG@C8UK<0Z-+/LI
M`H5N`2"3@!9M@,!@,!@,#`;2CTXEM=S&,5M8`:IG3^PKFF-63^U6Z;GP=Q7%
M_CADJ"*O"U"S/+LU$C&:C+6B-1!5A+&H(4DA&G-"LWR0YOG/.]5VJV&]+V]>
M-9.W2/7C6SQF^5"*<SR(S"O>O+PK9TDK):R83*Y*6&Q&6(I'1W95[>L"7)CU
MJ]$J2$K#4.!;A@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#4\OIJ(S:T:?MUX
M,>`RND?[@?LTM$M((:3?[DQU-&)#^M(S$9QR[[&U(':;XS2?B-^HA??K_#@;
M8P&`P&`P&`P->V+6<<L]'%$,D&Y%DPZPH19C3ML4E)1BD<`?4TA8@+!&IE.C
MFT:]*'1Y0=`&87]=:&'?]<#86`P&`P&`P&!J>]:;B/0U.V/1\],>"89:43=8
M;)38^M(;GLMH>"-IU8FQ<I1N"=*LT7O_``#&0:$._P#:'>!MC`8#`8#`8#`8
M&O:DK2.TO5-94[#QN1L2J>O876D7,>5)2UW,CL$C;;%F0;JL(3(R%;D-L:BM
MGF@)*`8;]PM`#K?VZ#86`P&`P&`P&!KVLJTCM3QMRBT7&Y&-CK85MV6I$ZJ2
ME:K4BNBUII<4P`4:2F2@`VE2V=K@HRMAV,A'HHL0S!!V8(-A8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8'-'6GHGTT_\`J]=G,M^]
M0PGE7<$OJ11CG#AR?\L#`1VMS6W1,@48LVI^L9!-(^E.MJ;OJDPY,U)33DR<
MU,%-^"IV-2%&'ZN:_?&:NO-=K=!]><:VI6C-$>Y_](</<H"&NCV1[72J\'^K
M6"..*-RNR2/`;`J)$@2@FBH.R6=>N-V8S_>2+XR@F=T+[/4#SM/>HJI>JJNV
M;VASG?O(/,$;@<!:8<Y/O0=X=L5HFL^GH34@':8,J72HEE$I"YF/!C:`G:(W
M:?\`)WLL`P@?R;[+S=/U+TZQ=45WT-"*]L3T9YUXKI:#6/&:W9G3E"96OSHW
MR-IBMGBC#\M`JCL^LEI6A;W=(O?4Q^UR8XL\*4\K`N3YY[;B?5E1]+VM5$4E
M3)'*'NGH2AX_(YB2R#9;4>N?]_HK[9$%_07QT&NK5SF9"UO1&JQ(UJ@38>,1
M!8!%B$'.]SSZB^GT!XN\_P#TYZ'MV@.@N;>M;SA-*W10;%SV=3METLSV-9TL
MJEAL2NK39[.D;78C@S/\<*5*VQPC[>6>F4?C%B`+>UR<+C9+ZVQZ!]6P[EFR
M>2NE:Y5V[/K>JF@[(E:^@"H[;]B5'''&2[:D40:KK=;3@[#9J)J'^SW60L;8
MF?0*D9I>@%'F#3AZ'-OK_0'5+QP7'ZK@EI+GKNR`]$V,B;EB.+IU?/L>YE5;
MC-A;O-)N2;7M"I39P@19N`VDN.E#IL0A;+(`(W`MEP&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!0WTSPF"
M:=9\L65W=Z@1UPHFO.Z6*_\`C'F"=UK0-)31PZ5_<#TZTK34:OS3^U3*W66(
M+W<E*T19&S_K3X0F++7J%YH2#"`C/+/-7GASY2[,JYX]8*U;.;;K[Q.N:A)<
MH:N>RFWDKLS70*VQ7VOEUCJYSI'<<N6V/\+$=%W$]E<R"R3498"U)PA!#'+)
M\NZ+<Y'>I=S^P<%4]\6%V[YU7-'K@EK)SG&)94?>=(UE*&WF*)D\[IYPRL;V
MNMNLW=2*)P)6%.Z.3(C`:4<[;`<K-#".P^(JYJG@GU]0O7;<;Z]ZTORV.=9P
MZ.*^5<\41-*G[>CS16B*AXX6$N<L$3K-8]R=`WN+&RKS&]W#%A@0E&NIXMK5
M874^:E+4_47EWSI1M;VG`;!@,8H5?%);;M=S>+SR"O\`8ZL<@WT%+&N:QYT=
M(TYA!<RV1FJQA5G:3JP'%'F;-+,W@5'\U^6W/U:<\<,H+\]@HOT?YT\[7/$)
MMR?`&M)S=3E`VE>R:>2M?7B&57,RRB8.5]?CV$ZN.FR-D/0`*G0G9(@'_#LC
M0873WFKP!$N]JNES3ZK<L3.UZD[_`+AO:%4LB1\Q:ZHF5HV$*1+)U1-VVPAL
MQ==5P2R%.3@3II(,;V]2SH"#DZEM5#&E4(0V3XV<ZT;!O4KU@O&)656*_<YL
M*8Q/E>IV*\ZBL&5L5'DVJIE_5<\C\#@$SDKS$JND'5[VG0%`4I6\;<N;M)%9
A05(@`"'41@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@?__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g575431g35e13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g575431g35e13.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`Y@&D`P$1``(1`0,1`?_$`+4``0`"`P$!`0$!`0``
M```````("08'"@4$`@,!"P$!`0$!`0$```````````````(!`P8'$```!@,`
M`0$$!P,&!@X'"0$"`P0%!@<``0@)$1(3%!4AU187EQ@9.5D*,2(C5[AY))34
M5E@:03(EM>7&UC=W2'B(F&E1LS5U)I:V83-#T[3$-J>W.!$!``(!`P,!"`,`
M`P````````$"$5$2`R$Q08%A<5(30P0%!J$B,G(C!__:``P#`0`"$0,1`#\`
M[^,!@1?[2<+E9>5[UD5!6/'ZFM.*UO*);'I[(Z^(L](R%19J4O[OM!$5TBCC
M0ID"QH;SB&Y2O$N;T2TPM0I0+R2QI#@YUK<\A?>,DYDYND4!Z2^YV<P[^'I>
MO+O;$\1U+2\H<>E+SB$"J55JMG=AF4#=XG$*S<WMY<5<@U%D;$YIC7IO*0*$
MY/H6`/:B/DP[@G]W5U>0;&##ZD<?)KQOX]WGB8%95BI0K8=T%R+7UP3^XGZ<
MNK2=;[=+4$WL<Q>P;02HIF+9V79"EO6"]Z<>%O,8[VN=_G)U4/G#5EUI<26%
MD62JJ.<W%2;_`#0FN5LA6Q1KG>U-%R6ZX0&.NLC;%2(D)CR4X:/2F>\2EE[*
M,-NM:S&9G"9F8GI&6"WSWKW%5\FI=EK;Q961=338D[2QJPY&U7/N/I*=BARY
MH3*9XZID],2H4B1HDZ\\X2(H:50/27>@;%H6Q%IK6,8G)$S/>$D_S)=%_P"A
MG+/Q#2_\BLW93XOX9NMHCASCWCW%;S=82NUO%M8E!*XG8+M%8JWO%T"DPY_$
MD)"8UML1":II:'::FU\,.,`4B&$Y63LD6SO=^T7H616L]YPV9F.T/Y=&][=Q
MU`"LQU9XL+)OS[8SQ!&9D!BN?4='7$44:#M?/EH2*:E?SM$U^UZ"1`^&4G;W
MKW6Q^@_836L=IR1,SWA)3\R71?\`H9RS\0TO_(K-V4^+^&;K:(VT)WGW':4B
MNAILKQ96-2;37<_61>O7]VNC4@(N&*$+GA,DL!J2GTS%A1YO<4S<0<!$88K4
ME:5:T;L'H'9F16LYS.&S,QVA^NGN\^X:6A##(Z?\6=D=&R5UF;5'G&&L5SAB
MJACCJU$YJ7&9*7,FFYEHY&SGHR"AIM)P&G;4ZV6+8@^P):M8CI.2)F>\82.+
MZ4Z,&``]\92P.Q`"+8?O"(U[.Q:UO>O0<'+']'K_`+(0[_\`3K7\F;LI\7\,
MW6T1OI_O3N*P;2O&%3CQ:6-54*K9];VRM;)=+F$[I+J;%*AX)7/K4S&4LQ%1
MA.V!0)]B*,7K3#MJ];+]HL&S!9%:S,Q,]&S,XZ0]#IKNCMNF:M5S:G_%]8G1
MDU(>F=M35BQ7.3$W)>@<#C`.#H2]:J*6)DX&@D'O1A/3E%F!]0Z-T9LL!BU:
MQ&8G,D3,SUAD-H]V="5G6Y\N4\02)?+ES$J%"X$?:XF<Z:SOY&I<V6`('535
MAZM`O?7`C2,HXYN]LL0]"&1K>MEY7RXF,Q.9B&;YCO#4=X>0SR%UIR=S+>]=
M>'JU+DNJY#'TNY.8&SHF+,,FYN^7_$"8AOTM*JZ2[FA<G((]X7LEG;O@M""6
MJ]R>()(N2V#\4^3/R4]'=&PBHNA/"7<''M2R-'+5,GZ%E/24?GK#!C6*)/;Z
MQ$KHE]S$#6._VKD#<E9RM)EWOB#EX#Q%C)*-V$/EY&\QEOWOY.+3\:5^\!2[
MDZ6PRK;"N.#3R0W@S6(98U?1"QVZ"1R2?8]JK6-(F%IG2)4<O3'IWQW`4)/L
MG7O@#TIT%[F`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&!JF[:/J?H^L9-3-WPEIL6L)B%K!)H<]B6@;'@#*]-TA;`J1MRI$L"%*\-*
M<[6@&AT+9?LB]H&Q!V$2%OB<\<;E`JVK!QY"J%?`JB.D`J[C2UJ<5:*.(98N
M:G.41T!A[F8K<X;(E[$B,7,:TQ2SJA)"?>)A:*!K0;@5<,\AK.B&_K%1SY6H
M^B&L2!0BM$+&$I[`Z-46-@S/(CD9)I;(LES+"#QLR)Y.2F.J-I%M&2H+3_T>
M!&UN_;0S'^[`K7^U;:^!9_@,!@,!@,!@,!@,"H[RN4'(KT'P^*/7-/*<^[CL
MJLYXZC@:U<B'8+6V;/VHKN6Z1.S3\?"'_P!-;7I3-FEG[*+]0;]G+I7=GKCH
MFTXQ[UN.0HP*9`55Q?OSRG6]^8:2"[MUX[-1?\L(XXX@B8*+^^$HS[V29K]E
M0,9KYM\W\OVR?.!N'N=B6?#^XU[00N;P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&!6`W?MH9C_=@5K_:MM?`L_P`!@,!@,!@,
M!@,!@5*>5?IJ&<W#X@#,H]-7\-N]F5E5L>W"VA(\":Y$^`6#0.,D`J<FWY;%
MR0E#^*6@V>)/_-_HA:%O8;I:*YSHFT9Q[UM>0HP.:4,-EX_XKLR9`BLD%$"?
M$2!(=*PL;F*-E*C+S^&+3&/NDNVL"@:C7N]`V;H6Q_S=:]?HP.EK`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`HQZOH.6=-=/7]$)=YH.
M@^9JVJNMXQ99G)W'>ZYH.XJPK)7!B"'ZSI?<[@Q3JS;`8Y+*8\\K4RQ$WID+
M3KV4)>_BB1&#"$_C>AMF3NX8I^5_R9>89@9(RW5M=<GISRYT_&[G:>F>:)-+
M@:='ZHIT_-$)E47;Y$A+&D2NR=>!T:C5B80D0R/4O0=4V`P&!6`W?MH9C_=@
M5K_:MM?`L_P&`P&`P&`P&`P&!7'Y)X"5:59UW6XY#((<*PK%+@.IG$%@6R81
M(J91]W839#%'799FVV0,VU85:,[TWHM406/>M^SK.O%Y]SG?Q[U3O^K0?^<?
MY?O_`!/?\!YR=#_5H/\`SC_+]_XGO^`\"H3]+&SOUM?TQ?U6/*%]TOY'/S1_
M;_\`,W(/O%^U_P!X/V0^SWM^Q]FOLW\%_2^GP'Q7O?\`\7V?HP+>_P#5H/\`
MSC_+]_XGO^`\"JSS/^)BR?&=X_K1Z^J7RP>4J<SF`2BK69KCL_Z=?OLRI*G%
MAQZ(KU"O[-%,3QI0B1NXS2-EJ0:T<`/M:$'UUL.YNM%JQSKB`.3@I.6+W"$Q
M5:N6*#!&J%2Q6Q(#U*D\T6]B,./.,$(0M_3L6][P,VP&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&!RP>=*U+`.Z/J>KHY2T=9Y+"(+`Y]0'04?
MB/4)W6LZL:PYY-(C.:>Y&LJC*:M.H6!<Q1F*(1RF.6;M9&GU/($AKFSC;$VU
MN@GKXM^0#^(+$MFG97QO3<"FRV)M*]L[=YS8`,%7=(0*//AB%JB\FKUV=7%]
MYMLR/FO9:Q5"FD:J%JQ#4+68\!1(D:4+JL#6-FW935*(F=RN6VZQJ1ND3EMF
MCZ^S9[%8$B?'?16S]M3.JE3JU$.;EHC6Q^X($,WV->OL^F!_8^XZA2V,UT\I
MM2MT]N/C.9(62K3YQ&";&>&`E.K5&OC7"#'0,F<&<I*@/,$I)2C)"628+8O0
M`MZ"!#=^VAF/]V!6O]JVU\"S_`8#`8#`8#`8#`8$(NTO^KK_`-H2$?\`[K.O
M%Y]SG?Q[TW<Y.A@4NET#S.+SV*>C1=4M>^K"_':37P..OLT$IW#5H[>VL%=?
MVV,==DJT>W'_`'.^2EHM*BQ?X8(_9'\S`NBP.<'^+`_8E=&_]('._P#_`+?"
M,"_ZIO\`FKK3_H_AO_TXVX&P,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@5.=0>//J*QKFFE^<D>4_J?CJ93Y.R@?:\7Q:L^G.:V];'8BRP]N
M=(;1%O-A;;"5C@E8B5+KIN<B2G):,U1L!9YIAH@UY4?C,[;/L*NY[V;YE>J^
MEDE:3"-S=MK>FZMJ#B.LY@ZQ20I9`U,]I,M+)G5_GD+5#0EE.#2:Z$$N!?M`
M-%LD>R<"Z;`Y@OXA+GB^;PFE#N=/5U<BHF/<N=U00ZQ*GY\5=8%RN0W/%*SB
M[5R_*:P2D+#*=9[E+;!*!6D`!2B.;:M%DGIQ&"/*"+,!XZZ2#T]5T4?N-[*A
M%V*O*#PUV$DZ#31(B6U?5O%E-<.5I`9M1&NC5:AU2I554OT8>(*F9E#B8[R0
MU66JTC-3FF*-A;)S14]KU'Y?+/9;;ZCM#JIX<_'!7#JTR^U(-0L$>HVT;Z>L
MM(",(4'/U35#&5[>!4G,5?$+$!ZW9J@8??>Z"66`+O\``8#`8#`8#`8#`8&A
MK^HX%Y,,9:@2URA;A%)6CEC6]-B(I>H*6HDBQ.3H!0U2(11I1JD)I9H3=;`(
MO^3?KZZNEMJ;5W-.?E:N+_3!MC_%3_\`E1F[Z_##-LZR?E:N+_3!MC_%3_\`
ME1C?7X8-LZRA+^39/^?K[5?>6[??U^7WY3^8CY"3]YOV`^TOOONX^;_-_C_L
MO\R_PKW/Q7N_??3['K].7FNS=MCNG$[MN9?)V]S1T[U7855\M5+Y".A./W:M
MZ[W/G6W:=T,,@LE0J5&LKDVSEI226-#<TW]&G.1"^/\`\#&6;O83A'B$&)B)
MIO\`.51,Q;;['.EYSO%/VOR[XR>@+AMCR^]>]HP)C<JA0OE&VE&QBA+B%WN2
M!HT4E=E:ZP)N8V"B[@,I22>G3ISO?:"6(_1)AI1W-:N9O\BE$?+T/I_$C^7.
M.:^#3>D>;N;I&:WL.O<@]&9"8W7LSMYB-KU_0%"(2)2=@!K8"2@^@`A.>X?-
MWQE97(?-G.,8\V/DOK&T*1=)2OL3I^.<RC!9'0J9\7.ZA@;IZ!KG\>=4B>#H
M'(M$B]AW4_%DIPFN&EBS1:DH,1XH\R_'_+O1D+NBWO.=Y/>N*_C"&6)'N@K3
MYO?2(+-3)#%'A@:SWI2XVY,!IA1=W<B'9,).F+/$K0E`V:$H1H!ANWQB?Q0O
M.5+2_O`CN'I7IBXH=-.LYO+.1G1^KU7+'5GY^6.;V"-MZAO;34">$>^:](#-
MLI(=)41GMA)`#7M>H6Q_ZWEX;?\`/3H#\"7SZTP'^MY>&W_/3H#\"7SZTP'^
MMY>&W_/3H#\"7SZTP'^MY>&W_/3H#\"7SZTP'^MY>&W_`#TZ`_`E\^M,!_K>
M7AM_STZ`_`E\^M,!_K>7AM_STZ`_`E\^M,#V(]_%K^'B2O[''$,XO@I=('AL
M9$9JNC)`6E*5.JTA`G,4C)7GG`3@./UL>P`&+0=;]`[W]&!TS8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8'/OY>::0UF>1U$O[5\S$??+?LFIJ"JODOQ\WA5D98Y-
M9TH;3&=B;85$)[5[@C8SG=%'%KL\+5[[HC9I9PP:]L99.PTSX)+^:+8MJUFP
MBQO+]*#WF@X1:\6;?)O=E#V+$GFOWZQY="T<VI5CJYD9'P:S[40ER;G-<9HY
M*F"262;[HP]/[T.F[`8#`K`;OVT,Q_NP*U_M6VO@6?X#`8#`8#`8#`8#`8#`
M8$(O^O\`_P#=[_XS9U^CZN?U/1LT4'CFNJ@3[[=M6I0*GQ,OW<[)*^=;:]2+
MV]2@*CX[1GRW9W]![&TWK[S6]Z'O7KK4YGY>,=,JQ&[/G"2&0HP&`P*9O%9*
M.#Y#>_E?2\:P"UH;/&'OFPVKK]VL52$V/33HM,I=4DW?JL3:ETC.1PDZ5)'8
MS6CDS8:8J/,&`GX;:<)87,X#`8#`8#`8',%_%E_LXZ0_[?\`S1_O79N!T^X#
M`8#`8#`8#`8#`8#`8#`8#`8#`8%=WDP@-J3&CJ^E%+\YPWJ&QJ+Z%J3H2.UK
M+;[5\TJ2EU2+G20I9%$+:"VNC(SR9"MT4F&E>BML;@TK%R=;HPDS91@5!>"*
M?^/B==3]@IJ+J;HRGNO(=%V]LM*K;DO*&=$531U8RBQ7V=**GY:GM9SB8PEI
MJS=FR%0X*FKT2JB7`6MZ+"`(O4.H[`8#`K`;OVT,Q_NP*U_M6VO@6?X#`8#`
M8#`8#`8#`8#`8$(O^O\`_P#=[_XS9U^CZN?U/1_N];UW]KUUO7KSUZZ]=?RZ
M^TV]>NO_`$Z]=;UCZ/J?4]$W,Y.A@,!@<Q_C[HSO7@N4>?BWBN.7:T)1<G<M
ME]*<@PDNUJZC"7I*/S^=V0YH4;:^C<W@<("QL3HWK50G=*G-.VJVF(+$>4/T
M#\MWE(\_FW!#IQ_A\5!S?M8FTN*2=L54A5&H]G`^)+3+5;2I2HU`R?:T`TTL
MPLL6]"$$6M;UL)G]\]N>52@;P30#C3Q-J.Q*F^Q;&^'W09TK`*V(4R=R5.93
MK%DT/=41[LB^SY2(G8SSS/52)1Z@`$`0B,#T.4NU_*3:E/=4S'HWQ-+*"LZH
MJ_+E'.U9D=0UQ)@].30QFEJL=;$OI#7M/6:A.Z,C:1MW7!5)!A>-;T5H286C
M0@P3Y2?X@,)I6S_X?(PPC1@-G%D]IU@0:85H6MF`*.&U*`$F"!ZZ"+98]!W]
M.P[_`)-A-WNSMSRGT5.JUC?'_B77=8Q21U*P36P)PIZ;K>!$P:R7AU>T;Q4)
M;*J2*E#LJA[>U)51[R4>)"X?,P`3@#\,8,T/UQMVYY3+A9>B%O4OB6<.;W6M
M:C=YQ234CZ=K>7??S9#<D<CFVFB5!*$`(4X252F(+*>UGO&Y'[S>SPZ_F^T$
M'@>4G^(&T,.S/X?00@:$'8P@[1K$`Q`]=>T$(Q-IF@"WK^3>PBUK?^QO^3`A
M;_%=WIU0NXOXUBZOCM<PP&96M0-P6182FW(B[`J[HA.V2K37RX8Q-Z,I?)%P
M].*W9LH)]TU&Z2ZT47Z[%[(7H^._LCR;=%VC-8AV]XNCN):]9X";)(I:@>BX
M-:B>03(B0L;877YL184)3P4<Z,CHK<2W+1FDR4+4,DT(AJB=@"WW`I^\A_?W
M>G)EK0V#<J^)>TN^8/(:]32M^M:%7NPU<SQ65G221-"BO3F%15UBNBUR0-#2
MC<C%9@DB<93F665HP91VP!G_`"=VMUW>]87?,;@\=EE\\V#6M<-\O@]0O\V,
M7++/FBR+/ST.JF"=R>!U_'E+N6\M29N$[$$&MA)R\.S=@T7ZF>;_``WYG\G^
M1_)_??9?>_8\OVOVOVO+%>+EMG;SUS:-U<UB,8B+?UFT1%HB<3#[E_Z;_P"8
M_H?Z7^A?J7[5^K_MOX_\]^P?GOL+<_W_`-AP12.7\3RQ3AM\CGV\W)>+1;DO
MQ3'-Q\-K6X;<G'6_':)B)?*'E,\GMY]"5G4]W>"J[.8ZMF;PK;I??#YTS&YF
MS5N@3L[DXEO;I&E%*033JC,5HBTXBRW,E1O9VO<@.-]@DSTCX:KG4>6/M6C^
M@/(Q7TNL159)-Z7[TURCXO(\Y0B*"*KGKRH[@JNI856*95'(II9)F%^C_3\<
MDYJ5_+<-C105U&!0#1BKVP^KG'M7NN]JSX=YUF/4E[)99*:=\FMS6;;]"0'F
M1NZMZ]D?(7<DIYZK/GVCQ7K'/R^0:5%0LQ._NHAI?B5;:TA(,4I@'GJS0]N"
M]>]&=22APD]/>1WJ.A*JJ#Q$)NNHO++LJ[C-$ZR2V&+K+L.HW]\ZSB354T[A
M#FSI8Y3K<VKRH>Z,0#B4&ER<PA6>9ZAA-/\`E"[OO*14]TX]6C)ZS`@ZV\//
M+[]Q,Q1.J]0"<1#O'GNF[,NVP9(.3P\^T29,^.-PJG"$G)Y@V(F=O92@KTIO
M^%&""3=P=I=P\ZUGYU2GGHU+8MA\OW;Q37M&6(LJZ#1&+THS=85]SHID[^R0
M4E-($:IAJ8R[%CFF+?E<@4*"V@`UIJP9AVC`WM7G7/2%&\I><@N36G..A7[Q
MK/%Y)Z!NJT&*NQS>4`9..(3T$TQZPA51$8)%'UP@4\E1I:I65'6TLMI/(`9[
MS9!NRPTS*['ZGY+F_&MG7=?G;,CX@05CXTJ823VCK%Y1LEFG'1-BR-\C]N2#
MK%#>D8FO3]CQ&UGB2PLLU?"5A#L6W+UYR783`I1D!NKRI]2WNEN<FF>>>H'S
MG*-5MX^/(%VB^SVLD=/2AWL&Y>4E-9,,0IA\467`;,:FZ+Q-?*7!QE;8F);'
M)6F#HGXU*,GZ0VO:WDDZ1@E%>,)=7E"UO8/0/D`J-=*G1BLRQGJI(374GA_(
M2WJ&;F.*J*PVV7%2G2I(\YI2D"<)GO#P%$Z5A"/:@`0Z8?/A>_W:P*>3OD*K
M8L=T-3W'5X<]I&*]K*L`A'"^J;A=J75)[<;(CSBX6";)H:XL![V6W0UADRA<
MW*B2/0HTI6<2$@'3I[I#L<CQ:4C*88]<MVKTC<LLZOZ#@D4D,_;I+$^1.,)1
MJ2MS>^ADL9J^QX^T]$6HX5XV&DN3<VFFLKRM2'IQ[^))*"N;QU^=2[EGCVJQ
MWE4$+MFQ8'*.3>9))/[ML*S#+3L"V+_B4VM-TMZ1UY7E0VO;3Q4#=!F=*A8'
M-I:WERECLF<S2R2&]L-6#"S'EWJKI>QN[.-7J[HI+J5WV=XTKGL"<<KN,FG"
MZ)U!/>?^B8(IKV9-L=G3##W1@G4TK"^CTDE`H86ES&)(W)U>A?+2@!"^#`YX
M_-R7.9?5,X@71D!X>4<=J+.YDU3KMU-UG<?+45L*SUJ&W%=CQ>WYG6(P:1,+
M#IL:3V="L-0M*_0E!RL\8TY)80D#XC:YNJMHJ_MSMR1XT.;N?'>-M#E7$A\>
MM@.,\26(_E+3$ZI9+W8<!BR!_3DMF]B+<Q+G%6<?L6AB^G8L"YO`8#`K`;OV
MT,Q_NP*U_M6VO@6?X#`8#`8#`8#`8#`8#`8$(O\`K_\`_=[_`.,V=?H^KG]3
MT;+W:#Q^:L-2Z:F'Y'JH12K;QM&=N2;7[?\`2?X,+C\3HD+1[K7M;(]SO>S?
MY_M?[&3M_P"O=[59_MM]B260HP&`P&`P&`P&`P&`P*@_-KXY[,\G?&K70%.V
M1#:MLF)WC6EU1:1S]$[+8D>N@9<B1&-;M\C;W9R3A.2R0P\H8$B@(CDX"Q@T
M`8AA"@'R57=_$N^+;F1=UE</?G&UF0ICG4*AJJ)0'GZ/;?ERR7KSTR,8MO=,
M1=*%M+$E%I1L"TH_0!?T>_:^G0=O6`P&`P(]?E+YC^>M,G%0M4F2)ANF0]',
MKT;"F,YQ:K[EC9\GDMOMZHU(,U+8+VV>A*AT!O2HP`0^H_4(=Z#")WP%Q':%
M4QNC+'Y1H.<T_#I9*)W$:ZE58Q5\BL6F<V?W^53&41UK<&T\EE?)1(I4Y+'!
M0F]V8K/7'"-V+W@O4,(?_%KXW96;6)LGX5Y4D/W,1-K@E6$/5'5\Y(H-#&:0
M/DM;8NPMZQB.0I6--*I,Y.?PVRQ%C<'!2H'H1IYHQAMUVXUY.?+SC/33OSE3
M3AT%#4+>W1>X%-?1H<]94S.V+&1DVCD'R_2T*I@9'%2B;E`A"/;T:@TE.,HH
MP81!K:'^-'Q\0!RM-WAO&'-D><KPB<E@EPJF^HH8`5F0J9.Z%_E<4FH#&HPJ
M0Q^1/;8F5K$BD)A)ZA.68,.Q`#O0;(B_'/,<"Y\G/+%=4M`ZXH:R8_/HW-:\
M@;$BC#1(4=H-"QBG:UTVVE%*'!\DC8N&4I7J!FJS`Z!H1F]`!K0:?K7QJ<A0
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M:Y.R9C<FXPE(\@3JR1`$6(!@9UQEXP:8XGD%<2*"S>RINKJ7FEUYAK\J>GQ$
MQ/'(9,;RD?05DN#:1&(K'$[8=,YPYM28MM1`2LC,QQIK0($9!2?>Q!93@51>
M8NW)15_+4*CL-C?)4FD?0G2-*<RM*?MZ$3NP^=&]SN=W<8^TNDSB\#C4D/5"
M)=RTY1!KI\"R)Q';,5J@!"$LT-&>(GPUKO&E.;ZN24WNPSV>]%H8^GDM64I3
M4=YXYBKL3&I$J*W7]6L#H]:.=@:WI-\U-,2&G)=;T-/H0MBT%Z&!7=V]Y#X9
MQK,*4JH$)#9=O7REL)\B$776K4]*Q)DAU7%1<N62N<V7;TICD;CB52^3AG:&
M=,`*I6[NK@$DHO0"E!I0:9>O+I`F3J!%0ZJB+0W6R;I>K.*YGT>7(:U40:'=
M9W!4:.X8K4QD60RM;,GYO0-+P@:W5^1$&-K>\J]%;V,@.U.P\FG+LIJ\?,38
M4@I2VZQN!@:/&E6S,ZO=6SV*V`T-COKJ.T%NVIP<HFZNR)$Y:1*BCO<&#";[
MHP`_9]D6M["XW`8#`8#`8#`8#`8#`8#`KUFD\A]==SA?YN_H(VS#H<AO"XN(
MQ@3B6J9$<:0FULLLP7O#2TX]Z^C^0.\[1$SQ8COESF8CDZZ/NW9M`?F,U>&K
MWA7R_P"[/[#;8=@7[6;7?.=N'QVEGNM$:2_#^FO9]G8_;_\`L^G,Q;9MQ/<S
M7=NRE;![IJJRG%6T02<L,F=$*+;DJ0-J@8E1*`)Y*8:O9)I10Q)RU"DL`A!]
M=!$8'6_3VM>L36T=X7$Q/9L_):8#`8#`8#`8#`8#`8',#_%Y?L;9I_V@*)_W
M\=,#I^P&`P&`P&`P&`P&`P&`P&`P&`P&!5MY@.?)'T]QZJJ2.<:L/=PG:RH4
MYN]!R?I^8<F,:UH9RWI6*4K[)A3['7-V#'G+2;8&4Y3I,J-.">((AI2]8%8G
MA(KMFYY[.Z<YVF?CRBOC_O9OYUJVU#&1!WK?/9+K9]4RVP)5'6U_:4MB268P
M2/L+%+8FK2+#TBPAW`L$46:GVF-+-$'4)@5%>3#Q;G]\RBN9]%K3KFLIG#*5
MZ/YV=QVQSZFZ+BSG673K1#V>5/D7CQ]F5>="+>@0HB!9&WXM6L(*-4'$JT2@
MDS^8&C*_\(P:UM2M$[!TJ)9R7`.G>>^TSJ)>Z>2K+,=.E.:^=X?0$-?B;O)L
M--'F^$R<4%:9(]M^H28Z&NR#19+F42<+18;WKJNJ^K?S*3]MKN"0V!-SEXSJ
MW<W%!"XPR19$X.0^I[33C<%J5C0H2%2X1!(`;-,"(S8`!UZ^FM8%N.`P&`P&
M`P&`P&`P&`P&!@\DK*MIDN+=)?7L'E3F2F`C*<9)$V%\7%(RS#32TI:MT0*E
M`$Q9IXQ!+T+0="&+>M>N]YL6F.TRR8B>Z#OW5UA^=_[)_=Q`OLK]Q?S?[-?8
M^/?9_P";?:'W'S/Y-\N^7?,?<_S/?>[]Y[/T>UZ9UW6^5G,YRC$;\>,,G[$@
M4%KSGF;O$`A<3@SLI5Q-`I=(?'&>,N*A"9*V<\:(]:RHT2DU(,X@`]EB%L&Q
M`#OT]=:S..9F_6<EXB*]$WV,8S&5G,,$(8QM;>,8QBV(8QB2$B$(0A;WL0A;
MWZ[WOZ=[SG/=<=GJ9C3`8#`8#`8#`8#`8',#_%Y?L;9I_P!H"B?]_'3`Z?L!
M@,!@1JA?8_+-B/G1$9A=\UL_O_)2Y4W]+-261I"EE)J$25^6*C+`+5[3_(D)
M">+.8A*C-_#>K<I#[SVB#=!#5[EY,.!V>AJVZ<<^JZB247<CL^L533XR0;VD
MLEZB[T[QV3-<'9P)A223+HX\,"TI>6C1FB1Z2F#.T`L.QX&+R'RS>-B)'UT5
M)^T:&8"+8@K99D#=G:9ID4==X"[RJ205#*E<G/+!'8\TBFT/=6@P;DJ1[3N;
M>H3&Z`<4,&@W$]]R\?QR]89S*]=&U0AOBPD;&NAM:CE:`U]>RI0VN+S%"23$
MXS6U,X2UI:CU+2E//*5.A(0C2EG:,+V(/[L7;G(<F8+^ED>Z/I]YB/+#@L:>
MB)>WS=E4Q&HG-M:1/3HWS*4%J=L#>L:D!8_BR]*!B2GEC3FZ`>`980]^G>L>
M;N@:F?KUINYH-/JDBBJ3H99.&=V"!IB2^%H@.<J02L"\M&NC*YC:3BEIY*XE
M.:%">2I]G9!Q1@PPN#]W\F6`[\SQ5ENF*HK`[!KD%M<[U9)1K(Q:]AUV.$+[
M&^U9%;/B5%,&1I##&I2MV:XI$@?93F%ZWLT`B]![$&[7Y,LR^)ES#`.@:QEU
M_5\&0;E]6LDD2K).T&Q%:VMLP1[)!_@JYRAKD\)DSPE3&G*6E0<$I6`D?J'0
M';M?DQBZ+:N2'CH&L6_I-Z"CTW4\IDB4$P.5N4=5R]K9S4NO5,DD3K$D)KHD
M;#C2W!4W!TI*)&2((]A*'`8$,NFN_>7N/Y9&8C?LY<HBMDE>S"U3%K=#Y7,4
M$9@$*G-55DX2:6EPUH?G9E;7*PKICS0@'M*/2I6K'Z>A:=086$S<"'GY\N8_
M??!?;AT^:_G#_(;\C^Q,S^>?F<^`^?\`V'^5?(OC/E?V,_\`B+YW[/R7[._[
MH_%?"_TF!59Y:NQN$UJ_J/D_O2L/M%3G+?*E<]P`&#I*;T?,[?L^2RVT:]K>
MGJR8*O>89-9"8K4QTTE4XB?!H4R]U2%J&P8`!5@"/'@19JPICH2YJ8D?C5C_
M``-TS;G+%*]>L[BW='VST^_SGF2;S&4PR,1R:22Z9-*Y;6<PADM9-DN+&4>F
M*6'>AIR4@24KV@ZG<!@,"L!N_;0S'^[`K7^U;:^!9_@,!@,!@,!@,!@,!@,!
M@,"$7_7_`/\`N]_\9LZ_1]7/ZGHVWU"^0*.TQ)7.RXFIF\2+61\I='$BTUM/
M6*#GYO`A,`O3JD:A+I(KV$W>P#UL>@>QO6PBWDTS-OZ])5;&.O9O9O-3G($)
MR0O9*4U&F-3$["$&RDYA(!$E[``0@!V`O>M>FM[UKT^C>1/=3[,!@,!@,!@,
M!@,!@,#4]TT12W1T%4UA?U4U_<U=+71F>U4(LN*,TRC![O'EY+HRN1C,^I%J
M$2QM7$!&69['M:U[0?I"(0=AMC`I\\AWB._4!MF'VK^?CO/E?[)5VCK[[`<P
M71]W]=O7P<EDDC^V#I'OE2OWLT7?:3X)4M][OWZ%`C*]D/N/400$_P!6@_\`
M./\`+]_XGO\`@/`M+\</C:_3O;[<0_G&[#ZT^]A9"5?M=76K]Y)4!^Q9,I)]
MFOR/EJ'Y"9*/M1_NN/VC/C--R+7H'W'J,*,YYXD^[WCH&^I)`H6AB5==W=L]
M8TIV6YJI_`!+5_C7MFUZ-N*+V='$+;-`K#9,O:XC/X>0TF%J7I,GGQXSFY.5
M[P\(9+37CP[QY?BO(=GQ_GB:3&2UG6?E`YU?JQHZW>5HK?G-A75W=,PO^I>F
M.?7V]WMVYE6/B^K4"1G<4:E9\<B;GHL@U&HV6J2)P^N!4#Y;8Q)C[%OGBQ^Z
MXM#H/Q+)>.[5>'NZN.XK&HS<2CJCKN=IFV]$R&RXB0^1U!5-K1K;VN@[*]EJ
MS!J`)O?J0F;P,%IGQ,=QT@_U9RVOKM;9$*3]:>(7IQX[92V166HG$X?X_.>:
M7@ELUPOB\DE**Y-OB>:5$8WUZD0Q)Q;S&I[+.7KB-)50-!LJS>,.WKH8_-3`
MXQP9)J-C?64RY!N+FQ'(K>Y/20B=D\?-7,<6?J2<FNJKKEKE#%5Y):C=S4`U
MZ!`R@:58BG)<WJ3-%X$GTW+74<EXI\\D^D53RJDK-\A#;T3*J.H&0R&N9?8<
M>9R^+(Q1L0#,%]2RB=PALG5FR2**31(FQ\=_ER0Y'L1NEGOR@!C;HV6[;UO^
M"KJOE7B.56_0]1U"R6C8-SP.R>8HR%/!KSX_L6C(A`R4=KW-!+4E*JGS+#)>
MUH!-YJ;3>K/*1&'N/Q"70:LY[XM[LIB^Z'=%?+;T_MWC\L;S%]",5DFW+1R%
ML[C>.T9#,G[GVNXDM,F;Q,HA.I"&4`3R)QE[+%VID-:4XQ'*BC-;&'J+N(NV
M9IUH!&\\X/49@-C^7#E[RHO?1KA:]+/K'7]=U1RY!H?,.:)(U()JLLQWL&-6
M)%S(VS_*8THCZEJ<358'@!16_8#)_)MX[^O^E>DNEK=J=FN$TM#5OC?;N6GF
MONIG*F4K58$)[`DKCUP^M,>9+E@:9KES#S'(E993P[HRSS$JX],RGF+QC*P*
M2_(+"9=QYT0_\X6M,[/KSF(APZ.M6CJY(NQ!8=EG49,KLYP/C1/(\=L7L^C3
M'R]']SC,M;FUEV;84@3(ERD!L3*`O2JU`6Z]#<W7+Y&:H\N=STO7CLYS>6NU
M`<`<<QF2F-,0=RJCXXNN&V!>,H1+K#=XY&R4,KOM]E83-JE@=K282C+",9GL
M`&%0O;VKNYQ?:6YV[2DT_B;]&*WZ9F-NRMFN*(S6PNMGF3]AU^[MO3'(\.DG
M8_/I`[XNJ$-A[4W0\2>9OL80A4-!4+3MHFM8J"P_Y87^JI^<'X!X_*-^L-]P
M7R7W"KWWWO?HS_E:^,^RWQ7N_G'YB_\`X.^*]KYG]IO\"]/COZ+`OA\@=+>+
MU(U,':'D7K7GH]NYQ"T"CUS73'$CHHB@125.Y1Z/)`A3*W"6!4RP_1B!CVF<
M='+%!FB$PAG&Z&&8<U6/P7>ETR+HOG*41&<WA?7.U039VFJ91,]264<U(938
M4>JET9V:8A2DQZ"[FS?(B1E-J-%[YU)-$N`)0$`M!/7`8#`K`;OVT,Q_NP*U
M_M6VO@6?X#`8#`8#`8#`8#`8#`8#`BA;/,KG85F)[2BMNRFL9"7%D\44&1Y"
M6>8>@(6JEN_85EN38H)+/$>'1A>_;T+98=^NOY,Z5OBNV8S"9KF<YZHD]441
M8\&I>12.1=%3^PFI(OCY1\6?B#2VQ:-6]HDQ!QPA/J[6AHC3-&@_H]_S@:_D
M_ER^.T3;$1$(O$Q'=,AJIF>'TNVP<N^9VGD1SBC?B[`+)+^=D-QB<L08T`OX
M\)_RHH&_HW\3H?M:_E]W_1YSFT;LXC"XB=N,O!B7.5IQZ3L#ZZ]2V=)6UH=D
M+BNCRY/L"%[3)%`#S6I:(]]7%Z1K@@]V;_1"%[L6_9]D7H+6S>LQC;!MG67I
M\P6',+!'=HI:[B==1FZ9;&V`O:5$F`UL2+:?:-L)VD3D#.)3:'O01'",-WK^
M4>\<D1&,:,K,SG.J5&<UF`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M!3QYMW&KXIRA75J6/?+?S0ZTEU'2MP5%<DJHV7=#5?&+@A9DD41=/<E=PAM7
MR`%9O[6I<6]6[E&(Q,:Q2E6@4!-)+`8$*/`9R^I8/?=(RCO3E3LYSB7.D;Y-
MJIGX]6;70"K:I(M*6W0\"GSBXN>Y2YV1+)C(0"$4YMC8:UIT8B0!,T;O10=+
MV`P&!6`W?MH9C_=@5K_:MM?`L_P&`P&`P&`P&`P&`P&`P&`P(<=Z?_\`-$Q_
M][1#_P"IVS.G%_M')_E+%@_]A,O_`+I;O_T9.1/=4=GK9C4<>>F2M60ZXPUQ
M*UTI^-N"4+98%8D.3%,,I-"EVY,*`XY`B"Y(D0_]HI+$<6;K?\TP7L[%N[S:
M<;M$UQUQJD=D*,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,"A;S`>2
M1SY\K^Q*CJFS[&YFM6-S;G2..]ZJ^.W3J*-NC'T*@M8UMC%)PC;R@C]C6<3]
MVAVU:9P!M`C+%HH03#3P[)"*7\/]7_$#9=?3]GT?(NV[-Z?L:%Q-7?EL=/\`
M-+?S%`WMK*?30M:"M8#%(/#XBU*#7(CWIR?9SFM"47]!^BM>QH.I;`YS?X@[
MR-V-R'3Z:I*&N4SGBXI-3]R]`&7$.,$/ZA(QTTS$EP:H802_1>1113/[QMAY
M;$AABD.P-T5:7HP6BU!Z`S8:3</(1TQ.>LD-XU=T/)%M&&>7+E+Q[P?EE#&:
MO#6DUYHOGE*'6\[7Q(5KW`4-QZG#\YS@R3,ZTB3)RF]H:3$IC0IV'8!A-_FB
M?7_8/E\L]RZ%Y[9^=9(A\<%<(&&,L]SLEV%/T?UT]99X)`H?6*)Q),S*!+SC
MD^T0BCQ:T3HSWF]#UK07?X#`8#`8#`8#`8#`8#`8#`8$9^NX'*[(HF4Q2%-(
MWN0JUT<5)&PM2C2FJ2D#^WJU?NCEZA*E]LE*6,?LB,#L6@[T'U%Z:W?',5MF
M>R;Q,UZ-8(;HZS0H4:+7)VS-(TJ=+HS=C,@=F:3D@*T/8?=B]G8O8]?3UWZ9
M6WC^).Z^CZOORZT_T2__`.QV3_\`*QLX_B-U]$=^?YQT?!S+;*CO.2V3#?+7
MDKT^Z62=&P_(WQ5I/M8QD;6D:TZDI->SL*DKU*,T+6]?1EWBDXS/AE9M&<1Y
M36YWO!]N9//B)-"BH._5_+38FZM13SIYT%<F`8!:48<%&E+`<C6IS"Q>P(P`
MO36P[]/Y>5ZQ7&)S$KK:9[I'Y"C`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8'.[Y^JMZ->HMRS>L&[WYXXKHGF_HNJ[3FKG?L`9WM&WV8Q/3J1!+,CS
MVM&K6RYXC)#L<G(A($Q1#U[X9QJ@`2/YH?#X=+2.OWI2\[:F/F4KGR56*AHV
M$5T15=)5/]R5:5A"FR?2*2E6`[PQO=U3`[SI]?9":W:="D:99\O*`0><H+`G
M`E#HPP,-L.O(+;4%EE96;$V&=U[.V%QB\SADH;DSO'9/'7=,-(Z,KTUJP&)5
M[:O2F"+-*,#L`P;WK>L#4*[CWE9RZ#0]7K^>:@5=*MJ,M$CO$V!1X5E%@)8Q
M1=,I'*?@=.2AT1188FI.M,&-8G:Q;2%FA3;V5@10;OVT,Q_NP*U_M6VO@6?X
M#`8#`8#`8#`8#`8#`8#`8#`8#`C#S59DNLD=TBE:\E:")W+*XM'BR4*-$%NC
M[?I-I"W>TD()&KTG]H6_?'[,/'L6_:'O7IK5WK%<8T169G.=6`<C?_SKK7_M
M"2[_`'X>\WD[5_XE.\^]-W.:S`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8'/SY9>Q>,!V)3W/5S2>]XK8/+_3_.75Y@HSPW>?2U<2HB#A.D!D%5.,1C
M/V35?:V%RQ6CTO3.!RB/N8RE.TYQJ7:<819\!\7KDKIWHAZKF_)[8$,@]%1V
MF:C@+YQ/<'*8D%(HKRLBT8>[6],+)96ALN.W8BXV.L9$2E"$'P[4-0=LL&U8
MP`#JLP&`P*P&[]M#,?[L"M?[5MKX%G^`P&`P&`P&`P&`P&`P&`P&`P&`P(25
MI/>=*+>+893KK8U3C)+2E$E=V]R(/1'1]S4G@3K&()A91Q;AIN4)Q`VH#[(1
MBUO7IK>MYTM%[XG'A$36N>OEJ+FB^*?B,OZ3726?L+.DEMV260QL]8<>$MX9
M5;F[')G%)L!`]B3G%'@%K>_3?H+7T95ZVF(Q'AE;1$SG5+3\UW.G];D3_P`8
M5?Y+D;+Z2K=74_-=SI_6Y$_\85?Y+C9?23=74_-=SI_6Y$_\85?Y+C9?23=7
M4_-=SI_6Y$_\85?Y+C9?23=74_-=SI_6Y$_\85?Y+C9?23=74_-=SI_6Y$_\
M85?Y+C9?23=74_-=SI_6Y$_\85?Y+C9?23=75_5/U/SRJ/)3$6S$QGJ#BR"0
M?%*`^V:<,)98/:&F"`/M#%K7KO>M:_V<S9?23=75O_)48#`8#`8#`8#`8#`8
M#`8#`8#`8#`J\\NC]"([R>G7S[IOL/DYE':D.3$VAP_%I9+KH4N)C;)3"(H>
MU0R"V"\`A;LG*-.7'?!DD@.2)]"/#L02S0K`\(-B6-*NQNJF",]'>2/L'D]J
MH.HG2'W3WA'+!K]-$[K7S27)YQ6,8C$[C$5!*EBJ*)6IT*=T:%`8B*VI2*2C
M@C2*3`Z@L!@,"L!N_;0S'^[`K7^U;:^!9_@,!@,!@,!@,!@,!@,!@,!@,!@,
M#6KG3%//3@L=GBIZU=G5Q4&JW!S<X+%U[@N5GBV,Y4L6JFHU2J4'#WO8AC$(
M0M[]=[RMUH[3+,1I#X=T-1N_IW3%3[WZ:U]-=1#?T:UK6M?^Q_Y-:UZ:QNMK
M)MKI#0]GL=)P&S:-@A7/M1N1-K/4F;5+@.%1=(-G`QHVG99A24IC&2O$>:]:
MWL)N]!#HOZ/YV]"#59M-9G,]$SB)B,1U;X^X6C/ZEZG_``ZA_P!3Y.^VLJVU
MT@^X6C/ZEZG_``ZA_P!3XWVUDVUT@^X6C/ZEZG_#J'_4^-]M9-M=(/N%HS^I
M>I_PZA_U/C?;63;72#[A:,_J7J?\.H?]3XWVUDVUT@^X6C/ZEZG_``ZA_P!3
MXWVUDVUTA$'M6KZSA]6QIVB5=P6+.HK0AZ03G'(BP,C@)(<6[#.2B6MC>E4[
M3FC)!L0/:]D6PZWO7T:R^.UIMUF>R;1$1TCRL6SDLP&`P&`P&`P&`P&`P&`P
M&`P&`P&!27Y][RG'/W"C%,X7T-/N;$3ST[SM`;%F5+HRU_0K_5<UFGR:=0_G
M5$:W+RE5PJ&HWYFA+$-+HQ"UJP^_#Z^P,-->%VU*-L.S+K2U1UCYB>AG)M@L
M=4.K%Y,D*I+"(^A/?SBRG:L!FU!7!0I4>>#W*W7Q"@7PFP^A>M>HM!T,X&DK
MFZ8YPYR!%3.A>@:2H<$Z<E+-"!W-:T$J\$R>$6D@EC5%13=^8]2%R2:<"-FD
M)/?&EZ/+]H.O;#ZA_57TASP@N%GYX77U2Z*_Y"SBD+!1BNT8.FN%\8`(%;H)
M\9ZR.?035S9PMC>>IVI)1#)T0089[7L`%O00H;OVT,Q_NP*U_M6VO@6?X#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`C=;]5O\XMWG:9M2YE3-E:/\O7OJ=Q6'IW%
M82[HF(28+,G*2G@6G%[93/>!$,OV-""+UWKVMZNMHBLQJF8S,2DCD*,!@,!@
M,"$?>_\`S.QG_I8A?_J'O.G%_KT1?MZIN9S68#`8#`\='(6!Q<E[,WOC.N=V
MKT^:-2-S1*G)M]K>@A^/0D'C5(_:%OTU[P(?7>!^F)_8I2SMTAC+TTR*/O"4
MM<TOC$XHW=G=$1VO4E8W.;><H1+4INO]J84,0!?[&\#UL#R0/[$8^J(N6]-(
MY,D:4;^JCH'%&)]3,3@L7-R!Z4-&CMN!+2N<&Q202I$7HDTY.:`(MB+'K0>M
M@8ZZ2^)L;Y%XR]RB.L\DFZIT0PN/NCVVM[Y+UK&TJ7]Z1Q=I5J25[^J9V)$<
MM5%I"S1ITA0SC-!+"(6@_C-)O"ZWB[Q-[$E\7@4+CR<"M_E\T?VF+1=C2FJ"
M4A:EX?WQ6A:6Q.8J4%E!&<:`.S#`AUOU%K6P^I-*HPM>%,>1R-A5R!$$P:QC
M3/#>>\)`%;+T:)2V%*!K2`E;-![6Q@UH/M:]?Y=8'V'/+.G<TC*H=6TAY<"3
ME"!I.7)2G-:G3:$)0>D0#-"J4DD!#O8Q``((=:WZ[U@>E@,#4]DWO2E-+HTW
M6Y;-=UBLF">3JXP7/I>Q1(#TCA;80\RY8A4/JY"G,1QMK4E'K3=CT6G+-!L>
M]>V'U#;&!JS[]*2]]\-]\56?$?>G]Q?P_P!X42]]]]OR_P";?<[[KYO[S[T_
ME?\`A/V>]/F_P_\`2?#^Q].!5CYVV!,]<71-=IVZ2C$@A'3-'65!)MR;S,1U
M3=L#L"O'1XEL1EL;@1\CBH6%*W.S4`"MY^+]@!)VT)I1Q"\TH81L\)_8UX=)
M7/T7`[AZS[1OQRK&`P-V75_UGX\N?>'5->J)D\.?R)]0#JAS/E\A52IO9U0"
M$[FF*0C(2FFD#&,L>M!T:8%"_G6BUG796%6\L0CCRRKS@E_+G^-="]`U95T'
MM.P^>*'0.T+?YE'JC9I@]Q\E+;5T+F-`A;EYRHMN9RVX;B<4J4I4100@8DXT
MZ"<NMV"+Q[E"XHTFDGEHX[[_`(ATO)V>#ZCD%XOIOCFOX"JI*8R=1+']XC5E
M5V\1=9"]1W28Y8N$O$H+--2!^*T%CG-%(RFB_+Y9\?E?2G0'3:MY\<%</:65
M=#**<4R2.)!=/66BU&6$=,4Y3#)J/EFI1*=:6(5BWX@\SU4[+]@L`7?X#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`CQ>O/Z>[%T%=P3J50)Y@"A]4,SM%#0)UVC7
M\MI+4&A5:&0K2J$X6@&BQE&!WH)@];]?77I=;[<],Y3:NY\]?T/)H4US=M<;
MYMJ9&2Y@-94+A(GTY:MB2@TA83\\CIRY0X&(W<G:H(BQA$`.A%ZV+0MZ#L*;
M1/B"*X\RUC^4:=?Z6O0G_P`W/'UWF_,CX:LV3K+9EET-*)^ICBAMONV8(%BC
MJ-B5$11[.;"GY6F,-&;('8+>I;]'NZW1F@FBWK8/0&O8"'^=ZY%HCQ$MFN?,
MOW6M#R6`BE`G.^+9G6Y#'U#(C^U+Z>XACJ@_>]A?6<+@I<0D.Z;Z/=#UK0=?
M3[01?1Z)M$^(@BN/,M8?E&G7^EKT)_\`-SQ]=YOS(^&K-DZRV?85#R6;ML)0
M-U\6U##8E'R&1>OC;Z>A5RU200C)V^R$Q"I0"5.Z@280S![V(.Q&;V$(?I]K
M(M$>(ELUSYE"7IVBI+6<`8WYWO6U;)2J;"B3:%@FKXJ<V@DXX:]0!R+)6K%W
ML+"`IA``('L"]DT6M[WK>];Z4M%IQB(Z(M7$=Y6T9P=3`CU;T-Z%D3\W+*AN
M%DKUA):`)G%F<X:ROYRIW"L6&C<P.#FUNAH"C49Q)6B0Z+"#9.Q?SMCW[-UF
MD1_:,RF8MXEBU*5YU?&#;H^^OH6-661*=,^J7^3UI'HR;5VR&5U3/(W;Y8@;
M0R_2QY5)#RP*MC]G206M"`$_W1>3-<](Z-ZXZ]R!U]U<U2YE<9[?T<E$12J#
M#'J/HZ_CC<I=4^TYP"TQ2]&Q-ZE)O2@0!^V`T.]>S_(+7J'=3/'CI'5D1;/6
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MV))]A2)T4!L/[RO*=0R^:S5RNSR`]"12NNJ?)KS$UUJWTI1JZ:2_GRI^.;IN
MWG2[V-P3<R@3R"YG&\(\SM;!(5*1;%G<?PS22RJO?&)5@1%56/V3:]@<N6+T
M'-.YXA4M%]S="&Q'I.H*1M&][JK.A[+\;38WJ)#&'.5^/>CY;.(F\7+-W=D+
M?7*F4NVDA<I`B-5$-Z1U&%J=US?I"?>)WQ42OLU#)&BP9QV7XLS.Q$TACK=!
M'94PK.FZ]/2++/A:<LAEC/V@FR:+J9&V;`A*0'*#P`((-*+2:#6E)-3#S/Y7
M;2E=/46SW]&YO-/('=_7%RNGC*MZK^G.9!-85$DBD0K3K>1M!*+IB+VS+T!K
M#&X['2SQ/#6,#DB&<E,*V((WW!!97='D>.M5EH"YQ])6EY#_`!2W_P`G7E*^
M:K1:S8+X\8Y2-<R#H&-BLE;%&M/4$;BZ@<Q;+$A;E(65:[/;CI*H0B/4E"$$
MS_+58GDHCO1=XJ>2+8Z,K^`TGQ!RE<];12J*;A-@0JS.B91VW8E96)'Y.MD]
M43AYE2=!1AZ=:Z1MJ<4)FB2$*X_V2"QZ4!`3LSK+R2<TR*?<RM_6/3!B>,6Y
MY`5\)Z!E52(G&:I:FK3FOQ^3^K;LMDV@.%;[=Y+SG3MM=&3TMX4L\(869>F0
M:0*9&V'M:4HX,^[Z8GOOZCO*!=56K95TM$>3O'M7?$'-4EBK*IESA<EXW8WU
M3TEU59<1CT;1Z4J)$ZPPRLF<_P"$;0&:.3.*<`2@`,`(-/\`37D"\DT0:8]6
M<XOF\N=[S1H?(Q.NF'EMI.4+*FYZ=JIN+GMCIFRF)77/&/45A3W@:`TE,'%T
M1/*A!&D;^8J5&N4P)<TORU.&POFS=^NU\P^V[A^3_P"__P"\'[UOB&S[)_FJ
M_1*^<_>C\7\K^Q_WH?<A_N[\1\M^"^)_PGW'Q?\`-P+ZNG;,EG2704A\=//=
MZWGRO=$#IN"=46!TG6,'J28Q^/PR4S:5UY$*=4HK1T\F*))/UC"XNPC4;0,M
M(B90A$K`-1LG81,X+I)KH7RI=00J^NI^G.KNTC>+*'>V"QKL:*DB,!<>4'&V
M++((;JWBE4IFS1;A%KG;W`IU,=$:<0#%H!I/;TJ4F#"_;`8#`K`;OVT,Q_NP
M*U_M6VO@6?X#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8$(^]_^9V,_
M]+$+_P#4/>=.+_7HB_;U3<SFLP&`P&`P&`P&`P&!A=A5S`[9A[O7]FQ&/SN$
M/_R_YU%90V)7AC<Q-3HB>VL:MO6%F$&F-SPVIU1`MZ]HI00`P.]"#K>@S3`8
M#`CA?7'O*W4JF-+.CN>:?N]9#D;XVQA59L"CTO4LC3*-MVY,RH3WE"J-+8Y'
MMH2_'HM[VD6?#%>^+'[`?0-KP&L:VJEI<&"KJ]@];,3M('F6.K+`8FPPYI<Y
M5(E/QL@DK@W1U`W(UD@?5G]*L6F`$I5&_P`XP8A?3@:BO3C7D[IQYCDBZ(YR
MIFZWV)-J]DCKM9=?1J7KVUA=5J)R=(\!0\MZLP^.N3@VD'*&\W9B,XTK0AE[
MW@>[^5WG+W7N?N/J_P!U]\'Y@?8^QC'Z??=]G_LC]ZGK\'Z_;C[(_P"Y'S#_
M`._^5?X'[7PW]%@0'[K\7$EZ9O"*=;\O=D7%P3U[&:Q/I1RMRLF!AL2'6/4V
MGETE+/$+5J"4KFABF08M*W8]:VJ?C4QA/OQA,T:(M$8C#(_'[XTG/CZ?W#T+
M>?5-M=N=;WHRQ6&3:^[5;&B(I6>M80K<W*-5Q6];QY8Y,D#BI3R\J%RH@E4>
M!0L$$P`2?0>AA:;@,!@5@-W[:&8_W8%:_P!JVU\"S_`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`BMV!7$XLZJF]DKYF*?Y"V3B.2$+6:Y-K5\0C;2
MW(L_V%;LK0(="`-6#>PB-#O8-;]GUWK6MWQS$6S/;";1,QT[L22VCVKM2GTJ
MYBBWPNSRM*?=VA%"C/A]F!]][!GVC5>['[OU]!>Z,]-_3[(OY-[MX_B_AF;Z
M)K9S6CW;U_AJ9];6+[JK5G0G!I"[;=(1&=.S,E"8L5HPMYR[XD&].9>T>S#"
MO8U[!1I0O7?M^@;K3=YB$VMCPT.U=YIW9S?VLKFGI5,='E29(I/5P#1*54-4
MG^)+&A-TN'LX`2_38O70=ZT(._3T%K*^7[89O]DI*4[<@;>3OQVJ]L2`C83F
M\H0)XP?)0.@7$"L8!M!OOS?C!(]HMZ4!]D/NM&%;]=^W]$6KM\Q+:VW.8B3>
M6KR"H^@NSV&L'>(VQ&*"O7R#UU)ZJ_*S/D37SY2?-//TXL"H[^D/3Z![3ULO
M<GBTFAM9%<:="CUKQH_W24*<TX!H)4_-!>4ORBVG0W34;AS2WW%TE&>9.&NH
MJ::G?DF14S=CO6U_2EU:>F9A4]$RNR6>+].P>HF-D/##79$YL!;\_P#^"&%*
MPC*`(.@CQX]#MG4'*%?VLCN8-[NJAVG\9ETW4TJ[<Y2-%+8C/I(PNT&G-'/K
MY(G:NY]7H493,\)QJMDKUJ(;@F+)2+""@!-G`8#`8#`8#`8#`8#`8#`8#`8%
M8#=^VAF/]V!6O]JVU\"S_`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`CDP\E<^1F!]"UDR5\%'!^JYE;-@7XQ#E$T6`GTMO)F)C]INHEZ
MZ1J72-!E+0G`3M,SGMZ5%K7M)"B![V+819A/A_X%K:)R6)P*L+,BXY,QP",#
MG2+JCK%7<<9BU5N1[S742KN\'>[W*WZRA<1=U)BE*R1][;6?9I@]FIC-#'H0
M3)Y^YWIOEJL6JGJ)A9,&@+0Y/[X!N$\R.4O+M(I6]+9%*93+)E,WB136;2Z2
MOKB<K<'9X<5SDM/,V(X\>_3T#=6`P&`P&`P&`P&`P&`P&`P&!3[,/+A'HIUF
M=11="RAXHMEZ_K'@67=1II_$$K4R]86S5"&U8["&VL%909$_1-F)?FMG>7G2
MY.:@=E@@@1*""O?#"&Z/RS^,HCRQ2RU3>[^7`UJH\>D"KE/.M7##AQ91.V[I
M.RI&NB9#T!S$A.?$K`Y)U@R`CV/28X!G^U%K>!87^M;XC_WC7('XX0GZTP'Z
MUOB/_>-<@?CA"?K3`?K6^(_]XUR!^.$)^M,!^M;XC_WC7('XX0GZTP'ZUOB/
M_>-<@?CA"?K3`?K6^(_]XUR!^.$)^M,!^M;XC_WC7('XX0GZTP'ZUOB/_>-<
M@?CA"?K3`?K6^(_]XUR!^.$)^M,!^M;XC_WC7('XX0GZTP'ZUOB/_>-<@?CA
M"?K3`?K6^(_]XUR!^.$)^M,!^M;XC_WC7('XX0GZTP'ZUOB/_>-<@?CA"?K3
M`?K6^(_]XUR!^.$)^M,!^M;XC_WC7('XX0GZTP'ZUOB/_>-<@?CA"?K3`?K6
M^(_]XUR!^.$)^M,!^M;XC_WC7('XX0GZTP'ZUOB/_>-<@?CA"?K3`?K6^(_]
MXUR!^.$)^M,!^M;XC_WC7('XX0GZTP'ZUOB/_>-<@?CA"?K3`?K6^(_]XUR!
M^.$)^M,!^M;XC_WC7('XX0GZTP'ZUOB/_>-<@?CA"?K3`?K6^(_]XUR!^.$)
M^M,!^M;XC_WC7('XX0GZTP'ZUOB/_>-<@?CA"?K3`?K6^(_]XUR!^.$)^M,!
M^M;XC_WC7('XX0GZTP'ZUOB/_>-<@?CA"?K3`?K6^(_]XUR!^.$)^M,#<5%^
M2KQ_=.6`DJGGKL?G:Y++7MKF\((+7MIQ62RE<V,I&E3LL1,S>X&K59+:E]33
MME@%LLH(A[]`A%O03=P&`P&`P&`P&`P&`P&`P&`P&`P*>Y'XE6^0=9JKOWT"
M_(J$>>S:Z\A$BYC*KB.CTLZQJVHFBIHQ+6BV-/)2]DA*[4<;7MV:/DBA<XNZ
M(._F92<0B-A/HCG5B(ZT=.M0R)VW)77G5AYU.B8DZ/Y$6Q1^RY)9::1%*]!T
MO^;'+Y*:F&7O>R?<E@WK6A>OJ&>7%3=;7]7SM5=MQL,N@3ZY11W=6`;J^,H%
MCA"9<Q3N,'B<8XYM#L6%ME4:1*ME@4!+/T3[HX)A(S"QAL[`UG5E/5O2C/)V
M"L8T7%FB9699UPR1&4Y/+H%RLBY9R^659<EV:]N+F>E,D\WDBY>-,0(I$F&?
MLM.222$!80/E/5O)+8KN\7N-%KK3J>'V9`J_E0G)Y),CL3N)?73G9#46T)G$
MEA</M*MJ:/CV>K2J%*73?[*8PD)ZD)P?=:U806[JNLFE[08@RFL[=@,QK"Q(
MR-P=F@$B@L^CSC%):Q"=6%>UOC8%W8'90GVH1*DRLG1GMDFEF!"/09@V-J%F
M;6]G;$X4C:U(4C:WI0",&!,A0IRTJ1.$9HQFB"204$.MB%L6]:^G>]X&A:+Y
MU8*(E_4,N8I`\/9W471`NBI`B=B419<7?SJ-H^D5,?9SD990E;.)%2*=P`,\
M/O@&KS"M[&$L(Q!GDTIZM[#FE/6',8T6\S&@YA(I[4CT)R>41D0EDKK::U#(
M'4M&VN*-O>/F-=V(\-VR'`E6F!I9[\!85)1!Q09\YMJ%Y;7!G<TX5;:ZH5;:
MX)1B,`!2A7)S$JM.(90P&A"<0:(.]A%H6M;^C>MX&'U36$%I&KJVI>KV(,6K
M.HH##JPKN,@<'9W!'8+`8\W12),075^7NCXYA:&!I3I]*%JI2K.T7[9QIA@A
M#V'PQRGJWB5G69<D=C1;;9%Q-=?LUDR0#D\GBDS=5J20H8(2<U*W$]C;C&%'
M*EQ>C4:9.<I`<'2@1ONB?=A^;0INMKF2PA'94;#)4]<V=!;DA98G5\:=LEDU
MJ[A?85)`&,3FUFK1,KH#1GPBD1R%3KU`H)-+WL.PV=@1UY2YU8N4*+B]%1N1
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M-/HGU(V5L8]B#'^E:19>F><K_P";Y(\ND<CO0-)VK2+_`"%C+2&O3$RVM!7Z
M!NCRT%+RCD)CHUH7XP].$X`RMF@#H8=A]=8&T(PQE1B-1Z-D'F*B(\QM+&2I
M."$!J@II0)T!9YH`?S`F'`3Z$+6OHUO?T8&'PNGJWKR:7#8<.C1;-,;\F$=G
MMMO07)Y6F2^612MH54,?=3$;DXK&]G^75W7;.W:(;R4B8>D?OQEB4FGG&@L&
MGJWM1ZJ60SZ-%R!XHRS`W#5:PQR>4'V4L@$!GU7@DH$[4XH$KN8""V>^H=)G
M`"M%KX[WWN?B"4YI09\YMJ%Y;7!G<TX5;:ZH5;:X)1B,`!2A7)S$JM.(90P&
MA"<0:(.]A%H6M;^C>MX&&U/5L$HZK*TI2K6+[+UE3]?PVK:ZC7S-X>_L[!*_
MCC;$XBQ?.9$X.\@=_E$?:$Z?XI<K5+%'N_;.-,,$(>P^%BINMHU;=C7JR1L*
M&U+9AM85_8,J"ZOA^Y#$J:<+(=:V:ALJES.CK:*-KK<D(_B4:1.J6:7Z`J-/
M`G2A(#`^F.=6+IB(UY$G^1.T:(KKHKFOHIN6-"=&J-7OO-EX0:[62.K2EH=@
M"TR5QA!:!48#83B25`C"][$'0=A(K`UC4%-UM0L)#7-3QL,3A@9=9,[TS!=7
MQZU]J[>LB66[8KMM?(G-W=-BD=B3EU<=D[/^'3;5[)3EDIRRB0!^C:>K<^XV
M^_S8T6*W6NLW>GD4PTY/(#2JW?92R35TC0V<#B&/*"SY/'$:H*DQ(-:3LL0"
MS@%&F@&"XZ>K>_ZSEU.V[&BYA6\[;R6N5QHUR>6<MV0$+DCF20)SCSBTO2/V
M%R$HS0DZDH?J#T]?3>];#9F!K.N*>K>HU-D*Z\C1<<46Y9C[<-B&%N3RX_:.
MR)*U,+*^248'AQ<`-IB]LC"$K:9'I.B![CV@$A&,P0@P.PN=6"PNAN<^BET@
M>&^0\XL]VLK`P)"41C-(DMX,,28WLQX,.+VN(4,P8>G,2[)&$(MF&!,"+U#L
M(2(P&`P&`P&`P&`P&`P&`P&`P&`P&!Q]`@$K7^5]N>2H+9&N\TGFN>)0\6:K
M@EDEE%>(=%Q2Y-K:RMEG`;$D%+Y_4ORE`W_*1NA@3ISM1O289@@E[#L%P&`P
M&`P*@/.%.Z%@?";^??/-:SK,B43R.PBIZ8$PS)\BCG<TE8Y6EB,FLD<+2KUK
M#6\&;`.+NZN)R=0%,6C#\*48Y"0AV'+=>5$$,5"5G6#4^W?U+-8;XL*"K7Q4
M74@J7H!`(GNN,]E62U7:JJ<,FAZ"457;D=<&N-EM*M?II/3U\V(Q;&-&2(S0
M?]`A)I4%*FTN&G,7:3DZ6&)"C"$IBK18=*!IB3CE!Q*<1WKL`1F#$$/IK8M[
M^G8?1@,!@,#F;_B48#U9=',LCK2O^;+-N3EN.T%>UKVD]59-JD0KS;X8X\!D
MY_:YM`IA8,1L>55M6BMT<YL>EBS;('%RDK4Q`+2^B0XL\(</<:L:;^3A@G$M
MI:W8)Y"GGRT\FV!$U+Q%9,\*JW\7)'&\0,MVOFNWX*:\5".M8Z^JI2PS(AJD
MBZ/.<S,T(`%9YP1'!V5X#`8#`8')%V:XW-&_-DNG#U3=;WPXM,\\;L/Y%K:W
MN7[;M]_U5<JF+N'HJV^9+ICLR:JPYRDE&2TURDDK?G!E<UIY:!L(4J$J`&BE
M08OX6(!*VKLKGQ];(+8\9O5NY0[/2>6^6R^!V3%U$TZ9?.KXLNIXFRI-*6QG
M8YM.-E%2%=#Q^]<UJ*%",T6(*4W0]AV"X#`8#`8'`/9$"Z+#WUWU)J"KF=F7
MI)EGFA'``QFN;,8>Q*X='7FU<U5)++KN-NKU-%+9Y<L.2PA6EH..-SB6&//D
MCCJ@IR<CRCR"PN\\%<*@\9N+M)SYC@LIKWBUWJ7@1OAS.]P><0!F<>GV&I)^
M5T^[(&*6M<<),L8L*V+I9RO3H/:7/!)`#C=G)30X'1Y@,!@,"AO^)'CU?2GQ
M2WW'Y<AL9[F3TE`U4=%J^#<3@&57$<VNJQA:9-&:I]\UR9I3L;>Y+2"920>P
MIW!(G4:T!<4C'H*IO(">7T-UU==HPF+6I-.@K#,\0#WX=K(#4UTI"XI#D'2:
MIW[`<:\>3HPRAJQP2LJ9V56#\W4,PS8V:WZ.#HO6Q;#./%=`)6B[ZY=?VV"V
M1'^HFIC\L@_+O-Y/!+)C:J:/DEZ;BH^14T]FL@;&F)3I&>W)3EM?%)E+H-'$
MB?Z/00A&8`.P7`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`P^PW5>QP"</;4?\*YL\/DSJW*?=$G_#KV]E6JT9_N5!
M9R<[W*@D(O9,`(`O3T%K>O76!Q5T-U/Y&>;_`!4\9>8I_P"_[<Z)06%;$&9>
MD>4;WC%6OM?2ZO;!OAUH]8GJ>8,D+8K$@,T8O@T3FC-$YJ4?O='>\*&1[Q*I
M"ZJS/-`X4[WI5?'$^HZB],=O=1MO+T=>85WG3U@]-,*Z4('@^#6M8'&L9ARF
M60:K)0L:@E#5KI(!8VA5$Z5IBE)Z9*>'CU3YS$-G(>8(<7RW(&_IFY.M^L.6
M;GYS;K.`_O\`0.^*H]()E?DS3/FJX:U=DK&6)?9H]`S&-,=$N5R<E+M64(H`
MU(2&\4WD]<O)S"9C9::IJIK"',Q+,:R-T.ZGCEYV@R+7-TDJ-3#K]JU%6]>/
M]"V$W-S,E6?+SC'M&I*6B"2N&)./V@MLP&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!B\W)9E,+EZ>1JU""
M/'Q=_)?ER0(AJD3,:TJP.BM,`*9:(:A,A$,8-:).WL0=?S!?[78<B'.O,?B?
MK:@_'9*K'\CW<O17`Z.]8>7P[6EL5'/H/R.YWPHL>2$00^SG*%<I058:<CLL
MQP.;`SM];F?1I:GWVCT(CB\#-(7S7XK"^EH99D;\B=VJ(NH\VDAE-;<WZIMJ
M+:VSR<E.TC6V'6DQG2KG#5\.<97[&M2-RQ_?T\72(P&?#N"D\7Q&@\_CEAY*
M?_XE#RWO33-7:"6FFIU)":KAT92O3NH=IXYUI3*KL>YJP<6B)/E?LEE1A>WQ
M=&H:]K5LF5K%Z]0>@V4`PD@+*/'G1W+U.=\=<"3]IV)UUWJ_TW4PKNU-*PKR
MM#X'2R2224=;I9>12U+5;7KY;B]V4G@?5;NH4RTW2<G:E(C*WZ&A>7@,!@,!
?@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g575431g37d02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g575431g37d02.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`)D%D
M;V)E`&3``````0,`%00#!@H-```*8P``)!8``"]D```[1/_;`(0``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("
M`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"`@(!`@(#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\(`$0@`I0",`P$1
M``(1`0,1`?_$`0\``0`"`P$``P$````````````("00&!P4!`@,*`0$``00#
M`0``````````````!0,$!@<!`@@)$``!!`(!`@8"`@,!`0`````$`@,%!@$'
M`"`P$1,4%S=($!(Q%5!@%B(($0`!!``$`@4("`0$`PD````#`0($!0`1$@8A
M$R`Q(A0'03*S%35VAL@C,Y/3%I;6-U%A)#00<4)#,((E\)'14F)C5"87$@`!
M`@0#!`4)!0<%```````!$0(`(1(#,4$$,%%A(G&!,A,%$/"1L<%"<B,4H=%2
M)!5`4&"",R4&X?%B8Q83`0$``@("`@$!"`,!``````$1`"$Q03!187&!D1`@
M\*&QP='A0%!@\?_:``P#`0`"$0,1```!E$2;``!YIF'[````K?+("7X`!YY5
MD9IBEJ!E```J`)@$OP``8_3I'*`QKI,O*],NY,``"H`F`2_``.51D37MKK4\
M0NF&^[:\6Y;(WI(R=RT``5`$P"7X`!5CKO2L)<4UYL4)VU/(J?;Y7*;PMI>A
M?GGD`"H`F`2_`!\%-^I?/L=L1PW>+K(-%LL=D5LS8MR&?;P^W/(`%0!,`E^`
M"N?((WFF-8Y%W6.H?-P^`W"6E+*-K[MS)_*^5VU;I!S8L%/N5`$P"7X`*W9J
MQ\?)8K1G2NR0QGGF?1?A27/],GF#;\@@`"H`F`2_`(YWUO\`S/>GM0[!8W,_
MM89A*VPNH%2UAVC&Y2T+#9[MH`!4`3`)?@&O<\4.V/:4$E0L.Z58,V=7LVH\
MQ\V1MN@[5Q.4P`!4`3`)?@'&8^X@1\E_7&%,6>Q>PM.3)F+2.\#?^?L/&Y4[
MAP[MP`!4`3`)?@`@+@D]OVL<J]"_MX38S7^/)>Y-C@9*8'UJ\C2CN*8`%0!,
M`E^`"$NL,I\/`><J!QSE6@^O2]GT>Q^C:N9LNGQ$ZV<O)U`J`)@$OP`?'"$G
MCVIPGRQSI.ZX_)C^W<9N^G7[MI?-=DF";."H`F`2_`!I--!_YO5N*[!C_I@/
M.U<774Y>I/OZ%TLOD`!4`3`)?@`Q>.(':*LN?^9Y30\5L]FPR[[O]`8Z8.ZK
MSV0`"H`F`2_``/RI.'Z![<.PNAV7)KCOWH[I]^X``5`$P"7X``*O3US42P@Z
MB``"H`F`2_``!X)H!Y1GG[F<=.`!4`3`)?@'FD"C1R41&@[,<H,8F4=D`!4`
M;*2;```````!6^?_V@`(`0$``04"TSIG5T_J[V"TWSV"TWSV"TWSV"TWSV"T
MWSV"TWPO1VCX\9O0VEW6_8+3?/8+3?/8+3?/8+3?/8+3?/8+3?/8+3?/8+3?
M/^`IOO9H+X;Z2V5$BL_]7*WIN!V>359#9UOKI;'G>3U?9C07PWU.NH8:N-Y)
MAVO[RNEIZ_LQH+X;Z;7,-@0Y6WYE;04A8$OD9`DHW7MHD+</U?9C07PWT[N?
MBQY1F,8_L#1BP^1ZS"!*`F4KQ?5]F-!?#?3L6C&"DL%-.JDAB<-M$,/\UM8T
M#6''\=/V8T%\-]$G/3EGD95<T^\3%1T>P&OU[E:IY4L54]<5J*,MU)G'DN5C
M;Z`X,+;*;`16=H82G.<IY]F-!?#?1>`$Z_)C)6.F@YVH@3&94"\Z_>/F)F4<
M`((@RZ9;I.99Z?LQH+X;_.VK%)577B_%TB)EI2`,JNV(B6<=:;>;N^L8L!C5
M&HM<6U5ARVNT=/V8T%\-_F6CXZ5C'=;T)V1KM$_^=&>1%1I(`,E$-IF(&F`1
M#]H"?3.4_!D7/=/V8T%\-_G88)TE1PC!#Q33QQU06K67R&&&!69[8"6\U2W5
M^&-N7EY<Z?LQH+X;Z+5#0MNEJ[5(:L,35ABX),O8K/9"QYNO"\/*"%#UW4I6
M.BNG[,:"^&^AL\:G%2UBG"AL/54"&R1^[D=>`/*I]8J:N6B[%5V?C]Z1I496
MMJ0%IEXC<F9T;\?9C07PWTW4J3_L,N-I77ZX+`):KL4/,PQ\D,4*"/A']1$^
M2B.CV\OPD,4Y^/LQH+X;Z)YR6:"G)!V3/?K8!4W8IO%?C`7\&B5EQAF29?9)
M;Z?LQH+X;Z'T*=9"HDG68AYM0[K<Y&.RSBE(;U>J3D(P``6-&Z?LQH+X;Z5(
M2ODI2PSB#]9#11\721P)#&,)QU?9C07PWU7-_9$997=FV"OQ4YF\V)%.E9R8
M@NK[,:"^&^HJ3`"*9O=/()5*T&$%7L&E-P<A?*A%3%>N5:M:NC[,:"^&_P`F
M((=$I5`NU&KFKXNZ5D:RU&6N2PM)V(6'*U]/^V$MIZUV^6!U)>?[2FUXVNM=
M'V8TR_N5.KO4;\YZC?G/4;\YZC?G/4;\YZC?G/4;\YZC?G/4;\YZC?G/4;\Y
MZC?G/4;\YZC?G/4;\YZC?G/,OWO9_]H`"`$"``$%`O\`%YSA."BG\)9=2_GO
M$$-LH)ER<ID'XIL*&GC(58;IKV>[(QA<F2N8D"(SR/()FFHP*1<EYN6([KBY
M2'?(#,!X:R_A!(18?(<&89C^X.,A2).$P7D],W)+)CR!5.%2TUR-9*C4..J=
M[@Y/Z<QGQYC_`,N.#`33X\!$#9*CQ'V.V,UA\A@089)<<P7PH9T-?&9,@%!4
M\:8WV_XX]M&-#=;L_P#:\SG.<O3*`$G291ZH5;F">V4AUP4H8@,B,BCY1Z''
M)AV,YSG)\K&Q/(2T5@M7<EW([.$I0VA@=XE5@:FA%FPLZRL,8LLIK"TM=N4!
M(R3+.Y@@S[[$9B9JQR$HN+M,M#Q=8DGY@+NV6SS\.:EEY3<K.RFP929GK`/&
M5<.?90VO+C?;4I*$S!!5BFXURZ-Q=2K;MGG0X$-<U59)UHKN["_8^18D1@F'
M:U-,0+2$N.Q-?%J\IW5(2ODM10I`F8K4\!%1-"&CI).,)3_I_P#_V@`(`0,`
M`04"_P`6K.$I+,(PELMA??**:8;*L#RL^I4VA@O+2(LL@W'=L+7F$86XXEX=
MT9UW#:5@.22E]V2#*$=\%MY/8(PA25)Y!D%L=UQW.,F"-R&30RFU>4O]F!RC
MU1\1@'B481W'&O'\9PE6'PDMY]2[XLDOMN=MU?EM./.NY8*<9XRZA_''!&B%
M,QH["NXBIOO)5$X$Y_'$!9(RP*T/@["?*[;64I=:<;>;*+'%08XV8OC`I)?#
MHN49QW`TD\SXJRXXAO`)48I3!\>YAYUIII7AE7;%?;\MTS&.9RI6>?LC*LYS
MX=W'/''B.,@;"1F</=]0S2GR7_3-(5^Z,]X5E3#?,$-9>S_##KCK?>\>8;;\
MSQ_U'__:``@!`@(&/P+]UU'`1^2:'NIJX)/TQ3;YG\.&/4,.G;DG+%,8>ZRP
M_1GE#B,\YX*F708TI\(N7AK>ZIO`JBRP_FJPDFXXN?I*:WMI4A4"K(=,^F'/
MU5LVV>Z"$)XG_0)MO[<QUU[&*Y""@'!5'1[QPG%KP/E^D8]0$FI7/K/MAMK7
M!S;:BI,:<TQFD?V.ZZYI@&FHY.W8!<LN$#77`+EYH#%IPZA*:S/J&V=K-$YU
MACI<I`7JJ=Y[HMOU#'VZVU,)S&\1;U=]X>ZZ%AOU5M]NMJMJ"*.$?J-JP'^'
MO=C4`92P7?+#:UOS@/!*-R]O'SQBUIM2KF66N#%I5K`@5R#HF9P&O0KNW[M_
MG*&6=0]UUMAG*N39#K/3,I'=6M1<[A5IP`._&%<B\`!ZMIW;L(E`NM_J#V0U
MWBI+;C7*VGE:2,)SGTIN$+;L,J3$S@VGL:`F*8<=HRR9!SP/28IL,:U/3Z8J
M[-[\0]N_S0B*;Z(<#D?N\T7R2(-K<[+H/L]4&VK6VC^'/KGM?TZ_J[/U+9$T
MN*<"X"A=^>^/RVM9='_6]OJ;"G&*7\S_`,,?-/R_PC"*!_3+9[2Y;L&F^6.#
M3N*2/IAVFU;7,U#"A!Q\_7%&B;V<78-;TNRX#$Y`QW?U5^]>(F7/=0/@83+X
MC/@V%.,#]1>0X^XT57$WHH0<7$+[JP-+H;U.H=[KP6N)Z3RD\`>K:]SJK-N_
M<3![0X#TQW5EK;=D8-:$:.H13:"PW0^$=Q]5<`F7@/G)&!X#`5DM3CNI,.N:
MRQ?+EYG(7S,YO"B>.,,TVB:YVK<[E`Q7V)ORQAK;I6X&A3O.>T-ZVTN8[=#=
M?K;-Q]LO`1N7Q'W>$IF7+C%RUX>QPO\`>4AO9EB+BIP"C%3F)EMRZ#;>C?LF
M"V00+.7WK;O:G27FZ347W/.I+2ETSJ;;5H8J-#,74@&60/BFIMV[7>O-`;C0
MV2N.?,N0'#;7M!>9:=8O6Y5@.Y2O9+:%'QL7>N+C>:UQM-Q*2'28T6BNLTUA
MUNWW3*6D!,34>9QPD,!D`I)_\1J[['^&:2Y[H$\2!6BD-+C(X&1[(1OCFGLU
MZ9LFN3O+B`H66FJ::BK:J>45%44%KR"TD`H<1P.T+WE&`*8-JS:LNUC[E([I
M>=,%+G)@,9>B-;_@>FM6_IW)<N--*M6ATK@=3STMQJX).&>#-O-TUQ'&IV5&
M0"A7<%&9RC4^%^(ZVS9M:<W!WF+7ECJ>12`0>UBI&'"WI;OB#]+I67*FMI+F
M/.;>%7&6>.VMW/`=$RSXB0U]R^T)0UG9YT$SPYBUH:CHU[O$7ZH?Y0Y[FA[7
MN'`AR$#$%05")2D6_P#);EDCP>[<H:]1C/W<:20X`HBCB%:Q[@QA<`7%4;Q*
M*98R"P[PBS5K=+=:RZW4]WR-=2589D`R4%J]H-,QMN::%?1#&Z9HLV5?<NW%
MJ>]SL&A3@JEV6"9QI/"[>JO:OP-FH!=9232YW::T5&F9SD2OO&*M1^8T1TS@
M:D[9=N^##C.*1@/X0__:``@!`P(&/P+]UU'`1_;V"X^BI<J9]"JDH2H5?=CZ
M,.F6W)<<,4Q3UP]NG'Y8M0+CQ^[T&&_3O>'4H9G#_=8+"%7/\/1Z3UPZ[<;3
M8$F[SO)VP=9F4G,'[%4>H],-T[=\H[K4BET?)*MCZG2LJ=V:DP\\SMG:EK:+
M!/`?96[SR$!TP<1%O6ZBX'NO-7CE',$@LLVQ<8__`)(9;EEM4;#>^,VX;IYI
MO^S?`[P?+G3@M(S*0&B9,4,5U+5ZE2""_O+9R+1ZXDJ;2H8^1'8)#;MIE185
MQ*KT!,(5J-*)R@"6Z4!X)/MVCGC$`F%N.)A,;>Z%MX[O)N?PBJ9>-^U^I99?
MW1XCU=J/F6"WX@?;$H42&^.3M;XJ/:7:-=<FP."]$"Y:(-LX0M\XY9GJ\Q%7
M=,8S@`O\Q]F'3Y/RX4;S)OI^[K2.]OL6V,Q,#V[6NT]S&\"1%3R7/WF9A7Q5
MKB\#<DNLB?5+K@-L7+:;E`^R#<O$"T!."6R:NTH<4(BFU,Q4['R4`BL912LM
MNF<&DDU%9P=0!\T_L`U)7O!'>HL!^\;>A[R\KY#IP?F@>2NXVARX?L!NH.\.
M?\)?_]H`"`$!`08_`ME7%QLJEL+.PI12)LV0(JFD&4ID4A%0R)JR3'[>[?\`
ML3_?X_;W;_V)_O\`'[>[?^Q/]_C]O=O_`&)_O\?M[M_[$_W^/V]V_P#8G^_Q
M(FS]D;6A0X@"R94N6KHT:-&`W6:1(.:2P00!9Q<YRHUJ=>&%%L';A1%8T@R#
M85XR#>FICV/;(5KF.:N:*G7C]O=O_8G^_P`?M[M_[$_W^/V]V_\`8G^_Q^WN
MW_L3_?X_;W;_`-B?[_'[>[?^Q/\`?X_;W;_V)_O\?M[M_P"Q/]_C\"_AZO\`
MPC^/_8.A_<?V.]<>;KU^T_INOS\>'ON^'TY^E)CLD'B/D1S!9+C<M),5Q1N8
MV1'4PRBYX574W4US=2<47%?LS<T>63=&W_#KQ-IB;G%&<.OW)57:[2%MB_"3
M2L,%A+[K(9*!_MR@O_T*U$W==.3=P=TN\+=LU^VZQ-Q2H0(^YI6URP-V&@UH
M+)L0-H&:$9!$<B/:9$<)4>Y^=B1ZK2QK'=FVJ';]9XAPI#K$6VH^WZN%8;@@
MUT:RKYMX^QW9<1QR'"E2#1QJY_(>X9&('O*";(Y0^>T#G/"AM*<U`O>UCW"1
M^>E51%5/)T_C_P"7O'A[[OA].?ID,5=(@C>4CLE72P;5<]<FHKER:GDQ&9M^
M)&LY,J$*S9(,_5!2`7G(-[4$8)#$,HNQD[++/^6<59DJM4@Y3^2LGDZ!SX+1
M]X+&>?@U8AB\OF(O9)V<\_\`@?'_`,O>/#WW?#Z<_2LN1*:V6*.JN:'(\@+.
MRY^H`W<\?-%V6DRTC<Y'.5&HJXFUHE"41JX44)#HWOC'(7Z665.WS.\1G*%R
M+_!'HJ.U:I+94EZ11,[M7*,RYLA*8Y>[Y(N:#1Q5=Y,G.7"U=M$[RQ"QWQ)O
M..V36M$4[R,C#:5@2".DPRO8[SGN1<T5,6%DX0`4P"B@52,<TL@[P-7O9I9F
M+H4B(H^#&,:BJO7ET_C_`.7O'A[[OA].?I0I??&HI6MCEU6$*0/G9NR0$-L@
MEA#TI]:O+:!57/SLU<Z8-KW2Y*-#YZJWCH:B-;Y%=I3!!$%RY*#5S&$5%;J5
MJ\O5H=YJK_/'_40-"97/8K&\$</J1534[+/CY<:]JU@#2Y4D<5DF0PLEP'R7
M,&K!:C<L:$:J(]ZM<K6>5.UGQZ_^W^72^/\`Y>\>'ON^'TY^E)M)E+'C4Y)*
M(%7+7QT6076ND$(=Y;R556)Q5JIP155K</6.9KG@)I?RW=H1&KY?*BHJ8B3Y
M4ELA\\?,Z^VU&M9DB^3@CO)Y</Y)AEY;M!-#D=H=_!V75AE)$JH=S:/7OP8Q
M)Q:Z4CXX^9E'-((E84C1?2(Q4U+EYW#"<,OY+EFG\ER54Z7Q_P#+WCP]]WP^
MG/T;*1ZZLZJDBV4^MJJVFDDJR%94SCP"6EA81=%C(-.E1G$&-I&`;'T(X:OU
MJL3\1FF[LI(32,CE8T27E1W@C%-,-7Q118VZ61Q#1!M1024R[39BKIP^ZJD8
MM5;S;'NJ,DI(G-9`,UCFV45%YM=+9ST1XRL"]K\\V-X)@8(S7D,4C1"$C>V1
MY'Z&-9EFCE<Y4_[\2Q4]>JDY*6$OE\"$C]Y$!S@(14:]Z*=5:Q%3/)V6+$19
MU-N5SHRQI4.355)I4;44)/I3:Y,Q@_H_JUR9GQZ\5P]H6MC"#+)-HKX1[RS5
M(6VKX86V-C3.-)(0-M5%A#=$1KF\I'D02CSQ);!MX0CQ+RQET,4R4ZP8\:3'
MW@X,HQ$JB3'2FRI\%$1[B,1-6;'<<Z>1<6XW[=$5S+"`1NWW2CPC?_HI&EL#
M0:B,]UM#_P#K;/Z-P8R_U'8?Q>NX'O4DOUSN&EW'7QZ_=$F,^J=7[HD29=:=
MQR1`K"D[42+&[N+5'<<#GN^LX(JII5415;P72OE3-."Y?X?'_P`O>/#WW?#Z
M<_1LKITZM)MBQG3+>1#DV$.!<TTJQD$EV1(0IT@`KJLD3BD-RV.24%SU8-AD
MTM8*PJIL>?"/]7(C$0@U5.#F+EQ84:\'-=DYJ\%3/$F5'*:FN),(]>2VKM+#
M2(D@:C)$L0N3D641S5\TB:V=8WC=VL1'$.&$"%-617[FIH#""*12@)&9.-8^
ML4@&"03=`WL&-7JNAQ%S7#B65Q:35>(8'C-.D)$<`6KEA]7B>.O8(>M<FM$C
M4Q'M:4ZT]G7KSH5A#1@2Q7L[6?!ND@%_W!N11D;FUR*U53%7$W+4"I;JSH(>
MX8?=9+Y==90C"BK,2.0T>+)C6%6:8)LJ,]B\OG,5A"HJJWH_'_R]X\/?=\/I
MS]#<UW3N4=G'C1(T,Z,81T,MI90JKO[6$S&YU>V:IDU(K?H^**G#!)9WDDS3
MN5\B=*(^3-DD=YQ9,LROD'([RN<Y57'K"EFD@27:><B)S(<UK>H=A"<O)E-1
M.".X%8B]A[,`K+[DT5R;)@=9O^EV).K^CE$R6.9Z_P"P;)>.3'%XKAX3#841
M6N&016M>,C')DYCV.16O:Y.M%P2VH;&!0MUHCJNU.T-00CL\A5AGO8^%))DN
M@&;@O7)K4$F;L=^E[NE;FE51&+;[1=`!MY\0^>;8]Y7]^MYLJ"KNIX)/=)62
MY/(S4W'A_%#EWT5K=V9&-R1[:.-M:WK9I%X9]V;;V]<U4ZM;F?PZ7Q_\O>/#
MWW?#Z<_0L*VW`&35SH<B+8`D+I"6&83F2&D=J:K&\M5[2*BMZT5,.+5W^_)F
MUG/S#/A[=JY#^4KE_M)LV='L+"*C?JS,J3(5N3FO)GJ4??;21,E:DT?CJTMM
MM%*[4B(SU7+#M>!+U+U)W=^:=7##A4>V]LQJ^:!XBI6U-8R/.CF8HC-.X`-,
MQAV9H_7JU^7/'</"V6DRN8<T>X#8(^7M#;KV:V.92VPS-FEFQCHC7U8%D1AH
MW1K@Y=M+.84EW?Z',6XGL'JC,)ES(]1#9_35$-5_TCS*1$3FD*J:L;/MJ!((
M-X-MS5=:>6,JAEUTVJLGVD"T2*\4F34QP@[ZK$=P/%&J*B\<2XF\6<S>EO$Y
M@;YDGO--<UE>]7OK=OL6+"]2,JB2^8^O>Q3*TG-Y\O20K.C\?_+WCP]]WP^G
M/T-T0:T)94N142F-A`^OL`Z=4NM#_P"]91$>!O5Q)UI@,N"9AXI6_1/'P3LK
MI<Q6*B.$03DTN8Y$<QR9*B*F!0U&6=.FH]L2IAB[U/G99-)RHJ?[#-:<PI%8
M`2+F1[4XX2TOX<.I8_4_\.4"I$9)0C$:K=T6<%([KG-G9=%9_2=;7+(;DN!1
MHP11XX!L"``!M$$(AM1HQ"$-&L&-C4R1$3)$Q)K]I1`[BM@<P19#Y"Q]NUTA
MG!13;0;#+*E,<BHL>*TKVO325P,]6&6F[XFXA7T@2PI&ZK8-;(H:X)B,>2)6
MCIK";^'*5Y!LYA3`%JT-62<FC6FSE&K?6/XSJ5JLOK%_IK#USRM/'+\+]^U^
M3EY]+X_^7O'A[[OA].?HVL.@V]65\@$MT2^WZ-I:^Q6P&UJ28=0M0:#,M["'
MJT%D23)&C&31HD.:0;'#K@E)*,T;9MM/,^=<62B3)CIUB?,YD9FNEG`0\UT-
M:F!=]*]\N5K[C61!K*LY[F:=?=(0_I'C%K3F%72$+5U$>QO'#HEO2[AIZ(A%
M&"IHD#9R+1OD];S*&9+N2-)_\2.$0UXL>^2W`JULJ'4D$C0AJ9H_4DL348CF
M"953QPI0D0:IDG+3A@QYKF=T5FAS7-YW>.=]&.,(*(YTHTM[T8,34<XKG(UJ
M*JY8VY8[KE.EW=;MR#4UM=R^7&VU#[K&:>-]<=9]X5H6#E37.[:"TC:QJDYG
M1^/_`)>\>'ON^'TY^C;U6X<ZJ.6^O[FMN9(GAI+*+N*YFWW+;99.AQK"')LW
MQGQS/88CA<QC58]%PPU!6R(5.20D8NZ+6(\*+Q^D]1TTI`2IKE8UVB5(:*'J
MTN9WEN:8GLK0S)%U..,<RXL3+(NK!HT(X,N7/<SC&9U-B#0<>.KU0(VMRQS1
M:6.:Y/JE\PC,O-RXL<CDS_EB11R1P)YG2'2[@9"19DA[2]I6%KB-T!0H^6-J
MO16M;QRZD1NX8VS-J4\UQRK7%KJ2OCRHX1JHGF8<8&/88I%<CW,1FI$3//AB
MHH!U39A]QLA,H7]X*-LB8V]KX%^&1IC%:)M126;;!.*O*(!\D[&>-NV9*6W:
M"U9312O0%6-LJYNZC;UA%@UO.O\`^F&,VYHK"EEJ,#.9];I81[14\&#<QWE@
M'FMF3A5HX.<6%2SI417Q[23([P`-Z+MH-8[M+]!')I5T<U=6UI#GW57U`J]]
MK(;,FT-PV!-@WD)$K'";W>GE'+*0[A#$6&\6M5>Q?\?C_P"7O'A[[OA].?I)
M&F_5,1Q8Z9B>W21<NR03`\QC=/#6Q'MS\O6K1J1B$?GH8KD1[LNO2W/-<L2V
M13RCNG25DF?**C^WQ\QK&L8WKXKEJ=Y5X)E(O!@RL9#.60G,>H^+6,<Y@L]#
M7O:Q,U_\5P)U>!LJ9ERXZD$Z49@T1RN%&8KE0;5;GGDF>6?'$8Y0H64URRN\
M2AC=+').#DF(CM/T!%`[E]C+(?9ZL=W]5UW=]#A\CN4;DZ'@'%<SE\O1H=&$
MT:I_Y&HG4F-0X,-CN7R<V1@M7D\H0.5FC/J^0!C,NK2Q$ZD3`BR:FLD%`T3`
ME/`BE(%D=7*!@GO$YPVA5ZZ43S<^'^/Q_P#+WCP]]WP^G/T4)3\GGL*UQN=R
M^$=,U>J<U4$G'+5FO!N>6"E,&"TVO2XL%#:#:4THNHI':^"=>28B7KVF]80A
MJ,:M-]"YNDK6\P:YIV><[+3E_/!;)T4LOEO&/DB71Q([2CB$TOY8T_CDO'$:
M7H>!),<,CE&324?.&TG+(WR/9JXX"<UKZK4+T<QZQW&&=%X$`]4<B#:1O#-W
M##31RC,)_F$$Y'L=DN2Y.;FBY*G2^/\`Y>\>'ON^'TY^B4;"N`\@WL89B(KA
M.<U4:1J+P5S%7/'J1]A*W39RI9K2;?S@JSN43@P<413FEF8A'C4CDYKG.=GD
MG'!P&S0X2/$1,_->-VE[?^5R8-2,DHME'"TY`:7Y(U=*Z4)ERU(UKVJK<\\E
M_P`\GN:Q2N:QSFC:K4<1R)FC&J]6L17+PXJB8E@W)M&RJ'SSR&-[Z`B,0`Q*
MU'JIF!(#FHY4:Y&YN7CU:<-B0Q\L+5<Y&JYSUS>N;E5SU5>OI?'_`,O>/#WW
M?#Z<_234F>ER/3/JU-XM7_E7C_G@38XTB!5TF5-EZG%DG.9?HQ,YCG9,1V;G
M=2=66(]W$"R?+D$!%LI#(RLD\I2#8U48QY=0E:U&N7SN">3J53Y3HCZXHW\Y
MK<N\D/EYO6B-C99+UZN.$:G4U$1/\DX)T_C_`.7O'A[[OA].?I[^W!3_`(PB
MQP0*4.V.<=DK;X[*7/KMLI"!MT<NVK;>!,;+6V63R(DV*1BB*_E]G%M%M;NN
ML+N+XPUNSJ<TBM!`-<[=;,V>Z_<R##*8+'UXKJ4/G]G0-C'.[?7X<U4W<ESM
MS<P=_P#B31BNQ#2MBSIU##W+8[2L)U0P4>NMJ>;`JA->WE*TK"/1N2O5<1Y&
MY*,FW[T)9,&T@*]#172H1G1WS:R0G]Q53]'-`Y<ET.R7JS7I?'_R]X\/?=\/
MIS].LA2I0@2[F2:)5@>JZYLF-!DV1PAX<7C@PBD7_P!+%Q#BAOH!),]\<,,:
M.?J,^;-MZ^,QJ\O).\3]ORQ-SRS(!4Z\L[Z^YE-"C5VY%]?6`XJ?0[JECK:=
M[S/&!Q'VAQR8T9SF9N74C%7K3!-R/W+5-HPSFUDBP=(1!1K)SV#[A+;ES8LQ
M%(W4,C6O:BHJIEQQZ@L;Z##M_P"F3N1U(U^N8PA(8M?+Y/>)C1.Y0]6LJIDU
M%7$QNW[45DM>_ES.4&4/NY-3V<IZR`"3FM<Q45O6WR]'X_\`E[QX>^[X?3GZ
M$H<0S8\LD8[(LAS.8T$APW-"9P_];1$5%R\N+AJS8\J^MX<M+FW??S]PRG&@
M4%@VJM:B$':6VV&M95]*1QVG0TEX$1'RI#VLT[CW*_:;!#)'JZ[U225?.N;A
ME!MJ25;*L#;UD26ZRW+O"S<V46:.']&-2.UZ6O=X<S+`OJ4M#8R+?<8:FZL8
M<T!INT+FI?$I+6`$!R\FULF(YRJ!"1D?_'0MI$]9U+;)FUJ>+MN?WNR.^'NO
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MEWG^D\>QO"#\R[S_`$GCV-X0?F7>?Z3Q[&\(/S+O/])X]C>$'YEWG^D\>QO"
M#\R[S_2>/8WA!^9=Y_I/'L;P@_,N\_TGCF=SVA^.?Q__`&GK*Y_"?['9>T?5
M/KCV1VO[7^Y[/F=K'__:``@!`0,!/R%+Y`-:%(30<?OX<.'#APL58T9,H#O@
M(,'>`T"&"B"!IX<.'#APX<.'^".[^,5XU^_A7NA($4/A7B*CNJ3C=6`$.RF,
M5,P2HS'^;I6%6XU,"*H6'B!-E*,7UI\H<*'7GV'W38-HLM8%>L6)ZM'="D"1
M2C&`Z\&C>ES;DF>/S["NB[)H755=3.1;'`@INOM,',@X=$"PG3%$I3G4`,Z9
M[-X#['*AW+Y(:<H$0V>;89N=E[BVC%`6S$TOTE!I)"#VPFIB@B+@4H@AW*F/
M&TK02DW8^!>\G`?M8P+.F$%P+"`@H-![!2C\'DV'^?Q[_6&(`WRD2\`@D%#E
ML:[D-(FF'V:XR62:)4APD1T`F3[#@\/4FM?RQN``M&M:L.U'!*BF@NX)[(/A
M3R;"9E;G!P8IM.674KASXN+!W>6$00"^AG23!X3?G20(>@>`;19<,E#P@A#;
M+3*I,ACTD8<JQ'I"3<E?MN@K7]AK=%#*_`"4)71PX?TAG7D'ECN28+#\KZ'Z
MPV7>*"W240%54>J:\&PW2H5CG%MVZ\Y7L5_&J^$L.B"9=+`574DWP-(Y*Y(9
M:*B4,,-._;N*Y<C)HSC1I^4Z4Q;TX%""3H05$)XZ5-A@T`NB;&*;>5(\KD,%
M3W_)#$L9..B15J+RQ7*^8\E6HPWUM0T8)ZZ2V?RZ`1,1V0I"N+F!R)`P$XP!
MP$IK212K_2JZG35NG]?'L*=G>"2ZKWC`!QCOV58T*V\<WA@S(7>"^D%MU;99
M?G0@%56I+S.#0]:[W67A1092[`0`C,-(176!J`\<L.()@++G#?)C*=4-">--
MA;"/$%N<-CT)7D+`)U"(V-:C#@$Z`G?&0`Q&)P9]5HB<0>L8UN$#3Q/R2_'`
M@9M?D:I'>A5"#*3=&8@S8?:N<N1IRFN[#LO['7DV$4$8185[2X&'61#KQJCA
M#9)28+Q!HK6FRZK$I&<3Y,H@4Y?<9B"98&@B$!(9J3(EXF5PK4$U*5*N'2OJ
M;+P'9Y.PJ=D'8ZBPGDD.^-N[1S9K@\\<\)K2.3)"H2S;$7UF^I.AEJQCE,*]
MR`M20>"S_O*BZ?W\:88#_P!+V2D<'",P;2+]<0`%TUB#)VU+M6ITMA<9@"6>
M):>&.'2=A;-<]7BYL.<DQP]?KY#&9SL0\\S@^T-9LD::.M41[R2@&%:Z0A0R
M'Q&]]TO!_>?9"S&7H%PB)GDA@E+(:NLS_P"2`$/+$>)#`(<P7IX&C^&KB$"]
MXP$0RT$M*^'82P:8@#:E`4![2((@HXA,C@3T-:PX]Z`LH;):EKRR'#8/+`I-
M/*!-Y/3;*0/@8/9BN6(,J/Y4$C;0PCCJ+R6E`'TGDV'AO%T/J1`]F17>UW3\
M/4`?7!X$HMHQT-8]:UD!V6@U1*Z0-ZP0?:9&-1H0%VABG\G0?YLGG#:Q5%^'
M5@ZKWKR[#`F0G`NCPHQ>`/(8!O/D9\931(-5'8HS3(!9!!>C,8R>GJ@G"%H4
M)H#-A'5@0K5@>?8;A+1;QDP952EZ;47#BG*&(=<U4AY-=E5X10WU1URSCX]'
MSC81[`R%,"*9)BKIG58V'LX%]LD$"]:!B.BWR`#'RJ)FU^$FS,!'F",/[+X5
M*[@1F""K(B,E8T->+8;WD)+T09/43`NL>,QNPXMSC>(%--E?Q1+`#8(2$=CK
M7NKCD+:C[)F[^$G9(?+]0<2C`$<=1QAX!@(($A*$I`2L*:\0<HQTHV2.^CZV
M'?[V"_1[,M\%"S_A-^_?OW[]^_?OW[]^_?O[^YE__]H`"`$"`P$_(?\`JW.D
MJ_1D5/[7ETFQ3-1XOQAKO=!>MZ[$3QPM\[VV--H[T-*:'@HJ&\@VXHX[[$E&
MK.RW84)#H7+4J!NAP'\OUI0#LQW%I1T&M2Y5L'.I#E./,@%J95'&P^GHMU6*
MF1&B![1EPMV=3X\+)25P<DYWUAT%KL=JAT"+Y-67`Z99`;9HV)DP?,;K0W9F
MSG^_YS&F,B$OL3]'V4]F?:`&(&GKN:X=8,S-T_*KD_R>S*O([0FQ<(:BIMX\
MHG:\#%A`8^"NX[`:%#W&L7,*9+V"7KL4_4+T8%7;T0#T4BC3'`9M1'(D@=6T
MER9C9C4'T.<II]XP#,YH?<`OSR]KY)`5O4Y_W@"X.IB#9>5*=E_U,-VX/9!3
M_P#4$IG!,B%(<&]0Z)/C*>/@`_$AJ?H]^1CZV^@#"1`2@?JY+\KFZ\/R?AP?
MO9@!>H+_`+%\/Y802/&,0.:6'\R'RIT=L,.EOJ[-M/<EXX\@JII,5COR&-*X
MC@.C>5R;8.OYI3CL37>46J[<JC5KM\5Z/O\`&7\ZUP/\ORX]NL1T3A^[K\^3
MYM9@L_%#B22CP/\`>\B4&Q1R^:(7?AO$NPLMS&FC7T#8/U$DVF(G5=Y0Q2"1
M>T);T+@]8>YX'2$2JZ2^O*ZL^##[E^X?RP(FE&LYDBO;R]KE3UV]'V\']^L?
MRZ'&D+("&G2<MAVHB!6Y!-J1N&0@4\G.OL=`BD"Y.!CU!M^7?DCN3V1`(G/7
M/&64/8-MU[$&*Y+6&(WDESW;LETZK"K(5[1U+;IJ6(VL[69`,H6P:$WQ,4PT
MNYVY:]=T@[>5LUSC$@$.1/#U8$=!)DJL@--N-$+U7-":7(E$=#G];,P]H9&4
M*D)0D^H,#Z.HI=W<!(1(X/<5&`7[#A^?(;1)'@#:OP&+:@L>BB4V:":F-"5%
MO@W!@!:#PH<GDDK"M;Z](*8W;9LY(-D!P&CMP=^]'#$!("\=G@3R_E/J7^8G
MZB?&$+A4243`,)ISH``+`DZBCP$!!.+CBA[`B*U**T4UC*>H"!02*`V$@T+K
M#,,P`U`F&F7F5+`P`^]A_#L](/(8U=W+M4H."`0:HL!5$Y0")N5:3:/8PTC7
M^0$UR64T`K60'T?^0__:``@!`P,!/R'_`*M5K)7Z,EX99YM)M+@#Q?BP14I^
M9U^$T\=E\])4Z;#MH8IH>!14-YH6)SH]GFT6+\EM>N?X>T^J0?."E4`ZH%6*
M"-$>8;K=]V!>CD?IP!SZ\P7!]6_'Y+0G'*[,CB[5='ZN55TJ:L?JF;F:-_.0
M)-*5OU+"W@8=A?-K@U1LO05_BX+QPDX^DSZW3B&CUPS7#3(]*-7+919\)R?T
MU]ZP\GHMCT@"#JHK[0:*?(:P+46M4%#[5-O/1C`J@`]O!DI?DFI3V[^V/K$B
M@\!'6^3UQQWSA$_,5GU?Z<>6I$YQT52/F/,>LT:HK`(CRA&N>Z8W.H;#'%`8
M=%Q6==BK]'[\C`K^C"XZ8/SK\'!FG_8_MZ_I['-KHY7)_D^3\A^RH15Y//V=
M_>GW<`SN#U?<A_/R)=/&=O4"%^1.CU->LY(3O^J_MP`30R,??T_V_P`.3PO9
M<XL<#3_'D."H'L.S\F".6HXG\==<9!3TY_"=OEX=IFKD=%7Z3?T^S@`(<9<F
M'=!]:-?@,P6.["`^C0]J?;Y1.S^6'ZB?KB:P\HI]K_\`,JZ?U?K(IEU:_E*O
MH#IC)=X@43X<?Y9L_$/$_O>`[XQE-%#T='D.3>]J]Y^O+U^/?\<Y;JX)U@^M
MR44^SDR,DGKKS`Q*B5EUJBOX_P`N:6QS_K&<>8T9JT,-Z[Z_+AJG*$/GV]&1
M823'DI=^8E(<YNR!K\]&W^O+G],Y.`3_`'[XU_O$B0K./>63H*]>^O.8&4BC
MVF/_`)%__]H`#`,!``(1`Q$``!`````````0```20```````*X```````!\@
M``````87L`````3&L<`````/6Z$``````TAP````"*$=0````"]AH@````#*
M>GP`````&8J``````&>T00````:5%D`````'`&X`````(;W@`````"4B````
M```22```````"22`````"2"2```````````3_]H`"`$!`P$_$'ON`JOW>10:
M_?H4*%"A0/FI9@)\QQ2EPD(,]6'5,4B(_P#`H4*%"A0H4$`;\*`C&;P\FNXN
M,5OI'2I)UTD./VH8W?[_`.=,Y%^"5L'C'&_TT$2*)TF.H%U*1YA0^O\`EEW4
M`%0+#`7@;A;B(O:#(I/FY4@=.<V1%YA05$2A*AJ(#%)&EV.!*6."M@COQS@:
M([7*29,8#G73V%P,U,AGMYST)BS**^44#P]^11]M)?\`&B<O#F5F6:0134:>
M($`0<2"MCA.S[8;RC4%0$T"`#7(':_#]=9;9`C4THHGA43HX\@H*@H*!02H.
M"J/RA^QJUUX@(5&@PM37$;+5MT*55#\JTAR_S4$0I5FEI-"LF\%Y4&Q@U50O
M8I.$98$RB28$(5$W8[`TIORB@HVUG'V'#YKGL`0F.3*B?0M!\(%2*V/6.*YZ
MX:8ON.!A`REXQL3\ZJ#"6\X^"@0R,XU!*IZ?O%[G(_E^S0;0#F%O07JJ:T"5
MEV2;=<`&S';$\%/9T6<)O!.W%,5(I**>$4&$8/"J$^YB;15;!.<92D`@#N,]
MQ&>38:UGJ\TO-JMI1AQ11=$AR[B&V#<)//0QULS-K.0-E,Z0+S9SQBR%`JDI
MHJ'^J2Q'5<O+10UE8SM9"7YA>\=!F6[=2A,NJ"S$<G*FUYJ]JEJ.B(Y>_;><
MHRF0S/V*0'SV<!*47.U@WTH$H8;LH>,4&/W+*0W@L8$;=W%V@:VVZBV&[8P_
MHFX1T*50#&<5U0U!%K8NH`!?C<"1&=)K[(J3T5B$;JK[UFRP>906+QL)C*D8
M(UT_0H!$_$:/ISP*X%RARA.`-J#Z?E@_T21(3*R*2X0A@&[KJ0CS4IA9?Y'0
M-IP`!C>G)T9&+@*Y#;R1G`L!`:5BM<FPKEL-*!$+[CXQ0M9?7!+,H/8)KOET
ME%ZS?Q7-4B,ZB]\#E,RQA=NK.F"U.FC2Z>N?$G'``*F90F(RS=*GXT<2&C*-
M:HM>3"2*`6R\@*&9"@/AA[!R!W5W'2A?W5.V@U6.P@ZMV6ZM:$`!.I,!O!1<
ME6:317(Z,3O-W&#H"(':$,W$"JS'`CX;'`ZJVUB_L`/_`,Y.^`8##((_]E%U
M(H^@#P"AL::/)P:LW+B!E6\VE6(NPV,A).5N4R:5,=LCIO8`0IVH&Q"(,KVX
M)K0IM(C/%H@W\_!>I`JEIGH=,D#1DPL@D``$R4C/9+W$M<*G91MG2WG`)?%2
M4STY'85/`*"UP?J2N8&!(R'`0(I9R7-SB-,YJ2@,YC&#<287=7@U@X+99=6*
M*^E<S(`W]&,>WJ(F]]1:`&1*)-9$TJ2=@=CY!0&=.#EF2+6(#B.BF%'LW@<L
MDF'FR)Y2C;7(D<+Z$@%+5I@D',8>#EO:N"D-!$.])*\X'&%$"(+LWC*W1@``
M!Y10*H=LA77.(D(Q!#ZJSQYWJD>!VWQF$[\P,J1L'WMPSP0E"!S>3C[2H^AB
M155[\XH+MD-B4;FXT[7[N]8PC9"<V.9F-K^SXW`9RBW<GM'(@U$KS@H''!H@
MO^W*,%0%I;"@AF;*Y@'',87YG0LO0&$""I!\CNX9TA5BQOL\HYME$,]3,8S+
MQ[EWUX10$NI9K.(#D&]OV?H189T%!PDJ4E3'*HJ2'!C/E+H=,BK\4'"`23;P
M(CFVQ948QEFVJ3?U)H_XO5D>CU4H8/M\3S_A"[?WFXL+:!O11&G_`'L#>^40
M^"1@8*$J'_![=NW;MV[=NW;MV[=NW8&;5O\`_]H`"`$"`P$_$/\`JV\HI%@5
M858'`+ZS9`T>9D!S:8(I&%NU97-$`%Z,2'0'S4+K:5JZ3U!4,H#IB;@!KH!K
M.P4SQ0]135J7'DD`7`M*6NFR:;`%DF#5!TOVB6G(I16WF`ZC&!*EP($4#&7;
M5YW-+"\".)P!1!%.E7VBP05;,A?>VE`>$J8FQ0&S>OM",I%H!T86;Y\L5B!2
MP,L1(>HG=D0T\6#A[+H=@ALDA,VSA"$`.`!CV6_SAO(P#8+-@C"C8PG,VP1N
M""!#`J"D?7K]*>0<VQ!0#8+(J\\SC6#_`$&;29HF"X!-$3TCU*:1AQ;J;Q:.
M]V@(D0K!B2Q+_9BV[<H6:(RF)D:O,P:"(H$`UV8/Y(I?F?8#.Y&_)P[$A17B
M=*ZFRP'04Q2SZ3D3D3A'8Z<,B/F`H&VB%CLW2;C#<_6#9*+.9M%@"9"=J=!N
MXQ`52EN[Q"]!00UVAHH$4\GLML""G.P=75EUD#)%)J65W:%[<J&Z@!4-&L&M
M:5*%P(JI:]&G9]<M(EQ``HV/#B!7U51G]A"1WP/U4Q:Z1LK94"JI'QF'5432
M)PCTF6^UK-H!G8@Q`&;D%MC4J)B.RA@1Q\AJHJOM7;CPO%FEFWT?LG%WBIQ4
MQ"ZIU']0"XP]A32-?!0OL7QY!"/GP]'PWX,4:@@-W;PY$H&"UB@-:U4X#L&`
M)CJM,(]UPX33+<4`,JE57:J[5>5PA=VH(=XJ1J(3E=V`=<`T%+QHJ7R?.C22
M%QW@=3:T*WX0..H@:*C,6%S><#HOPOR=%O`+K%B$F(ZE@`3-E&>J3H&CEBHA
MHC@O4YB:"PB;U`0`O2`("@G0:#JSR537T7E#PY`$#%IE"WG8I%622D+`&E8Y
M!K0!B<UE%BH.CNV&5FP%@&J+FW[H*2&Q><"Q&PSJDX0`25;Y-C735XOS@W\F
M2F.##6(<R1C8>=0*=<`7K!CG&3^)1)AEPB.CCSVZA`B`+"L6QK(DMN-XP&#7
M"BD@Z=AT$\C^L"`=0=`%5T!</6"48LH15#-6"X3\48>`J7"CFKEOFT)T!:JP
MT+\G!<\LXO14YP'\=*]CN8;RI%,&E.'R(I!'O0^3=^OE$:P4Z4<6:>!(0,,`
M)F\Q)%JX2":!R:IB1FQB:TX8I89.8K*J0<%,)HXM",,BR,GE$6+'@:HX4BXQ
M,0#=%2C.:<N48V3C.+=_2@?E[:<)G=T0#@596^498HJP`"M6!RJ^_P#R'__:
M``@!`P,!/Q#_`*M9:HBP%6%6!P"^LVB1CB)@8DP$4C&!K*8,$MAY+IA'1\_(
M<G7QUR=)$;2]_A69%2E.VF`#/PXO`;,XPE#0I(K2!<T*N-HF5$%8&Z1C<%U0
MNR!Z@';S<&Z(8E>>\-;01LR=`P`#1J?.CCG;A<.+"'<*V%FW?)A\$"%UZ6%F
MGCXZQIJ]SJ4`0FS/I5%F^?**0D@U+2^BT30H+@3)Y!:10<(Q$V:<G(%VHQ!"
M`.`"&JB(JT$I[+SABYVQ<JK<EU$=D$2@HBG#U\:I^B^1_(.3!K^>L4/L%U!$
M2`:THNWR9+%;H`&!8H$M)-NQ4@&FJPUMLN:#*G0*2X<X%C)6,3*4W95%3D-E
M.D7&S4;!?A50^#'0'DM6"-CH9W>M>]?6(3^![/8].&7:>@,')6F&E!1A@12Z
M9B*&PF0TA:.S`;$]T=40*SG(`SB@I05O2\C$B'DE^L/:P'XUON<8G++%1\<`
M=``9!7=7C/:^6_&SN#'NBZG\PU^8D:`P4::<-;."+[]:^&QO"8ZVPB^0!`3D
MA1V;+Y`"`HB/>!G3A.'8.0;6P1H3$8V3LN*`\]*CUK#A`\`0/H,+,IP;>X?T
M.^6$:4[#_/1\'YN"`!!=MM^DW]GD^#2@B_B$_.#':G5\/2<*BA0(F0!(0CUG
ME#8)*$F\";=`?6B/M>%310$8$@&@/09)W$5`7@2Y&JE!N&*=7MX;Q&QR;T,\
MG<LC0.>4]5HXC$P:LA'#BI8=&AT&1Q'1S\`Y?Z':8ET4K`<"/PPD:TR;<!"&
M@@@Z`AC+8J2T<1Y<!5H!4,?ZH9JBM.X0ODJXLV@*T+J[B6W>5H>SP^G*^='>
MF.UOE6_CX/0:R]H8Q^^S[P%,D&-D08-$H6GO&[!(E0_!P:]>913G`A'$*5G,
M.7\8&V"TWO@`#G;."J`"=2)IG`*5!0!?OVVVSCSY"=X#LF<A[`J("H>-$FW=
MPWG0)RE@_9'<)O)R\<D"!TEC\X-<5\K*D0E]?.*40%=::%)VU%$F2R3!`4TK
MPQFD0*:L1ZADQI!!0:"H5X*A[<@AZ!J'6PHV;-HII/.H;VY+.4&PFE^@+R@"
)P,5-:;_Y'__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g575431g37v45.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g575431g37v45.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`)D%D
M;V)E`&3``````0,`%00#!@H-```3S0``21D``%AR``!E.O_;`(0``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("
M`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"`@(!`@(#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\(`$0@!/@&T`P$1
M``(1`0,1`?_$`.X``0`"`@,!`0$````````````("0<*!`4&`P(!`0$!`0``
M`````````````````0(0```%`@0%!`(#`0`````````$!08'`Q4@`C<($`$3
M-A@P0#47$A90L!1($0``!0$#!`L*"@<$"@,!```!`@,$!08`$1(A$Q0'("(S
ME+34%365U;80,#%!(S1T%C9V0#+2D[/3=876=U%AD4*2)!=QT5(W4(%B<J)3
MQ"6UIB:&"$42`0```````````````````+`3`0`"`@$#`P,$`P$!``````$`
M$2$Q4!`@,$%184#P<7"`@9&AP=&QH/_:``P#`0`"$0,1```!O\!6V?(Z,Q\2
M")D'1GK``````````````````````#['I@1D,:'HS^'L229#\F``````````
M`````````````````"'Y,```````````````````````````$/R8````````
M```````````````````(?DP``````>#(FP!P3G`$G*RD`````````````17.
MY/#'1GN259#\F``````"%D:PL```;%=614````````````!!<Q0?P\R9Z)3$
M3"9I7++C`'!!S@9/+&K`(;QK30``!L'58G0```````````^QR3JSV(``(?DP
M"G::PB``#-Q<3<@0LC6%@``#8KJR*@```````````*J"5A*L``$/R8!3M-81
M``!FXN)N0(61K"P``!L5U9%0```````````%4I*0EL``"'Y,`IVFL(@``S<7
M$W($+(UA8```V*ZLBH```````````"!)E<R(?L'X/L95(?DP"G::PB``#-Q<
M3<@0LC6%@``#8KJR*@```````````(CF2R#!B\X9X`E:3\(F$S2IB:PV``#,
MA;/<@0WC6F@``#8.JQ.@``````````!]B#!D@F*=8=F`"'Y,`IVFL(@``S<7
M$W($+(UA8```V*ZLBH")YC`'S/B<H'H";X``````*VC,),0``$/R8!3M-81`
M`!FXN)N0(61K"P``!L5U9%0&J"5@@``S^;OH``````*RB4A)$``$/R8!3M-8
M1``!FXN)N0(61K"P``!L5U9%0&J"5@@``S^;OH``````(0'JR6@``(?DP"G:
M:PB``#-Q<3<@0LC6%@``#8KJR*@-4$K!``!G\W?0``````4Y$WCQ!BLPV8P)
M4D_B)A,TJ8FL-@``S(6SW($-XUIH```V#JL3H#5@*S@``9Z-U8``````^Q6*
M2\/;GF#U1S3E&4R'Y,`IVFL(@``S<7$W($+(UA8```V*ZLBH#5!*P0``9_-W
MT``````$*3+QG@``$/R8!3M-81``!FXN)N0(61K"P``!L5U9%0&J"5@@``S^
M;OH``````(/'L26```(?DP"G::PB``#-Q<3<@0LC6%@``#8KJR*@-4$K!``!
MG\W?0``````5^$HS,```(?DP"G::PB``#-Q<3<@0LC6%@``#8KJR*@-4$K!`
M`!G\W?0``````>-.01L,;G4GBC-1+0B`3%*F)K#8``,R%L]R!#>-::```-@Z
MK$Z`U8"LX``&>C=6``````/L>F!$DQ8=Z<$R42<(EDR"G::PB``#-Q<3<@0L
MC6%@``#8KJR*@-4$K!``!G\W?0``````````0_)@%.TUA$``&;BXFY`A9&L+
M```&Q75D5`:H)6"``#/YN^@``````````A^3`*=IK"(``,W%Q-R!"R-86```
M-BNK(J`U02L$``&?S=]``````````!#\F`4[36$0``9N+B;D"%D:PL```;%=
M614!J@E8(``,_F[Z````````1\/+'5GJ22Y#\F`4[36$0``9N+B;D"%D:PL`
M``;%=614!J@E8(``,_F[Z```````#Y%7)UQY$D42Z(F$S2IB:PV``#,A;/<@
M0WC6F@``#8.JQ.@-6`K.``!GHW5@`````#['I@```0_)@%.TUA$``&;BXFY`
MA9&L+```&Q75D5`:H)6"``#/YN^@``````````A^3`*=IK"(``,W%Q-R!"R-
M86```-BNK(J`U02L$``&?S=]``````````!#\F`4[36$0``9N+B;D"%D:PL`
M``;%=614!J@E8(``,_F[Z`><(A@'`.>`9],Q````ZH[4A^3`*=IK"(``,W%Q
M-R!"R-86```-BNK(J`U02L$``&?S=]`(OFE&```;'I=^```8E*WRS0K#)1D:
MSRTH``]39)0Q(9;,8$$8```F@9MK&)DXKX,#@``]@6GF)#+9X,J\```)KDJ"
M-Y;>``#CG(/@?<``'Q/L#XG\/N``#CGT/H`?$^P``.*<@_0/@?<``'Y..<H`
MX9S````"$!X$C>>R/9GO2#YQC)!-,FR`4KDTSMB*IZ@Z$\V7!@`JO.<8/)_$
M4CTQYHZ$M^`!4H2N.F(KGL3SIYTN1`````!Y8QT>O.N/V>Q,4GK3KS^&5@"(
M)Y$[`Q8>;,]F;S-(`,#F&3HSOS%!TIG4_A[@`&-SD'U,=F+R3!_#W`,]'I@`
M````````#'!',^9U9Y<]&=`>\)I@`A:32`````````/P4OET8`````````!A
M\XYATY9^#DG*.N)@``A^3````*TCSIZ$XAY$Y!:^```5`%OX`````````!A\
M]`1_(YG`/T6BD4R8``(?DP```"%)VYY,[(Z(Y!.X```J`+?P`````````#'Q
MA4Q<1H/9G<%A!&(FZ`"$1)T`````````^15*?__:``@!`0`!!0+@X)(7V[*4
M<R`]U%PN.37H46<LTO5.3HW>3T,NYQN9$:2:B/AK.,A>TX7M.%[3A>TX7M.%
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M7-)R4QG,Q%0W%#Z4C]""W8=3XY83O2W&Z6F@O1)A!MHY%`LB<'FZ%A'<W[VY
M!^]N0&7HY#%$L]'(7H_O;D'[VY`S'0L+#FLB<+(G"R)PW`)9(O$>/;$G%#4;
MV1.%D3A9$X61.%D3A9$X61.%D3A9$X61.%D3A9$X61.%D3A9$X61.%D3A9$X
M61.%D3A9$X61.%D3A9$X6@A^!Q434[,A.%#<Z=BAOXX2/WKBCCO7CN'T>Q[6
M=,_<S*HJ3C4HCI\K#BAOXX2/WKBCCO7CN'T>Q[6=,_<[C$IKMY+AT\@'T+%#
M?QPD?O7%''>O'</H]CVLZ9^Y<#M5V._(HSN$P@T'XS#3E0WTSG,H''TSD]P$
MWXS#ZZW'PT'=4$-_'"1^]<4<=Z\=P^CV/:SIG[E^/=]-IR,-;<[A2%CD9><H
ML,Q50ZBN065=0IM-V*Z!$A4ZHO9TDW,>280+.*F@=%<$@\JW)XXH^Y5N;QZ*
MX.BN#HK@W`4U7+$>/;%34LT;]%<'17!T5P=%<'17!T5P=%<'17!T5P=%<'17
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M.?W2&+G^DEJRN3W"Q(:6&FON=?6:ZUE=[K342)JYX@^G2L*J&DP@JJ%=`N)L
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MH^K42[QOR&+\AB_(8W`*R49B/'MB4TTI&]^0Q?D,7Y#&[0R7-S!BBO/DI2??
MD,7Y#%^0Q?D,7Y#%^0Q?D,7Y#%^0Q?D,7Y#%^0Q?D,7I'_#@=C(\??Q*'EMJ
MIN>$N1A4*0(E9*C$B_,T50V2)*%&%J5*@DB1^]<4<=Z\=P^CV/:SIGQW>:R8
MHGU3]M#?QPD?O7%''>O'</H]CVLZ9\=WFLF*)]4_;0W\<)'[UQ1QWKQW#Z/8
M]K.F?'=YK)BB?5/VT-_'"1^]<4<=Z\=P^CV/:SIGQW>:R8HGU3]BQI$)/\LK
M3`V4=QE9M9QE59DI(;U41#?QPD?O7%''>O'</H]CVLZ9\=WFLF*)]4_89^>?
MED0FZXXZ.G8W?ZH=I0L]U)'C5FO$NZ72W,KI2800LA1`M-,2#2Z+QQ1]2ZSQ
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MUL;^N?Z+!_)O5GTZ>3MYI,49YT-)/3W(A:BF<5U4^DIH'TE-`^DIH'TE-`^D
MIH'TE-`18IG%"5.GN1#M=>X1GY.GN1#R9^X!\-OQ*DP>)4F#Q*DP>)4F#Q*D
MP>)4F#Q*DP,&/IZCI#Z>Y$(3DW#+ZGT]R(D;;1+$G.7PE?P\)7\/"5_#PE?P
M\)7\/"5_!O;0)(;2_P!/<B'RZ]PC#;'3W(AT-K<([6[X2OX>$K^'A*_AX2OX
M>$K^'A*_AX2OX19#TVQ$0Z>Y$?9\Y?96*G2I4N&2G3I<L62I3J<<E2G4Y9Z=
M.KCJU:5"EES9<^7CEIT\G/%6KT2U+ESY9N7"I3IULF+GSY9>5&O1,TN/^>AU
MO1ELW5K+ZTLJ+:<)J>)%-MY3?K_:=1SOV2T.O"BCG6'.G5U`VQ'.G24GYS*V
M;I9(GS<RKEXRLI*.9:FA2*'8Q<SN4&S"JA+CX0JZJK.EX1VKR9(99<1W0N.:
M2<$P5>:D]W:[S*A&"U5/DXKD1YJ#/B17EA[ML\J*+G>C).R=)&=:;CI6G7(N
M"8S%0\[#RMD<$9,9Q':$!Y)ED!-3#CQ>:O'#L?KR8F=P.9R*J_ZBRAHSB(&(
MUCPTFF&HUC>0XR6<HGEMEM!RFRR8FDC#9C]OM@HM-!I.2M78S+-+#5:1%J<N
M+H7H.)N<\]MN*G1HR#M\+HKS78$=Q=F&H!9BCFD3;_GSMVE'J]DP/HA&^8H>
MD#;XJ<LSLVU5$?+(.WS(AO5=@9X!D'8!8QW[$V__`)%Y$V_E#/W7$8^ZXC'W
M7$8^ZXC"V^MO#E,'G]MY5`FR#M\1DUU.';ZYV^VLL`M]?-2)M_/\\\B;?ZIG
M[KB,?=<1B](]J]J\3YE*:*=51HEAK]H=S(;F><2Q<T3G!26ETM.A0Z1(2NH.
M20#A(FVIIP$R91RS5[/-ERY\MG3/(;VLA=@IR,G.*/JD.43J"2AI"HJ12&41
M+JYX<0,C:08?;J$KNK63`U=9,:).IV@M(4Q2`LE34IN;(AF);?&1S)\RO]R<
MJ,_UUE1Q_P#9/M9"[!:?:TBN!TE'><EE[<T1PS2J56Z8?$J&FH2IFJ))U:R8
M&KK)C4X*:2QF.PZE5L_.#Z%4G6A),S<\T"II<JIP&W3G/'_V3[5V4B%=JQ^L
MNJFU9),("@OD3NWZD;:)B*,BPFF(WY-&\J(I&3JM+V"J9.I,O7E1%Y41>5$7
ME1%Y41>5$7E1%Y41>5$7E1%Y41>5$7E1%Y41>5$7E1%Y41>5$7E1&=;4LN3K
MJ/W5_]H`"`$"``$%`OZ)C__:``@!`P`!!0+^B8__V@`(`0("!C\""8__V@`(
M`0,"!C\""8__V@`(`0$!!C\"[D;!>L*4E'.2U4[EJ==TLM3[5E%P\&:4CN0:
MEDC$&HYI53-E5*V.Y3&\XYM$"Y*"3J63CI..UFT3+U8U8M(E./&FGC!RR<(L
M6[HBQU7S`8V0`@BOC5SI,6*[):JYV/D&"%,45K$I.A7%-*122Z\RVE1BTYB2
M4E15!PV>E6F"Z,"=R12);<IA&T%K!?.6#^F:K/K4*WI,L8DW7AD:%8U`YASI
M2Y%M(=N7IZ=$'6<O)<MM`+=:*IVJI9C.)5/JKC=9395M$HQ1H5TXDVC%Y"(Y
MA4^F1Y"R!!245O6'`.(;&F*@>\GQQ%DD#.-&=NKE5Q$$BYID@Y7VPAX<-UB2
M<'*A),3J*I`X;-'Y@*L@<4UD%2BU*HBND<+C$.`&#]%MT7WB_P"+6W1?>+_B
MUMT7WB_XM;=%]XO^+6W1?>+_`(M;=%]XO^+6W1?>+_BUMT7WB_XM;=%]XO\`
MBUMT7WB_XM;=%]XO^+6W1?>+_BUMT7WB_P"+6W1?>+_BUMT7WB_XM;=%]XO^
M+6W1?>+_`(M;=%]XO^+6W1?>+_BUMT7WB_XM;=%]XO\`BUMT7WB_XM;=%]XO
M^+6W1?>+_BUMT7WB_P"+6W1?>+_BUMT7WB_XM;=%]XO^+6W1?>+_`(M;=%]X
MO^+6W1?>+_BUMT7WB_XM;=%]XO\`BUMT7WB_XM;=%]XO^+6W1?>+_BUMT7WB
M_P"+6W1?>+_BUMT7WB_XM;=%]XO^+6W1?>+_`(M;=%]XO^+6W1?>+_BUMT7W
MB_XM;=%]XO\`BULYG%L.+!YF]OQ77_%T?%==X_!W6=2SDW4\_P`EO)-_#P,L
M_9*T_$.I8BB3@[1LWC&SY4J2*HD1*X<+$1+D*`7!:4)2=03Q9KU6D:0I)[.R
M@KH41%2R^==<@#&LV3TCAN804256467`R*9,Z4E]DI9>6JAR0S^GYF5AUI1$
M\//U!3+-%I&3LPD=D9^L_P#Y<BJH$<)HN%B`90AK'<*+SLC&$]:.3*9D)!)2
MGX,U9IKH5$>*009MWY1?-W2J?EG"P)%5-@`HC?8T@VDZ@FWQ(1E3,>ZJ%\V>
M*1%-1RIEVD''`S8QZ962:PXKU056,)0O.-W<K[\W]9_:EY_I>OOS?UG]J7G^
MEZ^_-_6?VI>?Z7K[\W]9_:EYWU[4,ZN=M%Q^C:4LF@JY.32W:#%&Y%`IU3XG
M#D@9`R7WVY]>]!R_%+<^O>@Y?BEN?7O0<OQ2P)<IR@D$/.>17V9+D$;A*)`<
MWWA=D3\-N?7O0<OQ2W/KWH.7XI;GU[T'+\4L::IQTH[CRNU60JJMG#0VD($2
M44+FG*::EP%6+ENN^&0U%2E)S\8A4KF98T[43D\69C*O()L+I]A8MWRTHU9"
MF'DEE4B9V\!`N#;`VF4J.G(*!D&`/XN7E'U.+)2!15!($4V<9,OI)NH(8C>6
M13+<7PWW6>10P,NZA(>H(*E)^JT#L"QD1/5"5$S-L=LJZ(^<MFVE(@Y6(2Y$
MRH!<-D3/8:7C:6D3U>E!5BX,Q/%RRM#H.W,]<V1<G?LT<W'.-'.H0-(%(0``
M')8(5S3DQ33YY3#*M81.45CU^5Z5?N0:(2!>3W3G0W2:QR9YLK<HEG"_I[E?
M?F_K/[4O.^U?]P=J(3O"_O/*<$C/ACVM)QO1<NQ0.]BZ2/R_.HN:6II>\#F:
MPOJN9FO/R^`@O5C//!Y-,P)EVU25[#T;3-.F94._A8VB*&>RTTUJZIC/$G$7
M*R#;D>!1:-2+`"07)F732.<QU0*6TS'NAII*G*SK.D*]J!ZF_D.58I[#-HM:
M:@X^.Y/,W>)/I*+(#=P9T3-(B.(AS76C**EW<$VI&EOZG##S#)V]=3,MZ_M9
MMHP3>QBK!JWC1APGE5%C%<+YXQ"E*`!>:T=4=8!`M5J=U;QFK2,;P3][)$DD
M6;Y!\\GG*CR.C-!THS)$$FX%5$NVO/X+S0E1LU7T8==%P9!&0DHTXK-Q$R1M
M*BG;)V`%$?!CN'QVJZ.:MUTF<7K0UAQC)+E"1.*3)A4+EJU2,JH[.LN9-%,`
M$ZAC*'\)A$<MMS7W\_XS:6C6#D4FC55(J)#"HH)0,V04&\YU#'-MSC;SS_A'
MY5O//^$?E6.CRDLAC``SK8126)<(#M#WCA')^RQ$>4EE\`"&=<B*JQ[Q$=N>
M\,0Y?V6\\_X1^5;SS_A'Y5HF-?N15:.E52K$**B8F`K9=0+CD4*<NW(%MS7W
M\_XS;<U]_/\`C-MS7W\_XS:K5DB*@H3D'")G3M0-M4T,4=HHN<@Y!_1WA=58
MB@G]99,NT<N4@N!K&_NHK$+X[;FOOY_QFVYK[^?\9MN:^_G_`!FVYK[^?\9M
MN:^_G_&;;FOOY_QFVYK[^?\`&;;FOOY_QFVYK[^?\9MN:^_G_&;;FOOY_P`9
MMN:^_G_&;;FOOY_QFVYK[^?\9MN:^_G_`!FVYK[^?\9MN:^_G_&;;FOOY_QF
MVYK[^?\`&;;FOOY_QFVYK[^?\9MN:^_G_&;;FOOY_P`9MN:^_G_&;9O-K8<6
M/SQ[?BNN^-I&*Z[Q>"R))"18L3N0<F;E>.T&QERLFRCQX*(+*$%4&C1(RJEU
M^!,HF'(%DY:G99A-1JIU$B/8YRDZ;BJB;"JGC2,8"J)CX2CE#9U]^;^L_M2\
M[D]Z0WX$VV<#Z0XX$YV%7_<':B$[PO[SRG!(SX4M32]$O73"(7623F(?6Y0E
M*.9:/E8PJ$M%OHR95.]1CWZ"XHK$.F140+B(<H#>,P]Y`]63RM2O7ZL22H:>
MJ1L@/)\4S2!D\ID`CF[0C9F0A4!O6+@Q'$1-?LZ^_-_6?VI>=R>](;\";;.!
M](<<"<["K_N#M1"=X7]YY3@D9\*]:24A0II:3-)GD:EJ6F!F0.YBX!RZBHKR
M`HE+(SSADFU167/FR_X3&$+3RE)Q$/%4LE5TLVI]:"CE8R/F8Y%M'!RL5%4P
MYY4SK.-S+%`I%1;WE``V=??F_K/[4O.Y/>D-^!-MG`^D..!.=A5_W!VHA.\+
M^\\IP2,^%5,ZJ2G:WJ6CYZ(@2TXK3<6YJ*)B5HY)Z68CY");JW,7\B[6(H5<
MR8YXF$N.XEP2TA/,9F)1E:JG9*G(:H3*#,Q%,N54N3F#Y%55=1B)%2JG3;8A
M!LB<J9=J4`LK1S>IH9:J$05%2#3?(G?E%!,5ETLT!LKA!$HG.F'E"$`1$+@&
MSZ*I^I(F7D8XISO&C%VFLLFDDX%HJN4"CY=LFZ#-BH3$0#Y+[[-J5?5)$M:B
M>&;$;Q*SM,CLZKW'H2&$1PD<O`(.93,('5_=`;/*99U-#N)YAI&EQB;Q(7*0
ML\(O"77X5%&6+RQ2B)DOWKK/4:9J**FU8X2@]3CW1%CHE4,<J2V$,IVRQDS`
M14MZ9[L@CW*^_-_6?VI>=R>](;\";;.!](<<"<["K_N#M1"=X7]YY3@D9\*I
M^-IK5Q+5A#O6SI>5D6"K1/-*E2>9E@DNX>-T8Y=)1%-0ZCDHI+$4S:?E+.92
MIX%O3JB\J["'CD7[216Y#*1N#1:0<L'CUF+\Z^=`X)F````VH#?:Y>EZKIYG
M1(5;$48N6BZB293U45"S69255OZB0C`AF$$F<O\`*F%<1<''/G$`$I1H2?D:
M?J"!C]4&J"J&E=K2$$\B+WY5&BA(A@H^29HSCE<8Y9T3,'51\H6\X'/=:KX-
M&FZDY8KC6EJ[K:G)16!D`9(4TW:P3Q9X\G`1%A&JTZV9*HJHG7*L10^!,IKQ
MM3-#,:?GFE7TB?7JO.RSJ(?1["^J(ZJ&L&LTJ!PB@SE/6%:7;$)F%5#"1,3'
M`"$OM3\VC`S<+&4SJ.@J"F.6(-_`750A+-'9XM!&0;M#ON26[-3$HD4Z),\`
M`;;6,A24RP@9@5T3$D)&+Y8;%0*(Y](6>DM;SJ!X#8MK:KDG4M%N'R6M#6&E
M(NN1G`$=R*=0N2O7:*2<PB5L@Y<`8Y$\N;`;KQMSC%=#.^OK38.#IJ+9]#&=
M%(R"9AT-M=A2.LX,3)_MCLX0&YTTUL^O@.LD9=,HZ&YOQ)$6;F/D_P!L+<XQ
M70SOKZW.,5T,[Z^MSC%=#.^OK5:+EY'JH_\`8<::$8X;JF_^30V'"L>6<E+<
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M4\QE8B,];I4$X"8BBPKN`.DSBVQXP6`2$BH`>0SQE#B0RZBQE,`%,6^RC1^T
M;/FBN#.M7B"3ENIFU"JIYQ%8ITSYM4@&"\,A@`=C7WYOZS^U+SN3WI#?@3;9
MP/I#C@3G85?]P=J(3O"_O/*<$C-@>GZKJ?DJ73;H.CM.1:A?7(.0$R)\_&Q+
MQL.,`\&.\/';VY_]9K#\/V]N?_6:P_#]C&"MC'$"B($+3578CB`?%+C@2$Q&
M_6(!;$>LE6XWCY-:FJJ$_P#;Y"%73N'^VWMS_P"LUA^'[>W/_K-8?A^T;"Q=
M9:5)S$@SBXYMZO54CI#Z0<)M&B&><0:3=+.N%2EQ',4A;\H@'?U&;^D*#?1$
M4SEW<:\G-99*:>N8:2@'41/K.XT6><+'Z(]734O,8@"0I[P$`N!PFU8HA*RS
MR2TMC6"M<EEL:+1H$@M4"Q"'6<%(S!N*=WDBH`7PW[.OOS?UG]J7G<GO2&_`
MFVS@?2''`G.PJ_[@[40G>%_>>4X)&;![]@07T"FSU:>_]&]HH[O[RH8UKJ[>
MMW#BC72"E5M)1Q*M/55THZ<1B"K1LH1.'GLZ*;M,#>53']-UIIO-A`)O)>IY
M2?!I3";I&%9)R*3(!;-$7B:2J09]`YQ"ZZ\]^SK[\W]9_:EYW)[TAOP)MLX'
MTAQP)SL*O^X.U$)WA?WGE."1FP>_8$%]`IL]6GO_`$;VBCN_K1+=QJF00*W;
M+I!5VLY"F)HP+)WF.K$JQ#@4D<X`@F;&8#@%_P"H*@E92=@)U66K*;DD#TS4
MWK9$QC1TDQ,C#(2@$3*70;A\D!2@0I@R9=G7WYOZS^U+SN3WI#?@3;9P/I#C
M@3G85?\`<':B$[PO[SRG!(S8/?L""^@4V>K3W_HWM%'=_$K9"5-K3Y,8>624
MIM*G2LQSPQI:D]?\=)BWN*;<DQ<W>.Z^R'*_J#I^G.,[_3K1.1=R;7:;H``P
MY:_Y^9\E=@NLM&K5'-OH>0U4R,Z6&=/`+#1[M*KH>/1,RCFZ;=J"B+7$&?4!
M1P.<,`J8;B@A1VL`U4C5IZ*7J!>;E=8<E5U.2#!E)HMGKLK!^].A`.4CG)<;
M-X13Q;?Q#6U6-JBFDIBE];=`4K3,4SFWJ,0K3TAR*"S(\"@X)'RB=1$DEEC*
M*)**'P!FS@4MJ6UAL9^=<U;5"FO/ER&<2SY[%B2E8NJ',(V1II952/C_`%?-
M$-C$S2!#>4N/B`]UH"+1GYR9C*FU&P==302\[(3I!JEU,-&XRK<7[IT$?RJW
M=+7IHYM$V9"XNUL9_#4T_JMZ5=%,(B.=,6;DZ:@B"BX+2"J+?`B'A"^\;5<Y
M7IR4;.'>M#6&Z<LM(ACGCW+BH7*J\>LH:31!1=DH84SF(`D$2[41"W,,K\]!
M]<VFSG14;F,NA>BL*(J$_DVP7&%NJNCE_48=G"'(BHX,5=>Y%$404/\`R;D+
MBBX501R?K,%N897YZ#ZYMS#*_/0?7-N897YZ#ZYM5J9XF0;%-R#>NNI%&2)=
M4T,(8@;2;A;;"%V0@Y1_1WA<B<8^=E]99,<ZW4C2IWZ+&[6YW(-5<0?[MUN8
M97YZ#ZYMS#*_/0?7-N897YZ#ZYL\.HV6:&Y!@PS+@6YE,B"F6]JX<I7#_O7[
M/5P8I#*F+7M'F!(F`#J"%0QX@0@JG33`Q_`&(P!^D;<PROST'US;F&5^>@^N
M;<PROST'US;F&5^>@^N;<PROST'US;F&5^>@^N;<PROST'US;F&5^>@^N;<P
MROST'US;F&5^>@^N;<PROST'US;F&5^>@^N;<PROST'US;%R+)XL6'-YV'QW
M77X[^5LWA\7QK_U6>0XT!0B3PD6DY;U[K-CE!@I$2M17"+B5D89?E!XCN0$5
M>MP*KDNNRVB7KI_"OU9XB=074_`1=.1D>$HS:*\E(LXJ])<T>("0RZ@BLH/Q
MKK@`!J1>CZ>5GS.@?&EU(MJ=^9V6["X,X,03BJ%WAM44+"PC*FR51&+0LJ^A
M6K=&0/$.@S;J.07727T9FJW$Q`3*`)IXKRE`0"T?/$I6&"8BD&+=A(:&07#=
M.,:Z#&B!AO`ZS!IY-%0UZB1<A1"S^H6%,0S69E`=`_D$F20+.-.,!GV+)@*+
MXQ;UQ*`"L/Q[[/!I>GHN#&0,0SP8]L1$RP)8LRD)@RE;H9PV!(+DR8AP@%_<
MK[\W]9_:EYW)[TAOP)MLX'TAQP)SL*O^X.U$)WA?WGE."1FP>_8$%]`IL]6G
MO_1O:*.[^^HNK4I%DL#Q2/5TZ%7>QKIGR*TEBR(YE)P#B-=BY%L3`553/)&Q
MD(2XPN%]73:/:P*TJ[462C(QQ$-.4S)M]*,1BX:L\T(IYOXA`)^C9U]^;^L_
MM2\[D]Z0WX$VV<#Z0XX$YV%7_<':B$[PO[SRG!(S8/?L""^@4V>K3W_HWM%'
M=_I-SRK)4Q!C,/4JAJ^$IX*@FX%HI$.]&*R*#"4<QB<J\`J*KE)`PE"XMX`;
M*\=S$@_FFR-0RK2FZADX@8*0J&FDM'-'2KJ-%HQS1S***I`;,IYPJ0'$`$1V
M=??F_K/[4O.Y/>D-^!-MG`^D..!.=A5_W!VHA.\+^\\IP2,V#W[`@OH%-GJT
M]_Z-[11W?PIU&,I>2(6/<O52K5Q&Q<T7-Q9GZ1%XN1;M4V0',7:>67,X)\4`
M-<46DXI$N(4Z]P&:+OHB1`1S**V>;NX:0D6QVYP6N`#BFL4P"!R%V=??F_K/
M[4O.Y/>D-^!-MG`^D..!.=A5_P!P=J(3O"_O/*<$C-@]^P(+Z!39ZM/?^C>T
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M*\+)A(/'NF/&PO4ATA+,D/E\G^@TK44LPA8TJJ:)GTBX3:M@56&Y),551`N-
M00R!:LG:4U%F;/\`6IK&?LUM/;`1RR>5&Z7:ND1,H&-!PB<#$-X!`;<\Q72+
M3ZZTVLW5371.N@)%43E43.`,VP#A.01*;*&SA%G"J:")%UQ.JL<J:9`%FY`,
M1SB!2Y1MSS%=(M/KK<\Q72+3ZZW/,5TBT^NM5J#:3CW"Q^0<"*#QNJJ;#4T,
M<V%,BAC&PE*(_P!G>%TG<@Q:J^LLF;-N':"*F$6L;<;`HH4V$;K<\Q72+3ZZ
MW/,5TBT^NMSS%=(M/KK/%FKA%RER#!AG6ZI%D[P04O#&F)BWAL]7"JIRIIIU
M[1YU%#F`A"$)4,>8QSF-<4I2E#*-N>8KI%I]=;GF*Z1:?76YYBND6GUUN>8K
MI%I]=;GF*Z1:?76YYBND6GUUN>8KI%I]=;GF*Z1:?76YYBND6GUUN>8KI%I]
M=;GF*Z1:?76YYBND6GUUN>8KI%I]=;.<K1F;Q8,YI[7!CNQ8,6=PXL/B[JE<
M+UB\$JL*O2ZL'R-$"T/2[M\C(/(87.;TGR[A'=]V`,@#95Q!U4[G9Z`HV4HW
M5MRFUCH]&ET9=8H\HNUTD5PE7K`$T=N9,I110P9L1-?95R]JZ1<PTK-TU5-3
MP(QL<5.=J6FVC1$C[32%*JQ9RCMBDNZ;D(.(Q;B&(%DV$E4,C)TC&^NHT]2Y
MF;%N2(/7B+UM,8Y$A3JR)&[>3<@U`Y"YHRN(<0@%DYF3J5Y4\BPI5A0\(LY8
M,XXL92T<X!TFS,1H)].?+KD3%9R<0%3-%VH6T=^T:OFXF`PH.T$G*(F+\4V:
M6*<F(OBM7*""::**.MO68DBBD0J:222=3NR)IIID`"D3(4+@`,@!W)[TAOP)
MMLX'TAQP)SL*O^X.U$)WA?WGE."1FP>_8$%]`IL]6GO_`$;VBCO@]??F_K/[
M4O.Y/>D-^!-MG`^D..!.=A5_W!VHA.\+^\\IP2,V#W[`@OH%-GJT]_Z-[11W
MP>OOS?UG]J7G<GO2&_`FVS@?2''`G.PJ_P"X.U$)WA?WGE."1FP>_8$%]`IL
M]6GO_1O:*.^#U]^;^L_M2\[D]Z0WX$VV<#Z0XX$YV%7_`'!VHA.\+^\\IP2,
MV#W[`@OH%-GJT]_Z-[11WP))_%4_5+"+=,M/92TU'-&D>_2%4$@(T50D79SJ
MB(B-PE#(4;+4\NRGEDF4S"T[*U$U8(*4Y#3M0E(>+C)!V=ZF]SRI%4\9TFZJ
M*.<*"ARCDL#!1&<8QJYZF2C:I>QZ)*:F%J.17<5$G'.DGB[\>3TFJPXE6R1%
M<T;-B?QFBFL94,*^/!-*ICD:@8-F?+--/UQ;-9R,%H^?@+-1:X,*V97#&%Z?
M<K[\W]9_:EYW)[TAOP)MLX'TAQP)SL*O^X.U$)WA?WGE."1FP>_8$%]`IL]6
MGO\`T;VBCO@)Q3*!S@4PD(8V`ICW;4HGPGP`(^.X;K5!6$71[BE:9AJ%?,F]
M!-ZO?52G5%6:8FO$'CVY"OB1B!Q#1BJ@4BXY[*B`8K5!#JPT<V@ZZKNC:_DY
MH)M%12GPC6\0ZGH30-'*X?/"/XG--5"!F5"GQ'$G@M#4!(M8Z-@*2_JN+*J"
MRB;D\Z%<LZ@:0I"1J:`N6!V9JA,=UG"W84;B7B:^T54M5Q3.!]6=5L7JT:M6
MTJA+&F'#>1;/W\X4S=,I63$^@)%12..>VQL7BL:)/-5'``9=%?E"EI=:$EBY
MD1'-%?(%,H5!2_;E_>M5S'E2<<\GZT-8;`';N5<K/G@,ZA<MP=OW%Y1=/W.#
M&LJ.5101&WGTKTDY^7:;3`ZBF%=#;K*&54'^3;#MCFVQO#LX1,3J)XEU]NBH
M9)0/Y-R.U.7;%\%O/I7I)S\NWGTKTDY^7;SZ5Z2<_+M5JH.I!02\@[1=ZNJD
M-]30Q=LF<PE-=?\`M[PNH+E\E_\`)9,N%N[603R-8W+@((!BRV\^E>DG/R[>
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M=R>](;\";;.!](<<"<["K_N#M1"=X7]YY3@D9L'OV!!?0*;/5I[_`-&]HH[X
M/7WYOZS^U+SN3WI#?@3;9P/I#C@3G85?]P=J(3O"_O/*<$C-@]^P(+Z!39ZM
M/?\`HWM%';!_-2[DK*,BVJSU^[.50Y&[5N03K*F(D114P$('[H"-O;V/Z/F^
MJ[>WL?T?-]5V]O8_H^;ZKL1(U=MQ,I=A%.%J55,,1L(8UDH8Z*67_$(7!EM[
M>Q_1\WU7;V]C^CYOJNWM[']'S?5=GCND)M";;QZY&SQ5!!X@"*RA,X0@@\;M
MS")B9<E_>5@9O&KO1E3(.-&<)+YA<OQD5LT<V:5+XRC</<K[\W]9_:EYW)[T
MAOP)MLX'TAQP)SL*O^X.U$)WA?WGE."1FP>_8$%]`IL]6GO_`$;VBCMAK&]T
M)S@2O>*X^WX[_P`<;O%:<BY_EGU3J/DG1K])Y3Y'>:!H^';9_2L.&[+BM!.:
M(*PY&1U#4VTJX\.4@-@K$9AN=JE-F1#"-2$:D>9S.CI.$=OXK&]2E*<3G,^C
M@-5*,FO$Z->.D8B1*[=YG\/Q-MA_3:J',`XU3)H+ZQ*Y6?EF&%8'5Y94G7!Y
M46FA21"%C!=".C@>]4$_CB(V\\U(=&UYUM9W+.YC50FX>'(=4C9K5Y$0$B1$
M@P%456.`84_&8;<]ZK][U7_?;GO5?O>J_P"^W/>J_>]5_P!]N>]5^]ZK_OMS
MWJOWO5?]]N>]5^]ZK_OLTEFDQJH4<,SG.D1RUJ\Z(B=(Z0XRIJHG$,*GB,%O
M/-2'1M>=;6IT[T^IIR%1U;`T@UT6,K;R#VH'!FS9ROG9I/\`E43%O/AO-=X`
M&WGFI#HVO.MK2-+RTGJ=;Q\IH>?6CF-:I/":$_:R*694<O7:)<2S0H&O3-M;
M_`.6WM-0O[)_B5O::A?V3_$K>TU"_LG^)6]IJ%_9/\2M[34+^R?XE;VFH7]D
M_P`2M[34+^R?XE8T!"2NJ)TS.^7D!4E&59+.<\X303.4#M'3)+-`#<+MI?\`
MKMYYJ0Z-KSK:U51;934RBK24TE"/5%HRM\VY76BH^7!5M@FCFS((R)2[8"CB
M`?%;SS4AT;7G6UE:JGJBU>-)!5FT9&1B$ZD09YIF42)F!-X@_6S@@;+Y2[]5
MO:ND/XIGJNWM72'\4SU7;VKI#^*9ZKM[5TA_%,]5V]JZ0_BF>J[>U=(?Q3/5
M=H.HF-3T0J]@)B-FF:3OEX[51U%/47S=-R1%@@J=N=5``.!3D,)?`(>&WGFI
M#HVO.MK/ZID3ZFGC2/6BT5&[*,K;23FE9=A#HB3/S225R:[\IC7F^*`^.WGF
MI#HVO.MK35,R,CJ:183L:ZBW:K)A6Z;M-!VD*2AVYUW[E$JP%-D$Q#A^JWM7
M2'\4SU7;VKI#^*9ZKM[5TA_%,]5V]JZ0_BF>J[>U=(?Q3/5=O:ND/XIGJNWM
M72'\4SU7:5CJ;FM5CU&7>(O7)IMM5KE4BJ".8*5`6!XTI4Q+X<0&&_QV\\U(
M=&UYUM;^D^CZJ/6+DSESE?0ZOY%T#1L[HNC\JZ=IF+]^_!=DP^/9GS2::><4
M,JIFR%)G%3_'4/A`,2AKLHCE[@@DF1,!,8X@0I2`)SC>8X@4`O,8?".S-@.0
M^`XIGP&`V!0OQB&N^*<OZ.[B3.10H&,6\A@,&(@X3EO"_;%,%P_HL7.)D4P'
M*H3&4IL"A,I%"X@'"<OB'PALU%UU$T444SJK+*G*FDDDF43J***'$"D3(4+Q
M$<@!8IR&*<AR@8ARB!BF*8+RF*8,@E$-@<Q"$*90V)02E`!4-<!<1Q#XQL(7
M9=FHX<+)-T$2"HJLLH5))),N4QU%#B!"$*'A$;`("`@(7@(90$!\`@/C`>Z*
M:J9%4QNO(H4IR#A$#%O*8!`<)@O_`+=F(B(``!>(CD``#PB(^(`LFX;K).$%
MB`HDLBH55)5,V4ITU"")#D,'@$-AI&81TC#AS^;)GL/^'.W8\/>M5M*/)%W$
MTK5M32;*I73-^M%*/=`@W+^'I\\BV40=-T)V13!,Y4E"'5`,%^6R&KF@9V.@
M6#.DJIK5S+U(L]JPI'$4]:MO5=FI)3!%&:+45C.'!3*J&00^(4@!:;JAB2`B
MV]-41J]K!U%.8EVZ5E%ZD>'92#)-V:11T*.<`45DCYM14I<`7CE-;_\`1%0A
M4+*6:T;+Q"<'!OXQR9)IRGR$HWS"_+(YEHVCG:B2J94OYAR.?Q)[E:K(HU14
MFVD-7>K\*ZDW+BGEB-ZN<O'DHLE%1S96;!1A%LFS0C'/%,HLLZ,!APXLV&MR
M74;&9J2DU1TB=H>\3M3O:'AW)FQQ$I!$R`J81R!X+:CE4VU0RKFN*WU@3-2P
MU/U$M34E/R#M2H')T590LO!E3.R41)NCA/(C=X=J-)TU.2SYW/HZM*\E\#C6
M3,T^$4X3G,Y!O'4_'X"U'+P#%9-/"OA1<"`XE,)<0T'K3G'$Q65%C36K^,<@
MG4[VG*FI*HUUVQ35`O3D=(),YL]1.5TE%D\9SJ)#XVX;;7/"(A_VYAK&4D&G
MAP)KU#"1<I*-TO"4I2OSF4$H>`RHY`OV&NR9+,2S2=U=?TK#5ZBUEWS)%J:;
M%DY?BG&-W"+63&;?N%&RV=(KC3(!`NNM7:T-5J\>^IIG)&<&IV:;-G9)=E&+
MKI0DDLWSCQJ:]9-<Z!#(+GP%`1S1CD.YK")6;/)2*H^.?(*O,3Q!5V#9F507
M.!8AUAQ''%MP&^U6PTM(0JKB-G=5R"$RQ@EBG8QM?1\C)2B;2%/(K\J.HA*+
M,#?&KB4*83&`P@"8TG2M1.6W+FM:JU(C"P8A'JMJ$C7KB1EG:Z24G(I:4ZIF
M)O6#.%S9WX(X<1!-:0:P[NF&<3'ZXH/52PCUX!RN;1JACVVCR3IPE+MLD0NL
M4Q4DB)YT+P$P9+:IDZB69NY.EM96O2C5)!DT%@E)IT_2BZ"+\S+/."M55B'R
MD*<P!=L:@B)26DXZ*IW47/UK`@PF7T*5*JT9=VVY7SC%PV%X[BF[5'-E4QID
MSH[4<5M64>[GP0F*ADM3S'6(5C)E93,?#U85H>65>"V6*]ATI,Z9R9T<&(HF
M`!\-M>32/JFHH^.HBO)QK2BC6><`YS*,?$JG@!E5CK2B\=&/GJABI$6*?%M3
MF.4!+:4K*$,S>2$5$13AN9UB=-5E%7L>S7SN:5(8XX5C_O9#6JJFIF4AEG</
M7U$0'K%'T^L"B$15E*O*I>Z#3YY%R#UW&@P%)/&L8QDC&.(',4"#JZH^J5&8
MS>L^H@6ED&+(K(B-"T\N,_+`H1.2DTBKNX]FV05\K\9]F\-X7"J$=(4RTB_Z
MY.]3;5DO`.G2Q$EXD\@UGG+HLRWSRD=M;FY"I`L-^(X`(7:EW%0':+RL/+Z_
M::<O&3862#\()"&9)/09BJOHIUTBAB(!S!?X/T;&OVLA,2D8C1VI%S5U(I,)
MI]#%)4O*,H4)D`9.&XO71'+%NV*!\9"@82@7$>^SQ!Q4YXRI&E%Q$G400LHS
M93<:^?0A9-)!X`9YU$EEE$C`6X$E3IWYHX>&T/4A'G*,M':N.5#.'JQWIU9-
ME`G>!IYQ5SRIS*D`3XC8A`;2;R36IR07?ZF*4UH0H(Q;B/0B'=12Y(4(I4II
M-P>5!,%@5O,='.+;3R91O"J2.9)!=W6-4--6^KQR$*6&D7"<Z1LS=S4@W1E'
M>C+H(N7BI2&*W,FFQS@Y%`PUQ#TDK3[2F]4#35*R91CZ(<.G,NRJHS6&T)9\
ME(MR,D6@%$^,B(G':@%V6^G*<J=W'2;RC?\`])4''MY2.CCQ*;MI(TE,RA"*
M,#/'^;.U.N8@&SHXBW7Y<H]\5BYZ*CYF-7N%5C)M$'K4YB_$/F7!%"9Q,<I3
M?&*.4+1\.YHBE5XN)445C8]6!C3M62BPE%P=NB+?`0SH2`*O_-$-O?9ZF[IJ
M`=)R;1E'R1'$/'+$D&$:.*/9/2J-S`[:,#944SXB)#\4`M)2<A2U/OY"98I1
MLL[>Q#!VM)QZ*C99)F_,X04TMLFJR1,!3WA>B3_`6YD_J&F(&;>QV1B[E8ID
M^<-B@?.`1)5RBH8J8*;;#\7%E\-GSMG'L6CN463<2;ILT00<2*Z214$EWRR1
M"J.UDT"`0IE!,(%"[P639HMTY%)C/SM001I-JS<K4XM4#IPZ>-H9?1P5:(%.
M[5*4P#G!(<2F,-F[BHJ7IV?79E,1HO-0D;*+-2&,!S$;J/FRYT2F.%X@6[+9
MG4+FE*>7G(\J!&,LI$,3OVI6A0*TS+D4,X31"A<E_P`O]VZT^+5PZ=N*EJ65
MJB2<NQ2%4SV4%(N83S2:92-&35NFBD7P@0F41&_8-GM72>KQ.KX3-Z.YEEH4
MTY&"0PJMRBHKB=MCH'-C2`UPIB.(MU]]G+:2F=5,@V>R?+;QN^+3KM%W,Y@S
M7E9RDNDH1>3T8PIY\P"K@'#?=8]-MZCU9(4ZJ54JL"BI!)0JA5E,\L4\60@,
M3E55'$:\FV-E&R92ZP:%AWI)B$F7#UJI3CDLPI3S=XUBF-0M':1TIR+9HOCY
MI%4;DC`42"6ZS*7;ZTX)^_8IU)F$UYJ!;135W5DBUD9EY&Q3!LV1C#*:$DW3
M32$$4FQ<.&\1,)U3U+JT.HI,-ZA44,M!F.>?:`4K2<.<2XC3#4I`!-R/EB7!
M<:R%14JWI&4*E)RLBA,PK:)<F0FI9/,SCTCUHF91"5DD1PNCW@LL7(I>&Q:3
M&L9I21F<6X#09"JD8P4FKA40',MEY$OQEQ2`12+NF$+P&ZTH$C4>K-]RV@U:
MS`NEH1<TJW8"(L$9`ZA1.\38F&]$#B.:'XMUF5/+2FJ=Q!1RIG#"'<EIYS&L
MW!\YG'#=FNFH@DX4SQL1P#$;$-XY;>K!*CU9%IK"8OJ\52""#PG<B].7DD":
M!A.\,*H^3RJ#B\.6R"_]0Z%BI%.;83SIVF>G'Z4X[C8YU$L4ZD9/DU$IQ!FR
M=B"&='$@)2X#``7"RDF6M*#?/6,7+QB`.YR"3CV_+\X:?EW3".9-FR,<JZ<X
M$@*D())MT2D`M^,Q\?K+JTQ<N>LV+/0>+UDS68]8+\-_+F9VFE[OAR8KK-GC
M2I=6C5VS<2;MFZ;K0:+EJZF\'++ELNF4JB#B6S9=).40,O<&.^W^8U(=.,OK
M;?YC4ATXR^MM_F-2'3C+ZVW^8U(=.,OK;,'E0U%JTFW46?''N91Q#/EV8XBJ
M>05<8SID%0H&$OQ1$`&TIRG4&J^1Y;%@::TXT`[Y7-%AAC!E,^FIIXQQ<B&=
MQ9K]VZSN&AZCU9140_,N9]%1JD$QC7AG2!&KDSMBU(DV<&<-DBIGQE'$0H%'
M(%GL$6N*%@]*AHVGTI*'=4^@^:0<3(-Y-C!)"9$Z8T^5PV`IF(AHYDC'+A#%
M9O4Y]:E-NY1"5<S0-&K^FH:G`D%8,E/-UT8"-:IH-U&$<"F;,4^(RRZBB@G-
M@P29GU2ZM'AIKD[ED72T&X&6Y'/G8GE,52GT_DM3;-\[BS(Y276,]4J75HH\
M-*-9LSLZT&9R::8MS-&4N9<Q15&49M3BFDO?G4TQP@(!;_,:D.G&7UMO\QJ0
MZ<9?6VY=Y6C.1-&TSEC3VO)6B77Z5RAG=$T:[]_'A^#53*,CYIY&TY-OVBEP
M&S;EG&.7"!\(Y#854P&ZQZC8QI7!XVDT9^0,(X7U0S2[(CE5W*R&!1==U(R+
MB]18^,2`?(%P`%BU97TM&U"G*MXA!E3=-T\,<_2J:;=-D6$+%OG4VN@^9',Z
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M1[A')L:I5F$"/2T!3%'$IINY`BS5@]JA:H7DM+(H*$$J<HH2(;HE5#;%3)<'
MA^""4P`8I@$IBF"\IBCD$!`<@@(6_I5H:?\`3^[^H_JK_P#Q?6/DC->8W9GD
MS2_YO1=PTG;8;MK\&KCW0J7_`,,]M&P4NW!U&2](Q\<_;B8Q,ZU=Q***I043
M$JB9\)LABB!BCE#+8].S%=5O,L&Z4:G`&=N8))U3BL.];/XR09.64"U4>RS9
M5H4ND.](,*5Y?WAO9STC-5#,U(A5C6L7LX\5B4G,M),(=6"8-'C=E$MF2,2Q
MCUA*DBW31,4?W_%:D7$1.5#'NZ/FZIEV+L%(ARLY2K-SI-0Q;LCB).U%FZN`
MA#E3*NB0-J?'M[1E/,):?CU8*JW5:0<\BM&*2\9./'K]ZJ8F>BS1SAB89%5(
M4%4#E.D-QKQ#%:!J`DC./IN$D:PF5W[UPP$T[,5PWCVLW(2Z2$<BGC(A&(E;
MD;:.FD4MUQK:H?L#6G]!1NQUO?8&JSZ"LN\:SFM9,XEG%4KZY/:5<1P.6Z\N
MQHJH7\%)QSPSMXZ(O-";0C$S)4P-I&0F3)"4\XC*8BJ[G:NJR#57.VE#P-/Q
M%'1$9*S;UPQ&3%[)2;;E,J*:0.$2*J9=J4!M3WJ]5%`5;)SFM&'H+EI&GIUI
M'L6TK#OY`QI""]8RN22;=9L6[`[S1D3>`#6'5:JVIIG7GK3#1`U$@TD7=,\@
MR]/R%1%F4(5:11D.42(1BB&B'>804VV=$OA&`B$Z6C:HIZ`KZ?J9\\CI)_#O
MQHJ?]7VS&*9IRS-RS3EUS`=10ZRHHEOPE'QPY"RL'1$6E35#S<Z\F::J&I$W
M,I6".DDB"/8ITQCZ=BFR08!?/5-LHJ6X,AN\?_0/^A^#5Q[H5+_X9[:FO=^&
M_P#'-[:LJ2IF6:0GKF[JQ)_(N8E*8.B2!I\9AN"+95PU)Y4Z0D-MO`:_Q6D*
M6;'@"ZRT-8[N@64D5L=.#>M8R.3J)Y4/)SITMHN&%\FJB9<X$7.`@:X;@U-3
M<?,I4XQKF/J)>IY).EW55KQSNGH/2'B+6'9"+I1)"9;JHJ"&YI[<^$I#6U0U
M*$]#0B^L.HX.EGD>E3S63;HIRW+SAK4C9R:4.-[Z-CFZNB7W)BJ(8\EUFB+U
MT5\]2:H)NWI6Y6A7CHB12KNBM2G5*V*X5`39L#&`E]UXVU0_8&M/Z"C=CK>^
MP-5GT%9=XCC2#F36&.U@SFL`NW;E!PM4,H67DH%R71[E(19X@C>7=!!$NWLI
M(1\W,P]1)5G.5Q#U"ST([N(D:B00:RD>5LX:JLWL,\;MRD516(85"_O64S]:
M5`,^KK!::RC5"@RI])8M0,8M:);`E&J13B,!D1NKB$ADSWG#]&2Q)9&IJA+7
M!:C:52>NG7)3N6<2#2-5ATVBS'D]"'"%+&KF2*U303*4MV7],?R)5=0PDN2(
MJ.#G9Y!.+<OZECZM?\JSNGE=,CH(.5)$15041`NC^*^X+CLF$O+PU.24)2E/
M5-3K0K!9"HHVBCE&!*L^=-57[%<B09I=1$Y3+)_H->;O'_T#_H?@U3(RKHS*
M,6I^92D7I$CKG:,%(YR5XZ(BD4ZBQD&XF,!2@(FNN"T.QFZ0D5G,=',62,Q$
MOZ;4B:A9H-4TVDTQ1>3<?*,2OVY"J&0<MD5$3&PY;K4$6=8ZQH*IDW51#1AZ
M6-!JR+A8T0'+Q0T1W,%`I(D!OQ@3:B:Z^T2I*Q$@Y*DM634K?6,I`@P<U/IL
M*>KY*>&M)1`I:S`2-"B#DZ:NC&+FTLWA$*)7I9C5BUU8ZRW-$,FYX`*?/)N8
M<Z581T48KQ)CZO1[(%%&HE5!N)Q-FE%/BAJR*R8UL>ET]9B+W5ZH)X7"XJ@7
M%1:'#I`9X58($%#O,R90I$LV4MRV'!?[)U!OBEOQ+:`>U+&J4L2/INJV-#1#
M]9@^EJA<+K4\K5,VJK!N96+C&$>T2:(HHJN0<*BJ<^$``0V,^]IJ-4JDDA3=
M*,:YB&"S!C+4\X06J%6EIM)6<<Q47)L)!HJ[1612<BX2%(A\(@(!;V3J#?%+
M?B6WLG4&^*6_$MO9.H-\4M^);>R=0;XI;\2V]DZ@WQ2WXEM[)U!OBEOQ+;V3
MJ#?%+?B6WLG4&^*6_$MO9.H-\4M^);>R=0;XI;\2V]DZ@WQ2WXEM[)U!OBEO
MQ+;V3J#?%+?B6WLG4&^*6_$MO9.H-\4M^);>R=0;XI;\2V]DZ@WQ2WXEM[)U
M!OBEOQ+;V3J#?%+?B6QS!2%1*"4IC`F1S20'4$`O`A!4JA-/$;P!B,`?KMZV
M:`C_`%1PX/Z5:5_W#^F_)N@Z5ZS7>IGK/I'\]F=.S.9\CG,>6W__V@`(`0$#
M`3\AZ4'W)77(P-+1UPM,5"80<:@;'KYGE16=DT*LM!7O2)'4>4<0Q)Y/AE#L
MU;#/J6TUHO+F%7JDMS>1($Q0/WD<,5*E2I4J5*E2I4J5*E2I4J5*E2I4J5*E
M2I4J5*E2I4J5\!4J5*E2I4K_`#9OB/\`P1^74)J_\/@MRR"4,2K;FT)!HS`B
MG(^_OQ]=8#F0957;)=?A\Y*`;F5@;LJJS@?IH/'CQ_N]#)!?B;*68'L@0(")
M[D399N!;`6,U:=8$"`3+7)N6)=L7C7U@!V!BSQ,?F7#+-^&.3(M"T3($_69:
M10AQ72Q6`4==-'TE"2.]YJ3-2SV!KIR0]X:N,_)T@*5_[=(/?U>(EL1,LND$
MCY=3<T[E@`GXKJW!WP(,-RECI_K!E'?4@!PO$)I@V3Z9ER8OM9,KDA9E0J/0
M_C=VP5E9\>'X\/N_L4ESI@X<F>[^Q27&F!@P)\>'X\(]#^-W3!6$["I4K@9X
M%Y-E/VJV9\!XM?MUAF=K-7]25*E2I4J5*E2I4J5*E2I4J5*E2I4K_%F^8_\`
M)'X1)&;-"]+M58LR[)6]!?2"RXQ2<L/9LWAH`;$\ON_`<1ACG:!J.?[EQ9KE
M1[-F\-0)'@,ZR\TXE)EA&=>CW9Q1FO+#V;-X:7(=3:!"B=B%B[*!)DXB(JC'
M6UWE#!5H,@N@K*6U4+EB^O=P0UD'1$MQ4)BS)!3/5P;("AMK6K2N[RZ$0M@>
M>,\B/9LWAH&3/`HE2H#6K1ON0//)-Y1Z:)<\LAT+!)^&2Z^AD2@7)"SH8>B%
M4^OGZ<UQ&HD.N@TX`(M%ZE"7YV+:;%!H,E4#AL]*TS%BF%RV`A8L>^@X%.V;
M2&XJ4VN?@[D4[9M(;FY12Y^'J.'#A*O8('*^INL3%T[ZH"WT<_Y%5E*VO'U`
MX<.'#APX<.'#APX<.'#APX<.'#AWY8_B?^0M=8]TVHA?D-TJF6@C4*4FF`$+
MSG70C:6B[==6>43(?7#V;-X;[@,(5G4VB](=>^RINW,$8E"C/.4,P%5)00:;
M[8;^YU[[_D/!GVG:>"%\XBO)%/VP2S*:/?+NUP70%6P'+#V;-X:METOH9I7K
M-%(T$9JF\_::#Q/95Y8>S9O#5LO%&/(.S_3K8K(+'D3BHF(V(/+1[-F\-6RT
M%!NUC79(LG6A/4/)M>Z&OCFEJ!HA-9-C,[>%!J#.KA&(LT0VR";8?\J1%VN.
M2A7O`>IBO5M1IY?K@CX<!3[%!0CHF+XK;.P2^'5CM;9@.:!Z*5V\5CW$B"\>
MGWQWKMXO'J)$-X]'OCL4J5/J\V")L<#JEU9._%C7T1NI&WW,+FNJE2I23*AA
M1?LMKY@[VNR*WI#1L-P&?,I4J5*E2I4J5*E2I^S%>MO\GV9@[FI&$)MAPLN,
M[L>:@9+;UP0M3U,Q=5W-O$]7$HB`<A^;(:_>B402PTD""!HJC[>S+@,6I9N8
MRJ;`]95Y$OD![-F\-6RP`YE-G0K^985A(``O<`6'#T/+#V;-X:MEBVZ5]GL`
M@B4,8=C9Y]"=Z>+<L/9LWAJV6G+6^:@\'S%^*_.;C*@B"$.C/*CV;-X:MEC"
MU#4&$0EJX/4(-KA<K^J]P-)1$F8!F2&2`Z(P$P;!$2$?U\9-(#/852PS>4@7
MB9PE8C5:BI$#:!Z#8D[IK1#\!9G"KH%ULP+NV\O*^89.AI5LC>*,PQAV=ZK9
M&\49DC+M[#1HU[K`PZ2TBC`7P/E!W8_.@=-4UV&C1I97*B&FD79>.]['DKE)
M.*(`6^8T:-&C1HT:-&C1HU]N<<^Y976>KH/"SR>O+>\A,0!QZ-BIN(D\>J8W
M]?!#N&^>@]",:GYY2*A*19_U0T!I"'`VZ>#>.V6HY59#8OR$3'<8!1C]5V;-
MX:MECV;-X:MECV;-X:MECV;-X:MEE,;2$N!X3N7BD*6*L+S*ELXT.3S\H.B-
MI?<!#O14%X(F6@I;7)#V;-X:MEL`J24D)*<<)FG4!POR>-2"Z6SWX^&>/"SJ
MY\@L0J:)/5K=.HS:X-!;`IUJY5K-!JX;AP5%`S*X*G$".941AR])0%D0L'<>
MH89].\"R(T#N/$<,>G9*E2L!%7H5J`N7H#Z>!H28W"]FMG;V2I4H%T7:M%<C
MT/3O-<Z(B3J;^PRL^:5*E2I4J5*E2I4J5[.?.O\`[W]%Y_1L>S9O#5LL>S9O
M#5LL>S9O#5LMU-45"D-46]#LI4J2O:.AX)!MZ\49[*5*DT8D`\\TY$?/A?:A
M;>*?X*+[<L/9LWAJV6:4?9RX'_`Q4S(,+(*&S>F6@[[3<"N"I8H=&6"3$/!T
MRZHM7I\/>8$QFT!=B_QW].G3ITZ'O,"8Q:(FQ7XZ?"+*S6EG^GK+Y^?X"4`*
M0C!@'>N7+ERY<N!Z7;XSA%8%;6*GS.)I%J>$KTG8+/A<O!\=5J74G0[W3ITZ
M=.@C^PO,1%&"+H3XPP_'0DM+'&N@SXM_5Y;M*):[6O`Z=.G3ITZ4AX<2I<;'
MH@&.GS[3[Q]][\/PI9`/1"LI5GI7$^^(P,ML7??\!VA#+N06LG5FL";M0H%`
MVBF5W=;U;$/(?!WNI<D(&.ZP"W$/L3,XPKNQ,)V`144Z0`2&UF@.\K1+J:/T
M6@`AAG/@2P+`.'J\*6^JI9!&,`>]PSGP):%`#+"M$NIL_1:$3L_TH<U\&]+K
MQ%9=0%%?B0FHQ=LM=,,B*2^IM1ZZ)F?')`2U0VS\C@))C!`7#P0'"]?Z[N3!
MW6OHMB5LM>AJ9>HR$'5E>XZ@O;D6PF*OI.I):`O"`E#HE?,A"12:M]@:AE>T
M,@NV`*D."WR`+,CLMCA4!GE40W:;^;-N'(^]4O\`1,P$Y3@?;SWF1>@*CV]A
M8&Y^!._R:KA9@J.J5"YM>T%E!$B;,MBNRF(]X<?WS01Q#S6&@FD81#$FEZ"K
M`W>,H4;;I(U`_,IPXF`570%'8DN<>%Z[`MRIF"ECJ6M8)-OV:Q:U<!*H&G8J
MOOUF<T,`P@,_X!;374R5&(8%K9@3'5',)=P?YG1<$8J.`QHEW\)7Q5_0T88E
MF30UH]+J(Y#4+05Y2P+Z8?*(>AK15SK:09`.8JFQ%['4J&(VDUJ(CH?ZCY"#
M#7P^3-`)Z:@`HPA4-!6MJ:]H;]07=MZ0.*`(XP=%!:E$*PPU=4L;:98"!W#8
M#C@)IQ*-D-!!?)>&P50:0;!/7/>K2(*P6Z7JRQ^M!F.WSF+*J*I@K/5T8U$R
M.9E\4!"?$TS(JLJA*ID+*'QN6?C:*W!J,DB*B&52=1(0V_FQNVK7*>O04L!$
MU+5T,[ZBQ)%<U^9Z:$\W)]2^;+6H3EISZ`@G@IYQ0A.??#76NO"C#XWJ!G.2
M"M3?<=J?W)HCX;3;)#3LHVIVFC1HUDH4W&!2##9A8,]X)C+RTZV\XDZ'B^W@
M;==X`1<EL;7SQ0C4,?B,5EZ\@4@`UD=M[::F?*YCT[->-4EMI6IU-&OM`Q?W
M#TOK],$M2RJ6*5P8:@PHN.>2DV$(;CI*1_9=1$8&"P56CNZP-+T),7LW+27)
M#2I@R9'L=_6+0XIN<X4+F9VY.JT88N/7K/:R#(P/;G$)%=C%07(7^D`?\`BC
MRNI'"3_##^Q?U-^G279#C@>;DM,$0`R[5RJG9)M1K!8R%<;(#95!%B+HEC`]
M5%^\"J4">4%6%DERFBA5'P6DPN/L@\WW[138R)Y;"%O8(;U_O7+,447AG.=3
MY+5=2^JQ&(7//3U#+=,%&V7TN>\[7\(06,2'(L`:@>>;Z]KN.2CK*[/%2J![
M"\)S^Y[;KHW")QT`3B)RMC60!!=Z1<]M%9NTC5"Z)\[)`*Z+\WWZ)3`K<VM[
MK"V5L2#>A!*'P@4F.V*)FU>YF=7-GKF4:S5D?&'3`94=32.W[:0%^+9=:2+8
MI$:9D^M;!.5241:JJ"M1_4Y>SWN=C06@*!;J0E[,O<JP4:*'4AVC]<]75N@=
M+"JM'J09Y>7,#N,MO?1+G(M.C_I1W@M['D6G1_TH[PV_1ERY<N7+ERY<N7+E
MRY<N7+EVS]/!!,<V&Y!F?U82$W__`/_:``@!`@,!/R']F!RYRYRYRYRYRYRY
MRYRYRYRYRYRYRYRYRYRYRYRYRYRYRYRYRYRYRYR%2I4J5*E?N<__V@`(`0,#
M`3\A_:K4J5*E2O\`YD;ERY<N7^ZC_]H`#`,!``(1`Q$``!```0`222222222
M22222222222220`2000``````````````````````````"``````````````
M`````````````0``````````````````````````"``````3;;;0````````
M`````2000`````!6VVT```````````````0`1?\`_P"I)K;;;I))))))))))
M)````!`DDDD`%;;;0````````````!```($DDD@`K;;:`````````````(``
M!`DDDD`%;;;0````````````!))(($DDD@`K;;:````````````!()!`+DDD
MM;?;;;;;;;;;;;;;;;:0```($DDD@`K;;:`!```````````(``!`DDDD`%;;
M;0`(``!```````````($DDD@`K;;:`!```(``````!```!`DDDD`%;;;0`(`
M`!```````(`((!<DDEK;[;;;;:```!;;;;;;3!)!!`DDDD`%;;;0`(``!```
M````!```($DDD@`K;;:`!```(```````(``!`DDDD`%;;;0`(``!```````!
M```($DDD@`K;;:`!```(```````!`(`+DDDM;?;;;;;0```+;;;;;:0(``($
MDDD@`K;;:`!```(``````````!`DDDD`%;;;0`(``!```````````($DDD@`
MK;;:`!```(``````````!`DDDD`%;;;0`(``!````````!((($DDD@`K;;:`
M!```(````````((`)DDDM)-;;;=)````))))))(````($DDD@`K;;:`!```(
M``````````!`DDDD`%;;;0`(``!```````````($DDD@`K;;:`!```(`````
M(````!`DDDD`%;;;0`(``!`!```!```!((+MMM1`)))(@`)))((!)))((```
M`````````````````````````````!())(``)((`!)))(``())``````!!()
M)`!!`)``(``!))(`()(``````````!)`((`!``````````(``````````())
M!``(```!`(``````````````!`!((`!`````````````````````)((!``(`
M````````!/_:``@!`0,!/Q#IE4)&#4;`\R$Y(Q6ED168<E>@_(AS\U2HJJI[
MHHR&)DO&)J>I^5G]=$#"?;8`P%:VL5V2*<]M<!U%,JHLX50H4*%"A0H4*%"A
M0H4*%"A0H4*%"A0H4*%"A0H4*%"A1X%"A0H4*%"C[Q]U]Y]5C+'8!J6(7)A]
M)0-UKLN1:*MK:BAXX8-X?W'0AJ!J(Y0C6:B@^Z]X=R5]P_33`H4*%'Y%O.E(
M_CJAAU\^?+D*&Q#`0!;-=BO/GR00NX,0*0V6)57U9;:(-*)L-$U/AI@I5@T*
M5-"/`1^V=E`6H1Z6\60&AS*V=I!'IUKR(+:'FKDRB3MAOR!*9Z\/J">$Y=6?
M^A=Q_0LS^C(NYD(F")R1>E>><N/8&\>N];D>KC0/N0@R`NRS5#`EH0!2H0"4
M#TZ"AZ0=^[&`"X&C`=;]_P#M>HEO\[,#UG]KU$M_G8@>G6_?>D'?NQA`N0IP
MO8H4*/?2`.D\#&82@"=YLN5SMDYM._`J!7U"A0H4*%"A0H4*%"A0H4*%"A0H
M4*%'WC[K[3ZK.685``]`V1-2\F@$@1D_`A0B(0\LHQXY.WEH6%Y%ZQ2`J(OU
M[5%;]6]Y;48\<G:P9B!X09%T0+-=OB3*<?Y,ORRC'CD[3/62-BQ[B/([TSGN
M(*87S5RO"BM$RTJ-RNVREK@@JI!&*N.)[B0+&I$*\H1=I)SI*;%L5`T%F9#5
MU'(*,>.3LH]639K:PEL,L>>-[>:B']J+(<47T72R+[R>:ETYZ4&%',J.-9);
MU]4*5WS%`+[K,'M:'>1WL\NK0P`64('!#AN@V3D@4*=?"HR13,W%0_=UF(E"
M(N#8$[P?NXS$"A`70L@]@J5*OQ091B2^=#<>!N9Y#"P)C-M4M`^I*E2I4J5*
ME2I4J5*E2I4J5*E2I4J5?>#X/_:&R*P2;3@@._YR0;,D"_$GIQDV*9F(!L2'
M55`X^M48\<G;\+SEJ\!CBET=5EBT*+U/M1P0S@5DTLY#U'$#/H=5EOX'J&U&
M6A"A\P1=>GS<!2Z29H2N3SU$(8-(Y51CQR=K:B^)K=P#H>7AE5/7*0PY[,**
MORJC'CD[6U!N=>(49AYCO(*D)V;G_1#QFO+*,>.3M;4#Y:HR?&+52$`11`:*
M"V]+L]@L94C(-Y!T5]%,OMO>PL^4Q&4S;DF>B*B^>BS)(3'Q2CYREAR(Q?5S
M5><,D>PCZ0+ZD0`S<1ISV%-_RCE>@J5]&/P!ELXPM+#N5]&/T%EMYPI:+JJ5
M*O;A<B-!9A"*W@3\<I",:8%!L-JG85*E3_J0?AT#;*`,CO,[AL%\BD#)LQY5
M2I4J5*E2I4J5*E7VLN-\6]W$OJVJ:&8L3=<6'Z,:3S,0YPW&M]0L128B@-0"
MA*,!M6<\9,JO%'[@JBP\S`D;OJC1J8`0S%(.7!(C`-0JY+*,>.3M;4*94$3`
M?EM^NN((UB-%L@,A.548\<G:VH'*'[6>H.ON$Q4IS0&(AP<MY,HQXY.UM0BV
MUJ*"Q90D2-"$MQ&8`AM'\M48\<G:VH-,V%+GPN#C"("JL`"-#$,:A4-8M"S>
MY"J,B'YM5/N@^(#@7'D%)1,'(@H5(0VS&SRHT.0*NBW(132.N/"=!-[JCD%D
M:@"<-6>R\#7FC?14EC<;!?FJX(;'O"QN-@OS5,0-IV*E2KYL&)G))/NE`IWF
MSACE1$-RA`X>Q4J5-8ES^)]`*RWWNY@^(O1"3D`7S*E2I4J5*E2I4J5*OO9T
M/_535GK?&E>]GDLO%&.+71FH"^,^`X`^[RY"[:1[DN&ZKW*^:E02[*=;>&7P
M6TN=-FP3-16ZX2%O*;W&&V=0`'ZKX\<G:VH48\<G:VH48\<G:VH48\<G:VH/
M%R]%0(3>ZCJ,.%L%$JTG5GNNN9FX,11<LSUNNPL&VJ7DRHQXY.UM0#5@`N]"
M!5'"L!<K"+-9JPDI6DG<_#:C`2$C%#@S"?(M5%(BG*:`4=&EH`\//,82@>B=
M.%B6P<+SAD6%+Q>D@)E\CN76H4H`T=X3+Y'<NM8H5)I[)$B1N301-RJ%9J&1
MX+B-,X(WZTIH`='9(D2+K/*LQJ"]U#7>Y^R^*:&N8$&3S2)$B1(D2)$B1(D2
M/L;\+1]7\K]&U&/')VMJ%&/')VMJ%&/')VMJ``D&B+5!5%(X[&S9LFL4F66?
MH8LSV)LV;+,)!?7^0"F$./"UES]ZBK1+9,CEE&/')VMJ)%K[D9-?]N*H@)G;
M-'^IUFRJ+ES"@=#T6[-2I?K2+4TDV'L2Q.;)RI_O91:T((.ZG3ITZ=,V3E3_
M`'LHL*5!43UAANWBP@B-%S'1/_,,Q%9*'"D\!_?OW[]^_&.C<CP]<[:@1T)R
M4,S):ZDKAOHR=64&%M5F&@5</<+%BQ8L6]6',`HQF*MZ!.+HG\LS&EA7TDG.
M``!=G-B1$^7>+%BQ8L6+>.3NIRLTMET`G^Q/+O\`H2N__P`+A65@`*S1T=X(
MLHJ$5`NM+W_Z1!U*,7O+"^JJ`>J=].+9`(D$(2PJ8($\.F4=Z?R6]QAMG5`+
M#4J25#%5]0(H]AJ$/H=_',%Y0'>S(7WEQ0`[6H0+[H2C:(D%$;.JKE(AXC%5
M)2D'O2^Z$HVJ)1`"V$R%]Y,4!.UBG9]^5Q>T>F]/$N,Q%G1BX]AO@SG^A=/?
MVPH3+MFZ/B4LX]>+-29S#[3VS3:]66(CA$PR8K8/[7`T86ZMAJ3G(@JF8Z(7
M"BJT$*?(XIN4PZSOB[*$'(;*L*=75"C7,68#UO[GMF.T)N$YH0`F5#K`,9-P
MKB'8V3=/%V[F6-K=Y[5K./+,-D?@Y3B8(JTE%BZ<F'!TI2,@I9KP>S,1`T/8
M)E7H;`!6ZVM'Z)$CJ.+K<81(]X"?VP^U*0FC$)JIT5U6&FD7F3LJ+2U.D`:!
M-QVR7?:5;;`^N=H?*PD!0$0I#Y5[0]J@J2*;EJ?+`M?#_7I`$X6IS2,7U$TX
M%G+1Z!Q+?_.5?Y9`O"N!\'()1!I:+@4A_P")'PT012EIP4"!B/E[1%=+62"A
MS!X+5_,"1GW(IZ)8L$")4Y[$"YC/:)K_`)`C9E(U"V@V].>V50P*<#I?GQE1
MT"_6<PAN-X9E15,PA)!=X_H@88FF0QP"SGF:&&I^"I*+79V#5:C2W[8([3@\
MSA"OHO,]7GLW?>6I3.801*PS3D[,I7UH'$(%(O+[Q2PQ8@;HY>B8-!AD4#J5
MT!4"=(0/8EB@X!G+-3$?-U?**PM$6VN(^Z"0S8_5U,AX=IK[TKY5H061#]O2
M<2$788=)**'XCF+S5,_;=-_YTA"+9`2'GN=S8=V2)$B1?QXB1.8H:0G4P(AL
MR5(6%JG$4ISBQ*HC#TV\V@BXFJ%@AA8<MUI!HI[J*/FDZZ5^V]<I;B!]68R%
M&JAY>DB1]Y0H?^Z#'Z9>!=[F-GA3HB,+Z['Z`]ZJM0`08)F8%'0,$ZV1O=N$
MB@1U!B)<<.U$X>ID*;[5*`@J#AD&->9==8V!`KQ*BZF8^C8B(!/:A)KJH.3#
MJO'](@\%N-:``*$2I_1&_3JW^]MHA!)`LXBZ/0ITAU6:48F^YUA1E];E'"T8
MX]E!,SA:AL%(=NS1#1/'BP_5U?!4`E&\/+/GW'0==06L]I((LH^YO@BNA3&F
M'NG`T$:R#*F#="J,7%H/!Q+'D*PK2!Z`*@59M7V;`D&\?`);;AM;+`+&D`@+
M.O&L^?JV42Z]A3!AN-T4Y'N]WF_WQ4+#/5H->KY%=`>R!%^6?/N&O[<*KVPP
ML<OLYAKN8>69=WDLSF'N@'9U.PJJ2L9D@=`1ZLB^$U(B=R!HI@)SHW;C/KJX
M51I!Q!S(;"D0AGP"*B;#7"PAT/??KX%`D%CW"O5$U*/804V[>Z_R]^P\C]SO
M$7AO0VM/JF9TCQ-V.`[F6.D>)NQP'<RS-FS9LV;-FS9LV;-FS9LV:9@YN`*P
M#9`BS0AQD!`S_]H`"`$"`P$_$/URLEDLEDLEDLF^/=>#3A+ERY<N7+E]CKP:
M<>Z\&G'NO!IQ[KP:<>Z\&G'NO!IQ[KP:<>Z\&G'NO!IQ[KP:<>Z\&G'NO!IQ
M[KP:<>Z\&G'NO!IQ[KP:<>Z\&G'NO!IQ[KP:<>Z\&G'NO!IQ[KP:<>Z\&G'N
MO!IQ[KP:<>Z\&G"5*E2I4J5*[-RDI*2DI*2D"OW-_P#_V@`(`0,#`3\0_:I1
M*2DI*2DI*.0-=[KD#7>ZY`UWNN0-=[KC\0UWNIB8F/%B8F)B8F)B8F)B8F)B
M8F)B8F)B8F)B8F)CQFN]UR!KO=<@:[W7(&N]UR!KO=<@:[W7(&N]UR!KO=<@
M:[W7'TPUWNI3*93*\-,IE/AIE,IE,IE,IE,IE,IE,IE/C-=[KD#7>ZY`UWNN
I0-=[KD#7>ZY`UWNN0-=[KD#7>ZY`UWNN0-=[KD+9:6EI:6EI;^Z?_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g575431g42k43.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g575431g42k43.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`(0+0`P$1``(1`0,1`?_$`+8``0``!P`#`0``````
M```````!`@4&!P@)`P0*"P$!`0`#``,!``````````````$"`P8$!0@)$```
M!0,#``D!!@,$!0T````!`P0%!@`"!Q$("2%1D1(3EM98&3%!%-46%U=A%1B!
M(E(E<<$R-H;10B9&9G:VQK<H.$@Y$0`!`00)!`$#`08&`P```````@&2`P01
MT=)45086!Q=2$U,4,2$2<E%AD:'!@G-!,F*R,P4T1#;_V@`,`P$``A$#$0`_
M`/OXH!0"@%`*`4`H!0"@%`4QV;4+RWN#.Z)K%C:ZMZMM<$AEU]EBE"O(-2+$
M]]Q=UAEMAZ<VZT1MN"X`'H$!JH6R'%9$0UK(R:&L;^E#:6?Q8:XB&Q$M0U+%
M0VL:QOU_5E#6?N.9`<+W&`5;T;1H/;:(@``$ER..NFOTUF@CT6AJ-=K"W0SZ
MA+&0/^SBL@,90QB40_I1_0<Y'RAER,K[X\JC[OVJ4S^9-;PP\80]`[1X1:/3
MT#),C_9_QE]?^2MO*>X.*S#B+!HT5E:FCU(5/YJK(_#!QB:B`;183<'1TVR3
M(P_77_MF'TIRGN#BLPXBP5F2<KM^)2&\NLC\+_&%[2(.'\!DF1P'L_.7VTY3
MW!Q68<18&B<K,^92&^JLE^&'C"'Z;1X1H`B`C^9<C:!IK]OYSZPIRGN%BDPX
MBP3165J*?4AT?FJLF'A@XP@#7^DB#C_`)+D;4?MZ-9F&HTY3W!Q68<18&BLJ
MW2$^JL?#!QA::CM'A%NGU`9)D?4.R9#K3E/<+%)AQ%@K<DY69\RD-Y59X_AD
MXOPN`L=I,&`RX-;"QDN1@NO#01UL`9F`W`&GV?2G*>X.*S#B+!-%96IH]2'3
M^2JR8.&+C!$1#^D>$`("/UDF1@UT$`$?]\^L=.NG*>X6*3#B+`T5E6Z0GU5D
M0X8.,+70=H\)M'JNDF1P^P!'_KETZ:Z4Y3W!Q68<18*W).5F-H;*0Z?R561^
M%_C#U#3:/"!#IZ0DF1]`^GU_Z9?;3E/<+%9AQ%@:)RNWXDX;RZR%W#!QA6ZB
M.T>$:`&HC^9,C`'T'[1F?\/[*<I[A8I,.(L!N2<K,^92&\NLC\+_`!A>TF#^
M9<C>LZ<I[@XK,.(L$T5E:Z0GU5@>&#C"`-?Z2(0/\`DF1Q'I'3H#\Y=-.4]P
M<5F'$6!HK*UTA/JK(?#!QA_;M&A(=.G3),CA_IZ?SF(=`!3E/<'%)AQ%@K<D
MY79\RD-Y=9-\+_&%[28/YER/ZRIRGN#BLPXBP-%96ND)]59`>&#C"`-?Z2(.
M/\`DF1]?_&5.4]P<5F'$6":*RM=(3ZJR4.&'C#$=/Z184'6(R/(X6A_:,S^V
MG*>X.*3#B+!=$Y7N<-Y=9$>&#C"`=/Z2(1T_3229&'_SGK3E/<'%)AQ%@FBL
MJTT>I"I_-59+;PQ\8%PWVAM)@PW%_P"W;;)LBWW6:ZZ=^VV9ZVB.GV]5.4]P
M<5F'$62Z)RM=(?T_U*K)QX7^,,/IM'A%PB.F@27(W;TS,.BG*>X.*S#B+`T3
ME9OQ*0WU5DH<,/&%TZ[185;I_BD>1P#3IZ0'\YCK]/LIRGN%BDPXBP&Y)RLS
MYE(;RZR8.%_C$$/_`(C0@/\`B3(_K*G*>X.*S#B+)69(RNW_`-.&\NL7<+_&
M';_]1H2/^B1Y'T_M'\Y]%.4]P<5F'$6!HC*]SAO+K)0X8.,0=1_I$A6G7^8\
MC#J'6`!-!$0'MIRGN#BDPXBP&9(RNWZLDX='Y+K(!PQ<85WTVC0D>C7HDF1A
M_P`71_OGT?3[>@=:<I[A8I,.(L$9DK*ROB4AM_K563_#!QA:Z#M'A(=`#J,C
MR.`#K]@#^<OJ%.4]PL4F'$6!HG*S/F4AO+K(_"_QA>TF#^9<C^LJ<I[@XK,.
M(L#165KI"?56/A?XPO:3!_,N1_65.4]P<5F'$6!HK*UTA/JK'PO\87M)@_F7
M(_K*G*>X.*S#B+`T5E:Z0GU5CX7^,+VDP?S+D?UE3E/<'%9AQ%@:*RM=(3ZJ
MQ\+_`!A>TF#^9<C^LJ<I[@XK,.(L#165KI"?56/A?XPO:3!_,N1_65.4]P<5
MF'$6!HK*UTA/JK'PO\87M)@_F7(_K*G*>X.*S#B+`T5E:Z0GU5CX7^,+VDP?
MS+D?UE3E/<'%9AQ%@:*RM=(3ZJQ\+_&%[28/YER/ZRIRGN#BLPXBP-%96ND)
M]58^%_C"]I,'\RY']94Y3W!Q68<18&BLK72$^JL?"_QA>TF#^9<C^LJ<I[@X
MK,.(L#165KI"?56/A?XPO:3!_,N1_65.4]P<5F'$6!HK*UTA/JK'PO\`&%[2
M8/YER/ZRIRGN#BLPXBP-%96ND)]58^%_C"]I,'\RY']94Y3W!Q68<18&BLK7
M2$^JL?"_QA>TF#^9<C^LJ<I[@XK,.(L#165KI"?56/A?XPO:3!_,N1_65.4]
MP<5F'$6!HK*UTA/JK'PO\87M)@_F7(_K*G*>X.*S#B+`T5E:Z0GU5CX7^,+V
MDP?S+D?UE3E/<'%9AQ%@:*RM=(3ZJQ\+_&%[28/YER/ZRIRGN#BLPXBP-%96
MND)]58^%_C"]I,'\RY']94Y3W!Q68<18&BLK72$^JL?"_P`87M)@_F7(_K*G
M*>X.*S#B+`T5E:Z0GU5CX7^,+VDP?S+D?UE3E/<'%9AQ%@:*RM=(3ZJQ\+_&
M%[28/YER/ZRIRGN#BLPXBP-%96ND)]58^%_C"]I,'\RY']94Y3W!Q68<18&B
MLK72$^JL?"_QA>TF#^9<C^LJ<I[@XK,.(L#165KI"?56/A?XPO:3!_,N1_65
M.4]P<5F'$6!HK*UTA/JK'PO\87M)@_F7(_K*G*>X.*S#B+`T5E:Z0GU5CX7^
M,+VDP?S+D?UE3E/<'%9AQ%@:*RM=(3ZJQ\+_`!A>TF#^9<C^LJ<I[@XK,.(L
M#165KI"?56/A?XPO:3!_,N1_65.4]P<5F'$6!HK*UTA/JK'PO\87M)@_F7(_
MK*G*>X.*S#B+`T5E:Z0GU5CX7^,+VDP?S+D?UE3E/<'%9AQ%@:*RM=(3ZJQ\
M+_&%[28/YER/ZRIRGN#BLPXBP-%96ND)]58^%_C"]I,'\RY']94Y3W!Q68<1
M8&BLK72$^JL?"_QA>TF#^9<C^LJ<I[@XK,.(L#165KI"?56/A?XPO:3!_,N1
M_65.4]P<5F'$6!HK*UTA/JK'PO\`&%[28/YER/ZRIRGN#BLPXBP-%96ND)]5
M8^%_C"]I,'\RY']94Y3W!Q68<18&BLK72$^JL?"_QA>TF#^9<C^LJ<I[@XK,
M.(L#165KI"?56/A?XPO:3!_,N1_65.4]P<5F'$6!HK*UTA/JK'PO\87M)@_F
M7(_K*G*>X.*S#B+`T5E:Z0GU5CX7^,+VDP?S+D?UE3E/<'%9AQ%@:*RM=(3Z
MJQ\+_&%[28/YER/ZRIRGN#BLPXBP-%96ND)]58^%_C"]I,'\RY']94Y3W!Q6
M8<18&BLK72$^JL?"_P`87M)@_F7(_K*G*>X.*S#B+`T5E:Z0GU5CX7^,+VDP
M?S+D?UE3E/<'%9AQ%@:*RM=(3ZJQ\+_&%[28/YER/ZRIRGN#BLPXBP-%96ND
M)]58^%_C"]I,'\RY']94Y3W!Q68<18&BLK72$^JL?"_QA>TF#^9<C^LJ<I[@
MXK,.(L#165KI"?56/A?XPO:3!_,N1_65.4]P<5F'$6!HK*UTA/JK'PO\87M)
M@_F7(_K*G*>X.*S#B+`T5E:Z0GU5CX7^,+VDP?S+D?UE3E/<'%9AQ%@:*RM=
M(3ZJSJ+7"'6B@%`*`4`H!0"@%`*`:!0&MN[#+CSAK##V^0Q,E<<IRYTC^+<+
M,JONB0\YAR6[I8E`BE15P7>,T,[JY?S1SZ-"VEO5&CI:6(T9]&4,^`::<9,@
MFN+5&?\`C]S).9'D?*&SF9MZV%9(FZT5LOS#MDS=:Y3G#V17A88/^9.S,[VO
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M428RT4W>+`UK6_5OR#J\U;(-N9,6.C4L@U^4G%Q2C9(LAY3>W>:Y.D[B<4!:
MU\<9RX++7Q`[++[1O_RV]`G2B(6I2R2[+++;]ZV?1C6T`TYVY3;)&UO?A)./
M#)4\E&5L+Y5PF[;E-ELUR&\+)+D2&L<'D[1#<V[<);-'.XYXGZ""*I0SO,9<
MW`T]T+97`Q&J/4"D+-J4M^04O@O5.;CLFDZ]Y?)'(7(=Y&^1IN<95(7J4.5K
M7$MT>389&6DER?W%S7%-;%%H\B1)2+3`**)3VA;:'U$U36_+0>GN8C;;.N9+
M9)`)3>[NL$D&R/>,]O\`#/S'(D,5>WF)9&V]$QEV=X^VNJ-I<W)B*E#A8F./
M),,*M6&!:(`/16*4SX:T&;-W^UM_A6%9WES9&^.N$-RF)(L]9$QXE9WE[4XM
MRJMAZ(Q]4XDS#C94X*8U*X?D%(A,;;E-J<AW:E"@M8B5DFE"%YJE-^6@V4V7
M[E&#>-M2V][I(TW7LS/G?$T/R/8PG'@J.CKB_M9)[Y'3%(!;:IN8'L%"+Q`"
MWQ/`UT#Z5C2T&E7-'G/(V&-E\E-PB[OB[,#G+H`[)\3XX7/B?-V8<,PJ?121
M[CH=B&R*(U\I;Y"?AXEQL/=DA9/\K(/$;5*<\PBX;2T'DV8M6T9]N8>1?:SN
M.>VS:IF7"%L=?,9RK*DC68<;)Q^;(XK0SI2RY`EJY#B[+,<M;U<<?4-@$7*#
MS;?%M`ZRZ\ZM6MORT'5"-2J*S-LM>X?(X_*V:Y0I26NT;>&Y];+E:,T25:6U
M>UJ%205"4ZT;#+`O[Q=P:7``U*6@]QZ2D+&AU2*"_$3JFU>F/+"ZXOQ"3TAQ
M1MG?+NL,L[]EXAK:("'U`0I2T'RI8795L;X"<8[P(-/9S$-Y,"QA+9]BG*J:
M;RUZF63,NLV7)6T0C%,N;G-W7%989\K'(DD8.8W`A:"@A9:">TLXLHVRM6IK
M*&M^@.L$JRI/MT6\YLV3%O#WCJ`X6VWX[W$;P/R0\+V*42^7YC>7R/XJV^MD
MP;5*5XC$-\.%/KU(E#>>4X."4E"B+.+(/5^)*6L^`;#Y3V$X$GD/,8X8S.V"
M9PWIC#8/FC![VX0+*,#D5A8BVR-$^MJLL).*-5W;U#>]EN3:Y%=XI40=9?=;
M67WK;\M!Q/W2[JLQYLX:-X#+F%Z.CV[C9WN<Q[M<SC*<9N3O!29'-X/N+PL0
MVY/B7Y?<$#C'V+-.)YHWNAB(HT"2OYJI26@)-@!6+%-8VEC?J#H5FV)J]N&^
M;8`W[7%CS'_UYR!E&$;C<)H7U\=8!)L#1;#TLEIF8G**.+@O:XC),99#;F)"
MD?DA:0U?>_?RU1>?]X)L+K5*;\M!1.2;:)@G&VQ??GG&(,$N9LO1W;5N4R>Q
MY%39<R];)FJ>%P"62=%(F]9;.K;$2IL?"[#DA91=B=*!1991=A=EMH7N+_5H
M,Y;4=FFWV_$>V',=L1D89-+QAAO()DR_53*YKJLE:B#,2]<XNA2J;GMKR4YG
MJ3OO:960<F4VFW`86.M3[UM90UK0<]-IV.L)YGWM\RS=N-=S7QHQCO'QFGQV
M5+<N3.-I<>LCCMRQQ,'BR'@GF;.1&FTR3N*EP,!(!)0*K[C!#4`T?>OXI:#:
M+E_L$W'NP5$A=GLILDW)WLJ@[V+%)WYGME,%FLK>&64QEY6,3FB4OL=D[0<)
M*M,>9>2IL$+K@$=!HQ2F?#05Y(R/&".4?#N*\`O#^&%\O[:<W3W<UA\Y^=WZ
M!XR>X%)L>-F$<M1YO=USB&.9%D1TD+PR'I4ER9&_IVZ]0">\YO-.HU2F_+0=
M<]`Z@[*E+0:N1_<:8][Q,D[3KH.>D_3W`N-,Z_J&,A2GHWI+DN:9`A22+%QB
MU!8L0*V=3CQ4>8JO4WEFV'%VVV`/>$%+0(GN/,E6[S-FU/\`(A[=^C>%L(YC
M,R'=(TRA)(TV;))E:.-T?3QHMO*6MBIA4XA7F'J+U)MAUB@D+;0$;M)2"RLC
M[I)LP;IR=JN.<0H)Y+SMM#WN6)=GO(Y4);%[4P9*:L:*(.B+_*<BN+D2YP>2
M5!"M1>2A`OO6FW6B`#0&9MM^=XGN:PQ",W0I&^-3%-4KN%[!)DA2&11F01F0
M.D.E\5?DI!ZI,6\1:7Q]>W*!(--3F&IKKRK[R[K;A`SEH'4'95I:!H'4'92E
MH&@=0=E*6@:!U!V4I:!H'4'92EH&@=0=E*6@:!U!V4I:!H'4'92EH&@=0=E*
M6@:!U!V4I:!H'4'92EH&@=0=E*6@:!U!V4I:!H'4'92EH&@=0=E*6@:!U!V4
MI:!H'4'92EH&@=0=E*6@:!U!V4I:!H'4'92EH&@=0=E*6@:!U!V4I:!H'4'9
M2EH&@=0=E*6@:!U!V4I:!H'4'92EH&@=0=E*6@:!U!V4I:!H'4'92EH&@=0=
ME*6@:!U!V4I:!H'4'92EH&@=0=E*6@:!U!V4I:!H'4'92EH&@=0=E*6@:!U!
MV4I:!H'4'92EH&@=0=E*6@:!U!V4I:!H'4'92EH&@=0=E*6@:!U!V4I:!H'4
M'92EH&@=0=E*6@:!U!V4I:!H'4'92EH(U`*`4`H!0"@%`*`4`H!0')O)T@R_
MN0WR)F7;VMPT\Q;8*TVGSHO)RZ7GLAVYG.D54$LZ%$1";CKQD&(L%JU!IMJL
M-++YV7W0M-([UH&L>\&3[B]GVYG:=R+YWOV_L>*F.3-^S#<\]8O59#3*;<);
MDY6R(<=S28F36PMJ*8,.9]3M*FPZT?&(2OZX/]B^^@+RWR1F`Y+Y=.(.(S="
MQRAB><5\AKD6SK5-EQ#G>BQQB-2WK$MA"DLY07;I=>7=9<-MUNH](:T!Z6"7
M8SB?W/N^T[):E6CV';K,BR+(FS;,[X<I5-.#\XSAR->,A[0\KS!P$XU$URQ^
M/->L>.[LIU5^.>RW'F'$I;!`W`R,N0_*MM01BL1_>S=D&]$\M**DD%5Z?]8=
MFP>.6G\0#KR!$N[^\%HVCW1_P]`&NN\C!>5MH&;WGDZV5PYTF3HO;VE!OZVH
MQ8H/_=/B&-E@03EW'K1XA*(G=5A=C`PYM-M"V^5,Y1C4?<)GW>X0-$&V&9`R
M)Q,\86]';Q"Y%E26;-,[-&\QKQ@SM]]DVR=A-VE.7HGEJ'1QFNNNN'(@XDR0
MJ7HD'>$TUP;_`+K8%QAEMH@?1C@O/N(=R6,V#+^%9]'Y_`)(CL5H7IF5V7&(
M#1L"Y6S2)N.\)QC4E9SAN(7MJ\I.N0J"[RCR[#+;K0`Y_I(\.Z+E`Q?N"AE]
MKAA;8_@;.&*KLB(PL,C^0L\[BY!CNR00N'NI(WIY$V8D@N-+;GM6GNO2$/#P
M0CMON4)E=I`&*^#"51=#L;E8K9+'D8)]Z7($H/%2]-A`$)[]X>93RSCN^IM`
MHN]/<!@7#I:-@A<`]T0&@*]EB1QYYYLN/]Q:'YE=&]TV";WU[6N;G1"M2.2%
M9DK:_<D6MZA.>82M2*[2+Q*,*&ZPRVRX;1$+1T`WUW<9[C.",,39\5!=)IP\
M1A^C^+,4L-MCG/LM9&>&P]OB4$A$=(,N<'=T?'Q2G),OL+^[HD]]ZE284G*,
M,M`L7C:VT/FSO8AM5VSRE2F62W$.&HI&YD>B-L/06S0].8]3%,VJ;``%38BD
MKHJ)3&AT&D%VW:!K0'.;>7N?:=@?+%B#<=N@+71S9CGO:'_2^S9_4(EBB$[>
ML\L>9W'(AB'(+HC(4!#8QF-A<V\@QS.\(DQ2S)K3;O!3&7E`<_-W#IB38YF5
M^W'<:<\V_P"\7$&])V-3[J.(V#SN*9,'.<ADJ2[[UN#VLP:(63>R.S1.3=]]
ME*2]M!F<$91BBZZTT+;;0.Q'"7DG:R_\=>V;'NVO(4/D:7%>-&&#Y!BC<19&
M)A!\JM:7[UDJ,S>`.()91%Y`VRM6J`RQP(M.4%]P_OF6F`9<!UD<C"RVU>:8
M9865:A5&7FF7VV%V%VIS+KK[[[A"VVRVT-1$1T`*`XZ\'$<ADMXI-B;ZZ,D<
ME"N+QF=.L6=5B%N>C6%U#+&0DYCDQ*CBU(-[F7;:)?C$#:=:`#:%P=(4!:V9
M7C^@[E84;M\E`>U;2-\N`\7;=<F9:.M.&+8(W&8.E<N<,/.>4W$+;TL3QQE>
M(3U<SDOJL2D")[2$%*C2;%-E]`=C)1D:"0N%KLCRF81MB@3:TB^+9<XO"(A@
M+:1)M4%+BW/Q+DRDE03<`D^%=?<>-UH%A===:`@?+?O-Q,ZQOBLY5-S&2&5;
M!OZ[-Y>&\WQZ%S`L6)[8L.-^7MLN&<5%RQJ5B0>Q2B:PO'H/ZQ`9<"E"#O8F
M.[IY)EMH&^.Z+$2[CES_`!SDAVU8_?Y)@PV',V'-_6#X6B=I6\7X22O*QYB&
MYG$K%=>XN1\NP6[N:@V1M3<(`]Q=2::!5RI$7>(&R_)#DF!92XA]]63<>3.-
M37'LRV+[AI#%)E''9$Y1U\8W3#DI-;U[>Z)CC$QQ2@#``/[P7VWCW+@"\!"@
M-M=HIY"C:GMD-3G%'E&;><+&%FDF6&EF%WXXC@V&%F67767EW@.H7`(@-`<7
M=C^#=N.:M]W.65G/%6'LFVE;Q,4,A%V28E$I0<F9S]JF,/OK<D42!$K4(T5Z
MF\T3+"KK+0-[PC_>#H`S9S&!C:48:X]V(%D5><?O7*QL5BH)4CLC-8'%N23Y
M[;%C(G5MZXNPRQ+8CO(,+)."\H2KK1[HVCH!;648\'$INN>-U,7:7*[CQW7G
M1&)[P&Q$6YR"[:9F.-(K8UC'<NBLO!Q>D>"98T76L<U3%W"B858)7<+;";UE
M`=T6=Y:)$TMK]'W5M?6-Y0I7-H>6=<E<VEU;5I-BA$X-KBB-/1KD*M.9:84:
M5?<699<%UHB`@-`<S8>[-2+F"W(%K7-N2&!Q^;63!+4KDI!@%VYVW.C=>-AI
MMEX66A<`B.F@`(=84!3\0RJ+J.67>FO(DL?.0J]CNPU0D6%/+:8E5)R\J;WO
M$4)S[%(E'$%_\Z^T1MMU#40U"@*0\J&V7\OK(0Q2R]*0_P#%7D`6^21)R:U*
MTA*HW7P`BUV9%=Y;DAN-*$;O!.\(TNV\!Z!$-*`Z3XGQ5!\)8]B^+L<-`L<.
MB*`U"TH+U:IP4WWJUJIT='-R<EYJA>Z/+V\+U"U:K/,O.5+%!IIEPWWB-`9$
MH!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@
M%`*`4`H!0"@%`*`4`H!0"@%`*`QY^JV-_P!P('YRCGXE7D^E.="W%U&/<A>1
M`_5;&_[@0/SE'/Q*GI3G0MQ=0[D+R('ZK8W_`'`@?G*.?B5/2G.A;BZAW(7D
M0/U6QO\`N!`_.4<_$J>E.="W%U#N0O(@?JMC?]P('YRCGXE3TISH6XNH=R%Y
M$#]5L;_N!`_.4<_$J>E.="W%U#N0O(@?JMC?]P('YRCGXE3TISH6XNH=R%Y$
M#]5L;_N!`_.4<_$J>E.="W%U#N0O(@?JMC?]P('YRCGXE3TISH6XNH=R%Y$#
M]5L;_N!`_.4<_$J>E.="W%U#N0O(@#E7&X@(?J#`PU#34)E'-0_B'^9?6GI3
MG0MQ=0[D+R(+)B*W;O`5LI<82KPM$W&</-TDF;A&EL#8%TND5Y?A&/\`*%;2
M<D/D#T:5_=N5JQ-/&T`M[_=``!Z4YT*<74.Y"\B#SSIUV^90C:R&Y)686R!$
M7$U*<X1:;KH)+(VO-0J"U:(Q:Q/QR]K5WHU95AI0F%7"6;9;?;I=:`T]*<Z%
M.+J'<A>1!213;8;GR%2>]+@4R28V:C&/'4@,''=[Y`64Y,"(]HA;Q?=<XQ=K
M4([;23$Z$T@J\JT+!M&T-*>E.="G%U#N0O(@N24RG!\Y8G&+31]Q++HN\$`E
M>(U)WJ%O[`[)@,M-!.Y,[LI5H%Q(&V6W!:87<`76@/U"GI3G0MQ=0[D+R(**
M0=MR32%@EY)^%+);%(\=$8K*K5L$MDL:B:CPQ41=B?O&%U:XZHN)L$Q$2;8G
M,&RT;K![MNCTISH4XNH=R%Y$%\CE3&XVA;^H,##3300F,<Z-/IT?S,-*>E.=
M"G%U#N0O(@HL<E^%(>RI(Y$Y'BN,Q]`*NY"R1^01!G:D5R]8H<5MR1N;UB=(
MF%4O5FG&=RRWO&F77#TB(T]*<Z%N+J'<A>1!AEYQ+L?D$F=IF[P?;8KEDA/^
M]220`3CU*ZR95KJ*B3JT9J<R1GW?2ZY;X]UP:`(Z!I3TISH4XNH=R%Y$&:&F
M:X>8FQ$RLLOQHTLS:E+0MK0UR2)-K4WHB;1L*1H6Y"M3HT:4HL>[:6599:`:
M]'33TISH4XNH=R%Y$&O:W;YQXN*<Y(MPILW4)E-YYBHB^#X7\%48JN,O4FJ2
M[6\+5!J@PZ^XRZ_6Z^ZX1N$1$1IZ4YT*<74.Y"\B"[Y'C_9G,+XZ;*XEMLD1
M\08DL6B*IX;L8+5D3BZ(`!'&HLM.LN5QQ@2=T/#2(S"4]@``!8````]*<Z%.
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MT]Z63Y.8T>,FB?R(@T;!.L?)<WV)WUV\<2K>^)YY@W]T`N$0`*>E.="G%U#N
M0O(@RHKR5BUP2*4"^<8\6HEJ<Y(L2*I;&5"96E4E7$*$RD@UPN*/(/)ONLOL
MN`;;K1$!#2GI3G0MQ=0[D+R(+9A+MM^QI'4,0QRX8:@,1:[C[VN*0IQ@L5C+
M8*HXQ2J_ES$Q'H6M#]Y4FWFF>$5;XAMUUUVMPB-/2G.A3BZAW(7D05IZG6'Y
M&V.#)();C)\9'9$H;79E>))$G-H=6Y67>2K0.3:N6GHUR)43>-AA1MEUE]HZ
M"`AT4]*<Z%.+J'<A>1!A&+8DV/0=:@<(=!]MD94M*HM<SV,Q&/42%D6DF@<4
ML8FHHX&QD5DFAWBS$I)5Y8B(VB%/2G.A3BZB=R%Y$&4YRY[>LGQXZ(Y*585R
M%%%*E&L51B<+H)+(\J5MQ]BI`I4LK^:X-J@]$J+M-)OO*&XHRT+[1"X`$'I3
MG0MQ=1>Y"\B"Z",F8P3)24::>8_3I4Y)2<@@J71FPHE.39:64065:X!9:467
M:%H6@&@6AI3TISH4XNH=R%Y$&.26O:PGB$@Q\0WX!)@$M4.*N504FW')4,DJ
MEW.L4NIK[%[!!C=;G118%ZKQB+_O-^MQO?N$1IZ4YT*<74.Y"\B"]V&;8<BS
M0V1^-RK&#"P,J!*U,K&RR*(M30SM2$JTA$V-;:@6$(T#>C)L"PHHNRVPNP`M
MM``"GI3G0MQ=0[D+R(,,/N*-C4H=GI^D>.-JCZ^21R4/$B>'6.XE7.L@=U0!
M:H='UQ4)C%CRXG6AW;CE%YAEUO\`=$1"GI3G0IQ=0[D+R(+C.C&T93%HA!E,
M=VXJ83CYR1O,"ARE!C$^+PAY;SC5"!XB#";9>V1MU0GJ#+R5*,HDXJ\RX;;@
M&X1%Z4YT*<743N0O(@R<KR-BQ>D5MZV<X]6H5Z<]&M1K97%UB56D4E7D*$JI
M.H7WE*$R@DP;3++PNMOM$0N`=1IZ4YT*<747N0O(@HL0D6#(`Q(HM"'[$T1C
M#9:98UQN,/4,C[`V6''7J#BVYG:525O0E&J#+KQL*+LM"ZX>CIJ>E.="G%U#
MN0O(@M"6Q_:;/7A5(9NQ[=)?(%J!.U+'V4(L8R!Z5-B/[Q]T;5+J[6*UY[>E
M^]F>$1<9X1?B7:`'>'5Z4YT*<74.Y"\B"AK,<;*7`E.G7P/:RM(2,C?&4I:F
M.XD-!-&V@DY.TQY-WTUWW=C:R%!EB=);HG)LONMMM`+A`;Z4YT*<74.Y"\B"
M]V(W;=&%[.Z1T[!T?=F"*$01B<V8['[6Y,T(2FV'IH<SK4!A"AMBB=46!UC<
M3=8DM-#O`6%P:U@J4GTMH3`B+9^Q+64?O8:ES,M#4Q*HL)BF_P"#5,8UO\3-
M;4[M[TD)<&IP;W1N4EB8F7MBQ.O1*;;3+BK[B%24TT@VVTRP;1[MPZ76B%>)
MWD]]LLIGVQV,I:EK?JQGQ]6&U#6J9]U#/M_5C:6%3K:9"@%`*`4`H!0"@%`*
M`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!
M0"@%`*`4!^2!7Z2GQX*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@
M%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0$P?ZP_P!=>NG?\[/[;3V__4?\S/R8
M?HN<('_Y@;4_^[$W_P#5:=5\.Y__`/K)S^XS_:P^ALN?^,S\?YG6&N-.F%`*
M`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!
30"@%`*`4`H!0"@%`*`4`H#__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g575431g54r32.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g575431g54r32.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`)D%D
M;V)E`&3``````0,`%00#!@H-```890``7RT``'M```"6U/_;`(0``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("
M`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"`@(!`@(#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\(`$0@!)@%4`P$1
M``(1`0,1`?_$`3(``0`#``,!`0$````````````&!P@$!0D#`@$!`0`"`@,!
M```````````````%!@0'`@,(`1```0,#`04%!P0"`P$`````!`,%!@$"!P`0
M(#!`%5`3%#8W$1(T1#46%R$Q10@R,V!P(R01``$$`0(#!0(&#`D)!@<```,!
M`@0%!A$2`"$3,2(4%0<@01`P43(C%D!A4C/3))0UM7:V=W%"<W2T)74V%U"!
MTK,TE=66-\'18D1419&A<D/4)@@2``$"`@0&"P\#`@4%``````$"`P`1(3$2
M!$%187$B$Q`@0(&1L<$R(S,%,%#PT>%"4G*2LG.#LQ1TH<(&@B1@<&*BTN)#
MHV05$P$!``(!`@0%!0$!`0$````!$0`A,4%1$"!`83!0\'&!D:&QP?'18.%P
M_]H`#`,!``(1`Q$```'W\```!CHV*````````````````````#+YJ```````
M``````````````&7S4!\?G/[?>``''.0``````````#*5=W1JNPZ8_7WX```
M`,ODAAMF><5']5[5M7G^N[)I&.<\:G2[0>D8``````````*7BK]=$K00``,T
MGDD=876;&-RE85R8L^QPX%3'1EZE?$7.\.(=^0$DQ\#FGQ+1!49:QT))```"
MEXJ_71*T$``",G5G,/Z4879$9]35B;L>?BO-R?BN*2PC)H`F1F@O$J8X)]BS
M2*'4EL%9F5B^RK3T(-1```%+Q5^NB5H('X,5$5-\'*`!E\O[$PZ_BHJ:2,CT
M>?(<<J<C!IH@95I8I#B3E;%@G4D_.Z.@((3H[@M<```%+Q5^NB5H(%/F/2WS
M88`!E\O_`!,3,E-I>C[=<,&Y^?\`DE9TI;)+BDBQR&'5'9$Q.C.].<90+H,R
MF]32(```*7BK]=$K00!A,YQMX``Q^:(SL;SOV-5M^:^LU91F9P"DB(&PCHRA
M2T"!G:E6EUD=)@2XKHZ@^Y=YH``BV/,5]A6>ZI6@`4O%7ZZ)6@@#'QGH]1@`
M#*YJ@KV1Q;"CLK%Y]B?G6$R.<5T3PC!\SNCD'7GQ)89V+$*9-.ET``I>*OUT
M2M!`\?\`6?N;V`V9X9`&(C/9ZP@`&7S4`````````````*7BK]=$K01C:K[X
M^?SGLVTZ$`&.R!F]3E@`R^:@````````````!2\5?KHE:#@2F^E]J6KS_7V%
M9[HE:"`,N&53U-.A.I.8?TH8U`````````````"E8J_Y]A=G[=MGGKG\\:EX
MJ_71*T$`91,PGJ89$/-P@)=9LPW*````````````0;$L6&JEZ)W7;O.4SRH$
M4O%7ZZ)6@@#&!31Z:``&7S4```````````,\0FT;LE=?=WW1^0ZUO'K.O+V?
M:=!@4O%7ZZ)6@@#.!Y^GLB``9?-0```````````I>*OUT2M!I:*O_"X]_.Y8
M]T2M!`I>*OUT2M!`'G*5$>NX`!E\U```````````"EXJ_</CD0O%G]46'35+
MQ5^NB5H(%+Q5^NB5H(`\^C\GH.``8W-D```````````QE5M]RG(AM26'3HI>
M*OUT2M!`HB'V/>LOKG]??@&/BG#TD``,OFH``````````#A\._RLU[[,]+;W
MY*F65`BEXJ_71*T$```9B.I-9@`&7S4``````````!E.N[GD/?%Z+F]6"+X\
MQ6&!;[WE]<`5!59RWK3!_P!^@,>&0SU_``,OFH``````````97KVY9SEUS[_
M`'KNB5H(``$!@Y*?3D:`,J&;#T^(.0<^1S2#FH````````#@<,FIHVZ\GEU=
M#TR5^S.M,UP6V;YE];=WW1X``@,')3Z<C0!B\IL]-#-9A\J0M\T6;E``````
M``!04-LJ%8M@UE8]*@`=/B=\=P,J=34<!7%?E;'L$4`,S&'3U[``,OFH````
M````#J^O,\8M6^^/9O:/@CMNW"``$!@Y*?3D:*SKLOGJBVC:.W*``/+POXV*
M``9?-0````````&(*GZ&Y7+HVK:M````0&#DN#T]L5C<VR[#$=9C=L^G(T``
M``#+YJ````````'GS2_3NYK=YUJJ.N=ZR^N0*QKDO/9N-['(ZJ0IUAJRM36E
M]AU&5R>$(#!R4^G(T````#&YL@``````&?H79V-:QOGT^OWC_C]?.BJS=-%6
MV@@5U`RG,[>$"A).QI^)X/1V3Z<C0(#!R4^G(T````#+YJ```````SE![4S#
M`;?OZ9UGJVQ:8^/#ED#5=ZM^U00%,5*?T->JM8]@BA`8.2GTY&@5569FU++#
M?WZ````&7S4`````!6>!;<BUK>&Y[=YT@D5,=+B97)QHOY<>7/[NJX;7!`0&
M#DI].1HZ;$[XC%9UCV"*```````R^:@````!XTZO]Y^F%\\DW))T*L*Y,5?7
M)GD=G#2>P*G^/B#PTC8,[&`5W`RDSE\#L>_J````````R,?DTV````#-5"LW
M<<8K]/EG6.'@'S"X_7QM7,Y<GN[*=R(JY\:6`JWNC9]\S^TZN<3RL?I.C'G'
MW-X_+YU7=PSU,Q.PHJV_8[H```'G`6L6218E)'3NCD$6)218E)2-(J6G)R1C
M?W[)2)X>#\>'"P).5@G3T5M7*W:5EL\D*[(O7:W*IJ:L+(RHA@1_0XV+9LQ-
M1HDIG>"K5LW?8$,-9@```'E0>JX```!U9Y6FMC6````.L/(4VD:[````/&,Y
M9[(@```H(OT````ZLS<703T```'2&?2U"R0```?(S:1LUV``````````<4Y0
M.G.X``````````````````!6IX_%D$K*)-RE%D!!NDUD````````````````
M548O*V.L+<(\?<[T@)J0UX``````?__:``@!`0`!!0+@"L[:V9P[*4]:.RE/
M6C7>6>_NU52M4Y92-IUF=/TX:GK1,6O()Y#3`<FH9)<H_F95QR(WH*2^R13A
M*9KG9:-A3N\9'1U"EY4[3?EKO4/?RFB&5'&%Z%?XK;(GYP9HZZEJS-ANEMV8
M=63*.*&;;9W#KVPG)N/PVO4BE<<B0MF1H$HX@S.*N3[;.X9>^4DS!5Z0R?CL
MD,::Q,U@$G,1.>GB916/.`$VB3H_;%)Q'$I$I?1)-G=VY_:M^[U#WW5E9WT8
MR+QIQ$78&$IR18&(=T4]:'9B$>:VXX:Z.C=&&]K*S\05]WMS)/2I=$\=Y$@6
MC<<Y"NQ'EF)3J2"RUDD5DP?X+D"0$AQJ6KYA-@4W<#K,>Y.LF&/,7R^,!R6-
MO0?]<FN%R8F6S6%SV6&,[1+SLN.6*7IVDB]LB99B7!9I,8*PK'#YBPP,4+C/
M?N]0]MUUMELE<LR.TCHC_91C40O441W%/6@YW:6NM)Y%:N@C^PGK/\QBL5J/
M-X@6^L&5VN4,Y>:FT6$.DD8&/4HG(\>+*S.S`&AS]$B<J9>9$7>W);'6;M.;
M6MZ"3R2)?CL'*@!,D?IN"P21]FL1BZ_Y)@'2YAD\6.)$9'@X(C!*D'UVX%WJ
M'MGD4LF\5NQS!,.FPK.^-,@OFZIZT'-+4Z:2Q"U)NX;"Q-ZV7H9-7V7#8EEC
MDX`8/MCZA>"BB(-D7%M9^))X6ZN[TX8<>W<T'&Q*&1EL0N)3G9@ZJ;I"\*"P
M<200`Q3##;BXK[C?(-,7LB<XTLFJ^2<2219P;L?R"0@3+"\N;K(@PO0TMX%W
MJ'N?V-[ZW&$#<\FE/VZ@[-;AF]Y?AV.B7]A'"^9M,I#>"IUE%G@9J&6F161P
M_+[W*V!QS-+D,5S/([+!4I=*I(A)'G*4Y82&^>OM^6BLI2P$M/+I"F3(1F*:
MS5INGTD$PJW9*E%93.9^^Q673?*+5!2SL[QQL`G60W]%(S/T7;F*+R5P<97M
M=:/54(8ZR-\;MMWJ'N9S.;6_'V)\>RF.2_=JDDGFK5(E%+3]9$Q8YS21"X5C
M2I=V*H186KB&%*L<FQY$Y>E(80Q2>MV'8*HY"P*/C23\4PRK]^),?THV8VB3
M/1Y@K8XX]`QO'!GXK&,8/0?X1'9-?.\,#28MEQHB,#+L$#.I\9BBK&[[F//)
MFTG+[W^3MS^PK>Y.F,<0-<#$F.ZIZT<UCSR9LR&5,GUTCL#C48F6Y*(5DI1[
MI!<Y/%Z"7<(;BGK1S6//)FI9(GZ>/S*UILK3=ZA[F8)4ZP^%XRRJ\/SWIQ=&
MQG&*DD>!"(>V40ZQ[9E7-3UHYK'M:4A1DVD,WE*(HP]VKO4/<S4^NT=QYAJ/
M'1^3:S2]M+%$NC1F)M=K`\!-4;;E59JPM;ZUYAYF1R)KBK3C::F2BYAC[/&6
M[9=ZA[F>XZY2?'6+`U$97NJ>M'+3&Q_%7;AB1!-2DB,Y))PM#!(XP;;O4/<R
MJ*SF0[%L1'0RSNJ>M'+33_5J;$R%1B@$($A#-CSR9MN]0]S,D7;FQ'#JBX4Z
MW5/6CEII_JR%,:0MAQE"SF`?6//)FV[U#W,URN#T2QS#3760;HKJBX9QY;*\
MZ9(Y=C%PE$D:MF//)FVZ")7'T_3<G[YE&KKC+!)T1F.ZIZT<J0NB*A*&YIRX
MK'V02-LNS'GDS@9=ECY"87#LR1B;N^ZIZT<K/FITGHCZU`L;1L=2W`-"!I/K
M>T;;K'OK&YG1X>&/'N,'MM"R?NJ>M'*91E;HR`P"%BPAAFG^K?KYHW,T2)^B
MN/\`$*1H4FU(I*PQ)J>\D0B.MY>3(&"ZBY#A9LE4]:.1*6J,.V31)T<)O,`(
M2Q8X^[5(]J<.U*+MQZ3D)O5\T;F?&$N18ZQ8HI=*]9=2(*QX2#*@T4<;3II8
MV&(2RZ1L,9$C.8>2:CA6UW94XYE>W=-4.239',]U0VW+(_=&YD^]F+CV,X>2
MEE;=4]:.1.+1;PD9,7E.8`@B-@>]%_H&QTE;6VJ@1DHZ9;DY8<D.>=85'\SM
MSYNJ>M'(Y#K-)6]X\Q_&XY)=^+_0'25M;:KT^42'36R-;,E7S1PU/6CD)*_O
MF2GQN"09VR-DCW23:]WNXZ@J9"2.I>^(H!Q5BD;LUM;(ULR6ROFCABEN!&<>
M-DA2+"QV%NKI('%$8<?1R-A`;.T,]KIMD*B=MKK(VEGL]V4R/32PM;(G%_H&
MVOFCAJ>M'%G.1@H:J^1'(L_9<0PQ*)1G2E;[4V;(`UKQ]\L]^ON=U6UX^;KZ
ME4:D3HJR15G8;=D7^@;;@9'U+AJ>M'#^[&0@VZ,9,R*HW-HS8%+6\`X2+#LK
M.$I+ZG7_`&TZN^H^TMH#EM?_`/#8:N4@G&['$4'CJ>M'"R%!LAN^0(A`XY"Q
MJUI2ALQ80U)!;(92V1>!M*8":::5BUE54@V&H96UW;W<]46A5$>1`S`S'R91
MR;OS+U9JUU9JUU9JUU9JUU9JUU9JUU9JUU9JUU9JUU9JT[Y/M;G;[T/=->!8
MCM`G1!M3E$P@B`44F$$7#I*XM6M\DC]EC)EF(OIOW"P:^X6#7W"P:?\`)T4C
MRX,LCAX7W"P:?)S&V)KCN1HS([%)9%4;OO&(ZK/H72OYQ:+I!U9JTFY-RM_`
M9L2RH:0W83@59A^)\6:<\)XM<KOQ/BS3OA?%KLTI8CQ8DE^)\6:9L*8M9V_\
M3XLT'A/%HCC^)\6:-PNCU;[)B.G3'$3<D?LF(ZD..H\]A1W&\?8A:Q&*UH%C
M:+`B,F'FQJ<$<<Q-%U^R8CIWQNT&.\EQ(WO1=^+XZ1'_`+)B.GS'$==&Z.8M
M9&6W[)B.@,<1,%;[)B.B<*-!;E^)\6:<\1Q*UPX+M.)G9(>";86H$V3><*P+
M$CX].P'`-376#3FN00&?%[P^+N?!=<DSB%./6LA_E[@+8PA!$IX)H:#@$-AC
M'0C-&XRRQ)LX#DW".[<)AW'H3+%XDQ0UOX%]EJEC?B#'K==^"L9>$Y5-=%6N
MRC@!<=V-,FIS?8G`T[(6-$)O/(WBN;9HEL=>G0W*D9R/`<GG9%G9T#B4^_L#
M`YP\Q_'`6<)\,PXSF3Q-W+L&;VQZZ)P8+#@4@HVX#IB<4+^M5L9QJ)AX.5_U
M-%BXV/,C@87(G3D-@@K&Q@^,AL78&&CH>)>+_]H`"`$"``$%`O\`GO<4\5Q"
M4S+ZIAGT.O1=*WV^WW>:^=XM'8"JO.?.\0D-(O5&`?Q*#<@,IS?SO$4701UU
M,+OK"AE;N;^=XBB"*VJ,*%%[!1DKN;^=XB*%R^JQY.@2HMZ-O+*=[[!5%U;-
MOSO%\67W?,!?"[:N2OC^Q@OA=AMQ2JB(:"!/8P7PNB%UC%DD^Z3^=[&"^%N*
M6+(I;;39\[V*NLF.F"5<OI%%-"S9\[V$3WUM;+:VVZ(J@=5K%M01V_.]A%?M
MHJJW=!B6B)!?"[?G>PBOV-)\*B`+>C307PNWYWL)Q+20T!>0NGL"^%V^$I[_
M`&#6M+:$6)N544K4$M@7PO8IB:AEJJ=B2>Q2Z^V@E%;$]M:&>+[`<"%$K0Q;
M1$2OVW_Y+G;J^REA5%+RR;!40?$51T6I^ME]+[=[^2YY.ZVQ1+N''>5N6MM#
M(6)LVUNMZESMUU++:+W.!-EMMEN\V_!;"7,8>Y%N46=N=-\40J$&@@OOMOP1
M+F,/=W#B=H8,82W^2YQ=94Y6RVB=B%U._P!IE2D[DZ7VV:=3+;$FT,\D88,8
M2W9_)<T=X>U$511:^E*4TI^M@]?>7VG5I["3Q1:>QR/T,$,'1M^"V_R7,EFV
MBU5&-,2;1:#(:K[?8(^)T*ZR+7742;M=\\7Z<F\\FX-M$"IL;?@MM43_`!'+
M^(2K=W!YNK++;+3O92P15*U*KIWU>GDE:!%'1(VG?ML5O4LHWT731YHT0U0P
M81`6FEG4)*IU#G(=N91J(4MI;2ZGO6I!=TIM*0*6N3[SW.=<78AN7ZF43KPH
MRVD;FX>BE[85:C>V#)^."U0H6NJK#4N\4+KQ0NO%"Z\0+[EY`R=_BA=(K#+*
M4)%JA0A"NN^1U[Z>K$A5%.6,:532>G`ZZ<!KIP&B6H5=(5I%'L\"%KIP6AV%
M)%7IP&NG`:Z<!HQB2(O2;!+4^G`:(:1%DA&4<>G3@-=.`UTX#2;/W)?_`&U_
M_]H`"`$#``$%`O\`D'NW>[SEKK?1@XC$9&!DC9+$5(F(YP*P5:J=RW-4\K\6
MH!5$^<IY7XB)%Z&NJK=RJ8HM9S=/*_$4701UU0'OK"A5;N;IY7XBB""VJ,"%
M%TQ1DKN;IY7XBBE$]=4N[^Q:V^O+!=/[Q_#:FXK;3ROQ>X1][F)1]?VI09O^
MT.QI1]?V1=%A;@W22.SNP]C2CZ_IE:FV-MIYES@;3ROV-)_UD"$?:X\SWK*J
MTU3ROV*U-9CR;+(^@ST<G,YW*V4\K]A,56Q9,I5)=;3,D[Q-*?OZSJY[:>5^
MPF#_`#U'TFNUQDTA7D)\H^O[:>5^PF#_`#C#%U]RES^.Y*:E'U_;3ROV%"XZ
MX.M)>*SM1FR4?7]M)'?0;L%--191G*-A%CFX+.I^R4?7^Q8T:'&EFTTAQ.V!
M("KJ22]N*.V^T?N.P(<RAN!$F?UI"Y,'^>_\GSJ*?>JEL%X8L>8B9`Y2KHEK
MGJ/!?^90UXBV]\GSQ@ZQ8)]SK"Z[J=$ZU(231NV^[7P?.CH7DD7M*,-8B"%B
MU]XSXG8B$LK10NQ,#G8OT!E;Y1)W5U:=\SXE$)96G>!BZ6(6(K\GSC2V-T3;
MBB%#BW9)6C3M'HA=2^MM;M`CUNO,(%166(6(KL^3YJ*6O"SH_AAM@MZJJND5
M+T5BG5T4'VBTKI$5=>O_`,8NEB5B*F?$[?D^9CL5(?K&Y[BT9<)P_7O;OJGL
M]J[9=W'3EZ:\&C;KNVZW098J-"#5R=IGQ.WO!>ZY?HC@D/1WB,5M**5+(:CB
MPE'0T]Q4H#W=/%HH:*6542VC?OL3MLNJ5W5ZG-1>11<&,ODD=7]728!-]!O"
MAK&.2U5*UK6M*^RMY/OV;4%4$Z7^Y[W.C!#D(=ZSHZZR(GI1Q25KUD42VCT*
M99XX+7BQ=(NP2RGBQ=>+%UXL72[H$/JTP2ZWQ8NE#Q$K!W,,BSQH=->-#UX\
M+5'@>XGEEV\I:O30-=-`UTT#130(0F(T"C6>`!U5L!K0:/HH*]-`UTT#730-
M&,*1-Z+4&FETT#1+0(LD&R##4Z:!KIH&NF@:HPVV%?\`;7__V@`(`0("!C\"
M_P`02P[MU=IRS8GSU8\_=1]JL)&4>0P%JG.U2K!X9()0\FQ.B@>*!:YVZ_E<
MH[MJ`OI;4I655\&[?E<H[J-85B6(RC6S5JY8Z;6.<:U!<M95$[L^5RCNO3+2
MF>,@1J=8CFSG,2S3QQ8;<0I610.[/E<H[KTR$JEC`,:^UYTY619S2Q1::;0E
M61(&[/E<H[J;)0)>DH)XS'W&LZ35SP69R]*J66+94V1_I6E1X`=S]%9GEC6.
M6;)Q3VGRN4=VU6M<U4I2M&4L4MTHS;28`L3L[T^/O.C-L_:7<$)(I5DA*$BI
MNO+.OO.C-L&Y76A(YZN3PKS0&Q,@"/E<H[SHS1J;E0VDZ2O#P.:*,.Q\KE'>
M;6N<V!=4)Z`)TC&K:$D[/RN4=XPI#A`*@)23ASB)*)4<=')L*N()MBF>`1K)
MS4O:?*Y1WC1\5.P4W6E_/5EBS6X:S",VT^5RCO&CXJ8M@36:!G@O/4WA=?BV
M$9MI\KE'>-"5<^T%2R""^_*RHZ(Q;*,VTMZQRUG\G>*T:H%X1-.F$9\L!I/-
M&RC-WF#+"DZNUI^*&FT<T.)V=!-H\$!IQ,I#&-IJ-<;-BUS4XY=X0RSU[E`B
MQY^$Y81\5/<!\`^\-W3KBP$+F#315^L:Q5>#*8MWDZ:C/,-A*0E9(6DT))Y(
MM">^)<>W'P#[PW>^M5"0H>XF$WE23H*,LN7;="D*5E-GD,:U:`ELBC2G^T;0
M4CJ3[PW<5FH"-3S&G%S.\/)`0BA(V[>;EV=4)N7CT4TGR0'KP@-I/269S\*:
M=W?9L@I:\Y4.%/.20![(/<&\W+&J$W+QZ*:3Y(_N5:B[^BGG;ZO#-%EA(''P
MP/@'WANTW2ZT-#G*Y/"O-`1@`A[UQ[B=HE33@"5+2F5F=>_$G%6EXY2V"PPL
M_>FH)I._`+SRD70X!7Y(LL)`X^'9'P#[PW7;?WL\);N0L-@"VK'%$$2"J*L<
M%(NS:2A4B9BB@'T<NT;^,CCCI%:6`"DG>BG^VNW_`)#_`,>.),)D<>$[\-YN
M7:#X!]X;J"`"IY50$%=Z(0D4A/AXXG.:ER.Q17#FO380M4R9SE)(3@335'1!
MUSU4'EE'175[^J28T66D>LJ?%"';R6K14$:,\)RXHZ(=)Z1K\F]LMYN7::^;
M,[-FI6.>/=!;;(4\!5']R=4QZ(K\,_!`0*@)1-2+8'^JSRTP7BG5-2%:P>6B
M+'9S:G58ZD#?B?:+NAZ"*$[YK,/AI(`"T^XD\9VC7QT<>S-M%LYP..`P\BS9
M%<P>+=9(!()H."7)'1C2QX=BP%6W,2-(^*"G4AMD4S6=*C$!5OPAY_360#+S
M1/)XXLIH3!2"0<8@NAUTDF9G9IHEZ.+:#5J;#:5!5*3.8_JY(Z4@KR"0XSNX
M-+9T%"TDSK$R,6,$;T=`&FD8W%"?LCEB=_O6MR6@E/`#%EDM)&0B#K7F9(23
MU@&\)&DG`,,)4TZT`X@&6LG+(03HD81'7->T/'$M8W[0AU&N9FTH`Z8IF)Z/
MI#`95&.L;]H1UC?M".L;]H0%EUJ1<2CG"M6'U1A-0@H+K<P9<X1UC?M"-7KF
M4Y2H`4"<-OAUNRX)RM"8P24,!BA:>$1SD\,<]'M)\<:AN\-JO/VZG;(IH3YL
MQYV3$)[G%X6]S>:+$P!.<N=C).^8ZIO@CJF^".J;X(U:$H;RA*9Q86$N4^<E
M,XZEKV1%#3<_5C6+5;3B*1'5-\$=4WP1U3?!`+)2T@"H)\H@)<;;4L"NS*<=
M4WP1JVTH;5C"8(=LNSQIJCJF^".J;X(ZIO@C[QAVPJ=031(T$5X10?\`-O\`
M_]H`"`$#`@8_`O\`$%N6CNTWS[>X_<"]);G]LQS=6H^AC%=?=5I[>NCMX=*M
M$I64R&*06CEA=VNZFPT;N4H8\\*EHB6,*IM_U3,-IO?9MX5>P@6B'%2*I4GK
M16<@A2F4V62HR%<A@$\,MUJ_/3])?=M:4]'*=8\>[5?GI^DONIL6:<8G%B2;
M<\5$LT6%!,LV[%?GI^DONO3+2F>,@1J=8CFSG,2S3QQ8:<0I>(*!W8K\]/TE
M]UZ9"52Q@&-?:\Z=FR+.:6*+;3:$JR)`W8K\]/TE]UI"CF!/%&JLZ-J6&?!C
MB0"]])&YS_\`1UQ:E1J[(,_Z@:(5<KC]P7VU2)642(E.BR`=HK\]/TE]VMV$
MV\<ANF\^O^T;35NK<3>2W]P5&@)<U9H(]$`R.'#1WGO/K_M&RK^2=L.(=>;5
M)J[@BT5X%*'%YHKI,A#UY?=4E+E]";*20D(U:C8RC'.LTGO/>?7_`&C81_)_
MY``X^X)W9CTIB86>/$@4TK(`=OJTI0IU95)(D!/%"OST_27WGO(%=L>Z(/:G
M\I3;OSZ9,W>9!]94J0<>!`KFLR"0ZI2@D2$S.0Q#$-A7YZ?I+[S)N%Q3-]6\
M`!62<4.]O7J\%/:RWTF[H3(C1LS*IC!7B%%<Y0;YV@X7'S^@Q`"@#-GKV5?G
MI^DOO&ZS>[FTZXU=W7+16\"2D3`(2XE,L%`$%QEI++9\U)40-]:E*_788_EJ
MT(-T=);L%4EK2H3G50*)@UT<VR8^Q*`ABZSEA)*@)DU9)#:*_/3])?>.]_@/
M^[L-7CM^TCLJD\U1"RGS:`:)U\!E.->="YHH:1Z*?^1P\%0B\^O^T;17YZ?I
M+[QWO\!_W8^V6L-W1M-MQ6)`KEEXJ\$-]F=EI".Q;IHM_P"HX59L6$\XTFB+
MSZ_[1M%?GI^DOO'>;PS)-U4PXS:/IK3BK,L,([*[("P^PW9>7,Z:C+!QRHIE
MYNS>?7_:-I]I]G<=1:M2L*YTI3Y]<N\266@5.J,@!62:A"^Q[UJGS]JN]2!D
M6U`4H)IF#*@Y\$.]HWB6N=5.BH8@,PHV;SZ_[1WF<[2[6N[WWVI!NP*9)-J>
ME3*BJ2A,2M891?[[>U6KPY<KP2?Z>(5#)LE-[?#")5E*E;TDPN_W&\!W6+YM
MA:2*,:A([36ZNFU*LXN\+O:7:JDI[(N0"W)^=793+$94X^:*X-[5HW9.BVGT
M4>,UG@J`B]_@/^[W#YG)NY+94E%HRFJH9371`O:[U=%(6DJ2$K42L!13HZ'I
M`C>A-Q8H;K6KT$X3GP`83'VW82)75E`053G;6*U<DZC*>P_>%O75"';J\VD+
M?:0JT1(:*E`C.1!866U*&%"TK3O*02/UV_S.3=_9-VNZ2I];"P`,)-Z>A[L)
MAYI1O+*"X4C237H3K%'^U0(E/;=(2!FGRB+"5%2ADERG:?,Y-W(NS76.+"1G
M)D(_^J/[GM&YW<MH)H`UCJE%4IXW)&F=D2$K1A=YO*BM]:IDG"3MU9]FV=%K
M&:!&K945$:,_#)NX_P`E[26A[M`*(98!%H*'G$<2B))%-*BF+FA]02Q>&UK6
ME(D"4ON)3ED`D8:Z33W!6>+9T6L9H$="-:[C-6\(FZ9Q\SDW:C^1=O`.=HN)
MG=V.)2O#0RK(`<O2@`ZZLJDD2$U&<@([-FE5%V<P?^R]M"%IFH))KQ1-`DG8
MUKJ1]MA)H$'5MA3XPFKRQ-TSV?F<FZTW?L><U$%RJ5A)IG/!3^L/WS^4J^YO
M;BW1=6`96$DT*T98+-=`JI48&L4I5D2$S.0Q#)"76U*0XDS"A6,HEABP]?[T
MXTXGFJ6X01.5(*I;1?PU1H"C&:HHZ9[_`&CQQ-PT?I"L^T^9R;J7>U.MW?LU
MDZ;BL&&@4?J4C+#5V[`0Y>7W%:MUY2B`4D^:*J%2/-%`E:,Y@MV+#-U*FQA)
MDJE1SRH&#8IJA&J5:4D8JYF>.BN-,H3G4(Z1]O>IBEQ:LR9<<*0R'+,BJF6"
M-,Z&+!LJS[352<KG@W0U?KXVMGLUQP)UA313AE7*5.7`8EV(U]_VL/\`O.<Q
M)R?]('Q(<O+O/=65*E0)DSJ@FZ.!M:I>8%\:3*$IO3FN=255-A)IKYJ1.<HM
M7M8;&*M7!$KFC2])5)\D-%:B9I/O':+^&K9TU61!<;5.9Q'=;3;KC3;B$=(@
M\]2Q3.7G3\W>&"+5^<Z`&:4"A"=['E,SEV+1%E&-5$!6L*W*M&JG+"FVM%(,
MLL3-<3KBQJT"0HYU'^[:&VE14016,.]'1SLY?`;N+Q=LV>=DPX\1$=+>$K5B
M21QQ*ZZE&68)X3$W'DD^L(UB'4;Q2HP'''4#.4I,=<U[2?''6-^T(+85(C'0
M(ZQOVA'6-^T(ZQOVA`M+!GBI@*UB*<HCK&_:$%9<20,1$6PH)]8@1UK?M".M
M:]H>..M;X1`NR*237@KW.ZD/R8>4DE-F8T*O.X<<=2WP1U+?!'4M\$:M"4MT
MUI2)P4+"7*?.2)QU+7LCQ1(--SS1K%JUB<13Y8ZEO@CJ6^".I;X("F2EI`%0
M3Y1"4.-MJ6!79KCJ6^"-6VE+:L833!#LG9XTU1U+?!'4M\$=2WP1]RVY*2Y@
M6:,U?^;?_]H`"`$!`08_`OB#2H,5D8]QZ=6$VS>Q7_C<MF35`6G(USE:C^FF
MG)$_R7#_`'867[5U7^2X?[L++]JZKX.EO9U-N_I[DW[-=-VWYVW7W^TP*D&A
MB,(08E>U"$&%1H5[&:[G,$IF[E3LW)\OV..K\\R](1,<E6C@MS#(V_CC;6-'
M:YJI8ZM&@BJFQ.[QI\GRKK_\UYK\7#_=A9?M75<0WX;DU=1QF!>V8";7QY+C
M&WZL,PIJ^>J)LY;4V_Y_=#GS037R!7@9L_(T(G@9$1IVNDE9([K7#D1$5B1]
MJ+M79L1.7$TE9GE+'K22SOA`+3PNJ"(\CG`"_=2R5<X(U1NJD<JZ=O&$N]0:
M^SR3!8^+W@9;:^DM[BL3..M4>%L;6EHHLX^TM:R5X1SQO8$JKMVNY\0*ZK7*
MX=>+*,4K*G%)6)D^KYO3:7CM<>WO;3(Y5-(L`WM=+4[=I+$;AGCH%PE<1W!7
MVV0YF:78X)A&627P<:K8-A57+LL''NJN"&MQU#Z#IF(8\=S"&W,5>0GJ+C.;
M:MOLF-2U=G@E13#9B%7(L!8];UF#3LJS*-"\@%+M[B`.5.5`=!P`$<5K@=QK
M!8G/N4N[*MK0^KU929!<4KZBPL*!TSTX6FEW45E74`BS910RAB7PT?Q(H_41
MO-?L>/\`J9,_3D'X@4:2.KEE=8#+#K;?.;'`H4\PHTI%::TK&ODS611D4WAE
M38YPT>JM5C53`Z[*LGO$HX?I'ZCVL.=97<JF)9YM2WK*YJLF0K!$M$I*]Y/`
MZF)J%$<K$75.+;(+J\LV>I=&+T"%A5>ZZFQC''?0L8/:%;3LE`C6A,@)8RUF
M]0;]'(K%V[=.,5MHMU,D9Y;^L7J)CV3U);J:=@<8K(]VP5;)HW2&QX]=40J^
M*43D"Q6KH[FO#/K:+'12/\-;#PB8[(LI`5#]:*K?XA;*-&>TN_LVHJ:?`E>R
M>]9KI'A$C^`L4?XCJ=+I+K$1K51_)=>2>Q<W3,CJG56/6):BZG-E-<"OM`E`
M!\`SD_\`-*>2-C6-U4CWM1NJJG%/=RLNHP5.0*9*>>2:Q(\WPQF1I;F/_B#A
M22-&=S]K0$<C7JU5T^`,S)+F!31Y!O#QG33H-TD^BO4487,TA[1HKG(QJ[6(
MKEY)KQ%J&9ACKK*=Y>D.&EK$ZLI;:$&QJVQ_I-"NLH,AA0(G,K'IMUU3B;C$
M"^K9=_7,*295!D-=*"R.5@)*[>Q_A3O1A=JJHGKM=HO"XTW**/S])3X7E"V,
M9L]9HQ(<D1L=ST>Z4T*[NFG>V\].)F.);P5O:^M9<3:OKM\7%K'O0;9IA_Q`
M[E3^#<W[I-94^/FF.'APDC.EG%:17LC,F*](I#;7JK!2%$Y&.^:Y6KQ8Y3"O
MJZ9CU2&5(L+:(;Q,2,*%$9/DN<\*/5W3B$:_1J*JHJ:=O`L;C7]>Z_-$'-93
M/(X%ET21&ST82&=HS!EM@O0S@/1#L%WG-1.*VJN[^LK+&W<UM=$F26"-)5YF
M1AJC5^]L+)*T;'.VM<1=J<^7$W%Z[(:J9D%<TSYM3'EC)+`D8WAY6K$7O.B2
M%V%1-5$_D[1?A)BY9KV6K)E36[/#G>!]G=5ES=0JY)`V/&R6M30GD.W[6M9L
MYZD8BO([>K1L<]R#&0I%1J;EV"$UY2OT3DUJ*Y?=Q7W=1*9-J[6&"?`E,:1B
M'BR1H43^F9@S!?M=WF/:U['<G(BHJ?$1_P!3)GZ<@_$>#NZFLN8:$0J1+6#%
ML(R%:CFM)T)8C"ZB-<J:Z:\^(4"PQVBG0:US'5T*94P),2O</1!NA1S1WABN
M&C4TV(FG$2ZDTE1(N(`^E!MCUL,UE"%JY>G$G$"Z5''J]>3'(G/B1>`I:D%W
M,&T,NX#70QVDH3/FBD6#`I+,-ON1SE3B'^["R_:NJX`LHLT?A^IL2)++&1>I
MMUWH-='+W.'R_$3/"K'38Q)1$EI-4CNH99.F[IJ+3EVZJO#9<<]D\C6O;MD3
MSG$J/31=PW+M=]K[?&-QC):GI6T/7DP:M)#K289<EK7&#BH_,*R*3(SQ(JA=
M_M3_``A7ITF[VOXR+)<;J)CYE%EOJPT-I/RAS85P`]980<;Q@=++/T8\4&1R
M12U<HTC,:)7HY7O5J74%!Q[RMO<6QZ,>9ALL.-V\;(*$PX#[!'Y-9V89-Q9U
M<EQ3R?HQ$=&:W8/5.(."MJ)3K$DC(#M;!OZ"/":R;>NGU\;._$C5F0-DC,I9
MCH*)U'HJ:<]W&+MQ;8*=51;0E^>+:NIXMQ7GAQ(L[$8XNKU0_6)RJHI+^4%`
M:[T<[C!,VHJ%E\+'ZG(J>9CZV,&OG0O/15;PV->>85*UY8WEJQS)U&JHR]U7
M)KQZCU*8G`KX/J1+P&<V\?D%>6/BCJ3'L<B6O0C!%YA-GUDRN*V(]@A,>]K7
M]UO`<M-7RXM##K,EJC/NK:HM(W2ER:_RLF'PZ]K)].L_P'7F>+U^=L3[I<LQ
M[R")'J+_`-8*KU"C9D6XA;ZNMK/JL1_EM:'K6*7A?(2!8KD&-&'75R>]N>$'
M0%-:93E0[.G$CA74?$KZO%CT`<N]?;+5V$:J@8_62FQA1AO0N_O*[<CI,>W"
MMD:=Z.5^,19<JP@O-CEO$6<V7B41L5P0%IY99C)(Y"L>]'#<UY51!\?5E\57
M75+Z;T,.PKP**4IBX_5UKKBN%MZ@I*R!02A;MW;]W=UU3B%);`CKC?\`BI9>
MJ\?*TGQ>K*K+;#254.C97*GF3)7B9J,(KVH+PX$T<JZ)Q<2VXU'C?7S",7QF
M<AKVM.["9E)E,^TE%>7:WS&.^'8]8*Q6O=XD6BM1-'<6.3Y-BGAZBMB6./X5
M/C6].6+!JC$21/MYT0<A;.1:9+)CLT3IM;$#HU=SE>_B1:3AV)03LXRPT[9E
M-A'"7#)6'F;1PO"1K,0F15R\(".`UJ+KJI$V:\>GM9FKKJ6^AQWTL!8QH99-
ME<DM(LR]2Q+6$;91Q3JOKK'?=$$&<X@([>^QS-.*B[IBOH\LRS/+GU!FS)"M
MC2:2OM,-RN@QF,_JHR4UT"IE5D5Z#3Q`5<][-'-UXK!W];:5@*F7318E!%EG
MM)--X;TT@#,Z;+):_C6#PK)T@ZR&1R]2PVD<955X^,826(@'RAV=H`!1($D>
MNN;NRMZJ.X*(WI*"LFB;MT14TY\_B(_ZF3/TY!]A7.5&M:BN<YRZ-:U.:JJK
MR1$3BPH\*_P]QZIALBE%;Y!/E75]913`CD?/AT5;H.!%')*\/XU]\5FJ+HY.
M$E>-]-,ZB-T<>J4%IC%F5$55<.NFHTU>(KTT[TC<U/DX"\PECE>(;R@5[2*$
MCFHKQ*0>K'J-W+5.2^S#_=A9?M75<#2RM*ZN4VY0I.FQHBE1FF]1]<@]^S<F
MNG9KP^L\ZK4V0V2_'+/B)7N5Q7#6*V6INBLIB:.VZ_-7[2\-C0;NHFR'(Y6Q
MXEE#DF<C$W.5H@F>]4:WMY<1TR._JZ5TIKWQVV$L4=Q1B<,9"M:Y=W184S&*
M_P";O>UNNKD3A<8BY)3GR%%F-6G%.`^>CZY[F3A+'1V]#Q%8N]GSVM3733GQ
MD]I0TEY.-C=B*$VL7RB%*N(TWH/J[JND6-I$K6TUB`RE:4YA*C!/U;JB(M5G
MK<6R:3337V*6+1+CXY5*VJL_)Y:F%*O`>:/+-1?#M@K)4S&J[N\#\YMX%4IH
M<^P$EA(9$4D.K$,UD=B'5BN;!"9KB^]B+SXI*F%3VV39!D3)LBJI*7RX4E\&
ML&$MA8RI5Q/JZ^%$CMD,:BD*CB%>UC45==+./88QF,&#02,:B9)>'AT:UN.R
M,IJJZV@LM@@R`UTQD8=F,<D@HA1!+KWE;HY2X+(H;JOEK7V%G7V<A].>OL8E
M7)B1)94'7VLRQKFJ6:SH^+`#JMYI[M9T"319/'K*W+Q8-.RI\>F?CT7(I`H)
M(L>1X>\->1XLEUG'&V2^$V.A"HCGISTM<&\-9)/J:F19/L.B'RN5(@Q:JPL*
M>(=9'4+:PJV\B'>S:B;#=O+@TJ#AV:*5F,0LTCP"-Q!DN=BTXLD+;B._ZWK`
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M='@7FJ*GQ,?]3)GZ<@^Q98P63X4-D2M4[E:1S#`@6T&R/!.@31S>%L@PUCEV
MO:[IE73B'ZA'M(&/U-':Y%,LYYHTTLXM1>0&U5%B,?IEG2I5;3O5C@C:US]0
M,1C$3=PF.XM<RIMJZ-(EM"6GM(;'`B[5,[K2HHA)HCO>J:^U#_=A9?M75<#\
MRK*^QZ.[I>.AQY?2WZ;^GUQDV;MJ:Z<-M73E(B3?%NKG5D#RYS%+U'1/";5"
MV,K5VHB)W4[./$0*6I@R$:K4/#KH<8R-=\YO5"%C]KO?SXH[C&:5MO'AT;(C
M@R9P`4LF>+(H-N*+DH&Y1C5BM.)8(S:B99ZD8B>'3GOR&;+R*/C@6Y9ZEW.,
M@#1QIT\,K,JF;CL6_/:Q[P?6BQZV>\HH:B`9#Z=0FUK6-F)CN2(:NLL6JL8L
M*/.:7Z[4\L%',&6J5\1]M2[84.`^1';&:Y&)U]R*FS:ZNP=,FIB1XAK:2ME8
MX9YA,IY%E8)-"3!%^LL=V&>5BU"!$=,1K?X.,<ANR(U<S%W$L*\Y:X5I--D`
M0!C5-E82328[I4*,/K>)B:-2:XJ;GMV)KC64T>0Q:/)<>AVE:Z1+HR7-/95U
MRV&Z=&/5-NJJ2)6RX`BA>R7JS14=O]V4I99T(E%G+\5+E]='Q44>QLB8Y34]
M3)9$MG79HU=%N5JMY&)#>HVE5C7<MW"^H$FWJ1O:"ZBI"H,8\@FVX+0D?P;<
MQMVW4],G?218K!QG+&CZ.3?V\N+]DK+QNP_(\ZAY]98V#'6BL)%A`\D)&K39
M`6XDL6I6301WO:R$,KM-$>WB)D0\TN?K$S++[)9YB!<6DE@R1DZ%9UD:@=/Z
M<!SZ60&*V1UB.;X9CMO\5)L&IN0#BW&!P\4O0`HQQ1V=]!9)`',=&6#^A+-$
MF$8<'>ZZ[7J7<B[G^G5;)9/LZS"ZNDK)16>"%86>.0H?EQ"C\21(@ITVM9N1
M2O0:/YJY$YQKZ5<H&C^N$KU);B+ZD!)T++K/'EII##Y&*S+'E5\)\DYF#9$:
M[K.^_*QJ)Q@<TF9T7CL+G/MS2#X5+*VYM2P;&K*3H1<R@,KX2P+%=`IU'(5J
M.ZBM[G%V=ULV`MQ@%O@S=:Q)JQ/-;"+/\T1RS8W4Z"QD3H]W=V]1-.)=EC3)
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M3N[]-VBZ=B\+CRXU_5_U@-5=1D>U==^%'.?&:[R=`>+\QZ;><?9O1_=TUX\(
M"MR:(_I/+U;;%[VHBZ,5J*WQ=C`CQ^JN[DW=JO$"NFU=S;S9\;Q@XU0M(PJ`
M=9U]*%!^=W5,V9(/968F(("E(UNKW(UJ:JE"6HR"#&6WR:@;D<T%:.@=<8E"
MEV=M$ZH[0L\;&U<$AV&?':%S6[=V]KVMS24]N/UMK4BIL@H7`K[O(`_4_)&H
M:K-:4=+*/=3[N&./(')#&47TVQ-HT77C'L\CMQ-+*3)MH]G!=59)-KY1(%QY
M?&#XR'.;'PA3PV*8[[<[FQ'*@WINW:4IK>):R@Y`\\2J/3@C38\JW;&257T@
MREEQ?ZQODW-A:H@2.8N]X^6N+8;B@*:/<9#775W)L<D%*F0*RMH_+QD`VOJY
M\$TV?+E6;&)I)8P36N=W^SC.9DNNQ653^FTK#H^20XJ6P[.<*^Q^ELK>3233
M25C.=`EVCO#A+'1QA,1JN1Z\2<#FNHB53JFUL8RLJ[VFM(Q()Z[PL84^W/Y;
MECI$.:I#+7"1D7:J/=R[V2VQ:_'SXCB_J;"]/[&,)M@+(O#628\`%S%.Z4:#
M+*&;D@MT;H,5PV.5'IQ;8D@Z5V/B#?5-3+9(<MR?+L9J*N\M(\H'BMB53XLZ
M0$:H)'^(@&15TTXN9<./BR&JL,JLLD2?*LA!$KYDUL\[\:E1)EB"1/.6%$0H
MIL<OA]ON=KP;U&LVTKKFPQ:!?4T6NC2XT&*;(*VO6GB34FSII)+X]G/1"O:Y
MC7L[&HO$.'*!2R,6)Z@S/2QQ1QI[,A??5F,2+DU\\K)'ES:^5.@E#X9L9%$S
M0G65.7%/7J&!6XA)B5A;+)[7'LJLH`IT^[?6>6+;TS5J*<[Q*/8^:Y@]Y6ZK
MIPL2=29':]"B/DUA(IHU::-644.:&#-GS'3;2`94C$.U>F)A2.;\U%T72=)G
MT&3PY];<SZ:;1RFX]%L`/KL>9E)Y+I$C(14RL=2$1[!)*\2\OT?3W:\-/BZN
MJW5'I7EGJA?1+.+!D21,90R!8C2SV#+,&$I;IQ3FZ!>]Y<K$*YCEW0KQ]7D%
MC%F+?)&/!%2`%:!Q7P`;VQJ/-+VO\9$983T``:+XJ4]CE$)XTW\9WCEBU&K0
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M=RDW;MW/7X*K(*O)UQR375?EH9(`VJ6$`GF+9RV4`U9>U$>4=PT471G"E1FZ
M[MFNJ+D<V])/M3WMMF,T0QVEO$A5T;,@D@V"18`YZQ`6;ZDKHKY0V,>X3E[-
M>/'U=4_&IGEC:A9&)S9F,$?"9.BV`VE6D-"ZQ62(C>^[5ZL5S%56N5.`XWTK
MP5*WS#QL*-D^0QV7:VTM)UD^_4-DQ]R69)U5SSJ]^URM14:NG$&/?5GBH]7"
MF0JP`Y$B**N\8R,-9<)D4HDCV,8<1K8YT^D`F[8J;EUJ#67F@I]"I_*KBJN;
M2FN8B2P-CS1MLZN5%EO#.$QJ&8YRL)M1535$X?9'B7$GK+1/EU\G)\CD4UB?
M&H,&NI9-M4%M'0;>3"C5H>_*857N;N?N<JKPW+%\UFW(?-D@$M+RWM(U2EX=
MI[5M/!GS#Q*QDMS$;H)C4:-$&W1B(WB1D)8MF>3)O1Y.2O/?W9,?^L81QQ!O
M/JZL_P`F=9@9%9L(X+E9M33YK=(;F8_&'-A7LC(QVXG$'=FM)DJ=+EDFW+')
M8S@27V)6O$4CQJ-4;IHUN@4KX)P('#QX)IXZ8Y"8V$CR@BG1QE0\B.XK^F=V
MI6H1R([1>)7IY#<6OJ_JTS&ZPR/(<U:*'"'$JI"$>1"G+`<`3^;M7JSFO`<K
M/',;($D.M#J.?9#I/K#(J0TT^^BX^Z:2LBV4N`+I*78K]B]JKSXJH=@3(K"!
M4BKQ#K9N59%)KIWE4\EG`+;P262QK:0&:3>KSM>XFQC7[FL8B6!+B(4[K3&Y
MN)S-DJ0#J4EA('*E1TZ)&;"/,)%ZB=]/EX2RI+%E+8'NIM[9E.MX3Q-E*I(5
M'&G1CTM_0SX1:X%>)S1-+X<SD^D8O&71<FN9.5GS.HK<=M[`X/+I9:*NQL=!
MX-Q(\@I%/*.:;+(5KF?33';6IMU6)/Q.Y=BQ!/OY#N_D!?!6]_Y$ILAJ'561
MT;P3@$HF%6,5209)WJ0@E=SXRF[F6;[2=D9Z5O5<'HJ"NH:6-6Q([T0CVDD%
ME^)DD>W8U7R-$:FGLT/\U)_2C^QXB-#A'@!FOQ<40;7&-)K'6HVO*,[2)K-D
M$$CQJB;$U1NBIV^Q9PJR%D%H\UE2>,I\:B2Y=E<5C+(!+"M1((S20`DQFKN(
MC'M;RW)MUX`7'_2KULQ&Q2OG-;;9S7W,?'QB4;>K'>6;>3@>),G(7T>O\'M0
M_P!V%E^U=5]ET/\`-2?TH_PQ\$Q>%+KHL^,A[O*2"(R(*`1586+%D-T;OVIH
M]J+U7Z[4T;N=Q4P(=='.^%B4F8DZ6$9I9+%MO$'Y@KW-7IR-A'(W;IL:NB>S
M-O,&]4I%.*<\)#8QD-'!OZ(;Q1@QE\M.Y!6%4`G01[AL5^I7O=JFO'0R'UA@
MU-6NB2&89BD.):26:]Y@K6Q4I*U^G_W!M<O+LX"#J%-T1#%U3OZAR]-B,ZAB
M+]\*_35R^]?9A_NPLOVKJOLNA_FI/Z4?X)?I[A3RPH4$SH^6Y'M(QL9!D<*1
M!`Y-C]$>QS%1%1\AZ*U-!(]RU]2(\F4.OB!B,D2R=625!-V[ROY=Y?M<D[$Y
M<1_U,F?IR#[);2GEQ*N3(N*&F+?V$59L#&HES:QJ^5D$R+R:85:,^[1W<WZ:
MZ_-7T\QI^85>:S9<;U4;FDF!&IQ$8''\E=$P^\*&H:@:L=E`&B#&B[3",TG>
MU0B\+-M[&!5PT>T:R[&7'A1D(_DQBGDD&)'O]R:\^(ME-OJ:'73E:D&?*M(,
M>%,5[%(Q(LHIV@D*\;55-BKJG$6KE6]7&LY[4=!KI$^*&=,:JN:CHL0A6R)#
M5<Q4[C5[."TH[:L)<@'UCU+)\5]F$6T;NJ6`TJRACVF:NJMTT<GR\0_W867[
M5U7V71*JHB)$*JJO)$1),C557W(G`L>].Y#8E/421ER#*5`.1'(UKE18L1#,
M>,@G[51FG>.Y-45HFJ]QG1XX`.DE4\EP1#$Z0=R(BF,K&HI2JB?.75?@C_J9
M,_3D'V;>PJ(E3*(\];`FEO8CK"GK:NQG`A6%K90&->LR'!`;<]NCD1O>5'(U
M6J7I9]Z.VU?-ARG2J7`<?QBIM)9$T?'.XM,(4DD6&KE7:NYJ(OP#/8XM%RV9
M(LQ0Z"#8U#K>KA7,J'-`.XM&MB37Q8%?#*92O8Q2N8JC9S?QA,6<V?E>'Q?2
M3U!QJGL7XQ=R1.]0;6ZC39365YXCY4`MBTA@P^H)G=1$1Z]K;;%+NGLW^IMR
M#T#7"ICZ2P.8$2AA8PVW2-:H"0&N3'C1)J3G.(--^YRZZ\L8IX]7.BY]3>L7
MJ%D.6VKZ.:'3&K$%_P"%L36Q@OC'J[>'(C!C-Z[D>J;4[->&,O<H/DY2^FM@
M\!S5-94K%&F452.$@ZP0F%1[N>KN?V5(N;@S@PX^QOT;.H8I2NV"``::;RD=
M_F1.:Z(BKQ68;7T@Y&-PZ:6+*9\Q2"*WQGC$"**H3;&L,KD9HJ*]_>5-J,UX
M'54D(<&$-SG[&*][R%?\\QS%<\QRNT[7*O)$3L1$^&/^IDS].0?9F5E15MNI
MS;:CG"JS6=?50IJ0;($DD>QD64N#'?!*QFCV=8;UU16KJFG`7N__`)]Q/TZ_
M$9B+DU/FF'W<P:JQOXHVOIHPYRCE]BNUVM]_M0_W867[5U7V/62:S*K&M#97
ME-4.@BK\?D``.:5`&,$DZHDRE*OSN\1S=?=IRX&"78R;4[-^^=+%"`8NY[G-
M1PJ^+#BM0;5VIHQ.2<]5^"W]-12YC+.O&.S)9QXK9$"!+B'&)P'.ZX^J=B2=
MKV=UO>5-^]-$=<-E$ES<A:)YE<-`BC@B$D#"`;$>3<Y7/<YSU7GRY)IS^&/^
MIDS].0?9EAO,*M\_KUEP7/QRC&\M@8C3ITY(VCEPB;(KN\[1_9]KBLR#$O1_
M(O3C'HF,W$&_-E:.'XB9)*!U:^F">9-D-E]US#*U_3<%>;6N:BN]F'^["R_:
MNJ^Q\:_7/&OZ;\%C"PM(\K(W>'`K/&Q0'K8TO=NG:2"C:PK1M7I[E3[I-=-.
M$B-<DFTF*V3<V*\WRY>B]UKG=_PT=7*@T7Y5<O-R\4/\U)_2C^Q'_4R9^G(/
MLVF>6/J)ZUU77)5U\'%<!RU8$29:2$CUE?`J*KR\Z#DV)T1Q._S>KG=O+@%;
MDT_U\J;R5564JEI/4O+A9#C=Y$CJ)DTD?H5L-BVE<,K";%^]H[M[-?9A_NPL
MOVKJOL?&OUSQK^F\+.%&?-LILAE;3Q&,<]"V,AA'"ZNSO=,;1J[:G>>NC4[=
M4G9!D4@LO+,E<V3:O(_<D06O4%"33N*1BKW].ZWDQO=;JO%#_-2?TH_L1_U,
MF?IR#[(\(S&UR###2?*,@Q_.`4\N145UY7V3SURAL([##\PAR(2.*,B#:@B)
MWT5=4@>H.0^K\7U8+2P;*MQHE15T574U3+?HMGR"-I)$D9K"5%CL:[7:K.Q=
M^B:>R:**+:`?5>G5C$,2?53Z^-)>N3U).K6298`@M(NBZ=4"O'NY:Z_8]#!D
MN-(L@7-3?+"C,U<D&#*>JN(1ZM&-3N&J,3FO)>7$S(\G+%?$N)R2\>K1A!_5
MD0#BCU0K&(]V]Z(C-^KTZ>[75_PT/\U)_2C^QYG]9\N29T'Q4*VSB:MBD,V0
MZ,W^K?O758B_+RX_[_8;C.!X%2V\256#D3<JRVT8+'(Q)!I0'5Y*F-_6-@X;
M`M>_8NNCT[FG-2^H%]>TSKJ1!D0G4.'8W"QO&8S)6G4[H$&:P<U_-I'C&_7M
MUY>U#_=A9?M75?8QI4DHP1XXGG.8KD8,01-5Y"$>O)K&,355XAY17^8TS6Y%
M7X:R3)CLD1[2'(D.45B`74CO":.LE=S-5U31.2Z\5U'!4CHM;':`;RJBE(NJ
MO(4FU&MWF*]7+HB)SY?#0_S4G]*/\3(R''HS)L^)8U37PW5T^S?*A&FC'-!'
M%7IN#*?'5>F0F@6N^<O-.!4E76Y;$F%C&E;KG&IU9%8P#4<1CY9M0(7GR35=
M?=[4/]V%E^U=5]C0J'&[NK;4>:DC9@6/,8:7'9%Z3V0M@.HG4:_=U`OVNZB#
MU[N[C#JFL`V/!@Y;C``"3[E)O-[U_CE(Y5<YW:YRZ_"PE;4$N3.*C'1QS(D)
M1CVN53*28]C'(CD1-$Y\^(=+<43ZWR^*Y&S/,:^8*01TA[^FT<4KRC5&D[53
M3E["5Z7Q$$ZO).W>75^Y%;*&!!_>M%3:_M]F9,J;*=1C?:T4.\OZP#I%C0XY
M.M(\6ZMX0QZEZ\2(1=',[[-=4VJFY*C',`]4<L]3\;MJ"^GY8+)[$MXF.R83
MH;ZBPB61($)`OLI,@@GA3_ZGZJK=/9A_NPLOVKJOL6OH<=`<V3964L"J>%J_
MBK&=)LJ4TGS6G&T[=JZZ#YD7DW@=:QWB)\AWB[>;S594][41^Q7=Y(X43:-/
MDYKWG+QC7ZYXU_3?B!_V`?\`2$?V;6XQY\&/*')JXLNQL8WCHE15S["/"L+4
MD'FDQ(03Z[-'<N>UVFBJ%/73TWS6#)BS#FQ3$:#!*F;*D?/98/=CCFSW)$5[
ME=JCD[W/X)%WDEK#IZJ-HA9DTFQF]WS!#:FI#R":=T;$<]WN3BHM+F_C0X=]
M$6?4OZ$V06;!;%9-)-9$BQC2V0P12M<0CF-8/<FY454XKZ63D]:VQM!UA80Q
MN+(`\=TJI3N+.CB+`B^::?B_5(SK:IMUU3@N(1<@A&R$)Y45U>U#Z.F0`LDS
MH(9BA2!(L(0'[B@85QAHB[FIM=I#_=A9?M75?81I"`/*4(WD2/%:Q\@VQ->F
M%I'B8XCO<BN3@M:''LG":-)%%FDE0(@@0"FC!F,\6]+!ZL18IV/Y([D[B1;S
M-"&^\UT+=H^=.<U>D%/>T;=-Q'?Q6(OOT1?'YC*ZMC:RB6,>(H6`=609#1J"
M&]K&M5J\E?L75PT=M7FB_!401561S"U^1T-I))7XY=3XB1(QT.9PYD6$6,9X
MQKS:URKKR[>!S`AFQV$WH@K&!+K9;=CW,7J0YP021ZJWEJWO)S3E[8_[`/\`
MI"/[,N#`AU\^8*WHYX(MM;0J>J*Z%8A-LLC6&V-)A$:FUX-XG%1>Z]%X"CO1
M_P!)\,_$9FMYA]]A\^X8NQOXN.-30PSO#R.QZ[MJ)V_!E5=!H;'(+*WH;REJ
MXM9$!+D1["VH[*OC37]<P/#QA.D;2$:JO:U_8NO&&WJ8'E5FS_!:[],9-..)
M6^95&1/6G2/.DQB2^Y5V?@'C\0A'(P6BN:WFCKSTZ+C=M.FY>/T5)$RR*M>6
MFIF89"QJ/D`+.<DD)(ODSZ4S8K6M>X['IMYKWL8QF5C5S!'BGJOF^;V.8/\`
M!#J;.DN6WQ:Q\&;'.,\BQL5M!B(%HT<!&:O1$T1&`B6.16+9/IK8%<_(LDN\
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MO0V=A'&1TB09*JCB10QGG08VNW#J-S4VHQI2:KNV-XC5\``XT.&%D>,`2:,&
M(:;6M3_M7M5?;K?Y%W^N)\/A&*2RLG+M'6US/$R5?]R39JT/V]>]I[N!S[2`
M&N$9I+Q:YITD*BC*,;&%5$V[BRGH1Z?PIR[/9\3Z?W<3&",])JT$RXM*3S6N
MD,3,+LBUHW$`4`YNKF%T^=L3Y.&2<XS_`!_(:)(TAKZVMQP%;)?*<C?#E\4P
M`G-8)=55->?M0_W867[5U7V$/`:")*JJ0T<4B^R4@BMC&B%^?$CG3:Q[$3NN
M$UV\S^ZNT:/5<H+$CD-+HYL"L@3)97%*(,S&JB;,(C4VA::0>:35R-Y,=M31
M/B*W^1=_KB<>$8I+*R<NT=;7,\3)5_W)-FK0_;U[VGNXUM97U>K7?^VUI$?8
ME8O\63.^:+5/N?X%;QTJZ(,&J?2%^><O\J=^I7\_=KHGNX'_`&`?](1_C(?[
ML++]JZK[!DX+AI"P*.`90Y5DFU[$^C(X9849>XY1J]BM1J*BR')[@HYSH5>,
MQ7QZV&"(P\LW4,X<831(209VFYZHW55Y)QGR-D!527U1TT0K%4G_`.H8\WN<
M^]S3W>Q%)#LA`#*GP8*`?7L,H_$NZ;R]53-5ZHO/31.&LE2$E&3=N.T*1T=J
MY5;]$U[T;M;R[>?P$KJ^>=M\1S/!QJUJR9?41R:L,,:.Z8R,U^=S]Z(NG`73
MKV7!IC(O2AQEVRRB81[7)U58GA1$=K]UN3M3CI5T08-4^D+\\Y?Y4[]2OY^[
M71/=\(_[`/\`I"/\884RI)7`B>G5B*OE/F1)*6L=<GJ7++8*.]Q8;4?W=A='
M?'GG9.@MH&2`5CG]=2^8RH[^B..R.N]Q'*+7Y$1NJ\DXJ*OT[C>15D"+2FS3
M(S@ZS[&5'`BEA-9*ZS>^5Y41&[7$<JN548WF3PX`@ZQ7'-T1,%U3/^>8FQ$W
ME?IS<O->)0"1`3QF`0;X4I&+'EM<U46.9"L*-1E3DNYJIP[PWI]C5;(JY06$
MGQ@5+#Q"DC"E,+'<"L&57($Z?-<G/V*I'/8B^>U+M%<B+M\1VZ?)PBRI+7F)
M]YB1M#S)"JNB((#%UYK[UT;]OCOJ[%JEW8UB[[N2-?NG<D@[D_@>U?E3A65\
M5HWO^^R'ZEDF7WJ4[]7KJO/3DW[7%;_(N_UQ/8'_`&`?](1_C(?[L++]JZKX
MZ'6CK9]W?68U)754(;OI4WJ-KBGV$5J.>U41!L(_EV(G/BQGYG,@8_#A`):4
MM!&BB.0,F.)Z[IIFN<=K30U>W13O5".W;&[=JC/XMTR5D(X5M(=LZ0@,+$:^
M/&$S<]5433+N?_&5>Q-/@>X;4>]&.5C'/Z;7O1.ZU7[7;$<OOT73BS\PAMKP
M3Y*2#F?+(?PBQ*^/"Z31!@J^2\CXONVZ;OM<_P`3CV]E]SX&KD/W=OS>L@>W
M_MX_$L0NW_)XY05O\&O54FWCZ*AJ8.O_`*VS65IV]O@T;KQ72[4],AB2XU6U
M*YDINT<LSMKGOD=XC0N7DGVUX18D?J2M-'3I&A93OEVNT1H6Z>YB-3Y?AK?Y
M%W^N)['F*'I=S8CX31J&=MZ3SL/N7Z;7J:L_@^,A_NPLOVKJOC+"GJK"':WT
M"$>8M3&DLZA%"FB`\1HZ.,BF<UKDU5P]VJIPKLML/J;C3W?W?JWHLZ2'WLD.
M:YZ+U&^\[G(CN:!3B!`CH]PJV&&#&(=ZFD(``F!;O._ON<K6)K\O`O,*HMJ$
M'B'JP=J^L0;5&G4W=.7%61O:WYO>XD2XU=Y#!,"$_J2KI9H7!:PK@-T/-.D/
MI,)V:-UU^UPZ/C-9)NBHJL=,5%B587?^.25$ZBM[=J:;D[%XWY/;O>%W_L]2
MKHD#3[@YO]HE-Y^_14^ZXR(<2&`30SH`A=W<K!^40#[6N?N=]^.YW\*^Q4_V
M_4_TCX6NB073WJ_11M."/M;HO?5QW-:O/W<`@3JYT7PP51#^*C'85RD<NU&A
M>Y[>3O?]@0_W867[5U7Q=@>-`LIH)DIK:NR$]_@8M>9B#&%TA';((X[%5I47
M;JNJ\]W/IU$)J3""0<NS,O6GRN;7.:XZHG3"KVHO38C&<D737GPJJJ(B)JJK
MR1$3M55]R)QT&2EL):KHV)5C6<=R_<ITOH4=]I7HO!@^1!JH`D\8V1:R%\=K
M'1S_`*&,!JK'(]FK>^BIHJ\09MBUU@>0$,SH%>O@@N,-KVHD=-$*Y&+H[?N1
M?DX:,3&#&Q-K!C:C&,:G8C6MT1J<$&TI`.>Q6H8/3ZHE5--X^J,H][?=JU4X
M)+;=7!7',P\D9G5JBDO&$<=O50=8-Z)T1-3NJWL]@/AIE:&-&E19HF'@23&Z
MT9=Z(0K+`3'B<[Y&-73W^_AJ321RR.]O?%"0`5[R[=HRGDO31O;WN:_80*)*
M>[!63LANL2J\L.VO2CL<DH`E-95H6-GNM1M:L8S!F)':$Q!*C'+V\0R>/A=/
M_#*R9U/%`V;_`*TU3MF[?INT3LX_.5?^61_PG'YRK_RR/^$X_.5?^61_PG'Y
MRK_RR/\`A./SE7_ED?\`"<?G*O\`RR/^$X_.5?\`ED?\)Q^<J_\`+(_X3C\Y
M5_Y9'_"<?G*O_+(_X3BQKH\.'.'7E")\D4Y=B]:'&FMUT"YNYHI3=>?;QI7.
MH*8"_P#F[NWB*?3Y60`&Z@GI_P"/5.$?D6;`N>:*L1MM"@5VO;_LL:0FNGR[
MF\=*!88_$9[^C.@,5W\H]"[R+]M57@)["QCVS/$-CLC4LY)LI'2&KJ\@*^8U
M_AD0?>>[N-_S\'/`G`I40Z1"Q;J>D,ZNCB&1'QQ3YCNI$3Q&UI&=QRHJ>[A$
M3):!57DB)<5VJK\B?C'#WK=U*HQKG*C;&&YR[4UT:U#:JO`H(#3(;CB,81K.
M,D&,K`(W?U#&)M"15=W6NT5WNX_/E/\`[SA?AN/SY3_[SA?AN/SY3_[SA?AN
M`QY$HTYYHY)*.J!LL1L&)Z,<A"!-M87GR9\YR=B<1)P[BN$.;%!+&*5-BQY(
MV2!-,UD@!#(\!V(_1S%YM=RX_/E/_O.%^&XDVIK`$\<7H:Q*J1$FSR^(DAC-
MZ$9LAJDV.-N=SY,15]W$QPI#JQ811A(RY?$@N*X@^INC:RGH<34Y*Y/?QL+D
MN/B?V[27-<QVB]G)TA%X_O5CG^_*S_\`)XT^L]-R^2:)4_\`BBZ+P*E'33"1
M39#%H1722HR07^+E,C,L6[D1RPDW[M?DX_.5?^61_P`)PT8I\(A'KHU@Y0'O
M<OR-:UZJJ_$TL*RD8\3!L6SS*,\J3@-8/OY[\A;;.B4TZ"6&V"!E9*M2.*9#
MDZ[$:B,35VT-TF#X&E$S&Y-62G^JM-TW6Q+2)+#9^&\N\&KV0Q/%O^^)NT[%
M7C_II@'_`";CO_#N*QWU%Q.O\MM`6:MK<8QV*EAT!2!>767]5O\`$UANON(+
MEN<QO/EQ_P!-,`_Y-QW_`(=Q:5:8%A]8ME73:]+*KQ7'8MG7K,C$CI.KI7EC
MO#3XG4WB?HNPC47@8O\`#C!"=,;!]0N(8Z\I-C4;O(_RU-Q'::JOR\?]-,`_
MY-QW_AW`J]<%Q*TZ19A/&V^+X],GD25,D2VC+)6L:I&14/TA\NZ)C4]W'_33
M`/\`DW'?^'<6]A]1<3E>;$AD2#+QC'35]9X.&R)LJ8WE:>$9*V=4W-=Y5UX_
MZ:8!_P`FX[_P[@CZ(U'0T$HBR"5-=1LAQ81([8K(H(U;#,"(<<S:1TA^Z.N]
M-=K]Z[.>.4^O\Q#_`-R\1A,K`5JQ[*LL5+6@C`+(;6SP37U\A7@)OK[%H>C(
M9R5X7N1%3MX_NY3_`)"#_1X'$C0H%(YDAAUE5E9"#)>U@R,Z"D8,:])RDU5.
M>JM3@\:3%@WG5D==I[2K@GD!U&,:A80@R.Z/T>J-[$<JK[^%3ZM4'--.5/7M
M7G\BI'147B=&2O!,)+FVTT<JPCQY!8?F<N1+%#C[!@VP*Q#H*./75HF-3=[^
M`S)4]MO'&TC20)M:-0E1XW-:NJR2;7C<J.1=%[.+"S\LCE9.AUL5M88$9U;!
M=7DL7NEP0=%'!E6"3T;(7<J/2./DFBZ_W<I_R$'^CQBLR!75$.OJ;2?*O(?A
M4;YO"D4%M7Q8BM8SID2/:2P2._R3HZISTX">MEP\?CBCH)8L2F:3JEWO<XY"
M-G1=55JHB)MY:<`II`0CEC%!&2\K88(5B584@!NIN-X[:Z8P&P^JNWM>[LUY
M?W<I_P`A!_H\$A08%=3&(\2^.C5P7R&,&1"*P6CP[.IMT5=?FZI[^)3+!L2_
M0ZB<)9U:)KXVQ'H]&.4IM6EW)RY=G']W*?\`(0?Z/%J5U8"<EG9>8L%.!&**
ML:L"#"\OK$:`?0K]T)3;%W+UC$77GHG]W*?\A!_H\$EFF1RP23_%OI#TP)%6
M\"24/Y<:,64HS0E:FQS')HYG+3C_`*:8!_R;CO\`P[C%+/%<5P[&YU#E,"YE
M3*W'ZVKF'KHT6>&1"#)KH(RJIB26.VN5&+LY^[XJVR*/D$L-;1^MF.>F`L-'
M#K'5MA2S8]2.PF2'OA/MUMI1[GJ`*R0C&]+3IN3L^)ECKY`8D\D4[(4J1'68
M"-+<)S8T@\1IXKI00F5'.&A![T33<WMXKXDC)Y!+R[]<C>FI<I\!6#FPJ?SR
M7'))A1/".JPS'18*C%O"1K7%[%Y<9E77E@>X/B'J'DV)0[>6&*&;95M;X&3#
M/-2"")"?+$R?T7O$(;7J+7:BZ_$RQ197@9)8QQQYW2'(\&=XG-%*Z!OH3>'(
MJ.VN[KM-%X]09%;F<W(\:+E>#X;A>;VM73M,R=;6<:HR^SK5@08E?8UM<:0H
MP%<-X>NWN[D1^[U%Q>YMIF0-PW*@UU9=V(8(K"5`L*:OM4C3EK8D&$>1!-)<
MW>T3-6JFJ)\5ZDQS7V2RW5'ILZ]IH.=T5#$G3,A\_=62+['VX]!CP'8Q!"1O
MT!R.*KU[%8FO'^#G^)ESY;Y!]9_K-X#&O/\`Q/D6OEOB/)O+?)O,?QC3PW7Z
M7<ZG\?XE,R+3;KWQD:S<_P`PLVUY;6%'\+"MS4K9B4YK6''[HY#@*5O;KNT7
MXJ7`D];PTZ*>'(\/)DPC]"2)P2]"9"+'F1#;'KM()[",7FUR+SXM*`%+-\LN
M)T2TEA/DN4S2LM84@TN/:U\J==29559)).Y[SQGB(5?OBNT3AM/0P_!PD/)E
MDWR),R3*F3"N/+FS9TTTB;-F23.W/(5[GK\NFGQ,^IL!*>!:0I5=."TI@.+$
MF@?&DB0\8@I`5($BIN8YKV]J*B\3\<%3SRT5E#C0)%5/RC++.$.-#..3$2`&
MRO)2518L@+7C)%Z)6.:FCN7!:V@B$CADRRV$TTF9,L9UA8'8(9I]A86)Y4V9
M**,#$W/>NC6HB:(B)\2\;TW,>US'M^5KDT<G^=%XMGLHB3275.7'IY+JYO;X
MJT1EWDJ(Q;JRGE@P7$[VP*C[VB^Y-/"^13.IXCK^:?6+)//M/!^6^$\_\V\X
M\M\L_%_#=;H=+^+KS^QB((PBJ)ZC*@R->HR)VL(C578]/D7X7U;9T-;,<9LP
ME<DD*SF1'OZ393XF_KMC.)W4>K=NO+_(^24U-/\`*[:UH[.OKK#4C/"3)<0H
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MGU?EU+'N8L;!,5-%:8DD!(QB&,-YHYXA@'"56>]'<91`;FL*'"QWU<N,"Q3*
MLBJ[;+9L^B%M=7PJBGJR)/O+A7O^@;N</HN5NF@TXL[NR6!+KL&]3:2ARZ>;
M&+''ITS"KIC!^8EI)\A\FFLX<J0SNJG/>WY%4GJ'8D=#7%*K+2XSB2QQ?2R&
M4D=@KBP?*W*V9&G3BHH51$1NUR<_\A7K<K?('CSH+VVA(GF*RQ@5[$:^*E0P
MEEXAIMJLZ+5?N]W%^R/;Y=<9:_$#OL2^HP\W'?"P92_2BKTRFLJR+3H__P!.
MUS_M\"BFR#,78%(RF`[&K&>'-O,8%^YAEJQX4R32-L'@8Q#(/PP#!W*7<JOW
M<>IPRV]P2L*7%0>H)[P>:)>1;H<RU'1S'):U8[MU\>S62\J#81=R?2,:+N\9
M$N*VF1VV;"Q5190/,VY4&SE53902-DW3LMJX#62":A'SVHD;;HS9SXLO(;*#
M86$G);"5D#8`[-@*V01HFUM8`EO"@S),:/5,$Y";7,4KR(CG*B\6QLFN\X@Y
M4E'7^?1,4%GCH[J)K2^%6S=B]1,C^$(/=NW$3[>B\81'KYY:W$WY-7I@,[#V
M7S[T.7(LQ8SH#*^%/NUN7.0R%\2%SMZ]_O[./7%N(S;"Q,6'-%F+\S^M`)4;
M(5K5CBE6"WU<"W=,&14.YHV/>XR;6Z*K4XPR-C%B&VK15Q$+8@#*`.5;K,DN
MO'M#.C0YK&)<*9&=4;7=-&^[3X[_V@`(`0$#`3\A^`@^R^0@^>E>N_\`S`T;
MMZ6FCA6^1-)?,I]1A!^,H$=Y%]-#B2-%)BU#?C1@@%@`HM:VBGN[^(-<N-[,
MQM>H1+RP=1D#IUCQ07I&&8<U(A4;%-.7FG!WC:&H#=@RBGC-4*6.F32D.KY<
MLH>WD=9T^0RXM@49Z/A3O^&G"#M7U^BX,B"PRA=S(:%&0@.=+*KH*[7YDS#=
M3S6#R#X:'R#;TJ"LR5_YJKC\XNH&^%#H1RTY,$1U&>2AE>U->IO)ET]/R%3]
M>?4!EX`CS:4(O$U#"P?F4I^8EZJJ3L)[ORY0[3^4G7C)$G"0BT8/:,#M$UMP
MZ]Z["("XJF&ZD\KI(`:.&AR>Z&5UD;%!@T&#%5'A-KFN,&>[AVQ4D*[D$E\!
MLW@0_I/5XC@<1*_<*U]YV,R!!.#P;!N@K,34B9A3$@,R7'Q]`8P,4(B!34$=
M<"0YG,KB!O`3.NR=J@H1W9=W`/1%:`HN$4Z'@-A!@HU;$%$79O$1ME(@<.$5
M3%DPPQE)?<X#:XVY,]M8E?$E\O;P:.\B,'X-%(\D],]#QH@-^-31BYAI_@/2
M>8[U(5Y.T!N!"X:&/6L%6VF@@8H"%1G'/.-95,6Y'M:FSG:HMYAT7_;X3UF6
MCL&XH530=UHH7D%=BZ-7MI).F7T:QH"M-Y2V8/#L3-XJQ)VXNS.`<'TW.B4K
M!(!Z]W$%=:WA#F&%EYV?7A188>$O<DNHR+(=$73V^]]$-E.R%:A;S*EIW[T0
MO$53'M'!1\30`_X!%7@=5=!D"9$BKHD:6'8%"`*`T],`E/;5"IAM.A:6[*FO
M,-,<#$"0N*YC1><X];9?;!+E/X16QF*HP:5&AMPPLI2,.$8`[13(=6E/-!\X
M/$Z=$QYF3ION&Y3_`#KUCX!8^`7"<R=VQ(AHT&+]2IF<;^.IV)Z"@?#5>ZY2
M8DED@5M$75>!3X58[=OLDASR5V!(FCA!TMDU=&S>F0N@EMPX/]9:AJM.>;$Y
MVOUB<=><XF9"L40324G@Q'X(D7/8&9LO58WFXO/>'3]7`FZY%CU*'I%4<2UY
MCTI12CWMYZC8JQA4OOQ,\VQQ\71?X&GPV(GAJN+XZ$(20FV0K(G-\56>2H,X
M&]><;](@L39HL+QBP6W36VBN*NB#@HP-4X0D#31PF;MC)50-=@'G;U+5TZ4D
M4OAEM8Z?2T)\(SPDD(*J>14TA[&N[_.V5FFN3EDHG\,\X=`U%3#L=JV1#_I^
MU+C,S@/@J@-1@K<]-M`&+AA+8+3VZ>)O`5@F?+`:$B:AO*4O,U.K;;=.N*%#
M@8J`9O\`/LI-Q(ZQI8'0Z]OVS)@\!@H9N=ETX+'C\BNCYB;P+#PQ":8Z1!#$
MX$MZ;`;D<;K\#:[-,)!F,(L?QM"L0\=!?U(AR@B#EH?SC+WQ/,7,HN:W"%`[
M)AR!"Z2IDSN/-:"1!-3Y+`S>;U*8K*=$6#[">Q@QP8`P",C3[A*6%\R_UGR3
M52&3X\#B>(+:*4))E>^QHIB0S$YK,1!/$8603U8K_93AP,ITD/,3!:"GK*G8
M-2HCYFJ/FB;$80^Z+@O;TU4'&JEJK-=B"E'0UGN[ZV4LQ<P@:,=D-*:!85E1
MIAPH,;MI!@MZY,)7SJ4;GQ]`E0WQ*JVN)H&1'2XUMK9E&HUJ>2H;(1H<%3!5
M/+8JY0XV8B5FZ4Y3V>1I3,>G(+?Y>0U9C#_XW4MP-1GP=#Q8OVV]?1:,+!@S
MI&:/\1J`43A\HC4H'(>X"TSP<MJ7U1@L]Q3LWX*5LWD:E5FT6L@!X8X$U?(P
M;*/FFG4EQ@O.'\;*5YMA`4)RS+E!/2L(DWC*KF$,[,^&)$"!4D;PGX]N1^0'
M9Z/<T?<;Y,4U8UM0SEOCE3/$*J!H(8YFN8&*%$B6@/%="8^U773,$[WX%Q"P
M'+,_9Q;6W,^Q(Z`NL&:N=LP83P)@(T3(`SV]2HY!UHOM<W'O%DC?ZGA%F4`#
MX#@F9N:;X>3O<-F%%H>_P&O($%<Z.;0383Y4KS`\Y(K5I6Y*5\=I$X`#9&/R
M0-:C&-%9A\`6I*PJX8'UEFCZ>SRC55UN@$2PX@0D;*.)0/6@2.MR=;6_4)AV
MI-J_(AK5T6+2]8"843E<%Y@[S&&'`!@`#S:"@?`+(*^+TIG!=Q)`4\B>\(JO
MQ56ZK:!-SHP)<M!550<:IK!,@1OUI&0JSHX0^::85!RO3NE]6-1<XP@D-`Y<
MX,(!J90U&4A`V_Q`/U\:H&_/H?.1B>*]=^F=`V88V]SI$1@')@B=JC.(]OT[
M@7`EZN9/]22<&-B97H55*8AG*47W1%(EK]1XKS3H>TQT\&O5+$-*%"$F-%`*
M".C6;M:1CAVR.J,'530\Q>"81Y]#<>S!P+T71"U!V[PZ4A:4IS]:-A4K6O=-
M0$-F@*O92;`+A3-%1<OUWG@3G$VDA<%=10'SOD1$%#\%H=-F4SYD,WZQK%_U
MESJLK%5]?CC=.*=#N=C*6%TNQ]G"5T2NN<,#X5:Z"*%4!B>TJ)=5A_\`\G7.
M,FY]7UP-T0O9&P`%<1+B<E(1``0SW:R,#!^&M=$\<A\"[773FYSV,@1]"JG5
MZ?,/0D25!PH';.#TX=P>W15]8MD$5Q;,8O%&..\Z`\S7C:_FM`D<*NC>"`JP
M"[+.J]5\G0/UT>DCPA.C(^EY`%JQ.\UD'JQJXW6F7(ZHT!C1N-"&M-H:.C%Q
MP4E?P*P+("'Q&K3)[VZREV``8##:"Y[(,C:;/K!IAG%G@M.M'$&>_P`(JBF2
M+8M@MOB^BA>-\?"S;X'-G*$""E9;2MC+XQ]57&IO(M;IAH"KKEE?=@%?(1_*
MVV@#8$$X,3<?QNS!9O6GJYC=8O.,:!NJ%$FT'8+="Z"F2,)4OQ=.=ZWS[SZ:
M;-I!BTSUD,1IUN7UWP@66G>AYZAMZ=R*$A"NS@_9E"?6:)A4+TO"29]&Q6=R
MF0#QH`U3<U#77IX17KG*Y7Y2:J3(05F/:V[SI#0UU_%S`*3L:[H,$3O(9I5J
M'F$8AOBA,11:)LE4H8"B*'XG-=J*X[:@OF(9>$^X<W&'TH1OX'\5).D9`V"!
M(RO$DP1G=S!!K@?C]-)2%(#]MC3%U^D[KN<#P$8FVWC,-[:!?1TY2VE5RS0*
MF@5R`O\`FQ?9@#1Q#S*40JCZA"0[ZW6(`R=*C@C8^SY`(C$TYRG1KQSY3R$Q
MUJ(K$H/!KJ#AF0$HM3->H@V(AVB;-M@BE<V(TY+A$9$68D9;+6)RL*E0JJK\
M*K8>B;\(%T.-AX>#U%T'Z<"6*CR=%0=4(\'$OU6$`NA#%]F,#/4#00XC!H#K
M</Y4ZQ_J2,:=!9O1^!5L/1-^$"Z'&P\_X)PLFGL*)IN:D^`&/==UH57`]=S&
MU%W/`!E8P,WE"'*Q3^VZO1P!`>AL5`A(V7.6Q\DNMD->#P$G2]<8WT3H`LP<
MFE\&3VNA<4(B1OPC`(2!FD4$77TF.:D^`&/==UH57`^/S?655Y/!,+RR?'DO
MV\4E`ZZ+\D<!5<PA)PA>Q,X]CM0OT+C8EMQ6^/*[2I.&[$S3=UFSF.:FDIY`
M&MAX-FD0]^,"Z!UR)2-0]M8]_P`C<<+CV2:!,N2`$3-[`:H/`]?5YC0-W*:&
M2SR[LPPSN`5X8.4R$./D-#%"2RD1X@/"HGW`+IW0=1N..C^D`0@73JG.#U]7
MW-'(P$LX>\[M;S;GNYJ]OQM[J4]LOMCC_!24A)!-&>2?F/>'/0(%0Z7`&SOS
MU5#KLAJ)J"4X=,+"RS<XO6>WIQI.B<J#:3$D!F<F<!-9#`;T>+6!914R-%'=
M"Z36(.\C-H]!QP1T7>CM8?)+R#M7>IP5D!65_P`D'6>5\GD4Y<3J!0-(R=E2
MGK#,4FUJ^>@$%GY>0P@(KO.2>P(JQEZ)KU8T_P`[KQ`%!D)@.`7N\]4WW#62
MPB9RP`J&@<N>\)BVTL+K:/SE#M<A>5%$8WAB4K7,FLOE%%J,!^_@-#A>P3-L
M?7@AS67:N1P?WJM;`G>_E;OR>[*@B\WF<"VVKX,3S"^XB7L=<>B&^,#^B&'*
M!TX9R=(B=7L[6'PRY<N7+ERY<N7ML6*"46$AFQ<"\.>+U>T"*WKS@U,8Z;A0
M2T%$Z=M.4`2OA^XE,$.X+T7*!NJ5,*O&TI)`'HSEN*F@0D,`+5<++%,$="PT
M&UQ@'!VL"P;35H\G'CQI*4#8/(U9YA@BR0#[Q$*$5L\.+:0#3Z%ONEEQMTH(
M3>HT$TR(8!$G(U1\-*142.Q#-(#W-.$%M9BN@`K[+?`O_0D1P16#X(-,KC%W
MJ/5G!$-%:*#LI=4/"2P]!YE,-W/,''@ED&\6ZR5'3P+,_:5X<`BD57PES8.D
M;K<HX\"I:;@X3YJ?0;[KQX2QG5>M(-Q<A!GP2*8*AB]4&1^7`21EB3E^80K8
MQC6*4VAJ3'/L#&`K3P+):R3D)XV2&6H"/LS(B8]"^;WB-L!ZDP[/&,I>M2"C
MKC@*L6S#23$O@1B%I'D8?X&L8:.!9`$X4=QG+FW'[L(G,'(,)JCX&-MAOBJ(
M3/.*&'\#$N0;5(AOKX,663K=E8)*EI9\!B0_9*XF*K&Q0SPE\ST?LW35514^
M$?>'$M'YC'%CX1]B/;\($A.-H`1ZA\&099[8(*C!?];SN\``?!0*;3BKWOV#
MD7(`AGWP[N\^+T!^V8F^V\^(^%=RZ!`Q#X8*VO@_'V93,S`R"U\:W!B0?!_$
MN$2^H1W-@OHQL>R-@O(0%]!ANYU=6V&@'P"]5EW1GN?&,$O<Z(N>/EBRB-`R
M[]91#&/&?`+&F%CS9&09[(28C4>992YOIPM/^,IZ:IF,)*BB0-@GC.@I.ZQ&
MX1ZF_)])^!C/Z1+0-:!BD@Q3GVVIR^P\<@_D37M`E>4B5*,)F/\`W$(Y:UZN
M+%^;L^$P0:#[/+-E&+C60R!PBP&"3)D$"0A)+%J``,*Q6$W1);J$VF9-N@(<
M^9$@`C?R(GO1L(07:%B+C&0UM6+VG+HN>Z?E7IK?K)R\"![T>1/!K"IM#YOY
M\,0@M(?*LUL2AX"60`C@B0D\H34",%C9G0TWD[U>:'2Q"S4A\+N+/$R!J;2`
MA.^N)L?B_P#_V@`(`0(#`3\A_P#04OK1ZAW'4D_Q\5JC]@->^\")B7J"[W[F
MOT3")6HXCH<^/O@(*P5XKU?5O#[OC1=M]4[2?GZUX?=\6<>XR_*<SGC!KL\O
MFWU9/WN&5@)H-^SZQX?=\6FB?#>3M4N#O@?<V<D[IV_.6BO1#]!OK'A]WQ:7
MV-J/M1RY6?DJ]CLG3/>$J'ZAZQX?=\6Z8=U:]I7C<XR8\3GUCJY>Z3=S>7I/
MU8F>_I_N+WR?C`4X:-G/6KY'A]WQI:O[`IR234X]3]![ODWF#3RON=W)TZ?)
M_H/=\05BNG[!_GJ\<5PF:JT5T_J_CY/]![OA8%4['<?QW6NIP$P(KRS'A]WR
M>T^IRX<?HC3[%_;^`JBI!58<O=\'A]WR:4+#^K[&/DJ;<[L"/7CN[XF#A']5
M>7Q>'W?(X[-;P'!2K^^!.](#^P/V\(]'H*@\<\[V?O<D*Y72!8?_`'R/#[OD
M=]%[^#YV@X"'W?M^N2#J.\_\.GZ]<^@]WR/#[OD=]%[YM`J/=?7YXQ#7;]OT
MY_0T>'T'N^1X?=\CEJDS.Y_?3&!V,#0^M7>KU\?H/=\BW1<L<6SY$<J!*O8R
M,'L)0+P-1+QEQXS?\_GQ^@]WY-P`4AJ3V?N/6=+A-P\_7QHVMQ3\MYWJ>I=^
MV_)I-CK?HQQ[_(1-5M'3N_??XYZ80.UOO?\`!T_ZY]%[_`?7!4Y8.#E^V,"8
M*$H'?V(XJW\!^Q_WVSE5()*<']SIQX;:3(4&NR'`1`>XOT`^=]>$KM0OM@`$
M@"\<.'7?[D;YB#;<<+O?VY@RO47YFS3^KY/W87KKF)B_8WE7T@<K,"_YKUA@
ML`H'G_=?Y>.P(X/?[S7Y;]G"S6^R(`]-NOR:X]=#0"]%.P_URNM%P0%4%Z+O
M:JOXU\#]U_EFP(X/?[S7Y;]G.70Z]9^U^/LX]Q->5]UM_CMCZT).E\_K?7[B
MGQ9BKO7=Q.PWY$K`>!%1;R^TPX;J<C\5\!RV)]O8'`G??4&9QX9YX+UFKOO>
MI)GN)KRONMO\=O%]6$DQ@)RY&I,HR*Q:#C=]_OSP97D*UG?O@1F5MQ[&CS]L
MA*H-4VD"Z'">0XJ7(+27_20_EA[YU-7H;'W?\/<R1"<K?WEO\<>V?NO\O(^J
M"&+G^C_@N%HJ(L3N\[+U;Z$F$=07VUH_?GP8:;.BROWW/O,B38#X<E&OMY]M
M_P`_!]']YU>^CS?#8_&)VZG,O*OY<JJ]>S]?\(]_']U_EY--D<=!'Y->HOZ)
ME[=+QS^F+;^J`]\.%U"[8:YQ%;<L$$]QMVWA<W>@(BG5IV9^V.O$7\X^?MJ]
M'.7%=[[7T/?"6R'6'6.^1^[YT"ZJ\$'O<)K[1G?94Y]7[#^@72]G7_[D7NFU
MM?GM[$,4"O&5:[=3]/Y.?N7]!W1*<M+AXMM/`'[F:=A[87$#@-!^,=`1T*>Y
M1+]QQ3$0Z6#:%X!I./)%5$)Y.T(E]C[]<)!UJM^`4X]_7%"=MSG/V.>^.`V_
MY1*/Y&?M1_6SFF?9+YOW;7\YU$DZ0-@+TS5:#-<Z&+G'/*X4_3*:*9D.J^GG
M*$(M'2*NC:<"/3/JG^\^J?[SZI_O('1SGZ"+KD?1SC#*J'&,TW9V>N?5/]X$
M%`L8ILU[:[L,OED<#:1&AQU-FL#K3ZNN?Y;_`+X;!FQ"Z<B1.IZJ+7IS+0`L
M&N784-1=&\_SN?Y7/\KEEA2Z8=!E-\S?3A<9\W"H>UE3[\8N3Z/[8SU.G1W]
MNOVP^/?93?SJ/8]N,_RN?Y7/\KD$H(6O=?M:FOSD=S&7W)N>^\_RN.%B:BA[
M<2]\EL(25[MUTZUT_.?Y7/\`*Y_E<?6%0``='@KUD6[?_P!;_]H`"`$#`P$_
M(?\`T'6&\LU>UXOK;@AB;=(];!K\L6M^(0M"=0VNH;OV:FYS!IML3=(E240V
MT"R,V@%(E&$K`Q]S!VG6G4$+UY^4_H0=1TY;^'RK]KQ:<'#[XL/Q!PZ/=<E-
M?8C^ORG]/$^&\G:I<&?&^YLY)',[/LY<&=1?H-^4_IO8VL^U&9=K/R%>QV3I
MGN8U#]0ORG]$V'_U(9@OZ7:;/=]G?)NF="_5`].A!U,V1R@TO!;,4:A48-(C
M4YIZ+][LKR+WLM]_4_M'D=1Q(`""33ANVZ6CY-^T>+91?`&T=R\TTKP+JH\#
MJ!Y0=DMC\G_:/!()6P6#E3A`HH$8,T2AN)8.W[O+M^4?B[`LE7*L5J=0`TUT
M`!E**?0'W7\!#Y1^&=>[8"]"!^70"H92PL([X%AH37;R&,05@!P("[`VJV5^
M2_C-K?S/6,%.MWD:W23`&(J[:]NH:\`8U',()=>M:%V$(XA#3*I!``:VJW7R
MC].[))NKTWBEQ'\@(Q1O2]Q#6D6=@:,_:/E#^G>X"Y"L-FJ4*Z-=T0Y\@'L=
MVN_J+I\'[1\G?P]7MZ@T"PHK1L+;*.P/35R80O"Y)-O#]H\CO<E3<$7[Q.V^
M,=M^0FS&94(!U5T&6F2GF^F,/01H&,GR6S["BL`%5UMOC^T?)EB"K:8-\PZH
M9N:1O>6Z3L$#@`'B#1V6[3@J:K76LV3V9J$J#8<#=_?R&R,G\\WGV^0@0"%R
M:3DLXYU!=0$E]F.K-=9[Z?!$YR^W^?K@)`:DMU00.J#]L=54@@Q%ZHFUTRFO
M0>A?R+[H."H^6N86LU6](142(N.Z'D`.2I>`$WQO(%QVE0=I\[FC1V><Y?;_
M`#]?S3E>`A]:.76<RTSS,<RGO:/YD5-\G\&"Q9;LOUW?IY"K3Q_GZZ6FY=$5
M'H5PX,41,A9)RA8@?H;GMA?^'`:->?Z+V/'0[K_MG?\`CWQU(VN<BZ^VA^.?
M7%IK4<!MH]>`^8%!DH!^[4>.PW0GG^B]C-#NO^V=_P"/?.)-Z>O\OY_#E#>P
MZ'V.,.7V_P`_6[$^D/(/*+$51"FL11G.D$0N#<#;W5WBB(MVUOWV\B/Z7K>4
MDQ-["M_?7@?A/8G<7E/;[,P\Y:X##IU'XG?*&]AT/L<>)R^W^?JWJF8XK3U!
MIW6"KFM"Q;=K302T($@.(PV(.*<#H&C#AI11QTB$'(B.4[YS3$,Q3J/D0H&?
MU9,1/.@?=^G+TP_K?7[/MFX,<'`^Q].?1>QY#E]O\_50%T:=%%>`BNYY.L&#
MP`BTP-V@2V%3#)]I09#D.P.57P"`I7W_`&Q]B0$&S5>(]W'OGUKGVN=$/S_C
M/"=$[AN>0]N+_6-279U_]?F^/T7L>0WT.:\Y.W'J&H\O1^&X(8$RF:3AQ?<%
M#AZ,32L70!H[<H=!5F0?LK5'4XIZDP*D%LB+79AMLGO@?J:C\./OTZF<(G^)
M./IK%X"7W9_P!Y/J7;Q@`AS%_C'V#Z$U[^K6O9$4*$UN*+.0T+./N3`)UPI?
M:FFL!6'.?<1B?WW^V.HG@/UER==9LIBCG&<]/:3$3JNKA&@`\-C]XC^^&3%!
M&U*ZJZKS?)1BI")V"V_EQ)0/>%_4/X>ND4.4`.&RC5%]\_;.?];$^V<U^MZ?
MUGW-]^UO6*B?M^D-XX$[6#%UJ_?O<OHID3+]3]\''U$)JZ5_&?3/]Y],_P!Y
M],_WBPHNL_5'6"`P#LG?<N?3/]YTJD*>9HN?;3$/YQT$WZ^OAV^NO[PF-2!'
MH7^_3\PO+G1=*=="@[&?XG/\3G^)PFCA@Z75AK_F7X]58U)8ZUQ]\6)AFHR-
M,ZP2,;31I]TG.?XG/\3G^)R=%&S6\K^+C`B*&1IU2NWKOG/\3B]\341&ZXY_
MC(BR)*]T:\Y_B<_Q.?XG"EF%$1I['3_];__:``P#`0`"$0,1```0````@```
M`````````````````$`````````````````````@(``````````````P````
M$,-$````````````X```@$`0`$`D`DD`$````'````@$]$@@D`@``$D@```X
M`$```AY$@$DD$D$D@```'`$$``$RP`$@D``D`D````X`$@``C#@$D$```D`@
M`O`'``@``$$`$DDDDDD$$``X`X`````@````````````'`:``@``$```````
M``````X6X`$@$`@````````````'0'``@$@@`````````````I`X`$```@``
M````````"8'`'``D``$```````````X%X`X``@``@``````````'`'`'````
M`$```````````3`X`^`$```@``````````T@'````D``$``````````$H`@`
MJ`$@``@``````````/```#``@`DD`````````:P#```8`$`D``````````'H
M``?`#``@``$`````````:```8"H`$@``@````````E```#0S`````$``````
M``<``^'V`8`````@``````"C2`%L+`#`````$``````%M"0PC`8`Z`````@`
M````NDQ'`#`K```````$`````I/%1X`\````````$@````#CN*SVQV(?````
M```DDDDD;@'_`-!`QR(-(`````````!`````)````!(```!`````)````!(`
M```(```````````````````````````````!))`)`````````````````()`
M````````!__:``@!`0,!/Q#X#4QZR,OG4@4*5_\`+^_8H$GK:!LINH`M\Q5S
M;T<80]8:].IP^*:^F"@`/2"L:4G`!>D-HIVJ_$][/R=%ZD,IK7."'U=&D([`
M8<N*$!5'0OR'-5,WUWKH)!9TA_#;F]HN3N0#5PAPRRM6\BDP0D\$V-2B<]G,
M/?)`^%N[#5]>\DH!*B]&3<YH">;.^;>$TN6K"LH`Q!!,+RE`\Z+;.:S\7B""
M$24EG0`U[AIX'\6<J;)#L"%`*>,*G*/3"F0$8`.OU-UX1#[JE96"3;:'*$<(
MDF^T1"RI-XYR2:$.Y.B-0&(O*-D!#E=K7<X7DSQIF(SS%9`]=B@.@9CL6(8&
MS&:'-FX[E-Z8A5T\(,G38QI5W!@+&'PC'!G3>3/_`./29B`\%L#<'YT8&J-%
M8Q"494COF-!S$+T`<<A).^(OLNE:DY!"407<,4H'5(`BFD("K>EN`.6@=R,=
M'?F'X`3P]\2)65+D^2"+'-)4:B3%BM+@!LYB_)?:T*$#0@^.L?UB[XMSP$5*
M=4(OF7^OYJ0[>TQD64C>USS"<IH-=R<-5=@.,?+``$37A`W[/DZ[&&)T,?)=
MP7*LIKK^O(2W2E)S!BUU],^TRXP/"55X7IF*@G*'@&AQK@B"9034#`\KS>$!
ML&EL=\A_Y51@0%%OPZ)!F`(8*!>!`Q@8T7<>MU.JFL8Q-P:JQ]#%_#\0P/R'
M&3M2(HF3GK`Q[1GW_1!AY"ODI"DM@!`^')0>"W&M`$`"K,6LPK7C.E";M'9\
MO;72-P-G`D4`-\]9A&U0^;V`(XNBG$62M"+KW'4X<+A[4V>79-2.$^E`-@%Q
M'\N*KF$"%8BES0>@+A*`3E\#H=^[*-=\Y&M:@Q,"\C$AS`]B/K2.42DX;C_-
M3!:`+0@A\";HQIIZFV_07`B@_1)DC,PJI:NC_!>L&18B\"I(&1:OH%AXG<SJ
M.F4BX:)^J2=$.X#C$:4TW-V)5J;*Y53BY#E`<:@)B)M6!M"@U.$-T:WE_@@1
M``1AS1XA-?CGG7,-31,1+I=B)\8!N9/L:T1R-K)-C3>5,T!(HB#A?%KRU4=T
M+P%BFN0V\[5!E>;W]1I^&![K(C#083<,$5"B&"=M@4+%0&$V.6C@A58D-7')
M*EPW["$!\KP7X=E)9)!>2E@C*"IL(S.3\?!!Y&R$%`8:D2>47*0MG^[?8>HQ
M44*U,;48<,AF)3&4`D`4^UM&[?;,K*NKY<^US@&YA\SB@HUJ?L&<,\#4&3F<
M,4NJP`-)+'7I$H(IJ/H!UVBM5"3;[!;MADBC0@>>X)X;#J1Y`4,WT6Q+PYED
M"1:PP]!%(\*V$4R<7:*TC,WQ9(4$K<VG49O>;V,4$NW)2RN!\Q9UP4VR`\@V
M'"Q#[@H*^!0362LXP"4?0*R8AO#0;*QE`[$22QTT+!DC'$.$D'M+THH!"GA(
M#+&&T'>%KV01AV'D'C;/MGM@:I$MR!USX_M69-D95*U,#(?IE3_$E>HID8#U
MH^4B7J86')7U^1>5AUQFL'B%=XHO;F.0N_VO,Q9^D<S):/C-J$1#=8ZP4K>S
MO,,@5RFQ^(0G",8$<9895Z-D"HA+AB<2C2U"IC4LS^I-*!A/62G%`@Z"ZQ15
M"AZ?F*3H[(G.S^0L)W*6;ZR(9W*)!-@M8YB*-*6?`D@]8\#8=&CSND/[@A^^
MVU&EY@L)\.@5``T$L\&;03YRAMH^IO@:N4[YGI@^8C1''9>W#,I.2XFQ)/<1
MDQX)E=Z:<WKCMU@C".F)]W=G"%7X8B93:[<88K*,PS>\=,JV=X#_`#43^?0E
MQZHLFK0QQG-186!-@`YWP*`K>?(JTG7SYH306(.O&,<LPW)^1.#(/?U0%8G5
MQ(.%N_$ANQ)"8@2+NM[,'B(7G!_*FA=^L&24\$F&P=P>`!>.QB3_`$[L&6)N
M55T&0R+PI?!>Q(8-Y";9#,#>5RSB$X-*#L2UC;IBY[P<ROI\D]^V6WS$@`D1
MR[R"`<N)YIE8U?WY!Q.+OKB8IC@KWT3>K7C*@H5(5`A<00S'%B%^1^_:2#&B
M@(:@!#10([H?9[ET">629(44SU['F:N+'"$7[9OB*OP1Q#LT81'26$#,;YZ-
MN^Q$5*"@#D>Z!J((*:06M38S90;?0%]8]KG+F=6A%40`KDEI/\H+<BDR@/O`
MN%J(OP)0'GDN[`<7Y`4ML/6$'3.]$3J>&GB-XWG940!Y12\1Q@+*3!+6+$"-
M$D"+P0"82BC2<N`,5RN%5B0^E_C2*4-/5`?3X_:9RV(>`Q).M`UPKS-N5U6V
M=!`A;>'X!,E=*LGP11Z2;*R#8D@HKJ[!8)ZWV>?[M0T0S5P9&AHW5M#'W2H\
M$B4;S)=,T$9,(P8-0,:RA8_^#,F@=%2WSW("JTMDCT,/LF/OUX=[O4+`QI&`
MR":BN9&>]!W].A),N^#[DMI,+!J:.2C)QHS7S<&Q+:'-]=]WN\_DY=>X#@F2
M2\;_``RY_&M+9]R9?):-JT0L7BP+1L_%`@X-\TO,P$BOCMAM)0^G)C`1;;$&
M,E'*USM8)474L]YT^VS&3+ZX<E`?N>J[VTP:1I5>KY&KNB-C2AA0%YR?.3)T
M:593I/6#[7P6;U)::BRL,J`A$$+9#UW.)<<OW6JA48*'P_=!KI=GX@UXK85/
MFE!'031P`KZOVN)YI!SZ.&-V9.H,.PVRYZ]4?&_89VP,V"0B@XA`*,1^'I4H
M/D3'EE_S5*@L-;<"@D`R($0ZR,`['EXX-W$KT7AUN7QU`H$LUSZL;]ESB@&"
M`P"HSYEA?E,/`!RF^-H2^L%`$8YN:;SLC(ZTBABAQ\#2+.2RO(U+OL?Z"F,Z
M<V"Q-26,903$95R[H@F^:CK-5`BN=57Z/WV/@H)FVU>#@FX%<S;4CW]!?!`Z
M\:%+8A@$`&QJ+8C,F,?!E,K&5DW&]==FC!(-3P72B>;JPGQ*R[5H]SE(0U6Y
M'%01W-`<`$\1TX*45,A+%(0N=B[IOA`$HJ446=T,]SD>$>!8GS,(VW!`N_)\
MJKKY[;W]'HP-!4B74%3#(?,+=D54,]L:0@364J;X^L/HDK7RG@.H=&!%IXF[
M'H%ZB2*WZ./*[03+.0HYYBX]I`_O6*0%`N]1]JO;9Q?7/3I%+C&01B*;S8.J
MP\BI-^A;<*1D?!#AS>06,"TXCLDF1$O*)!2*UV,>4I.',(H<<"HY*$9&[)69
M#10D;/3^]UX#=R&1O4.-";_:(T[FM0'X/#AS>06,"TXCLDF>Z;_$\3%3D%<7
MET1-#-5+9ACUZZM[%W#H]EE7KO*;@`3I&)'B%(?B*I\'$3E^B#<B>0V`Q+BC
MY62/2I+GK)F@K]++19X+I,7N>H*CPRL<12.1C4DF5!LO+HB:&:J6S#'KX]9O
M[6;/9V6J-1^.1[NT2@*8`"0G#/WBW9GL0$?_`"<KA;\6*0QLJ!.1?)0S%PS1
M<]I!F2:4V%\CC=,>--H:B)SG)+!Z3EQ/#H.LD5W"T3!A!#;)5,1FG./Y;4G7
MB>O#UO8961(N#5B15"XQO;PJ1<-DYB$QA<"<A)U@OAWA!A@^T"<Z4=05'7R?
MG8`2;D6G[`<G4FGH+S#<VGA);;J#9=GF'&QX\LZK2Y8=:CP-P!U--,,OJS5*
MX;T&).KZ4X3!*\P<7%L10=E<PL\Y/8*YN#J;VXOI_9N$O"P;>:`$XG<,!DL]
MZ.Q2&`[$F0@-OT!P`"^FH45!.:$2P"`L8R@97"A#$,`@C)3R&P:&:$AIJ"SJ
MT5`1"+4`8%ID4[^VZR*$\V2_:-:&K1M5N07-U)KNV5(*-E&#ZKV6@O`KXLT6
M#UFY.T*@H!E;C8_\F9QM"*H@!7`R<#9FWQ)$E)J&4H#5Q_W/T3,)$60@*EZ;
M&`!32HZP@OG0(=#!L`@R`;)H>"+61HONH1B3FD"UXC<TT7A+51I!A@7_`*+,
M*9E(X`4'H:VK>XP$B:CC!P&*%;UIC.RS(7X=*E2I4J5*E2I7SG-&L>$GG@("
M!^E;80H3KN1@05*B+<1,D`DJ%P/9^W[ZN[IZN`BN%"F'!GJ.$]0H-1].:+P+
M`P'FHE*N``JXK)2E^@CIJ`-N)ZH\@4;!EL$OD$B1(<9==`HH:`5NL!<B#A:*
MBB40\!(-:]X$/%<!QI"H6]R_]1(#?+<8E#.Q5/F:9'P5JH)2127_`$TB&Q3!
M9TY\@T<Y%`IK*0$T+2BC)@6AU\+EY;/7])']_P!]R,H@6*F;?DQ042#"[A)&
M,]<G%`EK3)8-$=`6B_RWQ4DT`)!9X*%OZ%<QA.7(+9Q0%22:HN,L8\K^)1$8
MYYN4-\KTB$,"6THIG@4#J\X9#T(STS[>`^!8C^UJ)B00BLH<*<=V'+1O1T*5
M/=.%0QS#MEL1+BDO'X5N%;#H"G2$V$93&;!$@U]`(ZSG'"U/#8"YK_:1%^P8
M+C?O-"Z_]JK;H'%E,VB91AS2/!810,-(Y/4NK0D;$O\`J?IQU'"T&6'->C2=
MHW\7/`EA@QE1K%^89)O"HX$$%#`BWGPN^"Y93A<4J;\_A492"?U)\G<@.;FD
M1.-*',G_`-4N_1(<E)-QGX!W$)A6"*N_PQN;RLHJ4%9^-<`$B@[X`2Y'\)@?
MS@>D;"VCEJ$H1$QIRB&P.0',>:R%VX)@MMY'`Q"JZV=7G!BA:RQ`(V%)Z/@E
M%L`"MZ:.[<254"&</7RG!OPLP#!=>$`YR;J4,D.<,5E$8ZS1Z4H_64:(>'^G
MP`6(^B:&:\,7<)0B:\44(H6J]$0.G7Y/S'"N)"Q"$%RDR%MF#Y:T<!R4`E(+
MNT92=AX4=<`-MH`$MQ0*H49D(,)`*T:S=6U;B)8)Q+JLR>'P2;&DQIRLCG';
M7PS)$P.FU23"DJ86GK]IJ`D7U)`^0ER46$@FE2EM1U)UK"/N$IQ+PTK>UG2C
MQ*!<"_-$V\A=OR(Q&;T)?/M@`.7G`,\+K`H`YL@U3X+VY!Q38D`UCZU*-(XD
MK$ZA1<A!+-*3IN/9Q@,LF,8G\9?_V@`(`0(#`3\0_P#0=>-++N=YS/6N$:,'
MJ).DBD:]L"$^(5WL8::#T&IKONZ73M71"S02H@8C!H44@E%52V1"JLMP$Q$!
M`!`Z"UG3CY2V1EDS=5T@FBJ!M4"_*FTP)@.\T*+2+LWB2N,!"5HV2!:I+`,D
M"0.01K1[EX8\A\I;,6<[1+T12RREYR$:%KU2&^"(-KV@Z/E'4"J+0&W6CY2V
MZ]%U*EX2PLEA>,)**[H&FN88!I)$,+%8FM7DC8]2[^4MEQRMULG3?<;%E,&=
M#J=BSN#6Y.AN:^IV`;OH=N(:KL].6:'-#T/`QMG+)<,RW"`B-B)!XCZ)M4#.
MVJ(Z'`)@U)ZG]\\EOWDD4R*!V@(:4A-OR;]\\:RU#$*TFU9P'<"8)>?*4CLF
MH4)(80^3_OGA,`JA0E3@/(H$`B!"\B5L$J_0<&CY0V0AT"R&",Q(#TR([(VM
MBC"RO``IV#;[N_E#974)HJ+`.JOX-J@+@*W;0=L@40CL$5B406%57E"H]U=`
M&@#Y*V>7^`!4*/7:+TFL+FK5"M*#PT0:-UWX&=F9084Q1IH-H0@]((T0D`5N
MU5.]`$W\H;4G^RAM+=@"!R3LLB$82=7VQ=[D#[K:S]\^43:D9!Y18%+-P!8;
M4'-'#F(MGD[*=FC1;'/WSY/-D"B@W3M6!0@VZ62532;[,G(5K.04FZ^'[YY+
M2)66MA#MH/XYPT3Y"FIR&`%5>@&UR"L*!,EBH6FD%&XGJ&'D]5=*E6`;T3Q_
M?/DT9M82*4BMC=)BY@9,P>W6]U:KRJKXG&F$3$>3!W"&]XVNR24I@-&GEUKR
M1@N)`A=-)5YI@0COY`C/2CB0-X`"/&S0V4&WWD;EWT!VV[/D],%3G,Q&'0*"
MO04PR?&*@-U.D#I.N04ZKVAKV!RN@>6"-Q!*1"H!.M*A$T0P!:A;;`<@<@K=
M<ZRS+M!XS9#C5-FS3\F@GW3C@#K];>#>*OT'BH7`0=H\!YFRV58(=#5L-'-N
MHT\X&=$A0X+3L3R"1``X<\///MSZZ^FDML%0ZL,:-$1:'8!I1H%G$.48.`-!
M_P#>5V[^$AH9*5#LV0ZBUV9,#!@,7B&Q#X2Q0/6LCE0(GG4$Z)>4BER;UE%&
M:V$AI1"GP4-#)2H=FR'46NS+\+[)=."QV%$TW>;#DD?U<W;BP\`UZZ#K0%2<
M*/"RB`(L=AP(^':D$*G+K;H[`:PJ'8-F].N_D(512<ZPH=D#I>N#B2P!I4U`
MA#G<O7PI6@IBBA-!)&QH&&*!NAPEBOW3U2S8<DC^KF[<6'@&O703-I%VN@;*
MR]@*P,WB`D;0DMJ0(I4EGGST`5<J<KU7;CD4%PU<P`X*H[F6:Y1%%0>\"E)?
M(>^5B@SKG;WR05]-ZP&7;H2NMLY_$24/L%FY!=)NQSUIYG*V*NX0/`]>A@W$
MH,[W!8>40-%P&\8VLVA.R4$44$/,4!:$@$HE>!7J7@`\#_&U(`:&(+II.8\8
MPFYA.%8".M:-[8?PNV7/$<M3CA[SO9XK[=N.E[;YFWJ5[L<\R7IQ_@'I``)3
M8A%#F0KR8UZ0MWD`$U`(&SOSH4"9!1W!Y;@O'.L+-\^GU7137\@-`E6JDS:R
MO+]@A>>Z0=APF56%H`5;5`N"]HD2I79`8.AXNS@@;F@MH>!-G,!]6J8L]B4<
MP0YK@SN\8_P+>QB/#,T94^M"*<C;5%77G#<GY9%%I0=PA7?8RMDPH*V"-%5)
MIWQ?5'ZT&L2"J`4+.K'9F:0>^*/10,-`R[Q$X$JN@#E7H&4M;!K.QQ/2"WII
MDDGE^Q=`MQ`.0*);$95``,"0F@T#"@S``#@``!V"8_%8;.DX+<D5Y'&H_$R3
M(QRUT;:^39R$E$#D\@BUL5MQ>AMLC4@5=:@&CUILNH`Z"5$&O(\(X&[HKGO%
M70H=+S!`=46A<\)9P!'E*ZU?S=:.Q3[I??"]LJI:*2$%M$N,SSQI*1:9"@HB
ML%""S`02@V1O6WB>^6T%4*4,$TR)A4^.'#A3GTF%$"2080JK!2M^5S).42AH
M1-/AA220G2&P*,`*@%<1EC"HH821"010ON"\0_4\'84I-]C+Y0P!ADJR7$$`
M7TTRS;$3`!JHTH1A'=OIZ9]$_P!9]$_UC9*0Y[-6+"D(+8&I.00$W5T;*=D-
M0%B@DT+^$L^YO+>F-(CH5``=M%-7(5,-<FDWN"/`/(Y]$_UGT3_6?1/]9L>X
M,15*CJ!1"C5A,`"N&K*$\@BU`&'T3_6,:/04:FU(C5"AMH%*`C0$!2]0TA3E
MGT3_`%GT3_6?1/\`6!U)Y>50W<E0J/\`^M__V@`(`0,#`3\0_P#0(A5\UQ7@
MX-RV;];42`M"A0J5M'J<1E*MT`?@(![!#I\0_E(YR=U=;4C`<6<DQNT``U8R
MI@,0;.$&PA",$#%D-M83@**L%E&_E.)<4.>G2):.P!7H7Y5B,%750VD1KEN"
M25UZ`CPY%9($W<2(@;;#2`I[SDU\IQ.EXSP)>B*664O.0L1M>J1WRB#?P!LF
M**(%46@-NM'/RG%UG[K%+U1"R6%XPZXKJH::YA@&DD0<&BXFM7DCAZEW\IQ#
MO=9J9/<%U9=SARY<RA(.M>#F::2YL41NI=-L[%KZ=&K$<<CUK!W`%PZRQC$0
M)$VA>&>BQ`1#WZVO=&]K=WUO3;44C$!J0!`R?*GHL)80TH6Q5P3$T^)CL8DT
MNI\I`="?7-8`'>YX/X:A.OS96J"\JI747Y/B.!``%50`#:KP85%LAPBWCLD&
M6\^NU<"A,`JDQ5"K\HQ"P0IK"2A6V**R`&[]L@T[K$)^)NOMUYTPH4VGR9F)
MU,=40;1:42*K1FZ-^D)`F4$"(,@0@<FP6$JU8&1*.M6KD@531F3Y3Q<]Z8`X
MR!`F`##$8$20.@(:NA"L_*7TQ<G%6_28D`5W2%CG>,>D#5)$@2"T_P`INF(X
MM!X@`0$/`$4,-_/QMBL9VQHQ'SNDUH=,TXH[!#9A4@*\''X^0N#Y(6$JK`"J
M@8*!U8B@_P`EP4BEZ8.@0*5,B`%$K\HZ)'>CGCRI`Z#(3B<.Z0>"`^B(/%$%
M@C,"G*T1$6H,KY:"91S'20Q*/&\G`:D4^Y>'&.WY`"&+7<`0"##$96?"T$F6
MQU$I0DQ\FY?K5H6&#8T5$%:R@.K$*YLT9*$%PP!3=%!>E!5I%'.SD@3*A`-7
MPR%ALB0ZX5OM!@MB)RS0<;18043&('R5^*9_*5CH;=J@5`*+<@%<LE%L5(`6
M^9+LH#:TTJ)*VO$F\GTJ1(EIW`)'W\C9\[P\<_''OZZB6Y>AD.CK&%9AX6Z5
M:C:$$]-UXLJ5BCH'0````#S?MWB2P<JX'>M^U#;2,>ZPME$$+8"W-H8KZW0.
MLB,XILU!8AL<`V$U;6T#P/@#]NPE@Y5P.];]J&VD9^F"S=^2'KL<J9KCWL?:
M8.U"O5?7/R"6M9-6HXZ*%K48IH%*+LH38*NPJB6*TZ$=S2/">22.)1A$'.UK
MWG3'!I(VS1=A-:\:L\$J3;2@9$HCR.I5Q^T:58@[,$]SBJ9KCWL?:8.U"O5?
M7/\`5LV+0^R$(@!@%:=3"(W.M=Z+C[ZT-/>NXZ5&!A#US;E<R`,01'&]]H!(
M3D]"(#'R+X(:#+T_?VQ4CV6^U4FCD+[,Z?U9U[0YC\EL5A]7$?P1@:U=HY7/
MV[UP_)UG=R4!*(<``')C<V"@,"(.%#@IN$(BL@0D3D0\&9*!0H+M**AN4O%,
M+$.>'?"`@WM''`_(V"?>N._T?:_J$C].*Z_7!T,_<?:V?G_61$EE'0-42+QI
M^$>R4J':EKZUH>(:\?V[R`%8E[4.3[R]_?&77'IP1[(BZBQBJE1@AUBDAHH%
MM*6P+AW.:/P$)%V@\K5KPB?)746EW6E6$U-&$K(*P5LDEJ;4"AA?9';BEK@Q
M/`.S;OSWVHG(<VGBB&PH0]DT$/.>K.J%>TU"IWKK6'=[R1!5`.S@WOU=N!B)
MEL?UJ:+Q5+N-Q`!9ZB1@\``5,`Y7(>"5()W>C[B/VRX"WQR#=`F!8T-/"_1&
M;2R5U"BBQU;CXFJBJ]U=K]\,/A>(=-`>L#[XSJQ(!6@6S0;DFO)2"RD:4$!U
M0NYT$C3X<+W0G=D$-;Y]<$U$RO`8$"H078XKI_IE]FL=67VXQ,A8@O\`LCLH
M]^_:;UX?9J/8`QY*P42"DM_DFT.IAH.NM0HI[0JD0\X.$TZ,B12"ZP]6,B!%
M1':QS1Z3R4:-%QP02RLJTCEO3B\8*8H#`""6)=CL=>%&0:*KT:%LM>P+TR&>
M0:.]AWG%QKV41\/)-F$;.,W@@A.3>G,'T](67(YYW$AL```ENGT],^L?ZSZQ
M_K"[UK8`:D$HN]QTN+'9[M"*3B3@*CG$BFDT;^$"?<V8TAA3I-,U8[E+W,"X
M0VN`;L*!!XG#GUC_`%GUC_6?6/\`64+A'V"DMJ`X!RUQB36>Q+(@#LM.K#ZQ
M_K'=>20"-I8!;U$W@3.B#`0;$HUJ)>KGUC_6?6/]9]8_UD[EDPQH'4+X4KR_
$_K?_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g575431g63f08.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g575431g63f08.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`)D%D
M;V)E`&3``````0,`%00#!@H-```7LP``;NT``(=(``"<?/_;`(0``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("
M`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"`@(!`@(#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\(`$0@!+0'L`P$1
M``(1`0,1`?_$`/X``0`"`P$!`0$!```````````'"`4&"00#`@H!`0$!````
M`````````````````1```0,#`@4%``(!!`,!````!@0%!P`"`P$($"`4%A<P
M0#4V&!4W4+`Q$A-@$2$C$0`!!`$"`P,##@D&!PL,`P`#`0($!081$@`A$R(4
M!S$5E1`@0$$R(Y/3U#75%C8W,%$S)+26MG<(84)VUK<X4%)S-"6UAG&18G*2
MTD-38\,78*&QP8*R@Z.S1'2$)J88$@$```````````````````"P$P$!``(!
M!`(!`@0'`0$````!$0`A,1`@0$$P4%%A<6!P\(&0D:&QP='Q@+#_V@`,`P$`
M`A$#$0```>_@``!J1MH`````````````!SH)W``````````(<.@8`!#1SR*R
MG1HH`=;BP8`````````````*OEH````"KIS--U(U+ME029R+"6R!"63K^5?+
M0``&ED5'W)^.+9:.7H+8`````````````*ODC'Q,D2<5A,*3@20"$BMQ()K1
MLYHAL!OI+(/.205?+0````'%LD>7JE9ZP````````````"KY%!YS;"Z9"!I)
M98]X-((&)#(Q,>;^:(6/-X`!5\M```"D1S".LQR,+I2T7LNV?L``%?#O$```
M``````5?)*-E/6;,5A(Q+P'L!K!5<W,RA[37B)"4RT@`*OEH`#P'O!&9B"83
MG$3U+`]EHR>@``<H#J^`````````5?(D)B-D)U(0,06&`-<(!/>:H;H>8UHV
M`LN`"KY:`%$CGZ=AB:0`<X"W,O@*16=4@``<H#J^`````````5?+)'^'Z/:0
MD1:6_`-;(?-P,4>\ULC(E\FP`%7RT`.:124_H'!SC*"G6(K@7-EW6RG9/Q8<
M``Y0'5\`````````J^2;+^3T62:56-H+`@&LE9S;B-#<3XF)/46\`!5\M`#D
MB8DZ,DUD;FH$ZG.(MK+]#4K*MEB2UP`*2%>P`"`#L:2B`````"KY:```````
M````J^6@!YB"2?P`#G`='R')9(LT26E=G2H````%`"SY,``````*OEH``:D>
MHV,Q)ECSFLGM/T9\P!C#XF9,^`5?+0`KV<:S^A@%(2EI?PK@=0S036I<&4RL
MZF`````H`6?)@`````!5\E4'[)(*O$)F--3,T6;*OFSF)-A/*:<>`MN67`*O
MEH`5R.$I_3.#5S4"53G$='P#33DY+V5L````%`"SY,``````*OEH````````
M``"KY:`$`E`CKV``<X#H^`8PH9+FK(&.LH```*`%GR8``````5N/````````
M```;&3Z#E^0.=N`<XBDIU"*XG4,`%4)9@*,6=-@```4`)E):`````````-O/
M@1R;(8TR9L1\S-@UL^!M8``,<59+;@T4U\EDYPG1\`$9RQJ1Q9=T```$;E*`
M`````````7&,:4X)K(D)+*LDR$8FRF.,V?@OZ;\`"M1S'.YH`!S@.CX`-4-!
MEKG9"9UA``````````````*(GV)((!,H;,;H0J;J:22N:Z;.:L7H`*TG&(_H
MS!2DYR'3PKB=0P`?`A^7*65C+QGL`````````````!%9A3<#!$3DKFRFBGL,
M@1@3$1Z2T;4`5@.:AW*!'AB26#G"='P`"#Y<\?JSGL=60`````````````:T
M4B.@0``````!7DY+G>X`\YZ#G`='P`"ODNSDA65*+G@`````````````YUG,
M`_I3```````(!.3)WD!SX.<IUK*Y'4,``AN63;(REJ79T8`````````````!
M4$C$Z&```````%<CAB?TM@^)'Y(QS@.CX`!JA'$LQ6<R3J,`````````````
M#CT=-R3@``````"MY2(ZMF2/.#T'.`Z/@``AN69+*1F1*[FY'2$`````````
M```X.'>,YT&J$H$5&GDL$7%[RP(``!5\X6G5XZ*%)3FL=32N1U#``!!,L[6:
M@8F7]V5`.@(```````````*V%)CK8:*?4QY%Y))@3;3-&Q@``%;#CX?T+`T@
M\YOYS@.CX``(<EF.P`4!,,;N:@1.=9P````````#R'\^!_04<8C>B"B:C7#8
M3TG@-U.J(``!7LY#'?T&-/F98YP'1\``$#2Y4`S]F7/R?0_12`Z$@````%8R
MS@``,&<#CLF3T`:R;,``````<[C92]@*&%#CI<5R.H8``````!R1.MA^@```
M`5?+0```XZG30E8````````%7B"SHJ#7S&&YG.`Z/@``````%'BZYZ@````5
M@+/@``````````````^1CS*G.`Z/@``````%"3!2ZE9IQ-!^"L1VI``*N%B2
M@Y74E,U$L,5_);(X-X(L,$2X=.0```````#GX58+Z%<CJ&``````````<FCK
M*``5?+0%<3<#82+R0S23S'Y,(2">4^Q&A;0```````&#,,;J<X#H^```````
M```0D4?,L;V8,T@M>6@*.GZ-H,,1@3R8$Q)\30R;323)ETP````````#G`='
MP````````````"-B20```````````````#F*9L``````````````````%O"8
MP`````````4L+BGN``!54^A:8`$`D%E\@`"HQE2T@`-`*8%K"8@#52I9*Y8<
M`%8R/"[X`````````.=I?PRP``*!&]%PP`4](3.C1E``<WS&'3,`$''/LON3
M\`1><S2[Q:0`%7R-B](````````````````!\S_3]@&&,R``8TR1AS+G^@``
M````````````````````JJ<P2?#4"=2>"HA7<\Y8(E0IV;H32;Z;Z70`````
M`````````````````!K13`UHQAKQ=HH^:P6E*E%IRNA-1]"$BVQ;<```````
M`````````````````````````````````````__:``@!`0`!!0+G:WYF>[_>
MQQ%\=$0UX4B.O"D1UX4B.O"D1UX4B.O"D1UX4B.O"D1UX4B.O"D1UX4B.O"D
M1UX4B.O"D1UX4B.O"D1UX4B.O"D1UX4B.O"D1UX4B.B./`82)N60$*IP#VM2
ML)6H:<G8N:EYY(K5'$32>1"R6,I$;90%O>0]](]&9<^3!'6$_,\+IEF$I<11
M1+I$&LK5)[GE.C8K<L#1(A.K:%+%(9$P9?+)FIR,Q\2I$"R1\K^ZU(OS/*_#
MS*4-WB:._P"%<(JCQU3VVVV6Q%FZDR:Y%'P=Q]Y#WTC(?`N+)Y"`:2&H:X*:
M=Y*PM#@FDR_NH0(-2L:X2(])!T0:CN*W"P?>HT)R.\Z@S%8H(8A2+&XFB^\M
M3F4)J\(+A%S$2[3%J[3%JN#A#)?4B_,^CMYT_P#<RFDJKXS><&?"JP>[A[Z1
MEVPP9FR_ER"J8MO$.C3Q3V!LSR3ZQ4SKHZ2IL")-P(F!"3M'AP5P+V`!81=Q
M6PH%KL.D%A-CC=&+#F4-D'!S*D&Q]`*L?)(OS/-+XX_/BX6S+RT83%!DBBF+
MHS.)!(#6)L$J-PZ`2#I+5L#2U?;X$ERO`DN5X$ERO`DN5X$ERO`DN43,4H16
M=^SA[Z1J=@]N9U(6!BIK>F=[PT[R5A:'![F+(R+D^37-@X/*_.UM6.7\&548
M21C%'1S/T3*289."<V(VDC&'*U4Z)T:$2D7*4.O)(OS/'$J39K^!(&BYAC>8
M]!R&M--+=-OWRMMUC&^3QJSK8=BNW)9&'-N*^_>SA[Z1KM>@O6XSAV.)!4`\
M:A,;X*>P-F>2<?CQO:&OB[M_\LVV12S?PKC%[$ZJ36-EI.M1Q<))\;Q%[$^Y
M]88%*&XZ2C!!R2+\SP-8O;)%+7L%VML!`""[L(,W)M^^5276VEA#B5)EZ(7W
M/(EO-N*^_>SA[Z1U*:NJ35HI3ZZU:;I\IDSRY@=UG%W<K&=LPR0SY\+V6H6%
MY6&[6W$6,]!\N`MD5G#E2J;QE(C:S+1Q(.21?F>$X+1#^:'D;,0K.$]6KESH
M-9<90/)B$[Q13ME4.*NUW2X\!"1)T>1),P>BE&,XG:WQECCEW%??O9P]](U$
M6V[7M!MK$*-^'+1+'>JS.GC8;3O?%Y1*7%KQ1@XX&IY"'EZ4'D>OY`O0Q.T8
MK2&+NYE"*(L+=H'1IV:_<DB_,\)N<`U.5X9VVY)A`#+%YFS42"`R7X%L81XX
M)M--+=-OWRI)KEQN7<O_`'Y9+9798)0>]S/I4.2?Y:$N28X@5RI=X$ERO`DN
M5X$ERO`DN5X$ERI1CV7(U!`A4H7!?J0]](]K(OS/#-FQ)\3*?1JYX>7;]\K1
M'\DXI-5R)8S9,2.!=!0%6>ENC_HJ/?H/J0]](Y,C^Q8G/(\-.)QK5>AT75ER
MXL&+5_8;;U3LU(5/\HW_`,I2QU:V[+J1#]NFI,-Z9FQT;WI#QD7YGA*PPY&<
M=6L4F/UO"?/X)&"/(OT&5,0G>**=LJAQ5VT\LU[I?VXY4XLBY*BCH:U9IS]+
M='_14>_0?4A[Z0C3$-BSIB'^0RIB#5?3<'NEDG+Q0U;%XZ&2?JG7`<NXF+L6
M3,[<D;'N^,L8B6J6(Z`R,T?))_GF]];0R3LB:0@XO+ES1'A@VZ#T;G+#AB?#
MFQBO&1?F>$NYB5/&C:=BR%HX.3(T/%Q$"AY;GTTTMTV_?*\2#X=\:5N3<#Z6
MZ/\`HJ/?H/J0]](]K(OS/"4L;YDCT6E20$6+EV_?*\5B7&M3/PDE-V^/8+1Q
MZ01BSO;%N,]#='_14>_0?450]%BY3X4B.O"D1UX4B.O"D1UX4B.O"D1UX4B.
MO"D1UX4B.O"D1UX4B.O"D1UX4B.O"D1UX4B.O"D1UX4B.O"D1UX4B.O"D1UX
M4B.FF+(X87'A+$A^.I;C'<BSMF#A.&CFZ%F)R89!0)GP\211ME4.*NWD3YDF
M%.PO&+/@*9:D(2FGT-T?]%`)0,X@7NP6KNP6KNP6KNP6KNP6KNP6KNP6KNP6
MKNP6KNP6KNP6KNP6KNP6KNP6KNP6KNP6KNP6KNP6KNP6I*K2+L%[@@QY,Y^$
MIVYW)QU@;\AF(XG!"3,#G2]>B:D+<X)79#P2.[<N7*'QH2Y>96K2H$MD\0_D
MS<'\8'2M&Y`00\8_]JV_?*\CNTMV)NPIM4+2;&H\Q$_H%PFR'`]^3X2K\GPE
M7Y/A*OR?"5?D^$J_)\)5^3X2K\GPE7Y/A*OR?"5?D^$J_)\)5^3X2K\GPE7Y
M/A*OR?"5?D^$J_)\)5^3X2K\GPE06$#<?,;F&#O68XU/M0\\'I!<V_Q,[9%(
M"`E0B5/D;FN?!(`83E)27`4FTMC*3K6\CB605M]L/$Z1X3Q0:YL(JVK&47Y)
MB9%!)&(]E>42?EV_?*\CY\2TY]5+&:0]DDQ=-:=T337[U3,-C&89)W94*D9E
M%O*2?#,SAJE(IMUM8\4Y-%SC@EIFS-C3,BW5JQ3HU9$PW,+IB:6.96@B6K)1
M<497FF!N0+X>D(P.\W&8GI\'8P=,@V##7"8!%S)[[78:D=$F=Y`QQ1MERN2B
MWDR8[,U@S;;8X,MRG&Y2[+N>,2A.HP*\'O%(0)+:P1N")L3:+C[.XZ`@AIH-
M0X*#RS$!A^%QM&V*QBLC4$QHW./0EYUM"!.S5HB4;9C/.*#BIO31B)IWE"R-
M+8IXE#K*&!Y:1R36$HX$(D+EN%R`PEYL_P!JV_?*\K"H3IW)4GNQ$9(%")A0
MG=D3[K_>/+N@8&G;[,%\LLGKRP..1;'#W&I:38N.3+BQ<-OWRO*1-J9%E?TF
M"Q6B<$SAC;9&P*IP]YN%$3$X%]JX2=)-?7E(6<#:/<\8DD@-O"?W!=D9V;(Q
M$`TE<Y!2Q/MERN2BWE+:S)D2S51;<V/3ZSPUAF;WD^.VC+#FUEJN:X4]>76=
M^((T2Y+G!'PR8\>7&L#Q)QQUM^^5Y71IPNN@[@M2O2E+@683$%>7F:_>;S"#
M5(!!3#H+"'KR\VY'>-&,AW.#S*D6)'!-63+BPVY,N+%PV_?*\S/]BJ0XZ8Y5
M7QO"([&*K3:.#:9QXI(LVYKW)1?Y=W64:D-SB3,$P%.%(BE`BQ1>DF,QRN2.
M?C%V2K"PD21X+2&2B51H]E).*\\T,CP1Q8X8%R=#MOPX<8Y4ZLV%Z$<*@<)V
M9*ND3'$^V6]TRV\R:Y0C*:7,R99:G8/^A&B8>CPBRP&3SA[B6I`2QH";2P-4
MT"E+Q<:=7&X;';W)Z&&YY&QZ+`-J'7!E#T61U$&(F;NU1C5R;%C4KP<\P$#R
M+1D[*+0`8X/0R.$ECB*"SOI6W[Y7F6?;.1WAH+<95D*"`4Z*<\2".".@>"`:
M-"6-&=8U[E?9Y\^%+@=5:W=5+V#`G0I5(/*RMF;D<F]W'N$I#4&0=DA8_H66
M069H6M<O.2AP#Y%<EJ%EE#,2PH/&*4DYY7>5X['(-)^UU$JX*EB1!A4+T*32
MMOWRO,]*K4)%WBFKO%-7>*:FTBPN2G,QMV=2J8FU9G5LC>NS*F9O6Z@Y\^KI
MM]-5D5C<A<SDYM[,@/9'+-QY#&\=L,8B_'.RLZIP]67B0XS&,,G#ZZIN$^+P
MQ,/.;0,--B53(B2)]LM[IEM]=^?&>,YLTUTNT](N_L/F.X.D^5Y`#0D9`67V
M1]#H%)BO!M5A5/FX+FEJ=*S#@\IQUM^^5]>7X^2FKMAM_P"&'TC+_P#(\]]?
M?9CL4+D2/AM^^5]><8D>91TL89+[%"A:6Q4Q,0>:\Q2>,,E*1T('Y,!UKF"S
M.T6\LF6:/%-R+1M024RES&RL>`_55(J@]>B[HG]VO"'HMQ,.5P-I`=B"0SK0
M\\H2#@P-Y[)^JT3)9*2ZLA!)R1*I-)@N;O8[F$K`IBDZ6B3T^)5,B)(GVRWN
MF6WVN\%-G6QOREW]ATQRF'/&-*?A*["W%(V\96&4@]X;+C(4MUQEL99EF<T$
M!PU2G(,XK%<M#5K[I(@'K:\2`/-8U;(`KBO*YE%!19[!<V-KG;E&QW/CK;]\
MK[4]9G9W'Q4-W$HG8I$MP#Z_6CTT*P"-!B<&LGN#=Q"TJ+?_`+(M:0@WXT[9
M!K.@<A2)&T1%$,*LZ-0BVUC25$RQ4S-*A1#K7D?&Z$6=!@9821,^5WA5<UI$
M,6(;Q`JB=<J8[H/&;<WL]OWRONT8LW)7[_`V1O-`4^='NOKH]U]='NOKH]U]
M='NOKH]U]='NOKH]U]='NOKH]U]='NOKH]U]='NOKH]U]='NOKH]U]='NOKH
M]U]='NOKH]U]='NOKH]U]='NOKH]U]='NOKH]U]='NOKH]U]='NOKH]U]='N
MOKH]U]='NOKH]U]='NOKH]U]='NOKH]U]`^,\Q,WM#67<PNYIE.%8FYF63,S
MX0@LB.!00\D@EC^(-)?/#0+@O+Y.7(3^/9"7GVO(4D:`2'[)YN4#P`7XCT/X
MOCRA'67'+RU.'!)NL)7/DDH[>(^:2N67\1;O:'49F3F]H$>)N0\R46EM$=1,
M(E@C@Y):%3<R32'"A&;L:+#G3(N2^*B)UD.*X>(!`AY#D+[U38X.-T8W&`P\
M!P/Q-AWNX/QP(5+FT"%G]`0\DCA;L=*#80D4@.?\'==;9;;=;?;QU<6^U?RY
M5B1/FI>X(&I)_O\`X^6`1I,&&/!!B_/#=+3ZR-^FX24\@\53NHP9HADBZ26`
M65YGV3=MI8YB3G%[V3O\XJ=P!\M9GZ:2?.9R!-Y\10E+CF>Z&+?/I"C%6ER(
M)8C3;T2*BF'_`/'/**]S9QZ)WAG@-CAE[:R?'"3[8./L%/\`_P`H_8WAB915
MJS,TR$FVYY>XHLBB]`>Z0/*#8/HHDSM4I*-NS\HBAPC@_*GYNC$Q'WI"&N<.
M#T%"BH+BC_QG_]H`"`$"``$%`O\`1-/_V@`(`0,``04"_P!$T__:``@!`@(&
M/P(33__:``@!`P(&/P(33__:``@!`0$&/P+U]D.HLX5D^FL9%1:LAG8=U?:1
M%TDP):,5>C*`ONF+S3V<>XO<*QRVM9F7^(O>K"?519,N1W?Q#RB*#JF(Q7OZ
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M0XHM@K8<8LCNXY9`'?%9(<-$>\6PR-UVO:O/C^&3%KJQM3TV6XU?V61HRVLH
M<F\FT6*0I5;'G64.3'L#MZ\PDE6=7WQP$<NNWC)8.29#D#HN">$^87>)3FY!
M:0#DG5F89;7P,L++BS(SK255Q:8$892J0348NO-SM?#B\Q_`I.>WE]CU'*R`
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M08T31;T-N=P3ZOO`:<V'C72ZL27:QYGFCPMP.22%,Z3Y98Y3V4N6+WH8$<X!
M-YAO$N](<V_QY<9/E65T+`]*.!\:NJ:*);55PZV[^K2),FD?'158@GHFB:O3
M7C*#8I>;+B?XJYS,L2U-M4C.6%38<4&.(]T@4EQ8A@0(@Q[7;=ZZ>ZT1OA?8
MU64$GGP[%KZ[O8D"]CE9?&ICX".?760H$L<"?9V5(2S2(QW)TA54:<EXMRV>
M4]P'DU_66]O;&#-S%,4;<XG*OTJ*BCCG-MC1K@H:Q[F-4(5'M7WQZ/2I<6WQ
MRE>ZO\(VV\!(D>;ML<YM+&IRL@93K/\`-V8J$+)3Q+U>DNU"N1FN[&\E9EK+
M"^J/#`C;D-Y7$61-M1972BEX^=#R8A7S6#ZBK):CR%:Q7-Y:KP^':6]7)+CO
MB]@1,=EPXI:ZL973,IL:BQ"&3:#A39<^-BQG]\5&DCMW[AF>PJ,;QX1_O/'^
MP.?>N?4W]>&SKB$85\4ZD0;GBUV*O2>-W+7\?`L?;BT$53'L5MHL:.69'?$L
M71APW2H<L$D<V(]\031NZ9&HYG)4XJ8DW$ZLD:C@^;*P`V%BB#6;VE=7$;%*
M%)E>0K-[@FZ@WO[2HJJO#6,:UC&-1K&-1&M:UJ:-:UJ<D:B<>/4"(YW?:SQ2
MRRXDHFK%'"D6DX`2L)R1SU)`)V6]KE_+QBF%CH+PJ9A8"!2MQVHAK4U:RY8&
M2)-FWO<)\"-U)W7*X8B:-:1ZIKY?9B?TO\2_[2LMX>(N:8F,HWN&09,CIV$&
M1B[7L>QTQ'->UR:*B^3C[<8A^LM-\MX#"@9;C,V9(?TX\2)?54F2<GEV!`&4
M\I'\O(B>ID-.^I*6XJ;;#*VJ@),:QV0"S:0"%7SXSW1_S<$68V8T_)^QL)[M
M>?!ZZ9!C!QB1E=GA=3D'7<+2\H<?;;V;)W4W`Z!YH9D0*HX:M-!<B[M[=*C)
M.XEK1747O\2*8G5+YO.1[JZ2]W3%HLZ!TS[=.QU-NJZ:KZEK=S:(62C@+!Z=
M*;NZ-FR9=C%KXS$?*#("-R&EHNY6KIQ+/(QBMB`&M$R`,&+NN;:S/<X\F0GC
M!H::EF6R2*>.TC92(-_1Z3E?M1.)V.T^,0I2Q*&@R(-NW$?]!SZ_(A2CPW1K
M7S9W)'=&.GNWMZCE>P>YX)#1-*]E$@G29<;J_4NP4;/-Y`@GRS$2@5@*N#(D
M-$:8_;$$75CB(]%1+FOEUU5%G472[]%DX1/CF+U[(5/'\T,+0L7(.\VAQ@%W
M#O/4(1J-UW)K9T)\4I*OO*XRM?8GPV3%=9S[R)-:.+=*>@`RCGB2L0`1SGB*
M56[&IJS3@IXD>EE(.5`B#%&PFP/,GDM>^K6EIH`J!TV\A36ULAPY$,9X[F@>
MN_1J\4F3+B&.P_/$5TGNS*N`9HD0Y1(B$="$YVJ#U]RGEX^S6/\`H:N^3\?9
MK'_0U=\GX`1^*XV]\8R2(SW4=8Y\<Z,>-#@<L741D&5S=S=%T<J>WZGA'^\\
M?[`Y]^"_B23\>6V"?[^4Y5Q@$,3J@-3E&6QZ[)IMHTNV!2B/!#+E@.TX!1N@
M&<\BO?N1.GY-->`R8Q1R(\@0SQSA>T@C!,Q""*(C55KQD8Y%14Y*GLQ/Z7^)
M?]I66\$,_!1HXI'D<@L@RL`D<]RN5!@!>C"$>J\FL:C6IR1-./L-_P#V;,/Z
MP<5U]2X<V):U,H<VOE.O<FEI'E"YB-W>;=2(I'#7FF]CDU]2DS,G6;?X[%E@
MK%ZG^CBO,"6*(2TAHU'3?-KYYG@[;-CBN7RZ:5_A_<RYLAD?NLV7=5[VU]D6
M_;.\[6%S%(K)"136%F4SG)V_>S.;JOEXCPX@F@BQ`"C1@L]P$`!M$$3/^",;
M41/5D4MDITAR2P3$6,1HC;J^?&L0;7N81$3O$1N[ES;KQ8VM9*OJ2SL+^1D;
M9U58C$6NG38$BOL!5K#Q9,<$&>&65Q!.8_0C]S-FC=`V%$LZ`,6,TV*+6-DH
M6N-78^Z6M.8S#C)*=.AMGF;U$*B/0B[T<[GQ2"*V=NHF6P(QW^:YA#Q+JU=<
MS8DD=E5SHNSOKU49!C&<;55$)S76YM1$NPS[F6^>Z4&<`<B!/7)HN7@FPI"0
MN\/E0KZ(T@G272-&>]KN&C6H^7-EW5C*-88O9RI$Z8$Q)<O$UF.KG'TB,:HS
M+.?UF-1K531&;$33@46J/<P%A6%98U,R(6LCV%0>IC6<&,D:8&J8::Q\&X.$
MBS>]O>QWNM4UXKL?J^\>;ZP+@1>]&61(Z;BD+[Z=41Q7;B+S7G^/UOA'^\\?
M[`Y]Z_"I$>DDY7B-7)OR9=BT6^BT#[!9-6P=%8DD3;"JBGC4TMA'N8IT5.HC
MT:Y6\20YK86CTQ;P%OLFQ=Q;B:-\>6'*LKC5V4CD"./O=A#K*N",4AVJ(Q/)
MVU3C#LBKL5D9OE<W',4/84R6L>D.:3/J8AK.6^9+!*&QP3N55;MU77CQ6R^J
MSZW\)K4_B'?P;R@KHBW#V2N^FLR0I5C&N:84OS;(L2!_);7[5<GNM.`8]*O(
M-5+C\HMD?'9%O.85KXYY)X+A7U5&A=X%"V$:]IMS7\M-.,Y\/`^.61TC,-QJ
MFFFR-`2V1Y%?YNI#1X7FQ<E!'K(M<"TVHJ'<W06NB;N2.;_$SESFN1'-<VFF
M*US5YHJ*F9Z*BIQ_>7R_T+-_KGQ_>7R_T+-_KGQ_>7R_T+-_KGQ_>7R_T+-_
MKGQ_>7R_T+-_KGQ_>7R_T+-_KGQX/1[#QHRG,(&79[3U<V#(',K`=T%<4K)(
M3M=>6K989@9RL<U4;R_'K[$3^E_B7_:5EO"QES+%4D(7HJ!<AJ$,AD=L42B[
MWO0J/Y;=-=>!)=WE/3]?=T/.MG"K^ML]UTN]F%U-NO/3A\BEMJRWCC)TB'JY
MT6>$9=$=TWDBE*QI-JZZ+ST]3(:=]24MQ4VV&5M5`28UCL@%FT@$*OGQGNC_
M`)N"+,;,:?D_8V$]VO/B<I(5#YE=FTC"*BTN<A'C,'OM-CA[?()EI;2P38@0
M#M8Y*X#48USI`E15[2<`*Y!M<4(R.01>N)%>Q'*@SHUB&&BKR=HFY.?JS["+
M7'MCQ([S#KXQHD8LE6_S>O./'C"8Q.T]5=JC$7:USM&KX=`6LKX`<_QJDR1D
MFYR(58."VX=`1*F'OK2LN+=C9VHQ(X'7V:)IKP>#YF/91ZFHK,@R28.:",ZJ
MIK>Y/2PCQ(I!O=:R>O"D$>)'"VC#R<KG-:M_7VJAAT.-8WCEQ:VZLEG,.?E-
MY9U%5";&BA,1PM*ISGN1JZ*1OD1'<"*EN4?5E2H/0DT]Y#F@FP3]WE1)L"76
MAG5\D)535AQC=M5'>Y5%X.!*8]J&IQXF69'('-!$6KQX4YL%9$4!1D=:3E<T
MST`BB38%>WN5K5/9'QF4R#)KBW6/2ELX_0GTL;*JW$YEI=.9&>['HL.1<1Y)
M.4K;$<YWNF.9Q0QG525\/(\'/EU>KY'7D(^OO`55@)7L:T)H)`V<,T8J(USV
M$55:GD3UGA'^\\?[`Y]ZQXPR`%(+\HP1AO>/1=O;:URJWG^/U8HLFI(%T.$\
MKXK9H]_2[PUK)#$5%:JAD-8B$8NK'[4U1=$XK$NL5H[!M,!L2L8>O!LAPF;-
MD`0V-:SS>WIM]X5%#R]SPB(B(B)HB)R1$3R(B>TB<>.W[[\T_2&\/<3=(2*X
MGN$1BO4P%3R*YVU&]7_S<>(=I#@P075C4P62RB#%2WE18%Q`5$DF$U)<B/&C
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ML>02LE@4UQK'5QJNJGS2,CL$HGMCN43G.8JIQE!X5H&`#*<>Q&HEM5I^N*9B
M64R[R-."82]CJP;(P>7-KVL=^/A>]1YUO+)8S;:39V=E+6=+L+`K"R)$A83X
M49?R3&-:T36,8Q$1.'R+&QR$SY3;&)9-\Z=BVH[&W6Z7&IZ.CN5:.')<HX[!
M],HXZJ/J;7.U[$O(!+%()]`K+(:_59@KP61I'HF%B$$V,ZVCB(K)22>06-]R
MQJ)73Z^0OFFGQ6UHH,8ZN+/)/R/)DR7(K&6?1@-)DJ*!6L8QK6.WHU&LVIZW
MPC_>>/\`8'/O5F0<F\1<B=7CK(4^-X<TEE%IHX(!-T)UE9C$AIMM'F6$4VTK
MFLZ;O>T7ES/CR'S.BM:B<"!.R>DE9"6#16ANFQ@9=T0$^NB26/D,1Z[%8)SM
M'*FBZ%IK3+K;,FCGF+66-X,7G6)5N!&8"LF3!N5UH0!Q$?WAZ->Y"[=-&IZW
MQV_??FGZ0WB=N5$U%M35=-7*R-HB?C5>"3XTR/"DFKYD>LD&$22P-BL$P(QC
M@:Q4>`,@S7.37FB<5TNY\9L*?4I/@I+8^@J!ME1R21-?&&]N+07.+):NQB-,
M-SG*B(Y/+Z_^'#]Y\'_7.+>Q$_I?XE_VE9;Q_G`/A6?\[C_.`?"C_P"=QHAP
MJJ\D1"LU5?\`?]25A<:DN9,JO#`/8VS"XZ&JA,LXTJ5$W#F7\:]EJYD-R.[M
M"-L7371.?%1!!BUS()?^=9U4:#/QWNJXU!R)V/P[^6^ZN*$S?.?8DMC1ARS(
M%Z:;UY>LFVA(TZ:R$!QEBUL99<X^G)!QP(K$5[E7RN<UC$[3W-:BJGA[(977
MW=_$D,$M+(6"#N\%;&BE9%%!<R.^=`$I\"&3L`=(5'-_Q>UQC-+*A6Q2Y59$
MJH,V+$:^MBS&5UA9M'/F%.%!N-&JS;6C0I.SS:C>?%K2V#X\"#1X]3WMM>S)
MHH\&$Z^MI]350#]1J,&22^L*_<XC=$V\NUKQ&E,S#&>A-><<0K[RM&V22,=T
M60P'4DM4CPR6JQR)Y'<N.[3H5O-Z%4^^N)%8*"0&/T`Y@X+KFU[W80CNB==Z
M]B*R3(5HGNZ>C57B9.)49(L9@12Z<B"HALR>`3*ZW#'V%*61?A`"''NK>/O6
MP=!=T2H5$5G/B#1%J)5:2RQ/ZU0W2IE;)*HPVC*V="?YHE65<]\3OD4G4!+.
M-R2$\FG/UGA'^\\?[`Y]ZM/#2GS^5XE0JU;>CO?#"@=;Y'C=6LH\<,JU3O$0
M$S'Y,X96.BE4C7^^:(Q7;N(__B3E&88_CWB'.9;BETEL^M\+?$:>YXF2@VD0
MT/O&)9#--#1L^$4J#(4;^@1C>DGJ^&5)5Q%R2?8W5[(^H)IYZ>KRF#6TJDF2
M;*W%*C,AICZF&4*.ZF\Q$["HB\6%?D-S=S1X3X$7EW4+.GSJ\]3E43),FCV-
MF!63S+(D8U)K@P8LAQ"IW<#=?=N3C#KVCQIN8YA-QS%),^IE6T2CZIYU3$-:
MRB39[V@801WJNU5U55X\895Q`;56TGQ=R:1:5;9(IC:VQ,@"38#9@%4,IL.2
MYP^HSLOVZIRXK#-5ZNERXI"(Y4T16'$--FC45$T3V]>&29O>5'%?R;&<-KG=
M9S&<^HUW+E_)Q(IZV1*A6%+)\\T$-)<.(MC<UM5/CP:TIYKW,6,5;'FN]B[T
M;VDXP^KR5AQ7L.G".S'*DMER&25>1ZM-(84[2D1KDU[:^N_AP_>?!_USBWL1
M/Z7^)?\`:5EO"NZTWFJK^4![?_ZW'Y>=\(#Y-P,K33%<(C"-U(#35CD<FND=
M%TU3U,VR"C6L3,,FI(E-4V=K%9__`!OI09U4>97S@QI$\120K(CMK=&O>QK7
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M'^P.?>JV5F^-^*M$&!6!@Q?$7`Y!Q5L^K-^>FJ;<\8K>@.).,30;F.>JZNUT
M7B)@<&)99!0CB,K08RW&+&>64SM%U5+)@&'END>^*3J=3K+O1=>?!KJ;B=[A
MXUL#1ZZ!D8V1[697C!%>.T-";JZ"TYRD8T;E<N@MVJM<GJ1HV34D&X%"/WF'
MWL6XD0ZMV.)&.Q6'`Y[.3MKDW)Y>*B',PW'CQ*(*QJF.M;':&'%<3K/BL8QK
M6OBE/VWC?N8]_:5%7GPB(B(B)HB)R1$3R(B>TB<>.W[[\T_2&\5<D8"&[OM*
MK6([GTSM?MW(UVW=IP&+)J-&R"C'[\;<WM/:W=L?$1';57BV9BYXE7;-KY[8
M$ERK&0,Z2%H8IT<&.;:X9=%W;>SQE-5XD09%I$QZLB)CUNR,@OK!*%WOKL#9
MR$`2T*=K6)U%8B(J=I=5YERE*3S!T[B;5=Q\Y>=->Z!B&[QWGN%=IU.]:;=G
M+3RKZW$9%?EQL/GXC92;2%.CU*V9^]E6"^,8#FVU4Z(:&:"CVN17<_Q:<?WE
M\O\`0LW^N?']Y?+_`$+-_KGQ_>7R_P!"S?ZY\?WE\O\`0LW^N?']Y?+_`$+-
M_KGQ>9K_`/Z#R^Z\R^;/]&]SFUW>?.-Q7U/^>?6>=T>CW[J?DG;MNG+75,0F
MS#$DRY>+T$J5(,Y7E/(D540IC%>O-Y"D<JJOMJOX5/Z7^)?]I66^QO"/]YX_
MV!S[U2R)!1@``;S&,9[1B"(;5>0I2/5&#&-B:JJ\D3BSLJ3)L6)%K946!9V0
M)D&/$#*L3=*"`D]ZB`1TZ0FT6CW=5_N=5]=X[?OOS3](;ZE)_E_^_C\'BH_I
MJ9&IO5-VFCVN\FJ:^YXBM':/A!A1U:9_OB->Y7;W$781NB;G<O+QDO@K4W%G
M?76.%^M%C:R*H%=6G#=@K%%'@=.QG%>^%'+'0N]&;GN56\M4;^"SG_9G]L,?
MXP?^B&-?ZFA?A4_I?XE_VE9;ZT=(6ZJ1W)D1P:@EC#99E:K'$11P'&24]%&Q
M7<F^1.`TY;2N';21J:/5DFQF6)Q-1ZN*&$XB22C1!NYHU4Y+ZC*M9L1+(D0D
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M.Y6!)7BZ^^:,STT:HT<CE\G`;*KEBFP9'50,D*JHWJ`Q(YF\T14<(XG,<B\T
M<U4]9X1_O/'^P.?>KEV,4YF@L[:H*"$KR=)A3C(.0V(0OD&*;T>BY5Y(U_/E
MQG&"U?@F7!HF?$P>%)F]4,;&L5%BG0[]8Q21X@@63I)0]4?3(I$7_K7>7U)M
MU8P9%A=16/J,1C1K*T@D-D61$C08(VBKI\))NV0QAE:_=H,3M/*NMSAF2VME
M*9X??P\NR*HD.MYX=F5OEW!+;+8Y$.QY)D:PBL8%[]R!'HS3FNN'7M'C3<QS
M";CF*29]3*MHE'U3SJF(:UE$FSWM`P@CO5=JKJJKQXPRKB`VJMI/B[DTBTJV
MR13&UMB9`$FP&S`*H938<ESA]1G9?MU3EZD9[)*1UCH_1=BN75RL5%14>W;M
MV\?/9_\`Y_RC@YR6QCL&U-PEZVCT5[6Z+N,Y/;XS')YUU0B9E^.5T*AIW6+!
MWTXE?%JDL7AK3-&0X8+:=SB.$I$:TC573GI^"SG_`&9_;#'^,'_HAC7^IH7X
M5/Z7^)?]I66\#?*EB?$1[MXT5NY6[7;4_(-\BZ>WQU.]B[CWS?TM6[NZ=;7I
M_D-=>CR\O"D%+$D'KL=TM6[NAJW<W\@JZJFOM^ID^7'FRHM5*A8X"#""RA-%
MMB0JZUBRUG.DU<N]A+`+*8X?=I,1".]WU&ZIQXGOJ<7K+ZPRZS)>X[E9KIE9
M(K$;C4.IC4\AX30K^(>O/">V*Z(8;=LE54P.:\8M'OK?(1!J[3-YLQ!9;+[R
M>,9U;,PR%9R4NK*=91P2@O:X994G1FHWD>)Z[\>#5WM\^R^I%.'*B3,KDR9T
MG(2W='-R2'6S%MH;XQG0P'8`P9$9J#38TX]^[@+9>0YMUH6%DB1>XY2.#.+D
M!\FN%;WX;;XT:=)A8M.&)"EFN5^QKN\=X8,PPU>28^"\O?-'0F42V/G8<F4A
M_P`WW6.464Y3ECIL,KI$R0YCV:(4BHU[O"#';3`W=SQ&NQ-V23HMGB[[8EGA
MG=@U$"/*+9C4-(Z6!TTKQ*0SQJ@4:Q7D7BMM`54VEF2EIJNUE.L\9FU<2EQ;
M.I-Y`E-ZT`]X*TEQ$[R-(3A:O,,9GMZ.J^(\NI2U98V.$^%R4,VK?*C':RMS
MV^!=U\>>!CG1R*RX$XB)JG2+JJ*F[AB^?I]1'9=W$B'5VN6W%K9PZ0\P9*Z#
M/M@K8K9G&QI'(I)!E&PC1[U1O%N4..Q=EWBUM@\(QK:O<3''MR59,+,.VU'H
M&QKD')Z4;=+"6.-BIKVVMZE(HRTF-6^.NG5$_%GV&53+7-ZS(PY!"'D%?8U3
M#P(]8XFEF%'H>4_9HJ=5?#;S?7^;+ZEB5]7>V(K&DFXR/&QY3;6LZNFP)X)5
MU*O2ULI%ZT)1![X7LN8-G$HSPEC`L<R\0;6MC&&\)`U5IG.03:_WEZ-433QC
M(5J?XI$]9X1_O/'^P.?>KF9\/62F1"I)!*]T+?WYFU6+,)!Z7OO?AP.JH=G;
MZB)MYZ<>(F)^&N19I:9#EL[PY7!>\.NG9%(O(Q!2+\DR:T,<<?9+WL,B.V%:
MNC=S.?JUS[6MA6+JBQ!;U:S(XY'<+2*CTC6$7J([HS(_4781.TW7EQ#DY+CE
M3=2(".9%-/B#,08GO0CXZN7F6*\C451/W#5?:X1$1$1$T1$Y(B)Y$1/:1./'
M;]]^:?I#?63?^(S_`.L/CP4G0X<T\45;?EG3&">^)%=W6U8K"G8-!`[&WDYV
MJJ]/QI^#SG_9G]L,?XP?^B&-?ZFA?A4_I?XE_P!I66^QO"/]YX_V!S[U<L;C
M1;H-_P":B/J7X\FZX[\-XR!;#;N8YRD<W:]$5'*-7:<^*EME_#EE+KWN\.%;
M9$`+@EF&VC!)L#&/3$F+U].H_J&>NOE<OE]=X[?OOS3](;ZPL4JO:,J(CE&J
M(_DY'<E<UR>5OXN%Q:1:75$DFQCG;;4$QL.Q'W5I_P`U5[@%0D60KTWMY=IK
M5]KA+^/G6=7CDAR(BUMU;#/6D[QM]]/'''9U7ATU9SY.Y\>+5<:?DUI1,I(=
MA"EW<B7*C=>\)2VK@QS.:R'MCF-(`':FJ#`K>:M=^!SG_9G]L,?XP?\`HAC7
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MGN$9@T>Q7"(K?]Q?5P>VM%R4^,.Q+(`S:^C%(F!-/-+"V*4\'O`(A2"V^Z=V
MFIY.+N#E8?$"TFVV<7LZF,:L-8MB4-G*#YH@]23/WQ11&Z^\L11B3DWU?"?$
MP1Z>?4WLO,IEC5Y'/FU^.V4NBI8DFL!</@1Y1I<<39$@S(RMV%*-N[DWBUDV
MU)'H*3'_```M[S$,?9)<M?07-?D625<[(:)_83O`Y=0'NIFHCF`5C43FNN'7
M%)C/UPS&3C>)EL*B9;1*1Q)$JIB$M9)9U@]H6E"=556JNKEX\895Q`;56TGQ
M=R:1:5;9(IC:VQ,@"38#9@%4,IL.2YP^HSLOVZIR];9*]VRPZ@U@O:A4(U4(
MO45A!IH-=OXU3B)",0I)KF&5SG[G[D:0JIJ5RJJKTV\4>%S\:JG8/F-O45.,
MW+W$'8&_-:A;^0BBFE0BPY]KTT:0(N2-TUYJOX#.?]F?VPQ_C"Q%R*B$46)X
MX,@R6T!A!D93PVO8]CI".:]KDT5%\G'VEQ_TS7?*./M+C_IFN^4<?:7'_3-=
M\HX^TN/^F:[Y1Q]I<?\`3-=\HX^TN/\`IFN^4<?:7'_3-=\HX^TN/^F:[Y1Q
M]I<?],UWRCC[2X_Z9KOE''VEQ_TS7?*./M+C_IFN^4<?:7'_`$S7?*./M+C_
M`*9KOE''VEQ_TS7?*./M+C_IFN^4<?:7'_3-=\HX^TN/^F:[Y1Q]I<?],UWR
MCADJ#*CS(Q-VR1%,.0!^QRL?L*)SV.VO:J+SY+P0))T-A@J)"B?)"T@E.US@
MH1BO1S%,UBJW7W2)RXCVY<JHVU<R;)KHE@EC'?#E3H?5[U&C2!O<(Y8_0?NV
MJNFU?Q<"M;R[JZBN.K$!,L9H(@#*03CM03SO9U'=!CB:)Y&-5R\D5>`U1,GH
M664B#YR!"=;04D%K^ZDG=\8Q3:K&6$!YD=Y%"QS_`'**O%;YMMX,]+=M@^M6
M$=LILL=2;N]F0;@[V].!)T$5RZ(PJHQ>TJ)Q,L[&2&%7U\8TR;,D/08(L6,-
MQ3G,1W)@Q#:JJO$6R@N(^),$T\=Y8TF(1PW>Y<Z-,$"2+7\3V-7U;6MB2F'F
MT9XL:U`UI-84B9"!8Q@D<YB#4A(,D9-&JNC7IKY>&@/8Q6G=91*?HM*A2LM)
MP&R8<(PQ;W@/(C/0C4?M][5'>1?7R)TZ2"'"B!)(E2Y16`C1HX6J\ISF*K1B
M$-B:JY5T1.&`'X@8^\I"-$QK3E7<1SMC41W1VKJY?+KIZK:_):.JOH0S-D#C
M6L&/-$([45K3A0[']$VQRMW-T7:JIY%7BJ#:XAC=@&C8T=.&72UQ@U@6;=H(
M0GQU''C)L3WMJ(SDG+EQHG'CM^^_-/TAOK9AAQ!,*T2N:]$75':IS\O$>[`9
MS9"]4#6Z-VLWF.+>BKKS1./!FLO<7CW]MEME)!271APG&QJ:T%0`\Z.IXY"M
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ME#*(!3-D$71@]K--R<6$H]G`-CLVO,XD=CGRI+[.3(CS^D`T^*:X#$B6,JP>
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MOK<TI(<*;8S)]*8<*%7/&R6>8,@CQ&CZO8<U)`FJ]G+>Q%;JFO%+"E_P:43Y
M,4<"-(N$9CS'N*%!#)8Z2<6ERFOW)U.W)>_7RO7R^N\=OWWYI^D-];._R"_^
ME.$A0V!/,C[NH.2S43$-(.YA$WHHW/:BZIY>,:FY'>7M";#32ST<C'35D0W5
MG/KG%<AF1BE`X/FH735NU6ZKQX`SH%G>)'MKLU9/JH\N0E0@J>QK)W>5AAT9
MWF4"T+UW/U1P8S/(C%]G9=!OH<WZJ5<X];77D8$+ND:7C^"+FF1BD;IK;*47
MIHX3=@%&AD8/75_$Z+=XYD-$6O\`.(3LFNI9#UL:_&0Y7YI$VKM9Z%LI-7)&
MC!(N[KNZ:Z.XF8S!H<@&2M9-%96I8\5]3"M:Q\<-C4GE1Y9E;(CRS/`CE1&E
M-'*C-6LW+EPI$&9'/WS*289=>;8,RLEUM;FE7@59M@-NX,Z88MQ:">WK.BI(
M3>C7:,YWWU?I;3SBF-V-CB]S*%6%K;B0._@X=7205T>TD6+!V.16+>ZL.,?>
M!-W)RUX@4'U9RN1D);*16V-9%BU<N16)$O28Z6?(=!LY$<X'3HYG?F[BHT<8
MRJJ(/M75H:#8U<2`F4K42[!@7Q\B#B+[1EK/@)!/)*"O'YMW-?)2/U&N[&NB
M\8[#OHDVGR:.VHE95WFMK94>37?46US:VE1&P;YC:EA(M2YK>KN.!2"WQ_?.
MR=78KDX;0+1R?,9G4`YOFOZK@S"39G.2[9`AAA4TABD&4K#(4HV;-S^423?P
MI5Y:3/JS5)4TE=7P7`O9N!$\0KU[[&;>#AG@5M5*`PRJR/W9S%_*[N6-QZNA
MOB1,EDPJ^-:$\TCCQ[63BHLRDUYXWG1;)SJJD*G>3#"^.PZ*+?NXS5IAM^J&
M$GKJM[(F+6LZRO[VQKZE1U4#)G7L&@K[+SQD,,`XI8Q'EU7M,1=[9%/<X[>U
M%U%=2./5&=52SI"MVY#)/9L+6V,V*2OJ*S&)4J21']D>UOY1VSBS7(8%5$BQ
M:7'+#;&J;2BGPK.^#)GK6/BVMM:%MH`:SH/'8L9%"=[W-&QVURIZN:76-J1M
MU7TI30S"&A2144@AR9HV*CF[X,-Y#(JHJ)LUXIL^P'QYR/+?$0DNC>[&9>41
MK@>2&G3(XK&MGXZQGG6&/IE>[\[<3FS1/?%8Y/4Q*7`C8Y:@QR5>VMECV2WD
MZBBW44E(>&QK)<&#.5'091V'U)L&U6MW.1%UXM;";2K18]3?P_VF1X902IA2
MLQ^WBW^1U\Z^K3O0:EL8\RK$T,I&M?TMG93<NN'6F/TD7(\TDXWB9K"ON)[:
MQA#R:F(2V.:24C-#C.Y5TUYKQXPGNH@8%P;Q=R8MM`CF20"%9$0#YT0$A%<A
MPQI2N8U^J[D37UKAE8T@WIHYCDU:Y/Q*G%RQJ(UK2[6M3R(U#'1$3^1$XLQR
MWE;U";HHSD75S.J==0L>[7;L3VO:X\+Z\K*AF/Y?:6\;([*S[TA*N!7K2C;*
MAE`=@A*-;57DZ@RHK6:)IKKP"5%,*1&DA'(CR`/:4)P&8A!&$1BJP@BC<BM5
M.2I[-D),H*^4DLUS(DMD"ZK#FR&,V'<D*QZJU[Y\1B#?K_,Y)HG$(`,7JF!K
M[Y,HALZ&Y`Y"@1`\\=MSE?/Z06]MVJKM1?+Q8VU951(-A;E*:QD1VJQ9)I!>
M\22J/=TF%ER/?#.:UJE)VGZKSXB-\P0-L%L5D5%8]4"V%=-R*,B(KUUV7@VR
M>>NXJ(JZ\6L\C7W![0M2_;,AU$*+#91W,C(:UL:'2UU9'W#N9'7<YZ.U<,:(
MC6,1O$:W%C]>.SB'ER0S6,<DCKSK*7<R"&>C_P`Z5;6>:0WJ[^F4CG-T5>"X
MRVLC)0'BRH)JO:O=2Q)O569'(U7:O')Z[]^J]K<NO"UX\7JV1',M!O$T3DZC
M+J$.LM$*]']0O>ZT38Z[E54`U!IHWEP=UIC-5.=*EDG'=(C[W$DEJXU(1SG:
M[MCJJ$$.SW&T3>6K47AZLHH+%(^Q([8Q[=26U9&I;`G9>FCY-5#''54YH)B(
MFG"YG&<7O(`'!5UHX5/#KZQ)4&%6G(QT&MCSY1NX0&"8I3.T8J[M[M');54B
MGAFK[V<2SMHI![F3K`I`&6:;5=W>FEBC<QZ*CAJ-JMTVIQ=6_F\)O/.,P\06
M&\(4CP:&/YP67#AD&QDIJ6[[%72G*17$5C?Q<2ID"""))FQJZ))(%%;U8U2(
MH*T.S7IM9$"9S6Z(G)?66T+&<1H[6B9B!)=78V-F(+IF6]]024LJ*LT)6P70
M%5ZOV-9K_P!+_-XK[,7@-X*4]S(F=6,<-G`#,&J.1TB14Q%R!S0R`CU74`M6
M^K'CY/C]/?AB$<:*.VKXTY(Q'HB/>#O`WJ)2(U$=MTW(G/BK%:XCC=B*D:@Z
M@4NEKSBK1-VZ`A"?'5D>/V$][:B,Y)RY<:)QX[?OOS3](;ZZYZYPAWR%1G5*
MP>Y4.?DW>J;EY\0YQB@&!S'"&A"HTCW=`@MHV+S7WPR?[_$/ZTXY3Y!YN[QW
M'SK!#,[IWOH=YZ'6:[I]?NP]VGEV)QG-3'>0-3"\+:L42N$YS*^*R.3#6QA@
MB-5(X6A88B,1$3:CG:>5?9ME=VLAL6MJ84FPFR'^04:*)QBN_P"$[:WDGE<O
M+C(CSVBCVU/D,U.Z,V;QT-F8TRAW[=-RQQ=2+NT[?=MR\W+[`S#':B4*'8VE
M,<,8QR]`"JQS#OC'/Y`@F"$X+W+V6M?SY<7.3Y/64M#XGV1<0J/"/%X&8U(O
MJE4T$R*Z5:P'>=F1)P%"QY4&)3D]UHQ'.Y>JSJD&/J$:(?4>UG4*_P!P-FY4
MW$=IR1.?J>.W[[\T_2&^NBF`CT?*DE<7<[<FNYCN2>US?Q"L221@Z1!J1KU(
MYY$&1BMZ0F([R(G/AQ(KU>QC]CE5CF=K1'>1R)[2\9'X;NHZ^*2KQ"%;MR+K
M,2PGD>:I7S:YB@:J@1EPBL3J+HHG+_.[/LR;5UUO78[AM772[_))1$DS+>Z?
M5!+.!61H`6A`RO!W?J/<0Z.(;9V4:/5X_%#%Y$&96>=YV+9%BT@W=)EI2LCU
MDM\VMDDW073XLN2CA#.Z-S`J=7:1?8&5XM52AP[&YJB1X9C.>P*F:01VQSO8
MCGLCR^ETGKH[1CUY+Y.,TRVU;B)/$5\W#J##H&.91"+`\-H-).C:RDE!GE&`
MYVB>]H-2%5=4:B*]4;ZE?BZ5622,>N`VUAE5G0T-U<L%7T<1)4&DD$IXLA8+
M+VV<%#$(K&)#"9->UP@<MCL6#0_PP,DXJ.^B/CI&M@2+2-87=&R>-%\XI(AQ
MF@D@[;Q(SIJK7<\-GT%)&R+-28WB:V-==6#:U'R#5,1UL:1**1GYR,^NJ:ZJ
M[CQA/=1`P+@WB[DQ;:!',D@$*R(@'SH@)"*Y#AC2E<QK]5W(FOKJS_+E_P"Y
MX;UQ`D*Q%V[T:3:BZ:Z>7373B.X32PZG8UTA1-*R%U%:9NI=GO2O5=OEY^3C
M$LDM9$\GB#D17MH$&6<^J4]17,AB4XPCZ`7H%Z=/<[1Q/+[-\0I:NV]?'Y%2
MGDYK?$%1HWG^/SAQBSB-5A;4US:D:J:=D]O,#&=Y5U0L*,-R>3DOL#,Z;&7/
M2\GTD@,%@GH(LGFQ\B",BJUK26$1CP-U5$U)S5/+QX@>'&"^$F;8[)SB1X?Q
MZJ'8U<@$+%Y>-O`6XL[BRF&(=FR:-2,*_3?KJ_8O97U'B*QA1%8X9!D:CQD&
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M#?7W/_QOTEGJ`HKF9>THZ@IIK)>,SXU?*F$(``]D_O-?/'(8-J]CDCF_CYKQ
M;2Z7(<SLG7$%L$XKVYC2@!8TG4;(BB@UE<C)C5Y(1=RM37335>$D_77Q2ZR&
MZ_4^LM5OZN_J;^JF.(7?N_G;MW\O&:8<:WFFQFN\.X$^%4%(CXH)S38M^>-U
M;O[R_P`YGW.UU?OYZ[6Z>R:#'@?G&/\`AFT9[!S%W`[S3$;:6+B)_P!K>%C5
MY4_[+U/$"#:9K9X70>'>*U5@(5)8QZJRN+>ZB6,];`IWC))EPX0XH8\>,/LF
MDN>CD=V4XK<=NH]4_,%G>$6+]"7U0SI%KEM+7WF66,^&(P-4JJF5OT`UK&'1
M475-&\7_`(IW,"E\WNB$EXE30$F#DD$ZTEUM8:[LI$LT=1VCBQ7^\B9T!;GJ
MK]R,&?%S2/#[SNN3R<<!E8VV@\-C>9,6%E&32)`3W39<J17=^!#8%LD2.*CR
M*]&]E*@T&NQ*!(<W`X$^OM$M5FWUUX@6I8E8N+QQS@D!6QZAK+%W7ZSB"?TT
M5%;O7QHS2OL'%F)EN1U^)MFFE'AQ(=(2MPT(:H#2Z`-+M*^246S0;Y94<Y%U
M=K38Z<U'8UU1F;\!OAS+#(+C,;6QA4A[W*\OC2[2[E+"IZXJ.=TBB(QS$56N
M`UPV<5>390"F@OR"!`MZVLJ13=T"!.BLD";/ES)9>]R3M(A.P(*"1VQ=ZIN_
M`9M2T$99EM.IWLB1&Z=23TS@.:.%%5$=(-'$]HT]MZIQ=8_0^'7C3%\/<CFX
M;(E4%[3VLR5(/C5F^=F16$0SUAI+C-8B;7)UC,_F;$:S,34];:4^&S,]MY6%
MUUN*0&0"F?"K&DZ`Y3S%9"6P878F]W;1_MZ^I+CMK,&L[)E5D#X:9O9N@BK0
M+7;)EQ3"[G+$:V@/<+81RQ^CO_+,W+N<N2*^954_\,+9>(.RD8$EAM8DJVKK
M*\KV/?(8&Z[W6@:(H7*9!=/15W:KALS'*ZLMLW)C>)OL(N2R3QH[CEJ8CK<D
MDPBC+WMIU7^=S=QXPDO`18UT3Q=R9]Q&A/<2%'M'H!U@"(1[G/)%%+5S1JJJ
MJM1/7F&K$:DXAO=<U4#E>1CFZ+RU</U#*U$CR#[-\IC=2:-<Q=/=-\NQ.)D3
MOI7][Z7OJLYBZ:Z\DZBZ[N)PN^$+WP"@W.9HHM6D;O;[XNJ]O^3C)L=B5LU<
M\@XC'/97Y(P!Q9=0IJAZ0FD264[BC6;&YJ-NY&::KL;[)N\H,X:S!![G21B?
M_>7DQKV5X-O\]C'(IBI_U(GK[7%EX@WF\M_X@25F,-(360E,(QB",YSDWH^X
MFE)(=[1!]%?4AW%GCM'8VU>B)`M)]3`EV,%&N5Z)#FR(Y),9$>Y5[#DY\&NG
MT%*ZXD(%LBV=5P5LCMCB<".AIR@[T1`!<K&:N[+5T3EQ+Q5/]%U<J&R`C*V+
M5[8L0:CT!'A6%?85*@V#V=,D<@MBZ;>&T/F>MR6M)9DO"%OZ^FM6R;4@11$G
MMCCKP5$5X8488!-BQPC$(:-:U."919T^.QST\#JDOYE;7,D5M;5-66URV10]
M:+#KVBZB=M&CVZ\N*.,.0>)C\.S@Y$VJI.X1*B[(":.ZA)8L;"(0T'SFULI6
MA>'JDYO5R*J<3+GZN4/G>QCOB6%KYHK_`#E/B$&@219D[N_>94=X6HU6/<K5
M;RX(.H/#-&K))Z@@X+AJ&%*K7=VD5RL%V`$A.;L4?+9II^`S+(,>Y7%;3D-#
M+TT,L57E$$TY!N:YCE@1RO-VD5O8YIIQ4>(V*?Q"W.;9<^52$)B<S(Q7$+*'
M3Y<<-C5^8N]2)D/H",]54J/<'I[4V$5NGJ1QY%C])?LB/<2*RZJH-HR,1^W>
M2.V<`Z!>[8FJMT5=.*]+;&J"T2IV^:DL:>NFI6;$:C/-_>8Y.Y[$8FG3VZ:>
MIX[?OOS3](;Z^!_D&_\`N2?6B\3)63Y#"R*--J925L&?"AUQ'U0XC`19*+7O
MEFB2F1FH8?63J(Y4\G$[([W,LUJ[&4*$$D"JR&NBU\9D6($`DC1)E/.)&0K&
M=1R(_:XCG.TU<O'_`(5R,LRT52DM)OG$E_%3(?\`/>_MC]Y=7=R[EU>72[MM
MTY^[[7$/)H&79I+FABRAAB7N00#5Q@S0NCN>:-$J*]\E&H[5B.>K$>B.TU:F
MGC`HG7$FBDTD*UBS)SSGAK)R%])<&%#.K&1^[BEEDB`UON!!V:KL7V(:3)*.
M/'CB(>0<SVC$$(6*0I2D<J-8,;&JJJO)$XBU%=WH?A3@Q>K,EMZ@6S@N*J%F
M:.1-D_('@Z,5KNV&*QQ-J.ZC>!1HH&`BPXXP1XT<:-&&/'&@Q``)B:-8,;4:
MUJ<39I[#Q#6[L/#V59DC#RRXC";FMYE<A])4#$&:Y(8,.JW]1X@N8UW91^YG
M8XFW)X?B"LVJG>)<V:I[26+%;B%75<FN\/**IIA6'<9PR]9DO>@6=64Y=SGJ
MU4'54TN^SR5=G\.J27#GAS2U9(+XI75I'HY$VV<EQWONM9"BC%"C,8\1W/+V
M2&4A./$";,G9\V535&?AQV!#??1:K(*[S02KPZ$"X9DJ5;I1=!S4[M#;8=_>
MY2G1!Z+&Q;$ZOQ(B0K+P^P>BK3RK*PC`QZSF9/*%F=R99E@KZ:;"KG"[N*/H
M0,?38UC$>K<X8B9O$J,BZY,$CK<RN\40LARNMHKWSV])##!+!I!OL:Z,XCQ0
M(Q2(WWU.S,MSR_$!HYS/&&Q+50\GMX`0U,*3'B>'6*Q8P)JLC&MNCWK<'IF<
MWLN=L['&.Q;AOB(LFGLO#2(2YAW4^+C:XK3XU"L,K=.[O/&VYMLER,!A2]XB
M$VM:W>Q'(T@[.UKLPH@K2Y/-RV/D$HC:JRRK*LK2\@BHZILX\%&U4'JN++$Q
M'N<?8_M;FL]?E]W5G@1IU93'E`)9PR3X*]-S.H"1$&PJF;*#N&FJ*U'.17=E
M%XH;M<+\UYF](+C]+'S2(D&[?TV%-71FRC5D5K9?:"X(F*---J-7EZJR)TJ-
M#`CFM4\HXXX4<]=K&J0KF,W.7R?CX`LJ;$C)**P$99$@(4D&)^3"!2/;U2O]
MIK=57U/';]]^:?I#?7QI3FJ]H8[%5K>2KKUV^W_QN/\`,S_\MG'^9G_Y;./\
MS/\`\MG"1F1R#56/?N<YJIV?]SA99!.4[GM>KNJ1$W,TV]E':?S>'R3A<XI-
MNY4*1NNQC6)R:Y$]RWCKR1.>16HW5"D;R;Y.37(G`ED"<Y0B0(]"D;HQOD3L
MN37R\>(GAM);&^K^*T\"94+TS)-8I65#W-,5QG#*-R6BZ=A.36_RZ_@\<BQ[
M*SDU.<-R,<VJL)DBR!`MJR&VXCV%26:4TBLC$CC.$D4;NZ\QJP;-JZ^NE6EM
M-BUU=!"X\R=-,R/%C!;Y2&,56L8W_P!?"^&/A.*3&PL9!NR'(9`RQ1SH[3?Y
MY8.Y$B4J*S<",J)(E.3M-_F-AXS0C[`_?[&>1J-E6]F]C&R;&5HKM'EV(C6:
MJ@AHUB<D]9&MI-362+2&SIQ+(\&*:PBC1SW(R-,()T@#$<1RZ-<G-5_#87X<
MX/DL#"SWU?<WEQDLZ)%FN#!K.D,$.(&6QX^H4RNW>X<O9T>B;D=E>-9S<U-G
MD>%9,6A=>0^[0PWT,@!28,U(XT`))';<UW38UNB-\KM57U(D'(:BDO,DO&6M
M-A$"^6*R$&SG11!EW!Y%@]D*NB4PWC,64Y6D$FC1N1S^+3'\KN*7)*VA_AH>
M#$K>9(BS:^59AFVX+>9C1GN,SSB.?'`(717O;!C$U.,-+CE=66N;_5O$TL(F
M2R#Q8ZG6IB>=WR2B((O>V'U]OW7'C"2\!%C71/%W)GW$:$]Q(4>T>@'6`(A'
MN<\D44M7-&JJJJU$]@0\G6!,L[;Q9O:_")Y2V08D"E@PS5%4*='C-KR$.1&C
MC*]'DT5!/T5%=R1R+JBHBHJ>147R+^#\)/\`\_,OV2E^OLAYAF?<O"Z!.:>C
MA0%$V2>,4+"H(-6)G=4F1'D>!TR8KR\M6,<QVG`:#%:L%97B7>39VY,R2K4:
M^9/E/U-,ED1J:O>JZ-1&IHU$1/85?.R^KD3Y-9'+%B/!9V$'8`Q$*]CF0Y`F
M/[:>54UX"<>.S^H`HS,UR&[5-XW(]NJ=^YIJGJB\YUM?8]#?T>_0X\OH]39U
M.EUQDZ?4Z;==/+HG$(4BAICBK7J2N&:KA%'`(KMZDA,>!6Q7J[GJS1=?4\=O
MWWYI^D-]@>&EA(R>NQ\F*94EI&C6'33SV1'PIG<(CGR0.23K6)[EI%V*JZ<N
M!-U1VT3&ZIY%T:B:I_(OX/PDDD5&`\]Y3`ZCET;WN9AUJ2*#7R;SMADV_C5-
M/+[/<0CVC8Q%<][W(UC6IY5<Y=$1$X"LN9%B]Y*P$;O$@0.\')[@(>H]O5*_
MVFIJJ^IX[?OOS3](;[`P\]%D(,=L,3LY=D"26(^2[KF[B^.8*L,+IDBF@H[G
MKKK_`"<,P5,^L!Y:RTV_7U*QF[NC+!7I#2'R7H]W39U.MO\`_9Y<`E91XH6>
M8TL=),:14$J>[@FOD!40"K(<20H$BF>A=6IJJLV^15XOI%/XR6T"JDV4F775
MXJ3WNNA2W]XC5S'#D[2M@"*@=_E?LW+S7C&,=H?$*QJ;NEC1O/F3`J1O=DI4
MA-`\I0,<CH2]9JOT:5R.W=K541>)QLN\0;#/P654)L&*2N2&RKE*57+*ZCEF
M*0C6)MV<FKKS\B<5TFS_`(B)<&'8$$CCS*P,-D;KF$)C7N-8##U%4NB)JFJ\
MO78IA*=$3\OO2L+8OCCD2J>%0U<V^D65/UFO""\:>$$48SD=T'&ZNUVS:L.`
MV3-F)#C"C)+L9))L^3TF(SK3)9??)$DFFKWKY5X61$S3,;5MM>0HQXXX<E:^
MKCR[4%M9GGEPZM7*H]&^MJ?-PFQ7=03YJ]M$)JR@JY;,_CY%%?X?RJ$,P^5Q
MJNNKC7)LGSJ7<6*N)`F!'`7S*&/:$+)%'8(2LZCWJN)5C(.04J)'JN^Q<>G9
M1)A]ZM<MCA-9U%Y3P:JD/.QW'ZTA)B7"CCB#+1!L([579RV-/R<8K&P%(I\G
M%`SRJFV<R^R2QL6X%&QN^N:<0PU<(44;["-W./'"Q4D*K.NBY]<6N-6TW***
M',C0DD2+`J9`:@%;L@4E3&E5L(C&/)&8_KCZZSG34*KT>JQP8EBMY8/2@M\D
M'8GD+BD_'VW$&AQA]U>URU-L<<V10P<C/$AL>9OOSGNW=3I)K?4^*1'6\+'+
M&HA$J!8Y82!V34QDV19#ORIFE97R8XYD,`@=L[I)1IMVN76N[\=P67EUCL45
MG_X>Y$R1":N/7MUG,:NQE^^YM*^A+&@QP2E9^6,3>KD8NE#36])-BV=G'\-W
M22CQF=W&"&;+N+'.9\V:C#UT62&FBQXC8_65PI;W;6N1NO&,4<:!:U+KR[I[
M:?W_`!&TL'&B9Q:W689-93[Z0X==5/I8+T@!`[<5#H[<U4V[,?N)[KVUD)CS
M)4N9<XCD'7Q&;FN<,@VKWU<1`RK[ZNU-9)TCJQR1V]%6J@.;XA(<+IEBUDRP
M(67B<ULJ]9:9^"@PP9J]3C\R3#X^`DNP'J]\<9-58Q=NSV#D+KF6,,J-"/(H
MHI;8L!DRT;TVMVP62@#MSQQ/<Y@WM*C%[2)KSXRH^1RZ*QIQ_P`.D@N'2)1X
M<R#YR;-MH]N>B-N*'S\&?%`)>A^=-5C&IQAI<<KJRUS?ZMXFEA$R60>+'4ZU
M,3SN^241!%[VP^OM^ZX\827@(L:Z)XNY,^XC0GN)"CVCT`ZP!$(]SGDBBEJY
MHU5556HGL:#&A094R8N1UI/S493/:#IRPJU0B1SG(208:>3W6GKO"3_\_,OV
M2E^ID3R7-76.QJSNX5B*=:06%#$I;DU&ML9G518T*;-#[UNYJCV?X[=32(65
M4,H$=D,AC1[*,43&6%D^F@N4C"*W;+MA.C#_`,8R;4Y\60*F^J;(U/IYT'!G
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M5M.K&VB^=X7YB\LM\`8Y'OVK"$FC42-\JD[/E5.(^513+D5;.LX%-5_5\]=)
M=:V5C<,H@QX4J9/@56C)SG=0A)`Q,8-RJ[EP&);V]=C]P^/!D'H+:VI?.T%+
M.2")`'+;6V5C"ZDN1*&@^F8C7[TVJJ<=S<"TOG@#+/9/Q_S/);4LA7$:@..4
M.?<5LJ5,2UD=)(T,<J2JC?[WR]@L995\&P8)RN&R=$!+:-RIHKF-.QZ-<J?B
MXA!/04I@UI'&KA%JX)!P"O?U'EA,<!6Q2/)VE5FBJO/U/';]]^:?I#?8TYF.
MS75F1(!1U%D@&RD@R"$'^<=V)[V56(WEKY/+Q#L[_P`4A657`E!-,I'4$+?;
MQ^?4B->R+'437^17H]'-\J<^+>SQSQ+#B],X8"0*-]%$+T'#B,&8`3/CRB&4
MT@2DW/=Y2:>1.!T'U['!S.,7O9,N?11%[^+O1B>;%C:.`)$CE:U"M%O7I<_=
M+P*7GGB#Y_Q]L.6TE8E-"C]:2]B)&>L@<8!`]%_:Y*NNFGD7@DIGBHVLQ\]P
M66R(['*]_<ZQ9#I#(",6.[J]('O**I.UY57CPE:FBN;*S4RMU3=T68N4+R[?
M+TVED#:J^TKT_'ZE.R/D%A'E4<2G9"E,A5[T=8UV6FS&792XQAE#*=:6KV.>
MQ>37!:_57<8W9&OKF<^ACSN],)W</GZUE7UMDL>ZLG@8S276W5R62%!HUB&1
MB_S$3B\QB!8D>^XIGT;;I:^$&S!";!DPX:F,%K7S3Q72WE[3FCZCE5K&;G:J
MQUQ8R:5DDUG$I2!A-8&X/B#,)[\:<,39DL<6BZC`!<NT2D]O:W27#-D%[+65
MC+Z)\A_=$,L\@ID)V0&=TW]YFLIIKJ\;'^]L@JX7MZI22"F;*\SU^4Q7"%`C
M5XYLS*G4XY=J98WOZ3H]93MBL)O<7I$=V_:X)9`MYT.J,_%WGQ\<>*:.5,-F
MEN*&.ZPEM/8]T'?'=+.-'Z'<C6KHB+NKP^>;$[J_ZAL22H@#E/#@AIEE%&A6
M<Q><+^<^:94_Z3;^)%XI3/R6SL7428:""V3"K1,97X.+(O,\'9$"!'-)-ON]
M'([<0L@.[5-W+&I6'6#Y%]C0,>AP7SY<.KBH^K7+I=C<RFOHL@CS)EO:Y2IR
M#4#4&0;"HKG#V/\`#W%KTX[(&'28-K:!=''(A9%<`J[*/*=+'*8NZ$>VM'R]
MKFJYSF-1?;XS6MQJYZ"99;4=K'K942L'"IYT*PQA"3P2VUYI94K*O'T2%'7W
MIGN%U38HQRHQS"FP1X8RDGFCQY5A4$Q/))F43)@9CD8=\_*["P/YQ+JU2H1?
M8GCM^^_-/TAOLR5DQ23;&ZD`-!#,L)/62LJSR&275=3%&P,.!$<00]ZL'UC]
M)BF>16HO^`LOE^&N2>'LNJS3*KG,9X<OK;R'-KK"WED)W",ZK6S#,BQXVQ.J
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M+.*&<:#&FY$DWSBV*.'$(9!P&S"5V@722LU1Z.>@TXR[$[[%G8O?X@VE/+`*
MZC7\(\2^C%E07LG1HD+I24&+MB5G+7DYWK26U)B"Y2&%`M+6W>^^@T$:MKZD
M#))E4TD$PTF7($KU$-@MJ])V][.SNQC,P44^V)D]1'OPT39((DR!2.CQBS+*
M<=S#C9'AR)T>/JB+U3'8C>2ZIZV)A.18NRF!:U-[=55N*_C6A/-]"YW7D758
M"$-*@,D+-XG)(D(ON5T=N1JV`<?@UN-R(+IU9,?DT>9D!1$D#;7.M<:!7M\S
MCLX:N.->]F7:U$5.UZVTR&RWNC5D92]`/.3-DO<T,*NB,7\I-L9A&`"W^<4B
M)QA]C'Q08+G,<@R+'HU;<Y-%J:>NE8R26R<MCDGFZ6(;Y'==([&QW*4B[47V
MUI,M#7R:L=S',7N,IS2$`Z/+D0B;#,:QLF*4D97A*B-0H7-?HFNGK+:_LWN'
M74M;-M9SV)N>D6!'))/TV:MWE48UVM_G.Y<6V:W>+1(,"."F6GKJW*HEW=3Y
M]]*%#KZBTA#K8@J.P<:6'>WJR>FUSE7W"\95CMW1,QW)</D53+2!'M4NX)(M
M[`6PJIL*R[A5O,PXAO:Y%`S8\:IS];-R$>+Q[B@JZ[OME/+DD:G*`O7Z`X8(
M9J^6^48[G#0>CDW/(C>**^LO#N8F.SF8RRZG.R*N'/J9^1=!KH$&G[L^3<OJ
MY$A!E<YT7<[7:FB*J>Q/$-V,OH'U/BMCF/T-[*MI\V+-QTE(V=!).A0H]7-'
M;LD5,YR,&IHRH?RKM\L*O!NZ$&)'AAW+J[I1@L"/<OMNV,]?FV818OAX-<FQ
M^+45["9!D<A8,FBBVWF27*CIB4=L@4J;,%WD;2MZ8T=L<]=$6U'E47&S65Q(
M6VN<EJ[ZTM[;(;TR[3'G`G8U11J^"`/8C!`YS`L3:B>5SO65%)C[L=)BY)!#
M9C5V]Q;4DJ_CA4+X%.*PJZ*[)'JC&:Y9FU&%*U$8US45VMM(AW\7'LCM\5I\
M7+CL=T.7A8(%39ML&0(MG)Q9<BAPE)[ZJQQ@4A&,1R;&II$C29AK&3'B@#(L
M)`XP3SCB$UA9APP@QH8C2GM5[FB&,:*O9:B<O6BR5U5BN$0>[93#R:?B]Q93
MK//PY!$)'C):5Y::IAQDAF5)#^J^4]#(FQRZ;DQNQM(6)4\?$<3LL865BQ9+
MIN;'GS@'';7PB55:V.D<$=%V.?)>Z2JNW::(GK*8"7UG0$H[V'D,616@JI6^
M?7C.D+O,6X@6,(XXQC=5B.&NA6-=Y6IQC5-92J'/:RJRW+K^ZPZULST5/<"N
MW&6F,EI78WUUEUASDE$":.\/6.Y&+L8-.*3'+VP'93ZT<EF\)I,J-#BDF2#0
M*J++FL'-E1*F$1D<9"HCG,&G)J:-3U<GQ=#I%=?T5G5#DJBN;'--B%`$[V)S
M>,17(KD\JHG%T]\;"\0L_JMA='4UN.'F&H[:ZPZ^#?.R6]VT]8X1;-X>[M1!
M'*(3UW.<J=K.LTR@57!M\U/CPTIZBPD6T2LK<9JWP(C7V4FNJG29<H\HY'Z`
M:UK5:FJ^MPRL;(KQ8G7Y-'O\OC2"R4FVP:=$D5%3%`.,2.>))L>U)ZA1*U!M
M5NY>7%3<`BX7=8EC/=Y^.T%UD%Y3JF2M9V[^V%`Q6Z'.D0=[F0V=5!B]WMWK
MR_P&Y[W-8QC5<][E1K6M:FKG.<O)&HG".:J.:Y$<US5U:YJ\T5%3DJ*GK&U3
MIT-+,D99K*Y9(4GOAM)TG2VQ-_>'1D+V=^W;NY>NCQSRHP#S'/;$`4XQFE.&
MB.(V.-[D>9S$7GMUT]0L^TG0ZV"#9UYL^2&'$#U2,"/JR)#QA'U#$:U-5YN5
M$XU3_!YIUE,O89\;JKV;7K2W4RI:XQ(8RKWQD5[4EM8^"S;N]SJ[3W2\6/B=
M>/R'([27B&;-LJRPRBX;4S@PKBVA"'T!'1P'="N'VVKKKJO'@IAF#835RSYM
M@0Y=5`F7DP$>I?!K][&$G2!R3G@08D9Y2;M3$:S:B[EUXS"S'X>XVDCPSMY%
M9G1BWDA(A'QYZPR1J&*U%D+(#TWJ0A"O&C416H]7;4\/:;%(F-QKK/<4AYHL
MW.+IU1CV/TLZ)WB(DZ0`?7E291&%&U&;51P_([=V;.9+APX%QC^06.-7(*V8
MEC5%FU_2<DVJG)RDUTL1D5CM5]OFJ:.7^)3*WD>.3C-+%PND>-[FEA185?:&
MG=%_)XNK95;#HJ+[MR_R<0ZW*[R;)H/$'"#YG32[6;(E"@66,S+2'>11O.YW
M34E=`)(+I_T8A<8EF=G:6S*_Q&9X@VM72%FRNY1<<JPR*ZD`Z&XJAW-6$KO)
MM71KTXR#Q%Q?"*2P\+L<N"UQ9$ZTE1\EMHD4T<$FU@"8Q888VZ2UW::16IKY
M=':8KB'A_BU7?/S/P[K\YJ9US9EJQ0V6)I[AOL6B$??$%!A:JP:]1Q2(B*B)
MP[)Z:*F)6U3FY\4RR756AQ'A3Z]L&0!*G3<\T2>D[:9'/79L\KD77C^'&PL\
M:J/KNE[G""Q^#<*M40RDQL,+?:E`JB#W=6E*NURHFJ)SX\7)F4XG#3*_">97
M19U=1S)!:RQ;=2R0J^0,QAG.&/'<%Y#N[7O";M&KR3-XF4CP:776V-/;466$
M7DFUB.D3*^:9\6P!-$.176M%)%'>J.U:Y[_^`NN%V4XCBS009%1)(]5<\BTD
MZ55`(][N9"%B1!N<[VW*OM_X/M:T;VC)85LZ$PC]=C'RHI0->_;SVM5_/@_A
M,:RK27):+)ZM+(7>O-B'O+.VGQWKN"V5TA-L&M?V-=471./!*]+:U1`>&.(3
M\=M@C[WU9\J723:QAJ[<!&=W:67JO45CMJ>3CQTIO.]3U_%3);>[J"_GG2K@
M6$TTL0K+\WW]5J%T=TD>G'AA?4)<+MLCP;!:C!;6IS6#+F8K=PJZ"H>\C4$6
M1,CG!*.8@EZ6JZMUTT5'%!?5V$U=E(GFE/B8%6GK:,85$`045)31R)<Q$$N\
MSFLW)HB-1$TX\=L)(J`3Q$Q^%F&/G,U4$1I03*RW>CMNI%%:6RHK45W9%JFG
M/CP^PR->U4+*<+):`)=(DWN4BHOG3TMX(7,"V7I(&</)S4:]&.:O)VO'AED-
M1*A@Q_P^Q&QQ?N!4+W^0T\%T*(8:C%W==$7<57*U57\>O%_X7X_E>'@\+<@N
M"S5ESH=L7,ZNME20'D5D,0Q^:)#=L=&JXA$<_5RHH]=$P[,:V;$9CF(^&<7`
M(]<93.M']Q+/[J?<T*1E"D:4Q%7<CMS5Y<9S@:WM0EKD/B',S>IEHDSS>,96
MU8PP;!>[=Y&]PX;]SAL(C55ONN?'@[E.66>),N<`M,CFWX:)ELVOFAM%K60&
M5/?1..I1AKO?E+TTWN[/+CQIR&CLL7+/\19^.2Z.-<Q9TNL""J+/2S@Y!'&-
MCGALH4]X4Z*OVZ[OY./&+Q*R%V)T\J[QYH8F,8)'G@Q:'.``L*K>-+`03+-L
M[2:-NC1,&-Q'Z:[M&X=13Q.#8MKR6-@$B;2@EW,R1;$C&3VBPTF(%?\`)_\`
MDU__V@`(`0$#`3\A[PFU9D/,[)7Y\[\X[,`(L9?P`\8T:-&C1HT:-&C1HT:-
M&C1HT:--6V[TMBFL6>CN8G.XG'TZ4)J-(+VR5Y$O$2Y/HD*3M!Q9R[#Y)`(V
M]M8-FV>_(']X"YF>K`7&>9;C_8<W(?3K]4`N^G866*NCBM7>6]ZPYMK,)2<W
M3A>PAASP&Z,(H_6,S;*7MK.U,`/78(PD^5,\'KDG`.07(?@7J(;8*8.?U%KE
MB#"#X3C"@/GI;M%89N3K8ZM$&73E-=L/Z5"#2'X.X^<`2SY7K;UHW>,7/0^,
MYP%E`MM*M*1G\6W1:)]B9G"$-P#09;'QUZ@KVB)9I6$L?V<D00H@/G%Z;]&`
M4P4`%$>BXZ>D9!#4A-3KH\]Z&:@0A3U\`5*':"OU1T#<40<02#1^F$NHIN-<
M$+/<D(."`9=P7.DZN9-HCVU&P%08<..<VJ7:(])''.+/J"MB,_=5NQ7>@IA%
M2(>+0CP)Y(0'48W7%W\6,>ZGV4TG7CQ<$X:/A&0@V(OD?,7*5=%%O],M+7,/
MPD[CB\A]]U'DD^<H$\U>>ES^)I;T9@`=.U",!A@U*0`#*#T%GC\>22,B6>;%
M)0Y3VA300C3`_)[0,!5-RN#J>W90MYZ$7H:6@:Q667F%`L58382#+YL_3/$)
MM-/$_43A<8Q7&,TB&:"M'-/@BD#AE4$#0L,=![XGX==OBR\:X0D$*!<TY+5^
M-\C0U[9[K5>*)I=;G=3B0/',)S3\D!<_I8N0QI)V9<)1-"(VNU3CB2>S(;I"
M&"9[PDPY<S&1'O`Q%ZNHFD[[5JU:M6BLS])X$K)"WT>(O<EZ_.T)&_P$N+,Y
M01,#,>7++O(;%90V>IJ*#T>>]#-0(0IZ^`1-=QUJ\\TP8C7)M+OF`9\`LZE$
MOZ6:6&)LD705-5'2B)I)&,%&[^&6\F#6&3T'E*HRM@DZ!3',.1?MD@,*CM0=
M$7@*!:?&OT7N3VW?V6ZG<M6),HU$*$/A'R[\1Q$0\PS0WU:>*$M0LG(/!`O]
M#30V#5J'TPPSCP)`(`-'2V]4JY<0(!^V_NP`75!SR-B&:#@K@\R,@*0;#SYC
M]>W`<C>0*S<$`U)E"61%]H6)0,2N#`V(2*#Y7VR[Z"SQ^/))&1+/-BR93C/*
M0V:\7V-)94X/3?FX"D!7X%6<!T9IN\%S4,:G+3$26`B=WKHA7`@5D_;L!%#P
M"@>AM;V"-W6F!VN!A@1&BE[D\G+F25O"7E5<\U@(?>^1H:`>8$66D<X(&!%#
MBP8"$KC0"R4?KW/0G7VV]AOQHK<GX1RX\!4XHW(R+C$$),`K(]9,J#RWZ^6D
M$Z9H$3`@HT`%JO308S&1B2,UK4HR-Z&B[?D==>Q?&!R8&65NS`LDL+!?F@6L
MW[C4>P&AU9EZIHSZCU%E]'S8+(:W&$ZS55JG6\"'2_U4/IPPGF$E%!?](^[5
MV'W++[JCF*'<#\%]Z:KBZU93B*>O,&N81$:%R'6/-R'(?/R1DI##5B#P56R5
M<"5ST;@%$]3#`,M.<6'*9/E#$)D0G8$C?6V0@!4A(G(CA6/,4>23:;243KA]
M[,>%]>1%U=>6_7L:[,G56;:WTSE.@F,R*BV1.G*UQ\+E91V94"1]<TFS6@2(
M]B:24`P6JJ_=&'):4!/Y^0M.LPX[/-^F8U<*>X!O4M24!8F14VY;3L%+#<"D
MW./1&&Q%+1A0SY7OP)?$>X]$*$7'U];!Y,?`?<+5/#49ZU(#.[*Y3:J?4<"-
M-$>YMC<ZLPH^B\,?H21@H@!4,'N/X7KO-2JI489QX$@$`&CI;)`ZHG=W6FQG
MXPXT[?I",:XF9<ES^\\#`EF(4Z*BC>#M=(,$RD55)R%/M?/NUV-1%Y70!62L
MGL[K5JU:M0L<3DLFHRE>NUK;:'Z9>^3A6WN227P2K,1ZF\+HQ])`H/@M_P"G
M9`$!4C>TK6G.!)$FH;;_`$-!JYO39MWIZ42NCSEVN7@XZ"2?'DJ+/`XFGM,Q
M-'$X;M/0$1)2J"-\2F!..I<D(&.ZP"NL<(CJ"*"311-)GII7P4'L-B<V"H($
M4":.*C.NC-H#H$C<OTVMK9A\`?\`51$H*J)@^:.'+UQG@E.,.\"&-#?`4"G>
M^W$#&8=%5MM>3#0JGG(\!3C1W]=CCFJ73>K<_`6@%&^/5RTT9$KGHW`*)ZF&
M`9:<XL.4R?*'3?V=/>M4L_\`O9-^97Z*1;>QXS@U=%+0M#04?*=KEZTV6Z0(
M$J^CC/\`S/,W^I-]^\DP46H:>@?^7IZ6N)_DL)Z@<7_DJAUX0U2>1$Y*8X<*
M<\H<%[;+S*;7.CF+%J[?OU8C-PS#5"`SJS=#4+'QK;R!T!KFQ'HC;"E0DI"B
M5K+8C<ED#$/"S+'=P3R=`>(2G6R0KJZ7TU`/&.KIM_7OC02>(12];6!\([PY
MEG5-U#C6YR.5.]\.S<T(QX9M]:99'*LRN$R!B8V/1&Q!@@)@:2J4.!%V4DB$
M9<]6X89QX$@$`&CNMG=K(3>-84=9!Q/V/:Y>^),-;1^0%&LR<3'P6O@)-;A^
M);8H1:0+D;^1:P]I]>**.[\L.&%&Q%8(@E=`,>F&7J0)N,,%N@O'[7(8'(\=
MVMMH?&-&C1HT:-&C1HT:-&C1HT:-&C3Z"QRDJQ([4ZJ?1`.*C0CLF+'.LZZ=
M@1P;375=PG/4RW!5;6:NN":63F%-%.U<)_E*F2(8!EISBPY3)\H=K72_SF&-
MD#UA">)L?ET<_MF])TJ,_H`]K\6=H^";`&"@`HCXG'CQX\>/'CQX\>/'CQX\
M>/%T&!N1BRD2@CLP>B'>',BH*6HXBJAW@?*`;=N6$M,X\>#,58H8O?1)$7>$
MMD4RDIM2!&#5*M#K@\]]'`UMP&7H_&7H/)2`W(]0U`*429535B,?!%FM+[6:
MX27N?5OG"RW30*N%E"R%AXB!_<3K*\0I=#C;#5@?]BA1U0X1C$``````0`T`
M'`=UNV^6S:G"[PXM4>C@)+8DP7[N*76DBZVC^#\@48LK?N<4V3Q08,&#!@P8
M,&#!@P8,&#!@P8.0C\A4GXT"0#+,O!K]^9\[>11=I4F\9LG<:7T=GDR>K94R
M8LH;?V]171.L".,T#;8+P"$.Y$`>^DH.EYG+R62YU*F0@PV)&;M91S*]<R6>
MZG),_P!Y3AN5:(O0CA!"`$?W'.X`AP9U>(V'6]."#<IR#"`1QU#<6KF/:MGH
M#P"'Y&-($%-Z@(%<.E<E\FVSHO[3(P9(-+R8!)ZOK.8W^FANV6HH.85VKDWS
M0UX9D+@Z,"SUM?.U@N.F(1PF*/QG8TZKJ)DI!^,6'6TB0@''L>K\2U+KU2`8
M,)T11(^"=%=;*=*7BC%BT?OTF35MF?TCBA4^#)F+O-F(9_<A,4:DAQP+-*ON
M^GUQ43,Q5)3_`.MW:XQ2LY-KQ>]9\"?%"+0Q)(BX*4%V3:<B(R9R@&P@XUX<
M;ZDIM>"AU0[3Y'3[B079@X6W2CQ9-IB%@WF`2X:N+:O.#=>@^LV,`>F]LZ@-
M?F%I,`6<""['`(90>'LTEB!UD95NBC.1XPBDT4J.I/=D!2H37FF(4-;?//AH
M^LR[60H@JD-M$:7-M\FL=PSR(K,?)&QIMBQ_!R,?5]<1E_-'/&7TJ74E@;0&
M6.4"1%?0QN%/>5R7@^V8*S:I")D;Q3(W;K4IZV"Q0M$0N!J41L).P#2=V!:H
M+EN4*IMMLAUQ;+'V2?EM%?12W+@8VC]$6R;"=4-<2XS$\#-$+DIWHUJ_)YCL
MTH]$+]#Z=K:"`4&:ZQ[KT6_Y(8P`````!`#0`<!WV_RG()GI9''YR@5K,1^Q
M+Q_2X=K7:N;P9PJ$[[DH*&)L\Q(D2$%`HUP]D&TRFJY!4`2.NZ#O@2B8S-M"
M;G&+J<?BKX:3"<S=>]G]5+(![0K:4U\%MKA&J<_&ML*A>T_QIP0!4N6V0E&D
MJ.G+_A--(WIJQB`\W*;<!:?/2OAC'=D\4D>+5"B/`VH<1%NGU^U:J&D<XMD6
M._\`4#V0RUBKK(VUHQ-$]'SY$BH0;DD*T"9N%M&IYP;KT'UFQ@#TWOARX^&;
MRM"%PCD=#,P:H_Z&%28"O62CI$1/-W]BN8\#!N7W.-XH6N:C>VQ@'I]OSJ*W
M*(_HY(=!0>0\:X`!`(INI(O`9!#$H`@8Y*APOD3XD,Q^/@MGQ.=Z(_#/PS2%
MLH,BHGHSF2\<&LU/4XI;:P"Q>'(G?'F4=DDCV>!-)?U3*UT\R=D2MI+[\!F"
M<3;?2O;8<N;H``(F:'$$<'S$BHH;DA4:Z.RM8F!@E<"[<_52R`>T*VE-?';E
MIQCMKSW[4V0#R,N-VH%#OCF"[&"&7`#RP*WMO`/KD$$=%)V0)>4]^#RK$%=Z
M<\M<KD1'K:(_D,B7./NL`0M+G9:F;4NK&J9WDJ2R9WM"B&$@O.7-GE,9J7&0
M489GM29*]"`Y"P7LT[#9,^"<('CN^5I,5;*`??8`<%;L0(*8;<HPARZ829-S
M.0\>W'1BK.@J=[B/GMI]/2)-TPP5J\@(#4H%),-H0RDY#-CR+<4XU-!&1)!%
M7O8$4P-&]_W=SUTW:B`US)(2S]AQ'_2\#LS]H=UJ&FWEX8IIO'(>>$.D7D[=
M+N"$GJGXV$8!0J]?;1@C)RG0(7N</(42%+SBT'@LA0;#CH*85#=_13;9O&<8
MGQ9(?/V(-<&B;X,K2J)'3NEQ`C2H_IR.?JPJ3/9]#R6-P(A,UCXL7`87BF@D
M^"F@=&+C>F.VUF&XTE2`;]9K1>L,%W=B`OF(-X,%(!!`L!D?@#.#YK?$'!I%
MG!\,;D4P.(7"R5*TX51?'&AVY(X@$L*I3+6[X-8&K</?T7KUVR=30OB/ONH\
MDGS@"N)WRY"#+#YHD,!PA``D`00`#)?*O\*LSX\FQ'77B)XH,E/',474IF(T
M!<0K)PC,%H@^</IERDNN/=G4Q,0!?-1$E*-(+<,J>Q(GV&^VNU)'`LM^KR1J
M>`9)`7+@76F35\`VS2(.9T!;6@8$Q\D7;L]^J#CH<%F60#BX+5Q@#F&KT*%_
MM`?#;<?G1'F.A'']5_\`&?U7_P`9_5?_`!F@KP_(I-ZW`_XQX"H-0>LT*O[Z
M#(P3&S:9&4/$,WA$04J;`>3O(;XH`L,,E3>:OD&#<O4]T8XLJ]^4UB.,A10*
M[0&TQL,Z^Q41^1Z*9TCQ:D\Z`MR25ZEB</$*B($J]OS0?`T!J-5^DRR(@U1*
MPCA>P!U,&KS,Y49&R#Z,&^70[><X6A2C@MCQK4X[U<4XU-!&1)!%7P"8Z\MO
M`CW9"X,D\R@4'V(^$M8S)O*[304N4='U5856R(`'P_CQS<44"[A`LLP"Y!*+
MOH'3K_4$?JP:^5P9S#MO3E5H6VY\*W?IZ-:/!H?@'WW/*[OS]PI\<0_"[NSI
M(%-54#YPHJB*52.Y5F'%3HK8?J_]JCPK;YQM8`E&Z"O3DFI*<]<!PY0/RR4'
M@A`IY+:PF>D/YVH3CB361`#5"%>CUMS:@?J(&02N=H5N0JN+)C/GQNESW(\[
M":;&Q98ID*(:,+4/M4.N+%?Z*D=)[&1C.OL2^=D?&,[O$ZAW.`,$N=(G:M7`
M+-$C;*B8W"24"R?03JE?3B$RY=K#SJ;SDGAEH4X,WL;%S@2IXMZ5%O4_"!UO
MI!69L*DH<;"Z'+!G\KH+4*BVN&@%W(1V639[GA-@L2P_#$24I#2@[/-:XJ@L
M<4HX+8\:U..]7%.-301D2015\85J34\8%[;@Y?@6Z&^C2N0#K]K##962?_+4
M`M]M<:QHD&_X46/5D-4/1U%+3_":`FFD1)RM6CTTXH@I*@'2%+HN1=7O/7*Y
MH!`8!%QAWG<ZB(FA[C#_`*QZ5P`&`5#C3!=FFXX)$^\[&S57N#AA7#?ARB7I
MW=2XX;G_`.\LM4D4?`X3K&*TOE84Q:$83[&U0]R;Y%M0)Z,"V/:J/@R8#;0`
M"`3ND%V@,Y8T[`L?+$T@,(:7LPXI&VQ05R-TO'W:+JS=*)Z.8G>I8*N02N0Z
M"O#LPXN,%=CIHOK5=*Z"Y0+G):7>[>52!R8=]T6-C6(X-!<ZE%YW'?PMMH'-
MR(MN^G0*3@0X.)U1NK1,:`,0"S.-]Z,\7,A%<"V5'_=RF064@,FB]PQ_>)4R
M491`,R>1+L8TB@^T!4?[)"=5G@TGMUGQV(_%"BL!1/Y]5OU]OT2[Q(N4MD%G
MT+@C15T_)S1XSZ:;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;DV
M1EP<YR/=.[+;XK[B9;&Q,(L%86#*KL*(QQ^_?:P!SZB[(>>0OKCU>@V.R"2I
MV)\-&!FTI>2@0EVD>3Y!TBG<&U)!)9/LK*2\5<"NNF?KX"-"=D!JX#`$#^_Y
M%GZ6_,PG.#<L,"'(7M`(D-):+J0E0-Y5**PH#;FM!5^Q5>.HFIJ`C^TAV+UW
M%[5&>>`20#J')=X61#DT;0,.]>+R#"^B:D_JPF+C_8A*7DC7V]^P9S.QP#(.
MAX(T9L25OX$];VX]1.V>`$2_U<%&I:QI):K7BPZM&IGQ!)/"P=E`[SQD-SC$
M`,M6"/HS$:/S^V'>JGK""\EYO8*_PJFK[8*.<=EI/LX=8*<Y0)H%G[DA/J+`
MBW!&)?(45NK.PR'5V4"XYJ*J,[)A7<-N?[GK6%@E*>*0V"-6OI(_8F9QA#=5
MT&`/^`1%Y7432=C">WP&9#44>2]QRR-9`VND()>GZ,`XPE`'RFT,$`@B"(T1
MV(G(_7IAI1?4I"\81LU%&>J7#X8D-N4"ZT=^?ETX@Z$N^&@A1,785B)$\@.=
MI!,B.,Q("?WMR1CIXB';`?Y^BI)CF.>@AI=.P#7.=)](?E.^+HM2OV%N/UQ!
M(MMED0RXJ,#T'Z%T_,.LW]R6T&8H)"^#WL,B7$`@&*\&<5I1RMD[37722W4B
M`,'(1RM3//,M):^O,5'J%,"SV"PP1^B<@HSASI-4V;X5Z2P[<4TP=2BH_9*Q
MD<HO&/(3-X*JJ#VXY_`]>7CNW"Q$QL+H)_0IE@Y:,MI_GA9Y!(BD!H$OY@"3
MH*H+`S`U'_)[RL!&2"6J8.T9%I"4RE[V.PZK-S@`,*.GO!,C:E5F`Q()6MA#
MI"MK@21X'8==A)"`R&LW"+:Z'GT^W/\`#7__V@`(`0(#`3\A_P#Q-/_:``@!
M`P,!/R'^83_+KU_#ER_S=?\`[Q/Y\^OOYDR?XJ?_V@`,`P$``A$#$0``$```
M````````````````))))))))))(```(`8`````````````!````!!`((!!``
M`)`<`````````````!)()(!)))(`!````!$`````````````!``(``)((``!
M````)-)))(`````````!)`(``))((`!```)`/8``!`````````!!()``)))(
M`!`!(``$@``!`````````!!0)``))((`!`(`(($;``!`````````!,B)``)!
M)(`!`)()`,C```))((`````!``````````!`!````J@`````(`````!`````
M```(`!`)`!(`5J`````(`````!+:(`!`!`)`!`)`!``!<`````(`````!```
M```````!`)````!'(````(`````!)))))))))))````(``&@````(```````
M```((``````!`!```%X```!``````````)!`(``!``)`````+C``````````
M`````!`!!!!``(`((``)B``````````````!()`)!)``(`)```!E(```````
M```````````````(`````!T```````````````(```````(``(``!A@`````
M````````!````````)`!````<*`````````````!(```````)``````,*(``
M````````````()!(```(``(```$+K0```````````)!))!````(`)````$`!
M9````````````)!))````(``````%MJ220````!````(```````````(````
M````0````!```)`````````(``````````!0````!```````````````````
M``````%3:0`!`)((()`````````!(```````````0`!!`))))(``````````
M``````````!3:3`!()(!)```````````````````````````````````````
M`````````````````````(`````````````!(`!```!```(``(`!````````
M```````(`!``````((`!(`!`````````````````````````````````````
M```````````!(((`(!(`````````````````````````!(((`!(`````````
M```````````````````````````````````/_]H`"`$!`P$_$.\^9(8*)$H!
M`>=^197T"M]T9`/&D2)$B1(D2)$B1(D2)$B1(D2)"$(P.O)M(QEEVF5`%2SN
M+N"QAV)18,M4@Z8VS0T?LO3A5KSJTO>M1).BSQ8$@\4D=]5J`(P6/7+/AJ'#
M8^GNF<V/8JQ%6T805*7+J/<@ZSD0V!GBOX"AO:GB^CVGR+)U<6$_1LOOFQPQ
M``U$26`"6HBRO5?P)]X+/A@`P6NJN#6R@80!.CB;"B'%B(6B21?CO*+`XP`3
MB>R\Q.OX*7.7W*W"*_$8)`3-1LM,-S!53LQ._AXH^@4=R@S4J25#%4\```9?
M(8W:;IEUH`N&*^*</(XCQ"\[=1#J'%AU3%`(G2V>GB2NKK#\3-=$.KV^R\9&
M!FIHSZ0N:K84CA@I)F"Y$LXCU$>8JFL6GUCA%H\D#9X"ANP]>'#!SRLU`?7S
MO`!A5F_"GW)<CE3U#*)@&9?@K+@0NZND5JDYU%FQ"I40?!@F85S/9.N*:5Z-
MVY@S)K.2)(.@OQN71"4H!5;@7;CN"(FCO)GQUF$JFC.'W(LX1'S;JV"(OR[.
M"4"ABS1"1(V%B"3,1B02,FWH,QC16?;7$.;5I;Y,L_K/"SEC"D.KU`HY2MG^
MX(@I.E8@[-+0"&M6.R+:Y8^A`%,1-'@"$FC0R*L"C<G)U!%L;P>-URK-%F9*
M30@CN1=KFQ"D6F02$M9,,*(?E-.?$!SAYX#5E&<_B0UYF"YB8JM1I!R(+?H%
M%<G?K/9<$+,9>$6GB[JK0![%2>:!%(1==!@".A;C6@""@1G?<N7+ERX1':S'
M7Q$Y(L\7=07K&"VP"`3?!BVW>U-702BQI3%QB"Y9=GM$2(]$.KV^R\9&!FHF
M3=2<WVFE@1J@K;L01"``X='XN/F%1RJ!Y;<Z`2BSZI33(Z=KXO#H;*F/UHIP
MAFN!B0L?0NAPLK@G"R8YKV8O^GLZDX-2F4KCD`=)2?%VJGIN=V\YPLY3BS1Z
M1=V("G/84P/R./-,CHZW'4H1C9<_CH%]T)0M$0``$.@/4HPJ[*<,CH:*@S]X
MF4<`MG&PV*\E4E5<%0"/F3KH:@>1!*)31(`F0T(^BH:>AD0&Y$!@)N@R;-O0
MD$C)MZ#,8T5G#&SZWW0@K)1V5O'8:B0VIZ7`@-$*F5.*MLF85W(*R_!%#<%=
M=0E;6,G.$`)7*;1;+XSI\,1=PHA6+DO;..Z.5/T3#0]_AP?3#>XAR>",3D8:
MB-#YVL31\1<`>X?!:R''?<^$_P"9E3`!]W`:H*VY<)PD"IP9^61QPQ/5N6_-
MTM[@3V-3"*$ZZH4@B(HC$1H1Z#$7E`1%ZN@&UZ"G`J554)#!G"4SBVV,AIM=
M%ZSYFV$H2+`V:A'`I5F-'.LF4D?<A8(L-99"JP/);A)@%"Q/B]\S@0U!&9)A
M%V8\.]%+-3C5*L$K(:I.ZM@0?EOEQ\HOX)<F'[V:_"KJP"9O#DIX%)I$`!T,
M*/(QA@7JX?-[G2LR:H"9VIP>YU1PAKE$<**X-,L%68NJPUP*NOT+0A:B&LO#
M,W>2JTUA=K)M%!LXR1="H4DD+IAI(MG72#RIUTB<Y`%D%@.E7H*#[:<Z820(
M3A'?2F,\>K\J*EABX,74Z.T"W9X[%Y@G*_L`#%#28U!E2QP(=V:,52H^]CT(
M5AQ8ZXNX2;PIR3^M#_U28B55V<%ZS'&X5T.G&6KZX\1F^T$_PSK"U1=HERNU
MRY*$2W[68(F/8`S.@8\^$UU$XO8$H;8]*F(>+=(Q\UR@$NA(`)9"J"PASA_<
M"^Z$H6B(``"'0&F1G2*S8FYO6I,5!('4(*K(TV&SG'25@MIXP-(I0'17NIGO
MS\(A8/@9H<@);$UZKVT`JVX:^(G(,O?N7+ERY#3NB4<8P^:R59_K0U^FNN3L
MN>?;?>W;!<E"]4N6(2B.)?@!FZ+\BOL*&B.;E8%SKQ-0(DRDJ!BR$QOSI<.<
M`K6[H=W0>[/&6/:!:2%6ZFD>202P:#M'B)TC.+0"?R6]QAMG5`+BD'4/M-$$
M/J%TJCRD@,UG@E3!V!ETM(1C@D-T%)(CT-6AMO/V&!B>&PJ>X,%$P!>C%JRH
M038$QX2+T,28FR)#O<WEFB4`"6J#D!!@;.FL8\5ZIU"H-7.C+,=P['%G]B[4
M6JER#C3@]SJCA#7*(X45P:98*LQ=5T"^`E""22)6HB3H;/>=[Q*B#`G"ZCG`
M/A6DL>4*UNZ@_'0Z#TC-2V\/]%&>?I3^XX:GR5-9(*!M7AR8E8=CA?3%TBQ)
M2YO2?Q;["$E^70&XIT.DY9!K;VS'>.GV&&&7Q,&-W-0'L&:@?&@Y+&!&;IM.
MUYF#V$5$*E;5=""/<@G_`&U=11A,88EBBES9,)41Q&V;5:2IM":RHT5D/S#)
MI?O,P(D8+?M!Z)X#6#E,L\%\N`!W.48.J[!"P4+;(3W6ZNW\;44O<O+H(KBV
M109<2^051_A&`=\P+[H2A:(@``(=P/MHZU+ER4B/,OV3+6[KEN#?AK.Z.H$,
MH^H'3YY;5'/7P@T'#(TYK`'D'WO&+V`31T!`/O4=#B:#!@DC-96H3&WB^E."
M07C+6WL>GL%6?ZT-?&D2)$B1(D2)$B1(D2)$B1(D2)`R:,T5H+4J-+U:"[4F
M:Q%$FDQTU8)[KMVUL"#8$9Y^(@(+P9J.%5B-,Z<-AQA030\7YMA'"BN#3+!5
MF+JNWG[(>V[(BH&J</C30&F1)L[(A`,:181QG9=4/X@LJ`.>O"JF*`1/$;MV
M[=NW;MV[=NW;MV[=NW;F@)^F0VQ9&D!Y2(@S^5+00P&*"^C#I7B4,(^C3;9W
M&3^Q49W'UD5;#B<>&"CPQGJF12E6)@B8I&<$6YSYV%?"P`%F@7H>$CI,D:=A
M3!Y/J('6IK:^=]EZB>EYJ>KH`7%P4497),%!'V==\,'F]/D-G+-"DU@4==5U
M"S>(Z#GAP```@&@[@9/"`;&ZP[]>\A2H\H+-$A+AIVNF;J-=(_#0_<^OYOX:
MCJJ>(S9LV;-FS9LV;-FS9LV;-FS9C-<CT]84-R&HKF@H\2B<*Z;MY3`T&42(
M^<ILS<B2H"()A5,TI@L$93:RRC]8T&%PDK*8B!0!96+LV)Q.]\^7(/(3T0PH
M<[7'0\(',G-'`9JEREP6Z<1["BV@;PPBXP;XNW*QI/%``LK:/S5>47U7SL`^
M#H%'PT`W:I8THX\H5LS-*%@FD9N=/9"KXP9><Z)%@I(`"(VS`0$[TN5@)3%0
M,)6H,\C?.2-0PULD5,Y;#NR_E3GM*W0!T[*H8DC3\%S)?TQ(TR3R7P3PB-*;
M!>_\QROW_!R10<F`O0.'!P8T7'!.X\LLLR1*;%.A0;'%A+=$'>4V*+UQX19,
M&G<WJM3R@0X1O`<0]`V!O7%)5)"YLWPR!D8%K"+S0[1(3;Q"KR`[!*X%:DO,
M$38=E^E#.3K79PFY]-3$TG*`=:1#`&ZT#=N1@F2VT9D9BS#S6PX<)S?1F1'(
M0I[$F`5A10U:&G!="ZG>8*`:`Q*Y$TEM@V-(>#0SS<QE"0M,C&[=GD&^(K[2
MA\U"G(4G_451[A08:/M60+VJ99/613B<!0DP#,+VQ/:(I$Z2Y@;3H>;]T(R@
M$!YC-?3FY'MCB*@-A@"A`8$Q[<MJM$:DZXM''A^`%218,*LBGB.NU;`E42B,
MHAM-*OCUS)!@=_Y+*20!TV\O'+S"I2Z(&A?A8[$4H!AV8M!;_P#S=M]$H<.H
M2@&BH>Q.H'@@*RH7<@D<#?[I>IZ:EPHM4.@YX<```(!H.\'_`)@/.M1$+2/R
M91H$&:6*%3WOWG]1PW:G^H34?(8H#H+%@@/-P<G,&I853A5,BD)&#G_>J$.>
M!Q7T)-=!0!Y+C<!$:E!)#78Q_P#9<*RL`!0Q^`&OV^=JR#@)=0]98-:QQ%AM
MV#\.0WJ@N*/V4$W,2:3_`#DDTQF=="$5J^F.07.,+HAF*XY)=BO`K``Z_)R5
MR!5@#]LQ<!JIUKCFO3U)AVBY"O$%S36>&!7RNF$^G$K4U=R=APX3F^C,B.0A
M3VN6Z!5?678<;Z"--(-*&$O`(V29DX:C`BLS#<6QF(0;\R,(+5PR@$*6H08+
MQ&W5@Z'2$I'P.%,&,`+P9RQPD+E"?1Y,R>.HZ`&:K#JF*!%,%-13<$@L(9R)
MW@U-(K(G0H3-.6YZLDYG,PI@7UGXX@&$K*,$9&FL*H6*.0W+82/FF/\`$H2&
M(XMR2T3JW$/<">8,^`%R=UQ.XZA5E.!*A9_TX4!X%((%KJ*`_473T+NH_J*1
M74@%7/\`LN%96``H8_&#\W>%J^/QEK"?-500^)@"&"2^=#'2RV-4G4.L9,A.
M\S3D@8`@>489Z,R(I26Z"#HB.\V1*G(/2O\`ZMD#%0EB@$GU1T^`T];,IHTT
M=I2[*4`<,&04B^91>>/#+7\:%Y8&`[_^GT&4<K]>C'!&^B(K==@:B^!DJB70
M570S:#&3[B%-!O1/<DT!OOL'8=#-Z!Z>?`DN0A]]$72$P;C8+;M\AX/<)TVI
M6N]CQE+;`J!/X17N71^2&+)/BP1%'HU1@EXTI&[('O/[O2&?U]>C/SG_`*1<
M`D8@=[T0LOAE_-?X-GDLS!$-P5.'F)@$X"20Y0>#1"8%+1OPRS%QL2I-.#\!
M?O%'(0(0%T)V"&TE$S'K[$^@5#<XEFQ]H10N&A4G`#01:`>4;'&\O&X$MLRG
MU(`$!M+D:18LZCO+4<>@B(A)(IKSH1%C,RM=4B*63K4'1!TJ=0`+*I6>AR08
M)?*#=U0Z[9OG(TTV1S4$MO:4TM1X!VJ;Q5D(B#)LL?\`VQ[13FLI:A&1QAJ1
M0LK/AI5-&</N19P`N(7)340D..:\WBJ4^AHL90Z`#$Q=Q=?DBYP@@>AK<)70
MFD7P-F:4GA9VY,`>WTDA,C%#0%LE]I9/;`,8I5K]$528F9/X04.):PD5;/']
M,7/GGM&9N4^A7G`VY+\DNWP"K>%OJE:%E+*M60;$-,LJ8.J41S4,6;/*0"ZQ
M>AJ3!@[K![3X09B0BP'68#OT=B9,F+]X`%J1+HX2,CP?3Y;"&;YS\]*&T-2J
M!4KM<:X2OJ@>AYE<=GK$'>(PY%^<,0<%=5A41(;PTU0%0]&$6$R`H.QCJ6BC
M2I(T\H`TKTP(X_'V>:;#28TK"'8##9;(00:N(5GY=2`U%33GNV,N(KB@=`D-
M*#L&MS5GKPS``;]H-HRJ$\_LF\C=/^C@^I2Y*X\92VP*@3^$5^=AL$J.$AUD
M$X!*L('$M#D?8^%]ED$_+VA_XLLXFB:>+*C1>'>.;0[WUTY*R7`!$H".Z8`N
M.377^D(21`_6YJ&`;22`,S=H/+P@8=D>X/43L%8G'_O-'OY0]C\88C(6DIS-
M(/S\YM!`L0_(H`.7"\L7J14`F,FSP@<3I&KR5&+5Y#)^<".#%B-"<M,H($/[
MK[+1K6P^)B5PLL%"YOU@;%,"XB];)G0"O+$D*L;A1SAZ,;$*UL9X'=I[6O#;
M+M!*^'I/,A)O@QGA8*?XM(%"LU0AT;Y9O>)9^4PN824)9=D!G4ZQD:.SQ9%%
MBE@><*0Z;9O,5\TDM`9?PSUD%SH(NB^_50.Y#,S'[L&4<!IF;L8<XX4XZIE\
M*A`S5;FH&KNH&CRMK$)N:70IBU8*/^S[PFU5AM"4R@]\]K<N/5"CZE4!'`W3
M_HX/J4N2N/&4ML"H$_A%?%2:PB%]0+ZT&B]_W>DU[,^Q3=0S`V7'Z[B/>DPY
M/(`]&J3,0*B9.'2!8M<([7(3(MAX`A$G0YK'C\Q?);9CKD8DY$01V3-J025;
MJBW!U7,,^F)""'*WWF@E/6QIR/DL[<_'OS()KNR$.63AZ'AL4G0#Q4A0`.OX
M:3-FE3X*&("`AC5*T"S'6*?R/9$S5#OD`[>DX7/QY@QMA(O,J!L>S8N1-P!.
MP_ZEG*X-T@@<7LJ<&9B2K0]$2PL*&"0+9J,%-3TO6F4G*@Y0@%9-X&X7RQTJ
M.%[QMY`6%(H]([/+E69F7^S'*R;U`1V2IL>D&T,Y%6N/']>ZLJB)@%'.D<`?
MY"BLZ(#B%-S%NX+;!S6?@N0-/(F2@#>$D?A0]*BZO-'+>56104D,G3$B"E=Y
M/?Y9U?PMPIMG8"J23?IQ,$$?V$&\QA20S,`'T2G8$4TB%K56/Y#^E8L6+%BQ
M8L6+%BQ8L6+%BQ8L6+%BQ8L6+%BQ8L6+%BQ8XQ6K@@AV1(UW-$\21L1%P;U3
MFQR+V00*K`4(#.\\PP?-]"!_[,>X3P#V9F`9O;"]*WE[7<T6*<(.9SQ@DXRN
M[B42DNIY'VTA51ZJ,PJKM%7R,=@0O<CY`XW(*$[F?Q`W)`V#A!=4+CK>79QG
ML)=@2MLPBC!(8X(2[B@)@M-9_I,@CT,P/RA.R,OU[0QKID)H7YB7U1BZRO%(
MAFB^DMW>`\TSM)'N*<BVC<CWO7M6M8@QZ@A`EJ=I5[!\G+NRD$AT!""TM\5>
M-!M\M>X?C$Q`.O6!R-:NP1;@C%_(FV`*DR-:,AAX][^T"=<Y80VB21E7\CM@
MBY'`)RZO9D]@\53P/971D/31016D@&J'?&,LP1BPY0"ZLWP4%VJ=*^]GE5S]
MV&<,DD^Y)%;`#$Q?I+J5)*ABJ^`50,`>"W&M`$%`C.Q9+#=P<V/`HZ]S;B92
MYYOO<`1Z?WE@"$?VLMN'0<\.$!`-$TGUZZ:2/E+G$J`,2U.XV]&*S3]:;Q7U
M^)C(=4D-V/8>UNYZ!`BH7G;7L%V<)F-/]S:(T"VAYP$NAGXQBV?$CX7D8&F0
M`A>@%"M$5ZI68XK@7%JTZU#CEG<J!/C=?J`6+$!:,5=KFS`"<T2-XNVU!4HJ
M7`VXU2$H3DI-73[B4"1.M8Q!$X=I!26+%-8_7GY<Q^$,:9M!<<<N8NG/27!&
M<#A#?N,($PZI9!*;C6"8"LL8K"4?NV%YM`%SJ.3J^GK]53`\#.P/;B+,4.1`
M`40$4;3N:'`)I^^IE20HNA,:_+2AO$..Y(DB)4U7R9-Y@3,>^JCX.`E%M6EF
MW5PJSQF_'UP`21?<"Y1'_">?ZD]$-AI9*:`3D.NDJ%?PS__:``@!`@,!/Q#^
M81_+KW_#DR?S=/\`[Q?Y\^_O[ER_XJ?_V@`(`0,#`3\0_D&(8_QX>/ON3$GW
MSDGFQR.1\XXP_3$?,K*ROG'&28/^?WIPX:R_I]X,RGXP=X\^5KUFO[YK^_T)
MS]\XQX^^_P!L3W]Z+<Y9C]X<X\[QGK[UX,>/O7@SU]Z.'$SC[YR?KG'W8S'C
MH_G[QXZ>OO/70<N+<6_?)K)DR?;&SL"3*Y7*Y7'[Y/OC[^:N3)<"F!<GWWK[
,X_&3>)B&)D_P#/_9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g575431g68p97.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g575431g68p97.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`80+0`P$1``(1`0,1`?_$`+,``0`!!`,!`0``````
M```````'!08("0$"!`H#`0$!``,!`0```````````````0(#!@0%$```!@(!
M`@,'`@(%"`4-```"`P0%!@<``0@1"936&2%1D1(3%%@Q%4$6(M-4%QAA<8$R
M0B,F-E(DM4@*L<'18C-31'1&=G>W.!$!```"!P@"`00!`P4!``````$"$=&2
MT@-4!I&A$@15%@<785(Q(5%Q8J)!L12!P3(3!23_V@`,`P$``A$#$0`_`/OX
MP&`P&`P&`P&`P&!3'9M0O+>X,[HF+6MCLWJVQP1G?-HI4@7D&I%B8SY!`'],
M].:(`NF];Z;]F\LD\,/$AB21HQI:(PC^U$:8;X->))_[)8R320FPXPC"/Z_O
M"B,-C6%Z*G:P*#[.%]6A#UUK6@JYEUW^OZ=93O?L#KKO_-O.WPO*7D"22$O+
M_P#UN8A@0A1"$LLOZ4?Q*YS'TAIG'FX^8Y/"C-^\8QK=P]E?M9[_`%X8U<'?
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MOKCVKY%ZOS5F6HCHG2</SR.!MFK=?18[6/7Y?\&57?-O]`_=3/6Q:Z=>H>LH
MUUU[/]&/:WD7J_-69:CLG2=-'_!P*?YFK-=ECM9;]G^#&KM;]OLVKF6NO3IK
M?3_BCW[Z>_'M7R+U?FK,M2=E:2R6!MFK<Z[*W:SW[-\,:O#O_P!95,]?PUOV
M?\4>W]<>U?(O5^:LRU+'1.DX1HCR.!3_`#-6[>BKVM.NM:X8U=O6^OMTJF?3
M7Z?K_P`4?QZX]K>1>K\U9ENK#1&E(_CD<#;-6X%V5NUF'KO?#&KM:U[=[^[F
M>M=.F]_KN4:U_#'M;R+U?FK,M21T1I2'YY'`VS5N?15[67X9U;XN9>:,>U?(
MO5^:LPNG9.D\E@;9JW&^RMVLM:Z_X,JMW^GLTKF>]^W?3V:_FCVX]J^1>K\U
M9A=.R=)Y+`VS5N/16[6FOUX85?KVZU[5<RU_'V__`%1_#7MQ[5\B]7YJS+=(
MZ(TI#\\C@;9JW;T5>UE^&=6^+F?FC'M7R+U?FK,+IV3I/)8&V:MQOLK=K+6N
MO^#*KM_Y-*YGO?P_FC'M7R+U?FK,M1V3I/)8&V:MQKLK]K/>^G^"^L->_>U,
MST'7^G<H]O7)[6\B]7YJS+4O9&E,C@;9JS?97[66MZU_@RJ[V_Q^[F7FCK_'
M+[5\B]7YJS+4G9.D\E@4_P`S5N/17[6?7>O\&-7=0^T6M+)D+8=?P^;6I1UU
MUQ[5\B]7YJS+4=DZ3_7_`/#@?I\S5NV^RMVM-:]G#&KA;W_#2N9?^7<HUKIC
MVKY%ZOS5F6H[)TG'\<C@;9JW7T6.UG[>O"^L0]/^DIF>M=/;[=;_`)H]OZ8]
MK>1>K\U9A=(Z)TI#\\C@;9JW?795[6F_^YA5VO9_%7,^GQ_F?VX]K>1>K\U9
MEJ7L?2D?U_X.#1_,U;@796[6@?\`N85AO_+I3,^G^G?\T=-8]J^1>K\U9EJ(
MZ(TI#\\C@[9JW7T5^UK[=_X+JQZ:W^OW4RWUU[]:U*=[WK?\.GMQ[6\B]7YJ
MS+4=D:4C^L.1P:/YFK<:[+/:S%^G#"K]^SK[%<RW_P!+V?\`-'L_U?\`-OKC
MVKY%ZOS5F6I(:)TG'\<E@1_ZS5N_HK=K/KTWPQJ_7LUOVJIGK6^ONW_-'3KK
M'M7R+U?FK,MTCHC2D/SR.!MFK<^BKVLOPSJWQ<S\T8]J^1>K\U9A=.R=)Y+`
MVS5GHJ]K+\,ZM\7,_-&/:OD7J_-6873LG2>2P-LU9Z*O:R_#.K?%S/S1CVKY
M%ZOS5F%T[)TGDL#;-6>BKVLOPSJWQ<S\T8]J^1>K\U9A=.R=)Y+`VS5GHJ]K
M+\,ZM\7,_-&/:OD7J_-6873LG2>2P-LU9Z*O:R_#.K?%S/S1CVKY%ZOS5F%T
M[)TGDL#;-6>BKVLOPSJWQ<S\T8]J^1>K\U9A=.R=)Y+`VS5GHJ]K+\,ZM\7,
M_-&/:OD7J_-6873LG2>2P-LU9Z*O:R_#.K?%S/S1CVKY%ZOS5F%T[)TGDL#;
M-6>BKVLOPSJWQ<S\T8]J^1>K\U9A=.R=)Y+`VS5GHJ]K+\,ZM\7,_-&/:OD7
MJ_-6873LG2>2P-LU9Z*O:R_#.K?%S/S1CVKY%ZOS5F%T[)TGDL#;-6>BKVLO
MPSJWQ<S\T8]J^1>K\U9A=.R=)Y+`VS5GHJ]K+\,ZM\7,_-&/:OD7J_-6873L
MG2>2P-LU9Z*O:R_#.K?%S/S1CVKY%ZOS5F%T[)TGDL#;-6>BKVLOPSJWQ<S\
MT8]J^1>K\U9A=.R=)Y+`VS5GHJ]K+\,ZM\7,_-&/:OD7J_-6873LG2>2P-LU
M9Z*O:R_#.K?%S/S1CVKY%ZOS5F%T[)TGDL#;-6>BKVLOPSJWQ<S\T8]J^1>K
M\U9A=.R=)Y+`VS5GHJ]K+\,ZM\7,_-&/:OD7J_-6873LG2>2P-LU9Z*O:R_#
M.K?%S/S1CVKY%ZOS5F%T[)TGDL#;-6>BKVLOPSJWQ<S\T8]J^1>K\U9A=.R=
M)Y+`VS5GHJ]K+\,ZM\7,_-&/:OD7J_-6873LG2>2P-LU9Z*O:R_#.K?%S/S1
MCVKY%ZOS5F%T[)TGDL#;-6>BKVLOPSJWQ<S\T8]J^1>K\U9A=.R=)Y+`VS5G
MHJ]K+\,ZM\7,_-&/:OD7J_-6873LG2>2P-LU9Z*O:R_#.K?%S/S1CVKY%ZOS
M5F%T[)TGDL#;-6>BKVLOPSJWQ<S\T8]J^1>K\U9A=.R=)Y+`VS5GHJ]K+\,Z
MM\7,_-&/:OD7J_-6873LG2>2P-LU9Z*O:R_#.K?%S/S1CVKY%ZOS5F%T[)TG
MDL#;-6>BKVLOPSJWQ<S\T8]J^1>K\U9A=.R=)Y+`VS5GHJ]K+\,ZM\7,_-&/
M:OD7J_-6873LG2>2P-LU9Z*O:R_#.K?%S/S1CVKY%ZOS5F%T[)TGDL#;-6>B
MKVLOPSJWQ<S\T8]J^1>K\U9A=.R=)Y+`VS5GHJ]K+\,ZM\7,_-&/:OD7J_-6
M873LG2>2P-LU9Z*O:R_#.K?%S/S1CVKY%ZOS5F%T[)TGDL#;-6>BKVLOPSJW
MQ<S\T8]J^1>K\U9A=.R=)Y+`VS5GHJ]K+\,ZM\7,_-&/:OD7J_-6873LG2>2
MP-LU9Z*O:R_#.K?%S/S1CVKY%ZOS5F%T[)TGDL#;-6>BKVLOPSJWQ<S\T8]J
M^1>K\U9A=.R=)Y+`VS5GHJ]K+\,ZM\7,_-&/:OD7J_-6873LG2>2P-LU9Z*O
M:R_#.K?%S/S1CVKY%ZOS5F%T[)TGDL#;-6>BKVLOPSJWQ<S\T8]J^1>K\U9A
M=.R=)Y+`VS5GHJ]K+\,ZM\7,_-&/:OD7J_-6873LG2>2P-LU9Z*O:R_#.K?%
MS/S1CVKY%ZOS5F%T[)TGDL#;-6>BKVLOPSJWQ<S\T8]J^1>K\U9A=.R=)Y+`
MVS5GHJ]K+\,ZM\7,_-&/:OD7J_-6873LG2>2P-LU9Z*O:R_#.K?%S/S1CVKY
M%ZOS5F%T[)TGDL#;-6>BKVLOPSJWQ<S\T8]J^1>K\U9A=.R=)Y+`VS5GHJ]K
M+\,ZM\7,_-&/:OD7J_-6873LG2>2P-LU9Z*O:R_#.K?%S/S1CVKY%ZOS5F%T
M[)TGDL#;-6>BKVLOPSJWQ<S\T8]J^1>K\U9A=.R=)Y+`VS5MI><&ZTP&`P&`
MP&`P&`P'36!C?RNMUVI:EI!(X@D3.EGR5>P5G3+$JV'9+]<5EO*.&UVB4E"U
MO9S6A?W8M>Y=-;^DUHU)N^@2][TA^D*(?@8:=L623JM]7]P&NJ=R*RK9X9SI
M%J,V5-5?W<MN+C;=93A8%+68[J!BWI<YH58WN*.`RM?3+6QL0?\`:#UL9HQ_
M,1&/-EH3RSNQ]J^NGY:_*H!.ZLYYG3:$II-)FN*RTZ$P:KG>(J)(PL[JA:WM
M1&W-T4'(AJ2C!)S#A[!O6Q983S0_$8B3>&ZJ90#G!SIXV1>52>9\7:PB_'*;
MP-+*WUWF`Z5N"T6N=*[,I*-RU^6N3THBX(VR,$E)9E*H_;!^^:`3HI,I)*#(
MQC&-,?R,7.Y]">5CASKX>V+PJF2U'>-+<<N3MY@I![D[^UU7RM:*[G7'J*+J
M-G[<C=2&!`ZO,1M=]_EU\/2FC:GL:<8]Z*^80+Q3444_H-IO#SEM4W.6AF"[
M*MVZHF]T4/$0G]>2M(8TS^I;+C)^VBPJDLQ@,V!7&IU"7GYTJM.9K7U0?34$
M[&0<48*4Q&I^J>2-B4?VS^#T"JN0*U?(GF)?:OC54\VGZ]SGYL1>IM:EM2*:
M6P_?S*L<U\H*JJJ8<ZN2)`I-$F.5I420>OM]B!I&,8_D;4VK@WQV+BIL;F4/
M76P[N"78)%9-J2-\EUH25Q-*T6L>U4W/7)W=E<U0P[&$+0)M2H^N@)2B2P!`
M'+CGA"B$?T&('&R=V7QBYTRKMV6G/Y1;51V32KCR6X56!8;NKD5D1N*Q"4-<
M,NOCG-YHX?.[6"&NG&2-#O&W9>8>Z[8W+:58>H&C`=O'BC^13.QDN=W7A1)W
M%^D$HD[H+F/SB9Q.DPDK]+'4MIB'*&S(5%V<ASD;FZKRFI@BT<1(DI`3-%%$
MI]:"'7MWM&::/YB/%R8CJ&==X[A-7<G4R!P@$BX2\Q'V0PDF62EJB;Z]Q"Q>
M/A$8=WB/,[RWM+JY,1,J<`)CE!)AA0%@]!WK6_98330_$8B9N8'&"3U]2LYN
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ML&6NA5;68RIVY9'GUO!]'9RH>M&`"H+,$=>.>/\`J-I;,^L4C1[<8\\-+\WZ
M//2[7,S@C=$>E28>RU*;:I"<>1]PG,U\HP?-\P-^S>M;R4Q'=Z2D+&=U2*"]
MF$*6U>G/+",96S"3TAQ)H/JE"`:7\P![U\P1:%K?MUO6\4Q'RJ4RT.T9[!5<
M\T8/8MA1'F)6U5R^RZZM;^\"9R"26;9\?MN5-,.JF=-3R]N*&U66V!H4D6&R
MN"96(X*T&DFBU)91@;&>:,*(Q_0;8)=;,_Y/\R67A(B>'VLX/4/'"`<C>8A\
M(>%S',)+([>>GF.51QY9IBW'IG>)Q=2*'/SS)5C>>2YK$*5$A)/)*5*A"E,1
M/]I<!J*F\0-9H&@?Z!G[>E,-@UW4A(':$V;!I&`.]MTA"ZI%WV\U+3JN@E;9
M("W1L<R?F*5$FA'O+&>>/Z4Q&EOE'RQN2[^S-RX16R\J8ER]XA<F8!Q=O>1U
M6[/4$)>;!@7(VFD!-D0TR..+>ZL,;NFJYB@=OLBCOHE`=U"37S%%ZR0FC#\1
M&P.[8LOXR\X>W\AXQ.,@9$G(6Q[1KKD+1Q<DD#[`I/2L4IJ6S<ZYC(L].;F@
MATGJR=-+(C+?$`$8E^G\+<K$?M0F""QFFC^8BB=R+B-2-9\&N>-ZP]OL)GN&
M-\;.2=I,-BIKPNX$B:)X5`)9*$$@;C2["+2(3VE\+`:C)))+3)0%%EE%A+!H
M.K_[)_WB)PXI<-*$,J7C%<H8_-MV:&LJ<L(^8#N>YE+@OE2F#L;@X+W=$X6`
MJ9GM.ZGJCONTJM,<E4A-%H9>_9O4C//'](QC0,!>(U4U;??-CO*MM_.4BDK/
M5/,>LT5<E/-PV1'45<LKGQSKB9O!$0`US9G21IN,D[BI<!@2Z**TJ,$/>O9K
M6KQS_O$9,=WX)^Z^X$(&]YD25OE'<YX70%__`)<EDC8=RN"3>5O+)+(J]K8\
MZMZQ\CLG:#MDJTQQHRE`>@MZWOIDA--#\1%:2L[]0'=$I:HZ)?)*;25W\:KS
ML#D33BZ0O4DA56OE:2>N6JGK?BJ1\7NAU=.EB.LH=&%4C2C3M[\%!M0$@1Z`
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M]QU]<HG+(M(4`#E)*5]BLM8E[:K"4:<1M0E'LLP8-A%M3$3=TU[M?#%,0Z:]
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MM;84@0[B$1F!B]^JND%3BN/)4$E`+W-T1@1:-*UL(8P<KI9R+XF\MN)'<%O&
M.4+#:H-?D/![DT_5;.[`?S_[J^1$I:@T]-9B5,Z^B#8W,-2<@"$&M+-'&&DI
M9.L!\N@#$+07ESIA<1LGNY=HF(S=O)>F1QJ_N'K#6[3BO;1J3VZNJB/2'DJ6
ME<@<-@+WU%T"9\@@[_I:WK`IW&U[/[7'*M[X26NO6%<0^5MBRJT^"MX254J6
MEQ.V9FM&]6=PUM6<.ABA8LDACR,;S7[H\*AJGEL--:?KG*$1!6PS$L8TGU4>
M*16S2OJ"X1\TA?3V8'1GTPW#PST(6B_FT+8-;UTWOIO777OU@8O\PZ?L_@W>
MK_W.N(,0>9G&9&G:B.XOQ2AR,2A3>]:QXD"0CDG53`2,I/ODS2S$$9AY)80B
ME\>*-1&;^[+3F"#!,J/S&5]IWM;\XZ(B<BME5POO]HYDC@,::59\SL7CS(9+
M<4-ME%%8[\@UBJ;H*DLP]Y2-_3:DTYO$G`#9HPAV'TITW<E8<@*VBEO4W.8Y
M8];S=J3/48EL77DN#8X(E183/I&"+%LU"Y(ABV2K1GA*5HU`!DGE@-`(&@US
MG1T?)7NKU9<\+$!PJG@C05Z5E)I\@T`UAE%^<DWVM0*JOC[J7L29\459`JV$
MMD.TXS"FYP=T20S>E.CRR0LGL2FDZX,R@SZI7TR^:W<%&,?U"_D`#7,>YA;$
M,6M_*'6@;Z[W^G3V_I@5"W7%O<^]OP'5MJ]$X)57`CG*J3*42HA60H3#LSBT
M$"@@X@PPLX@8M=-##O8=[U^N!GKRWO&,4!1%@SA_^=U=38N^L<!@344)PF5I
M6(\MBAOAM<P./IQ#<)'*I8_J$Z0A,G*,V#1HC3-@(+-,`$5]LKC;(^(/`3B9
MQNF8TXYI5%*Q)AFH$AI:A&DFBT@U^EK8B5%Z^16A:9$[*4Q)H?Z)I9.AZ_7`
MU]\M.4$:X.]W^EK@Y3*M0OB?R$X=*>-U:WX^$F$UY2W(5CN9QL)_C4WD6RC$
M$';[CBRII!MR5#((/-9$Q9@OHIS3"`P(YI-U?=M*QY3R$X8K:8Y7\1.:KV8G
MY/=J!EE\-F;M8DUEA`OK7[PR@",4D+7/QX]:6RAD2MYJ!0D*&L#H(0`$C#<1
MV39!QN7=M'BI'.-,ZA4SBD)JR.1N7ZB@/VU;'K1+2;<+'CDOCBTI)(F"5M<J
M6*BU)3H04N."$)P_G"8$8@VHN`@Z;UHMB#H/V:C?S;%K0>GT1[Z_-O?3ITP-
M-_9%AD)F':GX'O$DC4>DZV(1V;/L46NS:A>!QYZ!;-@DA>67:DM06A=D^@["
M6I*UHXK?7Y1!WUP+9M%])X,=W)1R3M(X3!Q;[@5`U/QX?+;7C$5$*EY24-*I
MDMJQDLAW'_U&)1FY(-/EC>U.JP923;Z@`E,,`)05O8;H9++8S#XT[324R!EC
MT186I0]O4E>7-(W,;6T)B?N#W-:YJ3`)$Z(HC6Q[,$/0>GZ=>NL#Y5>7E5NR
M3M9=V#D[,&5TB;;SLYHTY=4)BTE3J6!Y1TDSVSQ@I6L7A^:U@4:]A>K%C-?#
MD0DIOR*TB5W3EF?(<`80AG9RAK8WMF\C(SW&Z6BTIDO&IRAK-1W/6KVXR43]
MZ@U6%/JMX@W*FKTKHJ?GPC=3/CF<7-FEN%HIRC9^EWT1*6_1FPRS[F$SBM@=
MI7G=/(5)F*70J6\%^0LBBLJCKFB=F!_CSK3$I6-CNTNJ$]0B7MZ].=HPHTL>
MPC"+6!E1Q(&`?%;C-L`P#UOCU2PM;`((M;"*N(YL(M;#O>MA%KVZW^F]8&EC
MA)QEX[\AN=_?)*O*EJSMG2?F'4[`G'.XBS210C9EO%.KC%;<C5.24]2B3''G
MF#$$H8.@][WKIO`GWO)LL-?*B[?L2.`VJX<O[JW!&*&MR5R-3(S6XB>/+:<S
MD+FQ<D6IQIRDPBM_0/+/*^GOH(.P[Z!8EAM:?M(\PG3D>4!R%V[N9)\*@_)!
MS<G!WDQO#V_HTC#&:NN):^/1[J_M_'2T&XW3+(RS5&VR,/GV[CKZ"=6JP-\*
M):C<D:1Q;E:9>WKTQ"U"N1'E*D:U&J*`>F5I%)`S"%*9208$99@!;`,&];UO
M>MX&M*"C!ZP/(\OYP?4]/WBP/Z?SA^I\G]_')[7S_)U^;Y>OLZ].F!YZ@5I5
M/=MYLF)U28\`N$/`P81DGE&A$`-K<X"Q#"(`Q:V$(P;UO?Z:WKI@6W(R]/\`
MW@VI"TR-2S&NO:QL(E'(6`38K7-WU.5]?D:<6S:],YMHU:88]_2V:0<4$S_6
M#OITP-B]/U)!Z*KB+557+<>UQ&(HE"5N)6+5+FXJU+@XK'IZ>GAT6C-6.C[(
M7YS5+URHT6QJ%BHTS?M%TT$EX#`8#`8#`8#`8#`8#`8#`8#`8%L38]0EADN4
MHS3B%:>,/YZ4].(0%!*@EJ5F$&D#!O0P'%FAUL.]>W0M:Z8'PF45>_-.HN+R
MBR+.L7D5&GBP^R?<O(V$;G?+_D_?;+S.M8#9!G91(8P<]F0ERXDW+Q[1D&KW
M2/Q%UVYN#=*`&(5IB9">86&QGF#W(^3,EJGN=5RV777U0SFHJTY=16LN.<&@
M%S-G,"%LM'1ZO%E8\GS;M8I0Y1YMC%N%RDUR2;6,[0G5(EJ).T."YP(7`V%<
MY6]VOFKQ=AW("N'B5TBXWG3'(VP:_@T]#QXD;77=OQ*)\(ZKY8MT24HICR4C
M;/#)<;)K)%'B1)7V0/TG3(]ELS&:XZ/^D%ZNW=,YPN,.MRZ=.?':IJ38^1?"
M+C61(Y13]@2)OH5DY/47QBNVR^3ML2HVV8VVR6!UJHM]?'$#>%.Q(PK%:54Y
MN11*0\)P15+^1O(=V_\`#W<F+S,OZ9N=K[Y@VFW-5Y1N76=7)@Z[.[HA$/2+
M(C)4S@\V;6U1G50I$E1!3*%:IEBIFBRMFZ)U\P;,.U7?%,;K$$-UR,JRSYO9
MMV31BAQ$"YI<D.;C<ZND4JUAFCO'6VR.2[`Q3-@>&F(MJET5,:8D+60FUI46
M,9ZD\.@T<\K^3M[0ONF\HVMBY#SM`\0;GWP.C-84S&N6G(5!;[W4$LAW%H=H
MPVB^#:&,.?&NZ8;*MR9]$]N,@=&X:`)SDI"#9J,G9H21<G=NY1W3(N5U,1.9
MM:*#1Q[K:4UY,JRA3]3MPUXJK7NR\=.,LKK:2$-MS6-*P)9A6<I6&N6I$VQ%
MX<$0C%9344S+B?F#TM?=MY15"[P6EY#S9XK'7-.^XKS@K6R$_(.E94B8J/X\
M5'R6F$>1N\IF3/?;`&+.PH<W)4U?1332J7/A3TV@&<!(A5NJ@/L*P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&!3_`-R2?VA-XI+_`%V7@G^-]U:(?:7?4?N23^T)
MO%)?Z['!/\;[I1#[2[ZC]R2?VA-XI+_78X)_C?=*(?:7?4?N23^T)O%)?Z['
M!/\`&^Z40^TN^H_<DG]H3>*2_P!=C@G^-]THA]I=]1^Y)/[0F\4E_KL<$_QO
MNE$/M+OJ/W))_:$WBDO]=C@G^-]THA]I=]1^Y)/[0F\4E_KL<$_QONE$/M+O
MJ/W))_:$WBDO]=C@G^-]THA]I=]1^Y)/[0F\4E_KL<$_QONE$/M+OJ<;<DN]
M;U]PFUUU^NE27KK_`"Z_WV."?XWU%$/M+OJ1Q`JRJ2KW.<O5>P>"PMXLV2;F
M5BNL7:&-D<IW+AI@(S9/+UB#Z1\A?QI"@$_=JMF'_0+`7\WR`!K3@G_KOJ*(
M?:7?4_2TZVJ2\84Y5O<<%@=I5^\G-ZAXA-@,S!+8JZG-*XAS;#7%A>P+&U:-
MN<DI2@C9A8OI'E`,#T$'6]."?XWU%$/M+OJ40VDZ)42NM9TIK"M54UIID51J
MI9<IC\>42:MH\O0`;'%EA#Z>68Z1IL<FXH!"@A(:46>2`(#-"#K6M."?XWU%
M$/M+OJ79/H97%J1ARA-EQ6'3^&O`2@NL5F36PR6/.'VYP%*4:MI>"U:(TY(I
M+":29\GU"30!&`01:UO'!/\`&^HHA]I=]2B%574),SBUC!A$)%/X/$%D`ALW
M,;FDV61B#N(TQKA$F9_.&:Z(H\X'(B!GI`&Z*.&26(>A"`#87!/\;ZBB'VEW
MU)+$X)1!UK[A+K>NG_Q2;I[/\GU_;K>."?XWU%$/M+OJ6S#(U!:ZC#=#($PQ
MN'1-GTMTT1R-$-;.RM>G!>K=%@&]M0B*2(RU#BN..$$L(0_4,%O6O;C@G^-]
M11#[2[ZD$JN(/%!3))#+B*9K]E?Y@L-<IDLB@=PTJ8N9XOF4N<O;HFYLK7*7
M%9O_`-N>O(4&G_[8A8X)_P"N^HHA]I=]2>8ZQ1&(L;?&(LV1^-QIH2Z1-,>C
MZ=I961L2:V/>TJ!K;=IT:(C?U!=0E`!K>Q;WOKO>."?^N^HHA]I=]3%HW@%P
M.,0*FL/%;C\E;5YZY4O;VZ"Q9K0KE;F<>I<EBQ*VEI25*QQ5*3#5!I@1&'&&
M"$,6Q"WO;@G^-]11#[2[ZE]R3BIQ8EZV&.<EI&IG1VKF*IX+7KT.-L*5\@<(
M2:+TGB$,>T.TSM&(X7]$'_4T9Q1`OD#\P=_*'HX)_C?440^TN^I<D-H.@:_?
MB95$JXA37*TI)Z=%*324CM)F].J!HM40VO[VI<G9N(5%ZT$T!!Q83`ZUH6MZ
MUKHX)_C?440^TN^I-G[DD_\`?IO%)?Z['!/\;[I1#[2[ZED6'!ZRMN)/$!M.
M&P:R8-("-)GR&SUDCDNBSN1K>]Z*<V%_)7MBT&A;ZZ^H4+8=^W73>."?^O\`
ME440^TN^I`U"<).$G%EX<9#QOXO<>*.D+L08E<)!6%:0&'ORE&<(8C$0WIG;
M4SF%`(1F^I`30D[Z_P"I^F."?XWU%$/M+OJ7="^,?%^N;5EEY0&D*?A=PSL!
MX9I9,4B$5CTOE0U6R]JU$@=VI.E/=5BS90?JGG?,<;T_IB%C@G^-]11#[2[Z
MD[KC&AT0K&QQT@6H'!(H0KD:@](:G5HU9(TZI,>6([83"5!!@@"#O738=[UC
M@G^-]11#[2[ZED5C755TM#6FNJBA<(K*OV`2K;%"((U,46BC-I<J/7K0M3"S
M`2-J#2Q>I,/-T46'0SC!CWU$+>]N"?\`KOJ*(?:7?4K\K8X9.X^\1&:LD8E\
M2D*`YJD,6E*)ED$<?FM3KY5+<\LCL%6VN:(\/L&4<4,`OXZQP3_&^HHA]I=]
M2!(MQ$XJ0O\`:BXW3L#0-["I(6L#`:(QSB4>5I#='HE$=AKLZ+HJQ'-YVM#3
M"2(R=IA:ULKY=ZUC@G^-]11#[2[ZDM6E6M1W?#E=>W'!():4$<%;:O<(=/FA
MAE<97K69:2Y-*I:R/(%;<J/;7%.6H($86+91Y83`]!!#O3@G^-]11#[2[ZE[
M@$TE-Y;67^WA0%)0(0(]G(Q)M(BRM$!2;)$=L`D_T-?)L.];UL/LWC@G^-]1
M1#[2[ZD0IJ#X]HZVD],I:FJY+3\T$[[E=6)8U&R*[?RW\[2E\3.,,`7J.FHG
MA1K8U1&D^B5`A"V8$6Q"ZN"?^N^HHA]I=]22XLSQ*$1YDB42;&*-Q>--*!AC
ML?9`-S:SL3(UIRTC:T-3>E,+3(FY`F*"6246$("P!T'6NFL<$_QOJ*(?:7?4
MQ]?.'/#Z2/\`*Y4]<?*9626=/1TCFL@U%8\E>IA(%!04YSU*G)'I.LD#H),`
M)/UU8S3-$AT7K>@!T'3@G_K_`)5%$/M+OJ7,MXU\9G*$U_6KC2M0N%?51(&Z
M6UE"UT2BRN-P&5M"A0L:I/$FH\@:5BD+<L6''$K4X0*2C3AC"/0A"WMP3_U_
MRJ*(?:7?4F5W2Q]_:71A?4C*^,CVA5-;PSO0&MU:G5L6D&)EK<Y-R[9R1>@6
M$&B+.)-",LP`MA%KIO>."?\`K_E440^TN^I1(%$8%5\7:H/7K#&H9#&$@25A
MBL93MK/'V1*,P9PDC2U(S`(VY$$TP6P$DA`47K?RA#K6M:QP3_&^HHA]I=]2
MP)MQ\XZV/)E\TG=0U5*YBZ-"&/.,M?8S'%\F7L#8-88W,2U]-!^Z*69`8X'C
M)2C-V06,XP00Z$,6]N"?XWU%$/M+OJ6TJXD\25H4^E/'VD!B2QAHA1*@N#Q(
MA8"'QXE60P172U.04KW'68I>?I,CV/:<GZYNP!ULP>Q."?XWU%$/M+OJ2'&:
MCI6&/+!(HK7U<1F11:!D5;&GQFC\>;'AAK9*K*<$\"9W!&46K00\ER*"ITWE
MC"E^X#HSY/GU\V8QABPC1"2::'[R_P"G\TT-<^)))&$(SR4Q^:/]X);(4!/U
MH0-@&#8="",LP!@!>W>M_*(&Q!WKK_Y\UPQL..+'`_&-"%-$:*:/WHA&*RQF
MC"F,/T_?_1Z,VLC`8#`8#`8#`8#`8#`8#`8#`8%.>'1(QM+H].`A@0-#<M=%
MHRP;-,"D;TQJM2(!8?Z1@PDDBWH.O;O?LP->D`[EU*3UO@[@NJV_JZ16C4B^
M\*:46A`([&$%KU\U(X>O=7"&NP)JY,J)R;V*P&M<-"\J6E6-$I$,L`]E'!+"
M<K.YE\6:D5G@EUOUP%>BL:$U'-RVR6Q)P65O))LJ=4\9#:X0/(#H`Q;5(%0=
MJ'7[<LL>A:UK8M[U@2-N^^/JAUKYEW=%.'O=IHT3_533NQ84:Z6,WK=&@;7J
MOD/[P)7+D:O11FB%+<%0`SY1:`+?3>!$]F\Y>(58URML-\O>I7^,B7KH\A;H
M;/H/+'F5OC<L8FMZC$58FU^,/E#\S"DR'[U`ET:H3%*B]F`UH8-""C<BN<M7
M<;)JI@<L@5S31:S4\^7_`#ESK&!II<R5[4$;>C65\FLM&8^M;B-*@5)CC1)6
MU*Y.!A)`QED#WK6MA?DWY=<::\C<X?G.V8&M<:]IZ27T^0"/R2/N5IFUE&(4
M?8#C(FRMP.),M5EG10G2DCJE!HP)I?MUH>MX%"CG.GAQ(R'Q<7R-IA@W'K"F
ME5.8)E840AJW4ZKU<A;)BPI$\D=VU0X',B]R3E&#(T84+9Q8@B$`P`A!&-F=
MQ;CU5L]=H*)BGLQ5,[V[,LB?82RQ$QMU)&!<C:I<T1=JDLQB\WN1]B#B<2B=
MDT&:)0I1.6MMQ@?W$HQ(6&23/R'XY/CE"VEJN2HCI#:$1;['@L=,FT512N:0
MQU93GU!+F2,K7!-(7-G4,+><ITI"G$'2=,:(6]!)'\H<$\G^-*B(/=@I^0]&
M'P&-.R%AD<W)MJ`FQ!@?',L@UM9GN2@D`F9J=G`I26(A.><6<:$P.PAWH6NH
M6Q8W,SBO5#A&6:<7Y534_P`OD=:Q>/QPJ<1Q?(URZW'IE88`OVPH7$]T3QU^
M5R!(8!S,*"@"E.">(W16]"V%VK.2_'%N;YH[.'("DT#77#X3&+#<EMJP5*WP
M.2J#ER<B/3)8>_%IHP^'J&Q26!(M$0>(:<T.@;V6/6@NV26Q5D-=X9'Y?94`
MBK]8ZS3=7K)(YC'61WG;@(:,L*&&MKFXIEDG5B,<$X=%H@'CV(\O73J,/4+3
M/Y*\<TS?+W93?U*)VJO7TN+SUS/M.#%-\(DIPUQ1,>ERPQ]"FCCX::UJ0A2+
M!$J!"3&ZT#J6/6@N2`W)4-JGO":K[4KBR%$>(9E+^1`IQ&)@<R)I$D,7Q]0[
ME1YT<1MI#ZA*&<C&=H`510=C+V(.M[P)(P&`P&`P&`P&`P&`P&`P&!KY]*CM
MZ_BW7_BI3YASM/8>LL]/8PKCGNU-/Y>%O$O'I4=O7\6Z_P#%2GS#CV'K+/3V
M,*X=J:?R\+>)>/2H[>OXMU_XJ4^8<>P]99Z>QA7#M33^7A;Q+QZ5';U_%NO_
M`!4I\PX]AZRST]C"N':FG\O"WB7CTJ.WK^+=?^*E/F''L/66>GL85P[4T_EX
M6\2\>E1V]?Q;K_Q4I\PX]AZRST]C"N':FG\O"WB7CTJ.WK^+=?\`BI3YAQ[#
MUEGI[&%<.U-/Y>%O$O'I4=O7\6Z_\5*?,./8>LL]/8PKAVII_+PMXEX]*CMZ
M_BW7_BI3YAQ[#UEGI[&%<.U-/Y>%O$O'I4=O7\6Z_P#%2GS#CV'K+/3V,*X=
MJ:?R\+>)>/2H[>OXMU_XJ4^8<>P]99Z>QA7#M33^7A;Q+QZ5';U_%NO_`!4I
M\PX]AZRST]C"N':FG\O"WB7CTJ.WK^+=?^*E/F''L/66>GL85P[4T_EX6\2\
M>E1V]?Q;K_Q4I\PX]AZRST]C"N':FG\O"WB7CTJ.WK^+=?\`BI3YAQ[#UEGI
M[&%<.U-/Y>%O$O'I4=O7\6Z_\5*?,./8>LL]/8PKAVII_+PMXEX]*CMZ_BW7
M_BI3YAQ[#UEGI[&%<.U-/Y>%O$O'I4=O7\6Z_P#%2GS#CV'K+/3V,*X=J:?R
M\+>)>/2H[>OXMU_XJ4^8<>P]99Z>QA7#M33^7A;Q+QZ5';U_%NO_`!4I\PX]
MAZRST]C"N':FG\O"WB7CTJ.WK^+=?^*E/F''L/66>GL85P[4T_EX6\2\>E1V
M]?Q;K_Q4I\PX]AZRST]C"N':FG\O"WB7CTJ.WK^+=?\`BI3YAQ[#UEGI[&%<
M.U-/Y>%O$O'I4=O7\6Z_\5*?,./8>LL]/8PKAVII_+PMXEX]*CMZ_BW7_BI3
MYAQ[#UEGI[&%<.U-/Y>%O$O'I4=O7\6Z_P#%2GS#CV'K+/3V,*X=J:?R\+>)
M>/2H[>OXMU_XJ4^8<>P]99Z>QA7#M33^7A;Q+QZ5';U_%NO_`!4I\PX]AZRS
MT]C"N':FG\O"WB7CTJ.WK^+=?^*E/F''L/66>GL85P[4T_EX6\2\>E1V]?Q;
MK_Q4I\PX]AZRST]C"N':FG\O"WB7CTJ.WK^+=?\`BI3YAQ[#UEGI[&%<.U-/
MY>%O$O'I4=O7\6Z_\5*?,./8>LL]/8PKAVII_+PMXEX]*CMZ_BW7_BI3YAQ[
M#UEGI[&%<.U-/Y>%O$O'I4=O7\6Z_P#%2GS#CV'K+/3V,*X=J:?R\+>)>/2H
M[>OXMU_XJ4^8<>P]99Z>QA7#M33^7A;Q+QZ5';U_%NO_`!4I\PX]AZRST]C"
MN':FG\O"WB7CTJ.WK^+=?^*E/F''L/66>GL85P[4T_EX6\2\>E1V]?Q;K_Q4
MI\PX]AZRST]C"N':FG\O"WB7CTJ.WK^+=?\`BI3YAQ[#UEGI[&%<.U-/Y>%O
M$O'I4=O7\6Z_\5*?,./8>LL]/8PKAVII_+PMXEX]*CMZ_BW7_BI3YAQ[#UEG
MI[&%<.U-/Y>%O$O'I4]O7\6Z_P#$RGS#F$WD#6$T:9N=GIH^F'<92:7_`/@R
M3<4O+2\4/F>/^\S,>KZLK^EX,P5K5T700V"Q<A4F8(XV#5#1-A"U>J=%11`U
MJA4IV$Y>M--W\Q@OZ0]]/9TUG+<WS6/SW,S<YS4W'S,__E-1"$8[(0?9P>7P
M>7EX,&7AEA_/_=?^>=N,!@,!@,!@,!@,!@,!@,!@,!@4*4-!D@C,B825`4AS
MVQ.[04K&7LT"4QR;U","@16A`V8$D1VA;#K>NNM=.NL#20T]EV.US6D+A]+S
M"%PU\<^($=XN7\N>(>\R-GG;Q$`0%Z8;:K\APDI[K6;TKED.5`?6U&H_;Y&U
MN"?2X(U3.VGEA+++VXK!`\5BQR*9T:OK2CN0I%S0AQ*J%0KN.?-BR]Y!>[BU
MVA.7-Z-)+<FQW>"R2_L"1IG5U*V]*@EJ0D)B0B<':BN5%(ZY2H+VA&JY@]ET
MU9B=D31F71<Y"HJ/F9/N4QL=$S1&2-+5/D\C;)B2TMRF3'N*2('ICSVQNWM:
M8(L/=).T[.4]-UE3]?SVCB$*3B=1W%>T':95&XN.T*>C[(%:*2RJA;&B0H"6
M2435\<58'(I>:9H*E.U..CS3F[9"D+XYG]N"Q.6ML$6:^_X4Y5]Q1=D4"8S7
M#5]CRU#$661VHZRN&S^&`CUB1E;J:M<.,0IG,`U28I2YIQG)34A(@E@")+*[
M2=[61('\M^Y/M,D81,%K-+')I.P2G4L=CK2X'ROAR<Y3.(1B11ZMW28H'N1[
MDCE*E*5QD3^G^5M$>A((+V()-?\`MZ<A_P":26MJF?&N844CY,V=R</K.P:_
MG*=7-9E,Y!&)G!2+`=6"0&$.[)4DO2."Y(UE%%H7=P):%JS7S-WVYH89V#P]
MY90.9O\`&V&`KY@:GO"C+<A\W#2$6N]MGP^.]OR^W:N0I)<X<CJ;5U(4HE$J
M*?WU(])$FM3,IU.(<E3<]"-3!.*KM>WTN%5<F%/8^T,-9HZ)G:*K1.#RYR<J
M2U-3CU!Y'`79WB8X'7-C2>829_6NA4T>T"L;1I88T-R%.W%D*`!4:([<7))G
MBG%RZ9(Z<>XG?M"U#QE@,=I?4`D)-+*&.I*+NRLG(%F%L\G<%FK20G<B77:!
MP:/N6]G`R$I2-*25J@X`2/6_:I>ZDK4^,QBR(`_3-%='">W&:1/U<J&UN4$<
M4D-:IGB%K$[:^*W1JC3\9$W+4>3)U!Q4=2JDJ?850231'!8%(=GA_K1UJ8,I
MLZ)3!DHN64<")+'<NV)@^S>"4Q/)3.TXI8T3VQGZ#0V1N;@[I#BTS$VZ1HW8
M*Y>6;H*[21.&8EJ\3;IG]U:MI')^/XMR^%Q>H9\@FU4.LW_E6N:ROR66[7\B
MJ=&\/QK<ELAR89.!$\"<`[;P/S:V/"8.M-Q:`X,:X%VKIJUR;CLX3>P*?6L7
M%@%"0F!H8E6#DV*[*KRB9?(YBW2VV_W1_7)5-MNB]Q2&$&)@FH6QR&[+RQ&&
M.OT4@9'\,^!A_$^21%[!+8N\)8YQE9J$6((Y#]Q@+FZM=V6=;8Y7OZ;@I*"F
M.+L42;2<8!FZ/`:=]7?UMAT&Q[`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`ZC&`L`C#!!```1#&,8M!```=;$(0A"WK00AUKKO>_9
MK6!X%SNTMC:<\N3HW-[.G3Z5J'5<M3)&TA*+0=A4G+CS2TI2<6AZZ#$/0=]=
M>W`"=VD*MO0"=&X*YV3J%;4B$M3:5N:5(`DQ4I;TVS?K+$Z8"@O9@RPB"#0P
M[WO7S:ZAV0.K6Z[6Z:W)O<MMJ]0U..D"Q.LVWNB30-JFU;]N89]JO3:-#]0D
MSY3`?-KKK776`1NK6XA6#;W)`O`W+5+:X"1K$ZH*!Q1;UI8@6"(,'I*M2;%K
MZI0_E&7U_I:U@?CI]8]JVU!IY:MKWE(<O9T6G%)]VZH4X"C5"QM3?6^LN2$%
MG`$,PH(P!",.][UK>L#\UDCCS<Y(69P?69"\.G3]L:5CHA2N3CU$(&OL4)YX
M%2OJ,.]?[L`O;K>L#]E[VS-2->X.CLV-J!J^3]T7+UZ5&C;?J`),!]^I4&ED
MH_G`H+%KZ@@]=##O_:UU#UB5I0?:_.I3@^],T4B^8XL/W9HB#5(2DO46ON#-
MIB!F:"#KOY`"%^FM[P/1@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,#RKBU9J)64@4E(EQJ506B6'IMK2$BL90PIE)R/1Z7
M:LH@[81"*T:7]36OE^8/7KH-03OQ6Y;RKA[S\JWE+;!M[*+/UR#<Z?BE9M<P
MK)_6M#@W2)="XYI[8;<?W8<6EI^T24$3":G3)4VC$2@U8G4&`P+\Y.)U$2X.
M<?&R0\49%R>GC&52+0QU2?!Y7/8A![#2P!0TF61=<#A21W=Y)7=7`$L5JFTI
MM<S5+J!$4E*)6;3+D@:^(1QBDT*?ZTCK/4%Y3N0(77M_NO'N_I#2\DA;I5E0
M4S84@DW*V++BE^B''CH!8RF2LA%#!'I379IEC4T(-.`"1_;!D[V^V%E:W*X+
M#;N-%X\3R[*C5/49#Z(:J#L."&UY!(VJLT$0L6RI](VHAHM2^711)U2N6R<D
M]P1L";3:A-7.`P&NBX,'*RXI<UE-87#7]/52PQVIWCC70U`6O%Y;%;`X43RY
M3Z\0W^ML=V`K0-=VJIC>D^0R.,,DSF*#6V5Z1+%A+(]JS22EZ4)AJ6KGQXL+
M@/7UG\/[(IR?U55/":16UR+9ZDL>UE;G.*HBB5+!N/=<6NEBY$>HZOHR>#9]
MFN!VFM(>2X+&,M,L^[<'9,$[6W!9C+.<]<<A:[J6\W.PY0X\0&MG26WQDJ=]
MI2/4(S2:<N-S.&[>D,9<K8X^VA7\>FCZX?M_[U'UZZ1%-1)"!W2J3=D!:=@T
MY_A\A'+E&#B#8W)T$Y[AT;L&F&2<LMHWY%1O<FXC4LPOO(VX&A.LE\VL:K8'
M*$4C+TW:2K]B>TJ-"W$MXRDBYO"TX?Q@Y4QBY>V&\Q:$'67QNXYS"+QR!O4V
MEE@U+9->QB0\8K[CMWV5;?'MWJ14BBSRZ2J1HV>,(1/AR=@:$#<SIBTG[NO6
M$A]#.`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P/*M5@0(E:XPI4>6C2J%9A*)*H7+3@)RAG"*2(DA9JI8J,"#H644`1A@]
MZ"'6][UK`U8A[B4RMGC-S+M+CU2$E9+*XS++?:&5OY(0VW*I@+N&M2GHP4E<
M7)VKML='%P0)&8U4OBR'6G,@W1212J1?<A5%AD):%QV"@XF0"[&RRZ?I3]RB
M5>3:U;0M*//TDCD+B3_%"G9\/AL%9WQG4RR;.\E6H6MF:CG,D)AB[>P?>*2R
M$*L,'X?SGY@N@X[(9K":Y@@*[D/":M+IJ!\A4P:9[,IAS,G".((I&SKE<O6*
M*@!#&J9QATW'EK=(%I*H3PUJU.SDQ)X`R@XJ7UR&GTAY",LV75?=[/54>B@&
MVP:7B4CKZOUG($P$X_O>XY0J03"52M/9K152AF9$XY45M$$EP=E#<N(`O0*R
M$H:]DW>!G=>UY9+;;KC51%\.=&5+8%3MT]@4_P",5?PZ]+40WJ*9T+8JRUY`
MI6R%AX]"I-4X.;ZA4)%3PE^HWITVG,:8LX,FX5S'Y$3UWX0O\,EU!6`T\EH/
M0DO74Y7T6D\GFZRNY/%$+CR-O^2V$DFFHS3L$JE_6_:,2=0B>$[RXD!:!+!.
M3B06B"^[\Y0\D*KY3ELXX@[L?%Y"HI.OV.6$59'Y<V6?>=O+):W-4!=K&'>$
M=DM5HGJ4JXE'4#@7"'Y`E=7C1B]00G-+&6&'L.[D7**2Z;H*['1MB?5S5QRG
M5M7`'B1?P6?BVCNMHY($RRK7VF5\I#-+(=(/:U&-42)DA"M(W)S)3H]Q)+$A
M&$T*G6_=-O>:/?&R7R.#-$+@]Q/'$N#):\'3=M*W*RE/(.:"J^R;6C=NF.6H
MC6C%45@GD`+C;TD4NVT9)A:TT!SDV&`#(Z<\F.1KGW")KQMALC=HQ6$#CO&9
MW^K&.)LLNY.XJ;>=+&U*M6':[98<>8JH;24<-(+2GJ&\[2<DPY4/9H0?)H*`
M+O'5`V"O5RDU9RA##J"B!5LS251::5Y8Z9LI%KM%55UA3UV#"'UV;2GRM#2B
MWIRCK8M>',QF,%I/]5R+$VX&T&H9\JM2L()9*N)/$%%.XTV2M-$Y`M97!]96
MQ\3A<&A.\J8ZX.S)IS-:CR33RTRI24089LO1H_DV+82-@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,"SWNOH3(8I,8.[1AG.B=
MA()*VS9D3I`-Z22I9BB4-TIVZ;;OM#SU3ZC5F`4J/GT>9\^]['\W3>!%-L\4
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MDCD](`#U]%4#99>P!1&W@1Q49XNKB337+NUH%+S$GLAY;K4M]#.F(^`L+O%(
M*VQ&RTL^)L6%1B&161.38U,S0Z(6EO;G-:F(3`)6*0&A<K9PSXRLLOKZ;,U4
MM+2[U:S0MC@C<V.\G00MD35NR/,:KM>*NDKX57[K(X$P2):D9G=:V*'1L(4"
M"G4%ZT'Y0F5FK2"QZ>3BSV6.(T$]LELAK-.9*28J$MD397Q;^5#$:PLU08D+
M+82Y0X:*V466(7W(OGV+H'H&,4;[=G#2*+&E8T4JA'^P)8NV1]N>9C8LF86"
M/0>=DV?"X:Q1J2R]VCS-`(A828IX:X\F2E,C>O*`:0E+V`'0,GJVK:$5!!H[
M6M;L">*P6(HS&V,1I&I7J6]A:QJE"LII:_W%4L/1M"`:D1:-(`>DZ),$"=.`
ML@HLL`7Q@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@?@J5)T*52M6'%IDB,@Y4J4'"T`HA.G+$:><:/?L`644#8A;W^FM8&L!K[
MK]&NM$QWD,17MCD02>3Z#5U6@5<VXN$KYR^3V)OL];Q#7!Y&&12N`-$(CYSF
MXIIDYQQQ2IQEA^V&<+9>@FN.\YH+*>0;!QI:*]G1EC+8%`9]+@'2SC^4BKI'
M8;$_21K9GE!N[MRN:.S2S,.SW$V&MDG;$I*M,9I6,LW8PA^UG<QE]9<A89QY
M4<9[UDSC8+-+)3$[$C[M0*>O'"(5W_=\&RI0I.DUW1Z7M:""FV6V@4DJ6@I8
MKWH[:(E2$OYA!-9/)'CVH+V:1>-2'%!;8&\B,*L.)C`!HM)F=Y%6SJ8(+KL)
M;;/8]'UZ]G/%T*<42(\\@0RB3!!#%FY^Z+Q#INO06EN?I[,@YL2N*3EO]5N,
M7DS:%;3+)$GMWAJQ:ID;4D;)?*"YTTELR=2,HA3]\4<:<0E,`>(*1!N[#PPE
MSY'XZ\6:T5RX.ZBVV-Q63Z00UGC<<G5(R>K(C/X&XR<B3+69:\)76VT!J14A
M,5-2M`F4JPJ@D!*&<$[\A^6++0DQJ^M$5:6!<%G6XUSV0P^"5\Y5@Q.B^.5B
M*(@F2Y*Y6W8E:1UW>4QTY;"T3*@6*GEP$<,9*;:=.I/)"U6'N'\3'.0RB(R*
MT6^KI;#E-,-+_%+?*W6DH22J^J_!9=>P34;E!B%\'/5$7^J)8SZ3_?(CTJ@L
MPO0DYWR!)Y'+SBVI9+!DB;D'4"EBJER0LUB.B>>QT])$G5U=E$?9T#L84O']
M-2^2)&>VH`AT+:YR(-2$?44%&%A#FN>5]"6Y:KS3E:V&Q367LU/UY>PC8XM2
M.S`Z5I9S_,HW%WYC?$*@]$[AVY0A3I4$G8M)@*$NQ;ZGAUH(YL7GA1E6WS87
M'.7_`,WH;%@'&A5RF#O3$GU')K!FPZ?:?(K!W\]S(2.UFL;?7BMP/93M)31M
MA@51(S225@TH6(3W+:!&95*4]BM%(Y6UR*8>-K2UG1=J&LCDDE,&A4_CDXE^
MD\C.):JQ=VJT(FG+<RQJ#M+I2VDB3Z^J,189:4K<,7OB`D63"TSP1%UTHL&-
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MHKL7*C7^,/3`!O3-R-H2I=-/W:94'6O^UVJ@)O'F(DV[#GBJ*&D%`S]*:;0L
M59[V63;C\TJ$C,T,-S,;^B,8:KD[FH^8]F5-;HK;&(2F/H5Q;2KT4F#/:8T:
M"6\C*-O\4E&A%2]>7Q`@Q734!27(PW<NIQ:-S,=]KB1-FXY_=+H.B=)S]*OO
M][V,KZ6M&!JG%V.*]5_SDWNE\S)3&IM!>1M=NC,DBK:@/+C4\B;S57%-,2Y!
M>SC!#X6TI-9+'&+8@;"\_O8U)P4HBM%#"YS.T4XOK!,0RB\VI),9U'[6C;\]
MQF&64\(STD_K*MJQ959RRX[\MF=N*R-H*^&IT!0^"3?27`0IRTQ",`S@E5\[
M:*V0KN3.G&Z$G[->M;<\JVBY!5<=7:"M_.]^J&7RI8[.!\T-2RL<%DM9J-(R
MB$S4!>@7E%'[":EV>H";^67$R5\AVZ"M#;(Z/?(E'6)Y8)14G)GCVW<@*BE*
MMQ"SELEAMK2FF5>2^'V9""D*PE`M1O.TIR-T4DG)_JZ3JDX0Y4?;;<JMLRII
M>LOIVGD>JU73\BT3*HHI56')IG6'#:W>&[@].<_',CP%%26.62F>P[_;C%Z1
M>@-*$J4%J0C(#&.*]E4B/P1@C*6^BEKQ4`:79Z/DH$=Z%+B6*BI#)')K9[/<
MR^3)K^'3XCD`TQZ>!K(&@;'1/^Z)4P3#-HRPRUH'A-:7%B1-TCJVQZ[?02.$
M537EH1Y^@<S1H3B8[R:NV\;"F<+>G"V)7(4:]^8.1TH1ITKR>^JQNR=`M5+S
MOG6EG!7.4_;T8>4"GD:[+K->H%*;CJ&H8-6LSCC`B4R6B+"IX7(0#/:#`K6.
M(29$!_:^0"YI=V4X"5,Y,7WC>><,AQ,^D$9R'M8LKXY7`[)KI?69;8O$>"<?
MX>%)%$IR:K;CA;9"6[_$TR%'/^AN<H7!I.MQ`:C!$@3ZAA6ONQ_=#^D&Q6E:
MO::3J"L:@8U(ES76<#BT(2N1B8M(>[_RVS(VLYZ5IRC#0%+GE0F&J/Z#'U..
M%O8A;WUV$G8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`MJ:1-FGL.ED%D9`U,>FD:?8F^IBC1D&*&:1M:IG=""SB]A,)&:A6##H0
M=Z$'>^NO;@?,7'*+Y@2UMA$AFL"NM.^WZIC_`&F[E*4%2<HZ,\=Z2#`$;YR6
M5H=;+`T16<R&M[=4MTA%H`%R2P6C83A:-3[V$JNO)[N!NTYN\N++;W@T%-B]
MJJ2?YTHE[?!5.]P/EU4$(B\?3`@O$Y8179,KX^2*0'$K&U=="A.S%%2<Y,8)
M*8F-"Z:@=.:[U/#>2!:GDE%WM3'>VS`I#"I57<.<F6Y8XOYF<C*RNF4RD?\`
M<Y%'0Q"QT3*")$F6LC;!EJ!M5H'9X;$HQ[1$A3JDG_<<BE>5W+&XB=L880#B
MO`VN@G>DX3`J@7-$XXHJI):[U-'#4!:Y;&&^+72-(4H7)7AL;(R-*-*>7](P
MXO012UWURTLV;P8$7MOE+:SA2LZXHV6I8)=0[55HO[V+HXG\[$KK`9T@B=11
MY6Y\>)#?;)"6C]S/*&SLVG+8RGH11!+F0&2U36-SAM:9U'7C3</*0FJ)I(ZE
M)N6[);QK@U7V?`9\Y<=.5LNO2JXXW3*D$,98X#&;-A->A)=SV-S_`&MT>364
MEU6B,T!.&>%(6Y.[DX:;8K%*?M<I6[BC#'BYXN;"7N&/B"Q+)J9P<$H2V8QK
M;V](\O#LA4B&@;Q"VW*=;(&62+0"\#21"J>E"GCK4[?P6HJ\:CL)D[<3W$>:
M!S)4%M<=%ME3D#'00-5XRGS^/5Z5.^3ZP;3--,LA:M*EK2)2IT8Y$;<$WU0W
M(<-$?%Q%/K66<4N/5I4U`15U7":82975MCT/5,BE;6KF)::/QVH[":8>[NMN
M1=C,T*22)%'_`)E)"EN0JW!4I2Z3I`U+0B,0N8:<;$C5+7K7G&A1</'=CO;C
M=)Z5Y/&6#/*&@KW<JY5R'Y,`F\'2G7%9T_MF21Q=(VIG,DC@AAS9H;\H6?44
M)&X/;`ZSNA,LA!;[6UUD72<_\3%'`*02.%VDOW4-!,?,*UWRR8S,I0-.J;*R
M5LW%Y<A3S9KDBI$XNL?4-;8>6L4$$IR0]M65YRD_D%SC'&JF+;;7"6\5*-K7
MG:JDT@DM#3AYY(%O-GK^04LKF:69'U39-;T?$NS&Q?+FD9Y);7(6Q>E7J#$+
M<06&SSAS%N0TQX5\=:8MRMW:B(J+AI3$5?)5&;SDC9R-CLS9X-%&-SCA[(76
MJ0V%KU38A.&<[%24Q[0'F;*^@2K#L\D-::F'LXZC[95*S^J;\BUUMW%7BJ;*
MN0[_`%IR:G)/&IE@K]&7%UCM<%0J)RY&P<L[)D#*:V.CDZF-AC6QI@K'Q4J(
M*1M3B$:SJL+W<&16EA4`MJ-6-IRG!'<MDB^J[;D#584<=NX52\C9UZ%I0#9P
M<A2&[CLGFSBUMT95KQ;KL\3/OY$RM,W&!O$[=+>^M'&5N9W6(BB3,U69="2O
M=[B<KK@J75ENTY4I@T_153,ERQVJ=LFC(H`N2QXH*)L0IC0;;T*!`8F1$!G1
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@6K.O^
M2)C_`/:LA_[(68'SX_\`AM?_`.:KX_\`RY#O_P!+5_@?1Q@6>Q?\SSC_`.>8
AO^P$6!>&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P/__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g575431g73g29.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g575431g73g29.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`)D%D
M;V)E`&3``````0,`%00#!@H-```,C@``+X0``#U:``!,^O_;`(0``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("
M`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"`@(!`@(#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\(`$0@`G`",`P$1
M``(1`0,1`?_$`1D```(#`0$!`0$````````````(!@<)!00!`@,!`0`"`P$!
M`0$````````````%!@0'"`,""0$0``$$`@$!"`$"!P$!``````4"`P0&`0<`
M$"`P$A,7-RA(%1$40%!@,2(D%A@G$0`!!``$`P,&#`,&`@L````#`0($!0`1
M$@8A$Q0Q(A40\$&S=@<@43(CD],D%C='5Z=A0B4P<8%28C,U%W*"0U-C<S1$
M195F$@`!`P$$!08+!0<%`0`````!$0(#`"$Q$@1!46$B$W&!H3(C!1`@,/"1
ML<'10E(4X6)R@J)`4&"2TC,&PE,D-!4E$P$!``("`@$#!`("`P$````!$0`A
M,4%187$@,('PD:&Q$,%`T5!@X?'_V@`,`P$``A$#$0```6B&;``````````,
MU#2L;\``"GBKBD2WAJCL```!D"-^-^`$",PBQ1P_KYK:8CIW&YM"X_M?)+2U
M``#($;\;\!;Q&QP\O'I[9%/LR/R*1E<.68WM<,/GV?5YQ=L#+9LL8`,@1OQO
MP`6ZR1$,GH=6L+,MS-P^L0&4Q)%"2$[S,:X*Q-JQ7YC1\`,@1OQK_C)I2-V#
M\K!9<2,Y>]==USEQDI]/FG)./ATM'\_V^/#\?6EU7E6LI%F[^+D`&0(WXWY"
M,2PI!J7>R_USPZG3FGL\MK:H9+"PG;@I)5Y+#SXV-5)_%Y.KFNK);/\`?2\]
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MJ]!JA-PV3QK@D_E7.0^QK-ZBY:O^<J-HP4M_6N3%T`!D"-^,&4:1$9TE/OXT
MYD^,>L,0ID1<_G#O2+-=]\A,M5I7O8OO2Y=``9`C?C?@5V*F5F.87@1_RDE=
MK.U[GM>EJU/:<\^$@&),@1OQOP```".>,K(_:*#-PEA6)[B0&BYD"-^-^```
M```)L5`00GY:PYQD"-^-^``````10])^SEDD/>9`C?C?G\#\%<D3.>=XN0H4
M^G*)H<D\I)"X#($;\O$4(_H7R5*0PDY.R"G;(H2$XI7@\1;ID"<\8\``````
M````SP/_V@`(`0$``04"TSIG5Q_5WH%IOGH%IOGH%IOGH%IOGH%IOGH%IOGH
M%IOGH%IOGH%IOGH%IOGH%IOGH%IOGH%IOGH%IOGH%IOGH%IOGIS1_P#T/H+V
M;[)2]UL-:IEDM9;8YO=1.2*I%Q(/0H,Q$Z-VOMAH+V;ZVBR#*@`ONT+(Z6J.
MJ;`Z(M%`I=GFS:_K;]R[5`1FKFJ<>H(RH'TMB*C<@5V'=C[8:"]F^FS)=]:!
MD89O8]C(:UHPX'9@2K.](DORG(ES'23IFTEZX+B68TMN9_S=M&EATW7V:K8(
M5E!]?MAH+V;ZWVY`=?07B$F>FPV.<3:!G8!E@H*B%X9@\.IC-@._@64Y\21&
M1Y49"JQH1?>OVPT%[-RGG(\:#LNH2IER/GPBIIE]YPA<`46!3I#'X,B&ADE6
MJRW*OC:]NJOH&S]].9X!WC/_`"`R<QAT>2CDFNOVPT%[-\.UL%9HEEU@Z!'F
M3-4CV&[BJ0!#D;P>F\J^WF5\;<;>;M6JA9?)<82KTNM4>PVB?#BMA;5K$!/K
MTXML6CA$UZVMV5WGVPT%[-]+;A_Q3_V;<:Y,>IE$BB34Z0/U/?I^:IK2WU-K
M-I@P\XJ1BY,/396LY`Q5BM>&4P#D2FU>DYA]/MAH+V;Z68>Z^WG&%8L+^0`:
M)4QL'B,6:)RJR;V3.AJG#&R2A8:%AF<3[5,ETH>QC7=/<DC]>BQL:'T^V&@O
M9OH:BHE#CT$K/9,B630TC)L0%8RB3B_&&&(K)F_M8=D!FBSI<.T.%U]$0Q+9
M//`ZY7Q200+I]L-!>S?1YEM]HM!_'S0MB$6-O5P,:-J)NQBP"+2U;[1`17A=
M1KP:GVF/#@P3UL>K!01:RI^&E#/7[8:"]FYT^$,B8OE+4]F^TK"/+D7:/BM0
M*P^V%F07*^TID],F1Q\5;SA&T1;FS-G1H,N9FN59(F:G_?O_`%^V&@O9NR@F
M[&)E:S?G$7=-)='5<`U5P$B#$EJ(!6K$[*K,L<S/K-T)VA#UBFEA-<?_`$&P
M$#HO*9_M-]?MAH+V;Z6V$6(UK%.M;MA,:SV.H?KT4=#5SA4C%#C-9@"\2OP;
M"4Q*(;@I@E2MNT1M\)L#70@$_N"H_N,;6H2G.?;#07LWVRHJ";@]+80UW&=+
M&Z!3[#82>H9@UZRZ_A%@I/4_G\^V&@O9ONMB2*53'I]TI!XF$V)KL)78^P-8
M^154U&ZV7GVPT%[-]U+!B9Y'\0)_3(H6KDVO!".&(L:-T^V&@O9OC;C;J6GV
M7\6&Y5ZK.L;.I<@DYM>C,C&-BT^38//9RN=M*D#G'-H4YH:C<&NW$0K_`%2>
M":V92W1A#:=%%M!KU7CYGGVPT%[-W0'-LM3>UJ<KNMZ4`V#4JW9*F=D6[&L[
M2[(3J*W,5Z/J8MC8\774^/M:5K"UH`D=:6`[`M6E%6(H%U42'46?JBTV(H[H
M$FL>#KL@79.?;#4/_H?TT^4W/E-SY3<^4W/E-SY3<^4W/E-SY3<^4W/E-SY3
M<^4W/E-SY3<^4W/_`*[Z]?_:``@!`@`!!0+^5XQE6407%8<;4TOO6&_-<CN)
MC)2A*,.Q\LQF8S$M2X<?CD9UONQH]R<ZEI#?'LK6E"L*PXC#J(L3S4O/>3CD
MUK/B[6<_IA,R/E5A,J`CPNTZC/2DA#<:;S_CE.,\BK:PX]'RXM`F8ODH8]%;
M6GS&W65LY[3S#,A,^JDG6M>#)8:"U6Q"51JWEM,L>_$Z1I;\3+!6(\F>2CK8
MQCPK+/MO,NSX;.6G_.SV8'AYY>'%?HY`E_EQ_P"BS2./JRZXIU#>"%E1C(8W
M^]P[B3(9/3+`./AA82+'[4)W"<\LAA0<-C8%L3)A;?.L\$W%<N//*2R"FVW'
MEB@3L9"JV*FKGT2ELN1842"WVHR\H=>0XO$V''(1#&I<1,":Y`$\SG.<DRT`
M0@C:BTURM7T]$(-I3R>C'<)5E.6'?-;>8=8X0>==E1HDB8Y$KB(R"H"N+COZ
MM$3H=?U=!'E)27(;3KGFN=PVZU&YB2J4F6#@3'8C3<?+SS<=J+<@A0M$)LSF
MUNMM\ES/.1W2'7&^(DN8XU+:7RP!Q]@'3-=US_K?-8CM/.Y>7WRUX;0,A^3_
M``*T)<3_`%'_`/_:``@!`P`!!0+^5YSC'%2D8RA>%I[UU?@0YC+F5*RK*%^-
MU3KC&,27>(>;7W<N2F.C*U+XTG&,J3G&4*RA3KWA4TWYF>1G,?IVF4)==D5(
MXRP!%CB*95+DN<E!BD%Q7]^/-K\*%^'&9;&.-26W5)SX%MN)<QVAQ8B(>AWN
M(\Z:?,,@&+]:(S9*P_D'V93;W1YAM_CD-Y&8\5Q+G]TP&UI=A56Q$,E`BA*.
MS+\7,.K;1_C(:_92>8@YXWGP)PG*^1Q><\GC_(X*>@Q"$5.!W#YFP^?VI+><
MXX+A8FS<UX0II^F#U\F!$MKCQ&8V%*2C"+#$C\5L,VRTQ<CSRB!@B5QVGD^)
MMM2$Y8?<C/0;AY_)9*1+Z1HC\S,<5$923KX]V.O.>159[C.,*PZCRUH<2OD=
M"4M.O-L)=*Y=56V39DF9O*OR!*UOOQ&?T?6VCP)[A2%/<4SAE3)&2PA]:G,0
MX<@A*R*>$UDL$>#24H4OC$?+:NZ4A*N*91GCD=Q/`!W(/D>9'37W52ITEM'E
MI[Z'$=GR[H2CNS/X"%-D#Y']1__:``@!`@(&/P+]UH+Z5UE8'>6#=%.:UC"'
M-2T4C0@IN9<1@=6&9S6L2^BUOIMI2+/)HWJM%;H2DA55OK;6!W5HB-`&-H%"
M;?!Q&C=3QU%M8''#)J=91[UX1FRT?7#>MAUA;+---:)CE9#HD!;^JX\U<:![
M9&'Y2#2:16VL.:ZA^+1S^?HK_AM<]FL!`><HWIK>PM&TJ>CWUQL0>P7V(FV\
MK1:-(I'>/@F:'-J2+N3,G`]I6&;M(G#2-#VK=8]!JJ;_`![_`"?*MQ1R+&2`
MX%AM.$G[RZJ#<IEVLD<;,"LMYDI)9G'I(_,='**Q=>'6/:/;=R>#L3N?*;OL
MYN=:WW"-^IWL.GSLIT$&\YX38`;[?=2"XBF[@81JTUADD8':EM]%;K78-9L^
MWH\8_/0"`N6RFN>%+#T$)ZC2AZ[$*^JRNRC<>4@?U>JN(QK&;`J>?(*67=37
M7#R30[:;N:G1YBR1HIY8_@/3==8?73<M_F'>$\G<;W(U^7>UH_-AW@$O0\AO
M`;/W4QA8\+Q.L7;2\J3RKX_#2T^#,=[$8Y(H[%TFX+L6^CF69H@DW868>1$^
MW;0&=A@F;L5A].\/TT[.9K+30N=U6N(MVZP-I:%T+2S'L_E%U<.(%SS1GS$K
MHGD?"EW*0>BF?6OS$N7-_:N'J3;1ERV1@*N'7;B/37"R;&QQ:FV#T>.$TV4.
M&<-M29+-MQ9>1I:X;#3I\GGF"'0V5MO\S57^6A*>VSWSD6-_`W_4=[5AI3?2
MYUW;)9&WKG^D?>=^4.I8'NRT#3NMC)'.7#><>CY0VHLOGIGYGN^1X:YK[2A*
M*'=91RV]-#!_;%!ZV^0Q-OK%IH"4(HIXD7=<0FJN'EVESJXDV_F.@4[-=ZY6
M%\ITX4>YQN&((:B:Y\N7D8THUA!:%*_$I)T$XE*7T,[FYWSB%ZM;@P!1<N\5
M2_139I6[C[J+_(A\>_/^D<WQ'ELV&^@]Q)]E<:0$2:4TT8,NP-RXTZS3IYCA
MB:%)IW?G>V:A@[HRQ+<LQS@LCKG3)T-YS:"$9-EVOX$EH)"*-=;Y2A$%+1T<
MGDT84I'$EE8>K7_FYJ61C'=9K"F/E<JHF@7VK66[E[KB+<K`T39E[G%WX&6E
M-Y"2/NIIH-C3``@`K&?+F1UP%29M_P#VLP_&X^H<P_8<#^K_`!)__]H`"`$#
M`@8_`OW6IJRVL0\LNF@2XJ"M*ZC$`<0I6`XJ4U9?Y/[QK>-+)=6RL3;Z5U[C
M2*G@P$V^.V-[VQL<X#$51NTX02@V`FOK(8OJ<C_N0$2M_3O#\S0E9F'/.FCS
M<4>-N#";`4D5CDQ%JAR8VV!U8^[\Q!F`;@[L7^B1(SR-D=7#ST$D)^^T@'D-
MQYJ716REAOU5VQ#3R^9JQ3Y^>BL"%KO3[J4Z*4>/]1W=*^*39<?Q-N<-A!H3
M=]1QLS8L$N#B-M!:<0_O-!:2#PY"U+HJ@S_<^=<,K%,Z,F&4F-S7[[%:#86N
MX@/$:'!6V"C']2UV6^(/BA<#RJSSLKCMR\$11$C:(VG:6-L!T6)272:O=X-_
MK:]-;HQ-V4))+`+:4WBD!+EH#+929'7%PP`\[\(I,SF,L[-K_:C?C<W\1:.&
M.3'BMN\8?+3@UQ#"+=O+KH@7.JT=(K?<.:WW5A<7.\_/36Y;6*<ILH/BM::C
M.;RWUN7^*-7`_EPF\:`5:=(IF8#/IN[9VGAEL7TIQZ!/A;QL/S.:YUEK'.%/
MR&=/`9\D=C7#0<:ETS3>'.>\'1X^-;!X(\IU6N=T::$3HE`TJ5]==@^1A](]
MGKH012,>!>0/,=-=F-[76)U@KAMR.6S<F*QTW$(Y,#9&-//3HLCE\CE=D418
M$U%'VTLOTO$TGZ:`]+HS3&Y^3&V,(W=:U%O3"!XY6M\+939X2DC2HH1S0.QZ
MVGV'WUAZD&H7GE/L%G+X.Q&Y\QN^T[!SI6^!(\WEP7T"X>:DTZ2!@CS+02"W
MVBZCBZYHMT>00W4FBMVAATBL4A05A99'ZZ9W;W7*YD=[W$JR-@O<1=R#24%'
M+=VM8_NB#<C)ZSTZTA1`LAMNN0)97!A8&%XM*K9Z!18PVBL/D4?9'TGW>NL(
M%<-IW:XDKEE.BF9+*-QYF1R-'GTFX"TT>[.XG0F?-$MEF=)'&H`1[AC<'82I
MBA:`=SC2.`X@HY3,R0NG:UI.`DIB"@%0-Y$.F_6M;HK&;_)[PI18ZEOJ=PRK
M)WS-PXW.<,#=+1A3K?$<5HW;E5G?^<RD,3@7/:UO$[2W!!&[B2/Z\C9'O1.R
M99?3\SF23/(XN<XZ2;2:P^7BR4%LTKPT<KBE-[F[N/\`\S)`1C[SF@,+N8-#
M1R%WQ']A&;RAPYAH<AU8FEJC:AL.@V_Q)__:``@!`0$&/P+95Q<;*I;"SL*4
M4B;-D"*II!E*9%(14,B:LDQ^'NW_`*$_U^/P]V_]"?Z_'X>[?^A/]?C\/=O_
M`$)_K\?A[M_Z$_U^/P]V_P#0G^OQ^'NW_H3_`%^/P]V_]"?Z_'X>[?\`H3_7
MX_#W;_T)_K\?A[M_Z$_U^/P]V_\`0G^OQ^'NW_H3_7X_#W;_`-"?Z_'X>[?^
MA/\`7X_#W;_T)_K\?<K[M5OW4YW4>!Z"=%SON#UO,T\S7JZOO]O;CW>^SX?7
MG^%1;-L)CQ7NY(LJ54QV`)(0S8I@A<PO3H4D92<USFO(UHE:$G?[N)^S=O2Z
M6E@[:H:2]M)%O42[:7>/NILT8X-<P-M4C@PH\>N<A)'SSN:1$1G=X^\A:3;M
ME7Q=N4GO%!5;P2/82X\7<>SXYHX/$H\W;@Z*,V;8)JBL2;+>_EY'"//+'O&N
M]TVG,I=JVXH03NA!C=/$I]E;<L;V4T<6*,LA)-K+D$^454=F-F36M3`3H,L<
MA``*:%)Y238+SA8;I9HA%,P,H2/R<U'.3/L5?A^?Z;8]WOL^'UY_@6FY;ETA
MM93QEE3'18IIAT'K:/N``USU[[TS<N3&)WGN:Q%<EK1S+=VPZ:PV3,GQ49`'
M8SPUM_M0CJO=)K*CDW-NY:G=`I$62R%%&"$$/4$E*CQ(^%(EREV/=UM_#W)1
M6%;85VX^FFRJJ94;AAP*YT)E1"VU9UTEJ`%S)!B%S.=5<NET>YW%7.?.APB5
MK9\>WMZ4I*PINH)6SB5%C7^(UKS)JY$CF"S5>[WESLWMVI7RG7(9<>U>,/)!
M*9/"V/.^:U-8A9H6:3$:UKR)VN7%W4THQ4P=QSWV=B\0E/\`U0LF)(EE-'<9
MB.<?I6M5J.:W1V8W/:["<6?:;EFGZXY8EE96D"/.M;"TZN*($XXC.K#W,Q6-
M#`>0SR#UIDTA<+7[BMS+?4]:RSO/&@0ZN5$@2!=6R4<`#&&*!$8YT?G$>JD?
M&(JN<J*N"6="8Y`!.T!ARHQ8D@:FB1K&(1P3(B\F;6S0R!.3/,941<GHYK?@
M>?Z;8]WOL^'UY_*L/W>U'6V\T4IQ[-T^!"\)AQ6#(5L%LUDA)%_9-<HH*."Z
M,,O?.J-;I?3[IV(>[>1ZFKKLFX3PF!V@82U%;=['WMLJ3.A_TF16CFR"!C1R
M294\XW)(&`;'8I8TFM/8"VO$GUE`.QM+*0UL&SF@G+430)*'&NJJ.6$#EQYC
M#C8.,SAW<\5DB3<7$,U5/;8A6%+4;'R6:>60HGM>Q2!T]QR9.8BJB=N%+(*\
MKUXYN7@G_1;\EJ?W8O:,@CPUH0L-)G2E$.(YKE$G!W,U,S4R:<_EIA+3;U?,
MO#F-'&.+7.4C7B*CG=41!BE<P#&IVHQW%R=B9KB*>2[EN<P)3PW,C]QSFHXD
M=Y1";JT*NG-,3J.R&TT2U!T\V&5Q8KY`UR[J'`\;]::4R5C]298@0**]F4.U
M)Z;AN]P[@G5`]P>'6P9"VS\U'%3D&W0>R,\A9&H#&P4`!!E,/%?:0YH)W/CM
M204,2=7L=+$P:2U9`M!AL8H5(_4QI6H[EO:O%%15\OG^FV/=[[/A]>?X"SY`
MVQI5U-"(I8<0;Y!C<E`I+E:4:IG!B1M*.>JKH'DF>2-P)YI!#LTZQ:UX9/1%
MS1O#)53!8FU(US*=$G<N5:UZ508;WQ7$')A1I%K:UKI;PR$1'N"C@YL<Q7ZD
M5N%2/(<Z9%:-EA#DA6'91#*G_O*\F18_-5JJQ<N61.+'.;QP>#+:[E2.7S%$
M[EDS$]"#5'Y+\ES?3GBA@=%+*"=*%51&Q40BA^0B.(I7HKU[_9GJ=QQ&.L&3
M-:>2@')&^4/-JKJ[%U.=EDU.&?QX:[)6ZD1=+DR<F:9Y.3T*F)E%;Z9(9FL*
MQ9#GY%`0;&\L1-2.&YKVYMT*CVN[S>/'!V;?'.*V-8<)9*R1$JXM98E':3VS
M[B;7P(3H2&.KU@TW/G6L]C3V4Y$<K1^7S_3;'N]]GP^O/B0<48TTH0D*.)'4
M#3R7L8KF@"Z2:/'0I53)-;V-S[53"UDNQ=06[<N94[DCEI)K%=\EJ+-1D20K
M_P"7DE(CO1B@DT@J>7`LI;Z^6MBLMC629(%-4D'-A<Y``DD"X2JH2HI"#RRS
MP3[RT4W4PC2%D!$+<,(;\ET$^P-+.CM:W/)Q(HD:W^&'2Q3TE(K^G_IW)E'C
MF<UW$P7O:@5&J=A,N/HQ7U7=#8TD*'6VL!SOM$29'CL&]Q&*O,4,M6<T15X'
M&Y'IVX%(<IXEA%1W1VL`O2V4/5Q<T4AJ+K`]4[X2(0!/YV.3#WR8JV4:,Q7>
M.4S'B<[O-R6XK1N?(K^4-.\<"FC/34KFQ^YI8^S=:39+V-,,$2)(FY/S>CM%
MC,Z>*YIDR<S,W=:N2KAR4^UG:5^0:XLQ@(WXE="KP3QO_NZEO]^`!W/7UC*R
M04026-8DJ,ZMYC]'4R02Y,ULB&Q7(I'(\;ALS=D[LQ#L`.'+CYCD">$K7B.-
M>\QXC,UL<U4XHJ9HN%(#4FE=)!OR1[%]&:(JIDOH7X'G^FV/=[[/A]>?R=%>
MUD6Q`F:CYS,C1W+VDBR1JR3%+_J&YJX>E%8SY%.\P-=.VQ6KG-*([)<<L,@V
M+M^>:-(`A&=7#:;-G&1B5)M*-T@UK$A'<&=5"%:PIL3.%-7G&R8L<T)`*U8Y
M7C<YCN/;D7<%I6S#$"X(8(XME9AER)AW91HP,YC1BU+FKG*F0V(YWHP)8_)K
MC12:X%FX\VUW#!%W,X3+N0:.R5`*K,W@/%>)ZKQ;V9#A;O8.$3@UE[&:Y*TO
MHSL`9O)6$7TO[\?M55%P;AA1/841&H\9!N1XWL<F;7L>U5:YKD]*8-/HG#H[
M5ZO*1C!YU,\KLW*LN(S+ICE?VG#D[-=3VE[,=#>PWUTARJ@'/77#G9+EKKYB
M(@I:?Z4R*W--;&YXBQAU5C#K"E&LZVG0I,*&&#J19#HI)0A==((+-HFBUIK5
M-2M;FY%@P&("MOZFPMR0A]R-$M*F=5QI4J,%.Z);<5VQ3(W)G,CZ\M9'N=:\
M^^GW$:60TK^H.[L"/VM8QSG/S>XBIJ7-K,DX-;QS(MAN6L10IF440RV)Q_\`
MF1ZYLHS%7^+4PY8%'N"/6()Q!W-K`960Y3]0T&.''E2&69T(URNYG(0?=^5G
MY//]-L>[WV?#Z\_EB.S^RY.1&_$?M57?'FS++^Y<%F30C**`,LS-X6F<)`#<
M1[Q(J*O,1K?1QPR9MC6<\2P98Q8<A&QB22PV28DJ"JO51L.Z-+>HN]H<32BN
M1%54+$B4-](E1R**0`=+9ZHQ45S59*<L9!1ES:ORW-1<-U5,2I8J_+N+2,SN
M]NIHZI+@V:^A'-8N?;E@CH>[*\HU:KDVX6MEK2J57ZG*R:LYTF"\F:]\$=J:
MEU/&7LPL:^86@LVI_P`.F_.$FYO:)JTA8W-'>H4KVHUD;6?-[6O&Q[D9C3;B
M^[E$YS"ACGBQ9>YI#V+J!-:DCJ8&W7!7OBS9(EHN2N2.YJM44'>6Z!V>V9<2
M02GW);M%%M8TN"K%+26SPKR[4\B(7F1C#&TQ.41KVJ[2YUAN8YEVHP<-T':I
M%'&+JJY9A3)TVP21S-/BBQ(J9-4;Q-"B\'.<Q)$>`)EE?5AP/NHMA8$W0CX*
M+\[(V]UDI:(DK)<Q#*(>3N!&,5458MS5#\9*BO0<^V:A9<&0QVD\=E<X,>+0
MR@/;I((,>.YJ\%3R^?Z;8]WOL^'UY_+UJ'3EQF9*!_=1,UXN&OI>]<N"]N%:
MY$5%3)47BBHO:BIZ47`X]$")7R)UA$K8:CC!'&ADG'^TS>G:UH7EC1&D(QKD
MTD*UK5X+AQ(LF\!+*NN1.%N&Z#*E%S5W,D\F<..=-:JJ#5G):J\&(F/L>Z"R
M?\H[ZJ@6(6)\2+5I037Y?ZSN7%MX?X;=PSJ41;QTV>#;M/*85$Y+8+HQELY<
M9C59R8DGNJF@Q!*J.PEI-,6ZOM#V>+SFCU11E_W(U1$8G35$-W8K1)S2M1.<
M0KDU8?/M9@(,1BM9S3NRUE(ND0`L3,DB2=_=&)B.(1W!J*N&7,R9;;2V[4Q2
M.KAZH42YD2"H8<JVE-)&E.JXY(;VL$$CED+FNM@']UU9]WK`L\5V.Z'6GLG1
M98A[C0#[4$G-82())((4SG=W/FY+_FSBQ=UEN),\<8O4)"W-N&+"$Y)1.3W*
MZQA@5#1<M2*BMU9Y8M[2OAMBMM+ZY&-R2)TA\J#464JG@23EF2I*G=)%"4S'
M\/FBHGE\_P!-L>[WV?#Z\_E.CR.&@6K(1R=F8FN7)S?YFKB*RJL?#2"EC,<W
M>[X6M=W-#4R+WE1=+LFN].#5QRE#K4)0RX^ALB),BF')B3`:VD'S8\D37Y.:
MYCLM+D5JJF(T.5$J]PS)3M$*+22I,>]L\G:7'#M^1%.".`6:<TKY_(%GWGM3
MCALG>#VAA+WF;5KSJX#V]J)?V0^6^Q<J<'Q0Z8G:UZR6Y+@4:,$4>.`;`@``
M;1!"(;4:,0A#1K!C8U,D1$R1,&K=J@%>V(GN#)G.(YFWJHK%TD9+L!(_KYH'
M(N<2+K>UR:3.!FCL.E[G(W<TY[=.JSCA?7Q&.5'*"JIW(2#7`S:G%$=((C4Y
MI2JB+B;*JGR8S(<8T@E0DZ7X+8QH[5.>O-7/*^'$ZE@]+3@8,P79.151%:ZJ
MF4P7AVI0QY3ZHQ&O_J]M8CY1)T1QE5Y($"$8PT/Q;)))=H70/-^XYK(_.6MK
M)MA%R:GSTX<=W2PE7AK)+D(QC$^-<4U*Q_-2IJX%=S5[3+#BC`XSE7BKS.9J
M55XJJ^7S_3;'N]]GP^O/Y7A*W4,C5:]O%,T7^*<4P0#=2BX."YW\S'-1>W)$
M56JN6)CJF4LAL.0Z)(7E'`K"Y?R\U@U5JIV.3%+8QPB=9WU7!M+FQ<U'3)<R
M8!LHH"G5.;R(!#*(0EX":W++//`>M*0DN7K;7U<(3I=K8O9EJ;#A"S*]H]2<
MPKM(0HNHCV-XX(R6=]#6':YB452=Q);FKIT+N"WCJUQQD;FA8T32!G>:XDI%
M3"RI4BW@].%P*^-46=E%9*FO(1X`0ZXIC5BL:%G%RQ7(@^/HRPR<2^B>+6`P
MGM`VM/UF3VCR%&$>OL*KI^2S@O<>-'J]6MXXLJ:YC1Z:IB$Z6S6*Z5)D7<=S
MRL+"`61'A,K8\L3,BJWJ'\I^3',54(EG25$\2S:3-)PGBD"T(,W3/Y&H*,.T
M1DTKI7+L^-,;0VRQ4=XIN>N/+<B9+TVWN?NPQ7MXY@/,I@1G9Y\#HB\%^!Y_
MIMCW>^SX?7GP>PL9<:!!BC4LF7+,./&`-/YRF*YHV-S7TKAT=-T4BG8#J%#X
MA'YBCZ=LKN,UZB$Z9Z/T-S?I]&.9]Z:-6=$.QU-L8ST6$4\2,R0W2]=8^HG@
M9P['&8B_*3-#=:"+M21J6(ZJE!E6%Z!'*T<SQ6,]XJJ"73FUD=727-RU$"NH
M6),.#`BP6%)SG+%"P*2?0PSM*=YV7#^"XE+1[@M*6--,>2>`$57-A#ERGJ63
M,@#M($QT$YRN5[FM=T[B.5ZBU.<JVW*A/E1WA8A]U3BDEVEO,$YNH))Q%TNB
M1WO*U@`M9'CJU48UJ+IP>9+(@8\<:D*1<UR:GH1$S<][EX-1.+E7),`/<UUP
M18(!SA5T2JGV`X*O((E=7%?$CECLF\&S)CW*C4*T(D=\RNJ!%!46R!G$,)DL
MP&-9\P8D=Y&M&\VH#2B74Y5;DB:NS&4:.0N7!7(F3$7XG$=DQJ_XXDV2QXD2
M1*3[1TP@H:6[CWYAAM12JS/AFJK@KO\`LML[78%J]K73-UV7.D,7XCPXFUPK
M\:,E_P`5^!Y_IMCW>^SX?7GP2L?)-"=UM19Q98&C(^-845O!O*PZB,UPCB'8
MUPE>-W`C,V^G$NRE[HED?*G"N7"96Q0,6[#M<FTV27D`0<E(+:X[U0(GB)K5
M,RKEQ%5$W/+-#B542KK4DP4(:K&"[@WY^B*.<'0R;.KQ->JHLCD"&SG=S-:V
MA!)/,%7">)AY&7,<A#E/H1$^2$*ET#;FY6C:B*YR\5&Z2!AG"ST:_1JRS14S
MR<G#TXD1(T=U57Q7NCR+!@WQS6)QZF%AQ`IRM,(3N!)'!SU32/TOPSIV,-'&
MU&(R,S3R6-3)J(%$^0UJ?R]F.NZY1;2A\B7$:.,$SHMB`"#3F!/%((SV2=9$
M<34UG#+)S4Q94$"ZL[4TD8*MKW@K!NK\AMF[@M1>&UT'1T$&9%"#4KOM4A,U
M[N!5T>*L&-#",+4(-PQ@"-N@3&M5$5W=;PPV,QVO)7/>3+3K>[TZ<URX(B?X
M>3<-ZO\`\]NBW,+XNCI7"VK`>-?^XEQ*!LEOH^?5?2OP//\`3;'N]]GP^O/Y
M;J#12EAV\F`84$Z22PG(5>T;)T=KI$`AV9L:<:*\"NUMXMQ%D@AV-54Z-OII
M+O:SG]!70Y>XB;BJ21UF$\2D7L.='$S4O*C+DYA$Z<68FT=]80YDO;&Z%GQG
M[CLGPJ^YMZS>/0U50=;!'N:"??0`*8P%3E5@3L>,HU:9(.X2N+,2TN9`.9,-
M-.*NF6<F7!C&*61,TNBA-RVL88K!C:U$=Y+"UFNT1*V')G2%_P#!C">9Z)\;
MG(W@GI7$[=$P,5NZ]TH>S&"6IF184>4<\^%!(K&O.`9CRG%)I158CVLR^::F
M`5]]M>RJY)WH(<ZL?]XMOE*NO@VPAA!90QHUN:DG080N*)J5<7([.1.CEIRW
M+%$*LG3>L'1ALB3#!/#`:$!'%I)PAH<HE>2(3XL=":TG@M4CPREI_N_N"3;@
M+.6N8&O=`AU<LI+=I+8#7Q6(\[%?Q;DBKBN@PKJ2VLJJV+&BR)M3>C?(A1(\
M]@IR&-5`2<.0*BEOZ@:*,O(*Y%[JXB1(7B\TLUP0C+X#>1(<:7*OJ_;L2%:'
MDUK2U9IDZP3EN,)H=#,W/;J'KC"2Z+S)AXP(J>"W_P`^DU:YL.:-RU>E:F6M
MO&Y4W_TA.<W(B^3S_3;'N]]GP^O/_8%K;(7/A')&><&IS6F2+*#+8(FE45P7
MD`B/;V/9FU>"^6RJ(&R96X+BPG2ZV,Q93HE?<6<W<$W:MX)TTEHDI@X-Q[V9
MO4*X36N?-.\:KRGD%+:6HL16D*U@6%K,//M"Q7RV;1O;Q]I!A'LC2+*4M)4R
M6+(Z9!2I35&I22!N:T(+.COJAL3;]CM8LU,CNVY0[:9N[:DF-.>&YG0SH,+[
MJ$,C.J*K7G7/2BO2H8/:4N.G,NQ6YKN?*=(B2-M74>]DEL`BLK2-<26'/:R$
M/)(\B'AD9GD_%)$@;2N0S2V-=7"'+0CIM4Y+^@=3^($E7A3])XAM2&X8F..X
M4>LY;AL&)1^3S_3;'N]]GP^O/_9UFX9NW'2)Y[67=E'0AJ(,ZUE[?I;&R'-M
M"&)`+<FA:-,4/-<1\HHT:URX-50-C0BFOKME/97Q0[8C%+$L*S?"2[=3KUAG
M2F5.V)SN1+:TCHTD:.;]HY:TD#<^PTKG$9$K9#IM55V$9@3Q:6XFR)$AQ91/
M#ZNL]Y\@\G4C4%KEC0;'$Y;GCE>[J-55=9$`VP692;80-&"XNF[3M`3H$<II
M,$,>9NZ>*5J$UA1]:K=;'/5[[QNUI=%=[.=&-TLZ-5PR"L=PQ+"7*.0<'FG)
M)&2?)&9RD4+Y6I<G$'J;CS_3;'N]]GP^O/\`V=?:S8(94^J#,!7&/J(V*V>:
MOD27C`YRQ^H4M6'256\T>E48YJ/?J<GA==D^0LMZ=%&R=*7FYR7?-\9"\]_?
M^5WU^-<<:V`O![>,..O=(D=I$_V^Q[8@D7X^4W_*F'-EUL9Z$G0+(^AJ@65,
MK)0)L$LQT=1.FH"5&&_076Q58F:+E@RQHX(_4&?)D<@(Q<^03_<.;0UO-,3+
MBY>*^3S_`$VQ[O?9\/KS^36(C"-S5NH;FO;J:NER9M54S:J<<:@&$9O#O"(T
MB<4U)Q:JIQ:N($>XER6R[-)3H$"NJK>\LI(H+&$G265M'`L9W1PF%:I3*-!#
MU)J<F>"U3+.6R2*=/J^;)H=PPZV19U@BGG5L&YEU0*BQL`"`]W)`<A%1O!%Q
M/MRV-F.%53CU]MKVMNQLVHD18@)\A]M5K2>*5D(4.2,JR3A''T/1=>$VN&U*
M^V<>/%'_`$JY;5FF2Z06Y(L$%^^O;0'GGHC)):!DE2J+^7@N7+0PM>M1Z.8W
M7S&L0CF:<\];1N1V7Q+GBW')M)KFT4AT.TDP]O;EL:^/8,D1XI*MEG7U$JOE
M6XI$IC71`D?):J\6<%REVKI%XZ+7'-&M6!V;O.184I`1&3R+>U`*`EM1A2&]
M"(26$(W,XHJX*5M^3D!IY-X^0ZDW`.+T4*C'N6:(<I]4V.:VAT)4DE@,<LX8
M_E!1>&+W<8;"0.KVR&6>_6;475;/JA0JUEP=TJEL:Z+<LSJRM.-.GS,-R*/5
MFF+JV=:2HD7;T6+-N`V=%N"IM(<.=K2!)6DLZN)=&!8.&J1W#`]#N3)FI<54
MB9<F2+<TH-R0IL>EOIT%M!(>`8KBPG0:N3$IZ[7*&BEEO`UFKO98L:"M6\6T
MJ?\`B0INT]V5,>(JHQXV%L+:DA5R$DB(CPMYN9A]\>IO'R>?Z;8]WOL^'UY\
M;@V_763J>9<54NO!9-:]ZQEDC4;ER&014:1BJQ5:Y'M1V:<<7NU:%E:T-K!F
MR+&%21IAK"PN9,^I`C(Q;"[JH0JB1MV$^-*&Q`O75K%WD5A;&35;>VQ7VFYM
MPWEL7;G0L@1ZLTZ?456WC$\*NBU]?55VVZY\F:`+Y1WF<UHW<S7JIMZ[8LJJ
M+:5]#;;9EP[R'*EU\FMM)E?8H<2PI460"9#FUK%^(K%5N;.W$B-(N]OLIDW[
M9^\*+RJVR)8GM3/D2:N')7Q*,.+7Q9Y6D-RG.,5C.6U[,]>+RABW="RNW5N?
MQC<-/IO5C2*CPR+!E4K;R5+G[BD)>'AM?-(0NODY@$HV<<,WN2PJ(8$N:F[Y
M$!MLXP^BV'$V;*IHL(LME("%*>%Q$DJ!\IH<AHJ9YI+]XW7P%C38LRM)3<@_
MS(75E'&C7`2:N7]X"&JWA.32B.@J,:<6*KMT;3K+R@6AN-R3-T5Q)]=8>*QI
M4[<L;<Y:Z4>/-Z<D4,UA$0VA2.&J)I3+5C=C+6\K!3]^V.VX^X_"HDR/#C[/
MH](I5)7J:2:3(G6T1QQED$T-TR%30B,3/<$R+)KJ6)-J-U"K8T,VX7!+=[FV
M9+V9XG95);9^W8?209S];H<-AY&3-3TTJCO>-M<MI!;(WW`M(P&1_%)4&JD3
MMJAVWU))EM+FV]@^0Z.TQ-3T:Q,AC:B-XU]I>;IA5;XWW9A$9M>N9S!U>TI%
ME>5O++N$-Q#F3I.ZCQ)+^=%Y(@Q-",<YZOP*O7<H)"4-39U.U#S!%=E'?O")
MN:HC[CKXC8=1;010@NA2(Z@Z9PU16#;DB)O&]-("1FZ#T1Q1Q-?JB^$TH*PK
M2/=P?S2"U-R]'D\_TVQL[[K?\F/N_P"#C\*\?^_'C/2\TNGQ#P[[%U&K/_;[
MN/R`_<7'Y`?N+C\@/W%Q^0'[BX_(#]Q<?D!^XN/R`_<7'Y`?N+C\@/W%Q^0'
M[BX_(#]Q<?D!^XN/R`_<7'Y`?N+C\@/W%Q^0'[BX_+C_`)C]1_\`ION3TOW$
M_P#O>H\-_P"KS_\`3C__V@`(`0$#`3\A2^0#6A2$T''_`",.'#APX<.'#APX
M<.'#A\"M#X6393]^=S)T0LQOJO$*&1].0+-4E;"WQ:`F!Q"A$@R",10X0\(!
MGD0H)@+!%^W80O=2Z*?7E3\AA-?45#E5%G.!H`2$JZ1%S>60E#3XAY0++9%7
M\E0)04=GBN5Z%[3/:;JQ`3&J]2P^\XEF&`^'_CP6G#+AAHU9!^H5>`^R!-89
MS`@K1%W:DOP*_4M=J:U;XC%`B>W6C.5E439'\5Z`U,CD6+H%7(.@FGP`Q"MF
M/G3I/<CK0DC<(Z";2/1A74J9;MGH*8I3$@#'F3NOPGB3$0JL<B_K>6DND#9,
MFXE;;^R58=+P,Y(KZ`2WI`FE"+B&I<ER1J4RJQK,LG.$<]VG4/<KBX?@ILBI
M*)(`3K->JQ`JI$.S8Z<&-*Q$.&ZX$^G?KS.O<IM1.G&MGATP#A,VT``B^/JR
M28$#MQVPV+@G-33;-6EO-R2[9(UT-@&VF\F0/I162MB=BOBIPFXT^'!1*C`/
M]1#M/F]@KC)9%R7#4I#4TF3-,/52#/F.PU&&RGR\Q\'.YBSR[\IL&RG0$-P7
M&18(O>_#QH]6*M,84B<!%D$<12Z-`(*<8`:=#!2%H[K&,\C]=AY@`$+D,(ZO
MJS&P&#;6#%-@.VV9UH'$!M8:.K!]A'FZ>>%)O:]KZB.[%Z1)T'&J3N)@"H7A
M>%V!AQ[ZF$;1$3+=7&,KNAS95@P4DO`+%ST=7H08*[0^=)(X:0G!/Y#8H$VU
M.PR!WF1?MFK$NN;]8WR'.@Z68#W8EM`!W.1LGU6&\%CVFG+?QWV;O'T+R7Y.
M:K`IWH&NC]D$RLFA<?30B6&2TN*F^EK.A@O3"&\+>KXH:ZUXCU8V'H=@D8!X
M9ZB'I`7P&CE8<!L5A?)N(.3`U8&T0&`U#(G`]U0G@?)?"T57,=)42`Z:U\B?
M*^JPG#^&J./10/0(\&.`<>!(A0#LP5$N@0?+<>,W$K`303O`TT!B84]@7C:A
M.U6^UQK=-#5,,SBU79.TG4)\,\0&7#)QW%P]OP8C0,3OP@GA^*D01RU!3@#0
M=,>)\,"'GEUB^+7R""X7)R;<[ED^A-^JP[MR8QW6ENN;$V9%?(6C6P%AA$TQ
M4>V=$EZ9<"80L%N1:%Z<4N2T`JI9`1!H[600-/$_)+\<"!B^3>M&J%,B[JLN
M*-*('G+3-FBBYXJUF,>T@^N!BP8_U4G+-)\=HXQZD*LN'2U-J6N;%W>&NWZ[
M#L7<G8B@GLWG3:SW`Y193QD-?O(JO>WXOG(YV:U@BUHTI=/$8$WV\;0%5):4
M*T_@)"*.'O!4#]>GI9/SYT!>Q3J*\B9":G>'L4\GYEM@=,?A.NW4AD-VE-S1
M!P:8M`0_4HL+>Q#C`Q%!0JARX0ZFYWT0@`5PIG0;HP?$-DT'-..31X0&3Q%F
MX`Q'31EV@JK!,0"P=32]_FHR9P72V,"&SBO@46V>``Z&%)0*A@TCDU7P*#%6
M,0<Z&PM]_`L95\)45RP@X=(SF!$:B/-0I/)P^?AS:W('0[0:^JL(-R!;_-U/
M.\*P:#).*`"MF5,P6N93(+AD949=V6]X$=X05`Y3RQ06*`!#P"&,_$$E7H#G
MB>`""[#7!5")L`Z,K9%&I5^U9:PJ6Z"@>^"DF@DH!C%VSWP(!.0MF\30U"S=
MR$A!77^'GSM7*4V`6NQ]@L(8A#>D$I-%%+&`)I!<Y,SN`RS#.RA_&]&66Y0V
M"8J7Y=8K)#.-XMV,K!V<R!WDB+[#4@H(@8$:<S'J#_T>)*`73\R'_3ZV02LE
M,!++@:::$Z=/!D;@B%G;B@K_`&$<@/9H0C.Y?#,#T&WAW&9]JP\Y6,H,Q^]Z
MA#_(J42L]IMS_/<*@H233&C)<?(UGHFXH,CWDH<E0?+/A6FZ8N[AV<G.G43'
M^[88Y3%BH,%"F`&4]V2?8_U7_ADUE%J.&@XA.G-&6G$UO9T%F&GU^)$8?+)O
MO.V$EV\U?7.W1$#A9"(!*\FK+K;EYO[RY!E:V\`7IF8V%\4C1(S@8NC.$8U6
MHF_+;]-A[<OJ'MPH'(F)0#8%G73HGD;A17([HK`H.D*$5NO-1IQW,PE1<2`*
M+E.@N<MHVXPTISR4>"H&JKH];R(H7!Q_`M41&PYK'$\5YH8CEJI&N'`(FCT,
M)YV@1`.1?M-80@9N.$$Q*B]#,+@F/H.5ZCF0I&L:("AK2Z!C?`7Z-A129$>Z
MX8T'DSADIE32[.WW$/WS)!-1U0%%A%`"7=>$45]P^;UZ.>=DR$YINWZ-AT2]
M5C%^LFCN+O$)-8OT]*21VUW2]B9^])]P!BSKKA*UWN#VJDJ:1_Q"8M[\):CY
M/'NZWU_%D^GLB/J27).T(`*%^A?;0:*BIK-&=F"H,05(",'?^;]*W*O,=4_X
M6VVVVVVVU.A__]H`"`$"`P$_(?\`Q<XKZ92!Z\XXY/[//WORK?C]:RX0GP/)
M?#V=ZR6V']0>?/[8'N)K^AIS\X-!Y"OP8N!['F;_`/OVT0FPUE]?K_[B*&N\
MJH#83KK:?Q\9RC7GI_;%EZQ%U=OQFH:QK#9<G>63SY?^_K9P4'!*^MP_=SXT
M8O\`G3^%Q#13%L2NC16NOV26C`C\&BWFG>"N"3S/>G^\*>H"?K].;G@]G/Z]
M<86Y#II\.ODT<L4:9!PD3PE#Y-N<W7Z8($REY+E,>FD<NR&]Y8'LYSS'X3A^
MM2X^3]3"YP+U.Q>@0YRL:2<X][$A2-&M;SDHM:*>8X-J:"X3?WWZQO?3_P"-
M9?#<?U?"]GIENSC//COD_'E[_!BQ(FT#]R`^-^1<5]=:":!4`ZL*W+#>!WD9
M[$_N_P`8^$6>SM?4^7RNH&6>-B^!7#U>.*'X%KYT^IR?T/\`]P3^P)I=?C.3
MY$'E"GNDLV1F#7EX.'PG]DP^O@)_BOW&,KGG8/EW!]CY;BE@BO2>;PGZ<=2/
M_P"9I?FGK-4KEZ3^_P"_EQR.E"`]LIO6]2:[,FT`1U-'MCL^29#";%3\B"?9
M/OZZWM\G^_6<;.<3`XBFL%<[#T+EM*DZMX-Z]_E6\EG^=O\`@T^/PP:JB^EW
M!J62#;EH9K6@?]OMPQP0`KD<5$83EN!^EQJ:9R7?<^V6&P$%UO=O/\3)"O@H
M?`T<]?6K"U_+`"XI?7ZZP`CX=A'V/A-CLWEHS:`/!3]D_G)S"WRKWV(\7X(=
M,1.J[RBM5(WX4X?T4W!,%V@3Q\L0]J&L2F+-!^0JVE+%'"6#4&'KVO?P;WW?
M6?@K/]G^_L!]!R6YYXI06-G'XQV(`709^_E[PQ_$![7K"SGP;_1W\OR9JAX0
M:=DKYKYYUF[)0!R$/')T'`,-,9XI5NMB`A9::7.>)/%+O6L9#O\`@^R+P4:T
M])^X=+9IP_=";;\,ON.3GY?]\X:$=#\F^^_R8$-)'`&<G,IB>AT\:F!V&!^&
M`',^8^LX`_M^W.&YX2V?!]L!0'-F%R7?X>3/-75XP??Q<E>B&@D>0.MQ1`<L
M.T.([48=?`\(:_C$(3P>/O\`-!E_&&=^H<\!\0A/WW7_`(+L*I3X;^VM^?\`
MV3__V@`(`0,#`3\A_P#%@TAD,7'5G[U/\7SAY/`/>4Q7/]L0R\RI#_9_\S57
M\:_;1FD4\'[9JNR?'O)RB9/0HX?[XS<B=/\`]P5Q,F7>AE:""[QTS/,KJ_6]
MP!62Q+LQUG`N3R3AKG+SCW3V#`W0BX$4P0EW^-=EW7>?*/"_1N44J</R;$7R
MT]Y^0P=3GPQBX_Y/P_ZYZVX/QQ:1]A?X9S)_1#]UN)NAQ6%\<0O7-<F%RX^P
M)\U8K3X2^HGK*"2Z/S;GPX3$-4D25P$4``W15^H,5ODK^^]&@&-R#VV:^8NT
MH&K5_F\[^7?P[^?\!:^@_2GI_"9/HW"+^YR?UX7()/(I5-A#C?-FO>+YPGX;
M_4Q9X@_H/=QE;^@,Z?AP$GD4&C5V*!NY-"_4*7ZN:($HH`V0='9>\%/@2O2(
ME_)OUB3(GE@_&]_C.HO@_P!H_G"E#RRG\?VO4Q@.?Q_UA5GHY_/_`%E%*)/&
M$#1E.>E$\R&Q.!+3&BQ\&P:4.A$`<3JE/;@18H;7U]"#C_`?>63KE'N&O>#!
M!K]RO_X]9;?8Y^UMA?8[S7IY3Y!1YF3?L+EQRH/;G:"X=H($.6E=^-8FB`*M
MX&ALYKY7-2"%!5NMB:XB?U#$)""*H!P7;[^LR*3?[8P8<0B>GLQ$B[B3^"8L
M'=W:/U?B+D`(<9*ZCO@^=_H-N639M`!\)0_GC`*_+H4+.@_&OX>>WF]!^OQ,
MXCY7[#CF94/PRFNQQOB@KYN3N_M^,D/^_P#Z?'[YX&/@8>TE"A>I;G$.`IP%
M:%>,-9BZ^S9US#1>-WO)Z=]OQ^<`QU]F]\6?N7IZ/R.,1$/]^\D$CBEF$T*_
M`^.NL:6$7M?;H`VD`H`N<]J$I"'8F:!$IKV+(URU`@@N@YX<8S%X[^?MKB"F
M:9.C7^N,_D/SA>_K'TVY=U&.C.6F3^P58+38U0)O,9ZU:CVJN#%O[Y5Q_P"@
M+ZWMZ-Y2\\ZWM330N^TS_P`"'D$Q:"G`5YH#8?\`LG__V@`,`P$``A$#$0``
M$````````!```)```````)$31(```!)E.=@````(AR%F``!\S2:38P``"F,(
MAU!P`!X'`'#,``!V/=O<Z``!:&K$LP``!76FWY@``)*)/8I``!(([HN!```!
M`(+9()`````(!!)```````)`````````````))!)))`!()((``)`````````
M!/_:``@!`0,!/Q![[@*K]WD4&O\`@T*%"A0H4*%"A0H4*%"A^IA/O<-.<FOK
MH)Z(Y1PJC3,N`LCK3B133U>"LLR])*$1W<Q9Q\20H#Y$9N>]&7B>A?<2TZ*"
M,"!`J`BUG_BI?(7GJ@E:7DL?_!WD6ET<H&N\.;<QB6]YHX"S&T>Q<.5\B6@0
M+$6;`@)="REG!`R<0U&9NF<HDELM^_?[*@!B(#8LS*^4(O2N\I=6W,U5P+&!
M0$9DK2^49N`E0[F&AHXC;+15`C>.82&T)T":``#8`&/C)_&;2,.8A9E)R@8W
M0A096J85JU2E-&+Y`QK#LSK;2ZJ"!6`Q;"-/(LZG7G_VLJSZ+6]NQ;TH*NO`
M6+9`C!>)1I`"9>8A(R`R3$ZJRYRXF,OPD3L6?N-<O:1Y-FS1EOI3E!(H7*M;
M$\+00`0`N%&KE5:&6);(J!C\IO00?;DP3$(ZVATF0V-!@FF3ZH`]@2N!4*!(
M)G/'``8"V0/<@^K7XCL.,),=L:-EJ/A5V(!0'LX2"EBH<]R@_P!J&##D0BX&
MP5XHY5ITI<<)R!G!_P`!J)6RC1L,YE]^WOS5B.A03&/=*`-$9,K6^@:<5$"H
M3.B"E#?"OM$L!39`02F!$4;E.KA?T1<:%1H!]105-1H`6@9'MI)D@ERG4`$0
MIM@8)Q:1Q5@&%SIS>6AI^%;3#BKRC,%*!K,=08@M,I!)P7A$7`)?+)A1A<,(
MHX]"\=>)D&$4*-RQ\FHW+V/ZPG@=2N^YWXY(*L""%Z&`Z5BDS<\.S(W#(?>5
M>PY)^OV-@130H:`M'&;356M&?I*'GU#9A=M,I)-8*PA]+3?TT`!W_CK@2P3Q
M0(Y]J/#P_#XE@YHIXA+-$D(,\M",,^@?P%4KT0X`C#QG>?<2ZL3QL2;01<'+
M$AJ$K%?IDVY0LUD4<HUP6E.?EJUP49![J4AW9K;0FM5+L5^L4$`E3@8D'L""
MJ*EET+8M40@B,<V-;1$H,+XU5B3S%@]:!YQ@9U/@I8O<<PV;XW^)CJAOP*5M
M$CK:6P;,#A2Z1TI1V<T,*NMW'[;%-BK01.)2;+X`)/>26#GF$;(T7+(P(5TB
M4BIL1@(</K!08.C2H\FE&\;@!TS]1R-8W-+U,ULJ60Z:MGP3[$(653!C-M;,
M=.8RSG[CFX58PLO\CH&TX``S54_Q-ZR#$$K1&=)WP!@J]J5]MF(^$'W%&>O%
MKW\$39:BQSIA`ZM'&F>)C<I-PE\VSLC4?K*!>&4DL`6<B`2CG22++@2]C!6X
M7`B?=TS4=4#;8)DNS5(>^52JSG<,4$9/IG!T3$I-@CCJ'<3D4$'=%<^,)PAK
MWFF(NGBEY(6F#]!(T4I8[$Z[.Q!>]XC/G0;,G0!.@Y9F>2\3Z2A!T1Y%[`(`
MB@(G;'+VN0)DRR7'ZN1&GL;LF0O'#NO%2]\"EDR`/)%EQC.&45%?\/J:P@!S
M/`R39>41SKXEU4:*YB"HT2/*$0-/=L+&V?N+@@MU)N$;25!V<M6V8P00%%$W
MQC`A$&<A63LTR''XA=#@:;*D4DWU%"I5!N1$2(P4@B(JN">TVCLL"0N<P*..
MWL<IPPAAX;;'-\[XBD!LX(/**E0*V-,FP(O@.X++F"O5&!B80W0`4"[@&JQ5
M&G/JKDOYXNR&&EN9L%&#XR::Z$`X!N&LUOHADBJM?\=P/'=$H(2T4/L8H+F4
MN'M@91;!QFGANUB=J-DJ'PK%39-1$P$IO"6PJ[**S=_QB%!+6EOP+1D4&!V4
M!43_`+_\/90XS&D$('$"0#TFP!AF`_D8FD2)YW$$*J/\!8[P:NLT0'$J,KM.
MM=R$K-X=:+A]Z6,9F(GVQ09`X#]E>XY#J[Z`&`Z82I4L;G\.Z,CX*8S@F!RJ
M4@J;C/Q@%G?&KQ.!\2K>K&U75(L-]YT%!.[*1.DS`3=*JA,ZE$P$,C_A>J`^
M$LN14J""\HC])UX`NP.9)'1IX8$AY_>"@75`'P<<?'[-IN=#(CM55M?("AN@
M-^$N4&B%E#[F:2:BU!`!/;)#&Z(2WBD^DH?.@TT)VR5A!$SJ:-+J,<E:0TC_
M`("2+0*P&.:N;R]"O.)@29<U7U"`2LL`K#E^`JRR(GZIS`>8!M0-.0FX`%GA
M,Z>V\;LE;$G,+K;Z3_H1"/Q?1W*!CIRL@C-@Q^$4-(R#00`P+0&JH;(NO.O\
M-S\W4XSXG-\&=[]Q_DH!M8'@AN5YBQQ>#8*:8"'`S!WW98=$ZLQ4X>:8-73H
MIMC3/+)`_P!+=^CLYFQ)$G<#&F5))X(V:#89@O+A:UCA%K]F\O+JO)%L4MM/
M>MA7A3+]2@.TV@3E&+7UZ(W0>7>:@'6DT'H`,I.74+PZ`_)<T]`R[!ZV^]AA
M8"`AK9=^`B7_`)/U;`0_H[;O_"````````M)G__:``@!`@,!/Q#_`,4"\8`<
M^`*OX,I1/"V_,T?NOD,+'38])P/3_#1V?>9P6OA.W?5X/E,46X`4M`1V5%$)
MV89,#H_MY7VJX"NZ2HS=I`\&.E#=R%0&<ZG*:O$096#464#@J"CG3'X<>1?I
M?*<#V@>_MMM,U!$E^U+/)4&&^=D&]=7?'[8\-R"'80J8RM&E/)@$*`"D'WTO
M)T]*9:-#AB(C3\AUO-?VMNQ=#MZVNO/.42A.QJWVO1J^3%"$IP\_G/"@,&@K
M`WPFWB+KZVFD3<`H*H\$#RF54+E@^.M.I'I<7AJ\D"(KB<BC3"G7PFT%YIAR
M(K7"<V<("BT!-FEI+<:;7=`0[]/(]&]XH.\!H/A\>55V.37(.08[WM,)+1QP
M!N"J)"#)TP+PWD87^4/SGWIZPCEO8E"+RU%!"89.#`--]\[/S@,!!:$/5#9V
M=?"/UDQQ(3+S'E>Q')[_`-!8IU1"C3&:5EVS]K:*);-![H`0Y#2P7<;28!(4
M-T@+.T6BJ]0Q#:.[*?6K/?"TLP`""N'*$%)N5>4&W]0NX@QQ<H]\5%;10=6@
MP0+):&U&^4]PQQ'B7`(H=2;-6N54AE4T@=`@#+L<!?B,!)R4K\&/$.D&JD"*
M"NC26Z^J+G,5\]0\2KYIXT^0$154(IRL4FL"#CV;?;"%'82!4BR=.W#3I43B
MUI<45X\HO9_='K&1M(Z3:)Y%HK%XTL"(`.1P'II2!9@%A;)V.(L#LZ@IM)1-
M27;FKR%D:X:,#:%`-L(I$6+05R+.L^1!Q^%#B@P"[,B]"(&:*!M#7ZKZ\'<Z
M-`Z!6G%:<N"H2#&]:<2ML#?CM=9??8C80&!4VLVF"$71`ONA5Y`/+!IO)M$:
M;IYI$H@6%,?#IU>QNP+,40463\'!Y71RH9P_'CN@VJ%`-)6L;#8!&RF-*`";
MT:A#0,A"-&S.]L5QAOW8!+[$G0VKROUA;8(>8PH])Y\4><A578V!U#G<:@\.
M5Y?$#$$0%J`0@!RR"1&<[<=;6C2=:Z/TQ8\$%3Z*\H`95*JNU5VJ\KE7!I2"
MNI3$BNBLR.%J@0K+;444EV1<<P;@T"%!88;7=_/"[01T2C-B)`>[=IM`ZCKI
ML[Y^M&J:/A_.LT5;A.D4XJ@FSYSC0%)5KE,3QS@2C2,2$.*`85-XF-W"5"&_
M#'>]L8+C8$4-M)%.9L2U`1UC1EE3^%6=H"C15&G`"2:`VFNA8XHF!D/$Q)$Z
MX7Y0&G5\HO8$NG6F#F@]%L"!^W/NOV2AH@Z)5L0LC`!8Z[Y#)<HO!V>2.)4R
M*/XL17L3VS32Z=A"N^PNT2NYC\*E@U5?Z.5@;<`81,=E59;L33F#>UV@\JH>
M^)`K,4D7DH+L>05?@Q*L5.`Z1U>]!.GD^U`S=G<X^'?),?6AL5'8MIPQX61V
M*")`"".@31.`9U/&;?`TS(1#HA5)<`6^:F4JK1=(A2YA01`0!%``"O\`+D(!
M`I8.K"[JZY?OJY&+T%9[UKWA9J'2'T<&]+33_@7@942P(SE(!P*.E_\`9/_:
M``@!`P,!/Q#_`,50YQ"(>UA_.2$>TT?B[?VGBX*3;D['L?ULCW]X;81/DX^9
MR^AP?UQV#A3BG3R"AIQ8U_/^C@^##;D.KTX#?>O5<2Q<K>ZP>..47K;C?6JS
M\TA\4^<5+7T/X>'X&_;7&!"%0\Q^&?#RD20%Q??K*?UB-W(@75EWL0X<1;!=
M&D]=IWWYCD^MW)38F_PX02=H.7]CO09"OE$_7;N>,%-&/7&4/"2>(:%UR<'G
MZQ)`.!D2@II!U@D:_EB*@S];33!,5SYUK["7"'IC#6YR&M$'!&)CJH8"#]*;
MD9J5&0*0858VJCTE_P!<)TZQ1,$Y6Q_'GPD3IS:P%MB4\0PK2(T$$0!SDQBB
M1[W&CCG#YZ*I^$/W8"T3EZ*AN!H$"ERQBBO!U_6*;B,1Y/\`X]/UV)<-XC0F
MMO:=[;R3]@L$%'&#I$`5S^N8W":<@#A+@PBA&+]2!O(`"-DDA/2@-*7K+GU;
MMTOPGX74U7$1CSG"4DTA.!Z+\!KD8>3$6_`ZL\^6@N$*#$CVP*(*[DNF/SA:
M[00+WLEW&<!"4U[52H`VJ0:EZ#=4D$#\A,9VO.]IE?%7L+B-S1T;/IH3P0/Y
M7Y)/$?.Q2<KBR0```(`3>\6G-!T*%U$18E!=9!MR@`>4ZOR?6/+Z=`^?Z2PF
M1</!X`I/4@1##`4@(5KP/(?G3TIA%"FE-'R:%/!]X>X'1M2]:GO1Z)O=H>7H
M+5KDJ>XP)C[H:P8!43B/M.!/#VC108(0GU2T=IHV\CY=$>8;ZQ!(\8?08($!
M8:-B.XR0.";L#2&LLGJ#6`JK@1OA$?37O%[^`JS2VQ;0E.MA8H['YNCT?S@]
MRJD#]>,.F$0%H79`+KW(.@"DK!G%46T$!C@T@6E:_`V9>518XO"K9E$,D=G8
M?6E`%OV%B=G^XY76H#PLW>M=FSK&="!N)2CI.D1$HB.0*(L%[81[VSXF4<U'
M[0<43F&R)'`1@2`:`\!D!]"X<8`%+V1@%,.ZP&AI0J<T"S8`Y;YL"=$VG%`T
M(H.%*L3IX`S0J&N@NW4E/B'#Q%]]?#U]@":$3UFY3S3V)_,XPF$DZ3?Y-F'N
M@A*@//@L#HQ(=<7E>!ROZ<;H)Y6%NU_"#GA3"VJ(ES1DJ9$0@X1Y(8Z?F<WA
M(*[L0AD25M`TCL<VJR&AJ:X.G<][,V/1MDJ[7]=3[+6E*4&3I&C<E41=^0$*
MVA(Z_3AIA\'06?%IKTTS9]PG3U)Z*/(Z-7(4,!'M*`Y9"`@X#75Z9E?6@]E)
M3!BF.0(Z#/&E)/9P?*P/WPT#H@+7;.9UM^?/VJ9DE]_W^<)AO(T'I=%.KZY-
M-`L-45KM1V_)?>`AH'Q#CK@.$!X@H[8,F"%U<,69-I?D>=,:WT8>?DJR5>YN
K:A^/O^(&/+7'`:X@5H<D308->:8"$DK_`,'&XK:!AP@R"-XX_P#8_P#_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g575431g74d12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g575431g74d12.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`)D%D
M;V)E`&3``````0,`%00#!@H-```3&P``7#L``'07``")VO_;`(0``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("
M`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"`@(!`@(#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\(`$0@`YP'!`P$1
M``(1`0,1`?_$`.X``0`!!`,!`0`````````````'!08("0,$"@(!`0$!`0``
M`````````````````0(0``$$`@`%`@8!`P4```````4#!`8'`0(`$"`P"!06
M$1(3%3870%"@(R(R)34F$0`!!`$"!`,#"`,,!0L$`P`#`0($!081$@`A$Q0Q
M(A5!,B,0(#!184(6!U(S)'&18G)#--0EM39VED"!4T144,&"DF-S@V2$-2:Q
MHV47E$4($@$```````````````````"@$P$!``(!!`,``0(&`@,````!$0`A
M,1`@,$%046%Q0)%P@/"!H<%@H+'1X?_:``P#`0`"$0,1```!W^```````&G<
MR$+K*F=HL4_"X#H%^F')E:8TDKE))&+>.\=HQ/+C+C)[(4)V+`*V9MG.````
M``````````8-%0*:5HE(ATM0E0M8G0_2!#MG0+Y+:+Q,?C,`A(O(AXR?(%*8
M<YU#-XJ8``````````!^$`F+Q%)22^#)$RS*@```````````````````````
M8U&E\U8$#@``OLV>'H%)1+E.T````````````````````1L>=TT\G4````*Z
M>SXAP[)D>7&#\/T'X<9^GZ<I\`^@<Y6"X#L@``````````PD/*60D`````;>
MS>:2P"%262;0`````#C**6\=,I)CZ6Z=H@\M"61+)Y,OBO@````&O<\F9:X`
M```!]'L?*P3.`1T7"9````````H!BT6T3"`:Z9<>E`IR9H6;+B]@```8KGC@
M+*`````!GZ>E<DL_0`1X7L32`````"$R`B80`#73+CTH`'(FV:S+D``%(/&>
M8E``````'JZ)T)R``!#!E"7$````#'TCDD```&NF7'I0`!3S:A<YQ@`&CT\X
MH`````!D4>MLN<J@``/TB$RY````(E(,)%```-=,N/2_ADHEP$8%AK:YT3<W
M<Y+`%%/#Z0^``````>CHS_)G```!&!.Y>@``!Q&#!,@```-=,N/2U4JY4$^U
MH12#J%=3?O9WP:OCRB``````%\'LQ/PO@```'Z1J92@``&+953G```!KIEQ[
M6;DLLE8L\^ULPLX_#8Q<[#`>9(TX``````&[HW$DN@````B`R[```,)24@``
M`#73+CTHOL[Q?J08M,`+V3?;8/%V8C@`V-'<.N0"8O@`[A[.02V````"%C+L
M[0`!9YC"2,````:Z9<>E%P'&<!T3@!Q%@)Z%K)1/!V6.`7V30?9>Y!Q:)8(!
ML\/0F2B#E->98)>Q/1DL?@!:A>Q*(`!C85`X@"&"S"LDV%5!KIEQZ4`4DX4D
M$D!9%29UF"YRR/`&`#/XH9(1$Y)A#IB2`>N,DDG0%M$2%BE,,D2_``<)12?`
M`#&<J``,;BSBMDKDH`UTRXIK<)?Z2&6&5<N<E=9#!?USF:>!XH@!S%\F7Q;Y
MB(40X`#V+%:)P!A"2J7\8\DMEBF6`!U2FD\``&,1508N%XD7E=(O)Z+!+L+4
M.":OPXSD(Y*0=-)46JGP7W<YIGB#,?P`5@F0IQ&Y;@`/643834##\EDM4K9#
MA?!E*<8+")<+]``,:BH'P=,LXIQTRBE8)-.^##4D::QN2\EC5+C(Q)P+%+C7
M,2YS#/)V:QP`````>GDS!)F/@C$O$PZ,@BKEGD_'R"%#,4^@`"'B.BO`AD_2
MT2XRTB="Z0=0POEM8N`'97JE@I?J]9,W+,FS2,>;P`````'HL-C)+8!89BD5
M$RM+K`!$1ER``#Y,'27"/2QB,213\,<B13,H^P6.872R,O>*46\7&=LC%-P%
ME3(9/#V4T`````WO&VLE<````'X6"9-@``&(9>@!$@(X)_*X<X`(1(\FK%2T
MRW2:B3%Y4V#6`>78U&`````&XPWCDF@````A$RZ*@```6:8MDG`C0ZQ^%?+V
M``!BH5J:[P!9IG+<RP`0">*LM4````&T(]"Q)````!UR/C*4````Q6.V58``
M```_#"N64E'6+IN<ZP`#3(>9X````&>!Z;"1````"!C(4U;&S8^P``"Y3%<E
M$[0````!1#$264%I-SLC/T``'FW-)8```!E">L<O@```$-&0YUC5J;*SZ*(8
M]%3)<+Q!<I?)A>7(7,`````0F62;)3E```.(\[9HM/P```E@]B)?1\```A8G
M8D\`%ID0$0GV<IG"``8Z$,DR'*```?!#I+!DJ`````:K#S7$3@``JI[4"]SD
M`!2B&C*,O,```````'`8S%HE#.(KA13[*R749.G:``````+`-'YIA(@``/:B
M7L5D%%(E+Z,E@``?);Q03K'V?!]'"<A]``^`?9\%5+J.X`````````4`U/F`
MIB\12<)ZS"%2K'P?IEL#\/P^S\/TMXHY=Y(AWP````````````#_V@`(`0$`
M`04"[\!NJ8&)@AY"@E@:EW"=XBRN8,8.U?9!*:0:OI'9$M$[7^";,\W<(18R
M:]0\2V$VL//RZS+@E\6GBMNH,9-'[PDLB4%^14/*Y)W[\(\.N)-T7GMA2**6
M=^_(A]NLRR7L-0-WO(%@\JL^21\"YG]D.Z=DDMGS"H,7&681QW;K8=)X7=;D
MR(6O4%KJEOE1/^:'HL0-<+TB"WB!FC1IQLC3(]-[!H&W@X=C2;4<P9^/`!NR
MD50AI$N7I?0L^!0@>`D;&$#6$W;T4#;2X=20EAP&HP6&&O*C!OV[ZG-3'$TK
M+27'9/1[)RO*86PECX]2@4[QI6OJ'+J@1Z@YS&BJ\8TI(<F$84,%82;:D&VH
MIQ1`Y6)LFB3!G_(.VK6T:R1\KZ5895\TJJ3W2\UZUSLQ\Q*@=\!+_IP_EJZ:
MO4/Z?/+=KZN$IOYIG7F91:%A33;J!2B21=Q"O,6P07%:V,'M"->X`/SIKHJY
M_I,KET<A`>U/+J2R/9===TMV18UX9)"F`^GJM;5:`>A/I.HSP)%08^RQ$@>N
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MS'Y&"E0WL6_:0JJ(C(I"8E9ON>-L`]^6;8ZF2RWPQCID<?3/-H9*MY"V[DLF
MS2-9;QQV4?\`3</YETC796/$ZYMD;-<]3]^S%L;GM!]:LT[OBC7_`+1KF*J[
M2`IU2=D^8.1)5B<&=J9S!<0J!CZ(37JN'\RZEV_UN*HM3:3YZ?,:S=A8GNU1
M"%K#GUANMQT99,FPUEU8S\.(RI[3EO9F4I2BHJ/!%12?7</YERU@[7Z#."AW
MQ/,=9.`AH4N$*<+)JYVJ^?ISP%S(D&@D?/Y>]GDQ[OAG7_H`;=7,DG?8EXIT
M4"1TTWD8+KWWU3T#K[RTWV+A_,N,L7N-4S!?.[B0G_5+DY"59ZLBQ)PL@LAG
M@%)'4(D35TW?-N7EK,?;55]V,@'TJD!#TM7US&PND>!]C&?AF"9^SGNNS7BS
MMLDDD@EV+A_,N%"3#&SDHU<.LF@3E8&>9C1ZY@818EU4=].5`27*POEYHR3)
M&?\`=\,X!]Q/&U,R.P.T6_XR9=;!;[[+NS</YER3:,/L[T,C[BWC`E1T\;[M
M7/.(&\Q><\KY,;'+AZ(M1?N-H\IV.M6DXJ>'PDE9%>;1*4=#=NL[<0./CJ<J
MB%#7;$+VK"TS[115T<(],@*:!`<08;C8OV;A_,N6"Q3#9T3)/N,/GNN5%%%M
M^6^^B>KQ^/+M(0<VDT/XDSO8A).;2+R,BJ+G,S&/E+9,JZQFU;!:.2Q:22)9
M_%9*)Z/%*`>\+'G:N3A_EIK\VX*[/O+IG=DF<0?:U)<XKY"T8SH7Z#S;#P#"
M'?KH=TVQOMM#M_A\_,A.P(QYBT@^S1K9`)XNT>M'^G*X?S+H=/V+#1L[7(<-
MHE.'W#:L%U.&E<PMILFDFBG3BN-8QTDEV#EE[C$N[#QM!WNU:2`.)0CLUB^H
MD$Q^SL>?B]#V44J>$Y4+Z\MS@EKPPKJ.,VJ=5QL,`5K.$3!-"/,4GG0IC&R5
M79SFONFQ]OBIT%ZS"F2Z=/B=FC"M561"+0X##6_*X?S)<R*;*MF\@(\-H',G
MG#:K17#HO"H.77M)9%HA8#Q70!*@$HQRJ?;Y"7!)KZ$CSV44WQ%F0HB?!URP
M*&4ZWC3U(LS48$\*JZI\_&]WZ^EJVS_X7D0:>KB2PZ3%'.#Z#Z/(`9"]B,M;
ME\L8F'D*Q'FOOA-O6&F4Z_Z;&Q\'G*2E4F;D,]DGK\R.3LS;T^8*QU`O-\AW
MQML&B^DPF&6T!(E"CBTH.E(=8XG'OM?'S:_-P\C`0DJE"026S2`Q]@^:LFK+
M''S8SFJ_^_XM<7D-9O0P=^@=_L4UOIK8$DP]+%')E_T>)+O5>F(%K](/R:3E
MR+($Y/A2&Z6,/;+FI,]:I:6HMAD_*2\)&M]?EWY2IWAC%XLS^WQGIM'/T`VV
M/ESQANAA<E(F`LKM+8FNIB51ML@WGX9R>(3F,#Q;5?5TUY2)C['+<2+3?<B+
M8&VKMZVE+4KND8-QUM&94D&5U5;1]BE/?H0QB4;NZBTSOR\MP&P>XNYX7.ME
MJUB7^)[QMKC;5G$`S19\+9DAIEC7+N-$'D0+N$8S'U6ZT!8?;<Y^;/*?:[.@
M6,8QCIL`7N9A8HCJ7%\CD)''GN84PRF-K_Y>/8@SZ257C&[(0S=L&W)=!%TB
MT16AI=G.DUG>\U&:<&I>Q9#5)D*^K[U%*:/I\Y;I;SN.X?`I4N5>4\WSI7_'
MFM%-GL8[GA"\^8"'^"4QYR8:_,`T`DS%PPU"%\Y!9*Y#=&^/N]B]6<8VQ$DL
MC->),\?L1L2>RH@\TVE#;>:K%D%HR<DS^0)H6!]L)Y3T&:Y4SKRD0!C)1(<2
MP5=MHN$:<.0X1;#`''$<MHK'6SG$9CZB2D;$*ZFHVW:-V;1N/9\6'$F\[A+Q
MHY'N^WX/.?@43Q]&RNU\==<5HED@WZYFA]AEW,O+QXDV%E>ICAK8HK+(213+
M,5$TU=>B:1E<T@$,('&,E8.7!B)!2P1XC%7;AK%6Q9F.XA0_:03WGY=5O[8F
MW;\+'GT[$(_X;0[4U7</$6C5!BUZY`$9R0+%B;QTUY%HJ.,NQL3;"MM8DSWP
M"`LX\VZIF(<A'[9RW>M^9PFH,90F,:1"-\[.@(^RH6<"DHX8[7B$\]+<,EU^
MG9'9552;I5^S6,NNS/@CUD[8/V91EW'[+V$8Y*JI-TJS`*G7_3Y5TGM*1O:\
M9W.6UV3G_%*NR13S.CLEF$3@XXIY<"B\CUL&!XU_84!X_84!X_84!X_84!X_
M84!X_84!X_84!X%RB,G%I&.4KIX@NBY1[9(<R+L!F[X`4VVUTUC,;4LASU^3
M/CWO'W'9I1[Z"V+%_P!"O8/FB"Y&-QX;%A$DB49F#$KXD`Q<AUKZ!_#]>P'@
MC"(.Q8^LKG#4C["#(BXQ6YA;]>P'C]>P'@7%XR#6SC&V"L8*0E808&'F/;G[
M`.\CL/A,BGC7331+3KWTT5TO[Q>5&[9QG&>N!./1SFTL?^9V_P!W46/D7I&*
MQ5A%&'09$)&V2@`O%&0<`0]LCZW=XAL<@9L%,>F15\W?OU92ZCJNF^BFG7G.
M-<8E*YM4!7B:#[MW/XPQZPMIA!Y5`BO4Q<>D?6-_EK?7;Y]>A\^9#&B"TDGN
M0,?$1@;_``%$TUDW55AT%%F-F!^%)FW8\)V+`5=_></^DK8L!1VTFC)WG1K9
M9?AM58YWE%!%LCW9)%H[+QEB^&&?FED!F<&<])578O2HY358=R($1XEHG*"\
MBX&5R@H[ZLYQKC8N)3VUED6WV1E\<<\(RH6YPC)=7/"!T@XPD5D:V$G<M5QI
M[OWX3;2W;A,;(L\)A"G&L;S\-8H-XQ$H_P`>S(C\R,:CC?*+=NVU_AE/M?H)
M37?B7)\G?'BJ?B2H]5GE>KSZ6R=92#?>',-T:9C,_:IQW,YES[=HG9AO@<-A
MP4R@ZEJO"'O#?A!M+\\(#))P@$*:X0CFR?",8'-M4@\+:;,$ZN2W%^R?I-O2
M_0_E_P#_V@`(`0(``04"_N=?_]H`"`$#``$%`O[G7__:``@!`@(&/P).O__:
M``@!`P(&/P).O__:``@!`0$&/P+Z?':VSNJ6QB9#>YC5SJ5V.2*4M#$QQ\SL
M)-?D9IS8%_-L.@W=%&QY6-773DJ\0;YV,9%#BW5FRGQWU*1C=8R\G,[GU!02
MI]X")#@U:15ZAY+PL<KFH/?KQ"S*LQVZM:TWK/?L'/Q6"^I?0$>.R`8MGD,.
M+82$43E$V$^3UVIJWQ36%0T%)<7$F9C=9D^K)./5I.PN:XMC7LC0[F[KIED5
M6L:,O;L(P!'IO5$U5).77^/FHNS=9.<@U`^-.C5ZF<0T!C9TJ0G202C?U=FI
M47;RXA?F/+LJ-N+V@["<#!H-`0MLRI"DE(/;9$6X`T]T=0MW,(!@-7*FYO&2
MGL\<R"#,Q?\`#Y)M6(^/7$D\;))O80"Q#T=W902F:9%W@ZJ&:O+35>+LL[&<
MIKKFFR&HQEN,205GK%E9WX62*=L)169*_I2H[][G/,Q!(U=W$6)=X[<Q+A:B
M1>VU,:QQ2/*IJZ+)6,YSC2LA!"M9)E:KPAA$D$*Q-43A^)TE!?62`A5%G-OA
M,KQTT&!=U_?P3R'GGCF;WZ]/IL$Y^[GIMY\97455_CT4>/4^+SJ+$[&E6=8Y
MK/N2]*55P)8+&)-!(&G-%&,WCS33GQ4XM:XM=P)ET98%;(=-QL@Y=LVM6Q[/
ML!WBW,,)MBC$>3'`)S_%6ISXP%UI0VN(Q[W,+2I/8BA45C26X:WU#J53G2+Y
M]M5$".+J:0T+O.-49JWB>HH%F,(:&]R*K+W>/R7W%=CRJD[2+!NI4RGDD:F\
M0YS([B#YI]7&16%5A>21[6MQ&!F=1%OH\&/'M:.?(9&]2_9[52BCPBO^(QRL
M,K=%:U=>,8QJ1BMR#([VC@WLN"2;C41($.8[IH2/WE^-]PJ:*10P^X,(7OM1
MWEXQ:H@0+:^I9^'9+:3L?IHU*LH\RN/&Z$Y\ZU-!6+'B`W[M)#4=JB;'NT3@
M]IVEND3\"@SRN<\48;[B"28^ND5D`;Y*.?;0I[4&1B^7S(J.5O/C\L[9K75]
M9DF45L+(@'KCV<^/52ZR1+,`,6N;*E/GA*UK?@-*[5%T1>/S.N,>L8X*['\S
MP>DQ^?,QJ>DF-67S!-M2RZ6<*'9RCB+N5C'#8]R>[XHO&`2$_,:O2+D]_>1[
M+-)WY:V=>V)7P*]3@!^#Y<QMGJR2-44F]JN1VO@G./\`F*ZYQS$30H=M,*LW
M'9,W\4L%+[?'5@0Y%J`M,R_'SV.20;<]NU-%XC976X[U<U+44TN;4#A'GK`=
M,[;U22.K"=DB2^OCD>5(^_=Y=J^"\878T\F+^:7XDS:/CDJRJZ@6-'ABD=/^
MJ9-1/NQK"R/<KMG55@--%=HG-:_&+#%KV%(MY3JVID$FXN5)=JE>^P9#?7Q;
M^1;PAF0:C8<P&!<_[VG/C&)>28I8T\O*LTF8?6."Z`^$4P26Z]UIZG)E,%"'
M5]$^Y$59"_#16<TKF1J2WDS;;*LGQ.!$)*H:QA9F*&0-@9UC<6\"L&DASD[8
M75ZYE71&<#(HWB5[&O41=O4&KFHO3)L<]F]G@NBJFO\`IU5W>3Y);TU#>VF2
M4N.R?18U9#NK8LHTB84T&ICVLY1$F/432R',8OLTY<8SB\>VLXTC#[&1:X_>
MO!53I4>7)63UVRX$Z`>IGQ3,E*UPWAYZ)HJ+Q2CEY-;),JJJ]I33AT^(,9-@
M9$136.RJ3'DIJR9O70<B,!AF#Y:JOFXP8A,BMI%9^7XZA:2K)!Q]'ME4T/LP
MF6Z'4LOF1Y>O4D1VR.B4GL1OEXG8^&XLKFGD3ITF%#MAURI61K`I3R*\18<*
M*62!Q3.74RO7GHFB<6&.Q<WS,.%3!6HPXD*56,B04MQF&<0+/TQ;DD('751`
M>9PVKXH[BTB'R&YDNM8>*02E%"QZL8$.'V*6%8@(M9418^I=NPSGH\A/'=KQ
MD4U]M;U]C>7.-Y!&GPG0T-26^+0NRKI$%#12C*-[/UPRH]K]=.7%=>$S.[_$
MP*XE3:7LJHQ&S=<P"R72]A*NQQ^145Y8Y':`?'"SILY:.\>,AR:-+EFEY'$H
MXDL)DBMC"2BA=D$D=D>.'8Z0WS/3W=WNHB<N+_.FFD%LL@K*BK-'*T"QHHJ=
M#((D14$AVD/UO/JY4Y<!RMM[<.6+ETG-(]<^-1JWU6;'='ECDVOI?KDR$K7?
M"$^3M%[.*8+\BOIU?CV86674]=*;5=**^U#.'-JW&!7AE'A%?8$=YG[TY(BH
MG%Q0BR2U+CUA36U'`K5J<4#)JH=OOZVEX"A'=SW1]_PNL=S43DY'\/BGL+7I
M$_+IGY;.Z;XS'^EC.*0V>UW;KI8]0*?]G_!XQ05[F=[;P\6+6R!`/68L$TB3
M4/:Z&05G$HP6M8QR#:T[0&;UVM\WBNM?DL;*+W&;BLI+.ACR*@=28;X5N0;I
MJ2`6E?.87>-FU--JM]Y%1R(O'Y.4M'`<Z@P::9EO82YP^X?0C$DKT\PO*2<^
MTM1L<NUO39S]FFF(SYDJ7')A^1@R6$R-T=DF5'CGCM!*ZHR+VZMD*OEVNU]O
M&9N6[NH)\TR'&\DDGB]@KZV?BXQ,@I`0\0K.F]1(K^JC^?&)S[[*KW([#$;:
MVM(DRQ%3B?,2VKUKGP9@Z^MA@[0`GN5FQK7:KS54XQNJ@YGE577XC>6U[0Q(
MZ4LF+#D64KNXXNUL*N7&,*F>]Z1-[%4:$7Q7GQ'HV9ID,:VC*`K,L$.F]7*>
M/)[AJRXJU?H\B.1/AD%VZ-(/DO/GQV3,GOTOWYE&SX^5]*F[XN31=J#D>F^F
M>C,AM8FB`0.WZU7B)DGXBO)+X65$S(421&H%4MU*B]K-?+LQ5`K8\4R<V`ZS
M0AU7:WPTCUD3,LEB^CYB3,\5EH&C*;&IT@L\TR+&1]7LL(<I]F75LKJZ>73[
MVY^&LRR_](F6]S;6ZS(.,VDNU->%$:41\B?1F=!GB(-S@R8O1(-Q'?9I$@@W
M]"%&!$#U'N(3I1Q-"/>1WF(_8SFJ\U_TE[+O.,9@G&BN?$6VB'GM1/\`R$4A
MIO[GDY\.:'(+"U5N[_VZAMM%5J+Y6OL(T`;M531%1=OVZ<*UE/G9VII\0531
MHQ=4UY(?)0D\OA[O#^MC><C:B_"44*@,YZ?6]KLA`@U_<5W"==,JJ]=->^I0
MDV^/CZ;8V'A]FO#60<^I`O?R1ENZ30+N_1_KR/7M557PT7G[.!RH4D$N,5-P
MI$4PS@(WZQE$YPWI^XO_`"@[\49#%!.V;Q4L1>^NS[DW,VUT=7%",GL(;I!_
MA<'BX#CL:FCKJP=M?:6%FK?885<![:Z&5/J>Z6W_`)G_`(FR^[M!/\83ICXU
M9S\=M5#[>M8J_8+G\_N\;OKBBD+IO+56,J"I-/NF2.4:&9_!=JB\#CY9"K\R
MA-T1QWM937*-\.4N$!8)=J?IQE>Y?%_`\GHXEK"B/D%B.#:Q6QRI(C[4,@GB
M*>/)$URZ;V/7[=%Y<3!>MU'4KC#C6`_4H>^!)-^ICS&];=%,7[K7Z*[A[1&$
M1PG;2M&1KU&[37:]&JJL=I]?_)1[W*+6-4UH.75.Y5(8NBJV/$CL1QY<HFG(
M8VN<O[G$BH_+UAL5I55XW6[^FN1SQ^9NX;TZ@:8;T7^25QT5/UJ<V\%DR3%D
M2#O<4QSD<4QB/7<\A2O5SR/<OBJ\U^B@5->)3SK*7'@Q`I_*2))6A$WVZ)O=
MS7V)Q&A1P]9F,THAH)C6M):7)]@F,7I(C5D6MO(1N[](G%<E_$URG>MO.R:O
M(Z#>MO9AW6$J0.Q&UI3#%+*NT)T+'Y<QKP5,KQ2GSN@-8Q[:5D57C5<N4`LH
M?.->9'CH(O0NYD-/]^KVI)9IRC)X\);TD>JGPK*W'D2SJTBHV5=`3II..^.]
MCEFATVO:_FG@Y.$>,,T2I;+>;0W-R$3K)R(CBO"*P:$@'Z<P.10*O/9KQ&(&
M?DC>VM#VVPF59',&>1(;M?'DMGV<KK5;?N0_YJ-?=8G$%69'DCVPY\R<49YL
M22VQ27NT@SG2(!#=A$5WP6!<%S=$U<O%?KE]]+;#+-?*;,B8NOJ@Y6[H!ENB
M8]">)M;K\%0=%SD3XJE\>(._*'RDC"FME]S35R/L2FW+"*98G:-`D'5-6B:S
MJHG/1>?$)'WE%)44&2R>K\;FA?-LG;NTDQGBR91UT(/+J!4<AY/85G$5"$QF
M0]M3([TC`VL-I;W_`'7M0J><L>I=_*;GD,GLUX9_5.,F?Z0XA&_B"UBM]>1?
M+#8_\,S%]((GC)TZS/\`8.X*[\-P#.'4MDL%&R+5Q[G70E4)951$8D1$YME/
M5F[VB;Q*5<3M9/;UD28-(-ACSWSIQW;9-1#2?;UK$D0O%Q3N`!Z>Z]5Y<3G/
MQ?)7]E%AR=`!J9#ICI6WJQ(+06Y%/*@*[0R>5GE7IN>FFL]2T^2Z0.QUZ%#.
MEK+[Y&Z=@R&P[Y7:J_0^B?"YZ\DUXG.D#NPMKI,&)(<[&,E5CSV"M2/V#VU+
MF6PD<[0I8JF$#^4<WB:A[4$?T^PBU,M9+#QVCL9VBQ(C7&$QIBGUY;-W/@PO
MQ)1(6-:CHI`G6T!I071M5#4%&XZ/'9F1-6`7XCT\$X7HW%67;/=5.Z=A$?I9
ML]^N7:5=)[?:']8GU<.4)1E1CW#>HWM?M(SDYCMJKH]J^*?Z.C9.VURB:%7U
M..A)M*YJ[VI/L2HCNRK6D;IK[Y7<F(NCE:2\RJR?,/YFQ(@]15U9'5=4B5T-
M%5D<*:)JO,A%3<]SG<_I).930*ZLQ`7[(YS7=,MY-8Y@='>XY8<17O5J^"O8
MO%%C*;25N-L9EU\BZ*PDU5+%QJ`]JIH[XR&DN;KRZ8G:>'RGR/#)@\?R$[NK
M8`<-7X[DRM1$Z>0UH]/VES6Z-G@V2Q^U2-^&LBJGPR4&5UK&K:XY,*PAF,5=
MK+"KE,T#<4LA4^')%R^Z]&/U8GTNCVM<G)='(CDU3FBZ+]2\,(^N@O(.2DT9
M'1([GCF(BM26QRCU;)1KE3>GFY^/$<OX:H.K#LBW40GH]=U(MP9=QK:._M]P
M+(KN;CMT*OU\1"1:>+%=!GS+2-VW5CM983]JS93AA(P9B258F[>CD73B+829
M4BIATQ9LH<F7E-U$A!=8?SKO'R+=D:3'Y>09]XA?<1O%:W$D_,3,O3!SQQEI
M[*_GT\KU#FXDW)LNMX=#>])>8'/FR>W3W-$T3B`VM;Z*"!!F1&ER'+17T^:2
M9NV3[2#%Q$@#3J]7_!5MCTM43>QZ<N(Z2?S-J7J&$^,_;@,'J23N>14L99DN
M!"?,8UR:($,:/Y4U$[FKJ2H#F$.8VRI+>R*<V+UHWM+63J6&UC6#+MV&2S<Y
M?JVIPBK-PZ8WEN9*QBS&KD3QV%B94!!.=]:L>GV<(EKAE/8-Y;C4V028)O#S
M=.OLJHX5W+X:S&Z?;PC+AMWB9%\5OJQ7045/'=;TQ;>I`/ZE,87+[>7`["GL
M8%K`-^JFULN/.B%Y(OPY$8A!/Y+[%^D2#!05AFEK'<^IKG^8$$"JX?JUGHJ+
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M+)\4NNJOJZ[I!I:3GX=G&`NGBJ_,Q+_"65_VWB7S%LJ.9.QZT=HKK"CE$KCF
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M.-.771*6N-KW$YC5T6?(1TEWW.DWR?.Q+_"65_VWB7SO7<8L7TMQY4.1C>K`
MM1L31L6\KE5H;*/M71%7:87B(C%Y\)3V01T.7A$YYJ=Y^I&LA"3XEAC\I[1K
M80T3F0>B'C>!&Z;7O^=,L[&0.)`KXQYDV49=HH\6,-QCF(OL8,;%5>)MX12A
MIHFZ!CE<]>4.K$]=A7CU5J39[OBG7GYEVZ[6-^F%>3`[+?,B-MBJY$Z@JM&[
M*J/KR=M<'4VB\T<5>,AS@O,5Q(](QW77RXO2E***<>YJ*@[><XTM/X)4^?%S
M6@"\UY0@>R;`$Y&+DF.;NK.IR:^1TN/S/#<O-IDV^#^(-O6F;(@6,84N*9JI
MYA%;N3715VO9X.3[KDT^CBX[CP`V&7VXB$A`/N["H@C78>^NWL\PZ^*Y=&#3
MXDDN@V>US9)B2I-M=63T/=7]AL=86DA/=1VQ$9%@1]=(\4>@@,Y)SU<OSL2_
MPEE?]MXE\\3VED19,4S)4*=#,^-.@2Q?JI4.2)4(`X]?%/%%5%U153C\+9.X
M(,OAQE,"2QK00\I@!T:^QA#3R`LH^J=Y%3DW7J#^&N@_FP/RUJI&V7>#9:9$
MX;E1XJ@1M($!5:O+U"6%SWIX],+?ND^FQ[&&,<Z+*F,D6KV[O@U$14//>YS>
M8]XF]-KO8]Z<0\7I%;&L<H/'Q2K1FC5APC`=ZI.&U$\J5U,$JM7P0JL^OB)7
MPQM%$@Q@Q(XV-1C6!`-!L1&IR3DWY^J<E3FG$K&5\M!E2R[W&^36AK[ABH3(
M*(>C&HT<C<DP#=>2.(B>'T22&`[^WL)#*W'ZAC]IK:WD(O;QF^U@!HU2&)X"
M"USE\.)4RRDMLLDNBMFY#;-8K&RI:-T'%AC57+'J:T:]*,/]!-R^=SOH,2_P
MEE?]MXE\O<NG:L=7XO*8(<F(Z4TMY8U\.3UHR(IA`&R4Y1N5$U=IX\7$(<B8
M@ZV7!A(\5I42GZR),\4B2[8$:'>$45'=H/\`:-=4Y\N(,R":4VPEV:P8X[!\
M*)&L@B"8DJ;#ZSQ.`"(YK&JI'*CG/V^]RXG5<AXB$A23@Z@2#(PB",\2$^&]
M_3W[-=CO.WP<B+\D>1%DF@6$&0.;6V,9=LF!.!S#)"O@NWP<U?*1BJUR*U53
MASY3!1,DIWC@9'7"5>F.6H]X;"&CO.M7:B3J@5==OF&JJ\;OF3[6P,V/`K(<
MJPFR'^Z")#"^1),[^"((U7C(,LG*_J7-B8X1/7<L2"WX-=!14Y;84$8Q)]>W
MZ:W_`#"G`TDW9%J:9S]-65<,G[8<?WV]W.3:NOB@45.+J[7S5F)C+B5)JB[7
MVCW#/E,X>J::L,P4)=/!T9WU_0E6L5&7E28-[0%]K;:KU,$/)%=TYX=\=R>U
M"\55Y%Y!LX092,]HB.;H8#OX<<R.8OVM^@<0CD8QC5>][ET:UK4U<YRKR1$1
M.).>2=5@=,]3A,=R(B`I.HK)]VK>>DK()`]&+XI$&W]-?H<2_P`)97_;>)?(
M9RQ9&R.()Y#D$]S8X9.SMRG<U%0+#=5NU7::[D^OC:.8=7D%!BZ-TU<*O,(\
M`7AX1SA8K?M3@I#SY#);9$<A7(@Q$257G,4#W=-C?C1Y!7KKXZKPP)GRYD('
M54>D9',$D5I9Q]I1AU8R.-7E<FNC&ZN7EP1[8EC/EG1\\KF@DRI!FF*N^814
M:\A$*=5U(OB[VZ\-:8;AJ\;2MW?>&_W7)]G+]]-/D@9=$1[P1&]GD4,>YRV.
M-F>CYC6B;IU9M8Y.ZC>W>Q6>!'<1YL0PY$26`,J+($[<(\>0-I0F&Y.3AE&Y
M%1?J^4]1'*HY^8SP4K-BZ$2N%^W6I/\`NGB`R._[)'TU/CE:W=-N;"-`!Y=R
M,4Y$:\SDU3X<<>KW?P6\1ZZC$WJ5%;`Q_'8Q%W=U;RNE75C2:^<N^:5"&7FO
M31[E\.*VG:_JOB1T[J0Y$ZDN<55-.F&5/>-)E/<YR^U5^AU3Q3FG&6XDOEBM
MECRFC9SVLK+Y7K-CCW.7R0K@14^S?]!5X5!.\$O+Y+X\\X=>K"QJ$U#WTEKD
M5%&\T?2.-=4^(9.!`CB8".`8P1P#3080!8@PB8GL8,;41/H<2_PEE?\`;>)?
M)D3"SBJRSJ:L,(81]P#JL!6%<AE20SHNC]HH?!53]SBJ,.$.&V"&,,W1Z[E>
MHCO([1#R3ZM1KN7@Y?;Q,,089+H[)ML`\B!#AND3F3VGJZU\49'H<"A>\143
M7D7716C1>'1Y`WF+_7_D</>`BV6-S:J.TNA1NV.E2$WZ>#-=.'03*6M1S*@F
M^)$0X4+6I;C)%Z3Y;"H$K;-'H[>OG'S3VMIQ"-UEBU/1*[EJA"VMK.:U^UQ&
M]7MYC%>FY=KE5OL^6SP>4_X^+.%)IMR\RXS9O,Z*%GUI33A&C:)[D?H?7\M%
MC0R;H^-T"2"LU_5V=Y(<8Z::Z<ZZ)$7_`%_36_Y@SA:Q:)BU%/N1%1UK,&U\
MP[>:.:Z)!<C47P7KK]7$.N35U3@<=EK-3S=,V4W$=PZL*\MJOJJ8CS:?^<;]
M7T>#7R(Y&R9,_$)SD]U0W`%FU;7<ON6<)=/X_P!!EF2*N^/",S#:7FCFMCU:
MME7AQ<O"9:F8S_T_T6)?X2RO^V\2^5LR0*4$W>B`(O<L<D]NJNF-CQEBMZ;8
M@-NK^HY$>Y$7WTT6IA*4<=R0B-4[DD&$*171IQMRB$+KN%U7:(UB*[3DFO$B
M&)UC&DZ5D@$:4GQTC3@4[V"<KHXHKY!RS3B34@T0[!M]U7*A0O'TE16O8Q"-
M,G1.QIXZM,WRF8^.5JH[[R+K\S%;[?TXKY[<<M^>B.JLD*""U2<].G$NDAR'
M*ONL$[Y?S!F.=NZ.12JAJ_P*%HZ-FGV;:_YN`VR29:4^28UE-Q?2F3:<1Z^;
M2KDO8QJ^#(>DZ0"1Z0#J.01=.HY=4TY?E:BNR7K_`)@$_+MDJV]2QI:R(_,4
M`2;&CU",]>0D0+W](KVJ'5J:JNO&--FDSCIWMA>UR8RP5',RJ5Z=+CP:JSKB
M1]L+T^\DE>T:/%UD</1&OY[<HK\>]6O\:QN5&B2K_L'OCP)9HT,DBMM)L-I*
M\,Z!,E]N_P`S=Q$\$U1/F@BQAN-(DF''CA8FKRF,]!B&Q/:Y[W(B<08<K1&T
M%*>UN2,7S2K(@W39R"ZBZN*>4_IA9JOW6I[.$EVJ-2]OY,C(;U6\T;8VCNNL
M5CN>H*\"M`/ZAL1/H[*:Q/CTIJR_C+KIM-46462YVOL_9D)^_P`".-=1F&PH
MU^MA&H]J_P"M%^=;VY%VLK:V9,U\>8`/(Q/^D]$3BBBF_G*P!S9J^UUA:.?:
M3U<OBYW=S'IK]GT6)?X2RO\`MO$OE%#2RGI$CJC@14F2.V"YI5.UP@=3IC5I
MUW\D][GX\/6;83IG4Z74[J6>1O[?J(#?U2.W=%"NV:^[N73QX1R2Y*.0D8K7
MH<B/:6$)0PR-=NW(^*%=HU^XWDG#BE(\I'KJ\A'*][U^MSG*KG+\JO(YK&-3
M5SWN1K6I]:N7DB<3JVN/(LI!@&CZ442;<'C'>-4&]?20RECD$]4<CG;=JIKJ
MG&,WY$VGMJ.MF2QJFBAG%BC[Z.YOW7QYF]CD]BM^3()[]=\V\MI;]=-=TF><
MSM=$:FNK_J^9`!6T=I92;2"2R@1:V$>PE28`9<B"24V+#8>0@62HKVZJU/#7
MP5%6@=&KXJ3/RXH<AIP`DP3M)%KK8EM'M76H7R!$60`N0E:GN;%VZHNBZXD0
ME%BCK/"DQ=E+>>F2_5^AB3P.JHTHZ62!-'=V[4*B#;O3ZN*VPK*&OO#UF0WT
MBE,:DL9ZUMQG*(2975SX<L3A%ENB%+&&BJ9KG%5B\UX>>)3EJH%].]/])QN+
M;1Z2SMXC(3SA'$?)F)-M?C@(5NYY-2,71-6\2O5J&VJGPA1I$H-G`DU\D,>8
M0@HTET66,,CMBE&K>IMV;N6NJI\P5U+#U*C#!LMC;D16%M"J\=0!4545=A6O
M/JG@H4U\>,;PIBZQ$>S+<D35?_;:F2GHL(FGLLKP?437DJ0G)\K&_I.:W]]=
M.,0JTC1$N+S,;ZAMHK8EL,$*LJP6A8TJ)-,Q(1Y9UA,W(A"::KY4XL\N?^$^
MI'F4T)D%*S)P-JUM+E]<2192I)4C600`3?\`L;]=47[.+S,Z^)B'3QVYMH#K
M&66Y;4Y5$@O""$7%XK&I/[BQEO<%&F?[Z)M1^O+'\<M["LJ,@N:ADZ57R+FL
M:ZHL'-C[*2:PDD<EEE*<?X(]FY_S;V(Y-R2J2W!I]I:^0UGCHFJ/5.,7E+KN
M-052OU\>HD(+">*N7WVK[?G'K6:JZ^M*.AT315<VTM8H"MT54UU#N\.>G#MJ
M(C=R[43DB-UY(B)R1$3YEK`DND)*IYF.09(VC%N(7*"'%7.C(X[7&&QT=>JO
M+9]O!YHZ;(C`9D/X7B]*/5.)96WJIZ?IPA^KH]HTF1W>8_1\O/C%V!BW?:9>
M1L:GM7UKAUJSW$F!]-D%>1#BF-+`*CM!N&W1-7(BHJE)#.R0P,DT,KA^#),9
M4:<*^'G&J\_EQ+_"65_VWB7S>I.F18;/TY4@4=O_`%BO8G">D5%Y<:^Z2#52
M6PW>U-+.:V'5\_\`ON$7TZHI&+]ZULUFRV?^AJ`GB/\`_P":G"+<978E]J@I
M(4*FC.^MCGR4N+#;_$.Q>&D=1Q[$[.;9%X63?&1WZ3'W!IO27ZMFW3V<-$$;
M!"8FU@QM1C&-^IK&HC6IQ9U2>%%F&4P6IX[0S[0F1QA_Q11;UC&_4U$^=,K1
MSX-:F2?E?^68Z*38&[2#(?0`J(V2UZS51P@*3(:V671[D$XD=4U0FQO&:V,:
MRIE#94T^#7V5]'<6IL[)$KA-F202XANIZA(CN,SNA;-ZHXZ(W?QDT_L\>.N$
MU]#DY#U]1&#47E[+Q6%CU[5#$"(*,>I__8'9R@1D8D18_>.&UC'Z<0/4YT:(
MX?YF83<$&57-1*VOBY`V;)5&)J@`.E,1VG/S<4,=S*?%I'K?YKQD6N+?E%5%
MR?"L8IZ3(I2S[&YGC&>8$H'.$_08VN>@]6^;/!RKBLMH_P#^OB`5:R86?%C2
M)F74!8=>DEX11EED,%96T+GIMW*J[T>U/EIY['!)-RI%R*QDL5=-)";(D=5?
M[G9PQM:Y/=W[E]O%OFTENA\QG=W`:YNTD;&H;>TQZ,OF=L<2&SN"-]AC/^6R
M,>QAQ1T1`):R)9F1HL!Y@AE!23).HP,1PC,7WN6NB\^,:!&)/>#&;^RRBK<Z
M4)_4G7(IC)'</:!$-$4<]^Q&[5\.:\$JI>29+^&H,FLM1QK2X@-KJ=U+9I;@
M*`JUP.U!W":$WN75G+5/'CU6HR.S?7%RJ=ET5^-759)J`Y!)8T,HT/\`8I\7
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MX6CF]G-E1=K_`'V]N=XM'Z<MR;>?S!M>][FA:K!-<Y503%>\JL&B\F-4I'.T
M3[SE7BNAW9G1ZLQ")*(R?#JGJC(Y2"$VRL`2H,!9!VM'U2C>QF[54XN*WTZ_
MKX2PL=GUU/\`CO&I0;6'8625Q;7\<1,>_#$YD4SU[>*R+US/<Y@W.(-S7=*L
MMK.3.A61/5QO[4<T%1&M<AA3!KCBQO58-J@H-<T'6?TSR+%&Z,:,CFSH98,N
MM='DE'V$Y=9<5J/78&0[I`WE8WQ78W7ZN'B:1Z"*K'$&CW(,CA[NFY[-=KE'
MO737PU7YF%.=N<@H,J%H1K?=ASI47;HFJ*S0?+ZT\>,:![85?Z<[GXN@%+%<
MJI]Q54?N_=\/E_-&K/5%N+A^89:L6(&"D^0,MJLF1C,I@]KEC[*B2U&F\NQK
M_'1>,*FU4]U7"BQ'-GPIU5^TA(L*('20(LV,4BE(-R(W8O3\?;Q.NH59.M11
MEF-CP&`'U[<L"1TAO@M5Y!$BR9#$>,G/R>9$U33BW6IDR:W(KO(FWUXV93&@
MM/+E6M;,,"M;-E17QX=?&"Y-ZJY3[5:O->,?&XMK/ABMQ+E+\;=,J;67`0!M
MI8B5DT-D"-W.WJCC&ZJIIIJF[BKDWQ\D#"KJ622OBR+J<F\I;Z;V`LB2/-<V
MVM(U0K-_6<1%U3?JJ<OED$7F@XT@BHGBJ,"]RHGV\N,3:[35:@#^7AH57%3Q
M1.:(_P"=@!/N-S.,-SOJ>>ML1"3Z_.1=/ES5;"5:-!$@8E'JPULV=`-WEHEJ
M]6LDPRA6.,\J.+K%W,:QC?,[1>*&&5(5G4.Q-DB;>LD2/VFV%*KX[WC7TM`N
M*YCR[1*1BE:BD7;IMXRB!7]K9[;V_.&%,A6:%JH$#&:R?%E/G]]T"55A.&Z.
M)@@L1IGJNYRZMXQJ\AMDPF7.302QPQA2!24QP\AS(_J+'*Y>I)`SJO\`=:C7
MM335%XHR622H0B87#-82ZN5.MK%8[[['PVMJ>*:H@+%O8U64JL8SN7\WZ+RY
MK.H)<JP`D\<6)*L.[NF?%*-KD+.M;6K.>'J[1)!);T:Y5TWZ;.`V/I<)X>TH
MT-5LJ[-M@2=:5\LD@@I/J#V"#$F"9J%0/?L56]3=H[C)I5C/2P&\]&2":/#L
M*^L1A:AI)3*R)83)SV";*54)M(OQ$5KM'M=Q59(.N2[G8RDGJ41B/[>[II?2
M=90!BZK`)/18[#1U?JQQ1(U_E7E%EXS#KHE9,"TH$KH0(#-ONJ,H`C%TC@>B
ML>QR;AO:K5YI\FS<F_:KMFJ;MJ*B*[;X[45?DM2R`N(2U]%98[9)6[EQ^0:=
M5MT8].BH2S'.733>CN?+@NB6#Q%O!Y'VI;2<6&&W';^N=S'BO.H8^^R\[FM1
M&N\%Y<5UA"2SBFJA$C0F!M[%D<40UF:V-#6/W'2)$++-YAJBM<-K&+Y6-1#I
M%$@DE2C33Z*Y>I*D:=8J[E717[4\.7R*B*BJW3<FO-NOAJGLUX_,)?8DO&V+
M_&2G<Y6_QD:]%_<7Y,^K=J-9'RZ_4"-1$3M3V4B1$Y(UC6_LI6\D31/9\T4K
MM8<WI;]8L\/<1#(0;Q.:46YBKHC]45%1S7:*BHJ<2(DB#12Z@P*<`Z*16HM3
M#90>H^DNB"&4<D9(RW$M5<I7*9TDBEWJ[7B58K)"Z=8WDZ_MY'1V/N)MC&DP
MSLL$$X;'QFQI\IHVL1G2[HJM5%=JA[&7TD,;8G3`SI@"((VA!'"S5RM"`+&L
M;JJKHG-5^;4`3;K!MKX#M%U5.I9'EIO3[JZ2/WN+&-S_`&++\S@IKIJC8N2V
M(FHJMY.7:GC\GV^S5=$U]FJ^Q.,X2[>&6"AIHMP,@\:N,;LILKHSD>!E=.?.
MFS:AK8+1"L4:H$?N9N79Q.R2FZZO%%CG"QT0@S=5TB(T@!@GBC=1[FE5C55$
M8J\]?;P>#:U-E3R(`IBS&'[$HPNC4<?(HHFDA2I`B&M:T^H6M7]8QS%T5.,4
M/$`V.V^99&.":Q''"P%(2RBL7IEV,)U$3?S7ERXJ)BPI+]<*R/(K0<BBO*H9
MY]6&,L,-=,L(@HYXA#F^(X/7T;SUX;DMG:T\QC28S-+"KZ0T+:&UL(L&77]Q
M)M;#KQ]MF-6O1@C(X>N[1=O#F_HN5O[RZ?+DLM?Y&AME;_WCX)A"_P#ND3C'
MH.FWM*2KCJG\(4(+'>Q/O)\ZDLM.51F.+3R+X;0>J#BR%5=4T;T9*Z^/"I]2
MJG[WR.E((:27B0#SHU$*\+7;VC<_WG,:[P^KBDIY#9+I-Z=0`>$;7@BZN:`!
M9SU(UP12YQ&1QJU'ZF(U%T3GPZO?>U+R&(2$Z,Z6'5[^JL,P5;N\&G^&_P!C
M7+HOCQ&BU<J'+9'L*V@;#KC1_P!A0D]E(WX>YK61:Z0G2?IR&J;?'CT)FB$[
M6L/UG3(&G4M$E$$)K.YVF:$$1SB.&XGBW:CN:H>U6WA2`B:;8,$D3BR2`BK-
M<(#5<FJK%3J(ON[/-KISXBRFHYK94:/*:UWO-;("PS6NTU3<U'\_E/D$=NF(
M7DI'Y$!J>3'KDZM&W(Q-\!UE@[1D]$Y#?MD?[;=QD@O069"632XP.!`DACR8
MNK9U\V7,>&41C7`@$+'(5&>=5Z>G/;IC[!RU]"@XRM>8,Z.J6!)8%I1123%%
M9."Z<0,8SNHT:M'JYO/<B\9&:K?-@AD6DVR63+],6E="!AD`$-XO,LULA^0P
MAL+NT^`U_@G/C')SPG=*F9%1Y`2*3HB+75)+<5@"*5J;&]2NJ58TR>95*UW%
M(&0UTOM,2)!/7A;&A'8/UK%94VB[ITQXCGM*RO.%KU48TTYJB+P1F.X_(I]9
MH&C@`'7USQ"<>/W,T4:&0XD$@]=P_AE)M73;JU_$:5(/*6>UL,!(9TK$@DUQ
M^0V5(.V.S>A/65&Y=A-J*WRIL5VM[,LQ6;%L&4*L+;.KUEF+&K.C.U2N<HF-
M'*U3P3^#Y-O&?3_NRLU[<'U*&MQ7&(3_`+J(KN_8=.2KX(GBBI\EA/V;0Y-3
MT]R)43R;A1_13HFB:;^M4J]R>/GU]OTMW'555(66RAL31J(B%K:V1R5.;O,5
M?'C.8?LC9S=%1$7RIZGT;1=&?<5SI>J_I+S]OR.:NNCFN:NUSF.T<FB[7L5K
MV.T7DJ*BI[.+"2_U"QD6=8M+)/;VMC:E]'59"NK0NFR"]",]THBNVZ.>KN:K
MP:GDC<L"0!D4@A&+'=T1J-6-&<+QG"K.DFCFN1R:>/$8[,C!Z789;!N)MY-G
M6%O*L"XFBQ#C;->=YV"K@,9'(5R]`,?5'\EXVRIT4A,=BR['X1R#%&B2H3HT
MDK2"T#(:V([16M5RCU3DBZ<5.D/KQ(-),IX(I#C$"^GN`#9+CR`'_7MD@:B?
M$373AM3$FVG8DET_=1[2VMKD25%1+[\59`%/G%'#_:Q"5":.<C6;>:::*Y?%
M55?W_ECTHU^)DM_0T*)KSZ4FP'+EJGMT;$@OU7V)PB)R1.2)]2)\[):\/Z\M
M3*)&^M),5O=1U;XZ/0P4T^WBLMF*BMLZZ%8<N7FEQAG(W3V*PCU14]BI\LFQ
MES+84QT6#&@$B64N,&L6#(66A@PPE9"F$-*1CW=R,S=PVZ(G`A+*EZ#A64'5
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MMK=Q][I"D:ZHJ0Y`J6H_@,W.?+QX@RBY]+<U=5W-XV.AV_=;&&[#L=9;8A()
MK$4MS$+TVA)%C$5$5W4WC4>WJ>7@DFG+!NY_6B`#7!L`C>\LH;I2,.Y.HZ*[
MT\1#(CVZJT:\N(XXP;&<V6&O-&-$B;PE2VB2)U:U'O*/S2HT5ZZ^X/EO5NJ:
MB='9+5DD$0D:26.H8BFL:I;>NC$>]R%::3%3PV^5VC7:*YNH"!@=5!Q)4VR(
MP!#CCLBX[3W3Q?SF.]B:W+54C4-M&W38YR\I]:R2X\V`I6+&C](YSG#80JI\
M4(!F4[#^I6`@M0K1(1SM6*YK7.3H28;88G_BG8CUT-'_``Q>1:HB2OB/%K('
M/8[R^5JL=S5%3BFGN8K29$:URI=R*CE#DMM-N8.J+X(.MF!8G\%J:\_DQ?,8
MXM7T5E(J)[VIYNQN1L+&*5?]E'FP=B?4Z1]O+Z3.*_5-16]=,V]3S?M$-P->
ME[$7M?>]O^KC\R@<]77E%-8B^T4C$J8:NU1--.O'>FGCR^9.JZV8"`><T<<D
MB0$IQ]DXK>^C[0F`1.]BHX*N1=6L>NG/14F8KZ`LAE]D&31YY*`M*Q]7BMB5
M^]8P;N_AA+)MHQ5"'XBNCM57/3>B<;\:I94`,2/5RRPS383R3ICID/N(D2-(
MFFI$+%B"4YW%50R936)X#3=6K>(B7"QF^HHWHZ=QN=_PSG1]VS3=TUV;O#E\
MW':U-KX^+U-ADLY/T9UG_5%0-_LW,"TY6_NZ_/5%1%14T5%YHJ+XHJ>U%XO<
M5(J[\6O9D:,BLV:TML]]Q3$1/T.G)*)/^Y^01:]LK<^TJXTPT*O+:S(57)E-
M'8SXM>$4@DD\..JN1$$;^([PXE%O.K$A1(L7M8Y*GLWV3Y$FX9W97F\X3#B1
M8[B`:B;7DY[=VSC/BX[&GG*:+$/3NL$R2&(<ULB6R0V/&RF%/25-=OUUCZ1%
M&U$T;\/C%)<5+",^/87CYGH=;.R1H]V.6HX("-#7/?VLJ:HQ]8D=$:KONKYN
M/2+F*"(L"HKKNTZ(TZ+'7<"(R'3H57O7JQ+(,YSG>*C"Q%\55;M`):L5<>R9
M-MA'NR3"G7/\@=!;5*PHE;8+3*)0\G+VRLVILTXS8EO^)0Y`S\2/6<H\B;2"
MKQD(2F?6249^&MHX'2Z:#U*V3N73?SX:IFHPRM:IF)X-*K4ZC4YKR:_7Y9%3
M/WM8786/)`[IRH$V.]#0["&7Q%+AR&->QWUIPE'DE='_`!5B?JKMZ..,-G7Y
M.Z:V7?01*=4-7WBR"]8+M[(LI%8B)M"O"***5ST8H^M)L+&9(4?9N@()TF9+
M.=PF17N:UJNVLW*J:.55XK`38D4[("+'K(\M>L-JI$<#08#N<PYVPV.1'*CG
MHW=S\>.G7B"KJ\P/ABFG,L0L<<MD83V=R_I($4TB-&OE1JZ::-;HIU)O&PD&
M#!B.L9B18;H=4VGCQNW[Y029J17>5Y&J=-WCKHO$D*0VO$<,F%):V7+744BM
M@4\D*JDC<QSJZM`/EHY-FOO*JK,&\,GI3BOD'`RSLQQVR22A3G2XL<<QH8$O
MOA(9"@09$+JY%W.<JMA4SS1YU^I\2JV*61*(*;FUM$==6Y#RC'/)-'8#NW;E
MT8V.]>>Y>(L"(-`Q848$2,)ONBCQA-"$:?8P;$3Y,EQ.1L3UFK.".1Z(K06`
M])-9*7DO*+8!&3_H\2H$T+X\R%(-$E1R)H0$F.1P3A(GL>,C%1?M^D_,&&J_
MK(-!(8W3E\(]H,B[O_%;QEXO9*Q_%;)=%^\I;:NU<W]/;!3G]6GT:N>YK&-1
M7/>Y=&L8U-SWN7V-8U-5XN\S*Q6DRZT?(@[_`'F8]6)Z=1#\$5$?'$XW_B_0
M464-3;7WS!XA?O\`*C`R"%4^-6!7.>B(UDYSXRK[$D?,A4920FR9($EF=-M(
M5<@XRE0+6Q12']Q8SBKJK`C;S1JZN1=$61K72(B)5^N5ZN-'D)8U+GO&,[>@
MYR`,]6M7IKKY2-YZZHD&X6%"1+B6"-(?66D&Q-&:R"^:T5F\#!N2UC!<YJ0_
M,5';D3V\"L`MVB.I%$WJ,>_IM>J#<5&:H$A1Z/Z:^=B.1':.U:BL*QA&+IJP
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MOZC]IB;M2-1VNO!+)S=:K`XSPA=]P^6WL/8_:O/STV-R%1WA_P"YI]7S!9G7
M@VT^:;RRMC?AQLBC-;W[5T]WU$*MD)KS>13>QOTE_!_XO%RF_6:?S.PAI^K_
M`)3^<^/W?]?#_JL<#B#35%YK57UD5>FJ<D5$M/-K]FGM^CKL.K7JRTS*2^N<
M1GOP,?`UI<BLET7<S;"7H,7P4AN(T**-!1H@`QHXF^`P@&T0F)]C6-1/H+*C
MG:]M9121GO;R(%SDU%($J*BM-'*B/8NJ:.;Q*JKE?_DF-R$J+U%Y=R4;-T*X
M'JJZQ[N'H=%U7XF]OW?E[J428UI0!BSX@"C9%M(T>0V2`,W<%\A&C(GB$@7;
M7*BKPCXUE;*]@PQH[BEAN[:M!());5A1(+6K#4CTU5^XRHQJ;^7$SOIUE:/L
M35S[(DU\)BV`*IA6PX$H4"#"CK!:X[W/8UC>JKU1ZN;Y>#Q83Y!&2)A)I'R7
MC<3J$8(2-^$(+%08@M;N5%([35[G+S^>_.:6.20SI##F-1&9O+:5D=%0-U#"
MGZR[I&*O)/-*C;A<W-#M!,B'%)BR@CD1I`7(\)P&:CQ%$].3F/8NJ?,1T4'>
MVDZ0"LI*YJZ.L;B<_HP(FOW!*1=Q7^`@->1>35X@4W6[N8WK3+:PTT=97,\K
MY=I.7[R--+*[IM7]6)&L\&I\RXQ2?M&Z8'K5DQ4U6NMXZ.?7S4T17;!E\I$3
MF\+GM]O%E17$5\.SJ9AX,V,3Q&<#U8[1?!XW::M<GE>U45.2_1QQJNG?8]<P
M_=5=><25IR]W^:^/&'$\.[Q?,X[O.NKNTE8T<:*SW51O<.T]O/Z(LB01@8\<
M1#G,1=!A`%BD,5Z^Q@QM55^SB?\`F!8@(%]T)D'&(LACF%KL4CO5\8BL?Y@R
M;TZK**FB<E8GL^BCYY01W2;&KC=GD%4!GQ<AQKJ=4PA(WF^VJ7:GB:ZZ^8?@
M_B)95\@<N#.`R3$DB75A@D3RN3ZE3P<B\VN147FGTJ-;Y,*R&:J17?R6+9%.
M*KEAO77X-'?R'_!^[&F.V>X9NSY"'.1@0A&\IC%<T8Q"&U7/(1[E1K&,:FJJ
MOAPS\Q+8!!14`6-@L"0-1O%6RDVR\H.$C4(.;?"T;&1='"@_4IWHGS7_`)BX
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MF\/C4N145O($/K$!5V\">88MR-ZKQ1)!7M'N7354TUXF9%`CE-A%E)65D5=%
M&0Q,7GG=K(R2`!F]SJB4]=T\#$^$OQVI[Z*&3&,*1&D"8>/(`]I0G"5J/&41
M&*K2#(U=45/'Z295V4<<N!/CEBRXQ4U88!FJQ[%]O-%\?%.'8;>')(.,)9.-
M6Y_>R"D`K6N&9_@2\I4(UDI/$HU8?[Q-JN<J-:U%<YSET1J)S555>2(B<`LI
MPW#_`"]AG0T<1$<UV<R0+\-ZLY?_`!&.9-R:_P#N+VI_NR?'^?,_,/"(+G4$
MEY).1T\4::41WKN?8P@C:FE0=RZD:B?LSN?ZI?A_0X#)54;_`/(X(-7-<Y/V
MMRQ--&\]5Z_^KC`9?_"YY`W:+HY62J/((.UOL7XDEJKK[$^A#AV+;7Y//C)*
ME37,ZD/%*9[^FZZL53R]X716P8_O&+YE^&U5XC4U6-S8\?>\ABN4DJ;+.Y2R
MY\TR^8\R8=RO(]?%5^KA:W)Z.LO(:H[:*PBC.X*N31213*G7B&T^^)S'I]?%
M9E'Y?V(XKZZQ!-)BV5A]9H)H&E;UX393A&F`$Z/N1.N.9J[VIPF[!L/1VB:H
MF-TSD1?:B+V*:Z<?W'Q#_+5-_0N),L'Y;XY:F`/<.NK\;QILR6[5$00%GM@P
MT=S_`)0K$T]O%HPGY258,@J+JJH9&,EQ[#^]+/O&H2J6-."0U22-,$NY'J=N
MW:N[3B-ZK^3]7'GOAS;6=6"HL)EGJZ:`8("V<@PI':&8\AVHP87D*OM1.+!L
M+!,4?&@&#'6=^&:-(\F0\#9!1QOV3J.[9A6;U5$35W+7GQ_<?$/\M4W]"X_N
M/B'^6J;^A</DTN.T51(*/HD/5U$"`8@MR.Z3RQ(XGN'N3715TUX5KD145-%1
M>:*B^**GM1>"V>(PBVV+%(21:8;&V=[4O*[>>QP]JHQKQ*[5YJUSD:]=7`5K
M]6/98U$P4V(]SQ]0>J."<2[319(7HTT29'?Y2"(UI&.Y*B?2'/;V0J-U61EC
M5WSE:A:BV"CFPY,='?SAY'$Z3@)KW(R.%HN_3B%9?F!7I18\@A/_``H-\ADK
M)9"-\TJ\ZB!E5U`Y_F%7.^.9%TE:-11/8,;&C&-K6#&QJ-8QC4VM8QK=$:UJ
M)R3Z!XR,:09&N80;VHYCV.3:YCVNU1S7(O-.)F9_EG!>:M7=(M\2BM>617KS
M<6;2#U<21!7Q?&3SA\1ZC\HU14T5.2HO)45/8OT&&RN?[/E6/F7:NU=H[:(Y
MR:^S5J<0I?\`P>58?(\-4T-D5="\VG-$1)GCP[]U?_K\\N*88P,O)$1GJ5F<
M?7I</`5-4F7&A!]W8N9SCP&+U"KS)L'S5\:,0\Z=,,LVZNIRM)9W=F1$0T^<
M5$1-RZ:#&W081HC&(C4^:M>>790XY"C=(6JG&K94@3%U=%6=%V38P3?><`@B
M_4].+:TQZ5DF96K*WLJ''[^^A]C&^,IFC]0DABRY"=5VKSS9$N3TV[&O1.7%
MF'*ORT)E=K;6P;3((UY(PR4.YGO8G[7`B&M9]7%A5&U!1PD*-S&)JFKE=PL*
MTKF2+CU"T)10&W<Y8V,U%M)8X-%(L1'A.MZFK$W>Z.]A@*]$:T;FM1>`G&'9
M6P[&TE>MI.&BV%#-JF`@XZ2$Q_75\*Y4LIS'"9%8I-PEW>5/FFR#&Y[\6RDK
M6]Q/C`235W73;M$+):57A!:,:G)IF.#,&G)AD3EPV'GU6N-O5Z"%D('DFX7/
M<Y4:QS+OIL=3$*O\C8LCJB\F/+[RM(-S7C>U'L>Q4<Q[')JUS')JCFN3P7Z!
M7.5&M:BJYRKHB(GBJJO)$3AT+!*QV5R4>H2VS#=IB%:]%VN6=D2L*&6\+O?C
MP&S)+5]YC/'@&09;/3*<D`[JPG/!VU#C[U3FF.TSB'9'.FNG>'<:8Y/Y1K5V
M?22L@Q9T;&LO)N,;X:MI;LW-56P"%JNAS"N\9(FN5R\WL>J[D?39732ZF8FY
M0J9FL6:)KMO<5\QFZ--CZ_>&Y=%Y+HO+Y\.5R_9I4>1YD56_!*PGF1NCE3R^
MSBQ.G\A'H[1--4T6NM*RR:YGUN:L;5$7DJ\EY<,?^FQC_P#KM1W_`#_-//L9
M<:!!BC4LF9,..-%CC3Q>8YG,&-O[J\(R@[W%L1?KU\JE1ECW]V']#%*Z4U"5
ML4J?_P!C*'N5.8!+R+P*II(;(4(2O?M17D-(.5=QY<R25SY$R;)?YB&*YQ'N
MYJO^@O$5C"B(U6$&1J/&]CDT<Q['(K7-<GL7A\K$;"SPB2][BOCT;PEQXY'+
MN<I\7L12J474=[[XHXIW:_K.%ZU1C^91FHFDBAGOQNW?]?\`4E\255*JI[?5
MF<_NI[-+S'\RQ]R(JO6?BUK-B#TUUZMOCP;NC9II_P`3HOLX07XRQD1UU7MI
M5S`A2]$UU7M)9P241-%U\OLX4_XKQKHH[8IO7:OI([]%2=UM1W/CINS3%W&5
M-S8X;VMD2G-Y^9D6/()(>GE7P;[.-E-2Y??$]GIN)W@HKO'DEM;1*RDU54]L
ME.-(=#28C'=_OF367K=F+7_\!C9%KB*B?_EV_P"OAILTM[+-RHJ.["RZ4#%V
M.31=$QBN0,":/5.7?K.>GZ7`H\<0HX`L:((`C:((AL3:P8AL1&#8QJ:(B<D^
MF+3Y-3P;JN-KK'FA0FQRIIU8Y4VGB2&IX$$YA&^Q>#6/Y9W+4:NY_P"',@*O
ME\5Z=?<C8NJ>QC)#/XQEX[7+,<M*5^[8,TJ.JPI#N?\`-+$*E@2_=7]61WSK
M&1H]Y)?Y<2I+4<W>1QOP\\S/*WWGJ1J>'MXKC,5'-+`AD1S5U14=&&O)?;\I
M9]K.AUL$',TR?)##BB^KJ2)#QB9KI[5XZ>"8](M1/:BMR6^2308FQ%73?',>
M.MS>\N;>SBNCD_XAOCQ&N,SL7YA<QB-D1!2`)$QFFD-]TM)CB$.`<AGLDRGR
MI?+D1OA\]5541$3557DB(GBJK[$3AK7VE<QSXQ9C&NFQFN=#!S/+:BDU6,%/
M>?[K?;Q&8/)*(KYM<>WA##;0#%FU47=W-E#$,[B2H`-B[RL1S&Z>/$+M;,<M
M+*KD7,!T,,J6.76Q=>O)`2.`C";=.3$7>[V(O$-T8-X9MA7'M(KVXQDC1+&C
M[MXY$@M4.-!GOV?#BR'BDD^ZQ=4X@]&CR56SZV39#<:G-!Z';ZZ0)S+!T4L&
MRDJGPQ%:W7VJG$)S<2R$+9E?(FO=*+C@$KI`M_2JK`?X@?*2=*5OD4`SQTW)
MO*WGQ$7\*/B]Q6R))FS;NN:^!8CW=O5RNQ]08]).B?'`XS&:\TX`KZ.ABH2L
M,61U,DFG-%N4W=O!8`.-(&57/Y;Y/7&1NO(#N(_43&XVZK-W2,=9SNC=>;H=
MNYS*_N:M.6_<@BK[-.(_7N,?&GIAA2V1\>L'$=<.W="=$DFR78*N%RW1G@(1
M^GZ]OLC]QDS?+6&BRTATD2.T]B3=TK6.DD\]T7H:IH!RE8[3GQ'4^77INE6F
M@R!LBXU'#,DEW[;@G3H%E@L(^[R-"8<;R^83N?$?KY!DLGHUAZPBNLVQEF=?
M?K/D>G1H2-LQ(_R%%TMFB:)PWJRL@DJE2^F=W&4Y(X9H9-^XIHS;1D,EGY_Y
MYT^[1--"<DX;O@=QMJ742]Y+G3>K5$W;XLCNY)NYW[UU>3<1?KX`]V+X^0L:
MM]'`8U1`/(%4ZN5:QD@P'F2`JO7X6NSGX<!4%!2`6.+H`4-5!&H`^;X0=@$Z
M8O.OE3ESXV1P!`Q5W*T(V":KOKVL1$U_T23ZUV'I?37O/5.W[#H^WN>Z_9^G
M_&Y<$(N38#CTM^[63C&=X_4[=?T:_OI%.U47_P`MP0F,_P#^A\":WGTH=[=8
MX]?LZEE7W@T7_5%X=V?YJ?DI;LY[.T_,BHCD5/-IN98I#8QZZ>"/<G/QX1&7
M7Y<R45-=X/S6_+5K6KJJ;5[G*H[M?W$TX:UUM^7@6KXE)^:_Y8JQO+[R!RXI
M/WFKQ15MB6!N'^7X(<P\6PBR:W3T3I%**SBG-#+$V\^LPCF;>:+IQC\7T#.Y
MT\=+#0[08+DT<'5#':CVLL9]9`IR[MOD<,ZL?]U5XBCI/ROR%&S`RRBEY595
M..Q&=JCO+)9"+D5G#)(<W03#1AN?K[$Y\05M2DQ>+.C2Y!PXW"Q@LVL<#J(*
M!-NLDR.QWRY^U.DL>F<QB.U>0:\DH?6*FNDY581Y!A2/S`SVJN<CA31;^RCU
ML27+LA"),T;SK!C$)%\%TT6`IJ.AB-+&EOLM<DG230I;=_8QX@F8T(,\!_*I
M2N*!1<T:PGCQ`62W&XVL>7ZHP#[2;TY?G[%(!2#K^K'3R]52,8Y>>U/;Q`67
M<X^W9'EMM!P\=L-TB6_?V)8$B1DA&PH\;5.H,@9#C*G)X^(2RLH81109D><D
M2BB11S)AM_:SPI(D3WPW0D5-![BL(J>;B%W.77LET:OD0Y2)%QJ,&RD'WHRT
MDH&A[@$Z+O\`AMCE#'\J;Q/Y\0%-D.23'0JZ37$<>P"'U#NM=9T]E?$A"=8@
M1?AE$T6SV)Q"4DW(#^G5\FO:29E.1%8:-)1_6+9!6T2)8S&M>NR3(80XON/;
MHG%6WJQ'%A4UA&KN^O)4T[Z4J*MDY[Y]@<MA'1NO4*52*Q/O)Q0C@+@RG;2V
M"8RHBT9I7X>^)ZKZ*7>^0^GTW]QT54/COXI_1?PMT>PD^@>E^D]+TO<O>>C]
MIY>PW?K.C\/7QX'V70[;3X7;=/H;?^SZ7P]/W/\`3/_:``@!`0,!/R'SD;I!
MI@`A58@8=F`JWN[=+F!B9^^Y.0Q&T],1@`80@`6$XQ,KO^6*B(Q%MDES;1!Q
M^B9JL@B5XLGE!0DT!>&;:94P&Y#3R<+Z=??"O]?G5#"I3#JL"*@>]!S9\&:.
MIJ)G$:PH.7F>.C5N%"`$.+3LUV42B8L^6"'/MI*ZL6;>50T7Q:ZR#-G7+9EB
M6K%<HC0BC\L.@*B)R2CF=*D;E=>&"L+BO]>&"@";QM5,+EA06X`<'!]N#XB^
M(H"N-<&FI;^D!?BX5W2-U[,,$Z[@!<GE5T,:GR"691S3JX\)')HS.E#YLUC(
M*I''BG]%Q0,<O/!8#+<"Z0&9X>:4W_7&YR2P-^FN7+#CW"!I3M=9P*ZW=H@=
MMBYBK*;(#P0:>&[<`'9<$"!`V`'H6:8WOMTB/]1)1M"W3/2Z`>5UN$6IT%OZ
M=I%HDV"KYUTM_,?3'\9#_JQMU5P8.>ZKXRN6Z1`P!12'/AW`0D#SG.S=K8-,
MK+LB@FHL/OYS#)8PAUVS:Z&=MQB_K!#%?]'T%,@57#PDU8)N)VJ@@78`[H=9
M0S02$,,#S45NU6+@,;G\?X-^2DO"&LJS`/Y;.V#ND!)X"1*N=PAC`;\U9^NQ
MH>5Y"VVIM'OI1E(<(Q`2R@Q/B@V6]WLU>M]A?K0&9ZC>,7QX3&#G]D(F6E9"
MJFW^HXVZ#ERSX9J&UE40%HA7-\+P9(Y)X%+?9A549-XBAIJ@IJF\#>8B!;%%
M-?R_M0\Q!K0EU@KZ'7O$]UK)0W:247[9M0?8J;I)RA\@J!Q#15$:<X=3E2U7
M>7@I7W_[Q)*T.'L]6"D@!X.]^DT%[$1/-B;23%G.`)P!VW_SD7-&DG5Q_P#P
ME$!HFX]_N4V<S7]8<#PAA<!2"LAGQ6V;YPBY<<A"R%/=`XM`H"0#"5P<GVS(
M@UU4ISXJA_EJ4(4CZ*+HRLNS*DL8>-@X;,_I'/)D-0-8PUW>WV+D"M&N1Z$8
M;<-69<;Q,YLH<1VRFRBHK.4SKJ]4[9-K/[N55FJO,,P=+O6@S$_F(O:(N(5<
MY!R7&`39)BB7;_V[(,>+9J-S"';?%8]N^K+H_P"6!*R$LXQD.^-[F-Z/'*UA
M0+*X8:/DM@`0/"O8*Q!L*3"K1I<FE/F+(6Q@EPV93'4HIZKBYDZ%H+R!8X*.
MLB=0%)"XX`2N9^W,$[T\=GZ9)`PGLK$U2;'G^G<`%GNS0+<2.<]V0/#\$IH-
M@M?C;CJ.".3MP@GC)[I;96D383W!8M:[7;T)&W4-)Z9^Z[P:EA*]_8E]S_,-
M\KV<)`)0I]..DFF']CP8(CEFK`$23[%-73M>;.S798@3L`93)TP_&;4L<4YT
MP96_*(1J]HJ2)8$P-[1"$H=5P:%S$++EFR9+LO+"^-[4H#2X'*;Y0:,.T$[/
M7(-HO2FST%'J+R%"J^TD^[*HY!@!M*:'T&R[>?)85V`5F08-0C`%[L6M#]0Q
MP@P!XWL@>7;,4,`PG#+W(1+JST+7$>B@%`NT3A"\O8#I2R47X0SAP`>I\;+V
ME(*-GG))2S2M5*8HJ`5#)L@"[^&.ZNCW=-:'-BD!_2!R/`S=Y"<%I=GWSWDZ
M?I.&]T(TR8'"X`^:6K,%$:\/T(C64ZL"Q"8F::?C$%&X(Y`\KTPK-=H-$54L
M'+;H0EN`;(C#`8HDQ("T*`>CMBK%Z5[4BNPB,CJ"*PHEKU:(@'RE$5D^@QS5
MSRJ>W&L`Y%8YW;GQL]%]!W0J^BU>#;(1GC-_82]WBN;#U?L_V9,,?A3B2LM'
M(H$N7RR@I:[30&+K=]90(U*FOWQTHA]=Z!Q7`CF&FVB6IC#U@`H"52VU"V>-
M*`]`IIV']'C)&NN9'L#1.F5^:LRNVWX+7,"D$U`77)N&6'Y"B[]U>518OE<C
MP@1\P>6AX2)G][`\3)!YXH.AN'5(R0;5A+O>R'M[T0B@0TB;$?L<4GQT'@;#
M5`5XD5D*7"=P`M2C#G\6-9;*5TEU/A9N<.4U]LS>6`+P9QJ.ZH/Y;L-((118
ME.OO\8E!`Q$AZ]D;(5@$Z51G[L\]$M]O"3'K(,17?@'V<=J"2:OFM'_#`?2/
MHS:!<'VM5?->H>FXN-HL)IQ:D<Z4^E?3B^B\*6]1[:[H%TY7&;X`#^VG^C;>
M`-%HFZ1)RKP9H<CH%.NL+$!/',W2@_EL-36#4X8$';1&[.8K^G$2H2DY[`/=
M5<U7YVY1Q(QE`%SDE#-&?=*#M6`<$HD+7L4H_$6Q.C+,$H&@@GLC\HK2PM2-
MDVTKJ@:2T//4$9;7C]GE4S.2*)T>3S9E5]IM20HP[[4,?D=,?K@$=L?"@)$$
M/2-'_9S70I]QO1+PT#/H[W[<D/JKE.X.,^C(,"B8B^CQ,S2/,13[!X_WRV>.
M:?"4D/5:;)51TNQ8[NHM))S]QC*R`"$/%'T,8&E7'<8:%=88X:,0'&J8QM,@
M)2F6&FL45PJ^B"(['2/LRI[@UL9XDT"+)O3>+^VZ>VE6#OZGFGRW.*D\LQE\
MX?;["A$SVKT_/C,1A<#;4OTD6.?!=>M];VJ)",==^5G1=$JMAB#6C".;E#_&
M]R;43%4P&_#)B^V\6`<C0"++_"3P!06=EI4WMX6!=T):J]6.<J)$+#49-/)V
MS;ZH.*I!X*3BGFD+&?06%20,CX]$Q-DE47%9/%Z!5#;76@G;3ZLOHOM'#VN-
M7+L7G5FL%?39[+LPIP5C?X)XR"%0`V5^@,?_`)SOWR?<%M!1Z>?:$_7-F?NV
M)3D8MOE,PFUMB4JX"2/]L?3-YJ5+5WL]!6$2=A"1T4C>!,UFC3Z&O`<KU@]P
M!G*I_(PT#&I$9?0F:%Q1US#F4$;WB.G/:RK:0S58#\[&&(ZX71'Q*D/2_$'(
M>(Y\473`1)MUC=5B]BDEJ82YN"K-!+E#BCQ+VB393JWL//2>EF4`/6*VA=01
M$2OK6))H81/,Y`@?8&.V]"=4'$Y`TG[O(G!]#-@A-?SB&5`W0%SQ>2V,E&:_
MB^J1R1!85]1ZN)Y]R9HN(BB(C$=(G(GWV>CZ+++E`@*A3>)[N&J4%07<J_;W
M!Q"N5^4#A/8F-KH2RLUS1@-!V.+C,T\LD:,A6"V'0`ENH@68'C%EB"SX#)5#
M9F.4M9:T)HYX3.![J8HUQ:$V4A]Z^^,"0OM7_3$?<X=7G%=JE8!("O3^OZQS
MJ?P`PY]`X@,*9L?S@T/T`98012H`GB9-QG8]S07.I!:.E3`8Z/R<B';?E6D@
MW+]!)RV!^X3EFR+7WR>P$S'K?;O;+2S-"<(>.="YTE>$+L?HOADCMX#GTO)4
M'D:N7-.'L^VO6KQ<5P5G'1%#7-ISO!Y.JF-M6W-`K0V)"40[&)+[Q\6-N$0:
M838#285?D`^AVGD)%1?O:(XSN@W<I"6('T'<Y5YE#X&J)'$+.>T\M,U7Y))>
M<F7$<7QGKC))&*<0DS@F_IC3#HF4HT1,#U2IV.[U2]2"8_T[@""J'?0O:XX:
M#MD[]-$I%QZAAH]N'X';BGV3PHUFS<6"JA3_`,.!4:F5"Q?[M"@,%"DN13,/
M5/1AN)1%OT/QL?8>KOP(0]Z`;[3?0YW/<W9'8<!:\>^QRK6^X)22`\@N<@^=
M8"5`V;!AF#Y;,%%9+'TNRAC.3>+](3'=D#97@&@00>P#DAO?@90VW"Z7+V;(
MH0;LAT96_L9-$F<K3H#O+K[&=0X2`6SUJ3^E7[,WF,IQ#`W<&(0QW[D%/3:#
MEH/!Y']Q?@,,'+R$W&M;,.$LJ?0:P:Q30G8%=C,V/$*-<6!;/6!:B$.N>Y%1
MUHHDX70UP>X=3C7&B!]F5B"86A2%0MU_EAZK`J(DXTZ*K1V:#P4@S_4O$V$*
MC0R,=X-V+5RV(%/HZ,H4(3F_:96D$YX&9P'E/EI@5;$#`1L@B]-0%R0*-,5\
M-B=H'1,*(ATU]T':D6M#%XJ=$ON_5=%##0&\8Z!%1`)Q(BRI.F%V+?6%T("&
MG($IP;X>UW8@31T-)M$,-B;#B\YL+:8;!JO`G',7V=$4,"+8>"M`FM)VZS$8
M8H5Y"Z&#C9(6Z'1-FHJ1>BO*:\&W(S2#YB^C96#B'T5>Q%&177W@=)[AQ%]"
M]]2+4J.>FW1*_P!``>7.-+6,S:,@:=8EB^JC,CBZP`TKFYM+-LWWW=/G-..0
M?K$TZ.\2D(U;**`F_B"O_.=U\\5HGP?V7LOYO^G4&K.<T?D:.$CS%0$T:#5G
M@[J+=HP6T0#TT>+L5?EW^4G_`%T@W#K"><C"HN,=&UL5JMO(P5*4?.K]VW(M
M$X@9@:0`^$YQYCD&6,PI:L4(Z82$X6F6[J@![&/)13O/OR4+(4IU70W7&U'1
MK!M!61$$1$$1$1V(FD3!%LI.VF>D)!MC2DI4!D[X)@B-2(^G(P*GAU#%ERDE
MS@$XQFT,19!X!`EE4EOH[6!ZNTIA(.4!><NV@'#&)$!GU08MIC<:*JW;*E84
MW;_@#R&(@&%E"H;]X`U!:*T?*ZL&,<FO++N+.)G,-J7VK<P^U>E!.YCFL.VQ
MGM"#@V4C03?V=ULQ!]K@KB<W*U`=XA2^%/;+H/=SC^<GM-T/LI1%.Q-0!ED?
M52O5P\`@@(H6G-#Q.7Y8G^57_EZD0)N#_+16Y-X"8``0!`#T!W!86)#;>38?
MZC*?5``20A[A@.H]?1Z(=)RN5+P<^GP$E_=,N3$Y0N-(86X2"*P_/E16#^MZ
M6Z[C@>Y@-SGTF20XXU;,<>;15ST"P$?\@70$B9]N*O$2\>91P#D/2-]2&%HO
ME,4MI%);(W"$C#,9S["93O&<P`[JX8GI]"B.^/5)F>=HT3'09G]OJM^H<66,
M*/=+;>9%\U8$6O(P.3EV_P"[?L@F117U4M^>4I<FHTJ$!%1]OT7;RA^QT@#'
MR=![!,!"QH[$4FN5KSTB];13&#;XT`CQ%G:=L<P/4O.D>W(B75#VVY1A$T6A
M;]W?G&SU=OO[!%7RD%"#-G!WN&<>!(A0#LR7!DF0]R5?\?73F",==\\3@N:7
M9Z4Y*LBXB2">?KO.<<!6T)2]6U[_`(X+&7P,JG=;,-WZ8P!KHTT`=F9OC#.D
M1CUQO/W!A6`D!B#P<$:#;HY>H*-31R\19N-XE,/6TLJ#$],8K5C/*.I`;F(>
MDY7)2O`/8/P*W::&G=!&?0<0,JZ,-?BDR(,)##9V`B"'HBM%3/;F'@94O47C
M<`+^Y+\25L_!0PQ%G0!$T%'X=)A$FC8NTZ;FB.\Y2&ZLP99>AY#:;&O)**,@
M.L@,A#QHMH8HTD<GC0!?\_)X.$=`9H)2)>^A:&A:GM[U%^')3N4'@L2:=)I'
MUU68X`46.8'B(+0F)$,KBCA%XKUQ38%FJ-70%@^'PIWZ#(D8YU6K)&B1!0I]
M/:-%"Y#=Q0SV0V3NWNOH/1-Q-<Z-TLT`(V@8.-DQB?JJ`M&;B_B3HO3$SK7*
M3*N$W$=]L8+]!^RE@^AICS9_3V,K&XXS&0L[T0\@EICYI4'CL?=@EG%$FQ"`
M":HZN7BW6S6@!86H0SDS0`VC\\-S^/`9-V+!%F?$`W(<1L4*$DPL!7KZR[:Y
ML&]4'*:.2KRQZMYHFM'8*:7$HA4SX`0]T5"""<@">\,KBLY#*E,E2E3-[3AT
M*D=0Y'L=7I<-H-Z%W:G9SQTY_>AL\(KL&S,DJ,($Z<%3?!S<)Q(]W[U)H/C$
MAC1IIB\MJM:GO(7*""DKMYJPKUXN>RGR/:E7TQ)`%2O_`&&R->)M#V`&*;M.
MSF[.9L%/8<,HA"'DYT@CI'8CR)[')<^W`J&RU3U0/6]_P)!F5(`"N*]/99+`
M(W9SN>B)X5QD]W]5YO'*\"B0YAJ;OF/88'V2*.A9L/8'M/$`!`7H@60;`D)A
M9&#5@',9Z:C.';2_GR07$*I@R00`,`=3LE9X%RY<N7+EWI,,9THZB4EQB7O1
M$>8`]N+!P5"4/-:R!\D>*`L2Z'"")L1QP;GEK.PC(,&C(#_@&]/`*KQB00Z#
M5_4Q"ZPV8XT:#@[X2$ORK8HC+CA\4"&-P(OV[`\)KH<),IM16`]X2"Z;`?`A
M:Z!"]X%+-(>^TQ#:47QG2@``V1#G)_3>H!@VJT4<*<!*%#8MUS.3#@6O<+]=
M%VZ'S$>.>RCAY:1RJ8'50VTX`PO.#$00NR'EC+B!E("4N$B^8XCHN7>DPQG2
MCJI"S'H./!T0H!V8>J]-T6"F04K$LSZO%'=DZJWDVZ4=3G22T8@DT@4+2B"\
MRV$3K52_B0^```\#UJI?Q)?""(Y?&Q,-G(Z-6AAHF>@*"(.Q'P;3)OJ@?4J&
M];WA2;"[O%:;2CAEU<T#Z_\`F=Y+O@"X:A>.EC<G>F%$A\`(.73ML[IHGXUL
ME9-VL2XWG)0\;DG\:LB8G0:UW$T$EU`Y>Z4Y)B2N'4[M%7.D&7"E@(V!,,YC
M(V\)$"0)VZX@W@`E5J)K5:"B>`_8$CUC`#:X:))O`OTH,(1F_P`$]?`6+=/!
M&^.HSZ)8G\%LAC0[H=R9;!ZR>`$=S![G;L;5[$(4XSV\N6HL%(!2`V'.??<0
M?8!J]KAGZ*S03[#>LMDP8QJW'4J8&@]F;6EK<JFJW^A<./?0PC(@B9R.=&CQ
MD&E2W$0`&Q#TG<P9'B#CBD`?Z,2UM^\<,)8)ZIMX,=5#L<'`QA(N3<2-6[PG
MSIF5B;$5@%]95-"V$("LP2+W#>(23PQ5)NF-(=0;-OK5P2^UA8,XX6,]4\#2
M`@"'F%?6W6[\!^:'$<H#5?K'2Z2X*@K6#'`C-A]/UW&LVMG*N_KCTWF]CVAK
M]#?4<O`^V^T(D;AG"T:B2@%"Q-IC<'M?W!\DF:,SW.&<^!*A`!MPXQ,Q4#B*
M>KD8:+FH3$Z[62B9]^\:#CN10].PO&4?G53!`SGEI]01C(Z-PB#>!:B<7`#Z
M56<%QK/U,"6V@#829HDM!Q@%WM=H;='.CXCW3?)QP.4D>/0+-==:I7%2EE!5
M@6T';49@-5.3XE!G<(]I(HE<DARX'55"X$V\=P3*%@XP'1R^EB^Q[R2DCO)4
MB'\5(Z;OKNS@AP",@&61P.S6W'*DIR`+7,#?/])_V8I'\]ERCT]>+7>VZ?['
M6L?Q,*YZ?H"/_61[BT-^&$B@$;E2B_+1@-&2[(>;0?NJ0[34,4GL/UFAKH#(
MV504[7;+]F=)TZBP.FU@$T*?S_C54,?,F\G^6(&#JK<4K"FG99^E@C`P0;R,
M](\&)[*E76-\,IF`4`H&("*'PJT65@&E0H';UJ;3HIDMT3C%J"-PHC;T9=A)
M%=&H1IO)55;&I%8"@X`_6IN@@M."1#$U2@<[SEHB?MG^D<0'OYG_`.[?3_O/
M\/ZS_]H`"`$"`P$_(?\`V=?_V@`(`0,#`3\A_P`I4R?+GS)\R?,GS)\R?,GB
M?CSYD^9/_!'_`!C?\Y?_V@`,`P$``A$#$0``$``````````(``!(`)!)````
M`````````````(((((`!`)``!!!```````````!(()(`````````````````
M``````````!``````````````````````!`````!)!))!(``!```````````
M`!(`````)(````````(```<:````````````(``(```````!(`$DF0``````
M`````(`````````!(``DDEP``````````!`````````(```$DDEB````````
M`)```!`````!````EO\`I(`"0``````2````````"````!+;K)<`0``````0
M````"````0````)?OK+$```````"0````````"````!);/))@0``"``"0```
M``"``"0````))9)+,``"""0`0020``"`````"2`!));M=4``""````"22```
M`````"``++O]Y(@`"`00```""2``0``0`220`99;?+$0``20`"`0222`2```
M`"`"0"[IMOZB``````0`00"0"0````2""`1?]+Y@```````0`2```0`````"
M"2`1K;9>``````````````````0``"0`1?MI`````````````"````0`"0``
M`7)+0```````0````````````````";+4``0````"`````0"22220``````-
M&`````````0````""0`200`````"4````"```""```"``200```0```2````
M``2```20``0````````2`2"0```````2```0`20```00"```22``````````
M"2"2`"202"0``````````````?_:``@!`0,!/Q#SF5&\`$:H;2"I6G]!$[P[
MT,'H:T2Z/WVE9T/7M\=.=I?-:J\Q#Z8G4UAPM+I,%M48\0F(FM!$VW7^21P7
MU1UN^+<&XR6T3@6<#$K0U4'/;%.=U#TPQ%4^?7E<7UU^1J:A=>08-'4LD)<(
MR1UHETFC`*92$S"_@#8[PZ^P$)P[,1&"].K!V\%6M8=#C.=M68O`9@%R:("*
M(N+945%+IWH92!X-DUL0OR.\I4_:&+-=:GS9R3^3KDQV#U67&-'&I!J^(D6-
M$]&0&^D2,X;BW%-[Q7,69@,@80>=Q'I1"A4N\/F=NS#$1A3AO'#4E`5-<OZW
M5PPJC@$WVVN3ZS'9YH6,2EPF:$4+W#1&L_%S,+@FB@F<63@RX[0AC(/$VS+I
M?^JF6#]5?3[):%LNJ$&``,6*7-F#W`E>=5_6BFI&N<\S"*P+17?<,Y?6+X-?
M@$;_`*V4;NZL6I0-(ZNR6#M_)HFX(YU@&B%EK\ZI<)[!]R:6.#>P%09():\*
ML(CH2H9HRR+\JX,#!DCT*3',Q-'H1!S%SAJ+KT2B(6/?)"Q:XSQ0YPNPJ^"4
M,1B=[A1ZO(DAZG+LI#E+P9:I9,I1!54\N6U'[#6KX7"NDMPDS3:BL7AI&-@Q
MT.30]]7#P3$#'\C>1*.2<K15_J%`H`5$``JJZ`,VO_'!DF:"@((';(7B@L&"
M`A13;D2!NAJM-4$8L)H@)PA!"J1!P3N"7(POBPB-+`AG:9-(728=;S7QJ'EM
M^@V`Y^0%\"-1(NY.--FW/8PEAHDG!(IPPTM2Q@RJ+<!`.Z<%,6PZ0-VA29*9
M7T[*8T%-*LA=+4'A,9I3CKDED43='BF$FP#SD*"\#!(AD^*$,-\.G\>?%XPK
M9#J]`W"U'X$U+;[B0]N52OB*P'+;D9B01;1E[<U:!4]A(`#1K!W&J1$X*-*6
MJQRX*CJ^`7,-]Y"0/K6GJ6SE<21<0#6T\88F:(8R;'.#_#VT/GF^%0P`N$F8
M57-^!>,1%UW#0Z'TZ&>AL?&W8^6O]A)@(%;`*([0+2DVVD;+%D4HT^TG3IGN
M`Q]MIR%`/CJF)P#3(KLY-<SKZ>H4-B`0(P6S/`B"DBTNBTO_`-L9BX;[(\8H
MAJ#)%Q2Q=RV\(UZW+'0R$9>-HU:D&&3/CB>O;-'K`?Z=O#BYHP;A^_ST2X$+
MBNN\F68P66!35CO+B,$TTERE?'E&H0@:(BA1VJM5?:N#-FDV)ZS;[S1>\"45
M:7`#Z#T=4QDKN>9Z?C\J#27B2@)O`OWH+EGLQ1"$(I$@46&Q!=;>&=$'P;%X
M2Q@<<7X75U!>!UK8J"A/%RH)B#FS%D64N#?O66XPQ:>`/OK^/$Q&--KAFQA,
M,B.]$'E$"A?B$HP>G75M_MBH*CDUXA+>K@`Z^MN=I5VB%@9+0`O)Y+!1VIJ1
MS58SUAL5S3K/)0+JGC31>UB0J`56&,6'7SHZ=N9LK3E);1QQ(-WJ+UFX:KK'
M$(OC;C?RH00W.VWYIYZ@I^N8;4D1,$'@N`O.N34K1F":(58&R4@$L(OZ_`#\
M`@'X'?E(*&]W&2._<+J(D6GUGL4[!IVY!N<#H#!9/#,6SC(I`:"#9!\ZJ=(D
M<DZ*TOR/`)NE2QR<4HYO_4"N@29!/"$1\^/K`);0`=K<Y'AX2#`#[*PXNI(K
MCA8A%'D+JKAU42J'9M%)=>5IF%JB(<5555555JKM5=JOCRC5:NQT6X:<R9*.
M-`O/`U.MS[]K<[Q=E3Z!1@L,="FN*.\DI/J\T3_D>+/O)4)0@@]C;(HQ(T#C
MWJ8I^,*1F6E@&*PBPW`IU*BGC>TU^#C&4XPHY#_&H3%1_AC?,9<MN8!MO4@,
M6([L&%OWITNFX[G]!]'R1"W_`&(6^4P42%;8'$MV<%V@.QU-`6I;N2U#\*#"
M`);O3Z$:G`FP%'[QX!'$L:F`MF%GANZ"6?&+B^J=CCY5A',2EM?B>RJ"_0O]
MC%7RX*!N'5S>X2]GH?Q;8]N8Q3&\U@)LFSYXN5@WG=W\MYB,M@A2F4Q.6<XP
M'D^+4O[)$*B=>!"$#:NDF+69SO2?_LW0(J0>4G9G--`:4Z9-6$_(0&>`A@.:
M4?`U0X-0ZTJ.'BF"'5H,$(U%%X#UX'F_YN^$X0`5R!7)%N540(V'?%ENM')1
MX/HJ=M180UVB-,)LN4HDD.*">LZP\4"5(TH3J4_2$8WM]G<6QT[<#@LE>U@A
M3G&F@9A-_2LBLF2PN?*&U">#SH'"IIZGJ"B=:D(D1`5\W2%D@-.\@0;=97*;
MKX_WBE$BEG&9,A$3&M@5\*;.9$,#]"XI8$J1V&4((*3P&Y:*-(E_H;RXY?Q\
MA%^?LA^+*A`C0#`6'3!,IXEK&+L7!74S#W2Y#%;Y-))F4IT<XXE_QS`C"YZ*
M`2Q;:H1-:K!6R)3G!3.V_LPJ<4=&*%0$`"`(A$1TB.%!Y+5Y-2#I&ZZ-$9T0
MUMG4P2$^42EZD425?CJAR-L;0?[R&T!>#Q/8-\(K8-F"(*%[['_$2#I:"CT%
M\N6'+.H$VPF8^2@N5P#)7UON!Z;F;PI(4N0QW!&ENZ6K#U0.J"#G0\*+Q)D`
M>@O%26?>U!-+8B+V"(:II0$QA.?,EI`AJ*5%74G3-(JO/<GQW[RWX!I"%'-G
M-[;MGWV%M/KZ,QO=EB^\ZTE=QGQ&G1#;SH98(\;EEM@N0`K:,@YPS9>R`?*1
M3_?NE?%B3`Q#`=(760@AH^]':!0'H`\F4%5<%Q2UNV")Q`STSZB/I`3A41\X
M@#*Z"HD,!>77M$))`J8'5Y;N-1%][4&*(2-0/?JR#H!\C=-GA-":`3H4H`0Y
M.:51IX!KLXZNUVK^#K@.(:49N5QZ-03!AAK$,>L3`RO.EL"\S'26<M3*LP"K
MKNHW_JR>Q!7)F;;U'FQ*M40Y42!'!F@V4?$>@O>7R<2BE5=`!?0&@.DGQ8;!
M`2#2XX"0".$XNVR@R05]ZC/N`*A&&O!&I9&/V.RZ.>O_`*L+-=8HBB8@"@B$
M0)L["6D+:9D8"`!07%N;"VG$D%+5V5[3%J;(C[5Y9"E$$^3^`\$@@```[%[P
MLSMWZ;*TP>@4J`UC@RSKTD!4-R0!DDSBJSP\7N!B4%TO@RWAI1G-FG&S[QT+
M&ZTU_!!(1(AP^+5EP1]T[&&(,%$PJS$8LNUP7!DP$GI7B;0%Z5E$`$^=L0T(
M^L-Y%F(T`#&T<]T9XIE)YXRB&4CLEZ)S3R!A>7B\RB>@,K3J!)K")'"939[[
M.V[GL7@6K"6@CLG66D&4X+.$0B$]57:$DN88Q#U&N8IK9%2Z$TS-`25B&ZD>
M-R1WIBH364L!?.\72E&44#(=X0J.MN$!(V>?=<Q4:-%.TG:)"2#&#IN#I&8<
M#ZXTGBKL$&@[M+$6A(`,8E:4".R:'6(\;UH0B=1)I?Y>"HRA.L*)N<K,W80V
MR5B0Y\0YTIFVAU7Q;93BL%DV&4)4P^^&V03M*(/+PUMMAK00LM4;AUB%@#J;
M#<\J7.)&W%ZDI7]6V=Y%N#Z@[0S$$F*V@!/$P4^W?N*[O=E,D1ECS%T]#J1F
MS1MWKQ`"G0[;$6\MNE(`2P.P'.5.OW<2H"Y&#Z9)343=<LZ+:VYC99_'9$R?
ML2(,'H^35J3&6Y:OY+.D!@M,B/D,XS#2;NHP;6J83;>XU`DQ*FZ]OBVAH.R5
MU*Y@U'S8]2@/#?!PI'55_<;`!EGU]#MS#V."`Z(J/>N%T_(>%4[FZL'M%Z##
M3+)M<"*0G1_9YELH#(48I"NTS7PIVNL7!$%BD7M#."BXJHAHNUT>S_:F:7_?
M*>YMFT%!5L;9JN!0##ER8PJ5T!N[2(T-7'OS7S;RBROS!N"F8N!?AB!..5#E
M`[,.CF-A@I='2'D#%1;D+I67R[>.,Y%NG!8-VTZ3P?\`"?9!'WQ`]#!V!+4Z
M0,?`P,[M):2.*K'O7:,:TC7"W'4$%E'Q00?$>G`8FM`]+#?274R?)<)]@1LQ
M'J,"?:J#.B1&<GD6(?CPD2-"GLJJ+1.@(B;-%H@8C"E:1G&=@$X64"NO+H&X
M)N$+9&NVW+PJDG$W&_7IX%]V1,JG'\3C"VW33H&A8(`=$#ZT?H*XX%Y5[/)H
M03KDR/AA<@;#Y\"<4E)YR!BJSF"RCB/A+Q-.&@98MA7L.$D>)FS_`"\$+Z-@
MS7#8'+GO::UOJ:E/(Z5I0Y(TU^XX`%06J)5H5>#CN(@?XNDI+%6TU84.VAII
M:>F]`W?5U0V,O@=*W#QRWD6S?]K/+)^&4/&W%":.)V,T1UHQW9(L?)D=N0@Z
M=,`L^B'P';^;Q'SU)>QNR044CT%$1B;$TB<(XS[<3NW)BM2%B`,YYX7E<(BB
M-,)[;_%CU+0XG`X.OTG@"_)S:@^3?0(%KETM\T,4(O+G0NN:5:U9`6-"'&,B
MN\C;\DUNZUDB7%MI:.*==_O>K4ULB)(*"-,.N(TXH+F+#IH8`$1:_P"%3$5/
MD+A3/9<'0HP-<:"*8*C7>H[71YGD:1+HD,92H-'MM;2#VA!L;UJZ/WP)9P&0
M-`@W)L!@?2>6HZTO'C\@\1L-ZSL)X4DMH-E.?,HRUB+*L<FHJS]O;J2B0PH7
M82$:G1PP)^A`=`(`.#N:I<8A7)9CI5.<MR5<$)A]`('75:L@%"YD7ZE.1?BQ
M5-R%2(&AEFIDYLUTYYV'P*=ZRWU*H[#:`SE,0UK]1O!DF&FVSDG6$O.=UAG.
MMU(*ZE9&#1:Y(D,0MMQ9*NZ'W:51P]K9.*V8CB:1=6466DF1!]?J)&5T&4[R
MTC@>69K47G;UIV2[B/F1#J:7U\1H&$<FZ$-DY4%@3U>RD#>]6O;.J&L9`3(H
MA#T!GI&^E#`HLJ]2\I>:A`Y<"8X&1&WT^HN]N9O(>PB:G_32N\OQIG'6M@[+
M\/&?GEQ"`/N(/F788'!TA@9@@>QM4#L':'KJ?#T7HDBG<E]T)0M40@B,<;UU
M\0:+>6`84'1+[E-@?KFZ!"@DZ?VK_P!$"/Y:R5["L;(/2]4P(4].XV)(Y+QB
M[4!408@G`I\I[T=")-J5-W(^DID;RLUP;62$,21!@3D>CX]0B[4\0@!E-O0C
M@4'87HB<H#82/,VF[>>[Q!:73<R9V9`%,3\1'F.(7A&T%[C]%/4,3QQ;VVA_
M"&>THW0.-*1>/9^M!OH\/H]`[@`D/#$`/`%0`!T%G8#GJ<%`-1`&_:W^J39W
M-)Y(<[1DB+5"J@4B-K<IDL(TVPM,H>-YZ%C,55>%E895:4KTM<81"]O`&B*(
MHHZXR6-A$2"A`10Q$=B/4-[-8]L_1>C83KM#0SP81$`SN<MBFEIBF#,`75(%
M(P&=A<P!#T1`8BZ)H$V8JJJJJJM5=JKM5["F;E%5$"PBB8H>)J;X%\V@J^*6
M[2A=8<>,9'[F(D6+M@61IHWC#5@81*QJJ5/#[@=I;`=%U6P.!J/O8"R['T"#
M"-M.AO"T>,W%:-HC<`Y#9(\$IPZ0/H!`>0!XQ-*FI>L89UL\(6"LBCO7Y@\#
M4/(*T?O3*@ES8P%GY&WJ&A#T$/2U?U8O"@X)@5DP&!N7/SZ`JOR1P9L$>`'7
MHLCE+KS2=]@\8Z26+3\(`H^)_MQJ64!V28Z-:HW&^%A2K!XW.-AKD_S'5OGG
MT<&VQ@L%*)P/CNC3["[\09%P$SD_02'@,'.1H)T`<11A/#&ZKHS<1[A18+K$
M#$'/+.R)+1)X5,L%M!MU=HL"0BS9[E?%P@Q"\:`0`@`"("`8CI,<9C@$!>K/
M#5X6B*(B,1TB<B>DZ.)HF8?*IBD`7%)0C7%]:C[[GZ*D^^@]/,BL<8B*(B,1
MTB<B??B_*0.&;).5YH9$``"8X`%-UV(1X1H0CF_-B*SY,+,%F1U2AH.%K;6I
MX)$C>@^H4OV8TD`D:AE9?!;MV[=NW;_`7EFR@WB;$,1E_HWWBD!)&4.P(8+,
MBS4BCY(`[*HM*5Z(1`D1B6<KT$0L/#<>`RJ@)Q``5QA:KRL5%<#5K$``````
M`(`&@#O("B6C'K.R8P\5P995XI8+C%G&=J8$^@BIU`.42*?2G]O`IDW'_P#D
M(LQ2,*X+`)[NX%<&#%/=0$EA`3778H6=4(E/<"2L%[(/`G750<Q8LZ6W3`8D
MV3&:+,#`)7=VG<OP@?F;=+5$F]W13?!SGDA^CO!4-?KMV_P%Y9LH-XFP'$$N
MM1%JB$$1C@X`>L;D4@-*F8D4;9RBI&:1Y'8A;V:P#I@QX#T',5:TTR&S8`R@
M$5*B2<``'@0,H!%2HDG"(IFD/P;4#E7%);BX"/X@S!R(@B>!^2XW?&T15HN%
MR!]A,]GT#3IY.#^`_P"P=YI4=]T[%M[MRX4OP9SNJZT6B468=GAA#)G)?;:!
M!2R0ZSH!`V+4#^L"\W;1B[K-/2(8([OCW2HN]"0P=P:U0ELKEA>`N/=J%_`>
M*QQ(&`+=]V3-JR811\#U.I6G)-*``KFR""9\PX%H*LA1"5B']-2ODS,I*G^D
MY,^-BX/@1^W(8ER^=^I^Z>LI!OSA!#''-&7:!T3CL(112JE+7:E\PT/';!G3
M>"SN0F*!5!U^X6`8>P7A"^P_3?9UTD&;%_0IKY9.*,:AD1,"GZ-1;5&OF,I`
M)/IN(!8.,48?;5J'.86U0HTID1CH/4T@"6"-"O9(>GJQE1K9FJW0&D2[A8%!
M)>@/)PFO2H+D'N?1(!(!#`(6.5D&``2N6Q9H0$'.EL]]!<@`#S2Y/^$;JMN%
MK=YI<DXAJ6L$C1*B]^Q'=@62*+.T[2S*[@&Y`!VA>CAP143&ZBJC[ZF96.&U
M[>@$(7-,9!?P^4:Q'ED7Q:X@6]^[JA+[H2C:HE$`*XX_:VD)NC(%$973<XFG
M81@W($O?8>J*Q(/7!C*<]TX,KD8Y`P0_,@>;;),/B2`9F>Y,M@`8L`CB'H=@
M-5E#2`/N"2OIE147,5S^\5E61G4+!0MVM,M=6$!PE?:RL01M':M-RY]A7%$4
M%-^.M;I_)%XCX!F1PL]G7HGV`%BM%J``L%&,*H`+W63HY`/7RK8,9C<3M2B&
M'[`+W"X%GF44`77])_H647_>G+C_`%:-KK=5"SV$"/\`JV-EH'`ON!AKI4C(
M3Y,!Z#%PAWXA!Z=QW(&D@$H9`(+84*1^PF06%L<:M3*P#=@9)\2[RL1JQL5:
MAU@E``EOMLMT=,9W@"_PSY(*E73B'+?]-Q#"H+_D,JCS\&"5=F"1!7B"!Z:?
M`F'N%,1NL[CB$'%7[:73S7:)6!ED#>S^$JI2`X1AWQV2%`C-5C9]=J\E<IA1
M85[/"[JE'AS*9_U&<@_YFN=S_4/V_5_M?ZS_V@`(`0(#`3\0_P`I5R_+OS+\
MR_,OS+\R_,OB/CWYE^9?_!#_`!C/\Y?_V@`(`0,#`3\0_P`I(7HK(_-$N(_-
M$')/FB3Y1<O8ESCY1#M2_*IOM2?*+_;MX?,GCY5<WTAT>?CU.F\F<9<O8\_'
M&:[9D[.7QXSI[Z^LWG\8='GY`?67+BY>ER_)D>Z8Z/DQO0R8?*AG:L^5'UV+
,?EA]=%OS"W_&K__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g575431g77g14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g575431g77g14.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`)D%D
M;V)E`&3``````0,`%00#!@H-```<9P``<H8``))H``"T@__;`(0``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("
M`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"`@(!`@(#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\(`$0@`M@'``P$1
M``(1`0,1`?_$`30``0`"`P$!`0$!```````````'"`4&"00#"@$"`0$``@(#
M`0$`````````````!@<%"`$$"0,"$``!!`(``0H%`P0"`P$````%`P0&!P$"
M,``0(!(3%#0U-P@1,3(S-D`5%E`A(A>0(V!!&"<1``$$`0($!`(%!P8,`P0+
M``,!`@0%!A$2`"$3%#$B%0=!,B`P42,6$&%",[2U=G%2)'1UMH&1L7*R4W.S
M-"47=U!B0T!@H0C!DJ*#1%0UA28V1A(``0("!`8-"0<#`P4!`````0`"$0,A
M,1($05%A<3(3,$"!H;'!T2)"<C-S%!`@\)'A4K(C!6*"PB0T=!500R60T@;Q
MHE-C9!83`0`!`P($!@,``P$!``````$1`"$Q05'P87&A$"`P@9&Q0,'14.'Q
M8)#_V@`,`P$``A$#$0```>_@*K=3Z\P?/K8:]F\5%W[EV(``&A'&'2N[+`W9
M!^K5T0L``"(C\K5]UMUWJF9=BXUEP`!BC\R-JPR5\=VOT65W*0*TE%"5C3R5
M2/C;SPGA+)%G3BD6/(J)>-](%-D,R9TOZ4.Q/;PG9^56//#8O[=3Z]0/2/6N
M;?I^0`.,NMUE;UHO>W^/3?6"2I+C;OYWH;T`"C/8^>M..*-UP"/I=@_T>:S6
MW;[K_4`#A7,,%SDV*JWH#KO:-M(UE[I]/[3/QSKYBSPD='N)',>8@^1)9D30
MCYFKFF$U`P)JI+AL!RTJJ62/BNW"=@1WP^86T6F;65/VGV[J#U`'.*$9R,O,
M/:'0-T*5E:[81;VLY-'U]P"Z_P!_P`.-\@QNSYCI8J)YCD%LK4TC1'.?J*HR
MQ-K`*&][K?GSV;J29*\D_16JYG+TMPWJA.>Z.];ZB+BB)-)!Q!);PT,MT6#`
M.7I/17<T\]9-AOI<P%-.I]?\TC.H%E^&JE$,Q9WSZV%^_I9K+U0M*+"O77^G
M-WS3V9T"2XR1-]*#Z)4M-Z@VE$^IDRPW^@`5H_7%')G@\)U?K5;Y\U,V2JB\
MU!V5^@N!201FX_+SL#6>IY;I=(-<[3L?,<+%^#[_`&,C^2R8`!#I(!L0(W-*
M)O(J)C!\2#">0``<RH]D;84W-:#6[#=`T_N+9Z9FMYO3O5VS63ZW%S3"Z=SU
MOLK^>G.K]G:QE,9R'&=`;3BVZ@``YQ]KXZ[,\'!<=R=-Y]&:^VM#.[.LEN='
M\7W/S<6;$:IW/`NCNM%M2=E>K_/QSTEB&9FAR``(!)1-M*N8CM\]8+GNF]HQ
M;GD2[WNO$7:^'8/#]_SE:BSH``/"<O:^D5FH'GZ36]#O%YJ[+Z_=,*GK8RM\
M;YI[-0WZ,ZWV-[ORWS$]J5KKA%F?K^0``/X<>LOTI6E&*@>'9KF%L!6?RZGV
M[,4G8'%S9^H;.4C8-NHUF)"R_2GZ%9V[_P`OV``!`)*)MIRPU^L'0M(+SPWH
M[K;D\=V>86W]*>7)=7];-!65YRM19T```AOA46GYG@L]CHIUYL72:FELV[*U
MG'.F]S;GZ@ZMW!I2;Q1=4(Z!Y7J@"%"238@#33D=)\5CN>(YD.*YQVO"^HM'
MV%S=V'J_IQJ;=4^3C`82)9GJUC^R`/X4S+F@@$E$TLJ;"LW433:YNH=]0+FS
M>\!J9;\*R_8^'?"I9M*I6HLZ```"#N'O.:>F]SZ96$HEG8*O-'U`N+I?ZJZH
MQ1^>;C_KC^@'^#\Y1<DZW@`BPU(Y%V3%.;MKPOJ+1]A<W-AJO_1;J5=GB+E<
M<^H`\IRN.>!W,+/$7D2FHGM_',14//OC(.A"%Y0*7Y-BH%B^6OGBNYN9MA,P
M````...FUSZ?64GEC8"O=%U`N+J1ZJZHRP``"LA-!N8``.!=DQ3F[:\+ZBT?
M87-S8:K_`-&>I5V7!XY``'\.8QTZ`!7`J?"LU9>M)3RBRO2GO8>N-#D..VG'
M=J\<3S%N@`````<<=-KGT^LI/+&P%>QUJ-;_`%C]3]5)(``````!P+LF*<W;
M7A?46C["YN;#5?\`HSU*NRX/'(`````ISU/KE:,GG/*+93Q4+/H@]<-/:?2G
M#]O(-)=0B>7ZO8SM@````#CCIM<^GUE)Y8V`KV,-3+<[`>I.J^Z@``````X%
MV3%.;MKPOJ+1]A<W-AJO_1GJ5=EP>.0````!4_J_2M$#D$%8+O:QJ%<-,/7S
M37S=_K=,*LF<E=?Z=0<?V0````!QQTVN?3ZRD\L;`5[&&IEN=@/4G5?=0```
M```<"[)BG-VUX7U%H^PN;FPU7_HSU*NRX/'(``````\9%YD#R$K@``````XX
MZ;7/I]92>6-@*]C#4RW.P'J3JONH``````.!=DQ3F[:\+ZBT?87-S8:K_P!&
M>I5V7!XY```````````````''/7NPXL@F>LC<<-J9KA9/>C>NA\R``````#B
ME+<)RPL.+]G*JF?$RZ(#^J+7RSIQ```````````````!_@^1Z#QGL```````
M!Y#UGC/8`````````````````````````````````````````4</Z;H9$\QI
M)MI[R,B:#4#22(RT!K!]BX)]@4T-.)G/*?TB<ET\A%I84B,UTC`LX?`T(N$;
M(`"J1HQ8<C@V4AL@(O60V:*;61^=#C.`%."'#"FS&&)`(N-_-#+*$,GG,4>(
M\IIYU[`*Y%2#,F8-*)`-1-K(7+@%?#.'G,.?0A$[)&2`!4HAH^Y!Y+!B3>"2
MC72-3RDMEV@``"KQX203Y%?C93W$BGG/L3X?Z```!`!&Y,!Y2*#223S)&[&C
M%ECU```&+*"EE#82-RO99\B4W<DXU,V$F8```H.4=)B-C/H>HW4JT=`"J9U+
M,P```"CA4<\QN!,)%Q,)4(Z+E.CHJ2R```:"<MS1263*F=,R:^0V3L2Z00=1
M````1,:$3F8PTDRY"A*Y-(````!HA!)8@^)H1FB(#S%N@```:(046'/@:";^
M1F8$G8\AK!KAIQC2W8``!'QR+-R*N$^ETBK)/9T"`````/@<<C,E*2PQ>HK>
M9<ZM````\AR!/]E,2S!.!DC(F]%5#7BWI"9DSJN````?(U0W``PQF0``````
M:2;L`84S0````/X:8;H````8<S`!_]H`"`$!``$%`N:YY<3A=?Z52`WUI>P"
M9//2D\E$P\!^TE;.5J,J8BL]Z<]DFT/AA#+^4N_;M;S]R\Z3YZT&L[&LLW:I
MNAIQ((K/.>VY(6B\(:6U(&8LK=YIL-$6A(PC8+=CXZ;G-@2IH47O9PBW<7L9
M$*O[=*KXK>>%YGMOMC35I;<W>*JWD^'+JVP?:9>WB5'H228&7:$?O"1)B"-\
M2!MJ=O)R/?Q6R3G[_P`BUNGGY_20C[C%Q0F61<2P044VKV<#+#BW1F$@_P!N
MS(@_9BF-;Z-X^._W-/L-HU)`\N!]"<7$Y"R(#:"4Q?2V'DZWE2VCCK4S:#>S
M8MT?<A9V\@)_XZ:^WR$I+NM;_DQ7$$G02P@/(D)%F6V0$>33U"10J@5-U>$)
MM*XB[26I1V/H$OVB*M5G'\(3>AAT$,"D&3-KOG&,X912+#4]0\4=<CV:^BS`
MK"H#9@TA&X\6P^81U!0@UAH=NW5K(J=3$BTE^51+:Q]2Q8<]D#62:[VY$8Z>
M828.W-K5+,$5D7*//=\V?+*B!3((-"`];<ENKC_=$O+F1T=&4`.?L:[Z&FFT
M5M:6QE"4BG+7_P"@*^0W<?&(3$E6\J!FQLD$<]\VKFO(ZT;=V2@$">VE+)L3
M:SXQG+=FW]O2#A[CFFPM\;B`"K)@/(V)$)D?/#:IE.[Z,QFQ9(SC-8$!<P95
M1)&TSJL"2C$"Y]ZPEK8@;@LB>U,<KJSB!DA$C+&Q$Z?G+\%:U5&9Z4B$?D[B
M9\UMP,B=1A,O'3B/2Y%_6TFE,DB,5LAPW;/FU,RM>'F>:S)^RKJ,1($]&I6/
M)2;)FB4`RN.BQC$./:-?]VS'&,:XZ%I5ZC8,>ATD6/,Y.R+A2EXO87(7NF^B
MJ?M[LO\`@Q_FF$L$0B.&Y`7FLB7_`'!=2.RD-'ZVCP`?&`ZHYS;$J9,VHYIT
M;!)/0\'$+J.A7-))?&(@W$6C`C9%RY;LT!MB0`R]YE,_#2L"Y$]`NE8(I>JY
M2BLU(-`H<'69\.W)0.0RR.:R094=B9G@%^^9BV2!-Y9\KDTA9Q<0/T*5)&Z\
M@S*!1^=DRLJ-QV/BHJ$Z5S0M^/>!R[`Z-'JCZCFMI5]M5\J=-DWB'MXM568A
M=MM=-;JLK-GREPX2:HUJ*:U'#H9&W8SE+C17O$`A`JOHSTK4]-P'D7*R[-;5
M^C%K`+1&6V%_`58Q4Q`-;#V[9Y6L.:T3>C9RMR5^U3/I?TG+9N];`=5ZBETJ
MC`F8@<#BMA!HE(\R(<8<N(1*[U?NY'(?^AHWBZPI]O7\?,D25@3/,0%U?7^(
M($X$M!_Z>ESYDS)L@3%L8&NQQ>/EFQLE$2GN+GY1G`$$$VZ51PAE+BHUR_LF
M2RB2,8H'IROGT?;].U/3<!Y%RME'9E<,M':EXQ5#%_:27N`!#QL>D,L>SR8B
M6RKZ5\E?M4SZ7].>PD58$:KV7$5UC[AJ4NEYKKK==F?BUD^M4\_"9YAL/AIR
M2!(X$JF+$SI3H3^>@ZVC@@HU-B^>0`!<H"A%2,'/SW=)^6]SJ>FMHG?)O<5^
M.*_V1=L5?_DK0L&R*JJ-K6)(>C!KI!S"6<UJ>FX#R([,6P0_[BT.ZA90D\F1
M]BQ9BF/?_P#9\\N&+?QXU1(G)JY=9<EB9J_:IGTOX$QK:#S[$/@$-@+5[ZV6
M'C&XFQ<?_O,\_"8F/8%J\&>W^HQ)+H9^/PON87D8@].S&]76>A*X3%)RPA]6
MP"`J^Y_U..^3>XK\<6^Q0J::U+[^WBG%"***+9'G6V4T1WLSW*XWO4[9CMO3
MTAE\IK_E-@KN1Q$5M<#)`GLX7O7W`[C-:CJ&$O(J!LTP3(+F(FTI"6%Q+(X,
M]K\;S%YW,%WK:V'SJW>\5['W\5A?">^ME@>6V+Z\SS\)@?X3TK;KC%J0Z.B,
M1\#TO<_ZG'?)O<5^.+?8H'T;Z8:FI)*K&Z$GBQE]-UW'^VK)D1\;%@D*<FVM
MJ>[TAVX:IIHI*0,T:%1;J.9<3J4<1[ZV6!Y;8OKS82O8P6'(=UB?&]S_`*G'
M?)O<5^.+?8H'T;XESR4R*!1>-C8B`G!]I8]B6;E=M&O<*=2D%I,)`O"CK)XU
M),ZM(K0*Q>(]];+`\ML7UYLG\!C?X]QO<_ZG'?)O<5^.+?8H'T;XEL0XW)1[
MN7VD=:S""LJ6=SB4@W4<G8,I#YQ"P'\WG[J*R^J"-=Q*722><1[ZV6!Y;8OK
MS9/X#&_Q[C>Y_P!3CODWN*_'%OL4#Z-\9PW0=H`X!!XRZD\-BLS:16"P^$-^
M,]];+`\ML7UYLG\!C?X]QO<_ZG'?)O<5^.+?8H'T;_H%F)KUY9B#_2UY!=HX
MA')H;DS*QF`YIA@/XWNFBAS!@0.>V"_]QL#..X<V>Y.+5K&7$-@7]`SC&V$T
MDD=.23=!OC]`D@@ACEHW034_\3LBXMZ]F"EQ_"WAMV5N5V#W%79S`^YZ[(CT
MK?;%)B-NVN"N!=R5Z82-74.7%67-G$&`-+EAW\2+^X&#C=D?<%U"KVYZ\9"9
M?=T+CX*,7)&'T-TWU4TYKAM-[6#62WBD+E@^W($5D0*XZ\DI8'<5?2%^_NT<
M0<L[?@#\^#N:NI&0D5Z@?XA(YEI&8+&[E".H0>]PD($AR-_=AC%R5_D`XNBO
M4`M:70(E@(.68'A?0M2PWM?MXG;+R4J26<Q^)N2=T5P'*JVA"T9)([MC:0J2
M^X!T,F;>QXHYE4BL>:-IO)K^080R<VZ^!%'ESS=42-W(*C^>>U5B=2$/0SQH
MBA24S(##%%.C:!>EYE,]']93"7D-:1FA8:8J"2.>0NA3+1*<UJM.Y1&*2)1D
MHRIR3!1>M-300=%TK-8DFG0\FCS8K3Q'69<\V@ZDN-Q_V].P@V/4Q*A[X323
M]F/845*'S)G6<^>M0])RIJN&IHT*;#_;Q)L"IU7#N;!G%!/T-S]-R%XF6IF3
M/2FE,S5%9E2LN!N)A2LA9Q5FT08-.A;$`*SM"-48Y"/9C1R"XYQ6E@RF2,Z*
M5'S'>F)VI7\MIDG(N46A<RBDMD,`GV\[8^W,?HNT]OVSUOK6TE=1KIR:QTX]
M+HC:&#@!G9,!(!E[,@#:/2Z\1\:!Q.WQ19F^N6--,QBSH1+1\ML^(PZ)O+3K
MH<IC.,XX$NF2X$_#K;_EN@JQ8(<RSLN`OPKRYHZEBN+KUF.J=NQ<B^@UOP.P
M42T_BHF)Z7-6?[&BLBY1Z;UVBP9LKN*O&+^S8*%7>3N'#CTDMB*",2'W`-1$
MP>69%F"NE]P=HJ+MN+?Q1:>0Q`R6M"(`YP(L2#'S73.-BHVZ9C7$E`Q$Q4-@
MRKDA5LO#*R&H9I(!TII^5O#Q.O9G+2\[@TN;PFR8"X/5A)*SL8HJ/:]Q8<"Q
M$'(ZS)37DJ;8;5).YZ!WIV6NP[V`S62GB=&29^+;1"=G9!)8-+X15J=>=UJ!
MO75GCN4$C>\/AO3E0S<W&OXQ(;"J5U#9X4D:U)2!*4KUG8O\5DM/2`ON*@<]
MCYT#5<LC[UK14W$CF-;3`'+YG##Y"R(%5\X&$^!,9<A"Q48M:,20<J8$H.6T
MECCU,Q8L+!,I1-([#V;B\8$@)S,D4I[PY&<_CHN)7)%98S5.!4.2$@`NG9FQ
M84""2.91Z+1U2XHTJ+&W$`,;<"2'<1L3%+CBTK9*G`J/)O(0#QP;L:%`(_F0
M`=74NLN(0ATC;40<GR9@2%0=GP3!&4S$)%!"]A@1]?YMV.N&(6XH_(=NG+6+
MHG%9M65B$XD:@3T.Q`1YW+`I*I"+B*6I#I'+&92!6*)J)XL].W-PU,9V3<5S
M/FU=0&JCX@A`F&9,T4IHT1AD]B!F75IM#[?C5>%!>6J'`7USN@XKR?-JX@=4
M'0N\!$J2D&^ITT8@*T//Z6#=U:36;FY:(L!O,;KCLED.P.F).J/*59->YR6!
MRDQ2&8E<,5@;H3W1+@[]3J!OV#N_.G^W]^XPS^.=YY]_V[OW#%?QWM.#MW#O
MW/\`_]H`"`$"``$%`N9=;5N@K8DCV?`S#8Z.Z<IL%]H_A,C7D([@,P###8H/
MV'N.F&!IN$CHI%C^I<O6[7DDLBY3FT:R!(0V2;1\CKMKOKT;`E'[8U;-EWCB
M,@48\+_<F7:=%-/=3*B6Z68^2[=,@RT?ME4MT%.B&&Y?N/[:X,D>_N-6ZNVO
MZ<TAOJX'O,M%BPMH<'%!KD2^KF3]?7H2`VW`#7KQP0=5Y%^Y(%GW9:IZ;*[I
MZYT3Z#+?')5/"NFFZK58>^T?MI`,[=/H-FZCI9FT39-Y"3ZF&R/:[?+DMMC=
M7],NCHX2<M]VRHA]U<SJ,?O;%-15NK$Y$G(1G,JJF@E+9$I(24&C&3;YZ[U9
MH[[;;["F/8:='&<XRBKA71RCVFHHAL/<Z[:J:G!G<UN<&,[F@5(:CVV,*.%=
M-,::NU_U)!EAVEG&=<C'W>DK#C'<7$>..(^29NV[]KRL63]IL&$NC9!BR9@Q
MKMUN[6$L>VVZ:2N4M]=L;8=H=7,>)]7+ENFZ1>-5&3CE'QG;[K*Z()OWJA!R
MW1[+5PMV6O"?/FHUJ'F`,XXYF[9=TH[8.V6>$78_'DBMN@IG#4NQD@)>/DZT
M.K(O9B:5!!/^Q92%QK6/CBC[O&[)IL[6TTU3UX#5?J9SC&<*I[(*!R6'[<\R
MT<LV+;OCM)/1%,^3[RHT0^')3?">N^^5-N%92&ZL;"NLLBYA]G&0RR_>HNCU
M49)MK@?POGR),<M5`>BN.5K_`%P#\JL_\=COGSW53=JFDHJHT:ZM$>$U7ZV'
MF=>SC'C2GEP'S13[?Q_SZVO5<+=KMPY&S[^"@@?&V^VVV^T?'=@D/=]Q=RE7
M_+BVO]=>8QF46CY''?/N7PQQHQXTIY<!\T4^UGY\7;&,ZJ8;HZ"6?>%FBO4V
MVUQMAVHMNIQ;7^NN_P`HM'R..^?<>,>-*>7`?-%/M9^?%,/.R323V64`2!N^
M-#6O?7G542W=)=IIQ;7^NN_RBT?(XUKUY#QXQXTIY<!\T4^UGY\1975!)979
M=22/U@0*`.^Z2:+I=9R>;8QIC.,X=)=GOQ+7^NN_RBT?(XM^1\>,>-*>7`?-
M%/M9^?$62U722![85FX5<R"BL>,+G8RY0TQ)'B?=T'79ZN%^VSQ+7^NN_P`H
MM'R.+?D?'C'C2GEP'S13[6?G_0+7^NN_RBT?(XM^1\>,>-*>7`?-%/M9^?\`
M0)_&WQQM`XB4'D9H"<'@\2A9K0UQPSY-B[+&F>S,<ZPS>.CK#5M_P)__V@`(
M`0,``04"YM-,J;ZQP;A!\S48N>F*CR&4#8U,<YX"Y)SVK-UATETWY#9/<<\W
M<?J4T%%>6^FZ6P0GW]N9&X(-LXSKGHQ\7WI5131%,F_W(.N[+=7H[;8UY:[8
MVY$VG9[-G&S973?537HOG7=D_P"^<L&O=DLJ:8S^G9;ZY3<(]MHT=*L7+5RF
M[0D@OX9Z`]BH0<HHIMTI$4[?=HAU\[YQKKMGX[=!?&>6NW5SMC171RWV;*C'
M?9[=!575%-=;9PJ+:?'*F_5QRTQ\-?TVF^4]DU,*Z/$/CR!%.XK[:ZJ:EAVP
MYSS:Z[;["!VHYL=*=Q002RMOC&-<.U^TST?GRWTZF4M^KEXVPY2SC.N1SOMT
M^<B[[=1FVRY5_P`4],YZV4=/U+=?L=_GATAV6T=*=NF18ID&RR*B"O*."^KA
MZ[28MUUEGSE%+"6CM?JXZ>^O7QG'PRCO\>11I\>22NR*B"VJZ?(F[[/73393
M9LAJV24WZ^4].MGA((*N57@=\Q3YE%4T=47*+CALU^6^FJFO_:S7&O\`0@VD
MS#3=$,RU?OO\=-31/)!PU0[/5=;".F<YVSP%=.MCY<M-L*:OFO=E1KC9)=PK
MV".^VV^PUIV6JV_+77.V=<8UQPHTIC0D]2PNT9H?'D]TT[(OO\=Q6,Y=<-LO
MVNK_`#KRB?RD'E47\Q(^`1SKA7;?73553*N_"53^')#&>L7\.T\41\)K]7_K
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M\+FF6S+COV^SA!DP7PNZ1RN@B.<Y5_X$_P#_V@`(`0("!C\"\CY[]%C2[U"*
M\5+>UMWCV5D%L,1,+6[$'%"I,^H7:IVD,+786G-OB!P[`;G]!>UEWE&!?9:Z
MV[#"T"+(S4UQ3G7P#Q<EUEQ%3J(@Y#C&PMU[;<UPI,3O05BN2=$^F'8/%7T&
MP=$5;IXDV==Z)3C"&+;,)IYQ5N6;3%K;N/\`&3C%GV3A9N='[.,@KYQ/\;.H
MF#%B?N8<;=Q![#%A%!\[^)N;OS\YO./N,/XG8,E.),NMV:7WB8Z`&,^E>*M-
MN;*9YYTQWO/Y!4,BU5OG;WK\Z#%!Z\'./SF"C*/8C)=I=$XBC*F"#VGSHO\`
MTS-+D6)H"@S].RK+E5H"C;&O_MN](*)[(U\J?<;Q3*>*#[IP.&;?%%14SZ?>
MQ"=+/K&`C(12O_S]^=SQV).$89>Y6W)$8!YK[].I?4QOO.P#C.1/OMZ=:GS'
M1)7\W?F_FYH^6#T&8\[MX9RO#2NT->0>U"6REQ0::P/-+,*LE![:)K2A.;I=
M(8BO&21\YM>4>SS6R)6FY"[RZAOG&O`23SCI\G*HG0"R(N%6US*F:)1E/K7A
M9NCT>1>,N@_R<@4?;;A9GPMRQ&%";*);.8Z(.$$(3C`7Z7S9C<OO#(ZL;HP>
M5TZ<0V4T1).`"M&:V(N,NB6,GO'*[D&!>,O3?\9(-/VW8&YA6[U85:Z>`(O?
M2XK7S>U=O#SHBM1PJTW3"M_V30X>F)![*6$+72A^6?O'%R>9KIH_,OWABY5;
M_O.T1Q[BII>:U9;4M4W=VSS>V%7(H&AP5A_;MW\J_F[DW\G-/S`.B\X<S]YV
M<)M^DTRZGM]YF$9\(RY(IE\NKK4B8V(/D/\`Q^Y.YC3\XC"<#-SI9:,"9]/N
MNFZL^ZW"XYM\P&%-NDCFW:4WUXR<I.^M8ZK!F7B)G9"K*?9L%H*T*EK&U+P$
MX\TZ/)R)TB;H.](HW>;6-\8_)XR>/DMJRGV(SII@QH1FNJP#$%]LJ`TSL;K[
M?7AEV96?2LX@O"7-[A><#7BS:S8-RO)Y=5=VEST/$M@#NC8_%ROO<O*A-EZ0
M3I4YH==YC8.'IO'=3KG,IDFF6[WF\HJ.5'Z%-INTP%S/LN%)W'"G.,I3KU=_
MU#W"6TXBX'G;@!AE@L+ISCG))X25;G@?R4ZE^3$S<PXRM5+[%N^58&@*R@QE
M#1L-AV@5`U*C<7/_`%#*^5&?_=E".YB3+O4'%"5+$&-%"\))/R&&G*?8M:ZO
M`K15HU[&9C:I<YA.:-GCBKM>V]"<T[]2\+*,/>Y%J1$RRILXZ1=9]7_50-9>
M(;'`U*TSL#O9$]Y[(\*N6:9^!7?,_P"`IG[IGPS%<_W,OXD]LKM(+5,'/0EM
MKPY]CU;M)6>E%.ZBG=VI>ZG=4\"B<:M=%4:`V2]70:3I+H9X1&^C_P`AO8^1
M),)0]Z;CS,KSP5IU+BO$3.T<K3OTTRAV0X'<JE2,A/)Q[-<LTS\"E1_\;^!2
MOW(^%RN?[F7\7DCAV9W44[NU+W4[JG@V<@U)ERN0LW&2(,'"=TK6O[)F^58.
MB59-2`G&):T-&85;-<LTS\"E]V_@4G]R/A<KG^YE_%M!W44[NU+W4[JG@V?P
M[.T=7F]J$MFD5>?HMT@;M=Y8@[WG`PF'-$@#,FW<U'B"==YW:L,.0[JM#2&S
M7+-,_`I?=OX%)_<CX7*YM_\`H;O4[0=U%.[M2]U.ZIX-F,UU0",U^D5KY0(O
MEZ.K8[W!"+G9R-'UJ0#H3`YGK%'_`'03YV!K-\^R*'U!NFRAV5IY%$5*(T3L
MMRS3/P*7W;^!2?W(^%RN??C:#NHIW=J7NIW5/!LQE.J(7S7`RM\HR+FVU>93
M@]HQPH(&6R3!2'ZB;+ER9K7/<YI:!9,84PYV(5[BF2'D":X@C*A=&&,PNIS#
MVJP_15&B-EN6:9^!2^[?P*3^Y'PN5S[\;0=U%.[M2]U.ZIX/Z%<LTS\"E]V_
M@4G]R/A<KGWXV@[J*=W:E[J=U3P?T*3/^G"U>)!=S*K0="J-$1"K#PGZK]39
MJFM80UIA:).&BH#+25X>Z0\5+>'M!Z4`19C@KH]"I5]^H2C(NLAUJF$7'``!
M'UU;0UD[LB('(G2+NZW,>(9DR\.I:#2G.E/MS"V@4[^+_04__]H`"`$#`@8_
M`O()8K)@M4YI,R&E$QY$;O,P5'&,>P:Z_M)F.Z,2(#<PH"3V+Q$9-A.K,&`J
MUTQ7L&JD:0K*+)ND,.V>94H.H*L3/U+*\N7ERKF?J6:/)N\*@:_.\7.'R&&C
M*>0(S9AA+:*49QT*FC$%:A1YU*H6O9H&O.M8*L*#VZ)\[F]J:N595%W:NK4#
MMBQT@OMA"?+TF[^,)MXE:#O2"_D)`H.G_NY<N?S1(95A.()LF4(,:%X&0?DM
MTLIY!PK6.T0B34B?-M8%%632PK5FK`M0_0-6?S3,?HA&8Y>)F58.59?)`[7M
M-K5MJUK:\*U,T_E7[QQ\OL18ZEA"L#L'4M/%G'E#&4N*LGMW:1XMQ:F4?S3Q
MZACY%#!A4!4K#=$>?D4#4H=,5*R=(+5O[5N_YFK9V3=]6?[8K5%042K9VS3H
M%9%$:!7@IQ^<T<W*/9P(R'Z6`XCZ5HR9HA,:?)_(3Q2=#_=R)UXFU#?.)&:^
MF8X^GJ5D+5MKV""@59-:\3+KP\J$QFD$)C/)J)>F:\R#&:15@;JR+)L8DR!:
MF%:V<!J\8,89_+;F&#5\HQV/5.W%9=4@YAA,:8@H3FZ?2&(KQ[>T;0<H]B$J
M9V8%HY88%B8`H,_3,T<N7=5MVF5'"HFO88BOR4JCLC5R(2^@].FXD7NTBM<_
MM#O!60H!0&QV3TF$<:F2CA85K7[BM]()C,$(JBJSLD#V@0'34[[O&IGW>$)W
M='A:IW=NX$"_1BK1J5K8[0J4<"'63.LG(9U0H85EV25-P!X7\?)TWZ61OM4!
M4M6W1"@.U;5R)\S<V:=]WC3NLU/[OC"G=V[@V@.LF=9.0S[0,^?3/?6K(TBK
M0K44=743'=V:=]WC3NLU/[OC"G=V[@V@.LF=9.0S[/K#HA6C4I=]F]K,=5B$
M.:C-PH3&:#E#!LT[[O&G=9J?W?&%./\`ZSM`=9,ZR<AGV:R%9"U;^QE<XC&<
M`S8T_&V!]-Q-EXSP+PQT759_)EV6=]WC3NLU/[OC"G=3:`ZR9UDY#/LUH+FC
MGJW.,)3A`GTRIXMM<Y["``08QXDV8*6!:\CF`*(K6799WW>-.ZS4_N^,*=U-
MH#K)G63D,_\`0IWW>-.ZS4_N^,*=U-H#K)G63D,_]">R\42WPIQ07A+L;9)B
M3@H6LG=DYL#DRITF[NMS7B&;:%EFF"A,FBRUJ=+%90#Q!H/^@I__V@`(`0$!
M!C\"_):VE&HV7DL]=1TYSHBAAS[N:&O'.)N:\?\`01F<5N]%8KVHCM4Y<=[.
MGY!-RMR(4F:.O;4>0I/^;O(\ALSI@Z9.;&;5:GYUY\6/M_FDI#9KC#$*">]$
M&N5XV]VR#?!;^G(%R%*TUVDT55U<J)]*TR6]D=K5U,9TF23DKW<T8(`6JK=\
MB29S1C;JFKW)P;*O<61<**R(X]!AX;>QKJS&ZI__``;'AKCPG&M2AT4Q'\U\
M%3EP_P!N3W$^YQBWQ^1?XXRUDDG3J`U=*%%EU0YA5))+7%&7<+J+M'MT3GKK
M]/)<G8)#DI:B7-")>;7R&,TCH]-6ZCZSF[N:>7C\0939V%S>RU24Z>:?*18C
MB?>,#6L$5HX4>/KH-C$1&Z<?]-LSLR3I[1N-B%U/(KY=I"$W4U3,DOYR;"$U
M-6.<N\@^7/;].583Y`HD*$`LF5),[:(``L5Y"/=\&M:G$N7ZC:0,)CF<#'J*
M+*DUXIL<3M/5[5D=XB2),IR:C1R_=-Y)ISUHL4]3GV.*948\#TF=*+,;56+0
M/D`F5I9)'DC"<K-"L1=K]?#714_+83J!_3OYDJLI:0B-AO<RRN)X(,=[&V*.
M@*1G554ZR*+7YN7`)MC86][+J[O/Y88O<T-?(G0L<%!J*JCO3T%&ZFMTF7EL
M-.O`:$;';?,3:YO%N!V/4E?=UA<S;)=,R@H*AD+$X]6PYX%@ZB4\^R/:7(HP
MP(!K5>QSM^U.&M<*5E%MV\.KF>MW3:^K`;&\!_%^56XFQ*.4>.1DJQ%&(U7'
MZKMNW9HJ+C-=%QR`&-?V-;3E9(O"I>1)Y,7B97=2&5#*I4?4U,28P"&(83BF
M7Y&IX^X$NDRHM?\`A*RQ7'<8Q0-;06`LJR&<%)UK"DAD5A\BD$,"=':SM)0.
MDC7.T7GQ9V"8]7GA-Q[)+NF#%OGRK4CZ"W!1107L0=4@*EM_9&VQE:4[DY;D
MW;D9-6^PV''A5T_+ZV2:LR(E@<DK%,<9?'[81:6$-8J'*R$0KR,1#.U;N:G!
M8EG"CU9:?+Z^#*DXEDOJ$:2.GQN9F^3`?,F8^+JPX$&&.-)8QC5(I'(A6+X7
M`;G'X]#*JHF,27,BV9;-BOR*E'<.AF>6NK^C,@,(WJ-3>B=1$UY:JYZ^#&JY
M?Y&IJO%R65<6797E'DDJ@K0KBH"C9:9Q`Q+")%'.JZB594T@(K!JO);=RDDJ
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M:;.Z&9A&6$K&2W5KIH+$9HK)+'P,DQRTCH`=@*#8@8Y[-K%:[R.U3=Q:89EB
M-#F.)D9$L5^4=Q!<G_+\@A;D;U8UB#17*B>5_BC=43BLRC%B-BYGBAUL*,R\
MF3Q::3J&;M5BD@VL?5BIJFCE\6ZJO$#)*W4+C;HUG7%7^E5%O&\D^LEL5&O8
M:,;PU1-XU:]/*Y/I(",]7^W&"6+D"K7ZQ\MRV-JU\O1$VGJJ555HEYM>354=
MHJM2796!V18,$#Y$H[^31"&G/E^DY?!K4YN<J(G->+[W\]PR+31YE7V>-5QD
M5QZC$^NA8S>DWF6UR&3L)L_S?EU5$6]7V3N_PJC>YZZ9/4_BE*Q$5ZSEQ1T9
MI.KTN?;]QU$^WBNR*AE),J[,"'C%VJQZ>+2!.)WG!)`1%81CN;7)I]%^'89B
MY,QR.(`4JZ<2R%3TE""0FZ.R;8O#*<:<9.:`8S71==?AQ)]MO<C%/PI99)73
M8]=LM`6U'D45X',E`@6/0C.!:"&JN0+F;^6Y%UY<3<,M5>8(D=,QNS>Q6MMZ
M-[W(%VJZHLJ)^K*B*NCDXCRH,DD&SKY`YU7/"NTL.<!R/$5COL54T<G@J<-E
M'1D;):AS:_):WY5!.8WE+"WXPY[4WL5/#FWX?2)[84$ER5-<\9<UF@=HDJ2U
M>I'QYA&KJK&*B/D?GT;ST7CX,8QO\C6,8G_P:UJ<2/>/*B)6XQCH)WX:66J!
M"=PF.98Y";>FO;1V(Y@?YSM=-=.'6>*>TEI<XPKG+#M;#)ZVALK.,-51TN#1
M2(,HRB>C=1;RM4OYE\!WU(LD;.L6'.KYXNWL:JQC+MDP)\?5W3.%?L56JG@O
MY%A7%;7VL-7L(L2RAQYT92#74;U!*&46]B^"Z:IP)%I*9@8<=H`(M;!:.+%`
M=DQ@1)T=H8X9(FE1J:-:]J.\4XC26U&/V47J2)T,[8%=,!UIJZRI<8J"(/J2
MU_6$:NI/BJ\-H[>5B,"VEC-MK)0JYDN0.T1K)6D=1;RMGMCHA4_]1&)N\.'Y
MHV/()=^?ME)(7M(/4@I6N6+%$T3/^`U$WJ=3IL<J,VZ\$N@45,&X,KE-;"K(
M0[(JN:C'*2<P"2GJYB:+J[PX)#],Q^/)NI'>%B]E7"-;2H2]QW9`]-KY\B(O
MGWJCG,\>7!*R4/&V3G]TPL,T>O0SO68DV?/:0;QZKZG!JCE/K^M&!SGZHG`C
MT%=BMC2%6>()*R!5GK"J1GI5FT2QPK&(APQN@73D]C-JZHG$@D6)&C/ED::4
M\`!!?)*P(XS"R'#:U3$9'"QB*[548U$\$X5%35%Y*B\T5%^"\**OQJ@@"4\:
M6HH5/711K*A/ZL.2K`1V-Z\0B;AO^9B\TTXEU[*O'I/;A6OG06P:TW0CRRI9
MK!EQD$[I!DG<DCIO31[EWZ:\^!S,B#BU)7;EA"/8Q*V+%W%(RR=&8I!(Q.H:
MO:=6_%X4?XM1>*^9Y)U(X]G);Z+)2'!M2V!&@M"R"Q&,*4LAT91D*-["JBO3
M?S7B&EK0TUFE>US("6%7"F]BUW2W-B=R`G;-=T&:[--=B?8G`+JSATH2U0NG
M%MIT>",E:%R[-@)YV(Z&)RNTT:YJ<!2SAX[7Q3#=``DJ'7@"\$%DO('1!M>)
M&*&(R">9L^5G2<7X*O$ZKC?@N?DDF,2390AAICV\B,9(9)#YHMCI1FN1([B(
M_7ETU=^CPV4*MKQR6'ER62!PX[#MDV&U)\AI6C0B'FHQ.J[74FB;M?R91[:6
MK%C91C-_=69>MKOOZ2\M9%C79'&([3N@E'+:(BIS&YK4>B.7BNO<:D-K<[Q&
M0ZUQ2T\$<;9I*I9WAU*NY!]T5J\N:+\NY'57NGA4)T+W-P7N*^\QMVY)<CM5
MW9#A-@Q&H8R[E<>`KFZJYR:-:\GEA75:_=&F"W;'<BQS-\AXIV_HGC&16.3[
M4^SC\:`:1V%9*>-"S^"%KG-K9;WH&#F(`L1?U;B;)FWS/:NNCWJF@I$<K#@.
M-A@F$Y'C*(C4>,@WMU:]CVKJBI]"-[58E)45_D4;K9)9@5=<8Q5R[)!%<WD.
MRMFZC`WYD8NY41'-=Q#J:T*`AP0L``:>.C?%SE\7E([FY5YJJ\$@F<W_`*:X
M-,;(R22KM(N29'&:AQ4F]=!DJZMJ]24JKL<O+FBHY!6W/_I7@M@X>.QMNV/E
M^3PU41+M[.2$J:=Z*R,G/5_/R^9O$Z]MY+(=951WS)DAZHB#$+X-3EO*1VC6
M-3FYZHB>/$>1.@$JO6[F]R"#6%38^'6V]D>7!8X2(SHN(!Z/V[6Z;N::_1S_
M`!ZW:H9&86RYCCDUZ:!M8!(XP2(0"+KND5A&:*SER\$X[-3.@V,0P["CM@\I
M-3;QEWQ)@7IYD:A&HCT_2;_@XFT%L./4^[_M^;3Q0>EB)NT4T6[574F2`'ST
M56L?\?+Q(C3HQ(-G7R"0;2`9JL-#G`=L,%[5T5/,G+[4XAYE5M(<#&MAY+5C
M=HEM2.>U2Z-YM[R%IU!+IXIIX*O%=>T\EDRLM(HID.0SP($J:IK_`#7M7DY/
M@Y-/H,KJ9['YGDB$BT8=458(?EEW1V^*!A-7R>".+I]B\;5(\YB$(>5)*JN-
M*EF<I)$DSUYN(4BZ\"QF/O%0P.E-R^R8[9T(&]-E6!__`.=L5\NB<VMU7EIP
M'VPQ;IQ/;3"'Q0Y6:!Y8]O/A(G9XG#,GSQ(:LUE*BKJY-%5=.:N5118D0'->
M0P1HP&?XF""-O^!$X]P<S8`L>BS')A2<?ZS'B=+B5<1:\]FP3O+T)TA/(Y/F
M1OY<EIZQ`K86=+808:2#$CA4\F.\0T(<7W@FJKO%/#C&PL`*HK:21ALB%,CY
M58%935-)'$M_0!I1!'%F3\CG"=W!W;@N"337R-;P6VQPT>&2MP'(ZJBE.E]`
MR9)>2Z\>]KD&1\/I5<8K6'Y[7D\.%]18:FQIUY.MB4L7+KRS*.OKL4=58_7%
MG,D-G2V2;:>>3+$SR/>SP=KJZ]-6-OZL_HF,5=I-EVV2UQLEFR<B2VS653+E
M$"(*JF2H,1HF(V(T00O:%S_T687<6,0EA`HL2N8B2;+('3[.JOK&Y!8,T:&+
M!AR(HXC7!$T(V""CW)YM$<[)LZM*K'+X\YV12*^H2'$CG.:V*&GKQ2+"5,DQ
MNE"HH/5=N'S=*>FFJ^3'Z*XAAA6<".=)XH\@4D#IDF7(FRSA(%K6(,\J2]S6
M_!%^A?SA4T*<"ZS^\O;>"'+)U2N14\BJ[;&QR9(0N(&)3V#&'-&5WWC_``W-
M:UCJK`GSAVEJ\6+U=]8R)!7#)`#:5S\B(,LO63*8VM&9@4?]X1-N[GKQ>V4?
MILG$?[B%K[9<ML.E,]:@&I,'B^CZ#AU<7&ZJ<I.37/[L3B)S?J2EQBI!DMA"
MB7V$R1W+[3,T!6X_5M?;96L\QA,II\G(K`2(<SI1=R/8!B(\:-9*3)5EWUU+
MR/$Y=Y&GY:UU1=0:[(?5;TM:&/71WPNL%J!C]T\KQQ'*)C1[$WX['@^B!QZF
MK65NRR@=^43;*S@"MR@59\<B.C4$!6#_`)[RZ:\]XY&1Y?01JL536SJ;"HD"
MTA2JNAJ),F%UQCC!$V0:XN!Q&.D2';&#&%H1L^9S_P`E=F6'=./[AX;U9-*]
M?*.^KEU=88K9+JWJQ+(>O2W*G2.O)S-[W<0[^N1X>KOCSZ\_*94VD9>G.K)H
MU1KAR(IOM1-S=')R<G'_`%:QR,635R&`A^Y]!%35;&G%Y09/$"GE6VHD75_^
ML#KS;YW<2+3#;!MIA661*VYS#TL!CT^'WEVK4J;DTX3%APF9(QR*4#E:]KO.
MO+:S@T62(<F)+"\!PD3<(X#,5A&.3XM>QW'_`$AR&2\D![#3/;6VDNU=+JV:
MEE8P<B_-.I4747/S@^#$:Q%_(>Y*+OK225E;CM,S59%S=R_)#AC:WS=-'><K
MN6T;5_25J+/M[Z1ZAEN2R?5,DL/YTHG,<&/R39!KF.Z8FHB-3Q1$UTX?CN+Q
M;"PR6PKY,X[:B/WDZDQV-RL[OMT(+4K!JK0IO9J_GN31.,9]F?9V>5N*OJ(U
MAG^3Q]1RH=1,^\/3E)M8YF2Y$??W2*C5$W<BZ^=B0JFKC#B0*^.*)#BA;M&(
M`6HQC&HGYDXZ?ZSVJP6R1T@B+K&SC+8CO*%BIY9-%2.\=/(8GQ<BZ-1K41$1
M-$1.2(B>"(GP1/HI&!(]-R2G-ZIBMVU/O*RW$WR;E3S+"F;4&=O@K>>BZ:<2
MHMK&]-RBAE/JLFJ7<GQ+$'E<8;?TH<Q$WC=X:+Q`]QL0'NR;'AJRPKT\K,HQ
MSDZ;42---\D0V[X[O%')I]B<8Y[BX&9TVWR"H+-R['JZ,>3*CU4#:,MY;BC,
M>VKE5AW=`O51G4Y+^?AI!N0@R-1S')S:]CDY?X%3AN"W4A&8GDTM74,DY-HJ
M2^.[SP'.>NP<.U>OEUTT+_G?EM,FO#H"!61U*Y-?O))E\L>'';S4DF4948U$
MUYKQ99GD'*RMG;8L1%51T]2Q5[*L!KX=,:ZO7Q<Y57B/64L(]G>V;UC55=%8
MI9$@^Q7*K1IXM&Q->*/V\]J)+BY]F#I?XOLYD=8]KC!Q*@,AL;R.Y2$AS(?,
M$,3M4Y;FHO$.DJV*D:(U=2/YGER2+NDS9+N:DDRB^9RJJ_9\.'8!6%.+$Z5\
M>3[B7$9=J&3=U(V)Q#\V]Q-V??\`\T?P7B-`@@'%AP@"BQ8P6[!`C@8@Q"&W
MX-8QNGTLKM:TZQ9]?16$N'(:UCW!D!CO>,B-(UXW*UR?%%3BLDF=N-(KX1RN
MT1-Q"QAD>[1-$35SORAE9+=P*@<DG1B-E%_I,TW+[F!#&A)DXW/Y!,>[@-1!
MR.*VTE?\'7V0)U++G*GBV`"YBP"3GI\6B1ZIP65+D!BQ@,<0\B25@`!&U-7$
M*4BM&-C4\55=.&5M1G&(6E@1=HX-?DE/,EE=]@H\>80I%3\R+^5ZIXHQRI_B
MXQFXMI*S+&=7]67)<P0E,3N#LW*P#!";Y6IX-3Z9O=.D`0F'WY0Q_<^FBC<_
MLCO>@HF<PHXT5>J)[]LY&)J1J[]'.57L$<!`3(,V.THB,5AXTJ+)&CF/:Y-P
MS`.)_P"='-7BW]M[^MAD]J?=F7(]&E$$QC:G(Y@&BD8S92VHTG2F,$UU<5R]
M0;FHUJJY%<V3[7Y$=\E\(*S<+N3<OQ!C&Y6A$YWR^IT^G2,SQT;JFK4W*@!2
M'U]O`D!M,?MPJK9%3<PW=6'+$]/-MWIH]/BU?M1-#"M!,@9AC9TJ,MJO!06`
MT5!SX[%\RUMJQG5"Y-S?F:CG;57B796$@<2!`C'F3)1EVBCQ8PW&.8CO@P8V
M*J\.]Q[090T,%)$#VZJ)#=JQJUZ[).12!?"?=;-6_P`T.B:N;M7B1:RVO.YJ
MLCP8(45TJSLI&K(5;$&U'/(>47EY454;JNG+A9QPBM_??W:DL%`K]6F'4MV_
M<1UT0C04>+1'[S+YVD-RYL^4=6%Z2K*45]C?6JL1IK6WD^>5)?IX#1WE&W]%
MB(G$?VDP^0^/:6L=LK-+T'_^4Q0J?>MW<VMN+L:],#%YH-V[31=S:W'Z2*R'
M5U44<6*!G\P:<R$>NKBG,[S/>[5SW*JK],?NOB$9YKJGC(#+*8"?_P!GQD7,
MB[$^>TJ6)O$Y>:L335-.<*XJI"2(,X+)$<K?'1?%CT\1F$[DY/%%3B;D1*^$
M[`,_Z=5F.L02K06)G.;'L7/1F[T*<I7)(&NHV*Y5T3XMBP]385DSB3L4FIYP
MPR/^]/1N/N<QW21VX"Z^<2IP^.75$=HK7M71XB-YC,-R:*T@W<T7@F)Y'):N
M8XN$8B$?Y7WE0GW<2V'\"%:U$8?3]+S:<^'/>Y&M:BN<YRHC6M1-5<Y5Y(B)
MQZ?6F5V#XI+**#HBH.^NQKTSVC]4121(NFP&O+]+3GP62=VP0FJ][E^Q/L^U
M57B3[PYA"4V89*)E;@V-N:J36`G(G80@"7[QLRT_6'<B)TXZ<UY\6F19"X,G
M-,MD^IY+,&QK6"(_S!J8NB>6'7LT;_YG)\=->*S#<2:DC-,J<^/7)IN'3P&I
M_3K^=X].-"%JK?M?Q"QRKWFZ.Z186!N<NVM)&CIUE+=S5QI)?SKM;HGP^GF_
M\-6O[*_BE_LFN_8P_DK(<6JD9'E.0%*&@QV*9D5TOMT:Z7,ES2L(.#70FN3J
M$5KM-4Y>*I+RKW8Q2,4F23VPAYU6VB6@L,K9+F`K\?\`3"Q1$KJ=C^9Y$==3
M$7<3J+M1LEON&>E!CIM&]Q;G#'8R0YJNCEKI"N:<=BS3<%P%ZR*FK>#UN8Y7
M49C!P:=,J,3QR7,"4^21Z^4=T7.\BK";%NI*U;P@'O8\3'C*5S=Y$=Q'Q6VP
MJ!F5S9Q>XC8S'BU\9L2$Q5$*PEV)`O\`1Q]0:M`0;5+O;Y?#5(GM[EH+.KL)
M$^4'#IUG8LN12:]Z]6!03[U4CFDV\1%402$$WN&-8W]9\_!/\Q_^BO&&_P!E
MK^UR?IR(<L`I,26$L:3&.QI02(YV.$8!A/16$$4;E:YJ\E1>&>V]H4K\+R(T
MB7[:6\E[GI",YW5F83,D/U^]C/)NAJY?O&+MU5RHQMACMT%2P;`6Q7,T;(BG
M8N^--B$T7I2XAD1[%^U-%U153B9[89/.9"]XO;/9=83DZ^3\15C-!0;9BN=O
M+%LQ,;%LF>9&EVO>BJFQ"++BOK;RKDEJLBJ#(K#U=Q#7IRH[V.\W35R;F+\6
MK]NJ<8[[C5!.@_U*KQO+HO/H7&.6LP4-I3,;S?-J3$:\+D\WZ.NU-%Q;VP88
MD6BLJZ1EN4=-=K[>NK9T>/`IMR+JR.2=]X?^<B-TT5./_2C18H?%=H@1XX&:
MJJJNC!"$-O/X(B<3_?+-=T?`L,22'V_K2HO6O;1%4!<@9$?MZLB7);T(+7::
M?.NB,0BSO<[.1JF7Y&%HJZL?YA8?C.O4@T41KD3IR"(O4E.T3<1>>JZN='96
MPUM\KOY'I.(T(_,6SMB(FA"-3Y:^O1W5D/71J-317-UW(;U"1ZKEE_)=;Y=>
MO\Q;&VD>9[!N5$5D"'KTPL31$3G\SE^I6?&8K/;3-[!.HUK5Z&'Y5*5=4Y>4
M-3<.YIX(PG+3X\2J^>`<N#.`^/*CDT<(X"MT<GQ_E:OP714XL?\`Y?<^DN+&
MDQRS_:W*#*B2>E%1SXT#K$W)ZO1$\$^8L?5.?CQ9XOD0%C7M$?MYC=%1DH/_
M`.%LHRK^LBS!:.:Y.7/BNS*E.Z-:X\5)**U=&S8+E1LVMDIX$CR@N5-%Y:\^
M,:K:1[ZX_N+L#+E,>J2(5.Z`.;."%Z-Y%D,,@MR*BHU5X''`U&"$U&#:GP1/
M_I7B9FF5/9$]ML"<^=/DREZ4.YMX3.L@%<[D:%7:(XFGS/T9XKQ_U*O0/CU,
M3J1?;JB,U6^GUOR$R&2%>26=IIJSXC'X:<M9%O.1Y=JM!"A!17RK.P.NR)7Q
M!IYGFD%5$_,G$[,LM3JYYEK6&LD7FRAK$T?!QV%_JQQ6Z*7PW%^'+G]/-_X:
MM?V5_%+_`&37?L8?R8+/*B/!<XKDE0!SD72-,@OCV*[7+Y6DEA56I\51%XOZ
MURM;W=3-$U[U:B#)T'J,NY_E:HWIJB_#BBS_`#BO8:JQZBKL=PBFG-25&?)@
MQ`1[O+S1RM[<DR=-!L"[;Y$9RT<Q'+6YI0A#59W1W](S&IU>P46=.DS+`$=U
M<_IHU9@^B]Q-B[M-B_H[M<CRNR@OK9IEJZ@M<1=5KI%17`CV<5GF<YH5M>J]
MJ+ST5->>O&#P(VO=S<TQP,9[==0D]1"]3:M\S$&-JJJ_!/R$_P`Q_P#HKQAO
M]EK^UR?J)V.6N\2&VR*^P!RF4]K'U?`M8)$5KAR8A>?)4W-U;X.7BPP3-7AC
M>X&*N2-/9JT;,BKMNL')JIJHSKQIP-%+L3[HGBUB.:G'M774CF2,AH79'9Y"
M2*Y%=58S(J'1F@M7,UVLGSRLZ(G:JCEW:-1V[CWA1K4:B_@1W)$3S.Q:.YSN
M7Q<Y=5X__?<8_O!7\8Q_VOLO[Q1>,L_AZU_9"<>P%I:C:W":2SH"W[$8G9PC
M$Q_H8]82F-9L!#@6"\R+M8/=S\>)61W%@"-3Q(_<OE[V.:9CF[@CB>9$D'E>
M`F-^=5X/[NYI#?&NKB+VN'T4C5?PEBCG*\#5&Y$V6]LU>K(<J(YJ.VZ,57M^
MB;)\A;.?7!D1XJLKH[),IQI*J@D8,AHX]/+S57)Q7W$+>L.SAQYT;JLZ9.C)
M&TH^HS5=K]KN:?0LL?NHS9E7:Q7Q)8'?I#?X/8NB["B>B.8[]%R(O!_:_+)2
MEDQ&+(PR\E+T_P`38]N5H!;WKH^UKD3IE9JJKI\>,"Q^L<TV7ES6CL*D(%:Z
M9!@Q#]6WGE1NKXT-T)NU7.1&O\->7%"]K&->3#7=1Z-1'/VV<AK=[DYNVIX:
M\6?]4?\`Y6\>R7]4)^X:[@R_8$J_XANXQ1\..5\,2TEOD(XR+J:G'?/D7#S,
M9S,'I<WM^+4X;<QY\%M"D1)09[##;!'`8SR.0B+TV,&---OZ*IM\>7`?=&]`
M4>,TQ"!]N:F0S:DHK7*.1ETD;O%Y%;MB_8GF^EDF#S*Z;BV4T-A*!'J+IS&R
M;BOCZ?\`,(GE8U"*WSJ%%>O15I&N>W=M_)F_\-6O[*_BE_LFN_8P\8QC3:VP
ML[7*32TC#A+"&*%!KF#+8V<TLZ7$;T(@R(NP?4,_P:U5XPW*T\J8KG-+(ED3
MQ].M'/J90E7X,(^6S_#Q7^UU05XO4V+/S&P#KK4XH$B-D"W)R25;O^Y&B^.O
M/377B)70`#B0*^*&)$CCY#CQ8PT&)B:_!@V^*\U\5X+D.[J87@,N168RS74%
MQD[41ME?;?E*&L30<9W/S+O8NBN3@>:P1[:BY>&%D8V(NR)8_JX-MM;R:R1^
MK*O+S:>*NXQOR[P8[5760R6^*(O02KA$_P#NYDYJI^?C\%RJFSAR3T\B[J;4
MO9$JKB+`-`CV8XSH\PLR/(@&LPHYIQ"W;M6ZIIJ3_,?_`**\8;_9:_M<GZF-
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MJ^@LL&U&GPV='I:?H\"CQQ"CQP#8$``L:((1#:C!B$-B(P8V-31$3DB?0*X+
M.J5HGN$/7;U"(U58S<O)-[N7#T;[%P%:CG(U?Q#$YM15T7_]2^SBHR_+/:Z!
M[?WM381&T^95N01&7"E8Y2#@H(,TDFQ8/17MT15!S=R;NUH[G-ZCTB\E!\R<
MA.L8B(WM;=\/1%KWV#%W*)?\Y-&N1J<9)0P'QQS;>GG0(KY;R#BM/)`X8ED/
M"&05@=R^96L<NGP7BMA'Q[VV6+$##BF,'-,G<=0@&,1"B$_`6#4BM;JC5<B:
M\M?CQB8[4`H<.%B&3&Q:0$W</N)QR5HKD4QJ]!U>ZOAZ.&Q&F0R.<[>W;MXS
M)MF5@NK7(.L:Y-[I%YUANIHPF(BN<4U@UB)]GC\."VN0JLC-,L>&VR:43]:%
MW21L"H15YM'61O*J?ZQ7>.B+Q4>V.*G4649PI0R)@UYX]BXD_P"=795:J.$3
MM]1@YM<XB^35S=.*F)5M('VXS1L.K9US*1M#F42(P`CF,1?*')(X-7KX==%5
M=K4:WB=3V04/"L(Y8L@3OYA&[=S5\6$8O-JIS:J:IQ[BT]S+82]KJJGBTJ.1
MS33\667+>ZR9JS8X:&[8;]KEVEU:OV\>UKZJ.R?-DUF:5T^&9[HH8V-F)C$F
MUNTFHT_]*K94.*P4;I+W+C[=XM-Z2V0,>]N'P>L=D,LO,\F#+?%WN0!)(0X&
M<(I#A:*]C2/:UW)'+X\8]CUH2(6PJX"1Y;X!#&AN-U2D=VY9$>*9XTZGBX;%
M_-]7[P?R8%_=2-Q0?QSA?[\C<5O_`&E'_>NPXRS^'K7]D)QB7\.4W[O!].1B
M2W"T?6FPIJ6"0/4MBQ'.=L6+WD#>A-_CU$TXIZ-IUE)4UL2O22H^DI^U"P/5
MZ6\G3W[==-RZ?;]/'?X-)^])'%G_`%1_^5O'LE_5"?N&NX/_`+`W^[=Q[?\`
M]A-_:9/U%CGOO%-@W,>FL"AP;%X3WFHHL(;T?&L)$8W+=IM51.W.(9-Q%5K6
M-^C@F75#ZMX\;6Z@VL.RD2HCGUEY'"$\JO+&A3D+.B*!%:(B#&37F1O"S>1O
M;_VNL'!K4^:-D6>-9M/-^+"Q<<&_8WP^^7])KN5GD-P9`5]7%)*D/_2=L3R!
M$WQ(<[]&L:G-SET3C`?<W)3%!.]P+F?0FJWE7HU=3<5A&8M4M;HUJ$$X*%?R
M3<5_@CM>,)Q)A7B?<7LNU,X;M'=K20'HY-/L238#=_G-3AT"T(BY)CJC@6J*
MOGF!V_T&V:B^9S98DT>O^L157YDXJ/<+%Q=3)L,*^5VJ;D]<H2)I<T9D:CE?
MW$751\E>UZ>315UXQSW.@2JEV&LPVRA8^V.>2:YER<BF4<FS]7"L8<&O6J-0
M]#IC,=RDW;MNFGUOO!_)@7]U(W%!_'.%_OR-Q6_]I1_WKL.,M?IN_P"13F::
MZ?K1]'771?EZFO&-1E=OZ%#5"W::;MD$+==.>FOU^._P:3]Z2.+/^J/_`,K>
M/9+^J$_<-=P?_8&_W;N/;_\`L)O[3)^MK,;QE>CDV>VPL6JIVJM94CDB(6QM
MGN14<U84$;U9IN7J*WDJ:\5>.5`]D&KC-`-RI]Y(+\\B6?QUD2SN<1WYUT\.
M!X%'DC+CF#=.]R4+":I=78R,%"K'-;R+!K"F1QM55JD\O)S.&WD1-9V,W%+D
M45W\QU;8@,9_@NFD;?Q$9%*AH-'AM8HO_++R`C[%SO'3[RNZ*\5^71=5%&<R
M#=Q47:EC32BL:87V*<#]""5?!Z?'B+/A&9)A3HXI44[/D-'.Q"#?HO--S'<T
M7FG@O!\`\S\6SU+3(L7&FKDIK^`#NL@K6ZK]W`FQ6]=B?*QZ;6M^9?K?>#^3
M`O[J1N*#^.<+_?D;BM_[2C_O78<9;_8TC_2'Q1?V17?L@OK\=_@TG[TD<6?]
M4?\`Y6\>R7]4)^X:[@_^P-_NW<>W_P#83?VF3];1VV*ECMRK#;L.0TL::_IP
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M82-.N,;[Y[CR*"34F-$(2N#(<YP#-<J,8NCE5R\JSW!R>ADXE2XM`M(V+4]F
M07K\^?=`2%.L[2)'(4<&*.%N&,+UZF_S>'UOO!_)@7]U(W%!_'.%_OR-Q6_]
MI1_WKL.,M_L:1_I#XHO[(KOV07U^._P:3]Z2.+/^J/\`\K>/9+^J$_<-=P?_
M`&!O]V[CV_\`[";^TR?KRQI0`R8QV.$>/(&PP#">FCQE$1',(QR>**FB\$GX
M[B&-TDTNY'2ZNEKX4G:_YAM.`#"#$O\`,:J-_-PR#E5!67L83E>!MA&89\9[
MDT<^*?D>*]R<E4;FJJ<$C8GCM71#-M[AT*,ULB3LY,[J8_?+E;/AU'NT^O\`
M>#^3`O[J1N*#^.<+_?D;BM_[2C_O78<9;_8TC_2'Q1?V17?L@OK\=_@TG[TD
M<6?]4?\`Y6\>R7]4)^X:[@_^P-_NW<>W_P#83?VF3_X#D&97,:4N'9U!HD=?
MQHQ9,:AN**"VJ[&T9&84P`S@-:095;M5R[4UT=MQK&<*:>UKJ_)*>_RG(Q1C
MLIZBNII"3DB=Z83!%L[$C$8)C-_VZ:(]6T/N;V$VQQL>-&Q'(R0`.E'H1)8D
MM85R:,%KI!8+GF>,KFHJ#T15YJU'%P;V_>[);S)&BA/?#CR5KZ.O*9BR[:YF
M$$,,6,`#':-W=1S]$1-=$6#!1V](<2/%WKXNZ`FBW>">.WZ^@SV%`DV-)!J)
M%-=K"`62>J3N72PV)Q"8YR0%0BM>_P#05.?CP#%<3C2+:;:D$"0:*`CHU5!>
M1O<6$^0]K0Q@A'K\RIJO+Q5.,,GX_"D77X%+LL(,,1#3SUCZ\,,DR+&&CWE=
M&6.CGM35=J_FX948[&E7=W8;HT*J@QCDE/,3[M>LS8G;C#KJ]S]$:B<^7&*X
MQ+>A)=/41XTIS51S>Y74IVM<WRN:,I%:B_'3_P`!5KD1S7(J.:J:HJ+R5%1>
M2HJ<(,(V"&WY1C8UC&ZKJNC6HB)S_(Y`!$!'NWO00V#1SUT17NV(FKE1/'_V
M%4`$04<Y7N00VC1SW?,Y48B:N7[?R$*,`F%-^M(P;&D+_M'HB.?_`(?_`'4Q
M6@+1LFT]P`4V]NW3UCK0UYKVNH.^='[4C#`CRK,3GZO;Y5X![;"IA.J>G:!E
MY2^QV#!:T]#%R&QA-C=KT7-A0[*,A7*9-KB+K\NG%CVMW(:.MI;/(W2)5'>Q
M(\^CIF/?:6=,617#2YCPVL55[;J.=^BB\7+X5_M#0T[,AG2)]=:5@'43]^EO
M")8PXWJ$#>Q6[P[T5VB?%-;VS2[-`C8W!CVELEQ47%/)%637;(,\$2Q@QY4V
M-.)Y!*%KU>]4:B:N:BX=54[6BQZZKLOE7<B_J+BCM:X^.1JN6+:RU].:"*L>
MPZA'O"1BLTT<FB\63X]W*&*KI962$+,HKZ$R9C\)VV5;U/<UHW6\,3OC&0CE
M^"<79X%Q)*/'X,*TF[J.]&0U99$Z4"PJX[ZY)-Q$EF\K'1F%U54_G-UJ9^&.
M9*D/]Q\3PB_@W]/<UDVK%?RVC.KH$OTN4&6L1Z/`]R/%]K5T5$#.K:KUZ]M+
M2%2T-(A^W]1GRNH8C7&1A7B&"!&,551COD1/CQB&4V\LM=^,8:DK:R/"L[B6
M2R`!I)]0%E9!.\LR*95'HK6[W)RXP4\=TZSI\W?:;;.+679'5@:MDD95)71J
M>7,ER_48JQWQFHAA?.Y-G/C%W2CTD[';NTS>%)D45#FI[8?H"0W5,(-9/KX-
MFELYLA>[:D,PD5/*Y$15XH[KUD\Z)D425850JJGN+6P+`KUVV,P];!@GG0HU
M>_RF<9@]CD5/%%X[Z!;LGV-GB-AE./#!57%E$+$%%-Z?-M/3XV^OKI-@UH5<
M5P?,NBJWQ3\09%:1J^RIZ'&;3+XD:LN=E67)HT8E>L2+V\R7-B32R40+@+)U
M\-VJ+PPC.;"-:]JJBMU:Y-4\KD1R<E^/Y<=/!QW\1DNK&9&+'28Z(4$2N@$L
MIIPHV-)ZQ&1`O73R_+Q@V.TE*.]BY6RAD6%HRQZ3*B/DQ"LID08XQTD&E)'>
M]/,W5$X9C$&X*6P/,G5T*1Z7:LI[*QK$<MC`K+Q\-M382X:,7<T17?FUXCTM
M/>$/*EQI\J(4]3<5\&4RK54LQ@GV,"+$?(@::E9NW-3@M?771>HR#/M`2)M5
M;5M?8UE6KDL;"JL)\*/#LHD/:N]XGN31-?#GQA+<+_I\7(LRKJ"<:XHKZO0E
M5/CR2LL:,LQE8*6TKPIL*WKCT\6\?AN-<E).?+GU\:3Z5;-IY]C5L<2QKJZ[
M="2JGS8;&+N8(KE^S5>&UU1=FDF+6V%K&(^FNXL:7$J5<EIVDB77@9(D5^W[
MT3?O&_9QF]KAI7R<AQ2A%?#K<CH,@J1GA29`P19_;3PT\J57G5RZ.&]OPX-E
M\P##E%50I(X(W]%)EC/:`<2"!7J]R=Q,D-:GS*B?;PN6YD/\(&A7QL6NZYS)
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M5&=(K;2(&=!.^/)BN-%D,0@2]O,""4+>Q=='L:[Z.,=A`IYLC)<A90M+?72T
M-5`W09DSNYE@D.;TQ)VNWY?CQ@)'Q*:C%E,[+:N5`DGMK.582<;8;;+Q&TKZ
M[TB;4F<%7J:6L='CY"WN3G70K1]D6?:-DFAU]/2V]]/?%@]+OISX=-"G2!08
M?79U"N:C&[DX/33[XH9L.970;+_DUXL.J-;`C2*UUI8^F^GP02V3!HTCR(W<
M[;XM?M;BK[,Z62V@J%3^EVJTK+\X.Z!0DO\`L_1F7)@+JV/U^I\-->7%^7&+
M>!WU#)"$UED-)F"8H1`W4*JM1QK6GII?J$F,^3TVI'ZGWJHJ_=HYR9Y3`LL?
MJ:_$O2JJ`E_C&=2PV5U,(Y)YY]O05\WTJ)#</I!:Z/I*<NYA%9S0N%@FRI%[
M&+VDSMJBW/51;#M%G+72+L<)U2";VK=_3>9%^'S>7BZQ+$L+J\C_``]CM9D4
MY9F2/IILL5@>:+M*YBU,R*LC^B<NH1C=5XQ#*\9QTU\;)X=Q<FJ)$OL#U5'B
M\.5(RJ7(*T$E%)4'C='3;H1Z^/@BXI7XS6X[:!R?&[/*`V60Y+^&X"0(`X)A
M-')?`EBZLH,W5N]6I_)Q[?Y!38)3.J?<6=44].RXR:9"L8UQ:1YY]DP(:`X_
M342O>HY#552#<UVQ-=$ADMH\:)9OC"=/BPY#Y<6/*5B=84>40$9\@+'\D<HV
M*J?!/H%L9<V.*LD>WN2866,X)'R62[J5$EQ+,2ZH/2O-$1Z-7Q>B<88VSR$<
M^961O=%<OLT$9)M]9^Y$"/7OGQG.Y#?!!':WS^+6-XKJ?)LAQHD3#_;O+L"P
MPE/7V(#G7)Z$>.-MLB[DY&(L6NC,^Y!NW/U=N^TL23>QP`-[*T_M>I`QC/*R
MSJ+=MN.V1KGL:^"\HVHHM4>J:\^,AM<PR''(^3RL:Q_&\??CM?8>CPQ8]D#,
MG9+LQ3S=:22QLQHU[&(C`C\-W%79YK=XZPT?&\[QF5'QJ%8B`*%E]5"JPNAD
ML)!#&/%Z!"O<_9JYZ-1$1.!5N49#C+F8[[<W?M_B+Z6!8A<7UB)'K_6<@625
MR(4<.$Q.A'16;G*J*G@ML>ERH-+8S/:W'L"ASHXY0SQIM-9=[)E]83FE#$L8
MRNCZL^]&TBN3FG$SJ6M+&?-]PL`S;MH:WDP$8&(L1)=>V9<2IEC+/*7Y2D<B
M*O/:Q/*F,6,Z]L:JCQF':FC!Q^PG4U[Z_8J".V<.UAO8\,8-:-X]&^9>J[X*
MO&(H"_!*Q_"\WR[(J:+*;)+9#I\FIB1&U99+O*:3&LCE,XJ_.C_MX]O/2+JB
M+<X-F65Y`OJ4:P],FU^62;3N1?T9[939D.'8>1/D>1.:HGC%RC'<@QKU:OR;
M/<ACQKB!9EKI(\R+$5D&2L.0"2#M1A<JD8KO,B<E15XQJTQ3(<:D9+`QS(\>
MN_7X%AZ.=N37\K)9$RL;`(D@1(-C,<P;'IM()$W:+P.'A^246RU]O78%E)L@
MK)YG.1RS2/N*4,&6/I&(Z>1J!*_8Q-':OTV\>SU*'U"165N/5`,]G18,@5'/
M#@#FGQI),YS7`=,/8R=&QW*C^BS7FB?0P2Q[B,R%BUQ9SK*'(81ZV,.RI)E0
M6*)6<F*J2N>OZ/%?%)D0+"9"S^CR+O#A.CVXMC<0\"HQR.NYSQK&BEY<U8UW
M&+55K?T$K"L(R.WR:C2)`G!R2PE6"S>UAVSR%6`&/"[YVKPZO+HFO&`5TNZB
M$'B8<_C6#P`.U\P6:QI$5BP]WZHD-DC5=WBO%-09;D-"^@P[%K[&,7?0P)X;
M65ZS%;`%97CI9^@,D.*-/N0:M([]).,"AY1>XH^/@&04\Z"VDK[0!+"MJH)H
M3G3"RCO0=C):1/*-B"9]JKQ0TEE?T$C"<2R.ZR>D[:!/%DLV79]\L6%:D>5T
M`46$^>Y5>+4A=J:Z<>WHQ9'%!*PG'<UIW3HT8W5?,R=#=G/AM(NC/3WD1RH[
MFNG+C+@660T[[/)\#%B!)C"Y%9.-.!:BGK>6$JZER9#R36C7>(2#8-RZ-1?'
MC#\:+;K!I*>RK9V0=HX\:QL&U$72".LFA5"0",GHA=_BFU-.?%_"J<G*:DN<
MJPK,$_$4F?<73;C'IJ%MR2;(JJ26EG%8U&*Y5<CF\UTXS&34W-,RSN?<NC]P
MZ5MC'FK`"ZFB@CI7VG;*DA4*X:KN%Q<WD*_I(MI8^X&)YY&Z\&;)A1SX]0NK
M9$,H6G`8HI,MZJS1[507BN[@68BO<8_ZB?CJ7FDD#X=I^#R-E4_H?I(D0GJP
MFBB)NZ_-ZO\`A\>,?RFEO\<+G,.[RVTNELX%C^&SBS1`LGQZ^/$.R>/TQH&]
M!7.12_IJG'MYC$&7*L;TN4W]-=7=-5RT@-Q',CR9N1-M%1QDJX'31.;U=]YH
MQKM5UXBP8K$%&AQPQ(XT\!@CC:$3$_,T;$3Z.*.J#X\V3C.2,ONURBND6E+8
M-9`FP^UF0HQ@$,-72D73<GAQBDR3<5L@=7D&8Y!<5U?7&JJEJY94-K'5F.P1
MR3^G0(BMUYOW/\>2\557[>PZ'&^Q--E!O95CEB9)C]A+[)B6./V,2R>0B=&-
MH6(=4`5R,553:NONWC[9<.KQ;(K["&VUS=TEDEG;QZF@J>\LL9.-X:J4^0>*
M\9FJU6#(O)[533B=9]+&K:CG9@F7!/;2<I;>5!2=NZ1%B0(5D+'YA1O!K'D&
M9J/7SL(B(G%M[7.R3%TQ49B%QZ6E=:+>/ZN4"R!J71'2>T;VS%*S[ECE*YS5
M56Z<_=SHW,"/_P!1SX,6%U02'>FIB>G<)*V_K>[T\FWP^/&2$@V^/%PC)LJL
M\QF`D0K!^3BL+6&(4FN`=)#:UL+NHXWH16N>C$5NWGN2\RS#LDQJG%D>-U>.
MS77%-86L^`VO/.+WE8P%C!A*?^F<NMO9JG-.(D2=DM\VBI,0'BM*&DM9U+8G
M[^=/M,JEW<B(]K90[R?,34',?38B.UTU7#JS,K"JR2KQ/%<MQ0:&@N=+?&N)
M`?0)T9QVN9#L:.$)!M(S1S5:U6+Q[3U-SD$&?:>W>6T][/LT!(1+B!2Q;:!%
M"QCE5XYSHDT2/<]51SF.7X_4?A]8?6A56!Y![A91,^\=(AT]41(T$%>!GEDS
M)T@1_*Y4T:'EX\B99DM*'",9.*IDTMY9Y+1SX-I'N"D"!"DA&_Y9,"5!M((W
MRN*B;E5':6.10LNH9-)4'[:RLQ6`%BPY"N:P8BOW<GG<]$%_K=4V:Z\#RL^6
MT@L>-)="%9NF,0))K'.:^&UGZ]9@U8NX6W>U$5533C-;P8:.=%H!XM^&R1\H
MA27Y*7+8(YU<XT(($/5!2,YQVZN*Z1%$\C-$XOY]W985%I\:KZ$T_):/+X]M
M5&GV<<JSHW:%B1)U8.),%T@=;5\K7RM1>7!+0,FHL<.'A-GF'X@A9#7]])?6
M6S*A]5"Q^0@#'<:61H6G<<;$E.:!41RZ\1+"IOZ_631KD)($B9#;80:P;G"E
MFG@%(,P*0)#'".J.<P9&JFO$7-+">DRBGEKAUQJPD,[K'U(C$`6"LB5%`<3`
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M7<_1".V[=>(2V"X6$;L?G9%=RJC,0R7XV$1F=K`LZJ9#C3$.V,Y5DFW($3DT
MYZ\J3\/VF.W5%8%MP65TW)(D,E46JA=\K!51@+)LU(%%5=KF;&>;FG$=:*Y`
MR=*-."*EG2(([A>P5_5)VD:7+3IO"SJL\VJB77EQ9YJMI&GT%6.4XLJM/%D=
M<T0K@%AQ7/.&.28LEO31BO;Y^6O%%D$S+Z:L@Y$/?7-GSHS)&]G3[D!A@+(:
M,L$A$8==RL&_DKN!2(Y1GCG&PP#A>TH3!*U'B*(K%5A!D8NK7)R5/J)4Z0[:
M"''-*,Y>6@@#<5Z__5;Q@HX>%$MLESZON,@JZ0-U74P8V/U\I6Q7EL+@C1R;
M63"<PG0&G\[FUJ:\1X&0Y/1T%P7T\9Z:QM(;)\*39!ZH`21L*]&)Y512?JN7
MS>'$7%YV25$:_F]%(U466-LI[I.O:C5-=HBS-/N6O5'%_01>,@KZNYQVWRK'
MX1ILG')&10Z949&VODI)LI`I$:'VP55Y-4<K$3FB<6&.QOP<H*;&06LSUG+Q
M4\FROK".8L''Z:2^$>N^Z<@>N4RMT$;>C>2(Z'42[FB!E\^I%8Q,8)=1FF,<
M\3N0Q.^V*%K3N\HR.:G4;YFM5.,9@9'85M)9Y%C3LC5[;RJGX_7,14:*&6^0
MT7N"S'[NW>,"L*C'>&G&/9+E=MCV,/R%LYT:(+(HE[%=V$P\8[HEI""$<X`&
MB1QB-&U@5=M<O+B#CQ,EITNK-D4D&O28-YI#)[5?`5JL5PT[]B:@1513)\FO
M%)[?V,_H7U]%=(A[B0VQ&$<<4:%"D.)+9);.M3$TC,:)_4V.YIQ+QRERJDLK
MR#U4DUD2<$LEJQUTD=-J+H?MU_6=/=L^.GU$J9"B0I#LO]J)572>J]=M3(R#
M&[@LM]58%CA,\4>57VK7JNUR[6/T1=-.,]MOPY28?6Y#:^WX8.`TUQ,R"D]6
MC93#[Z[.Q*Z#&KX\QKV,Z,87ZI';O!-<IR>5&IL<O+3*_;R]A8W49#*:$\/`
MZ^Q@%:3)`58G1+"U]34@"=J[H.CBW>&J8MEE%CT,EU1YGE.2V6,W^<R+8EV3
M**.NIRVQ<E?1-#%MHKZ_>UO0*W8]R[]SE3CW8ZH<:B6&>PO:KT^+%F2/3H,[
M$X]0V]"USX"$##&2*5D5=JN>/35&Z\9C?TS*-[9&4^U>5451(E$BQK;\"U$B
M#95-FK(;QP6RCR-X7Z%;O&U7(G$B\N(..T);7VHSK"Y-?"L3V0(%MD=TLNK(
MXWIL7O&LB;7RC-8W61NVM5-%X]IZT<>-C^:/W^TD\%1)6V'8XI>P>A;6!3"A
MQ^D,(ZY9;F[5Z745%>]?$N&8T""V5`'0>CQ9;^A$<E#80)*1>OTS+'ZT:(YB
M.VKS7GRXS@,.AQ/M/=:@Q2NM#R[LBEP6135X(<R.$;*C_P#D,&.HU?#Z7;;"
M^94XA0NH\W9Q(\7JD74A>@)HNH]?BY^W7ZGVERA@E?#21D>*R3*URQX4N]K4
M)5&E.;S8$TJ'TU7\_'N#F1\:Q_"(C\"RBNNX6)7<NT!G%C*&U\*U?4+65T:N
M[7:Y=7;Y#GN_P\=S.C8]B*)[20,+HFUMC*DCNR&D0;5LVW&RMB&KXC&QT9T=
M"O8]RKS3B98-IV1<J%<X7:.CY!GLO*8N3BQ$A',@2#.I(HZN,B/_`*,J]9R?
MI(WBUR2XK,;IRV_MGDN*>DP[0UBR-:6DMYH"R9;JR*R4J,5.L=K&^;P:O$*O
M`>F@O'[-"PB209B],^0@LXT_20T<5KI%5(8#8]Z^?G\O'MQ?9!0XQCPL0E6(
MIE=76Y;0IX1J!*H1E+Z7#`17R$\@?_1#R5SEX!I$KJ_*\.SLQ\*LZN22R6]'
ME<V3`*,\!E>)\1[HUELV/4B)T]VJ(G"^W$)XF'_")J9II'WHO4I$1ZFD%<B:
MN:^P*YV[37GKQ#LXN+8C-ESO;-GMI8TTW(WMBT_9_=BR$$AM(0<P-FQ=\F,U
MK7ZHB;W>/&-8N67WQ:.HAUY9?/0Y0#1"/9NT=T]^NW7GMT^HOZ@3MI+.GL8(
MW?823%*)G_VG<8-41,'QFU-!QMM#ZG<7DS'\BP7*:4CZB1/"Z/633FC@+`:_
MI#()Y%1-45NG'NEAE;`I<BDVV%>WV+7F49#,D0CQ#-J3ADWD1O83'6?WH7$5
MG485#(-_F77BU9(#(R7&KJQQ.R9+3.9V.)#/C=;6P$-=4HZBP]4.$M>AHZC)
M_P"15;\W'N'[?"J\5-69!99G=5N6R+>0VRF'R8I9$6-)K6U;W1I@2%Z<B2IG
M(X*;6M^/'N(^.RDWY/[9XUBE2XQG(X=W4I)26:0O9N4`%0C=I&[G+IX<9=&B
M5>-6U)F[<?DRKZ?;'%94KZC'8U-(@MKTK#.L7-)&W0GH43`;M5U\./9R4M;0
M6[<7P^PPW*V/L>AVC;$T-_JT!2UIO56Q&!?H%4"YRJB;FHJN3#T<QMOZ?B.4
M8A?4]-F<O%EZ5SEUCD$>3'L?2)8YT*3$EH&6![&+Y6JF_;QB4K%(8<7JH47$
MX>62F9A)NZV^IJ*H9$-4R,=G44=YK>(1.A#L&D#H%$>K&N78F$Y=30JZ9!@U
M5[CMXX\_TZ?6Q[HD#I7<!>REI./6L`1S!:C<K]$1R:JYOMC"OZ_&ZRH]I19&
MR+=T]D65/RM]W%DP@[(#JZ*M-'4<E2S$(4JG*G+37E]0MQ*ILAN8HW$[EN.U
MJ69X<<,<LDTV6-3QT#"$,*[GZ\ETXCVA6V&*PYZ1'U!,R'"Q_P!=#-"T\>12
M]>>1+`#V/;S9]J<,A'M*X,PK^F*(6;&')(10/DHQ@'D0KW]L-Q-$3Y&JOAQ(
M-#OZ26&(-Y998UK!..*(3E80LAXCN:$8WM5%5VB(J<4EE.R"N6OR&X!15,V'
M('.B29Y^JFG<1'%$R.%0JA2JO3$OS*FO$&=>6$>*"RL:^MA[I,0:F+82@14.
MU9,@#%B1$D(4[T7[L**[\W%-<,E3YL>^N/1H+*Z%WQ&F]42H[F:6.9\*OANE
M/;L<8K'$:Y-K57EP+!9,)X33<:7)*JQZR.#.''G+!LH+@J)B@DPE>)_)S]["
M_#1?K"VBU%Y=H)XV+`QZ!ZE9/ZBZ=0<7JAW#'XN7=R3@]IVUUC-,)$Z-WF$6
M'0U$XW7+')%@3S6!`R)4<@5WLY;>(ZFMZL*2TCK$4L^(/NDEOZ<58^XJ=9))
M.0]NN]?#@U?&NZB1/C.(R1"!90S2P/"FXS31AF<83A)\R*B:<2,AF9#6FJ(D
MX%;(E5TD5F@ITDK0CBN;!>=R&W/\S?%K>:\N#93:V`&TXAB>PXCQG=VIWM8$
M<-2'$*04JNY(CN?%E:T5=D.7CJ[F72R@8G!B7!D-!A,GR)BE;8"@`KNW=Y"&
M,/K.:J#1R\>WLJNBR7T?N(6Q@5UG(<D<T"X@@?(95SH&POWLE`D:CVE5N]OQ
M1=?J3VRU-W=H!X&K7X]`]2M'H8S!*043J@W"!NWD7=Y6(J\$M>UNL9IF[F@N
M\OBPZ&HG''(?%+$@SS6!`R)0C"<CF>*;5^S@"FN*L22F1R1>K81&=R.61@8K
MP;BIUF23$:T:MUWN<B)X\'AQ+RGE2XSC,DQ8]E"/(COC_P#$,.`9G$$X'Z:.
M1-OQXD93-R&N-1Q988)IM9(%:L28<PPLC-2`Z0YYD<1%<U.;6\UY)Q"A.NZA
MLVR9U:Z(ME#258#U5.I"`INK*9JGBQ%3B'"R"S#%DS8EE.&'N(32#C5D"3.>
M4HY$H!$25VRA!HB]4[D8GVIBV-1B6$FQRV$V=7O!!<2OCC?7%LV"FV:/[!);
MHP'?=!>9[53S(B:+PV5<VE=4QG$039%G-C0`.*[Y1M+*((:D=IX:Z\)(G753
M"CN`.4T\NQAQPK%,08124*8S&*`I3,:U_P`JN<B?'B7:SYT'>*KGV<"O=/B1
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M[=S8_NW59A84.6Q_;R-9SZ1:X$/(!55=CQ4QN#&M3!"AHSGC21VR/>WDWC`P
MXZ"#"949`RSL8LRKIK(5>")33RPT04N=%"1C;`0HJ@%N83N$<Y6L%KQ@V"5F
M(KD=K#L<=O[@\"?BM&"L-46L6S-4F29;A2RD[6*-)(U<U^FY=./;#JUI:FQH
M\"R*^R&"\\>8^L2[+75\2KDS(+RQ"E[N(716/<Q_356\N?UCT3Q5CD3^547C
M`,<=B099X=UE;K]HX6"Y!=54>T),=6%J5RF1)Q\`IJE:DDS=YAB\$1>,&M,U
MQF*^+A_M?8USR3)599-JK]EW(G`;&%"E3#]<4)=PS1V.Z>OD5'<N)5#!4:YG
MD'M[E\##I4`V..CPPEMGSK%<BD5LLF11;"Q:Y`"/8C&1J/5KTUUXRI4Q#(GY
M&6KQ".*MR8'MK"@'-CT\198,=CXBK(O76&UX4ERD"XXG;7*O%+CN.TD7&'EF
MXZZ10G@41QTD"/-`>0UHA315HO3VCW:1W/5Z:L:G/B50X]3AFVV7Y7=2<D/3
M?A2BL:/'I,@C'>GI*N!U<B=:1D^Y7JO[-K]NU53E[`X;"Q.3B,J!G+)H:*19
MUUS/@TV.P94B?:R9M3)EQS=UU45[]_S$Y_9]29C>;G"(UJ?:JL5$\>7CQ@&-
MNQ0,PT*^RLM^,,+!,ANZN-9S+<M86J3+#R,;$*9W(TD%17G$-W)-=>,)L,WQ
MF*^-A_M3D-:8DN166J5N0KE-A8PT`&))EF(9M.7<PHF.:/71%1_+B9C]<@RY
MM?>U=M!QH]:?%BP05OJ8K"SCY!+JI9;>):W"D[89[-HW*PCF/;NWKQG30XKD
M/XCGQ\0[2MR@'MO71C2L<E:R$QZ)AB,K@G'7*2,R49`/D#+L7EKIBU_BOM_*
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MCS10T=5M0A]XB/<1`JP>Y7IQ:U&,5()MYE^:9`>YDU#<5H+&AQD]G.8R76]>
MY'6%L+>O098[>JOI_65FFYNJ?_+[@T'$Y6&R:O/B78:279UEO+!1XO3V\BVL
M94^HD28;ULY%HUSUWIJ8NBIJY$^J=U-O3VKOWZ;-FGFW:\MNGCP_\/>C]IU5
MZOHW9=OU]$W;^Q^[ZNGCKS^A)Z79^I="/WG3Z/?=MJ7M.YV_?]#=OZ>[E\VG
MQ^OG>C>B=YU/^9^F=CW/5U7_`([M?O>INU_6<_H1^KV7J?1-VN_H=]V^K>X[
M?=_2.CKIOV\OM^LF^A^B];J_\Q]*['J=?5W_`!O:>;J[M?GY_5!W]GZEVY^W
MW='ONTWA[GHZ_?\`;]39OT\NNW7X?0__V@`(`0$#`3\A\--Y-0@,!!<50,DL
MX6,FP%0F*N'NC:/*0C\^E4H,/X@`U;($23-.PZ'&I?\`<R3*'RK=U`B!0LZ2
M]`;DEY1),+`(AA&E.!(A!#<"$"UJ3*JG(;U9C$5,+YA[%>9GLG=W2].]`Y\;
M:LI(.J_-'R.R:+ADH^0(;8`GY_(F`(9E74(N3$1$K;MU?FC_`/%%`*.)P2<D
M;D3]"4JB2AU,CB]0-P:..KNK8=[J9B50V[_4)`[<QE4G;RQC&'S%/DS#"QY?
M/H8D8@HF66[,00ZA3JJ++O6<=@I`8!S:%P,0'(FN@=%H0DW7(ZDAA:2#D:+D
M%,$JX@KM@CJD=5&Q"#YI`LQ<<J,2L@DN@8GDK?X8K'DE<4.B@`D=:C>&9WM(
MB)I")7;'\I\8?#>D!+T"S#(`34D#W%-E_`5^B$,!#D3B$PE:7EK7FIDJ5N(%
M6&42\&F?W"/1(?*K_0=9918DDY3E[_V2LC)<6S$@5,2J8MN1+4WF*EOGA>\M
M?4<<NPE,S4^O!83B'UCRNF=<8!:=A"4Q,&\"*3];3P6@4`?$3"5I>[%;5:B-
M"D1<+R#<2U%*:Q"]A-!8E(8^9E\.#6#"I(&1`:QRWPM\:^P`K7V7.(R)9%TK
M#"0/$]_#D.0"8H?YQYQ@FJ7>AR!4W%B?"J7=X8I;F("A0C(H@`:1U&+95DOY
M(J.&Q)?JP#0Y0"H4T`]0Z!!+"%#H_)D[[9399`8J5+=1ZM-,G+GE24)L5V^!
M.U*-K6ZG\QB)'&C13("W#Z%RX#L``F.@`"$&R)0AJP@5#%0H<JH\$-HG8`X*
M5,J0+;M`RW":R*R2A3.U0JCDF$:&"14,'@F%#<Z$1TQST-8)D6-:>#F0WX34
M&%"42"=CY,OBJR1.@PLUD(4K/+D#PD#1K"1@1((E*1)RH'3LF>:`HIEH@9+`
M0\H+!@U7R4X$;=V8T8%@JUUC'H+FRM)#<90GT"`:"(^14)GJ)/,P64`#EWE>
MPKO+):5E5J$R=H5<05!"C7KQMXNYM290!MZ2&FMX-G,GU<J%`*#A'VDF9F,E
MY4EN&;K873EJB]*VQ0E1:B!R:*E+YWA/E`4%6JG.E4A$:%P2+B+A:D;00G5`
MJR*2X$4U<QQM$"W)MV+'D@'K^"+WR&D!,424XSJL"XI;TWTZU!@G)8226$J(
M-`IEWEC!Y/E%)Z7.1S"+9A:`4#(M(Z$`RZJMSQEP(D.Q;]7Z9-L,]_3F$I2!
M';+<A@2$0C*+-S_DM@^_!?%KC[MFXVUNO`QIGZ6>6!RZLDJQ(0PL)0'1PVZX
M;O##W!8A)AOY"O#$]"%X0$PICJ+WZGE`%(%+R8-&2E&1>>%`)[F#TV55:\G*
M'EBD=Y4($K:O2+(&4VWB+JI78.U;49?NF`/CE[MKS(Z<-C)!:,O'XX"YV3/S
M3%6N^:]N<C9QT&N'>_C!,<5$L4`-)LUF&8=&U"90\ZE\U:L)XT[^IJS6\#;B
MP&A&'7?"&=#U$@V,?<:F)CD3-<)*H!RJ<+OZSQ!4`I>P;$D+CE;TP&;^60JO
M24D9*HZ#CP=`$`"QY9TT9W8P@;A6*&N;,-?Q3`-=!:(H[[?V6$()%6P+#BMD
M7N!$A8`A;J/9=$P+447*!22C+2(5WC'=EXQ9;0,7L0&5R(&H!SDC;-J-82,I
M6'M=JGQ2O`Q%(K0D1'81)`+XN]!Z@5YV6,2@5@N%75,1YQF)P4-VI`!18X.G
MF*#2247A&'-2M"]9EJY>8`#QZ+)A6L<,,<5)I218"7_V)72*@]?4O+Y)"!4$
M`[N9UNPC.?%'T(&R-'YI75BM0M5&M+>>;ON0RO\`.<%5E(B[_J0Q(FZ!JQ-2
M5_H5FTLFZ*V>C@"-C$1LJ!VL8]9U'OQ3$VA,B6S"(59;*BIE-[;Y&Z&15_7N
M9_A$8M[;&%*QRGL1Z`8G65[!;#/4/@,89JC!=4>6+MVWXY7R38)&#K*A>5Z9
M8Z.*!&LLN(PKY]F\Y,>$070K04<YLT$9L<Q;%,G.YSP05N>E+529,4$'K/9<
M`$-7S+"=SH-@$9*L*$4$2\68)(V)T@#YB)2!TJV"E@%9G1CO87;ZFB)_!\.A
M@U6LE+IY4?4WX@H]%C=4AZ`CW+84"J0E9;F5#2QFE5#<42H--X"5N?1_O)9#
M/TVSGG`K*`L:T*;=M)&P2L<J[^.C[2\FR4SM@"<U83Y259Z)UQFW(+,2=4B(
M>NQD:YN&WTIB04+-<4@OA5AM4AP=.E-%\U21)!`2!B:Q4TL"B6Q;X$91B]>0
MU4U;,Y%),LKBF"&.\?Q0'.I,A2JG44\*R@8P(LYFT&<\5'S<[>F)9M2GX\&*
MRLNY(U`BU3T&8(*(KX#6CJ<&!S03:1Z@CR,HL]#8,&!627SI-FXV1UI<(5`J
M!)^P3N"8I/XE,<+B!N:I!I4!62D29R:8X!1W!&(UPT-RA:II2\RA%M%PG"LD
M(8[$9#Z9+P\<T'D>@!P8REUU6BL?W0"LBSG8L-0D=?Z]12JE@"-#T#:O*9N%
MI%H6($;",W'AY%E_IO[QA!_0L620&%5/2JCV!/C;(FI-D'B32!."$4(VG)_4
MRG",&!"EW8I_?HF0I)8H>4`[;#A]Q=9CTS$C<;>6Q'>%_NT':>N*5DC>$K4&
M:)-S^'A,5414C*`)5T`EA,JS6?QW81/^``EF!:MA#!6/Y^0!2-#$B"UZTOPE
M:<9?*1"2><-B7KA4'*0U@>0UK=QAU\A=Y7+`6;#TD9BB9W@%S1+@7Z-!L2=-
M2%DAFU%---2N(@QMR#Q".6@9"ZH.]6Z$2(SPPMG/&C\!PJH@.8FP`HO5,EF(
MF%*S!(!\CC$\B)>5X*/=HU-`DY3@PJ\O^\S'D@YR<^RX=4?H2Q?,=:W85=1N
M9S0A[@,@!N5/`QU=`RBDHJM),RI;E`O1(T%(@RVR(0#)EHNW34Q8T"+_`&DC
MDI'9;I!:9L*DD>G,2,&S-,R0%<QO67I039WA"2X9U87*\B?.PLP#(DF3E182
MRY,3[@WAMX$;).0;BI+"7)S4G%!ZRZQH@9C*````"`+`&`-`\C#$:/"!<A`M
M88K`(YFV9I8H$;BA"'0.1,9J3?N'D.(EKD#0@"1"TY+!])S/U`T:#RK@CF'*
M/+/4M``$##3BR@2,H2`LA*[HPX@XP-''`0$>0KJTD+F@(DG$U*GS!`I@#(R6
M:AY=9I]$!A0*&ISG+,#_`+U001'X>`1[]-E$.!\&M3ALL6D`?G(53##)3;FV
M2?#-)?(.R>X_N8@FCLD@H[UA#9Q363<94<.HT+PJ0A!2'F"L#9-5$*74EU2R
M#$44@DU"R3`)4!=[(`L"R11L7`A-$J%/7<%IVU!0@DW<2%)BH\$$8?C>844B
M9BI.1%YL01\MBCDFR+.0#YZHEG\-<$<PZPG87P7T8A:M2/(.U!OU7W/5&74Y
M9!CT.Z?2+F2F<B?D3N`B&5%@K4G#-K.,"ENU;6]1I.=D&1)TH6]HV^1!J>&V
M(*NCN\$\4C>,K&WVX^&A(1<WX"\PHO$-C@V$7B+9I3A)&%15N!B7_`+@CF'6
M8^L+,&XLD&1!4$8LARI#*QEB%8%1BS%/;D<>YX,TD`,K3\P@S-.E*9,0=Y1#
M'&N:ZS6%P5#:!5(14O8<('4$`@"2`B4\RV2BM2R,D"A7_(>847QO7!',.MM?
MO8?<A:'>ZG]Y4RQR*/L24"H>276I?)D)*(W]2G[%(F"`5)F<!:S.(,;#A%")
MDI.@B+"]$#>K115-$D2%Z`KY:=M?=Y3-D?Y+S"B^-ZX(YAUDG+!$-]>%@S1<
M>BQ:%>V]!"TZK4@@O@H+%0!;PS^Z`(J76?\`PWF%%\;UP1S#K04.<=##^9JX
M:EP#3_\`,4HAE*H@\"JUAF<LU`@E7UK?'4D@JZ:(`Z"&>0$W\'KV3%:K*H("
M8(%0;.6U_,2TSB&-A3$$DN4`R#*H/_(D*(3IL\4!:TUN](>2XL)7_P`"?\"1
M^YB"$<U,]ZY,7.2FQGP:/4FL`&8%7@_!98^Z"1F_*N^"9,%U#"F3F?\`RERO
M&7>U3*Y`O>CD/ZF?=)R*,"D:#B1LCNS'$GJS+@QH<WA>!):UJ5:/1WEI-8@Q
M8<L-7YXA*NZ5Y.WJ^RXA+-(YI46%.#'FV2A-$S$P<Z%!O:)7-Y`I7!YB8&1/
MTD6:F9C,V^\1CP.Z227*O%2BCL!I(6>H%KY8IG5)KM(L]M":!''HUD[..W-!
M66#K;,,^4I*`[2BS!NHK@`FOC:[D?(4T]PW-1+F2-8H:H#WD<!P+UVV4;B^A
MT3A<I2K#%*EFAFGY(F?;!3&31WX([[2,6<L@U<*@8Y6$3LD8E71\EG!MNXP3
M;4V+MM(00)M,E!)W.C6AL*EI.%.73"U+(!(C?"]07&P7@^T7@@!F)-@F`BI;
M(9@HB@$B/1E/0$NK0IYA8/&0=.HEOZ7T^1H?)`%X8L5$2G$8;GE<;9RJT"\)
M(7SI0I*EFQJ1ZXU!:CKIV!AL0*90IPEQ&7K<;6R05`!7$C0C+FRJ7I1SG!!`
M.^9J.2ZW[LM7V(39U59*>(\VTX4/%KRKQI;ACS`Z4,3<&)]05K2&A)W_`#\<
M,-C.Z):@G6TV'>O39<<2K-LGA,<4N+R#G%8AO>IB="FGTJ!`D]QO%1$4%G<_
MB).K"6]M1;N,AAI9Z,H3-9T_*0V[F";\!->1?I?NTB:108.IM9T4V,6B@9D!
ME,JXXM\`"R($F/K9S.@<5M_.29W-4H8)B,N@S&9Y;D+)*Y<J@=%%\Q6I:2DI
MO=T"8XBD0-2I]/WB2!J@F)_"8WN57%*PJB]5BFGSIR>,].$;PT;UVLHO1>ET
M68NX39`E*P>UR2;_`-!+=J9CPY;+"3!*U&O:O:`<W4?5U85CR6NBJ&XM:#[_
M`$HR+$Y`$FE>-30/9,RB7QA$U#;<_OI!,$F(I.S3@4FAX`0\4F$H/B[.F!2F
MW@8W(,[H0;I--U&'I%DI8%[]6ZB0L$JAZ$%TCP&Y)6&'B-[3\3QP;04@3(`7
M((GN.UD.GENB'^RDH##==0\L#]UP"=\H`)AJ,E7'@)$%2747[[OY`"0H4WQ2
M.#W/AJV9<5*R-P@<0`,I[NTZF]U#0HK^@LO=Y[*AJ7\PDVQB6@'*,B_NMJ_Q
MYS30W?/$5#F81P9:5LX3W59I9JOH8!!A+I<A5%RC5!0J@,Y\:<\+4#-(RBG0
M^`SQ*>3K`,`?4W2"U#[[^'J-_`--7U\T!#!12\@)GG?N5-9S`#-)F!(/Q*F*
M%MF@ZZ?,D'_DPI<1Q"X:#6..,1H:!,<0`$B%D3T;CM.#HR%N+^VH)I,4$3(:
M7YN$E]C1JEC'9RPLJ#!W102#=E?#"UHK\UV<K%,=6%GK('#1J^K"#A("Q[LN
MG?6XS!2/:_+A@,N`2ZJ1)7(SE>%7U&BY#ER70P4Q^\Y*U_95",>@"I^P)LFU
MEJR85$%C'\U4@I09,?`LE=L729-)>,1TV88I2$T"!`3B<'$&B7IZV]D=\PI?
MT57%E'^!?-(((11E=-H=\D$4YL.!;HJ'[QD<F2K]/>@*B;C`&C#3BE(IQ-F$
M@2UGHA(<NFDDXEI]!63I$)P?0?F,OW6O>O?J:$8-:(J+RV/$1"%-`V2+N&'*
M*,9U,W`2LF:T;S+0>VSFC&135#%KCO652ZL93E`NV1Q=BK#-=%;4::AV,QT$
M@E++TZ-%8+*F`"O9GAIQ,JYOHP@,!FO:?(`0%TI32=XR#C#9.K>H$_R;ET?8
M&R5T/V!Q+'\.V(Q%3Y0P&T5,2@6TT:)WN6!XJPM4JZTM6%IDB(2B'8=*?21X
MW,!)OF`N241B(0U&@9EW9I_E%_;R*X&V"!(`G$1!('T+-S"F1$0S8J'P"T;,
MJ&<%=(C6]6@VDGL2`J/5F,MSOMH11(`C,D&$_(_]A+-CFXJB9A.XP5<+H_SJ
M$*HBE"TC_0SLX31BA)"(1\!B2V&Q(/7\78@`K0O)7-!Q#YP:2*9U!S[6X(&U
M`VQ)]$U:"7,3?4L01>H,SBAK0%372!FB^\3V%V)0.DEIGXMNE;P,D%DI@"A(
M@@?4\`<)1_-HAB>RI!&R?Y0X2)5$7%*R<3[EE`;.'.QO4&($AY58[+)5!3!9
M7>NGE"*"+$B22G*FT&;69TBZV9#3',4(V$_7*,E"$D!:V3DO`GQ'H71J8M;4
M0G\VV$B2V3FKR``DL)$]%@+^:J4K:6>1%6H*S:40R4YFH-K0!1^:"H2"@HB1
MURE`_#(-BA,:U!*XT3/(1K%O&[);/B_BLS^T&S36_E1HN$[(5MY#<I%0PZ]@
M45(H,D4,^*JBH5(PLJ!3PC:VU7,`*.:(FFP*46,+9!>B.&C0`5DA2DH9#X$<
M)2PQ]`OU"%V91_WD@2T/YF;">LQ60-85T&ORLR-$L-3^9[US/G`^E6W.\5;Y
MW`M-1<WXP#H?!,(JN!8:Y0C=VYH*)K3%]R&QP3WJ!#2*6)""6`E:0OBKZ@$B
M6Z9JR0)VDXF:G"GSB^WGQ1D`FJ,UX!F+<`H_#2C-E/152)U0G%G*OFHRM1"<
M(I8S5>QY@@+:B^C*2Y@$-)0)6M$[F[SVNVGF02,@9%^,^_R%XLT%TV8U5%FJ
MIXJ6IAJD.:QJ1_LNA*&Q<6ZL?;$'+;Q$>(==?#MBTZB`DC9H<?P>?OAQF0W&
M"2)?X#6&8@4!D&-H=HH]BL*-%5;+2;\-<S8T)J2-1V1Q4S#X>CP_G[BGI$_V
M(8/=VZT5Q<U"T^QCR<(TF/F7ZZXN'_[P)\G%"V#Y4QL]/KC6O]T*O^N\\_2X
M^WI_W]/(_]H`"`$"`P$_(?`@E?!=AE!JP6I>'6Y+S)6,F9H40V`B61_,6&T@
M6'H/;!+(;!X!)76$`=J*42B#B!@+22`('H6"E8"))R!;WYT_ON=PV>37T)H&
MNLC<(8Y$WJYU*56039;Q&Z_DKD/`!+&_2HDEL_L1J5^5L9G?E+.I"C9,#M*;
M[6I92A]BD&1&XCJ/F!=,C-L],.HG`ET`8!\I]&J;`58:@&ZT`2^P#L-:T)=$
MPW>R/UYH434`(FN;P7X^OTJ/,SX&SAY=*M7D3GYH$-A6^QYOU7+^R`?H*>7S
M'W>_3E7T;J1&'/X\G7,!V0C^CWVK+BV?TYG<DJ)F7.[EY]=Q7*L<!Y9-U"')
MO#:H>TU=AOU#],)O)'##N'[!ET#K`J:4=ST-@+!@+4A1+573;IGWA+(5?RW=
MN:=?IUH89<!3#R07H>4LN;)SI9[3LTA;-#T_3]5:SQ^1]G)RK0XVFGKU^G3R
MAW*1TW7D:UBE+OR+C%3.ZAH?WV6KW5.?*K#85E%/XXQ2'QLG,K!VPZ)HG'*H
MYKLMG^M.=M2@NE*0OEY@OET.89]@K)2)S&K2("TC8.7R&ZJ?%HI[8`E/(+TJ
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M]/M5VPB\:M3=:/B#KOSH+_,_E>VARYTLLN?2&4DK\`!*C8!5L%.+E,B!EO5!
M>XC>P?$$PZ&VZM@YK0HN(R)[BD\L^G&0N8''A.]-U"?.X\FEJ.;SR<DR%Q@:
M5*MUT6SV'0,6A5#>7?0G6(TFB:C4Y0G/5):,DDE?O[7?*'JM60D/MR+M.[=<
M1%_[W^SH:?-%K%[:/ZZ?.E`5"@/1_P"'#2*\JG30F5QJ5$E:@[[>_7G6.T0[
MZE]G.GD<B[&6K(Y!7.4!I_K1SO4"'@S2_&=Z:YWIH6QL:K)R$\D3I4N$QQ,I
M&8%V2T:U)DLH[?L^W.F!@63,06>5[>]0PL>8A*?(^*B?)W(W?H3W]-`9%4)W
M3YMWZW.8T9*(HV1..FK_`"N$[^)O:X9LK)*M_9[DE&E+8C^[1K5Z+-;\,<O3
MO39CF?VHY<JN[_97=OU7`<FE"&?V*AL<OFBP);G2*3VQ_?4@I/M^E]@5)!E+
M:DZ7DTIA*0-(E=UJW?ZMCVR\XVJ"2%-C@CD:E(V$^\'J"#9QX<)WHQ"XIUM^
MEI,>E?PS9X0,`]9W?[*[M^JX#DUQ?=62I8C3U<@,9Z40&(N,KU66:L!>_@>V
M7XUK_BZ_[I'E%3+G&\W[>MPG>G%]G@'X9L_`[O\`97=OU7`<FN+[JR>M<>S[
M.*.DT,\O!QL5;`,.>W^M442ADA/*:"/ZK<1G,T.0O7_4<V];A.].+[/`/?J+
MOR^T1^!W?[*[M^JX#DUQ?=63U=<_?ZI;[L_P]J4.'O%2-")J.2I%0YYSQ^%)
M7T1U?XI8Y@YDCY3;WH%>5=1'^^KPG>G%]G@'XKL_@=W^RN[?JN`Y-<7W5D]7
M3'W^_:AB-=)Z#H?+1&A;MET"0!JVJ'9Z4@I"Y$#S6DDV1@8@"0<R<99Y4<*,
MDO%R^RP@HHA=$:5`PC!OZO"=Z<7V>`?BNS^!W?[*[M^JX#DUQ?=63_`\)WIQ
M?9X!^*[/X'=_LKNWZK@.37%]U9/\"#"<2%=5HDYD@L,@4:H_Q0HH3`$B",Q!
M>;\B""026223:2&!A-@&7`"+%E%6!`J_@7F2V+LM8^]:*5B@P-54+[&=XH,,
M,UALQSHN20)*4C(PUGVG_P""G__:``@!`P,!/R'PB-CB<78K6(")+<)ATA-Y
MS637H$P.O9DT]`>)9(#2F0RUO;$33!-@-VZ$G4V7OGT58B`@TWDK!!:'/^/H
M2[#0!AV)MUM5GR<Z).>GQ^3-HLUJ`</$E%.6PY6GO^&P2K:%Q6^[^FT-%IP:
M%A'3S<MT;?\`T>=M$HY4PG0.+&K8JPF>@<>[EYUQ\_'F'FH\UL;?]G\-$>3&
MYQBD)D)/,</Z+_3[KJF_*UU0.38J5%ZS<_'C/^DZ_JC@.1_/>K6K7-FIR>S#
MDI.9#W'5<QLU)7E8:.GNQT'5Y;0N?S+UT.?*:MAD#C5UK54W'Q\,]!7MG<W_
M`%6F6HB;"^544/&I79-,.;6YQFKFW_9_#]^5HH#@K+&X-C0JQ%N//A:K<9U=
M>=,>2/QRN)13`]G:H4=G!_M:PF_QG3IR0T.D@D<(TYD?86[X'V=?$V%8`95P
M4(B8GG;.6CW=:Y1E\;UN/<Z5[O5QJT9MFO\`HEYD!#BFA]E;I:C?>7/;HT]&
M$OR:N18^&_\`?)<B]\M_Y1OF%RVZM+"$%`4^I5^E_);W!_:$D+JO8^Y<OY7,
M<CIZ=>_H6K)F7Q+T<<G.*10@)TXLZ^$1:5CH:^[')?4KDEQJF!U[$NE+OV;8
M.0[4&S:N[6]7/+CC3T!E9I-8J%I,5"@LQY<+TD=SYY>]8>GLZGA=*W=M_3]4
M94I!0_-E;O&*3D\5?G'TUFKL'%@U6Q1AK7")TP3KCGXQ%<7N^U%+*,F'X?3C
MOVX1_*8YE"U#@<8=3J-6NC;Y'V<G+G0&RYS2P]5;H\BLLF#8CN4GE-<ATH`^
M@*F.R(.Y_38BO^<1QFMX.*<9GH[9:%4F:^`$IY/U6_L^JR$:$V=&K:2BW72E
M1E)6K;V;<&6I=O7P':(O3*A<+DQ_$5&=:=+9]J*P$W?=%:`0J-<'\K'TU-,"
MGZ^_3&+F:.?W.?/^TM/#L5W]/=^"G<>W5B<<.],7PIT\:>G,U56)IKL5=JKZ
M_P!UVS[J,<HK(4RN?J38Q(=%A[4(-;E]GKCTFC%H5>_@XX:ZN_,:_P`<ZO35
M!]OZ];OZ6D>OV5WVGCV[PEB-/6[%7:J^O]UV_P"Z,>LD"9FI"2)78/8L5_R/
M*V(?5)`R4^"%HYL^MW]/#MZ[[1Q[=^!V*NU5]?[KM_W1CUN!1_U33&*E%%3N
M)#K`KUJ*L(CW8K2'2<MSV:O+/UN_IX=O7?:.#F2/P.Q5VJOK_==O^Z,>JHYE
MHGC"A""'54=`W^%2\)<?9O\`:HTS/[#^I2EKCR`^DS2*AS5L</5[^GAV]=]H
M[G^!V*NU5]?[KM_W1CU1&8IT7%O@_M'IA[:;B\H$_-33V8((FTV:N/>ECH$8
MTF/NG-1`'==O:M"Z93+U>_IX=O7?:.Y_@=BKM5?7^Z[?]T8_P/?T\.WKOM'<
M_P`#L5=JKZ_W7;_NC'^!5N+A64LA>&<Z=+@R&(!@:!8E7:Q%7W2&+W(V:XOK
M'Q0S\4&!JJA[&9_`W-@-^5225-XN[$?=(G!6ZU`QQ633;?\`^"G_V@`,`P$`
M`A$#$0``$`"D```$P``!%P``):`(())!(````!?G```"L``!9<``-Z*!)((!
M()(!(!7J@``550`&50`!8LT!!(!``((((`:P.!*,@```7#`&JSP``!``)`!`
M``$'1QU[8``!69!*I&P```!S!.(```)*/G-.0``!#,$1,<`````LO8(````0
M@9.4````(**R/0`)```-4C(````/IM(``)(`!,*VS``((!`0%P!`````(#``
M``````*WP``(``(4]M``````(#(```````*WP`````%+P0P`````("``````
M``*WP`````+3J80`````("````````*WP```````(```````("````````*W
MP```````````````/9```````!3-@```````````````)!````````((````
M`````````````````````````````````````(!((``))(!)))(!!(!``(`!
M)!!(`!`!)`!()`!!(!``!`!```((!`````!!`(`!````!)()!(```)!(!))`
M````!!!)````)!!!`(```)`!))(````(`)!`````!!)!`````(!(`(!(````
M````````!!`(`````(``(((`````(````````````````!```````/_:``@!
M`0,!/Q#PCPZ(*@V`Z8R8;TC(0D)6$]O##9N,A+M(W\^:+S-D2MFY@_!!LP9N
MF2JVU]&U=YOL\FCG@)Z'7%';"VWF<B@(]1TW@6/&%Q0I(-&JYZQ3A3SQ2H1,
MN/HG8&"`H&=R8Q.5BWFPYJ2P.\BUQ'&$,>C\+AH^(%LS&0L[;Z3=[414V57'
M4S$.7T1X><'VQ54R,>HYGY'N=@S@0$H+>FT%2SRJBIIG)T?Y[%.'X/C<6)I>
MN$,1#KS15K:&7!<(4DV2(YKV.H"E<K-FKV?P=F]$6\7"CXMN4LE"@BY$6?@/
MDI@UQ[-;)H](A[>:Z6'(`)+5E$?4715H3C54G=:J.>Z$+%\K6^#)"0*+I?&_
M?&ZDRN9T+,WG:T2#CX,C2[;">C[+F-"2QVJIJO1-"@B5.E!2`&-3@@F>S)Q0
M5PVCJFX68A(/D:]QWF8.IA).B.3ZDD,>-"Q7$(S:DPE#U4@Z5_Q$E1(NH?19
M4/:)>$5(@-`$2D08'6?*%^/7"4A1=<-D0E\3K^GN^D#D6!,7`Z]M6E(%Y6+\
M,BFE0*E!<UYH8"_.G`O,`,VQ6>(VH84`#@6!80!]*T#'7.98"[O]B#0LU)$7
MD,4@2NO^D6\/620=)\!DSK,#T'+FD-"RIHY<:"#:)4EXSV<,F(244IM4V+6B
M&.)QHAN#3`6'`%X*MQ@K/\:Q7L@*10D\?5,&3?)U"#R/$10@ZD!E0J&[$7M+
M3_A98+1AK8,LM*XX"/X@S5R(B(TM99+:5?$AALT!>Z!<V*!?`CL/6H6L]*))
M:BAEG+PJX]4M$%'^36Z!%#$)J8-+H8M18O8*!JQC'U,9YZV@9OH-D@/@@%0"
MVH!S'$;B`45.^5'0@\>2G2)`BVAKY.>VE\"<)U]ZV68'T`A`!#-+#H,NM4@:
M",-X`<(FH34V4Y^HV,L<BCY&ILM;-*=309[/9Q*@BUY.>86IKU28C:S`!JT2
MIU(-["<%I8:Y7<:$&MH/1^2592,H+%+73$`\K*RI1WHWT;(#20=,Q;B(&`C&
ME#'QL31<LNM!5!<LZ;-QT"22"P;RICN-%<&21TMC@S42_,Y%Y+`3[!O!LC-@
M$4#K!'4!6UY3>\K>]?Q@'K'6N7=0[4NZ9<1%-3.LHM07A#/8`""P5+RY:B,!
M=9JV#P)L<'+I`()DG`TY8@0:C4'T0:D)US/'XH?@I4C0%4]L2=E/C/Y<B&!Q
M_P#:;JHF[JX0KU!M&=O.+B>\UJK9N&1]$7N!6$/)!5:T_P#)N".`9$BY4L5)
MF$#4$\_`BC4!5+G@"_L<O-M1PI`ZQSQZE1Y^6H4@/L3'=8*+E:]D(?2_1Y^*
MIQ+8L]9S7#1*3$TI9QTT'"+K[2/]),DT51!5+I%<DW:5_3T&$Z>\9@0'S"-Q
M#",QGR&R9`LOB9QRR&T*AHR&`-49>H!K*@WYZ,-$H;R[VVFMT&F(VQ$@#(7Q
M!M:`6F-:&0*):[4RT*:1B5`UTN[&AX"76HBT1```0>4E<FD8CYBZF-60KZ,)
M)`A"7R=0;;HO;7L-+25"1^FDN2/#EB4X]5]$@C9HG,3)3J,:;4N=)'NA/"?L
M`99)C6]D2X`@HGN(*>4AD@+291K&M8J#);59"_O_`)P1*`*KK';(Q4P)0V35
M2$Q9Z99`ZO$T59=\CLJRK=BY6_F)E",`Y0R((0M1VC>.<0Q<2$`%O&,KONL%
M1,BP6-Z@C<AOKH>R6A"BQJ*PF.6"5*A2%6YWYYZS2U!MXP4B@&S4B,#6K'LV
M(,')6KDE5\PZ:A\H'DX5_D?IK60!.&2G4!':+>)11^W.8S>U@O)]0+7U#,._
M1S+1FP4*>'OP=>SP-A=6`<D:I6$O0%E@6"@Q7(M&>\*M"RJ;89B$#S`/T6I8
MBM<*AM$U*M=.]`19<RUASH&BSJU/S/<5H%7F]NSCBN*6B=KYI)^;8LI$9B;G
M0)V,$768$/0"84AV#;,=!C8V*FRMV&ZZ!:D,*1P*`>2$/:8!):4-S^EQHE#6
M%)T'\U3,J6`*L59#%!-V^:['(E?)Q2@*%=6#7%4/M0?XMCCFA8ZDT/#C4(($
M$K5,AV#49J)-TR$(!47\QN0;ID1OI.U%CG9W#[KKM>`FIG$;]3PY%3:"!W1-
MH>D5`KDE%!+,YFFVGG:A(B%!,G)TA0=8]@FWV/*%^#/2Y'40R7584`APE)4N
M/A7CS`7EFKBMW*@`LI6G:YDRH[@W-@PW9@)M^K[_`#\'J*-8)8SAF'F"JUQ$
M3IUS#T:.H4$EOO(49C3A`+2FS`@6Y!/T;T?XLRH97HWE2KY"IS)=]4V;5:*?
M$C'R_P!!.U.`0`(`@2$1LB5%HF*[0=L7J8"E#]<=35TLEB!FOLT"(?6AIL7(
M5W&@(Z39"4@B//);Z$KC)&TD6V78L1-`$Y07EJP22`2FJ3K3<H)BO8-SLP5I
MS(@E3:.2'DPJ`H]\%`4382E$`C2]HB!<A4F,^F"+'#0*DECBOJ-VPF<M!;\M
ME$.5J4U&?]949+4WCSC\48?U.04=?9XL;3)+3FH`FGE9RY)G&0!?3D=5HO/4
M)5]T6&YA4G0+.-61QE0BN?+;1"3,-T'4QA^;R"\;LE5?(_'MD0W+==LGMA).
MHG"DJ(ALO+]$AVSFI6\L93B0O(T:T3_VD8+,JA4V.:SC@($'*"+^2UK-U)*C
M.5W1J1FX;],$T$4%.X8RO$3NP,%@3T$M6&1GF&06\42!Q888&&:&S`JWS&]T
MD!#58`1O!E">.V^I0BE]@>&G;'!(^6?I$B0*7`$@E(\T*'Q9!0CH>5RK%18Y
M'LP7&W?,/&*2N`+BK8'+$;N$2%MLA$:B,^K"EN=/5Q48P$$(<F;EC<[N)D@H
M@'A-M$M*-J,5@?<:59F.R9.B:);(9JEL2X2GIR1U5@"]XUX-8[)52D5':52+
M59+;P0XDA8%EA*.X'(44+4F!@*64&TC(F$4V`<I5S@X1B`!`$0AB.L21)>QF
M,`F<,`(`@`0!CR2;P@&MEI!R$PT\:""$ENX(PEB5BAC"9=!,!(SRI0L56\HT
MII(!3XA`])>S]@I@\F)$@#!_T@J'FLQ0(I2AP9=?`G_4(A#]AG^%_P"UX`!Y
M'&L^UZ!`8!)8*>C=T,LQF8#(`,4#8S1Y5Q3>)^8O19AL#!2/`Q;N:-_S>+&I
M(%(.`K<Y],Z`$T.#L5.-SE.2K%JS>PCL4KS2(%V,,1L!:BU:H`(D\'>^8QZY
MJ>%>@SZ3$PZ947#;<DB)&,"!`D4)8;HBB+S:2W9\P8_B1(-!1$J*0P5JL&;J
M6.&>AH)PGZ+^-0]6-MD8ABC-3E4!F#%0M/0\W#\W9C+\'$B0!AS,,0,64D'2
M223W/-U=ER;'8!]G1((L5"Y999"JR_UHF[>CXCR2CR5;`V`'S20A5!]'"/P1
M)`1LR*,3^`EW:'F@%56L)847!6/BUB"'LN9(QHM*LI^B"@1"HN3UX>K'I/\`
M-Z_[D&E!9KOUB0BIR@G/^`Q(D`8<Q.)2K\=$U:T1RZ@QN$1(7",6FT(GY-'@
ME!2MZ/N[@P6`,V0B?9S!<AMR!)>J`A.@5Z-,ESB1>#GOM0'I,,D<$0E!:!M3
M-\^_R/LAZL8\#B1(`P[F\UH_N-*J$Q7`[?O(7'0^E<"(N?02IJ4A?_3GZ<G+
M44,01BPI%`@R!N*@6M2&!$WYQ2@N-I,F=59-)"57#ES6@78,F%K_`":'JQCP
M.)$@##ER%]QH/UQ"!&@(0.J#LX0$Q2#^*<)_]W5^LH'@$51C8V7$F+_\.AZL
M8\#B1(`PZ6NB!78KV!'@@_85OPH\Z&X>8JFI;6I%`\$7QI,#1J1,=EL/@@-R
M2`+X/7@,L]5-A""2V4QXB+(XWLV(J$6F/UK.&D7M1OVK89#FBG,$0:>:1T)Q
M"6$,O^`>A]*Z))P!`PVHUVDI`1G>H)2Y?`A<IA(<1"L!8#\%3]$?C83DBUU?
M`YW?HP/EA"P_\H;\F"YPUPF"!($A?:<H*RNBG5FE"J//.&A4*HXF480:R:9Y
MU`?8Y^-M7%)#0PG7\3U&MTD]%M)6SXVE"A0%E>I-^X@BE;DL!R(_32""C97M
M3FIIQ(ID5I9?UB`#[`$,!17T3;P<'1X$*L:P$KT9MRPXV-J2D`&J6ZNI>*E!
MB(<_A`K&B5GN;K&)L9H6N-%;Z=*U6`B>+K+>EJ07SK)DBHE<P0?]>/H16>IS
M+B]PM[(D0M\6/$P_WYQP+^6//'I-R"RD@A[8.KG7(H(:JB-ODK*BN217D-_1
MNLM:9$3%903IYD1J#9[PNBYWF4NX)2,YUG9.(.@X3/YH"!)=X-JLT/<^<B!5
MKKLNL*F#:ZO'%420^,&]`7$"9DFF;Q_%US4!]Y@`J8;KM5<8D9\H7RR.RSZ5
MS*(*Y"S9O.T[X)*&#/?0IT>.JFXMIBG@&.5/5*0\MJ@ZX`]&%F?$')8BKK%6
M)J7LCAA:K]9X`V"P3G0**;!@Q-*[:U2Q9:"8@@[$OQ#AM#H9I:59Y6D[VW(R
MN$&I=E8RFTYM#W>"\,;`LHPP\38%*5V^*)B,12\Y<+_R?VP!D!:8O\P+)V$H
M5AG&23%8:/V^"TEVS-#P0&.OO"01_DL$X)NH"YE??FVA5JN!)9J>3(+ZBK&K
MG^860U/M07EP6<^!93O<4@*+$FRM3N%X)D(E^%%ARTDP8W4D]Y?'?1AS;M!=
MUY1;X5#]5JEV7"\QO^Z5Z2.P\8Z1NKB1E```$!8"P!@#Q<;7&,5I@2)5E0SK
M:K9SU?AHE3I/U447DCS$Z%>_ZZIG(*@9A>C-\HZCI+(8Q2'Z@X*/N81%"(YR
MIEB4?N)`)'L6`-L29#4P-)?GY.;2<LU1635WWR*BTF5`#N"]?.ARI9JE2UVR
MR;P4&A:`[W@_YY:19)01_L!^$F1K`HUE/4Y+F%^-0#?"MK;_`(>A;="`G#L!
MTH`A`%O*0%XL];((^86)>F?;.*6H\U"(%#9_E+-T3.@;$>!`90(TF=II^@>N
M[&DR#<`#B\14=^A;+S-W;FG/7\2>=0S0C_:X\K"#1%/KM[Y$"'U(IL:G,QB<
MVH)1!NS*;T3WTZ@PMP$YY++9I0'GB2#--:EXF9)U&<$0J",;NI-7/+6!Y.D$
MT*E&_P!EP7A9AL@;'YQPLY`-]%19NT>FS<RL\5H!-21YKV$G%1*XY5XN_,]3
M<.?-]<CXSUNBA85XV^IHA7!`,!'\0YJX1%$?17>&I'Z'Q3FTQ(&"6MS</5C(
M.F7`BG\"&!.E$@#)*=O;,.)!%!8=#S<!G):^R&J)?2:%U,W`:7N^G^5!,?VB
M:5X_$V.[U6MZC=*R&S+H:*XH4X`@-MEM2VB'[?\`VT#)AVR'T'N]Q-7;3A.M
M$1M$8H($FBB$DNAH/<I3?254>R^N.;QJ7U@4:;!0U_E!;,X([_85!>6K%3J!
M?H2*\IXW`$4GZ-@3;+P<+FEQ"`O,2NAU5'@3"A-WW/)Y%3@I%$3TJT<&JHU7
MDKBCDKI$!YUAM2E'*0XA*T2/3FT?1GV@,U>$?[K][.;#U04S#[,K]BD'DCQS
M*S=N!D/II$M+"E?21\0UJW[?=Y*6*(50#5;;HKS%'CF4-V)+;_(]RTTH+#)Z
MWU$>N045'Y`NOA)!@E/129'=Q)4V*,MIVB#9B,&B--H2)'<'`V$+[C43NURB
M++7.#J-K6BE,+!,(2<^-#@F5\B`R!&W]8VO&[WU$0N!U&;(LD45@=9`KS](.
M%8.[2K+(H,5LXIE!!J2%>A08%]`>=2@L3WMK9L.<-$IJ,3302)=?IP-;PEL_
MT,/X4.U0$!C,[OL3%$SVK^89LU)%R3='/O9'`U)@O&UUBXUT.(%84(5`T:(D
M-@GQ]YJMP.I%XF-^B:'`4P6AIC&N<XC,3\9W'GA.:*PGHP!;)9(XPQHI"0RX
M%T%43R]F`T/HV+#-3;4$C3JOW)DUQ^!($Q-8.J(%(\R:/+8M_(L!M)2JHP_`
M\&>9Z5W@S$`<DX_.2)GIC\%(J(#O`A#0I!8+#P>&$4JH,SU&T>12)EI5)7ZJ
M8"BJ:.2+T05'-^XC($40L;`X"VV):*88$C@>S&M+^.0J(")&ZZKI4<+Z!RK[
MORY.\('=,91K.#D?M=$"7PIQV%0=.SA^BTSRDK`L40HNK,1S.**`Y?/":>"T
M)5!,C2.?ZTE:XP+`:1G&;_#/(=;M$*T#`GM>$8%(,-)UOCY(39-,[B$R0%_(
M;!J($P_O+"MR"/A4@_A4G2Q$VL<:#_%D`G`'S"_\_M+-K2'M;8PFU7/\)Z-`
M=#2JIT99!>U"%\,BR&8Z+]$WH@,2TD$"BN(:R<4)"6O,_IA`%U,A)=>1U%$<
M@IY?@;XW@/473VM<%B`"5`I<Q7L$KA28&`@7N39>B2='APM&YI2J(E"W)TA"
MA4T@13J%9S!+.R\/H/3KGX4)GM"N@07N\:4H1(V@0]%LX^QL\M)0&K%/-78Z
M\,KHBJ0W2[=I=?/F/:Y3K#_(_5@ORB28T4HGMCSN2CNH.?TO(/S-*:.G29C=
MC*@OM./!F)_&HUSEI#BSVW<R;M\+BJA`/YZ]TBDJ7>EG9>N%2X$E*X5Q2O=(
MJ7#5\^?X'6(=UF,FO)=&!#Z4\3MG^_/-JXT:7?:@M'DX/AG_`-FSUW&WBXV:
M9\G&)0C^DUZ9B&RQNB(B\S:(KFY_]O+OD_681()=/__:``@!`@,!/Q#P#94L
MI!K"`U8*>'5MYL"J@7@,D`Q)"@*6T,@4()>A"7H5$1=Q$Z<"L",/B6!23D5]
M$;J5&XKA`(A(A1+DEJ',4OW;H`2V$;)9]"1E+)CRS*;"5"F(%&5(R%#%O(8.
ML8_(0<*5+Z)!B0@J2C$PQ?8D$PQ9TC#<2$9)$59,K$LG85TBE@@9:J\A%,;U
ML&Y##PT%$AP`4`B(HC)Y@9#1LR%P8)),W45;W$G48+Z!-Z(B!0DH)$$+8$DI
M*5*C=_Q(CF=9ZJ$23'E721EF`ZK]9H)8ED9'HGUFH^5<2X;LO/NQ94:C^,M,
M19G.@F5,,"EG..R!^G(ZB/F&F)HCRC%F^I-B@*'LX?L#V"LZ"/=K=1T1O=HX
MA9)*%.0HO+?2:1&@81R/X]R.@P>EM(7LS#*!2*S8F@<U>9D1`_!!`A*N&39!
M'(616+29UW8E$H-@`@MB6`%"LPDKR1BO+1L*GP&QDB:Q)PEU,0Y$)5@L0P@"
M``BIR8F(MDL<!.:T*8T/FX.P^+XL1;HH-5^@RN`%;%<^Y(("WG[\HT<Z0!"=
M3-6$7/P#^G<H`0P:*Y9"SHI-:@G&",I%G<8)7*B:5;R^RET\YGWO*I$T;#5:
M!*FT%`[E:[]XX-`%8U@576Y,UL1>(()I8*]/,T'77E2S6`>P'Z"MJ.\XM/O$
M_CV!3<UE6B7/A$40/NS!=_"3K"*N-9!VZY&5NROMEH"VJP4=71>Q6P2JN,UN
M"EM!C?4A$M3ZBM(NM0"62*03P5`N4J-N`*=BEZ!;T8L4'$<PP@4@H<S119M*
MRAE`K)P1XP(,P8.%CE9,BY4T9596KR2TD+7B,EME<(@-WE1A5(FB4"$%K:=^
MCD^*.*M?%IU-/C:K=9W5YV)O669)(O0%>"A&D=D3(\QIY8)02CW79:FDRD\0
M`*F`,K4"P51RUPVT"^)0)2723KS&X>\S`P$MJ4JN],K*.-BB^@/==5YM%?KA
MQX1^3;H#<#F;X5T&09)22B,B%QU$3J-1*0C?A";Z1Q=8"HCT$5TFPRI3%P(H
MZ)V3`+)8<+=$+2&37Q9.83*I&!B`G@,C3`!0%4(`V6+A-%7Y(*=%(01@D(:!
M7$RQK5$3R^:LA^HY";'5RM4U&Z]Q9V>;?-LW#YR$SCP%S)SIJY.1XU-:D"OV
MFIKT[&G*^%=ENM7F[)%A*LEU=R]HMS&IA:T]",C6:"_)DT\",L*:VR-EX=9B
M1:AO*.V-#=+!JI01!NO`;!B67JF[!4-(@+VV'([M%,VHY&J_7.D1%3*^E>\[
M5B4`%(9.(6B50:1<ORHD0-T'@!%EL`#*`:0A$H3*%8$JZ`R!@;DA>(OZ>(.M
MLA@'+')&EU==,;#0:A9/<1!+_)?XA#ZKB``\15?3AI9Z:P#"<A"3J!!%%EY,
MXIB&"0H;J\KRA&H@=4!19%M@!`,`)(@"4`2M"'+>UBA4D:@44\-$Y]PV*SMR
M&^^J"5J`#=P:9SW014?$,&`+'&OHWMN676UZ.OS1L@X31'C]T5``=1(9(2XG
M>$H&8)JC@#;'9.]ZM!<CDS&^B^2P<S5M5#6&Z<X$.:4,HPN@?MRNJK4K,O):
MR<9Q93*RU15\P=#]W3YVIZ[%C5:!U[4H\I[!H'(],]%#F,6&;H60W*FPLQ0]
M"1E"X4H.,@C#?5+DEFTB)1%2.]]0D1G)@W#8WB`#@E.!M\3)G*8PT-$A(+`J
M;9@TAKZ;T`"(DB-D1LB9*;M++!1LMI&6[$M`M"C*923OA8+*A*J/(8.WC,I<
ML!E)(MV$,JP5@.K&SJ[&2<!47"X<+%WH8&@,LOIB-EWK['1W*,R+"-0U=P<<
M_"9P'>G>TFQXYU$H3/<^BYM21G@D0ZN7^JRD(AWW7-['J*`DI:68;A[4<T$,
MA(`<H&F1*F=\NC*)7W6L:X$$N(G<(.A>$FON1(W%C`+-O,+$/9Y?=2O@ZI]0
M!`5HT`$%CP,"(94TR#9@3LIK1#K-4T4ADY2QU?$R.@++!+U<OJJK+=\)G`=Z
M=[X*!W#]UK+RZ?'JXLZZ@CVI::XBQ;1E!U3,$Q60P&$MENV3!N0"+*OC#6G&
MB],'V=**^7"=?V:;4N)H<JN[H07<O+*_X$P^TF9G`=Z=[X*!W#]^M!0;@9Q)
MR;AR8,5'D$-"<KL$JM@%:F$,-?-LSK+9(M+_`"7,04>R=8*"A'>-T1&M[PVJ
MVDDIOJ<SJ<[:_@F'VGGF:)V<2<U-IF\0_@3.`[T[WP4#N'[]6915`RI@<U@.
MM34&K8-#D(#D;T?J`"!L667LF02A`9HZD9LNYG2]0ED#;!CLO>HS5BD($',I
MOPY,%.B"$=QHX^)@;.CI>3K&G^!,/M+F9P'>G>^"@=P_?JS>CDF2<#FH2;6H
M&XF"0'`EW5.7O48%[E!)XP*B"9,CLNNOK1LH$L@*4;U,I5(P*R)0)"%2X[*+
ML+=PET%BQ42&54)EDA02;YLSF;7.&8.2Q*Q;0@O&][?X`P^TN9G`=Z=[X*!W
M#]_Y4P^TN9G`=Z=[X*!W#]_X$5FB&.P2AI&-.#0Z'!YT(#`FHJCJH^2@34R.
M[:5_PF>]2$3B<)1ZX<((38$BN@E@*,7S@(G5:(TL(&9-F5,?LQHE+@@,DV8B
MBP&Z24H$)3D8@4567+_\$__:``@!`P,!/Q#P90*B@)!70ENZ%!E>&&>)"'#B
M:E#WE)@B6Z8$)+"MUZ!/D3B";ME<,`E@J@DEN6*Y2"2"885"O0@?>D\BB6BK
M&!`T!O1#23TW&74/AN>AV/XB%*072HL&]6M$("0Q81(=@1I^21*I"D"=I<O3
M&L25+1"2_P`(=,F'G0P<06'&9T1"TE@:?)"L@G+MH9V!224K*`10PB-Q&R./
M,P(SHM?%G*PEAC)I-W!:@$O5<!=`%0HU7K`&#NDKJF+12$KMF)+-[I]HGEYI
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MYKJ+F=R'#4]9%AJ'W.R^C368,:V]I"MCR7!0GPR1H1W$:+R31K.Z853!)9`G
MB>4KI0`#55`H>`1-8V3-],)6$44-D*$-VG<%S"C"D)E28>PZ_![NE!@!@-`*
MNL2,HS+KB#E9=4!\SDY9"4QS5UR_I5^+_P`._1UI=$3;+<^!VLZ4B)@#9!^S
M_95D405SA.LQS7U\5`EL%+D0",#9YPQ[F,4N!(.R!]CD2T6`8#%K`4UR.(]J
MQAT?O^?DWH6(.VPYFNY)F(#("LY$?L2EAV?W,O!<WA:,IUTK[KJ4&\#"UH$M
M/W(>9H6K4((9\MM%1;<<A8(BB>&7"`LLB#>3.&]N(D`(8GB6UUT,L,"$*F)3
M\7@8RH(`:"KK.?R#^CE4XY'=.'Z72;F8+O06VM#L\9IX4%AJ[-B[<VZGU0/8
MP%KHAN8W%[U%HE<AJN0L_.E-U;N:ADYC_?#!FP&[:;GLQ)UI.PP'/Z`N\JC]
M2;G57D8&A5L<A^_?ZINNW/E_:`"#!Z4304;0E54`"H`%4*EY\`$$`1(;`&<%
MR#X/CEB665P`"G(+`N"A19((<T!CF2:3/IR"^9N_]YYK;%"O)>XZ)S&Y5D(`
MF&1V0LDB7!)4+G.4`@9=9U1,!`X2,]I\KI`Y8E@J>*!ED3=H%+.)&$/GP@?E
M;`$K8`FE><R$I@3K"Q)$9F3@;&.UU<^PTE0.&8,Q+]P:XZS$H3*2OHV3L?)_
MJC#P61I:`5)6+D-M1*@2SJMV4^G\5>2!RBP\[0[G2CS!QNK2Y2WY4I9Q&J_H
MP;%8OVU+I?VRO*"I:UN6_+^T0R.>1JT+P._/TPG+BEPP;*/F%-:@,!RQ"7$F
MQ*$7"4)H2!/P2'4-HF,)!&P0!181W(EY1UIW?MA7)[$'5WIPR*\XP#G</M/I
MHA$#(FE!!`0,0T)^F'82EB&28RD6>N3I\\-V\C5@$1S0)G!LO(@O2C2!EG.T
M=>4\A:MTM@;&GOOV@`]-H[>#1WZ/:I$&X+H['6N);-<>V:[;Z*`BX?K5(QK)
M\6ILIOB-9HO<#^O;U)_)?-H/NDK"K)G)$TPNQU@D:`D%`:`=:W<1;5POO@S8
M4I+!(N_G]\)Y!I-0E72=!#OZ@49+-9NYKANU!-(">9?'R#[4":+GCPA<)8:3
M;U0`@Q7$MFN/;-=M]%<9VU@Z5!,Q?U<&<)U&U)PDOF<%Q@(R6,LU=>"2V=1Y
M+@]TQ5G+?S_ID]]Z!/#24-0I,$'>D^^T'K<-VIP#=^$/$<2V:X]LUVWT5QG;
M6#IZRP%^V;\D=#DO#>$I78G/\.;@-ZB.B9M;KIH[<B"-.=&$'"@#O0OIZD:O
M.0^K5<W1Z.C^G_7K<-VIP#=X#[>3:C'^A,\XC\#B6S7'MFNV^BN,[:P=/5L:
M0IV-7V+T?D`-6^K?=OI>\%#$',+00:H-!C!BO941!S^5)J7*YHH3FH*S.*\@
M1S!B],2@L/4I=KQYFC^O^^KPW:G`-W@/XGN?@<2V:X]LUVWT5QG;6#IZMQQ9
MC<U+7N6I^*(E$FXC/N"D5I9*2FJP0M";HBIAL#HQ@X22N!`J!@9GB9I2A>`1
M.!`<E(2"HC";LA*4M*%/("%QF'G:;Z8J>E.2,6P'J\-VIP#=X#^)[GX'$MFN
M/;-=M]%<9VU@Z?X'ANU.`;O`?Q/<_`XELUQ[9KMOHKC.VL'3_`L^A@!9PC!Q
M#())-`HQ[$HA$D%9`A98#P0BE`*"4#$&104%&=F)I1&`P(*R"@'X#I"`Q`A,
KR;"F%0G-.PR9(A`$VO+8;+1%+B<09)Y.*>>R:$(<%DQ!%MTK%O\`X)__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g575431g79f34.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g575431g79f34.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`)D%D
M;V)E`&3``````0,`%00#!@H-```5M```5?0``&[```"+"O_;`(0``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("
M`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"`@(!`@(#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\(`$0@`Y@$T`P$1
M``(1`0,1`?_$`2```0`"`P$!`0$````````````'"`4&"00#`@$!`0`!!0$!
M`0`````````````!`@8'"`D%`P00``$#!``#!0@!!`,```````0#!08``0('
M0#4V$%`3%!4@,!$2%A<W""%P,4$T8"4G$0`!!`$"!`0"!@4("0,%```#`0($
M!081$@`A$Q0Q(A4'$"-!43)"M19`83,D=R!#-'2T)76V,%"!4F)3A787<34V
MP7-41982``$!`P0)$`<(`@,```````$"``,$$!$Q02%187&QT1(RLD!0@:$B
M0E)B<A,C,X.S%'0P\()S)`45('"1P>%#-"7Q8\+2!A,!``("`0,"!04!`0$`
M`````0`1(3%!$%%A($!Q@9&AL3!0\,'1X?%@_]H`#`,!``(1`Q$```'OX5BI
MG)RRY&$3GS89BP4P```!KL(0B?R9^4<Q.0)%F)EF````````(+B8TB91F([B
M=MF/R6'F````/(5GIG)R0\2?O,;*3C,````````<DZ/I)*-SF-;B9OF,66YJ
MI````KU3-6XJ\YO\Q^"P4Q&D3;ZJD```````><K$:##&DAR]IFBQ8!7^)S9B
MC8"6I@>,K$1I$Y5&W2]IERQH```````-9-C/V"L'Y_I[ZHFK[4;,`0G$XPD0
M_*-]D-:,J4S^-5O/M3L`-9-F`````````(*.97+G:;]?H^?0KICK'9[]OQ$<
M1-9XG:2((F09BZE5(''C!-^;?SWV'U;?;`/8'8C'0&G&X@```````_)7PWLY
M'\Y=D)RPE>\%;3XJ[.[P8-]!7VFK[H^"?.>Z8QL3::JF@]K^I7SE]M)N/A?O
MPO1K6_IGFRR/L;65Y+#````````YU>#^^0\1WC7S)MK2[]*:^<O]H]P\/]^G
M=%=<>M><+&B^)V=&!3L"/H:LGS4N6G.+9*:<,7I!.TN*^C^[^#:OXDO#`_>C
MI/E>T8U)4A4Z*OX;*1S$X\LM536"FK:ICW&UGG))F)TF`.<G@^A9_"U[:K]Z
M(FS;8U=L*WMO_/;8?1;C\VSO4'5N\UQ><`!YSBKJ5ER:M+<UQ/D2W;R]-=8:
MX6)[]UK`N&K%P^==?,]DZ&6`(UB<*9H\)FT?<^QH2=6)",@?9&_2`Q9S&QS<
MEV<>W'7KV_P[_FFR.?>BV=YVUER="6=+$ZP]$M<Y4D`.6.,+H\O-#9OX?2G-
M=-=8?Y[GX;G8AO+2/T?*.\VV-?/TOS0\?"$015K9YX;#+"&4)NF*K4U;Y,;[
M,5=IJV\R$K_54`0;3-9,-WI9FW?2I7?/@ZC?MOZWS%VAE*Q/=B#>3!?:7:/%
MGZ!4[S?TT8YB;0RA8ONPYO%@SZ;*XSOIA&^M\_-]:79<L[J1=?DB*#*&!B93
MF,3#R'A/>9>6L0]A]S!IQ1N2-JD`*.?@^^T81OJ1OR?:E.7+/_%M^EY^:&S7
MC^]&X].-7^F.0+?TXXZ:'9[G36G)D(YUL2\'0[774L,WK8_P?0I;?MO])<EV
MQL(*_F\Q-8(GQ&BQ,K3&8),F*\1,Q(T%,-Q/16JC99```<OK8]2Y&'[STS]'
MSBS-MBU)U9RK-NF&:8CR5;72+IMK!0'`]_;QSWV&T"YO,L/U`U;CFU?7NE85
MP5O][S[!9GLFP5<`5_+`&,/T?8^1KL-@E_#WGF/@90```&%.:&-KFNK8%PUJ
M][S]_P`S651SE[M),N/KAD#JMJC5?3C,LT:X9)U#?[7Z3,QV;;3#UYZ'^GY:
M+FZQ;V^A^<`5^+`@`````````@.B:MX>O/)_G^ME\V6-R@YM;*V-P[>4@=5M
M4:HZ7YJF[7G(F7Z2ZU>:]/%M-BJ[*B9;M#I[='E9(`$;$D@`````````$1&'
M)U.$/-#9JRV)[MD#JMJC5'2_-4W:\Y$R_276KHOF*S:DPN1+0#<S*&+,H:E#
M:9>8]H``````````.$',[9RR^*;KD#JMJC5'2_-4W:\Y$R_276KICF*S0!S\
MIKRB,-$R%,:B9(UF)VF8N_52`````````!P@YG;.67Q3=<@=5M4:HZ7YJF[7
MG(F7Z2ZU=,<Q6:`,:13$S!,?(^!ZCY'W/0``````````<(.9VSEE\4W7('5;
M5&J.E^:INUYR)E^DNM5^,Q6;O(```````````````.$',[9RR^*;KD#JMJC5
M'2_-4W:\Y$R_276JZ&8K-F$```````````````'"#F=LY9?%-UR!U6U1JCI?
MFJ;M><B9?I+K5=',5FS`5!IJQ!LI@C73YEX*J:NTU25,37,``````````#A!
MS.V<LOBFZY`ZK:HU1TOS5-VO.1,QTHUHNME^S]]-1B?$;$C$IQIM"/"?-.X3
M&8``````````!P@YG;.67Q3=<@=5M4:HZ7YJF[7G(FP],=8[C96M283FK17>
M.JGG;35+)[ICUDFHLU5````````````X0<SMG++XINN0NK6I]3]*\V3=KSD3
M8>F.L=Q\K6I,!B3SP^THPB<N9Y&PRR(```````````.#FF&:=CPS>O1[I5K-
MSMUBRAZ-7,J7(Z4:T64N/S90```````````````,`?DU8DHQ1%Q(QL``````
M``````````-:()/F88SQ\3<2;P``````````````#GA37*2-7-^,I,:#$[.:
MR?`GV8EJ8``````````````B*)U4\QX83Y,5JBJ1YCP@VPE*8``````````'
M_]H`"`$!``$%`JPESMDTY[';Q5TI4LNY/6QU%&4Z;%KEM.QF5X>/<NWJ/I>$
MW7<K)[,;<P\92LFNIL$H\_'8`ZKK&YH%(S.!#8F,V7@:C$#%?8NW.BX^JT$P
M$('?(N/0Q",.'N5UT!DDM?,QK8WZZ'#S>82`\FC:YS;DT]9-7DHBWC@*\#'5
M'6/1Y632%N:FQ\=?+#RETQ:X@8[X2)]7C8.T?<[4QRS@I9SM&2':5R-L%>Y"
M[-!)3X\#Y0DD[/*).$9?ICP"JJ2"7W<U[\'*<ZS<1A9'EY!+9L0!JVW8):[9
ML*!/CGVJS*PK@3.&H0I#8+8LJS31E?G3L(R0315VSKLC%RF>N3EK2VR[*ALZ
M(MXUMO07&F78,!<G+@'EH"?FS'''#'LENY-=PIPANVH!/"G9H">Q.W*%"%M[
MA$HIFHI'6U4IBCH,=2['AI"?6Q9<4`5;]C=+H$M;JV/@'8[-`3V)P>S9*3#]
M?0F-"QYGEL6L_H:IV(EL.-]DK1="&?.*RTH$B,.=WUIM)7MN(B,E)`[=E2&^
MUY6D**./K*]X)M?MR?VE-WX"][8V4VUJ](V4L#?-8I#CW,:].99^O),U.C>^
M-C@5D``ML%?!O6V.,D7(94_MPK/(GP=5.3OI;XI.%'EKK=D_<&A"/L($::+W
MMC;3S:3.)T\2&/QU!H?6.0#UM'"UHAP&UE3)G-T8!!D&YB*RT9*=VP%P=AX^
M^M\F9\L;96U=(LM82TL0<X?"#1W%PO&6'+,J(-B]EXVQDWNP-F.3?#FYMPG\
MW:=>Q>*-3M=>G41QV%))A)H_IZ#Q758J^4XU^+%Q8T^#2>.[2Z$?6Y1W9<)@
M2[X#SJ6+(DR(ML.&>Y#)W6TW+2*A[O)SRF\AP^K!=CRQ81:2219FPF$ASIGF
M,H+.@[ZZ/`_;MFQ,(FZ2J2Z4A8&N4,NII6Z-+EL2._:B7U)8^#*&;2NPCI&#
M[*JJ2"1CXKMV8U+I$JP@Z]A[7J*%1%$_9<GK:\E5;6&(L"<5BNTNA*1C\6,;
M\6B$,BYD?C+NJI!HFH*E%XZ@@S1YH8,;L#-DB=`8^0/'M<`-2PT9BEW@9FC1
M`[:SL$:]@T(1R#B]RM5RNMB0Q65ML.D;+N6"LB+I!Y!4H!>&\Z%3!GGD:]C=
M$L(ESR**.",>>(UA:+BZDG,E1V6YYACCCAC)I&TQ%BU+#W8HVI^UG/,-5E0;
MM$P23*A93M(9C(S'EHD!\BFI<HRE4C/DR4[?'9K9'Y8V/X3F4I"&2&2-Q.MK
M*8K-,@+8(ZH8\/K?YR0N3KV[#@C;L.-:ZESD[IU.PW>!OMM2'[*B42DEI*UT
MPO\`]GYG:]LK=FW=C7@+#$HW:-ME,C#?<,SEC/(8+.8O&6F'L-[VQM&P;[IE
M_9.7@QAB+#&6U@'4CD2#:<1AL5E$&A8@J/L)QR#?&A7DUF%):@@16\#!DB[.
M'8>/O8P.#*`N[1=J=6UBAX#.J6Q,AZ'L;;A3JNK$I2U3-@J/&_929;HBB\1>
M1B1S1G%O#=@=(3`QI,J0/S5%V1DS=)F_U*#WAP/=3HWH'6^NX:7'1:F1+AL2
M2-+4WL;9V;2Z$F#@X-,4>4Q2@E9(8,S7F4D^F#RG\`QL=$W9RE\BN/"7-]=P
MD=D"9#Z[E9QL?!R?<R"&8@HMH]N9`9:=F&&>"N$DCK3+&/54G<$R"&1;4<RJ
M7Q\EZ#UA.,=A0W9;NKLN>5)I$#%F;5L2PUY'8:,X;$DE;%F1<=%UK`1->QWM
MVET)2(08V"H@J^'@(7LL**3@0Q-Y)(H8H0B(08R.6..=EAQR*4"#6M[AQ;@7
M<")9GZRE%;*B)3^VY!,V_-1Z^>3G^(5^N73D6R\1_K7L?2G&UM@^-LK8MK6Q
MM*),TP]AU)#7;,KV-H]#\)L>!`[#C<$V#=PRV%L1OB@&LHFI!H!J?H2OURZ<
MA_-:T9UW+3L-:;=(=FL,","Y;CE`A8QXWL'1D9T=N%E4"ADX1B>LH#!LZT__
M`#KBOURZ<A_-:T9UVXMS>[@H?KQI@<U)))!)<`IM.S."20H,T1P'I1^8TKXY
M8YXJD#H7X;3OXUK]<NG(?S6M&==^Q:0B`P<"1N#CL&&>IBIZXL5;4!),+4U)
MF\FQ>F61O2RL5=G]0_A=._C6OURZ<A_-:T9UW['DQ/FQ@S59PLDE:D1AQK8@
MA8*9(HYV3%&1PLDE;AM._C6OURZ<A_-:T9UVL]6$>>X-._C6OURZ<A_-:T9U
MW+/]GN#3OXUK]<NG(?S6M&==RS_8J)X"*1`Z;2QC;+229I*!OLA=I1CLI[PJ
M42:9(-(>)F`QTPD*5HJ[/CT9PVG?QK7ZY=.0_FM:)M\TUFED,6=L7-)`2A\:
M0<`X-%`$BXZS&TG#HVEB/!H>%1D<8S\6Z-`MCFI$(VJ["`!@6X;3OXUK]<NG
M(?S6M!]02W^5ZCUBX["D$5QF>++D1)G+E$S96Q"1/""'U/(V\2)NK]D_\1IW
M\:U^N-KWBL/YK6@^H)9_L5Y`'R@#4V-0EF\"V)L#CZ@D>BC='TPX['VZL!!4
ME.("S3U(Z/>PH^WHZ<AKA!X%),?M3/'>?Q%F$T1%7IDC[@WN#L]<>>YA-E.;
M2U/8C+#(?&U:-!"<A6?74`CYISH$W9]P/#.V/[;EJ\+X_:X>G&)S9DSOK)'+
M#[7#TRP!C9G+CR'R26CB<TE)LEO/Y/F?]>ED9ERIW4UQ,HVU-.O<Y6]MMF26
MNCLXL,UFAXD->%WIKXW+Z/\`2%/H#ZKC7VW]:.0A16LPO3?26_[3>5??H?PV
M3[?U_P"?^FQ+Z9].X;__V@`(`0(``04"_I`HJDCC@I@KC[SY\+9<1)7LM[<X
MS(RH\>.0B6A[J<2CT(/-95177;\6[M_#SB.9LCG6NY/Y1;W+P[#,C>YN)+L=
M_>H-'LV)KX1Q*N(/<DB^38?YK%Y:1GMO<VXEI.M>]KPB3>N@>W>]L;322W?W
M"M=Q?SB][VQL:YK+J-[DM@MP3B+<H;^U)*9HJ"$X%HSN,>M`TTNA+,>U.8SP
M![6Q9/X6%1E@6D+F,.B(@[G?->FT7(DC@W@'L!+R$6QRQSQV%&/3R:@TF]#/
M_O[,KD24=;5E5"%1QUBUXRP(QYM<SO*ITDEFNH*-@*CP=[6O9Q"N(K30=X>1
M8B!PTB8UX^YUKR3^<0[3"QP!9"^$2!RK7D7\HB21@*BLKFNI38#Y9/A2!\"4
MET<QU::SO,IRR.IR%L52405&)7#(C3\A(6SLV#*/42J@\8]<.O?'#$\RYBM-
M`/SWX=S"\TE22N:*@I.!2.QHQXF-1:0*QYS34P63GLER9@::&HEZ<&ML&:`'
M<[Y[T`'<Q7'&V-N(=P?E[&\NXB^6..>,I;4&A_J/=/[0RM>05K=J&&9'0NXJ
M%(I9KJ##X"H\3>ULK'MZ@J@02I2E3[JVH]T_LWJ.H#TD[B9D)6PSODV@^53X
MZ<WOE*JCW3^S>HZ@/27<,WZIJ/=/[-ZCJ`])=PS?JFH]T_LWJ.H#TEW#-^J:
MCW3^S>HZ@/27<,WZIJ/=/[-ZCJ`])=PS?JFH]T_LWJ.H#TEW#-^J:CW3^S>H
MZ@>-\8GW#-^J:CW3^S>HZA'2W<,WZII@QO@Q;-ZCJ$=+=PSZ)."S@SQ!Z=BT
M$<!T=A14US4`C+XXD-#=@TMO]-/_V@`(`0,``04"[I^/9\>Z?\>YM_P+''+.
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M.ZF<>=41<2',$=,LBY9/]&?YXO\`_]H`"`$"`@8_`ON@RWRDI1;)F;+=D*1;
M%GTN02,NUJEX_?J/,I40[34E,]BQ;.^-9V&#Y!)@E'I$5$6QQA4=B@ED1,.H
M*<+3.#;!]'X6#5_:OA8XB:U_DF[.=ZW/O%*4^)GRB;,]N>EGL+&J*W\,4[HT
ME*YYI[9&2;-J;5!?N1_7Q!*D\4[Y&QO>+>,GT*-5\,\/1'@K.]O+JXW*]$\^
M8168@6!6I521=.U30&>1\69WSP_A:`N`6`TPI;+B;$=$3*6."!FIOB<DW3-5
MJ7+1UA,P;+RU95]N:>]>-ME_+XK,50:TJJ4+VV)Q06>0$6)GSL_C:(N$60TX
MI;P\2?[-P-UQTU+_`"5=OCT&4JPD-D.#_6.20CC&M>S5:3?,GUV-3\*[/1CA
M+&^O(JMJY+92J`TSDE+FXP=/25.E&:S5J/)3U@LAIC2P>.\\,'J::[A;QT(/
M[-P+''124WQ2G9&^D=_,(4](@T5*%:3<(QTL[^80AZ)8V0:TFZ#ZS?;/_GX%
M72J'3$5)J1[5*N+8K,B81,XADV7BN"G&J@?C0"R(6&2$N$)F`M`-X1UF[[%(
M#^VDSG4GBW7M8\<F5^V:6"TV4EOK4$GX)\K=C@+-?)7M*OB3PL4?ZQ^=UQ%5
M+_)5RSO6G%'V2^$QC7EATF[PC<32=@5LI^^)4^69R3632R(:'25/UJF`MDLF
M%3,8E5EXKA*Q)H3^-)+9".O5M7<4@=.\XL'2-FZ=23&AMSU*J,4GA7N8:+AM
M;.%EP<4G*AWB9B/7:M%E0+VRZI0KA(J-^HW9/H<:KXIT.C/"0-[?1H\G["XR
M*5DP[M,Y/KM"LLJ.?6'="$\%%0OUF[)]=CD_%/!T0.]0=]?75:3RF+U?^2Q>
MO,XR<X\Z]6U<QZF+I=&!BZ>9PDYIYUZ=L6\;%R)A&N]TZ5=X)N*H.P:F4Y?`
MI>H)!!J(I#(BH912_=JG!NADQB)@_%AXG@JQ&E-RZ#+]'@E?`N5;LC?K'_%&
MV9S:D\5%#^K<'=<=52+U:KEC?-.;"`&G_:%&.3Q3W-&;CU1E(Z]-%VY('KO.
M#!ZG9N%C_P"@@D[M/7`5BIYL4*N3&HR")LF$7N7B;:;=]-(V16R7SHSNU`$&
MV#0P@80S?,(@&SP$5JOFA.R:I'?R^%ZQ9LFI*:U&X/TI9W\OA!,Z0-DFM1NE
MO"NLT9V*28]4*<39*<T:I\6ZHWV.2?\`:-./88H6)T$66B("&ZA"@1<"TI7-
ML94TD#Y-SW:6=@50B=-X9$_-$V8N)*IS:2A:DA(N;G*-LW@TR.M71^9D#IWG
M%@Z1_DZJR54%IT`EQ4?R+"QT59DB^R[EW)`^3<]VEAY9&%<D)VO?/&"W=E:*
MK[9`!RVRWG7JVKF/5\63PD]VB2!\FY[M+#RR,*Y(3M>^>:Q1?+3H)D@?)N>[
M2P\LC"N2$[7OGFL47RTZ"9('R;GNTL/+(PKDA.U[YYK%%\M.@F2!\FY[M+#R
MR,*Y(3M>^>:Q1?+3H)D@?)N>[2P\LC"N2$[7OGFL47RTZ"9('R;GNTL/+(PK
MDA.U[YYK%%\M.@F2!\FY[M+#RR,*Y(0'_9MO5ZQ1?+3H)D@?)N>[2P\LC"N2
M$Y"M-6L47RTZ"9()!I$(Y[M+#RR,*Y(3D*TU:Q'YU\M=J>NW@&6E-E04!-/D
MTD$`45SSLEQS+QRXGW2UI*0!LS3FT!LS"RR(=WU:$A(O`3!D?-OEJ2\>I1DK
M0*9A.0I(KI((%FB:MA#.89Z#/9*DE*4\HD;5-H,Y^7.S.ETB:>V:SLF<_=K_
M`/_:``@!`P(&/P+[H)D`DM,JP?2SU:I2AV-V1NC;/K0Q09@^&:JU^C%T\$RT
MF8^CYU\/A44W3:Q_JV0D`(M,EZX$R'@-BZ/\ZHYM?\AV)C=M''=D\>X'2I&Z
MNBWL8+WHDP[JD[0MLF'<YB9)G?4.[`NVSJ68YK39(F;*3F%DQ#JD;8M,F(=9
MBAZB3G'7\5=%P\'%<O>@F%+93S^2NFYQ<=V3P+@]*K.N"ULX+[3"EMV)UL5(
M$RAJ.<YLF2JALDMS#T_#+/X&WC_214.]S3M765#O<Y.W=^W]0?C<C,O\+8JN
MWI"]/6&PD6SB%;%Z\,ZU&RW.JIJDXQU)S*MB2;?5-,:6\$^/3(%BZG&,$G.N
MA\4BBZ+6+]?M9'[";*C<M7RP0@3(`8O7AF0D3EB]/5"PD6AC-;92LP292J&R
MCJ6SGB3G4YU;!\Z,SQ)8/TYV^%H^M$GCG`Z)1W5PV]G#?^P'+H3O%&PP<(SJ
MS;,G@7!Z).==-K8PWFR`V2FB3)3F#4V6ELM-$F4G,+9?["K"A^=\,%HLH(8N
MG@G=J%EBY5U=*3;'K3+XQ\.G6+%Q.,X).:='XI=%P6\7Z-=;CR<TFFO5$QS#
M)DJH;)+?3WYL',_ZXI.;_=%E)NXBQ0K.!;GWO\=WMFUCD5$/<T;9M,J(?9ZO
M69N=535)QVG-.J>:5L2<8-.*6=Q#WK"+.P2-N:1_[Y>D65[TX$R&%/5.YOQ(
M!GVYFLYHDRE4-EG54XI:SUC<:1U[6FJ1_P"^7I%NT.`2/?9T$M,J@M/4TR<P
M:O<WCI&1_P"^7I%NT.`2/?9T$ZQ.;QPF1_[Y>D6[0X!(]]G03K$YO'"9'_OE
MZ1;M#@$CWV=!.L3F\<)D?^^7I%NT.`2/?9T$ZQ.;QPF1_P"^7I%NT.`2/?9T
M$ZQ.;QPF1_[Y>D6[0X!(]]G03K$YO'"9'_OEZ1;M#@$CWV=%.L3F\<)D?^^7
MI%NT.`2/KXP#6)S>.$R/C_M7I%NT.`2/KXP#6(042H(4G-)H(-UBO+2MY4`9
MY\3%XK.)G8PD2<E!,X/Y%N<6\3L&<F\RXE5*C]VO_]H`"`$!`08_`N&P]L3\
MV?G7\FD8@G=KO9,[\MBR/U>JHOR8U9Z-U_5X<^+R-8U-I`/1X[;Y00"GHYIY
M%91J))S6LKKB6D6<BR![12%%NW^/)VVC&ZOMX7J])D5G%ISQ:MTF6.I?1N"8
MDEELO8R"CLT08')S5[NJH]B;KQU9%G5ES06N#MEQ]U);/)`R+*8=<X<9]?-M
M8)#RHHI(58KD(-_--/*[BG@`BSJ&R%FE+3WE;8,K)!7UMK66,^.X4B(>QAO!
M,:!/.(F]CQN9RTYQ*J.$[1V9K*/3V*R*LH+(U2TQ)2)%C6![.&P@(Q2!=(")
M"C&J\M6[O]#9>C]!+9(,I:SNFJ^-WZ`>L1)#6N8Y0J?3=HJ<N,4-2PGRV6E%
M,R:WAL[=)H(,<`(HJUCYLN##BSB74YK54I$:C8IOJU1Y4J+8LYF1Q<6]+AOI
MYQ7VD^M;:0E%-C6KJM\,T8C=2=;Y3M=Z-1%7C)46#/F&IRTO4K/[D@^G)8U,
M>81K[25<BA21`<YSBD<YFU?*-"<E7#ST5?92XUJ3,H-A1B]&642PQ\D>)HZP
M+,].9'B2&E<A12NF5BIIN56MXKK-9)H6,?D;,+ZTB2XP&RHL_'+VAK9##[$*
M9)5<XLH#AC(HWO\`][RKQ+KFQ)%?/B1(MCVTB353.I`F$,$1D/3V%E&849@*
MTHG/0C%TY*BHOZ$;+H%N*:1(#(Y:V+(BR(8K!6=JETY0N<5)SZMG:\UV])/K
MXGQ'7)2LEXCD>&C(.L@QI"0,A+$,2?.D#U-:6XGQ?,8BHTN[7:U=RNK!RK4L
M(R8YD^+1&!*$$J2._B5J2Y$1SEZG>005'4;L1=-55?#BVB/NGB-;#PT;I%74
M5M6.'^2[@MM`)#AM9(!U9#B(A%+U>::_9T8B6MI=&L+=V0U5\>4.$&%'>VE@
M2J^!7!AM(;H1V#F/>YV][W$<J^&B(`8+*O="82Q-6P2TM:.X1DA2O(#UEKDE
M2HT+NM$T$TFS:CWN3Q_T+SR3"C@'S(8Y&"$Q%5&HKR/5K&ZJO&6A@W13QLL>
M]!2(ZQ9,>JC)9SK=U;$:/4)Z];BRDO*-WVV&4:^5$T0Y++J2%RFNRLW:UT2N
MA]U74Z4[(D:%'\D:&H&HOB\FJ>9SE556ZZ=PP5C-M,;R`D,T>-81P+31E@PF
M3ZMY1NF5TWMWKHY6?-9JU=6<5#ZK(3Q+"FG9-8`DOK(!8QS93*;*G#DUXTC!
M;%&NNQ@5#MY:*B)HHX$F=-E!7%\GQJ:]R!&::[+;2)<VUIN8S8"4L^.Y[&HW
M8WJ?JXGA9>T=S)C-!$D-J:JIK),56*_G:)7F.1TLRISUZ0_+Y1IS_0L6OAP*
MH$T7M5?R,6-51')(NK$%?!FF@Y`]VCI9XT6/W0`M:Y"JPJZZMT69,7(A3Z>0
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M:J<,CL;F=4\5@&U!+I_;/W$A2@V`4>UDK5,+>`[U&5S50K"-5'>'$BN]K*;(
M[S(K.R-:S,@S3&<EHZ<,SMPMERK2PO:NA0DF5`BCB!#!8Y1[V.5B#:[A_J=!
MEV/VDMO4LX!/;?,I9>LNYI$+8T>.V-7:-1^Y.L$YAO\`H=QN1N6H[:C-4]L?
M<E%V)X,U_*/V4^KB)!$<\>TG$45>S(,7R'&RSY`1]7H0#9)35;9DE@F;NF)S
MG[4UTY?R+4DAKWUH;J'B5/$C]JV19WR0"6MB7NITB'#`)@W=N-I"C131R)JY
MY!MX='-'L4"P\N&2P0(%@CGU]1(O;"$Y_==920JZ*]2/1B@ZC5$CU(BLX&):
MK((ZD+C['.DP!":`.42F0:25(3NU>)DN:3IJ)4[D?-SQ-8BNX/55KC&($,P[
M9*(!T4XX$T=?*<SI2"20(DHJ(-3C$DEJ.<'J,:Y4^!2RG!9&$QQCDD*QH1C$
MG4<4KB>1C!HW<JKR33A^AKFUC21=/N:[`LWNZV;'U>F@K"NQF;7SHRJJZ;"/
M8NO$63%F^X5">+#/7-?1>W7N%#1\"05AR17!+@\F.QO6&CD<-K"(OWN(F.>T
MN,VTN9'B`KHLO)L4R?'\:JZZN%N4-G89)`J9$XD@"=$8P=<O5.A'IL1_`(EC
M0Y?CLEB-*6F=[;YG*;#.CM7(.518[84TM&':NAHQB#<J:H[ARM3+6[W;GZ>V
M7N2FYVB-W.TQ'F[:U$_V<1*^`<U=93GO!7BN,6R#%23S-&I7QH!,AI:EDV1T
MFJ[IB<Y^U%73E^@S*>R8XM?8![>8%'JSN(SE3K1R*GB"0Q-A&_>8JI]/"-:B
M-:U$:UK4T:UJ<D1$3DB(GQ2GN[]'7.WJ/IZF%/N[$#.2[ID:IC2U@^5R*G6V
M*Y%U37@M=CE^(UL!KB&II\:94V[1M^T5E?9@BR)`FMT57"1[6HJ;M.$A3QJ\
M3)<">%S5V%CS:N:"QKY8">(SQ9L9CVK]:?R+*JLI,DU?87%S8'C1COCCEQ;J
M6Z:>!.:FN]C2O5$<W:]$3RN35>+0DZ6=K2LL^YBNLU0$'\VH^)8%'&Y]`ENY
MST1SM?,YR,T3EP:81#.,>W@W1-2^19=;!%!A,VZ?T8"!0B,_YWFX)&KR2^U7
M]C%.?JAB,1SW(..FUK]OGTU>KW;41-=$^,RGLAJ:OL!=O-`CW,23&<Y.M&(K
M>:@DL381OWF.5/IX+(D%CPX4,#BF.8@X\6+&`S<\A2/5@@@"-NJJNC6HG#XS
MLWCO49>B^1'I\BEUR/543_W6+4&K%'J[[:%V?KXC6M//AVE;,'U8LZ!(%*BG
M9JJ:C,%SF.T<FB_4J:+\4A3QJ\3)<">%S5V%CS:N:"QKY8">(SQ9L9CVK]:?
MHF7Y+":CIU113I,'=HK&S5'T8A2-7D\89!&O<W[R)IP%W]*N+1K+*_N#KU9U
MM:RT[B7(D27_`#7LZY7;&K]E/UJJK'FUQDJ\JI3#L,:OQ>2376,9_6`UQ&HK
MGP3O3:4:HYJM7735$X[J2!M=DU,?TC+:371];=1TVE<-FY[O3Y^U2QW:N16+
MMW*YCOBX-2.24SYU4DH4&2*'/+5)9Q%MPP91Y,,0))JU"-1RE&J(J[7(_;Q8
M[DN81?3LN6HA#R@^T5A<6;(>/LDR16W5,RBIJH$A$4G28^0Y&>9.5I/9#GC*
M[*,=E1[@ENC([Z"II8<HB$!'LNX*TEW!*$XWQVZLE^1',WN2?(H36+Y\:FQF
M!93!Y""T2UM+&U',S`U:2'D3*:+*#6PV()`S(91BD:(X*H/22!DG)!.912!U
MB.O>Q=&N\@MBI)+TX5Y.7HXI#AA/&865(9H71JD>FUOQ-A5>5S_;O#IB?FR2
M%ZH'*<H`K2"Q\91N125U([S2-%\Q^6G(;^&PP1@!B,'T611!&..P6FG2:!C4
M&T>GT::<1,:J?D8M[B5-U.6E'RBUF28Z.-)+801Z[(H9U>?80;$1%>B+X-1$
M^(Z(TKM[0[7.B1Y0),5MATQ-.9M9)D!%$M"1PNW%;'>1PDUW(FB_H*JJHB(F
MJJO)$1/%57Z$3A:XON%AK)C2=%P79%5)M-_RGD[GI,(B\M%77=R\>+O'))4[
M#(J>5![H&TO3;-CJD>;'T<C"N`]S2LY[7*U/HXL,)RAB1\OPUPJZQ;SV6L!&
M(E9?PE=HIHEC&1JJOT/\4;JB?"/[HT(2R(X@C@9_2QT36[QIKO\`W$0^376]
M#^U&Y517#;M5R,U18%Q52A3:VSB`FP985U&>-(&A!$;]*:M=X+S1>2\3IS8L
MF<Z'#DRFPH0^K,F.CA>5(L06J=23(5FUC?I<J<+/CT\2>P%%<Y#8%C7:M@PH
M=/)[=8SSRJJ-*]3D/!(9T71Q],T=S'N;S<VSVTUD6II_4FV-DP,C='+55I9T
MGY*Q.TZ/<B[)NLE)#IB[6A4>I$/_`'<*#:QZ*ZMQ1&V`9L(SA+4P:N/+D>F=
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MGN146ZLYKQCO[T.Y.4`0@=J-4UZJ\]4VJWALG(+RGHHSUVLD7%G"K`.=]32S
M3!8J\_KX690W-5=Q$5&K*J+")91T<J:HBFAF,/54_7\),YNC9=-:8]<5Q]//
M&G0+ZN(-[%\6H4>X1-/MA(]B\G+^@X_[2#F2H&/%Q^1FF<K#*^-)MZ9EBE55
M4#)8MI8\:=8C(LG8Y'O$W1%3Z?2!8?C25O3Z2Q'4M>03V\OVO4`Y2O7357.U
M<J\]=>(M,:1(7VCS":D:K)+.0X\`R<ZN4<%3F5SPXY<KR8KE5`EYJJ)O<^%G
M^'Q]^<8>(BMBC1=<GQQ54MECDA&(KSETU+$\=I]4:FY^Y(-W6$ZD2<%"(B_M
M`D3RGC';]P\8R*QZ?6GU<*UR(YKD5KFN35'(O)45%Y*BIPSV_LB[<%S":4^#
MR2N^509')>I9>*N>O(<.T>[J0T54T+JU-SGN5"Q90^J`R:/9JYO@J.:K7L5K
MV/8]J*CD5%14U3A9SJ^.]C(,"#%AJQ>VCLA3[.S(16;]LDDV=9*4O41V\@VO
M75R:\6)'5D=WJXY(K(;D>Z/+;,:ULOJQ7.6-OE-;\QR-1S_I7B&("=H`$FN-
M*:U''/.%56;+F'$+)DD*]`>I#1Q?%Q&>373ABGK0/<.9)GM?YVD[J;_3'J1K
MT>YDI$1",5=CVHB*FB)Q'/'BA!,@^JOKY6U[G1C7)^[L7JWJ,Z[)<U&F(QR[
M7$:B^*(J8\`#W]ICO>2@QU8Q.\N9HG`)<S',VH^4@Y,G1J-1B.D*J(FUFECD
M]NKGLBM:&%!%_2[:TD>2!5PF<W$D2S?4B[&(YZ^5J\6F7Y8])&9Y85LRU=XC
MJHB)_=^/0>;NG#JP:,T1?,].:NT1?A&]K\?.6,(XAS\\NX__`.BQIR\X(B;7
M,;;WNG3$U==K%W*W:JJV,D"N:O:CBX_AV+P47KV]L5O1JZF*Q-Y7*1Z;C$\S
MD8CG>9W)5RKW,!$S+/;9.XL9-LQEE64C2JI!T=!7R.M!B0*W>K6N:W<YVJHN
MBHG$OW#]M8T?%,NQL!+<@*D?8T^35T!.[L*2ZJHO2B2638XW[7(UI.KIYOI2
MBR.&US(M]3UMQ'&]4<\0K&(*6P)%;RZHD+M=_P`2<7G_`$S\8K^+2L#*-!/.
M@28T>;'*\)X<@@G)'E"(/SM<`VCO]G$&\+.;3,Q?%'S;Y"1I4Z('+K:8^A;7
MFK8,J,>S=5FJYS4CM>CG$.'P73@M>@Z\=JS.ZG%&S+6EFU^V#;8Z*Z[N12LM
MS$9-BN+Y4[C89B)]C=JF8`[J'$GAM,3KP2Q4]I;GMI]C11GN%%I&70VMDE4:
M])&/8,3$5Y=^CG+@4AA8%9="F^YM.:5*JY*A:VFEQZ]9"TOJ;2BF&%%3<%92
MM$1575R)M4F8RH8#6%;[=92(L>+U&PI4^FS9E+UP[W$,*OER8?53FYS`N\7*
MG%G%OX!FQXX($B!:$I2T'<%D+*9-@K`-:6SE[-0C>TB%\S3:*FK=7,(BW,%9
M'NC?5OY@D7LLM+)@15EF_+'HC9L@*%FB#M"XL<(VO;JTF_8Q\G(6T;CT2UN5
M3T&:K+71ZIE)!L9=6X]^2TD!G)-)7]"1^[AV$,BM\K%W6,^P[&QK(EU@<>N.
M7&,DQ0LF;9Y13Q[%7!FWB2R#JDE)T]&-$XFB/4FPC%B7R.JO09F<NPQM+V4C
MU884R(^,>J/LO4.EW:3P==P.VVMBKIKN3>N.FEI2OKLAR+-L=#`BQ)@)0%QE
M<C?"FOL#6$@:ODICRL(SH[?F(Y%3[/$X5Z8++N"^-ZE4-II50>E-)"I.U<LB
MPL16D-RM7MY87=,K$^M%_D8W[M]$DG'&TSL%SA1->0E14RK1+&FOD$W7J1H=
MJ9S#JB;FL(FB+KR&<!!F"8;"A,)[2"*(C4>,@R,56O&]JZHJ<E3BQQ^ZC-EU
MEI&?&E!7DNUW-A1/YJ*0`B(\;TYL>U%3PXD^T>;2G2,AH8W<XK>'\OYQQ)GD
MC2=SE\UO4M;TI3.;EV[O-HY_#\L@CZ?MYG-@QF1!&F@,5RZ3Y0W.U/*&KOET
M8==$:,R:JO-C/A,IIZ*@I+$41Q\CPI8EWQ9L9Z*BL/%,B.3GS\%Y*O$[#\L(
MU,]PU!1K5RZ-]?JUT979/#3EU1S1Z)(T_9G7S(W>UO\`*(<Y!A"$;RF,5[1B
M$(;5>0A"/5&L&QJ:JJ\D3AN7E1Z8+BLB3$P*$1JM9;V#'="?F$@3O'Y@U'"W
M)JQJ;M&NUW<`%7176>1W4H=3C5.+S%L;:4J,"FU--(L;=U#.541&)XHJIQ.F
MW]D!]H=ALCSO)Y*Z-E6'24LIW4V(_P!.K6:BC#1J>5-4:CGJG">[>1QC1ZF,
M.1"]KJ"6W1U;3&7:?*9@/!MQD#6:L_Y<?3F].FY./RQ2A=89EG22,;Q>K#^U
M<>:%P9EH=47]WKZ>*13%*OD9HFNB:JF.8T)Z%904E74=9$V]=U?##&?(T^A3
MO&K_`/;Q>?\`3/QBO^%N"-`K9%;D<R7,M^VV$!93R.:&7(*43UUDH6-S<U4<
MPC->3N*^N<VI@S9MFVTKHTN<U+"QMXD?M^]#W<E9EC.''?HY_G<NNKN+*/)B
M1)$H\BMG6*"D/%.'*B"V54M2QC#EPCC"+03VJQ5:B_KXB0EI(K(\`DPT%`*>
M,2$:>1I9IH<B.44B,:2]GF>QR.7FG@J\,C"IX#8PZ@E`V/T&N!Z,9R/-7O$[
M5A(YGMU?N1=R^/!6549\=#-"PG4ES9CNG&0B1PL=-D2'"`!"NVL;HQNO)."1
MUKXZA+:MO'LT7G;LECGML$77<V2DL37ZIIS3BY9"`^JE7$6T`^5$-)Z48UN`
MP9DV/6N/Z<*2?KN4CF#8]^Y?-JNO%B6<RB(&>.H8M5CV/)C-$A:6>MG#L2UK
M;.T[BV27L7K=1J;1M3;Q(N8L&$^T!/(:2\)WD'&MBQF]:22`TZPH]L6))17%
MZ:'5A-57S<0>TC5\B-&/9V,!8Y&E$P]QZ@*TE`<,CD=WGJ<A'KS3YCN")"&&
M"^TE!80LF68TF?*:)61@=S/.:2=PP#5!#W+M:B[4_D2ZZ?'#,@SHQH<R)(8A
M`28LD;@G`8;O*\11/5%3Z47AOM5=F,7&K3N9OM;>2WN?U(;%ZDS#)DA_C84_
M4UCZ_M`JB<EV,^$293RO2LQQJ5ZQB%VWDZ%9B3G%.[3SUEHQO2D,75JIHJM=
MMTXLJS(:Q@9R-D8UG>+2=6FJK@3>G+#INZK`D>G6B&:NOAH[J,=I+]KLE.23
M(K`=[A]T9-OYDQ3<K(^J_9]4J=O2.SZFZIJB;UXJ\]Q%J?F[%%<0,;56BR"E
M>NZSQR9MYO%+%N47TL+]G15W)5Y11E5\*R!N<$FG<P9;/)+KIK$5>G,A'16/
M3PY:IJU45?Y'_B#')3Q0T$&9[EV\5^CH52;SQL6`5J^6?=M34R?=C+]Y%>U(
M\.(%D>+%"./'`)-HPA"Q!C&Q/H:QB:<2K&>=D:%"`23).3[(@B:KWN7Z5Y)R
M1.:KX<.]Y;]C5?8"DU_M_6.<PK:+'D*^/)LR(W<QES=$$N]4\PP^371VUI<0
MA/5_MAA%D-V82QJO1S#*8BM-'Q<)&\C5-.30DSQ1Y-&Z)\LG#6,:C6-1&M:U
M$:UK6IHC6HG)$1.++(KN0D:NK([CF=RWD7[(HX&*J=23)*J,&W[SG)Q-]U<X
MC*'+<ECH"DJ#:K^3,35>I"J1M<B=.SG)\Z8[1';G;=&KU$7C(:^L&A[)\!QX
M$=SD8DJ9!(.=&B*]>3.Z-&0>OT;N+RWH).^;"I;`ZPB-Z5I5V(X!S#A6M<_]
MYK[`)AZ.$5J.14XQ/%*R^=C%=&]O(EVVPC`J9,B:X#8D-HT?<0YT/LX0OG2=
MK$(_JM\[$U5:3(+&<X9)OMI53I$`42(V&;KV<P6H7%`Z8&-(D";,9H3?JK6J
MY6)IQ[D7U3;/@^C0L'E/A-API`;37O&/BSBRPG,.*X#G)^[J$J.77?RV\7\>
ME8=(V-WE)7=BXV+AJI,"7$J9TR3;.LG-R)#RQ6!&Q7Q7#$CAMY%7>WAE?16]
MEVEX7.JJN-;1<62OCV>/@F-CFJHL,/K_`$*^SB](CI^]IV\T:FK>)V55RH&H
MQN+C#[NN[81"DF<K#.8:E5I"B?24TL6U&K_2!N15XNLEF24%6$DW4VH*,#"]
MMC]<UT:)+1H]5E]ZV"^:W755:=&_0B)E""GSU4%)A%U32,BC8O(G1TR2_D02
M*:/BZ`@]H>`QCVA*O<LU7S\VNXN,==D!"O3,L4HX^1RH%0V=70,BK!33H@`P
M@5!3,D,4,9Q`.T4[=Z$5.?N$PUEZN0>?R1/L.G&$Z0HL6Q0?S60T9%20+;L)
ML:QO4:OE9]E*N1"2&`H?;D\GOG089)P=V:Q(+NG+.UJ[`AF/>,17I%ZVCB>7
M5>*"5^9),P!_<^HBT,^2#&RV,2`*DFH:1+!21Q5S;$DPA]C2-5J,:)[A^9S%
MPR-(R>:(M?[AYOCKYXXE2,EA'K*+(2PY$X"0FP'2>@'HJC!,$NN]&(]&JGQE
M4,XCX<EKQSZ2XCZI-HKR'J^NMH9&JPC21B_:1KFJ\:N;JFNO%GBV6A9!S[#C
M#K\CB-\HK`;FZU^1UWE8A*VY!H1-$38]=-$16:\?^8,.B.F'C1&P_<#'1*K&
M9+C8&^2R9M:[^^<>1-['Z;G`:K==K58]WN7)RL-K[GW`HF0X?<54B0S&<>CQ
MD,6OQ2MBFV+Z7)&9X9KCLZJF<JO3<UW44QXSZZXKY!:O(*<Z*R14W4->G-AE
M8[SHU"<V*OBQ4^G5/@^V>NSVZSB<`.3"_F<8R8[D#$R1B?9#7V3G(.9_Q:/U
M71C>$5%145-45.:*B^"HOTHOQ`*J$RPS+)3NJ,/J%5J]>P<U.K8R6K]FLIQO
M0IW+Y?LM56[]R*$TE]C;V$@MID%P=5=)M[F8O4FS2O=Y]'$Y,1?!J?7K\'4K
MD5_MSA4T)LL*G[')LB#H:'B[':;2P("[2S?'7DWDNQ_!O;?V=OA0(/N/7S+.
M\Q]P2G'[:B=(`&=E=(49&-K!V@'D&&/JFAT;LT^3LKL=I`="OK0((>[13'(J
MJ\\N2]$;U94LSE(1W+5SOH3EPKG*C6M15<Y5T1$3FJJJ\D1$X#D\MBO]K,(L
M'_EF.]/D9KE<5ZC)?%8O(])2O16QT7RE+S\-[/C?VM=TTLHU>1M:XS=X!V4I
M6PZ\IV?S@`S#L<]OWFHJ</8'K39TL0!VMS9E6;;W+@=96OL9I=7E8U\DJC"F
MT`.HYHF,:NG%#1W,2LLH4$H:RA9D,:!8/878_LXD7N8^WK"B@V,T3J*P?-57
M5>.X;'`V1T&QNNT3$-VS'*]D?J(W?T&O75&_91>),0P:XLJ;'$69&(.,^1+B
M`>HPDDA<BD/'"1=K5<BM:O).(]I-I*B99Q-O:6,JMAR)T78NYO;RRA?(#M7P
MVN3@[HU;3QKZ4/U.0<,"*&QE-U?#=,))8%II#F]51N=N541^B_:YVM5&1M:R
MV!8#.:"``R--9#(R3-1JC41);G$5RN>UVYWCKQ$K(HFCA0H@(,<&FK&18P6Q
MQ"T\%:T3$3@S!5%!55Z['2&L@5\&'Y3]<:F1HA`Y2G;TU_G.?CQ.1`4]O#L%
M:&S1!PI\::X+![!3N1125$+;HA-=&Z<%IZT5=".*-%G&KH(H\9S(I$=7PY+X
MX&LT$YE:H6.T^R#:G)O#ZUHFUB*R,,$JMCPA2(K(EA'M!!$AHIXSXCIL5KB`
M(-X2IJCVJBKQ/F'*^WL;&7$FR)DV)6A1AH$=T6$Z)$KX4.)%>`!')O1O5<KE
MU=X(BQIU/53(RS/45CRZ^)(`MAJJ]\HC">SO-7+\S3?S\?Y,#W)P<*+G>(A(
MCH3?(S+L;5>K8XS,VHJD(Y$4D1>:L-X<U16U^14Q5?#G#U41/+)AR1KLE0)@
M]5Z4N(9%8]/U:IJBHOP;025Z?M7GMH]U%(=RC81F$S5Y:8COLQJ*^>BN!X,"
M7EHB=0B_^7\=BO)"<($'W+JHS-5EU0O)$RD(6\W3Z75&F\=T;_=1'NX!,B&9
M(BR@CD1SB=N&8!F(011N3Q8]CM4XEUM@!DF%.`2-)`1/*01&[7)];7)XHJ<V
MKS3GP7VARF6\]A3Q5E8-:R5\V08F+5&07/Y-?:8\QO3>WDK@(CD3:Q7+Q9Y#
M=RF0JJHB%FS9#_NB&G)C&^)3F>J,&Q/,0CD:G-4XF^Z&3`)&FVP>TQ2F,N[\
MLXIN5\0.GV4LK-KNM(<G/S:<M5:G%5@6(.3\WY4KABE<U%CM,Q=++(YFSFQD
M06J!\%>7[.JIM6NJZ:$^=+8HJ?&ZAOFM,KRF?X/-TTWE/-E*II!$31C.3?N-
MXGW61R4M,[RLS+/++;[2=SM_=ZB"O/IU5.)>D%J<N6O)-&MX3VBQF26-#009
MGN9?QEYTU`;S"QZ,5.27.0MY:?<CJJZ.17;8%/4Q10:RLBAA08@$VB!&`Q!C
M8WZ5Y)S5>:KS7G\;S_IGXQ7\9)9U(^K9U])9S(#-G5_>H\,I0KT>?6V/;KL^
M_IIQB$:LS:=?];.<<<^S[NJG2X3I%1;*XD=X(?2C.F#3J-&1KT&JZM1$Y<-J
MYMS:/DMSG*,?@V+[BLH.K"IDG3!>N7TFOD-'T(HM&]$:%,YC=VJ=1>%N/4-M
MHSV?N;GO$C0E,MK!N`Q@3%=VK6N=LYJW:@E<NNSC,Z(64D<L6+@]E#E7,^NK
M)#WVTR[;>5D&R['M8#[*'1Z`^2]`/>[;M316^UEK!)/,V=!RZ.4UF^*2Q=7-
MBQW&20:#I%DC]3@QM",W-(B,=JNNO$O(**>)0E'6.#<1^G*#$K+"RA19MT+<
MT@"LK:V222FY%9\OGRXRJ#CV62[2!%-[;LA7[WUMG(J[+(LM'5W-:R5VRQ9V
MZJ4)]CVOZ/<?0CFHEE#0Q)KV$HQ--9.0SSN7(:O3NW,8SJ(NNCM&^'%95D)$
MI+*Q]=G!_+=C"QBC4=9$@JX\^;95LV06>Q3-00!L^<FN[5K.0[^RRTN.VLCV
M-PR_0T<E=%]0MNKD\U54,F.7N1#E&_HP]$+OTT7EQ52IXNWG2:V#(F`VJWHR
MC1A$D"VKS;TRN5-/]`7.Z\;T]N<RFB%GD$**H<9R*0X8(>7@"U%Z<*Q<O2G:
M:>=4=YE5B(P@WM(,C6O&1CD>Q['IN:]CFZHYKD7DO%CCUW&2566D=T>0/DCV
M^#AG`]47I28Q6H\;_NO:B\67L_GY63\BH(.M/93&M>+.<+(CH\><YA=Z'L(0
M_D31NW*[[2J_YCN$PHZD=A.3FE3O;^>55<RME*Y36&'R3.551X7OZD17?M&.
MTU5^J-XB3*B5Z9E&/RQW&,6S=-T.TCJCFB)R7="G(WIF8NK'-7FUVFG%;D+H
MW8V.Z16WE=S_`+NO:PKHME%377Y769O'S5>F]NO/7@^'-73!O;V;$->C1WER
M7+5`V3'KC-^]6T0RZE:[D\_)47RN3B7<3MSV@1&1XHN<B?-+Y(D"*Q$57R)1
M?*G+EXKR1>+SW%]P3QXN57L1UODTLZ_(QJDC,4T+&XCEU<P%>!$ZJ-U4LCEY
M]K%X7W=R:,6-#01H?MG024YTU`;RER&2)>27.0MYZ_<CJB:N16[>*^DQR,EK
MG>6'?68G4_:3N-FLBXGI_-U-.)>J9R\O!.2;G-;6-.ZRN)\@EKDUZ;59=[?3
M//-G&>[S]/?Y1-7[(T3Z=57XWG_3/QBO^"#CQ(P!H13(,(!"8AE\2HUC4;U%
M^OQXZ9HT<P^JA]A0C(SK(NY#;7-5.JCN>[QXT4(M%8HU3ILTZ;EU<S33[#E^
MC@@Y$8!V%1K2L,$96%:Q55B$:]JH]&*O+7PX[M[2,,VGE48'!(H.S@3GA)+2
M'T]JQRG=%#JY.:=%FFFG$>!$`*/#BQQ1(\8;4:$,8(T$(+&>"#8-NB)]7"1H
M\2,".CMZ`"`0@H_<C]R"8U&([>FNNGCQM>UKF\O*Y$<G)=4Y+RY*G`^N`)^B
M1IA=8;"=(S/L%'O1=A&Z\E3FG`T+$C%0+@N$A`">@G1]W0<-'-78X&]=FGV=
M5T_T,VJLXH9M=8Q3PIT.0W>&3%DC<(X2-^EA!N5./_$V02#2:68R1.]K[Z4[
M5TVI#YY.*S#+R=:T2.^7_P`R/HNC?(WX1;O'C+7YQB!276)68FZD[P0EZU2=
M$_;5UR).B4:ZM75-45-46I/.8L'\QU4.VB28_G/CV1QD<U)<$BJUROK+)A&:
MZM4@M6KIN7BHLK/IK8.2;#ED%KL.>KLIE4^2B*B;5E=EU%3P17<OAG?\6\[_
M`+3$X]V"M^P_W=S%K=?I[;T^&7E_]^,[_9\+V?=JTM7[5^A^A5&FX$C(;^M6
MP]>FH[R/+5@\D=O/8_0B:*G-GMN5SF85AD*IR7-8Z<OS#;6)"FQW'Y&B_P#M
M8PQ5DE3^=5-NG)KD1K41K6HB-:B:(B)R1$1.2(B<6.179^A7UH%*3;HICD54
M8")&8JMZLJ69R#&WEJYWT)SXG>Z.<Q^GFF51ABKJLFKDPS%-W6@4$='(U1S3
MHY"S':-<I5TT:[?N_D6S/%\B11Q`M3FI),S(*J+%"U/I>:09K$_6OZ*:G.9]
M?91C#L\<O(^J3*&_AZOK[.,]JM?\LGE(U%3>)RIJBZ.0N)9JZ-0^XU&_LKBH
MD/9&;:J-=@KRAZG39/K;-FA$Z6NQ5TTV[54E=6D9;YO:HM?C.,5[F2[69;26
MN'$>6&-W4!!`3SE(_:W:W1/-HG&*8H9["2J>H`&:\;E>);`RNEV'1<[FX"39
M#]B\O+IR3BK_`,0R;_--U\,[_BWG?]IB<>Z/\8/</\97X>]?^(8%_E9>)F2W
MFL?#O<VJHJLM\1/W*DRG&VRXT*'9'^S"A6-=*56%?RZB.UT:QSFNM9=E`C5;
M!==UB>6`4%`JFJ%66\B`Z:I].NG`<YL(\G_Q=A,HIL-KRQC;LQR2(CVFR@L'
M9UCUU4[5D%FU7$+JO)>H/@,R&9DB-(9O$5G@Y/!>2Z.:]KDT<U='-<FB\_Y,
M*SLYDZ:"KDCG5=,YP!5$2Q"/8&R($$<<FPF`<KG"[@I0A>J/8-I&M>GZ*,.6
M8W57B!1S0%F1FK+C-=KN;&G#Z<R,UVO-&/:BKP\V*8I44\DC7#?.#'ZUBHGJ
MBO#ZC+<>=T'*B>3J;.7A\,:>O-Q16!R.7Q<4]O8&*]?UO(]5^&=_Q;SO^TQ.
M/='^,'N'^,K\/>O_`!#`O\K+Q)K+6%$LJZ8)0RX,Z.*5$DB=XC/',UXB,U3Z
M4X2>S`ZUY&D<9L>1+MY=8TCM-RI32K`U0B+IX=#3@8`#&$(1L$$(F-&(0AM1
M@QC&Q$:P;&IHB)R1.'65,/JBF&:MQ4;QB9(>]4:MI`<5S`@L1I^U:JM9)8G/
M0B(Y2223(HXP2.$:0^0)@!%87H/&0KG(QA&G\BHJZH[EX_!DN#(%*C$<5K#@
M>A!.<$KP%1'MY*HS#<U?UI\+%'W%8CJ@!I5J/OHREKHT=BE,::)"*2,,0VJJ
MJ]$T3AKV*CF/:CFN3FCFN35%1?J5.`H<X0K),D>.A2,&IY#F/(T`4>J=4RC&
MY=J:KHU?J_1\5_JLO\3F_#._XMYW_:8G'NC_`!@]P_QE?A[U_P"(8%_E9?Y.
M?QX=I7,O(N8YW(9!4T(\T;?SS.=U75YNH]6=-^NKF:?3PZI+D$VO6)E%L&1"
M-94$:NL:B##.E955E07J7S[$DGIF,]1M:4"$<PBHHT9A<<-[:,B9/(]P:Z3$
M;V7;P&19-Q+ARJQKH;E%.CR`[NH12[MZHJ*W:B04I[(UC:?EAW:-<:(5U;:I
M4,0%6)(XA=%L:0C51A=Q45WF7PXL!59*1UDWVVR/HB18:W8SIC4E+E3#7^\!
MS.OJDM7>;J+Y^:\9/%G7EW/KXN#8ID##(ZK980Y]I8W53)9`.6&R#!@F[`*K
MU&.9'3<]%3@40]@V6*'[ITM0`KI\+(%;`EXKWLN(VY97PVRNG/>1-Z#:42ZB
MW+MXPB=-OI\],FEYI`GP9#(38(@4Y+$E<Z(*/%"\<@/8HCB*YSGHY=?NZ?HN
M*_U67^)S?AG?\6\[_M,3CW1_C![A_C*_#WK_`,0P+_*R_P`ES^UC;WZ[W]`>
MY^Y=7;G;=7;E\>&3'3+<L8-T?(@4Q9K75(;N3(/,)/8-`),5W>22%:-QG!:]
MW)G)-&Z#8G3W*S1C4V*_7>K>7EW:\_KX>D8`8Z%*\Y$")@D(8FF\ST8C=Y7Z
M<W+S7B09L2*TTM-LHK8XD));III(>C=QDT_WM>'H\0W(0?1(CF-5'A\WRGZI
MYA^=>7ASX8,4<`ACV=-@Q#8P?3;L9L:UJ(W8SDFG@G#=!L3I[E9HQJ;%?KO5
MO+R[M>?U_HV*_P!5E_B<WX9W_%O._P"TQ./='^,'N'^,K\/>O_$,"_RLO$2I
MFQ#`;:/(&GL&N&6)-D@@DGG@%1%:>).;&BG(UJM4;Q!54?N\B?Z@Q7^JR_Q.
M;\,[_BWG?]IB<>Z/\8/</\97X>]?^(8%_E9>,._5F$+\*N?]0XK_`%67^)S?
MAG?\6\[_`+3$X]T?XP>X?XROP]Z_\0P+_*R\8?\`]X0OPJY^$7W%LELIU\M9
M8Y!8N;:6+/GL%+?)I&PFR4A-AP-JQV1U%L8X:.5.IYN&6,]]#8K;X%D^6UH8
M=?,C#JY]#50[0422]UK(=:5A6348XK>W?O:GAU$1N15O1JK6VCXOC^3U+:^!
M("@6W$VUA3(+X\BU5;5\!E6I1:%C.D*NSR:II@?8Y)7FKY=5F7JP'8W:U[CR
M*.\HXLV/*KI%^,M?:Q@2$`SJ,=VIVF?L*PK1BR`P20;:$#`,KS*DL'8]8TL*
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MQ1(Z3`[D4SM2?2+N0_*-I];>7#[054%DHD@\MR(21V:S)3'CDS?3>MZ<V9(:
M1V\J"ZCMRZKSXG`BTL9@;&O/421.?(,/TF3NZ]7&:<Q$@UQ=W,`.F/PY<DXD
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MZ,Z:Q^UR.3<958WC%KB6<&1'D2/<&9`(>)0EL4K*ZEG2*B&R331^A"F2PPQK
M)Z#MSGD5CN2=-L&6F2-OUO?;S),I>Q8-2,-)-JX$"5#E5W8Q`E=4DD37!V2W
M2'J]K?F?:3A*VVMW6XK##*7)V[X,&$E?-ERY4:5&A=D$3W5[VM:K6G<<K5;^
MT77])Q7^JR_Q.;\,QD?S<SW3SF2!?I42S0"U5/NKO$O'NC_&#W#_`!E?A[Q?
M]U4G^6XG&'_]X0OPJY^#X'9Q>Q*PPR0NW%VA!R%>LACX^SHN8=2.WHJ>;5=>
M$@5E=`KH*;](4")'AQ$ZGV](\<8PIO\`IY<^(C$@PT;`$H(+4C!1L(+@]NH8
MB;-(XECILVLT39R\..VJ84/&2>H1;19-%5U$933(BO4+IL8L`\.P'\Q>1ANT
M7S-5KT:Y#;%=/F2;.7<'L)<>"P_J$Z.")()&'"BQ8T%CXL9@]HF-U1/-N<KE
M6;Z?14\'U/<ECV=9"C>H(_<CDF]$+.ZW(]==^[Q7A##C1QF;'9$:5@1M(V*-
MRN'&1[6HY(['+JC/LHOZ3,]N\L?Z57`L+"3A&0344%/=4$R428&+ZB]$C"M*
MQTGIF&YS=/+IRTU:&JE@R:^FKT*;'Z`P[2QLIK^0A-#"4[@BW<W/=R1J+IJO
M+BKJ;E[7WTLT^]O^FY'"';W<LD^5&$K5<Q6PT*T.K55KG,5R>/&3Q\A1T3$<
MZR&;E6/9*1'K7AN+C::[HK22C=D`S);5*!7Z,<)?M<E1O=&O*^4XB)VD*ME`
ML+"P(_RA#!AQ2$*=YB>5%^QKXJG%SD.31'UU_G5X7(9%437JU%:D<,.FK)+?
MHF!A!WDY(Y%)M<B.;IQ4*088U/0SUM>JINI+M9WILJ'&",`T1L6!%=8N(Y[W
M]1Y0HWI]-5<OZ?#6<;H-G3XU9'>K7*Q9LURLB!>YJ*@^X,B#:KM$4CFM\53A
M]?=5E?;P"_M(5G"C3XA.2IYXTH90OY.7Q3@DC'<4QN@.5G3*:EHJNK*0?)=A
M"08H'O9JB<E^!H-C#BSX4ANP\2;'%*BG9_N&CG8\1&_J5./4:/"L6J)^Y7-F
MUU#61)(]?%`&#&:2.S_A8K4XKQ2S(,MK/96P!:*XDF8\)Y72&QNJKTXL4A7+
MX-&-SEY)_J&73W$,4^MG#Z4F*;=M>B/:0;FN8K2!,$K&O&1BM>,C4<U4<B+Q
M\G,O<R,)$1K`CSZ^,UB(FG[2;(E27_\`JY[EX_\`G'N>OZOSS:__`$X"F%99
M<38]H;TVT!EDT5YZ!%DO5[LFII,\??GGU(T<UD,I2@D*]NY$V:JU"9S[F/-K
MJ20F:3P/*NQC?,"*R/!$FK=V@Q,35R_1HB?_`#GW/_\`[FTX#<ND7UW<1@%C
M1+')<AM[XT$4A$;)]/#82BPJ\DIB;2/`(;WM\JKIR_U!=,;$E]FSW8-#2_\`
M6FH8,5/=F/&2&R)_2^VZ/[ML1VWI+X;>7$@%;4&DTT'+&XU*`E,9VV&(@8T^
MY??^J($1(IC=9`=HJ+'9INWNU;+!4=A>ADT&4W%*5^.V51$E2<9EUC%AU\DM
MS)?<!EBF/%U=H4ZR,(W4;MO"W->*";#07&+54B:\9N\>*_@-+)L`F;,2.V-`
MF7=8UVHG(UK).JKR5F19?$"%DA*O(K7'D&%Z_P!V1TEK13I#'D,AR280ARG:
M:,T?MT^E;^=6'G3),BC"PDZ7<6<QEJIID`_?RQGE'C%DF>/<A49N8U[FLT:J
MIQE\"XLJEDVF/C25UC$H;"0,SLF>@@5K*,=N^7.G=RQP@*V0W<I&*YNC7:XL
M*TB`[L><Y/CA3OBSJLZ`@XA9VP9/IB6D@,>81$:,C2ND#TU<Q&N5NS'Y1H]%
M/E9=@=[D=15PHTN`V-<4PZ=8L,TZ59R4/%M'7#4=JT:@5OVG)YE,67-9+FQ)
MQ84UGHDO'Y-?)8&.=]?/K9DV>]DH+9".WM(HR">QS=47<OZ;,W]AZ-^97=YK
MOZ'YG_-`]W4^GO/S5M_5UOU<$_9_F3O8?=]KZMVGJG2%V/JG:?W)ZKT>GT^X
M^?MV:?=X=^6O3_6-MITNEWF[M>\;ZIZ7W/R/2^_\>V_=NKNT\V[B_CT<^JJ\
M/-77C)-C`B=]#B`4LGUHP(HG->:4U_5Z>W5R$VJQ'>5JQ.SZ'H_IP.U__%]-
M[9O1_:_S':Z?:^[X\3^R['L/2W]7K>K>G^B=Y"ZOI'>?NGI'>]ON['Y.[I_\
M/&1>N=CX47K^[N.YW]9?RYIVW[SWG<_T7H?.ZFFWS:<57HGIV_UR?Z;T^OU_
MS%Z$;U3=UOG>J>B=3N.K\S[6_P`^O%)L]/\`3ORS:^@]'N?_`(ULJ_5.PZ/S
M^AM[373YFNW;SXD?E;;VGJ$COM>][SU38'N/4_4_[R[[H]/7K^?I[?NZ?H__
MV@`(`0$#`3\AC[X@NAA6(1;RAB%"IF>CIL,:8J!%R\$._P#V.!KK'HJEE?G6
M&=$/]S42D3MS9!E)1L=XJZD4/Z2MG8(X`K<;J[3`F^V0<%BM8U::)O9VGI^5
M[09AT:4YS4T!+J24-F)I_DVE2,W@M@'EU2)[N$]WI=8B'.U.S?8XW+`HNZBW
M2C8R`V4GHPQ$0I[/7+IVR.F%4]Q`-.ZF<?B6CLM(LCN9'7'"C6VWWZ=@-2<V
M/THI8`"@#`@M,L5A,F4L>N\S$)G0:SZ>>\E"&7:?MY&B*%V<#9B77;QEO:0U
MOVZJ=W#RL*FMO9T/"B([BN5GV1R/5B`TWAD9B/W+8T*)P0B6'[)N?\R6[.ZT
M6H-!(H9DF4JC&2)>(F6:Q`*0308-P:R_I7;]]C_P",\KJ)EM"":902)IFW:+
M$5WTE/+<B7(E"\SZY&'S+/1XLA^+;;T3"L:"^GM3D#>BV6%SIPXK14+#V.G4
MN2$#'=8!;B`.0;Q$AR&'"C#)&$SZB16ZTTCKZSY[;PORPN%3GH_3A5HI6(+$
MBD+V0N,XT(O,8)!N[PL:**NI=\%KK7T`0L#"#OGV32[>`4+^2GIR+C`<9*61
M(1N(.9P^MZTU@OG(N\P;*5,]`%7LM0"L!',X&<WNUI,J\"]6A<O_`#<*QPIE
M+$9S,NIZHXA636?`;@<T#B#D%'#;(8980J]@EU1X3Y2VU'^%`'_`(@\#J`P'
M5*MQ#^N.12-",S+H&+FAR6X434JIL#%@$%[LMBCU"M/#ZCMU)Y3;M@$8:\B5
MW8;!:U01X3AHUNWMJ6$N&O\`-H\#VAU7'EHTK1ZU'>(:.CI"]F2]B:"#.?=J
MF'8+2+S!FS6PYOFIC;J$3K538&+`(+W9;%'V=6_`*\1>3X>%W,C$R:C,VA*6
M4(JIM)6=Y:S;)<DYP6$C,DP,$=$,.%TL6#G*X2AVX@"\4-MAJX3$$?T\:#+E
M(`0]U86.`A$V@%DM*]2YG*<_0XCL8,J13&9,#.:^YK-&TK@XE+X&'L&Q.BR]
M!&`E]\:>)"XL4]@X9SX$M"@!EF#XU9845+<HR&D=&O-;FN=,0+4O[JH$!IN<
M+WH,OD6`)>/5L$B$MX9B?W$*-8%X!$ADK;.;0YQBNN8^Y]I@=2$,R:M#<^:8
MCLD-@4]1MAL-JY%J@HNOODT<%=D240*SQ@*`G,DI%FD3-VEOS^\#$$Z&\4S=
M(HVYZAH9MSH]2H!#O-<5%`X9SX$M"@!EE:L[\OY7:198FK3Q$JK+_3!;,I(1
M!I5G-#).@-A<#B.[`R,D$?840%3PU@58#BP/``$*9!?E,VRRESA7+Y]B!O%.
MD3KBW^X3TZ`&.,F!1]*7PF+Z6BA_``;R\@I'<81B!$R%"`:%)@+FO>UJ?!IR
M"#,[!SY"Q7>)ZS<;P9\Z5TYUUL>CG$A+8TBZ0>,>3OQ"PNBC+@&-\!1<2YYV
M%YQYA*0]L*%1:!2C!QQ1>*B:"%L#//N;LV6RLVSYLK[%E&&40E*DA9F#-67!
M&..\BF8C,@AOE-!I(2KWI!+DV;I+4Z1[A:>3M=I#H4^_4V?&+CJ[P1%(W3Q4
M:!4^W"\N':A8;L3'/HU-\BZ>=P2(_P`8T=)H((%:<:9)(Z91F#`3SR")P@DR
M?"J96CR>LA9,-ASC!7@"4#/-L$Z#<"%7BMW@/4L)H5)C4'&>78B6K9A-'.M(
MBCY&#&``QV&**WV*;H=<X<<S=^CH*-F:ER0@8[K*+,2C6I.$H7(_W82_:W')
M`1O$!6EVY:54UL;:`(8H1!&QR)I.Y,)[1D'AK8,&XBJUL:.F6QT^H&.I<D(&
M.ZP"W$OH72BA4:1@X/I$[7Y7%1:@G&2HYT\`8[<V`BZI$RR=PI!LP3H$&=V=
MC5!S.9?6>Q:DHN6VMPX>LHK^&A&)`Q0B4K':_P"SI/-61K"MRY$BB5;C%\!2
M`X:+?2;BKC90;UJZ"G[R$BY:K>UW:>C/@>YHN:CXJQIJNO\``*+MUYES7:A"
MJ%A6BI%UV';&+BKAQOAK4+%>)+(9:?A<D3'*)%.@5U`L5+4$C!+]!\S4^3"J
M-BA+8X\H_`S*L<4Z82L=)K7)H5/TB\<$+6*NLLH!%!184=03-M:-302NC<X)
M+"1RBO.3'0H,8*M)EVY3;](S1T<,2SHSLHD,*M_T$OTD>"->79*F(5,`:0%0
MB+UR\"`<H;5LTQL/S`<8!4'$2-!O\0)`Z@,!,H$_BU3A?7"8W"#OD(B6(&"Q
M]$6)S,*,0KU0R*;FN47%5F]N;*3,K$YQ."B.RU)(.S<ZS!)_8`"$*)^[3A;=
M&[RQ*R(CDDH9.M.Y;GI^\MC7-Z+F\-B]3$M48#=/>#4BT-QL;R!LQ\1K(+E3
M-(@A'L5<.O=2!D>FGD4O?E^DND-R58SR97;\H#UHLC;`&X=QA8['&L=<I8O1
MF>8M5K32;6@&T4KC`W)+-@Z.C@2E3JVH4"OTB`A2Q#_6.20DL:X;F&W&A-Y<
M40B*)C=H/ZQ=)$E,,Y\"6!8!P]<C$@!VUTM5Z]!D_P#8,@J9P&N[&7V!B'S5
M4$6-5I=Z;WJY%=M\HYMN`)BU2H"J*`?\"1_!@"U=2[@&P2=T+RRW:73Y#L?X
M1TMEA=P?Q)E6#NY*D5%*[<9/57_6]6HHP"'!0EENV%"XZCJV!_=KA:&;GPFI
MR^=<`ZBE`9[U.XSAT#&Y+Y2(&I5#NE($[+(L8">Q+_)'VE.F8ZJG.#*CCK'-
MYJX@%0DWA5:K0M3@D*S<18O)`H=:EC$?F[C"'1N0;`JDH=6VYBY>EY$9.6[B
MXA-$GEP3$$PBF;B784((B")2.1'8G(Q?!,MBAJENPSP>"&M;3H@LV3F(GYC*
M`63D9;7Z0FL8L+8*(`8*R&NI3H2>BQ&Z/HSO1%W/(J1;$6S[,VQ@Q;5Z-A(G
M6,RFNRXCM`9GTK=#)9"`J-W;;VX;X8_[$1.DHY[?#H1SFKN$JISQE*-E#.ER
MBE]!7-7F?"E@&)?)C,"IAY0S$EK2<V"FIA*WL:!>/1J,(:4`C7*<`M]^WT*Q
MV4-(:]V3O!S=[L2\OTN7"W1-3W+<A(:0[)-9A%(H&/<[@S[Q0+YQ5%W<(PV[
MBZ;,XN0O":>X)T+``G5(TOOF+VR5^@,]X),;$J.5P,ZU4KJD/D%$9L'),6B&
M+A>,2_5&I!+PS@L:+Q*A1KF%&REW1+CI6G24*GI!J5=.\K6+4WRX1B$@W3!X
MV@Q9)0CI:FZ\7]@,2E5O-#87\B!+@\YU[1SV^'8CC,74.E0\X*'=D<TK2JP!
M?)^@+4SK[=6_5"M19Z1.]?FMN\^A&!9UM*4<W%AED(K%57)=%C@OW`G+6@(E
MJ*>;2N$<P?Q``A,>"W*VU*2HDYQBU/+<I>X_0E*RDR"D2=DGE$+4<I]A<#,,
M>CH6%F:CI+?T28(!6%]A-.<9@G!(/"F>9%T0=&KI3Y=/*WSQ@H[NJ%I>,9.3
MH:EG-5%R%*H@3``'5F%DM3!2VB@!+V!YZ;B/H5H[;*]E+I%J=9[G(-UF`,H_
MX$C^#`%`:F+;@"8M6J`*VP;X\`:4:1K@D],['8-D92%'7D_:XJYL"!29%P:Y
M426OMY*245K!U#@\%F;T#%D4E:=3UZX(J%CV!ZH[,#76[O*V;6Z1P%"J`I_R
MEYAG1L;,2-8%IL0SX`?<U!!*$H``GI!W/>C[80_V,GLX_9P+JN]&"Y!$P=B2
ME+MG<'`Z-?J\+7F>7>+?4S`UZ5(O%E3(&F+!V3`(*&2K*1&$"J(:ER0@8[C`
M*,08)ZU`>/KFT(!J'"2DW6B9/AT1#QF7<>TK<XZ4AGH4W9AB$=JCM('L*+(Z
MQGZB)A6]95+]A$LP->CJ2^B;J`I`G8PV1&X$Z#3;TH/D0@K5-%%8LC%WQR3G
MQTG>T0*CHOQP4#*C8>ZM*!56*3H8BK!.+8_M(YY`C2TZ.8-R7_._&G[!$LP-
M?E\O,UUFV6VV&L)X)%*M#8%,;'[L0`Y+\*RS,6VAV2M19E&64%TL\B5*ZI"I
MC"[GH5(5Y=Y,99=#$^EO3.QC08FQ^[$`.2_"LL^\$LP-?*-_*VXW7?M?LX)9
M@:X&T&T>&NSLT_M(EF!KL`DD'LJ/7JHUL6!^Q$&U?A05@G1H%=J[WV6B:&I?
M<YN3L+IH,`[\6L&@-ED>+.8FY!?`CDYHB\<7C&WQ4S\YJ%3Z&O32=!%TX+",
MAE2F$>\(EF!0LZ:#`$7RU9,++:"C276BU5B$P_D_=UP8P![BA=RLGSH0DBL9
M:*JPJ-/P"[>=A%G0N-E[YIMEGTA,H+!V!(=2$5PD^$EQ[MX[[8\"<.=>A`2V
M.+514DIZ/0F.P]79L1E)@Y(Y7J[$2Z)`-PH\9OWHEF!6@""L5HN3"]I&F0Z4
MG8?>]WN]P8`=3X=C_AN.@.BVXEI#.@+\$6L#)V\D59&<XHDQWVC9^P!"C56[
M0)]QC7X2/4J/*)?7DS94]V)I%3,2GQU:#3G'J`K6``S(6\2Y(B/,MB1W3([5
M!_?0<3+8AFBCLM.D3K.ZWZ)39I@)RFO^1?=1:Y4*H(8P7&*^7M9ML:V(OLN-
MA-BP]SF+T"I1=!RXNG.55&KFF:F,#8['%P,('0(**E&HS;R0-.5;`9+ZMR:!
M8&`,K9BN'LOGBC(6W\1?78+!U)DY_P#L`9XB_P#\Y?G$24E_$"\P-;@3+A8S
M*R9RC0%6)8=+\6?814'IMD57J`/8:/PF!P!U%,F&:P@1_80=;$IY5WHL^CP$
MN2L`9J,K.\!1:B-JGPV&GPP%$PO?CM"9=S$>6R+X60/1U0Z`_3DW<I6F<L=M
M_8"[9"MD5K9B#3M@D`'H!Y<LQ)1D*-*,PJ.UG@!OV""8.P4V&HEN?'.0:.H7
MC%!@*P%RZ,*LMX-J"6_@K]:61GY6JHXY4721$)DXZLTK1H@`84CF^;PM&5P^
M^G_.18O,5QQ_'#$?\DAT:5B.J/7ST/\`"^'K(H/LC'T6D'\TJ=_DS=&G3'%,
M\*K?A9[A$U`).A_CE?_:``@!`@,!/R&7+Z7+E_IW+ERY<OV7,KI4J5^G4J5*
ME0]GGI<)S^DZ]).?=W+ER_37N<Z"JD+^+1"KYI`/P3'IJ5ZTT)=Q?TW[G+R7
M<.@-*@=G@`"HP7]F@X-^+5FI#K*/H%C_`,<FG/5E=:]%>0[*NM#.5NW>Q84U
MDA"^XFSYNX0I(:QJWM)VRJV17VZ/%IX5M?B;[D;>C2\[CYGBWR<<DZ7+]%]&
MK^<%]8?1;R3+'7P-=E2#L=X"MBC,+?9`W^#L"]Q]HE^PA;;^0?6I;?GV_P!C
MVA3]/?XG/U@7X?"OK%]1<DP1]>PWW5+P.:<0$Z!PPZW4+[T>5?DYX"Z5TKK4
M?N`M7`!M7@)?]2/&A3X:OGL/1H.4_P#[/RG+D+U`*U[$6!;C1?*[SVT?&%K!
MDM3@1<UW.VO3;UOF'2WI?0]#+>_$2\?,?K416@10J6S^=GF80=!]0_SQ-TUT
M-_6.3STFQ*JV?R./E%XP,!ED"_7"QVMH>'9:%]6O!*MA?Q17P&51->*?A='T
MO.=(!X./H%!_JY7+F7B8.7=_QSYQP]."R3X.#XOXM]..E>BI4QZZ%#'#^?XS
MWZ&LW$>YW^)Q].8X("Q[C+RA@6OLFSXA@/HN,E+:T_"U\'E01!L7IS%$SGF'
M;?(Y3.+3#GE%I\K#K*/M%!_UP;<3'VQ_HGTCM=(,SX,>'\?-GB+>7<("WK_K
MX.9\Q!]1_P`\>DWTS+E]+Z'K1';*2?$8?;NOA]SY]*1,^?<_#^&87AAW(_A-
MHR`F26R_.\OR&G@M8I977LV<F^HM=^.2]0'-.X#MW7090#++S/E^7YC;RGB@
ME7P.,[GB7Q<N0<<>CZ`?S!;%XM_X'@T3<Q5@SX?V_P"./U,>BO5N[:>5PGP_
MY!BI/J<)X>F8,'\'<U]7,#.R1Q7*=L\#MPF**5RBD.XE,)(P^S(?+N.$PXF@
M5KPF:YYSNJ\#I96,P8VCSD#C:`^C9V!MK9Y/P>%$3T?`@#_)75F,_P!O+]M=
M*TLV'=_H<>?AZ777_.O'1UT_S]$:K!\CG_'GXL1&G<9"GL_G9TS$BZ'U#_/$
MT+0<(Q1W-?EKT-6&%W-#O?%V@X=`]M`M'A&X[`$#X!?\KNBX4?R`/I7/=:&0
M3%B>_P#47R_0H`EZV;+N_P!#GS\.F>AG?]/+]C,#D`4'8/<W$,].S_KGSGEZ
M#%M`^/[?A9#:)`<B.$3D3<N/J5_(DQ5R@+GK&W.%?C_63H/&06_,(/D!<AG*
M"[!]PLKRWQ-P>+?^+X-LXX]OU%_F"CW3T!*D[D0,/DK_``[\_6`PB_@KD'E>
M#^OT((Q*`/;#Y)2Z[N#'QYEB2VJ;^DQQ@SX?Q\WP]_E-:_D`?8]<8E!1=\_M
M3.,2@XG,(:F*Z?[^Q,XQ*"O_`+)G&)0,XQ*!G&)0<7+9GI<;Z7#WC.,2Q0M+
MY+/L]:E=*E'[&SC$F?'37TF>I[MGH)A^('Z))G7O*53TIJL;,44"%(QH5KO]
MJKA\IM-@!S7PX7V";%[X;;(9L)D&,5+N[XC!1G9\CB46+^L5<6T<77_U]LN7
M])Q<=2Y<MA[_`!,3%>.F)B8F/<?_V@`(`0,#`3\AE?25*E2I7Z=2I4J5]8GL
MKQ71?1<N_P!.Y<N7+C[+QYE$J5'4S^DVFY1*Z,;KV=_H5*E2O3?N?'(PM^TJ
M6CPE/IN6R_5;2/GQ[D(E5Y*,Y['#@\W")"\B[+W:3YF0C.G`>$ZDLZ8EGHYV
M7]+X>?"CNA$@*H`5VK509&.=%-UV&F.&_<'$Q/"U\W7]"=+/@"</Y<^M4J`2
MI4KIN;\O'(O!]V@RPD*#YKROE<L4"W4*Y[E[G[+0'@'FO:CQXM_R`T_)D_\`
M`Y_FIM*\G";7A^S3LCPW<^#RO(X8@E.H]!E7[K^WR,VZ7+E];@`+4*D*A\7`
M^'U=P'3C8YG+^7/M\"!6Q0LARWFO!#B"O'/HJ42IJ5Q&IQ\I1,2OK*(^@.?%
M/^P1+-1YF<3:N'N3S2WTSX77A3T%GCWRN!Y'_'#!)IOD.!X3/V<^NIS+!Y&_
MP?$>'2HI_D#XGT;2/*<4\K*U>7\/^='9PT?[\O1F9F9;+>MRY;,S+Z;_`.+X
M?YT[0-OYPQ%C$\BI>+C^-T[+TX8/Y3_?RQ"(T[](UV?X(^@=LO$"L$`:`T0G
M3B/`2ZL_@#XGT:"?^J3V_P!Z+M6/OEG8ZD\QU\X:)BI14HU/$HF(S_9_D_ST
M"C9N!\P?[TPCA]1W^7X^$518#_..YR8F-W7L.SX<^'F^EWQ-.7\.?^7HPJ`'
MG_.[P9F5S?ZR_#@.#STYV&9P_AS[_`@SYO@[P+J=/_<)[_YZ;?1GKF9Z7+]1
M38?<[0[L=/\`SJ>W^0BK?D+L^H>+.8[0$B:1R,'<P!Y&6\*_@>37EX3KX3"\
MW_KXH<ITX-/]KX^/+,!0,ME(=MO]?+I3OS^SM\_QZ3?2I1?SZ=X&>AN$_P!_
M1^9]X\_[-Y(^S./OEO<E3F63P[?FWY6<G1;B?#78_0?D\$*&F"=DPD8C:&/G
MGP&_D.>B)X<'/`/*_3;@CD6GR#@>`P?[*=>?V=_G^.EH-M']_*(F1>YK7Y_B
MO\Z5/S'^?.`G0MCV91I:/)O?N/EZ@$'>?Q_]=&`HZ'=8O.CL'EA7]^^>QT2Z
MD6?)\';W25H$$#`;._DC=L[3S_GI,`;.NF*L=>?)_P"QO*>?$^35Y>_^>_`1
M_P"J]0&S]GTP4`V>O3*S*Q&,9^J;E?B/N10#9^AIE^_%`-G[/I@H!L_9],%`
M-GITQW7$HE$Q4J%=*(^Z%`-G306:O["ZVRWI;+>ERWW8H!L].BG=='/UE'2B
M/NQ0%Z6AL_0T5<N7[I@0.@A=.@BNZ$JH5:S#)<75T[K\K<3=ZE\5MASK/ZM`
M4XT(N-VZB]\JP#X`.?CKND.BEM=C0?(H_P#KL7\I1*)7UE9J#F5*E$??9F:\
M3/,S?GJS,S,?/M__V@`,`P$``A$#$0``$`[-B````/\`S:````````"H(D``
M``#EZD````````1E)````!IVS`````````/@``62``+R0``````````8`"%<
M`#@``````````"-T!%*@`P@"````````"`,@IK'#I0`0```````"YPP@.-IY
MWV`.U9%6I4`!B:W```=[52`(:/\`EB8`'5V?H`!B5C0#5=MF-J``524<`$#I
M$8``'_X?^S``[T#A`C$*(`"-]UO/X```0CCECU*Y``$@G$$@````R\+#>D%`
M```````````'LA832H`````````````$@;":!``@8@```````````830`$NQ
M.(``````````#":``$@$D```````````830````````````````#":``````
M```````````830&.5L0```````````#"?`6ZGZH```````````838#QQK```
M`````````#";`K`W@```````````#C\T````````````````$`@`````````
M```````$@D@```````````````"J-0^``````````````");TM0`````````
M`'__V@`(`0$#`3\0E3"5=\EU`>JVZTV3!*_G?G[9&=SVQWW1J#'\7:!!M:LZ
M1Q3HDWJ0I=9#=?T^GOLS5KG"C`VU:L3U+6UG`:8\TB'H.'OI\\2ZY!#`NBTA
M5[QD'K:P%:94G=HUA6QCI>SE)Z;`Q9+`0UC3;&0KQ^$P,>R.51#3ME[H[F(H
M6:C`*>^%1!.@P&F#`!O(C)Q,-^'B*@D!`9B4W?;5/1D)BC*__-B\CFO0O?I2
M,ERD08WC)!E(7P/[1<?>@?\`E(GXJY^6T8*K&U$-J">B'.@5P^!]ND1_-RHF
M(C,!0:#=$AB=%5@%'M@N-8'V)@VU3TCQ6.9`O\(.8BE.CW8YVPQ3?84.8R:5
MOZ9<.+1;S"AU+UI-_`J$2#\:]?I3%5D?;`!PWXE(`(I`7!Y,D=+CX">5;3HY
M$1X0?'"(S9M]@_!`1`HA^KV;Y!"+X(3QPPUQ9F)V-D]E59^X&>-A9M1/Y+>X
MPVSJ@%BA@(E$J(<2&54@L&)L#&[1LHJ8W.5=<I!XR!XR5J.<BOK)C(!O22LW
M(-S802O;>^>XX+;_`*#+E%V21J+@4(4ZO])]5,18WG*VZ][GR^B#2-_<K$*I
MT'*7PJ6\?=$A"+!`[;*B'3XR1%UR7>JJT]AN)F!B\<8&O!0ZF:[@O]:8H\=A
MA<ZM=R7+<%E%`#`3VG>@_#`V^Q9':ON^Q&)K@#P6XUH````*ZU^,C^YEJND*
M1;9-([7VL;6^$J(1%,H"I`0]"`(-<I!!)W*G^?PY6L;!,*51$1GK9VZVKJY,
MP5-?@1$;CSHHZA=Z<,"[(-&2!&1HNE6Y$&2(0@L=G)1?%383,>NIU>#[]#4&
M=$J(1%,H"I`0]H@=9]>3;,RI'J(&"5`F)KE$8IASF$AIY-FD#N(^V"5&V9A?
M,/4$JE$S"5RT&@8FU;5N;9>3/%82W?!"0Q7)I/4P"1%</"0F!,(!SI6*^3T$
M4>`EUIK,R8"M*]S2*Z'+4ON3!A%YP,Z]>A!WM0G4S7R?)EY$Z7W0E&U1*(`6
MQV.+BQ.K-A_2=+-WSE!0IH"+6I#V%^6BJDG2E#`D0I,YL*_Z@Q.8JV-F0`@R
M>F#&K<<=!7<OLS>0=L3LY,!`!:MT+U,J@/)73`OBCWZN/=P@=`4-8(KR=E!M
M*@958D=5:P@;^">4L0/#CN9"#C9U*`L7N:+&M['`L@&!+[H2C:HE$`+8@3[(
M_80(87VXE">0K/+$"F,D$&XE"].[FY"NF+H'4$>'L>QQ>Q]+P7N',"\+)J&N
M[*'YTDF!2IS4\T0`4:F":]0D,27QT85Q!1E;ZR*J&-3)0^!5`$X`@:<18&Y+
MQ4C6$B!ADMVH\:`O@H*MV>YAG62%D7QN\T)6@A"I166(9<Y;@Q_R$VPBPV>0
MRN1T49VNIVF,)>4&J/70+T`X7'TF&<Q>Z,K5/23K,,*J&8IBCI14%$'6Y$;!
M74^+_P!"YS)X<K71<:D+5V;QZ)1,/N#05-1HFD`0$(GX2"$%C`B$-Q'"=TD0
M=#.,M9I&&.ICO-"&+P2-794S)(%C2VGPM8+[&6Q#M??B$Z<7M)4\^$Q=U/%%
M&OQ@]9Z2UKG)4P5D)@[/CKILWP9&+N]T'F51&?9A%="L'PAK]-TJ6DS.2`W;
M`O;KML&J5%AOVJ<HJJ\)Z.1K&S;"F8*7@/Y(>XPVSJBAE/"OS;H2@1)#`H-+
M$*SK&*N#UH@_U">0\3E]!``0%!8A8B.&+DDI(5CS5,@HLXMQY2",%)AKTI_)
M;W&&V=4`L%H2[T'L_P`Y1O0L_CID)`+)V2U9ML@_%DNI.JM5*S,]<L`4]Z>O
M+?Q.,&Z@)`PJ506G0!.6=37"K!(*T_*BE68SD7F^BXW86^51*Y26W*M*Z%+[
MJ6HX&BUQX=,*@MC/4N%P"U(0_P#9HSI'1'<@HEU*"*D"O/C*M2IW52U.)75W
MB]1')%53(280.`S<$Z/]36/70JL!!D8"MJ=SHTOT2)BBR3T3ZDL,?`R:ARY*
M&K1>'7(`EPQR?+Y$!G:%FN&V4-A2-Y0$K,&=+_/E`%%S@5,S@0@(4AQ:>*U$
M0_TOBF)+=2UMDA!!MA7RI>$BMR[%8"&'[8C:Q3%$9I<5TN)OG>F2_I7M\`9`
M&+"%;9A1F_C```"."X>7A"88;2%#D82'4]V(.@JM:%7HVDH*^!#&TVT\7A!R
MT!7V]]G"0`.@E`(:&!NX6>I@ERLEILG%0-1H%A]IM][J6B0W-D&,K:J\/`V!
MYDK6[-ZE$E-W#!TI><NT8UEYM)BIT5HC<&_:7GS-@XBN+A'-2^I`J17=#S+7
M6'9;-$LPHG?UEE)D]@F[AI5M=6HOZ&I=PG!2MNTBE%EL.?!6.5Z%T]$NRW45
M1PQ!8#[@N+!\H)'N+@V^"#0KT`44>>Z-!.O<0G=$+[H2C:(D%$;.J!7X!P)"
M"6!)$-@1<J&W'E-L].DSJ:CY!*,JR5!1"(RYHX%!8FH$3LT/QJY,R/0^E=4D
MX@`+<3/XP>%'/DJ!^N?()@E2C5<4`0#,+BHZ+O\`_:DAD9-3/R`1/.$4*M(4
MHCW4U2QJ\*^?!%@V$2?%I^%@L6KK1;BC3)C<X8Q]46$L=;]^FU)2=P\M>&LI
MXT%-25-;@N[QP8'!85D2XE`@H`-"CHY(A:]S$D"$'><@6X#U\C8BWJ8//L9J
ML#G3,UI-Z%[.KC-7Z#UIPFR`2"8+I267O;!WJE.NB9PP`I"P#2.X5^MHCI6L
MMLD>4TC23H"``YA6&L(A1)9)IN!,Q'$2=21`"1PE?M#F*U*+Q%]&4[Q'`VC`
M)P+U*C$<$?T2,2N=(PO5L,SZ#*HPK98?6A\<,6@IY;G:V&DX"WI/;\P?B[;S
M+1I#9INZJ1#M0LH6.G4W#,].66U>\`"F#KILP$*.LU5JC.3<T$+>%@L:+9Z<
M?OE_K#0N\?UKD&P9#H+I7G,_NDE%E<B571D\#L1S9N'5-H>$L&7&Y^Q\W^<!
M24Y(K/J]93@XGH39:,(>HZ@[).S/=/P-$YG`W)^@,&,^\V'0)"?F&VD(I523
MD41CJ(8VTZ3&+,6BX7P<$?P#[BWF>?1G,!-&O02O,',8BYO162(5M^C6S+N0
MN%Z!C\Q;>"'-=$@R:=.&)V<<"IB(&RY1$AK*GU;1\'XNV\RU*2V;ISXP]6<4
MIZD95K]YLEA6$25'J/FADS2J@)9`B[,+&12`-RT/9*MF7&4+F[&0\WT6*J\A
MAW:/00%83:C946U@.!9K&"N<^X8$Y0"!(V10K$B`5KT&*7<08IHB3`3(3_1\
MU[/9TT7+KD&N;WBMY(ROT'IN`:C#%"@60!%!)JUS<<K9(?1KBS)L2'[0SY0Q
M).3E[>T3*",'YORN`&KS$="XS5'A7B,#S)$H=&/@ZYD0$<(P]*2@-11V)BH9
MST=#Z5T2#@``HQ+@1.C0_&KDS("UQI;TO,7Q;C(>$1O#10]%B[]J>[@EEX88
M1EP4TJ%@I$BVO0NAM"[O]9G<M-S`T4":IRY.9/70BXZ&*Q.P,"!YU^4<[1Q.
MDD1&JX67J/H09**H"BQ<>0"H[=6$GW]!)G7HLB(_;1.(,`9LNX"(J(F<.VJC
M;@05"3E1'U\(:.CJK06@*#TEQT-X;DJJXJ!8B@3"2K(C=V2+&``_DM[C#;.H
M`"6X61*_X!`K.WM;F7`!+$I#H%0P-N>)8&W>5T-=T'!MMYJ5:A28'HAA'T,(
MW`;U!H**WHC23]@$%QT-6(E="MH3=Z0,#L/I%RRS6Z#`R%"P#_T@6?%*+IS&
M.HIQ3V(R.L8LFJ@.>_0O041#3,5O_G!3?TW220+<XQ+VHARY/[`1!<=#_.C0
MH4`-W-LH5?Q/7%U0>P?ENFQ!MY7696R\Z(LPUHK%-91"A@9(!,@1B2JB*.K5
M*7R"NGOA7^@I!4<24/%A/ENFQ!MY7696^\$%QT.N"*'-@`"RW_9^(+CH;@@G
M05DJEHY9FE.?VD07'0VF8-0?/PW;]*M+Q#L9C>\T>B*`Q-^5(DE!.F-^OK9&
M(L3$6^3&_.2V@8Z06G`)IC$7*/T056RQ'8D`'46P@/0$S)J4*8K4#&,37%1"
M>6K^\!!<<F4HB4!5@5@"DMA$#.."OR<<0@(<R@-=_8NN@"UOL[D<0.ERH8LN
MF2!0@@CUE<W:/114#O95*H$JO63Q>=#<!%[A_,9F@AZD*\%^-^!Q8<BX)7CT
M<:2;B0.B1!+K242\<7WZG?5BAPI:![T07'1!].X/X"[E%I9!$*\(3`3'DLL:
M[_#S!`QL98C/^-M:L4Z1\[?JOA>#6NTUX`N7Z4L7;K!DBOVT<[%#2*@8TUE>
M$ZA*O6L/="`Z\O1V0/U=`Z1?2.B-`HP<F5;+J+!777W#T9OAD#S0N1@B-.:,
M$&A%WX"=*;=G2G-+U!4KO5`*G<LXF))!J8S*B%BX9V=%A2-%<"J^YM[)1#ZU
M[R(2='HB-"[S9/88"P=8>8OA#^L4KR"5$:FFN481FNF1O1;R*40'Z!<L?C6L
MA+*1=E;XK`M(5?L"48LBA+Y1P9C!G7/'BY`J`6EM.,C'?'1&JJL.B87#8@%0
M5&AB,K^R/[L`V$.)&'L+KU`2JP`)^P"7)<AI_$>E!V(2*G/I6)[<%1D!3$5@
MPPT-:2/.,S>BS1)(8E@7%!)4Z2>`'II*SJBDUNC`%C'O\&`M03SR*DXJTR8!
M"/2I!3(2]\\IEF5/K49'Y]9"HM4&091I'1%\M+2P15RVB=C=&#C)40ETZ_,0
M!!,"4!V*QY!3_9VHZ%)]REG`!+*]%_GKK=CQ8O?/_G#$DT#71\N,S_F.TGC3
MUV(4\.X[(Q)R?XR1OX:^9TP"AS7[(026R/\`,^(/T7=$9&DG;_,=K/XWOMW_
MV@`(`0(#`3\0EJKFZE.>TO,<,;Q^8Y!IN`6OTFZQN954K7SJ<IL5YFU\4PMC
MGV5&4/QJ(/TG^?M.YW<*/C].E/F?VN(7S/!R?W*57A^\^(]D6`^)8+O$%P[R
M_B6JQS3$W7B-!_3LE][BI%KZ'YEN0<63D>8(V*]F@P`E'JV\2DIY@%H]*'Q`
M#'N,5J9#M%MC31=M3@AN9--M5.,._3I3$2B!6O282K$3,Y+V,.CA[>Y1WOB&
M0!\@$9),MO1LJDH(QE+EP9,[MA`72-.0$L`(=+5B6\\RF_G"TQNI;SKT6H!N
M9`I`5!"@PH6:5'/+LED&ZL7<RXOS(=R4,B+^XF10_C:&:H<BU`O$>O%N&5:*
M\@3#H)ZYI=3?Q%?G!=<RV\3(QXZ:HX%"Q+X\.Z0:J2]I#"Z^'5I+"\BJ5.@H
M``M5P`&571,=X8I-.YTMI]@]KUA4'2P",<-BAQL$L=B7>&CXH4>"@,544937
M@IQ4,<1`,@*4-[ED#9KW6\"%@A;3CU7?R[ME8:``@`#D%$1L1,B.1,C+OUW,
M"CCL51BEG2U+E$I*)1"E>(]FJP`M"@`JJ`%N(M/R$+5NIO`F@8.9D">%PK*'
M:Q@Z$>ZAB&@"U5T!E90MD4G.-7<+T4(V7);8#BPFA013*@AU2RI=Y[$^I=2Z
M7OB6J=\S;X'\Q+N%W\X;.):F=62V^+J"WXMB7>_1HW)ZH!OQ8#C8A<?@H1$I
M$PB.1'",7:2GY$Y"P.$4<,KHY7D-G<=KE#AL'"S(&*N'E23*NP@1&G"3(:9%
M,`>;0O"MHC5WZ333`:3LP?UB'4%0A*"F;@;*3TZ1B!(C&01Q=I9%)0/%7:``
MVK1:%"BE>Q&MT9"]G3WDPH8("G=JK![J57'84]:*\,H8YE#*2B`&I1$0!*M?
M,H@!Z=L]*S3H!YP>5<V06X$?=P#7/W9L"@,SBT"Q/B3@0)Y)4`9%C9EP,LA2
M:;`%-&-*KL6C'4`"(V(Y$3")I]*';3&,Y!(X'O`%FII;S?*%?+"3.[80%T!;
ME`+0"F.L490RCFIQ`HH<A3KV.]:_.SNMD,42BIM7F5V=!P=TX"U<`S-$F::4
MV?@<`.+ZNF'`8Q$MGM%14XJ+9KB66CFY9+-'\8.%=2V?E+=7S.7Q_H@H%=O[
MEK6>9EK/+_?H-`T@L1*1'")A'9+R%9V/)=[X7@;4I.Y')PC;LSCLM9IJ[:L/
M8[754@P$O4F44!,0!6GQFCZ1[Z5YX35L+7)GH/P@.^>@9?1"0T!J$MH;$F+#
M8CWA1Z0ZY080J0=I6!H*>Z%F%]*7\U5K3111,XX'L&@.`H.QRY@*HRL/6U1W
MO/!8?*NX^B@`>F)1=\RB_,K%3BI0[5,,P8(@E0!*/21^&Z+#]4OJ*L+,"IKX
M3*N0R?1I$-9(.?CM7)8.YP=Q3D#$H.!A<P$9*-BE"O:17F618.$CFF=I03LK
M0%22D<)9N9,2%:2-6[*)U>:8DY`38\,G1][X('9^_!7=6;1G3<*X#?0`?(CU
MT%?;D/&+V5E2L[@\#6TORX[RN*WZ$B3<>*;S+Q\Y;5\QDLOM-HGF+L17(.,?
MGIK6/^2^;S3^X:SO]"D:TKG:KYW?5C`D1&A:1PB;$[S)9TX\B<A8<BDR]FS:
M&SN<KE#1HUY6F:1!NPC@@#9D^`V_!V%RS3L%FI"\!O%$/#$1&,B;<&1%0RRX
M'TW\\M%I&E5646936JRM8%O+`!%<`%#$=@>#K;#Y<]Y#%[AVX0?:\)XT.PY4
M"'I`"@%`'8,>JO11O]<\II0;&@G94?"Y!'E7C-E@?$7SW%A0L+!ZDL00(B*,
M>;>U04.6R44RI>ME/KQ=I5O.59WK8]*>_1%A7L03"%8H5*D[)"CX!V!V%56Y
M68QP'8-J<!:=CEQ#0LRKI2OFJH+:+*/=.H8@L0I$=B82(I6P&EY"Z=!8--W0
M$["N(2E@4+`6VVT%/6'9?!I^2TTV%P+&R4+H)MZH%+]J%WXJ$Q/$O.%[Z48:
M!85]\LE-KPUCL!\LY]=E\'12%C?/IN]=+/V/A9?!J"[V_F"M+YEL9W<[.ZG9
MW4M+M=$%_CQ!;&]W^P\++X.E_P#V7"R^#X67P?"R^#/F1`MK4O(YJ6J4XS+Y
M[4L5'X3XQ6^!B6[U?O.%E\3MI\CD?"[!K9=(-G6EW*2B4^G0H8`-RB[YE5[_
M`(67W`Q:CX_.&MW#"Z_U+!X^4MP[W%3GB)NGM[OA7KAK)8*>2SU/N%&N(`8-
M2B4XQ`#XRCW5XA'RO%5)2]$SN\[(MW6I9&)8')`5;0@7E"%Y@5+;]E"RN0,2
MHC<'/K,B>L*)5$D:(3*W[JA2S06:O_ZZVOG_`'+'Q<M>-5+;(5M`!,L7>R":
MO=U]H8-9(K//OL5XO^?>;>898W'@C%>)]L=KAV=YIXJ%5CV__]H`"`$#`P$_
M$)2[[+_GSE\4[:FCX89EZ;^Q`4NRHL+_`$BKSJ87?>I?Y5<X>9B-^/O-:[C[
MQ#/'LE%D5OR,$:[C-M=_O.T,5&CS^G<13)&_TJ"`QC,SNS#7VE[L[C](KX3V
M32OS/^2QUG/$1;Q@_)*6B4"$!D%9J&3M^EIA5.0'ZP1NNW#`/'+CY:E#2F:<
M?"`PG)`*-[OV8ABK+?5IYJ_E+2_C_P`B@M](CS%5MWUOVN'T7:J-M!:.\8[M
M(#XB">G:S=0P5_*EJKQ%7?I%6QNC3XNN?<X/%;GA3M<II\A*="K&#D`6OR@&
MJX;>!!(I.SG26)D4>M+S*'CCB657C[QHTZMX^G$R<;_G'/HO$)LK"L12L!'&
MS0H*D90#I0@*<!42QZA3UYT-PE!2A`]N9@%%R)1.:'@"T6YPR(628J;+"VC>
M(P+:F]+S4O\`.(^%Q&]$I2N\?>8M/G[?]Z&AS$L6=?#Q8Z$#B(Z?-+-WD[N*
M*(@0`6KH(E='OD*NR]Q=IH]H&NM58L$"W%J>:NLS0X56+YXS\6&8MVM^+X/=
M\'BT!T'4PW?AK=`X$K]T.^@G!D-684I41BRD<B.Q.TM5*9UL;L'+O8DFI:JE
MI:6RWY13?=B)E``6JX`#*K@#</66>%W,[7M#5F4>EU4NJR;!31=U\.8'@H`#
M:N@CI,6@#P'&.]6O-41B#,%`"T0Q:72%WMKJ--RAC=OVG-Q5_>`0^<H#VQ*5
MV6?B`%D0_A]9FJ\XE6HW3R/$IKLO[7&AW8'WJ$-:]!W["Q1/D0OQ=9@!!18F
MDA:4:3^SLFQX<S)SMP<#\>$X1XS-#C"7#UV!@UT%:HC>34MT4RF#GM:2<)=B
M#A?+9LY;S6')=`$/5O20;<JAX0^$-*,S5LOE,*;HS8P`2UL`$4BU\>`H"@``
ME%C&#P/YNO#/)433F'\2GX`W\:.?18?)+6>)8^$YKGDYBKN6P>+T1;J_K<P5
MQ%Y1=G'IH"Y-W^=;\+.QT=XF?L/9^@_)XAL*D1V)LE/>SMF@9.PQWM4O3'DR
MVF]K[N_C\!(@!`TCL?23E(#BV$[H]AA1B!Q#J"`#L`!-/`@@6O=QH+5P"LSL
M(MTNTU9FSE`M)JC/GZQ\'/ACFX`%&HM]#;_0>5P'>8:AQP!H/[>6WKD@ZN(9
M1>9000!!-W`HO:>9L)JN_,H;;;_Y$R#?]S(:VZOMY@*FN''PG'C']L2UO^*E
M`N/NE`-'!]`)T+8FQ-)*`@J#W['P\]FS57++&<#@_(;[_`L1SC<)W[HL3"*$
M4E)9;N2'D58CMET`3&A@+#M0TWR)S@.JKCR<KNZ`6I@%("RH+B]+`=P%'"2[
MLLN+U]6'8N;;.5<.9V8N5P&U\..[1S"GHZ\O=>ZN6*!;J9'SX^]\''A;SZ<B
MFYXXEL%"A:ETYJ"W?:+;;N6G;<L=R-N6"&XI\$M-+Z5D[AQR+P_9IV1O;/YC
MR/D</^=,7Y>/C/P.7PLXRO\`0`S=\!W5Y%8\Q]:'6&`>1$1[322`H%/P>1,B
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M7F7;?/HM_2H,:9/(?F;\,<'14#$KYK[-/C3Q#[*`T@V(F1'(FF9\`AI!KPX(
MP(&*Z_\`1PX^']Q=,11NM$+Y!R!"4W+,I`=R_0:5\%<V`!1J-/1WY>P=U<$V
M8N!P&A\.>[;S[H>B@1-B:2`T"D0_L#R&G&J5A,Q#;>Q3@;5^!G]`+_<"<8"+
M:+*MX&V>&KQ:5GJ79"G>]1;YN\.XC[6T6X5#WP4T7?-!^:KZ_P#<"MJKQUIZ
M)6'I3VW^QX_]P*R+,4?B(+UQ*9QDJ=[5SN75/S*P0+MB/X\P%)6J_8,?^X%;
M+U7BO_LL?^X%C_W`L?\`N!<'E!&B\(30Z+J(%9G',KCO806'BTC7&H8#E+@`
M*W7O,?\`N)[8'YJ?1$_&.N"HMS+9L\SR2TBDKS,%<15W[_'_`+F.C8M=OE.=
M5,E7?X01QO/>49#&I8ZJD("K"LU[O'I%Y\%#U7,=MWS%7+N6P?.8I^$4[66^
MYOZ'L<+S3RZ(2B2S@';^K<GA@#H)X!?3`J2OBLU3<L=1@I4P:A<`E_-_T+-D
MK0NAF'H+=N\^:4<6ET7_`/75\3_$H,N:N8LXR<]Y73P?Y^92OU1$CWE&DTWS
MVB`:[#]X@NZ&H*<:]]MYK[5_G2./9##<-WG<<O,-*_G>/?V_N;O>_O+7[=__
!V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g575431g85w60.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g575431g85w60.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`)D%D
M;V)E`&3``````0,`%00#!@H-```-7```,E8``$'>``!2H/_;`(0``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("
M`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"`@(!`@(#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\(`$0@`H0",`P$1
M``(1`0,1`?_$`0\```("`P$!`0$````````````(!PD$!08#`@$*`0$``@,!
M`0$!````````````!08#!`<(`@$)$``!!`(!``H"`P$!```````%`@,$!@$'
M`!`@,!(3%!47-T@1%D!@"#$A$0`!!``$`P(*"`4"!`<````#`0($!0`1$@8A
M$Q0Q(A!!43(CLQ5VA@<@84*3TQ8WR'%2,T,D8C2A4R4U0)'1X7,F%Q(``0($
M`P0&!P4&!04``````0(#`!$2!"$Q05%A$P4P<8&A(C(0()%"(Q0&\+'!T5+A
M8G(S)!5`8/&"%L)#-287$P$!``("`0,$`04!`0$````!$0`A,4%1,&%Q$""!
MD:%`\+'!T>%@\?_:``P#`0`"$0,1```!:$9L```,0Y,\C`)+```"N`L@&_``
M/`4`3\DG!9.J.=SUN;AQP``*@!P!OP`!2Q*M;IDIPW9*\9BSP9SWUK;[;/#C
M!6#RLW```%0`X`WX`!Q>&>_G!L'?(]Y;['\8NVR++<N[?7VK;K1XHVTMP]?Q
MNA@`*@!P!OP`"O\`A?1%*%/]^=WLTWA=:Y>ENXWBPE_>?9X==O:_#NV^],`"
MH`<`;\``T_YF_FPA/Z"1G#=/\(BZ_6>/Z_?I'/3=7N$S>5YFE>$=:,F!4`.`
M,8=28&SI[G6W$EE=1"Y"ZI=0?9^+DF?O)K_D-,NG8>&6G3?D??1NQV9VH%0`
MX`VOWBROC*O-RH##4V_J%N8%!N$+W_U^H1.0B5VN0V5QY]<CYLZU;)7)+CB,
MK91Y8@;+TVC)U`#@'3WGFTQT;I/V;\_E8]'<JXNS1+5\NN5B%:EX9VL*B15B
MNYIV3N[%4^BTI#O(F=^/WY]?G[J`'`&_/,Q<N#*QY:?(+>UV+[;&4LVGR57[
MYM/2!5I;@N]T!]#5"\WSF304/IH5`#@#?D;$;6ZB3Y6;A55_.;TMG<:N?YZG
MY4X_3JQ'D7M0)K_;[^E.:Y6SBD4SGY^OT*@!P!OQ7B1B6Q#Z[T#7<CVIJQXD
MAF]^)?(W9IGY7DEC^C'G"PGKE0Q#./0"H`<`E@5L[0FL@FF7N"*-T>OBS^EL
MS9L&H^)3FOW!8K,<`:>S>.8R''):`J`'`)%%B-L,Z13%]GH1Q^L]OHR&?!73
M12]?]M61='I?AJXR(X_X_6KUYLP*@!P!FCQ,@S14]._5(U+W6ONQ9\G;A/&M
M]/=>;\VVV6;R)&&]0>.Q9VC))`J`'`&_``.??M=-=]7PC@M$?8K2K<1V7^C[
MH/\`*S+R1D@```5`#@#?@`%<9Q`S&ET%C=WGU94-Z!TTSY^=@:0``"H`<`;\
M``"(2.1:"9!H3M@```J`'`&_(K-82$)V:TV@Q(KYQ8SQQ9'1T0]8%0`X`WY$
M1"9*YKC]-J>QIS3G0'*GH=@3:!4`.`-^``````````5`'__:``@!`0`!!0+3
M.F=7']7>P.F^>P.F^>P.F^>P.F^>P.F^>P.F^/Z)TI%:]I_\\X-!M5?YVL,.
MO:T_S=;<>P.F^>P.F^>P.F^>P.F^>P.F^>P.F^?H%-][-!?#?4<<;:3;MKPQ
M):`(V3>(!.ENTXI&KP\MH.R7>R5U<#;X_P`3J_9C07PWU-J"3$O%@N=6)77:
M&Y8'Z[8[Z>NJ<*5CG^?STNQ":]J(*#.=7[,:"^&^H?L`FL##AO\`8"KG<[_`
MTH'#C438AC7S^L]O1;RW>J=;+-/AZCN"'M>`2H`;T?9C07PWU-_U,C8@TAAZ
M*_5OUWU21X'CN//2<N-K:5KW9U6I?(,V,2A=3[,:"^&^I/1$5$M[X\D>0TXY
MT8SE.908PV->2PG&M]I08&L9NX!4)FK;)@6>Q]'V8T%\-D'2_CLY<4T\0A1Y
M?-BDR,\^?U4.D,2XQ4',S&<PESRW@?L+S\*A:JG'ZL%UU6XM>5KZE9F1ZZ$B
M$^C[,:"^&UO--KX+U\Q!LO-FC!J7*Y>*_97B@D::AW#6UF'M^4C/*PPSC&A+
M1815%X5AS'U;`,GP5-#2F)PGGV8T%\-QJ6>>MI$NJ`X3;GR1\2-B(Q:"I&R6
M+*>]FK;?F#7(!"$3CW.C5RP,4:@A"ELM0<+5]77J60CUNK,%(U=SC"L(0AM/
M/LQH+X;YWD]Z3)CPV$J2M.S:5KTM;0=1T4.S6+3JJ+;=E1`TF:'HF/$N3`B9
M58D6V@5*6E"(9")/Q<)5@5;^C[,:"^&^=UQNQ;+#_LXJ"J4N'_X)+S2$46S&
MHDZX<%"!@.'8;L-"/#CQ3U5JSUD]4:W"EKI4:.B*QT_9C07PWPG8(X"W5JOR
M(*^;44#O3%(UD`I+)4N,!PK)?K05@B+K2(L=DL*D-:ZJK]A5EQM/$S(BN)4E
M:>C[,:"^&[I;VZE%@WF@,V?WVJ,IRDW2-<HIT-BCV^T[TK0YBRYN9?'[N4]/
MAVB3$K==$5J>5U%L!^&>N&N+%83<#4EFAS*.$EUVM='V8T%\-[*FM#JHWM"F
M2X$:]U2.[1R@8V%VY9#@NL2'4/9F32V8M='#2A1WPH4^3`((8`:>>EX;+#QO
M%6RM(Q#F1"$;H^S&@OAL@''%5^A`\);#B&ELPHL2);:U<G0+^N"4!W*W'E+B
MO8??8?BNTYAV=-JM""4Z-8M5M&R^=*IE1ZG76ZJ%Z/LQH+X;ZA(H/$,1=!/G
M"^Q`%+"':YJ'8V"!PG/.F)$"L`!%<M5<MT'J_9C07PWU+[5+C8+CK79U@ES*
M7$`V\_@^#RL[7-76BYXO!:]W:OU.;$V3U?LQH+X;ZMI%VR6B!1S-6U^O2-C4
MXWI]DE-KM=#U03UOLQH+X;Y;;G7J0/)7ZMBQ`8M"/""&Y5#C97<LT3`"[@EE
M+Y#O->G6GWX&K:);^FC1$2[EUWF/L\IZJG>_BUT5M.UFE]'V8T%\-\M=)!W+
M%^U2[;6(-,R,+R=:5V9*@:TKL&9[?USUF)0P$&UN:TJ[L!S5-8E0`FOA0`[+
MU%5)SS>GM?19HK7]<#+Z/LQH+X;_`('V8__:``@!`@`!!0+^4XXEI*'$+QVS
MBUMID2\=P6Z'>Z(#BE)[1:TMI48&SXLWROF^9:5'PR^ICD:3X_:3&5.ISC.,
ML^%W\_C\S2A0ZN9"E#WV9+36,9PK'9?\Y*$RVX$:!,FIXVXXRY*=F2U%(X=E
MJ$O*V.P2RZMOD5E+N9<+$B.WZJ+4Z!FM1ISH+(J#"F$7!(^%YR0XWG/6PE6<
M<?,+=@\8=6VO&<YQG&%83-<4Q"#@THPVWC!=EF.0Z`D:-+(R6U-2.E92(D=T
MAHL=J`ZRW(1/'^3YA6%8:><CJ?LI!UW.<JR);97-GJ87-YG.<YZJ$+<5G'XS
M,OL.J\9OX\MQ,E+[CLY,%)$Y*G<CY<P_TC40_3NL%GM#IKN&\.7X618L$2')
M(/`:[Z1EQQ;JI<J+`8$WNJHXR\U(:[,A)CH86M&5(;6XJ2*(IA%:Q;GGG(4Q
MI='@31U=[,I!6^AJ$K//"RRWYA?=2ZK#;?X4Y&?_``YV<I:TMEY\,DX2'$1:
MVDH6L?.6+GS'G9<AT:(F#\?G&.R?PYEORRN.R9Q1\J+?$S,XSC*.]GC+>(^5
MK4XOL\0N^IY+#:L-3''7%J<7W<?CML-8\;BX:%N_U#__V@`(`0,``04"_E"A
M4TU-GAR8Q_M@M9=-HJ-%D>IV"OVFOJ_&,\V<'APY7:#1LTM+@T*SU.>!]8]&
MY*>DF)%AK,&RMV^FKK?::\/P0LMEYJ2S8O7?3F/&\$#4JEKV.#/"+(/L-,.G
M9$AAV*_V3:%.N5FV#<EBUB!@GN2XD:=&"YK0MRI$KM-F;$%>FV#L%R&6W>.K
MRC@"TS015)"CWIN%L4#,*5^'L)%N/G:A5>;#V`7BP\.SY2NME:$YY&`-L$>+
M3A6,_CB5*1EN&B,4)V>S$%Y4K*HCSK\;HL4N9!%0W4/Q.EL-.65Z9[SJY*'%
M-9C2O'YG&<<6VAW#8H,W"QC&.&W9"!PM$EL?_P!YC&$XZKCC;*,9QG#5>=+\
M579$/GHJL`V6&Y"XT!ICCF$=SI+N3\ENM8ACQ8<QEW+("7&6/=>:81/(^;XE
M"48:;=D+E@2N>+0MM79BO.!YCJE/.?G\<8CK<(>%@=CQF>'7V9!'LT$W9;8J
MMF"[M;&5B#,_41WGI8%AXY8&G68%RK:WQ?9T@:-FEJ97CE6BU(]4;4DY.GCA
MU@`HN-8`,C!,+W'N`*QOK;<>[*MN"&"KERB*S#%5^I#ZC<1MP`LO-2&RBH+/
M#IZ78N-MH9;[-[8[8^%7YMF)QB%IIC0P0.AAAGG)/C=LZ>>_7^#M@D!P/^H?
M_]H`"`$"`@8_`O\`%5*RB:3AT_$H<+`S4`:1UG*!P3C#O]]*\&_ATS\W9KE*
M?ASGZ"@Y#I:E918V%X5MVK2E<9(R5^E6&/7J*C*'/D9_*5&B><M/1_5-+25I
MFF8([1.#3+&)'S](*,2(D<X^-Y(PRAIBX/$<3X4``#$]6IP@VUX@H>&G^D"2
M<=8F,NCG"><T@6+JY#''7$C?(PXNU;*TM)J5E@/0'6B4NI,P1F#'SEVI2UJ]
MXPPOE;RG%J3\0$>4X??CACE'\.'Y="IU(FVB4SLG@/02O(0+9*E);29@>[/J
MA=O;DI2^*#+)0^QCYF4T=1TW_=MBW;LD*',_^XH]6/7,XC8(%JQ@G:HTH';!
M;YS4EI)(\/ZAU:1P;84V:2:1^)_>.I]<D#`9^CY%MIIIM4JJ1YI?M]'@QW0*
M@I).T2B1RA-C=*4;%,O+*>&4]H@.6K3:AMS^^*0E-/5#C3'\N?LF)GO]*&;O
M^49[IG9"VUIH4%'#9ZBK.T8H=<E6J<\L</4;6V`5K3,G?^S*.&\FI,%Q"P6M
MA(J'Y_?$TY1Q654J[NV"VRZR$?N>:*E8JA"[AQ#;2%!1JUD<H=7:X6Y69>B9
MS]:AL$K.R)'.!:W-Q)2L:*:R)ZRT$4M\P34?=G3]O;$DJK$IS!J[\8K*I;ML
M4)\#&P?C">#_`#)X>I<W#B4KO$`4I5L/O;Y?AZ_'>$VRDIPS$]1"N$26YX$P
M]>.I6JU>D4KE,2"0);J<N^!;6:"X\=!^.R$W%T\I=V,D)4>$GK_7]T5N&:H^
M9OEAMGO/\(S,2<XK3QU4F?>,`(2^PH+96)@C(CI"EW''+?!+2$-@YT@"?7+.
M*&Q-4%VQX)N]*YTC?AG]T&ZO&U7"]J5!<OR&X1PW&70O928:8OIATE2@D^ZE
M1F!_U=O2<1KS`SE]_P!T3=\*>^`4)I;/?%,%D"=1[8`>40!W?E'"J*DGI)($
MYPT;*W#%+829:G[:G$ZPFVOQ22)C&8BE9I$(O&0E9;.1R.GV.D+O7$A/$43@
M,.R&5<KJ',4I!7OP\5.^>.&D2.?1R:\QA51`*80FX<4Z]@A,^X0;)\I4Y('P
M[XD<X2S<#X1RB;1(@N+\QZ2MXXF"TA)XN$H+SA)=&JC,GM@K5YHETY>.>GHX
MFG^4?__:``@!`P(&/P+_`!2;&P34^?8`-2=!'RU\RM#O5@>HY$=73R9N;1J]
M5_+96X`ZZ!YE)1.ND;:2,#E*'O\`D5O_`$S;>`.2E*U!&P`[P2(M?_F33">-
M<_U1=DLAH2I2.)/X?G*Z?BSII.<8PSS.W%+MP55C0E,O%UF>.W/.?2ILK%!6
M^KNWDZ".>\ZY"BVN>;7%NR+%Q<JFY8.ME*A3E(IQI5PTUYF+;_D%']ZX*>-1
MY>)+Q2T]F&S#T,K^G.86_`M[B5P$%+F4IH-),B!/PF6<](;;O5.(X1,J):RV
M@[(3<LN<3E[BJ1/S@RG(Z'+,>SI+A',EANV=;!J()\23E@"<0H^R$W#!J86D
M*2=H(F#VB/\`UZGY_B)SEY=<\-G9.$?,4_,4BJ654L9;IY1>W_+D_*VKOQ'E
MK6I0"43/O$R2F:L!MUPA/-.1OIN+!1(J$QB,P0H`@C>(?<=O9VP54PV9TC<1
MIAA4.LB%VSXD\VLI4-Z3(]&&V\5J,AUF#]`OO+<^IK&U2IWP21[O@2K4MA:!
M.7BSG%LQS>X0P]>.\-D$*\:\,!2#+,#&0Q'H<LKU"7;1U!2M"A-*DG`@C88/
MTOR-+3"K<5%E`I`JQ)V$X@JZXY@Q]6V#-I;M/#Y9;:IAU!JWDFF2340DFO+8
M7Q+A78X@Z\E]^,_WNA0PM0#KDZ1MD)GV#T>'.%<V"4/7#B0EPK$UJ2-*_,(M
M[_F2$F]Y>KC(0X9*;4)$E.58\([4C#"#RFI*+B8S<35XL02G3#%6/A!$]9<R
MN^?W#*OI,S%JVG.14"A60II1-*YSJ49Z0Y]1WU!OJ0A7!`<?4"0)4`SPD)SR
M`AEOZ)6V7W64.E:D^XX*D2"O*JGQ8Z$1\[S9U;_-%I%:U&K_`&C8D:`>N$J(
MJ5EOU]`YDZ\\\ZD$(K,Z9X?=AZ,8P(/5%2<%0YSRU_\`+.534K'S>8C8H[8(
MYE=W"CLJ('=%1)JA#CY)7*78,!W`>ERXL1\<2WR$\3#;K:JT%`\6W?ZB+^^N
M>(TS50F4L\,>SU%)5.0,I14@R,4J20O;I^R)&*%B8@+6BX5S$GWI!H#;AB3N
M,2&4.-VK2W7W$E`ITJ$IGJAE%X9W00*NN)&))P'K%QTA+8U,3&4<5MN8&LZ?
M]8F;<]><?W="DS2\4+;R4D232JG,@DD'9A%+M7#W9Y8=\3.*X->7J6=HTI;=
M@LFI2=2/=)TG@.W=Z_RUNJ3H6%8Y*E/`[L?:(27P$O2Q`Q`.Z$,I(#B,".W\
M8XCR@E$%#*`EO*HCQ'\HDG*.&PFI7=VF/#0M.XP4."2QITC5^[;A;:VR0'!X
M5I4)3]N((V07')8F<A.D=0),O0.7NI5QY3H'FRJECK3CM$H2RXRM@$3`4F4]
M^_KCS)]L+6QBG`3VD?:79TEO9N`J<:3PT[Q45)'M41U2BEAHH9U<7,)'YG<(
M=Y?:K3<\Z:3\0JTT(2,ACGKOCYX_S-LO%3^F?XYZ90Q]0*>6VNV:*:<`@CQ9
MG3S8[9#9!O.4V5O=7P(,BE.*=3EXNKMA?//E&;:\0$EP(5.<Y!7A`IPSGA@.
MD2]S*Y0REE25)3.2G%3F);AK[!%XGG_,U\Q#MRIU"E3FA!SSU.92GP)]W.'^
M>?3!0M=?#=504+F,<0=N8/O0JZY;;FZN01X`=-3M,MWW0YR7F1=M#=-)JH/B
M;5@J6Q0"A)2<E"8AKZ;L;CC.V3*4&I53LAJOK[LHYA:?5++;O(U.K2RD@)H!
M5\,+(GX"WX<1(JEC(PIQE-#142$SG(;)ZRZ-%SSJ?R;?BD!54H>4'=J>J6L6
M7R;#[R+U9`-,I`*I*L<\>X&+AWEMNU:6(K><X8.@FI6IR&`&`R`@?4-BEQFS
MJ6#Q9`BC,X$B6LY]\!YA06RK(C$&+_G_`-).I/.F2/F!Y@4^]AV3)!]Q0A*N
M9(9+B1*H)D5)_2K&1'9`:;\B1(=(WRWD#'PFD!(6YN$ITC;GB>R&N>WMXV.3
MMN.%\*`Q2!EEY98`=IG.&^5,<,\NN?`4,@(#2%>912`*)3G*4R<9'&&["S)-
MHV#(DS\Q*R9X:D]D+?0M2''"9TF6>>6G3M<@8FE@+4MS]\E7A'\($CO5U>@<
MI2VE;R9I2M1R1H):RTQREL_RC__:``@!`0$&/P+95Q<;*IK"SL*4<B;-.,JF
MD&4ID4A%0R)JR3'Z?4'W1_Q\?I]0?='_`!\?I]0?='_'Q^GU!]T?\?'Z?4'W
M1_Q\?I]0?='_`!\//)V)MJ.`:9D,=""$Q,\LWD)(:QJ9KX\,VVNV]D_F`@N>
MRDZL?M1XN4LC6V#UG4JG3IS/-_IIJ[..)%A1;<V3;P8BHV7+KI3)<>*Y8PYF
MF04,QS`.Z4S7][+)JXE+MBBV+?\`0OY<Q*F6R<Z,Y5<C%,T$M[F,+H70[S7Y
M<%7'Z?4'W1_Q\?I]0?='_'Q^GU!]T?\`'Q^GU!]T?\?'Z?4'W1_Q\?I]0?='
M_'Q^1?R]`_*/Y_\`^PZ']#^AWMCS=>O_`+GZ;M\_'R]]WP^O/]'64C!LS:W4
M1R,;J(Y!L;J<J)F][D1/*JX-M"L&\&Y)XYU;MZVMP`;M<^ZQ0`3(E)(?[2BV
M;N<Z8`3CL%TS#'8/F*3,>-LV!T_/%'S:??2U^]TKZ>#[>C#MMN[PV%8QXE64
MH60Y\I)E6]T0X@K&<UZN70Y97S$W1=4T6,>RK+U]7%9NB6E-N1-M!VT\.UX@
M]S5%%,)R`>ADR:Y3LCJ]B]SS2[#V)N2HES?RK'I>O;IJTF2VC!U[)\;-\FM)
M<"80:J_4]B%U=[Q[/AT'R^K]G6EA76L)WM85!:R&U&W15_LZ@VZVKW%50[-T
MR;9<P<;K!GZ2.9XP.)DW&B\A)3QZJHIF[MLWR'&BU&^;IL!0[!KXX(YY5W=@
MZEZG:'O`TL145SUT_1^/_P!O>/E[[OA]>?Z.T;NNH6;OA[5W`2WM]I*4(RVL
M9]7.@AFP6RW-A2;.CD24D`$7@]472K7Z5PVXW[M7<L",,$.&#;QRQGH6JBJ&
MSK)&\Z(<Z76EEBO)!SQ@M*CAB0;R\Q5&T=5^0[U.OG3^8<P&/'(A1(@]9!&`
M<;58Z1(,Q.**U[6O[<1&[HG]2VN$1(K``'%&\Q79DD%%&:,3I"M1K47+)&I_
M''!53^"JF+7;-RC)\.@]GR*HI\W28K3DD:0L*O>;TA8Z/`Y,GB\2Y(W*-9DD
M$L*^A9EL^FD,<Z/1RY8T?>7\PQC'+=[INI[R$?.-Z1@W:&HG%SOH_'_[>\?+
MWW?#Z\_T9%O=2V1(<=.UW$AB+Y@(XO.,<B]C4_CV9KB79RU>UUA8S9LEGB3J
M3.*QK5SSTC1VE$\2=F'<O/1FNG/MR\7@MF752>;)E0M%49I%$D61D_(BMX=K
MU:NKBJ(W+[6+`]1%KY2V3(XY#+!AWM1L93.'R^G.!S>)USQ)ASH#J^[@Q^I,
M.-J)"EA4PP-6(KW*5AN89J<MV?EU=N42946S*D8J"7!D16G8C9<HVX=OV(H\
MA25LUS(S8-<;44+A&YF2)W7.QMR24U0$U#<75M(4,X2OMB3MV;$LXN<J/MJ!
M,B%;1T<\7/5YI;'$:-3/CD>-+45M`K:L]A=R+1E=361K"I@A+$A11QJ]IJNK
M=$$UD)'$32[G27E.JHI5:G@^/_V]X^7ON^'UY_HT4NICOES*ZQ.!\=A!CSBS
MX^IYEYKQL=R2PF(GC[ZX-%D#4,B,4@#B=EJ$8+U&4;LE5,V/;EC_`.T<[V:D
M8ZH@>9FZ3W4$C^4K2:<E=V+YV7BP?I>8D;G$Z=#9*;D:UY/-5O=4G+RSR\>!
MM=WE;W6(C43M_AVJN-!&Z7>3%:OY:7J"!Z2[L0M&LS2CM228[E5%/J<N:C=E
MPX(N(=C#)S8D^+'FQ2Y*G,CRA-,%^2\4U#>B_1^/_P!O>/E[[OA]>?Z)EG-:
MZ*)CCEU-5^E@44CGZ6HKU5K4\7'%M;TL#V=3S;`Y(4?6YSM#G+F=S7*O*ZHC
M7$T)P'JTIV8<K&J[0FIWU)Y?`CFKDJ+FBIVHN(U[*C%]G3BN""6YS7:WLUIQ
M:CE>QKE$[3GVZ?X9C4)%>JM](BIDK7?^^$),&Z5/VO-I-ON@B)D<X+N[KZ2F
ME(FDCTCB+:,83)KE1!+PS5$Q8'?5RU9!7IV^E:Q9DX%K6TEB**QP^8^+6V=D
M@7ERU:QN]'EI5UAMH-=+CRZZ`V<<ZNYD9/\`&HI+PJY1A(U7)?CY7=[_`"BY
MHS2FKP?'_P"WO'R]]WP^O/A@*P(=*"0Q3R%R'FKG-:%O!>]W<UP-QF(,JL;S
M&-74UK\N\C5\:9XA03R!CEV2R$@QW+Z23T@N?)Y:>/DBXKX!;5!/F5M7$I8E
MU;]`9T65:NMIMI!KX*RQ*A@00)22''8W^OS&-7NHY%U[:,M-+9Q2(1Q#U,M>
M*Z2QU=JC%=_S1Y.\N:<,.K+6(6LFE30UCUYD:8WCWH$Q&M%+8OD3(B)VM1,:
M^U/X+XOKP/EM=S4XF>OFIPX\?K7`J-]V):\1^>*$6<+I@G])WO/TC55*[AY5
MQ.W.E>"QEI8#C4U=+.\,62",YS;&4_0J,DISE0;&N73Z-_U86JFTE?JLO9DN
MX&$;1B=/KY$>QC-!RM'+CUM@!K@(W)&JQ%[<=<_;]:Z8]`-YSQYO>Z.6NDL?
MQ7B;F4L9SG><[IVY]F"7,:MC!LS+-4LT;-)B>T650YNMR><DAE'$S_\`@;X?
MC_\`;WCY>^[X?7GP(9"C820YS`,<Y&N,]HW%<T;57-[FB8KER\2>!NYIE[=7
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M1F,5RJK1JG@AR()&,D0R/>C"Y\LB$:C'([+/[/\`P7$VRJQ,=:C6,TCP"=(9
M%$4[6&D,$[4K^6Q<LU[,]7BQ6RXTOKPGA1W,F+P=)]$U'%>W[!7.1=2?9=P\
M'Q_^WO'R]]WP^O/B%N"^W.MI"IW3'TU>*&V)RGRQ/CZI2C=RR.:%_%43-RM3
MQ9XY7123.>Q%`X;=0R/7AH<K<]&E<!''502#$C))Y:\1C?P/I7R,<O'_`$IA
MH&D*5&_;,]2/X]O%>Q/JQ<W-\YY[*1:3N8*2O,]F\B26,RL`Q^;8[*U@D!DW
M+BSCQPQ4U->-R/$0;G,*%[5S:\1&9/&Y%3Q8'6;F5]W'X,'.AM0U['3@G^5!
M#F2R8WQO:B%\N?9ALNODCE`5<M3-37#?EGRCA(C#QCM1>+"-:]/)@UE.>REL
M(XU7V^%PHZL;]E+#F9`F`UKYI..?9QRP*FWONN17UT@K&4YH%7/JH.Y7E>K`
MP@7<Z,)U7.<J9<ER\PB_TUQ>;;IX8H4)^W[#;U-7A1<Y%G>A-75\5G:\LJPM
M)S<W+FJO>KE\:XL@55586T^RBR:V..!DCH[Y<<@>J,17L48PZL^''5PX=N*8
M%T12VHJ^.R<]SM;^>C.*$?\`;(Q.#E\:IA45$5%3)47BBHO:BIXT7",&QHV)
MV-8U&M3-<UR1,D3-5\'Q_P#M[Q\O?=\/KS^#1J37EJTY][3V9Y=N6"299Q1H
MXDU%,=[1B8GE<]ZHB8:]BZFO:CFN3L5KDS14_BF+0E3'W)[<YZ$W+^7W0!4O
M7F&,Y$*2S:L5ER016D*@<U<KDU9.SPU=PTF[5R3TIMVLG2JOF:5ST=`Y\?3_
M``;IP/:.WX.VH2&JH]A43H\>,!TJ9S939D#48;)#9`8XAO8G:O>^K!V[-"I/
MF5I9_P!I5C8#&N+DK]ZNR6%T8V*Y<B?Y&K3I[4P"RW=)#?6@<B`A#$X6W:LN
M62K!@%S=+,G'TTC4_)<LN"8O0[ATNJ/9LETE2<7!TB=R31?M,GC-ETZL])S=
M.GCBCW?\R3Q]Q084:N<3IADA_D:3)B-C3+>37:WQK5L4AW(>7_7CB>]Z)H9A
MQ'.1K&M5[G+V(U$S5V?DRP]8I>:@UR=P<G;GEVIQ[,;,J8LN;6;?L"R'6,^`
MSTA90&$,*`8VA_3CD<MK$7AGS%_E\/Q_^WO'R]]WP^O/X#=-)BE(6'%++A$>
MJ2(\1SR`#(:U,_1%+%?I\KD=B-MJ)91HUT>1[7@0)#UTV8:I-,H1F-S7I6+,
M8JN7NH31B,Z<`4:8H!]2`!.:$1M*<Q@29-UB1WF_5B]H[)[(EJ+<%_.4<E[1
MNL8MQ<S[6%:17OTME,FQI;7/T9\HNH:Y:<=1-D)&&JZ69ZE(9Z]@HX69ED%=
M_*Q%7"2+V`FW:9_%!.`!N[;!B^,DE&J3;PW_`.ERR>'D7#*^HA!@Q&99""BJ
MY[D1&\PYB*\\DV29:R.<_P"O"UL89+N_5NIE-`<S6%.Q"V<I<X]9'1W:I.]Q
M\WCAMKO;;Y-P=))ZFKATMA'2EJ$8YJQRCII3AR[:X#Q].3/+[+4R:N)]^X[2
M;>]GV7M=DL2C)%#%"9EM!L8A$Y@)$=K7L(-R?^:*F-O5]NI4L/RS3QK)2.U'
M2<VLC,E*1WVBI(1<_*N!`&B(T0V,X)EGI:B:E^MWT/C_`/;WCY>^[X?7G\&Y
MISPEF23T&QJ2JK(^E)EM=.L=\2A5\77DW)PIK'/([T81HY[ER:N)-W=E'-W3
M;L'[1E#3_'KXK.]'H:E'<15<!5[?/DES*_BJ(W!MB5(Z^TW.B\TT]59IV>"+
M+#S9<Z0/_*&261JA''$O,-WU\T;L">-\FZMV9JMQ;$)(*)[LM:5D<Q##JQ+E
MV#75V][)<L%LKB='KX0O//)>C&JOB8-//*5WB:U%<N.OI*>QJ=F.UH>[%)A"
MW-,9SECHL.N.JDK(AW\&DR<?5]G)V>'"`4],/G(AW6L&7&>:4_AKE2RM*^3)
M)EYQ'*JY>3'/!:5Q!:=7,;-CY(W^9V9$5J?QQ:7,V29NSIM[#LX%*@N6#<D^
MKKX$<=[-*OI#5*2(S6BCY(R0^(PKLV9(Y=3V-RRSS<B9:L].>:^/2N$TRH[L
MVN>FDPUS8S-'O3)WFLRXKXL->QS7L<F;7-5'-<B]BM<G!47P_'_[>\?+WW?#
MZ\^*]_2]7*M9AX<5CBM!'$D.KL+F9*EG?YH(\&M(NEN9"$TL:BJ[#MV2XMT3
M<5K`IX"2!QY,^GC1R1Z191*)Z(T3A!)N.`.81$YB/.QG\Z8CQ*:/;V]C(EU,
M9((83@N8.TGU%>LAY3*@T2')MD&]OG*<)!IWF+B<8,23#)"E9:#B>T<BNF*2
M31V$8KD1IA650HC\.":_)DJW^^AQ2&VYN>N@IN8L0"E-03:%)Y16Y0C[[ZF9
M'FE64],U"1J/7NJN2BVHK-TV9&^C(%2"I8FIO`DR<K44FE?[0D<3$#=FZBR9
M+)1$6I([T$"&N3C"2L@-<K8J:456$745>/>RX8]GIP%Q=HU^@YZZ<I""1J9*
MBHJZ/-S7/MQ:;:2)'*"UE,E$EO<_J!O;R.ZUN2H3_;IDJKPS7RX9'OR"KH)F
M$1\ED<7>-EZ)DAVG+E*OC=FF:8@[,3<$FVJ)7/AU+[*&T`X2@$0D,(C.(DAK
M2L%RV"R<W6Y$14X)BPM(=^D0$H.W!M@\PPXY'U(-R#E%.T;'.:YSK@7+TNXZ
M5U>+%);+)J)$BCVY7TZ51Y4Q*^SD`C?,<$LLTT>.,J`D/W7"=DGGM`[7FY&+
MB#4SN4LL!;`\AP"$(!Q["QEV1W1VDXQHO/ENY0$S:`6D;5R:GA^/_P!O>/E[
M[OA]>?$B8NW8.Z)77T\"JJ+#IFQCW%Y:Q*&KYA)2*T3%F6C6O5.]H<J>-<-L
M8FRQV$BJ!8[B@^BHX@^16TNW=P3;>$>89B12]%>59.4N4K,C.YJ"NGV?_P#G
MR#NLJU'PJR)2G:6]#:4IC0!RQD8UOLNVW:IV2"Z!%TRB#5583'M.CJDJ(;I<
MBN2/R8P"_P#0W>QAH445SD%TXH2":-W>$UFA43++!X^VZ23</M03(DRP`#JH
M=5"T*&4\S69J\Y&O5K$\UO%5\2*S0/EY-1J_6N(M;-ER"0XN9(D4A-80ZDTK
MR_'P3AEGW>Q,L"AVMJRGB$:]5EO9K](B=P*9JT;%(OC<J)P\N6#)$.V:`!S,
M!(T*QLD+7.8PVAW%G,9Q^K`K*1"."%->[IY3@N;&,[BKD$[+)V2)BLMS7PJ^
MED.CO@[FJ')-'U7<<%SV:PEK522BLUDTZ#-TKDJIB-56EY#+:AK!RY#S/#%-
M(CB&5"V;XZ/5H`%=$*[/S4TN\F!J^]K&H:*::-72Q)JAQ^?SI/%W`(NF)F[L
M[B^3`YD&0&7%,BJ*1'(THGZ7.8[2]JJBJU[51?(J9>'X_P#V]X^7ON^'UY\5
MY+",DE:J>*S@HXAD8&>!KV@D*)A&B.X&O4SF(Y&OR<G>1%0;$IJI&")(*)GL
M^)I&66+DRBC;R<F$DA7014XO;P7AAQ!5=<,C^FU/'"C,>[HQJ&'J<T:*O2B7
M2/\`D;P3"08,<$&*P;QA!$"..`"/U*O*"%K!L[SL^"=N'P]M$"EFJ/@!D-E]
M*@($I3DEG12:=,A4(K$RX]_/[.-QQ[6RJH,C;<8)I(^J:?6:1&ZL,='#S1CG
M"R[?M.1/+ANIRO=P:W/_`()AL9K5,5ZM:Q@D5[GN?P:UK>U7*N'@DB(`XETD
M"5JL(Q>W)S7<47+&V-I?,.O-^6[89AT,A56(>-/(F4%SSL7)R.U\IC'-S].Q
MW%,3H-42P)6V'$U98263(+7N:K#/$%X4T+)8N1$S5KLNS$R<"S2%#E[5H]MI
M#)&+-0*[=MKNX@')S9C63XAI%LC)$<O]4`W,U)S%RNDL]PFE3;;;]C1#..*H
M!0AV-I?3E7DI)=U@XT>ZY(T(N:<I'9YK@=($W4`!/N90"*/EDY5K<S[9K#]]
M_.DCZ[20O]YZ*_)-62>#X_\`V]X^7ON^'UY_HMDV4V+!"23&AA?+D"CL--FF
M9&AQ!O,YC72)4@C6,;VN<N)^X-[W>J19S3SCUU.GF]07G(!TX[>ZD?S,FC<W
M)."XE;.HMM2"7<RMJ@4W3O.;_-E%,J/52&U<]SE17NXM5N2(B98GSD@.JIFW
MAK-BOG>D9:3@HKP0H+FJK)2'T9*]':&^5%5,2[">)K)\D@QE"(;QHQX!#B,$
M@WN>]'M8%$7_`%8(>R'61:FK`.1(F6O(Z>*.$-J-E&/+]&+E(S/5PXX=9;9N
M:^[A#,Z.4]?(8=H9#$1S@&1JZ@E1KD72[)<E^E\?_M[Q\O?=\/KS_1KV-(\\
MN2>6W;$]D0[ML?+>A"P`K/=DCG#:&Y^8\UIW!KAJNB+JUMX,>15JJ^@O[JKJ
M=IAD3*%QZZQO=OSHTRLIZRO/N&39QV2[.Q"DLDR)8)'FQS1".[PWLQ8?-`',
M><C5H(4"=&=%G;>DT^JOO(MC'+W@VK+`9!KEP07%%5'XC#2XK%)-C]7$8DZ-
MJDQ59S4D`3F9E"H^]J3AE@6X*?=0K=UR^S?'H=K/C3?:^Y:&O]L3H`[83B0*
MZ;-AZ2($VEY5UN:N6>G;`K6-*E[(NVTM]2[9BUHYT*_AH6.6,:2?E=0&_P!G
M;H'S+5ABCA1XL+S2N,Q<;LW>E='H*NQIZZB2%&,![MR3:^7)E)NB<"+Z&,\4
M62D4*/7GN;KUHU-.?T?C_P#;WCY>^[X?7G^E%-L[<%=0S0ND]4*UI5N*VR9)
M$,;7F8"=6RPRX2B1PGM*K5XM>UR*BM?M7:UG!EWTIU@>QW!N$!49/L[V5(EW
M5R>+!UJLAYY3G"%JTHB-8K\DSQL:N]J4/L';D'Y==>X4.O#9CL-E,&VR6*7\
MK&LK85Z@&M1Y;&)R&.>BB(UVC&XK3<MDQEA;6.VYM6;:`#;==0NVD&TA5,V&
M5\F>Y;237VKP279<M0HT>G),\1J.AAI`K(BF<&.A3&R?).25)*XL@A2D)(DF
M<1ZJO%SE7Z?Q_P#M[Q\O?=\/KS^`-EN&8^,&3)2%$&"-(FRI<KD&DJ*/%B#*
M9^B-&>1RY:6,:JJJ8H[LQYLB+N0(I-(&OJ;.PL9\<E<ZW<<=7#BFGM%&K&*8
MRN&WE-3O=[)%K+RN<\E?<0(EG`(01`/)#G`9)C%<$K6E'S`D1<G(BIGC>=:2
MIJ"`VG90Z8,46X3_`)GN+&T9ML54^/2OH65T>LDVFYPQW'?89CTN=H5$P)\B
M%L8ED[><?:$I`;[GDI:DIJ2\N'%M[+\F)80Y(UI>5R>B>CE*BH3+/";+?15+
ME2R=6&-5;BE6-B#E;5KMR&O7UAMNUX$VLAK%D-LI9*&<=S?0IJRQ.V9'D'=N
M*M8<TZ`L.2SI8H059VS2E<-!)#EMN!(`F>DST(UN:B)I&.-71)%LU_S,2PJ&
MW'^17C^7[=P/BE*OLYRJE\RE:OFIR$/_`'-/>V]9NIMG2W7\/<M@(<+>]J8.
MC;\?;!1T\8SMC#++W39'W$HAQ.4P.H;?3KKR97;2F[;%%CV^WY^X(LL-NLNT
MKH\`E>#+<=1[-""J;,DSE&!PY<G6\3DR3)<G^T-MP8VV%W].^7PKB+?EE68[
M./(-%B3)],:DA1X]?,D#:S4*8=XM>;FZ45<7ETW;T2*6#?[3B5(K.]?$@V.U
M=\3(L;;F[YDX--+D5D0["E>8*1SJ)`*B.?C9"P-H4'2;TD74:-+E;NLPM_Z`
ML\TNQ@M9LL_7TUC70T/`,JA?(0B:AB3O>'X__;WCY>^[X?7G\%6MNV4AJ:66
M97284ET8X"GCOBR$['C>PP'Y+FU51<E:J+QPT57N&742"&O.?839-]9S(47<
M%1"IIL2EY.X*T4.'T\)K^F>A`N/WU3B5"U<J!>7`*:L&1?8*SI1HDDZ4T&@@
M!5I3K&C5%=!B.,V*(34?.+SU=FF2[C-*+<%B;JD=;=5'M60*J/8)$KH8K$0`
M<HT6?'%4QU$49&O&\2.;QP"Q4MS860+^)N3VA:6TF=+-8P:&?MJ'SGE[KH\>
MILBL1F29KDJYJF!W[12F6HMT2=W,DLE/:J6DW;L7:TP>G+)8$JHAC:\78KFZ
ML2=Z1VS4W#.;,%.ENF$<V9$EBK!,@G"OHUAP$J!+&8F7*=K7M(_.)6O#+Z6$
M7>1@(DMZ.1^^UMEW!J=EWN;[:/R_^7FF79@=;9FNKF,&CW!MP/M6T))("FW+
M&IHUA#$30-6-&VA`X"^<)^IR<5Q,W#"LMP$G6#(S+!DRU=*CS4A0&UT/J6$%
MS'MB@;F-NK0PCG.1,W.SM"2R7IA6D^YME@K=2VUT*WOH\F+.M8,$:L`R>@)A
M.2]Z$Y#G:F9.R7$6=5T$6C=&6C(L>C$"JB2S[<O(>X*F7/!$"-LR9'GPDS*_
M-[AN<U5XXIG0!2AMV_:;CMJ@+I3WAAGW0LMUH$;%3_::IQ.4/^WGX?C_`/;W
MCY>^[X?7G_\``_'_`.WO'__:``@!`0,!/R%;]H]:%(30<?>\>/'CQX-935P*
M$B*C;B8-*H5G-KTJG"X@BV*0G0F-!7)JQ8@@<54W-1^]X\>/'CS^P>[^\7C7
MW8?987M-`]\B#;F_N`0AWE%>4@-=*5'Q"L_\\5^%A&U]B![L#@-Y,Q;&'FVB
M,7%X*D1:.`G\5%BC?/!;U:,3AZG89A7#8WE:N,7(2P'_`*?+M$[$]PNKL$[_
M`%$(C>/\:`C0JB3J3==C_.P_29.>2E'225-#)#.M^VA9];V'F>I-AWT>L"&<
MST]ZH0VAT98''P8.:&?]>V\MOT2HCR&P$DM#,64@3AAPL>0;#(C!0J#C[.^J
M(R07C*KF1-L=J>D&M6<(]OBUMTNBV7]2]0`[#S3!H\3K;$$N\[74?H0NE%*8
M-VW#$2;>X0UOEG#=UI-40#LZ;3'QFLI8.AH&W$"`!J</#2B.(V.:SY]5*3!P
MPF!@!F_FGCLOI[##>M\&"H+"K@'+S6$3L0N%XA@`DND[]JGCZ/0.4@&B/2.`
M=`-F"$`*`5PWV],%.=!RZO&#(,3:^AI2X:5T5%Y7:7L^"N84:9E2!7":ND/M
M;#O8(A%[%T>C0FS']4:TWC7B^,9;RH6))/8\/I1L*=L(G$-XP*(KI"G(L7EM
M-3#P(<`=+(KV9,76S!XET0[;X\X]/EP(".1$V'$#+&T$.5`K;(E7!#AK;G5`
M,;6Y6L)=.'/':@-*V3$]5:EY=56XN*:PZH0`+[,F_LV$=@5Z7P(RD9X/H>ZY
M`T*`1Y4@'Z:#RYC\Y*_DA<5"[K?2Z!2OEYP+DX"Z&(U8(8F:)K.A&/.&BI&!
M`G_-);['AC4F0HS'03W[XXRU&B/86!+[C9QV#\@A`AIVX382(JB+5";FL.1,
MT:1;DS6T6S[-AO$-(@:#*/P""ZOU^\02<K>1UFB`#LW95%=JIE=,-88^4[.!
M<%P>P>&.G@E6VY41:Y@B`1%=;UAA1`NPU#'8JP#%>!NLAB2#4FQB8TE1&.J[
M1,K1CA-JU`&1``5H9T/OF&LGKD/`(HYDJU'NVP#:`?4C8$VDCNY[QPSCP)$*
M`=F583O.(.@+[OV[#XY<=%;>!.KFW)>JYL"6&]K,-KPG$>W)<.+FIIHTH]:X
MG%.R0=%Q*]Q,DZ3E9#K:L]X@5-<R/`:$CNW#;BGN;N/(>(WV@IAQ<T067N7H
MK>&3!O\`-30:^5@L;%84?,X0+@[P'"#P$@-<92,V@V9/<H&OW-A58(9-!(`U
M#Q60RR$2@DTQH'G.*PAGE&`:0=+O"[@HH4(C#UI')*8\(ZEQKLW&\9H1,BJ%
MER)4*7-9U031ZY)D`:!E(0QEK+S(KBFAQ(#:[GN`&+LF2Z\7SS)U+,\4%\&M
M0ESF=O9FJ[@JHPY8J\KB#R#L=^38_(_=L(:%NI]((?B*>6?:!8;LPW5/TZZ-
MKW&):;**0$`RJ#71P#XC?E,'P?A0W:_A&AD_%%'Q+5O1``AN&LIL5P&!5`P&
M<L#?_!X$,`^C=N2EMR!OG<"FD]T0)Q/,<\FISND:S.*&X?,1\JJ43A/MV&G7
M"6>3$P&@UC2F\I8\K_/2IMS;48:/:0<PKNC+P*CV;X->04(HBH*-S%U7@2J.
M4`5Q(6'B"Y)#=W#(Y#9K)V[9"1P372OSC&_I:;G!2L`Z_+(&UWP-XFM1@'>=
M1]<B1<N=.4H#);1X.D0-^9FB&MN8T(*",.U]U.;*LJE8'?;L(JFYR[EQ3\*P
MW\65(#VQE7X-BB1!7-M:S9$WB<*H58=<`G03S*$*)7&F4.'@5ZC0V7#R\>>7
M-V7P;8Y:4I!H"F04!@(K&$UPE:#<RKDB0.@/DX%_8I'([8P\8BNS/1/B!TIL
M$ER!6C,:%6(=X%SC/J.'*J#W6")%`<V2=\J6Q^W86\,:9'4F`\(Q@2DD-X8H
M:$FKID$N.=G"OW=VDUFNX)9(1;R&UPS@(5&$O`'=4J+8IU8E0$O#V80.-J=L
MZ#EQ6Y_!P86<#-)U*]D<7!^,'6L(T1-'-L.S>/X;E[AG!BU5-AWS0P^>9`R8
M/QH2PR0UV74&QF6@PO;S1<JO1MAK:%IC>4[00Q^R^$UI^Q,P\)D@%4'(11IJ
M$O":,\5:_P#SA(.0*E?\%R(,M0Z."L13=OD4>V-^7%TDUP14I"`\/J;#!.U+
MCVVEZ^8$+F0LM[.QJN:]4\A(#Y,PY7\'4%P<@X#%5OQFCS+5$+XX3W#@3]S<
MJP0HP4@NNM'3,I!!41ZML,&47@.YLHG)`\AOHVBZOE9%5$0AL'*QDT(E=3&P
MR:>(Y5=;UKMJC5.O-OI;"Z)XE%H^2Y+"X%"NC8Q(9((6)U=1SE%9^+8'-EM:
M/*M,XW$#33*^?W&D2[&#6"<ZJ%`+AE"-L56RYVG0(F%Q']@M(C^\,R"G`.)9
MZ8`VIX*FJ^%ST4L17`4FIY4WYXB"`[B/#L_&+/$$@<8&;Y0IF[N?V[#>7YV7
MHD,(A,PM&>)E2?PY:95;_P#>7<DP$%CI`?NC&1+N+!'-B\K`UT32PNC'N+H\
MR9+Y#H<(8C1#I0Z1<53ENM`I(;84/S&(EX<8;%].FCA*`J+R^$4$`<`(K+V/
M@MZ8,Q-E^.XCDJ%[&G:\NK_DK13A=?TVP[__V@`(`0(#`3\A_JDKXC\^N8\8
M*E>",+XMX\YW;OZ##;O$A=J_WI#CZ;0XS\]>J\>#(.*J^0%5N\/@&?\`4<O+
MO][G._I%\Q61X@*>Y_O'D5[L&B@+[>HTFKCV?_S$6L,<\YH_O-CSZ^,Y#&.,
M3H6&SX^<.$PU'3PBD1]G^</_``WWAGF%]-05P8\E#G>+H"EO4XRQ:B/;VU+P
MNJZ?H:\"$!L1Z3.$A:U9H/@D/C$(_P!,C\`-A"#MO?`F.GK>]O,'7MZ+#_9J
MNSY='TVD=7FXG!@UA=]<5PP=D4GMR^!<.6F\2Z(=MZTV&=4P\CQ-(//1C(3O
M([)7A`7;(7KRN;2WQ<+&O*J:O&1(ELFOY@!2M]OO5,G5X+-^-H?/T=/!.5*E
M.M!U^-?30E//*_K'#A0:OBA<G&XU*B`!Z%R7BCV\9UYVMSYY#\[R/CPB?XR)
M@`P[`'X3\<?5,H2ET"E>_P#,G>;K2OFX/)X>S?V2ETIO&<FS9WQ7N?826$HJ
MN2_V3'Q%Z?\`7AP`%N0/B\<6D.*<=WD>SA,!,3W?LNI[7'J*-5Y7$L&'03!&
MK[]?K#PT#P2]'0\AT8*-.<HE?=]QOB("K^,1M`<Z4,,9>8LW=]YY7J]FOZX,
M1NUDKNZ(_G(K)^7Z8FI^^?EW_C&VM>GS_CS[?8/KG`$!!2J7\//WW11'P7YM
M3X7"*S013I3SYQTZ'+8/#9&CR3MG2QPL]UP/=F))-0ZG&B#/CJ\F+5OVYX$W
M=OX';SQK3O(`.3^=_P"BP(55JCA'P^HG&\3&CR.OFYPB]?G4'^GMA)#=&*DG
MAJOY`ZC-N<[?/,#P!#V@_>;(G*O?UO\`&`?RT%@^[N.M>O4[0I>5`_+1_>)U
M]CE?!U\NL.M!/?R>_P#&?%_Q?.<Y4?+7'GC'QD)>WM<%182GZWSO_/J-EP1>
M@Q#>#B%QQT<'Z)CLX/$'6DU3A.L,>[<=*V#H17PQUR4>L=&S9&]?VWSB4D2K
MQV!TGC5WUI@`M'IIO$>(=X%JCY[YQI!V)JLZ#EVNWE<'H;*1./(-]I_&03!A
MM7X.^O[]S+@5$WPG9V./A7JP-OL0]15W2P_[E``5+S^^<V`JH8<%*OCG1G,R
M_P!:S290\^ORAD/9K?Y_U]*@HMH>?_D?_]H`"`$#`P$_(?ZHP@5VSG)F'%\H
M&TQF'>4AY.^Z2=<XB,>?6VDE.S6T44E#5#<)H96"Y!%H[I*&9>#"L@L6$M/H
M9AX`<D+Z7%3'01U0=A]140=<#OC#VOP5055/^NOZ<ZJ*-!R9\2#Q`#ES!=@C
MZ.BO>SR'1R[R*IPQ,EHO$V?I,Y/99*T(0B27A&E],//;@##S!<36X8\L>#A6
M,02F/1O[.+>R6K#1WC<SLKM?$Y]\FVY@U]#8I;V!&Q8VC!R!3D\[PP!I$HCA
M7+"4I'C3HI=[&>V\S&!^$?3&:*'E(&]<^<>]A(G&T"Z$8H4<J'1)Q-3VNW-W
MC`XP0`UVD&)G,JF,C@"&0KK>Y(D8KH(<0L4C4Q6]<]6$T\P9HFIR/H[`1SGC
M/['Z#'!]X#7RD%#U(2/0-"8R.<@F*1N(<H3#BT",-4.&IH"E@83)%(0D$1'2
MICBYTDP7BAHH2/A@[P1@IP*48X$X23-R_MJ\[=+4,$]_O(P2!=H%!YT+\'T(
MF*:0JWWL_E6L?IO^3O!2$GD/^,`JAV:PI`&LB\4ZW.&A0YQ8L[?@"">)K*[G
MVK?WDL#T\O\`AR'L?6Y1#9M`C['ZMZRTVIVUY>%>3II]B#'(S*7@UI;3:AP4
M?JBHF=)_[S^<M=BD,'0;_M^,0X'/8:O)\/6-QC:Z$`7>2:?.`0@PD$YVK5:%
M=;L-<Y'L)+73M[3A>W$!R#DY`]&C[C+C5`#Y7"6]E,N<4<13J^&<81T/\_\`
MS&;C8FM-1"P3Y6&0T-9AJ"ZW`^V?L+?]>,?H:M^SMHN82DC$!\W[RP!6>$?.
MV^#(*1L\@+L\>V48\M!JF^_;^,=D';_KS^,K0`H$'F>'\\Y(4Q=[M\/?@,J*
M\&'\/+B-'Q6D?#ZBW@I80#N4=ARYR+RHDKU(/:]XCY?S^LITN!.+H<BS@3F]
M:2$=42IV8T7]P/X=XO0(@Z$7\>H)LBYM63YH/\)@KK8C?J^T+^LT91:NYPC$
M$4KO:93D:'R&S=VAKJ>Q@_P)H>2)&\2"N+F:SJ<')R3;3'&5I4NRD=O:M64=
MSTT61.=A;PH+Y=<BABV9E*%_=()JL2,=R&IKL*2G95,XA(@V\-#P*[O!2J*!
MK[O"4`)6I:-5.&L`.XK@XH&C+_N^/-D!2G0"[=/$N:6W#5=OIO\`\6VL1'GS
M:<`Z-V0&<<`EAW/%ES=Q*["I.A&EQDNBH*O<HSH%X8$!OQ5@/(FG'X9*S]R^
M'EPT8W%%.NL/="W+6TLUAB0@58'&U7]OID6+#(M^WGB7_,+5NV$;:)C#%CX`
MC4AG,*5<--$O*C`<74<D4`"*B&HYYQI8EI=J-C:NN)KUW50&\H_`D'^#<"@Z
M8CFT\MQP$(\O_D/_V@`,`P$``A$#$0``$````((`````!(`;`````!/LQ```
M```)52Y`````9PY\`````'UFH(``1@HQ2#``!QA\`UQ0P!R:3#/T@0``D'X0
M`<``">O#?(&```!K(&9``!)!XV@0```!(@:'[(```!-Z>L(```!.?\`````!
M`@A``````)``````!`)!!((``!)`(!(```````````/_V@`(`0$#`3\0><R.
MJS=Y%!K[ZM6K5JU2FD*7WH5"0.4PR+,#=/0G5!B8._B2:$979,+#$LZ97#Z6
M+D8^ZK5JU:M7^_0'^_U^XH+C=Q<VA=K8B0$ROAK1`/TWSK(F"E0R`2?4P@/,
M)!>O&(KL(!0:K-WSUX#S3UH08":-K[^8F;K'*-4+3U#ABA,L1=D=(I9?3(_B
M%DH*4OCDBBWSZ"VB(LE$F.JEPJYHS`5LD((J#%Y0BX+RU@9V.HJRXV_C7\.!
M(OZD<0*%TD((PQ``6"<I4WZE<U0#*`2`0CK,^4KE2SRKY?HKX71KLN@4!-I:
M1GOF$W4GHA&T!!#S@\RV'$DT)H[I650$<[([7<#&W`,:D4NSG414'Q_HZ6Q0
M''$U+<-]%O3'*ZZH:1;.\_D4WB2SENS`(=SJZ5IE*LB>(0"#L`F"6(3*;@ZJ
M>#YQ>'A4SI*`[')>K?!I_&G3!M,\,@!@-(9H()Z8H3=^Y;VZL%U!CR-N&ZDH
M`_K>XC)BI"IID!.JZ^CJ;:$0[8%'$ZFN>8"!>1@K"V3O#@:*I01@V-,8^X+?
M\XG]>5ZS/='*O-!1F?1IN:C^Q3AH7VL*#GI!BD`'$-7\EZ#V!L.[EML7>&A8
MB>)V<LA3E9]8V_<=V&JR/'6WZU3D6ZX'+>=M84^LRK;;`7H$=2IVD410$,ZK
MM9H)D5)4363=T!ZK6FU7J56E;C*W;DJZQVB4O.18]V+Y]_P,(N.]??6Q+*J!
MK#1[.7$@2$.X?:%`K"6ZTTEDEXC]-GJI^DE)4T9.;.2<(*8DY>C"QL(+>*^'
M'#X6J^UZDJ-QJA,8<%C006P%C-9"F)V6!<:(EL2F2X/YE2_=5^KKQ.4]./YC
MQ0'%GPK'6=!(HX$HTLTM--+8#)K`!6U=!.9!@@?44$IB_$Q!K!0JF,!-A_5<
M54Z)]B>@+0?/=X.P<:!L!,@;4*#8IE4&#/FNTK<H41[P23'G@"@#IG%]RQYM
MN-H:2`G!"N*?`>PF2E,BJ*PC@&QI&#D+#OUQ3(`4E=]]%00<EH6P.7NFJ.[O
MN28-[ZS`-*>6H+792^Z$H6J(01&.>U."PF](!47;]HH4VM`*J=M*A`+0X<>6
ML+L$9Q`T(50Q]%$5835/'LX=C"3T]M)%K1@CCPO*RM9!`'L+CMMTYB.1.0J=
MG,\KX1*MS"7EJ=`,3-K4`QI^-"`W:B0&Q:+HF/O'<\^GZQKCOJ14/)\&,2G>
MH$KGF*38:Q0OIF,TK3"1H3[10KW'?Y?P?`O="(M!,-/QP2B@Q1UL=61T#%X5
MC798"0/<``O!W="V&V,@L`T!0_CA7U/FI(0+A?59#PDWZS"`*[`O(ZP]/FH8
M5FE@=>30(5CE`9AO?!I.-3+[WN52HIP2AUI<+,18_')O.J%7(````,0!>`4>
MG[A02,:O%!C<LC'@#Y0;9!2]"%/I8%[[VNT`I*,+\926[LOV3"5@,ADKA2?1
MXP.7GZ!A$1_J@%E@&P1OZ@!`T``-7#$K`07^F^:8Z[OQC=W#CX1<6>W85`FE
M^%8Q4+GU@Z0?C<2(X>9NRQ`:5")Q]HH7837YV<7O[P!3(8W"@0_[-BQW\@?:
MI653Y#KK4O4RRX8\B2'+A,;YF&%E]X:1T'RZDNL';6_Q7$.238!0B5FVGHMB
M@.V4X%,KX21>6I[V1X4*EC@9@"L2@S!#-WO=0`&<C+4H+T9`\DBFD1K2UH^F
M5DDB_*T=!%HM*8^P4*`\WH*GS!'"10=3G&6ELV."Y:J;SK(0;)DK#6@YS(A@
MLZ."G^+-<9+09JY8JX?)D#H#!>YO&+"4\!`%U5)"!N0.L&L0Q9%8AP5]89'+
M"B@18.:]0E51RI;42&)2*#F[729?T\AI?/R<P`7)F#=,&@"E`"DE:`"OE$EW
MH^1:$/M%`GVO<#TBP]]&!.V(P#D2QDX$P0:0(EW8JON'(]/G!K&)5.2N+'7G
MW*<WL@'*0NM7FBI!H,8[9;Y#K@`#`[%V\KBB#4RUL1*57.8K`;X2!!"H>'%T
MU:DV7+<:0&-T36(,U$*8*R+&[]J;"V&$5$)R;#,*M13K9*+O;<LBEZ-,_P`"
M@&RSBFCO')Y7%:$4OJ[":VLV12^;!RC*I@`*_'06!1Q60Q-53AN]^5+8;<D]
MET.C3K^2&963Y3XTH;>>(+Z8H")]7XPI>"Y!)XR#G_U0Z3%0V(U[?RIX+*EF
MN+%@BJ`F)7;*A>*(0+M_,S`^C;1[E_%AQQAK3XL4X$`"OK10AOYA+[&551=W
MMFNCGW>OB?28W<%\*<:Y(@87DUA!#`<?Q0Z?R?1ULOI7U!0WUS9G[:L<TR/1
MJP2_F'6`[IE[;K6$!8!2(5[JW??Y61BA0HQ=1.-!8B2(ZH*K%&G&(0[]EN#7
M*ST2.1?#_K&Q`%0/H^=+`9P'-4(/OQ3Z+%&1ZWZTZ)W=HIPQY/BIOP:P;.3)
MI/\`TU+8]8=\^X%`4VX=2&.KZ[0(G%3+#3-.D*[9+>3N@<HW4DV93A\@7FK0
M9)#XUCS7OD":31"8FL0J+]`XMOL^.LS\R<"DM1_:A'LS0(4/:@WU04,PG2W!
MZ)1CNC-A.<,,W&T;Y1V#0)^7L#1$BN4`I>-5RV9O>`']**`__]H`"`$"`P$_
M$/ZJ88PUM5X`[?\`5>#`S][Q/9'8^R>NF6HI*#>J0$=@"@SS$ZA$&Q$U5.H@
MXP*;**;VE$(N&IQ4XQ-84WD*_0FO''$GJ`S_`'E\!VOC_61W_@)-M!F0471/
M%SSA=K8JM<4Z*:?HN-!-HHJ-B6(3"5``P]62)YSDGI.10I=FTTWS?'IM15(0
MT;=H:1^\-A6!Y$8GX=9_!E=]+(SG\SK.^[-N=M7WG/OC^`T`C,`@G0%:*Q&I
M5;'3!'"FQ&!",1D,KPCWO:,G`X@],'R)1_7IN5A*_!MR!*=D:($TR:@(I)P'
MJ!"W<28PD<#CW]N(0=M`(G#C!]"T=V%H$&@(.J@[I(\A>82*%W6.9H9&$(,0
M4%6-D]$6<(CRJZ_./TXHG\E<^Q..[D6)%P-V;-:@.WRT]QP1*"4;@W3LHN&E
M9EFJVU'"@`A8`CILC0&H#($%59B!,"I""\U(-HC54Y:$Y4+!@:,+6QN-RV3M
ML`VM"II0!]Y=,`%&!4:"0LJ#E^CD@Z,*PH:)P20D<V!*`"@.H4TND\SO#KAL
M*.=)'MN;@9-;P/DX3PG29(A88KT)JM4((P8((^7O"KR0G:1S369(Q\:8!/22
M&O\`1?X/J9V@)-\/*+!'1V,EE(.S>C=(G5`*/V`D:(T$E!L"0<E#ZOX!0)M%
M0=DD7=W.NAQ4>E<AI$389M8F./L42/8Y*L#"[7PC3_SX=X_$"ND6X_[6_?1B
MKJ#`SW&/-4<C9-JA$@J&JKM5VN5(,PF@<0Q("ELH^:@C9T>P7L`=8"="T32)
MPCYQ\Q\J59K:[XU]R_VBB/`!7R^#;K`C4!'D1B?APHLI5F'6$G8QT(X+[H4A
M?+"G$WUL"8R9B$=6"88"7;?MFG9H]MM@=NKO13G$"="(/M[^!,<*1BJL:9RN
MCK:Z^PW"#/+&P,W(3O\`<5BW#=>V:[MCK[P&KYH_DF,X"ELUE5HFJ!V.*T$E
M7'@I#3.^!^U'16"_!.D(#:*$&@6'DR6M?^![$,7<6.X2F^81'`V)FZNF`#JI
MH"NT6/>"U`\?IW(/R<((GU%./1!8#`+L0+(408,Y3"#&",3BOGW!(.P.)QJ`
M5_X'NZQBL1%*E,!H&3RF;A3VQ5NC2R+M%*^7Q@O`C%\G"4XU&(G5$[?4QN:Z
M$(:"ZC6[O>9&8UT11T"GX(]\9,_0[I1YZ"AK31JYQVO&^#A/XXK><*]!0+T`
M`JTG96<Y8%FPHZ*V7(I'KO`:(#(D%V/1PW:#)ZBE<@*HC?=&'7;X4U.E;1!H
MUX`;N%,>TB3*K4HW5ZA<%BH[%WT>"^5#\S&+8TNN!69(84='=2D#-8>#MY56
MUQI++!>$`0"1:DL30(%DJ<LZOCTP&.XNQR'S-'BWK+8-KR5$`G&N_*>\5M+;
M@)&`(<H:N<-OB8(H``-%!I2H5PQ&Q(GR9+H#3L<*?S`2[-F25FZUU'(!!H\@
MD=X3ITU"58!7<`/;TWVS?H*]]LKQQ`3PYL(B&C5$82MK\!)D;N,DTX$39@`$
MU@\`X("!`"*O`#[X3D,"!XX=]ZY]<<A`/`A?)I[?+6,Y6"-]V]#I=+;O?_R/
M_]H`"`$#`P$_$/ZIX@]8E2N`:%2R931+(J9-K:WS:!!$:%B.D3D3I]9*@V7*
MW`]RL.0I-%?.],"@%-+BB1$J\X4".(-P@>0?\Y-D"P11$K8[`!>J>$^X0_M2
M[]D&(+\6:42"E*V(PDE2.F"#%1U=90,3=9U%HPP0DH%CPY8A.[`#4"5]HN`!
MQ">)!P-W!ZAGC01,$`NI38(9:S+.K*:`0Q*#K`:41%ED'1W0AY`@]E$/8A(>
MHD36XFX9R[ATY0ZP`;NDJ0@AIM%$R?IGAX8,0';4%F(5I`.X<HQJ:937I[YK
M8$"Y`J"H"U0WB083H$H$ZZ*:"E@NW290WHB)%?H1":)>$*DHB*8HR:$0-&95
M%$LY'$&0F]&:NAJ3+[4"@3?>D_R"_>"=_1O+!V[5>_8(?0U2A3L2<>^]/6-0
MP&-0&EP%FXEXG5'`T6.6Q`2VI`BQ-DY\+7+J<*K&`]!I0*4:"(XDB)LN5<`3
MS$5JO,3#,5(GJ#>93Z/U>R*7[U2I$`$*U#(5$71](EK")0Y,&H"0B&:Y'@D`
M^5U'O!<PE%/%IGYUU;G&7Q%%T[-Q-)V:=95.:7?=G4IT&!XD%JPKJE#P*`3K
M%C,VT[Y2K^7-N4C4.=>@+@":GT/?%92S:L$1I*B;I%EP=AK1$#A%U-0$3[#+
M\K0UUM@`[7@`N$N+<8">I`>&=SS>?9@4"[&7V3A'PXSJ@%E]V1/ST"8C!'IR
M1?[$]EM?&O;`]<`XHRT=(C1$``S```@!P!X,(Y.NP*5M@A7<0E[7T#8HQ2I@
MM;<>@"1$HCI$>1[,'\6``K6!`JK\_=&+A3>4`;T;VH&W%:`D.$2B>R;Q*@:<
MD.MH)J0LO,0]F;_`J^;@$FKK%4*@E/%<1):C0$1U%EC4*8""?HOA^6]O#3C$
M,!60XE?SW\[Y^J3'LOE\RX/&J['#[=28Z#IDAT0]#I-F&QJ.XW`U)%M(.E+A
M&[D`F12"[%BJXP$#;67V'*>@+^,I-TM,BBOJ[=0I<##+@/Q_P^>7>\XHNQH?
MP$USO9!R&8+<V;D:2Z-',,<K$V$Q#I/_`$U]4'G?HM=/,.42S""Z(P:2>:)>
MV6!01Q,G#5<`*N70JZ%T<#AH]I&,TJ(3:<!BV2`,YTV)NYLV&#:`"M`/*@/R
M&</(:)R^05WMWZEM#P&T;(PFH,1<$(TW*HQ?*#DK(L<L:>=6`BB4Z(S5C6BD
M-V,!'$]%ANQM;)S.!H(1&#,,-0X[#LD*6YE'B9?`R:J;>OU`0F'ZF*!:/$##
M2QO@XW8(`O6H'(?'')F(Q/-W!R\%D9J``%U<PQB6PRTD`%3)"6"@3:5:%5"C
M!:&%=90NZXOO&RGD'P0@?$0"!(`KM]/PBR4`)`/01N100K^1@08`MKIK@,=!
M!08HN@!'<+LL.7*8`!`7`S9PRTB5D*)IY$Y,&?,$H#.-+LIAQP>RXYV5.,`Q
M,#!G`2*"IAJH^_ID(D2K4#R@*SG0O@<K.%Q=KLCLY-;@6E%R\@-@G;,(!!>B
MVD%P.3A#Q"RLK-FP6""Q1!@6O6'B%YFD]</N?Z$&<;8"#`3Z#'X&@$4W3<M_
$\C/_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g575431g95y29.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g575431g95y29.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`)D%D
M;V)E`&3``````0,`%00#!@H-```T0```RL8``0V"``%5/?_;`(0``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("
M`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"`@(!`@(#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\(`$0@!+0)?`P$1
M``(1`0,1`?_$`3P``0`"`@,!`0`````````````&!P0%`@,(`0D!`0$``@,!
M`0`````````````!!08"`P0'"!````4#`@4#!`$$`@,!``````(#!`4!%082
M%A$3%`<7($`C$#`B,C508"$Q@#-P)#0E$0`!`P$$!04("0\*!`4"!P`"`0,$
M!0`1$A,A,3(4!B*2,Y/3D4+2(S34%34005&AT:.4-I8@87&QHK)SL^,D=)6E
MU0<P@>%2<N*D)>460$-3UE#!8L)$@E1@\&.#PX1F$@`!`04""0@&"`,'!0$`
M```!`@`1(1(#,3-!49&AT2(RHA-`87&!X9+B!"`PL<%"-!#P8M(CHQ1$4%)R
M@/&"LD,D!9#"4V,5\A,!``(!`08%!`,!`0```````0`1(3$0\$%18?$@<9'!
MT3!`@;%08*'A</_:``P#`0`"$0,1```!_?<C-F&?````````````````````
M```````````````?3.B2+&+)++W@````````````````````````````````
M```Q2'V<B<2@`````#S*>93?&K/51Z`````!5QAEN@``````````````````
M``%96;4G$OD,U%8I6Y=L:6I*94>HP`4F5R5>9):!!2XCT"````>;S!/3P```
M```````*\*$(\3HH\[BVC7&&3D],@````%8V;8G$NG,$ZCH.)Q-(2$F``->1
MDRR-DF-(2`D@``!Y**+(,2\F!8![#````!CF(``<S@`:\CQP.)G&O-R8AR.@
MEX`.1Q``-F5C9MB<2U+RX0#EQELNVEC%F>7=P[```//9Z$/,T>F:I>+HH>32
MLC#.\_00`\X%5F46X7Z"ISQ>7&0([SU*6L`:BO!B;`UY@+:B>EE\?V<8D!%*
M]!EE2T'91\:M?3=EN&1+Y^L\[Q(B^ZN0[SRM%<FQ+OJZB;<;6-FV)Q+H+,5,
M<S%Q$V2[Z4``#RW'J2J9BYJ\_1Z!H:PQCK,`EX!@FE-@#<`PR.&09QT&R,X`
MU%06S4G891L#=2Z6S6&8:PW1NI==9K34F]-F9$NOLUII#:$A.\U1@FG)&;,F
MW&UC9MB<2UU>&H0```````````````5@N`<3E',ZC;5C$L2/X#:*'TOZ(`!]
M/@`!]/@`!]/@`-IZ?'8GTCY%7W+CF&W33+*3VC.=8V;8G$M:WAID````````
M`'6XX?'JV'+O`&N,L'([`8"_3I.LQ#:',^&T(9C\M4&&V0`#Z?``#Z?``#Z?
M``2+O\LCV+3ZJ-B3`N).:VQ.=8V;8G$M$XS+45J^Z;'O\L4QF8E63Q&%T]^+
MU]LJR6'\Z[=H\M2\8M$`PH\*:%LON;?-;V7*`#R/B_F=%^+3_P!%,_\`<MQR
M]0'GV70G03&KV052:1=VFL7?)98`*GUC<_-7SWZJ````````+JV[0_0>]_,P
M```.PM^=E8V;8G$M7\46Z/3K^CTY?;T<[.WEPZIRR>?7'^_S<S9FY`!7N(]U
MA9?P@`5#Y=9KCHP?IG(;[F7M`ITQC?&K6X4'$Z%RS',HS$`$4\_LK_R9(`#D
M<0`#D<0`#D3KUXZ3>CQ`#Z?``<RV9V5C9MB<2UK>&F0```````````````4V
M:]?L<2Q+)B`"A-2WSQO\V^Q```````#/O#](_MOYOV/H\@````["WYV5C9MB
M<2U]>&J0``````:;KY[GLX=*]R#6]_3K>WJD?C]?T`TZQXYG<=9+SM0````=
M''GB=?8`!]KY``'VOD`#E9E=O3\``/I\`!S+:G96-FV)Q+YNP&R^9M&^D[#T
M>;.[O-<>V:/Y*V#6+UDJ"O<L``#"CP%\TVWV_P#0-9\K?$/HWM3[W\R%#;;J
MOF#?M(N_5=FM37\[-,5DY#X_7516$N](V2DVE7<E3$8ESJX185DS`!1VJ[SX
MA^6_;0``````/T!^L_!K.V/4@````!V%OSLK&S;$XEK+J[(WT]_Q>WEPR^WI
M[^WH[3J.T``J/CRLCEQZ^GLW'=U]R]*"'9+'P'+8KC9(_'ZY9CLA(O'ZZK6%
M1EG6;`G-3E.!S.D[#X?0#D<#@``?3X`#X?3X``?3X``?3X`#F6U.RL;-L3B7
MSUAL]YTTSZ#M_5XL#I]$A]^,I;>_FL]3X;>(#5IQZ%!^,VMY7](-NPE\^7N`
M`J[8,%Y/^B:%8^#S%@X7+V5@\U+\;D:(EB!)ZB,2LUM>E$IHC\O=6KB4V=,N
ML.9=ME0:KO/B+Y;]M````%T[#J7N?ZW\&^````````["WYV5C9MB<2U+Y/9#
M_)[ODO*S([.J39/#8"]IUFO-ZG<#RQXO3?N1\DJZ^0A.+]LVRGB%89S"Q[W>
M.3>'VRCP>W:>?T9W5V1!:DC).8+FK<)J5[#F=0,<V!S,E-/Y?;$\;EP`/I\`
M)=E<)G]_F^GP``^GP``^GP`',MJ=E8V;8G$M#XO+T#J6\[?U^+"Z>^P,[K7C
MS8=7GR2@VL16K9BX@?E3A_=[TSV-N+I[-+Y>WSW\@WST]]I^?"#Y;%^6_H&B
M.OLL+$96V];V"?XC+43+TFZLC4LKLB:^B$K0BRY9J3-)>D0EZJO)*DUW;?)V
M@_50```/4VZ_-KKVO1@```````!V%OSLK&S;$XEIC'Y.&^+WX'3Z=KZ?')<A
MBJXP&T[3T^/(Y]5AY[60`/&>,]GI3,X^<=/9B<;3^F[!=>Z:\```.)!EYF$;
MY)."$KD&U3<@``C7@RE=8+9@`/I\.WGPMS:-*Y7B/I\``/I\``/I\`!S+:G9
M6-FV)Q+3?AR%,ZYMO7QY8_#MG>:UV'8G.97;TYW=Y[;VC2P`/S0QGK]M9?Q6
MKU\M?Y^RI?G^TW5](U(```"'KK37&^)J@@*XT;*IJ@``JG![/YDTOZ,``!F<
MN'L[Z-\?V7H\H````````',MN=E8V;8G$M)8_)5IB<[G=WGQNOMRNSIV'?YH
M!A-DZ>'9N/7X+EVS1N5@'Y^8GV^N,[CK+Z.P`"C_`!_0]KZ=-S>>/T"7:`#3
M&.2$`I]>42BR;```KK`[/YZT3Z8`!ZE^D_(9'D,4``````````.9;T[*QLVQ
M.):I\WIJ_#;#OO;CMAW^70>');CU^&/>#*9/9TY79U37,8#E8!X*Q_I]8Y3R
M6)U\@`*O\VXR'T:IRO5BI-P`:0XF]`-6<#B;D``$+\63J3$["`!?.>U+/[>@
M`#Z?``#Z?``#Z?``<RVIV5C9MB<2T'BLSY\U#?.[EPOK=_G.\]F/````_+S"
MY#W-L6*MWS]H``\D_9?S=Y_W#4?:/Q/](7+JVW@"&G:2T`HQ?D2:RS@``5!K
M&Y^2OFOV$`#W-]=^"R[*84``````````=A;\[*QLVQ.)8-U=L;\OLR>SJVOJ
M\?9RX````>2_'W^A/=YYAQH``HW=OG&JY]OH;1OH7T`&-*,FP`````:'K[X;
MT>L`"<>K'\KQ``YG```YG```YG``',LZ<ZQLVQ.)0```````````````````
M`-14>L``R9<:P`#)EQK``,B7'L``[SH`!R)MQM8V;8G$M1<N&JLT5F=+%;,L
MVDMG\>4]G(````````````````:BH]8`!DRXU@`&3+C6``9$N/8`!WG0`#D3
M;C:QLVQ.)=*G4=%<SH3D=BY,;A0```````````````!J2/\`*``9,8U``9,8
MU``=\=%``=YT``Y1-Y:QLVQ.)?/V'SE2X/9==T>G;^GQ8G7W:CR>Z5?0?EE>
M<N-J1;(`!A1X8T/9?<6]ZWLN4````%/'5+H"=V64"M#5D3EX$PLC*HFEEH%>
M8'9_/>B?3`````````-IZ?'ZQ^G_`!KE>(``'86_.RL;-L3B6M.OG!<?E=GZ
M?'C=?;E]G3A=7>R.*Q#<FY0``5OAO?9&9\`````&,N*?3Z;%`````(7XLG4N
M)V``#Z?``#Z?```"0=GGN?/ZH!]/@`.9;4[*QLVQ.)?-V`V7S-H_TG;>GQ=O
M/A/LWKE#;EH.0F2L\D@-:9;MD]"'Y%X#)_H7M&&NGS=P`````I8U\NA)Y9;8
M*S(++(;([+(+!&Y=_9=A16J;UXE^7?;````/97T;Y#Z%W;YN````````.PM^
M=E8V;8G$M<R:FP#G>.OX=F2?3NY]8&.9!Y#\_;Z,]/5,(``C7?U]DNXZ^7V,
MB4````````<3B````?`````````#F6W.RL;-L3B7SC@MD\]:?OFL\WKV7I\M
ML;-IM&Z;]!WWMQVV]7B]+_0_E(`'XS:QE_T<W+`W[Y.\`#\YMVU^9^7MI7*^
M/LE_2G1MBD?1V`0TY$P`*,/DLFLLX``%%:IO7B7Y=]L``_1#[%^>Y_FM=```
M```````'86_.RL;-L3B74)CH.GCV=W+K````C52&7L0``#%Y3*XT````````
M```````````````?5WRUC9MB<2^*ZNZ*!K7FW/IG&&18T)99&#4%ID(,\[2/
MEM155;$EA7YI"R3**T+A*H)&=!/HP2#5LS+,T@IK#)-N;TAI89%CF>DHN```
M``````````%8V;8G$OAZO0\>2JL,Y&F(F3`EL5!4H-J#2':;N*8KU+'I$```
M````````````````````````K&S<$VE\BEJ'G*MB=9+2FRYXTM;2(E7TF)7Q
MFF$".%HD`)*;$Z35$9)(:<];Q:(`````````````````````!6EDRC55C'<`
M`=)W`Z3N```,`SP``````````````````````````<C91O%QS@@`````````
M``````````````````````````[%[S__V@`(`0$``04",:A:*2B1:W<HNY1=
MRB[E%W*+N47<HNY1=RB[E%W*+N47<HNY1=RB[E%W*+N47<HNY1=RB[E%W*+N
M47<HNY1=RB[E%W*+N47<HNY1=RB[E%W*+N47<HNY1=RB[E%W*+N47<HNY1=R
MB[E%W*+N47<HNY1=RB[E%W*+N47<HNY1=RB[E%W*+N47<HNY1=RB[E%W*+N4
M7<HNY1=RB[E%W*+N0)2:1ZZJ:912I4TTR)$_LA9$BY&Z]31<O^OWNY3#(Y5J
MRQ'(UBGQK(D<G/C4L9##X!_%ROVGF8P+%XGF\`K(_P!+9_PLO^HSS+<JA'!L
MZR))PZS^<J_D^[V1$9P&>2$U#U[COH)J\[G59+8QG,K.3/HRB2EHZ2C<GR-P
MT3[HY(&/<G)'$1D.;2L*]>YWD:<_CN03#R=^S+=O[H\:=MDF\K[;+)%U$8XC
MDN6OYN)SS))YZYS"8(EY0RN*:1N=]P7>/8YF$MDLA+9=DB`\A2A9S",FF,F?
M?;9_PLO^H6CV#D*PL.NN6"@TWJ>.X^DWV]"IQSG&L<>A7#<=<2Z$!#M7WH6:
M-7)DL:QQ!.Q0?"TX891"#A6J],1Q,J;2&B&"_KRJ`EY!]*X1D3F=B^WN9(/6
M>"358&0QW*$VO;^(E\:F?M**%3IU20ZI(=4D.J2'5)#J4^'5)#JDAU20==`^
M;%B,;*:L'B]`A"XNV"D?`+-Z0F+460:PS4]8W'ZJK1D`JFSBL<CG'5)#JDAU
M20ZI(5<ITKU20ZI(=4D.J2'5)_1G_"R_ZB8GW4?)ESMS1T[GY9JBUR,RZ9<I
MD:-4,DD7+GUS,G(,YT'1?*Y:(N6<JR?TR[*\B@YV.SC*7JQ\_P`HC"FS7+DH
M#Z]QL@F8!HAW`FCEB\LR29EL%G9.81^F;2[R"Q^.[DY6_1C,WD7-8S-\I?LI
M+/,P3CL+GJY+`_5W^F<YGD,!(S^39%!4E<UFH40V9Y$^2Q;*):8E*_\`5G>2
M97%+Q&19$\RK(LI?MZY!FTY$S6)R2\QC!_TS23GF1GF>Y(FGY"R!XSD9"5CZ
M!3_>42>1-YY;N1E%80V;S;MW,OIEJ^"G[YI/9/'2$EW(FV:C3*\E>R$M+R#3
M)Z?[#/\`A9?]0XBX]VY+"1)538_"F9V>,ZLL!#$:(QD>VIZ\QB+A)A!\\=SX
MQ]%Q24^BC)FL:V1O--$Q9R(8_`MB?59LV<"L)"U!8]@0[./81]/HNW0=)GQ^
M!546A89P#QT>HK2)BZ*MVS9FE]7?Z.(Z/=@N/P)`E`P;=$\3%*43:-$35_ZE
M&C18*P\0LZ<1T>[50@8-M1LT:,R'_0R21SVV.YAL>@#5(R9I)!3_`'5%*JJ<
M;'(J;:QRB:D3%+*!3]SMFRM:QD:8QL<QXY#-&AW-/]AG_"R_ZA\<]'7,4',4
M',4',4',4',4',4',4',4',4',4',4',4',4',4',4',4',4',4',4',4',4
M',4',4',4',4',4',4',4',4',4',4$ME9(=U7-6U'*V<QZ!76;-6[=3-F*0
M6S=D2KW)[>KO%IIC)DLJ3)\DVW'^6T!Y;0'EM`>6T!Y;0'EM`>6T!Y;0'EM`
M>6T!Y;0'EM`>6T!Y;0'EM`>6T!Y;0'EM`>6T!Y;0'EM`>6T`S[K1ZSC)V<_*
MIZ^Z"C@J?<-RHWWX5FFKW,T8U3-;@&?\++_J'_\`]?M#G*F5!VU=>E1XT1,9
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M$LA6=,4,U;.!&Y,A*/\`T9CD#G&XORM,#RM,#RM,#RM,#RM,#RM,#RM,#RM,
M#RM,#RM,#RM,#RM,#RM,#RM,#RM,#RM,#RM,#RM,##LT7R1?[)?V#/\`A9?]
M1))D4=]`QJ5U$,7;=*-8(IVZ/XT9,R@T>P,5-JU1.3'X0C0\#!J-V<>S8>FN
M.M]P^F=:93(""Q3(<5(WZCI_JGA4:DH;!V!E'F*1[UTXPJ,<5^EO:G5K#QQB
MUCFM:6EARR,&Z1N0.0.0.0);'XB:1\=8,/'6##QU@P\=8,/'6##QU@P\=8,/
M'6##QU@P\=8,/'6##QU@P\=8,/'6##QU@P\=8,/'6##QU@PBX*(@T=`T#0-`
MT#0-`T#0"D_(,_X67_4/_P#Z_P"@2\\\C)!ID,HJ]+.R+)1+*90YH.26E67H
M[B9*MB\-Y>EAY>EAY>EAY>EAY>EAY>EAY>EAY>EAY>EAY>EAY>EAY>EAY>EA
MY>EAY>EAY>E@U[L3;APS567:_:+^P9_PLO\`J'I4NJTH#2@-*`TH#2@-*`TH
M#2@-*`TH#2@-*`TH#2@.NB>CTH`U6I*Z4!I0"CJ-26?2L-&J:4!I0&E`:4`_
M>1\:U6R+'6Z!Y^!(WI.X[6M)_':T)TJA-*`TH#2@-*`TH#2@-*`TH#2@-*`.
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MHNF>BZ9Z+IGHNF>BZ9Z+IGHNF>C$CY`>)^X7]@S_`(67_42KIBT4/*0R8I*0
MIEJR,10E'+`RI:-"4XMQ6C0U>+<<6XXMQQ;CBW$MGN&0CYD_C))GT,1UG%N"
MK)EIQ;CBW#K(8!D_R27P:'E4,7[?2KI+#L01K&1</#-N+<3[#'&\>>9P]-!]
M.8N@P5E\'"<OBZR#:+QEPEQ;C6VX\6XJJTI74VH-;84,VK34V&IL.+<5JB/Q
M'XC\1^(_$?@/Q'XC\1^(_`<4Q^`_`?@/P'X#XQ^`_`?@/P'X#XQ^`_`?@/P!
M=&H,_P"%E_U&:,3R3-G!SB*K.*EZKH0DJB?'866C7S^$F9*/2A)-NG#0\LA+
M4;92\BVV/2"+[!VLLR6^G=6=ABR';-1#97IDL;2?R<LW=MYIEE4-$5:=P\4/
M6%G8W(&HF\P9L'Q9R&(>6D&#.17R2(Y,LZAVH8Y>@T4$M`RSN:5QK(%E9;$7
MDA*M,:R=5LR@)=&4LF0<M'&<B([)C$ZFV9)KHL^X323>P&WLY&WLY&WLY&WL
MY&WLY&WLY&WLY&WLY&WLY&WLY&$P><(2/L2_L&?\++_J)V49Q-#9-#%53R>%
M66W-"Z$<@BEW97"9Z*2;%(Z;]HJH[DF+!$L[#G!'*2E.;0<V@RONUCV+OH2>
M8Y!$<V@YM`ZR:(:*\V@YM!)9G$14W/9?!Q4LR;8K)'ML1Q;IM6B?-H)YZ=O%
MUSXZC-UFBC".5SWD53S@I"1\DA(LN;0*2;-%<TBS*KU[6ABR;$R"<DR6(>78
M$'6MA5V@4<V@>R3)@CNS&QNS&QNS&QNS&QNS&QNS&QNS&QNS&QNS&PV>-GB.
MH:QJ&H:AJ&H:AJ&H:AJ&H:AJ&H:AJ!3?D&?\++_J,L8'DT6F*2[6K:`F^>AC
M,NW4B(=PR<24-F15V&%96TDL<Q&5B%V>.Y(V@4,.FTDL*B'D+&?3N*PS-R^P
M)L_8XL)%E<6+O`I(RWT=PA7:\MC;E&72RF(A7;;N0@J,<GBY"Q$WD4PP>7[)
MJK2,K,IR*F0Y65*2EY>E$)O(R.A+X[65>,L&9M%4,*9I*)X`Q(BI@S-5!*!J
M@FAA#9!.N!L:M2%T$S>"DLAA_%67CQ5EX\59>/%67CQ5EX\59>/%67CQ5EX\
M59>,+Q17&FGLB_L&?\++_J,FF;(@TRUH[?GS9@51?*V*"*$N@Y6+G*-O/EM*
M+M\K1.EU"HZA4=0J.H5'4*C,>[K_`!>2QK(C9'`=0J%W_3(O<]1;*]0J.H5'
M4*CJ%1U"HZA4=0J.H5%5U*TE<J9PRE<KC>8CF<.N@PR!M)5ZA4=0J'F4,(]T
M;)8XBB,PW<..H5'4*CJ%1U"HZA4=0J)6;:1#;R'B8\AXF/(>)CR'B8\AXF/(
MF*#R'B8)W`Q50]%*FIK,-9AS#C68:S#68:S#68<PXUF&LPUF&LPUF',.-9AK
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MC14:*C14%)74&?\`"R_ZC+W#AHU<9._:.4Y>95$9S:Q_V>Y<MD!)S`73]]AG
MJELL-)&D$I7J,"?2LCC/HG)0T2RB).LHG]<AF)Z+?N\@FVZT3-NY&1]6;3[C
M&X;RS-#RS-#RS-#RS-#RS-"!D59>(]L7]@S_`(67_42,.22%,38E3VRWTEB#
MD+:EA:EA:EA:EA:EA:EA:EA:EA:EAD?87'<F$'AR&/LK4L+4L+4L+4L+4L+4
ML'_:F'?+1O9O&X]6D2K2EJ6%J6%J6%J6"D)58)PG*%J6%J6%J6%J6%J6%J6%
MJ6%J6%J6%J6%J6%J6$C`-G:.SL<&SL<&SL<&SL<&SL<!&/*2Z8PZ8PZ8PZ8P
MZ8PJT/2G3&'3&'3&'3&'3&%6IZ#IC#IC#IC#IC#IC"K4Y:],8=,8=,8=,84;
M&XAG_"R_Z_TMW^GIK_U>D_Z>E3_?I4_?T4_V&?\`"R_ZB:R6USS#(920.ME4
MPA$RN6/X\%SN33CD<RFK73,)"^XV^?R45_0G?Z>FO_5Z3_IZ5/\`?I4_?T4_
MV&?\++_J%F+!<Z,?&MU5(J(625C(M>AHB'.F>(AU*6R+JLR8L(U'44:BC44:
MBC44:BC44:BC44:BC44:BC44:BC44:BC44:BC44:BC44:BC44:BC44:BC44:
MBC44:BC44:BC44:BAW6FCTUK3E>D]::/2>M./I4K37Z*?[#/^%E_U&9.GC)J
MGE;Y91IDKMT[:Y1('#++W:P4RV2K66R)\2;C\PR%Z?$<B6R-CZ7)5SMJY+F]
M&#,KDC7[6290K`N:9BD==OW!:+-X;(RRKOZ2[N4;*3$V[82B6<.5!3-Y$A7$
MS+%?[X=Z%,PDZ+QV0+OGPR>?VY&^6QY;'EL>6QY;'EL>6QY;'EL>6QY;'EL>
M6QY;'EL>6QY;'EL>6PR[K-5G-*T-3UE_8,_X67_42C1!THXQR'<@T/&'!(&&
M2J6(C2#;\+0KR!BI!6N,8[6C.*9L!RJ#E4'*H.50<J@Y5!7%T=R<J@Y5!RJ#
ME4'*H.50<J@Y5!RJ#E4'*H#M$%*UC6-26YE2B,<S;#E4'*H.50<J@Y5!RJ#E
M4'*H.50<J@Y5!.XY$Y$S\3X&/$^!CQ/@8\3X&/$^!CQ-@8\3X&/$^!CQ/@8\
M3X&/$^!CQ-@8\3X&/$^!CQ/@8\3X&/$^!CQ/@8\3X&(SMWA\.[TC2-(TC2-(
MTC2"E_(,_P"%E_U&>)J+1S=S(++,5SK/4%9$\<U5<UR8^33"\.YRJ5:EA\@R
M(^5I93*24&WR)^D\F)W-X@8),2DE0=US-5IGMTHH?"?N9,]R1J[O>3&4;9#F
M%6T!*3;QY])5S+MG%QS`R3HL[)0_.S9`B3C*3.%:9-7(F*>8E9P=<G3>CN'-
M.8&!\D9"/)&0CR1D(\D9"/)&0CR1D(\D9"/)&0CR1D([?S6033'V1?V#/^%E
M_P!1(51*XXM^/%N/_7I3@B$2QZ*.MKQ*9J<<$1P1'!$$1:)FX(C*,1[/NG,%
M&0,9'<$1P1'!$<$1P1#Z7A(T]96$*C51I15)1HNGP1'!$<$1P1'!$<$1P1'!
M$<$1P1'!$<$1P1'!$<$1P1'!$<$1\8_P/\#_``/\#_`_$?B/Q'XC\1^(_`?B
M/Q'XC\1^(_`?B/Q'XC\1^(_`?B/Q'XC\073J#/\`A9?]1G3,TA'Q24VT?E9S
M*B+A29=IP:DR>3;Q;Y6/;,))TLJVDHUGZ>ZDICJLEVP4:;']/<V079O9%9E+
MP:),'6=NVF(++Q46SAV7UG+CT<-UU$?KD..R[]\[@LB46B6,ZC(^KN&244@>
M@SL=!G8Z#.QT&=CH,[&+)R:4![8O[!G_``LO^H59(*GMK86UL"Q+(E;:V%M;
M"VMA;6PMK86UL+:V%M;"VM@[Q/'9"I8IF2EM;"VMA;6PMK86UL+:V%M;!*&C
MT*6UL+:V%M;"VMA;6PMK86UL+:V%M;"VMA;6PMK86UL+:V%M;"VMA;6PMK86
MUL+:V%M;"VMA;6PMK86UL+:V%M;"VMA;6PMK86UL+:V%M;"VMA;6PMK86UL+
M:V%M;"VMA;6PMK86UL+:V%M;"VMA;6PMK86YM]&?\++_`*AYEN;HS^<UR$L1
MC^2=T[>^RCNVWF\;RKN<Z:/\N[GD/N;ND5S&Y9W177@,J[K.2J9QW)4G<>R;
MN6=N_P`P[KU>URWNV<\I-=QW%74[W4BY:(G.ZBDNQG^Z5)%+,.\+V-Q[+<I<
M3NZ>Y,7"R&<]RF<Q(Y#G+[&7F:=U72,MEW>`R#S,>XR..(3O<5W(1N3=X(XU
M9;,7V/O<R[N':HYEW2.8LYW28(R.1=Q&](?*.X[EG62[L*Q2.1=UI7%SYAW+
MJZD<SSNDO'9;WCLL/D_=M5QDDWW28J.\Q[J5-*/\](NBMW0>GF,LSQ"96[@Y
MU690S+NPLEALO.2T?[IG_"R_ZAWEV;H9/EQ\A*VBLL[JQS=7)NXI\;A,XSE_
M(-LZ[AJ*-NX'<XD?%9WGA4I;+<Z9SCK,N[#@Q,X[CN'&+9?W`=8NCF7<9T_)
MGG<PT>KFO<>J4%EF?R5(CN/W+F6G;W),EFVW]79_PLO3\`IFD\69SE[/L(B)
MSK/7T*OW'S)L\E,VSI?'8_.\I<J2O<[.U%H+-LME9K',[RYW`E[@Y`2&=]QL
MX:MI?/\`/FE(K.,D=Q3CN-G2](3N'FDA+LLYSQHZC\ZSE5XS[L9FWBTLRRZ3
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M^(?$/B'Q#XA\0^(?$/B'Q#XA\0^(?$/B'Q#XA\0^(?$*:/I__]H`"`$"``$%
M`O\`C_P^O`</[)X_WI(OJ1Z.YR#<Y!N<@W.0;G(-SD&YR#<Y!N<@W.0;G(-S
MD&YR#<Y!N<@W.0;G(-SD&YR#<Y!N<@W.0)9*@8]*T-3W_&E?:.&J+LEECA98
MX66.%ECA98X6:.%ECA98X66.%ECA98X6:.%ECA98X66.%ECA98X6:.%ECA98
MX66.%EC@G$L$C_:=*G1)256JC217,4\JY40/)*E!9%<PK++429NU3N/75T\H
MM3CP]"IE`E4Q!3CP]E+/E&#?<SH;F=#<SH;F=#<SH;F=#<SH;F=#<SH;F=#<
MSH;F=#<SH;F=#<SH;F=#<SH;F=")ESOS_>K2E1R$>"C5%4A6Z)*<A`<E*@Y"
M%:%33)7UU9)5>^D]%*@B9TQ3V:B2:M.C:CHVHZ-J.C:CHVHZ-J.C:CHVHZ-J
M.C:CHVHZ-J.C:CHVHZ-J.C:CHVHZ-J$TDTJ?UB8<N&K:\3`O$P+Q,"\3`O$P
M+Q,"\3`O$P+Q,"\3`O$P+Q,"\3`O$P+Q,"\3`I,R_%(QSI>^UET^BB:ABI-U
MEJ>TK2E1H(-!!H(-!!H(-!!H(-!!H(-!!H(-!!H(-!!H(-!!H)[&32YS(B:]
M3)\_G41*LV;I52=_9_V#)FI)*T5HW,E.'DOHV>E1;-.01NY;F<&4C7I0LW6;
M&]C,4=&:<J>'*GARIX<J>'*GARIX<J>'*GARIX<J>'*GARIX<J>'*GARIX1E
M7U6WL3G(D6KA`HZA"IN>CPUDJ;['&G$<LFOT)M'"J3)"2<(&?RJ!*R;\P7<+
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M=2I3%KQ+[21>]`WW0-T#=`W0-T!JX([0]VJD1=.D:E155FBJI1LD45CFU3-V
MJ386QJ"QS8I5&*"I?0W0Y$B8VHWI.F50?Z]JNW1<DM$<+1'"T1PM$<+1'`A"
MIE]V]4.FV/(K)*%=.S!OJY'V4#.#RJNGF>IG$D:E*HUY<RDW1?\`LI9VLR:[
M@DAN"2&X)(;@DAN"2#)<[EK[LY"*EZ5M0O(1X4X4I]E)!)![4U35]2$^_1(Y
MR*2<%]F8I3CIT!TZ`Z=`=.@.G0'^O[HX?3@.`X#@.`K_`.$7ZBJ38LFL>J4@
MJHJG(KU",JJ85E'`I_FGV*O'E%:<>'N9%[T#?=`W0-T#=`W0-T#=`W0-T#=`
MW0-T#=`W0-T#=`W0-T#=`2R9,RE/\_=,0JA3LFJ@JW;U%&C4HH@A0=(TX?9J
MR3J^]TNW1<DM$<+1'"T1PM$<+1'"T1PM$<+1'"T1PM$<+1'"T1PM$<+1'"T1
MPM$<+1'"T1PM$<"1;!,_W9,ICLB*+G,B>IUB&7J@F92X_8;<P\RMPYONYA5R
MBTZ^;'7S8Z^;'7S8Z^;'7S8Z^;'7S8Z^;$.XD5B>WX\!Q''ZZB\-5!2M*^HB
M2:3FM:U]14U#CEJ<>%>%:5I_59)*J[-L5XFM1)V8IS.U2LS.ZN"-EC()H.%#
MF3<-TO2S*D?(EZUJMZ6!*&*2ADU:]50I3.:44.90WL9A%PNTMLP+;,"VS`ML
MP+;,"/(X3:>^I2E/9UK6O_+#_]H`"`$#``$%`O\`C]Q&H<1Q'$<?[)X?3A_>
M43&5E7&S5!LU0;-4&S5!LU0;-4&S5!LU0;-4&S5!LU0;-4&S5!LU0;-4&S5!
MLU0;-4&S5!LU0;-4&S5`OA[HB9J5*;WU:TI0BB:GM&;URP4W'+C<<N-QRXW'
M+C<<N-QRXW'+C<<N-QRXW'+C<<N-QRXW'+C<<N-QRXW'+C<<N-QRXW'+C<<N
M-QRXW'+A:>E5T_M,D$EU*PC>CBL2V*=.$9I.4X=$]3Q38H+!-ZKOV**;3U\E
M"I/3*.I#A%'79$1,<Z/LH.-2E'>SF(V<Q&SF(V<Q&SF(V<Q&SF(V<Q&SF(V<
MQ&SF(V<Q&SF(V<Q&SF(V<Q&SF(V<Q$Y`IQ:?WJ&,4=2XXHO7"*IW3@YNI<CG
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M#NFZ:KQ>.07*QC%STCF-`B@BW)_4XMP5J]7D(\Y%WC+EJ/V9RR;]DZ;_`&%S
M&I%ITI0GI79T567(H5RF];-P278U#9TB[)[''W39F_OT&+]!B_08OT&+]!B_
M08OT&+]!B_08OT&)B5@G+7VS=LL[7I&O:E-&/2$MK[4=@[31^Q5)0J134-3Z
M$;K*$^BS]!!RZ?-D%TR,5J].W!2$)3V*#==R>SR@L\H+/*"SR@L\H+/*"SR@
ML\H+/*!5)5`_MV#FC1TM,LE0K(L.6I*LE"O7J:Z7V%C%Z`O^"@AM![PD9'Z*
M-M9EVBA7%'J#8Y9@M0S==6G[&%D4XQWO%J-XM1O%J-XM1O%J-XM1O%J-XM1O
M%J)J9NI_;LFAWSI:*<HMJ0KRI4XMVH=1NND2L(OU-(I3EJQ:]#>DR)RH%-K*
M/\U!(UR=+W#1FY?*[;FAMN:&VYH;;FAMN:&VYH;;F@;'9DI:\:5]PT<=*NM.
M<\'G:'6O*25'DC5V@>=IQ6FS*A&6HDIZ53$,RI2O`%,8AKNYJG[B*D:Q;G>1
MQO(XWD<;R.-Y'&\CC>1P;,E>"ZRCA7W#-`KE<\0?0G&\UFWC>)ZQ+CE.XY5F
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M'5O!U;P5XUK_`'/Q_P`\1Q'$<1Q''_-/_",:B@N]-#-R%6BD4D58AM0+PB)`
M6&:BM.%?L400TU]U$QUT=;+&RQLL;+&RQLL;+&RQLL;+&RQLL;+&RQLL;+&R
MQLL;+"^'*D2K3A7[A#G2.G(O$A1TZ*#/GIQ5TYJ.N?<?L\\W3^Z:NW#)3<,P
M-PS`W#,#<,P-PS`W#,#<,P-PS`W#,#<,P-PS`W#,#<,P-PS`W#,#<,P-PS`W
M#,#<,P%9R563^[#F*G(JI-B$<)T(W4(V*Y5(E:?L*Z2L$_T]WCS=JY?6C'Q:
M,?%HQ\6C'Q:,?%HQ\6C'Q:,?%HQ\9`TBFRGM^%:UX?XX#A]-)N.DW"I:E]1C
M&.EZJF*4:BC_``/\?U6(7HVD'AV"S>J[$ITBL432!6)6BCMN1RJY:HD(JU=+
M^E>IRQ:?"B?I<UX5-P,3X>-:)`I:%I[''EFC=]=8`76`%U@!=8`76`$JHT5?
M^^K6IO9\*?\`+#__V@`(`0("!C\"_P"B`*Q3,]3LQ/N:Y/>[&N3WNQKD][L:
MY/>[&N3WNQKD][L:Y/>[&N3WNQKD][L:Y/>[&N3WNQKD][L:Y/>[&N3WNQKD
M][L:Y/>[&N3WNQKD][L:Y/>[&N3WNQKD][L:Y/>[&":J"E&-[VF%G\`AR22N
M'I!>UVUVUVUVUVUVUVUVUVUVUVUVUVUVUVUVUVUVUVUVUVUVPJ)IB8>K3PW3
M*6$QYVG<CB$)(MPI*O=C`]\[D!!6$Q?_`..>/L910`D\-[^>1*\?.X96.P]/
M$W"G_,_V-,F5ZA3QN$W$SB6+3N1/*%.C9)/]3F+&DMQ234=C$I3FUH>H_P#F
M?N3K3?\`K)5O/3*/LN5%0E,;?14GX'8F5PX]31MY&*U,`DK='H.AMBGGTML4
M\^EMBGGTML4\^EMBGGTML4\^EMBGGTML4\^EMBGGTML4\^EMBGGTML4\^EMB
MGGTML4\^EMBGGTML4\^EMBGGTML4\^EC2J(<H![Q9U^OBSI$NZ!@L;AD.2]\
M(?7ZXFE"0Z67JQ-L)R#ZX`T$IR?7&<K.*$NZ!T>QIDI`5T>H_7QXTDO,Z)]_
MI.$LK:DN=HV\C=4`(:[3D:[3D:[3D:[3D:[3D:[3D:[3D:[3D:[3D:[3D:[3
MD:[3D:[3D:[3D:[3D:[3D:[3D:[3D9U-(`_C*5^5O"MUCX.+6[H:W=#6[H:W
M=#6[H:W=#6[H:W=#6[H:W=#6[H:W=#6[H:W=#6[H:W=#8_\`"&2JHF59$1BY
M?.\28_1G2#(&*J220FWDL6L#6!K`U@:P-8&L#6!K`U@:P-8&L#6!K`U@:P<A
M52_F4C_.EC6KH4Y?#G#B=DJ39A$$DC$U*MPUIITG)PP"BH*MC84]#F5*E3UK
M2$@A3TX)R_XB-8]350)N')3<_P#QP'J__E!7^U*16ZYEPZ'I"N=;R8$AE#RS
MN-(97V/=!_,^UO+J_P"016*WINE#A@3?&9;;27.F$J7P^E?E)E25/L/_`.]A
M3I3)0,,`_&7L^E1JK1@5-;F_O:YJ`?7F:2NDI4Y\>1.\G/Q9QLO>Z.)K?,Y5
MM;YG*MK?,Y5M;YG*MK?,Y5M;YG*MK?,Y5M;YG*MK?,Y5M;YG*MK?,Y5M;YG*
MMK?,Y5M;YG*MK?,Y5M_OMO!C=]KG^IY%/4(2C&8,9EH$ML1!]C\3!`6B<V!X
M>6)G2X'&&D!$^+U,N'Z.*X<1SGX<OHFNA)-)-I:HCRLW`P\_-]>MDT%E2$)#
M@)0+.K/:T:AS<_WBW$KJF7_%#1`>]2<DX?F;C+2^IJ$V?"5C'@$JF`73=&F<
M#A(M9.'"#@QLA:J9*4)"2-76,M436_:%L63Q+`(G5_D2(':>\1P.]3L%-12"
M9K$GA<]CP%ZF./,RE*+R2]_3Z2O+:W!7;$?=9PE'ET#&>M[BW$\O1IF@ITI>
M7_YH:&?PT]2AIYBW"KARW/Y%P_+[<X][69VLSM9G:S.UF=K,[69VLSM9G:S.
MTTTE+#A?U<G-:L74Q_=@92)M9+GP/Q68(OYF"$JBISH'"]T7.#W&!BQ5/`'G
MY\MALQ%N"E7XAYC[;/4GRB5#]2':N'6?+E<<C%"]H%WTIH55I3658,PRFS']
M*_-H=PD6LI:5%-',HYLN-N$NHN5SG3O#A@@6O%Y3SZ3E+35"2KGY%/64$HYV
MOJ>5KZGE:^IY6OJ>5KZGE:^IY6OJ>5KZGE:^IY6GI$*1S<HX0PJ3F4"<P8+>
MDU1+AME*^;^4CK8<64A],DO_`/&M2L47O&)D5-2:FD)$;0!4#[(;=G,6!J.(
M112A/5M989/4BK60!Y;AJUX0(=*"+3.]7]('.Q(B/H72"B@J20\6AXM'.,#4
M:R*M.K2002JHE]2!^"#G.YX%YPP^CARB0VQ7'(IN(N04T"S6R6L/,I73124'
MN=8.MKVE]7^])#<(J"B[!TD>[D7`27:SVO$M>):\2UXEKQ+7B6O$M>):\2Q>
MHJ6K)D]_*#74"0'6<Y<QH!X(ECCF#X,Z)C`X#J3^S/S,2]ZP'NPX-+&FA0*T
MVL:Q0L020(/(67!T6E"5%)DC#X]G"TU;\,3%,2+1`V8O2_0B;CPP0B\V\SM;
M%#&QIFU)=D^AYL:GY1!*UU'12'B)<(Y^B.$/Y1Q?,&5#W83[&O=U7W6O=U7W
M6O=U7W6O=U7W6O=U7W6O=U7W6O=U7W6<*N96AGBSE/">[62<B@KW,DHJ:R78
M,16<>)3NII!4C_3_`.KAX^MEI6IR)H0^PA+[>8PSLJI,\%[H6/5-:_0R!4J/
MDE$`Z"9G83A4\GV,%3/J)D<98@(P6X1`M*%N/$4I[HZQ?".#(<(](>9K$'R?
M#4(;0.K([`[:GZL3/39]"J%4/I+201C!@6IU?*+JTJ5,OD"H$O>\E3U1L,;`
M!RG@E4HF>UZ<G:UZ<G:UZ<G:UZ<G:UZ<G:UZ<G:UZ<G:T:A=T=K"E3@A(Y3Q
M$VS)&50'O8HJ)+YR'BP#B%`?%]N)E4"A1=*YSHE4V,C^4Y#S/HKHE(15PD'$
M^P,*;E/*G`P<=:4X<!Q]3VEII78]\'1ZV)(3.1J6VSR..9J;@G60@NB]ZE%)
M`.!SL+*_4N/XD@E&(/\`B5D%N)_H_HBC\-P(4_!&:'-`#&_F924%Z`8''Z4H
M%K/Y+QY9M9UKO<6N-_PM<;_A:XW_``M<;_A:XW_"R?,4]E7+.&O9/NB,[!<9
M`+,9FG><<8MQ3,*D+#B>[VD=;4Y0X4MG(YIM9[WB)A&8NQ/,6_"?$#,VL"H/
MPQ%I+NAY>Q2D&4_>*X=98H5-*I1)CC#CU>C^N*BI,B@48"^64_X'%W]1:;TH
ML[DO#KB9#VNAGTM=#/I:Z&?2UT,^EKH9]+!"`Y`Y8I=,N7#.0,+(IE>S45-`
M:R9PG+:8.V67KJ&K5(@CX%.$L,6U-U,DK)4IUL/<`/5'RY*3Y5R2["+7Q^U!
MV(#G94CPAY=Z<]5":B]7:L!5B&%STX/YB^#F<JBE0"<2>L.=:,6%Q=8RZ?EH
M(%HQ'#]<%G(^+0=/,!'K:Q'=.EK$=TZ6L1W3I:Q'=.EK$=TZ6176F52A9]<?
M+)*@>@M+(F4AUF#$SI0Z.]M9<+.%GJA_R%,?[D)6'\RY9H6?".AGFWTT(,JP
MBQ_01@<^UI0133]G27G)R1RP"&V$Y`VPG(&V$Y`VPG(&V$Y`SA_8`-2BX+>/
M:&E"$ZRG!YYU"/=]V!IK$$/C8/PILC)XB`"KAY%K*?8'LDU$I""["<*%*Q?9
M:<`:@42(N("$KPA^%G^I/_&_O#&:%V7]4SP4CF<LQ>EHV\JX\LVLZUWN+7&_
MX6N-_P`+7&_X6N-_PM<;_A:XW_"UQO\`A:XW_"UQO^%KC?\`"UQO^%KC?\+7
M&_X6N-_PM<;_`(6N-_PM<;_A:XW_``M<;_A8)JTI48YGYG!G^MD6`4'&T4)V
MGF`CTX[6BA&08G>R'0PEITPZS5$,+00G(.CV$AG<*F[^D>J_^@]7%X<G,YY/
M_=ROAUQ,A[70SZ6NAGTM=#/I:Z&?2UT,^EKH9]+70SZ6NAGTM=#/I:Z&?2UT
M,^EKH9]+70SZ6NAGTM=#/I:Z&?2UT,^EKH9]+70SZ6%1-,3#I]<I"7@E2!E6
MEC5K32+X<UM@*D]0>D/9!$XJ?A.#R83K"\3Q+:\8F40M;PFG-'XYC,(V0<]S
ML#$/5-.IXBZ25,L++??ZDT>(^C*#)BEM=AC,DK."&-E.$HF,,7-RR;RI(JSC
MWMM+R#0VTO(-#;2\@T-M+R#0VTO(-#;2\@T-M+R#0VTO(-#;2\@T,?UB=3`J
MPY/?[>4/-C.P_0_Z'O@SL+0](>;I@#S("A,+7*=-E<&>?2>@$AB'%XMYF?@9
MQM_BII`$O4C_`#I?F;]0M*P5230."=/N2>@AA5J)J\1^(V_IW6._FAE#+I)G
M($"'0=(@XK9L&9JG'FEC@AM&5Q_IQ/YXLFA3I+"5IIA<"F*9E*M_PA^'G9-:
MJBPT7O29H0+CBPJA$8F_VR5)/'J02FT3&6+C#$\2XR!Z4B)N,M$SL"N#;S:O
M$_Q'^EE*5:2_+Z0J30`<[G>][<.FI)J"FY^#:LZNO$WXJJ8$,>/ZQ:5]*:W"
MTRK>12>6?Q)Q9UM\>4M\>4M\>4M\>4M\>4LA'FB^L[E\,/(X_P!K#__:``@!
M`P(&/P+_`*(!\NE<CD36/P@>]K\=WM:_'=[6OQW>UK\=WM:_'=[6OQW>UK\=
MWM:_'=[6OQW>UK\=WM:_'=[6OQW>UK\=WM:_'=[6OQW>UK\=WM:_'=[6OQW>
MUK\=WM:_'=[6OQW>UK\=WM8JHU4KJ8G.?UO8I5M#E[S8WX:@>CDAJ^6,JR'=
M37F8->9@UYF#7F8->9@UYF#7F8->9@UYF#7F8->9@UYF#7F8->9@UYF#7F8-
M>9@UYF#7F8->9@UYF#7F8,:2ZNH<4/5KXKY$TU*A]EN'-4-(%8-GPK2D=6MB
M)]W#*JA6*947.BZJ:0=[3]7(%0J6GC.=@(XBJ8%ENJ\QQ@#"PO`E7"Q0X@6_
M!\,H?S/:14\J#5Q/,G"S&8D<S<.:IPYBA\-H5>'GM<[I($637IO"TII`XE3!
M41SZL>GU'ZO_`$;'?:AFB_IA9%H6>CYJ@$@>5%.!D69@4:VL"X.Z&KC_`(TB
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MSOJTML[ZM+;.^K2Q@1"V<P92*2IZ8,#CY?+\7HR$B8L!44`56<EU2VTK*VTK
M*VTK*VTK*VTK*VTK*VTK*VTK*VTK*VTK*VTK*VTK*VTK*VTK*VTK*VTK*SB3
MR%-<N$J:A_+4[.P\OY:HE]/BR%X&TE"X%\#K*2#C:MY?C4U5:\RL$2@(*;-4
M1"L(>]D%2T2TZ2E*(*7+=K"F'?""Y*<-KFHJ,O&XE5[K8\.)S^K_`%KOQ@9.
MIPTN_IASL#5V'Q][5!Y<H`E5M@O>X[(?'``^PO+OI1YJ43H^UX&-2K*I1P1+
MNIG5:M-"\*769VO:9+3T5!27NY%_O^'P.&=MSGPQM^SR4V_9Y*;?L\E-OV>2
MFW[/)3;]GDIM^SR4V_9Y*;?L\E-OV>2FW[/)3;]GDIM^SR4V_9Y*;?L\E-B/
M^,N\/\K_`+/-]1#D7#HI4JH<`B<C)EIK,[Y8&+K78W86-0TZG#27$REP.(E@
MGAKF(>(&(QMQ"D\-[GX'XO4OP?1(\R^B**U.J*L#(5YIW&P<W.QK("5J5;K$
MV]>9H4Q]7:`W#HB5'\4%=1=*E>7AJ`SN;]/36!2_$"7OA.E"L`?%4Z64:=6;
M5K!QF)5Q*=-(M&!0-N)JE--4!51:E).MJ`JHF6R$$*LA9C97",28#7?>+,1L
M.<887GU-H*`ISL(G_P#S'J8)$`!Z2?,:O%19`_>9YF-=9Q#J<]N'7K+%9-H=
M#_*SISUI.CG;B4"]#W<BXOFRZEPR.N#;:>[V-MI[O8VVGN]C;:>[V-MI[O8V
MVGN]C;:>[V-MI[O8VVGN]C;:>[V-*$\6M\+A*[GF]T7XN3CR_EQ-658++`_"
MR%R:BYG%Z1L;3WF`&,N9512-5+WQ2^#GP>\@/$0'18)X<2'VCFMC"T0,8C&Q
M\PM#J0MB(8+'O]3QR/PHQZ+?:TR;#])J(2](_O\`I1Y5;^(NQDH*0JMG3]<6
M)N*BFB9[WRQSAMA&0<V@9`SD``<W(N'Y=!6O$&^7J]TM\O5[I;Y>KW2WR]7N
MEOEZO=+?+U>Z6^7J]TM\O5[I;Y>KW2W#K)*:@P'E''4^"5Y2A0&<L:;E)HF?
M`]TR:>!\==*NICP`L%U4`.A^+30C'!SB<+5*6N$5EE9,HU254E2[4;LQA:&*
M:3PJI7745U[`ZA-E]244R^K,-7&][XV:L.EG?0%N!<66E:5)44D:I@7@[3R^
MTY(?3/,9Q9!,,J6X:)C46;=7+8Q\NI"UU4ESWVGJ:ZJ?5VD%N($E(?AZ`??R
M(^8J`J$A$.IKI>;2UTO-I:Z7FTM=+S:6NEYM+72\VEKI>;2UTO-I:Z7FTLF5
M`3339_-EQ<W*$^500E2GQ-D`3[F3Y@N(,T,*9"XO::`+GD81^)PW=+P_HYX,
ME,KD*+IL&'0635J)(IJL+#RZ:B"]2TDQ<DTP]3X<X8J4M(6)X1_T]K`[2P1Y
M?\8R!6J#`*#TV@6XO2_4PX<>F'UAC8*%A'T.%K*JER0E]O,(Z.F&/E/!\JF:
MHY]H'M<USO(^\USO(^\USO(^\USO(^\USO(^\USO(^\USO(^\TQHP'VD',%,
MXV\IXP#]50Q;22G,][*%2EJ+FL5_,E`AJXT3=;FXBJ4/ZO\`W<8?#U-3531-
M4EUH_P#LJ*EV?M#6ZG,BE*XASXVRIE$'!T,;^H0:H:5%QJ%9BJ:*RB;X1!R'
M`<\264D((I+%29,T":@ML^%6L&G53F'"0ASX&1($=4O!RC`H>D:5-_'F'1AF
M?F=UM&WZ`M.T"RD50E9((>18_F#ASQPQY3^IDG,KK78N8M<;_A:XW_"UQO\`
MA:XW_"UQO^%KC?\`"UQO^%M6@)OZO"RJ]8OJ*+SRGA*>!(L]U"E>YA4I*2XT
MPIQ>\GA"JIT'0%CRR/-)J)#YYGS:H3*'P2<*A8^T?:=7IUPHU*.!)`C,ZTAC
M6"D.2F8B+P],X?!SRG%UN:>JI&T0X/?"W!8P"5+D2K7LLX?$>.IXBU68KU*E
M0/@X)0@+!(M+WX&2/)DA](+,Y?:9?A2_I-@PN]'CS:T8>R//F8%4%.]*IYVO
M54FG2=JI2"I147(2G6M4>:#5/+_R5%)R%W)?TT\FJ2]S\7.&^9_+\;?,_E^-
MOF?R_&WS/Y?C;YG\OQLKRM7;2?[N6"M2VA[PXY0QIN3Q";7""9!3<G%JP;@)
ME-*-H?M.>.C52>D-5G+S6.ME?[6DU997&`UM6038W)@&'&=`DY7/]C:A"2YS
MP'&P![\;@Y[)6L@K27OQO0$%_P#A2&341+,A`2("#B\=;/\`0_3.`+P9NA[^
M][F=Z4WEP@J#Y7_"5!S^?!:\/`YWFK4+ZBB\GG/)>+Y94M1SL'O:^S)T-?9D
MZ&OLR=#7V9.AK[,G0QJU"^HHO/+$TZHFIN5".!).!Q9=9-,O723('ER%&F5G
M#8\)`>_::G^&A6O02=:H_P#$0\SZV.*)>MEBFD(0%.<'X(823G]5Q`#QH]!Q
M9,[";:=Z9I4*M2C2UR`BU24?S&U)4Y;G*_E$L9FF3YA8)4[:5SN4]Y@7$O\`
MA>'VLBIYN*S8<)&`GZQMY'P/,/X<A,.IK:G>&AK:G>&AK:G>&AK:G>&AK:G>
M&AJGEJ:IT)-ONZ18>6"K2)34&$,%FHN<*FMPV/R!GSJ?J[D$]W!B:8VGU1\L
MJY)![KW>TLX>G4JIFIJJ#6ELM!@""ZSHYFFE-10_FT!PROY)-244JYH->U.\
M6O:G>+7M3O%KVIWBU[4[Q9YM_L`"EY@$TR%6<R26*E5%D)0\N`Q(5#O88V'"
MQ0Z:HE12\6J_&D#HN>YE<&HHA/%!LMI4POVF7J9::2UFHF;`/AJ(1C^V'=#<
M,J49R@`P)23473-A<Z$<G.SO4_J_]"QWVH9HOZ=7G:%G*OTT\FJ2]S\7.&^9
M_+\;?,_E^-OF?R_&WS/Y?C;YG\OQM\S^7XV^9_+\;?,_E^-OF?R_&WS/Y?C;
MYG\OQM\S^7XV^9_+\;?,_E^-OF?R_&WS/Y?C;YG\OQM\S^7XV^9_+\;%5"L%
MU1@EE?US%G&WUO$IDI6,(@6A44^24/)U07;,86-JU%]XXW^V/3%B%5JIFMUE
M1P1CB@T:BX_:.$O.<`](9_&JO_K5I]5^FA),_P!FCE?%\LJ6HYV#WM?;J=#7
MVZG0U]NIT-?;J=#7VZG0U]NIT-?;J=#7VZG0U]NIT-?;J=#7VZG0U]NIT-?;
MJ=#7VZG0U]NIT-?;J=#7VZG0U]NIT-?;J=#&E4K&15L`/8/7)J+`*4IJ&/-3
M4PH>7D-2GQ93`O)2A8MM("R[G#+"N&:+JTQ"4@3<.F:>$N,UCCC<R4J12*2N
ML$0_TPA)0J#GQ>XJ?APV`N3+PT.+@_B3JFC;LX,3N;U,\KEO=-TV>PNQQ8/+
MRZWEAI^<`-'ADQZ0UW3[QTM=T^\=+7=/O'2UW3[QTM=T^\=+7=/O'2UW3[QT
MM=T^\=+7=/O'2P_0*_%PH$0.=^`\T>K#R=PM9^#Z'8?HE<7L]Q<VL"/2X"B^
MB2(=%GIQ+/?`L[^+)KD@2IJ6X^&IV4M^DIKIE*.+)K`14*:\>,J'2"&-"DJC
MP98:PL'FIH%_\FL.HAJ==7"23$*FB3Q*H.'9EPX\+4OTTD^K88[`FF']>-W,
M',KS-6M3*Z:ZRD&8+@N1*0''^HRX+8,NA1J!Q'F"ERQ+$3)!3A5@1$.5@+?[
MM:%)'EJ45*L,@GA,'E^TXSX@3Z3U.X84[HGSQEZNM@!8!Z4KHDO?U-,H&4J]
MS:@5FQ,]RW=3.'(C4\Y+PN&;<;PUM+(&MI9`UM+(&MI9`UM+(&J+\D'4'_WD
M<QY>)B8?VP__V@`(`0$!!C\"O6RHEYJFO"BE]JVP[U9^#;8=ZL_!ML.]6?@V
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M;#O5GX-MAWJS\&R"MXJNI"11^W;%[5U]KK[L1"/.5$_\[(#8H(CJ1/\`\Z5_
M_!*MN)>B]U%]HA7VE2SSOMI%=+N-$M@_"M_?C_+TN)P[$1^1`>F<38W9;\**
M<^@1L5"@..,,2%=>?K4QF0#1((.)$*\DM+BU&BS)E/<1^L4M*BVV\L)VK\>0
MILNFJT_C-N2Q%CR9-_M1YF6F@5&U1=ATTV+ZOP^5%=]%.'DPX_&_$C]1.#6`
M=2'0HD6BS677VC`M_CHD<$TW6;$N':H<=>')L%B$492D#QJ?#E.BO59'\9)$
M>DU)M$2HDZV"OLF^CEQ(ZYQ1)J#TAX%GLQ*.CO0C!DQ6>(JJ_%T[$GB>NS&]
M0X&HS3:)A;'^3D09,EX'HSK<=P]SEK'66YZ._,VI*,Y#LIMNK1S(!)5P&J]X
MY@2F`]*5[>=R)W<96ZM2RK-=H#3#LC+P-$_5>&Y;8*O)7`FGEA?_`.%R/T)_
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M'Y1)5*@UPB_&:%B-2W9+L++XSC8W0`G45MVYDK@QJQ,IL:!3I$YRGPVT.251
M9D)PCPQQ.(3Q>89`%;])2@)4NON;3"F$B<^HH80)C+,:9Z5WIAR(#ZGZ-I4R
MIC@=5P";SBCH!:^3JTVH2RY$.F.SJ`7$DN36H,9&'&@>X?8W.-Z+J[H,QS])
MN>,(B>$R:O"Z\3X2D2*='CPY]/X"J5=*0VPF.FUZ@?Q"JG$-5@'%J4I8\2"'
M##,AL7A1W*;<$AO-%&C55P*;_FGH2"<483PG'DRJ/PI5Y51)Q9A?F[ZUE\!#
M#H$V%Q7H696'VHT>1`I,ZH4E*=D.[Y+?A?PYF\?)4`F(_<+3SD<80MY*Z4,L
M2K<B,</1'XD][TJM-EN0:4,>5CW"DU%-V:J=6&`0N,5+,;-7L*QS#3F7WOTR
MJ%%`,JNG#%F.TZ,UFC5:#3-YC52!4IL1)$0Y*M5&*\#+S$Q4%M%;%3/^1FO^
MEA8C.U!RN08_H]7'(E;.-2HV>_(W\$F4^ZFJJL(#1WO+XU+AN"M'5$=J`38<
M\7$@$V`/#Q1QCQ'5`::6>X*,SPXR=C-XL9,"VA8C5='_``U8J4%6QEQ(9NQR
M>#-;%R\1$C;Q!C1+]5Z6=X?B''-Z$'$#)U&-`B;J\_3IU.8@R9;4RJMN-1P;
MGY<E(^::OMFHB"7`C<B*P+='?I#]7C;O$BD8A!A<.A-&>Y/J+#B-,UN5.8+(
M`W$1I-%Z+?0'VQAHCM"X7K%2:*,X95%SB"LTVDN18!));W8HHR7#30ZJNFRF
MJ]#X3K]:B1/]LU*C1*O5I&XK&G.E+IS:/1Z6TW/D?F<6KU2#EO&WB=:-Q,/)
MS+5F<XU3O3-)]'T],N&P%`*KRI3$(PDD55.KBWGO<G+`Q0=97VH3[$EF-2ZG
M*XH$X90@62#5"E1188=>SRR9>"5EOIIPN-Z+M-N(,N33H906>(9=+0((5&-/
MBT2M0:4CD>HQZF\SFQ5EY51CR&X\EB7<("K8J9URBH<1YL*A0Z50IZ0G<;I,
MU:!P[Q?)EMY[3+CT6LSA:CM@J#F$B%?JM6B?+,IU*J`TL9$6#'B0G7VZ'1)D
MG,&547:NU*WZ>[R4;-D6T%,PETK_`"<C]"?_`!!6#\*W]^/L2]X@PW_2$,:?
M/SHS+N^P`WK!!EXP7>88[Z]<V=X)FGHY2WC*?I-,>DC,"H#(=@Q7'QGMM16&
MYPO&TKB3`9@L@CE^-!9!+[A&Y*D%&I05$7G9(U`:?$&:DB0T;#[Z2D9ST>>9
M=(#*^\A)470MH41JA4=N+3903:=&;ID((\":V>8W+A,BRC<64VYRD<!$)%TW
MV*E1:;"I\%5@D#%-C,008=I3<)FE/L#&;;!MZEM4R,,=;O%#';%.2")8-\H%
M%EY;K[[>\TJ"_@>E3%J$IT,U@L+LF>2OF6LWEQKRM-BK4BFQI$DH)4_*>CQG
M(N0>XXKV29\9R::P@H:D#>#D"*D:DW48E.AQ)34182'%C,1T5C!#9;$T9;#&
ML>/`;::OZ-I,(W(OU+9R(T=\F<W))YEMTFL]HF'LM3%5#.9-0*[:%;ET6BM,
M4"BLM07]YA-M4J"VW$DHC(I(B@#""P_ACMIB&Y>0/N)9E/0U*NC1F(4=/1\2
MYB'%C3H4:(RF3XJ-'AU22T`)<(MR'!309(KD/T9PPKN0Q1G8NYTI7-U8;BNQ
M:4XSEXLAEJ.R0,*F$1`%1-`V:E1J/2X\EF,L)F0Q3XC3[4-7#=6(T\VT+C<9
M772+`BX<1*OMV1D>&.'D:$\P6DHM-1M'$%H,:!NV%#P1P2_W`'W$LY*@TJFP
MY+K:-.R8D&-'?<:3#<VX\RT#AMI@30JW:$_D.)-TH[DVH5"E.M<-5])S$).'
ME+AFM0";!_/&:CA51_HA'+/?$-2\6>!J=1Z$Y3*+.<JM"2G(L"(5&X4XIBT&
MCUUL(L60<9A?245ZKHVVJWX?:<)1M10<H[K<!:Q_"*O5*^1%PM2>`*+P)2)+
M;C0OKF&Z4V4YB2^[T)]=O%P8RS0F69=`X0FL5('Z)3HDM*L+_P##IY(M-E,2
MVQ9JCX464C=1N>(<"Z%7#?`6D\-/-<1QI\UN;Q#O\-OTE4)W#_\`$.D1:RZT
MW(,CB09M<CR2?--XRY.!`O;,1J5,G4-Z%3V:52:+1'X+B3J2W3:=7^.:G`AM
M23R90LTNC5R'%O=:!2-M='\G>5^E;M%N^[G]-N^[G]-N^[G]-N^[G]-N^[G]
M-D+E7+>FKW+OK_7MWW<_IMWW<_IMWW<_IL]#G1FID22V34B+*8:D1GVBVFWF
M'4-MULO;145+03&A4H3IF+T:0TN$A4_&^,D]Q)&KXF*2*.+@PWFE^NT1?]OT
M;\UWDX7^4P/S59<M9DM8_B?$+*F^.<PW8W.4NFT1(W#]'CI3W2?@(Q28#6Y/
M$C`D[$P,CNSI#%:12"Y;FQ_JI:-#>I%.=B0HZ1(<5RG1#CQ(HY*#&C,$VK;$
M<=V;N`40?%C[B6*0G#U&1\R0B?2D0,XB%S-$B<R<:DCO*_M:;(Y%IL*,XC\^
M4CC$*,R:2:H]O-3D(38"N?49'C'SVGCTE>MI;ZT:FJ]4`5N>\M.AJ[-;(A,@
MEN9>*2"F"+<=^E+(R_1J:ZUAEW-.4Z&XV@U*2W/GH@$VHIOTUH7GO^HZ*$5Z
MI?8I=/HE+@RCOQR8=,A19!XA%LL3S+0.%B`$37J2W?=S^FW?=S^FW?=S^FW?
M=S^FUW*[G]-N^[G]-N^[G]-N^[G]-N^[G]-N^[G]/L2/T)_\05@_"M_?C[`Q
MF6&#C1VZ([-5S,SW`KE:*C-)$431L3C$"N%B1<2:-&NW$+#T)C_)8G%,QL05
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M.6&F_P`6EH<%VL4J?=%F"]Z/G19CLEUHFR24_&9@15IB"BJB(CKPZ4%<1>,]
MFL%3HSLVF4'ABB5N3%P4[=G=^D\9-26B(G0K3M1E+1(S4((PN"KQ7&-Q8A8A
MNR9+;T$^%Z+5Y84J#`C#/JW&_$W"4RIS8-5%:O!>J4.E1Y%,:!IQL'G@W@,H
MM'#[C\QJ;$K%*HY27Y$2(#L2KUGB)84516*S$8&GG#@/,()"3BR9#5Q>U;A^
MKXZHK]0X$K'&$K>8W"RP$?IS'"+S;Y#&-N8WPF/IMY7A%5JB`@J**HJB^S`<
MHV\JZXW7I#@16*<^X?HKA^H51@7`J;K+:Q-XC#FHV0OD&@%1=-I;S\B,VU3Y
MF1F1H;+T66M5_B!QIPC`!W/E1Y:-,-</QD:-E%/->QNB3=^'AF.\_-HS-0/A
MUJ7'2/0C.0E1X,XKXCDR6S0:MEB]-H+0@F,2%HC110E$A=2KO`4U*;1*B;+3
M,18MU5;F%O\`1ZA`DR(\_AR>45=RS+IH`!9^DA]ERHP%;&2-5X:B(KH(X&34
M^):33)7)7OEBS#N7VETV<"3.@TZ=1^#Y59JET*/NKE4IM)*H(Y)!]3-BDU:.
MK4O`#@.@P\*(XEJA,JM1B4.!0Y!ORMZA8QDQG_X@<:<-;@^6('6I,.F\-LH!
MAAN?<4W4(>2@ORY<NFU.%3N*I-2IITB/!:WB!1Z7Q/2&5CU*GE44;9A<0-Q7
MC0Q1\HV(,"JMFIE,W214*C*D-1*6_$`6V'*-_$;@[A!(JO9C;M_$]/K;KN-S
MHLP";T#RQK.8#S4FK\2M0W0;RD.G0>):O3Z86#7C6GQ6\7MJ6GZ@?[7_`)+:
MMI3B5(U/I68T3T>`Y3FY!\,\6U<5D%F#5=[*7164:PH4=451-+R0AEDLB8TQ
M$I,*4+E2C\.S93$^H3ZM#:9KT:C2&B9B5'<VFZ:]%$@1_-WKDHB6X:$O23B2
M6-^KRU"GP)3[#55=A42@@3]`#T;38CU6G'(1QU<1-PS!=>AR+-GA2%9HTRN%
M5JM`@O&VD/AWA2JHU*8ICZ0G:<_(X@>=3+5N2L:(8<DT5VS,.;&)AA:=7Y.<
M0PT"6Y3^)?1D=R-N\I]X&PBZ"1T&U4M-UF_[3G_LMQ/_`+>''Z!X0IE>%'6Z
M:5.:61)XI])/U)9#S=2<,(-$%8@QD(<]+G4P%>CU$DE5QBTQZ8KP"QPTE21I
MAOAF2UZ?P$]%)MP*NXH^C?&%')M>2[B1*R]`G-TN/1^'Z/56$J5*D"51E5FH
MU^G[F\Q+2-,8<!:.WD7"-QO8G,8:+41IG=2IQ!PC-K(.,<M*74:5_$B;Q!(;
M<0T("A1^&&)`(E]^207>,MP[5)9-G,J-"H\Z;E(@@DJ;38LMZYM+\M%)^]$]
MI%LU_9+\85J-%X>!YV=4'JH`,LA3"5YZ)1IDV&V\M5?C,##*6R&=@<!U6[\!
M(NFR1<C=9LQWCNE090P6ZDRY4*=_$.C<)4F;"@07WZG,8HD"H./R&S9;-X6[
MT37="G-D<3TO-X8@Q(L6+3)%RU.3PHQ5Z:ARI.=3.+*<]5Y(F$]M(>#+P\H3
M5>$P;)5&HUEFGU3TH$8JCDNP)TA!'T6H4T)"/1T0E!"##J]WV!_L!]ZEJ!3*
M`!NE,I==J#K6&G;L3E-JG"<1HJBY-=9D-T\(U8?4]U59&+"J(5V%6#8@/)69
MW"?`M4IK?HYNH;]4*E%XMK%:>9B4J1,D)"GT_AG)9QHV3#CB$0I:F!$E/&Q7
M:Q4&Z=Z*CT.0D^BQ9\EAB10Y\R4Y&8E1&$:;J+-0`3WHBR/%I;AN'3I`&_,<
M8WB!(CLN39,-B=2AK=1E/,D$:)$IM)?=O)NY"GO1@1;BRW++_-]I+3&>'P5Q
M*?P]&K+@F%-6$#?I.2U4GIZRG6IY95,C&L<8U_CT3&BBMA18;\;=JC2Y]2CN
M0`G/-<)1*+39_$LS%2I$]F/=(JC6!UPA!L2Y6'1:C4YR1+SZD,29(;HT?AUR
M^++I]?DLU"AU*=(D4Z3P],<I:9(O"E0;1H\S;!$H,.--B%`F26H,^#EL&]&)
M^#6YC;\DTD+.;<FE3VQB86<FYJ1F$JJWA3[/L2/T)_\`$%8/PK?WX^Q'F28C
M+TJ(J+'>,;S;4#S`^SEN<H;[\):4TV>>2!&S9#,R.^2ABSF*A(67-:<0KT-N
M3)52)/=6P4\J=&6(TZ;X,X="/.(8N.XK\:FX#I"2W\H5N71;?MS:WK*1C,3$
MB*R+1L"V32%E$`M.**(J:EL<$*=&&(;S<@FL.A7VD;%IW%?C1QH6A05OY(BB
M)HM#1B(RTE/!UN$@#<D9M^[-!I-0B>%/Y#>$9J"N06J?(8:2G3JQ&J;L60<M
MN-'SH=2HU"<1UM!<>%I'GD+"XJ-IIL;6.KQ([,F]67Z#5=V>R/2<#)CU9%;I
MB17D9&4JFV:KG!<>@,%HKKX54GMPE-R'9<:J-JR(%#;C1),J9':A3"P@3IDT
M9XY;KA`F7[)F]$C.FZD47"<8:,G!A/G)A(:D*J21)+A.-7]&9*J7*MI#_H^#
MG2W8C\I[=&,V2]`<1Z"[(<P8GG83J8FB*]6RTC=9&BIM/)H1CB+90XZ@(Q)*
M3(@H"MX4&+,%'6_ZCG*339QN-1*1';>8?BO`Q38;0.QI2-))CN"#(H;$A&`Q
M@O)+`E^I/J!WB.P_@1Q`SF@=PH\V3+R#C%<*.M&HE[HK=9B^D4M=U)XHM\"*
MN[%)>WB03'BO$D_(Y9X;L1Z5TV:<"##!QC*R#&,R)LY##T5G*)`O;R8LEQL;
MMEMPA30JV=&!!AP1?=5YX8<9F,CSRH@JZZC(`CCJB*<I=/LY,EAF0UC:<RGV
MP=;S&'0?9/`XA#C9>;$Q7O21%338'7*)2''6B8-MPZ;#)QLXK8,QB`R94@*.
MTV(@J;(BB)9-XI-,?N2<*9T"*[<-45PJFB8VEN2HD\2O_P#5Q+BOOLX^Y!AN
M/O-DR\\<9DG763!&C:<<(%,VS:3"J+H4=%GGTIM/1Z04,GWDAQT=?*G$V=/)
MYS+Q.%`)D59OZ)13#==9(\2.Q%8$G"%F.T#+0DZX3SI(VV(@A.NN*1>Z2JOU
M`_VO_);.I*@0Y*/H(OI(BLO9P@#C8([F`68@MO&*7ZD)?=LW@HE(')1T6<--
MAIE"^)`^+=S/(1X7%0KMI%6^S\=BC4IB/*!MJ2PU3HC;,AIDG#9;?;!E`=!H
MW244*]$4E]VP"Y3*>X+3D=YI#A1B1MV(TK$5T$5M<#D9DE!M4T@*W)HL)LQ8
M[1"+C8DVRV!"#SN>Z`J(HJ"Z]RR3VRTZ[-_VG/\`V6D9T6.[O<=(DO,9;/>8
M@Y^&+(Q"N=''>7.05X^,+W5L$YZE4UV:VZCX3'8,9R4#XC'`7@D$TKHNH$1I
M,5]]S8_U4LV]*@PY+S(/-,NR(S+SK34D,N0VV;@$0`^WH-$T$FNUT:C4J.FC
M0Q3HC2:&I3":`9'4Q.>#^R\::B6]6X<6/%;7+O",RVP"Y+#,1F\6A%/%18[;
M8^XV`CJ1+-?V2_&%9IPVFS<84B9<(!(V5,%;-6B5+VU("5%NUI9A[<(6=%<E
M/17=U8S(STYQ79SK!X,3+DQU<3JC<KA:2OL^14.CD4I%&214V$JR$60W+5'U
M5F]U%E-"YRK_`!@H6M+1V&XD9MF(2'%9!AH6HQBA")1VQ%!9)$-=(W:U]@?[
M`?>I8'U:;5]MMUEMY0%76VGR9-YH'+L8MO''!21-!*`WZDLR\S`A-.QH[42.
MZW%8!R/$91P68K)B"$U':%TD$$N$4);M=B92@45&CR,;7HJ#EENJ*,;$&1A7
M=A)4#^I?HM#>=IE/==IZ"-/=<A1C<@H"MD"0S)M2C(!-"J8+KE%/<]A?YOM)
M9PG([#A/,;LZ1M`2NQN4N[N*0JIL7FO)7DZ5LZ:T^"IOQRB/FL1A2>B&#;9Q
M72R[W(YML@B@O)5!3W+*V5!HQ`3^\J!4N"H+)4%;60HJQ<K^62CBVKENLW,.
M+'*8R!--2B9;62TT>VVV^HYH`5^E$6Y;)]GV)'Z$_P#B"L'X5O[\?8=1")$Y
M&I5_Z86VSYRVVSYRVVSYRVVSYRVVSYRVVSYRVVSYRVVSYRVVSYRVVSYRVVSY
MRVVSYRVVSYRVVSYRVVSYRVVSYRVVSYRVVSYRVVSYRVVSYRVVSYRVVSYRVVSY
MRVVSYRVVSYRVVSYRVVSYRVVSYRVVSYRVVSYRVVSYRVVSYRV5J0VZ;""T.8V\
M2/G*>1QP([3;H-Q"O9;Q<J0)GI0`+"5RLI%J1-@AJ;]\8+KI]/I[)HRY+%[)
M?=GWHJH*X`ON5%1;7DU5%,66WW&A;:4V1=D.L-H\6](RTA(P;F-2RQ`>42+<
MEGW@9GO9+$Q\;U9:;,(RQ6F#4U?4Q:G29C;;:H!$BJJD(HE]I`&U4LZ.,M2C
MINQ.D=.0CJ#089JMYD-L%)<1"AHGBU.SS;037'6TJN5BP--/E2H3TTU1S--Q
M&7P8)!)`7"J<M!O'%-WELMUAN9.8U+!93CB1(4UU1ANY"9+3$U-(N$2J-V&]
M119!Y-208IR!?6Z.N`66676W>3,55"8L@0;[[%MH":;.N,#+:%DF0+>,+:J;
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M2+K3AIO,S%3G*:Q<DN,&&2TCP8W4=:`25<&/`0SE1&8\?=G-R`BI#A;XCH.H
MF,;U6.7*:#%A+)N4O&<JU1"6\L9L^&:XU!<A.4UM&Z^]+:W`D57'G%1IEM=V
M,@1$9+QOC;[5I7B59+<6`%&:OI2D]*S#6JGFXL"-JJ88I/+>C*B3H$[C&RY[
M<?,W>^Z.M+PC,SI7BP5Y^]R$CJ,Z5PN;@I?_`"KK05XC.]@*/,&2K)0$8.I.
M55I8JJ$8L[/"GMEJ')0%33C4_8D?H3_X@K!^%;^_'V'?_H_%A_PI..$(``J9
MF:H(@(I>1$2Z!$4L2Q9,>2@78\AYM[#?JQ99%=?=]3@=E1VCN1<#CS8%<J$2
M+A(D6Y1!5_F6R8S`+T)4Q$@WH"8C5+_:%-?N6;Y8>-6YKE)XQ<!.7-_UURP4
MM'M)83`A,#%#`P5"$Q)+Q(2300DGLA(ETNFS'4`1!Z4Q">=$!4R`4)Y",1%7
M"N3VL2VQM4JF-'BQXVV8`%C0VG<6(;EQ9K`%?_6!%]I+(R5&I),BWE(TL:G*
MTC6=O.4@*F%&]XY=VK'IUV&0M*IRN`DZ[Q<+"I5)(Z3G"#9)Z2$8!,EY2CHU
M6DLR:7"NF7[R;6ZLO/(3P/N(X\VHN$CKH(I:=*Z==E<*DTLG%.0XIDQ`4U<E
MC@E&I+I4Y(+<XO?IKL\4FETV04A$&03[,%TGT$<`H\IXE<002Y+_`&K(ITNF
MDJ9]RDS!)4WED(\FZ_\`^XCMB!_U@1$71;!'CQF`7#>+*QFAY#8,AH`D3D,M
M"*>X(HGM69B58)"QV9"202)4GH99R-N-HI%#D-F:(#JZ%T6Z&K?2.K^?VZ&K
M?2.K^?VZ&K?2.K^?VZ&K?2.K^?VZ&K?2.K^?VOR:MI__`-)5O:__`+]NAJWT
MCJ_G]NAJWTCJ_G]NAJWTCJ_G]NAJWTCJ_G]NAJWTCJ_G]D\35M/_`/I*M]C_
M`._MT-6^D=7\_MT-6^D=7\_MT-6^D=7\_MT-6^D=7\_MT-6^D=7\_MT-6^D=
M7\_MT-6^D=7\_MT-6^D=7\_MT-6^D=7\_MT-6^D=7\_LW.C1)3K[71I.JTZ>
MR):%1Q(\N4ZSF#=H6[1:._3:AZ.EQ(LMIES/D`&;*F4AY5>&)(:SV=UA.@HJ
MNMQ"2XA14JG^>F57GQZ?'&<M2G*8##G5&0IE*10=S""8VI*`"KQ-83Y!+:/#
MC'%5&(S@K*?J,Q'G77JN51D,R!)J44B'):<)#O<3$:H1">6U@ILOTPKL6'4:
MI,D17E?=<E#4(4EE/'+-RQ5F0Z)(!-F`"ES>"WM<X?ALFK6G?#\/L2/T)_\`
M$%8/PK?WX^PVL465=E5"!"3/0U;#>L(8U1LA)</V;9V1`;DN-T]]AM=Y-#;E
MT^7.=;1+Q176]T721MAA77>EQ+(1FGM,N3XL%HGB?\63M%;K+IR%O$<&$LL5
M2[E$FC1IEG'9CQ32E"^+R:7&I'H>#5G'0;<>O-M4E*`)A6Y;B55TC9[DP#.,
ME<)R[-1'$I#]-;;%M$=(A.:,LT#7R\-A=;")F2VJ(H`2ODQ']()77"%01Q"S
MV4@B)ZKR1;$_N\!']W8G@S?)+'%<HP54VTV`S&E<05-3%+M0DO)5^$^K;K+T
MBM.,*A*LB*$"3"`6G>]R3&;<&CO?;OT`]'@-AO52I;4=_=XZMHQ5.$N&:^,(
M&WZFV^4]B16C3&X#;*BB7JFFT^"\_#B,1)@PE>JU,(Q;NH/#%9<$$H\]XZC7
M#6K/BU"8T/W`@FB[<F-6XC4.I1HU'DO,,"2`UZ0IS9NL'>]('/:GL/WB+AH`
M*"8BVE]F0W&>W:0;+H,2,L7<AX@)&GLH^2[E&J+A70MUI/!B-22XAW\8[595
M_$_Z,>\>3XG<!*\`WIF\D-:(H"B/I';F/))E`T"2'T`01UV[EF@@("B*ON(G
MV/J>.*=NC,>C1Z.HP9)4*KS2J3$JD&55_P`RCSFX,(X9FJ(9MJ/NHMRVXH#@
M^<QQ&H-TR0R@\.U>6,V013AW7.BS8S5/)EA1(E<Q8^5AV=,%^8UD2WH<9V4R
M@D",R'&0-]I`-2,,MQ52Y554^H"I'Q%&A%"8"(Z`.15)O(?E//8G5D`K)Y*O
M"J*G)PWZD)%>61Q#1F2;663J.16"CY#.;,?@[EZ1SBC0V)%XM8_%\E?LFJ\2
MM"4=YQU8S\8MS$7T:)8TE#G"RY%DA/C@HWCFA>"?^@E3B"E2&RB4^$Z&-N,3
M:4]H::WA1)SS6'>VU`!445K2%Y+[*P2C9L4MRCM$`*)E-G/LMM!O)O(QLN*2
MAA0L`*2*NS;D4RJ7E&9D-"3"`XYO#S;;#>0I;P)&#J%L7EI1M#5+0YC;,:)O
M<NIMB4R0AQ]VIQS+KWXQ&"/2@BW\G,$$Q$F-!N5C!3IJ;PY%CAB*,GYW/>FM
M0V55'EO!S<257$O!$5+L5]MP9A3&RRGWU>>1I&,J,]NKA-N"Z024WN\$)I7&
MU32A:[OJ&)T5EA]QV>U$4)&9@0#CRGE),LP7%>PEO5M,_P`5YQ;U;3/\5YQ;
MU;3/\5YQ;U;3/\5YQ;U;3/\`%><6]6TS_%><6]6TS_%><6]6TS_%><6]6TS_
M`!7G%O5M,_Q7G%O5M,_Q7G%O5M,_Q7G%O5M,_P`5YQ;U;3/\5YQ;U;3/\5YQ
M;U;3/\5YQ;U;3/\`%><6]6TS_%><6D1)4#)=9;SAD14<*+@O0<M[&I*TZJ[.
MFX].J[3_`"*?93V)'Z$_^(*P?A6_OQ]@\P`/`;3@XQ0L)@V"B8WZC%=2VP+"
MB*"9=P;LSA3)119Y."[Q2$N'W+[;J362SFMO*,5=W0G&@1H,:-W"X@MBB(A(
MMV$;M(C<+3<..@A%""E[0&2PVP1L(YF:*;C2`.I56U^XP[^3IW9F_DY6'3@[
MW("[^PGN):\8D9%Q(>AAI.6BNDA;.TA/FM_NFONK9`*##($PW"49E13+;R0N
M10NY#/)3W!T6)QF,PTXYMN-LM@9Z<7*(112TV2#Z*@N1!U,/QFI`:&6XH(N>
M+EZ-Q&09&_9:`03DBB6W1RC4DXN:$C=CIT,H^>TVVTV_DJRK>:VTR`H5UZ"*
M)[5GMSCMQA?-MPP:3`VBLQF(;0MMIR&FPCQA1!%$'V]:K]2G$6\/YZ,(SNWB
MLC0RZSC1<&:BJ#GN^U]5.@1&^&SHLV.<-P9SM6"<<>3%R9:$40<MLE(R0<*[
M-RWWVD!P]#X5CC-W<Y0R9W$$CQK(7<@S$^0BNN7:!T77_68WO)WK);WG=U-8
M^\8$SLA7$1Q6<R_#BTW:_J`>:E5!MYHKV'D6`KC"9E/=P"IP#1Q%<I$5;W,9
M>(1+[E-"=_.YJ1Y+-0;DMINB.&LR9'G-H#J1$4&HLIHG!'^LMVQ>*R9IO3&I
M,Q%"2XP4<<YO<1IPMN(<9P3%J,KN7?I;*0XHW*J7/+O=2:5]AU@E:<B7H+XM
M-O**N0W%3,;9%%'86[9]G>E&#O"@`9Q@.\8`-'`;5S+4\(.)>B7Z%MA5BEJ.
M$PPJRVHX'",W`NR;L+AN$JI[:JMA%=Q5!>20****@R$+&CXIE:'D+3BUWV)K
M*IN4>@V\IO+-%$PY09.$N2X2?85;$;>Y-F:JIF"()$JBV"J1"VBDJBR*?8%/
M<MT['/+P+=.QSR\"W3L<\O`MT['/+P+-L5B'3:HPT[G-LRVAD`V[A(,P1<;N
M0L!*E_U[?-?A[]71^RM\U^'OU='[*WS7X>_5T?LK?-?A[]71^RM\U^'OU='[
M*WS7X=_5\?LK?-?A[]71^RM\U^'OU='[*WS7X>_5T?LK?-?A[]71^RM\U^'O
MU='[*WS7X=_5\?LK?-?A[]71^RM\U^'OU='[*WS7X>_5T?LK?-?A[]71^RM\
MU^'OU='[*WS7X=_5\?LK'&H\&GTUAUW/<:A,A'`W<(AF$C8)B+`");;#NK\%
MML.ZOP6VP[J_!;;#NK\%MMONK\%ML.ZOP6VP[J_!;;#NK\%ML.ZOP63EAK3V
MU^#V)'Z$_P#B"L'X5O[\?8=_^C\6'_@+H`*2@RQ1J,(J+;*7,&4J<604ML",
MU;!UK-8(U1M4`T55;B.Q<K,KT^+B?10<6!&5C`+#8M*+A`+W+)2^NBKJ0()@
MY494BJ;NR[*RXZI%<JE7IV;AAP6A5F*W3V3,KETR/:3"EHS)48`??.E!=GR%
M!/2C++Y/HNYB:QZ7G`W(6[0XZ&J^Y=Y?C)%<SG&LH3)U.3A7;5L$514L*W7W
M$*H6`\38?419D>8Q#>?J;4;&^+1H3:Q9CIB@O(HWXFAMZ]IW40>SMZ]IW40>
MSMZ]IW40>SMZ]IW40>SMZ]IW40>SMZ]IW40>SMZ]IW40>SMZ]IW40>SMZ]IW
M40>SMZ]IW40>SMZ]IW40>SMZ]IW40>SMZ]IW40>SMZ]IW40>SMZ]IW40>SMZ
M]IW40>SLPRQ58$MYQT`;C!&BD4@E+0R(M`CJJYJY.GW+1WI,=8DAUD#>BJ8N
M*PX0WDUC'06%?Y-/LI[$C]"?_$%8/PK?WX^PYB<)%Y&A&\7_`"Q]O&ENE/J?
MRENE/J?RENE/J?RENE/J?RENE/J?RENE/J?RENE/J?RENE/J?RENE/J?RENE
M/J?RENE/J?RENE/J?RENE/J?RENE/J?REEJ/I2-Z/0%<6=C8W-&Q7"3BR=XR
M<"$EU]]UNE/J?REA$I.$G%N`2`44U]P45V\EMTI]3^4MTI]3^4LW&=GMMR'K
ME:9/+%UR\L*805[$N(M">ZMHS4ZI!&<F&K<<7&]+BBEY+H-<#8^V17#?HOTV
MZ8NJ_*6Z4^I_*6Z4^I_*6Z4^I_*6<FS))MQV<O,/=R/#FN@R/)`U)>6XEG9#
MM5`!9$B<#*57TPM.OJ*,":ND>2R1W(E^'3JL[)](*33%2&DO8(QF;4U9:0U`
MVQ)30&CO(SV0;$C7DBMG!2M1<31$#@XFT4";P9EZ*]J:S$4EU"BWKHMB],,8
M5)`!504SE)IEX,CQM[V8$@<&&_'?HOL+C<C,;<$3`P;0@,"2\2$D=5"$D70M
MNE/J?RENE/J?RENE/J?RENE/J?RENE/J?RENE/J?RENE/J?RENE/J?RENE/J
M?RENE/J?REKE+,2^^XV4N^SI-=-NC;Z@+=&WU`6Z-OJ`MT;?4!;HV^H"VPWU
M`6Z-OJ`MT;?4!;HV^H"W1M]0%NC;Z@+;#?4!;HV^H"W1M]0%NC;Z@+=&WU`6
MO0014U*C(HJ?SVVUYG]ZVTO-_O6VEYO]ZVTO-_O6VEYO]ZVTO-_O6VUYG]ZV
MTO-_O6VEYO\`>MM+S?[UMI>;_>LG*76G>_WO8D?H3_X@K!^%;^_'V)T-`,]X
MDT9HD;$B++*I4[-*X=-P-WJON(EG9T^#)4)OH%RJ,'&D2`-N%*J=/4'60;(W
MV$6(RZ8(BWMK>J7+:D3DI4^-'HRQ(*I=()&&:@_4(TU4;DKO;H"P^P6@2R\O
MVKK2D;B2Q.;48,.%&D,SLZG`Z20W*M)<>`1<FO1Q)YTDQ"BH*+IM5P'>5B^C
MJ$$;.)QQL,I:J),QR/1A;'"JHGME>NNS<Z>%??CG"6=5(5/FUM7&A_V?-J=0
MIT:+%!N$PU%XC92.#[;J2DD8&$Y)%?P5"9;>G/C5%]*R9%3D;M*S>&.)9$EB
M7(&/493<&-4LK))U'+R!H5+%RK<,&Y(KK[ATKA,*K&J,>4T!5&8[P[3ZBV]O
M<2,"$Q3)LR:*M&^;[C;JO8,AM%^JD1)`9D>4R['?#2F-EX";<"]+E3$!6?X!
M"LF-#?G-508^2@M@QNQ/%#P@2+D*3=^4BBRER"(@J(:+"HH7/QXJ,0A\61WB
MB#>.?<R<BZ]1S.0KFUHOM4`EQ9[<B0W2P@QIE/9JU8E`T[C>W*KP'MQHS"GB
M45N/=W<3IC@NO]BFU_<89RJ6KB-(5;?C-.`J>+)YOT(\VJ@NN^_7=>J(ESTR
MH>BYS[IH#<-7)DU(S*FHL,,,((*"#?J`4(EY1)IL(3Z_0:;)!72FTUNG.%D(
MW>J@ZXDIHV2;;5,0J*99\E=-L/\`N*D/FHY@Y)9-P(8M<I''WN5FFB7:%O\`
M:L<FES&9K#;Q1S<8+$(O`(&39:KBP."OV%3V%IE3!U0W=BJ8F\!@>Y2)$G*4
M,2&9([3=E$+%?IN1%5#B9=5Q0@?B&R3C;KL3,H\J)53(\XR(F*?"5'253Q&P
MF5C7%>=!F19DDY0%5C1N1EYKE5<JM(P@5[(9SLJI*`"I"/C<:W"VJV`W!F."
MVKL]E3W55="6K5*<?1F2=[3+_HLV\PP;RE`EQ`:MJL8?\SR:G`S2W4P(7H]!
M@Q,E9++X^-"/`Q'@7DN<I"`UPHD2EW2\I)$.G0'W\F]YJ8W$<II<DT3*)B:V
M(_\`-NV@3E8;"]36Y;C!-,`Z0R8PM,-YA[R41B1.",Y.5O91Z,8XE1<U$%6U
MB#+20B'.&1,)F7#($$:S&?RU5R2KP0EIY.\AK2J((+HT6EM01F'&ES%="2].
MCS-U9RZEC0$J<MYQK&X4;+``44PK>B>VTV9&5X,8W_\`)L0J=,;*;F(@B&-B
MJ+ACX`45%',R_P`6JSTJV/&-3DI"-S<D5RGX658)`A*0@&-21,:JZMUY77W)
M]0)T<*N<OTA'14HC,Y^9E*W(QWA3Q)_)O1+UV;[K>3?Q%_5G%786\F_B+^K.
M*NPMY-_$7]6<5=A;R;^(OZLXJ["WDW\1?U9Q5V%O)OXB_JSBKL+>3?Q%_5G%
M786\F_B+^K.*NPMY-_$7]6<5=A;R;^(OZLXJ["WDW\1?U9Q5V%O)OXB_JSBK
ML+>3?Q%_5G%786\F_B+^K.*NPMY-_$7]6<5=A9LN(1$9*X<C$*A,R,.A9X:!
M%_[K^MROY5/LI[$C]"?_`!!6#\*W]^/L/OS32.TWE9DAZ4S'8'$C8!B-UO"%
MY$B:5TK:0CDIAO=!;.5CJ,4=V%Y$5DI&)I,D747DXKL5FHXRV"D2&T=882I1
M5>>:*]1<:;1O&XV2"NE-%G'%D-(VRYE.FM0C8&G?^FX65<#GUETV5@2Q/HVC
MJLI+95U&ET(XK:,8\M577JM<##@)B,[A=;%,;AJXX5R1MHS)55?;5;=&]UX>
M;V!28<)6RQMJKK:J!X";Q`JQN26`U2_W%6W1O=>'F]NC>Z\/-[=&]UX>;VZ-
M[KP\WMT;W7AYO9RFU*I&S-9R<YAL)<O(*2R]*8:?.'39#;,AZ+'-T6R5'%:'
M'=ATVC5"`>]PIK#<F+)8E-FR^P\*&TZV:1[E$Q6WI#T:UO\`@R]^PQM\RT0A
M0-YW3.P825+K_;MT;W7AYO91%)""6M$D#<O^'MT;W7AYO;HWNO#S>T:ERI.5
M.EW9$=7T4CQ+<B:(JHB^W]9-*Z+4F176P"IXB.&X4EG'';%%3>GP4`16A,;@
M54-<:<G2.B74XT)BHR);CC\M]BM.RA=62>,T<`'#91EQQN_+NP7IJLA-4,1(
M4$4+>3O1&PA-MI>H*O("GM(GN8?_`%%?N=,@E$C8D+*;D7CB1IMG%RV26]0:
M&_W5TZ[[=&]UX>;VFS)-#64KBJV:1\C?#*IOM17=W)8MZ.N&]?HVBO\`;5;.
M2F:`Y)?-B5@"/N*K-"/23?E(,EP6VC!NE&.(B72+R(.)55+'(G4IU$I]4:HU
MTR3%%Q!@NSH^^M2C`KTB04ENCRD=6XA322*N5)HJMB+CT1D7F(*-/;L;=0>"
M.F7A7*2=G"&@RQJ+:$:J%M-&F.-0@7+1Q8Q[O&KL9I]O,<>1&H;%2:DJ*8C0
M`$;G%#0EHTR/262;=R)\9S"TA8E;:..^B%$0P,`;##[88!U84MT;W7AYO;#@
M<Q78L.\-WW)<BK=N]]R*MNC>Z\/-[7*AHJ8+T62VB^-+`W_R/^8:7)[JVTMN
M^YTX:_D]KL#E]^'RAO7=BN\GUX=/V+7HVZJ+I14?"Y4^3V7Q;NC0OCPT+=?I
M_-_<6R>+=TZ$\>&E;K]'YO[B6Z-[KP\WMR6W4^RZ)?:9&VR?.3P+;)\Y/`ML
MGSD\"VR?.3P+;)\Y/`ML'ST[.VR?.3P+;)\Y/`MLGSD\"VR?.3P+;)\]/`ML
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M4;<`7:DURCN.Y5]RT;>0(A::5),AQ(#C1`M+IT<$CO\`*J*2=YC*)Z<O`/V+
M3SDT215I[T.2U&E-/M1PITYB?Q0'$#+2'(;>?9G29(B#6%6GVW0799Y##^XU
ME((1./T2C0*D4-UF!49>\T2#&8:J#4.+47&B)(QHHG$0T;Q-B-R<+O)"J+(1
MY%3E51S,R:9$AS6.)G&J/`9>G;P,*G3YS`9>[#O2)&=102+E!7V*I'E/I_NB
MGR*;&-8#N^<'1^(8DI^$X&)MMR5(IC,EMQMW2;!-"2J6*T]QCAJHP6EJ;TDA
M8GQUD.\,.\"TZDCP]'J"U!IQ74KXHZ#"."RRL8L)BB@ISX]1%UMH:?3U%LRO
M0)AUKBIPD1H79#4/_)#I^&,CCJQFL#2F>!"7V.(Y$ELI#=3J$6%48V-L)+%/
MB/0Z:["8(V!.,[/_`-O%.>\9>R['I[9IXUT;42''$T2DQTI+KA@0;T_!\6Y.
MN(1N*>OCC#_E.&3:W$"HGU,*M&,`JA34<W5UV++(Q1;U$15NH`/(+2FC02K[
MJV,E?E.56IR&L0+&C-&ZX:H,8(^^1;C1H5PAIY*:$778H=6XDJK-3IXO[_#&
M,RY';-N]7@##3#1]6B/#B!50G-F]+(VM6DDJBAYDFG2@N0S9%J_(@@GC=X;4
M=&D#0M2WV.;2W3?C`^L?--EYA"-&F7KP1X`4PP/CI]W1K1?8<ADQ&GQVHYR5
M+>,LFJA37)+QL'B9<:S&7H["Z5$PQH:(276D16N':8N[-DV8M2!R2B,4B>[*
M*/\`Y<.:P=/;48ZHF"0TZ-ZAJ0(/HNG/4^3%9F;X\H#%>DU8ZK")DW_&"&?$
M-Y\WL!HD8']>)+(X[PU$PJT4QE)#X"=STTJ26>BPC5LG3IF!V[,3"K:%R2+!
M2GF*+39S4R!490XE!O*]"PHSJ"CK;4@<QB(P38I=>)(B7BF*T6"U"B-0GJE#
M@1&V99JL<*@$%]$,E9RQ?C%/7&Q<`MH"BAK<B%8*M#F1F0"+'IZL*4J/(<@B
M\],G-A4(ZJ<-9\A&0+`"J@-(6*],-D>*J&!L1'H<8V*S4@=RY%9"I/&KKL60
M@FY";2+RA>41%"1;T1$IL[?A)B-'H3-1$U<"542H52?J4=W&V@B#K4AY7&UO
M2YQ?:LTY.K<K>RB.+EOS2,(DI\LUOQ3+)CO4`KTS@?5%0L*)<(JL29*FI(C,
MSG)@LK/GFL02H[].1@4-O#4UO>%,U]4-!:Q[;AVIHMSTBI2X`Q&X\6I2&XDP
MV(IL@[,'T8COYR:CJ7\WR[TS,2H@/G774;<=HC\IJ/-D-JCU.I<6%,)3.(ZE
M0;FOLXB%P6R-$3$>FX`:],R'C%R`XI.U>KJY>RQ5&YF5),G7F"D%-"Y4O'D<
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M-&&9(;<>0#8B&3H!*>`GT)J,1L&B&MPJH+[BV5II83CJ--OJVVYC<1A[%DO*
M`O*2-.X%PEJ*ZRR9[D"%'%10I$MY(S(J2W"BNO/`"*2ZM-I>";2#]'KAGX9C
M1;DN,V[I=TG\V7,;(>7=I%4MB;",8WD.(%(DQ`2@8WHZJ7@8JB^XJ6Z!GN.=
MI;H&>XYVEJC3I])FRO13<9V<^S#,XC*NA$D8E<-Q!5N*DZ*AG_UI3+8(9E<-
M/K5/93<ZE%;E,9S3C3PBXFEMUO-7"ZV5XE<JI>FA533;H&>XYVEN@9[CG:6-
MIW"62+9RGF(TR3&A`Z:MME,DL9C,:\TTXEO$>45P<JW0,]QSM+=`SW'.TM3J
M!*8/?JH@;JH,&K*JXXK8HIJ^*ZQ]I%[NJ''<IT2?46KR==;;)V13&'`+9)L)
M#J/NB71\CQ:WJNE,13XU`HSCY.K).2[1,B2K[]QD^1R6&WB><NTEK54L*^A:
M1>&PNXM7AY-LKWOD;/5!_52R-18$*,TF&YJ.SDMI@`6AN!LA'DMMH*?61$MT
M#/<<[2T@F:?$F..E%B#$?S,J1OTMB$K1^-308R/L6)V'2H+SRQI$ADG9,F.S
MELTEZK([);RGGF`>:#"TB]*0.[&7:2[Z*A(<.L/06FXHS9;+E,@'.D2'$;C@
M#C#_`*+I3PAK9%W`1+@O1/&42/A.3)CL*W/-<>[,09*J[F1VFV5=9G"@)B)%
M=Y-Z(N*SF*ETQA;HD@&CG.,(HU.)$G!EED&4HP.4JR"1L<K$.U?BM$G,,L94
MMAM\4O4L.8**K9*#JCC;+DE[BI;H&>XYVE@C.[LV\8*X(GFHF%!=/2XIY8DH
M,.$@JMY"V:IH`KA8(H0O&)F+2N7&0M9.8J#G7W!O`7_VT]VV%=U1405TJ2)R
MB<!+B5S"JXF22[7HL,H3@K&(!=%]'/%*V;><)H>==<37*^Q9'&RADV0DX)8R
MN)L3RE<2]U+VL>C%J6S.)8WCY#D5JX7BO?:D;FX*X27`@2U1M26X<9(E]Y)?
M_P##V%=V_P#E(MRN=+L(OMZK<I(HW*J+>2II':32[K&^W0,]QSM+9\UR)#9Q
MH&:\>4&,D51#$;EUZH-O7%)^5M]I;UQ2?E;?:6]<4GY6WVEO7%)^5M]I;UQ2
M?E;?:6]<4GY6WVEO7%)^5M]I;UQ2?E;?:6]<4GY6WVEAD1'(\E@]AY@\ULKM
M"W$!JEZ+;8'W_AML!]UX5M@??^&VP/O_``VV!]_X;;`^_P##;8'W_AML!]UX
M5M@??^&VP/O_``VV!]_X;;`^_P##;8'W_AML!]UX5M@??^&VP/O_``VV!]_X
M;;`^_P##9.0.M/=^'V)'Z$_^(*P?A6_OQ]B1##`N9)I3A(XMPJU&FP9+Z:$7
M2K+)7?7LU(5R,]+:]&F2J^;6\.0I=5!?&C'-6B]&RVKBPKXP=5UFM\.*Z)NT
M1Z3)W@R=1:+5*A/``;W8<[/&0V-ZJ%URV@242$;M)B1J:PUO3HC+89BUN*<I
MQS=%R'%]*BJ!<6P6G2EFCDDVXW`HE,I$!1555,D+Z@ZJ**8=X<;:_F"S3+#=
M7DN-N$3SD>75J='=:])R6).B*WN!>E)9+,SD(I@MOZ0P"BV.M2W:957G`*GI
M#D/O[S&I;#E"GTLDJDAJ6S.ET:HTEXXB.QKLR2I&7**Z$<F'2\NG<(2*(0PY
M[U]3G2(W#+><3BT^,ZRZ04+=WG2(T5MJ.30-WN@G#L::_$K-9HE6J,N8Y*F2
M4BUEJ73*_2V5?<=CR7D$&ZPVIMD*HB,J(][906%2D2$O%344(LL(POCQ'Q>/
M$,67%;?I=0C07J`S'#=@=!X<UPTY*)B-^'+R@$9,8(K#`O#'8"'1:13)>[)(
M-Q_=I=6@2)#:FJF0/(JZ5]FK2:?P;4ISDRJL.O-C'.1$J46"ZY38B'N<M\#@
MLT:.@DT^@J\_5#>0<,,%&ETRH4]RFE2F!ID5AXV3?6GPA%F$3^0Z^&\`PB-N
M%B7-,%<30:>Q)@YN0DEM6E<PJ8X5NQ"X`D!.,N)R3%%%2!52]-=IF2=/E))&
M&K4F*3]$ID!8>%/SJA-R3"I.X6T3QB.MO!<V2`@\KV&Y13Y;<EA7-V>&-1G#
MCH\@BZ#:R*6ZN%P11-*KJL$2(51>F5&0;K<EY*4VTIWJXY(==&*!'A$5(\"*
M8)WI:K.T9^G56HSX<EZ.[/WDT%^4R0I@:&)R1PNN((IA0\"8E3%R;%_D%:1,
M-Z.7(ZTYRH.%6E-1/#D5)IPL0B0H:(J8KT0YP1'H8"\#8@_?B,3AQ)B'<0-D
MER2\"Z+L0KA4AN);2"ATZ2[3V(,E77'Z5.5IN7#2:1F,AO!>PXF22+<39A?<
M0DBVD-#2546<1MO%1ZFV$IIB!+EJK:+)7+.H.--`V)+CCFY@(3)-+!0([CU'
M>@071D!!D2E25*>F(2N,--B^45BGAG&B$+F8#3:79NG'Z#5"..CR-)3*D\3!
MK4)$/)-6WKGB;;CBX71JK;Z$**@7'37J3$)T'X=8.6#D&4\C,J`R#K4<T#=W
MFWG9#+C`7JEY%?<5R)9E%I;ZQI-4AM.`-$G--Q(\L(#DY5+0:E&>?>4I"XVW
M#!>2B+>-FY7I!^,"---OQ00U8F)'2H9#<D1?:0V$<J"FO_-$VP)IQHD559=6
M3GY3<%KQD5M5,8<J!.4E53+";TB`E^&X,"KR5<4W"8<*03JQSIAB*L-(W?2G
ML;"B'*P&\VESJIM&I'HQ769:6499;U-<4E:4L0TY)%P(#C[C36,Y)784P"%W
M)4T1RV4LGE[L,57$C-HF6-4F53"(X\;89TRX40KQPHJ+BTVA`U.<`HRU`77,
MEHU?8J4]JH26D%S&#:DZP(WJA^+Q)=>J$+*#*176`;!LCB(;:BU5Y=91IQLW
MB<.,LF6HX,>PB:;]-I$;>"7/WFXS:4\&?+I<K%ASAPD/HL1\6K0W+H0;K`&O
M`(C?<*;*7:@$03^9$2S<"ENP6GTG,R#*H%(%G);:D"2#N[3IYN8X/M777V\O
MX:ZRJ>96\OX:ZRJ>96\OX:ZRJ>96\OX:ZRJ>96\OX:ZRJ>96\OX:ZRJ>96\O
MX:ZRJ>96\OX:ZRJ>96\OX:ZRJ>96/>I>\3I5V\A'-U*<WA7DY#+F%3<N3I"3
M%[27)K_X)/LI[$C]"?\`Q!6#\*W]^/L3*@X#KS4=8J9+`MJZ:R'(\<4#'A1>
M6][MI$`3<;)G<<MYP6T:E'/9)YIMBZ\E(4;)%O1-*+;`CCKB$ZK3#P`UD/74
MENL9F,E'`TK+HA>O?K_5O6SQ[T+KS#2/.1&U:5^Y1CFJ)?<!*(2070NI;/QH
M\QIU^*JB^V&!2;5"4"1=&G`X*BMVHDN739Z<<6:TH,4Z4S&(8I/2V*H\;$0X
M^6Z8JJN-DA(6%1NL#01I3S3GHL4DM[IEYE81=Q'`;H.JCA:%5$5!UKHL;LZ^
MEB,N1"#>W(BYK\-UQF7AR#=N;8<;TDMPW:;;7O#\%MKWA^"VU[P_!;:]X?@M
MM>\/P6KD1CA]V?%H#$-V9+WAH;]ZCQY-X,@!N:IC8-#=>\J/G>#49P[4BO`R
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MU_:MK^U;7]JVO[5DT^VGN>Q(_0G_`,05@_"M_?C[#T;E`)2*<_CR5>%4A2HD
MQ6\-XHN;N^'7HO\`;U6C&Q-<S8JPU`WH!N8UARZF\.:F]`17QZBC2:4NRT73
M?=8(X3CQ"0KF%3C5%#_;W^WW1RTEHN(F[W$7%R5T7+KM.;D/$RQO)E#PPU<-
MQ3I5+@+*,DD)A#\U-,JY%OTXK2I2&;HO+)R6]T,'&1ES7)SHF^3KN;XURY,(
MMI<FE%73:"$JH/.)""`PF[0#B$<:FM3TBAB*3)PN[Q/5PSTWX41$'7:.XKRN
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MEF17A-'9.-MR`S(CP";6_DK"9D86_P"R-]ZI9U$ITBYYAN,[>],)39;&DB`*
MI&I7?Y*RO]K&NLROD38D20DJ7FK)?<-]TWC?=1YYQS&JXB,P'ZPHG)NO*_HG
M.87P6Z)SF%\%G7I<>5FOP/1CI-J8XX>\C*5H@(3;7QHZ[KTOT:;E0R>8F%G-
MNLOIB,4>9>J#]5-LL((HIZ0>S+PPER$2_#B$G)C2379#S;P/./W*KJR)13'G
M#RV6KR)XN2/1MWK@$<9XNB<YA?!;HG.87P6Z)SF%\%NB<YA?!;HG.87P6Z)S
MF%\%FZ='G>BB&:U)*0]33J"&#33X9*,[Y`PD1.HN+$NS==IO3YW1_HLY_P!Q
M6^=T?Z+.?]Q6^=T?Z+.?]Q6^=T?Z+.?]Q6^=T?Z+.?\`<5OG<Q]%7/\`N*WS
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MBR"/*:--DHR#+-/++0B*FBSQ.,Q">>84Z8(*^*$\M9]#-L244S4KW3`L0*FB
M_1HM3LL(OYU3Z/(.,:2<YV54*@_3Y,9A\35EC=C9T*XBWVDE54!U`J;U+8&G
M-91&Y'CI*<<,IT\6N6"W`VBYA%H%"5;K7WE[Z>\NE+:U[MM:]VVM>[:O,48P
M5BFG28-/A(W';=J4R?!9FJPQ(F19@O3W4?,DN46VFXR-*V3LIDAX=K51%MJ9
M5:1!J#PQ\8LKO;`/`ZV#BJ;2/-&AX%5<&+#>MU]M:]VVM>[;6O=MK7NVUKW;
M0J1"@,R'Y^<0RY4QUF+"8B,)*G3)B!%.Z/%CDB](A&NA+0<YN03C])IE6EN-
M+%9CPF:JCXP<>^3F#<.9)B.@VVSG.7CI32BK!?9;FN)/J7HMD?S9LD?1E7R-
MS/EM!E"T/M*IK[0K:;,BI-FQ:;(JS52=CK"OA-47=EG3C9?G,29$,6Y;9(K`
M.DHDG)TI;6O=MK7NVUKW;:U[MD>D$[A4L*"T!O.EA;-YU0:;O<<RH[1N*@HI
M806Y%718WX3IN,@8`CBH0H>9&CRQ(1*XT3*DCM()(OM6UKW;:U[MM:]VSD5^
M*\^#,5JHN+&,">]'GO$<S;:=<91Q]J<V"8$*]6RO2]4NM+!Z-4,$5IYTB%(Q
M*H1ZK*H[KJ)OG1G-9%`[_EWJB)?=(I[3,T#C;U>^\+01G2AR]R?!@D?)QP@<
MN5>3R1(;[E5$MK7NVUKW;:U[MM:]VVM>[;6O=LE0W99M\EJ/D[QN_2"Z6/,R
M7]67JNMZ@7];?Z;;U`OZV_TVWJ!?UM_IMO4"_K;_`$VWJ!?UM_IMHM2C8T9D
MAB03O0FS$E!ULO=5MP52]-"W6UVUVUVUVUVUVUVUVUVUVUVUVUVUVUVUVUVU
MVUVUVUVUV3[*>Q(_0G_Q!6#\*W]^/L2(S^'*<5@M$D&'0-G)>:<!<P7`-IYM
M"%?=2S3^;BCM--WL%.%2DRPJ;E563,<WC\YQ2SQW$FTGN:++-,S;DX8Z(XQ4
M6V5`HN\HRZ&%WDNBW,="_P#JFMJ:C0M-C20)N$`RV<(`4?=E0KW54_%>[[=E
M>Y2'GE(9PU(12(XY,2>]NB(]X@7Y:8R1+&D2Y,QMAHLR:RYR8V9EZ2<OO\:M
M_NV1'0WD!=%Q&I,YAYG"+STC=\HSRUCE(?4U&[E+=?JL^RT*`T^#;>6,UA`:
M;:J$BJ-MLCCN;`)4HKD_JZ+2&'5)&Y4IZ7(%NH@VCIR&48>;-!=1"9-L=2ZE
MTIILB(K-R)<GYPQJ3_\`=MK9^41^TMK9^41^TMK9^41^TL^;/&46'G33E@XL
M*^2R+E2*HD&<%;%7'R=;A^-3+1`ID9L`$$T#3'ZDS4E"1*>!Y$C0P`)+JO*T
M#&^2<*9ID6WA0B5`$&T%L=;/RB/VEM;/RB/VEM;/RB/VEM;/RB/VEM;/RB/V
MEL$UXV@-&&Y*1ID4-YCQWUD`P1$IDTBD1(I!A)0)4]RZ(K],I;Q066X\0G-S
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M>J'_`*2<0_OJWJA_Z2<0_OJWJA_Z2<0_OJWJA_Z2<0_OJWJA_P"DG$/[ZM'B
M10;:C1F0CL-(\A8&F10`%5-PG"Y*:R55*W>\\/"MWO/#PK=[SP\*W>\\/"MW
MO/#PK:PZQOPM%N]YX>%;O>>'A6[WGAX5N]YX>%;O>>'A6[SK&_"MWO/#PK=[
MSP\*W>\\/"MWO/#PK=[SP\*W>=8WX5N]YX>%;O>>'A6[WGAX5N]YX>%9-G6G
M?AX7L2/T)_\`$%8/PK?WX^Q.?BNJP^AP0!T1:,@SGXC)J@O`ZTJX'%UBMH44
MYX*D.I30J+KC,<7:A!:K$:FM(@BVC;;P-.NF2MH">(75JM.OJ$UFZ'Q-*9,X
MM*RL=&J>1&"G*D-PG`%GDR$?12]L%]NT,GY#DIUQAMUQ]T6`,R=3,TC&9CLH
M@8KDN%-":;UT_P`E7BA<4SZ4#;]/IM`!JK.4^F[SNU)9EN24B$RJPHE4J^4^
M2YAG,DQT549BOMVX:E5244RINTF+Z0><P(^DT1P2HTO+Y&_0GQ5E_P#_`%@+
MZLV(TV3`;3?7&VXBW/R(\0L*9QX!<CN2,EW#A<UX!4>5BLVL>N28KCT@6A_.
MIPH)FKPLRT>1YPUC.Y)$KG_*Q#CN0K[09=7-7GW,>1),%;=DQ-&2\\"H/+UC
M?WXBAZ<7U)20;%T\,LA1PE%M-TILZI+C5/:,8*A[5V*_ZUI9JT+6ZS2A\@U=
M!Q6X\9PW&W%!O,95QY<!7<L$0M%]R>RZD&&],B-06JB*-PSD9SF8["=I890H
MJN&;C3R+B0M"ZTY)2<JF')!&WRC`,:3A=5FK3X#3(F(*22'H;0RR)54<IO"(
MIBS+2(YPB9ABU*<CR%CRV\P&9Y1F#4WP;'\Z8Y:"@W7)>)ERQ:^J&H1BC"Z4
MUB-^=Z6U1QM\U1$S&N7XKW;=)1>K+SRW247JR\\MTE%ZLO/+=)1>K+SRW247
MJR\\M`J+T=8KDM@75:74OM(ZUI5<A]$QA?IPJG_#I]E/8D?H3_X@K!^%;^_'
MV'@?%AV.]@QLO"I"6#!=B&Y46X@OL;*1*>C3K"17&T81`..AFZC))@N4,QTB
M_M$JV0<B'A098(F7WD\\R:.SLRG-)_UEL(`30@`H(BF)$$12Y$1,.I$MTC?W
M7@VZ1O[KP;=(W]UX-ND;^Z\&W2-_=>#;I&_NO!MTC?W7@VZ1O[KP;=(W]UX-
MI*3JE6V1E/K)<"+.8P(XLRHSDP)+ITNX4D5>4MW?*^I%B-`(5@0'35E7W9"K
M*?=D.JX\J7WN&EZZ!33M&O*-2,B)>D;^Z\&W2-_=>#;I&_NO!MTC?W7@VZ1O
M[KP;=(W]UX-ICX.OP3GA@DI#=06UQ2&I!FT#T=X63<-E$6[DX571IL#[HN51
MT%0@])/9C0FGM[NPS'8<3ZQH=D1#:1$T(B8KD3W$Y-ND;^Z\&W2-_=>#;I&_
MNO!MTC?W7@V'-R#P&C@8D)<)I>F(>3H7"2I]=%5-2V/*R`S"0SPH28B1L&D5
M>3[330BGUDMTC?W7@VZ1O[KP;=(W]UX-ND;^Z\&W2-_=>#;I&_NO!MTC?W7@
MVZ1O[KP;=(W]UX-ND;^Z\&W2-_=>#;I&_NO!L+51C09[*.(X+,N.W*;%U!,4
M<1M]LP0T$U2_7<MOF]P_^IX'FUOF]P_^IX'FUOF]P_\`J>!YM;YO</\`ZG@>
M;6^;W#_ZG@>;6;%M&FVA3+;;;'`#8-H*"`@*((@(Z$1+;0^_;:'W[;0^_;:'
MW[;0^_85Q#RDO]OVE5/<^M;:'W[;0^_;:'W[;0^_;:'W[;0Z41?;]M+_`'+;
M0^_;:'W[;0^_;:'W[;0^_:[$/O\`P6VA]^VT/OVVA]^VT/OV32.M/=]B1^A/
M_B"L'X5O[\?_``P?[7_DOU3?]IS_`-GU37]DOQA?5#_8#[U/JE_F^TGU*?9]
MB1^A/_B"L'X5O[\?8H-*Q0T;J)+O:/DJ2;GWV84!(29HHI%*<)3O$N0'\Z.,
MBD!D]PK\D'2C2'@%VE<0R*5'0VTFM*8'%9O),0JIZ45$T6I,U1IIOR>&Y/%$
MQ$AR@:..SZ+5*;#'TB9MR5&I=,1&G(Z/E:'S%F$K47C!JC/JX+W)HX4%NM3I
M&)'T1)C8X[BV,*:1]NU*J,J+`!N36)T:>`A(%6*=&%LT<;4I"H,AH'+W%6\=
M"W):/)D1J<,PJ37IDAL&I.4,ND\1PZ,VV"++4\I67R4M-ZG=<J)HM4J24>&@
M1%K)L.9;^)QFGPF764)<_"KB2%+-N[P@U:U8FU!`1Z0+;HBW`>IX"TXPRXB"
M#\^H$^.(EN=Q"A)WJ7:?_`A_M?\`DOU3?]IS_P!GU37]DOQA?5#_`&`^]3ZI
M?YOM)]2GV?8D?H3_`.(*P?A6_OQ]APWXT=UQT8S;A.`)$00WRE1155TX8\DU
M,?<+3:4^Q#ALO3559;K3+0.2552(LXA1%/$1JJWZU55UVALO0(3K5/0!@MN,
M-&,46Q`0%A"1<L4%L=":.2GN6<%Z'$=1Y\Y3J&V!(Y)<B+`-X[]IPX2Y2K_4
MT6RC@0B;QON9:LMJ&.4."06&ZZ]X-!>[:.CE/@N)%?>DQL;#)9#\A[>7W6L0
MK@)Z1RR]TM.NQ2-SB9Y;SB=RPS%WP&VY=Y:UW@&10O=NLL>!'CQ&5/,5I@1`
M,:B(8L*:+\((G\UM:=VVM.[;6G=MK3NVUIW;:T[MM:=VVM.[;6G=MK3NVUIW
M;:T[MM:=VVM.[;6G=MK3NVUIW;:T[MM:=VVM.[;6G=MK3NVUIW;:T[MM:=VV
MM.[;6G=MK3NVUIW;:T[MM:=VVM.[;6G=MK3NV'2FU[OUE^J;T]\Y_P"SZIK3
MWI?C"^J'3W@?>I]4O\WVOJ4^S[$C]"?_`!!6#\*W]^/L3)$$VVY`.P$0W!0D
M077HK1Z%$DTH=WV/KV!H(,4%D30C1S>?=$$$I%1BJ3R8,=^.#?>**.E1OO&^
MP/8QCL2([4H6I!)NT45X>2H.9Q"WFN,B[>M]Z+]JT?>H+#)2?0;K8H;B%N]9
MK,BG`9"6R>[LHZ@_^JY;1#DPX;3+Z1",QDO>+"929]2;54)BY$;]'DA+IT$G
MN:1?%B.&Y-5-^2PIOM,RV&*33ZHTH9T=)(.X)*B-Z#?K7W+4^@TP8S+TT82N
M2YT61+;B^D8O$DZ,91V)<',%&^%)#1)FBN8^TM]PJ)9>+AUY9;%==@N0V9KT
M9/0%7X?@.JP_Z07TVL^+63<B@`Q,TVQ'$*'B`I,AEEAU&:-(08Y&;2M5;A^E
M5A+G#VLM^<XW]<00KDO^JD!%<%F23+HQWC',!I]0)&G"#OQ!RY53V[2.$EBR
MUXE](!%:JHBBN^C7BS7)")B#$ZTUH1U%1JZ^XT04D+'":X#TL6@20Z"7`;MW
M+4;A;2Z_V\(W^XFK^3CQQA#)64UF,>-4"6[.BEHP%BNJLJG,:-/YWBU#9EEJ
MGR5S'H+1*9LC<56A29M,$40RY3X-#CON%J];UT:<90)+;[,6#*FM(K3@L))?
MBMO-MF)^.<9CSXSUWMA*;^O=*@E"D1I$1V>R\2ICC9D"6$=QL)*7`Z>7(:+D
MWW7K?=<F+V*B<-]E`C4.1/9:=AJ^*R6<5R$0/,N$A(.J]-/<L['8-EP6Z3OF
MYY=\A;HO$+YRD,2Q"T+],8:TBH7NW:R&R.^BV2`V6KHX5$4<!TBJBK(5YZ*R
M&X(W%:SC<1E8V/E(M]R$KU"80K@>5%K,5@(S+P`0!)-X.4;-_C3;0FAQMK?R
M[,[M"!Z"<"ANF#Q9`A(K$Z7#NWC"<K&R0M*H[O=EXE54*Y+$7^WG16X'6<RI
MQ!:./GLQ93CLK`46*Y`D3HR/-F:$.,_^GRFT]"HVQNZODWO3CM0<)*XU24C,
MLI#!C>5%MXE#&5XW*A:%LQ%6`R##T1U_>V9QR`SFYU1BB+*+!8%Z*ZU3\P7<
M0JJ&/(]OV$J&Z;Y?):CY.?N_2"Z6/,R7]67JNM\W_P!K?Z9;YO\`[6_TRWS?
M_:W^F6^;_P"UO],M\W_VM_IEOF_^UO\`3+?-_P#:W^F6^;_[6_TRWS?_`&M_
MIEOF_P#M;_3+?-_]K?Z9;YO_`+6_TRWS?_:W^F6^;_[6_P!,M\W_`-K?Z9;Y
MO_M;_3+?-_\`:W^F6^;_`.UO],M\W_VM_IEFFIE(<AQS+"<EN;O:M7ZB5C<V
M%,;]=RWW:D759"342(J:TT*EZ:%TI_()]E/8D?H3_P"(*P?A6_OQ]B0U)W9U
MEU`%QB0&8!I@#0XV39@2:+(A,4\4WIN8\+;``,IUL'6QWM-VND!A>7:LN.-2
MSO'`N*,!7AD[O@6^/I'=^1=_4T:K-*W!H[:L*A,J$)H%9(7$>0FE&,F6J.IB
MT=]IL*#'I@H&#`@Q@3!E-.,-8;F.3ELO&`^X)*FI;""0*,@"6,1W%G")W`F(
M4W:Y"N;'3]9+9LYF#,Q1]U<:E-[Q'>:%\)36='=9-ITH[X8FU5+P4BNUVEHM
M)H"I/5M9R+38UTU6G4D-++_-/SA6GQ0QQWW&E^NSZ1-V9&0Z#S@-X@;16HD:
M`R+;8M(VTVS#AM-B(HB7![M]NG9[KG9VZ=GNN=G;IV>ZYV=NG9[KG9VZ=GNN
M=G;IV>ZYV=DXB](!C2.+.ZX"PWHRZQCS;K[L#FJ[6FNW3L]USL[=.SW7.SMT
M[/=<[.W3L]USL[=.SW7.SMT[/=<[.W3L]USL[=.SW7.SMT[/=<[.W3L]USL[
M=.SW7.SL).%%,@V",5)1Y;;O)56M'C60+^T*+[5C;5N`K;F9F`K*8#S<U7<8
MY-Q9BR#Q>[C+W5M<@0$2[#=DZ,*(R*#T.I!C-]6/N):^.$%A<`MWLM97BP(B
M%OD,IR!(U5$U7JMNG9[KG9VZ=GNN=G;IV>ZYV=NG9[KG9VZ=GNN=G;IV>ZYV
M=NG9[KG9VZ=GNN=G;IV>ZYV=NG9[KG9VZ=GNN=G8(-7'>XH2`DBVS-J,)<YM
MMUL25V"]$=(4!XN2I*/MW7HEO5;_`-(>)OWM;U6_](>)OWM;U6_](>)OWM;U
M6_\`2'B;][6]5O\`TAXF_>UO5;_TAXG_`'K;U6_](>)OWM;U6_\`2'B;][6]
M5O\`TAXF_>UO5;_TAXF_>UO5;_TAXF_>UO5;_P!(>)_WK;U6_P#2'B;][6]5
MO_2'B;][6]5O_2'B;][6]5O_`$AXF_>UO5;_`-(>)OWM;U6_](>)_P!ZV]5O
M_2'B;][6;G0*;ADM=&<BIUF>`+>BH:,5";*CY@J.@L.(?:MMC[_P6VQ]_P""
MVV/O_!;;#[KP;;8^_P#!;;'W_@MMC[_P6VQ]_P""R<L=:>[\'L2/T)_\05@_
M"M_?C[$YAHW&S?DT9C,:(A,$>J5.;-4(.4G();_K6=FSEE`Q.]`G.:-R0RVT
MRQ*J=-=`U:1288=DP&U<5$TB5ZZ%M"(-^:E(?#H1&')<N0ZD4*M5V:NAF3<9
M7V4@@F/,;2X<-^FTHPFU$#;B\/.U!,YQQ?3#E3EM5**JR$=)E,E6U,65"[".
MFY517`5V3F;]4!D,*Z^K`TH:="6":,*2QP%92Z"1+U)2^O8:C*KDRFSGQX:?
M:@L-0%:<HE6H]&GU&JN_FQNP6&*K-E1TDJ>6.[BWM%B*FJ[Q.ZQ%-[B0)1)3
MH$J;Z#AR.+UH=?90X0M34J,2G1!:?!<D7LM#;>WI,%'B2ZNU-C25CYK$:93Y
M!N0Y4#BV0TKD>#"&+(<B'#AC+EQG1:%]M4`,MS169)95/.G\44ZD;U'`V<7#
M[E8I3,SB(#J`N--Q)%'E//MN)C;;`+\:J*X:D2\15:;&@SY:R!2+3AEAPG$X
M`@5H*\W".GDF:=?(6@=PY;ZR53"O)P;A*J3CTG<XDB6__D\5F)$D>B%?DNG'
MIX2V'8]4>D1<]&UC;JK:W&^+JI/8J+Y3!8`'X\I<EP,)UGB*E#&8EL,QAJ,=
M(E#9D-R5;;*2$E',(H2"EN(9C]3%C>I,"FTF<X3K[-+&&D*E3Y9MF*@C$6L/
M2&18`A%PBFR%$G8(*/#82)1RYL6F,0J@;CBNN,U&&F[SH9NERGMRDMDTCB](
M((>F^_\`E8K5$:>>;E-<L@A)(:C&CBTZ]UW"N612:S&DZ;[F(+RW8<=@):83
M+#;T4'[J5/<)0EPY[DAS#F9CS5&D,B)(VF*42#@(4<%%POT1Y7F(<%TG@ITU
ME9LC.ISLMH6G!,&,R%56DNTJCC,I.2K7)E1ZC#(([*S<F8=.G4[>$";ABF#<
MG$(MN1SN0%7,3+Q+BQZ/8FK`BRI-\.CK%0`;-C,&IS$J8IF.MB+^XN`NG7<G
MN6?)F&ZXJE*8;58T+Q4QFLY/(;*5%QPAI+*EB(^6Z2IBU(D5H-XA5$)#HRS4
MG6^0E,FNQR4X$FF..B;QL(J@K7C=;:(BA8T98.2AO5A]LY"P\UO$\I4Z*H((
M"ZSDXE3E-J!8=*CXNQR'&7!BI.DX(63#QG3TFTH(RDN9F(\L"3*+;VV!^NAR
M%:%QFC/I'B`\+[+JM!$2&_O34)]DVF')3D^4V3EYJ:1PO'0-[S4AR6:E2LP"
M>W+>?2"T^6*L9S.'!?*1I>3=<6I;K1V:B$ER&L.+GR)&Z*6\I3(N\D:M'M[^
M*BB-BV":5PNXU-JS<R'**(^Y48\9'`:1U50V93A!A5MU-*,WZO:MZ[D?(6_,
MK>NY'R%OS*WKN1\A;\RMZ[D?(6_,K>NY'R%OS*WKN1\A;\RMZ[D?(6_,K>NY
M'R%OS*WKN1\A;\RL4BJ-"[!6_<ZD8[O(D$AX2;W<6P%UH-/C+ATI=RO:_P""
M3[*>Q(_0G_Q!6#\*W]^/L.DXX0;%_('"G(!$Y1.C91S3Q)K3+"]+]5Z9^B^Q
M>-/D[7BPY.B_E>/T:+8E=-!]W+"[NYUMMSJA[:UT<Q:C@I:&FF1:%3)3+9>P
M#>9W_P`]L.>N*Z_#@;ONUWW9]]UUN0^IW:\(-E=W'[;;G5#VUMMSJA[:VVYU
M0]M9TPO`WS1QXA8;0G3%L&4-Q4=O(D::$=/M);;<ZH>VL]%XE*,U+=<C2G8Y
MUBH0W<;KD]R&(QX]7:0,W,EY#2#LJ]EI=CLTW0<(4V1=,8..6],OC(`%;>:D
M'+>S62804;N)01M!0>2B6VW.J'MK;;G5#VUMMSJA[:VVYU0]M;;<ZH>VLVU/
MJ;,5YX2-IEW*1]QL5N)P&<_-)L56Y2NN15M#D+5HB1Z@Z#$!]7XB,SGG$)6V
M8;F]X)+KB`MPA>JW6%A9%S[C;CH,J+>:;31-`ZZ+>?C)MHWP0EU(II[J6!YF
M1G-."A-NM"VXV8KJ(#%]1(5MMN=4/;6VW.J'MK;;G5#VUMMSJA[:VVYU0]M;
M;<ZH>VMMN=4/;6VW.J'MK;;G5#VUMMSJA[:VVYU0]M;;<ZH>VMMN=4/;6VW.
MJ'MK;;G5#VUMMSJA[:VVYU0]M;;<ZH>VMH-SJT3_`/E6VT7-_OVVBYO]^VT7
M-_OVVBYO]^VT7-_OVVCYJ>';:+F_W[;1<W^_;:+F_P!^VLN:GAVUES4\.VT7
M,3P[:RYJ>';67-3P[:RYJ>';67-3P[:RYJ>';67-3P[:RYJ>';67-3P[:RYJ
M>';67-3P[:RYJ>';:+FIX=M9<U/#MK+FIX=M9<U/#MK+FIX=DTEK3O4\+V)'
MZ$_^(*P?A6_OQ]B;"%MQW>)-'`A:`G#RO2-.5X\(Z<+;**2^XB7V&IR(E0:.
M:M%])9<62ZN7%=JU.<!1%HC,<J.PXMR7H!BJZ+-S)4:K;TLC&Y^:2"-QYW@A
MN*ANLY!*0[^.22W84Q$*VJ,-M*C(%M5COQ4BF49ED:517V@!18T3-]<+D(6)
M!5>3=:I)4%E9*'*N!V.81A5*@\,+<WB;;$P6`@WX%<3VR5"O2T:GQJ1-;9G1
M.'XE4;<B/4]')-/])S)SCA2&FT1%$&&U=7DN*2(BE:)-F4\T5ISA1J4+U->W
MTBCN'%EN1Y1+XN(!)C?'+)#97:%--KZ7%F1C.OUPG&(,'+<DL;_)]'XGABOY
M3*-EXI3#=U%>40C=]5Q+,D72&YU4B4Z8K`M'.I\9D&J+(%D\5\6I3UX=E204
ML2#"@H"HB5`K4&'$<1WT5#;I4IP-+;TR((H_*86\DW:>I;PTE]XMNH*W$BBG
MU,VEE29!R:C4FJNS6'8P/PG:;"HR06H#)D!W.PWY+KF#1EEB<N\9>H5>K46M
MQ:14>+?2$6!&=8BU!EQJ@R6EJ+&>V`@U.FL%A5'(RXW<\3O5,1>A:1Q1.?96
MJ(^$TZ/'C99TF6T^#'YO*42?6,+;<<A99:1R],L5;0EE-T_C7<8ZO0GV6H5#
M)Z4YERH98&'7&6VVX[+@B)*+A&"W84%,2A!@A@8%R0_J;0G'93[DEYT\L&Q(
MW'756^[ZA/1F//S%Z/I,6[O[G=?R<OTED9N+D9./%R;[2-]WB_>`R=[5I9&7
MN4/.S<A!8Q;]G='XK_I^+P_4.S:5,8BWP6LE#D2HI-5=IQU@:AF16C*_T9*<
M;^OH$A4;[278M4!A9#;XH6_3L3+A5:?*CDGB%S&F*;)1@6M``I*8Z0&^1+J4
MEHX[[4K#';J$R6+#CD\GXS;+3L.&PC;$4L*G=F*NC91$^K;"D1*A,E+48][=
M-Z<6D9E*;A^-9\4BHB+IUJEO4?%?=3SZWJ/BONIY];U'Q7W4\^MZCXK[J>?6
M]1\5]U//K4T:N1E.W<"<%U/'L@?*:CR5Q%CDL-J@FONI[>M?^&3[*>Q(_0G_
M`,05@_"M_?C["N&A8BNON*[4B)]I+:CYUM1\ZQJ#>!7#S'%&X5</"(8SN3E'
M@!$O7VDMJ/G6U'SK:CYUM1\ZVH^=;4?.MJ/G6U'SK:CYUL4^D0)JX2"^7$C2
M5PFZT\8WO-'R3>C@:^Z0"NM$MA!O`-Y%<*X4O,E,EN1-9$MZ_7MJ/G6U'SK:
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MQ)R"+-3X?CLR'$>:1UDIPF)J-R`P7#92QG'4&H)[DTR\\#58CRJ(S/4'P<#=
MZ'4:DQ4'5NN1J(5_)OM7'*KP^UO4:A5^HTV/*A519DFIQ&(ZT:..[--TUV++
M?S&EC(\$Q5',T`0WR0&D0%ID9BL18FZ\,<13@G3@XD@0J;*GJ,ALHS)T(#E@
M4:0^V@NF)B3@`-JU(JW#(,9+7&;])C.4BJ,RB=@/</OT`'3>J'YVS-:J\L`:
M!MIQQ(5PE??9P:;PW&E@*<0&,A[ANNQ\35-X>DU*@FD9RL"XI\35)K(RL2.0
ME1`=17'1NEBO#U/=8BU>I0VT"AU9DZA!A5N+$BS&9!UQQJ.E1I3AN"2BX(JF
M/2**-@])</TZ'#)JEW.Q.'>)I;I29<:NNRHY-2IM->C;O,I\>*IJ!,-YR/DY
MEF-TDZAP\\RY3?X;5NHQ6GJ%5(S4_C%N1#;IM.G"]*,YDC!",Q&,\&:W)6_"
M?);E<.1(T,JA2JKQG(=!NAU*0<BETQZ"?#DB6@U50CP*T%6(0CXAD866G!<P
M%RIX5BC`Z]'@SY$=Q>'JM"//;J\1@!?ODA'FBS`DNFRQ%0GI0QM)MJ0*[2VH
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M,<ST;2ZSQ%PU2H5'!RDU:$`2*%2Y4^9(1],Y1:2]`1%5<\N$(,*2L9B5N3=.
MKV^9X5$6W*<X]+=BPXY2H6%T70*0+:&0FB$"V:AUZF$Q1GX;PM5`>%.(J0XM
M75ZA!#CX9<RI@$5[TA*#$YEKBB$>AM1(C6)09U5K)P9KJ)4:3Q#.'TI'>;RF
M3!N%0X\5AR,9+@;-QLU'D/*NBPTECAN!.D'3*O-BL)2*Q%6H2J7Q'2*6]#9F
M'4WHL>,S1JDDS?#O8>-X&1N("Q,^C*<ZO$[56DE-2DT^9#8&#3FIM5IH*UQ6
MQ3C!NM%'B19`7JZC,EPF^6@HC@P.'5I]\1?'+PI77YK<MNF;Y(5IJ5*"#DLR
M15I+\PGB(0:%Q<1#1$C\/.*\ZW1*C4?1W#-7BDR3T+AZ3/IKF^5.8RZPCU6E
M-KXQE\'(1(2"B8CIT^-PP#]9=J$MF9$_V]7\I8+=3I\>,ZW%WQ)T)\Z=,-[Q
MF8V60:8A6X2I\6;3=Q:9F5+>78%#J#350BI0^,-UD%(E2Y\>`TU48]/1&5(G
M7G3$T++7!;=Y=!*J-P6*6Y*D5"EU)957CQ:5!EU,*.5(8;@L5>1&4E7><#15
M$B9;3D*-D&MP9U$J[O$#5+23PY3JG(&-!8A@51K2LM#59#D5YP7QB(H*"O*Q
MCQ!B.T04X6;CO2)4+>$IE$KTA^/'."4Q\$?G*Q&1^+48^Z/8@R7&W1-EU;U5
MN&3G#,48[DZD0II_[;XB%QB-/F\4;_60CG4TD$U2:;2X)%&0",W95R.)B%+4
MF0-.=JBN<`<'O2(TNBS,1\7/-U4JU#>W63&*%+E&RUFNN)DPDPHH7GRJ&W#H
M<.2].I]$>J3WH:JDQ#DU!*NM5O;"JID#1#CP@5DW5=>WHC14%H[5%ZJ\.083
ML9:.VT#5,KY/`,BJ1(M3GK#)5;J;(4MQZ8$>+))YK+1EQ5,K[<,RS%V!4JMQ
MU#&M06^'W)C=+H#LNE@L1S#*(V:=$CM/YLG$&8*[0JN)9S[M!B4BN(O"*Q8<
M:!5@DH4RO,L5QA[TA^9JPY1_&XV'S*$!J+BHZ-XTZ(QPRRH3:SPW$*HN<.5X
M6&Z3.EU]CB&IOQ2J0%3RI"1X.`'G44Q,W-(&F5585$HD*J1*?-J\$GTHU87)
MF0J53IE'A./C/2-(_P!P2YCC920PM4U&D5Y"S$NC+(X?@/5%B#?+*3P]Q`W,
M>E0^%:U45%V,#]/IQ.U>MP&(XG%=(&">PJU>X"#3J=4:1+)MRI<`A/J?^V:C
M`?1I^/PN]Q2X+JO/4P8K+X5!B1XEI!OQM+<J8'#H=,K=2F-53->CK#):6ZPS
MQ)(R844AI$;+B/T1ML#=!^1B9+&N!_&2G$_VZPRV_`XA$JK`X;XGD[E)C,B5
M!E1F)!,O2DJSCPM91M-N1G<9FBLMXG*@S3F>(7Y4FI0*>(-P&`APJ#4.#Z*P
M]68$N;%;IQU6E\7RW'<!/;`.Y@Y8HHO.34XA@7/P8>"*VT.*7%IW`C%2=&-N
M+C;5,=G.UDVGVY#R/*NJX`6U7I'#%'AUAJCS7*?BDTVJ&:9?"%!KL(I55&HQ
MZ>[)J-2J3C"BB`K087"_]3%!BTRF+4':I&`6G*#6BD.\-.U@8CO$[T'TRP[2
M&VXA+^;2"S+Q1U2P&@),=_VO#%(L47&6W.&J^P[-?6A\6U=6Q%ZM"K!;W2*?
M!44SD%^9>AGR!LZO$4#<*FRZWB!JF5.G0W&7&&UQ1BJ9&\^K<L'FROP$F!%P
M99-N._\`%2/T)_\`$%8/PK?WX^Q(8:AONTLZY0J7NBTE=WI[1\1\5T^0Z%;0
M!CYU5I4&E.DR\1N-^DFW!P-WXJ4WPXKHRY%:C,2C;R1$("Q9KCROR7Z176X3
M&:VVBN[L=RJB:+[#$J].E5NJ;Z[O4G_9588@;@CL>.;M.=IV2WBCG*SFV'5-
MR1'8<N<1S`+E,K847(J8U:LE,H;-!JKBRJ93.$^)YT5AT)#B5"/Z8K,.(++B
M`T0.N`VHN8E`Q9F<(2F8N&3@4J%7*<\^X/#B5AH77J@?H^FMI4%2#B5Q]7G[
M]#=VEL)/"IQXCC6(ZH/"_%3V[.[PRWDN41"&I/931WJ3:J)XKQT-N74]M_A&
M>Y.P%Z0>/ACB`GRQQHKD48Z,1(U.%]QU\T,SP@P+2X@4[FRI;M>X6=A1&C?:
MK<UVD5E"R*<%*6=4Q1AL]R;=CS'WVD-E1=6,K0K>MX.4V'PHLFFMU%J&Y61I
MU4D-,Q#=&0_4FV&7!](-0Z54HO(:)"?E1Y38:401FY%`DTH7Z,UZ/).%:I4`
MCU401[EAI?4Y^:J7N7-119PF*N%?:GJ?"$NEQ#J49F62T6K5#)I]0;>PS)$9
MI!DN^BR9\:#1-DI.!J%%Q+*KW#TF'5([?#<<G)%`JYRU.9/?@5>I2:/$&.<_
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M%%,DPIS49EQN0O#U;HK$G"ZZR_C]*M@B2T#),@1&QQ.$C68#:N?^,2/T)_\`
M$%8/PK?WZ>PY#]'HVV/%%/IB,N0)AN.0Y?$DGA]V0$QAER(V#%*C-SUSB:-4
MFARL*-MR&'^'5+?':@U3EP0M_(2K,>51Z7)5G"5T:G\03X<F06RD9ES$J#B6
MW$BS*!,@U.-PWQ+5*6X5+<15EP8C*T?=VB%=XWN0X0Y#K2&KK185<&\6Y\;_
M`&>]*2`YQ!%Q,TZL-A.D4ZMQ*%1G(KQ`ZF56G*DW(7DDTS&8>)'G,+F3%J%/
MI#E'J"\0K3I3$BB2IKC<4^%I]11LF1D.(!LUT6HF?>0$=UX`2DTE99D\)R&"
MI<1_+>W28C,QZ._1V/2$8<3CSD)Y*A(/=[A=1()(VX_B)649I?#[C8PZK*AU
M-(](J$B4#;7!U.K=,0BDBK4%SB2HU;#&S&E6.C%SF-25$C4^3PWN$!TJ:R=0
M=@55I,RI</<2UAUX!DY.%JB5&B-TY\3N5UYW&A-W@"LR:K07`G)3^'EEOK2*
MI&"')J-0IM.J$N5#+3):BL3'9Q-,F"M-1B`U!5Q)7ZI+X7D->BX3<IES=YD6
M*V13JS$5N2W5AIE2?%8E,CSDRF$?1FHM`3(J.,Z[)#@YR7Z-DU"-2V6J;6!.
MNA`8HQ-U%@DSMUCU!JJN3`;)%46(A-(;CJJK=8BQ>%<Z1'@U!RFS8]+J\AJ5
M.C<55GAF-"&,F+QTJ%3DJP$KF6D>]LM!"_:I29=#<C.PI5&AMRW:9/%@FYM7
METR75R@LOOR'H+<*,W4$`3;=!J4(&@@*2'/S;A=RF-LNLOR'9-%KDPT9:XPX
M<HK\`&`!E]2>HU2>FYI-A(1I/)AP9ILLO\+R6H!N1`DD_39T=,#_`!-1*$CT
M*X748_,*XLXU-Z2!-1%PX!(C"HH_0JA76A(SB@-.>#%(;XFFTWT)&DQJ9`;C
MS7Z.XU*3.1]MEJ,I&\22$5G$'#*-1:I5.'J<&;1I[6Z.5.H)%J%;?1EQ<YF%
M$Z0%?5%)M"S6QO"U/>JO"IC)DT:)/9&1$GLRYU07B:5PTM!(19CLMU6<RP,X
M7D;;9`30%:1"`UK$A:8]1=RI]`D,21I4@ICSM4XBJ$&H$RQ*WZ*'HJF4^\@N
MDWJZCBJ*7`K34&!4TIKU9A<,QJDY2H\5YZ2]QFR\U6'\ZG3'XL.3_#_2Y(6G
M[HW)<6ZXD1M(#E2&J53?JA0*?(CR*&+8PM_A4]VIFWZ-I4(DW*8\Z"O.NX0!
MM5R2TY?%[,>BN(Y3F./TH<EZFRWWWI=#?DG0B1IIN/'F19S.%MEL1QN847&X
MM]])IM0H#L\)\V\ZXQ2YD**D-ZN,TYMER.;I%'?"`ZY,%Q,Y,EC"8BF*2(B-
M&D3P;H%+<GYE)ELDU6QK%4BUB)'-F.@)*W!V(ZEXNM"(H2"J&JV:C3^'9*S#
M<JC+M4<H-0;;AMMU"H-0)SD..XKDI,IAEC+1MI#-X7<6%,)0Y+`RI+SS7"2O
M11X<F2F83$M*&[7YE0B1Z>S,401R4*2(TIP1(LG=0-I7E<)>%)#T<X<%8L=:
M'5(Z+)])<1,O(;S3\]\4G0XD4A5IN6K2&AH!XT16I=0B.09^.0+\<X4N"B"$
MN2PPZ#4M3+`\VQB2XSO1471?=_X=(_0W_P`25E'V_:^S;"]%,R3OVE&XOKX2
MPX;8O1S^+'F8L+%^9EY6._'?CRN3?_5T6\AE?%=I;R&5\5VEO(97Q7:6\AE?
M%=I;R&5\5VEG""G/B3IYCI"+"*ZXC8-(;BH=YFC30C>O>BB>U;R&5\5VEO(9
M7Q7:6)MVG/N-DEQ`X+!@2>X0D:HJ6\AE?%=I;R&5\5VEO(97Q7:6\AE?%=I;
MR&5\5VEO(97Q7:6\AE?%=I9@Y%()\HSJ/QB>:C.E'?1%%'F%-55IU$7:&Y;>
M0ROBNTMY#*^*[2WD,KXKM+>0ROBNTMY#*^*[2WD,KXKM+>0ROBNTMY#*^*[2
MWD,KXKM+>0ROBNTMY#*^*[2WD,KXKM+>0ROBNTMY#*^*[2WD,KXKM+>0ROBN
MTMY#*^*[2WD,KXKM+>0ROBNTMY#*^*[2WD,KXKM+>0ROBNTMY#*^*[2WD,KX
MKM+>0ROBNTMY#*^*[2WD,KXKM+>0ROBNTMY#*^*[2WD,KXKM+>0ROBNTMY#*
M^*[2WD,KXKM+>0ROBNTMY#*^*[2WD,KXKM+>0ROBNTMY#*^*[2WD,KXKM+>0
MROBNTMY#*^*[2WD,KXKM+>0ROBNTMY#*^*[2WD,KXKM+>0ROBNTMY#*^*[2W
MD,KXKM+>0ROBNTMY#*^*[2WD,KXKM+>0ROBNTMY#*^*[2WD,KXKM+8&8QM*6
MA7'5'D7^V(C?>MC8_K-&'.%4]C3=;O;=[;O;=[;O;=[;O;=[;O;=[;O;=[;O
M;=[;O;=[;O;=[;O;=[;O;=[;O;=[;O;=[;O;=[;O;=[;O;=[;O;=[;O;=[;O
M;=[;O;=[;O;=[;O;=[;O;=[;O;=[;O;=[;O;=[;O;=[;O;=[;O;=[;O;=[;O
M;=[;O;=[;O;=[;O;=[;O;=[;O;=[;1=['__:``@!`0,!/R%TE!.!W*N\ZM?P
MW;MV[=NW;MV[=NW;MV[=NW;MV[=NW;MV[=NW;MV[=NW;^#[=NW;MV[=NW;MV
M[=NW;MV[=NW;MV[=NW;MV[=NW:MQ.$(>%@2X,@E%;H%P&5:4U"U.H0.QJ_87
M5.*Y?Z2%D^/=`_(D?CC;U]H^P[&V)5P-9/`N<RCS*",VO-*7\D!>ZQ:V!\<*
M%4%2!W43FT\&5:KH%.3UZ)8V-],>F\;C4AV@"7-7VO"XONK&N_\`'JU[5I>D
M%4.%,/4"8$@TA"--U551(*V%G1AD]T1>#I_4G4]$HRU25ZQGIBU&1+H+<%;0
M)K:A&&`T0E("]OU`_BI`#0?=$S!W9;_"7DR!6<\(U$M,I7"Y$8FZ:1D8!2>I
M`$[5P(Z#..<G40&#D-P;X&(2"F)Q'(2,-B0O5&8!3>$)6(OD97T@SNX/T^(!
M%D<O-KT2*!>3"L9)R:?K_;EH6AI0&L^HBDB7(F.;>`@X:1CQ#G/K,N(RVG!X
MOL(HI1G72+1G4';0DFQ22N0,_HYFFI;8BAU6]`EL3%A14E<5^)Y$$X27$6FD
M0""W5U-+7,L0V>EQ:"H3/U]KV_YV15AIU*,71S[Z`KW0JB@SU8[E\'3>@H0<
MGE99U9T5JT##1BAI"`Z%0B`,4+QVG(J054-2HWG`.K"==Y(9N@"%TA*-NW(?
M!Y4IS"7JZMV)(27!;2`U2=97I!#$IZ:>E.^_$YUP/4*'AU`V5)6^8ZX1D1T%
MJ&)X#$Y@"C%T-*N!4<Q[P#L'2/H/%+-]RRA>AX-"8W4K"WD05+0,::8>=%TW
M@N>TAF1Q!B6Q)+&*!9`<*R0X-0XKHLU'*K%-/I"L"A2\TO,Y3>F-Z8WIC>F-
MZ80UA+"[S1WIC>F-Z8KIX^+1TC5B!R@"\"!#2B3PN"+FH+N>WZF9SYP$@`*?
M\EA!#O0,B29DHD&$:&D.`G&F1TJ*V<R5I1MAVB_*U'FB:J0B)KR2%%U"#(]%
MD0,`E:1*'U^TP6-1?>1F@3>F-Z8WIC>F'RR.0XEQO3&],;TQO3`[7'T>$U[#
MD8A4"2MBL&&;('[Z[P`JOJ01L_$7L_4X*[+;\JND6S#.&K=RG4GU8%7'FW)J
MQH7`GV01Z1#]`VXBP61T79XB,J]B1M0D8`H+S9UM$@+^_JH&T@$J3W*'0Q5\
MR!W%NX-6B9S,Q='*OP%AB"@7%3^MX`*-%PR`$`AC7L"5G>;T`?A:E1_PDZIB
M!NB46RR9Q*1$]U1)M;D].K-E,,**7N"F<;."8?=C"X769<8LQ^N1&J'HV&"#
M_@V&00[_`!<+2"+RV<"Q[2E[%SYHE\EA9S5I9?#M=`YO@)A?B"1!(,3)Q?P%
MNZN\VQ'R\;RN):6E_P`58PLF-3GG&YC&=_@ZBS6\N4V-UT0=$RB21G>D!&!7
M4:"L0C&@_5,XT:"BF%!/H(+^\,=(K4KTN'.VCEJKAL,DH%4BF!RY@P2V=)87
MDQ[*L!0!:/R7L-YK'-`JL'[>N4V;$AMKL&"5<>5,.MH0;C.+I*_VVAL!8T93
MW)DT_IQ%+:'^Q^598WC'M*'N8)<A6VW6YHEW,\Z(B&!,K60A>>:8!SM`7DUH
M-$-W]8A#S_X'[\+7M1=A.`XZ5\;@[*4+2M29Q0N4ISB*6L^+^K@2FY5.!EE0
M(&'*$,$/J-W1CQ;\&@!4K%/^Z26AL.F/H)IUS_M.?D.:[&`5YYLZ%$`HJ&R0
ML\\"(L)^1)L)QD]DOG18M,,HZ`A+S,;@0BS$MHU[;(``H2LW!VC$V/[X1&DX
M-MK0X&:0T6-8K%(JW6RV4W,KK-:RG#S`>'MF/F`#(\@,U[(`;4`7C:E4T):#
M:4173`&//B?@.1[!J``GDI>E(JB:-\RR?QGYE)E)!8J!C9S&(OE&J=@IS1%^
M]="P6TM5\.PQ6P(#8AHN#F%?1K^?HM>M`*PL(?&K6N7?)92K/U`9Y5J,))15
M--!^_(F-&,Z\IO+E/ZT?O@3=!H:PHF\2!)8`D=U3J+URZ'SU&'8GH*U,I,"]
M)<<5)E80GH5BE&(9?,6H(+-R0JCB?D\])+[VD+%F(V22^-5_*'1I#ATK4R+>
M`@YSM&)V4(4(LA81!:F$M:1MXVH&"U@`T0$3XU;),$4N#"O`G53,10-&VASQ
M'?%EA+S6Q98]]^5KI-*4.E"EA\>*<!F(Y5J9:$R;A:%NI+,S_`_?A:]B(C$$
M&;0:UFY?O-R_>;E^\W+]YN7[S<OWFY?O-R_>;E^\W+]YN7[S<OWFY?O-R_>;
ME^\W+]YN7[S<OWFY?O-R_>;E^\W+]YN7[S<OWFY?O-R_>;E^\W+]YN7[S<OW
MFY?O-R_>(#N,`U\2+,6$AATJKZ)?&_@6Y@O(\#I@0=\DLIX!`@>,`A(A09.O
M-KXK10+&3P'=`+IUUD'!X_\`G-TD9-36>CJ5K(]Q1(HAX%*7*XI7MN:"6M6Z
MSB&DI((,5>;'B*E2I4KPL/BI4J5*E?Q.G"^G*E2I4K=*E2I6[E#J.@O.JJ:0
MQ[F+F.PO)J0]+A9W)]`Z@@-3@Q>&`9.`1G5,Z)L/&+4KQ3FFA:[1Y]>&<*>:
ME;8)$(N]-8-E!K/NFO:Y++H2C:$55:"%H@$0[I0&55ZUX6)JD?;`T&:T;@QT
M*$GJ4&7EK@UFXKXCP"MF=!@7W0E&U8B(TFU4P*L@\C8+<QF(Z\&S5:>67Q*I
MUE'RVEK&UG(ZI8ZH:@%J5$B6J2)&D37:1V;58L!$#*,UC2R7+P7(.2\&:FS!
M7##25(<!005D\PZ@$O+:5XOEUT&!@$UTR;4^^16S>OBL6+%BQ4,)(>2O&9KX
MK%BQ8L)":@IT5T%S)XK%BQ8L-:\P.MA+-/#L6+%B[N+</0'>SM>2F44`1A(1
M5]JG0CHN+BU$'.0O@,9%F[*@-99$@?87;E/K7!ZC4Z$?0/NL\-KV:1SEP=IM
M=4N62@T#(HOB(BH8XD[64X5R.)0Z$N@R*V91@MN+L!TO_KMGM89X++%%)26X
M.*F[1***R1*2,WT+IHW7P,2K#3W&=`$=<`,@DHOB-^RT4EIJ*54D_P"-06+$
M$TO^G9J&W'P985["^N*Y)$X8Q,'[07#N*#@V(5LG@/S3Z-/"X`>^/(*)<Z6Z
M9Q.0,CDW!2,@27`2W*!S#4*5?!>PVV=GS8,L8Q11,@.RLKIT@6S$!7+.!)@C
M;5%L/\:&>D[;7`-QVIST%;S$CR2B4`+--<*J5F-&!",3D:T418JA!(@7@N<$
M>>5_*Q!C!O'`R0:")F'A\("@`4+F,U2SL$NP2[!+L$NP2[!+L$NP2[!+L$NP
M2[!+L$NP2[!+L$NP2[!([O7(2.[7<*4OI&YN9X6O8I%"X+#76@R.D3<PHF+B
MIK.2JJYQOVI"3GJ!8HB*-%9DI605CQ@%)'`UKKC<N@\D>4Y"XI5"H%J$\X<0
MD7*=0'H:QB&LRBDO0Y7O*YERT&+Y@44ML.!4XHP%PG(DFS0JGG.^D8YYM(TL
M/@08TZ$]+`)Q<OJ\6*W=ZX'D&F@80`/W8&NO:)&1K+&D!BR&""S-!CU>#+C?
MI*1FH99TI'MV07<Z/"ECMH3;,(T8H4="TC,_7,-AZSS3:[*R^XV,1.!B!LS.
M>._YBO@ADG*P&6SMA!1E!YUW.&]<N`&(.8-%HLOO@FX"04O!Z"J1%(BD12(J
MN(0FY;#1FO$-&C1HUB'54K,567D;\1HT:-&D@;;+HN,I3S8\1HT:-&DN)@<<
M;AU$8RQ:=XSE!X$I$4B*1%(A(U=U*II$4B*1%(@.Z0?PQKVNL4GHLCP(M2VQ
M:$NCA72:T`R$"BX)!<[36IM59+P`TTR0!Y%A0>FS`D.MO@V$(^&:D_"KPS)8
M6?G[&_?OW[]^_?OW[]^_?OWQJREZ"%30C/*X%G'1Q6O57CJ#]/<W,\+7LQ=5
MJ(T>+LZ3M2>U)[4GM2>U)[4GM2>U)[4GM2>U)[4GM2>U)ZM+M7`5Q825.U)M
MMP99E$@'0N=J3VI(,<!B79U+@,%&8GY]HE94)BEH5@(F11R(<SVI/:D]J2GG
M@++%H1(T8,SB$Q":!%RT\89E#P9D3NTUD1)<UOD0*PA\5-F4J80V`WXAM"A)
M7@F8C\J041G:D]J3VI/:D]J3VI/:D]J3VI/:DF^*"0@@`.K_`&;H>\W0]YNA
M[S=#WFZ'O,!K9LTM*S>;FZ'O-T/>;H>\W0]YNA[S0J[CPLO7.)NA[S=#WFZ'
MO-T/>"GM:$&B!L2/!7!R9X^(44444\%3\/=X2BBBMPU3PFO:F]YSJ<'-[B%P
M0HZHI)W10AHH4/*LC)(&V+HH!,VTT216NRZM[:B\!EA];!E-0BO+]$B]<I26
M<"<0K0#;QN>A2KYQ^2;A*S1^/S`(Z@VR@26(Y@#U-)6Z;$L(H*Y4%M$"IW,B
MMKP4J"7%$;`;"-M:&;Q2FL[FQ)?"[SK\-?<>;/4J8T[@7K!KQ@H52(V2PRIQ
M1<%*X"IF9#BPW0AK>+C";#:,`5JM)T:XZ12FZJSPS#B>DU,1;"@%2$J>0&PE
MV6B;Q!,$Q<\E&T:Z1TSW9BYJT_+MX$EEW%H#L'XZFFT>6FU><0+S%&0GX@U-
MS9PJ!H$6]+`YED:2%I>ZY9"$C"J3I#`SI@YC3'ALZ3-_2I_BU,F:^P$"!`@0
M($"!`@0($"!%BZ`0\"$^5%=.7U=S<SPM>W&6TA<'1'50-:C*8%?.%0*N@.+A
MJ(=:,ZH`U`\H*F!RAH=;/&.B7Q`3A%@!`K:XZ>4/B)$.KLI<NRBZ4B?2F"U>
MIK:+XJ-&C1HAB2]ZMNCW%&82AYM2AM&+AN0%2".G:(TCCLHV.4K=A38<1MHT
M6X9^BR+C(MY<AC`H%F,>)'VPV,<`":CJ_P`9.,I`4+I_6@0MJJ$('<S22KLK
ML+6DRBD7C$^ZER2EBU3P[$`I2]==1:&S/?41+32'9TN34K&Q5?<6<H5/$R/D
M3%TF2KYAT)54$W#`"HE''S;&18',(%TMV45V.T9;>-RQRZC,:E&T%G:T#B69
M^A63E^7*>:"`0(:,B)1$@U!54#X%.`T/DQ*B*J$\BG$;'R-E%!D.--7E2\6N
MNNNNDU<VXTQ5&FO/PZZZZW$<!5W5BWP*UCSERNY7<KN5W*UX"P:OGCP8ERNY
M7<KN5W*UM@CJ[ZTERNY7<KN5KO63PVO9=R$P6,4;?-IA;B4Z1YY.AL5`&BH,
M]<<Z(JE%R0:Y==4/O0K+K.47@!=E`QA*/FW*E.E=T\>&3?.*-M-#`&H(DS4&
MR"W"[W.SHH85RU`]OX*Y3&Q@:F6\*9`)$IHG[2ZGM)G@[M>7U('SE2IJM0!1
M:-:<8B_%VH9Q8_\`!.Y'4"J&C_T%Z?!5-<!L=8$Y:X9`RK+$;0PQR5#:QA)J
MAG9I(YT1DE9:`2P#8IS+!)AV%1GX;1_QH#K4/<EY5?BC680LX.L"WIS0BQB8
M)[\7IHBX6I\!TV\C%NJ#HK(U.)LAF\I8*18PX:490.(F8EY11J!NHV#"-EBU
MN&8I0%*8M=L-V1R7!+ZR)>G?58<:N[U#@,'Z7''S3'&N@188JH$K137:TWNR
M8-G".FT:K*;@A;R0);$'>-&.FH,/TV;-FS9LV;-FSL,;N-JF6"7@3;E]CN;F
M>%KV:_66VM\7G*NW%L=+D`>`NK3KR$O!\%3[#,W@P5.-5C3:9L)JPJ'7*@<,
MF&R%)'QJAR(E8:NRAR0/*%3DP%F(C=6%+OTK0`;9E+3#<>3+/EN@Y,]?\'=[
M0SJP,Z#JX[[%/5`Y-N#`-^%6`<#H84%!E@WN^)"6"S,`MF#`K%0$#2B;0<*)
M&S!@`_43T9#FMS*"[$$OKB#2*TSNI`8H[`4O3).WN8;)P7:8P:)5832_5A&8
M4`&@!C3!F`V8`_\`4"__`%C!ERUQ<.2KZB<*K,&78IB9?!\P.&-$J=<CS[?.
MU+O"D0W,U)Y%%E<5X'*M`:7FLAD!RC9@KJOC@\!>26E,+VK6*2M@+R"\$4-:
MAVN@VX"AS(C-8+JG#BWCGI#/9$$^A@T'"I;(N`.)%.C!"3%C&.]&9>M5^FND
MPY1DQQ18C5"SA>S`4I=M340F(:X\39LV;-L(:-YS-UKIQ7@;-FUNRZ&PH4Q4
MFHZRO_&=,8JXUEE<Q7_C.O\`QG7_`(SK_P`9U_XS3RL&AZNIE?\`C.O_`!G7
M_C.O_&=?^,TO"Z![E*_\9U_XSK_QG7_C,?\`%N<\-KV%=E.?%5TP5FAC6"!V
M@<TZ")-A@ERP@/+RUA,51:B!&S>S!)TX`P7.0I@6_P`0IR=R^QKD%ML5K-2[
M0AV]P+7,K=VP\5D2(*T:(283D)O[T25H`(6T\0:`2P'C`.![)1$[M'.YM1VT
M<!/6@3_U=1#>??Z;K4(5=$(33HR!:."HE`B#63];Q,>51=B-IT(K:`B6RYAG
M$6X!;5[4%UQ20UR2:=$E9!38E@=*1;G&;%A"C%!DV8?F%SD=E5,_(,#NM2HS
MEUPY.#@L@,STYOW^4O09]>N#V,Q6:52VL"&*5</_`&]51"H9`L8"`5;6RV("
MF6CL$:(&P(<%VM#`L<'F-`JDL=\;C;H@QP+UIRI6/Y5>'(TTT(4LL<#J@-`O
M!&$O),9W*S;HYA=7]*""<*RE!?8)8\2"ST<H\(9#05+0"MRUH1P`EB9M@\6E
M0$<==7]%.G3ITZ=.G3V+FL,:`418Z8+/LVYN9X6O86B2!`1JK6]&DH?#7I1=
M0",:XDQC23C57`O4`#7=>09*PEL,AB+XR8;XZP*Y0*B+/,24%1RU&6^D`0E6
MV"WC0+,P3=&H[ZF>"U9\3KKKKIS,BM)53$T00*GV!P5.T38`NB$="Y43=@A2
M5@!MHD*CU5=4J'T:ZZZZZZZZD`!0T81&J)`L38NMZ(J%E5C`X626KE:VOQ7G
M,'QN:9T]5\QB[*$\6S`FJ%CVAUW.(RE$#0Y#"=<S=T7\A-HNA1O:!C2Z^`@*
M$>JQLWB======MI7Y9?V4P5K.A@Z&#H8.A@Z&#"%*+3JU?\`B=#`7&?3`@"K
MA5E0E(=S[LF"%B:S?'PF^/A+`.D>9?+FS?'PF^/A-\?";X^$WQ\(IKPAT#\3
M?'PF^/A-\?";X^$WQ\(HVY[G";X^$WQ\)OCX3?'PGZ*N8Z>%KV+MURY$4S)>
M;JEF%":];PFD&M6PY.SA+C!*PY1B6!Q=4$ZD@5%U10Z/AV!W@*$LLG+T/',F
M$U@KK^@@Z"2WHJ#$A;14CQ0]`IJUF!:/AO7KUZ\W#3DE_>/G5X583##\HCNY
MVS9>,RPW7&-ZB:BA?BF.=#0.-,K7TKUZ]>O7KUZ\A8CVP3DE.*G`:+1F.XYY
MC+!0)D)IQJ&&%0KIMNY\7`.0L0)2')1MF]>QF@,92J]0\A!D3<@5Q#PR*$SH
MHX45MF9&X,K5\>]>O7KUXD#'A2%PI>%;XA4J5*E3'>%NG`UK^%[*AE,:$6VR
M@`\\*&S*B@47>K*%16;M>TW:]I53JZ<3-8QG)-VO:;M>TW:]INU[3=KVE&I\
M>DZ<)NU[3=KVF[7M-VO:;M>T0PF]?@F[7M-VO:;M>TW:]IW:4=/"U[!,U@T1
M>K>*J79#&;)BE:E5$L!:`E:KZ^4`$\%<SQ!M*4;S<8*)IY:6*#X5!)D$0_K\
M\#M@!#),7D:F3[5UW(<63A\4=#^(>@E8IP%341J.>#&*@`"!4@EK9SFA.CF=
MS?,[F^9W-\QJP18NB)D$EUJX;PM9'E+XF=S?,[F^9W-\SN;YG<WS*N!`][[3
M44-%9S=-)QKPGC_"!4Q<+<>*<<\PS$"4%LT/',N9$'N;YG<WS.YOF=S?,>I3
M3H,UWF>):MO-D7H+WBP1%3N;YG<WS.YOF9GO5Z6V%L+G4.>DW'0V3L((YR6W
M+Z#4]E*JS:=S?,[F^9W-\SN;YG<WS.YOF.?7*U]-'XMZ^):UK6X+,/0@HYC1
M&)U'JSJ/5G4>K.H]6=1ZLZCU9U'JSJ/5G4>K.H]6=1ZLZCU9U'JSJ/5G4>K.
MH]6=1ZLZCU9U'JSJ/5G4>K.H]6:A?.>9X6O9;C6N/H;LP.2-:Y$<EE*55*9,
MB6B8,SS(#5FYQ40H52&VJO4VS"K(8P%'0*+@H``:M;!:O"7.U@H10X+::TW@
MV(".!XF;U%&A@IH(?&J$"#0%318904P0:84'D/`5*E>.,23"JD1(E!:&R)V4
MT3Q!"4J5*E2MWEO=H+!-2ZYS8$F\9I@ZS3IQ0K4J^NL!X45!Q$D<BYL!U*A6
M!PO`5*E2M$+AB'.N<*C2P&*$?1^?`/UY\!4J5Z>;XS8`\F/4$<*=W`9%;+6K
MU(K7"%\./=<52WQE2I4J5*TZ>8.0W(#:BV!X52I4J57#'4<PF`MBM5;9U9W5
MG=6=U9W5G5@ZFF9UK(7T<9U9W5G=6=U9W5G)\=`X37R>9U9W5G=6=U9W5G)M
M7^"'J,G5G=6=U9W5G:E]]GA->QF=2K2/C"J/".ZZE'XY+`\0@NBC-6$<$82@
M-%(%0B;-0=U5J%]$WW1("H=[O"H4G@6K^DP&AJ@?'0!-)#4\(X:M.%E'K0X-
MYVMKI)N,3#>VG&>MS#(^`K]<"5D67A88RJSRUO#42])@K7@993*8%JK>UH)6
M7D/Q\T&`%P0+27;=!USD<7QHQ4U"+\,ZAR#CQ2)$B1(XI^I*]";>:;5^VW-S
M/"U[.'N0&""52'4A&TL3X]+AU0RK.:Q\H\GZKZKF'UQT('J`*/I#########
M48-GVQ"<Z4FIMF#OOAQ(16"^.+C#####.<5I>#FD#4\:.5.EKCKH:#'GF`F`
M``"@"@!X1AAAB"AN`%%,F1K5%H*9G!1!<]$!A@^J,,,,,,,,,,,,&O\`63.S
MT2BFB^+%BQ8L0GP[X&DD`%`5-T^$W3X3=/A-T^$W3X1`4,.35?-&Z?";I\)N
MGPFZ?";I\(Z#P'X"'FS-T^$W3X3=/A-T^$W3X1PK"M.8O]INGPFZ?";I\)NG
MPF]X/E_*M>VV\N7V\R,H_P`#]^%KVHD@H,5F'%EJ"X`/8((`NP3%@+5$@$KM
M`C:P\":MB?W5)<>*@*V@A(8,$-G#]9B-P=H_P=X5D5@VY0:U#.GP@T!P-]YH
M6:)7*7K'^);;RY?;S(RC_`_?A:]C;!.N'V@/CTSF+V<8B"KXK&9+#27`N*H:
M\@847L[\%P12C*^"=='I2]Q,<$!))7JY`+<:8\!%P=7EW%/R!9O2-"8@:;!]
M#A.QOF=C?,[&^9V-\SL;YG8WS.QOF=C?,[&^9V-\SL;YG8WS.QOF=C?,[&^9
MV-\SL;YG8WS.QOF=C?,[&^9V-\SL;YG8WS.QOF=C?,[&^9V-\SL;YG8WS.QO
MF=C?,[&^9V-\Q]2=(E9S/66<SUEG,]99S/66<SUFD'G'*;.9ZRSF>LLYGK+.
M9ZRSF>LT"\XC9S/66<SUEG,]99S/66<SUFD'G$+.9ZRSF>LLYGK+.9ZRSF>L
MU"?D<DLYGK+.9ZRSF>LLYGK$:AHX]?"U[`=4DU5[=>,)30S/B<4M"P04N6$Q
MB0D(>CA=+.D4$IUHNWE=#3P"!5OY\T!*W+0ALQ9P%P2@2*WJ$75/5YVTW>MY
ML!KI]JBRLNHIS<JBL5N4N9!*MV#XB`OI2S\)<!%3/Y=,)N5LR@(PGQ"62:2G
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M%P-(N!&CK(`7$GQ8,&#!@P(H2&TW6"$#PTT-'T\&#!@P8,&#!@P4$,P'FLVN
M`\V%6@)*E;$SYL-[N,5$!(`*,%:B&E!RFM%JUF<_A\%&K]3!@P8,&#!@P8,`
MSPE61Z8+`HK`\-JU:M6L`ZEXR%5KIS?BM6K5JUH9+X:&4SXMJU:M6GG&#3T.
MLV6N65UM9H,YH6B5_P"LZ_\`6=?^LTG&ZC[A*_\`6=?^LZ_]9U_ZS'_5N<\-
MKV/VTI=-@&$YI<@9XD&Y#\,4NTFA9`)3D@M,*:8X6BTNK,,*16DSQR7]8>7N
MZC6,^LH'-E-^P3XB7$&"_+[,R7J^TA^K-2>D677A-CI;D<CJO*JN0BP+6"H1
MJ:3U9H'3`3)3<P+6R7V&3C=X4Z/)[`S8X2Q*P:N68^^AN`*^IF4I/3L*A3%E
MB,%$9<3Q@'*)3"BNP>"@\86J"6'=NA]C/]1\%MK"3^)Q'#8%:%:0>MK3@-I:
M'2#+>^"M1']</E5>TT&<T6)2<-(AWA?:K*J>4!=VB-OTDQS04-%0&BZ-\QG.
M'G7+-::5XUBGKD:B`SFQ1D9L^J,,A^3Z6K5JU:M6K5J"4#"J1-`#0ZC?V?<W
M,\+7L%M,[EN<39P,P0C4IH>ID<B;BP/S.\\(N"`-RJZ-JT[#XID)0>D-&+K"
M%XZEH?D0N^4O=*<4-+NJZ\!\^?$LA:EI10;(9H;#^;1P*!P2@KF8)K%)%]>$
MV.RGA/GSY\^KD"A$=8<"L"VD0'J@,S9"PRHPQ;H#EL54`1$J-B`LLC,#TT13
M[,^?/GSY\^?/GSY\^?/GSY]!K'C?Z<=Z(WHC>B-Z(WHC3QLV8NF=<W(C<B-R
M(J85-*P_+P,\,[Q*FE32II4TJ:5P>G9X\4J:5-*FE32IHG!3U+W2II4TJ:5-
M!WM!X;7M7J/P,D+=+HY("PP-)<U0($5.A7&6".$F>B-5VAMH^4^`(Q4BXEIE
M!*3;MT7["UB-$08UG%D@T288I>WPM-CC1*(LQ6^*QJE/+8F0/AJL>/;KP%Y!
M(F0BA4FI5G`-?%(25\LAC%.Z%HXH]'_5D/+-X==AS]RB!4(<$;RV]0_<66,\
M00*U+AVLP,CQOP,<(V(VC"P*`6[SLA[L[VH'P&GV4VM%/:RE4,Q:Q;HWL%FB
M;`^;65+FA@TQTA1'BP[KQ;4-6:CAN)X1`@0($81YI&<7A%UBT?;VYN9X6O97
M#4`87$.Z?B=T_$S:27(1DZQ#0:!.Z?B=T_$[I^)W3\3NGXG=/Q.Z?B=T_$[I
M^)41Q'M[2HIHLRB[K`-AAHMTXI7,[I^)W3\3NGXG=/Q.Z?B=T_$[I^)0"K(.
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M.X%.F$0%C(!UXIN8J5R8OII)!;%4V`[]D?F&FF*T_P``T=C6,=-2@;M%;:D-
M)LSB'D$XRMTYHXIP@X#DMF)K9Z8_P$X]L]#3#6).60X33CQC>\<S-9,U@N6!
MZA5F-E8XA19%$8BTFE-]>7<'NO#R2''NPU++^(\!B:]MW``Z)F<`;D->2W$Q
M,&3C@YI')K/=$!(GX%76I@_99K+T@/E)B:D=>%6PAK0-=<&97JPCT+,.8BM+
M;62?X"'&$)A/>JI6XKEZCK=:"&Y45B3@I54II;80[P`LL6]]EA`+[<IP[3"(
MXK0YW7&NYB3L`RCY0F$A#2K'SNX'6L7"_BVG=UEP"5VOVI\SHBV.T'8';:8B
M$TCI("RZ32Y?,A3#A?RZ05V]-Q'%A]A"G_5IL(H&UZM_RD>F*M$0GACJXY.W
M`T$35E'>RF&!DX2F.?PZY]\LH6)S7LOAG5BU`"`U8(,VNB$$08$`ZL'@72EZ
MD:05L>'A6$>B`3\Q,!LYQ=N;CRC"N3F6)1V5F=J;A.8_XT`@1J8.-8@R/Y/1
M`WW-J60H#ETXJ%,Z6@-?:[A>3.XJ_J7!ZQ]^HID$7OS(-^EO6KB9::6M#4-`
MGG2AF)\+0=A<H5F__@EY=[P8HI8O%,<RMC&%(C!GGP=5'8Q<:B:@K+2(_F41
MT&J-.QZ(/2="KW*TQ,@@<86W?JH85)SE-[XX2%<$G4!Z"1GE*<;RW>ZG!6^A
M:B2&A`AM])ZZ<,2`Z"[20F4B#+]F%"_<JTZ%,)J:W[..8-3H\1MXZ@B[1ZP8
MS;0C;/(<P_U@[''H"".^<@(N9E&7FF%J8`@VS=%]I[*0U*QL%QC9VD_.>`:8
MH[<;5"D1$!N1QO8>(2^AS8/'(J-=L\)4PBHM5@H*OJN'`,(38Y:GEX@8@7-P
MS(!\FJP&37=:Q_&@@*UG+G@"!Q0Q"EG=D5"(E\W>1A(Z,)"VXFB=6]*PP$Y&
MFN3^9;6Z'A,(XV*4XFMUDX*4?.B2)_C6!J72&-2-09$ZC#07^B_&EKR%)N4!
M-Z@="7A7A7A7A7A"14(8:``6/`!+PKPO90JX(C)+PKPKPKPKPKPKPD0?5AF]
M\*$7,O"O"O"O"O"O"O"O"O"O"O"O"O"O"O"O"O"O"O"O"O"O"O"O"O"O"O"O
M"O"O"O"O"O"O"O"O"O"O"O"O"O"O"O"O"O"O"O"O"O"O"O"O"O"[Q)@*6XA@
MHU32T!YRLF-U7GL_[E3<Q-S$W,3<Q-S$W,3<Q-S$W,3<Q-S$W,3<Q-S$W,3<
MQ-S$W,3<Q-S$W,3<Q-S$W,3<Q-S$W,3<Q-S$W,3<Q-S$W,3<Q-S$W,3<Q-S$
MW,3<Q-S$W,3<Q-S$W,3<Q-S$W,3<Q-S$W,3<Q-S$W,3<Q-S$W,3<Q-S$W,3<
MQ-S$W,3<Q-S$W,3<Q-S$W,3<Q-S$W,3_`)%;/__:``@!`@,!/R&5_2S^E\?Z
M9Q_IG'^F<=H63AE'XE2GXE,_PI]_QVVRV6UELMUEO\*??\?XU>Q&HUK8T8[:
MCMJ.VH[:CMJ.VH[:CMJ.VH[:CMJ.VH[:CMJ.VH[:CMJ.VH[:CMJ.VH[:A^.U
MT'F`->6>C#*VRSR?'Q^XTRPU`?M"FEQUI+]%G1>K.B]6=%ZLZ+U9T7JSIO5G
M1>K.B]6=%ZLZ+U9T7JSIO5G1>K.B]6=%ZLZ+U9T7JSIO5G1>K.B]6=%ZLZ+U
M99"UEYSSKZ'':L%ZV47J\5I,.0)E8\>9ST'6RHILQK86&Z"N'JF,9\Z]86B#
MD9A36$ND%Q=QUS5`RYMK7,408X-L@E7P!U7'NF#B,HX%ETI,:)AL>.Y$0/"Q
MZ'&\>)NL89;K=0QQ^(R$K#6Q"@#NN?/PZ>Y#9O&<W14)Z/B>?7$:+P/LP=\K
M:J5X)]F::::::::::::::::::XOO#CRM=/+.<Z5GZ?';3U&FR^9H^<MMT>,'
MH<.'+A-*Q4XP476N*,W5%9%%:<=`M2A+E*X,S7E_55<.P<B&4)N]&N<Z=QS8
MV`X?B*<.&!TQI%JIJ@%\T^@%36:V8'2J[M\>6/%8YDK-W_DMZB]<Q:OLP$=-
MY+G;4[:G;4[:G;4[:G;4[:G;4[:G;4[:G;4[:G;4[:G;4[:BY2UHKZG'^-?J
MBK#47#U";SXIO/BF\^*;SXIO/BF\^*;SXIO/BF\^*;SXIO/BF\^*;SXIO/BF
M\^*;SXH$+Q&-;I@O.F,RL)C;=N)?U>/V71Q>15&K>E>%REJ(-'Y@>&NG#Y>A
MG[46B)UG;R=O)V\G;R=O)V\G;R=O)V\G;R=O)V\G;R=O)V\G;R`-EWD?6X[6
M)%H8UK)Z%LSM!0B4Z"]"FJTIEA7/X@3*",#T(1CJH%S49L*6#1S-(IK%"J*/
M+%G6W7Z2`ITEIEX.-[/,1\U(XD\,_EO.AS5!>]%*2])@:U8A;#89RJO!'.FF
MO_<-W@7ENO5D^31H.(M4ZQ#+B%[%T;PSI,@%-9SPO@.$*H=!R9+]1]/LAB#C
M`P6YJTFZ7O-TO>;I>\W2]YNE[S=+WFZ7O-TO>;I>\W2]YNE[S=+WFZ7O-TO>
M;I>\*-=ZY/V\WU^.U:>:H`O&5QKB550C<JZF6KA>O"#JCO!',+M.I$4X8N`>
M3G#TA<E2\BZYUK77Z(S"5JSB7IZ\(B8=9Z-R89QQ5EQU?#^&V!O^\&9:RT$T
M7)ASQ2S'5DV,%4*44I;!XO-+@>/3B6\.+ZG0JP2G5\UX=5_6G\CQVZM+3H7T
M!8-?@HY.-NBX9>EV1UXMXKIZ-0C!NW"Y9X'>"@:4'/3)QB4D7(+"4O(O+!Y?
M1"(*J%("U8(F'%6B#Z/KFM=_[^/$3TTT*/\`5^>GD0$"/B`&K17J\V9:G9!#
MH];6G35F8"!R1I=ZO2AZB:D."7!8XM,U>;''YX_9&#NYK6`^4ZB>HGJ)ZB>H
MGJ)ZB>HGJ)ZB02ZRU'+/+UQ7/@_9\=N`-[:6K08"ZIPF6''"O)*5[8+,L\EP
M'A'((!"PE33B@:<6%%6&R[%9,,+6@L,"!>*6QR?HNS9?0KS4JKF@!4Y')&D]
M=M5<;'+;^#0M5A"Z=O7SISI>D=0]!:`]44>;@#6@AIH"T#!"C@:35XNO_9O'
M%G5I25UO5ZJ^;]EFHU6J+Y3M&=HSM&=HSM&=HSM&=HSM&"VC15G^?:\=K:NT
MMZ5_KB*K9.HL+6U:=IPTJ9%18UX(#A`MPS!98ZO3*W6P<'F9(L5$W1GIBQ^/
MT0U"XMUL:A9P.+L1-1NW7.<]>O'8)2;CO"[A9?40W4BP;:I52`(XJC:N;==*
M"FBTZ12H41G6@!_`MIYD'.<5*G/R%N:O`UF<4GEHG76-`RC2C5*"R`O0:35Z
MO)+IL/L0(76ST'YFX/Q-P?B;@_$W!^)N#\3<'XFX/Q-P?B;@_$'CT"T/EQ/5
MG@5Q^TX[=,\[4T"KZLT9!+1H#T(]1E,T-`K07N\%@S^Q*3[(4YGEH772(*#`
M=.'^.'DX<RT8->D+1<1L:JH,:-G&]*D.>*&-7$7%436*ZIPC*XX^)V0'&KUL
M-%!VY[:)2JM59+58>7+8B<"6KH$Q-.4O6AQXN5?N2YX*5D>@7A]#++++++(J
M2UK)'Y4AYK4`-1?;<=IVJ.`OA%6:X=+O.DN<$JWO7,?R\5<W4)GHZ\F7'.8-
MX<4ZRP'>=9;L>7%C=YY(!HP;!#*[+RXH-&1<P2<#B<Z>?9D70!JEM%?'@=>5
M<>ZTZ1?)]U?1!1M5V\1T\5YRK+KCDFUG.FRBB"GPW_S9TG4,4,9R*8@['62?
MB!859XBON0E8%JO02M3G]".......@O\5`_VWZ8'^$#I]MQVT0'5NO\`^8=9
M@FL4R#MJ`NCK>FCUN..D5:+%%UQ)9%";2C%D&^'26CIJ62T:JPM!X@3&X"D4
M94:FVGAP@&>W3H>1XJLX7C$6UJR++[E6\#,$1`6"MLJT9-!LX":FN?`WIH3:
MT6-;+A+SPU2Y))H4'#7"S/B-&7BX%:KCA*+G+^UZ<U.8.;Z'+Q"(B-M%6CJ)
MA/PXZ_<\=KB_!HTBA!-$`GE+*,FIPNW>MX/$Y8FB\9(4YAU#RRE6H%#D/JX^
M9@$:9FO^R4MS0&6\6K]LOH`6I]`'&0CBU>D#8,*O`!#D!_QB:1@I%M`UQ'#A
MJ9@`4:>"@N=FIK!DT3J6,ND`O+Q8R]0`4T/M<"):LF<\DYSNLNZR[K+NLNZR
M"L&@.`?<\=N;E$:&K3`31XC#C41M@'T*`+<QII,BS^:KK,]FC,\5QEJDE51;
MSTBZ*--;<_26',11A2VU7"S%,("1P(ZA>!ZUKXP3=1=#7J(<R^4$$-Y'I%:(
M9@_*&D'DH4-G!#RXUQ+A7V8`D\1>$Y$Y>+APX<."`KU7[.FHO-/W/':Y)K!R
M/&"!SF4ILOX6KYJSEF#IP5C\\\S`(J!1]*H49LIQ1-N'9HQ-;;\=H9W6WH15
M0'%FZSB(&S6M/J!^1%MMU^S'\P`?W-QO:;C>TW&]IN-[3<;V@`T`^YX_QI]_
MQVEA8@2E_F`?25NI2Y2K@!Q_!GW_`!VW+9;+9;+9;+O7^#/O^.U?0Y7.$G][
ML"B(L@5R:]=1C+JM!30^O4MH6VS>/:5J[!ENFJ<&BO6F9'9J8@G\+WYE:98@
M>2@(JP&D%A>KRBHYCZ#=8UG&"5YAGI@M1PIAQ,6N:P7_`+^_NNG-3F#F^AR^
MT$1$1$1$1$1$1%L3N1A_U'/-\ATB`#1^EQVM-4@!'S'$Q`"M07!.'#+6:CL5
MG2T--/8:1I*/0.K1C&<XXY@P#"JX5"*QP`Y"FC`@*#8<7&=.AZ'T@JHBF,5K
M2[RXUIC[O`"6K)G/).<[I+NDNZ2[I+NDNZ2[I+NDNZ2[I+NDNZ2[I+NDNZ2[
MI+NDNZ2[I((=['*GG2IY<G.OT^.U@;,&I0=.DJ*70H!.-:E@&1MPS+"0SJVK
M6(T%&68?:SF<SUW(.%E2BQ/$)Q$RH<*%J]7T4,O)J:#7BE"::V3D]-.1>/P,
M?>&G`,`M5;4>7TJU:M6K5JU:MI(=3(\J%(>3ET?:<=J!8$47(I*9R8UE@6TV
M64CKN9<C\IJ\?)\13W@4,)?YU\HA9;XC4(X\/6<`_8IL<WE^9P'%J_/L^D0H
MH?R7';6<(@6UD8Y67D%PWI[VPU,%N,#1#B:A9NLH7>@NU1:3C"8=:(.J=5U>
MB$VIQ4'B(!,+Z"BQ"P%S=OC0Y*\)`8138<T4NNAT+6ZC,N*VR@]`JG.3@'BO
M86V*5`1?#&/,Q%&E_#3*\=,^*CC/WI%F>8!?'!PF3VQ6K#*N1Y8&')9@\*NZ
M:O)I=N2UQ;JPKM!NIHZYU?*GC>)R7P]"C[(IKIE6*M.AONLZ&^ZSH;[K.AON
MLZ&^ZRGA9<PX"\4,+^]7[CCXEU(*MKBZ6\V@/Q]*_HZH7^3X_P!,X_TSC#^E
M\?!4J5*E;*E;*E2I4J5*V5*E2I4J5*E2I4J5*E2I4J5*E2I4J5*E2I4J5*E2
MI4J5*E2I4J5*E2I4J5*E2I4K^G__V@`(`0,#`3\AV7+ERY<N7+ERY<N7+ERY
M<N7+ERY<N7+ERY<N7+ERY<N7+ERY<N7+ERY<N7+ERY<N7+ERY<N7+ERY<N7+
MERY<O^GO]+X1_I?"/]+X1V-&<72Y;\SV2WYEL=?Z)PCLHUE$II*-9324?T3A
M'8Z_Q16$UG@4JL[9W_/?\]_SW_/?\]_SW_/?\]_SW_/?\]_SW_/?\]_SW_/?
M\]_SW_/?\]_SW_(-EIZ4)%\KHZD'*DI.2:^/A'8Z_:HG`EJ\):-'K8?U]3,S
M,S,S,S,J"#M30ZAK/4)O_@F_^";_`.";_P"";_X)O_@F_P#@F_\`@F_^";_X
M)O\`X)O_`()O_@F_^";_`.";_P"";_X)O_@F_P#@F_\`@F_^";_X(S:FF@DY
M69IX\]/#4K9PCL%&=&[:761,RM$!XTHN.5,%HTI6:_.X8`&MNRIO`@YN+J\=
M8X3#`U+P#4)MLDZG3@(TT>A5NN1)7&C=5SII&N;!V+;#2`\6J("SR8>6$#,]
MXE'XE9\1KG2');FZ3]`72FD!J_"8N3].E-]:6G,:9@%X?DD*I2Y7FM,W3M:%
M($4Y*?IULKQ7H1%;LK9'&7V8HHHHHHHHHHHHHHHHHN6K2HOK=*_`O#6\?3X1
MV(MEBFFK'4>CQ(#5SC-Q97R'569J9^VB*U:BU7%78<`KKN:P66D,%G4F+F7Y
MLN/')[C$E)*KI85KI1?`2E:[SFS9QXY.>6L+:=A$/(7'T`E2WS;H<],.'BOZ
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M6*L%@_Z?,$>5!D(LH4<=:O1PNM)G;LR"(H;JM'A)SL5+WUF#RLMI_P`R567?
M4:=P##_"W5,PN&74]'!:51J5APYF,XQC'&N;QB@1L3GAKT3U^ICQ,'S`YJ<M
MZUQUG2WG2=+>=)TMYTG2WG2=+>=)TMYTG2WG2=+>=)TMYTG2WG2=+>=)TMYT
MG2WG2=+>=)TMYTC8+^?S.OZ?@^OPCL"Z1A4HMH"M`OE`T<A1KZ&.7(NN,%ZT
MB!K0H2]',$)A1FY`K)U,2D#P!_(JKZ:_1L%AM,3K!NKQ?.M+\)KORC?_`*XE
M"W6U+'-DQR:<Z:8:Z2HL6MO(I3HZ2EH)U>`#CP/2ZMU!\@\@_0?R/".S1>V]
M>B\V(JKAPJ,E8"Q0>*E,!41S`2<@DW*KQJ4J[+47;FG"M8%Q4<8?0-G2U?#U
ME?0?6044@M`U11T^9@.4!7*L>)#CLLV?X/QUC9`G`5X*<UH<IKBNH434YJTL
MU=,1K/>@UJM#K1.B.D0L#)29H<7YGZ^R>$U`7DTQGDSN".X([@CN".X([@CN
M".X([@CN"'I.JC\C!^A=,GV?".S-O&0M8LH-!<L/M<Z)5K(,7-+DPN8OF29C
MAU%`W3-8KFA**-L$)V%BK"6$#2RI<'`;QD^B06/R-/\`BGK`^8A/)TVMBMV^
M1:N+1EJZ-=3;T`^,:U#Y+5"P?(6WR<2Z6\55B)9S=@V\6:'"WF-PX$Z2[%&E
M<.@'E]E@4MTJT<<>?TD$$$$$$$$'>NP$?1^UX1V%<`16OZ;+Z0DZ7,:6:C3,
M+,];F,BJ<R!6^2L%L16YAP@`-#`VY###TL/ZN9F[\OH[D1XXID&A@JXGI"@@
M$.&FR]@$TZ--T]'C`9<0YQ`Y@:,@TW>RCKV6M;:U9K#@W06/-3ZFLG)CU(J[
M!P/,T8&LI>)PY.>IY>.C,"6"78`^(%<6HX='F-64OT;ERY>RY>Q"]HTNU7%,
M8?I#########5;5\@KG?!T6N+;5?:<([.,#@4O;H7136W&+H!,:IL2KPDNZI
M<7J,0-V*'!T*RBM(>,^9:6FI!Y[;&'%GJ(G,R8E)&`U"!<.E"6-QNI<R]:]C
MP,@HZ#,1BU>A"S6%P+>%7X@:;.!PL&3K?J5I#M5!SKG.=@)J*5@@J=89_1'/
MI4^EF9\.?H:JVIH"K;8XG'Z&^^^^^^ZY-%X1CDA7H"O"!&`?;<([%S25[YON
MG]JJQK*?'2459:@=)F^%7$3;C@X\R^$:963-FDN'IEJA5%S9,JKB9B!>?9"%
MC@"VSMPP,+:`PO&+:6)5G00_*LE*4RI>H"\+-8YNM[QDE"A=4<;9?"00NEZS
M\BPT?VA29;#-T9'DF1@4?RA0)1:U:*)=R^EF9F9G;F9F?&Q%AUYBKOH:5QG3
MQZ>/3QZ>/3QZ>/3Q2PM,*T'J4ORL\YEX<=7?3[;A'9:70G6S?5(])KKK.$"N
M)'`NJUJS8=<"7<R-4<CC=]89MDY11J<X*D#:IT_5(LG!*#UU"B6%BR4LU37!
M`/ZC;5EXRL*+9K.8%H-RW!88.5RHFUJZ`5@'P<J590+CAKP5#:X:UG'H+7HS
MJ0NK`IR:R?CQ+N8.0NL:TU@RWPIMLYQKZJ.7(\I3]I?:7I2BJZFM^(1$1K]=
M4:(Y7Y$:U-'[GA'92QF,@B(".HB/1E$A^%#5*M(R'1YYE0KF)V,I>J:'(9:`
M`6ZJ:?+R<,0;=T7-0\P9A_UC">)4!GXB(6KWJ0X-G'%L%UEC\(6&4F7%;#SS
M,V&%:EP7H%UXF&R*JVKX+$4>&H8%.'(OR2NX3Q9K4HKE9!#`05$!HAS#*-5+
M5ZKF"FGVCZ]9J6%&L$X'6=?/U\_7S]?/U\[2F$>*Z_<\(["EHBD#396H&B0?
M!4%U+K*L'1UUF*8T&!>X`740X'@U*`!&!S,U5MK*U10?1`DV%^1HZ+OF2M&6
MHAHM-+K-=/&41<011A.0P;U(Q,CJ7`M/I`):(TVK"N#'/4O@#*[^S2.1F@;$
M&4>?BLV;-FR,.G!^W#D&+'R^YX1V:1,$I,5KY1=52-K*E'6@\@-"9685JZBW
M\,<K!&U;:UYK*E2I4J5*E2HZ=T;1O0.IQLYN`>!*E2I4J5`*JUAQ5L!1=:%X
MH#X$7LOR$\A!0HTE2I4J5*E2I4J5*E2I4J5*E]$*M*KE9-X?>;P^\WA]YO#[
MS>'WB4]MM7C*E2I4J5*E2I4J5*E2I4J5*E2I4K9PC_2^$=C0$$R]7TN+/67J
MY>OQ+X1*6_T+A'91*)1*)1*)1`#3^A<([,2@I5D#ERW(V09H;YQ6E:1A35"[
MI0'-H#0L*I.'67.Q95+L":ER?,1NCP#F4=./D,JW.!C@']@AEV+1:R+BZ?!K
MZ!KG2)/`+9Z3#6[`>>(45-+?JE>*I7BOM#TK15=36_M!$1$1$1$1$1$1#:%C
M_$T#RLJ]4UB-I&OI<([!BRPB'DF2-*VQ%J$\S8TF<'3>!SJZZ\?_`$@10*LU
M*PMEU.&-(FKVUWEHLSFT.8+D(LG=*7(F</)E]7G](/'9GS=H/*L.'W;Z]9J6
M%&L$X'6=3'U,?4Q]3'U,?4Q]3'U,?4Q]3'U,?4Q]3'U,?4Q]3'U,?4Q]3&SR
M5`M'*P:>.<F''T^$=E<A)1&V:XU#\P%J*0R6-`*5Q04DR[)L$I0RG5V\*8+(
M`.5*T)+7C08('/,Z5/&[Q)H&/T59C5J9OJX64']$MPR7S-:_G[;&W&T>*H)"
MZ31.?TH<.'#APX<.&7T/E-U6T]["OM7".PHA>B6+!M+8PYTZP2T'82NZ&LS_
M`&14_P!X"O$_4@5DN_\`BWU@!@T\3U$,QE'`R9\I=LLP46:?R7".R[,X4!H5
MO&@.:A$NJUP@-H!I[:0+2:3,8()I0IM5=M6)3Z&,&)-\"9E4-6(H9)D*\E14
M<JJ]1*L,20J%7&XIC)%`997(4H0+4,F(PA4HE6-LXZ<D*R:A7ATS5:LVX&N+
MJX-,P+'H&=<8SXE>SR!12OQG]\8JWW0T>K\O4UNX#S#G7#5Y^F`Z8B&E'&F7
M"<)_S]DI(J8V6I_.LW>]IN][3=[VF[WM-WO:7%?'DO`<$R'ZT/N.$=E2B40X
M(!1;=%K1R+5KFLHE$HE$HE$HE$HE$J42B42B42B40+242B42B42B42B42B42
MB42B42B42B42B42B42B42B42B42B42B42B42B42B42B42B42B42B42B5LX1_
MI?"/]+X1_I?#_P`9_]H`#`,!``(1`Q$``!"`222222222222222222222222
M22222222222!B`````````````````````````````````````2```````22
M0````"0`````````````````````*!`1`(`""`"````"```````````"0"00
M0`````:``03```000````20`````")))));;9;9)+))8:!2D$```0(8`"0``
M2`2""`"=]?'NW'JU'^VMLT:"%A@```(8(``0`````0``"&FW6DW$TU$FVVVT
M:`))))))))))))))))"1;05[;9;;9;;9;;4K/0:`;;;;;;;;;;7[;+;;""02
M3I)+))+)))))!-[X:!@\"\5[8U;;-7;+(;44';:222222222?;;;;(:#K=*Y
M;;;+;;,C;4T;4`0DE[;9[;9[;9K_`/\`_P#\:`;;;;;;;;;;;;;;;;$9';9D
MDDDDDDDL;;;;;(:"DDDDDDDT@D[DF`2`DDDDDMMLMMLMMM[;8[;$:!H<CW;;
M9L+9BU8Y+#517;8[;;;;;;9[;;;;;(:!^$4TDDA0PFNKD-MPDVFVGMMMMM]M
MMMMMMMML:"[6REE[4;;80\Y:)#5#')")))))!;;;;;;;;(:#5*60"DS$\ED?
M$=OPR02`')))I+;[;9[;8[;$:!N>@UG[3YO:-K[*JC$``H;R2222[;;;;;;;
M;(:`\E`\DDZGDDDDFR0DR$DDFI))*)MMMMMMMMML:#3`&DDD[$LDDDDP"$Q`
MDDG))+*=+I)+I)+))$:#P!LBY)>))+*M)*U)1%))*[;9))+))+))+))(:#05
M]=,DM$DE$LDFTDVTDDE223MMMMMMMMMMML:`S3;;;;0[;;37;:G;37;;;I)+
M[;;;;;;;;;;(:"]RVVVVE6VVO*VW:VVVVVTMMO-MOMMMMMMMML:`````````
M````````````"6VW6VW6VU6VVVVT:#6K3(````````````````"6VW6VW6VU
M6VVVVT:!8"F(````````````````#$DEDDEDDGDDDDDL:!B^ZG;;9A[;;;;%
M([&I6*XI))))))))+C;;;(:#"WV0$DD\DDDDDR2$DDDDE$DDDDDDDFE_8[;$
M:!AG"AD?3[;;;;;%:['%$XZ))))(;;;;;;;;;(:!$@G(DDY$DEZLDDDDDDDD
MG[;;I)+I)+I)+))$:`7QS';;:[;9.R;8W;77;;:221;;;;;;;;;;;(:!?S__
M`/\`^5__`/\`_P#_`/\`_P#_`/\`_P#_`/\`_P#_`/\`_P#_`/\`_P#_`/\`
MZ&@&DD$DD@DD4@D`@DB4D$D@@DP````````````&@&@`D0@D""``````````
M`````````````````&@6@`B"`$DD$`D@&``````````````````````"\MMM
MMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMOD)))))))))))))))))))))))))
M)))))))))))D_]H`"`$!`P$_$`A`57@$O7"FR^E,OPN-_P#"R[=NW;MV[=NW
M;MV[=NW;MV[=NW;MV[=NW;MV[=NW;MV_@NW;MV[=NW;MV[=NW;MV[=NW;MV[
M=NW;MV[=NW;MV&=[_,*2?8-W93`XTUCY"$.+"?P$M=6L'(C9D"$'*5R`76^6
MI3*K_24_TLF&>8$`1(\EY,"KRP_8.PXQ6#1R4'4TD-KQ<@N@JP:%,Q#`R;&6
M=8H1,C<SWDL@6%5(]N!5M*%&T^E@=$0;JP2QVT/P-A$VW'U5J?Q[8]K][D<.
MHQ55B=K]@G/S3Z(QB:`>)=;HW][,DB6DKF<-89`6=ZCD'ILV8(92A.E6_.2N
MF&B\5CGX.:5)BQAD#)&@"P!\)`1A\I@A7!FB`/$&H42[']TQV#=H-1%0QJJ7
M2^M>5@BS4S4`PC#`V<0E)I-SQD(`0S8<A<%L/TC6)RR?)'M*%<NF!2ZX^7B*
M3:&_.HM=O?;HI1HE8);=292U+DZC35V%-Z#`9D6?K9I0DIDZ/P@\VIG(L+H>
M0[7\L1L'D`7N<UX$X%2L"#X;#C8U7ZJ&6K%=_'U+C93Q)#O?5F`2#X_86=?U
M'S:)D*=Q[?\`)S7:+MUD0XS6P6$-(:D08=D:B`Z@NX(#?/"2V`$^`RF.:3BO
MFM\Z8.(J%`K8+&5"96HTS&%`'0<EZ*V=P<"JS'/P[=0R2:5O0YC$-%B(1@%`
MR94($J3$?$I&^&OVIW^>?ZYWM!2'@&F74`%Z->H\<0>*=M$-[0BP$Z">X$TX
M$:7CQ4U:,1B))KMB1PA2YA8(P'5AX4`[@H96(:D&3E_6=JY,VJBGXCV.Q]SQ
MFS1XR@DVS6(AJ/TP/K$!<0'!4=*#TH/2@]*#TH*^,"<1=S085.E!Z4'I03HE
M`&FI)AG",#)[R8@)^Q9Q'5:2'C5'*TN9V;>6`*8F&`P0,B]Q15F>P/$,ZCN,
MX`X[7J*)G&X$"/O)L`)G3G''F0AU?1"HHV32+Y=U4K_3`<?QR=%V6=B.E!Z4
M'I0>E!!/$NT8!33@SI0>E!Z4'I00@+(#G+1X?'L*0/O@\A!D5J*^-R'OPPFO
M(%L;>V,M\_7R:*[/(KJYJV&TT*;-#9\NC,EP5!,K@PY:D!/T:?13BZF*RMGO
M66VPM'T0[-.-E"4M`'B^_:X);8P1*2I#H:ZBNQS9'T;I6"LEJ`4MF61W+"!`
MF>&>M^BGLH/<"(NP5#3L5Q8/5GITD=</&S)!P(H1]$C,0\A.`2O>L:B#;`J5
M4.UG8]8JTD;HJ7'W(H4,+%Q`N.)[*-S2X/A_>9T9`G-!<`_"UXO1(N<#X5@"
M3E97040-O^7%+:6#E#IG1Y$U(T2B"FUWI/4,>.FMR$'/Z(D#&DI3'.+R!E$B
M8?.T8.+(ML17`&J.TI;]BXQ`L&!FC/=$JQ/4MB!;;P*>B^:2V]$N&!;22[6N
M">!"+='M"Q#;X%/<C+6`)DS1+S+Q(3%+GC:NUL`]Y%PE;)&%;AVM["X]J*)'
MFT$A`PJ"Z@K8*0=MD0$>58@'JD,*6#R'P&>V;5%_J0`&DD(,(X=C]#Y9N6)3
M1DBEQ5-RLZ7\G;U`VALQ--0.PLNO\/?O)X>/8P.,;I2*V!`C+*Y_C]":E7`$
M*NZ#T/9=:QQ36.MY_(EZ#H`Q+\DEX[&@KL0`Z9&!!=A*E`)0/I2G#\M;AA:J
MMEH)"XQR>]CPK6Q,M)"12!C-JV9!RK4[X`-2&!"@`$E<XUHD'?$UV2B#@H,0
M=<UKK3+JT_@CZ:BT]I-&*7^AU0NY;[*:^._8KP9C=/0(AX'#<,!V(AV4`;'P
M./P`*$;2@B#F>;9Q'`YG+^\QTPMLE4,6\#A5CK5`GZ$$(7<W1&2<O8%N#,J^
MY;1+5=K-O^7&AI"#W+5B10.&VBI;1OBZ_4!)0I_2*9W"9HP*D8B`.4"6)$;)
MX;\[[VAC>P1?^9@VU6+_`#./1+%6"N_!@*6'=6`,WY=Q7@B=WR1<SX)2P5"=
M=@[VX+QV*0D*E(`UK7,U%*2+O5L/FZ<BUJ%A?9H3TP1P@"&&]]GQ,K^]!`G8
M*99<N"GI.J@"!\69IQ/>9`A@S%$CM095"D:$S;@CIUB*C!4V)+14Y_L`LZ(S
MN0LKPF#%G,J.'E4[2+X4:68@N<#^ZT\:784;9OWD\/'MKN\+R*"+2^?\##AP
MX<.'#APX<.'#APX<.'#APX<.'#APX<.'#AV'#+KA6E3=H!GFD"`1O+<&%5Q4
MIU#=Z/3HI.AR"`O[CAVCXGQJ26N'L5#%)FES38'UG";1M4W7G,D'9TZ=/:P.
M4]QDS>)G1D.!P_JU:`B=OX9-G^DJEI@^'QX\>/%@*HJ&`6K0P%HOR\7CQX\>
M%`%@(%`*J!H%;\7CQX\>%-4H`M*#`=`>'QX\>-"34`FH,ES2L1B$&Q(BM)"(
M%7G/J8/PI)!3/Y]3<J7`2+I(!E"^,I`I/)#!:V8]"@B+;XMDOC%K.2(N+#/N
M>/;<.%;>Y))>$J@0S`M[V;(!5"K1\*?]&VKR#%$C#%D>EDHCQ>LRT,Q(:82(
MCF?%B+''P)6!;W)(+RA%';=.RGWUF^A4!O%G0RTKU)'!MKD-&"^*)%*5-S8!
MT(E>G+:J',PWL*=C7+IB!*:OZP^UQIZS5!S,DFZ4H$L`"H,;PF$S*4%8IH*Z
M"(9K<EIH\4F1!O$ORH!I&#XHT:-&C+G?):K;<HBM*`\-'Q1HT:-&PY:*J*6A
M;<(*9T\4:-&C1F`-'K$5E@-.CDX^&-&C1C74PB-F7R]FA```OK_+>TB0H1H4
M%RK2%,$]G8ISJ&2QO4^.6F[::ZA3S+'X%:Q?"WCVPLFK!>NI(4JR[%+@>%B9
M5)O@LR-+*[WVJ3$RF*:B#YY3],F(H"4D:-129HB%)1NMETM/L:$YI$%?W\P&
M.!C19_WU1?I)!^\&2>E2)FAD%>>`Y#2_B%3R$\IM4>H./-CP$K?TA%OZ4#(X
M75$IBWD?3J45$9N@N28.UVXT6,EM/!5Q$H606E%L'%"83T#3P!&4`=J2@:%5
M155"NU+.&<?F!Y6:J:-PQW'([/$)F;BSYOO^FYG8Y&\-6Z5`0*ILM=X@.9<[
MY$=J;I&4Z0HU^@"&&Z3B&SJ*"`:);M?U3-.N2)5*VSEIB`0$WPP`L:+6XQ8/
M/%TGV4N7+ERY<N7+ERY<N7+ERY9C^$FK:]BI@;'Z^MQ[%@!2B4'I!9R&<>[%
MJ+N!LQE2$X'0Z=[T1#U*V$#[2SC9F1@L`LI`V9`I7<LU*D2AMWW9CPQ$VD(P
M1P=>K=0!H4F?<=?0XYZDNNK<NT\%B34^".DR@VKA*,X_PD>,'PB0@`I0V\-+
MM:>A4V^(SWA5#PY]E;;`JS(;%L+^!=+^OU4(2)25LZFL=PA'N!8\`][8_H]O
M$4YC:TYN+_+/BX=Q74-EJR9)$EW+HLJT[!K^%K.U%_>(`&2V^RR`,\F;TQJB
M2KPJ6`_>C&16@*19<"`88+(3!Z,.B)8%<7OL4654,/PO'CQX-K(71Q'<7$:/
MB<.'#APG=L%Y=&)HLYI\3APX<.,LI6.FHUI9&N$\3APX<.$@SK"PH-K-64]8
MYI=$]>W/R&'AJU:M5UA:RBL'#32_#5JU:H%OK"7/*_AO'MO5Y**:(SH0+2Z$
M+P($B9TS5,?5L9.,I\C9=T.MXD1>!1K/V)[5TT8I;X4*4([_`$YK54ZD5=*_
ML%"A0H4*%"A0H4*%"A0HP$!G-J4JOT%$RU@QHJFJ@5<0#Z];CV;5L<IC1X*.
MBEKA?UR!`@0($"!`@0($"!#\XD\J%H962(FPA3>0A\'Q110.T@0;\40(:>R\
ML6!"J>`ZLMY$PL2@P&!"`EB)5$\!`@0M?=Z39NJ+8K`L>?26&']Z(&@02]Y"
MP7%`)\8UX2P0[28_KH/6JOL_%P>$"#1AN:/?]MLDY%'Z9`@0($"!`@0(.E`8
M$I(08-""SXA0H4*%-P(T4(#(6VLV457&_$*%"A0I(:$*414`-ZH&Z,M=?"*%
M"A1>Y-ZK&U-$;(*J"QL404,[!Q?&=KQVO':\=KQVO`E.`%"<9QBSUG:\=KQV
MO':\8"KA*'AG'L3`,0@#HXY3D(BBY3S56+7'Q!"STC]PM<30J[R>+JPDRSG9
M%:0F98(`@PE*WK&.9.I1Q^A@4P7%3->@@-EXT30PPR#BI?0H8:Z-A38`L(RG
MHN-56O<5@(622!+&ZNDBX1%N,I#IP2/4?8O37A>/]IJ$@^;M*Y.0L*(;XR=8
MF5:P5IB[?SRC"LOC24C8-D6X7W:6*'26/:`"UT&2E,)IBVD$D7`:"RT@`)B2
MR3;!$-2^X@A"&.X[KEU8$MK$>@$*ZF+;EXG=ZDDP!IZ'J;UGULN<+UUL@05`
MU&E9B37!?JD_A<CHV$%E7;F[SAI%2`*]$$W00&:QV&->+]W85CPRZB#0$F*R
M5P';["E2I4J5*E2I4J5*E2I0>*CY#8_(5,<2^RUN/;_;[07]*_2!"<"R-F!7
MIA6$CCP12RU`34**J8ZF5W7`Q0XA^25[>$(`4`-I&:#*-2.["T2BR\Q881JQ
M7ZI8TGPWKUZ]>H.6A7L7(E>@82NW)]$^V::0;(H6VE"A4/&NNI#+PE\!:U9(
MUT\S#MO7JOV"!@'T82PVY`13\HS`DHR>TO,VZN%"W:QHG.*^,*2_50]RP5.G
MB2;";"R[-J\7]@W).,MV`,""Y9[%3]05MP8Y<%"JTJB<XA5P`.$I$(D+LRXD
M24RY:**QAO,>8*JU$@;(=Y-AJLL?$@P4`6TV7N%J@TE_)R95X2=<#GIE'"P&
M6;MC<>LG`K,%<4'$7JZQ,)%0EJ9!D->H::'1(JDM3`LDIU!;8Z#LO$@BVF%'
M`DKXV^7B_P#_`/\`_6D&6TC,-)5&U5V8*SX/_P#_`/1U#S&7"D#9O`B2$J(M
MDN\T>&;-FS9JJJJ'+4R$K3H9HXNOBFS9LV:I:0H'8S8-ST/#-FS9N$V;I#P\
M>SILT#-6&#(`(+*=\%&34X#EQ%9$C4$D`V%@#%P,B,16EJ4D^3CM5;'G-%P6
M4H!72&RS.$@*'6OG#\*X4Q+Q*$!E".&*LCF@$R"Q_P"Y=<((/K.?!<N)B#(`
M=5Q31-<GM/)VLA\D4FQC-&1$Z8]))0&_A.>FO"\_Y9<31L;N`QVE@<;6A)[S
MS#FE1A@42-==43Y.V@V&MW]"39W)01-%$.7+D(WTV:8-=@/(*I*#<@,\N1#]
M=A3QS7B#M]%)2)/D@=5A/D91,E-'*V!Z"LSLROXAZ27?!":V2:.+`#]92-I)
M`3"PQ&HAR?.'"9]XR9C88-2(V`6JR-OVF$]X`.YRQ>'`A.BO:0Z$>5';#3E`
MNGD@BR,BXEL31#]5[!C!Q/&M'E+V"46N#8+#QA"@(`FJ!"GTGSY\^?/GSY\^
M1&-QYUA8/6SFU;11>"[HY7B_MJW'MT^%DG&N,0*`%&Z%54H,HRCA`"R`1&&;
M5AK\($J$QA&":3[>+6;ZBS=L_4E4([49=J1W8TB$!2H*:Z`%:'((L%.E"WZ0
M0)IP![5@NWZR"X%K/G3KFPI+$4BNMNXL_P!&C1(0-BE2).SU1A4$W%1UU[4T
M,<$`7/[8I4B$Z"3%P(%;MPBE2!G%'$6!3F*.Q<9E_>"XD0RK6;+EM[N6V0=:
M!.9D,_$R$C!(-.@F3BGY0!7!B*0I=*9C;=L@A+4J=<00)F9KM*+0'7Y$;2QF
MX'9KX4-$KJXJH8$R)3A5EZK.UA4./C[*06ZD38I7M3;UM;%NLWF"E&S3Z=X&
M081.YQ4XWZ[QDHLL4F:UHBQP3P?%'>#(8W9BV649$$X1@O&Y7*M!).I>S%F8
M1_2%;AKH1KLX`LLU75[%*CQGE.BP(R'R\1DR9,F5Z&I)X(%G30H-7P&3)DK:
MM"W5@"U20"5L5JAQB(LO8NRP:P&`\2M6K5JUU5(*R*`M;YCPOQ*U:M6K64M<
M@,5BUGS\*M6K5IPO%+3PWCV:ZWFO^6)8Z(4$F^XA+LD.Y@)1<N4?X7J+@@4O
M,?+@GGQEJK`>Z61P7>V-<&@!WZF3_$>8B9*F8N@N*.71-#H;4=[8HB/ECS42
M6'9QK5Q3+%Q"5_-H3XHZZVK)\C9:@D&WCGN_\F3FU`!KHM*CHYV83XR]W4M`
M=SX[P2R#[LROSMB`G/G74X=<V0<V$=J[CJMZDHGSN`MKRQ>8`M!XZFZ-03`2
MR*$^?C;CB08]#J>E:.WX![`=&!WSZ.)P^BW/%'<W/8S1P`OLIL%/[\$"8P`D
M4HQ*(J]Q8="2Q+EY4Q>2*Z$^7N/3Z'RH&;``<3R^&68<_D)$287##4E:&6LP
MU@,Q%,2203*#=#F70HFX`[O&I`:I`CI>)*DPZQ*K47!%*3V^W^$V8T8"92$.
MX!L[UI1(74)4R6%W0ZL#0N>D17DF@T`_2;-FS9LV;-FQ7=(?[E6$O:_<4ZW'
ML;L\!?#$L#5R:$V(4Q&XORD2!:O0L0:10P<`R#$9N44N;[A+I"AN>KC.J))1
MO(!`8:/B+BH*HI&++).MJ$`";@`LC'FN0%1"V4_$>>>>>LDK*'O2LSE0OQ)9
MC%M(6M[$/7.J8J3X(&@(M--5-`-+T8^C)GGGGGGGG@W5`Q5ZNI'"10!BUF]%
M+\WJ?.9E2>2+,@4L:FE(-S</80!.BY9H&3R&VGH#SU+14+?"U6M("E(KQ.MR
MEF)I[5&-U?VMULZ6!?'>>>>>>%.AERH$;F_&`I?AX\>/'BJVQ!IN9>;=-G$@
MP.IJDS;2ABE=YQL8D/$$")C:::L5@(Z(IF+N37Q&FFFFT#90,."@QPAXC333
M345A5;3H48":'A----4/'X6O'M0M>$53?VZ+'*,DGC2TY6E\@P!3OQS1?(@`
M@"1GJT%`O@W*K;#>AW3#.=G5"8WH%2A'&$$C@MZ!\5(6!^232*'R\&.\52:1
MHT:-&N(A:/+Y9J'0-I\XFO\`/BL>RT&C:WE7;"HL&$0I/^N1:/N/RQ:[Z(T:
M-&C1HT:-R;\+E!FM`DDCN$(EA(_7B!%F[I3<G'91"MS'O,"J\H+$$Q+;8-&U
MW[<EOCN4<J:NHW.+6%IX`[9"#U(5'GG@+QJ`-&C1HT:U3D/'>FU'C!\1-FS9
MLU`,4"6E*#BM%\KV31A!J66&BI@@+#\P#U2U06"`JNU(D1(`5:(!)34"&.)X
MDB1(D2-3*`+.PM%YB./$D2)$B11"-0*7G(WT\*1(D2"5\,DX]@#]BQY3U3Q+
M!:8*\SZ%;6-#*T^S"=%6;@T$E$;/CP#5A*)NPN!YUC1/9#4C`7AJPH63,,+>
MD=!;AP7M>"MBRK@BY$X:&#6HHI-Q.@@Z.)?\"LQ(N`!4@<@!PE^&M6K9>2SU
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MN2&%#:2=RS3@19\=^0SXUI935+J<YUG:7H(*`7SGTD&M-`'@\^?*^&X2G\]+
MC1Y)<>KN_E1R\4T)Y\^?/D]/FX;R=T]F]A<GI@OFQ@"04U.O>5`R2I*2'2V\
MX-E0G#!\(\^?/D)B=`6F_P`+1&YS*XN'H,62Q=@@;?/GSIMKA4*<!=BJO!]I
MA74BNJ%)M@-SPUX)H*2\<!?%Y\^?/GR<4G<A='2G2>(JQ8L6+$?BYS^>XMA?
M;PW+ERY<7*DK00$KA+P`*9T1\5RY<N7*87L&BBP4A1R.1P^*Y<N7+BY,E<U%
MX4:\'PW+ERY_H9/Q%O#Q[909'Q>2U)!LA*LT%8*G(KJ!`U14.I$B1:0+-`:N
M=%7"2O&OIO4UW]QK>]>97#'-/D3S&F>`>(#>BL;'::!T$"O8V@>:NL2TJ+<Z
M0N-Y=!4$O#+%SCZ`S)#8U$I!"S+&?27\.O`.-2J.RO\`U?`DK"5::UH8%,3P
M:E!16[E2\5\<IJ-=)2'1FA4VVIX=6K5JU-4S43;=S(&SE"?>=;CV(!I97$C5
MB@=2#++,"AK'DEA.!@R-086[43\$7@0]4'HA@/@8`G<H=RAW*'<H=RAW*'<H
M=RAW*`H-UP<F%3+IMR^I0$G47F1N/<H=RAW*'<H=RAW*!7/E90ZV#04M#-Y<
M,@`"'+ZZ0`0/[$0D'```!.Y0[E#N4.Y0N:)\%ERBHC8C;P-5/\`IMH?`!W*'
M<H=RAW*'<H=RAW*'<H=RAW*'<H=R@/6H,YQ!8`32?"A0H4*$5SV1_IZ4'``#
MQ0PPPPL]@IF%RP+5<7CQ0PPPPJIT'!`&Q@9>*&&&&%SO*<.`58=/"AAAA(VD
MWX%_C_'M_E_>L5"*2W[R>'CV-C__`$PZX2E)4AIHIFME5L1<X<XF)4+3BR2,
MRJ]*/8]MTV:#.'(R2)]Z?5K"3;H"Z@;MM:`QKM`U9%^B$^PM7:7I:O?-$?\`
M@P_R_O6*A%);]Y/#Q[43ZRTW!!D%U2OO&8QS10G*2QC.;.O%95(M3%:(['J-
MP4E&WJ'#T`\LRRW&O&XA5[FK_D82N78QX8"=4.)LW#V!,2$T:3P=X&FX?P98
ML6+%BQ8L6+%BQ8L6+%BQ8L6+%BQ8L6+%BQ8L6+`*U&DM:N&=N?,[<^9VY\SM
MSYG;GS*AE+3(719?&IVY\SMSYG;GS.W/F=N?,0!:6&AESG&)VY\SMSYG;GS.
MW/F=N?,90M#A,EQKJ3MSYG;GS.W/F=N?,[<^8Q!SB$_WG;GS.W/F=N?,[<^9
M_GY<G7P\>PATNO"8F2]P`(9'&&"(E+F]D<1D.>#HQ%*F$ES=4.:70E*HP!K'
M68CLJ:KFD!!3'!;5(V+\6(:^\R:ZSX@6H8<5TY[B$#&.2_KA0F0\,!7X<N&:
M8=_ZF%K6+NELJ9*>02V2TRG+;GRP4+4Q]/6LL(^X++>,14A:G>H4K+</#4,T
M^&1L8.C0L)LL_E0O=&K;H-HL!>@YY,40;,A=.LEG"/O=NI8KPF3'&F"I9-(,
M,9//&O0W(4E;LZ"OM+>=Y4J(A5I4YWB\<+&L+U.(0"T`0Q'=808L%-*FK8[!
M-K&PXV'01U:53V1'9$=D1V1'9$=D1V1'9$=D1V1'9$=D1V1'9$=D1V1'9$=D
M1V1`X,U]%0?V3IAD&:4,0@%A*#00<?5K<>S=&TLFC:D3HU>AU^KWR701(Z!8
M@/"1$081"ZZL(.>254J5]B:A((^*-FG@Q7!<87,9OARA00*JZJ6]78DV2X$!
MI51+=,\8,050@/\`405[3&'PCXQJ5*E2I4@MD$14)7UJM8?J*E2I4J5*E2I4
MJ>2L`,*[EL5JGA%X)"GM14N!=@)!+-FHHJ5H44<(4):6CD6@ZH%GZ:E2I4J5
M*E2I4J6!C>\=4T<L/$,$"!`@2-@4$\`&QIH4NCX@0($"!(CP"HLK0N2T+PN$
M\0($"!`A55Q+P+!M9Y#PO8"!J=<D"T@O61Y\#M6K60I<@<7BUCR\*M6K5ARO
M!+7PWCV5AL@H86Q=1BX(GB,"A%PCC="_#-D_O+&P$@@=*0==R>),(DE(>5/+
MU-9<"[&ECP0N#S+V4MFP_P!G]4T#BX?QK=E)S;K)HO!LPS7ZR4XBLP*D\C8\
MEXFD!$QY@.'XZ8&0?KO5H]S,^TSR_2&`==Q)PDEP2"O%DJ6/JR<4NA)-Y/0H
M$Y0%0<DP6LQNZ`3?2(/@T,$K<;:CEF'H1+MOF6DY$R0RHX>W3#>6#H5W(PPI
M.=BUI`?Q:E.+/#<J9)Z,QE3ZG!4`<!\B0Q\A%"-"#:&3MF%VRBEB.@Y@M0V4
MT<,*)&S)6P0$'&>,8K&ET_1)$B1(D2)$B2+0;RRP-,^7M_<*W'MG>#3E8%F&
M<BB\*6Y2^&PT0+2%FD1L@:R?ZT.ED.D<!B32JTN84W3>RQ5U&>Y<Q`5=VK,E
M)T&IJ[%3!5+TAK#81JNAC857K7@L6+"B!IC"$UX'M`2QP@,`!*$A]A50@`XO
MYO=A,O%58L6+%A(J3I51.L.T:<<;<Z6:RZT*`7-YUI@QNZB@_?&K=72"P:/V
M=BQ8L6+%BQ8L6+%BQ8L6+!QF6!P<Q8M\*)4NJ75+JEU2YP5DV``58L4YLHJN
M-XVI))*97>:VPP:Z(HU1%:A"!HVAG'5\+!@P8,'%:P7=:F!5P.CQY'B8,&#!
MA:;'`K?D",]?"P8,&&`[C6?AX]DMROT'9P_ATBT0D5OJJVP$JQLQL]-[5NKB
M/`C>GUV8Q19EU0K``03+M9XKI;(U=>2!D9#\3J*[=%LQDFA_I-IT`,GX-XCE
MBDM&Y!*P.]>TSC?RZ$I>([9/G)M<V1H(-(%L1=.G"*V<6[#(HO+SUV6XV09<
MX`EUR64<II@8$5N+O>667:UZI:5`A(5N"ZAB\%I3MM`$#BS%X#>(UJ%#6[$P
MQ"BLWT)*-C/TC9A!3X)8&E0<5(YYA)I"4;B^(R9,F3(F_,$UJ"3)6PI]YUN/
M;+LJ4XF1##^=O;LH=9`%Z6K6R]0/H]NW;MV[=NW8D-@Z3A=A=`F`\O3;*5.\
MMH4OT.W;MV[=NVDZY$6MLHY"7^&[=NW;MV[=NW;MV[=NW;MV[=NW;MV[=NW;
MMV[=NW;MV[?3[=NW;MV[=NW;M4U(M\H3U'AX]DCG@,G@502TZH051^"05(+>
M(@EP&HG;Z!\`R4AP*Z7OC"^40/>.TG)^6.P2+3FZ`*.A&/R:@&IG^.T!A2KO
M\H?9GM$3#<NR2-VRP&92V/$%"Y@=EY&*/0)!*KC20J'H^&:8IW(U:JFJQ"C,
M4%-"HMQ(4/I$R[4X0,GXE:""V,3TR@`HU#"E`0:0<$6?4^QPP6$4^;0`J2I$
MN0YW?H+C!F""Z_(EF"6XS@T4A,\():M"/)%$OSR"]O=DSK6MDUUE32Q-M`$Z
MD#:!M",A_,N[@17+QVJGQ,-`RKC)(YXNX)$%#Y)\X3/!)U]_*OF632@#A=Q.
M?JQ$8>@/J1\G7-QB2'J($9D,2S&!^^Q,+%Q1J%;P;:>2"B%HS@QP:9<""(V1
MT&@D0C?9RHYHP*"?@.U\^QF*T="S4#F-M=VO$;!7.Y-I2(=?R.3#`(O63)C@
M24AN@,E(V\=9^//[Q)]2BRO_`*C&S-[A!`ZY!LS"B`C&O6R5KZ"95*A?'_QU
M0&\,*FRQ$R5U,@'\M#2NRJ:"`!-!_?/<>P(G51*,VUXY4Z=:K:+ZFT",&I61
MW_W(ATK95@W/JEYOGPE6$T%BR(ZH$PQE9B=EM+H/0,V%8&UXJFZ\@C?$AY&6
M\D\JL95@"6B2CL$CC55D$CMFE.E=N1^`\/6Z8OC4/"S,KUXW;';,XB%,+]4)
M'_6<:T%L4-0Q>O2NS*Y9BIEPU]LV*`)U\/"5VI]Q7MF80KDK?`^]TUISE5W\
MQQH4N3'(7VV7$/.;K=3:V3F"`BK.:I(&$XTNS+U]EBTCS""`+9CY)Q;U3V:@
M`%0'M-P('FZ2*2S#0O5J"`1!*MN%$7&Z&QLXF2WX$V.L*<->S:+F577?2?S=
M(8/1Z`6`NPWS@QU4<"L_M1#8KQ0V$N;`7V;A!U?"*A`MSLO-,S%8&YN&G("Z
MA1@%O,@+*@DJ,^;SN)!8/Z1+8$**WPHU>.-++S^`DZLA3V#<'DXJA&B)8SW#
MLM`N=)'Q2.&$ZD-C-2L#+36B`O+#.4V.FQU</K>@*@*U;%U^AB(I9'+/C@12
M"N@,-G%P$M`L(5N&98V'1:-C2D#E_CK7BA3!,VE^V`L:-"4%N`[.4+"8>&0/
M$9MBTHP5;]`"<SYS3.[P[O#N\.[P[O!ENLD0=0T(35.[P[O!"^EA45DR#8,3
MN\.[P[O#N\.[P[O#N\'16B'0N/0,44G=X=WAW>'=X=WAW>'=X=WAW>'=X=WA
MW>'=X=WAW>'=X=WAW>'=X=WAW>'=X=WAW>'=X=WAW>'=X=WAW>'=X=WAW>'=
MX=WAW>'=X=WAW>'=X=WAW>'=X=WAW>'=X=WAW>'=X=WAW>'=X=W@)`5)6B"2
MJ<MY00%(DH@*,E+4M5G3?_9DXU[F2>;T?*>;T?*>;T?*>;T?*>;T?*>;T?*>
M;T?*>;T?*>;T?*>;T?*>;T?*>;T?*>;T?*>;T?*>;T?*>;T?*>;T?*>;T?*>
M;T?*>;T?*>;T?*>;T?*>;T?*>;T?*>;T?*>;T?*>;T?*>;T?*>;T?*>;T?*>
M;T?*>;T?*>;T?*>;T?*>;T?*>;T?*>;T?*>;T?*>;T?*>;T?*>;T?*>;T?*>
M;T?*>;T?*>;T?*>;T?*>;T?*>;T?*>;T?*>;T?*>;T?*>;T?*>;T?*>;T?*>
M;T?*>;T?*>;T?*>;T?*>;T?*>;T?*>;T?*>;T?*>;T?*>;T?*>;T?*>;T?*>
M;T?*>;T?*>;T?*>;T?*>;T?*>;T?*>[:'S,5TK_)_]H`"`$"`P$_$(*5*E2I
M4J5*E2I4J5*E2I4J5*E2I4J5*E2I4J5*E2I4J5*E2I4J5*E2I4J5*E2I4J5*
ME2I4J5*E2I4J5*E2I4J)LU?TK2)!_2W]X;`)1*)42I5RHG]"?WAX;ERY;+_@
MZN4RF4RF4RF4RF4RF4RF4RF4RF4RF4RF4RF4RF4RF4RF4[']X;!L=<_X7*4A
MU3_2X,WG`\\M1K1Q5/\`9DQ>#_C40,FS<^EQ^[U3CX35V]=IJ^(]_INFQ_>&
MP`H<,X5Z>TRY9F*KQ+W+,4NW7Z#LX_=ZO$:OB-7Q'O\`3=-C^\-AI_!62Y9+
M)9LLV5F1-8Y(V5A5<;O'VX$"!`@4($"!`@4($"!`@4($"!`IS^A'353FR!IH
M0!02&B%B=$;ELS,RV9V/[PV&GVJ@4H)PP.2/Z^GB8F)B8F)B8F($XT)0"##B
M`/-FYGO-S/>;F>\W,]YN9[S>SWFYGO-S/>;F>\W,]YN9[S>SWFYGO-S/>;F>
M\W,]YN9[S>SWFYGO-S/>;F>\W,]YF(DV`-+%%-2QII,@E,IE,IE,K8_O#8<@
M55:R"3Q5>=)<2P=05E@W\E,J"#ER'D6[>`JB6QI23@X@9SSDID$"RDV`E6H0
M*,`-\JBRQ85-(H;@#13)9"%%5L\B.C3B8(K76R=92A4D/D!`(NV"I7A*8[1I
MJZ>#7&N40W$(F@.HH)"0N+$H`+!0TRA;0N0MK2WPTB(.$1X8:C*5T:8!,Q7%
M/!8"AG-WFM,D_3*G)3)^'P)<J5U@5MO,N7+E^%6A[")4L78-:I<?9NNNNNNN
MNNNNNNNNNNN@NHA/(&8G;78-*7U!_>&P<'G0&DL+T#D3)PB"P,<)1,,,5.4I
M2V:Y_$JBJ5"$`BW1,!3B+8,$(0%B/&!TZ?.3JN3!RQ\!I1!8/!9U!0=;76PP
M2E!0-$&GH6+@A@MXD%X`N<Y=<_0H66C!HO-6A*!H;\-/TY6-$IY#C72``:N2
M9.6.KRX3#QP+K2^-7FKTOP5*E2OJ44>`@-)9?&E)OY[3?SVF_GM-_/:;^>TW
M\]IOY[3?SVF_GM-_/:;^>TW\]IOY[3?SVF_GM-_/:;^>TW\]HD;;!6=+:UKA
M]1_>&PT_@;ERV7#PG`XA`Q`G,U9IQ^QCCCCCCCCCCCCCCCC?P&MXD#%R<0RP
MC49,B`2ETL-/'U!Q]5_>&PTF9F9F9F9F9F9F9F9F9F6H54L#99>@IMNBFYF9
MF9F:FW=4%M@HHR\C+B#+6E*"T&4LX7(%"A3)AUF9F9EU+ERY>S,S,S,S,S,S
M,S,R2JZ`E\\S>KVF]7M-ZO:;U>TWJ]IO5[3>KVF]7M-ZO:;U>TWJ]IO5[3>K
MVF]7M-ZO:;U>T%&EP@)Y-?6?WALLQ[A6V[1FK1X`K01O(D3!*0)!*2$%/D&4
MQM#UCX>J@"7Q`[!#H`U!$MU8Q:M"XB4+@J.HL_1<G;$?)UA4M4%T"VZK&BP5
M0K$1=!05;CHO+5L/>@`\@!QH]"[;/FUEZO"[`4%524$@3=C000I**UJP@8!#
MJT%%S$%Q0J0MAFJ:"I=M@AJBKDJFRRR#V`I6@.90\T:CL4TF(UI,3!+-C,S,
MSXKR`%YP!F3(TNK^P8,&#!@P8,&#!@P8,&!&FYD4Z808<E!31G]=_>&RLB>3
M("V"T"W*@92(X@$`#9%"BZ@3*X5P9$3:'L@4!&FG$!HO:Y\?#J*>D:$I88O`
MRY%*I3>OT4QC0(A:R784<C--:,00H-(\(N$P'`M1BQJ%JM*M?#9^.BJH6ZHO
M(K7480":(`J$;Q+C2%=*B0A-0:+!!J,E'*&"(`J-#H#'(O.EXFT.,J!K!P"B
MEC`TH`1ER_XU_>&Q%2IB%H^4,JXH46T2\;&*DB"J(`P#160>C,"VD`@BN2!)
M94B4M#F$04RDN+`&>!9A<!M%S:<;<;';?=CE/.!38)K$B=+E4T>&!6R<5G#Q
M,0RGU6%;63&5(!NPJ%,)91R%,T6ZTTL8PM!$&$4)418QP@B!J9(AZMH"RG2P
M#Q+HKK+,&I,U6@+%ES27&B7L24RI3*93*E.Q:`T31ASYC$W3\S=/S-T_,W3\
MS=/S-T_,W3\S=/S-T_,W3\PWV-PV?..:O6J7^T']X;/R&4VP&R857;0+&<J>
MW1$K*3BZD&XGQHB[89E2"90)$;`AIE0D3`,2JP8LFY21#6("&U,G/94J5*\#
M)L-E!"`@6FQXE5$F/%2K6"QH)A3D[=!V+-3,(+&8M$!L26ZXH:"2CP2A2\N"
ME6I-(!&HJY5L0(1332Q`6`!;JP`<%,QC!YGJSQ97/[JQ#7Q*2R+E#.4=5V.D
MO9<OZEJX-)<M+.+0:.DW-]YN;[S<WWFYOO-S?>;F^\W-]YN;[S<WWFDUM&K#
M2DL<)J.'[5_>&P%V$.D<8'*`*RT8NX$R46S)BSYQL:(1;9A%H1:CE`T6K&ZE
M:V@#96T(-DCB#5*F11&&%.0L-)B62_$6;\*I:D%#;@%Z!+,\FSDLY0J/$+X[
M$#4D))4(JTB!-,!=VH379Z$7-VHJ(P'8-2@M*E!JT9COC+8H(T+4$GNRR(@9
M9#<O-M$L7I$*54N1P00#+!$)"$+YNBP78!=.FP0'8E9;&Y;%>$SL2Y4J5*E2
MI6P@5795%HH<J.&ESM4^U3[5/M4^U3[5/M4^U3[5--6L`(TR529+#`+^U/[P
MV/\`;#4L>L#1==+K,X"@:5(BJA8`4!:N7#2D8&="T5&K("(RD:91&"T2)4LK
M,7&4>+18J'G0U72T"HM4L+T@(5.A669)6_@+@',$5"!?0*(:L)<7,-7"JEJ;
M\6%\-$)V6E"4=1&'81VH3@M):HLIV-P4@`"U5P`95P&6/PPH54+)D@\=<!])
MB8F)C;B8F/&*NHX$E#4PLU6,OT!AAAAAACFS!MRT4RY@!E0S"*`!$R(Y$343
M1ELMERV6RV6RV7+9;+9;+9<MELMELMV/[PV.A(A:4NGF/?(4L^0UIE&5N1(4
M&Q;#0\3.PX.A;1Q%"$L8&1)2J@*H!`4:*3^&T(+IAU4P&SD!);+#V-%]*:MH
M;N\D#4BT**@46T`P@B*I;PRTZ*ST/"M*"TEL0*E4&Q"(*>98LU>4\AOFJKSL
M.`LB@J*@"A0EX1S$<<^&5_ZR"83G]'$HE$QMQ*)CQJF4Q>Z$PWE=NE5FSLN.
MRX[+CLN.RX[+CLN!I;2BB<00"FB@:TZ0D9AE:'5M5U5555R_;/[PV:&G-JIE
MA&Q7*J%V6000J%D3CL35CB`P([`VEF00&)G7%Q4R$*?\4QJRB\HF_%A`\_+R
MQ!,@BLX.0$&3,H!`*TLM5\`H%5E1ME3(TR<&2K2B!7!%A6*<`#KMD<8YE4GH
M`"`&B<J_QR?GP,5*(TAHEH%VXB8*<[DAE.$4MJZM\5T@LE`%T%@=;987#]0,
MQ*^G9]"FUO5V]`X-5ZE>*[N[-T6:*05\T6QBEBB?<O[PV$>F62H1"E1HC4Q%
MO<9.N_!"H514E#H$>T-+2Y.)$S<(21(M6(;MZJW>2L0Y`J`#5&@-)A<%```0
M"=W6[F]9U>,*15+:#!UVXF"Q`2A$GL'4JF$-,-!*90F>4!00F0VR&4!%0*/(
M\%I@H<.%>/<*[5(5=\.T"%\6LU;:\+<48\1E@5#6+!NM,<2RFE.5$1HJ#D&`
MF&7]+'T3@0"D*`',:%A:S=6'B"!`@0(?1)U`*`_'Y=7/W+^\-C,3(JLP1ME4
M!S4?G,-/L!0R0O&(&HQK@V@P4(K8*T5%K2@=8$:`X%K%]&BSQ,(B45I*&4+"
M>DN)ORJAU7XZ9I?6Y#6+[6:B4%42]0:T5'H<Q'!W8F6IEY.@'">$\#<M^A7$
MR*;!PB\,WSQXC9LV;-BC)S#)5:E7+*[U?N']X;!OT4R@@L=:03J0APX@"%%4
MX?Q0RK,+%$4Q^%,!UFV&"&`P`%`'(,$N7+ERY<N7+EV'45`!QTMKAH1R^!;B
MV@,UQHRZKEM5ERY<N7+BEW\<:8:0)E4G2@IK2RX\+HZI_&(J(J;5U67+ERY<
MN7+ERY<N7+ERY<N'2ML"!R702Z4ODOB<.'#AP<`$`!0!H`:`:$J5*E2ME2I4
MJ5LJ5*E2I4J5*E;7]X?QFKQ&KXC5\1[_`$W38_O#9K)C=G--3_2X.C-8?O.G
M2<TMM^;HEB"W17G'&%JS_2YBY9K_`&4#1YW['\'J\1J^(U?$>_TW38_O#8(T
M8H`K1*%1;8!HN^9QK;G6<S!5XBE>3_!ZO%Q\7'Q'TW38_O#8#$<$!AI$R4R8
M%2@,$YTB)B-2A!6V[$`U<X$C#,O0JLZ12')P;>#@19I.00#'W("\C0*KMQ45
M,7<-E*31JILD(&IFB`-.$LNGKSE>,IC"K2E@\%++\K+YD6%T#T`^IK*%+&40
M2818*4R@J!=!2&+=?J7+E[6++ERY<ME[*;6]7;T#@U7J5]I=W=W=W=W=W=W=
M;SUHOHMJRL*"U%+*R0F$PEF&D\G/TG]X;"OI0C:T!1T1@A3Y'#5;E5A9SK#$
M%;+%ZE>7!:?A0%I%(((6&P0M$)J+F%%(`:.L,0:.I!$)K"HH*&(T5F:#@5<N
M7XZ<!E\2D<>*Z1@1O[H\$`I"@!S&A86LW5A]H,&#!@P8,&#!@P8,&#!@P8,)
M7=S275F)=I'`*`GTG]X;+`(90%0Y&3=<+O$:N\-\<*I[%L%+J(Y+80C`5G!3
M04!6=:M\EBS70PI'##9F!0DF*Q`JW4V<-N([+=-TJ#4<EH!$E&X@R"V(T%U&
M`\0'C]5N6RVH7MS,S,S,S-])F%\=EX@!<+"@5AFN&OTE*E2I4J5*E35\WUR^
M+J!KTU34O[6_O#8W$-5:.6K!4)19>2]+-2^$]T&F+SRQG/#,;T"NMX]=@PB-
M:*/-TB-^-=4NM;K6JXR_3S6AKSKQ$E\YHE`O4[.-)F[$E#*JX*,O(`.GB>@5
M(&BZ#H%U"[06L,',R,"%6-6"RV@605!4%1H0H+H*(&J*M&(W(I$1'DCD?Y)_
M>&QMRX634942M$)`6(PW/=V!0O06!"N+T/6XL$E*G6JFVBV<2()T,-*,M4LQ
M*ZZE@%:8*"+!0`!-QC,P)0"B#`(YE:&<S#"Z2RR55O$JPHF+1(6!\)019(B.
MH%KX9RQ+VVSKJ7&:60<!KQ"(W@=K`$QK)3+I'%*:"*9BJ*Q'+J,'Z0:-@5:D
ML`O0U.#%+H&-G8$H*@@+LJ+GM<10$!:H`!5^!OAX:E,SXR$=A8PYB(U:'G7B
MR9,F3)K&R9;&>S7H!4IL/W(_O#9<MELN$Y0#08',!MH&@2V6RV6RV6RV6RV"
M,FOS+9;+9;+9;+9;$Q8`"U:#0+X'`T);+9;+9;+9;+9;+9;+9;+9;+9;+9;+
M9;+9;+9;+9;+9;+9;+9;+9;+9;+9;+9;+9;+9;+9;+9>Q_>&RB%<8A*)1*)1
M*)B4:RB42B43$Q,2B4<)1*)1?242B42B43%RB43$HE$Q,7*)1*)1,2B8F)1Q
ME%7*(_=O[PV40KC*)1*)1*)1*)1*)1*)1*(A*(AP_F']]JBH1"42BY1*)1$.
M$J42B42B(2B(2I1<HE$HB$HE$HE$<?QSQ]8,H=)74E.9*<R4YDIS)3F2NI*<
MR4YDKJ2G,E.9*<R4YDIS)3F2G,E=24YDIS)3F2G,E.9*<R4YDIS)3F2G,E.9
M*<R4YDIS)3F2G,E.9*<R4YDIS)3F2G,E.9*<R4YDIS)3F2G,E.9*<R4YDIS)
M3F2G,E.9*<R4YDIS)3F2G,E.9*<R4YDIS)3F2G,E.9*<R4YDIS)3F2G,E.9/
M,2@UEYO^F__:``@!`P,!/Q"7Z[%)24E)24E)24E)24E)24E)24E)24E)24E)
M24E)24E)24E)24E)24E)24E)24E)24E)24E)24E)24E)24E)24E)24E)24E-
MB]CR_I8XN:/Z61H_I9&C^ED:-C4%45?Y:EK"&'^&B(E8R?\`"X)%X`?4N8J:
MR/\`2X.@"A^M?^?T0C1L61&29[HMO_=9AP*F;#,PX%0*J--/Z(1HV*+9;+9;
M+9;+9;+9;+9;+9;+9;+9;+9;+9;+9;+9;+9;+9;+9;"V4RF4RF4S,IC9+/C:
M!,;5K1N^2LX^V_\`_P#_`/\`_P#_`/\`_P#_`/\`_P#_`/\`_P#_`/\`_P#_
M`/\``Y-JWS`?D7'76BHFV:H0/42F8EDN8E\MA&C[>=`I``!:JX`,JX"!@-="
MWI=FKIJ_IT\)45%145%146C]A7.I(HT*FM:)T\W3S=/-T\W3S=/-T\W3S=/-
MT\W3S=/-T\W3S=/-T\W3S=/-T\W3S=/-T\P7-92&M,&@!*6L*(/&5*93+05[
M"-&Q`UX1:F4C@6FM>DJXG-SZJ(6Y:0":%8CLH`3`"`7A`X<,>*'/`<"*)*JK
MF-E(EH`&-JC:!RYHK`(G9N"PBF&/.#"8O@3.T2P@2CI0(T<T%40499HE1\"`
M(NV32X))0K6IKA3<4):*)-M"):%M#@+BZYT7X2,>H8@YU`+"JL"Z=*PC)+^N
MC+KF2`/!<(-%&Q2E4JE7/@%);RE](YX;:Q>Q6PE>$()3)"E5L,XNPS5WW"'<
M(=PAW"'<(=PAW"'<(=PAW"'<(=PAW"'<(=PAW"'<(=P@SRXAM7#@"@415CZ6
M:["-&Q;:>XHJI)883":D0!K(7KEN3),LPV0FF!L+JV[*H6LHB4_$=`,:A2-(
MEX2+W,M&/0PQPZ[)QCP8P*%A,M1(T0M*D+$2#3=J7?\`<-Y1MD6[]5:!AC`8
MQILOQ#BRWISHSAA@RUSI7AJ,^*2\M@HV7H&!0^6:=.`#5D3/*QHPZ_6!F`LU
MP8++\%[%RVVNI*ZDKJ2NI*ZDKJ2NI*ZDKJ2\WN;;#9*LL&N9-[_>;W^\WO\`
M>;W^\WO]YO?[S>_WF]_O-[_>;W^\WO\`>;W^\WO]YO?[S>_WF]_O-[_>;W^\
MMT(';+HLT+EK65*E2I4J5*E0,["-'\'!<HE2B./#6;?J9S2/'&G6L?8V+%BQ
M8L6+%BQ8L6+%BQ=D`C1H);N:ZBX8)9!2&^BY!R49K/12GZ9KL(T;`:F5S2N:
M5S2N:5S2N:5S2N:5S2N:5S2N:5S2N:8620+,G0XK;P5;*YI7-*YI7--"WR+&
MBA;;<'-P9B%P!:T%KBZ.-`4+M!RR,KFE<TKFE'.4E'.4E)1SE<TKFE<TKFE<
MTKFE<TKFE<TKFEJG*M*KE8F,'V)(D2)$B1(D2)$B1(D2).4DI%A.2+F8F)B8
MF)B8F)B8F(5>PC1L9**"HVC0NI:@`J$I:UV<6SA-#G%"3A:H1$G966-P22K#
MC?SB^6%0$$;I)M9$6Z(`Z(PX3'T$#0-R^LV711S3=RKX`&L&JPC8<N"MR77"
M/W@B[<"5*6B]@VE4;17DRJ5R6[L;(0LP$L`JAQ0+T)%<IB1,2)Y"9T6"]*B1
M2[10;A3(7NP!AO%--,RTC8$1<FQY!T=@.I,PO69F8G'85QC4QL-</":CP:\!
MX7'Y##C]@Z=.G3ITZ=.G3ITZ=.LX"X(-\B6CQ5;X?U0UV$:-ECE,ZIF(`H:"
MN!BJ-`YJ5'<$%S$I44>)(N`A=@*`4LR1/RN7!ERM>:'J@)T09("H=A!6U`<3
M'68ZS'68ZS'68ZS'68ZQ%(LI=&JNFJ:LOE9!19D>L`HYDLP'D`%U=!R)CK+#
MG,=9CK-;C0MV:-"CFWH:&41ZZ@`!*T*)3('&TP,FKZJ`!;C`N8L1U5Q26FI,
ML&<K5%E1-W-7DY5O(YI;:JXZP3K/7?\`$]9Z^O\`R8W[2_.8ZS'68ZS'68ZS
M'68ZS'68ZS'68F)B8F)B8F)B8F)B8F)B8F)B8F)B8F)B8F)B8F(5>PC1L)X;
M>+0C@MA&J%M0M*-K05\.T>-G5*@3VC36B+$DUC!HF[`(,R@F*F!&4&+1*KJL
MW$6,48QL9C8[2Q5S))HEV'=B@70J,16H-#.M50\3/'Q`$>VQ>0*&'.&$I5HV
M$!A>*,!!XN)0ZTN@N^=`J5TV5#5N4.)T&\`AHFI*IN;"MP;9?&&(I68Q=ZA"
M!*><"4\X7$V"5+)<LEDLEDLV-(PE39BAE62OIQHT:-&C1HT:,D\"6%34C3A0
M!`^R$:["-&PD/EI@_P!8PNJ+4$"EC9$!B8LE"T$8$Y4M2I-1$[:J,$4`RP%*
MH>05D@M>)+$A`TXM!1&\#+Z$OH2^A+Z$OH2^A+Z$OH0G0LK=$6U=7ML-%13!
M59R`K-.1'.9?0E]"8E?"N/24I\>T-"R^A+Z$&BD9J[0MLXC:#RRV!JIL`,Z(
MY-TS2`1-J!@5G-+5>14RV1>S?HX6C'!@\?HJO+6#B`P`P!R`:!+Z$$Y$QR)^
M">D_!+Z$OH2^A+Z$OH2^A+Z$OH2^A+Z$OH1&*MV7`TLT(%ZDW$]IN)[3<3VF
MXGM-Q/:;B>TW$]IN)[3<3VE,UJ-V66`TF1T3)C9?BOQ7X3781HV-L%XB%(%,
M#U>`H*4IG@!2=0'4'5HF@LK#?A9/',()$+I92\4'1PS4HY48*OY`#C)%1)LP
MU+JXED68EQVJ8\WH5;L-LJNN:C3*!6A6"JT*+#AIPV%4B?NLI\:*'$4E+3[P
MRU+7(UX#:;[5T*Q`)5`!M=#.(BB-23:!*T"H3K-B5$?6"S#B4`63(:XP867*
M%.C/`)"!J8C4">B(X]E6$NP`2B`<=91*.,HK8->$+\`"4)QQS0H:3=IBK^D*
M********H`^0M-&+8X5;-]F!KL(T;`:&RD"I4%`H<I=%LR9+OK"H!+PK2"T5
MA%+Y>F1-)5P*X'HKGE@*T(#+#@:4L[*J$*&.64ZO+D,-AU;&4X#"U=-C+VVW
M.\*D-U!&1`AUH;N+8"W-1P*ELMELMEL<DR`%&C5%FN6G$40P$@H``#@@Y.#+
M83!0`!:K@`,JN@0@%$!J-G`#K2+46FV6RV6RV6RV6RV%NTMELMF=BV6RV6RV
M6RV-:*W6X:!7!DW@P_0.......6=2AR"WH#*&`J$%-4B)2)A$<B.$=);+9;+
M9;+9;+9;+9;+9;+9;+9;+9;!;V$:-@5(D+A&(H=!7,6H#<$!6;\6!U;*8J=*
MTV(FM*$.6DE6BP$N0Y(JNZPE8&P!HNGM9YEJNP8!HZ#-(IP0.VAF*E#B!BU)
MG.#5[:)5<-P+9-YM:L)4\F4\F4\F4\F4\F8N)R7Z)&-34ADTA&3H*4->3YU5
M];K$IY,?T0VJP%V6(.<2UU9(ZH$08B`EE/)E/)E/)E/)E/)E/)E/)E/)E/)E
M#A/)L4N$IY,IY,*<)Y)7)*>3*>3*>3*>3*>3*>3*U4[I.>!0S!Q7BGN:.YH[
MFCN:.YH[NCN:%,M8I&$5`Y0Z8IK$Z*I`OD``!H````HE,IE,IE,IE,IE,IE,
MIE,IE,IE,IE,!O81HV:SHU<`<B5A"[-(TC7X$0\V:Y[49EP7'N2#,C4C`JH-
M0O+=J&\WNJ$><UC'#OPU!3.1PB*5N;90L$:J464T8CE[#?0J#%A=\3-DH^3/
M*^!0I!T;\`,Q<.QI*;^046HUAL_"8?,Q+9;+86KB)4#661L913$B3/YH;N#9
M1=K+HNKJ6RV6RV6R[=;4S-T]J6&"D$U#ZMD+4`KJ0'4&@(*:!?M,RV6RV6S+
M,DMELMA;*9F6RV6RV6RV6I_V50^?`K1O%(*04@I!2!+JA;8P7B%X:E`C]N:[
M"-&Q6B=1-GR"\F4JG,-M$21IQZS>6NYBA=$G8\X&M!FBHV:9!A%I1T@!@`J'
MQ2Q9>TELN8#+8JN`UC>2&*T`P9K66`6!8SD"0X75"K6%)%:K-G"92ZV7F49*
MC]E4U2RE$C5;95QE<LIE,IG$B,CBO$*3Q0-(`48J%%I=<#\&/QG,IE,IE,IE
MK%5FHX2`\&D#61<M0]Q0IYLU)6.<IE,IE,IE)RE+RE,IE,IW93NRG=E,IE,I
ME,IEM=F7W"AUN8#"KI1\,^?/GSWSE$6JT\,KH`!@`*E2I4J5*94J5*E2F5*E
M2I4J5*E2H&=A&C90C8`LD87F\A5YBZPMQ8J'":&9@E+,JY@_;VH2"H"12M["
M,A:Z$,!])1V7?(HMPC`1`B`A@V4>-%%NHVG3QI[=V%]-#["9*!?MZ8Q`K98:
MM+`\[U"7)8!^0R'*\!$KP`,HB>.]Y2SIP&L[*UK/B?OW[]^F/.8:H;0$[T25
MD?;&NPC1L6B*L6DJ&2TCT4C88K=;F6RIIH;0$LS*[K?DC+:HT"Q13B,J+5>*
MK:R\O+R\O+R\O+RZ.&`!55`AP!DN!0`Z'*V]SAH8EY>7EY>7E7,4=6>`?8:7
MB1UK!IF.-6<@/-!@E6`H#`!P)>7EY>7E^<O+R\O+R\O+R\O+R\=6$%Q(J444
M&KJP>!XK]^_?OM`:052VJN57*N5EY>7EY>7EY>7EY>7EY>7EY>7EY>7EY?81
MH_I9&C9IS3V*G(+I_P`:YQ$X6^QC7K_R<HHK^*M_,J"#*WY0RD+L^C4R,<7_
M`).,1Z5[O]"(T;%-3<@2H%NL7`0HTBVH:_\`/U,=45+ZL,3-=%_,`H4?PEDL
MEDLEFRR62R62S99+)9+)9LLEDLEDLEDLEDLEDLV$:-C"L5B<FBL-RG*`VD4:
M!;(,/3O0`P'`6)8"1Z4,NL.5RVAZ":+X2L01"B*TP:-ED;%+"M``D/XB(W1?
MO:6!*+*\%:QD::L>7+I*\=`(NV>'^YKT@DUB-64/`@!HZ.FP2S0MH<!0+:U:
M+Y'TPN5L)6T,?F!C:42I4K9OJ*(=SX%:-XI!2"D%(*04@I!2"D%(*04@I!2"
MD%(*04@I!C+(<IJ*Z%ZE0"HQ\*61R-.2QSQ%'A]`UV$:-EYOS8U5K$I2Q&F%
M%UN0*T<#:F--*2$]/`:?1KS#C:XA-@F,V"54HL+7DDS+&T.1CQ/[R,H7KOA+
M"LR;/3BVU5UU)74E=25U)74E=25U)74E=2+Q;,64!=Z',6N=*KJ2NI*ZDKJ2
MNI*ZDKJ2NI*ZDKJ2NI*ZDKJ2NI*ZDKJ2NI*ZDKJ2NI*ZDKJ2NI*ZDKJ2NI+2
M[,MN%#K<P&%72C]FI4J5*E2I4J5*E2I4J5*E2I1,5AKK3^@`"-B1VUX3781H
MV.2BDD63)=2^2LU*>`=M`H&BJ#CJS2HT+1%W`14KH,9%*]&!IK85F0!;E<`1
M.`04D@`6>.SAM*CL"ZLP<@*OB#;4I$O`2H3HI("C@JU."U]4KC*)1$-I4Q,#
ML8F*ZQAK92RS%%"TWD!?'3Z2-&C1HT:-&C=K1L-/BQ0K58<:GV8UV$:-EI3T
M`JXO`9TS$PBZFL-:TZ-<:GMBYJQSSC''&LML7J@S?*M9CK!@+T2MY&KH\()0
MEZR5=U5Z7>*YQ,$'2RWE=7,=9CK,=9CK,=8H[6K<_2XT]497!Z:Y`#7+_LQU
MF.LQUF.LQU@QQ+!2TYA=UUTB+KP%@3H*Z5X!<H*RBABT*MJ]"RWA9S@)[>B4
MC^;F.LQUF.LQUF.LQUF.LQUF.LQUF.LQUF.LQUF.LQUF.LQUF)B8F)B8F)B8
MF)B8F)B8F)B8F)B8F)B8F)B8F)B%7L(T;#,V%!+2+)]1`J":F<%4/L(RPY0@
M;ISF<FE8`IG4+70<P'1K=718;U@[U=`9I-I%!0I3<GN,D%1,-R46?J<4!#)9
MI>HPV9#A_.X0A#S7O$=FJ[";*,EDIDS#)6@*FA7#F2J7BY\2S8@0*J!C5*K@
MW34BZ!(@HRMF`&N+39+Q)[<HH@UC50"+'`AU_`@L5.`I0"`TJ<`+1P5=>&5*
MK095\!7&/@&61JO'21^0:@`B8".@Y\7W[]^_=-5PH.4`5<CL!LHGV\:["-&Q
M"V[:HB/T&,:N@"BQ5K]*JJJ[#*_0JJ@:("WC&7CY_P`C5555555555555555
M781H_I9&C^ED<G]+(2Y:2WE+>4MY2WE+>4MY2WE+>4MY2WE+>4MY2WE+>4MY
M2WE+>4MY2WE+>4MY2WE+>4MY2WE+>4MY2WE+>4MY2WE+>4MY2WE+>4MY2WE+
M>4MY2WE+>4MY2WE+>4MY2WE+>4MY2WE+>4MY2WE+>4MY2WE+>4MY2WE+>4MY
M2WE+>4MY2WE+>4MY2WE+>4MY2WE+>4MY2V5C;B8F)B8F)B8F)B8F)B8F)B8F
M)B8F)B8F)B8F)B8F)B8F)B8F)B8F)B8F)B8F)B8F)B8F)B8F)B8F)B8F)B8F
..)B8F)B8F)B8F-O\`_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g575431g97j81.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g575431g97j81.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[0L:4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@``````````````:0```+T````&`&<`.0`W
M`&H`.``Q`````0`````````````````````````!``````````````"]````
M:0`````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````"'T````!````<````#X`
M``%0``!18```"&$`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"``^`'`#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#U5)`P\RG,J-E4C:XL>QPAS7-^DRQOYKD=)2/(R*L:A]]S@RNL%SG'
MP"I=,IOML?U/+!9=>W;323_-T_2:P_\`"V?SER&/\KYFXZ].PW^WPNN;^=_*
MIQ_^G:M5)2DDDDE+`@ZA.AV$L_2#4#Z8\OWO[*F"")&H/!24NDDDDI22222E
M))))*?_0]#SL:^B_]I8#=UP`&30/\,P>'_=BO_!._P"MH61GCJ;:\/IS],AN
M_(N&AJJX<W^3D6?S;6H/5LG-JSWFBQP;CTMN-0/M<`_:^1_:2ZC8UACIWZ`W
M5NS<BROVES0WV;C_`,(Y59<[`>Y<3>(@5_G+/!Z6P.6D>#45,7?[FG%ZG9HI
MJQZ64TM#*ZP&L:.P"(LRW/NHP,,UM];*R&L#6N/)V[['I.ZRP=,KS0S?9:0Q
MM0/Y^H<V?[*?]ZQ`D$T8P]R6GZ/_`'WKBL^[Y#1`NY<`\_Y1=-)9EF=U/&Q;
MK\JBL;&M<PL<2)+@PUO'TMS934=6O^U5T95;&"VLVM?6XNAH&_\`2-<T?FI?
M>L0D(RXHF5?-&4?G/!'B3]WF02*D!?RRB?E'%*G45?&=M?9CG_!&6_U7>YO^
M:L\=5ZC9CNSJ<9AQ&R0USCZCFCZ3]!L:JW4\S(R<S"Q^FV&BWJ5<ONB2RIDV
M.VC_`$GTO\S^6@.;QD7'B.@,1P\/N"9X82AQ)^[3NC0WXC=\'`.*7'PO0I+G
M^FNQ6=395C];MRW`O9=BW.%FYS0[=L=M9Z3JGMWI^D==ZCU%]9]+&94Y[FO;
MZI]6&C5S*=GO3AGCH#H22`!Z_E_N?WD2Y>0L@V(@$F7ZO?BZ3_N.^DN?P/K-
M;D9-^/?2VHM;:[&<"2'FDN:]FH_D_P#5HF/U[)M_8VZI@_:;;#=!/MV!KAZ?
M^=^<B.8QD6#X;?UHP_[M1Y;*"01MX_U93_[B3N)+!KZUU?.MN?TO$JMQ,9YK
M+K;"U]I'TO1TV5_]<3LZWGY/5+L3$KH]/&L%=E=MA;<\`Q;;0V-FVMON_P#.
MTO?AI5ZGACH?5_=5]WR:[:#BEZH^G^\__]'T5^&ZSJMEC]IILQC4X3[M7:^W
M]U5,7I&57B9;;=KK[*_0IUD;`#MU_-W.*MC_`)>)_P"Z@_\`/CEH*I'E\624
MI$&XSR#?]_TR_P#06Q+-.`C$$48P.W[CD-Z;FV7XY?9Z#,6AK&/K(<[U(VV^
MU[7-VH)Z+F"F[':YNUEK;\9Y.I=&UX?#?;_Y-;J2)Y'"=^+K^E^]'@_[U`YK
M(-N'IT['B<K(KZOF8=]-M559<UH8&N))<'!SG3]%C-H4:>DVX^4QU36MHNI]
M/*:#KN(U>R1^\M=)./*0,A.1E*<:J4JXO23+]W^OZD#F)`&,1&,3?I&WJ'"X
MC,/K-6$[IK&U.K,M;D%Q'L=]+]''FJF1AY-O4*ZNFN:W*Z0QGIV/G8\.'Z6J
MS;N<W=^;_P!>9_PBZ#,RJL/&LR+?HL$QXG\U@_K.5'H&/8W&?F7_`,_FO]5W
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ME]WCP\%RX?W>WDH<S(2X^&/'7S:V?$ZO_]+T4?\`+Q_\*#_SXY:"K?JG[1)G
M];]$2-8]/=_VW_.*RHL4:X]0;G(Z+\AOAT(J(&JDD&PY3236&6-_=<2PC^W%
MF[_,0SE9(T^QVN/\EU4?>^UCO^@I5C:0[\BG&J==>\5UMY<53??UFW2C&JH_
MEWV;O_`Z&N_\^JE9CX-64QW6LIV1<3^C;8QS,<'^1[?1_K;[/^,24JNN[KN0
MV^YIKZ929JK=S:?WG?R?_5?^D6ZF$0-O':.(3I*4DDDDI22222E))))*?__9
M`#A"24T$(0``````50````$!````#P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`
M<P!H`&\`<````!,`00!D`&\`8@!E`"``4`!H`&\`=`!O`',`:`!O`'``(``V
M`"X`,`````$`.$))300&```````'``@``0`!`0#_[@`.061O8F4`9$`````!
M_]L`A``!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`@("`@("`@("`@(#`P,#`P,#`P,#`0$!`0$!`0$!`0$"`@$"`@,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P/_
MP``1"`!I`+T#`1$``A$!`Q$!_]T`!``8_\0`L0`!``$%`0$!````````````
M``D%!@<("@0!`P$!``$%`0$!``````````````4!`P0'"`8""1```00!!`$#
M`00'!0<%`````P$"!`4&`!$'"!(A$Q0),4$B%3(C,[0U=19")+8W=U%A4D-C
M<[4V=A>W.1$``@$#!`$#`00$#`8#`````0(#`!$$$@4&!R$Q$P@B05$R%$(C
MM#=A<8%BLC-S=!4U=;5RLR06-G:A4E/_V@`,`P$``A$#$0`_`._C2E-*4TI3
M2E-*5&9V4SS(NQ')]=U-XEG.'5QYC)O+^4QO(T*#$K#`++K#/$J,+#HB.8IQ
M^;4D6C@Q?)CF/\KR`(ON-_)2I%L6QZ%B6,X[BE:226NQFBJ,>@%FE^1,)"I:
M^/6Q22S^+?>DO!&:I'[)Y.55V]=6B;DFE5W5*4TI32E-*4TI32E-*4TI32E-
M*4TI32E-*4TI32E-*4TI7__0[^-*4TI32E-*5IYV[[!R^)<:K\+P9"6/+W(J
MI58E6P1_*GU<>8;X#KY(@T>1\I\I_P`>O8K=C2]W(CFA(W5R--1N?PBJU<?5
M;KY%X'P)!VB"G<BY6HK;.[KW$DD=-=[A(]'&EJKG%@4Z'>BO\G?(DO*;?Q>Q
MK*.^H_P52MH-?%*:4II2FE*I1;'X4E@9Z#$"47VX4QJJT*D=NK8LGS<OLR%1
M/PNW\"?=XK^'2E572E-*4TI32E-*4TI32E-*4TI32E-*4TI32E?_T>\'`^2,
M%Y/JI%W@.3UF45<.>>LERJTCW)&GQT8XD<XC#"<3E&1KV*YJ-(-S7L5S515J
M05\$4J]]4I32E8UY<Y3QGAK`KO/LJ-M!J@H.%`&1C)MW;R$<VNI:YKM_.7.,
MW;?96B$UY7[#&]R552Q`%*TNZE<69-R-E=EVTYD&LC)\J(8G'5.<9&Q:.B()
MT0%O#BG5S@1E@.^/6-7=?C>4A5>\[")=D8`>VOI2I&]6:4TI32E-*4TI7FEQ
M(\Z,:)*&A8YV*,@W;INB_8J*FRM<U4W14V5%3=/73TI5I4UG(K+1V*W!7$*@
MU-26!?ML8:>7Z@COL67&:U47_B1J_P"Y75/D7I5[:I2FE*:4II2FE*:4II2F
ME*:4II2FE*:4K__2ZJ^5,&ROIER6_GGB*`6?P]D\V/$Y,P*-ND.H25+<1SHT
M<0T!75JO>JULK94@2R+'=_=SM$2^I$@TM^+[*K4CF`YYB_)F)4V:X?9#M*&\
MBMD1C-5J'CD3\,F!/`USUB6,`Z.$<3EW&1JIZILJV2"I(/K5*NF7+BP(LF=-
MD!B0H4<TN7+DE8&/%BQQN-(D',16C$$(F*YSG*B-:BJOIJE*BOALL.]_.WYA
M(%+#UMX@L'BC!(A8H\RMW*UR-?NC"/D7GLL(5NR/A5*-8OLGD^3[_P#5+_/-
M*E3``$4`8T8(H\:.(8(\<`V"```F(,00B&C1B$(;4:UK41&HFR:L4K]=*4TI
M32E-*4TI32E6-G]*6SI'S8"N'<4;EM*TP_0OE'V(8#%_ZK![M3[R,;]VJ@^:
M54<-R0.58_"MAJU#.18\X351?8G`V:=FR?HM?NA&I]O@]NA%C2KHU2E-*4TI
M32E-*4TI32E-*4TI32E-*5__T^^JSK*ZZKI]/;P8MG56D21`L:Z<`<F'.A2Q
M.!)BRHY6N&8!PO5KFN145%T]*5%C-CY/T%Y36T@LM+_K+R-;>,N"UQ9LG#K0
MK7.08&D,UK+6`%GZDC_XE`'[;W..%'LO^)5_GBJU<W9'F*Q[`Y+C/6;@&YC6
MP<RCPK7/LQK#*>IA8U)!'L6PGS`*G]PCP"MDV*-5'O<X4--RO*'5$72"[TK?
M7BWC7&N(L&H<"Q2.HJNDC>#Y!$;\RTL#+[MA;V!&HGNS;"4YSW?V6(J#8C1L
M8U+3,6))JE9!U2E-*4TI32E-*4TI32E-*5KI@,W^E.5LPP%Z^U!LD=;TPEW\
M&N:-DT80?<J?ELIS7KZ^L9$^Y=?9\J#]M4'J:V+U\56FE*:4II2FE*:4II2F
ME*:4II2FE*__U.T3MOSGEW!V+8K98=$I3V%_?28$@UW%DS0`B1(#Y+F@CQID
M)??,9[/QN>Y&M:J>*JY%;S'\GNX^3]/<;XWG\5Q<1\[-S6C9LA'D542,N0JH
M\?U,Q7ZBQ``(TDD%=X]&];['V-O.]8F_SY"XN+C*ZB%E0EF<+Y9E?P`#X`!)
M(-["QQ-P!SD3M"'/N'.:\=QV1\NC2:"'!ASJQMA7AEBCV03"E3Y18]K52SQ3
MQB@<,HU1ST1'#1VO)_&;Y&\B[5WSD'%.:X>'!ON/`)X#`CQ:T5PDR.DDDGUH
M7C9=-B5+W7Z+UZ#N[IK9^`[7L_(.,9.3+M<TIBE$K))I<J6B961$^E@K@WN`
MP6Q^JU4N_P`3PWH+QI<7>!>.3\@Y[?@IZRURP0RFCU8!EFDC_'K705=6U8A>
M3T8]BGF'$XF[&L8W9OR.[DR>G^#P[OM4$$O(\S)6#&24,4'TEY96561F6-%L
M`&`]R2.]UN#XGIOKF'LCE,FW;A++'LV-`99FCL&/D*D:LP8*78WN5/T(]K&Q
M%V=3^R?)',F;99BN=0,=BCI,?6T"M563:Z8"='MHE<>-(2393&.8K9:^35:C
MFO8GK]J+J;XS_(#GW:_+^3<;YEA8$:8>#[R^S%)%(LBS)$R-KE<$?6;BP(*C
MSZBO?=W=1\2X!QW9-ZXWDY;MDY7MGW9$D0HT32!ETQH;_2+&Y!!]/2MM<^Y3
MX^XNC5TO/<G@8V&V,<%;\MDLY9I(K!/D^Q'@QI4A[([3L\W^'@Q7M1517)OT
M[S;LC@_7./@Y/->10X$64S+%K#LTA0`OI6-78A0RZC:PU*";L+Z.XQPOE',I
MLJ#C.S2Y<D"J9-)50@8D+=G95!:QL+W-C8>#58P[-<5Y`HH^2X;=1+^DDE.`
M4^'[K6>_&(HS@*&0,,B.83OM81C7;*B[;*BK*<5Y=QOF^S0<@XIN\6;L\C,H
MD2X&I#9E*L%96!]590;$&UB"<#?^/;UQ?<I=HW_;Y,7<44$HUKV874@J2K`_
M>I(O<>H(JE9WRCQ]QE#!-SO+*G'!2E<D0,PSRSYB#V]QT*KB#DV4Q@E5/-PA
M/:Q53=4W3>-YGV-P?KS%AS.9\FQ<".2^A9&)DDMZF.%`TL@7QJ*(P6XN1<5F
M\:X;RGF$\F/QK9)\MTMJ*`!$OZ:Y&*QH3]@9@38VO8U0N/N=>)>4Y9J_!,UK
M;RQ`$DDE8Z/95-FL83VL+(%6W<&MG'CB<]J.>P;FM\DW5-TU#<'[EZQ[(R9<
M+AG+L?,ST0N8BLL,V@$`L(LB.*1E!(NRJ0+BY\BI+E'6W..%P1Y7)>/38V(S
M!1)JCECU$7"F2%Y$#&QL"P)L;>AJC2>S'`L20>)(Y1Q<<B*8L<X_DG?X&"]P
MRL\F1W,=XO:J;HJHOW+J)R/D'TMBSS8T_8VW+/&Y5AK8V9201<*0;$>H)'W5
M(1=0=F3Q13Q<,S3$ZA@=(%P1<&Q:_I]_FLA8=R%@_(,0\W"<JH\FCQ',9,6I
MG@E&A/+Y^TV;%:Y)4-3()RL]UC/-&JK=TU[GBO.>'<XQILOB')</<8(B`_LR
M*[1DWTB1`=<>JQTZU&H`D7%>6W_BO(^+3Q8_(MDR<.5P2GNH5#@6OH;\+VN+
MZ2;7`-JHF?<R<8<7^RW.\SJ,?D2!*<$`KI$VU-';Y)\@=16`FVCXZN8K4>@?
M!SD\455]-1'-NUNN^NO:7F?+,7!GD74L9+23,OGZA!"LDQ6X(#:+$C2"3XJ1
MXQP'F/,O</&N/SY42-8N-*1AO'TF61DC#>02-5P/)%O-4;!NPG#/)%@RHP[/
MJBSMC(Y8]7)#94EC+\/+S;"A7T&KDS2,:U7*T37N1B*[;Q]=17#>\NI^?YR;
M7Q3FV+D;FP.F%UEQY7MZB./)CA>0@`DA`QT@M;3YK/Y)U;V!Q+%;.W_C$\."
MMM4BF.:-;^FMX7D5`?2[$"_CU\5@;LKFM1PMFE7S;D,A\'%\.QD<Z\>!GNSK
M:6LZ?4U^.U$=SA,E7F1+9,C!:I&C&-KS%5@1$?KV_*^5;3PSCVX<@WF4C#A'
MA5\N[MX2-`;79CX%R`!=F(4$B$XAQ/=N;<AV_CNRQ@YLY/EO"1HHN\CGS947
MR;`DFRJ"Q`,?-%W3^H3V>L;>9UJXDI:3$J\[XHIC*ZGF"`]'_(2-/S3D*RJ\
M6L+AD=J(\,8`5:PB*HD<YCEY5P^V.[^PI\J7@/&8H=L1K!M*,!]MFGR62%GM
MZJBK8'\-R#76.;U%T5USCXL787*)IMT=;E=;J3]EUQ\5'F5+^C.S7(/U6!%;
M'=<>S7<__P"=L3X2[/\`#$>E@YJ')/RO.*^BEU884R@QNYR9S7W%58W>&WL<
MXZIL5!1W@,)YF/<]_P"B[W?!.P.UO^\=LXCV%Q18H<L2Z,A8V0*T<3R_C1I(
M)`0FBRE64L"2?0^`Y_UWU)_V7N?,.N>7---AF+7CM(KEEEECA_JW6.>,@OKN
MP96"D`#U&Y68=N>M>`9+;8?F/,>&T.341V1;>GF3)"RZ^2\`I*`D>Q&,-ID"
M=JN;Y*K579=E143:FZ=F\!V7/R=KW7E.+#N$+6=&8W4D`V-@1>Q'B_CT/FM3
M[5U=V#OFWXNZ[3Q/+GVZ9;I(JC2P!(N+D&UP?-O/J/%7+QOV(X2Y>E7$/C7D
MG&LODX_`9:70ZN29?RRN(1PFS);Y((XQ`4C517;[)MZ^FI#8><\1Y1)E1;!O
M^/E20)KD"$_0I-M1N!87^VH[D'`^8<6CQ9>0\?R,6.=]$9<#ZV`OI6Q))M]E
M4'"NV'7'D;)Z_#,)YAPS(LHMG2&5=+"L'I,L"18Y99Q0DD`".29D8#R>#'*Y
MS6*J(NRZP]I[)X)ONX0;5M'*,2?<9;Z(U;ZF(!8A;@`FP)L#>P-JS=WZRY_L
M&W3[MO'%,N#;8K:Y&7Z5!(4%K$D"Y`N?%R+U=6=\[\1\997A^#YWF]9C>59]
M(%%Q&HFAL7EN#GGQZL+&'BPI$.(AK"4P372"":YR^B^B[2.\\RXSQ_<MKVC>
M=WC@W+-8"%&#7<E@@\A2JW8@`L0"?Y:C=EX7RCD6V;KO&R[/)D;;@J6G=2MH
MP%+FX+!FLH).D,;5XLY[#\+\:YSC/&F<Y]58[G.8BK38WCTN/:%E68KBUDT=
M61IHD"3"C,G6T,H!J8H_)XU^Y-]6=XYSQ/8-XV_8-XWJ.#>,H(8HF#DN'<QH
M;JI4:G4J-1%R#5[9N!\NY#LVX\AV;9)9]FQ"XEE4H`AC02.+,P8Z48,=(/@B
MK^S3.<-XYQ^9E>>9/1XCCD#Q25<Y!8QJR"PA$<HH[#22#0\N0K5001^12N]&
M-<OIJ:W;>-JV+"EW+>=PAQ<!/5Y&"+<^@N2+L?L47)/@`FH3:-FW;?\`.BVS
M9=NFRMP?TCB0NUAZFP!LH^UC90/)(%:[83WIZG<AY/%P[%.9Z&7D,^8"OKX5
ME593C8+&?)+[$6%76>34-/56$J4?9@AA.]Q'N:UJ*KFHOAMI[BZUWS<(]KVW
ME<+9SL%572:(,Q-@JO+&B,2?`"L220!ZBO>;QTQV=L.W2;MN?$IUP$0LS(\,
MI10+EG2&1W4`>264``$FP!J^.7^T/`7`LB+!Y8Y+H\4LYH!RXU*@+:]OWPRE
M>$4YU!C5=<W08!3">UAW@:)RL<B.7Q=M+\H[#X7PQXX>2\@AQLAP"([/))I)
ML&]N)7D"D@@,5"FQ\^#4-Q7KCF_-HY9N,<>FR<=&*F2Z1Q:@+E?=E:.,L`02
MH8L+CQY%6H/NQU7-@<SDL7,^,$P^OMJZBGS1Q[Q]G"N+B):3ZFNE8PVI7*02
M;.'1S2QVNA)[S(AE;O[;]HY>VNN6V:7?UY7CG:TE6-FM)K5W#LBF+1[P+K'(
M5O']01B+Z3:3;J#LI=[BX\W$LD;K)$\BJ3'H:-&1783:_9(1I(PQ$GTETO;4
M+__5ZW/J-?\`HOCC_P!T6W_B6:X*^>G_`(CP'_49O^2*ZQ^)W_D/+?[E%_S3
M6`,C\N`>;^!^5HWG&QS,,'P*VMU&TC0>T;'*[&LUC^#?+Y)FP2,G[*BI[\AJ
MHB*B;:1W[5TEV_TOV5CWCV'==GVV:>P(72V+%B9ZV%];>V5R;>?UDJD`$"MH
M;3I[/Z[[+X3-9]VP-RS8HKVO<3R9&(U_T1K!A_X$(^TUD[FP[.P/;O!>*HKV
MS\3PA\8=T@WH2(9C!CR7,"(5-V-617QX]=OLJ(<>WKOMK8?;TR]X?*'AG6N.
MXFXSLY09%C=&``R\XW]!JB6/%_@D2WF]>.Z[C/5W17).:S*8M\W$,8KBS`DG
M'Q1;U^EV>?\`X&^RU>GI\B)V>Y^1$1$1,R1$3T1$3D&-LB)]R)J_\6`!\B>[
M0!X_Z[_<TJUWP2>F^L"3Y_Z3]A:J+S;#)V3[;57%$288>-X572JJPF1GH\44
M\.$6ZR2;LJO]L[[%T>L?LB+[@&_9^EJ*[?Q)._\`Y.[;UIBY;+Q_:('AE=#=
M49(VGRI/MLQE,6(WB^J-?3UJ0Z[R$ZCZ-S>;3XZG=]QE61%86+!G$4"?9<",
M/D#^:Y_BJM]!<OGXYD_(_">0*Z-,BR9-Y!AD<NT:YI)+*'*8;=U\7&(UL5R-
M1$7QC$5=_NEOA-RG-V'D7/>HM\)CRXY&R(XR?P3X[C&S$^XL0(2``/$3GS]D
M=\G=AQMVV?B?8>U@/CNBPNX_2BF7WL9OXA^L%S]LBCQ]N),2H8_9[MSE`LY/
M+DX[`GY)-=6-DE`1^-XO.2KI*`)PJQ\2.]Q@K(<+P>]%,YKF$?YIK'C&RP?(
MGY0<BCYE/+)L4$^5(80Y4G%PY/9Q\966Q126C,I32S7E92LCZQ[G?-SEZ<Z+
MV9^-Q1INLL6.GN:0P$^0GN33D&X9A9]`:X'ZL$,BZ3)!BW67B#!LWI\^PS'Y
M.-W--$L88X\&UG'JYH[.(:$4DV)9EGD]X(3N\'!('U7\2.V37?/&_CUU;P[E
M^U<UXGLDFW[MB12H%CFD:&02HT;&1)C(=2JQTE&3S^+585R7O7<'.^2<=S^,
M<@W1,O;\AXV+/&BR(8V#@(T806)47#*W\W3<U$7PG8<'UW(&;%YV@.L<>?#L
MV4X61[R0]+K\Z`Y'-2B*$['+!:5$<1R#W7_;LNOR]ZBSNGL#F_+I>YL(S[$8
MI1`H7(8_F/S"GQ^7*L#[>L78Z?/WVKNGL3%[&R^,<>3K7)$6ZB2,RDM"H]GV
MF_\`V!4_7I-E&K^2]9VZ5TTU_-><YWB%7=UW$]77Y;':>:\FRULF<*9CM!(,
MKWBL[F+#$(Q6H]WM^UYN<BN9Y[G^)&TY;=N\RYGQ;;LN#K/'@S5#2$_U3R*^
M+C,UR)9TC".XU'3HU,PU)KUI\A=PQUZ\XWQK?LW'EYO-+C-I0#^L5"L\ZBP,
M<3.6538:M6D`Z6TT7K+@M;V9YES_`#CE,1KV)!'^?2JI\LPHTJRN9I05,$Y(
MY8\E:JIA12-$$?@S80VN_5HK'Q'QZX;M_P`A>U^;<P['C?-Q85_,O"78(\L\
MA6&-BI5_9AC1@B+I6R1JWT`HTCW!R3+Z?X!QCCG"W7&GD/LK(%!98XD!E<!@
MR^Y*[*69KGZG8?59EK7=7A7#>(I.!9QQK"=B);&RF0Y<*MES&B!:5;8MC57%
M6XAB%KI0MGH_VWM9Y,&YC6N\W.E_EQU'Q3J_(X5S'K_$.URSY#H\<3R!5FA"
M2PSPDL6B<?4&T,%NL;*JMK+1WQZ["W_G4/)N.<OR!G)%$C*\BH2T<FJ.2*2P
M`D4^"-0)L75B5T@8@^JKFUUD?7WJG+E&]L6<"=F=U&%Y,$:W'A6/&BD\&N\%
M;&_J>6C45%V]ST5/7?=?=W)=PY%U5TYNV6P$FZ84.9,H\`ROAP/Z>E@9Y+?Q
MU&_';8<':.QNU\.!+_X?,V-$Q\D1C*F4B_\`#[*7_BK<6/F&:=:NDG7^SZ]\
M.S>8+2=CG'+9F.XY77%H98V6X?+RG(<U/$Q>%/L)C9=_X(][&^"/G-<KO%J(
MNZ4W3=N`]1\)R.$<6?=,EX,75%$KN;30--+.5A5F;5):Y`M>0&]A6GGVK:.P
MNX><8_.N5IM6,F1E:997C07AG6&+'#3,JKIBO8$WM&1:YK$?6[ZBW)_+78_&
MNO\`R)PK7<?6%T[*(EFTTK(:_(L=L<>Q*ZRMH;"CO(0CL<<=,H7"(@2-]YK]
M]F^+O,<"[TY#R;GF!PK?>)QX,\WO*]S*LL310R36:.10?(320=)&H'[+'U/8
M'0G'.+\`W#G&P\ODSH(?99++$T4JRSQPW62-B/!DU`C4#I(^VXC3YNR#B;%O
MJ)<GWO.6*6V;\6P<[RC^J,7HVL?:6?RL-EPZ3XK27N-,7X612(DA^\T/ZL3O
MT_V;M!<NS>-;=WER',YAMLN7QU,R;WH8_P`;W@98[7DB_#*48_K%\*?7\)Z$
MX=@\GW+H;CF%PW<XL/DCX4/LS2?@2TZM)>T<OXH@ZC]6WEAZ?B$MG3+(.HN=
M8GS-E76+BC(^-9=72CQ_+'9.-XYEC'FUMI8UC8GMYIF4-T9A(I?/8@2H]$\F
MJU6KKICJG-ZQWC;>5;CU]QN?`DCB$<WN@AF#*[)IM/.MK@W\J;^HM:N7^VL'
MM+9MTXEMG8O)L?<(I)O=A]DW52KHCZKX\#7L1;PPMZ&]ZY\L)Q?.,4PBO[)X
M7,/&+QQRO14AI(!.<^CNG5XLDQ>T(YKE1\&7*KI$<R/1HT>@AJKO>V3B3:=N
MW?;=H@Y]M,I5L#<HXR0/ZN32)87/\TE65K^+Z1YUVKN?>-RV;<]XGZ^W>(,N
MX;9)(`3XDCU&*9!]S*&5EM<VU-XT7J2[M?RO2\X<S_3TY3HE"V)F#<-L)40)
M5,E3=#Y/I8>04A"*B*\U)=QI$5SMOQ*+R3T5%UO[LGDF)R_E?1_(\,CVLKV&
M*@WT2#+C62,G[XY`R'[[7KGKK'C.7P[B7>W&LT'W<3WU#$6UQG#D:*0#[I(R
MKC[M5O6JY]1#_P#0WJ]_(>$__O#-M9G>/[\>N_['`_W">L/H?]Q/8_\`;[A_
MM^/5K?4AOLBYJ[G\7=<4MI%9C4*=QSB4*/YJL(62\GVL!)^3$`B>)9`JVXAQ
MV^2.\&1G>.WN/\H[OG-SN6=K<>X(,EH\!'Q85'Z(ERW75*1]I"NBB][!3;\1
MO)=`86!Q#J3DG/ORJR;BZ94['](Q8:-IA!^P%T=C:URXO^$6DJ3Z:W4J-"Q<
M=/@]O0W6*V=%;Q,KK,KO"9!83*.5'F*MM^:R;.EE"M3Q]Y+6PAHU'*D?V$\?
M'?@Z#ZSCBV]<79Y8<O&DC=9DFD,C-&0WUZR\9#D?4!&+7^C1XMSV?D'VA)-N
M39>\Q3XF3'(C0O#&(E612OT:`DBE`?H)D-[#7K\WB'[.`+PEWYRCDCL/Q;+Y
M3XVR')9MU35]JI`T^2XM*IAUU(E3+(U]792<*$H`O@R/P.?$1A48U["IS%V"
MC<1[HW'?N<\=;<=AGR&D17N$EA,86/0Q^AS`-*F-O!*6:P(:NI^NG7F'2.W<
M?X)R1=MY!!CK'(R6+Q3"0O)K4?6@R#J82+YL]UN5*UN-!SOZ60>)<HY7B84]
MV-6.<8'*R#B;\OO7VPN0J:@Y&;AXEPI;S^FXXCT-]>[/;+_I\SA^+G^^-J:V
MG#O/QT7C.X\EBVD_D'S,<RX>F36,E(\KV!['N>T`8Y,CSK_+-:Q.M0*U/-LO
MR3?D^V\9EW<?XA'AY(BS=4>@XLDN+[Y_,>W[I(DCQ_&C\RH-PNAB:__6Z\/J
M$4ES<X7QZE/46=JL?*+)9"5L"7.4"%JOU2F2*(OM(3VW>/EMOXKM]BZX;^<F
MT;MNW$N##:]KR,DQ[C+J]J-Y--X?&K0IM>QM?UL;>E=2_%K<=OV_D'*3GYT,
M`?#CT^XZI>TGFVHB]KB]O2XIV6XNG9CU9XXM8-7-DY-Q[CN&3F0`1#ELG5T^
MCJJB_@MAM&LA'@(H))4\?)C8B[I]NGR!ZYS>5_'#@6Y8>VS2<AV/`P)!&J,T
MIBDQX8,F/0!JNI]N5Q:X$!N/6G47,\;8.Z.6X63FQIL^ZY>6A<L!'[B322PO
MJOIL1KC4WL3*+5;?0+C&XKS9UR;E-;90[*8\.*T[KF++CSBC5P;;()NTYC#%
M'),L,;2IONX96[JJ.1(#X2==[I@R\R[#Y'M^1%N$I7#@,Z.LA'TSY,GZP!F#
MM["AQZE)%O<$5+_)[F.!E1\;X?LV7%)B1@Y,OM,K(#YB@3Z"0"H]TE?L#(;>
ME6QU]?>X%S1V>S2?C-Z^+4T?(=K!$^IL1I<2(N8I.AU\%_QMCFL%"C6>'ENB
M^7V(JZ\[T>V\\*[:^1'+<WCV:<?&P]TFC4PRCWV3.]Q(HSH^II=-ETW\'5Z`
MFICM!=MY-U[TYQ[&WC&$T^3@QN1(A]I6Q=#.XU>`E[F]ON]36/.`>M?)?+KL
MPY%F<A9-Q3;R+V5#-.%16J6^02;%1W5V8CQW^,R`PDE2`._YK#%5?T5'Z^%Z
M2^/_`&#V@>4\\R^<[AQK='S71I!CS>_DO+:?(8D9.(RQZVC/Z:N]_0Q^?5=G
M]N<0X*-AXI!Q;#WO!7&5PAFC]J!8[Q0@`P9"E]*N/T2JV]0_CPW/&N>]8>Q.
M%9$V;D/(L1),'(;/*HM!:>_95UQ)G5&50IS!S+UZ6?PG'7R><CG>Z,BINNVL
M/=NO^:_';O;B._+EYV_8WN1Y4V8F--JEBG>2#,CD`?(/N^V9#=I&)UHY%S:L
MC;^7<9[CZJY#M1Q\7:9]#P1XS31VCDB5)<9T)2$>WKT>`B@:64'Q>KBS[$>3
MNK78*RY5Q3%I>1X9<6EU9121(TLM62KR(A)%EC5L>``SZ>37R3?W9Y&JUZ!$
M1ON;$&V=YKQ?L/XX=X;AV5QKCDN?Q/+R,B5"B.T)ARB6EQ)FC5C`\3M^J9@0
MP2.0:[.@B^,;[P_N?J[$X3O>])B<@QX8HV#,HD$D`"QY$0<CW5=1^L"FXU.A
MTW5CM=PUV@SCF?D2LH:_B6;C&&!K[.1DV06)K&T=%E"@O)6QX\YM?3UL)QYW
M@SP(TY3,55:UB-54Z7ZH^17,.V>=;=LN#UC-MW$T@E;+R96EF*.L9,2K((H(
MHRTFE=+"1W4DJ$`)&DN?]-\<Z^XKF;GE<XCS.0-+&N/!&(XPREP)&9-<LCZ4
MN;J452`"6N`=5>H_$L#)^3N4*SDG`%GTQL:MQ1OZGQTJ#C39&0P@*>KESXC7
MP+1L5Y/;,!S#L3=6N39=<U_&#K'"Y%V)V+MW/^$&;:7V^<)^;Q39)&RHUU0O
M(@,<P0MI>,K(HN5(K=?>?.<G9^'<.S.)<H]K<%S(BWY><79%@<Z9%1K/'J"Z
ME<%";`@U7NJL+,>'>?LQXGNZB^-B&0FO*!TPM9,?3FG4BRI=%>.DL`L1H;2H
M$46Z*U'?*8C]O!$2;^-F'RKJKNWE76>[[7FOQ?.?(QB[12&!I,?6^-D%PN@+
M-`'2XL#[R:K:;"+[KR-@Y[UAL/-]OSL9=]Q5AFTB1!*$FTK-#IU:KQRE6^VW
MMMIOJN;&QL?)G2OE[(I)\&LLKPNW#+J@3(PY3(5U2.FI+IIL.ZCPYL>#=PO;
M:AXQF.5/(C/'9PS)XW8$["^)':.^Y$W#LC<^)92O"KH'$<^.9-<$D<ZI(L>1
M'8"2)U)%W6UFCE'I-V;B'R%X+M4,7)(<+D,#+(RL5+Q3:-,J/$SHSPO<E)%(
M'A6O</'7LY'R7ECNGEV*X]C''MGBV)X_(.A)D])4F#`/8K$987-[<$A5\)JQ
M886_'B":IW)Y^'N*_9N7SWD'9GRVY1QK8N.\&R-MXS@NUY)-;QQM+H$L^3.8
MXH_H11[<"`R$:].LO9<?B>S\(^/>Q;UNN\\IAS=[RE%D32KN(]12*&(.[_4Q
M.N5B$'TZM(6YI'=W'*KE;(,?ZBT,D<>ZQ#$,"7BV5(;^H'GU97W$9,8MY`AO
M6NK,UPVTBB]_;VX]A&AD*YD?WGL[M[#ZBBY#UEL_$=B95S-GAA7$+V`9<>$0
MB)CZ*)(QZ^`'"$D*#7.?5W:S\1[$W'E&\HS;=NCRC+"W)7WI?=]U1^D8Y/4>
M24+@`L16!.$>Z_9/ISC$7A'E_KSD^4U^+?,B8LMH6[Q&\KX'RG$^$"Y7'LGJ
M,GQZ(5[FPR1V-:P3T:PY!-&Q-#<1[:Y[U9MT?$>4<'R,F'&U+#K,D,BK>^D/
M[4J2Q*;Z"H\`@!RH4#H/F/4'7W:^XR\QXKSO&QI\G2TV@1SQLVFVHQ^["\,K
M"WN!C<D$E%8L3X>GT7E/FOZA%=V//Q-E>+X=97?(607E@:NM#XYCC+CC?*<?
MK*\F3S:RJAV,PUA-CB:UC&%(YZO036-<K;/5T?(^6]W0<\?C63C[5)-DR2,5
M<Q1:\6:-%]UD168LRBP`)N3I`!M>[5DXUQ#HN?@"<GQ<G=HX<6*-0R"671EP
MRNPA5W95"JS7)(``&HDB]K\CV^7\*?4=SWF67PYF7(-!09IE,IM-#H[)D2\C
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M\C=8NS7%'(>/W&/PL]N(%;$->4LV$:'.9CRFJ;Z#'L`Q_DGH+H4>4/;=ONB:
MCO1=M:IZ)X<^^]?=@\;WS"E@BS9553)&RE6]JZ2*&`N8Y`KC[+J+UMKOSFB;
M!V+UWR;8<Z*>7"B9V$<BL&7W;/&Q4FPEC+(?MLQM4<O''$_.6,\_<2<>9+@V
M:J/CWG*AC^TS&[B35P#KFU`R\FP;-M>@#4LI*ADEAT?\=PMS-5&D<Y=%;#QO
ME^W\UXSL>X;/EZ<'>(Q;VG**??C]QE?38QG0&#7TD?6/!)._=_Y/PW<>$<HW
MW;]YP]6?LTAN98P[#\O+[:LFJXD&LH5MJ!^@^5`$BW?[$<KN>_G6:WJ,8R&U
MJ8E+PT*7:5M+93JZ*6+S3F,J2.1-BQBQ@$CQCL(1'.16,>UR[(J+K>G=6V;E
ME=U=?Y6+M\\F,L6""ZQLR@C/G)!8`@$`@FY\`@GP:T)T?NFV8G2'8>+E[C!%
ME/-GE4>1%8@X$`!"D@D$@@6'D@@>17K^ICUJY7#RQB?:?ARDM+\M3&QK^HPX
M[7DMK['<GPV>LK'\K6JC`-*G5+X8HPB/:,J17P_(JH,C?&YW_P`!Y(G)=M[&
MXMB23-&L7NB)2\D4L#7BFT`$LA4("0#H,=VLK"UKX\]A<8?C&Y]:\LS(X%E:
M7VC*P2.6&==,L.LD!7U%R`2NL266[*;W3A7U.>:N2[+"<$P[JY/7.[J]HJW(
M;1\O)+G'H5<6PC1[RTC4<:CJIU>!D-Y"^Y+LO9@(WR*\[45=2.T_(/EG(,C:
M=GVKKM_\8EFC65[RO$JE@)'$8C1E&FYN\NF.UV+@&HW=_CKQ#CV/O&];MV0G
M^"PPR/$@$4<K.%)C0R&1U8ZK+9(M4E[*$)%5WFSO?8XEEW*7#G8#J%:9EBT#
M*LC@89*6(^31YEBD.?*B8_='@9#0V,`A)]8HS_-A2"HQQU8@AO8OEF<M[DGV
MS<^1<6YMUA)E;<F3*L!M>.>%6*Q2%98V4EDLWN(QL6L%4CSA<0Z6Q]SVOC?+
M.#]J18FY/C1-D#5:2"9E#2QAHI%8!7NOMR*+A;EF#>(?0]<.7WX98<^NX6RH
M/%0.0Z=!X8Z#DWG8X[+6\M3E"5@%O$Q&EBPAU9+HC&M4T]B#(XB%1O+R\#Y0
M=JGYH>)Y(XV,Y+0:9?JB/N.2#;W/9C"B(SD`:I!I8MJMU6W/^*C=X.$#E^,>
M3-@27GU0_1*OMH`1?V_?D9C,,<$G3$2RA=-__]?M>[7<Q9-PGQQ4Y3B<:KDV
MECFE1C[DMP&DQ1PSUEW;R7($!XSW$,E,@=_-/%A7.39R-5.>ODMVIR'J'@6V
M<DXSCXTFY3[M!C'WU9T"-%D3O]*LA);V`GXA978BS`$;AZ2X%L_8G+,W9=\F
MF3"BV^6?]4P5BPDAB7R58`#W=?H;E0#X)%;'P)*S(,*8K$&LN)'DJ-%\D8IP
ML*K$=LGDC?+;?9-];\PL@Y>'B917298E>WK;4H-K_P`%ZU+DQ#'R<B`-<([+
M?[[$B_\`\5Z]9-6*:4II2FE*:4II2FE*:4II2O/+EQH$63.FG%%APXYI<N2=
M[1ACQHXW&.<Q'*C1B")BN<Y?1$3?2E0P=7/E<^]T<MY@DA>^GH3Y%EL?WV+X
MB!($[%<+KBHJJY)<6KD,*U?1/*$Y?3T362_TQA:K4T^L:J4TI32E-*4TI32E
M-*4TI32E-*4TI7__T.P7ZA_^2N,?ZHTO^$\VUQ;\ZOW2<=_]CQ_V+<*Z8^*W
M[PMY_P!&E_:<2MWZ/^"T_P#*Z_\`=`Z[!V?_`"C:_P"[1?T%KG/<?\PSO[9_
MZ1JJ:D:PZ:4II2FE*:4II2FE*:4II2H^?J!<Z!P'C=>,:2:C<NY(C%CSD`5$
M/588PB"M9!D:JN&M\]JP1(Y-B!^2J*BC35V);G4?04J\>BG#1.*^&HUU;QG1
M\JY*)%RBU&5BL/"IT`]F+U96JC7M<&OD/E/:]$>,TT@U_0U25M36^P54UNKJ
MW5*:4II2FE*:4II2FE*:4II2FE*:4K__T>P7ZA_^2N,?ZHTO^$\VUQ;\ZOW2
M<=_]CQ_V+<*Z8^*W[PMY_P!&E_:<2MWZ/^"T_P#*Z_\`=`Z[!V?_`"C:_P"[
M1?T%KG/<?\PSO[9_Z1JJ:D:PZ:4II2FE*:4II2FE*:4K$G-7,N)<&X-89IE4
MA'*-'1J.E"4;++(KE[%6-65XWKNNZ_C.796@`UQ'(NR(OTJEC84J*#KKQ9EW
M;WF>XYOY6&LK":FZ'*G!(QZ5MQ90T$:GP>I`;W&_D-1%42S$W<J@\6/522'$
M2^["-0J^M5J;E$1$1$1$1$1$1$V1$3T1$1/1$1-8U4K[I2FE*:4II2FE*:4I
MI2FE*:4II2FE*__2[!?J'_Y*XQ_JC2_X3S;7%OSJ_=)QW_V/'_8MPKICXK?O
M"WG_`$:7]IQ*W?H_X+3_`,KK_P!T#KL'9_\`*-K_`+M%_06N<]Q_S#._MG_I
M&JIJ1K#II2FE*:4II2FE*:4K6CGWM/QIP'7G#;369!FQ8ZDJL&J)(G6AGO:O
MQY%Q(1I14%6]^VYC-<5[=U"(RM5J?:(S^GI2HW\$XGYH[RYX+DWE.9,QWC&+
M(>.$4(R18:UHY+5-CN`5TE2^2$4?A(LBH1GN-57O,5GM:O%EB&D?BJOI4R^*
MXKCV$8]58IBE5$I,?I(C(5;6PF*P(`L57.<YSE<4\@Y7.(4I'.*8KG/>YSG*
MJXY))N?6J5<&J4II2FE*:4II2FE*:4II2FE*:4II2FE*_]/NJY9XDQ+F?&8V
M*9DEE^61+N!?`?52V0I;)T`4N,U$,2/)9[,B'.,$B>'EX$56N:]&N37?9O6'
M&.V>/8_&N5C(_P`.BRX\E3"XC<21AU'U%7&EDDD1A:^EB5*L`P]CPCG.^=?[
MQ-O>P&+\Y)CO"PD4NI1RK>@93=61&7S:ZBX*W!R4$(XX11PM1@0#&$3$551@
MQ-1C&HKE5RHUK43U7?6P(HHX(HX8EM$BA0/N`%@/Y!7D9)'ED>60W=B23]Y/
MDU^FKE?%4VV);!@F)1Q($^R8HU#$LY\BLAG:A&^ZQ\Z-7VI8[U%OX+[!$\MD
M5$3=44K$MAS;7XLJIR'A>>X0(>Z&N7X](RW%T7;R8YM]A*Y`T`B-^Q908KV^
MODUJ(JZ^M-_0BJ7KY6]D^O\`:A]^-S-QL%FS55EIEU+2'3R5[418MS+@245%
M&NZ>&Z)LJ^BINT-_]35:^6793K]4B]Z5S-QL5FWEM6Y=371=O)K/V%/+GGWW
M>GIX[[;K]B*J-#G]$TK!&8?4(Z^X\C@8],R7/[!5008^.4$J'&?(<[Q:-\W(
MTIMV*[T\@#/O_91=?8B<_P`%+5@ZVY=[L=BD=5<5\;3.'<0FN<-^363SU5HZ
M(]O[5N47D>`=0_HJCJ:!\ICMT0CD1=OK3&GXC<U6LC<._3[PS&IX<MYCN2<I
M9<0_SY-:?W_Z2;.>Y2%)/;.\K3*B>]^)7RU"`J*J$C.^W7RTI/A184O4A4>.
M"(`$6*`,:+&"./&C1QL"".`+&C"``1M:,01#:C6M:B-:U$1$VU:JE?MI2FE*
M:4II2FE*:4II2FE*:4II2FE*:4II2O_4[^-*4TI32E-*4TI4-?>[^+7G_>-^
M\0]9$7H*J*BYU?I4Q70O]K5?RXG^'J[6-+5#ZU*AJS2FE*:4II2FE*:4II2F
4E*:4II2FE*:4II2FE*:4II2O_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>24
<FILENAME>filename24.htm
<TEXT>
<HTML><HEAD>
<TITLE>Response Letter</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g575431g68p97.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">September&nbsp;20, 2013 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>VIA EDGAR SUBMISSION </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities and Exchange
Commission </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Division of Corporation Finance </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">100 F Street,
N.E. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Washington, D.C. 20549 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Jeffrey P. Riedler
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top">MacroGenics, Inc. </TD></TR></TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Registration Statement on Form S-1 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Filed September&nbsp;4, 2013 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">File No.&nbsp;333-190994 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On behalf of MacroGenics, Inc. (the &#147;Company&#148;), set forth below is the Company&#146;s response to the comment letter dated
September&nbsp;17, 2013 provided by the staff of the Division of Corporation Finance (the &#147;Staff&#148;) of the Securities and Exchange Commission (the &#147;Commission&#148;) to the Company regarding the Company&#146;s Registration Statement on
Form S-1 (File No.&nbsp;333-190994) (the &#147;Registration Statement&#148;) and the prospectus included therein (the &#147;Prospectus&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also describe below the changes that we have made in response to the Staff&#146;s comments in the Amended Registration Statement on Form
S-1/A (the &#147;Amended Registration Statement&#148;) that the Company filed on September&nbsp;20, 2013. For your convenience, the Staff&#146;s comments are numbered and presented in italicized text below, and each comment is followed by the
Company&#146;s proposed response. The Company will also provide the Staff courtesy copies of the Amended Registration Statement as-filed and marked to reflect the changes from the Registration Statement. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g575431g42k43.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September 20, 2013 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 2
</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On behalf of the Company, we advise you as follows: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Use of Proceeds, page 46 </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>1. We acknowledge your
response to our prior comment 9. To the extent that you plan to use multiple sources of funds to accomplish the purposes specified in this section, you should include a discussion of those other sources in accordance with Instruction 3 to
Item&nbsp;504 of Regulation S-K. Please quantify each additional source of funds and the total amount of combined funds anticipated through 2015. Also, disclose the currently anticipated amount of funds you expect to apply to the development of each
of Margetuximab, MGA271, MGD006, MGD007 and MGD010 through 2016 and the point in the development process that you expect the application of these funds will enable you to reach as to each such product. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Response:</B> In response to the Staff&#146;s comment, the Company has revised the disclosure on page 46 of the Registration Statement. In
light of the inherent uncertainties in clinical development, the Company is unable to predict at which point in the development process of each product candidate the application of these funds will allow it to reach. Depending on the results of
these clinical trials, the Company may decide to reallocate its financial resources among different programs. Accordingly, the Company believes that any prediction would be speculative and of little value to investors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Stock-Based Compensation, page 62 </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>2. We have reviewed
your response to our comment 10 and have the following comments: </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I></I><I>With respect to the second and third bullets, you indicate that these agreements did not alter the fair value of the common stock or have a significant change in the fair value of the common stock. However, on
page 68 you state that you reduced the probability of remaining private because of the &#147;relatively low need to raise capital as a result of your collaboration agreements and anticipated milestone payments.&#148; Please further clarify for us,
and in your disclosure why these agreements did not impact the value of the common stock.</I> </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Response: </B>In response
to the Staff&#146;s request, we have modified our disclosure on page 66. Although the Company did receive an upfront payment of $20 million from Servier in September 2012, the cash used to fund operations between December&nbsp;31, 2011 and September
2012 was approximately $25 million. Therefore, the cash infusion as a result of entering in to the Servier agreement did not have a significant impact on the value of the company at that time. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g575431g42k43.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September 20, 2013 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 3
</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I></I><I>With respect to the fourth bullet, please clarify how you used a combination of the market and income approach to determine the value of your company as a whole for the December&nbsp;31, 2012 and later
valuations.</I> </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Response: </B>In estimating the fair value of the Company as of December&nbsp;31, 2012 and in later
valuations, the Company used a combination of the market and income approach within a PWERM analysis. The Company must use a combination approach in completing the PWERM analysis to assign values to the IPO and M&amp;A scenarios (market approach)
and the remain private scenarios (income approach). The market approach was utilized to determine the value which should be assigned to both the IPO scenarios by reviewing precedent IPO transactions to determine a range of pre-money equity values.
In order to determine the value of the M&amp;A scenario in the PWERM analysis, we utilized premiums paid on acquisitions in the biotech industry and applied a selected premium to the IPO value at the date nearest to the projected M&amp;A event date.
The income approach was utilized to determine the value of the company in the remain private scenario through use of a discounted cash flow analysis based on management&#146;s forecast. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I></I><I>With respect to the fifth bullet, please revise your disclosure to clarify that the higher market values of the companies that completed IPOs in March 2013 as reflected in trading at a premium to the offering
price drove the increase in the fair value of the common stock.</I> </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Response: </B>In response to the Staff&#146;s
request, we have modified our disclosure on page 68 to include a discussion that the value assigned to the IPO scenarios in the March 2013 valuation was increased as a result of the higher market values that were reflected by IPOs completed during
March 2013 as reflected by trading at a premium to the offering price. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I></I><I>Please note we may have additional comments on your accounting for stock compensation and related disclosure once you have disclosed an estimated offering price. Additionally, we note that you provided
qualitative disclosures. As previously requested, please provide quantitative disclosures explaining the difference between the estimated offering price and the fair value of the most recent issuance once the price is known.</I> </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Response: </B>The Company acknowledges the Staff&#146;s comment. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g575431g42k43.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September 20, 2013 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 4
</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Cash Flows </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Operating Activities, page 72 </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>3. Please refer to your
revised disclosure in response to our comment 11. You indicate that the accounts payable balance decreased as a result of decreased spending on trials, specifically ceased enrollment of the Teplizumab Phase 3 trial in late 2011. We note that total
research and development expenses increased by $4.4 million between fiscal 2011 and 2012, and research and development expense related to Teplizumab increased by $5.8 million between fiscal 2011 and 2012. Please further clarify the reasons for the
decrease in accounts payable. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Response: </B>The Company acknowledges the Staff&#146;s comment. Although total research and
development expense increased by $4.4 million between fiscal 2011 and 2012, much of the work performed on our Teplizumab Phase 3 trial was done through a Clinical Research Organization (CRO). As the payments to the CRO are often tied to enrollment
under the trial, accounts payable can fluctuate throughout the duration of the trial. The decrease in accounts payable is due to the timing of payment of invoices versus the accrual of payments due to vendors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Teplizumab: Fc-Modified Antibody for Type 1 Diabetes, page 102 </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>4. In light of your disclosure that you are actively seeking a collaborator for further development of Teplizumab, please additionally disclose to what
extent, if any, you are involved in the current Phase 2 clinical trial sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Additionally, please explain the NIDDK&#146;s involvement in the trial and specifically
how they may conduct this trial given that you have now regained worldwide rights to Teplizumab from Eli Lilly. Please additionally disclose whether an IND application was filed for Teplizumab, the identity of the filer, and the date the application
was filed. Alternately, if no IND has been filed, please explain why. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Response: </B>MacroGenics is actively seeking a collaborator
for further development of teplizumab in the recent-onset Type 1 diabetes mellitus (TIDM) indication.&nbsp;MacroGenics is working with the NIDDK on the &#147;At-Risk&#148; study, which is targeting people who are at-risk for developing overt T1DM
(but have not yet been diagnosed with T1DM). With the Company&#146;s permission, NIDDK, a part of the National Institutes of Health, is the investigator in the At-Risk study and the Company </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g575431g42k43.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September 20, 2013 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 5
</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
retains all rights to commercialization. People considered at-risk for developing T1DM are defined by having immunologic markers of T1DM, abnormal glucose tolerance and a close relative with
T1DM. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The At-Risk study is being conducted under an IND filed and sponsored by MacroGenics, pursuant to IND 102,629 filed on
December&nbsp;23, 2009.&nbsp;The clinical study is being conducted by NIDDK at TrialNet clinical sites.&nbsp;NIDDK, in conjunction TrialNet, prepared the study documents (eg, clinical protocol) and is responsible for training and monitoring the
clinical sites. MacroGenics officially transferred these sponsor responsibilities to NIDDK in its initial IND submission on December&nbsp;23, 2009.&nbsp;MacroGenics remains responsible for submitting the appropriate documents to the IND according to
21CFR312, including but not limited to, IND Annual Reports, expedited reports, revised clinical protocols provided by NIDDK, and new clinical investigator information. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Collaborations, pages 102-108 </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>5. We note your
response to our prior comment 2. Given that you are actively seeking collaborative partners to develop Teplizumab, that there is an ongoing Phase 2 trial relating to this product candidate, that it appears to be one of your more advanced product
candidates according to the table on page 3, and that you reserve the right to use proceeds from this offering to fund its development, please disclose the material terms of your agreement with Tolerance Therapeutics. In particular, please describe
the nature of the intellectual property transferred to you under the agreement, the basis on which it was transferred, and the provisions of the agreement governing duration and termination. Additionally, please file the agreement as an exhibit to
your registration statement. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Response: </B>Although the Company considers teplizumab an active product candidate, the Company does
not believe that the Tolerance Therapeutics agreement is material to either further development of teplizumab or to the Company&#146;s financial condition. Pursuant to the Tolerance Therapeutics agreement the Company acquired all intellectual
property, both owned and in-licensed, related to further development and commercialization of teplizumab. Therefore, the Company now owns, or is the party to the in-licenses, the intellectual property related to teplizumab, and is not dependent on
Tolerance Therapeutics for any intellectual property necessary to further develop or commercialize the product candidate. The Company&#146;s only ongoing obligations to Tolerance Therapeutics under the agreement are financial obligations. If the
Company </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g575431g42k43.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September 20, 2013 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 6
</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
were to commercialize teplizumab, the Company would be obligated to pay Tolerance Therapeutics approximately $3.6 million in milestone payments, a maximum of 678,398 common shares of the
Company&#146;s stock and royalties on net sales of teplizumab ranging from 1.75% to 4.0%. As previously indicated, the Company is not actively developing teplizumab and does not expect to commercialize teplizumab in the foreseeable future.
Accordingly, it is unlikely the Company would have to make payments under the Tolerance Therapeutics agreement in the foreseeable future, and that, in the event the Company commercializes teplizumab, such payments would not be material to the
Company&#146;s financial condition, the Company does not believe that the Tolerance Therapeutics agreement is material. The Company acknowledges that assessments of materiality can change with time, and it confirms that it will regularly reevaluate
the materiality of the Tolerance Therapeutics agreement and, at such time as it considers that agreement to be material, the Company will describe the material terms in a periodic report and attach the agreement as an exhibit to such report. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>2. Summary of Significant Accounting Policies </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Revenues </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Right-to-Develop Agreements, page F-17
</U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>6. For the right-to-develop agreements, please provide the following in the filing: </I></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I></I><I>Clarify in Note 8 if the options for licenses are deliverables at inception of the agreement and tell us your basis for your conclusion.</I> </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Response: </B>The Company has concluded that the options for licenses are substantive options and therefore, are no considered to be
deliverables of the agreements. Factors that are considered in evaluating whether an option is substantive include the overall objective of the arrangement, the benefit the collaboration partner might obtain from the agreement without exercising the
option, the cost to exercise the option relative to the total upfront consideration, and the additional financial commitments or economic penalties imposed on the collaboration partner as a result of exercising the option. Please see the
Company&#146;s response to the third bullet point below, also related to the right-to-develop agreements in Note 8 that also responds to this comment. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I></I><I>If you do not believe the options are deliverables, please clarify the significance of your disclosure regarding determining the selling price for the options.</I> </TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g575431g42k43.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September 20, 2013 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 7
</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Response: </B>As discussed in our response to the first bullet
above as well as the third bullet below, the Company does not believe that the options are considered deliverables at the inception of the arrangement as the options are substantive. The Company has expanded its disclosures on page F-18 regarding
our policy for determining the selling price of these options. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><I>&#149;</I></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I></I><I>For each right-to-develop agreement in Note 8, please clarify whether the options are substantive and the reasons why or why not. </I></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Response: </B>In response to the Staff&#146;s request, the Company has clarified in Note 8 that the options for license are substantive,
and thus are not considered deliverables at the inception of the agreement. In making this determination, the Company concluded that it is appropriate to exclude a contingent deliverable from the initial measurement and allocation of the arrangement
consideration because: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) Considerable uncertainty exists about the outcome of the contingency, and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) The additional fee the customer would have to pay upon delivery of the contingent good or service is consistent with its estimated selling
price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As it relates to the first attribute, the Company concluded that there is considerable uncertainty that the collaboration partner
will exercise its right to obtain each option license based on the fact that (i)&nbsp;the candidates are in the early stages of development (e.g., preclinical) and there is substantial risk of successful commercialization (ii)&nbsp;the collaboration
partner has a finite period of time to exercise their rights to these licenses (i.e., the rights to the licenses are finite) and (iii)&nbsp;the Company is not obligated under the option license to perform services attributed to the option license
until the collaboration partner elects to exercise the option license. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As it relates to the second attribute, the Company noted that due
to the unique nature of the license, there is no third party evidence of selling price. Therefore the Company used management&#146;s best estimate of selling price, which is evidenced through good-faith negotiations with non-related third parties.
The Company evaluated the market potential for each product candidate of either delivered licenses or optional undelivered licenses at the inception of the arrangement through an evaluation of future discounted cash flows. Based on the market
analysis, the Company noted that there is a similar market potential for each product candidate, and thus each executed license and future option licenses, although priced similarly, represented the estimated selling price
</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g575431g42k43.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September 20, 2013 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 8
</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the license and the future option license did not include a significant embedded discount. In making this conclusion, the Company considered interpretive guidance published by Ernst&nbsp;&amp;
Young that provides factors to consider in determining whether options would represent deliverables at the inception of an agreement. Relevant excerpts from this interpretive guidance are included below: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Contractual arrangement terms that give customers the right to future purchases of additional products or services from a vendor for an
amount below market value, in addition to the current products and services being purchased, generally should be considered an element in a multiple-element arrangement. In essence, the vendor is providing the customer with an in-the-money option to
purchase future items at a specified price. This contractual element should be evaluated pursuant to the multiple-element arrangements guidance if the right represents a significant and incremental discount to the customer, based on an analogy to
the guidance on identifying elements of an arrangement as significant and increment discounts in ASC 985-605-15-3(d).&#148; (Ernst&nbsp;&amp; Young&#146;s comprehensive guide: Revenue Recognition &#150; Multiple Element Arrangements) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interpretive guidance issued by other public accounting firms, such as Deloitte&nbsp;&amp; Touche, PricewaterhouseCoopers and KPMG, include
similar concepts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the aforementioned assessment, the Company concluded that the option licenses and related potential license
fees are substantive options that do not include significant incremental discounts, and thus are excluded from the initial measurement and allocation of the arrangement consideration. The license fees for the respective options will be accounted for
separately, when and if the option is exercised and the licenses are delivered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In response to the Staff&#146;s request, we have
clarified for each right-to-develop agreement, Servier and Gilead, that the options are considered substantive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In making this
conclusion, the Company considered interpretive guidance published by Ernst&nbsp;&amp; Young that provides factors to consider in determining whether options would represent deliverables that the inception of an agreement. Relevant excerpts from
this interpretive guidance are included below: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Frequently, agreements include options for the customer to receive additional
products or services in the future at agreed-upon prices. Whether or not these options </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g575431g42k43.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September 20, 2013 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 9
</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
should be treated as deliverables in the original contract depends on the facts and circumstances surrounding the options for additional products and services. If such an option is substantive
(i.e., the customer is not required to purchase additional products), then the vendor is not obligated under the option to deliver goods and services unless and until such time as the customer elects to exercise the option. In such cases, the
products or services to be delivered by the vendor upon the exercise of the option should not be considered elements included in the current arrangement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Determining whether an option to acquire additional products or services is substantive requires an assessment as to whether the vendor is
truly at risk as to whether the customer will choose to exercise the option. For example, if an arrangement includes an option to acquire services from a vendor that are essential to the functionality of other elements of the arrangement, and such
services are only available from the vendor (i.e., there is a lack of other qualified service providers that can be engaged to perform the services), we do not believe the option should be considered substantive. If the option is not substantive, we
believe the products or services to be delivered by the vendor on exercise of the option should be accounted for as an element of the current arrangement&#148; (Ernst&nbsp;&amp; Young&#146;s comprehensive guide: Revenue Recognition &#150; Multiple
Element Arrangements). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Ernst&nbsp;&amp; Young interpretive guidance describes a &#147;substantive&#148; option as an option where
&#147;the vendor is truly at risk as to whether the customer will choose to exercise the option.&#148; The interpretive guidance goes on to state that &#147;if an option is considered substantive, then the vendor is not obligated under the option to
deliver goods and services unless and until such time as the customer elects to exercise the option. In such cases, the products and services to be delivered by the vendor upon the exercise of the option should not be considered elements included in
the current arrangement.&#148; We believe this interpretive guidance is applicable in the absence of any specific guidance within ASC 605-25 relative to the determination of deliverables. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the aforementioned assessment, the Company concluded that the option licenses and related potential license fees are substantive
options that do not include significant incremental discounts, and thus are excluded from the initial measurement and allocation of the arrangement consideration. The license fees for the respective options will be accounted for separately, when and
if the option is exercised and the licenses are delivered. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g575431g42k43.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September 20, 2013 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 10
</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><I>&#149;</I></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I></I><I>Please clarify if you believe the right-to-develop options have standalone value and why or why not. </I></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Response: </B>We respectfully inform the Staff that this issue is not applicable because the right-to-develop options are not deemed to be
deliverables at this time because they were substantive options with no associated discount. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><I>&#149;</I></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I></I><I>Clarify the accounting treatment for any right-to-develop fees received upon the exercise of an option to acquire a development and commercialization license (referred to as exercise fees or payments earned).
</I></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Response: </B>We respectfully inform the Staff that there have been no right-to-develop fees received upon exercise
of an option to acquire a development and commercialization license. As a result, we propose not changing our accounting policy disclosures for this point. Upon execution of such right-to-develop option, the Company will disclose its accounting
policy and related revenue recognition treatment for the fees received upon the exercise of an option.<B> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><I>&#149;</I></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I></I><I>Clarify the accounting policy for right-to-develop agreements where the options to secure development and commercialization licenses to a product program are not considered substantive. </I></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Response: </B>We respectfully inform the Staff that there are no options to secure development and commercialization licenses within the
Company&#146;s right-to-develop agreements that are not considered substantive. As a result, we propose not changing our accounting policy disclosures for this point. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><I>&#149;</I></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I></I><I>Clarify in Note 8 the timing of delivery or performance of service for the deliverables within the arrangements pursuant to ASC 605-25-50-2. For example, it is unclear on page F-32 if all of the arrangement
consideration is being recognized over 29 months, the initial period and why that period of recognition is appropriate. Revise the disclosure for all your agreements to clarify the delivery or performance period as appropriate.
</I></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Response: </B>In response to the Staff&#146;s request, we have clarified our disclosures within Note 8 for each
right-to-develop agreement what the timing of delivery or performance of service for the deliverables within each of those arrangements. The </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g575431g42k43.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September 20, 2013 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 11
</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company believes that the period of performance approximates the expected development period for the respective product candidate. The period of performance is reflective of the Company&#146;s
obligation. Changes to the period of obligation, e.g., due to delays in preclinical studies, are treated as a change in estimate. There have been no material changes in estimate. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><I>&#149;</I></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I></I><I>For the Servier agreement you state on page F-32 that for the quarter ended June&nbsp;30, 2013, the Company recognized revenue of $4.3 million. Please disclose the revenue recognized for the six months ended
June&nbsp;30, 2013. </I></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Response: </B>In response to the Staff&#146;s request, we have corrected on page F-32 that the
Company recognized revenue of $4.3 million for the Servier agreement during the six-month period ended June&nbsp;30, 2013. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>5. Shared-Based Payments
</U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Stock Option Exchange, page F-24 </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>7. Please
refer to your response to our comment 37. Regeneron and Alexion do not appear to be similar in size or market capitalization to the Company. Further, it is not clear how the companies with large amounts of product revenues are similar in stage of
development. Please tell us why you believe including these companies in the peer group is appropriate or confirm that there would not be a material difference in volatility for each of the periods presented if these companies were excluded.
</I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Response: </B>The Company confirms that there would not be a material difference in volatility for each of the periods presented
if Regeneron and Alexion were excluded from the Company&#146;s volatility calculation. The Company performed an analysis of volatility excluding Regeneron and Alexion. For the periods ended June&nbsp;30, 2013,&nbsp;December&nbsp;31, 2012 and
December&nbsp;31, 2011, Company&#146;s volatility would have been 62%, 58% and 63%, as compared to 58%, 51%, 62%, respectively. The Company further analyzed this difference, noting that the effect on share-based compensation expense during all
periods presented would not have a material impact on the financial statements or footnote disclosures. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>8. Collaboration and License Agreements, page
F-30 </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>8. In several places you indicate that you determined that the sales milestones are substantive. Please clarify here and in your disclosure
how they meet the definition of a substantive milestone. Refer to ASC 605-20 and 605-28-25-2. </I></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g575431g42k43.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September 20, 2013 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 12
</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Response: </B>In response to the Staff&#146;s request, the
Company has corrected in its disclosures beginning on page F-31 that our sales milestones are not substantive and are more akin to sales-based royalties and should be accounted for as such. As a result ASC 605-28 is not applicable for the
sales-based milestones. The sales-based milestones are still recognized upon the achievement of the milestone (assuming all other revenue recognition criteria have been met) because there are no undelivered elements that would preclude revenue
recognition at that time (i.e., since our substantial involvement would have ended prior to the milestone being achieved). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;* </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company acknowledges that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">it is responsible for the adequacy and accuracy of the disclosures in its filings; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Staff comments or changes to disclosure in response to Staff comments in its filings do not foreclose the Commission from taking any action with respect to the Company&#146;s filings; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">It may not assert Staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you have any further questions or comments, or if you require any additional information, please contact the undersigned by telephone at
(202)&nbsp;942-5124 or by email at richard.baltz@aporter.com. Thank you for your assistance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Sincerely, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">/s/ Richard E. Baltz </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Richard E. Baltz </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
